

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10051317	C4591001 1005 10051317	12-15	20OCT2020	20158	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10051328	C4591001 1005 10051328	12-15	20OCT2020	20159	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10051339	C4591001 1005 10051339	12-15	21OCT2020	20160	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10051410	C4591001 1005 10051410	12-15	09DEC2020	20163	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10051412	C4591001 1005 10051412	12-15	14DEC2020	22270	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10051413	C4591001 1005 10051413	12-15	14DEC2020	22269	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10051414	C4591001 1005 10051414	12-15	14DEC2020	22273	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10051415	C4591001 1005 10051415	12-15	14DEC2020	22274	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10051417	C4591001 1005 10051417	12-15	16DEC2020	22785	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10051418	C4591001 1005 10051418	12-15	16DEC2020	22786	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10051419	C4591001 1005 10051419	12-15	16DEC2020	22794	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
10051420	C4591001 1005 10051420	12-15	16DEC2020	22792	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10051421	C4591001 1005 10051421	12-15	17DEC2020	23097	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10051422	C4591001 1005 10051422	12-15	17DEC2020	23098	Placebo	17DEC2020	Placebo	07JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10051424	C4591001 1005 10051424	12-15	18DEC2020	23100	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10051425	C4591001 1005 10051425	12-15	18DEC2020	23101	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10051427	C4591001 1005 10051427	12-15	21DEC2020	23589	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10051428	C4591001 1005 10051428	12-15	21DEC2020	23596	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10051429	C4591001 1005 10051429	12-15	21DEC2020	23597	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10051430	C4591001 1005 10051430	12-15	22DEC2020	23600	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10051431	C4591001 1005 10051431	12-15	22DEC2020	23890	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10051436	C4591001 1005 10051436	12-15	22DEC2020	23897	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10051437	C4591001 1005 10051437	12-15	22DEC2020	23894	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10051438	C4591001 1005 10051438	12-15	22DEC2020	23892	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10051439	C4591001 1005 10051439	12-15	22DEC2020	24039	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10051440	C4591001 1005 10051440	12-15	22DEC2020	24041	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
10051441	C4591001 1005 10051441	12-15	22DEC2020	24034	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10051444	C4591001 1005 10051444	12-15	22DEC2020	24043	Placebo	22DEC2020	Placebo	12JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10051445	C4591001 1005 10051445	12-15	22DEC2020	24130	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10051447	C4591001 1005 10051447	12-15	11JAN2021	24134	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10051448	C4591001 1005 10051448	12-15	11JAN2021	24138	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10051449	C4591001 1005 10051449	12-15	11JAN2021	24137	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10051450	C4591001 1005 10051450	12-15	11JAN2021	26654	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10051451	C4591001 1005 10051451	12-15	12JAN2021	26655	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10061183	C4591001 1006 10061183	12-15	30NOV2020	20339	Placebo	30NOV2020	Placebo	07JAN2021	Placebo
10061184	C4591001 1006 10061184	12-15	30NOV2020	20340	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10061188	C4591001 1006 10061188	12-15	01DEC2020	20341	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10061189	C4591001 1006 10061189	12-15	01DEC2020	20348	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061190	C4591001 1006 10061190	12-15	02DEC2020	20638	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061191	C4591001 1006 10061191	12-15	02DEC2020	20640	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061196	C4591001 1006 10061196	12-15	02DEC2020	20644	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
10061200	C4591001 1006 10061200	12-15	03DEC2020	20647	Placebo	03DEC2020	Placebo	24DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061201	C4591001 1006 10061201	12-15	03DEC2020	20867	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)
10061203	C4591001 1006 10061203	12-15	03DEC2020	20871	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061206	C4591001 1006 10061206	12-15	04DEC2020	20872	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10061207	C4591001 1006 10061207	12-15	04DEC2020	20874	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10061209	C4591001 1006 10061209	12-15	04DEC2020	20998	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10061212	C4591001 1006 10061212	12-15	04DEC2020	20999	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10061213	C4591001 1006 10061213	12-15	04DEC2020	21000	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10061214	C4591001 1006 10061214	12-15	04DEC2020	21001	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10061219	C4591001 1006 10061219	12-15	07DEC2020	21141	Placebo	07DEC2020	Placebo	24DEC2020	Placebo
10061220	C4591001 1006 10061220	12-15	07DEC2020	21143	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061221	C4591001 1006 10061221	12-15	07DEC2020	21147	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061223	C4591001 1006 10061223	12-15	07DEC2020	21152	Placebo	07DEC2020	Placebo	30DEC2020	Placebo
10061224	C4591001 1006 10061224	12-15	07DEC2020	21261	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061226	C4591001 1006 10061226	12-15	07DEC2020	21262	Placebo	07DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061227	C4591001 1006 10061227	12-15	07DEC2020	21264	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061228	C4591001 1006 10061228	12-15	08DEC2020	21267	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10061229	C4591001 1006 10061229	12-15	08DEC2020	21442	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10061230	C4591001 1006 10061230	12-15	08DEC2020	21446	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10061231	C4591001 1006 10061231	12-15	08DEC2020	21448	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061232	C4591001 1006 10061232	12-15	08DEC2020	21450	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10061233	C4591001 1006 10061233	12-15	08DEC2020	21561	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10061234	C4591001 1006 10061234	12-15	09DEC2020	21563	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10061235	C4591001 1006 10061235	12-15	09DEC2020	21568	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10061236	C4591001 1006 10061236	12-15	09DEC2020	21571	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061237	C4591001 1006 10061237	12-15	09DEC2020	21696	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10061239	C4591001 1006 10061239	12-15	09DEC2020	21699	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10061241	C4591001 1006 10061241	12-15	09DEC2020	21702	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061242	C4591001 1006 10061242	12-15	09DEC2020	21704	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061243	C4591001 1006 10061243	12-15	10DEC2020	21864	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10061244	C4591001 1006 10061244	12-15	10DEC2020	21865	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10061245	C4591001 1006 10061245	12-15	10DEC2020	21869	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10061247	C4591001 1006 10061247	12-15	10DEC2020	21871	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10061248	C4591001 1006 10061248	12-15	11DEC2020	22046	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10061249	C4591001 1006 10061249	12-15	11DEC2020	22047	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10061250	C4591001 1006 10061250	12-15	11DEC2020	22050	Placebo	11DEC2020	Placebo	31DEC2020	Placebo
10061252	C4591001 1006 10061252	12-15	11DEC2020	22051	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10061253	C4591001 1006 10061253	12-15	11DEC2020	22173	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10061254	C4591001 1006 10061254	12-15	11DEC2020	22174	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10061256	C4591001 1006 10061256	12-15	11DEC2020	22176	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10061257	C4591001 1006 10061257	12-15	11DEC2020	22182	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10061258	C4591001 1006 10061258	12-15	14DEC2020	22296	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10061259	C4591001 1006 10061259	12-15	14DEC2020	22300	Placebo	14DEC2020	Placebo	05JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061260	C4591001 1006 10061260	12-15	14DEC2020	22302	Placebo	14DEC2020	Placebo	05JAN2021	Placebo
10061261	C4591001 1006 10061261	12-15	14DEC2020	22303	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10061262	C4591001 1006 10061262	12-15	14DEC2020	22426	Placebo	14DEC2020	Placebo	06JAN2021	Placebo
10061263	C4591001 1006 10061263	12-15	14DEC2020	22428	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10061264	C4591001 1006 10061264	12-15	14DEC2020	22429	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10061265	C4591001 1006 10061265	12-15	18DEC2020	23313	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10061266	C4591001 1006 10061266	12-15	15DEC2020	22433	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
10061267	C4591001 1006 10061267	12-15	15DEC2020	22558	Placebo	15DEC2020	Placebo	22JAN2021	Placebo
10061269	C4591001 1006 10061269	12-15	15DEC2020	22561	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10061270	C4591001 1006 10061270	12-15	16DEC2020	22562	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10061271	C4591001 1006 10061271	12-15	16DEC2020	22566	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10061272	C4591001 1006 10061272	12-15	16DEC2020	22821	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)		
10061273	C4591001 1006 10061273	12-15	16DEC2020	22823	Placebo	16DEC2020	Placebo	08JAN2021	Placebo
10061274	C4591001 1006 10061274	12-15	16DEC2020	22830	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061276	C4591001 1006 10061276	12-15	17DEC2020	22831	Placebo	17DEC2020	Placebo	06JAN2021	Placebo
10061277	C4591001 1006 10061277	12-15	17DEC2020	23159	Placebo	17DEC2020	Placebo	08JAN2021	Placebo
10061278	C4591001 1006 10061278	12-15	17DEC2020	23162	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10061279	C4591001 1006 10061279	12-15	17DEC2020	23166	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10061280	C4591001 1006 10061280	12-15	17DEC2020	23168	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10061282	C4591001 1006 10061282	12-15	18DEC2020	23314	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10061283	C4591001 1006 10061283	12-15	18DEC2020	23315	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10061284	C4591001 1006 10061284	12-15	18DEC2020	23318	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10061285	C4591001 1006 10061285	12-15	21DEC2020	23702	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
10061286	C4591001 1006 10061286	12-15	21DEC2020	23704	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10061287	C4591001 1006 10061287	12-15	21DEC2020	23706	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10061288	C4591001 1006 10061288	12-15	21DEC2020	23708	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10061289	C4591001 1006 10061289	12-15	22DEC2020	23941	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10061290	C4591001 1006 10061290	12-15	22DEC2020	23943	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061291	C4591001 1006 10061291	12-15	22DEC2020	23946	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10061292	C4591001 1006 10061292	12-15	22DEC2020	23948	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10061293	C4591001 1006 10061293	12-15	22DEC2020	24050	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10061294	C4591001 1006 10061294	12-15	22DEC2020	24054	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10061295	C4591001 1006 10061295	12-15	24DEC2020	24056	Placebo	24DEC2020	Placebo	12JAN2021	Placebo
10061296	C4591001 1006 10061296	12-15	29DEC2020	24611	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10061297	C4591001 1006 10061297	12-15	29DEC2020	24612	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10061298	C4591001 1006 10061298	12-15	29DEC2020	24617	Placebo	29DEC2020	Placebo	20JAN2021	Placebo
10061299	C4591001 1006 10061299	12-15	31DEC2020	24618	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	22JAN2021	BNT162b2 (30 µg)
10061300	C4591001 1006 10061300	12-15	07JAN2021	26122	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10071409	C4591001 1007 10071409	12-15	22OCT2020	20265	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)		
10071414	C4591001 1007 10071414	12-15	22OCT2020	20268	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
10071415	C4591001 1007 10071415	12-15	22OCT2020	20271	Placebo	22OCT2020	Placebo	10DEC2020	Placebo
10071417	C4591001 1007 10071417	12-15	22OCT2020	20272	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071428	C4591001 1007 10071428	12-15	22OCT2020	20292	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
10071429	C4591001 1007 10071429	12-15	22OCT2020	20295	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
10071467	C4591001 1007 10071467	12-15	30NOV2020	20296	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071469	C4591001 1007 10071469	12-15	30NOV2020	20298	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071471	C4591001 1007 10071471	12-15	30NOV2020	20374	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071472	C4591001 1007 10071472	12-15	30NOV2020	20375	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10071475	C4591001 1007 10071475	12-15	30NOV2020	20378	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071476	C4591001 1007 10071476	12-15	30NOV2020	20446	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071478	C4591001 1007 10071478	12-15	30NOV2020	20384	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10071480	C4591001 1007 10071480	12-15	30NOV2020	20447	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10071481	C4591001 1007 10071481	12-15	01DEC2020	20449	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10071482	C4591001 1007 10071482	12-15	01DEC2020	20455	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071483	C4591001 1007 10071483	12-15	01DEC2020	20496	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10071484	C4591001 1007 10071484	12-15	01DEC2020	20497	Placebo	01DEC2020	Placebo	22DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071485	C4591001 1007 10071485	12-15	01DEC2020	20503	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071488	C4591001 1007 10071488	12-15	01DEC2020	20504	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071490	C4591001 1007 10071490	12-15	01DEC2020	20605	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071492	C4591001 1007 10071492	12-15	01DEC2020	20606	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
10071494	C4591001 1007 10071494	12-15	02DEC2020	20608	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071495	C4591001 1007 10071495	12-15	02DEC2020	20610	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10071496	C4591001 1007 10071496	12-15	02DEC2020	20750	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10071497	C4591001 1007 10071497	12-15	02DEC2020	20746	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071499	C4591001 1007 10071499	12-15	03DEC2020	20753	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10071500	C4591001 1007 10071500	12-15	03DEC2020	20756	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071504	C4591001 1007 10071504	12-15	07DEC2020	21085	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071505	C4591001 1007 10071505	12-15	07DEC2020	21087	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10071506	C4591001 1007 10071506	12-15	07DEC2020	21089	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10071507	C4591001 1007 10071507	12-15	07DEC2020	21090	Placebo	07DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071508	C4591001 1007 10071508	12-15	07DEC2020	21192	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10071509	C4591001 1007 10071509	12-15	07DEC2020	21197	Placebo	07DEC2020	Placebo	30DEC2020	Placebo
10071511	C4591001 1007 10071511	12-15	07DEC2020	21198	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10071512	C4591001 1007 10071512	12-15	07DEC2020	21276	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10071514	C4591001 1007 10071514	12-15	07DEC2020	21199	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10071515	C4591001 1007 10071515	12-15	08DEC2020	21283	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071516	C4591001 1007 10071516	12-15	08DEC2020	21282	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071517	C4591001 1007 10071517	12-15	08DEC2020	21284	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071518	C4591001 1007 10071518	12-15	08DEC2020	21369	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071519	C4591001 1007 10071519	12-15	08DEC2020	21374	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071520	C4591001 1007 10071520	12-15	08DEC2020	21375	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071521	C4591001 1007 10071521	12-15	08DEC2020	21376	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071522	C4591001 1007 10071522	12-15	08DEC2020	21458	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071523	C4591001 1007 10071523	12-15	08DEC2020	21453	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071524	C4591001 1007 10071524	12-15	08DEC2020	21462	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071525	C4591001 1007 10071525	12-15	08DEC2020	21463	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071526	C4591001 1007 10071526	12-15	08DEC2020	21515	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071527	C4591001 1007 10071527	12-15	08DEC2020	21514	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10071528	C4591001 1007 10071528	12-15	09DEC2020	21521	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10071529	C4591001 1007 10071529	12-15	09DEC2020	21524	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071530	C4591001 1007 10071530	12-15	09DEC2020	21589	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071531	C4591001 1007 10071531	12-15	09DEC2020	21590	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10071533	C4591001 1007 10071533	12-15	09DEC2020	21591	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10071535	C4591001 1007 10071535	12-15	09DEC2020	21596	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071536	C4591001 1007 10071536	12-15	09DEC2020	21681	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071537	C4591001 1007 10071537	12-15	09DEC2020	21683	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071539	C4591001 1007 10071539	12-15	09DEC2020	21689	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10071540	C4591001 1007 10071540	12-15	09DEC2020	21685	Placebo	09DEC2020	Placebo	30DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071541	C4591001 1007 10071541	12-15	09DEC2020	21767	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10071542	C4591001 1007 10071542	12-15	09DEC2020	21769	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071543	C4591001 1007 10071543	12-15	09DEC2020	21771	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10071544	C4591001 1007 10071544	12-15	09DEC2020	21773	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071546	C4591001 1007 10071546	12-15	10DEC2020	21827	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071547	C4591001 1007 10071547	12-15	10DEC2020	21830	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10071550	C4591001 1007 10071550	12-15	10DEC2020	21832	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071551	C4591001 1007 10071551	12-15	10DEC2020	21835	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10071552	C4591001 1007 10071552	12-15	10DEC2020	21976	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10071554	C4591001 1007 10071554	12-15	10DEC2020	21977	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10071555	C4591001 1007 10071555	12-15	10DEC2020	21979	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071557	C4591001 1007 10071557	12-15	14DEC2020	21980	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10071558	C4591001 1007 10071558	12-15	14DEC2020	22284	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10071559	C4591001 1007 10071559	12-15	14DEC2020	22285	Placebo	14DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071560	C4591001 1007 10071560	12-15	14DEC2020	22286	Placebo	14DEC2020	Placebo	05JAN2021	Placebo
10071561	C4591001 1007 10071561	12-15	14DEC2020	22288	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10071562	C4591001 1007 10071562	12-15	14DEC2020	22385	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10071563	C4591001 1007 10071563	12-15	14DEC2020	22386	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10071564	C4591001 1007 10071564	12-15	14DEC2020	22387	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071565	C4591001 1007 10071565	12-15	14DEC2020	22388	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071566	C4591001 1007 10071566	12-15	14DEC2020	22402	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10071567	C4591001 1007 10071567	12-15	15DEC2020	22407	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10071568	C4591001 1007 10071568	12-15	15DEC2020	22409	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10071569	C4591001 1007 10071569	12-15	15DEC2020	22411	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10071570	C4591001 1007 10071570	12-15	15DEC2020	22521	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10071571	C4591001 1007 10071571	12-15	15DEC2020	22528	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071572	C4591001 1007 10071572	12-15	15DEC2020	22529	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10071573	C4591001 1007 10071573	12-15	15DEC2020	22532	Placebo	15DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071574	C4591001 1007 10071574	12-15	16DEC2020	22727	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071575	C4591001 1007 10071575	12-15	16DEC2020	22728	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071576	C4591001 1007 10071576	12-15	16DEC2020	22733	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10071577	C4591001 1007 10071577	12-15	16DEC2020	22918	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10071578	C4591001 1007 10071578	12-15	16DEC2020	22736	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10071579	C4591001 1007 10071579	12-15	16DEC2020	22920	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071580	C4591001 1007 10071580	12-15	16DEC2020	22921	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10071581	C4591001 1007 10071581	12-15	17DEC2020	22928	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10071582	C4591001 1007 10071582	12-15	17DEC2020	23087	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10071583	C4591001 1007 10071583	12-15	17DEC2020	23146	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10071584	C4591001 1007 10071584	12-15	17DEC2020	23091	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10071585	C4591001 1007 10071585	12-15	17DEC2020	23094	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10071586	C4591001 1007 10071586	12-15	17DEC2020	23096	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10071587	C4591001 1007 10071587	12-15	17DEC2020	23148	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071588	C4591001 1007 10071588	12-15	28DEC2020	23151	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071589	C4591001 1007 10071589	12-15	28DEC2020	23155	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10071590	C4591001 1007 10071590	12-15	28DEC2020	24372	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071591	C4591001 1007 10071591	12-15	28DEC2020	24378	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10071592	C4591001 1007 10071592	12-15	28DEC2020	24377	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071593	C4591001 1007 10071593	12-15	28DEC2020	24380	Placebo	28DEC2020	Placebo		
10071594	C4591001 1007 10071594	12-15	28DEC2020	24453	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071595	C4591001 1007 10071595	12-15	28DEC2020	24454	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10071596	C4591001 1007 10071596	12-15	28DEC2020	24456	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
10071597	C4591001 1007 10071597	12-15	28DEC2020	24460	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071599	C4591001 1007 10071599	12-15	28DEC2020	24478	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071600	C4591001 1007 10071600	12-15	28DEC2020	24479	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10071601	C4591001 1007 10071601	12-15	28DEC2020	24481	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10071602	C4591001 1007 10071602	12-15	28DEC2020	24483	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071603	C4591001 1007 10071603	12-15	29DEC2020	24539	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071604	C4591001 1007 10071604	12-15	29DEC2020	24538	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071605	C4591001 1007 10071605	12-15	29DEC2020	24544	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071606	C4591001 1007 10071606	12-15	29DEC2020	24545	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071607	C4591001 1007 10071607	12-15	29DEC2020	24683	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071608	C4591001 1007 10071608	12-15	29DEC2020	24684	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071609	C4591001 1007 10071609	12-15	29DEC2020	24685	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071610	C4591001 1007 10071610	12-15	29DEC2020	24730	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10071612	C4591001 1007 10071612	12-15	29DEC2020	24692	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071613	C4591001 1007 10071613	12-15	29DEC2020	24732	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071614	C4591001 1007 10071614	12-15	29DEC2020	24734	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071615	C4591001 1007 10071615	12-15	29DEC2020	24740	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071616	C4591001 1007 10071616	12-15	29DEC2020	24777	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10071617	C4591001 1007 10071617	12-15	29DEC2020	24781	Placebo	29DEC2020	Placebo	20JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071618	C4591001 1007 10071618	12-15	29DEC2020	24784	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10071619	C4591001 1007 10071619	12-15	30DEC2020	24785	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071620	C4591001 1007 10071620	12-15	30DEC2020	24828	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071621	C4591001 1007 10071621	12-15	30DEC2020	24830	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10071622	C4591001 1007 10071622	12-15	30DEC2020	24831	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)		
10071623	C4591001 1007 10071623	12-15	30DEC2020	24832	Placebo	30DEC2020	Placebo	21JAN2021	Placebo
10071624	C4591001 1007 10071624	12-15	30DEC2020	24910	Placebo	30DEC2020	Placebo	26JAN2021	Placebo
10071625	C4591001 1007 10071625	12-15	30DEC2020	24915	Placebo	30DEC2020	Placebo	26JAN2021	Placebo
10071626	C4591001 1007 10071626	12-15	30DEC2020	24917	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071627	C4591001 1007 10071627	12-15	30DEC2020	24919	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071628	C4591001 1007 10071628	12-15	30DEC2020	24997	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10071629	C4591001 1007 10071629	12-15	30DEC2020	24994	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10071630	C4591001 1007 10071630	12-15	30DEC2020	24993	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10071631	C4591001 1007 10071631	12-15	30DEC2020	25003	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071632	C4591001 1007 10071632	12-15	30DEC2020	25062	Placebo	30DEC2020	Placebo	21JAN2021	Placebo
10071633	C4591001 1007 10071633	12-15	30DEC2020	25058	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10071634	C4591001 1007 10071634	12-15	04JAN2021	25064	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10071635	C4591001 1007 10071635	12-15	04JAN2021	25063	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10071636	C4591001 1007 10071636	12-15	04JAN2021	25149	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10071638	C4591001 1007 10071638	12-15	04JAN2021	25153	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10071639	C4591001 1007 10071639	12-15	04JAN2021	25154	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10071640	C4591001 1007 10071640	12-15	04JAN2021	25156	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10071641	C4591001 1007 10071641	12-15	04JAN2021	25202	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10071642	C4591001 1007 10071642	12-15	04JAN2021	25205	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)		
10071643	C4591001 1007 10071643	12-15	04JAN2021	25204	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10071644	C4591001 1007 10071644	12-15	04JAN2021	25294	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10071645	C4591001 1007 10071645	12-15	04JAN2021	25208	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10071646	C4591001 1007 10071646	12-15	04JAN2021	25299	Placebo	04JAN2021	Placebo	25JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10071647	C4591001 1007 10071647	12-15	04JAN2021	25302	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10071648	C4591001 1007 10071648	12-15	05JAN2021	25304	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	
10071649	C4591001 1007 10071649	12-15	05JAN2021	25369	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10071650	C4591001 1007 10071650	12-15	05JAN2021	25370	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	
10071651	C4591001 1007 10071651	12-15	05JAN2021	25373	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10071652	C4591001 1007 10071652	12-15	05JAN2021	25376	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	
10071653	C4591001 1007 10071653	12-15	05JAN2021	25437	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10071654	C4591001 1007 10071654	12-15	05JAN2021	25443	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	
10071655	C4591001 1007 10071655	12-15	06JAN2021	25445	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10071656	C4591001 1007 10071656	12-15	06JAN2021	25448	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10071658	C4591001 1007 10071658	12-15	06JAN2021	25838	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10071659	C4591001 1007 10071659	12-15	06JAN2021	25834	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10071660	C4591001 1007 10071660	12-15	06JAN2021	25833	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10071661	C4591001 1007 10071661	12-15	07JAN2021	25840	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071662	C4591001 1007 10071662	12-15	07JAN2021	26061	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
10081751	C4591001 1008 10081751	12-15	01DEC2020	20520	Placebo	01DEC2020	Placebo	23DEC2020	Placebo
10081752	C4591001 1008 10081752	12-15	01DEC2020	20525	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10081753	C4591001 1008 10081753	12-15	01DEC2020	20521	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10081754	C4591001 1008 10081754	12-15	02DEC2020	20527	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10081755	C4591001 1008 10081755	12-15	02DEC2020	20702	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10081756	C4591001 1008 10081756	12-15	02DEC2020	20704	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10081757	C4591001 1008 10081757	12-15	02DEC2020	20705	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10081758	C4591001 1008 10081758	12-15	02DEC2020	20707	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10081760	C4591001 1008 10081760	12-15	07DEC2020	21257	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10081761	C4591001 1008 10081761	12-15	07DEC2020	21256	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10081763	C4591001 1008 10081763	12-15	07DEC2020	21260	Placebo	07DEC2020	Placebo	30DEC2020	Placebo
10081764	C4591001 1008 10081764	12-15	07DEC2020	21258	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10081767	C4591001 1008 10081767	12-15	08DEC2020	21468	Placebo	08DEC2020	Placebo	29DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081768	C4591001 1008 10081768	12-15	08DEC2020	21469	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10081769	C4591001 1008 10081769	12-15	08DEC2020	21475	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10081770	C4591001 1008 10081770	12-15	09DEC2020	21476	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10081771	C4591001 1008 10081771	12-15	09DEC2020	21662	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10081773	C4591001 1008 10081773	12-15	09DEC2020	21664	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10081774	C4591001 1008 10081774	12-15	09DEC2020	21668	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10081775	C4591001 1008 10081775	12-15	09DEC2020	21667	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10081777	C4591001 1008 10081777	12-15	10DEC2020	21873	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10081780	C4591001 1008 10081780	12-15	10DEC2020	21875	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10081781	C4591001 1008 10081781	12-15	10DEC2020	21878	Placebo	10DEC2020	Placebo	31DEC2020	Placebo
10081785	C4591001 1008 10081785	12-15	11DEC2020	21880	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10081788	C4591001 1008 10081788	12-15	14DEC2020	22317	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10081789	C4591001 1008 10081789	12-15	14DEC2020	22321	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10081790	C4591001 1008 10081790	12-15	14DEC2020	22322	Placebo	14DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081791	C4591001 1008 10081791	12-15	14DEC2020	22357	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10081792	C4591001 1008 10081792	12-15	14DEC2020	22323	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10081793	C4591001 1008 10081793	12-15	14DEC2020	22359	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10081794	C4591001 1008 10081794	12-15	14DEC2020	22358	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10081795	C4591001 1008 10081795	12-15	15DEC2020	22363	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10081796	C4591001 1008 10081796	12-15	15DEC2020	22570	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10081797	C4591001 1008 10081797	12-15	15DEC2020	22574	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10081798	C4591001 1008 10081798	12-15	15DEC2020	22575	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10081799	C4591001 1008 10081799	12-15	15DEC2020	22577	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10081800	C4591001 1008 10081800	12-15	16DEC2020	22775	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10081801	C4591001 1008 10081801	12-15	17DEC2020	22776	Placebo	17DEC2020	Placebo	08JAN2021	Placebo
10081802	C4591001 1008 10081802	12-15	17DEC2020	22780	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10081803	C4591001 1008 10081803	12-15	17DEC2020	22783	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10081804	C4591001 1008 10081804	12-15	17DEC2020	23122	Placebo	17DEC2020	Placebo	07JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081805	C4591001 1008 10081805	12-15	17DEC2020	23123	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10081806	C4591001 1008 10081806	12-15	17DEC2020	23127	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10081807	C4591001 1008 10081807	12-15	18DEC2020	23129	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10081808	C4591001 1008 10081808	12-15	18DEC2020	23301	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10081809	C4591001 1008 10081809	12-15	18DEC2020	23306	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10081810	C4591001 1008 10081810	12-15	18DEC2020	23307	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10081811	C4591001 1008 10081811	12-15	18DEC2020	23308	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10081812	C4591001 1008 10081812	12-15	18DEC2020	23385	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10081813	C4591001 1008 10081813	12-15	18DEC2020	23392	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10081814	C4591001 1008 10081814	12-15	18DEC2020	23394	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10081815	C4591001 1008 10081815	12-15	18DEC2020	23396	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10081816	C4591001 1008 10081816	12-15	18DEC2020	23412	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10081817	C4591001 1008 10081817	12-15	18DEC2020	23413	Placebo	18DEC2020	Placebo	06JAN2021	Placebo
10081818	C4591001 1008 10081818	12-15	18DEC2020	23415	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081819	C4591001 1008 10081819	12-15	21DEC2020	23418	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10081820	C4591001 1008 10081820	12-15	21DEC2020	23629	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10081821	C4591001 1008 10081821	12-15	21DEC2020	23634	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10081822	C4591001 1008 10081822	12-15	21DEC2020	23635	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10081823	C4591001 1008 10081823	12-15	21DEC2020	23636	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10081824	C4591001 1008 10081824	12-15	21DEC2020	23654	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10081825	C4591001 1008 10081825	12-15	21DEC2020	23656	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10081826	C4591001 1008 10081826	12-15	21DEC2020	23659	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10081827	C4591001 1008 10081827	12-15	21DEC2020	23821	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10081828	C4591001 1008 10081828	12-15	21DEC2020	23660	Placebo	21DEC2020	Placebo	22JAN2021	Placebo
10081829	C4591001 1008 10081829	12-15	22DEC2020	23824	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10081830	C4591001 1008 10081830	12-15	22DEC2020	23825	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10081831	C4591001 1008 10081831	12-15	22DEC2020	23827	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10081832	C4591001 1008 10081832	12-15	22DEC2020	23986	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081833	C4591001 1008 10081833	12-15	22DEC2020	23988	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10081834	C4591001 1008 10081834	12-15	22DEC2020	23991	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10081835	C4591001 1008 10081835	12-15	22DEC2020	23993	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10081836	C4591001 1008 10081836	12-15	22DEC2020	24088	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10081837	C4591001 1008 10081837	12-15	22DEC2020	24089	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10081838	C4591001 1008 10081838	12-15	22DEC2020	24090	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10081839	C4591001 1008 10081839	12-15	22DEC2020	24091	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10081840	C4591001 1008 10081840	12-15	23DEC2020	24193	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
10081841	C4591001 1008 10081841	12-15	23DEC2020	24195	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10081842	C4591001 1008 10081842	12-15	23DEC2020	24196	Placebo	23DEC2020	Placebo	12JAN2021	Placebo
10081843	C4591001 1008 10081843	12-15	23DEC2020	24198	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10081844	C4591001 1008 10081844	12-15	23DEC2020	24201	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
10081845	C4591001 1008 10081845	12-15	23DEC2020	24207	Placebo	23DEC2020	Placebo	11JAN2021	Placebo
10081846	C4591001 1008 10081846	12-15	23DEC2020	24212	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081847	C4591001 1008 10081847	12-15	23DEC2020	24206	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10081848	C4591001 1008 10081848	12-15	23DEC2020	24216	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
10081849	C4591001 1008 10081849	12-15	23DEC2020	24219	Placebo	23DEC2020	Placebo	14JAN2021	Placebo
10081850	C4591001 1008 10081850	12-15	23DEC2020	24221	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
10081851	C4591001 1008 10081851	12-15	23DEC2020	24222	Placebo	23DEC2020	Placebo	15JAN2021	Placebo
10081852	C4591001 1008 10081852	12-15	23DEC2020	24249	Placebo	23DEC2020	Placebo	15JAN2021	Placebo
10081853	C4591001 1008 10081853	12-15	28DEC2020	24250	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
10081854	C4591001 1008 10081854	12-15	28DEC2020	24253	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10081855	C4591001 1008 10081855	12-15	28DEC2020	24257	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10081856	C4591001 1008 10081856	12-15	28DEC2020	24395	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
10081857	C4591001 1008 10081857	12-15	28DEC2020	24396	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10081858	C4591001 1008 10081858	12-15	28DEC2020	24397	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10081859	C4591001 1008 10081859	12-15	28DEC2020	24402	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10081860	C4591001 1008 10081860	12-15	28DEC2020	24465	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081861	C4591001 1008 10081861	12-15	29DEC2020	24469	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
10081862	C4591001 1008 10081862	12-15	29DEC2020	24471	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10081863	C4591001 1008 10081863	12-15	29DEC2020	24472	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
10081864	C4591001 1008 10081864	12-15	29DEC2020	24639	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10081865	C4591001 1008 10081865	12-15	29DEC2020	24641	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10081866	C4591001 1008 10081866	12-15	29DEC2020	24644	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
10081867	C4591001 1008 10081867	12-15	29DEC2020	24642	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
10081868	C4591001 1008 10081868	12-15	29DEC2020	24765	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10081869	C4591001 1008 10081869	12-15	29DEC2020	24766	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10081870	C4591001 1008 10081870	12-15	29DEC2020	24775	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10081871	C4591001 1008 10081871	12-15	30DEC2020	24776	Placebo	30DEC2020	Placebo		
10081872	C4591001 1008 10081872	12-15	30DEC2020	24885	Placebo	30DEC2020	Placebo	22JAN2021	Placebo
10081873	C4591001 1008 10081873	12-15	30DEC2020	24891	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10081874	C4591001 1008 10081874	12-15	30DEC2020	24895	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081875	C4591001 1008 10081875	12-15	30DEC2020	24893	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10081876	C4591001 1008 10081876	12-15	30DEC2020	24982	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10081877	C4591001 1008 10081877	12-15	30DEC2020	24983	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10081878	C4591001 1008 10081878	12-15	30DEC2020	24984	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10081879	C4591001 1008 10081879	12-15	30DEC2020	24989	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10081880	C4591001 1008 10081880	12-15	30DEC2020	25011	Placebo	30DEC2020	Placebo	19JAN2021	Placebo
10081881	C4591001 1008 10081881	12-15	30DEC2020	25009	Placebo	30DEC2020	Placebo	19JAN2021	Placebo
10081882	C4591001 1008 10081882	12-15	31DEC2020	25012	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10081883	C4591001 1008 10081883	12-15	31DEC2020	25016	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10081884	C4591001 1008 10081884	12-15	31DEC2020	25114	Placebo	31DEC2020	Placebo		
10081885	C4591001 1008 10081885	12-15	31DEC2020	25116	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10081886	C4591001 1008 10081886	12-15	31DEC2020	25115	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10081887	C4591001 1008 10081887	12-15	04JAN2021	25121	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10081888	C4591001 1008 10081888	12-15	04JAN2021	25161	Placebo	04JAN2021	Placebo	25JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10081889	C4591001 1008 10081889	12-15	04JAN2021	25163	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10081890	C4591001 1008 10081890	12-15	04JAN2021	25164	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10081891	C4591001 1008 10081891	12-15	04JAN2021	25172	Placebo	04JAN2021	Placebo	25JAN2021	Placebo	
10081892	C4591001 1008 10081892	12-15	04JAN2021	25245	Placebo	04JAN2021	Placebo	25JAN2021	Placebo	
10081893	C4591001 1008 10081893	12-15	04JAN2021	25248	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10081894	C4591001 1008 10081894	12-15	04JAN2021	25250	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10081895	C4591001 1008 10081895	12-15	04JAN2021	25269	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10081896	C4591001 1008 10081896	12-15	04JAN2021	25256	Placebo	04JAN2021	Placebo	25JAN2021	Placebo	
10081897	C4591001 1008 10081897	12-15	05JAN2021	25273	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10081898	C4591001 1008 10081898	12-15	05JAN2021	25279	Placebo	05JAN2021	Placebo	25JAN2021	Placebo	
10081899	C4591001 1008 10081899	12-15	05JAN2021	25274	Placebo	05JAN2021	Placebo	25JAN2021	Placebo	
10081900	C4591001 1008 10081900	12-15	05JAN2021	25509	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10081901	C4591001 1008 10081901	12-15	05JAN2021	25516	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	
10081902	C4591001 1008 10081902	12-15	05JAN2021	25518	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081903	C4591001 1008 10081903	12-15	05JAN2021	25520	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10081904	C4591001 1008 10081904	12-15	05JAN2021	25549	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
10081905	C4591001 1008 10081905	12-15	06JAN2021	25552	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10081906	C4591001 1008 10081906	12-15	06JAN2021	25555	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10081907	C4591001 1008 10081907	12-15	06JAN2021	25556	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
10081908	C4591001 1008 10081908	12-15	06JAN2021	25689	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10081909	C4591001 1008 10081909	12-15	06JAN2021	25690	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
10081910	C4591001 1008 10081910	12-15	06JAN2021	25691	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10081911	C4591001 1008 10081911	12-15	06JAN2021	25695	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
10081912	C4591001 1008 10081912	12-15	06JAN2021	25818	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10081913	C4591001 1008 10081913	12-15	06JAN2021	25816	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
10081914	C4591001 1008 10081914	12-15	06JAN2021	25817	Placebo	06JAN2021	Placebo	12FEB2021	Placebo
10081915	C4591001 1008 10081915	12-15	07JAN2021	25820	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10081916	C4591001 1008 10081916	12-15	07JAN2021	25929	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081917	C4591001 1008 10081917	12-15	07JAN2021	25931	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
10081918	C4591001 1008 10081918	12-15	07JAN2021	25933	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10081919	C4591001 1008 10081919	12-15	07JAN2021	25937	Placebo	07JAN2021	Placebo	29JAN2021	Placebo
10081920	C4591001 1008 10081920	12-15	07JAN2021	26085	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10081921	C4591001 1008 10081921	12-15	07JAN2021	26087	Placebo	07JAN2021	Placebo	29JAN2021	Placebo
10081922	C4591001 1008 10081922	12-15	08JAN2021	26089	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10081923	C4591001 1008 10081923	12-15	08JAN2021	26091	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10081924	C4591001 1008 10081924	12-15	08JAN2021	26205	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10081925	C4591001 1008 10081925	12-15	08JAN2021	26209	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10081926	C4591001 1008 10081926	12-15	08JAN2021	26216	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10081927	C4591001 1008 10081927	12-15	08JAN2021	26211	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10081928	C4591001 1008 10081928	12-15	08JAN2021	26362	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10081929	C4591001 1008 10081929	12-15	08JAN2021	26366	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10081930	C4591001 1008 10081930	12-15	11JAN2021	26368	Placebo	11JAN2021	Placebo	01FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081931	C4591001 1008 10081931	12-15	11JAN2021	26369	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10081932	C4591001 1008 10081932	12-15	11JAN2021	26579	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10081933	C4591001 1008 10081933	12-15	11JAN2021	26580	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10081934	C4591001 1008 10081934	12-15	11JAN2021	26587	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10081935	C4591001 1008 10081935	12-15	11JAN2021	26588	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10081936	C4591001 1008 10081936	12-15	11JAN2021	26687	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10081937	C4591001 1008 10081937	12-15	11JAN2021	26689	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10081938	C4591001 1008 10081938	12-15	11JAN2021	26690	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10081940	C4591001 1008 10081940	12-15	12JAN2021	26693	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10081941	C4591001 1008 10081941	12-15	12JAN2021	26877	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
10081942	C4591001 1008 10081942	12-15	12JAN2021	26879	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
10081943	C4591001 1008 10081943	12-15	12JAN2021	26880	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10091204	C4591001 1009 10091204	12-15	15OCT2020	20017	Placebo	15OCT2020	Placebo	03NOV2020	Placebo
10091205	C4591001 1009 10091205	12-15	15OCT2020	20018	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091208	C4591001 1009 10091208	12-15	15OCT2020	20020	Placebo	15OCT2020	Placebo	06NOV2020	Placebo
10091209	C4591001 1009 10091209	12-15	15OCT2020	20022	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
10091212	C4591001 1009 10091212	12-15	16OCT2020	20061	Placebo	16OCT2020	Placebo	16NOV2020	Placebo
10091213	C4591001 1009 10091213	12-15	16OCT2020	20062	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
10091216	C4591001 1009 10091216	12-15	16OCT2020	20067	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10091218	C4591001 1009 10091218	12-15	16OCT2020	20072	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10091220	C4591001 1009 10091220	12-15	19OCT2020	20133	Placebo	19OCT2020	Placebo	07NOV2020	Placebo
10091221	C4591001 1009 10091221	12-15	19OCT2020	20134	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)
10091223	C4591001 1009 10091223	12-15	19OCT2020	20139	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10091226	C4591001 1009 10091226	12-15	20OCT2020	20141	Placebo	20OCT2020	Placebo	09NOV2020	Placebo
10091227	C4591001 1009 10091227	12-15	20OCT2020	20207	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10091229	C4591001 1009 10091229	12-15	20OCT2020	20209	Placebo	20OCT2020	Placebo		
10091231	C4591001 1009 10091231	12-15	20OCT2020	20210	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10091233	C4591001 1009 10091233	12-15	21OCT2020	20211	Placebo	21OCT2020	Placebo	12NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091234	C4591001 1009 10091234	12-15	21OCT2020	20245	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10091237	C4591001 1009 10091237	12-15	21OCT2020	20246	Placebo	21OCT2020	Placebo	12NOV2020	Placebo
10091238	C4591001 1009 10091238	12-15	21OCT2020	20251	Placebo	21OCT2020	Placebo	10NOV2020	Placebo
10091240	C4591001 1009 10091240	12-15	21OCT2020	20252	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10091246	C4591001 1009 10091246	12-15	22OCT2020	20314	Placebo	22OCT2020	Placebo	10NOV2020	Placebo
10091247	C4591001 1009 10091247	12-15	22OCT2020	20316	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10091249	C4591001 1009 10091249	12-15	22OCT2020	20320	Placebo	22OCT2020	Placebo	13NOV2020	Placebo
10091250	C4591001 1009 10091250	12-15	22OCT2020	20323	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
10091265	C4591001 1009 10091265	12-15	01DEC2020	20505	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10091266	C4591001 1009 10091266	12-15	01DEC2020	20506	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
10091267	C4591001 1009 10091267	12-15	01DEC2020	20511	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10091269	C4591001 1009 10091269	12-15	01DEC2020	20514	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091270	C4591001 1009 10091270	12-15	01DEC2020	20629	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091272	C4591001 1009 10091272	12-15	02DEC2020	20631	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091273	C4591001 1009 10091273	12-15	02DEC2020	20633	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10091274	C4591001 1009 10091274	12-15	02DEC2020	20635	Placebo	02DEC2020	Placebo	28DEC2020	Placebo
10091275	C4591001 1009 10091275	12-15	02DEC2020	20786	Placebo	02DEC2020	Placebo	28DEC2020	Placebo
10091277	C4591001 1009 10091277	12-15	03DEC2020	20787	Placebo	03DEC2020	Placebo	30DEC2020	Placebo
10091280	C4591001 1009 10091280	12-15	03DEC2020	20789	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10091281	C4591001 1009 10091281	12-15	03DEC2020	20791	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10091282	C4591001 1009 10091282	12-15	03DEC2020	20914	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10091283	C4591001 1009 10091283	12-15	03DEC2020	20915	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
10091284	C4591001 1009 10091284	12-15	03DEC2020	20919	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091287	C4591001 1009 10091287	12-15	04DEC2020	20922	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091288	C4591001 1009 10091288	12-15	04DEC2020	21011	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091289	C4591001 1009 10091289	12-15	04DEC2020	21012	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091292	C4591001 1009 10091292	12-15	04DEC2020	21014	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10091293	C4591001 1009 10091293	12-15	04DEC2020	21015	Placebo	04DEC2020	Placebo	23DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091294	C4591001 1009 10091294	12-15	07DEC2020	21177	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10091295	C4591001 1009 10091295	12-15	07DEC2020	21178	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10091296	C4591001 1009 10091296	12-15	07DEC2020	21182	Placebo	07DEC2020	Placebo	29DEC2020	Placebo
10091297	C4591001 1009 10091297	12-15	07DEC2020	21188	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10091298	C4591001 1009 10091298	12-15	07DEC2020	21300	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10091300	C4591001 1009 10091300	12-15	07DEC2020	21302	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10091301	C4591001 1009 10091301	12-15	07DEC2020	21303	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10091303	C4591001 1009 10091303	12-15	08DEC2020	21304	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10091304	C4591001 1009 10091304	12-15	08DEC2020	21537	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10091305	C4591001 1009 10091305	12-15	08DEC2020	21543	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10091306	C4591001 1009 10091306	12-15	08DEC2020	21546	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10091307	C4591001 1009 10091307	12-15	09DEC2020	21547	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091308	C4591001 1009 10091308	12-15	09DEC2020	21650	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10091309	C4591001 1009 10091309	12-15	09DEC2020	21652	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091310	C4591001 1009 10091310	12-15	09DEC2020	21653	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10091311	C4591001 1009 10091311	12-15	09DEC2020	21655	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10091312	C4591001 1009 10091312	12-15	09DEC2020	21782	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10091313	C4591001 1009 10091313	12-15	09DEC2020	21778	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10091314	C4591001 1009 10091314	12-15	09DEC2020	21783	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10091315	C4591001 1009 10091315	12-15	09DEC2020	21785	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10091316	C4591001 1009 10091316	12-15	09DEC2020	21813	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10091317	C4591001 1009 10091317	12-15	10DEC2020	21814	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10091318	C4591001 1009 10091318	12-15	10DEC2020	21821	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10091319	C4591001 1009 10091319	12-15	10DEC2020	21823	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10091320	C4591001 1009 10091320	12-15	10DEC2020	21957	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10091321	C4591001 1009 10091321	12-15	10DEC2020	21958	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091322	C4591001 1009 10091322	12-15	10DEC2020	21959	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091323	C4591001 1009 10091323	12-15	10DEC2020	21964	Placebo	10DEC2020	Placebo	30DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091324	C4591001 1009 10091324	12-15	11DEC2020	22066	Placebo	11DEC2020	Placebo	31DEC2020	Placebo
10091325	C4591001 1009 10091325	12-15	11DEC2020	22067	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10091326	C4591001 1009 10091326	12-15	11DEC2020	22072	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10091328	C4591001 1009 10091328	12-15	11DEC2020	22075	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091329	C4591001 1009 10091329	12-15	11DEC2020	22149	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10091330	C4591001 1009 10091330	12-15	11DEC2020	22151	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10091331	C4591001 1009 10091331	12-15	11DEC2020	22157	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091332	C4591001 1009 10091332	12-15	11DEC2020	22160	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091333	C4591001 1009 10091333	12-15	11DEC2020	22198	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10091334	C4591001 1009 10091334	12-15	11DEC2020	22199	Placebo	11DEC2020	Placebo	31DEC2020	Placebo
10091335	C4591001 1009 10091335	12-15	11DEC2020	22200	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10091336	C4591001 1009 10091336	12-15	11DEC2020	22201	Placebo	11DEC2020	Placebo	31DEC2020	Placebo
10091337	C4591001 1009 10091337	12-15	14DEC2020	22329	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10091338	C4591001 1009 10091338	12-15	14DEC2020	22331	Placebo	14DEC2020	Placebo		

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091339	C4591001 1009 10091339	12-15	14DEC2020	22332	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10091340	C4591001 1009 10091340	12-15	14DEC2020	22339	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10091341	C4591001 1009 10091341	12-15	14DEC2020	22451	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10091342	C4591001 1009 10091342	12-15	14DEC2020	22452	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10091343	C4591001 1009 10091343	12-15	15DEC2020	22454	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10091344	C4591001 1009 10091344	12-15	15DEC2020	22458	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
10091345	C4591001 1009 10091345	12-15	15DEC2020	22618	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10091346	C4591001 1009 10091346	12-15	15DEC2020	22621	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10091347	C4591001 1009 10091347	12-15	15DEC2020	22625	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
10091348	C4591001 1009 10091348	12-15	15DEC2020	22626	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10091349	C4591001 1009 10091349	12-15	15DEC2020	22701	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
10091350	C4591001 1009 10091350	12-15	16DEC2020	22702	Placebo	16DEC2020	Placebo	07JAN2021	Placebo
10091351	C4591001 1009 10091351	12-15	16DEC2020	22706	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10091353	C4591001 1009 10091353	12-15	16DEC2020	22707	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091354	C4591001 1009 10091354	12-15	16DEC2020	22906	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10091355	C4591001 1009 10091355	12-15	16DEC2020	22907	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10091356	C4591001 1009 10091356	12-15	16DEC2020	22909	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
10091357	C4591001 1009 10091357	12-15	17DEC2020	22912	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10091358	C4591001 1009 10091358	12-15	17DEC2020	23001	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10091359	C4591001 1009 10091359	12-15	17DEC2020	23002	Placebo	17DEC2020	Placebo	06JAN2021	Placebo
10091360	C4591001 1009 10091360	12-15	17DEC2020	23003	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10091361	C4591001 1009 10091361	12-15	17DEC2020	23012	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10091362	C4591001 1009 10091362	12-15	17DEC2020	23181	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10091363	C4591001 1009 10091363	12-15	17DEC2020	23186	Placebo	17DEC2020	Placebo		
10091364	C4591001 1009 10091364	12-15	17DEC2020	23189	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10091365	C4591001 1009 10091365	12-15	17DEC2020	23191	Placebo	17DEC2020	Placebo	19JAN2021	Placebo
10091366	C4591001 1009 10091366	12-15	17DEC2020	23213	Placebo	17DEC2020	Placebo		
10091369	C4591001 1009 10091369	12-15	18DEC2020	23214	Placebo	18DEC2020	Placebo	08JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091370	C4591001 1009 10091370	12-15	18DEC2020	23215	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10091371	C4591001 1009 10091371	12-15	18DEC2020	23216	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10091372	C4591001 1009 10091372	12-15	18DEC2020	23435	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10091373	C4591001 1009 10091373	12-15	18DEC2020	23441	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10091374	C4591001 1009 10091374	12-15	21DEC2020	23442	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10091375	C4591001 1009 10091375	12-15	21DEC2020	23444	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10091376	C4591001 1009 10091376	12-15	21DEC2020	23805	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10091377	C4591001 1009 10091377	12-15	21DEC2020	23808	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10091378	C4591001 1009 10091378	12-15	21DEC2020	23812	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
10091379	C4591001 1009 10091379	12-15	22DEC2020	23814	Placebo	22DEC2020	Placebo	14JAN2021	Placebo
10091380	C4591001 1009 10091380	12-15	29DEC2020	24802	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10091381	C4591001 1009 10091381	12-15	31DEC2020	24806	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10091382	C4591001 1009 10091382	12-15	04JAN2021	24808	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10091383	C4591001 1009 10091383	12-15	05JAN2021	24810	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091384	C4591001 1009 10091384	12-15	05JAN2021	25498	Placebo	05JAN2021	Placebo	25JAN2021	Placebo
10091385	C4591001 1009 10091385	12-15	05JAN2021	25502	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
10091386	C4591001 1009 10091386	12-15	06JAN2021	25505	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10091387	C4591001 1009 10091387	12-15	06JAN2021	25506	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10091388	C4591001 1009 10091388	12-15	06JAN2021	25872	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
10091389	C4591001 1009 10091389	12-15	06JAN2021	25878	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10091390	C4591001 1009 10091390	12-15	07JAN2021	25879	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
10091391	C4591001 1009 10091391	12-15	07JAN2021	26073	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10091392	C4591001 1009 10091392	12-15	07JAN2021	26075	Placebo	07JAN2021	Placebo	29JAN2021	Placebo
10091393	C4591001 1009 10091393	12-15	07JAN2021	25880	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10091394	C4591001 1009 10091394	12-15	07JAN2021	26076	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10091395	C4591001 1009 10091395	12-15	07JAN2021	26079	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
10091396	C4591001 1009 10091396	12-15	07JAN2021	26113	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10091398	C4591001 1009 10091398	12-15	07JAN2021	26114	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091399	C4591001 1009 10091399	12-15	08JAN2021	26115	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10091400	C4591001 1009 10091400	12-15	08JAN2021	26119	Placebo	08JAN2021	Placebo	12FEB2021	Placebo
10091401	C4591001 1009 10091401	12-15	08JAN2021	26375	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10091402	C4591001 1009 10091402	12-15	08JAN2021	26377	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10091403	C4591001 1009 10091403	12-15	08JAN2021	26378	Placebo	08JAN2021	Placebo	27JAN2021	Placebo
10091404	C4591001 1009 10091404	12-15	08JAN2021	26380	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10091405	C4591001 1009 10091405	12-15	08JAN2021	26445	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10091406	C4591001 1009 10091406	12-15	08JAN2021	26447	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10091407	C4591001 1009 10091407	12-15	11JAN2021	26450	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10091408	C4591001 1009 10091408	12-15	11JAN2021	26453	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10091409	C4591001 1009 10091409	12-15	11JAN2021	26737	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10091410	C4591001 1009 10091410	12-15	12JAN2021	26740	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10091411	C4591001 1009 10091411	12-15	12JAN2021	26743	Placebo	12JAN2021	Placebo	01FEB2021	Placebo
10091412	C4591001 1009 10091412	12-15	12JAN2021	26744	Placebo	12JAN2021	Placebo	01FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091413	C4591001 1009 10091413	12-15	12JAN2021	26916	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10091414	C4591001 1009 10091414	12-15	12JAN2021	26920	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	04FEB2021	BNT162b2 (30 µg)
10131821	C4591001 1013 10131821	12-15	30NOV2020	20333	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10131822	C4591001 1013 10131822	12-15	30NOV2020	20332	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10131823	C4591001 1013 10131823	12-15	01DEC2020	20335	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10131824	C4591001 1013 10131824	12-15	01DEC2020	20554	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10131826	C4591001 1013 10131826	12-15	01DEC2020	20558	Placebo	01DEC2020	Placebo	23DEC2020	Placebo
10131828	C4591001 1013 10131828	12-15	02DEC2020	20559	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10131830	C4591001 1013 10131830	12-15	02DEC2020	20564	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
10131835	C4591001 1013 10131835	12-15	02DEC2020	20676	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10131836	C4591001 1013 10131836	12-15	02DEC2020	20681	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10131839	C4591001 1013 10131839	12-15	02DEC2020	20682	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
10131841	C4591001 1013 10131841	12-15	02DEC2020	20736	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10131842	C4591001 1013 10131842	12-15	02DEC2020	20738	Placebo	02DEC2020	Placebo	22DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131843	C4591001 1013 10131843	12-15	02DEC2020	20684	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10131844	C4591001 1013 10131844	12-15	02DEC2020	20743	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
10131845	C4591001 1013 10131845	12-15	03DEC2020	20744	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10131846	C4591001 1013 10131846	12-15	03DEC2020	20821	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10131848	C4591001 1013 10131848	12-15	03DEC2020	20825	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10131850	C4591001 1013 10131850	12-15	03DEC2020	20827	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10131851	C4591001 1013 10131851	12-15	07DEC2020	20828	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10131852	C4591001 1013 10131852	12-15	07DEC2020	21153	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10131855	C4591001 1013 10131855	12-15	08DEC2020	21154	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10131856	C4591001 1013 10131856	12-15	09DEC2020	21671	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10131858	C4591001 1013 10131858	12-15	09DEC2020	21164	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10131859	C4591001 1013 10131859	12-15	09DEC2020	21155	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10131860	C4591001 1013 10131860	12-15	09DEC2020	21673	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10131861	C4591001 1013 10131861	12-15	10DEC2020	21677	Placebo	10DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131862	C4591001 1013 10131862	12-15	10DEC2020	21678	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10131863	C4591001 1013 10131863	12-15	10DEC2020	21983	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10131865	C4591001 1013 10131865	12-15	14DEC2020	21987	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10131866	C4591001 1013 10131866	12-15	14DEC2020	21990	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10131867	C4591001 1013 10131867	12-15	17DEC2020	21992	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10131868	C4591001 1013 10131868	12-15	21DEC2020	23579	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
10131869	C4591001 1013 10131869	12-15	21DEC2020	117929	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
10131870	C4591001 1013 10131870	12-15	21DEC2020	23583	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
10131871	C4591001 1013 10131871	12-15	21DEC2020	23585	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10131872	C4591001 1013 10131872	12-15	21DEC2020	23586	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10131873	C4591001 1013 10131873	12-15	22DEC2020	24005	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10131874	C4591001 1013 10131874	12-15	22DEC2020	24002	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10131875	C4591001 1013 10131875	12-15	22DEC2020	24004	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10131876	C4591001 1013 10131876	12-15	22DEC2020	24008	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131877	C4591001 1013 10131877	12-15	23DEC2020	24167	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10131878	C4591001 1013 10131878	12-15	23DEC2020	24174	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
10131879	C4591001 1013 10131879	12-15	23DEC2020	24168	Placebo	23DEC2020	Placebo	11JAN2021	Placebo
10131880	C4591001 1013 10131880	12-15	23DEC2020	24173	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10131881	C4591001 1013 10131881	12-15	28DEC2020	24361	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10131882	C4591001 1013 10131882	12-15	30DEC2020	24365	Placebo	30DEC2020	Placebo	19JAN2021	Placebo
10131883	C4591001 1013 10131883	12-15	31DEC2020	24366	Placebo	31DEC2020	Placebo	21JAN2021	Placebo
10131884	C4591001 1013 10131884	12-15	07JAN2021	24368	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10131885	C4591001 1013 10131885	12-15	07JAN2021	25893	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
10131886	C4591001 1013 10131886	12-15	07JAN2021	25894	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
10161307	C4591001 1016 10161307	12-15	15OCT2020	20025	Placebo	15OCT2020	Placebo	04NOV2020	Placebo
10161308	C4591001 1016 10161308	12-15	15OCT2020	20032	Placebo	15OCT2020	Placebo	03NOV2020	Placebo
10161309	C4591001 1016 10161309	12-15	15OCT2020	20035	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10161310	C4591001 1016 10161310	12-15	15OCT2020	20036	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161311	C4591001 1016 10161311	12-15	15OCT2020	20052	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10161314	C4591001 1016 10161314	12-15	16OCT2020	20053	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
10161315	C4591001 1016 10161315	12-15	16OCT2020	20055	Placebo	16OCT2020	Placebo	06NOV2020	Placebo
10161316	C4591001 1016 10161316	12-15	16OCT2020	20058	Placebo	16OCT2020	Placebo		
10161318	C4591001 1016 10161318	12-15	16OCT2020	20099	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
10161319	C4591001 1016 10161319	12-15	16OCT2020	20103	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
10161320	C4591001 1016 10161320	12-15	21OCT2020	20176	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10161322	C4591001 1016 10161322	12-15	19OCT2020	20107	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10161323	C4591001 1016 10161323	12-15	19OCT2020	20108	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10161324	C4591001 1016 10161324	12-15	19OCT2020	20109	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
10161325	C4591001 1016 10161325	12-15	19OCT2020	20110	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10161326	C4591001 1016 10161326	12-15	20OCT2020	20114	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10161327	C4591001 1016 10161327	12-15	20OCT2020	20120	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
10161329	C4591001 1016 10161329	12-15	20OCT2020	20171	Placebo	20OCT2020	Placebo	10NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161330	C4591001 1016 10161330	12-15	20OCT2020	20174	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10161331	C4591001 1016 10161331	12-15	20OCT2020	20172	Placebo	20OCT2020	Placebo	11NOV2020	Placebo
10161332	C4591001 1016 10161332	12-15	21OCT2020	20229	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10161334	C4591001 1016 10161334	12-15	21OCT2020	20231	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10161335	C4591001 1016 10161335	12-15	21OCT2020	20240	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10161336	C4591001 1016 10161336	12-15	21OCT2020	20258	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10161337	C4591001 1016 10161337	12-15	21OCT2020	20236	Placebo	21OCT2020	Placebo	10NOV2020	Placebo
10161338	C4591001 1016 10161338	12-15	22OCT2020	20259	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10161339	C4591001 1016 10161339	12-15	22OCT2020	20262	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10161340	C4591001 1016 10161340	12-15	22OCT2020	20263	Placebo	22OCT2020	Placebo	10NOV2020	Placebo
10161343	C4591001 1016 10161343	12-15	22OCT2020	20301	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
10161344	C4591001 1016 10161344	12-15	22OCT2020	20306	Placebo	22OCT2020	Placebo	11NOV2020	Placebo
10161350	C4591001 1016 10161350	12-15	30NOV2020	20309	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10161351	C4591001 1016 10161351	12-15	30NOV2020	20308	Placebo	30NOV2020	Placebo	21DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161352	C4591001 1016 10161352	12-15	30NOV2020	20410	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10161353	C4591001 1016 10161353	12-15	30NOV2020	20411	Placebo	30NOV2020	Placebo	23DEC2020	Placebo
10161354	C4591001 1016 10161354	12-15	02DEC2020	20412	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10161356	C4591001 1016 10161356	12-15	02DEC2020	20416	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10161357	C4591001 1016 10161357	12-15	02DEC2020	20653	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10161358	C4591001 1016 10161358	12-15	03DEC2020	20657	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10161361	C4591001 1016 10161361	12-15	04DEC2020	20658	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10161362	C4591001 1016 10161362	12-15	04DEC2020	20659	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10161363	C4591001 1016 10161363	12-15	08DEC2020	21477	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10161364	C4591001 1016 10161364	12-15	09DEC2020	21478	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10161365	C4591001 1016 10161365	12-15	10DEC2020	21481	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10161366	C4591001 1016 10161366	12-15	15DEC2020	21488	Placebo	15DEC2020	Placebo	07JAN2021	Placebo
10161367	C4591001 1016 10161367	12-15	29DEC2020	24585	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10161368	C4591001 1016 10161368	12-15	30DEC2020	24589	Placebo	30DEC2020	Placebo	19JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161369	C4591001 1016 10161369	12-15	30DEC2020	24594	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10161370	C4591001 1016 10161370	12-15	04JAN2021	24595	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10161371	C4591001 1016 10161371	12-15	04JAN2021	25234	Placebo	04JAN2021	Placebo	26JAN2021	Placebo
10161372	C4591001 1016 10161372	12-15	05JAN2021	25237	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
10161373	C4591001 1016 10161373	12-15	05JAN2021	25238	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10161374	C4591001 1016 10161374	12-15	06JAN2021	25244	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10161375	C4591001 1016 10161375	12-15	06JAN2021	25790	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
10161376	C4591001 1016 10161376	12-15	07JAN2021	25795	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10161377	C4591001 1016 10161377	12-15	07JAN2021	25793	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10161378	C4591001 1016 10161378	12-15	07JAN2021	25796	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
10161379	C4591001 1016 10161379	12-15	07JAN2021	26104	Placebo	07JAN2021	Placebo		
10161381	C4591001 1016 10161381	12-15	08JAN2021	26105	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10161382	C4591001 1016 10161382	12-15	08JAN2021	26106	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10161383	C4591001 1016 10161383	12-15	08JAN2021	26107	Placebo	08JAN2021	Placebo	28JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161384	C4591001 1016 10161384	12-15	08JAN2021	26170	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10161385	C4591001 1016 10161385	12-15	08JAN2021	26172	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10161386	C4591001 1016 10161386	12-15	08JAN2021	26179	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
10161387	C4591001 1016 10161387	12-15	08JAN2021	26180	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10161388	C4591001 1016 10161388	12-15	11JAN2021	26698	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10391246	C4591001 1039 10391246	12-15	01DEC2020	20459	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
10391247	C4591001 1039 10391247	12-15	01DEC2020	20460	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10391250	C4591001 1039 10391250	12-15	04DEC2020	20465	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10391251	C4591001 1039 10391251	12-15	07DEC2020	20467	Placebo	07DEC2020	Placebo	04JAN2021	Placebo
10391252	C4591001 1039 10391252	12-15	07DEC2020	21109	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10391253	C4591001 1039 10391253	12-15	07DEC2020	21111	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10391255	C4591001 1039 10391255	12-15	07DEC2020	21112	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10391256	C4591001 1039 10391256	12-15	07DEC2020	21201	Placebo	07DEC2020	Placebo	29DEC2020	Placebo
10391258	C4591001 1039 10391258	12-15	07DEC2020	21113	Placebo	07DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391259	C4591001 1039 10391259	12-15	07DEC2020	21202	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10391260	C4591001 1039 10391260	12-15	07DEC2020	21209	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10391262	C4591001 1039 10391262	12-15	08DEC2020	21212	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10391263	C4591001 1039 10391263	12-15	08DEC2020	21357	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10391264	C4591001 1039 10391264	12-15	08DEC2020	21361	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10391265	C4591001 1039 10391265	12-15	08DEC2020	21364	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10391266	C4591001 1039 10391266	12-15	08DEC2020	21368	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10391267	C4591001 1039 10391267	12-15	08DEC2020	21434	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10391268	C4591001 1039 10391268	12-15	08DEC2020	21430	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10391269	C4591001 1039 10391269	12-15	08DEC2020	21431	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10391270	C4591001 1039 10391270	12-15	09DEC2020	21437	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10391271	C4591001 1039 10391271	12-15	09DEC2020	21721	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10391272	C4591001 1039 10391272	12-15	09DEC2020	21723	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10391273	C4591001 1039 10391273	12-15	09DEC2020	21717	Placebo	09DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391274	C4591001 1039 10391274	12-15	16DEC2020	22739	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
10391275	C4591001 1039 10391275	12-15	16DEC2020	21727	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10391276	C4591001 1039 10391276	12-15	16DEC2020	22740	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10391277	C4591001 1039 10391277	12-15	16DEC2020	22742	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10391278	C4591001 1039 10391278	12-15	16DEC2020	22747	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10391279	C4591001 1039 10391279	12-15	16DEC2020	22813	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10391280	C4591001 1039 10391280	12-15	17DEC2020	22814	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10391281	C4591001 1039 10391281	12-15	17DEC2020	22816	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10391282	C4591001 1039 10391282	12-15	18DEC2020	22818	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10391283	C4591001 1039 10391283	12-15	18DEC2020	23270	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
10391284	C4591001 1039 10391284	12-15	18DEC2020	23272	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10391285	C4591001 1039 10391285	12-15	18DEC2020	23275	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10391286	C4591001 1039 10391286	12-15	18DEC2020	23276	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10391287	C4591001 1039 10391287	12-15	18DEC2020	23326	Placebo	18DEC2020	Placebo	08JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391289	C4591001 1039 10391289	12-15	18DEC2020	23327	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10391290	C4591001 1039 10391290	12-15	18DEC2020	23328	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10391291	C4591001 1039 10391291	12-15	18DEC2020	23373	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10391292	C4591001 1039 10391292	12-15	18DEC2020	23332	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10391293	C4591001 1039 10391293	12-15	21DEC2020	23378	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10391294	C4591001 1039 10391294	12-15	21DEC2020	23381	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
10391295	C4591001 1039 10391295	12-15	29DEC2020	23384	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10391296	C4591001 1039 10391296	12-15	29DEC2020	24563	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10391297	C4591001 1039 10391297	12-15	29DEC2020	24564	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10391298	C4591001 1039 10391298	12-15	29DEC2020	24565	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10391299	C4591001 1039 10391299	12-15	29DEC2020	24568	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10391300	C4591001 1039 10391300	12-15	29DEC2020	24664	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10391301	C4591001 1039 10391301	12-15	29DEC2020	24665	Placebo	29DEC2020	Placebo	21JAN2021	Placebo
10391302	C4591001 1039 10391302	12-15	29DEC2020	24666	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391303	C4591001 1039 10391303	12-15	29DEC2020	24667	Placebo	29DEC2020	Placebo	21JAN2021	Placebo
10391304	C4591001 1039 10391304	12-15	29DEC2020	24754	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10391305	C4591001 1039 10391305	12-15	06JAN2021	24759	Placebo	06JAN2021	Placebo	25JAN2021	Placebo
10391306	C4591001 1039 10391306	12-15	06JAN2021	24762	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10391307	C4591001 1039 10391307	12-15	06JAN2021	24764	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
10391308	C4591001 1039 10391308	12-15	06JAN2021	25749	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10391309	C4591001 1039 10391309	12-15	07JAN2021	25752	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
10391310	C4591001 1039 10391310	12-15	07JAN2021	25759	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
10391311	C4591001 1039 10391311	12-15	07JAN2021	25918	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10391312	C4591001 1039 10391312	12-15	07JAN2021	25760	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10391313	C4591001 1039 10391313	12-15	07JAN2021	25920	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
10391314	C4591001 1039 10391314	12-15	07JAN2021	25921	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
10391315	C4591001 1039 10391315	12-15	07JAN2021	25924	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10391316	C4591001 1039 10391316	12-15	07JAN2021	26039	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391317	C4591001 1039 10391317	12-15	07JAN2021	26040	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
10391318	C4591001 1039 10391318	12-15	07JAN2021	26041	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10391319	C4591001 1039 10391319	12-15	08JAN2021	26042	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10391320	C4591001 1039 10391320	12-15	08JAN2021	26184	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10391321	C4591001 1039 10391321	12-15	08JAN2021	26182	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10391322	C4591001 1039 10391322	12-15	08JAN2021	26187	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10391323	C4591001 1039 10391323	12-15	08JAN2021	26191	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10391324	C4591001 1039 10391324	12-15	08JAN2021	26398	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10391325	C4591001 1039 10391325	12-15	11JAN2021	26403	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10391326	C4591001 1039 10391326	12-15	11JAN2021	26405	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10391327	C4591001 1039 10391327	12-15	11JAN2021	26408	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10391328	C4591001 1039 10391328	12-15	11JAN2021	26639	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10391329	C4591001 1039 10391329	12-15	11JAN2021	26644	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10391330	C4591001 1039 10391330	12-15	11JAN2021	26640	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391331	C4591001 1039 10391331	12-15	12JAN2021	26648	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10391332	C4591001 1039 10391332	12-15	12JAN2021	26769	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10391333	C4591001 1039 10391333	12-15	12JAN2021	26770	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
10391334	C4591001 1039 10391334	12-15	12JAN2021	26772	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
10391335	C4591001 1039 10391335	12-15	12JAN2021	26817	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10391336	C4591001 1039 10391336	12-15	12JAN2021	26780	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10391337	C4591001 1039 10391337	12-15	12JAN2021	26822	Placebo	12JAN2021	Placebo	03FEB2021	Placebo
10391338	C4591001 1039 10391338	12-15	12JAN2021	26823	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10391339	C4591001 1039 10391339	12-15	12JAN2021	26828	Placebo	12JAN2021	Placebo	03FEB2021	Placebo
10441251	C4591001 1044 10441251	12-15	30NOV2020	20354	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10441252	C4591001 1044 10441252	12-15	30NOV2020	20360	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10441253	C4591001 1044 10441253	12-15	30NOV2020	20439	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10441255	C4591001 1044 10441255	12-15	01DEC2020	20440	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10441256	C4591001 1044 10441256	12-15	01DEC2020	20444	Placebo	01DEC2020	Placebo	21DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441257	C4591001 1044 10441257	12-15	01DEC2020	20567	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10441259	C4591001 1044 10441259	12-15	01DEC2020	20569	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10441260	C4591001 1044 10441260	12-15	01DEC2020	20576	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10441261	C4591001 1044 10441261	12-15	01DEC2020	20618	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10441263	C4591001 1044 10441263	12-15	07DEC2020	20623	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10441264	C4591001 1044 10441264	12-15	07DEC2020	20624	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10441265	C4591001 1044 10441265	12-15	07DEC2020	21287	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10441266	C4591001 1044 10441266	12-15	08DEC2020	21289	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10441267	C4591001 1044 10441267	12-15	08DEC2020	21290	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10441268	C4591001 1044 10441268	12-15	08DEC2020	21294	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10441270	C4591001 1044 10441270	12-15	08DEC2020	21417	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10441271	C4591001 1044 10441271	12-15	08DEC2020	21420	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10441273	C4591001 1044 10441273	12-15	08DEC2020	21423	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10441274	C4591001 1044 10441274	12-15	08DEC2020	21428	Placebo	08DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441275	C4591001 1044 10441275	12-15	09DEC2020	21621	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10441276	C4591001 1044 10441276	12-15	09DEC2020	21623	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10441277	C4591001 1044 10441277	12-15	09DEC2020	21632	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10441278	C4591001 1044 10441278	12-15	09DEC2020	21631	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10441279	C4591001 1044 10441279	12-15	09DEC2020	21789	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10441280	C4591001 1044 10441280	12-15	09DEC2020	21792	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10441281	C4591001 1044 10441281	12-15	09DEC2020	21795	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10441282	C4591001 1044 10441282	12-15	09DEC2020	21799	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10441283	C4591001 1044 10441283	12-15	10DEC2020	21840	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10441284	C4591001 1044 10441284	12-15	10DEC2020	21843	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10441285	C4591001 1044 10441285	12-15	10DEC2020	21845	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10441286	C4591001 1044 10441286	12-15	11DEC2020	21848	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10441288	C4591001 1044 10441288	12-15	16DEC2020	22749	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10441289	C4591001 1044 10441289	12-15	16DEC2020	22751	Placebo	16DEC2020	Placebo	11JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441290	C4591001 1044 10441290	12-15	08JAN2021	26233	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441291	C4591001 1044 10441291	12-15	17DEC2020	22752	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10441292	C4591001 1044 10441292	12-15	17DEC2020	22759	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10441293	C4591001 1044 10441293	12-15	17DEC2020	23195	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10441294	C4591001 1044 10441294	12-15	17DEC2020	23196	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10441295	C4591001 1044 10441295	12-15	18DEC2020	23198	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10441296	C4591001 1044 10441296	12-15	22DEC2020	23202	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10441297	C4591001 1044 10441297	12-15	23DEC2020	24157	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10441298	C4591001 1044 10441298	12-15	23DEC2020	24160	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
10441299	C4591001 1044 10441299	12-15	28DEC2020	24161	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
10441300	C4591001 1044 10441300	12-15	28DEC2020	24163	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10441301	C4591001 1044 10441301	12-15	29DEC2020	24721	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10441302	C4591001 1044 10441302	12-15	29DEC2020	24723	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10441303	C4591001 1044 10441303	12-15	29DEC2020	24722	Placebo	29DEC2020	Placebo	19JAN2021	Placebo

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441304	C4591001 1044 10441304	12-15	29DEC2020	24728	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10441306	C4591001 1044 10441306	12-15	30DEC2020	24861	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10441307	C4591001 1044 10441307	12-15	30DEC2020	24863	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
10441308	C4591001 1044 10441308	12-15	30DEC2020	24869	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10441309	C4591001 1044 10441309	12-15	30DEC2020	24871	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10441310	C4591001 1044 10441310	12-15	30DEC2020	24958	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10441311	C4591001 1044 10441311	12-15	04JAN2021	24959	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10441312	C4591001 1044 10441312	12-15	04JAN2021	24966	Placebo	04JAN2021	Placebo	26JAN2021	Placebo
10441313	C4591001 1044 10441313	12-15	04JAN2021	24968	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10441314	C4591001 1044 10441314	12-15	04JAN2021	25210	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10441315	C4591001 1044 10441315	12-15	04JAN2021	25212	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10441316	C4591001 1044 10441316	12-15	04JAN2021	25213	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10441317	C4591001 1044 10441317	12-15	04JAN2021	25214	Placebo	04JAN2021	Placebo	27JAN2021	Placebo
10441318	C4591001 1044 10441318	12-15	05JAN2021	25392	Placebo	05JAN2021	Placebo	25JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10441319	C4591001 1044 10441319	12-15	05JAN2021	25394	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10441320	C4591001 1044 10441320	12-15	05JAN2021	25395	Placebo	05JAN2021	Placebo	26JAN2021	Placebo	
10441321	C4591001 1044 10441321	12-15	05JAN2021	25396	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10441322	C4591001 1044 10441322	12-15	05JAN2021	25521	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10441323	C4591001 1044 10441323	12-15	05JAN2021	25525	Placebo	05JAN2021	Placebo	28JAN2021	Placebo	
10441324	C4591001 1044 10441324	12-15	05JAN2021	25529	Placebo	05JAN2021	Placebo	25JAN2021	Placebo	
10441325	C4591001 1044 10441325	12-15	05JAN2021	25531	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10441326	C4591001 1044 10441326	12-15	06JAN2021	25645	Placebo	06JAN2021	Placebo	25JAN2021	Placebo	
10441327	C4591001 1044 10441327	12-15	06JAN2021	25647	Placebo	06JAN2021	Placebo	25JAN2021	Placebo	
10441328	C4591001 1044 10441328	12-15	06JAN2021	25648	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
10441329	C4591001 1044 10441329	12-15	06JAN2021	25652	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10441330	C4591001 1044 10441330	12-15	06JAN2021	25778	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10441331	C4591001 1044 10441331	12-15	06JAN2021	25780	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10441332	C4591001 1044 10441332	12-15	06JAN2021	25782	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441333	C4591001 1044 10441333	12-15	06JAN2021	25783	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10441334	C4591001 1044 10441334	12-15	07JAN2021	25905	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10441335	C4591001 1044 10441335	12-15	07JAN2021	25910	Placebo	07JAN2021	Placebo	29JAN2021	Placebo
10441336	C4591001 1044 10441336	12-15	07JAN2021	25913	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10441337	C4591001 1044 10441337	12-15	08JAN2021	25916	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10441338	C4591001 1044 10441338	12-15	08JAN2021	26229	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10441339	C4591001 1044 10441339	12-15	08JAN2021	26234	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441340	C4591001 1044 10441340	12-15	08JAN2021	26326	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10441341	C4591001 1044 10441341	12-15	08JAN2021	26235	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10441342	C4591001 1044 10441342	12-15	09JAN2021	26334	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10441343	C4591001 1044 10441343	12-15	09JAN2021	26335	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441344	C4591001 1044 10441344	12-15	09JAN2021	26336	Placebo	09JAN2021	Placebo	29JAN2021	Placebo
10441345	C4591001 1044 10441345	12-15	09JAN2021	26477	Placebo	09JAN2021	Placebo	28JAN2021	Placebo
10441346	C4591001 1044 10441346	12-15	09JAN2021	26470	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441347	C4591001 1044 10441347	12-15	09JAN2021	26478	Placebo	09JAN2021	Placebo	29JAN2021	Placebo
10441348	C4591001 1044 10441348	12-15	09JAN2021	26494	Placebo	09JAN2021	Placebo	28JAN2021	Placebo
10441349	C4591001 1044 10441349	12-15	09JAN2021	26479	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441350	C4591001 1044 10441350	12-15	09JAN2021	26500	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441351	C4591001 1044 10441351	12-15	10JAN2021	26502	Placebo	10JAN2021	Placebo	01FEB2021	Placebo
10441352	C4591001 1044 10441352	12-15	10JAN2021	26504	BNT162b2 (30 µg)	10JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441353	C4591001 1044 10441353	12-15	10JAN2021	26508	BNT162b2 (30 µg)	10JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10441354	C4591001 1044 10441354	12-15	10JAN2021	26509	Placebo	10JAN2021	Placebo	29JAN2021	Placebo
10441355	C4591001 1044 10441355	12-15	10JAN2021	26513	BNT162b2 (30 µg)	10JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10441356	C4591001 1044 10441356	12-15	10JAN2021	26514	Placebo	10JAN2021	Placebo	02FEB2021	Placebo
10441357	C4591001 1044 10441357	12-15	10JAN2021	26521	Placebo	10JAN2021	Placebo	29JAN2021	Placebo
10441358	C4591001 1044 10441358	12-15	10JAN2021	26522	BNT162b2 (30 µg)	10JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10441359	C4591001 1044 10441359	12-15	11JAN2021	26528	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	25FEB2021	BNT162b2 (30 µg)
10441360	C4591001 1044 10441360	12-15	11JAN2021	26524	Placebo	11JAN2021	Placebo	25FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441361	C4591001 1044 10441361	12-15	11JAN2021	26589	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10441362	C4591001 1044 10441362	12-15	11JAN2021	26593	Placebo	11JAN2021	Placebo	03FEB2021	Placebo
10441363	C4591001 1044 10441363	12-15	11JAN2021	26595	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10441364	C4591001 1044 10441364	12-15	11JAN2021	26596	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10441365	C4591001 1044 10441365	12-15	11JAN2021	26675	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10441366	C4591001 1044 10441366	12-15	11JAN2021	26676	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10441367	C4591001 1044 10441367	12-15	11JAN2021	26677	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10441368	C4591001 1044 10441368	12-15	11JAN2021	26678	Placebo	11JAN2021	Placebo	03FEB2021	Placebo
10441369	C4591001 1044 10441369	12-15	11JAN2021	26725	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10441370	C4591001 1044 10441370	12-15	11JAN2021	26729	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10441371	C4591001 1044 10441371	12-15	11JAN2021	26730	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10441372	C4591001 1044 10441372	12-15	11JAN2021	26731	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10441373	C4591001 1044 10441373	12-15	12JAN2021	26782	Placebo	12JAN2021	Placebo	04FEB2021	Placebo
10441374	C4591001 1044 10441374	12-15	12JAN2021	26784	Placebo	12JAN2021	Placebo	02FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441375	C4591001 1044 10441375	12-15	12JAN2021	26786	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10441376	C4591001 1044 10441376	12-15	12JAN2021	26792	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10441377	C4591001 1044 10441377	12-15	12JAN2021	26911	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)	22FEB2021	BNT162b2 (30 µg)
10441378	C4591001 1044 10441378	12-15	12JAN2021	26843	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	04FEB2021	BNT162b2 (30 µg)
10441379	C4591001 1044 10441379	12-15	12JAN2021	26845	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	04FEB2021	BNT162b2 (30 µg)
10441380	C4591001 1044 10441380	12-15	12JAN2021	26849	Placebo	12JAN2021	Placebo	03FEB2021	Placebo
10441381	C4591001 1044 10441381	12-15	12JAN2021	26851	Placebo	12JAN2021	Placebo	01FEB2021	Placebo
10441382	C4591001 1044 10441382	12-15	12JAN2021	26901	Placebo	12JAN2021	Placebo	03FEB2021	Placebo
10441383	C4591001 1044 10441383	12-15	12JAN2021	26902	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10441384	C4591001 1044 10441384	12-15	12JAN2021	26912	Placebo	12JAN2021	Placebo	04FEB2021	Placebo
10571376	C4591001 1057 10571376	12-15	07DEC2020	21117	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10571377	C4591001 1057 10571377	12-15	07DEC2020	21119	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10571378	C4591001 1057 10571378	12-15	07DEC2020	21122	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10571379	C4591001 1057 10571379	12-15	07DEC2020	21127	Placebo	07DEC2020	Placebo	30DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571380	C4591001 10571380	12-15	08DEC2020	21345	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10571382	C4591001 10571382	12-15	08DEC2020	21352	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10571383	C4591001 10571383	12-15	08DEC2020	21346	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
10571384	C4591001 10571384	12-15	08DEC2020	21348	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10571385	C4591001 10571385	12-15	08DEC2020	21504	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10571386	C4591001 10571386	12-15	08DEC2020	21508	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10571387	C4591001 10571387	12-15	09DEC2020	21509	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10571388	C4591001 10571388	12-15	09DEC2020	21512	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10571389	C4591001 10571389	12-15	09DEC2020	21705	Placebo	09DEC2020	Placebo	04JAN2021	Placebo
10571390	C4591001 10571390	12-15	09DEC2020	21706	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10571391	C4591001 10571391	12-15	09DEC2020	21711	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10571392	C4591001 10571392	12-15	09DEC2020	21712	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10571393	C4591001 10571393	12-15	09DEC2020	21754	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10571394	C4591001 10571394	12-15	09DEC2020	21756	Placebo	09DEC2020	Placebo	29DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571395	C4591001 10571395	12-15	09DEC2020	21757	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
10571396	C4591001 10571396	12-15	10DEC2020	21761	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10571397	C4591001 10571397	12-15	10DEC2020	21949	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10571398	C4591001 10571398	12-15	10DEC2020	21951	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10571399	C4591001 10571399	12-15	10DEC2020	21954	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10571400	C4591001 10571400	12-15	11DEC2020	21956	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10571401	C4591001 10571401	12-15	11DEC2020	22057	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10571402	C4591001 10571402	12-15	14DEC2020	22058	Placebo	14DEC2020	Placebo	06JAN2021	Placebo
10571403	C4591001 10571403	12-15	14DEC2020	22059	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10571404	C4591001 10571404	12-15	16DEC2020	22062	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
10571405	C4591001 10571405	12-15	16DEC2020	22896	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10571406	C4591001 10571406	12-15	16DEC2020	22901	Placebo	16DEC2020	Placebo	05JAN2021	Placebo
10571407	C4591001 10571407	12-15	17DEC2020	22903	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10571408	C4591001 10571408	12-15	17DEC2020	23052	Placebo	17DEC2020	Placebo	05JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571409	C4591001 1057 10571409	12-15	17DEC2020	22902	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10571410	C4591001 1057 10571410	12-15	17DEC2020	23056	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
10571411	C4591001 1057 10571411	12-15	17DEC2020	23059	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10571412	C4591001 1057 10571412	12-15	17DEC2020	23060	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10571413	C4591001 1057 10571413	12-15	21DEC2020	23709	BNT162b2 (30 µg)				
10571414	C4591001 1057 10571414	12-15	21DEC2020	23710	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
10571415	C4591001 1057 10571415	12-15	21DEC2020	23714	Placebo	21DEC2020	Placebo	14JAN2021	Placebo
10571416	C4591001 1057 10571416	12-15	21DEC2020	23716	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10571417	C4591001 1057 10571417	12-15	21DEC2020	23793	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10571418	C4591001 1057 10571418	12-15	22DEC2020	23800	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10571419	C4591001 1057 10571419	12-15	22DEC2020	23803	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10571420	C4591001 1057 10571420	12-15	23DEC2020	23804	Placebo	23DEC2020	Placebo	11JAN2021	Placebo
10571421	C4591001 1057 10571421	12-15	23DEC2020	24261	Placebo	23DEC2020	Placebo	11JAN2021	Placebo
10571422	C4591001 1057 10571422	12-15	23DEC2020	24265	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571423	C4591001 10571423	12-15	24DEC2020	24269	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)	15JAN2021	BNT162b2 (30 µg)
10571424	C4591001 10571424	12-15	24DEC2020	24271	Placebo	24DEC2020	Placebo	15JAN2021	Placebo
10571425	C4591001 10571425	12-15	24DEC2020	24301	Placebo	24DEC2020	Placebo	12JAN2021	Placebo
10571426	C4591001 10571426	12-15	24DEC2020	24305	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10571427	C4591001 10571427	12-15	24DEC2020	24306	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10571428	C4591001 10571428	12-15	24DEC2020	24307	Placebo	24DEC2020	Placebo	21JAN2021	Placebo
10571429	C4591001 10571429	12-15	24DEC2020	24309	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
10571430	C4591001 10571430	12-15	29DEC2020	24310	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10571431	C4591001 10571431	12-15	30DEC2020	24313	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
10571432	C4591001 10571432	12-15	30DEC2020	24314	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
10571433	C4591001 10571433	12-15	30DEC2020	25022	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	22JAN2021	BNT162b2 (30 µg)
10571434	C4591001 10571434	12-15	31DEC2020	25023	Placebo	31DEC2020	Placebo	21JAN2021	Placebo
10571435	C4591001 10571435	12-15	04JAN2021	25024	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10571436	C4591001 10571436	12-15	04JAN2021	25025	Placebo	04JAN2021	Placebo	25JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571437	C4591001 105710571437	12-15	04JAN2021	25257	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10571438	C4591001 105710571438	12-15	04JAN2021	25260	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
10571439	C4591001 105710571439	12-15	06JAN2021	25263	Placebo	06JAN2021	Placebo	25JAN2021	Placebo
10571440	C4591001 105710571440	12-15	06JAN2021	25264	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10571441	C4591001 105710571441	12-15	06JAN2021	25802	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
10571442	C4591001 105710571442	12-15	07JAN2021	25803	Placebo	07JAN2021	Placebo	29JAN2021	Placebo
10571443	C4591001 105710571443	12-15	08JAN2021	25806	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10571444	C4591001 105710571444	12-15	08JAN2021	25808	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10571445	C4591001 105710571445	12-15	11JAN2021	26531	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10571446	C4591001 105710571446	12-15	11JAN2021	26533	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10571447	C4591001 105710571447	12-15	11JAN2021	26537	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
10571448	C4591001 105710571448	12-15	11JAN2021	26539	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
10571449	C4591001 105710571449	12-15	12JAN2021	26799	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
10571450	C4591001 105710571450	12-15	12JAN2021	26801	Placebo	12JAN2021	Placebo	02FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571451	C4591001 1057 10571451	12-15	12JAN2021	26802	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10571452	C4591001 1057 10571452	12-15	12JAN2021	26804	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10571453	C4591001 1057 10571453	12-15	12JAN2021	26895	Placebo	12JAN2021	Placebo	01FEB2021	Placebo
10571454	C4591001 1057 10571454	12-15	12JAN2021	26891	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
10661394	C4591001 1066 10661394	12-15	09DEC2020	21555	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10661395	C4591001 1066 10661395	12-15	01DEC2020	20590	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10661397	C4591001 1066 10661397	12-15	01DEC2020	20591	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10661401	C4591001 1066 10661401	12-15	02DEC2020	20593	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
10661402	C4591001 1066 10661402	12-15	02DEC2020	20598	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10661403	C4591001 1066 10661403	12-15	03DEC2020	20829	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
10661404	C4591001 1066 10661404	12-15	03DEC2020	20834	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10661405	C4591001 1066 10661405	12-15	03DEC2020	20838	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10661407	C4591001 1066 10661407	12-15	04DEC2020	20840	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10661408	C4591001 1066 10661408	12-15	08DEC2020	21549	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10661409	C4591001 1066 10661409	12-15	08DEC2020	21550	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10661410	C4591001 1066 10661410	12-15	09DEC2020	21557	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10661411	C4591001 1066 10661411	12-15	09DEC2020	21801	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10661412	C4591001 1066 10661412	12-15	09DEC2020	21808	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10661414	C4591001 1066 10661414	12-15	14DEC2020	21812	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10661415	C4591001 1066 10661415	12-15	14DEC2020	21809	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10661416	C4591001 1066 10661416	12-15	15DEC2020	22668	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10661417	C4591001 1066 10661417	12-15	16DEC2020	22672	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10661418	C4591001 1066 10661418	12-15	16DEC2020	22674	Placebo	16DEC2020	Placebo	05JAN2021	Placebo
10661419	C4591001 1066 10661419	12-15	16DEC2020	22675	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10661420	C4591001 1066 10661420	12-15	17DEC2020	23169	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10661421	C4591001 1066 10661421	12-15	22DEC2020	23175	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10661422	C4591001 1066 10661422	12-15	22DEC2020	23176	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10661423	C4591001 1066 10661423	12-15	30DEC2020	23177	Placebo	30DEC2020	Placebo	26JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10661424	C4591001 1066 10661424	12-15	30DEC2020	24922	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10661425	C4591001 1066 10661425	12-15	05JAN2021	24924	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
10661426	C4591001 1066 10661426	12-15	06JAN2021	24926	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
10661427	C4591001 1066 10661427	12-15	06JAN2021	24930	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10661428	C4591001 1066 10661428	12-15	06JAN2021	25737	Placebo	06JAN2021	Placebo	26JAN2021	Placebo
10661429	C4591001 1066 10661429	12-15	06JAN2021	25738	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
10661430	C4591001 1066 10661430	12-15	07JAN2021	25740	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
10661431	C4591001 1066 10661431	12-15	07JAN2021	25745	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10661432	C4591001 1066 10661432	12-15	07JAN2021	25990	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
10661433	C4591001 1066 10661433	12-15	07JAN2021	25991	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
10661434	C4591001 1066 10661434	12-15	12JAN2021	25995	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10661435	C4591001 1066 10661435	12-15	12JAN2021	25998	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
10771274	C4591001 1077 10771274	12-15	03DEC2020	20843	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10771275	C4591001 1077 10771275	12-15	03DEC2020	20844	Placebo	03DEC2020	Placebo	22DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10771277	C4591001 1077 10771277	12-15	04DEC2020	20846	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10771278	C4591001 1077 10771278	12-15	04DEC2020	20852	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10771279	C4591001 1077 10771279	12-15	14DEC2020	22249	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10771280	C4591001 1077 10771280	12-15	14DEC2020	22250	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
10771281	C4591001 1077 10771281	12-15	14DEC2020	22251	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10771282	C4591001 1077 10771282	12-15	14DEC2020	22253	Placebo	14DEC2020	Placebo	05JAN2021	Placebo
10771283	C4591001 1077 10771283	12-15	15DEC2020	22476	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
10771284	C4591001 1077 10771284	12-15	15DEC2020	22478	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10771285	C4591001 1077 10771285	12-15	15DEC2020	22479	Placebo	15DEC2020	Placebo	07JAN2021	Placebo
10771286	C4591001 1077 10771286	12-15	15DEC2020	22483	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
10771287	C4591001 1077 10771287	12-15	15DEC2020	22545	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10771288	C4591001 1077 10771288	12-15	16DEC2020	22554	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10771289	C4591001 1077 10771289	12-15	18DEC2020	22555	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10771290	C4591001 1077 10771290	12-15	18DEC2020	22556	Placebo	18DEC2020	Placebo	08JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10771291	C4591001 1077 10771291	12-15	18DEC2020	23397	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10771292	C4591001 1077 10771292	12-15	18DEC2020	23398	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10771293	C4591001 1077 10771293	12-15	18DEC2020	23401	Placebo				
10771294	C4591001 1077 10771294	12-15	28DEC2020	23404	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
10771295	C4591001 1077 10771295	12-15	28DEC2020	24443	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
10771296	C4591001 1077 10771296	12-15	29DEC2020	24444	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
10771297	C4591001 1077 10771297	12-15	06JAN2021	24445	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10771298	C4591001 1077 10771298	12-15	07JAN2021	24446	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
10771299	C4591001 1077 10771299	12-15	07JAN2021	25979	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10771300	C4591001 1077 10771300	12-15	07JAN2021	25982	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10841541	C4591001 1084 10841541	12-15	11DEC2020	22033	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10841542	C4591001 1084 10841542	12-15	11DEC2020	22034	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10841543	C4591001 1084 10841543	12-15	18DEC2020	22037	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10841544	C4591001 1084 10841544	12-15	18DEC2020	22039	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10841545	C4591001 1084 10841545	12-15	18DEC2020	23459	Placebo	18DEC2020	Placebo	06JAN2021	Placebo
10841546	C4591001 1084 10841546	12-15	18DEC2020	23462	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10841547	C4591001 1084 10841547	12-15	21DEC2020	23463	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
10841548	C4591001 1084 10841548	12-15	21DEC2020	23465	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10841549	C4591001 1084 10841549	12-15	21DEC2020	23666	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10841550	C4591001 1084 10841550	12-15	21DEC2020	23669	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
10841551	C4591001 1084 10841551	12-15	21DEC2020	23670	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10841552	C4591001 1084 10841552	12-15	21DEC2020	23671	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10841553	C4591001 1084 10841553	12-15	21DEC2020	23853	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10841555	C4591001 1084 10841555	12-15	21DEC2020	23854	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10841556	C4591001 1084 10841556	12-15	28DEC2020	23862	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10841557	C4591001 1084 10841557	12-15	28DEC2020	23860	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
10841558	C4591001 1084 10841558	12-15	28DEC2020	24419	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10841559	C4591001 1084 10841559	12-15	28DEC2020	24423	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10841560	C4591001 1084 10841560	12-15	28DEC2020	24418	Placebo	28DEC2020	Placebo	22JAN2021	Placebo
10841561	C4591001 1084 10841561	12-15	28DEC2020	24428	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
10841562	C4591001 1084 10841562	12-15	28DEC2020	24492	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10841563	C4591001 1084 10841563	12-15	30DEC2020	24494	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10841564	C4591001 1084 10841564	12-15	30DEC2020	24497	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
10841565	C4591001 1084 10841565	12-15	30DEC2020	24499	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10841566	C4591001 1084 10841566	12-15	30DEC2020	24971	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10841567	C4591001 1084 10841567	12-15	30DEC2020	24972	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10841568	C4591001 1084 10841568	12-15	30DEC2020	24977	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
10841569	C4591001 1084 10841569	12-15	30DEC2020	24979	Placebo	30DEC2020	Placebo	22JAN2021	Placebo
10841570	C4591001 1084 10841570	12-15	30DEC2020	25066	Placebo	30DEC2020	Placebo	22JAN2021	Placebo
10841571	C4591001 1084 10841571	12-15	30DEC2020	25071	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
10841572	C4591001 1084 10841572	12-15	04JAN2021	116601	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
10841573	C4591001 1084 10841573	12-15	04JAN2021	25075	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10841574	C4591001 1084 10841574	12-15	04JAN2021	25076	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10841575	C4591001 1084 10841575	12-15	04JAN2021	25317	Placebo	04JAN2021	Placebo	27JAN2021	Placebo	
10841576	C4591001 1084 10841576	12-15	06JAN2021	25320	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
10841577	C4591001 1084 10841577	12-15	06JAN2021	25326	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10841578	C4591001 1084 10841578	12-15	06JAN2021	25327	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10841579	C4591001 1084 10841579	12-15	06JAN2021	25727	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10841580	C4591001 1084 10841580	12-15	06JAN2021	25728	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10841581	C4591001 1084 10841581	12-15	06JAN2021	25729	Placebo	06JAN2021	Placebo	27JAN2021	Placebo	
10841582	C4591001 1084 10841582	12-15	06JAN2021	25733	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10841583	C4591001 1084 10841583	12-15	08JAN2021	26194	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
10841584	C4591001 1084 10841584	12-15	08JAN2021	26195	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)	
10841586	C4591001 1084 10841586	12-15	08JAN2021	26196	Placebo	08JAN2021	Placebo	29JAN2021	Placebo	
10841587	C4591001 1084 10841587	12-15	08JAN2021	26202	Placebo	08JAN2021	Placebo	29JAN2021	Placebo	
10841588	C4591001 1084 10841588	12-15	08JAN2021	26278	Placebo	08JAN2021	Placebo	27JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10841589	C4591001 1084 10841589	12-15	08JAN2021	26277	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10841590	C4591001 1084 10841590	12-15	08JAN2021	26337	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10841591	C4591001 1084 10841591	12-15	08JAN2021	26286	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10841592	C4591001 1084 10841592	12-15	08JAN2021	26281	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10841593	C4591001 1084 10841593	12-15	08JAN2021	26341	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10841594	C4591001 1084 10841594	12-15	08JAN2021	26343	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
10841595	C4591001 1084 10841595	12-15	08JAN2021	26346	Placebo	08JAN2021	Placebo	27JAN2021	Placebo
10841596	C4591001 1084 10841596	12-15	08JAN2021	26414	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
10841597	C4591001 1084 10841597	12-15	08JAN2021	26417	Placebo	08JAN2021	Placebo	27JAN2021	Placebo
10911394	C4591001 1091 10911394	12-15	02DEC2020	117070	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10911395	C4591001 1091 10911395	12-15	02DEC2020	20579	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10911396	C4591001 1091 10911396	12-15	02DEC2020	20583	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
10911399	C4591001 1091 10911399	12-15	04DEC2020	20586	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10911400	C4591001 1091 10911400	12-15	04DEC2020	20962	Placebo	04DEC2020	Placebo	29DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911402	C4591001 1091 10911402	12-15	07DEC2020	20966	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10911403	C4591001 1091 10911403	12-15	07DEC2020	20967	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10911404	C4591001 1091 10911404	12-15	07DEC2020	20969	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10911405	C4591001 1091 10911405	12-15	07DEC2020	21240	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10911406	C4591001 1091 10911406	12-15	07DEC2020	21242	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10911407	C4591001 1091 10911407	12-15	08DEC2020	21243	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10911408	C4591001 1091 10911408	12-15	08DEC2020	21247	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10911409	C4591001 1091 10911409	12-15	09DEC2020	21611	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10911410	C4591001 1091 10911410	12-15	09DEC2020	21612	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10911411	C4591001 1091 10911411	12-15	09DEC2020	21613	Placebo	09DEC2020	Placebo	28DEC2020	Placebo
10911412	C4591001 1091 10911412	12-15	09DEC2020	21742	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10911413	C4591001 1091 10911413	12-15	09DEC2020	21617	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10911414	C4591001 1091 10911414	12-15	09DEC2020	21741	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)		
10911415	C4591001 1091 10911415	12-15	10DEC2020	21751	Placebo	10DEC2020	Placebo	29DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911416	C4591001 1091 10911416	12-15	10DEC2020	21890	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10911417	C4591001 1091 10911417	12-15	10DEC2020	21891	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10911418	C4591001 1091 10911418	12-15	10DEC2020	21752	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10911419	C4591001 1091 10911419	12-15	10DEC2020	21934	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10911420	C4591001 1091 10911420	12-15	10DEC2020	21894	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10911421	C4591001 1091 10911421	12-15	10DEC2020	21896	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10911422	C4591001 1091 10911422	12-15	14DEC2020	21936	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10911423	C4591001 1091 10911423	12-15	14DEC2020	21937	Placebo	14DEC2020	Placebo	06JAN2021	Placebo
10911424	C4591001 1091 10911424	12-15	15DEC2020	22509	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
10911425	C4591001 1091 10911425	12-15	15DEC2020	21940	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
10911426	C4591001 1091 10911426	12-15	16DEC2020	22510	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10911427	C4591001 1091 10911427	12-15	16DEC2020	22518	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
10911428	C4591001 1091 10911428	12-15	16DEC2020	22520	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10911429	C4591001 1091 10911429	12-15	16DEC2020	22869	Placebo	16DEC2020	Placebo	06JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911430	C4591001 1091 10911430	12-15	16DEC2020	22874	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
10911431	C4591001 1091 10911431	12-15	17DEC2020	22879	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10911432	C4591001 1091 10911432	12-15	17DEC2020	22876	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10911433	C4591001 1091 10911433	12-15	17DEC2020	23077	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10911434	C4591001 1091 10911434	12-15	17DEC2020	23076	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10911435	C4591001 1091 10911435	12-15	17DEC2020	23078	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10911436	C4591001 1091 10911436	12-15	17DEC2020	23082	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10911437	C4591001 1091 10911437	12-15	17DEC2020	23134	Placebo	17DEC2020	Placebo	06JAN2021	Placebo
10911438	C4591001 1091 10911438	12-15	18DEC2020	23136	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10911439	C4591001 1091 10911439	12-15	18DEC2020	23139	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10911440	C4591001 1091 10911440	12-15	18DEC2020	23140	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10911441	C4591001 1091 10911441	12-15	18DEC2020	23253	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10911442	C4591001 1091 10911442	12-15	18DEC2020	23254	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
10911443	C4591001 1091 10911443	12-15	21DEC2020	23263	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	15JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911444	C4591001 1091 10911444	12-15	21DEC2020	23259	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10911445	C4591001 1091 10911445	12-15	21DEC2020	23765	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
10911446	C4591001 1091 10911446	12-15	22DEC2020	23766	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10911447	C4591001 1091 10911447	12-15	22DEC2020	23767	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
10911448	C4591001 1091 10911448	12-15	22DEC2020	23768	Placebo	22DEC2020	Placebo	14JAN2021	Placebo
10911449	C4591001 1091 10911449	12-15	22DEC2020	23950	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
10911450	C4591001 1091 10911450	12-15	22DEC2020	23951	Placebo	22DEC2020	Placebo	14JAN2021	Placebo
10911451	C4591001 1091 10911451	12-15	22DEC2020	23954	BNT162b2 (30 µg)				
10911452	C4591001 1091 10911452	12-15	22DEC2020	24105	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10911453	C4591001 1091 10911453	12-15	22DEC2020	23959	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10911454	C4591001 1091 10911454	12-15	28DEC2020	24107	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
10911455	C4591001 1091 10911455	12-15	29DEC2020	24109	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10911456	C4591001 1091 10911456	12-15	29DEC2020	24796	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
10911457	C4591001 1091 10911457	12-15	29DEC2020	24797	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911458	C4591001 1091 10911458	12-15	29DEC2020	24111	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10911459	C4591001 1091 10911459	12-15	29DEC2020	24795	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
10911460	C4591001 1091 10911460	12-15	30DEC2020	24800	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
10911461	C4591001 1091 10911461	12-15	30DEC2020	24873	Placebo	30DEC2020	Placebo	19JAN2021	Placebo
10911462	C4591001 1091 10911462	12-15	04JAN2021	24875	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10911463	C4591001 1091 10911463	12-15	04JAN2021	24877	Placebo	04JAN2021	Placebo	27JAN2021	Placebo
10911464	C4591001 1091 10911464	12-15	04JAN2021	24879	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10911465	C4591001 1091 10911465	12-15	05JAN2021	25413	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
10911466	C4591001 1091 10911466	12-15	11JAN2021	25414	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
11231422	C4591001 1123 11231422	12-15	01DEC2020	20486	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
11231425	C4591001 1123 11231425	12-15	02DEC2020	20487	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11231428	C4591001 1123 11231428	12-15	03DEC2020	20491	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11231431	C4591001 1123 11231431	12-15	04DEC2020	20492	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11231432	C4591001 1123 11231432	12-15	04DEC2020	20939	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231434	C4591001 1123 11231434	12-15	07DEC2020	20941	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11231438	C4591001 1123 11231438	12-15	08DEC2020	20942	Placebo	08DEC2020	Placebo	06JAN2021	Placebo
11231439	C4591001 1123 11231439	12-15	08DEC2020	20944	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11231440	C4591001 1123 11231440	12-15	09DEC2020	21600	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11231441	C4591001 1123 11231441	12-15	09DEC2020	21602	Placebo	09DEC2020	Placebo	04JAN2021	Placebo
11231442	C4591001 1123 11231442	12-15	09DEC2020	21604	Placebo	09DEC2020	Placebo	04JAN2021	Placebo
11231443	C4591001 1123 11231443	12-15	09DEC2020	21607	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11231445	C4591001 1123 11231445	12-15	09DEC2020	21729	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
11231446	C4591001 1123 11231446	12-15	09DEC2020	21731	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11231447	C4591001 1123 11231447	12-15	10DEC2020	21732	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11231448	C4591001 1123 11231448	12-15	11DEC2020	21735	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11231449	C4591001 1123 11231449	12-15	11DEC2020	22018	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11231450	C4591001 1123 11231450	12-15	11DEC2020	22023	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11231451	C4591001 1123 11231451	12-15	15DEC2020	22026	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231452	C4591001 1123 11231452	12-15	15DEC2020	22027	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
11231453	C4591001 1123 11231453	12-15	15DEC2020	22610	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
11231454	C4591001 1123 11231454	12-15	15DEC2020	22607	Placebo	15DEC2020	Placebo	07JAN2021	Placebo
11231455	C4591001 1123 11231455	12-15	15DEC2020	22614	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11231456	C4591001 1123 11231456	12-15	16DEC2020	22615	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
11231457	C4591001 1123 11231457	12-15	16DEC2020	22835	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
11231458	C4591001 1123 11231458	12-15	16DEC2020	22837	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11231459	C4591001 1123 11231459	12-15	16DEC2020	22841	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11231460	C4591001 1123 11231460	12-15	17DEC2020	22842	Placebo	17DEC2020	Placebo	08JAN2021	Placebo
11231461	C4591001 1123 11231461	12-15	17DEC2020	23027	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11231462	C4591001 1123 11231462	12-15	17DEC2020	23028	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11231463	C4591001 1123 11231463	12-15	18DEC2020	23031	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
11231465	C4591001 1123 11231465	12-15	18DEC2020	23032	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
11231466	C4591001 1123 11231466	12-15	18DEC2020	23425	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231467	C4591001 1123 11231467	12-15	21DEC2020	23427	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11231468	C4591001 1123 11231468	12-15	21DEC2020	23430	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11231469	C4591001 1123 11231469	12-15	21DEC2020	23432	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11231470	C4591001 1123 11231470	12-15	21DEC2020	23673	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
11231472	C4591001 1123 11231472	12-15	21DEC2020	23676	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11231473	C4591001 1123 11231473	12-15	21DEC2020	23678	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
11231474	C4591001 1123 11231474	12-15	21DEC2020	23830	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11231475	C4591001 1123 11231475	12-15	21DEC2020	23681	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11231476	C4591001 1123 11231476	12-15	21DEC2020	23831	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11231477	C4591001 1123 11231477	12-15	21DEC2020	23837	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11231478	C4591001 1123 11231478	12-15	21DEC2020	23865	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11231479	C4591001 1123 11231479	12-15	21DEC2020	23833	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11231481	C4591001 1123 11231481	12-15	21DEC2020	23869	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11231482	C4591001 1123 11231482	12-15	22DEC2020	23871	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231483	C4591001 1123 11231483	12-15	22DEC2020	23872	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11231484	C4591001 1123 11231484	12-15	22DEC2020	23977	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11231485	C4591001 1123 11231485	12-15	22DEC2020	23982	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11231486	C4591001 1123 11231486	12-15	22DEC2020	23984	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11231487	C4591001 1123 11231487	12-15	22DEC2020	23980	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11231488	C4591001 1123 11231488	12-15	22DEC2020	24049	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11231489	C4591001 1123 11231489	12-15	22DEC2020	24096	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11231491	C4591001 1123 11231491	12-15	22DEC2020	24097	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11231492	C4591001 1123 11231492	12-15	23DEC2020	24100	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
11231493	C4591001 1123 11231493	12-15	23DEC2020	24103	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	15JAN2021	BNT162b2 (30 µg)
11231494	C4591001 1123 11231494	12-15	23DEC2020	24237	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11231495	C4591001 1123 11231495	12-15	23DEC2020	24238	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11231496	C4591001 1123 11231496	12-15	23DEC2020	24240	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
11231497	C4591001 1123 11231497	12-15	23DEC2020	24243	Placebo	23DEC2020	Placebo	20JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231499	C4591001 1123 11231499	12-15	28DEC2020	24335	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
11231500	C4591001 1123 11231500	12-15	28DEC2020	24336	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11231501	C4591001 1123 11231501	12-15	28DEC2020	24341	Placebo	28DEC2020	Placebo	18FEB2021	Placebo
11231502	C4591001 1123 11231502	12-15	28DEC2020	24342	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11231503	C4591001 1123 11231503	12-15	28DEC2020	24406	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
11231504	C4591001 1123 11231504	12-15	28DEC2020	24412	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11231505	C4591001 1123 11231505	12-15	28DEC2020	24411	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
11231506	C4591001 1123 11231506	12-15	28DEC2020	24415	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11231507	C4591001 1123 11231507	12-15	28DEC2020	24505	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11231508	C4591001 1123 11231508	12-15	28DEC2020	24508	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11231509	C4591001 1123 11231509	12-15	29DEC2020	24510	Placebo	29DEC2020	Placebo	21JAN2021	Placebo
11231510	C4591001 1123 11231510	12-15	29DEC2020	24512	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11231511	C4591001 1123 11231511	12-15	30DEC2020	24850	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11231512	C4591001 1123 11231512	12-15	30DEC2020	24852	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231513	C4591001 1123 11231513	12-15	30DEC2020	24856	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
11231514	C4591001 1123 11231514	12-15	30DEC2020	24860	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
11231515	C4591001 1123 11231515	12-15	30DEC2020	25042	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
11231516	C4591001 1123 11231516	12-15	30DEC2020	25047	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
11231517	C4591001 1123 11231517	12-15	30DEC2020	25041	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11231518	C4591001 1123 11231518	12-15	30DEC2020	25046	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11231519	C4591001 1123 11231519	12-15	30DEC2020	25077	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11231520	C4591001 1123 11231520	12-15	30DEC2020	25082	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
11231521	C4591001 1123 11231521	12-15	30DEC2020	25080	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11231522	C4591001 1123 11231522	12-15	05JAN2021	25083	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11231523	C4591001 1123 11231523	12-15	05JAN2021	25489	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11231524	C4591001 1123 11231524	12-15	05JAN2021	25490	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11231525	C4591001 1123 11231525	12-15	07JAN2021	25493	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11231526	C4591001 1123 11231526	12-15	08JAN2021	25495	Placebo	08JAN2021	Placebo	29JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11241236	C4591001 1124 11241236	12-15	14DEC2020	22307	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11241238	C4591001 1124 11241238	12-15	14DEC2020	22311	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11241239	C4591001 1124 11241239	12-15	14DEC2020	22312	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11241240	C4591001 1124 11241240	12-15	14DEC2020	22314	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11241241	C4591001 1124 11241241	12-15	14DEC2020	22365	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11241242	C4591001 1124 11241242	12-15	14DEC2020	22368	Placebo	14DEC2020	Placebo	05JAN2021	Placebo
11241243	C4591001 1124 11241243	12-15	15DEC2020	22370	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11241244	C4591001 1124 11241244	12-15	15DEC2020	22376	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11241245	C4591001 1124 11241245	12-15	15DEC2020	22629	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11241246	C4591001 1124 11241246	12-15	15DEC2020	22632	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11241247	C4591001 1124 11241247	12-15	16DEC2020	22633	Placebo	16DEC2020	Placebo	05JAN2021	Placebo
11241248	C4591001 1124 11241248	12-15	16DEC2020	22640	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11241249	C4591001 1124 11241249	12-15	16DEC2020	22859	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11241250	C4591001 1124 11241250	12-15	17DEC2020	22865	Placebo	17DEC2020	Placebo	07JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11241251	C4591001 1124 11241251	12-15	18DEC2020	22867	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11241252	C4591001 1124 11241252	12-15	18DEC2020	22866	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
11241253	C4591001 1124 11241253	12-15	18DEC2020	23356	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11241254	C4591001 1124 11241254	12-15	18DEC2020	23350	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11241255	C4591001 1124 11241255	12-15	18DEC2020	23359	Placebo	18DEC2020	Placebo	06JAN2021	Placebo
11241256	C4591001 1124 11241256	12-15	21DEC2020	23360	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
11241257	C4591001 1124 11241257	12-15	22DEC2020	24118	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11241258	C4591001 1124 11241258	12-15	23DEC2020	24120	Placebo	23DEC2020	Placebo	14JAN2021	Placebo
11241259	C4591001 1124 11241259	12-15	23DEC2020	24125	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11241260	C4591001 1124 11241260	12-15	23DEC2020	24128	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11241261	C4591001 1124 11241261	12-15	23DEC2020	24227	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11241262	C4591001 1124 11241262	12-15	23DEC2020	24228	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11241263	C4591001 1124 11241263	12-15	29DEC2020	24232	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
11241264	C4591001 1124 11241264	12-15	29DEC2020	24234	Placebo	29DEC2020	Placebo	18JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11241265	C4591001 1124 11241265	12-15	29DEC2020	24623	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11241266	C4591001 1124 11241266	12-15	29DEC2020	24625	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11241267	C4591001 1124 11241267	12-15	29DEC2020	24626	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
11241268	C4591001 1124 11241268	12-15	04JAN2021	24631	Placebo	04JAN2021	Placebo	27JAN2021	Placebo
11241269	C4591001 1124 11241269	12-15	04JAN2021	25306	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11241270	C4591001 1124 11241270	12-15	05JAN2021	25308	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11241271	C4591001 1124 11241271	12-15	05JAN2021	25313	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11241272	C4591001 1124 11241272	12-15	05JAN2021	25315	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11241273	C4591001 1124 11241273	12-15	06JAN2021	25847	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11241274	C4591001 1124 11241274	12-15	06JAN2021	25849	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
11241275	C4591001 1124 11241275	12-15	08JAN2021	25852	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11251241	C4591001 1125 11251241	12-15	07DEC2020	21093	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11251242	C4591001 1125 11251242	12-15	07DEC2020	21096	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11251244	C4591001 1125 11251244	12-15	08DEC2020	21097	Placebo	08DEC2020	Placebo	30DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11251246	C4591001 1125 11251246	12-15	10DEC2020	21100	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	
11251248	C4591001 1125 11251248	12-15	11DEC2020	22113	Placebo	11DEC2020	Placebo	30DEC2020	Placebo	
11251249	C4591001 1125 11251249	12-15	11DEC2020	22116	Placebo	11DEC2020	Placebo	30DEC2020	Placebo	
11251250	C4591001 1125 11251250	12-15	14DEC2020	22121	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	
11251251	C4591001 1125 11251251	12-15	14DEC2020	22124	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	
11251252	C4591001 1125 11251252	12-15	16DEC2020	22885	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)	
11251253	C4591001 1125 11251253	12-15	16DEC2020	22886	Placebo	16DEC2020	Placebo	06JAN2021	Placebo	
11251254	C4591001 1125 11251254	12-15	28DEC2020	22888	Placebo	28DEC2020	Placebo	20JAN2021	Placebo	
11251255	C4591001 1125 11251255	12-15	06JAN2021	22892	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
11261229	C4591001 1126 11261229	12-15	30NOV2020	20421	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	
11261230	C4591001 1126 11261230	12-15	30NOV2020	20422	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	
11261233	C4591001 1126 11261233	12-15	01DEC2020	20423	Placebo	01DEC2020	Placebo	22DEC2020	Placebo	
11261235	C4591001 1126 11261235	12-15	01DEC2020	20430	Placebo	01DEC2020	Placebo	23DEC2020	Placebo	
11261239	C4591001 1126 11261239	12-15	02DEC2020	20686	Placebo	02DEC2020	Placebo	21DEC2020	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261240	C4591001 1126 11261240	12-15	02DEC2020	20687	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
11261241	C4591001 1126 11261241	12-15	02DEC2020	20690	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11261243	C4591001 1126 11261243	12-15	02DEC2020	20694	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11261246	C4591001 1126 11261246	12-15	02DEC2020	20761	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11261249	C4591001 1126 11261249	12-15	02DEC2020	20763	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11261250	C4591001 1126 11261250	12-15	02DEC2020	20764	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
11261253	C4591001 1126 11261253	12-15	03DEC2020	20765	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11261254	C4591001 1126 11261254	12-15	03DEC2020	20904	Placebo	03DEC2020	Placebo	26JAN2021	Placebo
11261255	C4591001 1126 11261255	12-15	03DEC2020	20907	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11261258	C4591001 1126 11261258	12-15	03DEC2020	20910	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11261262	C4591001 1126 11261262	12-15	04DEC2020	20911	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11261263	C4591001 1126 11261263	12-15	04DEC2020	21033	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11261264	C4591001 1126 11261264	12-15	04DEC2020	21038	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11261265	C4591001 1126 11261265	12-15	14DEC2020	21040	Placebo	14DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261266	C4591001 1126 11261266	12-15	14DEC2020	21042	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11261267	C4591001 1126 11261267	12-15	14DEC2020	22342	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11261268	C4591001 1126 11261268	12-15	14DEC2020	22343	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11261269	C4591001 1126 11261269	12-15	14DEC2020	22344	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11261270	C4591001 1126 11261270	12-15	14DEC2020	22352	Placebo	14DEC2020	Placebo	06JAN2021	Placebo
11261271	C4591001 1126 11261271	12-15	14DEC2020	22440	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11261273	C4591001 1126 11261273	12-15	14DEC2020	22442	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11261274	C4591001 1126 11261274	12-15	15DEC2020	22446	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
11261275	C4591001 1126 11261275	12-15	15DEC2020	22690	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
11261276	C4591001 1126 11261276	12-15	15DEC2020	22448	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
11261277	C4591001 1126 11261277	12-15	15DEC2020	22693	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11261278	C4591001 1126 11261278	12-15	15DEC2020	22695	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11261279	C4591001 1126 11261279	12-15	16DEC2020	22700	Placebo	16DEC2020	Placebo	07JAN2021	Placebo
11261280	C4591001 1126 11261280	12-15	16DEC2020	22799	Placebo	16DEC2020	Placebo	07JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261281	C4591001 1126 11261281	12-15	16DEC2020	22802	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
11261282	C4591001 1126 11261282	12-15	16DEC2020	22803	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11261283	C4591001 1126 11261283	12-15	16DEC2020	22808	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11261284	C4591001 1126 11261284	12-15	16DEC2020	22929	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11261285	C4591001 1126 11261285	12-15	16DEC2020	22936	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11261286	C4591001 1126 11261286	12-15	16DEC2020	22937	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11261287	C4591001 1126 11261287	12-15	16DEC2020	22939	Placebo	16DEC2020	Placebo		
11261288	C4591001 1126 11261288	12-15	16DEC2020	22980	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11261289	C4591001 1126 11261289	12-15	17DEC2020	22981	Placebo	17DEC2020	Placebo	06JAN2021	Placebo
11261290	C4591001 1126 11261290	12-15	17DEC2020	22984	Placebo	17DEC2020	Placebo	05JAN2021	Placebo
11261291	C4591001 1126 11261291	12-15	17DEC2020	22983	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
11261292	C4591001 1126 11261292	12-15	17DEC2020	23229	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
11261293	C4591001 1126 11261293	12-15	18DEC2020	23232	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11261294	C4591001 1126 11261294	12-15	18DEC2020	23234	Placebo	18DEC2020	Placebo	08JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261295	C4591001 1126 11261295	12-15	18DEC2020	23239	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11261296	C4591001 1126 11261296	12-15	18DEC2020	23452	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
11261297	C4591001 1126 11261297	12-15	18DEC2020	23453	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
11261298	C4591001 1126 11261298	12-15	18DEC2020	23454	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
11261299	C4591001 1126 11261299	12-15	21DEC2020	23455	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11261300	C4591001 1126 11261300	12-15	22DEC2020	23963	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11261301	C4591001 1126 11261301	12-15	22DEC2020	23967	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11261302	C4591001 1126 11261302	12-15	23DEC2020	23968	Placebo	23DEC2020	Placebo	21JAN2021	Placebo
11261303	C4591001 1126 11261303	12-15	29DEC2020	23971	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11261304	C4591001 1126 11261304	12-15	29DEC2020	24671	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11261305	C4591001 1126 11261305	12-15	30DEC2020	24674	Placebo	30DEC2020	Placebo	21JAN2021	Placebo
11261306	C4591001 1126 11261306	12-15	30DEC2020	24677	Placebo	30DEC2020	Placebo	21JAN2021	Placebo
11261307	C4591001 1126 11261307	12-15	04JAN2021	24680	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11261308	C4591001 1126 11261308	12-15	04JAN2021	25330	Placebo	04JAN2021	Placebo	25JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
11261309	C4591001 1126 11261309	12-15	04JAN2021	25331	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)	
11261310	C4591001 1126 11261310	12-15	05JAN2021	25333	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)	
11261311	C4591001 1126 11261311	12-15	05JAN2021	25338	Placebo	05JAN2021	Placebo	27JAN2021	Placebo	
11261312	C4591001 1126 11261312	12-15	05JAN2021	25593	Placebo	05JAN2021	Placebo	25JAN2021	Placebo	
11261313	C4591001 1126 11261313	12-15	06JAN2021	25600	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)	
11261314	C4591001 1126 11261314	12-15	06JAN2021	25599	Placebo	06JAN2021	Placebo	29JAN2021	Placebo	
11261315	C4591001 1126 11261315	12-15	06JAN2021	25603	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)	
11261316	C4591001 1126 11261316	12-15	07JAN2021	25942	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
11261317	C4591001 1126 11261317	12-15	07JAN2021	25943	Placebo	07JAN2021	Placebo	27JAN2021	Placebo	
11261318	C4591001 1126 11261318	12-15	07JAN2021	25949	Placebo	07JAN2021	Placebo	27JAN2021	Placebo	
11261319	C4591001 1126 11261319	12-15	07JAN2021	25950	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
11261320	C4591001 1126 11261320	12-15	07JAN2021	26133	Placebo	07JAN2021	Placebo	28JAN2021	Placebo	
11261321	C4591001 1126 11261321	12-15	07JAN2021	26136	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)	
11261322	C4591001 1126 11261322	12-15	07JAN2021	26138	Placebo	07JAN2021	Placebo	28JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261323	C4591001 1126 11261323	12-15	08JAN2021	26141	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11261324	C4591001 1126 11261324	12-15	08JAN2021	26421	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11261325	C4591001 1126 11261325	12-15	08JAN2021	26422	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11311275	C4591001 1131 11311275	12-15	04DEC2020	20973	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11311277	C4591001 1131 11311277	12-15	08DEC2020	20974	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11311278	C4591001 1131 11311278	12-15	08DEC2020	20977	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11311280	C4591001 1131 11311280	12-15	17DEC2020	20978	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
11311281	C4591001 1131 11311281	12-15	21DEC2020	23841	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11311282	C4591001 1131 11311282	12-15	22DEC2020	23845	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11311283	C4591001 1131 11311283	12-15	22DEC2020	23847	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11311285	C4591001 1131 11311285	12-15	23DEC2020	23850	Placebo	23DEC2020	Placebo	15JAN2021	Placebo
11311286	C4591001 1131 11311286	12-15	29DEC2020	24573	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11311287	C4591001 1131 11311287	12-15	29DEC2020	24580	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
11311288	C4591001 1131 11311288	12-15	29DEC2020	24581	Placebo	29DEC2020	Placebo	18JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11311289	C4591001 1131 11311289	12-15	30DEC2020	24583	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11311290	C4591001 1131 11311290	12-15	30DEC2020	24938	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11311291	C4591001 1131 11311291	12-15	30DEC2020	24939	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11311292	C4591001 1131 11311292	12-15	04JAN2021	24940	Placebo	04JAN2021	Placebo	01MAR2021	Placebo
11311293	C4591001 1131 11311293	12-15	04JAN2021	24944	Placebo	04JAN2021	Placebo	26JAN2021	Placebo
11311294	C4591001 1131 11311294	12-15	05JAN2021	25581	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11311295	C4591001 1131 11311295	12-15	07JAN2021	25585	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11311296	C4591001 1131 11311296	12-15	08JAN2021	25588	Placebo	08JAN2021	Placebo	27JAN2021	Placebo
11311297	C4591001 1131 11311297	12-15	08JAN2021	25590	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11311298	C4591001 1131 11311298	12-15	08JAN2021	26303	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11311299	C4591001 1131 11311299	12-15	08JAN2021	26304	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11311300	C4591001 1131 11311300	12-15	08JAN2021	26306	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11311301	C4591001 1131 11311301	12-15	11JAN2021	26309	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	05FEB2021	BNT162b2 (30 µg)
11311302	C4591001 1131 11311302	12-15	11JAN2021	26710	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391144	C4591001 1139 11391144	12-15	11DEC2020	22092	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11391145	C4591001 1139 11391145	12-15	01DEC2020	20472	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11391151	C4591001 1139 11391151	12-15	04DEC2020	20475	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11391152	C4591001 1139 11391152	12-15	04DEC2020	20476	Placebo	04DEC2020	Placebo	28DEC2020	Placebo
11391154	C4591001 1139 11391154	12-15	04DEC2020	20479	Placebo	04DEC2020	Placebo	28DEC2020	Placebo
11391155	C4591001 1139 11391155	12-15	04DEC2020	21025	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11391156	C4591001 1139 11391156	12-15	07DEC2020	21026	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11391157	C4591001 1139 11391157	12-15	08DEC2020	21027	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11391158	C4591001 1139 11391158	12-15	08DEC2020	21031	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11391159	C4591001 1139 11391159	12-15	08DEC2020	21387	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11391161	C4591001 1139 11391161	12-15	08DEC2020	21389	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11391162	C4591001 1139 11391162	12-15	08DEC2020	21391	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11391163	C4591001 1139 11391163	12-15	08DEC2020	21392	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11391165	C4591001 1139 11391165	12-15	11DEC2020	22089	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391166	C4591001 1139 11391166	12-15	11DEC2020	22094	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11391168	C4591001 1139 11391168	12-15	11DEC2020	22097	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11391169	C4591001 1139 11391169	12-15	15DEC2020	22485	Placebo	15DEC2020	Placebo	14JAN2021	Placebo
11391170	C4591001 1139 11391170	12-15	15DEC2020	22486	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11391171	C4591001 1139 11391171	12-15	15DEC2020	22487	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
11391172	C4591001 1139 11391172	12-15	15DEC2020	22494	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11391173	C4591001 1139 11391173	12-15	15DEC2020	22598	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
11391174	C4591001 1139 11391174	12-15	15DEC2020	22599	Placebo	15DEC2020	Placebo	07JAN2021	Placebo
11391175	C4591001 1139 11391175	12-15	15DEC2020	22595	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
11391177	C4591001 1139 11391177	12-15	17DEC2020	22602	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	15JAN2021	BNT162b2 (30 µg)
11391178	C4591001 1139 11391178	12-15	18DEC2020	23293	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11391179	C4591001 1139 11391179	12-15	18DEC2020	23295	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11391180	C4591001 1139 11391180	12-15	18DEC2020	23297	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
11391181	C4591001 1139 11391181	12-15	18DEC2020	23299	Placebo	18DEC2020	Placebo	07JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391182	C4591001 1139 11391182	12-15	18DEC2020	23338	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
11391183	C4591001 1139 11391183	12-15	18DEC2020	23339	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11391185	C4591001 1139 11391185	12-15	18DEC2020	23342	Placebo	18DEC2020	Placebo	12JAN2021	Placebo
11391186	C4591001 1139 11391186	12-15	21DEC2020	23343	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11391187	C4591001 1139 11391187	12-15	21DEC2020	23565	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
11391188	C4591001 1139 11391188	12-15	21DEC2020	23569	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11391189	C4591001 1139 11391189	12-15	21DEC2020	23572	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11391190	C4591001 1139 11391190	12-15	21DEC2020	23734	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11391191	C4591001 1139 11391191	12-15	21DEC2020	23737	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11391192	C4591001 1139 11391192	12-15	21DEC2020	23575	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11391193	C4591001 1139 11391193	12-15	21DEC2020	23733	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11391195	C4591001 1139 11391195	12-15	21DEC2020	23740	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11391196	C4591001 1139 11391196	12-15	21DEC2020	23770	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11391197	C4591001 1139 11391197	12-15	22DEC2020	23774	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391198	C4591001 1139 11391198	12-15	22DEC2020	23776	Placebo	22DEC2020	Placebo	21JAN2021	Placebo
11391199	C4591001 1139 11391199	12-15	22DEC2020	23778	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11391200	C4591001 1139 11391200	12-15	22DEC2020	23917	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11391201	C4591001 1139 11391201	12-15	22DEC2020	23921	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11391202	C4591001 1139 11391202	12-15	22DEC2020	23922	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11391203	C4591001 1139 11391203	12-15	22DEC2020	23923	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11391204	C4591001 1139 11391204	12-15	22DEC2020	24025	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11391205	C4591001 1139 11391205	12-15	22DEC2020	24026	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11391206	C4591001 1139 11391206	12-15	22DEC2020	24029	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11391207	C4591001 1139 11391207	12-15	22DEC2020	24032	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11391208	C4591001 1139 11391208	12-15	22DEC2020	24059	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11391209	C4591001 1139 11391209	12-15	23DEC2020	24060	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11391210	C4591001 1139 11391210	12-15	28DEC2020	24064	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
11391211	C4591001 1139 11391211	12-15	28DEC2020	24066	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391212	C4591001 1139 11391212	12-15	28DEC2020	24347	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
11391213	C4591001 1139 11391213	12-15	28DEC2020	24349	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11391214	C4591001 1139 11391214	12-15	28DEC2020	24351	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11391215	C4591001 1139 11391215	12-15	29DEC2020	24354	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11391216	C4591001 1139 11391216	12-15	29DEC2020	24554	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11391217	C4591001 1139 11391217	12-15	29DEC2020	24557	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11391218	C4591001 1139 11391218	12-15	29DEC2020	24558	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11391219	C4591001 1139 11391219	12-15	29DEC2020	24559	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11391220	C4591001 1139 11391220	12-15	29DEC2020	24693	Placebo	29DEC2020	Placebo	21JAN2021	Placebo
11391221	C4591001 1139 11391221	12-15	04JAN2021	24694	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11391222	C4591001 1139 11391222	12-15	04JAN2021	24698	Placebo	04JAN2021	Placebo	26JAN2021	Placebo
11391223	C4591001 1139 11391223	12-15	04JAN2021	24700	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11391224	C4591001 1139 11391224	12-15	04JAN2021	25140	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
11391225	C4591001 1139 11391225	12-15	04JAN2021	25143	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391226	C4591001 1139 11391226	12-15	05JAN2021	25146	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11391227	C4591001 1139 11391227	12-15	05JAN2021	25148	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
11391228	C4591001 1139 11391228	12-15	05JAN2021	25378	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11391229	C4591001 1139 11391229	12-15	05JAN2021	25380	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
11391230	C4591001 1139 11391230	12-15	05JAN2021	25382	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11391231	C4591001 1139 11391231	12-15	05JAN2021	25388	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11391232	C4591001 1139 11391232	12-15	05JAN2021	25475	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11391233	C4591001 1139 11391233	12-15	05JAN2021	25478	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11391235	C4591001 1139 11391235	12-15	05JAN2021	25479	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
11391236	C4591001 1139 11391236	12-15	05JAN2021	25480	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11391237	C4591001 1139 11391237	12-15	07JAN2021	25969	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11391238	C4591001 1139 11391238	12-15	07JAN2021	25972	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11391239	C4591001 1139 11391239	12-15	07JAN2021	25973	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11391240	C4591001 1139 11391240	12-15	08JAN2021	25976	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391241	C4591001 1139 11391241	12-15	08JAN2021	26254	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11391242	C4591001 1139 11391242	12-15	08JAN2021	26258	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11391243	C4591001 1139 11391243	12-15	08JAN2021	26259	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11391244	C4591001 1139 11391244	12-15	08JAN2021	26263	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11391245	C4591001 1139 11391245	12-15	08JAN2021	26313	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
11391246	C4591001 1139 11391246	12-15	08JAN2021	26319	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11391247	C4591001 1139 11391247	12-15	08JAN2021	26322	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11391248	C4591001 1139 11391248	12-15	08JAN2021	26324	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11391249	C4591001 1139 11391249	12-15	11JAN2021	26568	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11391250	C4591001 1139 11391250	12-15	11JAN2021	26569	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
11391251	C4591001 1139 11391251	12-15	11JAN2021	26571	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11391252	C4591001 1139 11391252	12-15	11JAN2021	26572	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
11391253	C4591001 1139 11391253	12-15	11JAN2021	26613	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11391254	C4591001 1139 11391254	12-15	11JAN2021	26621	Placebo	11JAN2021	Placebo	01FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391255	C4591001 1139 11391255	12-15	11JAN2021	26622	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11391256	C4591001 1139 11391256	12-15	12JAN2021	26760	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11391257	C4591001 1139 11391257	12-15	12JAN2021	26624	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
11391258	C4591001 1139 11391258	12-15	12JAN2021	26762	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
11391259	C4591001 1139 11391259	12-15	12JAN2021	26763	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
11391260	C4591001 1139 11391260	12-15	12JAN2021	26764	Placebo	12JAN2021	Placebo	02FEB2021	Placebo
11391261	C4591001 1139 11391261	12-15	12JAN2021	26833	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
11391262	C4591001 1139 11391262	12-15	12JAN2021	26834	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	04FEB2021	BNT162b2 (30 µg)
11391263	C4591001 1139 11391263	12-15	12JAN2021	26837	Placebo	12JAN2021	Placebo	01FEB2021	Placebo
11401323	C4591001 1140 11401323	12-15	10DEC2020	21921	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11401324	C4591001 1140 11401324	12-15	10DEC2020	21923	Placebo	10DEC2020	Placebo	09JAN2021	Placebo
11401325	C4591001 1140 11401325	12-15	10DEC2020	21927	Placebo	10DEC2020	Placebo	07JAN2021	Placebo
11401326	C4591001 1140 11401326	12-15	10DEC2020	21930	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
11401327	C4591001 1140 11401327	12-15	11DEC2020	22102	Placebo	11DEC2020	Placebo	05JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401328	C4591001 1140 11401328	12-15	14DEC2020	22105	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11401329	C4591001 1140 11401329	12-15	14DEC2020	22110	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11401330	C4591001 1140 11401330	12-15	15DEC2020	22112	Placebo	15DEC2020	Placebo	07JAN2021	Placebo
11401331	C4591001 1140 11401331	12-15	16DEC2020	22763	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11401332	C4591001 1140 11401332	12-15	16DEC2020	22764	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11401333	C4591001 1140 11401333	12-15	16DEC2020	22766	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11401334	C4591001 1140 11401334	12-15	16DEC2020	22767	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11401335	C4591001 1140 11401335	12-15	17DEC2020	23014	Placebo	17DEC2020	Placebo	06JAN2021	Placebo
11401336	C4591001 1140 11401336	12-15	17DEC2020	23017	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11401337	C4591001 1140 11401337	12-15	17DEC2020	23018	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11401338	C4591001 1140 11401338	12-15	17DEC2020	23020	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
11401340	C4591001 1140 11401340	12-15	21DEC2020	23542	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11401343	C4591001 1140 11401343	12-15	21DEC2020	23544	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11401344	C4591001 1140 11401344	12-15	21DEC2020	23543	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401345	C4591001 1140 11401345	12-15	22DEC2020	23545	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11401346	C4591001 1140 11401346	12-15	22DEC2020	23903	BNT162b2 (30 µg)				
11401347	C4591001 1140 11401347	12-15	22DEC2020	23908	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
11401348	C4591001 1140 11401348	12-15	22DEC2020	23909	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
11401349	C4591001 1140 11401349	12-15	22DEC2020	23911	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11401350	C4591001 1140 11401350	12-15	22DEC2020	24010	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11401351	C4591001 1140 11401351	12-15	22DEC2020	24011	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
11401352	C4591001 1140 11401352	12-15	22DEC2020	24019	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11401353	C4591001 1140 11401353	12-15	22DEC2020	24020	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11401354	C4591001 1140 11401354	12-15	23DEC2020	24178	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11401356	C4591001 1140 11401356	12-15	23DEC2020	24183	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
11401357	C4591001 1140 11401357	12-15	23DEC2020	24186	Placebo	23DEC2020	Placebo	11JAN2021	Placebo
11401358	C4591001 1140 11401358	12-15	23DEC2020	24290	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11401359	C4591001 1140 11401359	12-15	23DEC2020	24188	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401361	C4591001 1140 11401361	12-15	28DEC2020	24291	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11401362	C4591001 1140 11401362	12-15	28DEC2020	24292	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
11401363	C4591001 1140 11401363	12-15	28DEC2020	24294	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
11401364	C4591001 1140 11401364	12-15	28DEC2020	24430	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
11401365	C4591001 1140 11401365	12-15	28DEC2020	24439	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11401366	C4591001 1140 11401366	12-15	28DEC2020	24435	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
11401367	C4591001 1140 11401367	12-15	28DEC2020	24440	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11401369	C4591001 1140 11401369	12-15	29DEC2020	24599	Placebo	29DEC2020	Placebo	20JAN2021	Placebo
11401370	C4591001 1140 11401370	12-15	29DEC2020	24601	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11401371	C4591001 1140 11401371	12-15	29DEC2020	24603	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11401372	C4591001 1140 11401372	12-15	29DEC2020	24606	Placebo	29DEC2020	Placebo	20JAN2021	Placebo
11401373	C4591001 1140 11401373	12-15	29DEC2020	24646	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11401374	C4591001 1140 11401374	12-15	29DEC2020	24649	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11401375	C4591001 1140 11401375	12-15	29DEC2020	24652	Placebo	29DEC2020	Placebo	20JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401376	C4591001 1140 11401376	12-15	29DEC2020	24653	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11401377	C4591001 1140 11401377	12-15	29DEC2020	24707	Placebo	29DEC2020	Placebo	20JAN2021	Placebo
11401378	C4591001 1140 11401378	12-15	29DEC2020	24710	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11401379	C4591001 1140 11401379	12-15	30DEC2020	24715	Placebo	30DEC2020	Placebo	27JAN2021	Placebo
11401380	C4591001 1140 11401380	12-15	30DEC2020	24716	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11401381	C4591001 1140 11401381	12-15	30DEC2020	24840	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11401382	C4591001 1140 11401382	12-15	30DEC2020	24843	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11401383	C4591001 1140 11401383	12-15	30DEC2020	24846	Placebo	30DEC2020	Placebo	19JAN2021	Placebo
11401384	C4591001 1140 11401384	12-15	30DEC2020	24847	Placebo	30DEC2020	Placebo	20JAN2021	Placebo
11401385	C4591001 1140 11401385	12-15	30DEC2020	24946	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11401386	C4591001 1140 11401386	12-15	30DEC2020	24955	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11401387	C4591001 1140 11401387	12-15	30DEC2020	24947	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11401388	C4591001 1140 11401388	12-15	05JAN2021	24956	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11401389	C4591001 1140 11401389	12-15	05JAN2021	25461	Placebo	05JAN2021	Placebo	27JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401390	C4591001 11401390	12-15	05JAN2021	25466	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11401391	C4591001 11401391	12-15	06JAN2021	25469	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11401392	C4591001 11401392	12-15	06JAN2021	25470	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
11401393	C4591001 11401393	12-15	06JAN2021	25715	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11401394	C4591001 11401394	12-15	06JAN2021	25716	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11401395	C4591001 11401395	12-15	07JAN2021	25719	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11401396	C4591001 11401396	12-15	07JAN2021	25720	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11401397	C4591001 11401397	12-15	08JAN2021	26159	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11401398	C4591001 11401398	12-15	08JAN2021	26163	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11401399	C4591001 11401399	12-15	08JAN2021	26164	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11401400	C4591001 11401400	12-15	08JAN2021	26165	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11401401	C4591001 11401401	12-15	08JAN2021	26270	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11401402	C4591001 11401402	12-15	08JAN2021	26271	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11401403	C4591001 11401403	12-15	08JAN2021	26273	Placebo	08JAN2021	Placebo	28JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421318	C4591001 1142 11421318	12-15	01DEC2020	20529	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
11421319	C4591001 1142 11421319	12-15	01DEC2020	20531	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11421321	C4591001 1142 11421321	12-15	02DEC2020	20533	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11421323	C4591001 1142 11421323	12-15	03DEC2020	20536	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11421324	C4591001 1142 11421324	12-15	03DEC2020	20805	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11421325	C4591001 1142 11421325	12-15	03DEC2020	20808	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11421326	C4591001 1142 11421326	12-15	03DEC2020	20810	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11421327	C4591001 1142 11421327	12-15	03DEC2020	20806	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11421329	C4591001 1142 11421329	12-15	04DEC2020	20950	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11421330	C4591001 1142 11421330	12-15	04DEC2020	20949	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11421333	C4591001 1142 11421333	12-15	18DEC2020	22848	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
11421335	C4591001 1142 11421335	12-15	04DEC2020	20951	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11421340	C4591001 1142 11421340	12-15	07DEC2020	21129	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11421341	C4591001 1142 11421341	12-15	07DEC2020	20958	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421342	C4591001 1142 11421342	12-15	07DEC2020	21131	Placebo	07DEC2020	Placebo	30DEC2020	Placebo
11421343	C4591001 1142 11421343	12-15	08DEC2020	21132	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11421344	C4591001 1142 11421344	12-15	08DEC2020	21136	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
11421345	C4591001 1142 11421345	12-15	08DEC2020	21393	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
11421346	C4591001 1142 11421346	12-15	10DEC2020	21398	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11421348	C4591001 1142 11421348	12-15	10DEC2020	21399	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
11421349	C4591001 1142 11421349	12-15	10DEC2020	21404	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
11421350	C4591001 1142 11421350	12-15	10DEC2020	21899	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11421351	C4591001 1142 11421351	12-15	11DEC2020	21900	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11421352	C4591001 1142 11421352	12-15	11DEC2020	21906	Placebo	11DEC2020	Placebo	04JAN2021	Placebo
11421353	C4591001 1142 11421353	12-15	11DEC2020	21901	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
11421354	C4591001 1142 11421354	12-15	11DEC2020	22161	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11421355	C4591001 1142 11421355	12-15	14DEC2020	22165	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11421356	C4591001 1142 11421356	12-15	14DEC2020	22167	Placebo	14DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421358	C4591001 1142 11421358	12-15	15DEC2020	22172	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11421359	C4591001 1142 11421359	12-15	15DEC2020	22536	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
11421360	C4591001 1142 11421360	12-15	15DEC2020	22537	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11421361	C4591001 1142 11421361	12-15	16DEC2020	22541	Placebo	16DEC2020	Placebo	04JAN2021	Placebo
11421362	C4591001 1142 11421362	12-15	16DEC2020	22544	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11421363	C4591001 1142 11421363	12-15	16DEC2020	22846	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
11421364	C4591001 1142 11421364	12-15	18DEC2020	22851	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11421365	C4591001 1142 11421365	12-15	18DEC2020	22852	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
11421366	C4591001 1142 11421366	12-15	21DEC2020	23602	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11421367	C4591001 1142 11421367	12-15	21DEC2020	23605	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11421368	C4591001 1142 11421368	12-15	21DEC2020	23610	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
11421369	C4591001 1142 11421369	12-15	21DEC2020	23612	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	15JAN2021	BNT162b2 (30 µg)
11421370	C4591001 1142 11421370	12-15	21DEC2020	23728	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11421371	C4591001 1142 11421371	12-15	21DEC2020	23730	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421372	C4591001 1142 11421372	12-15	22DEC2020	23731	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11421373	C4591001 1142 11421373	12-15	22DEC2020	23732	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11421374	C4591001 1142 11421374	12-15	22DEC2020	23925	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11421375	C4591001 1142 11421375	12-15	22DEC2020	23928	Placebo	22DEC2020	Placebo	11JAN2021	Placebo
11421376	C4591001 1142 11421376	12-15	22DEC2020	23932	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11421377	C4591001 1142 11421377	12-15	22DEC2020	23935	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
11421379	C4591001 1142 11421379	12-15	28DEC2020	24322	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
11421380	C4591001 1142 11421380	12-15	28DEC2020	24323	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
11421383	C4591001 1142 11421383	12-15	29DEC2020	24327	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11421384	C4591001 1142 11421384	12-15	29DEC2020	24332	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11421385	C4591001 1142 11421385	12-15	31DEC2020	25103	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	22JAN2021	BNT162b2 (30 µg)
11421386	C4591001 1142 11421386	12-15	31DEC2020	25106	Placebo	31DEC2020	Placebo	22JAN2021	Placebo
11421388	C4591001 1142 11421388	12-15	05JAN2021	25108	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11421389	C4591001 1142 11421389	12-15	06JAN2021	25110	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421390	C4591001 1142 11421390	12-15	06JAN2021	25655	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11421391	C4591001 1142 11421391	12-15	06JAN2021	25656	Placebo	06JAN2021	Placebo	29JAN2021	Placebo
11421392	C4591001 1142 11421392	12-15	08JAN2021	25663	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11421393	C4591001 1142 11421393	12-15	08JAN2021	25664	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11421394	C4591001 1142 11421394	12-15	11JAN2021	26542	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
11421395	C4591001 1142 11421395	12-15	11JAN2021	26547	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11421396	C4591001 1142 11421396	12-15	11JAN2021	26548	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
11471261	C4591001 1147 11471261	12-15	12DEC2020	22227	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11471262	C4591001 1147 11471262	12-15	12DEC2020	22209	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11471263	C4591001 1147 11471263	12-15	05DEC2020	21047	BNT162b2 (30 µg)	05DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11471264	C4591001 1147 11471264	12-15	05DEC2020	21049	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471268	C4591001 1147 11471268	12-15	05DEC2020	21054	BNT162b2 (30 µg)	05DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11471269	C4591001 1147 11471269	12-15	05DEC2020	21056	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471270	C4591001 1147 11471270	12-15	05DEC2020	21058	Placebo	05DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471271	C4591001 1147 11471271	12-15	05DEC2020	21063	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471273	C4591001 1147 11471273	12-15	05DEC2020	21067	BNT162b2 (30 µg)	05DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11471274	C4591001 1147 11471274	12-15	05DEC2020	21068	BNT162b2 (30 µg)	05DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11471275	C4591001 1147 11471275	12-15	05DEC2020	21069	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471277	C4591001 1147 11471277	12-15	08DEC2020	21072	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11471278	C4591001 1147 11471278	12-15	08DEC2020	21078	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11471279	C4591001 1147 11471279	12-15	08DEC2020	21079	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11471280	C4591001 1147 11471280	12-15	04JAN2021	23792	Placebo	04JAN2021	Placebo		
11471281	C4591001 1147 11471281	12-15	12DEC2020	22214	Placebo	12DEC2020	Placebo	04JAN2021	Placebo
11471282	C4591001 1147 11471282	12-15	12DEC2020	22218	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11471283	C4591001 1147 11471283	12-15	12DEC2020	22225	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11471284	C4591001 1147 11471284	12-15	12DEC2020	22219	Placebo	12DEC2020	Placebo	04JAN2021	Placebo
11471285	C4591001 1147 11471285	12-15	12DEC2020	22226	Placebo	12DEC2020	Placebo	04JAN2021	Placebo
11471286	C4591001 1147 11471286	12-15	12DEC2020	22231	Placebo	12DEC2020	Placebo	04JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471287	C4591001 1147 11471287	12-15	12DEC2020	22234	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11471288	C4591001 1147 11471288	12-15	12DEC2020	22235	Placebo	12DEC2020	Placebo	04JAN2021	Placebo
11471289	C4591001 1147 11471289	12-15	19DEC2020	22236	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471290	C4591001 1147 11471290	12-15	19DEC2020	23498	Placebo	19DEC2020	Placebo	09JAN2021	Placebo
11471291	C4591001 1147 11471291	12-15	19DEC2020	22241	Placebo	19DEC2020	Placebo	09JAN2021	Placebo
11471292	C4591001 1147 11471292	12-15	19DEC2020	23494	Placebo	19DEC2020	Placebo	09JAN2021	Placebo
11471294	C4591001 1147 11471294	12-15	19DEC2020	23496	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471295	C4591001 1147 11471295	12-15	19DEC2020	23508	Placebo	19DEC2020	Placebo	09JAN2021	Placebo
11471296	C4591001 1147 11471296	12-15	19DEC2020	23512	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471297	C4591001 1147 11471297	12-15	19DEC2020	23502	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471298	C4591001 1147 11471298	12-15	19DEC2020	23513	Placebo	19DEC2020	Placebo	09JAN2021	Placebo
11471299	C4591001 1147 11471299	12-15	19DEC2020	23515	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471300	C4591001 1147 11471300	12-15	19DEC2020	23517	Placebo	19DEC2020	Placebo	09JAN2021	Placebo
11471301	C4591001 1147 11471301	12-15	19DEC2020	23521	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471302	C4591001 1147 11471302	12-15	19DEC2020	23525	BNT162b2 (30 µg)	19DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471303	C4591001 1147 11471303	12-15	21DEC2020	23528	Placebo	21DEC2020	Placebo	09JAN2021	Placebo
11471304	C4591001 1147 11471304	12-15	21DEC2020	23556	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471305	C4591001 1147 11471305	12-15	21DEC2020	23560	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11471306	C4591001 1147 11471306	12-15	21DEC2020	23562	Placebo	21DEC2020	Placebo	09JAN2021	Placebo
11471307	C4591001 1147 11471307	12-15	21DEC2020	23564	Placebo	21DEC2020	Placebo	09JAN2021	Placebo
11471308	C4591001 1147 11471308	12-15	21DEC2020	23689	Placebo	21DEC2020	Placebo	09JAN2021	Placebo
11471309	C4591001 1147 11471309	12-15	21DEC2020	23691	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471310	C4591001 1147 11471310	12-15	21DEC2020	23696	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471311	C4591001 1147 11471311	12-15	21DEC2020	23695	Placebo	21DEC2020	Placebo	09JAN2021	Placebo
11471312	C4591001 1147 11471312	12-15	21DEC2020	23781	Placebo	21DEC2020	Placebo	09JAN2021	Placebo
11471313	C4591001 1147 11471313	12-15	21DEC2020	23786	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471314	C4591001 1147 11471314	12-15	21DEC2020	23788	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)
11471315	C4591001 1147 11471315	12-15	04JAN2021	25187	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	23JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471316	C4591001 1147 11471316	12-15	04JAN2021	25190	Placebo	04JAN2021	Placebo	23JAN2021	Placebo
11471317	C4591001 1147 11471317	12-15	04JAN2021	25193	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	23JAN2021	BNT162b2 (30 µg)
11471318	C4591001 1147 11471318	12-15	04JAN2021	25196	Placebo	04JAN2021	Placebo	28JAN2021	Placebo
11471319	C4591001 1147 11471319	12-15	05JAN2021	25402	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11471320	C4591001 1147 11471320	12-15	05JAN2021	25403	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471321	C4591001 1147 11471321	12-15	05JAN2021	25407	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
11471322	C4591001 1147 11471322	12-15	05JAN2021	25409	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11471323	C4591001 1147 11471323	12-15	05JAN2021	25557	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11471324	C4591001 1147 11471324	12-15	05JAN2021	25559	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11471325	C4591001 1147 11471325	12-15	05JAN2021	25560	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471326	C4591001 1147 11471326	12-15	05JAN2021	25564	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471327	C4591001 1147 11471327	12-15	05JAN2021	25570	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)		
11471328	C4591001 1147 11471328	12-15	05JAN2021	25576	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
11471329	C4591001 1147 11471329	12-15	05JAN2021	25577	Placebo	05JAN2021	Placebo	27JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471330	C4591001 1147 11471330	12-15	05JAN2021	25605	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
11471331	C4591001 1147 11471331	12-15	05JAN2021	25580	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11471332	C4591001 1147 11471332	12-15	06JAN2021	25607	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
11471333	C4591001 1147 11471333	12-15	06JAN2021	25615	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
11471334	C4591001 1147 11471334	12-15	06JAN2021	25610	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471335	C4591001 1147 11471335	12-15	06JAN2021	25681	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
11471336	C4591001 1147 11471336	12-15	06JAN2021	25682	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
11471337	C4591001 1147 11471337	12-15	06JAN2021	25683	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471338	C4591001 1147 11471338	12-15	06JAN2021	25688	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471339	C4591001 1147 11471339	12-15	06JAN2021	25761	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
11471340	C4591001 1147 11471340	12-15	06JAN2021	25764	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471341	C4591001 1147 11471341	12-15	06JAN2021	25771	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
11471342	C4591001 1147 11471342	12-15	06JAN2021	25860	Placebo	06JAN2021	Placebo	27JAN2021	Placebo
11471343	C4591001 1147 11471343	12-15	06JAN2021	25768	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471344	C4591001 1147 11471344	12-15	06JAN2021	25864	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	12FEB2021	BNT162b2 (30 µg)
11471345	C4591001 1147 11471345	12-15	06JAN2021	25866	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
11471346	C4591001 1147 11471346	12-15	06JAN2021	25867	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11471347	C4591001 1147 11471347	12-15	06JAN2021	25881	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11501118	C4591001 1150 11501118	12-15	15OCT2020	20002	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
11501119	C4591001 1150 11501119	12-15	15OCT2020	20005	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
11501120	C4591001 1150 11501120	12-15	15OCT2020	20007	Placebo	15OCT2020	Placebo	06NOV2020	Placebo
11501121	C4591001 1150 11501121	12-15	15OCT2020	20010	Placebo	15OCT2020	Placebo	03NOV2020	Placebo
11501123	C4591001 1150 11501123	12-15	16OCT2020	20075	Placebo	16OCT2020	Placebo	05NOV2020	Placebo
11501124	C4591001 1150 11501124	12-15	19OCT2020	20076	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
11501125	C4591001 1150 11501125	12-15	19OCT2020	20077	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
11501126	C4591001 1150 11501126	12-15	19OCT2020	20078	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11501127	C4591001 1150 11501127	12-15	19OCT2020	20122	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11501128	C4591001 1150 11501128	12-15	19OCT2020	20127	Placebo	19OCT2020	Placebo	10NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501129	C4591001 115011501129	12-15	20OCT2020	20131	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
11501130	C4591001 115011501130	12-15	20OCT2020	20132	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11501131	C4591001 115011501131	12-15	20OCT2020	20200	Placebo	20OCT2020	Placebo	09NOV2020	Placebo
11501132	C4591001 115011501132	12-15	20OCT2020	20201	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11501133	C4591001 115011501133	12-15	21OCT2020	20202	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
11501134	C4591001 115011501134	12-15	21OCT2020	20204	Placebo	21OCT2020	Placebo	10NOV2020	Placebo
11501135	C4591001 115011501135	12-15	21OCT2020	20218	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11501136	C4591001 115011501136	12-15	21OCT2020	20220	Placebo	21OCT2020	Placebo	10NOV2020	Placebo
11501166	C4591001 115011501166	12-15	30NOV2020	20222	Placebo	30NOV2020	Placebo	22DEC2020	Placebo
11501168	C4591001 115011501168	12-15	02DEC2020	20228	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11501171	C4591001 115011501171	12-15	03DEC2020	20799	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)
11501176	C4591001 115011501176	12-15	04DEC2020	20801	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11501178	C4591001 115011501178	12-15	07DEC2020	20803	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11501179	C4591001 115011501179	12-15	07DEC2020	20804	Placebo	07DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11501180	C4591001 11501180	12-15	08DEC2020	21334	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	
11501182	C4591001 11501182	12-15	08DEC2020	21339	Placebo	08DEC2020	Placebo	28DEC2020	Placebo	
11501183	C4591001 11501183	12-15	08DEC2020	21341	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	
11501185	C4591001 11501185	12-15	08DEC2020	21344	Placebo	08DEC2020	Placebo	28DEC2020	Placebo	
11501186	C4591001 11501186	12-15	09DEC2020	21635	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	
11501187	C4591001 11501187	12-15	09DEC2020	21637	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	
11501189	C4591001 11501189	12-15	10DEC2020	21638	Placebo	10DEC2020	Placebo	29DEC2020	Placebo	
11501190	C4591001 11501190	12-15	10DEC2020	21642	Placebo	10DEC2020	Placebo	29DEC2020	Placebo	
11501191	C4591001 11501191	12-15	10DEC2020	21850	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	
11501192	C4591001 11501192	12-15	10DEC2020	21851	Placebo	10DEC2020	Placebo	29DEC2020	Placebo	
11501193	C4591001 11501193	12-15	10DEC2020	21852	Placebo	10DEC2020	Placebo	31DEC2020	Placebo	
11501194	C4591001 11501194	12-15	10DEC2020	21853	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	
11501195	C4591001 11501195	12-15	11DEC2020	22007	Placebo	11DEC2020	Placebo	31DEC2020	Placebo	
11501196	C4591001 11501196	12-15	11DEC2020	22008	Placebo	11DEC2020	Placebo	31DEC2020	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501197	C4591001 11501197	12-15	11DEC2020	22012	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11501198	C4591001 11501198	12-15	11DEC2020	22014	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11501199	C4591001 11501199	12-15	11DEC2020	22137	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11501200	C4591001 11501200	12-15	11DEC2020	22138	Placebo	11DEC2020	Placebo	31DEC2020	Placebo
11501201	C4591001 11501201	12-15	11DEC2020	22140	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
11501202	C4591001 11501202	12-15	14DEC2020	22145	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11501203	C4591001 11501203	12-15	14DEC2020	22257	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11501204	C4591001 11501204	12-15	14DEC2020	22259	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11501205	C4591001 11501205	12-15	14DEC2020	22262	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11501206	C4591001 11501206	12-15	14DEC2020	22264	Placebo	14DEC2020	Placebo	06JAN2021	Placebo
11501207	C4591001 11501207	12-15	14DEC2020	22389	Placebo	14DEC2020	Placebo	04JAN2021	Placebo
11501208	C4591001 11501208	12-15	14DEC2020	22393	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11501209	C4591001 11501209	12-15	15DEC2020	22399	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11501210	C4591001 11501210	12-15	15DEC2020	22400	Placebo	15DEC2020	Placebo	07JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11501211	C4591001 115011501211	12-15	15DEC2020	22583	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	
11501212	C4591001 115011501212	12-15	15DEC2020	22587	Placebo	15DEC2020	Placebo	07JAN2021	Placebo	
11501213	C4591001 115011501213	12-15	15DEC2020	22590	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	
11501214	C4591001 115011501214	12-15	15DEC2020	22591	Placebo	15DEC2020	Placebo	07JAN2021	Placebo	
11501215	C4591001 115011501215	12-15	15DEC2020	22653	Placebo	15DEC2020	Placebo	07JAN2021	Placebo	
11501216	C4591001 115011501216	12-15	16DEC2020	22654	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	
11501217	C4591001 115011501217	12-15	16DEC2020	22657	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	
11501218	C4591001 115011501218	12-15	17DEC2020	22664	Placebo	17DEC2020	Placebo	06JAN2021	Placebo	
11501219	C4591001 115011501219	12-15	17DEC2020	22989	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	
11501220	C4591001 115011501220	12-15	17DEC2020	22991	Placebo	17DEC2020	Placebo	06JAN2021	Placebo	
11501221	C4591001 115011501221	12-15	17DEC2020	22994	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	
11501222	C4591001 115011501222	12-15	17DEC2020	22999	Placebo	17DEC2020	Placebo	06JAN2021	Placebo	
11501223	C4591001 115011501223	12-15	17DEC2020	23063	Placebo	17DEC2020	Placebo	08JAN2021	Placebo	
11501224	C4591001 115011501224	12-15	17DEC2020	23067	Placebo	17DEC2020	Placebo	08JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501225	C4591001 115011501225	12-15	17DEC2020	23070	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11501226	C4591001 115011501226	12-15	17DEC2020	23072	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11501227	C4591001 115011501227	12-15	18DEC2020	23361	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11501228	C4591001 115011501228	12-15	18DEC2020	23364	Placebo	18DEC2020	Placebo	06JAN2021	Placebo
11501229	C4591001 115011501229	12-15	20DEC2020	23368	Placebo	20DEC2020	Placebo	12JAN2021	Placebo
11501230	C4591001 115011501230	12-15	20DEC2020	23371	BNT162b2 (30 µg)	20DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11501231	C4591001 115011501231	12-15	20DEC2020	23530	Placebo	20DEC2020	Placebo	12JAN2021	Placebo
11501232	C4591001 115011501232	12-15	21DEC2020	23531	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11501233	C4591001 115011501233	12-15	21DEC2020	23534	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11501234	C4591001 115011501234	12-15	21DEC2020	23535	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11501235	C4591001 115011501235	12-15	21DEC2020	23638	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11501236	C4591001 115011501236	12-15	21DEC2020	23640	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11501237	C4591001 115011501237	12-15	21DEC2020	23642	Placebo	21DEC2020	Placebo	13JAN2021	Placebo
11501238	C4591001 115011501238	12-15	22DEC2020	23643	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501239	C4591001 11501239	12-15	22DEC2020	24073	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
11501240	C4591001 11501240	12-15	22DEC2020	24074	Placebo	22DEC2020	Placebo	14JAN2021	Placebo
11501241	C4591001 11501241	12-15	22DEC2020	24077	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
11501242	C4591001 11501242	12-15	23DEC2020	24080	Placebo	23DEC2020	Placebo	15JAN2021	Placebo
11501243	C4591001 11501243	12-15	23DEC2020	24276	Placebo	23DEC2020	Placebo	11JAN2021	Placebo
11501244	C4591001 11501244	12-15	28DEC2020	24277	Placebo	28DEC2020	Placebo	20JAN2021	Placebo
11501245	C4591001 11501245	12-15	28DEC2020	24279	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11501246	C4591001 11501246	12-15	28DEC2020	24281	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11501247	C4591001 11501247	12-15	29DEC2020	24526	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11501248	C4591001 11501248	12-15	29DEC2020	24528	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11501249	C4591001 11501249	12-15	29DEC2020	24529	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11501250	C4591001 11501250	12-15	29DEC2020	24531	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11501251	C4591001 11501251	12-15	29DEC2020	24744	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
11501252	C4591001 11501252	12-15	29DEC2020	24746	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501253	C4591001 1150 11501253	12-15	29DEC2020	24747	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11501254	C4591001 1150 11501254	12-15	29DEC2020	24751	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
11501255	C4591001 1150 11501255	12-15	30DEC2020	24899	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11501256	C4591001 1150 11501256	12-15	30DEC2020	24900	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11501257	C4591001 1150 11501257	12-15	30DEC2020	24905	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
11501258	C4591001 1150 11501258	12-15	30DEC2020	24906	Placebo	30DEC2020	Placebo	22JAN2021	Placebo
11501259	C4591001 1150 11501259	12-15	30DEC2020	25032	Placebo	30DEC2020	Placebo	22JAN2021	Placebo
11501260	C4591001 1150 11501260	12-15	30DEC2020	25036	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11501261	C4591001 1150 11501261	12-15	31DEC2020	25037	Placebo	31DEC2020	Placebo	20JAN2021	Placebo
11501262	C4591001 1150 11501262	12-15	31DEC2020	25040	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)	20JAN2021	BNT162b2 (30 µg)
11501263	C4591001 1150 11501263	12-15	04JAN2021	25126	Placebo	04JAN2021	Placebo	26JAN2021	Placebo
11501264	C4591001 1150 11501264	12-15	04JAN2021	25127	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
11501265	C4591001 1150 11501265	12-15	04JAN2021	25128	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11501266	C4591001 1150 11501266	12-15	04JAN2021	25129	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501267	C4591001 115011501267	12-15	04JAN2021	25282	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
11501268	C4591001 115011501268	12-15	04JAN2021	25283	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11501269	C4591001 115011501269	12-15	04JAN2021	25287	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11501270	C4591001 115011501270	12-15	04JAN2021	25291	Placebo	04JAN2021	Placebo	27JAN2021	Placebo
11501271	C4591001 115011501271	12-15	05JAN2021	25354	Placebo	05JAN2021	Placebo	25JAN2021	Placebo
11501272	C4591001 115011501272	12-15	05JAN2021	25357	Placebo	05JAN2021	Placebo	25JAN2021	Placebo
11501273	C4591001 115011501273	12-15	05JAN2021	25362	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11501274	C4591001 115011501274	12-15	05JAN2021	25364	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11501275	C4591001 115011501275	12-15	05JAN2021	25449	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11501276	C4591001 115011501276	12-15	05JAN2021	25451	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11501277	C4591001 115011501277	12-15	05JAN2021	25459	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11501278	C4591001 115011501278	12-15	05JAN2021	25460	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
11501279	C4591001 115011501279	12-15	06JAN2021	25629	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11501280	C4591001 115011501280	12-15	06JAN2021	25632	Placebo	06JAN2021	Placebo	28JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501281	C4591001 115011501281	12-15	06JAN2021	25634	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11501282	C4591001 115011501282	12-15	06JAN2021	25635	Placebo	06JAN2021	Placebo	28JAN2021	Placebo
11501283	C4591001 115011501283	12-15	06JAN2021	25823	Placebo	06JAN2021	Placebo	29JAN2021	Placebo
11501284	C4591001 115011501284	12-15	07JAN2021	25827	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
11501285	C4591001 115011501285	12-15	07JAN2021	25831	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11501286	C4591001 115011501286	12-15	07JAN2021	25832	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11501287	C4591001 115011501287	12-15	07JAN2021	26004	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11501288	C4591001 115011501288	12-15	08JAN2021	26007	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11501289	C4591001 115011501289	12-15	08JAN2021	26010	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11501290	C4591001 115011501290	12-15	11JAN2021	26011	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
11501291	C4591001 115011501291	12-15	11JAN2021	26553	Placebo	11JAN2021	Placebo	03FEB2021	Placebo
11501292	C4591001 115011501292	12-15	11JAN2021	26556	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
11501293	C4591001 115011501293	12-15	11JAN2021	26560	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	12FEB2021	BNT162b2 (30 µg)
11501294	C4591001 115011501294	12-15	11JAN2021	26564	Placebo	11JAN2021	Placebo	01FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501295	C4591001 115011501295	12-15	11JAN2021	26626	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11501296	C4591001 115011501296	12-15	11JAN2021	26627	Placebo	11JAN2021	Placebo	03FEB2021	Placebo
11501297	C4591001 115011501297	12-15	11JAN2021	26629	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
11501298	C4591001 115011501298	12-15	12JAN2021	26632	Placebo	12JAN2021	Placebo	01FEB2021	Placebo
11501299	C4591001 115011501299	12-15	12JAN2021	26853	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11501300	C4591001 115011501300	12-15	12JAN2021	26856	Placebo	12JAN2021	Placebo	01FEB2021	Placebo
11501301	C4591001 115011501301	12-15	12JAN2021	26859	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	03FEB2021	BNT162b2 (30 µg)
11501302	C4591001 115011501302	12-15	12JAN2021	26863	Placebo	12JAN2021	Placebo	03FEB2021	Placebo
11521604	C4591001 1152111521604	12-15	02DEC2020	20769	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
11521605	C4591001 1152111521605	12-15	02DEC2020	20770	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11521607	C4591001 1152111521607	12-15	03DEC2020	20772	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11521608	C4591001 1152111521608	12-15	03DEC2020	20771	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11521611	C4591001 1152111521611	12-15	03DEC2020	20884	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11521612	C4591001 1152111521612	12-15	03DEC2020	20882	Placebo	03DEC2020	Placebo	22DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521613	C4591001 1152 11521613	12-15	03DEC2020	20877	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11521614	C4591001 1152 11521614	12-15	03DEC2020	20886	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11521615	C4591001 1152 11521615	12-15	03DEC2020	20925	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11521617	C4591001 1152 11521617	12-15	03DEC2020	20928	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521619	C4591001 1152 11521619	12-15	03DEC2020	20930	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11521625	C4591001 1152 11521625	12-15	04DEC2020	20988	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11521626	C4591001 1152 11521626	12-15	04DEC2020	20931	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11521628	C4591001 1152 11521628	12-15	04DEC2020	20989	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11521629	C4591001 1152 11521629	12-15	04DEC2020	20991	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11521633	C4591001 1152 11521633	12-15	07DEC2020	20992	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11521635	C4591001 1152 11521635	12-15	07DEC2020	21225	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521636	C4591001 1152 11521636	12-15	07DEC2020	21233	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521637	C4591001 1152 11521637	12-15	07DEC2020	21236	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11521638	C4591001 1152 11521638	12-15	07DEC2020	21234	Placebo	07DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521639	C4591001 1152 11521639	12-15	07DEC2020	21312	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11521640	C4591001 1152 11521640	12-15	07DEC2020	21313	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521641	C4591001 1152 11521641	12-15	07DEC2020	21315	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)		
11521642	C4591001 1152 11521642	12-15	07DEC2020	21317	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11521644	C4591001 1152 11521644	12-15	07DEC2020	21323	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521645	C4591001 1152 11521645	12-15	08DEC2020	21327	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
11521646	C4591001 1152 11521646	12-15	08DEC2020	21329	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521647	C4591001 1152 11521647	12-15	08DEC2020	21331	Placebo	08DEC2020	Placebo	06JAN2021	Placebo
11521648	C4591001 1152 11521648	12-15	08DEC2020	21527	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521649	C4591001 1152 11521649	12-15	08DEC2020	21531	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
11521650	C4591001 1152 11521650	12-15	08DEC2020	21532	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521651	C4591001 1152 11521651	12-15	08DEC2020	21533	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
11521652	C4591001 1152 11521652	12-15	08DEC2020	21573	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
11521653	C4591001 1152 11521653	12-15	09DEC2020	21577	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521654	C4591001 1152 11521654	12-15	09DEC2020	21581	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
11521655	C4591001 1152 11521655	12-15	09DEC2020	21582	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11521656	C4591001 1152 11521656	12-15	10DEC2020	21914	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
11521657	C4591001 1152 11521657	12-15	10DEC2020	21915	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11521658	C4591001 1152 11521658	12-15	10DEC2020	21917	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
11521659	C4591001 1152 11521659	12-15	10DEC2020	21993	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
11521660	C4591001 1152 11521660	12-15	10DEC2020	21918	Placebo	10DEC2020	Placebo	04JAN2021	Placebo
11521661	C4591001 1152 11521661	12-15	10DEC2020	21997	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
11521662	C4591001 1152 11521662	12-15	10DEC2020	21998	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11521663	C4591001 1152 11521663	12-15	10DEC2020	21999	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11521664	C4591001 1152 11521664	12-15	11DEC2020	22081	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11521665	C4591001 1152 11521665	12-15	11DEC2020	22078	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11521666	C4591001 1152 11521666	12-15	11DEC2020	22082	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11521667	C4591001 1152 11521667	12-15	11DEC2020	22128	Placebo	11DEC2020	Placebo	30DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11521668	C4591001 11521668	12-15	11DEC2020	22085	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	
11521669	C4591001 11521669	12-15	11DEC2020	22129	Placebo	11DEC2020	Placebo	30DEC2020	Placebo	
11521670	C4591001 11521670	12-15	11DEC2020	22133	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	
11521671	C4591001 11521671	12-15	14DEC2020	22134	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	
11521672	C4591001 11521672	12-15	14DEC2020	22414	Placebo	14DEC2020	Placebo	04JAN2021	Placebo	
11521673	C4591001 11521673	12-15	14DEC2020	22416	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	
11521674	C4591001 11521674	12-15	14DEC2020	22417	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	
11521675	C4591001 11521675	12-15	14DEC2020	22420	Placebo	14DEC2020	Placebo	04JAN2021	Placebo	
11521676	C4591001 11521676	12-15	14DEC2020	22462	Placebo	14DEC2020	Placebo	04JAN2021	Placebo	
11521677	C4591001 11521677	12-15	15DEC2020	22463	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	
11521678	C4591001 11521678	12-15	15DEC2020	22465	Placebo	15DEC2020	Placebo	04JAN2021	Placebo	
11521679	C4591001 11521679	12-15	15DEC2020	22472	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	
11521680	C4591001 11521680	12-15	15DEC2020	22680	Placebo	15DEC2020	Placebo	05JAN2021	Placebo	
11521681	C4591001 11521681	12-15	15DEC2020	22683	Placebo	15DEC2020	Placebo	05JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521682	C4591001 115211521682	12-15	15DEC2020	22684	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11521683	C4591001 115211521683	12-15	15DEC2020	22686	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11521684	C4591001 115211521684	12-15	15DEC2020	22713	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11521685	C4591001 115211521685	12-15	15DEC2020	22716	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11521686	C4591001 115211521686	12-15	16DEC2020	22717	Placebo	16DEC2020	Placebo	11JAN2021	Placebo
11521687	C4591001 115211521687	12-15	16DEC2020	22958	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11521688	C4591001 115211521688	12-15	16DEC2020	22721	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11521689	C4591001 115211521689	12-15	16DEC2020	22959	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
11521690	C4591001 115211521690	12-15	16DEC2020	22963	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11521691	C4591001 115211521691	12-15	16DEC2020	22960	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11521692	C4591001 115211521692	12-15	16DEC2020	22967	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11521693	C4591001 115211521693	12-15	16DEC2020	22968	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
11521694	C4591001 115211521694	12-15	16DEC2020	22974	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11521695	C4591001 115211521695	12-15	16DEC2020	22975	Placebo	16DEC2020	Placebo	06JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521696	C4591001 1152 11521696	12-15	17DEC2020	23241	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
11521697	C4591001 1152 11521697	12-15	18DEC2020	23243	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11521698	C4591001 1152 11521698	12-15	18DEC2020	23244	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
11521699	C4591001 1152 11521699	12-15	18DEC2020	23250	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11521700	C4591001 1152 11521700	12-15	18DEC2020	23471	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
11521701	C4591001 1152 11521701	12-15	18DEC2020	23473	Placebo	18DEC2020	Placebo	06JAN2021	Placebo
11521702	C4591001 1152 11521702	12-15	21DEC2020	23475	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11521703	C4591001 1152 11521703	12-15	21DEC2020	23476	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
11521704	C4591001 1152 11521704	12-15	21DEC2020	23749	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11521705	C4591001 1152 11521705	12-15	21DEC2020	23751	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11521706	C4591001 1152 11521706	12-15	21DEC2020	23752	Placebo	21DEC2020	Placebo	11JAN2021	Placebo
11521707	C4591001 1152 11521707	12-15	21DEC2020	23755	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11521708	C4591001 1152 11521708	12-15	21DEC2020	23878	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11521709	C4591001 1152 11521709	12-15	22DEC2020	23881	Placebo	22DEC2020	Placebo	12JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521710	C4591001 1152 11521710	12-15	22DEC2020	23885	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11521711	C4591001 1152 11521711	12-15	22DEC2020	23886	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11521712	C4591001 1152 11521712	12-15	22DEC2020	24144	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
11521713	C4591001 1152 11521713	12-15	23DEC2020	24145	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11521714	C4591001 1152 11521714	12-15	23DEC2020	24147	Placebo	23DEC2020	Placebo	13JAN2021	Placebo
11521715	C4591001 1152 11521715	12-15	23DEC2020	24148	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11521716	C4591001 1152 11521716	12-15	28DEC2020	24515	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11521717	C4591001 1152 11521717	12-15	28DEC2020	24518	Placebo	28DEC2020	Placebo	18JAN2021	Placebo
11521718	C4591001 1152 11521718	12-15	29DEC2020	24522	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11521719	C4591001 1152 11521719	12-15	29DEC2020	24524	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
11521720	C4591001 1152 11521720	12-15	29DEC2020	24816	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11521721	C4591001 1152 11521721	12-15	29DEC2020	24822	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11521722	C4591001 1152 11521722	12-15	30DEC2020	24823	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	21JAN2021	BNT162b2 (30 µg)
11521723	C4591001 1152 11521723	12-15	30DEC2020	24824	Placebo	30DEC2020	Placebo	20JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521724	C4591001 11521724	12-15	30DEC2020	25091	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)
11521725	C4591001 11521725	12-15	30DEC2020	25090	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
11521726	C4591001 11521726	12-15	30DEC2020	25092	Placebo	30DEC2020	Placebo	18JAN2021	Placebo
11521727	C4591001 11521727	12-15	04JAN2021	25095	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11521728	C4591001 11521728	12-15	04JAN2021	25221	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11521729	C4591001 11521729	12-15	04JAN2021	25228	Placebo	04JAN2021	Placebo	27JAN2021	Placebo
11521730	C4591001 11521730	12-15	04JAN2021	25229	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11521731	C4591001 11521731	12-15	04JAN2021	25230	Placebo	04JAN2021	Placebo	27JAN2021	Placebo
11521732	C4591001 11521732	12-15	05JAN2021	25426	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11521733	C4591001 11521733	12-15	05JAN2021	25428	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11521734	C4591001 11521734	12-15	05JAN2021	25430	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11521735	C4591001 11521735	12-15	05JAN2021	25435	Placebo	05JAN2021	Placebo	27JAN2021	Placebo
11521736	C4591001 11521736	12-15	05JAN2021	25617	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11521737	C4591001 11521737	12-15	06JAN2021	25623	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521738	C4591001 1152 11521738	12-15	06JAN2021	25627	Placebo	06JAN2021	Placebo	29JAN2021	Placebo
11521739	C4591001 1152 11521739	12-15	07JAN2021	25628	Placebo	07JAN2021	Placebo	28JAN2021	Placebo
11521740	C4591001 1152 11521740	12-15	07JAN2021	26145	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
11521741	C4591001 1152 11521741	12-15	07JAN2021	26149	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
11521742	C4591001 1152 11521742	12-15	08JAN2021	26150	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11521743	C4591001 1152 11521743	12-15	08JAN2021	26151	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11521744	C4591001 1152 11521744	12-15	08JAN2021	26243	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11521745	C4591001 1152 11521745	12-15	08JAN2021	26245	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11521746	C4591001 1152 11521746	12-15	08JAN2021	26251	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11521747	C4591001 1152 11521747	12-15	08JAN2021	26252	Placebo	08JAN2021	Placebo	27JAN2021	Placebo
11521748	C4591001 1152 11521748	12-15	08JAN2021	26433	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11521749	C4591001 1152 11521749	12-15	08JAN2021	26434	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11521750	C4591001 1152 11521750	12-15	08JAN2021	26443	Placebo	08JAN2021	Placebo	28JAN2021	Placebo
11521751	C4591001 1152 11521751	12-15	11JAN2021	26444	Placebo	11JAN2021	Placebo	02FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521752	C4591001 1152 11521752	12-15	11JAN2021	26603	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
11521753	C4591001 1152 11521753	12-15	11JAN2021	26604	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
11521754	C4591001 1152 11521754	12-15	11JAN2021	26610	Placebo	11JAN2021	Placebo	01FEB2021	Placebo
11521755	C4591001 1152 11521755	12-15	11JAN2021	26606	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11521756	C4591001 1152 11521756	12-15	11JAN2021	26745	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)
11521757	C4591001 1152 11521757	12-15	11JAN2021	26747	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
11561243	C4591001 1156 11561243	12-15	15OCT2020	20038	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
11561244	C4591001 1156 11561244	12-15	15OCT2020	20039	Placebo	15OCT2020	Placebo	03NOV2020	Placebo
11561245	C4591001 1156 11561245	12-15	15OCT2020	20044	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
11561246	C4591001 1156 11561246	12-15	22OCT2020	20285	Placebo	22OCT2020	Placebo	10NOV2020	Placebo
11561247	C4591001 1156 11561247	12-15	16OCT2020	20046	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
11561248	C4591001 1156 11561248	12-15	16OCT2020	20086	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
11561249	C4591001 1156 11561249	12-15	16OCT2020	20087	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
11561250	C4591001 1156 11561250	12-15	16OCT2020	20090	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561253	C4591001 1156 11561253	12-15	19OCT2020	20094	Placebo	19OCT2020	Placebo	11NOV2020	Placebo
11561254	C4591001 1156 11561254	12-15	19OCT2020	20151	Placebo	19OCT2020	Placebo	11NOV2020	Placebo
11561255	C4591001 1156 11561255	12-15	20OCT2020	20152	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
11561256	C4591001 1156 11561256	12-15	20OCT2020	20155	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
11561257	C4591001 1156 11561257	12-15	20OCT2020	20156	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11561259	C4591001 1156 11561259	12-15	20OCT2020	20183	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
11561260	C4591001 1156 11561260	12-15	21OCT2020	20185	Placebo	21OCT2020	Placebo	12NOV2020	Placebo
11561262	C4591001 1156 11561262	12-15	21OCT2020	20186	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11561263	C4591001 1156 11561263	12-15	21OCT2020	20189	Placebo	21OCT2020	Placebo	10NOV2020	Placebo
11561264	C4591001 1156 11561264	12-15	22OCT2020	20279	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
11561265	C4591001 1156 11561265	12-15	22OCT2020	20283	Placebo	22OCT2020	Placebo	10NOV2020	Placebo
11561303	C4591001 1156 11561303	12-15	30NOV2020	20287	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11561304	C4591001 1156 11561304	12-15	30NOV2020	20403	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11561305	C4591001 1156 11561305	12-15	30NOV2020	20404	Placebo	30NOV2020	Placebo	22DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11561306	C4591001 1156 11561306	12-15	01DEC2020	20405	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	
11561307	C4591001 1156 11561307	12-15	01DEC2020	20408	Placebo	01DEC2020	Placebo	21DEC2020	Placebo	
11561308	C4591001 1156 11561308	12-15	01DEC2020	20542	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	
11561309	C4591001 1156 11561309	12-15	01DEC2020	20549	Placebo	01DEC2020	Placebo	21DEC2020	Placebo	
11561310	C4591001 1156 11561310	12-15	01DEC2020	20551	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	
11561311	C4591001 1156 11561311	12-15	02DEC2020	20552	Placebo	02DEC2020	Placebo	05JAN2021	Placebo	
11561312	C4591001 1156 11561312	12-15	02DEC2020	20661	Placebo	02DEC2020	Placebo	22DEC2020	Placebo	
11561313	C4591001 1156 11561313	12-15	02DEC2020	20663	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	
11561314	C4591001 1156 11561314	12-15	03DEC2020	20665	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	
11561316	C4591001 1156 11561316	12-15	03DEC2020	20666	Placebo	03DEC2020	Placebo	28DEC2020	Placebo	
11561317	C4591001 1156 11561317	12-15	03DEC2020	20859	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	
11561318	C4591001 1156 11561318	12-15	04DEC2020	20861	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	
11561319	C4591001 1156 11561319	12-15	04DEC2020	20862	Placebo	04DEC2020	Placebo	23DEC2020	Placebo	
11561320	C4591001 1156 11561320	12-15	04DEC2020	20863	Placebo	04DEC2020	Placebo	23DEC2020	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11561321	C4591001 1156 11561321	12-15	07DEC2020	21165	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	
11561322	C4591001 1156 11561322	12-15	07DEC2020	21168	Placebo	07DEC2020	Placebo	28DEC2020	Placebo	
11561323	C4591001 1156 11561323	12-15	07DEC2020	21173	Placebo	07DEC2020	Placebo	28DEC2020	Placebo	
11561324	C4591001 1156 11561324	12-15	07DEC2020	21176	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)	
11561325	C4591001 1156 11561325	12-15	08DEC2020	21489	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	
11561327	C4591001 1156 11561327	12-15	10DEC2020	21492	Placebo	10DEC2020	Placebo	29DEC2020	Placebo	
11561328	C4591001 1156 11561328	12-15	14DEC2020	21493	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	
11561330	C4591001 1156 11561330	12-15	15DEC2020	21500	Placebo	15DEC2020	Placebo	04JAN2021	Placebo	
11561331	C4591001 1156 11561331	12-15	17DEC2020	23109	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	
11561332	C4591001 1156 11561332	12-15	17DEC2020	23113	Placebo	17DEC2020	Placebo	05JAN2021	Placebo	
11561333	C4591001 1156 11561333	12-15	18DEC2020	23117	Placebo	18DEC2020	Placebo	07JAN2021	Placebo	
11561334	C4591001 1156 11561334	12-15	18DEC2020	23120	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	
11561335	C4591001 1156 11561335	12-15	21DEC2020	23613	Placebo	21DEC2020	Placebo	13JAN2021	Placebo	
11561336	C4591001 1156 11561336	12-15	22DEC2020	23615	Placebo	22DEC2020	Placebo	11JAN2021	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561337	C4591001 1156 11561337	12-15	22DEC2020	23621	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11561338	C4591001 1156 11561338	12-15	23DEC2020	23624	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11561339	C4591001 1156 11561339	12-15	28DEC2020	24385	Placebo	28DEC2020	Placebo	19JAN2021	Placebo
11561340	C4591001 1156 11561340	12-15	28DEC2020	24386	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11561341	C4591001 1156 11561341	12-15	29DEC2020	24388	Placebo	29DEC2020	Placebo	19JAN2021	Placebo
11561342	C4591001 1156 11561342	12-15	29DEC2020	24389	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)	19JAN2021	BNT162b2 (30 µg)
11561343	C4591001 1156 11561343	12-15	04JAN2021	25174	Placebo	04JAN2021	Placebo	25JAN2021	Placebo
11561344	C4591001 1156 11561344	12-15	04JAN2021	25175	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
11561345	C4591001 1156 11561345	12-15	05JAN2021	25176	Placebo	05JAN2021	Placebo	25JAN2021	Placebo
11561346	C4591001 1156 11561346	12-15	06JAN2021	25177	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11561347	C4591001 1156 11561347	12-15	06JAN2021	25701	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11561348	C4591001 1156 11561348	12-15	06JAN2021	25708	Placebo	06JAN2021	Placebo	26JAN2021	Placebo
11561349	C4591001 1156 11561349	12-15	06JAN2021	25702	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
11561351	C4591001 1156 11561351	12-15	07JAN2021	25709	Placebo	07JAN2021	Placebo	28JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561352	C4591001 1156 11561352	12-15	07JAN2021	25954	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11561353	C4591001 1156 11561353	12-15	07JAN2021	25956	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
11561354	C4591001 1156 11561354	12-15	07JAN2021	25957	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11561355	C4591001 1156 11561355	12-15	07JAN2021	25963	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
11561356	C4591001 1156 11561356	12-15	07JAN2021	26050	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11561357	C4591001 1156 11561357	12-15	07JAN2021	26052	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
11561358	C4591001 1156 11561358	12-15	07JAN2021	26056	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11561359	C4591001 1156 11561359	12-15	08JAN2021	26059	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11561360	C4591001 1156 11561360	12-15	08JAN2021	26217	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
11561361	C4591001 1156 11561361	12-15	08JAN2021	26218	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
11561362	C4591001 1156 11561362	12-15	08JAN2021	26225	Placebo	08JAN2021	Placebo	27JAN2021	Placebo
11561363	C4591001 1156 11561363	12-15	08JAN2021	26226	Placebo	08JAN2021	Placebo	29JAN2021	Placebo
11561364	C4591001 1156 11561364	12-15	08JAN2021	26387	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
11561365	C4591001 1156 11561365	12-15	11JAN2021	26395	Placebo	11JAN2021	Placebo	01FEB2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
11561366	C4591001 1156 11561366	12-15	11JAN2021	26393	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)	
11561367	C4591001 1156 11561367	12-15	11JAN2021	26396	Placebo	11JAN2021	Placebo	01FEB2021	Placebo	
11561368	C4591001 1156 11561368	12-15	11JAN2021	26662	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)	
11561369	C4591001 1156 11561369	12-15	11JAN2021	26663	Placebo	11JAN2021	Placebo	01FEB2021	Placebo	
11561370	C4591001 1156 11561370	12-15	11JAN2021	26666	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	01FEB2021	BNT162b2 (30 µg)	
11561371	C4591001 1156 11561371	12-15	12JAN2021	26668	Placebo	12JAN2021	Placebo	04FEB2021	Placebo	
11561372	C4591001 1156 11561372	12-15	12JAN2021	26811	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	04FEB2021	BNT162b2 (30 µg)	
11561373	C4591001 1156 11561373	12-15	12JAN2021	26813	Placebo	12JAN2021	Placebo	01FEB2021	Placebo	
11561374	C4591001 1156 11561374	12-15	12JAN2021	26814	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)	
11561375	C4591001 1156 11561375	12-15	12JAN2021	26816	Placebo	12JAN2021	Placebo	02FEB2021	Placebo	
12231267	C4591001 1223 12231267	12-15	07JAN2021	26015	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)	
12231268	C4591001 1223 12231268	12-15	07JAN2021	26017	Placebo	07JAN2021	Placebo	27JAN2021	Placebo	
12231269	C4591001 1223 12231269	12-15	07JAN2021	26022	Placebo	07JAN2021	Placebo	29JAN2021	Placebo	
12231270	C4591001 1223 12231270	12-15	07JAN2021	26024	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12231271	C4591001 1223 12231271	12-15	08JAN2021	26289	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
12231272	C4591001 1223 12231272	12-15	09JAN2021	26290	Placebo	09JAN2021	Placebo	29JAN2021	Placebo
12231273	C4591001 1223 12231273	12-15	09JAN2021	26295	Placebo	09JAN2021	Placebo	29JAN2021	Placebo
12231274	C4591001 1223 12231274	12-15	09JAN2021	26293	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	29JAN2021	BNT162b2 (30 µg)
12231275	C4591001 1223 12231275	12-15	09JAN2021	26457	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
12231276	C4591001 1223 12231276	12-15	09JAN2021	26461	Placebo	09JAN2021	Placebo	28JAN2021	Placebo
12231277	C4591001 1223 12231277	12-15	09JAN2021	26459	Placebo	09JAN2021	Placebo	02FEB2021	Placebo
12231278	C4591001 1223 12231278	12-15	09JAN2021	26468	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
12231279	C4591001 1223 12231279	12-15	09JAN2021	26484	Placebo	09JAN2021	Placebo	02FEB2021	Placebo
12231280	C4591001 1223 12231280	12-15	09JAN2021	26488	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
12231281	C4591001 1223 12231281	12-15	09JAN2021	26489	BNT162b2 (30 µg)	09JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
12231283	C4591001 1223 12231283	12-15	09JAN2021	26490	Placebo	09JAN2021	Placebo	29JAN2021	Placebo
12231284	C4591001 1223 12231284	12-15	12JAN2021	26866	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
12231285	C4591001 1223 12231285	12-15	12JAN2021	26870	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12231286	C4591001 1223 12231286	12-15	12JAN2021	26873	Placebo	12JAN2021	Placebo	03FEB2021	Placebo
12351232	C4591001 1235 12351232	12-15	30NOV2020	20363	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
12351233	C4591001 1235 12351233	12-15	30NOV2020	20364	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12351234	C4591001 1235 12351234	12-15	30NOV2020	20370	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
12351235	C4591001 1235 12351235	12-15	30NOV2020	20371	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
12351236	C4591001 1235 12351236	12-15	02DEC2020	20711	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
12351238	C4591001 1235 12351238	12-15	07DEC2020	20712	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12351239	C4591001 1235 12351239	12-15	07DEC2020	20714	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
12351242	C4591001 1235 12351242	12-15	08DEC2020	20717	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12351243	C4591001 1235 12351243	12-15	08DEC2020	21405	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
12351244	C4591001 1235 12351244	12-15	08DEC2020	21409	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
12351245	C4591001 1235 12351245	12-15	08DEC2020	21411	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
12351246	C4591001 1235 12351246	12-15	15DEC2020	21415	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
12351247	C4591001 1235 12351247	12-15	15DEC2020	22501	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12351248	C4591001 1235 12351248	12-15	15DEC2020	22503	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
12351249	C4591001 1235 12351249	12-15	15DEC2020	22506	Placebo	15DEC2020	Placebo	04JAN2021	Placebo
12351250	C4591001 1235 12351250	12-15	15DEC2020	22507	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
12351251	C4591001 1235 12351251	12-15	18DEC2020	23280	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
12351252	C4591001 1235 12351252	12-15	21DEC2020	23281	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
12351253	C4591001 1235 12351253	12-15	08JAN2021	23285	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
12351254	C4591001 1235 12351254	12-15	08JAN2021	23286	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
12701173	C4591001 1270 12701173	12-15	30NOV2020	20391	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
12701174	C4591001 1270 12701174	12-15	30NOV2020	20392	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
12701177	C4591001 1270 12701177	12-15	01DEC2020	20394	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12701180	C4591001 1270 12701180	12-15	02DEC2020	20396	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
12701181	C4591001 1270 12701181	12-15	02DEC2020	20722	Placebo	02DEC2020	Placebo	22DEC2020	Placebo
12701184	C4591001 1270 12701184	12-15	02DEC2020	20723	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
12701187	C4591001 1270 12701187	12-15	03DEC2020	20724	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12701188	C4591001 1270 12701188	12-15	03DEC2020	20728	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
12701189	C4591001 1270 12701189	12-15	03DEC2020	20890	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
12701191	C4591001 1270 12701191	12-15	03DEC2020	20894	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
12701192	C4591001 1270 12701192	12-15	04DEC2020	20898	Placebo	04DEC2020	Placebo	24DEC2020	Placebo
12701194	C4591001 1270 12701194	12-15	04DEC2020	20900	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
12701198	C4591001 1270 12701198	12-15	07DEC2020	21213	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
12701199	C4591001 1270 12701199	12-15	08DEC2020	21214	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
12701200	C4591001 1270 12701200	12-15	10DEC2020	21215	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
12701201	C4591001 1270 12701201	12-15	11DEC2020	21222	Placebo	11DEC2020	Placebo	04JAN2021	Placebo
12701202	C4591001 1270 12701202	12-15	11DEC2020	22186	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
12701203	C4591001 1270 12701203	12-15	11DEC2020	22187	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
12701204	C4591001 1270 12701204	12-15	15DEC2020	22194	Placebo	15DEC2020	Placebo	06JAN2021	Placebo
12701205	C4591001 1270 12701205	12-15	15DEC2020	22196	Placebo	15DEC2020	Placebo	05JAN2021	Placebo
12701206	C4591001 1270 12701206	12-15	15DEC2020	22641	Placebo	15DEC2020	Placebo	06JAN2021	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12701207	C4591001 1270 12701207	12-15	16DEC2020	22645	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
12701208	C4591001 1270 12701208	12-15	16DEC2020	22647	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
12701209	C4591001 1270 12701209	12-15	16DEC2020	22652	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
12701210	C4591001 1270 12701210	12-15	16DEC2020	22942	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
12701211	C4591001 1270 12701211	12-15	16DEC2020	22944	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)
12701212	C4591001 1270 12701212	12-15	16DEC2020	22946	Placebo	16DEC2020	Placebo	06JAN2021	Placebo
12701213	C4591001 1270 12701213	12-15	17DEC2020	22947	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
12701214	C4591001 1270 12701214	12-15	17DEC2020	23037	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
12701215	C4591001 1270 12701215	12-15	17DEC2020	23038	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)	14JAN2021	BNT162b2 (30 µg)
12701216	C4591001 1270 12701216	12-15	17DEC2020	23044	Placebo	17DEC2020	Placebo	06JAN2021	Placebo
12701217	C4591001 1270 12701217	12-15	17DEC2020	23048	Placebo	17DEC2020	Placebo	08JAN2021	Placebo
12701218	C4591001 1270 12701218	12-15	17DEC2020	23217	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
12701219	C4591001 1270 12701219	12-15	18DEC2020	23219	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
12701220	C4591001 1270 12701220	12-15	18DEC2020	23224	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12701221	C4591001 1270 12701221	12-15	18DEC2020	23225	Placebo	18DEC2020	Placebo	06JAN2021	Placebo
12701222	C4591001 1270 12701222	12-15	18DEC2020	23485	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
12701223	C4591001 1270 12701223	12-15	18DEC2020	23487	Placebo	18DEC2020	Placebo	08JAN2021	Placebo
12701224	C4591001 1270 12701224	12-15	21DEC2020	23488	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
12701225	C4591001 1270 12701225	12-15	29DEC2020	23489	Placebo	29DEC2020	Placebo	18JAN2021	Placebo
12701226	C4591001 1270 12701226	12-15	04JAN2021	25346	BNT162b2 (30 µg)	04JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)
12701227	C4591001 1270 12701227	12-15	05JAN2021	25347	Placebo	05JAN2021	Placebo	28JAN2021	Placebo
12701228	C4591001 1270 12701228	12-15	05JAN2021	25350	Placebo	05JAN2021	Placebo	26JAN2021	Placebo
12701229	C4591001 1270 12701229	12-15	05JAN2021	25352	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
12701230	C4591001 1270 12701230	12-15	05JAN2021	25533	Placebo	05JAN2021	Placebo	25JAN2021	Placebo
12701231	C4591001 1270 12701231	12-15	05JAN2021	25536	Placebo	05JAN2021	Placebo	25JAN2021	Placebo
12701232	C4591001 1270 12701232	12-15	05JAN2021	25541	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	27JAN2021	BNT162b2 (30 µg)
12701233	C4591001 1270 12701233	12-15	05JAN2021	25543	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)	26JAN2021	BNT162b2 (30 µg)
12701234	C4591001 1270 12701234	12-15	06JAN2021	25667	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12701235	C4591001 1270 12701235	12-15	06JAN2021	25669	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
12701236	C4591001 1270 12701236	12-15	06JAN2021	25673	Placebo	06JAN2021	Placebo	25JAN2021	Placebo
12701237	C4591001 1270 12701237	12-15	07JAN2021	25675	Placebo	07JAN2021	Placebo		
12701238	C4591001 1270 12701238	12-15	07JAN2021	26025	Placebo	07JAN2021	Placebo	26JAN2021	Placebo
12701239	C4591001 1270 12701239	12-15	07JAN2021	26027	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
12701240	C4591001 1270 12701240	12-15	07JAN2021	26028	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
12701241	C4591001 1270 12701241	12-15	07JAN2021	26030	Placebo	07JAN2021	Placebo	27JAN2021	Placebo
12701242	C4591001 1270 12701242	12-15	08JAN2021	26351	Placebo	08JAN2021	Placebo	03FEB2021	Placebo
12701243	C4591001 1270 12701243	12-15	11JAN2021	26352	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	02FEB2021	BNT162b2 (30 µg)
12701244	C4591001 1270 12701244	12-15	11JAN2021	26359	Placebo	11JAN2021	Placebo	02FEB2021	Placebo
10011085	C4591001 1001 10011085	16-25	28JUL2020	40018	BNT162b2 (30 µg)	28JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
10011125	C4591001 1001 10011125	16-25	04AUG2020	41040	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)		
10031111	C4591001 1003 10031111	16-25	30JUL2020	40149	Placebo	30JUL2020	Placebo	20AUG2020	Placebo
10031124	C4591001 1003 10031124	16-25	31JUL2020	40820	Placebo	31JUL2020	Placebo	21AUG2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10051024	C4591001 1005 10051024	16-25	11AUG2020	46639	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10051036	C4591001 1005 10051036	16-25	12AUG2020	47597	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10051052	C4591001 1005 10051052	16-25	13AUG2020	47929	Placebo	13AUG2020	Placebo	02SEP2020	Placebo
10051071	C4591001 1005 10051071	16-25	14AUG2020	49468	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
10051147	C4591001 1005 10051147	16-25	25AUG2020	66642	Placebo	25AUG2020	Placebo	17SEP2020	Placebo
10051198	C4591001 1005 10051198	16-25	03SEP2020	79548	Placebo	03SEP2020	Placebo	25SEP2020	Placebo
10051216	C4591001 1005 10051216	16-25	03SEP2020	79923	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10051217	C4591001 1005 10051217	16-25	03SEP2020	79916	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10051236	C4591001 1005 10051236	16-25	13OCT2020	106687	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10051238	C4591001 1005 10051238	16-25	13OCT2020	106696	Placebo	13OCT2020	Placebo	03NOV2020	Placebo
10051264	C4591001 1005 10051264	16-25	15OCT2020	107793	Placebo	15OCT2020	Placebo	04NOV2020	Placebo
10051273	C4591001 1005 10051273	16-25	15OCT2020	108272	Placebo	15OCT2020	Placebo	03NOV2020	Placebo
10051283	C4591001 1005 10051283	16-25	16OCT2020	108430	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10051295	C4591001 1005 10051295	16-25	19OCT2020	109828	Placebo	19OCT2020	Placebo	09NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10051341	C4591001 1005 10051341	16-25	21OCT2020	111573	Placebo	21OCT2020	Placebo		
10051343	C4591001 1005 10051343	16-25	21OCT2020	111578	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10051371	C4591001 1005 10051371	16-25	26OCT2020	112983	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10051393	C4591001 1005 10051393	16-25	30OCT2020	114466	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
10051394	C4591001 1005 10051394	16-25	02NOV2020	114472	Placebo	02NOV2020	Placebo	23NOV2020	Placebo
10051398	C4591001 1005 10051398	16-25	03NOV2020	115318	Placebo	03NOV2020	Placebo	24NOV2020	Placebo
10051400	C4591001 1005 10051400	16-25	03NOV2020	115320	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
10051408	C4591001 1005 10051408	16-25	11NOV2020	116096	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)
10051409	C4591001 1005 10051409	16-25	09DEC2020	116098	Placebo	09DEC2020	Placebo	29DEC2020	Placebo
10051411	C4591001 1005 10051411	16-25	08JAN2021	117970	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)	28JAN2021	BNT162b2 (30 µg)
10051416	C4591001 1005 10051416	16-25	16DEC2020	116101	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
10051423	C4591001 1005 10051423	16-25	17DEC2020	117906	Placebo	17DEC2020	Placebo	07JAN2021	Placebo
10051426	C4591001 1005 10051426	16-25	21DEC2020	117907	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
10051432	C4591001 1005 10051432	16-25	22DEC2020	117910	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10051433	C4591001 1005 10051433	16-25	22DEC2020	117911	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10051434	C4591001 1005 10051434	16-25	22DEC2020	117954	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
10051435	C4591001 1005 10051435	16-25	22DEC2020	117955	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10051442	C4591001 1005 10051442	16-25	22DEC2020	117959	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	13JAN2021	BNT162b2 (30 µg)
10051443	C4591001 1005 10051443	16-25	22DEC2020	117962	Placebo	22DEC2020	Placebo	13JAN2021	Placebo
10051446	C4591001 1005 10051446	16-25	22DEC2020	117967	Placebo	22DEC2020	Placebo	12JAN2021	Placebo
10061013	C4591001 1006 10061013	16-25	11AUG2020	46294	Placebo	11AUG2020	Placebo	31AUG2020	Placebo
10061031	C4591001 1006 10061031	16-25	13AUG2020	49714	Placebo	13AUG2020	Placebo	04SEP2020	Placebo
10061033	C4591001 1006 10061033	16-25	13AUG2020	49712	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10061043	C4591001 1006 10061043	16-25	17AUG2020	50872	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
10061062	C4591001 1006 10061062	16-25	18AUG2020	55590	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10061071	C4591001 1006 10061071	16-25	19AUG2020	57393	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10061081	C4591001 1006 10061081	16-25	20AUG2020	58344	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
10061088	C4591001 1006 10061088	16-25	21AUG2020	59828	Placebo	21AUG2020	Placebo	11SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061091	C4591001 1006 10061091	16-25	21AUG2020	61613	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
10061104	C4591001 1006 10061104	16-25	25AUG2020	64944	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10061114	C4591001 1006 10061114	16-25	26AUG2020	67561	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
10061130	C4591001 1006 10061130	16-25	28AUG2020	73081	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
10061131	C4591001 1006 10061131	16-25	28AUG2020	73083	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
10061136	C4591001 1006 10061136	16-25	01SEP2020	74866	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
10061137	C4591001 1006 10061137	16-25	01SEP2020	74868	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10061141	C4591001 1006 10061141	16-25	03SEP2020	78076	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10061153	C4591001 1006 10061153	16-25	23SEP2020	97102	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10061154	C4591001 1006 10061154	16-25	23SEP2020	97105	Placebo	23SEP2020	Placebo	12OCT2020	Placebo
10061155	C4591001 1006 10061155	16-25	29SEP2020	101552	Placebo	29SEP2020	Placebo	22OCT2020	Placebo
10061156	C4591001 1006 10061156	16-25	24SEP2020	97108	Placebo	24SEP2020	Placebo	14OCT2020	Placebo
10061159	C4591001 1006 10061159	16-25	24SEP2020	99089	Placebo	24SEP2020	Placebo	16OCT2020	Placebo
10061162	C4591001 1006 10061162	16-25	25SEP2020	99100	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061164	C4591001 1006 10061164	16-25	25SEP2020	100535	Placebo	25SEP2020	Placebo	15OCT2020	Placebo
10061167	C4591001 1006 10061167	16-25	28SEP2020	101549	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)
10061169	C4591001 1006 10061169	16-25	02OCT2020	101554	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
10061170	C4591001 1006 10061170	16-25	05OCT2020	101559	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10061171	C4591001 1006 10061171	16-25	08OCT2020	105593	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
10061173	C4591001 1006 10061173	16-25	09OCT2020	105598	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
10061174	C4591001 1006 10061174	16-25	12OCT2020	105601	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
10061176	C4591001 1006 10061176	16-25	27OCT2020	105602	Placebo	27OCT2020	Placebo	19NOV2020	Placebo
10061180	C4591001 1006 10061180	16-25	06NOV2020	115140	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
10061181	C4591001 1006 10061181	16-25	13NOV2020	115141	Placebo	13NOV2020	Placebo	04DEC2020	Placebo
10061182	C4591001 1006 10061182	16-25	30NOV2020	115143	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	07JAN2021	BNT162b2 (30 µg)
10061185	C4591001 1006 10061185	16-25	30NOV2020	117101	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10061186	C4591001 1006 10061186	16-25	01DEC2020	117109	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
10061187	C4591001 1006 10061187	16-25	01DEC2020	117110	Placebo	01DEC2020	Placebo	28DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061192	C4591001 1006 10061192	16-25	02DEC2020	117112	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061193	C4591001 1006 10061193	16-25	02DEC2020	117245	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10061194	C4591001 1006 10061194	16-25	02DEC2020	117248	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
10061195	C4591001 1006 10061195	16-25	02DEC2020	117251	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10061197	C4591001 1006 10061197	16-25	03DEC2020	117252	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10061199	C4591001 1006 10061199	16-25	03DEC2020	117378	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061202	C4591001 1006 10061202	16-25	03DEC2020	117380	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10061204	C4591001 1006 10061204	16-25	03DEC2020	117381	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10061205	C4591001 1006 10061205	16-25	03DEC2020	117383	Placebo	03DEC2020	Placebo	24DEC2020	Placebo
10061208	C4591001 1006 10061208	16-25	04DEC2020	117557	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10061210	C4591001 1006 10061210	16-25	04DEC2020	117561	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10061211	C4591001 1006 10061211	16-25	04DEC2020	117562	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10061215	C4591001 1006 10061215	16-25	04DEC2020	117563	Placebo	04DEC2020	Placebo	22JAN2021	Placebo
10061216	C4591001 1006 10061216	16-25	04DEC2020	117629	Placebo	04DEC2020	Placebo	23DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10061217	C4591001 1006 10061217	16-25	04DEC2020	117633	Placebo	04DEC2020	Placebo	24DEC2020	Placebo
10061218	C4591001 1006 10061218	16-25	07DEC2020	117634	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061222	C4591001 1006 10061222	16-25	07DEC2020	117639	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10061225	C4591001 1006 10061225	16-25	07DEC2020	117713	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10061238	C4591001 1006 10061238	16-25	09DEC2020	117719	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10061240	C4591001 1006 10061240	16-25	09DEC2020	117722	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	05JAN2021	BNT162b2 (30 µg)
10061246	C4591001 1006 10061246	16-25	10DEC2020	117724	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10061255	C4591001 1006 10061255	16-25	11DEC2020	117895	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071082	C4591001 1007 10071082	16-25	28JUL2020	40035	Placebo	28JUL2020	Placebo	19AUG2020	Placebo
10071123	C4591001 1007 10071123	16-25	05AUG2020	41903	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
10071131	C4591001 1007 10071131	16-25	05AUG2020	42926	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)
10071154	C4591001 1007 10071154	16-25	10AUG2020	45272	Placebo	10AUG2020	Placebo	31AUG2020	Placebo
10071289	C4591001 1007 10071289	16-25	27AUG2020	69892	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10071341	C4591001 1007 10071341	16-25	14OCT2020	107807	Placebo	14OCT2020	Placebo	04NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071353	C4591001 1007 10071353	16-25	15OCT2020	107811	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
10071378	C4591001 1007 10071378	16-25	20OCT2020	110827	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10071385	C4591001 1007 10071385	16-25	20OCT2020	111025	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10071391	C4591001 1007 10071391	16-25	21OCT2020	111492	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10071398	C4591001 1007 10071398	16-25	21OCT2020	111766	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10071399	C4591001 1007 10071399	16-25	21OCT2020	111495	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10071400	C4591001 1007 10071400	16-25	21OCT2020	111769	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10071403	C4591001 1007 10071403	16-25	21OCT2020	111772	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10071404	C4591001 1007 10071404	16-25	21OCT2020	111814	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10071408	C4591001 1007 10071408	16-25	22OCT2020	112068	Placebo	22OCT2020	Placebo	03DEC2020	Placebo
10071422	C4591001 1007 10071422	16-25	22OCT2020	112376	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
10071423	C4591001 1007 10071423	16-25	22OCT2020	112378	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10071424	C4591001 1007 10071424	16-25	22OCT2020	112379	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10071431	C4591001 1007 10071431	16-25	26OCT2020	112537	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071433	C4591001 1007 10071433	16-25	27OCT2020	112540	Placebo	27OCT2020	Placebo	17NOV2020	Placebo
10071434	C4591001 1007 10071434	16-25	27OCT2020	114209	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
10071435	C4591001 1007 10071435	16-25	28OCT2020	114213	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
10071436	C4591001 1007 10071436	16-25	28OCT2020	114214	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
10071437	C4591001 1007 10071437	16-25	16NOV2020	116279	Placebo	16NOV2020	Placebo	22DEC2020	Placebo
10071439	C4591001 1007 10071439	16-25	29OCT2020	114777	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
10071441	C4591001 1007 10071441	16-25	29OCT2020	114775	Placebo	29OCT2020	Placebo	19NOV2020	Placebo
10071442	C4591001 1007 10071442	16-25	03NOV2020	114784	Placebo	03NOV2020	Placebo	23NOV2020	Placebo
10071443	C4591001 1007 10071443	16-25	04NOV2020	115649	Placebo	04NOV2020	Placebo	25NOV2020	Placebo
10071444	C4591001 1007 10071444	16-25	04NOV2020	115652	Placebo	04NOV2020	Placebo	23NOV2020	Placebo
10071445	C4591001 1007 10071445	16-25	10NOV2020	115654	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)
10071446	C4591001 1007 10071446	16-25	18NOV2020	116405	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
10071447	C4591001 1007 10071447	16-25	11NOV2020	115659	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
10071448	C4591001 1007 10071448	16-25	11NOV2020	116136	Placebo	11NOV2020	Placebo	02DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071449	C4591001 1007 10071449	16-25	11NOV2020	116137	Placebo	11NOV2020	Placebo	02DEC2020	Placebo
10071450	C4591001 1007 10071450	16-25	12NOV2020	116138	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)
10071451	C4591001 1007 10071451	16-25	12NOV2020	116140	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)
10071452	C4591001 1007 10071452	16-25	12NOV2020	116167	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)
10071454	C4591001 1007 10071454	16-25	12NOV2020	116168	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)
10071455	C4591001 1007 10071455	16-25	12NOV2020	116170	Placebo	12NOV2020	Placebo	09DEC2020	Placebo
10071456	C4591001 1007 10071456	16-25	16NOV2020	116174	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
10071457	C4591001 1007 10071457	16-25	16NOV2020	116275	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
10071458	C4591001 1007 10071458	16-25	16NOV2020	116277	Placebo	16NOV2020	Placebo	09DEC2020	Placebo
10071459	C4591001 1007 10071459	16-25	17NOV2020	116281	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
10071461	C4591001 1007 10071461	16-25	18NOV2020	116406	Placebo	18NOV2020	Placebo	09DEC2020	Placebo
10071462	C4591001 1007 10071462	16-25	18NOV2020	116409	Placebo	18NOV2020	Placebo	09DEC2020	Placebo
10071463	C4591001 1007 10071463	16-25	18NOV2020	116489	Placebo	18NOV2020	Placebo	09DEC2020	Placebo
10071464	C4591001 1007 10071464	16-25	18NOV2020	116415	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071465	C4591001 1007 10071465	16-25	19NOV2020	116492	Placebo	19NOV2020	Placebo	10DEC2020	Placebo
10071466	C4591001 1007 10071466	16-25	19NOV2020	116494	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
10071468	C4591001 1007 10071468	16-25	30NOV2020	116497	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071470	C4591001 1007 10071470	16-25	30NOV2020	117030	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10071473	C4591001 1007 10071473	16-25	07DEC2020	117471	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10071474	C4591001 1007 10071474	16-25	30NOV2020	117032	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071477	C4591001 1007 10071477	16-25	30NOV2020	117036	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10071479	C4591001 1007 10071479	16-25	30NOV2020	117038	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10071486	C4591001 1007 10071486	16-25	01DEC2020	117126	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10071487	C4591001 1007 10071487	16-25	01DEC2020	117129	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071489	C4591001 1007 10071489	16-25	01DEC2020	117130	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071491	C4591001 1007 10071491	16-25	01DEC2020	117135	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
10071493	C4591001 1007 10071493	16-25	01DEC2020	117173	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
10071498	C4591001 1007 10071498	16-25	02DEC2020	117175	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10071501	C4591001 1007 10071501	16-25	03DEC2020	117176	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10071502	C4591001 1007 10071502	16-25	03DEC2020	117180	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071503	C4591001 1007 10071503	16-25	03DEC2020	117464	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10071510	C4591001 1007 10071510	16-25	07DEC2020	117466	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10071513	C4591001 1007 10071513	16-25	07DEC2020	117472	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10071532	C4591001 1007 10071532	16-25	09DEC2020	117799	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10071534	C4591001 1007 10071534	16-25	09DEC2020	117805	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071538	C4591001 1007 10071538	16-25	09DEC2020	117806	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10071548	C4591001 1007 10071548	16-25	10DEC2020	117808	Placebo	10DEC2020	Placebo	30DEC2020	Placebo
10071549	C4591001 1007 10071549	16-25	10DEC2020	117847	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10071553	C4591001 1007 10071553	16-25	10DEC2020	117849	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10071556	C4591001 1007 10071556	16-25	10DEC2020	117850	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10081155	C4591001 1008 10081155	16-25	01SEP2020	75853	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10081160	C4591001 1008 10081160	16-25	01SEP2020	76695	Placebo	01SEP2020	Placebo	22SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081191	C4591001 1008 10081191	16-25	04SEP2020	80628	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10081281	C4591001 1008 10081281	16-25	10SEP2020	87273	Placebo	10SEP2020	Placebo	30SEP2020	Placebo
10081290	C4591001 1008 10081290	16-25	11SEP2020	87977	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
10081310	C4591001 1008 10081310	16-25	14SEP2020	89467	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10081333	C4591001 1008 10081333	16-25	15SEP2020	90305	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10081365	C4591001 1008 10081365	16-25	16SEP2020	91618	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
10081419	C4591001 1008 10081419	16-25	21SEP2020	94821	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10081420	C4591001 1008 10081420	16-25	21SEP2020	94824	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10081435	C4591001 1008 10081435	16-25	21SEP2020	95299	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10081444	C4591001 1008 10081444	16-25	22SEP2020	95521	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
10081480	C4591001 1008 10081480	16-25	23SEP2020	97573	Placebo	23SEP2020	Placebo	13OCT2020	Placebo
10081493	C4591001 1008 10081493	16-25	23SEP2020	97702	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
10081499	C4591001 1008 10081499	16-25	24SEP2020	98019	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
10081551	C4591001 1008 10081551	16-25	30SEP2020	102317	Placebo	30SEP2020	Placebo	21OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081553	C4591001 1008 10081553	16-25	30SEP2020	102318	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
10081554	C4591001 1008 10081554	16-25	30SEP2020	102322	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
10081558	C4591001 1008 10081558	16-25	02OCT2020	102932	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
10081559	C4591001 1008 10081559	16-25	02OCT2020	102937	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
10081577	C4591001 1008 10081577	16-25	09OCT2020	105903	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
10081583	C4591001 1008 10081583	16-25	09OCT2020	106112	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
10081598	C4591001 1008 10081598	16-25	13OCT2020	107170	Placebo	13OCT2020	Placebo	04NOV2020	Placebo
10081607	C4591001 1008 10081607	16-25	14OCT2020	107727	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
10081611	C4591001 1008 10081611	16-25	15OCT2020	107785	Placebo	15OCT2020	Placebo	04NOV2020	Placebo
10081630	C4591001 1008 10081630	16-25	16OCT2020	109279	Placebo	16OCT2020	Placebo	06NOV2020	Placebo
10081632	C4591001 1008 10081632	16-25	19OCT2020	109285	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10081633	C4591001 1008 10081633	16-25	19OCT2020	110083	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10081638	C4591001 1008 10081638	16-25	19OCT2020	110090	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
10081647	C4591001 1008 10081647	16-25	20OCT2020	111080	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081659	C4591001 1008 10081659	16-25	21OCT2020	111556	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10081665	C4591001 1008 10081665	16-25	22OCT2020	111826	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
10081673	C4591001 1008 10081673	16-25	22OCT2020	112464	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10081678	C4591001 1008 10081678	16-25	23OCT2020	112890	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
10081693	C4591001 1008 10081693	16-25	26OCT2020	113591	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10081736	C4591001 1008 10081736	16-25	30OCT2020	115099	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
10081739	C4591001 1008 10081739	16-25	30OCT2020	115107	Placebo	30OCT2020	Placebo	20NOV2020	Placebo
10081741	C4591001 1008 10081741	16-25	02NOV2020	115277	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
10081742	C4591001 1008 10081742	16-25	03NOV2020	115279	Placebo	03NOV2020	Placebo	25NOV2020	Placebo
10081743	C4591001 1008 10081743	16-25	04NOV2020	115283	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
10081744	C4591001 1008 10081744	16-25	04NOV2020	115288	Placebo	04NOV2020	Placebo	25NOV2020	Placebo
10081745	C4591001 1008 10081745	16-25	12NOV2020	116194	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)
10081746	C4591001 1008 10081746	16-25	13NOV2020	116195	Placebo	13NOV2020	Placebo	04DEC2020	Placebo
10081747	C4591001 1008 10081747	16-25	20NOV2020	116197	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10081748	C4591001 1008 10081748	16-25	20NOV2020	116199	Placebo	20NOV2020	Placebo	10DEC2020	Placebo
10081749	C4591001 1008 10081749	16-25	24NOV2020	116818	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
10081750	C4591001 1008 10081750	16-25	24NOV2020	116821	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
10081762	C4591001 1008 10081762	16-25	07DEC2020	116822	Placebo	07DEC2020	Placebo	30DEC2020	Placebo
10081765	C4591001 1008 10081765	16-25	08DEC2020	116823	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10081766	C4591001 1008 10081766	16-25	08DEC2020	117763	Placebo	08DEC2020	Placebo	29DEC2020	Placebo
10081772	C4591001 1008 10081772	16-25	09DEC2020	117765	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10081776	C4591001 1008 10081776	16-25	09DEC2020	117767	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10081778	C4591001 1008 10081778	16-25	10DEC2020	117771	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10081779	C4591001 1008 10081779	16-25	10DEC2020	117857	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10081782	C4591001 1008 10081782	16-25	11DEC2020	117858	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10081783	C4591001 1008 10081783	16-25	11DEC2020	117864	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
10081784	C4591001 1008 10081784	16-25	11DEC2020	117868	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	31DEC2020	BNT162b2 (30 µg)
10081786	C4591001 1008 10081786	16-25	11DEC2020	117882	Placebo	11DEC2020	Placebo	30DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091028	C4591001 1009 10091028	16-25	12AUG2020	46847	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10091053	C4591001 1009 10091053	16-25	14AUG2020	50938	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10091066	C4591001 1009 10091066	16-25	18AUG2020	55508	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
10091070	C4591001 1009 10091070	16-25	19AUG2020	55515	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10091088	C4591001 1009 10091088	16-25	20AUG2020	59553	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
10091102	C4591001 1009 10091102	16-25	24AUG2020	63814	Placebo	24AUG2020	Placebo	16SEP2020	Placebo
10091134	C4591001 1009 10091134	16-25	31AUG2020	72724	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10091174	C4591001 1009 10091174	16-25	14SEP2020	89841	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
10091198	C4591001 1009 10091198	16-25	28SEP2020	101601	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)
10091200	C4591001 1009 10091200	16-25	29SEP2020	101604	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
10091201	C4591001 1009 10091201	16-25	13OCT2020	101607	Placebo	13OCT2020	Placebo	02NOV2020	Placebo
10091207	C4591001 1009 10091207	16-25	15OCT2020	107271	Placebo	15OCT2020	Placebo	06NOV2020	Placebo
10091210	C4591001 1009 10091210	16-25	16OCT2020	108980	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10091217	C4591001 1009 10091217	16-25	16OCT2020	108985	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091224	C4591001 1009 10091224	16-25	19OCT2020	109076	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10091235	C4591001 1009 10091235	16-25	21OCT2020	111217	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10091242	C4591001 1009 10091242	16-25	22OCT2020	111807	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10091243	C4591001 1009 10091243	16-25	22OCT2020	112520	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10091255	C4591001 1009 10091255	16-25	26OCT2020	113805	Placebo	26OCT2020	Placebo	23NOV2020	Placebo
10091256	C4591001 1009 10091256	16-25	27OCT2020	113808	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
10091257	C4591001 1009 10091257	16-25	27OCT2020	113810	Placebo	27OCT2020	Placebo		
10091258	C4591001 1009 10091258	16-25	03NOV2020	115462	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
10091259	C4591001 1009 10091259	16-25	03NOV2020	115463	Placebo	03NOV2020	Placebo	25NOV2020	Placebo
10091260	C4591001 1009 10091260	16-25	11NOV2020	115465	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
10091261	C4591001 1009 10091261	16-25	11NOV2020	115467	Placebo	11NOV2020	Placebo	02DEC2020	Placebo
10091262	C4591001 1009 10091262	16-25	13NOV2020	116238	Placebo	13NOV2020	Placebo	04DEC2020	Placebo
10091263	C4591001 1009 10091263	16-25	30NOV2020	116242	Placebo	30NOV2020	Placebo	22DEC2020	Placebo
10091264	C4591001 1009 10091264	16-25	30NOV2020	116243	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10091271	C4591001 1009 10091271	16-25	01DEC2020	116248	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091276	C4591001 1009 10091276	16-25	03DEC2020	117306	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10091278	C4591001 1009 10091278	16-25	03DEC2020	117308	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10091279	C4591001 1009 10091279	16-25	03DEC2020	117310	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10091285	C4591001 1009 10091285	16-25	03DEC2020	117313	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10091286	C4591001 1009 10091286	16-25	04DEC2020	117510	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10091290	C4591001 1009 10091290	16-25	04DEC2020	117513	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10091291	C4591001 1009 10091291	16-25	04DEC2020	117517	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10091299	C4591001 1009 10091299	16-25	07DEC2020	117520	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10111005	C4591001 1011 10111005	16-25	12AUG2020	46501	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
10111043	C4591001 1011 10111043	16-25	17AUG2020	50284	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10111116	C4591001 1011 10111116	16-25	27AUG2020	71014	Placebo	27AUG2020	Placebo	01OCT2020	Placebo
10111118	C4591001 1011 10111118	16-25	28AUG2020	71017	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10111124	C4591001 1011 10111124	16-25	28AUG2020	71571	Placebo	28AUG2020	Placebo	17SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10111150	C4591001 1011 10111150	16-25	02SEP2020	77869	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10111151	C4591001 1011 10111151	16-25	02SEP2020	77871	Placebo	02SEP2020	Placebo	24SEP2020	Placebo
10111164	C4591001 1011 10111164	16-25	03SEP2020	79586	Placebo	03SEP2020	Placebo	01OCT2020	Placebo
10111174	C4591001 1011 10111174	16-25	07OCT2020	104711	Placebo	07OCT2020	Placebo	29OCT2020	Placebo
10111210	C4591001 1011 10111210	16-25	15OCT2020	108138	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10111213	C4591001 1011 10111213	16-25	16OCT2020	108143	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10111215	C4591001 1011 10111215	16-25	19OCT2020	110094	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10121144	C4591001 1012 10121144	16-25	05SEP2020	82878	Placebo	05SEP2020	Placebo	28SEP2020	Placebo
10121185	C4591001 1012 10121185	16-25	11SEP2020	88521	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
10121188	C4591001 1012 10121188	16-25	11SEP2020	88926	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
10131002	C4591001 1013 10131002	16-25	28JUL2020	40033	BNT162b2 (30 µg)	28JUL2020	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)
10131005	C4591001 1013 10131005	16-25	28JUL2020	40063	Placebo	28JUL2020	Placebo	19AUG2020	Placebo
10131020	C4591001 1013 10131020	16-25	30JUL2020	40404	Placebo	30JUL2020	Placebo	19AUG2020	Placebo
10131026	C4591001 1013 10131026	16-25	30JUL2020	40493	BNT162b2 (30 µg)	30JUL2020	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131059	C4591001 1013 10131059	16-25	03AUG2020	41544	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)
10131060	C4591001 1013 10131060	16-25	03AUG2020	41547	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
10131077	C4591001 1013 10131077	16-25	04AUG2020	42311	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
10131121	C4591001 1013 10131121	16-25	10AUG2020	45611	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10131171	C4591001 1013 10131171	16-25	13AUG2020	48549	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
10131174	C4591001 1013 10131174	16-25	13AUG2020	48556	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
10131200	C4591001 1013 10131200	16-25	17AUG2020	52614	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10131229	C4591001 1013 10131229	16-25	19AUG2020	55842	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
10131246	C4591001 1013 10131246	16-25	19AUG2020	56092	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
10131276	C4591001 1013 10131276	16-25	24AUG2020	58695	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10131319	C4591001 1013 10131319	16-25	26AUG2020	67251	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
10131353	C4591001 1013 10131353	16-25	27AUG2020	70093	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
10131366	C4591001 1013 10131366	16-25	31AUG2020	74737	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10131371	C4591001 1013 10131371	16-25	31AUG2020	74926	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131373	C4591001 1013 10131373	16-25	31AUG2020	75188	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10131394	C4591001 1013 10131394	16-25	01SEP2020	76718	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10131395	C4591001 1013 10131395	16-25	01SEP2020	76719	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10131413	C4591001 1013 10131413	16-25	02SEP2020	78196	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
10131421	C4591001 1013 10131421	16-25	02SEP2020	78345	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
10131422	C4591001 1013 10131422	16-25	03SEP2020	79590	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10131424	C4591001 1013 10131424	16-25	03SEP2020	79593	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10131425	C4591001 1013 10131425	16-25	03SEP2020	79641	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10131427	C4591001 1013 10131427	16-25	03SEP2020	79645	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
10131437	C4591001 1013 10131437	16-25	03SEP2020	79859	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
10131451	C4591001 1013 10131451	16-25	08SEP2020	83403	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10131463	C4591001 1013 10131463	16-25	08SEP2020	83518	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
10131470	C4591001 1013 10131470	16-25	08SEP2020	83709	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
10131471	C4591001 1013 10131471	16-25	08SEP2020	83790	Placebo	08SEP2020	Placebo	29SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131486	C4591001 1013 10131486	16-25	09SEP2020	84959	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10131499	C4591001 1013 10131499	16-25	10SEP2020	86408	Placebo	10SEP2020	Placebo	30SEP2020	Placebo
10131524	C4591001 1013 10131524	16-25	14SEP2020	86824	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10131533	C4591001 1013 10131533	16-25	15SEP2020	90153	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10131541	C4591001 1013 10131541	16-25	15SEP2020	90218	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
10131546	C4591001 1013 10131546	16-25	15SEP2020	90220	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10131556	C4591001 1013 10131556	16-25	16SEP2020	90997	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10131559	C4591001 1013 10131559	16-25	16SEP2020	91000	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
10131563	C4591001 1013 10131563	16-25	16SEP2020	91223	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
10131575	C4591001 1013 10131575	16-25	17SEP2020	92321	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
10131576	C4591001 1013 10131576	16-25	17SEP2020	92114	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
10131587	C4591001 1013 10131587	16-25	21SEP2020	94689	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
10131592	C4591001 1013 10131592	16-25	21SEP2020	94693	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10131599	C4591001 1013 10131599	16-25	21SEP2020	94768	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131611	C4591001 1013 10131611	16-25	22SEP2020	96368	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
10131612	C4591001 1013 10131612	16-25	22SEP2020	96370	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10131622	C4591001 1013 10131622	16-25	24SEP2020	97443	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10131624	C4591001 1013 10131624	16-25	24SEP2020	98729	Placebo	24SEP2020	Placebo	14OCT2020	Placebo
10131626	C4591001 1013 10131626	16-25	24SEP2020	98731	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
10131633	C4591001 1013 10131633	16-25	05OCT2020	103717	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
10131634	C4591001 1013 10131634	16-25	05OCT2020	103781	Placebo	05OCT2020	Placebo	27OCT2020	Placebo
10131638	C4591001 1013 10131638	16-25	06OCT2020	104185	Placebo	06OCT2020	Placebo	29OCT2020	Placebo
10131653	C4591001 1013 10131653	16-25	07OCT2020	104654	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
10131683	C4591001 1013 10131683	16-25	12OCT2020	106402	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
10131697	C4591001 1013 10131697	16-25	13OCT2020	106509	Placebo	13OCT2020	Placebo	02NOV2020	Placebo
10131740	C4591001 1013 10131740	16-25	15OCT2020	108026	Placebo				
10131749	C4591001 1013 10131749	16-25	19OCT2020	109966	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
10131761	C4591001 1013 10131761	16-25	20OCT2020	110730	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131763	C4591001 1013 10131763	16-25	20OCT2020	110163	Placebo	20OCT2020	Placebo	12NOV2020	Placebo
10131817	C4591001 1013 10131817	16-25	22OCT2020	112251	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10131818	C4591001 1013 10131818	16-25	30NOV2020	112252	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10131819	C4591001 1013 10131819	16-25	30NOV2020	117007	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10131820	C4591001 1013 10131820	16-25	30NOV2020	20327	Placebo	30NOV2020	Placebo	22DEC2020	Placebo
10131825	C4591001 1013 10131825	16-25	01DEC2020	117009	Placebo	01DEC2020	Placebo	23DEC2020	Placebo
10131829	C4591001 1013 10131829	16-25	02DEC2020	117010	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10131831	C4591001 1013 10131831	16-25	02DEC2020	117199	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
10131832	C4591001 1013 10131832	16-25	02DEC2020	117198	Placebo	02DEC2020	Placebo	23JAN2021	Placebo
10131833	C4591001 1013 10131833	16-25	02DEC2020	117207	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10131834	C4591001 1013 10131834	16-25	02DEC2020	117016	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	09FEB2021	BNT162b2 (30 µg)
10131837	C4591001 1013 10131837	16-25	02DEC2020	117200	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10131838	C4591001 1013 10131838	16-25	02DEC2020	117222	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10131840	C4591001 1013 10131840	16-25	02DEC2020	117224	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10131847	C4591001 1013 10131847	16-25	03DEC2020	117226	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10131849	C4591001 1013 10131849	16-25	03DEC2020	117231	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
10131853	C4591001 1013 10131853	16-25	07DEC2020	117701	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
10131854	C4591001 1013 10131854	16-25	08DEC2020	117705	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10131857	C4591001 1013 10131857	16-25	09DEC2020	117707	Placebo	09DEC2020	Placebo	30DEC2020	Placebo
10131864	C4591001 1013 10131864	16-25	10DEC2020	117710	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
10151006	C4591001 1015 10151006	16-25	12AUG2020	45333	Placebo	12AUG2020	Placebo	03SEP2020	Placebo
10151022	C4591001 1015 10151022	16-25	14AUG2020	50795	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10151029	C4591001 1015 10151029	16-25	15AUG2020	51189	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
10151035	C4591001 1015 10151035	16-25	16AUG2020	51423	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10151038	C4591001 1015 10151038	16-25	17AUG2020	51424	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
10151044	C4591001 1015 10151044	16-25	17AUG2020	52348	Placebo	17AUG2020	Placebo	07SEP2020	Placebo
10151049	C4591001 1015 10151049	16-25	18AUG2020	53999	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
10151050	C4591001 1015 10151050	16-25	18AUG2020	53996	Placebo	18AUG2020	Placebo	08SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10151075	C4591001 1015 10151075	16-25	20AUG2020	58508	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
10151081	C4591001 1015 10151081	16-25	21AUG2020	59103	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
10151082	C4591001 1015 10151082	16-25	21AUG2020	59104	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
10151099	C4591001 1015 10151099	16-25	24AUG2020	63921	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10151122	C4591001 1015 10151122	16-25	26AUG2020	68314	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10151133	C4591001 1015 10151133	16-25	27AUG2020	70273	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10151147	C4591001 1015 10151147	16-25	31AUG2020	71732	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10151150	C4591001 1015 10151150	16-25	31AUG2020	75023	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10151153	C4591001 1015 10151153	16-25	31AUG2020	75453	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10151154	C4591001 1015 10151154	16-25	31AUG2020	75454	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10151170	C4591001 1015 10151170	16-25	02SEP2020	77882	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10151180	C4591001 1015 10151180	16-25	04SEP2020	80700	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10151189	C4591001 1015 10151189	16-25	07SEP2020	83065	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10151191	C4591001 1015 10151191	16-25	07SEP2020	83066	Placebo	07SEP2020	Placebo	28SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10151221	C4591001 1015 10151221	16-25	11SEP2020	88552	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10151225	C4591001 1015 10151225	16-25	15SEP2020	89727	Placebo	15SEP2020	Placebo	08OCT2020	Placebo
10151250	C4591001 1015 10151250	16-25	20OCT2020	109914	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
10151252	C4591001 1015 10151252	16-25	21OCT2020	109922	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10151263	C4591001 1015 10151263	16-25	28OCT2020	114076	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
10161003	C4591001 1016 10161003	16-25	29JUL2020	40137	Placebo	29JUL2020	Placebo	19AUG2020	Placebo
10161010	C4591001 1016 10161010	16-25	30JUL2020	40434	BNT162b2 (30 µg)	30JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
10161014	C4591001 1016 10161014	16-25	30JUL2020	40440	Placebo	30JUL2020	Placebo	19AUG2020	Placebo
10161017	C4591001 1016 10161017	16-25	31JUL2020	40441	Placebo	31JUL2020	Placebo	20AUG2020	Placebo
10161028	C4591001 1016 10161028	16-25	03AUG2020	41590	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
10161047	C4591001 1016 10161047	16-25	04AUG2020	42612	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)		
10161058	C4591001 1016 10161058	16-25	05AUG2020	42828	Placebo	05AUG2020	Placebo	25AUG2020	Placebo
10161114	C4591001 1016 10161114	16-25	13AUG2020	48605	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
10161125	C4591001 1016 10161125	16-25	14AUG2020	50042	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161154	C4591001 1016 10161154	16-25	20AUG2020	58086	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
10161155	C4591001 1016 10161155	16-25	20AUG2020	58088	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
10161170	C4591001 1016 10161170	16-25	24AUG2020	61296	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10161171	C4591001 1016 10161171	16-25	24AUG2020	219978	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10161206	C4591001 1016 10161206	16-25	28AUG2020	70023	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
10161210	C4591001 1016 10161210	16-25	31AUG2020	74700	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10161215	C4591001 1016 10161215	16-25	31AUG2020	75727	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10161234	C4591001 1016 10161234	16-25	02SEP2020	79025	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10161245	C4591001 1016 10161245	16-25	04SEP2020	80667	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10161273	C4591001 1016 10161273	16-25	10SEP2020	87177	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10161284	C4591001 1016 10161284	16-25	11SEP2020	88023	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10161285	C4591001 1016 10161285	16-25	17SEP2020	92153	Placebo	17SEP2020	Placebo	07OCT2020	Placebo
10161286	C4591001 1016 10161286	16-25	17SEP2020	92160	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10161287	C4591001 1016 10161287	16-25	17SEP2020	92163	Placebo	17SEP2020	Placebo	09OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161288	C4591001 1016 10161288	16-25	17SEP2020	92164	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10161289	C4591001 1016 10161289	16-25	18SEP2020	93329	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10161290	C4591001 1016 10161290	16-25	18SEP2020	93331	Placebo	18SEP2020	Placebo	07OCT2020	Placebo
10161291	C4591001 1016 10161291	16-25	18SEP2020	93334	Placebo	18SEP2020	Placebo	07OCT2020	Placebo
10161292	C4591001 1016 10161292	16-25	18SEP2020	93336	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10161293	C4591001 1016 10161293	16-25	21SEP2020	94675	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10161294	C4591001 1016 10161294	16-25	21SEP2020	94679	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10161295	C4591001 1016 10161295	16-25	22SEP2020	94681	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10161296	C4591001 1016 10161296	16-25	22SEP2020	94684	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
10161297	C4591001 1016 10161297	16-25	22SEP2020	96606	Placebo	22SEP2020	Placebo	14OCT2020	Placebo
10161298	C4591001 1016 10161298	16-25	22SEP2020	96611	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10161299	C4591001 1016 10161299	16-25	23SEP2020	96613	Placebo	23SEP2020	Placebo	15OCT2020	Placebo
10161300	C4591001 1016 10161300	16-25	23SEP2020	96615	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
10161301	C4591001 1016 10161301	16-25	24SEP2020	98576	Placebo	24SEP2020	Placebo	15OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161302	C4591001 1016 10161302	16-25	24SEP2020	98577	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
10161305	C4591001 1016 10161305	16-25	13OCT2020	106865	Placebo	13OCT2020	Placebo	02NOV2020	Placebo
10161306	C4591001 1016 10161306	16-25	13OCT2020	106871	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
10161317	C4591001 1016 10161317	16-25	16OCT2020	109196	Placebo	16OCT2020	Placebo	06NOV2020	Placebo
10161328	C4591001 1016 10161328	16-25	20OCT2020	109202	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
10161333	C4591001 1016 10161333	16-25	21OCT2020	109203	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10161342	C4591001 1016 10161342	16-25	22OCT2020	112506	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
10161345	C4591001 1016 10161345	16-25	28OCT2020	112513	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10161346	C4591001 1016 10161346	16-25	28OCT2020	112515	Placebo	28OCT2020	Placebo	20NOV2020	Placebo
10161347	C4591001 1016 10161347	16-25	02NOV2020	115301	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
10161348	C4591001 1016 10161348	16-25	05NOV2020	115302	Placebo	05NOV2020	Placebo		
10161349	C4591001 1016 10161349	16-25	06NOV2020	115304	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
10161355	C4591001 1016 10161355	16-25	02DEC2020	115310	Placebo	02DEC2020	Placebo	04JAN2021	Placebo
10161359	C4591001 1016 10161359	16-25	03DEC2020	117322	Placebo	03DEC2020	Placebo	22DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10161360	C4591001 1016 10161360	16-25	04DEC2020	117323	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
10181007	C4591001 1018 10181007	16-25	29JUL2020	40199	BNT162b2 (30 µg)	29JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
10181015	C4591001 1018 10181015	16-25	31JUL2020	40800	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)
10181022	C4591001 1018 10181022	16-25	31JUL2020	41117	Placebo	31JUL2020	Placebo	21AUG2020	Placebo
10181032	C4591001 1018 10181032	16-25	03AUG2020	41702	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
10181042	C4591001 1018 10181042	16-25	03AUG2020	41997	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
10181046	C4591001 1018 10181046	16-25	03AUG2020	42004	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
10181054	C4591001 1018 10181054	16-25	04AUG2020	42304	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)		
10181091	C4591001 1018 10181091	16-25	06AUG2020	43676	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
10181126	C4591001 1018 10181126	16-25	11AUG2020	46853	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
10181133	C4591001 1018 10181133	16-25	12AUG2020	46860	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
10181166	C4591001 1018 10181166	16-25	14AUG2020	50961	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10181194	C4591001 1018 10181194	16-25	20AUG2020	57506	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10181195	C4591001 1018 10181195	16-25	21AUG2020	59685	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10181197	C4591001 1018 10181197	16-25	21AUG2020	59690	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
10181221	C4591001 1018 10181221	16-25	29AUG2020	73698	Placebo	29AUG2020	Placebo	25SEP2020	Placebo
10181224	C4591001 1018 10181224	16-25	29AUG2020	73708	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10181228	C4591001 1018 10181228	16-25	31AUG2020	74090	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10181288	C4591001 1018 10181288	16-25	14SEP2020	89793	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10181298	C4591001 1018 10181298	16-25	17SEP2020	92333	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
10181314	C4591001 1018 10181314	16-25	13OCT2020	106949	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
10181315	C4591001 1018 10181315	16-25	13OCT2020	106952	Placebo	13OCT2020	Placebo	04NOV2020	Placebo
10181316	C4591001 1018 10181316	16-25	13OCT2020	106953	Placebo	13OCT2020	Placebo	03NOV2020	Placebo
10181321	C4591001 1018 10181321	16-25	13OCT2020	107114	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10181324	C4591001 1018 10181324	16-25	14OCT2020	107552	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
10181326	C4591001 1018 10181326	16-25	14OCT2020	107556	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
10181335	C4591001 1018 10181335	16-25	15OCT2020	107748	Placebo	15OCT2020	Placebo	13NOV2020	Placebo
10181341	C4591001 1018 10181341	16-25	19OCT2020	110502	Placebo	19OCT2020	Placebo	11NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10181347	C4591001 101810181347	16-25	20OCT2020	111127	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10181351	C4591001 101810181351	16-25	21OCT2020	111130	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10191032	C4591001 101910191032	16-25	13AUG2020	49054	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
10191041	C4591001 101910191041	16-25	14AUG2020	50393	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
10191125	C4591001 101910191125	16-25	27AUG2020	71250	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
10191171	C4591001 101910191171	16-25	08SEP2020	84138	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
10191175	C4591001 101910191175	16-25	09SEP2020	84941	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10191194	C4591001 101910191194	16-25	11SEP2020	87810	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
10191197	C4591001 101910191197	16-25	11SEP2020	88097	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
10191218	C4591001 101910191218	16-25	18SEP2020	93537	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
10191246	C4591001 101910191246	16-25	01OCT2020	102254	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
10191251	C4591001 101910191251	16-25	02OCT2020	103236	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
10191265	C4591001 101910191265	16-25	13OCT2020	106371	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
10191273	C4591001 101910191273	16-25	14OCT2020	107574	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10191321	C4591001 1019 10191321	16-25	30OCT2020	114001	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
10211083	C4591001 1021 10211083	16-25	24AUG2020	63329	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10211142	C4591001 1021 10211142	16-25	02SEP2020	77923	Placebo	02SEP2020	Placebo	21SEP2020	Placebo
10211230	C4591001 1021 10211230	16-25	17SEP2020	91080	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
10211235	C4591001 1021 10211235	16-25	18SEP2020	93677	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
10211240	C4591001 1021 10211240	16-25	21SEP2020	93681	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10211245	C4591001 1021 10211245	16-25	22SEP2020	95507	Placebo	22SEP2020	Placebo	14OCT2020	Placebo
10221111	C4591001 1022 10221111	16-25	02SEP2020	78325	Placebo	02SEP2020	Placebo	24SEP2020	Placebo
10221112	C4591001 1022 10221112	16-25	02SEP2020	78328	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10221122	C4591001 1022 10221122	16-25	03SEP2020	79070	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10221147	C4591001 1022 10221147	16-25	09SEP2020	84183	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
10241043	C4591001 1024 10241043	16-25	19AUG2020	55797	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
10241091	C4591001 1024 10241091	16-25	28AUG2020	71777	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10241095	C4591001 1024 10241095	16-25	28AUG2020	71784	Placebo	28AUG2020	Placebo	17SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10271129	C4591001 102710271129	16-25	02SEP2020	77243	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
10281009	C4591001 10281009	16-25	17AUG2020	53298	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10281029	C4591001 10281029	16-25	20AUG2020	58266	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
10281053	C4591001 10281053	16-25	25AUG2020	64310	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10281065	C4591001 10281065	16-25	27AUG2020	68690	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10281090	C4591001 10281090	16-25	01SEP2020	75811	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10281094	C4591001 10281094	16-25	01SEP2020	75817	Placebo	01SEP2020	Placebo	24SEP2020	Placebo
10281120	C4591001 10281120	16-25	04SEP2020	80707	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10281131	C4591001 10281131	16-25	05SEP2020	81754	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
10281135	C4591001 10281135	16-25	05SEP2020	81759	Placebo	05SEP2020	Placebo	25SEP2020	Placebo
10281154	C4591001 10281154	16-25	09SEP2020	84971	Placebo	09SEP2020	Placebo	30SEP2020	Placebo
10281184	C4591001 10281184	16-25	15SEP2020	90622	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
10281191	C4591001 10281191	16-25	16SEP2020	91212	Placebo	16SEP2020	Placebo	16OCT2020	Placebo
10281198	C4591001 10281198	16-25	17SEP2020	92240	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10281200	C4591001 1028 10281200	16-25	17SEP2020	92244	Placebo	17SEP2020	Placebo	06OCT2020	Placebo
10281211	C4591001 1028 10281211	16-25	21SEP2020	94841	Placebo	21SEP2020	Placebo	15OCT2020	Placebo
10281213	C4591001 1028 10281213	16-25	30SEP2020	99755	Placebo	30SEP2020	Placebo	30OCT2020	Placebo
10281240	C4591001 1028 10281240	16-25	30SEP2020	99752	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
10281242	C4591001 1028 10281242	16-25	01OCT2020	102919	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
10281248	C4591001 1028 10281248	16-25	07OCT2020	104639	Placebo	07OCT2020	Placebo	26OCT2020	Placebo
10281249	C4591001 1028 10281249	16-25	07OCT2020	104642	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
10281250	C4591001 1028 10281250	16-25	08OCT2020	104644	Placebo	08OCT2020	Placebo	03NOV2020	Placebo
10281258	C4591001 1028 10281258	16-25	14OCT2020	107664	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
10281284	C4591001 1028 10281284	16-25	27OCT2020	114162	Placebo	27OCT2020	Placebo	17NOV2020	Placebo
10281286	C4591001 1028 10281286	16-25	27OCT2020	114169	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
10281294	C4591001 1028 10281294	16-25	29OCT2020	114504	Placebo	29OCT2020	Placebo		
10301072	C4591001 1030 10301072	16-25	11SEP2020	87751	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
10301145	C4591001 1030 10301145	16-25	09OCT2020	104147	Placebo	09OCT2020	Placebo	30OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
10361011	C4591001 1036 10361011	16-25	20AUG2020	56329	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)			
10361032	C4591001 1036 10361032	16-25	26AUG2020	68384	Placebo	26AUG2020	Placebo	17SEP2020	Placebo	
10361047	C4591001 1036 10361047	16-25	29AUG2020	70837	Placebo	29AUG2020	Placebo	22SEP2020	Placebo	
10361048	C4591001 1036 10361048	16-25	29AUG2020	73867	Placebo	29AUG2020	Placebo	19SEP2020	Placebo	
10361060	C4591001 1036 10361060	16-25	01SEP2020	75829	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	
10361061	C4591001 1036 10361061	16-25	01SEP2020	75832	Placebo	01SEP2020	Placebo	21SEP2020	Placebo	
10361062	C4591001 1036 10361062	16-25	01SEP2020	76949	Placebo	01SEP2020	Placebo	21SEP2020	Placebo	
10361073	C4591001 1036 10361073	16-25	04SEP2020	79227	Placebo	04SEP2020	Placebo	25SEP2020	Placebo	
10361078	C4591001 1036 10361078	16-25	08SEP2020	81628	Placebo	08SEP2020	Placebo	30SEP2020	Placebo	
10361084	C4591001 1036 10361084	16-25	09SEP2020	86084	Placebo	09SEP2020	Placebo	01OCT2020	Placebo	
10361093	C4591001 1036 10361093	16-25	12SEP2020	86091	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	
10361094	C4591001 1036 10361094	16-25	12SEP2020	89192	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	
10361104	C4591001 1036 10361104	16-25	19SEP2020	94447	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)	10OCT2020	BNT162b2 (30 µg)	
10371043	C4591001 1037 10371043	16-25	21AUG2020	60775	Placebo	21AUG2020	Placebo	09SEP2020	Placebo	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10371054	C4591001 103710371054	16-25	24AUG2020	63426	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10371074	C4591001 103710371074	16-25	26AUG2020	65716	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
10371078	C4591001 103710371078	16-25	26AUG2020	67690	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)		
10371140	C4591001 103710371140	16-25	03SEP2020	79636	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10371152	C4591001 103710371152	16-25	04SEP2020	81841	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10371180	C4591001 103710371180	16-25	10SEP2020	86360	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
10371198	C4591001 103710371198	16-25	11SEP2020	86368	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
10371214	C4591001 103710371214	16-25	15SEP2020	89626	Placebo	15SEP2020	Placebo	05OCT2020	Placebo
10371240	C4591001 103710371240	16-25	18SEP2020	93713	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
10371241	C4591001 103710371241	16-25	18SEP2020	93720	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
10371271	C4591001 103710371271	16-25	23SEP2020	96419	Placebo	23SEP2020	Placebo	15OCT2020	Placebo
10371272	C4591001 103710371272	16-25	23SEP2020	96420	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
10371285	C4591001 103710371285	16-25	24SEP2020	97484	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10371288	C4591001 103710371288	16-25	24SEP2020	98649	Placebo	24SEP2020	Placebo	22OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10371302	C4591001 1037 10371302	16-25	29SEP2020	101850	Placebo	29SEP2020	Placebo	19OCT2020	Placebo
10371315	C4591001 1037 10371315	16-25	02OCT2020	102814	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
10371316	C4591001 1037 10371316	16-25	02OCT2020	102817	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
10371328	C4591001 1037 10371328	16-25	08OCT2020	104752	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10371332	C4591001 1037 10371332	16-25	09OCT2020	105446	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
10371343	C4591001 1037 10371343	16-25	14OCT2020	107198	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10371344	C4591001 1037 10371344	16-25	14OCT2020	107599	Placebo	14OCT2020	Placebo	03NOV2020	Placebo
10371358	C4591001 1037 10371358	16-25	20OCT2020	111164	Placebo	20OCT2020	Placebo	09NOV2020	Placebo
10381006	C4591001 1038 10381006	16-25	19AUG2020	55870	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10381020	C4591001 1038 10381020	16-25	21AUG2020	59327	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
10381038	C4591001 1038 10381038	16-25	25AUG2020	66133	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
10381075	C4591001 1038 10381075	16-25	01SEP2020	76333	Placebo	01SEP2020	Placebo	23SEP2020	Placebo
10381079	C4591001 1038 10381079	16-25	02SEP2020	77827	Placebo	02SEP2020	Placebo	21SEP2020	Placebo
10381098	C4591001 1038 10381098	16-25	04SEP2020	81571	Placebo	04SEP2020	Placebo	23SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10381117	C4591001 1038 10381117	16-25	11SEP2020	88010	Placebo	11SEP2020	Placebo	01OCT2020	Placebo
10381137	C4591001 1038 10381137	16-25	21SEP2020	93519	Placebo	21SEP2020	Placebo	14OCT2020	Placebo
10391016	C4591001 1039 10391016	16-25	24AUG2020	63593	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10391017	C4591001 1039 10391017	16-25	24AUG2020	63594	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10391065	C4591001 1039 10391065	16-25	01SEP2020	75537	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
10391093	C4591001 1039 10391093	16-25	04SEP2020	81822	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10391198	C4591001 1039 10391198	16-25	16OCT2020	106094	Placebo	16OCT2020	Placebo	06NOV2020	Placebo
10391220	C4591001 1039 10391220	16-25	23OCT2020	111719	Placebo	23OCT2020	Placebo	16NOV2020	Placebo
10391235	C4591001 1039 10391235	16-25	29OCT2020	114323	Placebo	29OCT2020	Placebo	19NOV2020	Placebo
10391241	C4591001 1039 10391241	16-25	02NOV2020	114708	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
10391242	C4591001 1039 10391242	16-25	02NOV2020	114711	Placebo	02NOV2020	Placebo	23NOV2020	Placebo
10391243	C4591001 1039 10391243	16-25	09NOV2020	116010	Placebo	09NOV2020	Placebo	30NOV2020	Placebo
10391244	C4591001 1039 10391244	16-25	11NOV2020	116012	Placebo	11NOV2020	Placebo		
10391245	C4591001 1039 10391245	16-25	30NOV2020	116013	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10391248	C4591001 1039 10391248	16-25	01DEC2020	116020	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10391249	C4591001 1039 10391249	16-25	04DEC2020	117535	Placebo	04DEC2020	Placebo	28DEC2020	Placebo
10391254	C4591001 1039 10391254	16-25	07DEC2020	117538	Placebo	07DEC2020	Placebo	29DEC2020	Placebo
10391257	C4591001 1039 10391257	16-25	07DEC2020	117542	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10391261	C4591001 1039 10391261	16-25	07DEC2020	117543	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10421003	C4591001 1042 10421003	16-25	29JUL2020	40293	Placebo	29JUL2020	Placebo	17AUG2020	Placebo
10421004	C4591001 1042 10421004	16-25	29JUL2020	40295	BNT162b2 (30 µg)	29JUL2020	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)
10421020	C4591001 1042 10421020	16-25	31JUL2020	40884	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
10421111	C4591001 1042 10421111	16-25	17AUG2020	52517	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10421112	C4591001 1042 10421112	16-25	17AUG2020	52520	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10421114	C4591001 1042 10421114	16-25	17AUG2020	52522	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10421155	C4591001 1042 10421155	16-25	24AUG2020	64890	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10421177	C4591001 1042 10421177	16-25	31AUG2020	72939	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10421181	C4591001 1042 10421181	16-25	01SEP2020	76174	Placebo	01SEP2020	Placebo	21SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10421206	C4591001 10421042 10421206	16-25	08SEP2020	84608	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
10421228	C4591001 10421042 10421228	16-25	10SEP2020	87294	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
10421253	C4591001 10421042 10421253	16-25	18SEP2020	92307	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
10441034	C4591001 10441044 10441034	16-25	26AUG2020	67918	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10441121	C4591001 10441044 10441121	16-25	22SEP2020	86870	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
10441129	C4591001 10441044 10441129	16-25	22SEP2020	97062	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10441141	C4591001 10441044 10441141	16-25	24SEP2020	98404	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
10441171	C4591001 10441044 10441171	16-25	07OCT2020	104889	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10441193	C4591001 10441044 10441193	16-25	17OCT2020	109563	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
10441228	C4591001 10441044 10441228	16-25	16NOV2020	113002	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
10441229	C4591001 10441044 10441229	16-25	17NOV2020	113007	Placebo	17NOV2020	Placebo	07DEC2020	Placebo
10441230	C4591001 10441044 10441230	16-25	18NOV2020	116384	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
10441231	C4591001 10441044 10441231	16-25	18NOV2020	116387	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
10441232	C4591001 10441044 10441232	16-25	18NOV2020	116389	Placebo	18NOV2020	Placebo	09DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441233	C4591001 1044 10441233	16-25	18NOV2020	116390	Placebo	18NOV2020	Placebo	07DEC2020	Placebo
10441234	C4591001 1044 10441234	16-25	19NOV2020	116517	Placebo	19NOV2020	Placebo	08DEC2020	Placebo
10441235	C4591001 1044 10441235	16-25	19NOV2020	116523	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)
10441236	C4591001 1044 10441236	16-25	19NOV2020	116522	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
10441237	C4591001 1044 10441237	16-25	20NOV2020	116524	Placebo	20NOV2020	Placebo	09DEC2020	Placebo
10441238	C4591001 1044 10441238	16-25	20NOV2020	116574	Placebo	20NOV2020	Placebo	09DEC2020	Placebo
10441239	C4591001 1044 10441239	16-25	20NOV2020	116577	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
10441240	C4591001 1044 10441240	16-25	23NOV2020	116579	Placebo	23NOV2020	Placebo	16DEC2020	Placebo
10441241	C4591001 1044 10441241	16-25	23NOV2020	116582	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
10441242	C4591001 1044 10441242	16-25	24NOV2020	116825	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
10441243	C4591001 1044 10441243	16-25	24NOV2020	116827	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
10441244	C4591001 1044 10441244	16-25	24NOV2020	116832	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
10441245	C4591001 1044 10441245	16-25	24NOV2020	116828	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
10441246	C4591001 1044 10441246	16-25	25NOV2020	116925	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)	18JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10441247	C4591001 1044 10441247	16-25	25NOV2020	116922	Placebo	25NOV2020	Placebo	14DEC2020	Placebo
10441248	C4591001 1044 10441248	16-25	25NOV2020	116923	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
10441249	C4591001 1044 10441249	16-25	30NOV2020	20352	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10441250	C4591001 1044 10441250	16-25	30NOV2020	20353	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10441254	C4591001 1044 10441254	16-25	30NOV2020	20437	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
10441258	C4591001 1044 10441258	16-25	01DEC2020	20568	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
10441262	C4591001 1044 10441262	16-25	07DEC2020	20620	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10441269	C4591001 1044 10441269	16-25	08DEC2020	116927	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
10441272	C4591001 1044 10441272	16-25	08DEC2020	117787	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10441287	C4591001 1044 10441287	16-25	11DEC2020	117788	Placebo	11DEC2020	Placebo		
10461034	C4591001 1046 10461034	16-25	15AUG2020	51027	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)
10461055	C4591001 1046 10461055	16-25	18AUG2020	54976	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
10461071	C4591001 1046 10461071	16-25	20AUG2020	59644	Placebo	20AUG2020	Placebo	08SEP2020	Placebo
10461104	C4591001 1046 10461104	16-25	26AUG2020	67413	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10461118	C4591001 104610461118	16-25	27AUG2020	70566	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10461119	C4591001 104610461119	16-25	27AUG2020	70567	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10461125	C4591001 104610461125	16-25	27AUG2020	71397	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10461134	C4591001 104610461134	16-25	28AUG2020	72336	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
10461148	C4591001 104610461148	16-25	31AUG2020	76025	Placebo	31AUG2020	Placebo	22SEP2020	Placebo
10461164	C4591001 104610461164	16-25	02SEP2020	77428	Placebo	02SEP2020	Placebo	24SEP2020	Placebo
10461171	C4591001 104610461171	16-25	02SEP2020	78316	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10461172	C4591001 104610461172	16-25	02SEP2020	79253	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10461194	C4591001 104610461194	16-25	04SEP2020	82390	Placebo	04SEP2020	Placebo	24SEP2020	Placebo
10461209	C4591001 104610461209	16-25	08SEP2020	83646	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
10461211	C4591001 104610461211	16-25	08SEP2020	83651	Placebo	08SEP2020	Placebo	30SEP2020	Placebo
10461227	C4591001 104610461227	16-25	09SEP2020	85105	Placebo	09SEP2020	Placebo	28SEP2020	Placebo
10461233	C4591001 104610461233	16-25	09SEP2020	85108	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10461247	C4591001 104610461247	16-25	11SEP2020	87157	Placebo	11SEP2020	Placebo	02OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10461291	C4591001 104610461291	16-25	09OCT2020	106058	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
10461292	C4591001 104610461292	16-25	12OCT2020	267853	Placebo	12OCT2020	Placebo	03NOV2020	Placebo
10461303	C4591001 104610461303	16-25	15OCT2020	108151	Placebo	15OCT2020	Placebo	05NOV2020	Placebo
10461311	C4591001 104610461311	16-25	17OCT2020	108947	Placebo	17OCT2020	Placebo	06NOV2020	Placebo
10461319	C4591001 104610461319	16-25	26OCT2020	113489	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10461327	C4591001 104610461327	16-25	28OCT2020	114008	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
10461336	C4591001 104610461336	16-25	30OCT2020	114992	Placebo	30OCT2020	Placebo	18NOV2020	Placebo
10461338	C4591001 104610461338	16-25	30OCT2020	114995	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
10461340	C4591001 104610461340	16-25	30OCT2020	115110	Placebo	30OCT2020	Placebo	20NOV2020	Placebo
10461341	C4591001 104610461341	16-25	19NOV2020	115114	Placebo	19NOV2020	Placebo	08DEC2020	Placebo
10461342	C4591001 104610461342	16-25	19NOV2020	115115	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
10461343	C4591001 104610461343	16-25	20NOV2020	115118	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10461344	C4591001 104610461344	16-25	20NOV2020	116609	Placebo	20NOV2020	Placebo	21DEC2020	Placebo
10461345	C4591001 104610461345	16-25	24NOV2020	116614	Placebo	24NOV2020	Placebo	17DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10461346	C4591001 1046 10461346	16-25	01DEC2020	116615	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10461347	C4591001 1046 10461347	16-25	03DEC2020	116617	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10461348	C4591001 1046 10461348	16-25	04DEC2020	117595	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10471061	C4591001 1047 10471061	16-25	27AUG2020	69835	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10471079	C4591001 1047 10471079	16-25	28AUG2020	72653	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
10471089	C4591001 1047 10471089	16-25	31AUG2020	75154	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10471115	C4591001 1047 10471115	16-25	02SEP2020	78239	Placebo	02SEP2020	Placebo	25SEP2020	Placebo
10471124	C4591001 1047 10471124	16-25	03SEP2020	80171	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
10471147	C4591001 1047 10471147	16-25	07SEP2020	83141	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
10471151	C4591001 1047 10471151	16-25	07SEP2020	83216	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10471155	C4591001 1047 10471155	16-25	08SEP2020	83221	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
10471163	C4591001 1047 10471163	16-25	09SEP2020	84314	Placebo	09SEP2020	Placebo	30SEP2020	Placebo
10471179	C4591001 1047 10471179	16-25	10SEP2020	86512	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
10471232	C4591001 1047 10471232	16-25	17SEP2020	92454	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10471243	C4591001 104710471243	16-25	18SEP2020	94198	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
10471275	C4591001 104710471275	16-25	23SEP2020	96936	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
10471284	C4591001 104710471284	16-25	24SEP2020	98286	Placebo	24SEP2020	Placebo	13OCT2020	Placebo
10471291	C4591001 104710471291	16-25	24SEP2020	98776	Placebo	24SEP2020	Placebo	13OCT2020	Placebo
10471306	C4591001 104710471306	16-25	02OCT2020	102349	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
10471310	C4591001 104710471310	16-25	07OCT2020	103874	Placebo	07OCT2020	Placebo	26OCT2020	Placebo
10471312	C4591001 104710471312	16-25	09OCT2020	103875	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10471317	C4591001 104710471317	16-25	13OCT2020	107232	Placebo	13OCT2020	Placebo	03NOV2020	Placebo
10481021	C4591001 104810481021	16-25	24AUG2020	55292	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10481088	C4591001 104810481088	16-25	04SEP2020	81142	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
10481092	C4591001 104810481092	16-25	04SEP2020	81143	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10481114	C4591001 104810481114	16-25	10SEP2020	86197	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10521005	C4591001 105210521005	16-25	19AUG2020	56721	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10521007	C4591001 105210521007	16-25	19AUG2020	56724	Placebo	19AUG2020	Placebo	09SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10521013	C4591001 10521013	16-25	20AUG2020	57572	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10521054	C4591001 10521054	16-25	28AUG2020	72584	Placebo	28AUG2020	Placebo		
10521064	C4591001 10521064	16-25	31AUG2020	73115	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)		
10521079	C4591001 10521079	16-25	02SEP2020	77378	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10521080	C4591001 10521080	16-25	02SEP2020	78907	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)		
10521104	C4591001 10521104	16-25	04SEP2020	82056	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10521109	C4591001 10521109	16-25	04SEP2020	82413	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10521114	C4591001 10521114	16-25	16SEP2020	82585	Placebo	16SEP2020	Placebo	05OCT2020	Placebo
10521116	C4591001 10521116	16-25	16SEP2020	82586	Placebo	16SEP2020	Placebo	05OCT2020	Placebo
10521117	C4591001 10521117	16-25	16SEP2020	82587	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10521154	C4591001 10521154	16-25	23SEP2020	97769	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10541007	C4591001 10541007	16-25	19AUG2020	57209	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
10541012	C4591001 10541012	16-25	20AUG2020	58541	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
10541022	C4591001 10541022	16-25	21AUG2020	59079	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)		

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10541043	C4591001 1054 10541043	16-25	24AUG2020	64112	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10541090	C4591001 1054 10541090	16-25	01SEP2020	76786	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10541125	C4591001 1054 10541125	16-25	08SEP2020	83660	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
10541135	C4591001 1054 10541135	16-25	09SEP2020	85294	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
10541165	C4591001 1054 10541165	16-25	17SEP2020	91164	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
10541191	C4591001 1054 10541191	16-25	13OCT2020	106544	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10541200	C4591001 1054 10541200	16-25	22OCT2020	110411	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10541208	C4591001 1054 10541208	16-25	28OCT2020	113750	Placebo	28OCT2020	Placebo	23NOV2020	Placebo
10541215	C4591001 1054 10541215	16-25	29OCT2020	114750	Placebo	29OCT2020	Placebo	17NOV2020	Placebo
10551021	C4591001 1055 10551021	16-25	11AUG2020	45684	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10551074	C4591001 1055 10551074	16-25	19AUG2020	56974	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
10551103	C4591001 1055 10551103	16-25	25AUG2020	64702	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10551121	C4591001 1055 10551121	16-25	26AUG2020	69055	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
10551138	C4591001 1055 10551138	16-25	28AUG2020	72365	Placebo	28AUG2020	Placebo	18SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10551232	C4591001 105510551232	16-25	15SEP2020	90452	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10551243	C4591001 105510551243	16-25	24SEP2020	92745	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
10561061	C4591001 105610561061	16-25	27AUG2020	70724	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10561076	C4591001 105610561076	16-25	28AUG2020	71834	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
10561116	C4591001 105610561116	16-25	01SEP2020	76638	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
10561171	C4591001 105610561171	16-25	04SEP2020	82188	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10561194	C4591001 105610561194	16-25	09SEP2020	85284	Placebo	09SEP2020	Placebo	25SEP2020	Placebo
10561317	C4591001 105610561317	16-25	22SEP2020	96483	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
10561392	C4591001 105610561392	16-25	02OCT2020	103362	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
10561394	C4591001 105610561394	16-25	05OCT2020	103369	Placebo	05OCT2020	Placebo	03NOV2020	Placebo
10561397	C4591001 105610561397	16-25	05OCT2020	103819	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
10561405	C4591001 105610561405	16-25	05OCT2020	103947	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
10561443	C4591001 105610561443	16-25	08OCT2020	105423	Placebo	08OCT2020	Placebo	27OCT2020	Placebo
10561475	C4591001 105610561475	16-25	12OCT2020	106201	Placebo	12OCT2020	Placebo	02NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
10561476	C4591001 105610561476	16-25	12OCT2020	106203	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)	
10561511	C4591001 105610561511	16-25	14OCT2020	107485	Placebo	14OCT2020	Placebo	02NOV2020	Placebo	
10561529	C4591001 105610561529	16-25	16OCT2020	108997	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)	
10561541	C4591001 105610561541	16-25	19OCT2020	110204	Placebo	19OCT2020	Placebo	09NOV2020	Placebo	
10561554	C4591001 105610561554	16-25	20OCT2020	110969	Placebo	20OCT2020	Placebo			
10561559	C4591001 105610561559	16-25	20OCT2020	111189	Placebo	20OCT2020	Placebo	13NOV2020	Placebo	
10561560	C4591001 105610561560	16-25	20OCT2020	111190	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)	
10561592	C4591001 105610561592	16-25	26OCT2020	113680	Placebo	26OCT2020	Placebo	30NOV2020	Placebo	
10571014	C4591001 105710571014	16-25	13AUG2020	48839	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	
10571044	C4591001 105710571044	16-25	19AUG2020	55856	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	
10571103	C4591001 105710571103	16-25	27AUG2020	68455	Placebo	27AUG2020	Placebo	17SEP2020	Placebo	
10571109	C4591001 105710571109	16-25	27AUG2020	69907	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	
10571139	C4591001 105710571139	16-25	02SEP2020	78126	Placebo	02SEP2020	Placebo	21SEP2020	Placebo	
10571147	C4591001 105710571147	16-25	03SEP2020	79572	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571195	C4591001 105710571195	16-25	16SEP2020	90336	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10571204	C4591001 105710571204	16-25	17SEP2020	92538	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10571207	C4591001 105710571207	16-25	17SEP2020	92548	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10571211	C4591001 105710571211	16-25	18SEP2020	93241	Placebo				
10571216	C4591001 105710571216	16-25	21SEP2020	93709	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10571217	C4591001 105710571217	16-25	21SEP2020	93710	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10571218	C4591001 105710571218	16-25	21SEP2020	93711	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10571230	C4591001 105710571230	16-25	23SEP2020	96772	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
10571234	C4591001 105710571234	16-25	23SEP2020	97538	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
10571235	C4591001 105710571235	16-25	23SEP2020	97540	Placebo	23SEP2020	Placebo	15OCT2020	Placebo
10571239	C4591001 105710571239	16-25	24SEP2020	97883	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
10571248	C4591001 105710571248	16-25	25SEP2020	99562	Placebo	25SEP2020	Placebo		
10571249	C4591001 105710571249	16-25	25SEP2020	99567	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
10571252	C4591001 105710571252	16-25	28SEP2020	101336	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571267	C4591001 105710571267	16-25	05OCT2020	103845	Placebo	05OCT2020	Placebo	27OCT2020	Placebo
10571273	C4591001 105710571273	16-25	07OCT2020	104211	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
10571277	C4591001 105710571277	16-25	08OCT2020	104696	Placebo	08OCT2020	Placebo	27OCT2020	Placebo
10571298	C4591001 105710571298	16-25	12OCT2020	106424	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
10571304	C4591001 105710571304	16-25	13OCT2020	107201	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
10571314	C4591001 105710571314	16-25	14OCT2020	107652	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
10571319	C4591001 105710571319	16-25	15OCT2020	107902	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
10571336	C4591001 105710571336	16-25	20OCT2020	110726	Placebo	20OCT2020	Placebo	09NOV2020	Placebo
10571363	C4591001 105710571363	16-25	18NOV2020	115021	Placebo	18NOV2020	Placebo	08DEC2020	Placebo
10571364	C4591001 105710571364	16-25	18NOV2020	115022	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)
10571365	C4591001 105710571365	16-25	23NOV2020	116717	Placebo	23NOV2020	Placebo	16DEC2020	Placebo
10571366	C4591001 105710571366	16-25	23NOV2020	115024	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
10571367	C4591001 105710571367	16-25	23NOV2020	116721	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
10571368	C4591001 105710571368	16-25	23NOV2020	116723	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10571369	C4591001 105710571369	16-25	30NOV2020	116727	Placebo	30NOV2020	Placebo	22DEC2020	Placebo
10571370	C4591001 105710571370	16-25	30NOV2020	117053	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10571371	C4591001 105710571371	16-25	30NOV2020	117056	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10571372	C4591001 105710571372	16-25	02DEC2020	117060	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
10571373	C4591001 105710571373	16-25	02DEC2020	117063	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
10571374	C4591001 105710571374	16-25	03DEC2020	117354	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10571375	C4591001 105710571375	16-25	03DEC2020	117358	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10571381	C4591001 105710571381	16-25	08DEC2020	117359	Placebo	08DEC2020	Placebo	28DEC2020	Placebo
10661137	C4591001 106610661137	16-25	28AUG2020	72781	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10661142	C4591001 106610661142	16-25	31AUG2020	74779	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10661160	C4591001 106610661160	16-25	01SEP2020	76436	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10661163	C4591001 106610661163	16-25	01SEP2020	76438	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
10661166	C4591001 106610661166	16-25	02SEP2020	76441	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10661185	C4591001 106610661185	16-25	04SEP2020	81016	Placebo	04SEP2020	Placebo	25SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10661214	C4591001 106610661214	16-25	08SEP2020	83103	Placebo	08SEP2020	Placebo	30SEP2020	Placebo
10661290	C4591001 106610661290	16-25	22SEP2020	97029	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
10661293	C4591001 106610661293	16-25	23SEP2020	97034	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
10661317	C4591001 106610661317	16-25	08OCT2020	105213	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
10661324	C4591001 106610661324	16-25	12OCT2020	106722	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
10661336	C4591001 106610661336	16-25	14OCT2020	107676	Placebo	14OCT2020	Placebo	02NOV2020	Placebo
10661340	C4591001 106610661340	16-25	15OCT2020	107680	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10661391	C4591001 106610661391	16-25	04NOV2020	115688	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)
10661392	C4591001 106610661392	16-25	19NOV2020	115689	Placebo	19NOV2020	Placebo	09DEC2020	Placebo
10661393	C4591001 106610661393	16-25	24NOV2020	115691	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
10661396	C4591001 106610661396	16-25	01DEC2020	115695	Placebo	01DEC2020	Placebo		
10661398	C4591001 106610661398	16-25	02DEC2020	117187	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
10661399	C4591001 106610661399	16-25	02DEC2020	117188	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
10661400	C4591001 106610661400	16-25	02DEC2020	117189	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10661406	C4591001 1066 10661406	16-25	04DEC2020	117194	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10661413	C4591001 1066 10661413	16-25	10DEC2020	117836	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
10681002	C4591001 1068 10681002	16-25	18AUG2020	55553	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
10681010	C4591001 1068 10681010	16-25	19AUG2020	55560	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
10681018	C4591001 1068 10681018	16-25	20AUG2020	59485	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
10681037	C4591001 1068 10681037	16-25	24AUG2020	64962	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10681047	C4591001 1068 10681047	16-25	26AUG2020	69285	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
10681086	C4591001 1068 10681086	16-25	01SEP2020	76424	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10681098	C4591001 1068 10681098	16-25	03SEP2020	79662	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10681099	C4591001 1068 10681099	16-25	03SEP2020	79667	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10681100	C4591001 1068 10681100	16-25	03SEP2020	79670	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10681119	C4591001 1068 10681119	16-25	10SEP2020	86799	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10711039	C4591001 1071 10711039	16-25	14AUG2020	49684	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
10711080	C4591001 1071 10711080	16-25	22AUG2020	62086	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10711138	C4591001 1071 10711138	16-25	08SEP2020	82595	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10711206	C4591001 1071 10711206	16-25	26SEP2020	100604	Placebo	26SEP2020	Placebo	17OCT2020	Placebo
10711231	C4591001 1071 10711231	16-25	16OCT2020	108507	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
10711233	C4591001 1071 10711233	16-25	19OCT2020	110195	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10721049	C4591001 1072 10721049	16-25	26AUG2020	66836	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10721089	C4591001 1072 10721089	16-25	04SEP2020	81432	Placebo	04SEP2020	Placebo	23SEP2020	Placebo
10721091	C4591001 1072 10721091	16-25	08SEP2020	83539	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10721093	C4591001 1072 10721093	16-25	08SEP2020	83542	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
10731038	C4591001 1073 10731038	16-25	05AUG2020	42468	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)		
10731048	C4591001 1073 10731048	16-25	06AUG2020	43741	Placebo	06AUG2020	Placebo	28AUG2020	Placebo
10731064	C4591001 1073 10731064	16-25	11AUG2020	46350	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
10731067	C4591001 1073 10731067	16-25	11AUG2020	46353	Placebo	11AUG2020	Placebo	02SEP2020	Placebo
10731083	C4591001 1073 10731083	16-25	13AUG2020	47545	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
10731101	C4591001 1073 10731101	16-25	20AUG2020	58710	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10731114	C4591001 107310731114	16-25	25AUG2020	64143	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
10771008	C4591001 10771008	16-25	10AUG2020	45358	Placebo	10AUG2020	Placebo	31AUG2020	Placebo
10771010	C4591001 10771010	16-25	10AUG2020	45363	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10771058	C4591001 10771058	16-25	17AUG2020	53205	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
10771079	C4591001 10771079	16-25	19AUG2020	55224	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
10771198	C4591001 10771198	16-25	04SEP2020	80955	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10771240	C4591001 10771240	16-25	18SEP2020	93608	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
10771247	C4591001 10771247	16-25	19OCT2020	107989	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
10771248	C4591001 10771248	16-25	19OCT2020	107991	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10771250	C4591001 10771250	16-25	19OCT2020	110276	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
10771258	C4591001 10771258	16-25	20OCT2020	110281	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
10771262	C4591001 10771262	16-25	20OCT2020	110961	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10771269	C4591001 10771269	16-25	22OCT2020	112339	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
10771272	C4591001 10771272	16-25	29OCT2020	112340	Placebo	29OCT2020	Placebo	20NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10771273	C4591001 1077 10771273	16-25	02DEC2020	112345	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
10771276	C4591001 1077 10771276	16-25	04DEC2020	112346	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10791013	C4591001 1079 10791013	16-25	30JUL2020	40306	Placebo	30JUL2020	Placebo	19AUG2020	Placebo
10791059	C4591001 1079 10791059	16-25	05AUG2020	42979	Placebo	05AUG2020	Placebo	26AUG2020	Placebo
10791113	C4591001 1079 10791113	16-25	12AUG2020	47611	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
10791142	C4591001 1079 10791142	16-25	18AUG2020	55158	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
10791162	C4591001 1079 10791162	16-25	20AUG2020	56939	Placebo	20AUG2020	Placebo	26AUG2020	Placebo
10791170	C4591001 1079 10791170	16-25	24AUG2020	59283	Placebo	24AUG2020	Placebo	15SEP2020	Placebo
10791171	C4591001 1079 10791171	16-25	24AUG2020	63929	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10791186	C4591001 1079 10791186	16-25	26AUG2020	68107	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
10791188	C4591001 1079 10791188	16-25	26AUG2020	68110	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10791230	C4591001 1079 10791230	16-25	02SEP2020	77158	Placebo	02SEP2020	Placebo	22SEP2020	Placebo
10791238	C4591001 1079 10791238	16-25	03SEP2020	80202	Placebo	03SEP2020	Placebo	23SEP2020	Placebo
10791239	C4591001 1079 10791239	16-25	03SEP2020	80203	Placebo	03SEP2020	Placebo	28SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10791252	C4591001 1079 10791252	16-25	08SEP2020	84212	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
10791253	C4591001 1079 10791253	16-25	08SEP2020	84216	Placebo	08SEP2020	Placebo		
10791288	C4591001 1079 10791288	16-25	16SEP2020	90180	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10801009	C4591001 1080 10801009	16-25	11AUG2020	46038	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
10801019	C4591001 1080 10801019	16-25	12AUG2020	47382	Placebo	12AUG2020	Placebo	31AUG2020	Placebo
10801022	C4591001 1080 10801022	16-25	12AUG2020	47389	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
10801054	C4591001 1080 10801054	16-25	18AUG2020	54237	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
10801055	C4591001 1080 10801055	16-25	18AUG2020	54240	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
10801079	C4591001 1080 10801079	16-25	21AUG2020	60670	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
10801087	C4591001 1080 10801087	16-25	24AUG2020	64361	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10801108	C4591001 1080 10801108	16-25	27AUG2020	67787	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10801119	C4591001 1080 10801119	16-25	28AUG2020	72230	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
10801153	C4591001 1080 10801153	16-25	04SEP2020	81259	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10801179	C4591001 1080 10801179	16-25	11SEP2020	82311	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10801193	C4591001 108010801193	16-25	16SEP2020	89927	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
10801201	C4591001 108010801201	16-25	17SEP2020	91489	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
10801213	C4591001 108010801213	16-25	21SEP2020	92592	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10801219	C4591001 108010801219	16-25	21SEP2020	94716	Placebo	21SEP2020	Placebo	14OCT2020	Placebo
10801221	C4591001 108010801221	16-25	22SEP2020	94719	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
10811012	C4591001 108110811012	16-25	10AUG2020	45602	Placebo	10AUG2020	Placebo	01SEP2020	Placebo
10811013	C4591001 108110811013	16-25	11AUG2020	45604	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
10811075	C4591001 108110811075	16-25	20AUG2020	56848	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
10811146	C4591001 108110811146	16-25	01SEP2020	76362	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10811161	C4591001 108110811161	16-25	02SEP2020	78499	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
10821014	C4591001 108210821014	16-25	03AUG2020	41495	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)
10821024	C4591001 108210821024	16-25	04AUG2020	42209	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
10821025	C4591001 108210821025	16-25	04AUG2020	42217	Placebo	04AUG2020	Placebo	25AUG2020	Placebo
10821036	C4591001 108210821036	16-25	04AUG2020	42550	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10821044	C4591001 108210821044	16-25	05AUG2020	42877	Placebo	05AUG2020	Placebo	26AUG2020	Placebo
10821054	C4591001 108210821054	16-25	05AUG2020	43181	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
10821139	C4591001 108210821139	16-25	28AUG2020	70400	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
10821171	C4591001 108210821171	16-25	21SEP2020	93435	Placebo	21SEP2020	Placebo	14OCT2020	Placebo
10821196	C4591001 108210821196	16-25	09OCT2020	105290	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10821201	C4591001 108210821201	16-25	19OCT2020	110299	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
10821211	C4591001 108210821211	16-25	27OCT2020	111097	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10831001	C4591001 108310831001	16-25	29JUL2020	40326	Placebo	29JUL2020	Placebo	21AUG2020	Placebo
10831062	C4591001 108310831062	16-25	07AUG2020	43395	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
10831082	C4591001 108310831082	16-25	11AUG2020	46171	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10831084	C4591001 108310831084	16-25	11AUG2020	46178	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10831094	C4591001 108310831094	16-25	13AUG2020	48484	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
10831105	C4591001 108310831105	16-25	17AUG2020	52365	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
10831113	C4591001 108310831113	16-25	18AUG2020	52371	Placebo	18AUG2020	Placebo	08SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10831124	C4591001 1083 10831124	16-25	19AUG2020	57487	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
10831127	C4591001 1083 10831127	16-25	20AUG2020	57494	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
10831132	C4591001 1083 10831132	16-25	20AUG2020	58577	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
10831145	C4591001 1083 10831145	16-25	24AUG2020	64061	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10831163	C4591001 1083 10831163	16-25	26AUG2020	68505	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
10831174	C4591001 1083 10831174	16-25	27AUG2020	70466	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10831191	C4591001 1083 10831191	16-25	04SEP2020	77967	Placebo	04SEP2020	Placebo	23SEP2020	Placebo
10831205	C4591001 1083 10831205	16-25	09SEP2020	86158	Placebo	09SEP2020	Placebo	01OCT2020	Placebo
10831227	C4591001 1083 10831227	16-25	11SEP2020	87707	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
10831253	C4591001 1083 10831253	16-25	22SEP2020	89011	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
10841029	C4591001 1084 10841029	16-25	03AUG2020	41654	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
10841031	C4591001 1084 10841031	16-25	03AUG2020	41930	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
10841069	C4591001 1084 10841069	16-25	07AUG2020	44344	Placebo	07AUG2020	Placebo	28AUG2020	Placebo
10841072	C4591001 1084 10841072	16-25	07AUG2020	44461	Placebo	07AUG2020	Placebo	28AUG2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10841101	C4591001 1084 10841101	16-25	10AUG2020	45509	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10841214	C4591001 1084 10841214	16-25	17AUG2020	53277	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10841228	C4591001 1084 10841228	16-25	19AUG2020	56167	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10841280	C4591001 1084 10841280	16-25	24AUG2020	62344	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10841393	C4591001 1084 10841393	16-25	14SEP2020	89528	Placebo	14SEP2020	Placebo	07OCT2020	Placebo
10841409	C4591001 1084 10841409	16-25	16SEP2020	89977	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
10841410	C4591001 1084 10841410	16-25	16SEP2020	91409	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10841423	C4591001 1084 10841423	16-25	18SEP2020	93977	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
10841492	C4591001 1084 10841492	16-25	16OCT2020	109184	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
10841495	C4591001 1084 10841495	16-25	16OCT2020	109187	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
10841512	C4591001 1084 10841512	16-25	21OCT2020	110560	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10841517	C4591001 1084 10841517	16-25	21OCT2020	111516	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
10841530	C4591001 1084 10841530	16-25	23OCT2020	113219	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
10841533	C4591001 1084 10841533	16-25	26OCT2020	113222	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10841535	C4591001 1084 10841535	16-25	26OCT2020	113223	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
10841536	C4591001 1084 10841536	16-25	28OCT2020	114546	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
10841537	C4591001 1084 10841537	16-25	30OCT2020	114549	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
10841538	C4591001 1084 10841538	16-25	06NOV2020	114554	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)
10841539	C4591001 1084 10841539	16-25	11NOV2020	114555	Placebo	11NOV2020	Placebo	02DEC2020	Placebo
10841540	C4591001 1084 10841540	16-25	20NOV2020	116598	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
10851003	C4591001 1085 10851003	16-25	30JUL2020	40554	Placebo	30JUL2020	Placebo	21AUG2020	Placebo
10851019	C4591001 1085 10851019	16-25	01AUG2020	41323	Placebo	01AUG2020	Placebo	22AUG2020	Placebo
10851035	C4591001 1085 10851035	16-25	05AUG2020	43214	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)
10851041	C4591001 1085 10851041	16-25	06AUG2020	43628	Placebo	06AUG2020	Placebo	02SEP2020	Placebo
10851049	C4591001 1085 10851049	16-25	06AUG2020	44156	Placebo	06AUG2020	Placebo	02SEP2020	Placebo
10851050	C4591001 1085 10851050	16-25	06AUG2020	43636	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
10851079	C4591001 1085 10851079	16-25	10AUG2020	44992	Placebo	10AUG2020	Placebo	31AUG2020	Placebo
10851081	C4591001 1085 10851081	16-25	10AUG2020	45896	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10851165	C4591001 108510851165	16-25	25AUG2020	65972	Placebo	25AUG2020	Placebo	17SEP2020	Placebo
10851175	C4591001 108510851175	16-25	25AUG2020	66848	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10851229	C4591001 108510851229	16-25	01SEP2020	76892	Placebo	01SEP2020	Placebo	24SEP2020	Placebo
10851244	C4591001 108510851244	16-25	02SEP2020	78298	Placebo	02SEP2020	Placebo	25SEP2020	Placebo
10851245	C4591001 108510851245	16-25	02SEP2020	78301	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10851276	C4591001 108510851276	16-25	08SEP2020	84047	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10851281	C4591001 108510851281	16-25	08SEP2020	84052	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10851299	C4591001 108510851299	16-25	10SEP2020	86031	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
10851350	C4591001 108510851350	16-25	16SEP2020	91584	Placebo	16SEP2020	Placebo	19OCT2020	Placebo
10851365	C4591001 108510851365	16-25	06OCT2020	104363	Placebo	06OCT2020	Placebo	29OCT2020	Placebo
10851373	C4591001 108510851373	16-25	29OCT2020	107039	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
10851374	C4591001 108510851374	16-25	29OCT2020	107041	Placebo	29OCT2020	Placebo	17NOV2020	Placebo
10851375	C4591001 108510851375	16-25	29OCT2020	114857	Placebo	29OCT2020	Placebo	20NOV2020	Placebo
10871021	C4591001 108710871021	16-25	07AUG2020	44233	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10871060	C4591001 10871087 10871060	16-25	11AUG2020	46284	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
10871061	C4591001 10871087 10871061	16-25	11AUG2020	46286	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
10871062	C4591001 10871087 10871062	16-25	11AUG2020	46281	Placebo	11AUG2020	Placebo	02SEP2020	Placebo
10871064	C4591001 10871087 10871064	16-25	11AUG2020	46400	Placebo	11AUG2020	Placebo	02SEP2020	Placebo
10871078	C4591001 10871087 10871078	16-25	12AUG2020	46883	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10871087	C4591001 10871087 10871087	16-25	17AUG2020	52408	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
10871089	C4591001 10871087 10871089	16-25	17AUG2020	52589	Placebo	17AUG2020	Placebo		
10871108	C4591001 10871087 10871108	16-25	18AUG2020	54654	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
10871182	C4591001 10871087 10871182	16-25	24AUG2020	64403	Placebo	24AUG2020	Placebo	17SEP2020	Placebo
10871214	C4591001 10871087 10871214	16-25	26AUG2020	66396	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10871239	C4591001 10871087 10871239	16-25	26AUG2020	68302	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
10871243	C4591001 10871087 10871243	16-25	26AUG2020	68308	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10871267	C4591001 10871087 10871267	16-25	31AUG2020	75993	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10871279	C4591001 10871087 10871279	16-25	01SEP2020	75995	Placebo	01SEP2020	Placebo	21SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10871325	C4591001 108710871325	16-25	03SEP2020	79046	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10871343	C4591001 108710871343	16-25	08SEP2020	81382	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
10871354	C4591001 108710871354	16-25	08SEP2020	83469	Placebo	08SEP2020	Placebo		
10871356	C4591001 108710871356	16-25	08SEP2020	83475	Placebo	08SEP2020	Placebo		
10871363	C4591001 108710871363	16-25	08SEP2020	84246	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
10871473	C4591001 108710871473	16-25	17SEP2020	91979	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
10871490	C4591001 108710871490	16-25	18SEP2020	93207	Placebo	18SEP2020	Placebo	08OCT2020	Placebo
10871491	C4591001 108710871491	16-25	18SEP2020	93917	Placebo	18SEP2020	Placebo	07OCT2020	Placebo
10871529	C4591001 108710871529	16-25	29SEP2020	99688	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
10871531	C4591001 108710871531	16-25	06OCT2020	102851	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
10871556	C4591001 108710871556	16-25	14OCT2020	107355	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
10871565	C4591001 108710871565	16-25	15OCT2020	107921	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
10871593	C4591001 108710871593	16-25	28OCT2020	113959	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
10881054	C4591001 108810881054	16-25	18AUG2020	53607	Placebo	18AUG2020	Placebo	08SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10881130	C4591001 1088 10881130	16-25	01SEP2020	75397	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
10881200	C4591001 1088 10881200	16-25	11SEP2020	88560	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
10881227	C4591001 1088 10881227	16-25	21SEP2020	95193	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10881239	C4591001 1088 10881239	16-25	25SEP2020	99866	Placebo	25SEP2020	Placebo	15OCT2020	Placebo
10881256	C4591001 1088 10881256	16-25	16OCT2020	108195	Placebo	16OCT2020	Placebo	09NOV2020	Placebo
10891015	C4591001 1089 10891015	16-25	30JUL2020	40572	Placebo	30JUL2020	Placebo	18AUG2020	Placebo
10891120	C4591001 1089 10891120	16-25	13AUG2020	49030	Placebo	13AUG2020	Placebo	02SEP2020	Placebo
10891121	C4591001 1089 10891121	16-25	13AUG2020	49031	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
10891179	C4591001 1089 10891179	16-25	25AUG2020	65226	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
10891181	C4591001 1089 10891181	16-25	25AUG2020	65230	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
10891192	C4591001 1089 10891192	16-25	26AUG2020	66254	Placebo	26AUG2020	Placebo	17SEP2020	Placebo
10891225	C4591001 1089 10891225	16-25	01SEP2020	76344	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10891257	C4591001 1089 10891257	16-25	08SEP2020	81360	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10891273	C4591001 1089 10891273	16-25	09SEP2020	85566	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10891279	C4591001 1089 10891279	16-25	10SEP2020	85571	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10891283	C4591001 1089 10891283	16-25	10SEP2020	86402	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
10891306	C4591001 1089 10891306	16-25	14SEP2020	88081	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
10891317	C4591001 1089 10891317	16-25	16SEP2020	90933	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
10891318	C4591001 1089 10891318	16-25	16SEP2020	90937	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
10891338	C4591001 1089 10891338	16-25	18SEP2020	93733	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
10891343	C4591001 1089 10891343	16-25	21SEP2020	94811	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10901031	C4591001 1090 10901031	16-25	03AUG2020	41935	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
10901038	C4591001 1090 10901038	16-25	04AUG2020	42238	Placebo	04AUG2020	Placebo	28AUG2020	Placebo
10901043	C4591001 1090 10901043	16-25	04AUG2020	42533	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
10901044	C4591001 1090 10901044	16-25	04AUG2020	42544	Placebo	04AUG2020	Placebo	24AUG2020	Placebo
10901090	C4591001 1090 10901090	16-25	06AUG2020	43951	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
10901157	C4591001 1090 10901157	16-25	12AUG2020	47967	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
10901197	C4591001 1090 10901197	16-25	14AUG2020	50231	Placebo	14AUG2020	Placebo	03SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10901201	C4591001 109010901201	16-25	14AUG2020	50815	Placebo	14AUG2020	Placebo	03SEP2020	Placebo
10901222	C4591001 109010901222	16-25	17AUG2020	52672	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
10901314	C4591001 109010901314	16-25	02SEP2020	79127	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10901315	C4591001 109010901315	16-25	02SEP2020	79130	Placebo	02SEP2020	Placebo	21SEP2020	Placebo
10901328	C4591001 109010901328	16-25	03SEP2020	80915	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10901350	C4591001 109010901350	16-25	08SEP2020	84260	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
10901369	C4591001 109010901369	16-25	10SEP2020	85632	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
10901377	C4591001 109010901377	16-25	10SEP2020	86746	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
10901416	C4591001 109010901416	16-25	17SEP2020	92043	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
10901424	C4591001 109010901424	16-25	17SEP2020	92507	Placebo	17SEP2020	Placebo	09OCT2020	Placebo
10901435	C4591001 109010901435	16-25	22SEP2020	95088	Placebo	22SEP2020	Placebo	16OCT2020	Placebo
10901443	C4591001 109010901443	16-25	22SEP2020	96345	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
10901517	C4591001 109010901517	16-25	20OCT2020	110697	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10901540	C4591001 109010901540	16-25	23OCT2020	112934	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10901550	C4591001 109010901550	16-25	26OCT2020	113529	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
10901559	C4591001 109010901559	16-25	27OCT2020	114032	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
10911019	C4591001 109110911019	16-25	03AUG2020	41673	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
10911020	C4591001 109110911020	16-25	03AUG2020	40897	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
10911067	C4591001 109110911067	16-25	06AUG2020	43324	Placebo	06AUG2020	Placebo	27AUG2020	Placebo
10911088	C4591001 109110911088	16-25	10AUG2020	43862	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
10911095	C4591001 109110911095	16-25	11AUG2020	46184	Placebo	11AUG2020	Placebo	02SEP2020	Placebo
10911106	C4591001 109110911106	16-25	12AUG2020	46680	Placebo	12AUG2020	Placebo	31AUG2020	Placebo
10911111	C4591001 109110911111	16-25	12AUG2020	47268	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
10911120	C4591001 109110911120	16-25	13AUG2020	48681	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
10911122	C4591001 109110911122	16-25	13AUG2020	48683	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
10911125	C4591001 109110911125	16-25	17AUG2020	49370	Placebo	17AUG2020	Placebo	10SEP2020	Placebo
10911149	C4591001 109110911149	16-25	19AUG2020	56290	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
10911160	C4591001 109110911160	16-25	20AUG2020	57096	Placebo	20AUG2020	Placebo	08SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911233	C4591001 1091 10911233	16-25	02SEP2020	78882	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10911238	C4591001 1091 10911238	16-25	02SEP2020	79301	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
10911270	C4591001 1091 10911270	16-25	09SEP2020	85331	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10911297	C4591001 1091 10911297	16-25	14SEP2020	89862	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
10911311	C4591001 1091 10911311	16-25	16SEP2020	91185	Placebo	16SEP2020	Placebo	08OCT2020	Placebo
10911322	C4591001 1091 10911322	16-25	17SEP2020	92635	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
10911328	C4591001 1091 10911328	16-25	21SEP2020	94838	Placebo	21SEP2020	Placebo	15OCT2020	Placebo
10911331	C4591001 1091 10911331	16-25	22SEP2020	94840	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
10911334	C4591001 1091 10911334	16-25	23SEP2020	97091	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
10911341	C4591001 1091 10911341	16-25	25SEP2020	99545	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
10911342	C4591001 1091 10911342	16-25	25SEP2020	99430	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
10911344	C4591001 1091 10911344	16-25	29SEP2020	99549	Placebo	29SEP2020	Placebo	19OCT2020	Placebo
10911351	C4591001 1091 10911351	16-25	05OCT2020	103902	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
10911379	C4591001 1091 10911379	16-25	26OCT2020	111608	Placebo	26OCT2020	Placebo	17NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911380	C4591001 1091 10911380	16-25	26OCT2020	111616	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10911381	C4591001 1091 10911381	16-25	27OCT2020	114199	Placebo	27OCT2020	Placebo	16NOV2020	Placebo
10911382	C4591001 1091 10911382	16-25	28OCT2020	114200	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
10911383	C4591001 1091 10911383	16-25	28OCT2020	114204	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
10911384	C4591001 1091 10911384	16-25	29OCT2020	114207	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
10911385	C4591001 1091 10911385	16-25	29OCT2020	114761	Placebo	29OCT2020	Placebo	17NOV2020	Placebo
10911386	C4591001 1091 10911386	16-25	03NOV2020	114762	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
10911387	C4591001 1091 10911387	16-25	05NOV2020	114767	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)		
10911388	C4591001 1091 10911388	16-25	16NOV2020	116297	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
10911389	C4591001 1091 10911389	16-25	18NOV2020	116298	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
10911390	C4591001 1091 10911390	16-25	18NOV2020	116302	Placebo	18NOV2020	Placebo	09DEC2020	Placebo
10911391	C4591001 1091 10911391	16-25	25NOV2020	116303	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
10911392	C4591001 1091 10911392	16-25	30NOV2020	117066	Placebo	30NOV2020	Placebo	22DEC2020	Placebo
10911393	C4591001 1091 10911393	16-25	01DEC2020	20577	Placebo	01DEC2020	Placebo	21DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10911397	C4591001 1091 10911397	16-25	03DEC2020	117073	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
10911398	C4591001 1091 10911398	16-25	03DEC2020	117075	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	08JAN2021	BNT162b2 (30 µg)
10911401	C4591001 1091 10911401	16-25	04DEC2020	117547	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
10921001	C4591001 1092 10921001	16-25	18AUG2020	54917	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
10921002	C4591001 1092 10921002	16-25	18AUG2020	54918	Placebo	18AUG2020	Placebo	10SEP2020	Placebo
10921055	C4591001 1092 10921055	16-25	24AUG2020	63229	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10921083	C4591001 1092 10921083	16-25	26AUG2020	67629	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
10921098	C4591001 1092 10921098	16-25	27AUG2020	68906	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
10921101	C4591001 1092 10921101	16-25	27AUG2020	71098	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10921109	C4591001 1092 10921109	16-25	31AUG2020	71103	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10921127	C4591001 1092 10921127	16-25	01SEP2020	76961	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
10921128	C4591001 1092 10921128	16-25	01SEP2020	76964	BNT162b2 (30 µg)				
10921144	C4591001 1092 10921144	16-25	02SEP2020	78814	Placebo	02SEP2020	Placebo	24SEP2020	Placebo
10921146	C4591001 1092 10921146	16-25	02SEP2020	78815	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10921157	C4591001 1092 10921157	16-25	03SEP2020	79902	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
10921158	C4591001 1092 10921158	16-25	03SEP2020	79904	Placebo	03SEP2020	Placebo	15OCT2020	Placebo
10921177	C4591001 1092 10921177	16-25	10SEP2020	86239	Placebo	10SEP2020	Placebo	29SEP2020	Placebo
10921189	C4591001 1092 10921189	16-25	15SEP2020	87904	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10921192	C4591001 1092 10921192	16-25	16SEP2020	91530	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
10921197	C4591001 1092 10921197	16-25	05OCT2020	91532	Placebo	05OCT2020	Placebo	26OCT2020	Placebo
10921218	C4591001 1092 10921218	16-25	09OCT2020	105765	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
10921223	C4591001 1092 10921223	16-25	12OCT2020	105769	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
10921225	C4591001 1092 10921225	16-25	12OCT2020	105770	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
10921227	C4591001 1092 10921227	16-25	12OCT2020	106568	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
10921260	C4591001 1092 10921260	16-25	20OCT2020	109864	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
10921271	C4591001 1092 10921271	16-25	27OCT2020	113924	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
10931040	C4591001 1093 10931040	16-25	21AUG2020	60157	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
10931041	C4591001 1093 10931041	16-25	21AUG2020	61577	Placebo	21AUG2020	Placebo	11SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10931055	C4591001 109310931055	16-25	25AUG2020	65667	BNT162b2 (30 µg)				
10931058	C4591001 109310931058	16-25	25AUG2020	67013	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)		
10931072	C4591001 109310931072	16-25	26AUG2020	69019	Placebo	26AUG2020	Placebo		
10931087	C4591001 109310931087	16-25	28AUG2020	71137	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
10931088	C4591001 109310931088	16-25	31AUG2020	74722	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10931126	C4591001 109310931126	16-25	11SEP2020	88626	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10931133	C4591001 109310931133	16-25	18SEP2020	93263	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
10931139	C4591001 109310931139	16-25	22SEP2020	96204	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
10931148	C4591001 109310931148	16-25	22SEP2020	97109	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
10931168	C4591001 109310931168	16-25	02OCT2020	97920	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
10931171	C4591001 109310931171	16-25	07OCT2020	104981	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10931174	C4591001 109310931174	16-25	12OCT2020	104985	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
10931203	C4591001 109310931203	16-25	23OCT2020	113171	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
10931204	C4591001 109310931204	16-25	23OCT2020	113175	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10931210	C4591001 1093 10931210	16-25	26OCT2020	113576	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
10931218	C4591001 1093 10931218	16-25	26OCT2020	113727	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
10931219	C4591001 1093 10931219	16-25	27OCT2020	113784	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
10941049	C4591001 1094 10941049	16-25	24AUG2020	64793	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10941069	C4591001 1094 10941069	16-25	28AUG2020	72051	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10941075	C4591001 1094 10941075	16-25	01SEP2020	77681	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10941076	C4591001 1094 10941076	16-25	01SEP2020	77686	Placebo	01SEP2020	Placebo	24SEP2020	Placebo
10941117	C4591001 1094 10941117	16-25	09SEP2020	83259	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
10941156	C4591001 1094 10941156	16-25	25SEP2020	100025	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
10941169	C4591001 1094 10941169	16-25	05OCT2020	103974	Placebo	05OCT2020	Placebo	27OCT2020	Placebo
10951002	C4591001 1095 10951002	16-25	30JUL2020	40445	Placebo	30JUL2020	Placebo	21AUG2020	Placebo
10951038	C4591001 1095 10951038	16-25	03AUG2020	41918	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
10951046	C4591001 1095 10951046	16-25	04AUG2020	42379	Placebo	04AUG2020	Placebo	25AUG2020	Placebo
10951055	C4591001 1095 10951055	16-25	04AUG2020	42388	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10951056	C4591001 109510951056	16-25	05AUG2020	42774	Placebo	05AUG2020	Placebo		
10951106	C4591001 109510951106	16-25	07AUG2020	44850	Placebo	07AUG2020	Placebo	28AUG2020	Placebo
10951110	C4591001 109510951110	16-25	19AUG2020	44853	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)		
10951122	C4591001 109510951122	16-25	24AUG2020	61401	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
10951132	C4591001 109510951132	16-25	04SEP2020	81485	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10951170	C4591001 109510951170	16-25	29AUG2020	74018	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10951217	C4591001 109510951217	16-25	02SEP2020	79461	Placebo	02SEP2020	Placebo	24SEP2020	Placebo
10951225	C4591001 109510951225	16-25	04SEP2020	81488	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
10951243	C4591001 109510951243	16-25	25SEP2020	99901	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
10951244	C4591001 109510951244	16-25	28SEP2020	99902	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
10951260	C4591001 109510951260	16-25	07OCT2020	102493	Placebo	07OCT2020	Placebo	28OCT2020	Placebo
10951271	C4591001 109510951271	16-25	08OCT2020	105511	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10951278	C4591001 109510951278	16-25	12OCT2020	105516	Placebo	12OCT2020	Placebo	03NOV2020	Placebo
10951284	C4591001 109510951284	16-25	13OCT2020	106701	Placebo	13OCT2020	Placebo	04NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10951308	C4591001 109510951308	16-25	17NOV2020	113212	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
10951309	C4591001 109510951309	16-25	18NOV2020	116456	Placebo	18NOV2020	Placebo	07DEC2020	Placebo
10951310	C4591001 109510951310	16-25	19NOV2020	116457	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
10951311	C4591001 109510951311	16-25	19NOV2020	116458	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
10951312	C4591001 109510951312	16-25	20NOV2020	116464	Placebo	20NOV2020	Placebo	11DEC2020	Placebo
10951313	C4591001 109510951313	16-25	23NOV2020	116671	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
10951314	C4591001 109510951314	16-25	23NOV2020	116676	Placebo	23NOV2020	Placebo	14DEC2020	Placebo
10951315	C4591001 109510951315	16-25	23NOV2020	116677	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
10951316	C4591001 109510951316	16-25	23NOV2020	116678	Placebo	23NOV2020	Placebo	15DEC2020	Placebo
10951317	C4591001 109510951317	16-25	24NOV2020	116876	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
10951318	C4591001 109510951318	16-25	30NOV2020	116879	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10951319	C4591001 109510951319	16-25	01DEC2020	116881	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
10961010	C4591001 109610961010	16-25	13AUG2020	48883	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
10961027	C4591001 109610961027	16-25	14AUG2020	50900	Placebo	14AUG2020	Placebo	04SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10961030	C4591001 109610961030	16-25	14AUG2020	50907	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10961031	C4591001 109610961031	16-25	14AUG2020	51006	Placebo	14AUG2020	Placebo		
10961032	C4591001 109610961032	16-25	14AUG2020	51007	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
10961053	C4591001 109610961053	16-25	18AUG2020	55568	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10961057	C4591001 109610961057	16-25	18AUG2020	53691	Placebo	18AUG2020	Placebo	10SEP2020	Placebo
10961081	C4591001 109610961081	16-25	20AUG2020	58958	Placebo	20AUG2020	Placebo		
10961084	C4591001 109610961084	16-25	20AUG2020	59844	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
10961096	C4591001 109610961096	16-25	22AUG2020	61024	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
10961113	C4591001 109610961113	16-25	22AUG2020	62381	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)
10961141	C4591001 109610961141	16-25	26AUG2020	68100	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)		
10961168	C4591001 109610961168	16-25	28AUG2020	72569	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
10961178	C4591001 109610961178	16-25	29AUG2020	73739	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)
10961195	C4591001 109610961195	16-25	31AUG2020	73936	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
10961196	C4591001 109610961196	16-25	31AUG2020	75212	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10961205	C4591001 109610961205	16-25	01SEP2020	77053	Placebo	01SEP2020	Placebo	24SEP2020	Placebo
10961213	C4591001 109610961213	16-25	02SEP2020	77656	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
10961219	C4591001 109610961219	16-25	02SEP2020	78652	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10961220	C4591001 109610961220	16-25	02SEP2020	79363	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
10961223	C4591001 109610961223	16-25	02SEP2020	78648	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
10961245	C4591001 109610961245	16-25	04SEP2020	81790	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
10961313	C4591001 109610961313	16-25	10SEP2020	87642	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
10961319	C4591001 109610961319	16-25	12SEP2020	87652	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
10961321	C4591001 109610961321	16-25	12SEP2020	89179	Placebo	12SEP2020	Placebo		
10961335	C4591001 109610961335	16-25	15SEP2020	90525	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
10961336	C4591001 109610961336	16-25	15SEP2020	90530	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
10961341	C4591001 109610961341	16-25	15SEP2020	90814	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
10961367	C4591001 109610961367	16-25	28SEP2020	93111	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
10961372	C4591001 109610961372	16-25	06OCT2020	104371	Placebo	06OCT2020	Placebo	27OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10961373	C4591001 1096 10961373	16-25	06OCT2020	104370	Placebo	06OCT2020	Placebo	26OCT2020	Placebo
10961385	C4591001 1096 10961385	16-25	09OCT2020	106161	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
10961387	C4591001 1096 10961387	16-25	09OCT2020	106163	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
10961388	C4591001 1096 10961388	16-25	09OCT2020	106165	Placebo	09OCT2020	Placebo		
10961390	C4591001 1096 10961390	16-25	02NOV2020	106167	Placebo	02NOV2020	Placebo	23NOV2020	Placebo
10961391	C4591001 1096 10961391	16-25	05NOV2020	115819	Placebo	05NOV2020	Placebo	24NOV2020	Placebo
10961392	C4591001 1096 10961392	16-25	23NOV2020	115821	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
10961393	C4591001 1096 10961393	16-25	02DEC2020	115827	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
10971083	C4591001 1097 10971083	16-25	01SEP2020	77226	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
10971096	C4591001 1097 10971096	16-25	04SEP2020	77236	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
10981020	C4591001 1098 10981020	16-25	20AUG2020	59249	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
10981077	C4591001 1098 10981077	16-25	02SEP2020	77166	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
10981143	C4591001 1098 10981143	16-25	11SEP2020	87328	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
10981154	C4591001 1098 10981154	16-25	14SEP2020	88909	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
10981177	C4591001 109810981177	16-25	16SEP2020	91103	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
10981187	C4591001 109810981187	16-25	16SEP2020	91803	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
10981197	C4591001 109810981197	16-25	21SEP2020	94963	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10981198	C4591001 109810981198	16-25	21SEP2020	94965	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
10981200	C4591001 109810981200	16-25	21SEP2020	94970	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)		
10981243	C4591001 109810981243	16-25	02OCT2020	102511	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
10981244	C4591001 109810981244	16-25	02OCT2020	102512	Placebo	02OCT2020	Placebo	21OCT2020	Placebo
10981251	C4591001 109810981251	16-25	07OCT2020	103213	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
10981252	C4591001 109810981252	16-25	07OCT2020	103215	Placebo	07OCT2020	Placebo	30OCT2020	Placebo
10981254	C4591001 109810981254	16-25	09OCT2020	105252	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
10981263	C4591001 109810981263	16-25	22OCT2020	109250	Placebo	22OCT2020	Placebo	11NOV2020	Placebo
10981265	C4591001 109810981265	16-25	23OCT2020	112853	Placebo	23OCT2020	Placebo	11NOV2020	Placebo
11011004	C4591001 110111011004	16-25	01SEP2020	71950	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11011014	C4591001 110111011014	16-25	03SEP2020	78712	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11011022	C4591001 1101 11011022	16-25	09SEP2020	84539	Placebo	09SEP2020	Placebo	28SEP2020	Placebo
11011026	C4591001 1101 11011026	16-25	09SEP2020	84543	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
11011033	C4591001 1101 11011033	16-25	10SEP2020	85852	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11011034	C4591001 1101 11011034	16-25	10SEP2020	86923	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11011038	C4591001 1101 11011038	16-25	10SEP2020	86925	Placebo	10SEP2020	Placebo	29SEP2020	Placebo
11011040	C4591001 1101 11011040	16-25	10SEP2020	86927	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
11011042	C4591001 1101 11011042	16-25	11SEP2020	87667	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11011046	C4591001 1101 11011046	16-25	14SEP2020	89407	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
11011052	C4591001 1101 11011052	16-25	14SEP2020	89412	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11011053	C4591001 1101 11011053	16-25	14SEP2020	90065	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
11011056	C4591001 1101 11011056	16-25	15SEP2020	90068	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11011057	C4591001 1101 11011057	16-25	15SEP2020	90067	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
11011062	C4591001 1101 11011062	16-25	16SEP2020	90735	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11011069	C4591001 1101 11011069	16-25	16SEP2020	91306	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11011073	C4591001 1101 11011073	16-25	17SEP2020	91847	Placebo	17SEP2020	Placebo	09OCT2020	Placebo
11011075	C4591001 1101 11011075	16-25	17SEP2020	93042	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
11011079	C4591001 1101 11011079	16-25	18SEP2020	93050	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11011080	C4591001 1101 11011080	16-25	18SEP2020	93051	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
11011088	C4591001 1101 11011088	16-25	22SEP2020	95344	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11011100	C4591001 1101 11011100	16-25	01OCT2020	99056	Placebo	01OCT2020	Placebo	20OCT2020	Placebo
11011105	C4591001 1101 11011105	16-25	12OCT2020	106460	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
11011107	C4591001 1101 11011107	16-25	13OCT2020	106464	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
11011110	C4591001 1101 11011110	16-25	17NOV2020	113542	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11011111	C4591001 1101 11011111	16-25	19OCT2020	110264	Placebo	19OCT2020	Placebo	11NOV2020	Placebo
11011113	C4591001 1101 11011113	16-25	20OCT2020	110265	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11011114	C4591001 1101 11011114	16-25	20OCT2020	110267	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11011118	C4591001 1101 11011118	16-25	26OCT2020	113537	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11071010	C4591001 1107 11071010	16-25	30JUL2020	40320	Placebo	30JUL2020	Placebo	18AUG2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11071025	C4591001 1107 11071025	16-25	03AUG2020	41795	Placebo	03AUG2020	Placebo	25AUG2020	Placebo
11071055	C4591001 1107 11071055	16-25	06AUG2020	43566	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)
11071122	C4591001 1107 11071122	16-25	17AUG2020	52781	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11071124	C4591001 1107 11071124	16-25	17AUG2020	52792	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11071179	C4591001 1107 11071179	16-25	27AUG2020	69775	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11071209	C4591001 1107 11071209	16-25	08SEP2020	80690	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
11091020	C4591001 1109 11091020	16-25	30JUL2020	40384	BNT162b2 (30 µg)	30JUL2020	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)
11091030	C4591001 1109 11091030	16-25	30JUL2020	40507	Placebo	30JUL2020	Placebo	18AUG2020	Placebo
11091046	C4591001 1109 11091046	16-25	31JUL2020	40808	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
11091059	C4591001 1109 11091059	16-25	31JUL2020	41031	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)		
11091092	C4591001 1109 11091092	16-25	01AUG2020	41308	Placebo	01AUG2020	Placebo	23AUG2020	Placebo
11091132	C4591001 1109 11091132	16-25	03AUG2020	41811	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11091176	C4591001 1109 11091176	16-25	08AUG2020	42576	Placebo	08AUG2020	Placebo	31AUG2020	Placebo
11091242	C4591001 1109 11091242	16-25	16AUG2020	51340	Placebo	16AUG2020	Placebo	06SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11091251	C4591001 1109 11091251	16-25	16AUG2020	51813	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11091309	C4591001 1109 11091309	16-25	22AUG2020	61887	Placebo	22AUG2020	Placebo	10SEP2020	Placebo
11091320	C4591001 1109 11091320	16-25	23AUG2020	62939	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11091321	C4591001 1109 11091321	16-25	25AUG2020	62941	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
11091332	C4591001 1109 11091332	16-25	26AUG2020	67831	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11091333	C4591001 1109 11091333	16-25	26AUG2020	67835	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11091335	C4591001 1109 11091335	16-25	26AUG2020	67839	Placebo	26AUG2020	Placebo		
11091370	C4591001 1109 11091370	16-25	29AUG2020	73972	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11091372	C4591001 1109 11091372	16-25	29AUG2020	74142	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11091391	C4591001 1109 11091391	16-25	01SEP2020	75866	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
11091393	C4591001 1109 11091393	16-25	01SEP2020	75868	Placebo	01SEP2020	Placebo	29SEP2020	Placebo
11091434	C4591001 1109 11091434	16-25	07SEP2020	83201	Placebo	07SEP2020	Placebo	26SEP2020	Placebo
11091441	C4591001 1109 11091441	16-25	07SEP2020	83242	Placebo	07SEP2020	Placebo	03OCT2020	Placebo
11091457	C4591001 1109 11091457	16-25	08SEP2020	84124	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11091514	C4591001 1109 11091514	16-25	13SEP2020	89286	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11091515	C4591001 1109 11091515	16-25	15SEP2020	89287	Placebo	15SEP2020	Placebo		
11091516	C4591001 1109 11091516	16-25	15SEP2020	89290	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
11091522	C4591001 1109 11091522	16-25	18SEP2020	94098	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11091525	C4591001 1109 11091525	16-25	18SEP2020	94108	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	10OCT2020	BNT162b2 (30 µg)
11091532	C4591001 1109 11091532	16-25	21SEP2020	94893	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
11091539	C4591001 1109 11091539	16-25	23SEP2020	96790	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
11091540	C4591001 1109 11091540	16-25	23SEP2020	96793	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
11091563	C4591001 1109 11091563	16-25	06OCT2020	103528	Placebo	06OCT2020	Placebo	29OCT2020	Placebo
11101010	C4591001 1110 11101010	16-25	01AUG2020	41311	Placebo	01AUG2020	Placebo	21AUG2020	Placebo
11101030	C4591001 1110 11101030	16-25	04AUG2020	41892	Placebo	04AUG2020	Placebo	25AUG2020	Placebo
11101038	C4591001 1110 11101038	16-25	05AUG2020	43169	Placebo	05AUG2020	Placebo		
11101039	C4591001 1110 11101039	16-25	05AUG2020	43170	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)		
11101057	C4591001 1110 11101057	16-25	07AUG2020	44695	Placebo	07AUG2020	Placebo	27AUG2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11101084	C4591001 1110 11101084	16-25	12AUG2020	48121	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11101085	C4591001 1110 11101085	16-25	12AUG2020	48120	Placebo	12AUG2020	Placebo		
11101110	C4591001 1110 11101110	16-25	18AUG2020	53188	Placebo	18AUG2020	Placebo		
11101116	C4591001 1110 11101116	16-25	19AUG2020	55365	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
11101122	C4591001 1110 11101122	16-25	20AUG2020	59142	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
11101127	C4591001 1110 11101127	16-25	21AUG2020	60569	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
11101156	C4591001 1110 11101156	16-25	28AUG2020	70776	Placebo	28AUG2020	Placebo		
11101311	C4591001 1110 11101311	16-25	28SEP2020	101393	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
11101316	C4591001 1110 11101316	16-25	29SEP2020	101931	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
11101320	C4591001 1110 11101320	16-25	30SEP2020	102235	Placebo	30SEP2020	Placebo	20OCT2020	Placebo
11101337	C4591001 1110 11101337	16-25	02OCT2020	103326	Placebo	02OCT2020	Placebo	22OCT2020	Placebo
11101338	C4591001 1110 11101338	16-25	02OCT2020	103327	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
11101344	C4591001 1110 11101344	16-25	08OCT2020	104331	Placebo	08OCT2020	Placebo	28OCT2020	Placebo
11101360	C4591001 1110 11101360	16-25	19OCT2020	108382	Placebo	19OCT2020	Placebo	11NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11101379	C4591001 1110 11101379	16-25	13NOV2020	114421	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)
11101380	C4591001 1110 11101380	16-25	04DEC2020	114422	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11111001	C4591001 1111 11111001	16-25	30JUL2020	40473	BNT162b2 (30 µg)	30JUL2020	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)
11111018	C4591001 1111 11111018	16-25	03AUG2020	40479	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11111050	C4591001 1111 11111050	16-25	06AUG2020	43284	Placebo	06AUG2020	Placebo	27AUG2020	Placebo
11111053	C4591001 1111 11111053	16-25	06AUG2020	44071	Placebo	06AUG2020	Placebo	27AUG2020	Placebo
11111079	C4591001 1111 11111079	16-25	10AUG2020	45004	Placebo	10AUG2020	Placebo	31AUG2020	Placebo
11111143	C4591001 1111 11111143	16-25	27AUG2020	70081	Placebo	27AUG2020	Placebo	18SEP2020	Placebo
11111171	C4591001 1111 11111171	16-25	04SEP2020	79353	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
11111183	C4591001 1111 11111183	16-25	21SEP2020	94626	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11111188	C4591001 1111 11111188	16-25	21SEP2020	94629	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
11121019	C4591001 1112 11121019	16-25	31JUL2020	40679	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)
11121028	C4591001 1112 11121028	16-25	31JUL2020	41233	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)
11121031	C4591001 1112 11121031	16-25	31JUL2020	41235	Placebo	31JUL2020	Placebo	21AUG2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11121045	C4591001 1112 11121045	16-25	03AUG2020	41848	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
11121058	C4591001 1112 11121058	16-25	04AUG2020	42276	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)		
11121078	C4591001 1112 11121078	16-25	05AUG2020	42884	Placebo	05AUG2020	Placebo	08SEP2020	Placebo
11121098	C4591001 1112 11121098	16-25	10AUG2020	45388	Placebo	10AUG2020	Placebo	31AUG2020	Placebo
11121125	C4591001 1112 11121125	16-25	17AUG2020	46906	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
11121148	C4591001 1112 11121148	16-25	20AUG2020	56052	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
11121157	C4591001 1112 11121157	16-25	21AUG2020	60934	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11121193	C4591001 1112 11121193	16-25	28AUG2020	72739	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11121217	C4591001 1112 11121217	16-25	03SEP2020	79604	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11121228	C4591001 1112 11121228	16-25	04SEP2020	81670	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
11121229	C4591001 1112 11121229	16-25	04SEP2020	81671	BNT162b2 (30 µg)				
11121237	C4591001 1112 11121237	16-25	09SEP2020	84478	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11121258	C4591001 1112 11121258	16-25	06OCT2020	104160	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
11121260	C4591001 1112 11121260	16-25	06OCT2020	104441	Placebo	06OCT2020	Placebo	26OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11121269	C4591001 1112 11121269	16-25	08OCT2020	104967	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11121271	C4591001 1112 11121271	16-25	08OCT2020	105401	Placebo	08OCT2020	Placebo	28OCT2020	Placebo
11121273	C4591001 1112 11121273	16-25	08OCT2020	105406	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
11121297	C4591001 1112 11121297	16-25	12OCT2020	106538	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
11121298	C4591001 1112 11121298	16-25	12OCT2020	106535	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
11121307	C4591001 1112 11121307	16-25	13OCT2020	106856	Placebo	13OCT2020	Placebo	04NOV2020	Placebo
11121324	C4591001 1112 11121324	16-25	20OCT2020	110754	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11121335	C4591001 1112 11121335	16-25	21OCT2020	111148	Placebo	21OCT2020	Placebo	12NOV2020	Placebo
11121345	C4591001 1112 11121345	16-25	22OCT2020	112218	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11141008	C4591001 1114 11141008	16-25	12AUG2020	47826	Placebo	12AUG2020	Placebo	01SEP2020	Placebo
11141009	C4591001 1114 11141009	16-25	12AUG2020	47827	Placebo	12AUG2020	Placebo	01SEP2020	Placebo
11141012	C4591001 1114 11141012	16-25	12AUG2020	48174	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
11141014	C4591001 1114 11141014	16-25	12AUG2020	48182	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11141021	C4591001 1114 11141021	16-25	13AUG2020	48893	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11141024	C4591001 1114 11141024	16-25	13AUG2020	48894	Placebo	13AUG2020	Placebo	04SEP2020	Placebo
11141033	C4591001 1114 11141033	16-25	17AUG2020	53432	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11141038	C4591001 1114 11141038	16-25	17AUG2020	53705	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
11141041	C4591001 1114 11141041	16-25	18AUG2020	53715	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11141065	C4591001 1114 11141065	16-25	20AUG2020	57436	Placebo	20AUG2020	Placebo	22OCT2020	Placebo
11141076	C4591001 1114 11141076	16-25	24AUG2020	61499	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11141085	C4591001 1114 11141085	16-25	24AUG2020	64359	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11141089	C4591001 1114 11141089	16-25	25AUG2020	65313	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
11161043	C4591001 1116 11161043	16-25	28AUG2020	71415	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11161044	C4591001 1116 11161044	16-25	28AUG2020	71416	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
11161047	C4591001 1116 11161047	16-25	28AUG2020	72463	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11161059	C4591001 1116 11161059	16-25	31AUG2020	75043	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11161065	C4591001 1116 11161065	16-25	31AUG2020	75044	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11161076	C4591001 1116 11161076	16-25	01SEP2020	75784	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11161099	C4591001 1116 11161099	16-25	02SEP2020	79016	Placebo	02SEP2020	Placebo	25SEP2020	Placebo
11161100	C4591001 1116 11161100	16-25	02SEP2020	79018	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11161110	C4591001 1116 11161110	16-25	03SEP2020	80095	Placebo	03SEP2020	Placebo	23SEP2020	Placebo
11161119	C4591001 1116 11161119	16-25	03SEP2020	80103	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11161171	C4591001 1116 11161171	16-25	09SEP2020	85950	Placebo	09SEP2020	Placebo	28SEP2020	Placebo
11161175	C4591001 1116 11161175	16-25	09SEP2020	85951	Placebo	09SEP2020	Placebo	28SEP2020	Placebo
11161196	C4591001 1116 11161196	16-25	10SEP2020	87545	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11161235	C4591001 1116 11161235	16-25	17SEP2020	88923	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11161256	C4591001 1116 11161256	16-25	19SEP2020	94255	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11161276	C4591001 1116 11161276	16-25	23SEP2020	94527	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
11161292	C4591001 1116 11161292	16-25	24SEP2020	98815	Placebo	24SEP2020	Placebo		
11161293	C4591001 1116 11161293	16-25	24SEP2020	98817	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
11161320	C4591001 1116 11161320	16-25	25SEP2020	100296	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
11161322	C4591001 1116 11161322	16-25	25SEP2020	100297	Placebo	25SEP2020	Placebo	14OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11171050	C4591001 1117 11171050	16-25	24AUG2020	64842	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11171063	C4591001 1117 11171063	16-25	26AUG2020	68407	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11171068	C4591001 1117 11171068	16-25	26AUG2020	68925	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
11171070	C4591001 1117 11171070	16-25	26AUG2020	69274	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
11171084	C4591001 1117 11171084	16-25	02SEP2020	71148	Placebo	02SEP2020	Placebo	21SEP2020	Placebo
11171099	C4591001 1117 11171099	16-25	04SEP2020	81368	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11171107	C4591001 1117 11171107	16-25	10SEP2020	87227	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11171113	C4591001 1117 11171113	16-25	14SEP2020	88140	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11171131	C4591001 1117 11171131	16-25	17SEP2020	91816	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11171138	C4591001 1117 11171138	16-25	15OCT2020	108571	Placebo	15OCT2020	Placebo	17NOV2020	Placebo
11171169	C4591001 1117 11171169	16-25	25SEP2020	98149	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
11171178	C4591001 1117 11171178	16-25	28SEP2020	101273	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
11171187	C4591001 1117 11171187	16-25	06OCT2020	101919	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
11181017	C4591001 1118 11181017	16-25	12AUG2020	46616	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11181027	C4591001 1118 11181027	16-25	13AUG2020	49265	Placebo	13AUG2020	Placebo	04SEP2020	Placebo
11181042	C4591001 1118 11181042	16-25	17AUG2020	52709	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11181059	C4591001 1118 11181059	16-25	19AUG2020	53942	Placebo	19AUG2020	Placebo	11SEP2020	Placebo
11181101	C4591001 1118 11181101	16-25	29AUG2020	73461	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11201037	C4591001 1120 11201037	16-25	04AUG2020	42040	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11201038	C4591001 1120 11201038	16-25	04AUG2020	42486	Placebo				
11201115	C4591001 1120 11201115	16-25	07AUG2020	44641	Placebo	07AUG2020	Placebo	26AUG2020	Placebo
11201130	C4591001 1120 11201130	16-25	11AUG2020	44822	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
11201157	C4591001 1120 11201157	16-25	12AUG2020	47401	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
11201172	C4591001 1120 11201172	16-25	13AUG2020	48977	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11201191	C4591001 1120 11201191	16-25	14AUG2020	48987	Placebo	14AUG2020	Placebo	02SEP2020	Placebo
11201223	C4591001 1120 11201223	16-25	18AUG2020	52959	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
11201237	C4591001 1120 11201237	16-25	21AUG2020	55380	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
11201240	C4591001 1120 11201240	16-25	21AUG2020	60354	Placebo	21AUG2020	Placebo	11SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11201249	C4591001 1120 11201249	16-25	21AUG2020	60811	Placebo	21AUG2020	Placebo		
11201250	C4591001 1120 11201250	16-25	21AUG2020	60812	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11201259	C4591001 1120 11201259	16-25	09SEP2020	60818	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11201279	C4591001 1120 11201279	16-25	11SEP2020	88837	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11201284	C4591001 1120 11201284	16-25	21SEP2020	95814	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11201337	C4591001 1120 11201337	16-25	16OCT2020	108328	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
11201392	C4591001 1120 11201392	16-25	23OCT2020	113047	Placebo	23OCT2020	Placebo	01DEC2020	Placebo
11211009	C4591001 1121 11211009	16-25	24AUG2020	63700	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
11211010	C4591001 1121 11211010	16-25	24AUG2020	63944	Placebo	24AUG2020	Placebo	13SEP2020	Placebo
11211060	C4591001 1121 11211060	16-25	02SEP2020	78249	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11211067	C4591001 1121 11211067	16-25	03SEP2020	78535	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11211080	C4591001 1121 11211080	16-25	03SEP2020	251734	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11211093	C4591001 1121 11211093	16-25	08SEP2020	83636	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
11211116	C4591001 1121 11211116	16-25	10SEP2020	86685	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11211118	C4591001 1121 11211118	16-25	10SEP2020	86891	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11221026	C4591001 1122 11221026	16-25	11SEP2020	87404	BNT162b2 (30 µg)				
11221032	C4591001 1122 11221032	16-25	14SEP2020	88477	Placebo	14SEP2020	Placebo	23OCT2020	Placebo
11231027	C4591001 1123 11231027	16-25	04AUG2020	42620	BNT162b2 (30 µg)				
11231033	C4591001 1123 11231033	16-25	05AUG2020	43253	Placebo	05AUG2020	Placebo	24AUG2020	Placebo
11231045	C4591001 1123 11231045	16-25	06AUG2020	43980	Placebo	06AUG2020	Placebo	25AUG2020	Placebo
11231051	C4591001 1123 11231051	16-25	07AUG2020	44108	Placebo	07AUG2020	Placebo	27AUG2020	Placebo
11231057	C4591001 1123 11231057	16-25	10AUG2020	45473	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
11231068	C4591001 1123 11231068	16-25	11AUG2020	45916	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
11231069	C4591001 1123 11231069	16-25	11AUG2020	45911	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
11231073	C4591001 1123 11231073	16-25	11AUG2020	46820	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
11231075	C4591001 1123 11231075	16-25	11AUG2020	46825	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
11231085	C4591001 1123 11231085	16-25	13AUG2020	48047	Placebo	13AUG2020	Placebo	04SEP2020	Placebo
11231115	C4591001 1123 11231115	16-25	17AUG2020	52970	Placebo	17AUG2020	Placebo	08SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231116	C4591001 1123 11231116	16-25	17AUG2020	52972	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11231135	C4591001 1123 11231135	16-25	20AUG2020	58822	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
11231154	C4591001 1123 11231154	16-25	24AUG2020	64052	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)		
11231157	C4591001 1123 11231157	16-25	24AUG2020	64386	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11231164	C4591001 1123 11231164	16-25	25AUG2020	66278	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
11231184	C4591001 1123 11231184	16-25	26AUG2020	68173	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11231204	C4591001 1123 11231204	16-25	27AUG2020	71165	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
11231229	C4591001 1123 11231229	16-25	10SEP2020	85833	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11231237	C4591001 1123 11231237	16-25	11SEP2020	88050	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11231303	C4591001 1123 11231303	16-25	24SEP2020	98589	Placebo	24SEP2020	Placebo	14OCT2020	Placebo
11231308	C4591001 1123 11231308	16-25	24SEP2020	98888	Placebo	24SEP2020	Placebo	13OCT2020	Placebo
11231336	C4591001 1123 11231336	16-25	02OCT2020	103313	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
11231337	C4591001 1123 11231337	16-25	02OCT2020	103314	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
11231353	C4591001 1123 11231353	16-25	08OCT2020	105583	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231369	C4591001 1123 11231369	16-25	12OCT2020	106526	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
11231377	C4591001 1123 11231377	16-25	14OCT2020	107060	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
11231381	C4591001 1123 11231381	16-25	15OCT2020	107068	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
11231383	C4591001 1123 11231383	16-25	15OCT2020	108488	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
11231398	C4591001 1123 11231398	16-25	22OCT2020	112305	Placebo	22OCT2020	Placebo	10NOV2020	Placebo
11231403	C4591001 1123 11231403	16-25	26OCT2020	112312	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
11231407	C4591001 1123 11231407	16-25	28OCT2020	113649	Placebo	28OCT2020	Placebo	16NOV2020	Placebo
11231409	C4591001 1123 11231409	16-25	29OCT2020	114716	Placebo	29OCT2020	Placebo	18NOV2020	Placebo
11231411	C4591001 1123 11231411	16-25	30OCT2020	114722	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
11231412	C4591001 1123 11231412	16-25	17NOV2020	114724	Placebo	17NOV2020	Placebo	09DEC2020	Placebo
11231413	C4591001 1123 11231413	16-25	18NOV2020	116442	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
11231414	C4591001 1123 11231414	16-25	19NOV2020	116445	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
11231415	C4591001 1123 11231415	16-25	19NOV2020	116446	Placebo	19NOV2020	Placebo	10DEC2020	Placebo
11231416	C4591001 1123 11231416	16-25	19NOV2020	116452	Placebo	19NOV2020	Placebo	10DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231417	C4591001 1123 11231417	16-25	23NOV2020	116684	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
11231418	C4591001 1123 11231418	16-25	23NOV2020	116687	Placebo	23NOV2020	Placebo	14DEC2020	Placebo
11231419	C4591001 1123 11231419	16-25	24NOV2020	116688	Placebo	24NOV2020	Placebo	14DEC2020	Placebo
11231420	C4591001 1123 11231420	16-25	25NOV2020	116692	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)
11231421	C4591001 1123 11231421	16-25	30NOV2020	117017	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11231423	C4591001 1123 11231423	16-25	01DEC2020	117018	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11231426	C4591001 1123 11231426	16-25	03DEC2020	117024	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11231427	C4591001 1123 11231427	16-25	03DEC2020	117028	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11231429	C4591001 1123 11231429	16-25	03DEC2020	117450	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11231430	C4591001 1123 11231430	16-25	03DEC2020	117451	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11231433	C4591001 1123 11231433	16-25	07DEC2020	117455	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11231435	C4591001 1123 11231435	16-25	07DEC2020	117459	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11231436	C4591001 1123 11231436	16-25	07DEC2020	117665	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11231437	C4591001 1123 11231437	16-25	08DEC2020	117669	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11231464	C4591001 1123 11231464	16-25	18DEC2020	117672	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
11231471	C4591001 1123 11231471	16-25	21DEC2020	117673	Placebo	21DEC2020	Placebo	12JAN2021	Placebo
11231480	C4591001 1123 11231480	16-25	21DEC2020	117943	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	12JAN2021	BNT162b2 (30 µg)
11231490	C4591001 1123 11231490	16-25	22DEC2020	117945	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)
11231498	C4591001 1123 11231498	16-25	23DEC2020	117950	Placebo	23DEC2020	Placebo	20JAN2021	Placebo
11241018	C4591001 1124 11241018	16-25	11AUG2020	46019	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
11241030	C4591001 1124 11241030	16-25	13AUG2020	47884	Placebo	13AUG2020	Placebo	02SEP2020	Placebo
11241038	C4591001 1124 11241038	16-25	13AUG2020	48599	Placebo	13AUG2020	Placebo	02SEP2020	Placebo
11241049	C4591001 1124 11241049	16-25	17AUG2020	53046	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)		
11241068	C4591001 1124 11241068	16-25	19AUG2020	57028	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
11241069	C4591001 1124 11241069	16-25	19AUG2020	57021	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
11241071	C4591001 1124 11241071	16-25	19AUG2020	57450	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11241081	C4591001 1124 11241081	16-25	24AUG2020	58887	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11241118	C4591001 1124 11241118	16-25	27AUG2020	69172	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11241122	C4591001 1124 11241122	16-25	27AUG2020	70822	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
11241141	C4591001 1124 11241141	16-25	01SEP2020	75361	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11241170	C4591001 1124 11241170	16-25	04SEP2020	80962	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
11241198	C4591001 1124 11241198	16-25	09SEP2020	85440	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
11241219	C4591001 1124 11241219	16-25	11SEP2020	87963	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
11241223	C4591001 1124 11241223	16-25	14SEP2020	88314	Placebo	14SEP2020	Placebo	07OCT2020	Placebo
11241227	C4591001 1124 11241227	16-25	17SEP2020	91271	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11251004	C4591001 1125 11251004	16-25	12AUG2020	47408	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11251050	C4591001 1125 11251050	16-25	17AUG2020	50739	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11251059	C4591001 1125 11251059	16-25	18AUG2020	55115	Placebo	18AUG2020	Placebo	10SEP2020	Placebo
11251078	C4591001 1125 11251078	16-25	22AUG2020	61777	Placebo	22AUG2020	Placebo	14SEP2020	Placebo
11251096	C4591001 1125 11251096	16-25	25AUG2020	66406	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11251134	C4591001 1125 11251134	16-25	31AUG2020	75677	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11251140	C4591001 1125 11251140	16-25	01SEP2020	76812	Placebo	01SEP2020	Placebo	21SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11251142	C4591001 1125 11251142	16-25	01SEP2020	76813	Placebo	01SEP2020	Placebo	24SEP2020	Placebo
11251144	C4591001 1125 11251144	16-25	02SEP2020	76816	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11251155	C4591001 1125 11251155	16-25	03SEP2020	79487	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11251175	C4591001 1125 11251175	16-25	04SEP2020	81588	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11251197	C4591001 1125 11251197	16-25	10SEP2020	86599	Placebo	10SEP2020	Placebo	02OCT2020	Placebo
11251200	C4591001 1125 11251200	16-25	10SEP2020	86602	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
11251201	C4591001 1125 11251201	16-25	10SEP2020	86607	Placebo	10SEP2020	Placebo	02OCT2020	Placebo
11251237	C4591001 1125 11251237	16-25	21OCT2020	98690	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11251238	C4591001 1125 11251238	16-25	22OCT2020	112414	Placebo	22OCT2020	Placebo		
11251239	C4591001 1125 11251239	16-25	18NOV2020	112418	Placebo	18NOV2020	Placebo	09DEC2020	Placebo
11251240	C4591001 1125 11251240	16-25	20NOV2020	112419	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)
11251243	C4591001 1125 11251243	16-25	08DEC2020	112420	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)		
11251247	C4591001 1125 11251247	16-25	11DEC2020	117872	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11261053	C4591001 1126 11261053	16-25	20AUG2020	57700	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261092	C4591001 1126 11261092	16-25	27AUG2020	70371	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
11261194	C4591001 1126 11261194	16-25	18SEP2020	94402	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
11261200	C4591001 1126 11261200	16-25	29OCT2020	95364	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
11261201	C4591001 1126 11261201	16-25	30OCT2020	95368	Placebo	30OCT2020	Placebo	18NOV2020	Placebo
11261202	C4591001 1126 11261202	16-25	30OCT2020	115150	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
11261203	C4591001 1126 11261203	16-25	02NOV2020	115153	Placebo	02NOV2020	Placebo	23NOV2020	Placebo
11261204	C4591001 1126 11261204	16-25	04NOV2020	115154	Placebo	04NOV2020	Placebo	23NOV2020	Placebo
11261205	C4591001 1126 11261205	16-25	11NOV2020	115156	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
11261206	C4591001 1126 11261206	16-25	11NOV2020	116141	Placebo	11NOV2020	Placebo	02DEC2020	Placebo
11261207	C4591001 1126 11261207	16-25	13NOV2020	116145	Placebo	13NOV2020	Placebo	04DEC2020	Placebo
11261208	C4591001 1126 11261208	16-25	13NOV2020	116147	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)
11261209	C4591001 1126 11261209	16-25	16NOV2020	116152	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11261210	C4591001 1126 11261210	16-25	16NOV2020	116324	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
11261211	C4591001 1126 11261211	16-25	17NOV2020	116326	Placebo	17NOV2020	Placebo	09DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261212	C4591001 1126 11261212	16-25	18NOV2020	116329	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
11261213	C4591001 1126 11261213	16-25	18NOV2020	116331	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
11261214	C4591001 1126 11261214	16-25	20NOV2020	116623	Placebo	20NOV2020	Placebo	10DEC2020	Placebo
11261215	C4591001 1126 11261215	16-25	20NOV2020	116626	Placebo	20NOV2020	Placebo	11DEC2020	Placebo
11261216	C4591001 1126 11261216	16-25	23NOV2020	116629	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11261217	C4591001 1126 11261217	16-25	23NOV2020	116630	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11261218	C4591001 1126 11261218	16-25	23NOV2020	116759	Placebo	23NOV2020	Placebo	16DEC2020	Placebo
11261219	C4591001 1126 11261219	16-25	24NOV2020	116760	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
11261220	C4591001 1126 11261220	16-25	24NOV2020	116761	Placebo	24NOV2020	Placebo	16DEC2020	Placebo
11261221	C4591001 1126 11261221	16-25	24NOV2020	116764	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11261222	C4591001 1126 11261222	16-25	24NOV2020	116897	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
11261223	C4591001 1126 11261223	16-25	25NOV2020	116899	Placebo	25NOV2020	Placebo	18DEC2020	Placebo
11261224	C4591001 1126 11261224	16-25	25NOV2020	116900	Placebo	25NOV2020	Placebo	18DEC2020	Placebo
11261225	C4591001 1126 11261225	16-25	25NOV2020	116907	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	17DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261226	C4591001 1126 11261226	16-25	25NOV2020	116957	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)
11261227	C4591001 1126 11261227	16-25	25NOV2020	116958	Placebo	25NOV2020	Placebo	18DEC2020	Placebo
11261228	C4591001 1126 11261228	16-25	25NOV2020	116963	Placebo	25NOV2020	Placebo	16DEC2020	Placebo
11261231	C4591001 1126 11261231	16-25	30NOV2020	116968	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11261232	C4591001 1126 11261232	16-25	01DEC2020	117118	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11261234	C4591001 1126 11261234	16-25	01DEC2020	117119	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11261236	C4591001 1126 11261236	16-25	01DEC2020	117120	Placebo	01DEC2020	Placebo	21DEC2020	Placebo
11261237	C4591001 1126 11261237	16-25	01DEC2020	117122	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
11261238	C4591001 1126 11261238	16-25	02DEC2020	117211	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
11261242	C4591001 1126 11261242	16-25	02DEC2020	117212	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11261244	C4591001 1126 11261244	16-25	02DEC2020	117216	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
11261245	C4591001 1126 11261245	16-25	02DEC2020	117218	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11261247	C4591001 1126 11261247	16-25	02DEC2020	117283	Placebo	02DEC2020	Placebo	21DEC2020	Placebo
11261248	C4591001 1126 11261248	16-25	02DEC2020	117285	Placebo	02DEC2020	Placebo	21DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11261252	C4591001 1126 11261252	16-25	03DEC2020	117287	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11261256	C4591001 1126 11261256	16-25	03DEC2020	117288	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11261257	C4591001 1126 11261257	16-25	03DEC2020	117479	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11261259	C4591001 1126 11261259	16-25	03DEC2020	117481	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11261260	C4591001 1126 11261260	16-25	04DEC2020	117482	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11261261	C4591001 1126 11261261	16-25	04DEC2020	117484	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11271021	C4591001 1127 11271021	16-25	30JUL2020	40622	BNT162b2 (30 µg)	30JUL2020	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)
11271033	C4591001 1127 11271033	16-25	31JUL2020	41082	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
11271043	C4591001 1127 11271043	16-25	03AUG2020	41708	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
11271059	C4591001 1127 11271059	16-25	05AUG2020	42231	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
11271078	C4591001 1127 11271078	16-25	07AUG2020	43668	Placebo	07AUG2020	Placebo	28AUG2020	Placebo
11271087	C4591001 1127 11271087	16-25	11AUG2020	46577	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)
11271099	C4591001 1127 11271099	16-25	19AUG2020	46586	Placebo	19AUG2020	Placebo		
11281050	C4591001 1128 11281050	16-25	05AUG2020	43244	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11281057	C4591001 1128 11281057	16-25	06AUG2020	44177	Placebo	06AUG2020	Placebo	26AUG2020	Placebo
11281098	C4591001 1128 11281098	16-25	12AUG2020	47468	Placebo	12AUG2020	Placebo	04SEP2020	Placebo
11281175	C4591001 1128 11281175	16-25	24AUG2020	64170	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11281176	C4591001 1128 11281176	16-25	24AUG2020	64738	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11281177	C4591001 1128 11281177	16-25	24AUG2020	64740	Placebo	24AUG2020	Placebo	29SEP2020	Placebo
11281196	C4591001 1128 11281196	16-25	25AUG2020	66902	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11281210	C4591001 1128 11281210	16-25	27AUG2020	70157	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11281216	C4591001 1128 11281216	16-25	27AUG2020	70158	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11281247	C4591001 1128 11281247	16-25	01SEP2020	76632	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11281263	C4591001 1128 11281263	16-25	02SEP2020	78032	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11281282	C4591001 1128 11281282	16-25	03SEP2020	81129	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
11281289	C4591001 1128 11281289	16-25	04SEP2020	81983	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11281294	C4591001 1128 11281294	16-25	08SEP2020	83695	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)
11281299	C4591001 1128 11281299	16-25	08SEP2020	83701	Placebo	08SEP2020	Placebo	07OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11281338	C4591001 1128 11281338	16-25	11SEP2020	88881	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11281339	C4591001 1128 11281339	16-25	11SEP2020	88394	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11281342	C4591001 1128 11281342	16-25	11SEP2020	88883	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)
11281343	C4591001 1128 11281343	16-25	12SEP2020	89129	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)
11281359	C4591001 1128 11281359	16-25	15SEP2020	90289	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11281384	C4591001 1128 11281384	16-25	23SEP2020	91726	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
11291048	C4591001 1129 11291048	16-25	04AUG2020	42108	Placebo				
11291097	C4591001 1129 11291097	16-25	11AUG2020	46436	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11291143	C4591001 1129 11291143	16-25	25AUG2020	66191	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
11291168	C4591001 1129 11291168	16-25	08SEP2020	83263	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11291171	C4591001 1129 11291171	16-25	14SEP2020	83265	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
11291216	C4591001 1129 11291216	16-25	06OCT2020	101884	Placebo	06OCT2020	Placebo	26OCT2020	Placebo
11291223	C4591001 1129 11291223	16-25	12OCT2020	104778	Placebo	12OCT2020	Placebo	04NOV2020	Placebo
11291255	C4591001 1129 11291255	16-25	13NOV2020	113264	Placebo	13NOV2020	Placebo	04DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11291256	C4591001 1129 11291256	16-25	16NOV2020	113271	Placebo	16NOV2020	Placebo	23DEC2020	Placebo
11291257	C4591001 1129 11291257	16-25	18NOV2020	116477	Placebo	18NOV2020	Placebo	09DEC2020	Placebo
11291258	C4591001 1129 11291258	16-25	30NOV2020	117080	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11291260	C4591001 1129 11291260	16-25	20NOV2020	116482	Placebo	20NOV2020	Placebo	15DEC2020	Placebo
11291261	C4591001 1129 11291261	16-25	23NOV2020	116485	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
11291262	C4591001 1129 11291262	16-25	23NOV2020	116487	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
11291263	C4591001 1129 11291263	16-25	03DEC2020	117081	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11291264	C4591001 1129 11291264	16-25	03DEC2020	117082	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11291265	C4591001 1129 11291265	16-25	03DEC2020	117087	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11301021	C4591001 1130 11301021	16-25	31AUG2020	76210	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11301089	C4591001 1130 11301089	16-25	21OCT2020	111669	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11311061	C4591001 1131 11311061	16-25	20AUG2020	57652	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11311064	C4591001 1131 11311064	16-25	21AUG2020	60176	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11311091	C4591001 1131 11311091	16-25	27AUG2020	70493	Placebo	27AUG2020	Placebo	16SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11311102	C4591001 1131 11311102	16-25	28AUG2020	71388	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
11311107	C4591001 1131 11311107	16-25	31AUG2020	72826	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11311221	C4591001 1131 11311221	16-25	25SEP2020	98860	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
11311263	C4591001 1131 11311263	16-25	13NOV2020	114849	Placebo	13NOV2020	Placebo	04DEC2020	Placebo
11311264	C4591001 1131 11311264	16-25	16NOV2020	114851	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
11311265	C4591001 1131 11311265	16-25	17NOV2020	114855	Placebo	17NOV2020	Placebo	08DEC2020	Placebo
11311266	C4591001 1131 11311266	16-25	18NOV2020	116470	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
11311267	C4591001 1131 11311267	16-25	23NOV2020	116472	Placebo	23NOV2020	Placebo	15DEC2020	Placebo
11311268	C4591001 1131 11311268	16-25	23NOV2020	116476	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11311269	C4591001 1131 11311269	16-25	23NOV2020	116474	Placebo	23NOV2020	Placebo	15DEC2020	Placebo
11311270	C4591001 1131 11311270	16-25	24NOV2020	116790	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
11311271	C4591001 1131 11311271	16-25	24NOV2020	116792	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
11311272	C4591001 1131 11311272	16-25	02DEC2020	116794	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11311273	C4591001 1131 11311273	16-25	02DEC2020	116795	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received				
						Date	Dose 1	Date	Dose 2	
11311274	C4591001 1131 11311274	16-25	04DEC2020	117498	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)	
11311276	C4591001 1131 11311276	16-25	04DEC2020	117500	Placebo	04DEC2020	Placebo	23DEC2020	Placebo	
11311279	C4591001 1131 11311279	16-25	21DEC2020	117502	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)	11JAN2021	BNT162b2 (30 µg)	
11331037	C4591001 1133 11331037	16-25	31JUL2020	40958	Placebo	31JUL2020	Placebo			
11331043	C4591001 1133 11331043	16-25	31JUL2020	41166	Placebo	31JUL2020	Placebo	21AUG2020	Placebo	
11331047	C4591001 1133 11331047	16-25	03AUG2020	41485	Placebo	03AUG2020	Placebo	24AUG2020	Placebo	
11331093	C4591001 1133 11331093	16-25	08AUG2020	44971	BNT162b2 (30 µg)	08AUG2020	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	
11331123	C4591001 1133 11331123	16-25	12AUG2020	47092	Placebo	12AUG2020	Placebo	04SEP2020	Placebo	
11331135	C4591001 1133 11331135	16-25	12AUG2020	47556	Placebo	12AUG2020	Placebo	04SEP2020	Placebo	
11331207	C4591001 1133 11331207	16-25	19AUG2020	56917	Placebo	19AUG2020	Placebo			
11331273	C4591001 1133 11331273	16-25	27AUG2020	69787	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	
11331274	C4591001 1133 11331274	16-25	27AUG2020	68594	Placebo	27AUG2020	Placebo	18SEP2020	Placebo	
11331332	C4591001 1133 11331332	16-25	29AUG2020	73447	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	
11331360	C4591001 1133 11331360	16-25	02SEP2020	78143	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11331428	C4591001 1133 11331428	16-25	09SEP2020	85767	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
11331473	C4591001 1133 11331473	16-25	18SEP2020	93748	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11331480	C4591001 1133 11331480	16-25	21SEP2020	94928	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
11331485	C4591001 1133 11331485	16-25	21SEP2020	94930	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
11331587	C4591001 1133 11331587	16-25	29OCT2020	401280	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11331602	C4591001 1133 11331602	16-25	29OCT2020	401315	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11331603	C4591001 1133 11331603	16-25	29OCT2020	401318	Placebo	29OCT2020	Placebo	19NOV2020	Placebo
11331605	C4591001 1133 11331605	16-25	29OCT2020	401336	Placebo	29OCT2020	Placebo	24NOV2020	Placebo
11331609	C4591001 1133 11331609	16-25	29OCT2020	401341	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11331640	C4591001 1133 11331640	16-25	30OCT2020	401483	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11331647	C4591001 1133 11331647	16-25	02NOV2020	401497	Placebo	02NOV2020	Placebo	23NOV2020	Placebo
11341046	C4591001 1134 11341046	16-25	12AUG2020	46419	Placebo	12AUG2020	Placebo	01SEP2020	Placebo
11341102	C4591001 1134 11341102	16-25	18AUG2020	52741	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11341173	C4591001 1134 11341173	16-25	26AUG2020	67446	Placebo	26AUG2020	Placebo	16SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11341180	C4591001 1134 11341180	16-25	26AUG2020	68181	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11341184	C4591001 1134 11341184	16-25	26AUG2020	68186	Placebo	26AUG2020	Placebo	17SEP2020	Placebo
11341203	C4591001 1134 11341203	16-25	27AUG2020	70987	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11341213	C4591001 1134 11341213	16-25	28AUG2020	72549	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11341268	C4591001 1134 11341268	16-25	04SEP2020	80785	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
11341313	C4591001 1134 11341313	16-25	10SEP2020	86286	Placebo	10SEP2020	Placebo	01OCT2020	Placebo
11341324	C4591001 1134 11341324	16-25	10SEP2020	86942	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11341327	C4591001 1134 11341327	16-25	11SEP2020	87727	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11341328	C4591001 1134 11341328	16-25	11SEP2020	87728	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11341332	C4591001 1134 11341332	16-25	11SEP2020	87826	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11341379	C4591001 1134 11341379	16-25	06OCT2020	104273	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11341428	C4591001 1134 11341428	16-25	16OCT2020	108838	Placebo	16OCT2020	Placebo	06NOV2020	Placebo
11351001	C4591001 1135 11351001	16-25	03AUG2020	41781	Placebo	03AUG2020	Placebo	25AUG2020	Placebo
11351022	C4591001 1135 11351022	16-25	04AUG2020	42683	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
11351080	C4591001 1135 11351080	16-25	08AUG2020	45029	BNT162b2 (30 µg)	08AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	
11351083	C4591001 1135 11351083	16-25	08AUG2020	45030	Placebo	08AUG2020	Placebo	31AUG2020	Placebo	
11351088	C4591001 1135 11351088	16-25	08AUG2020	45041	BNT162b2 (30 µg)	08AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	
11351113	C4591001 1135 11351113	16-25	13AUG2020	48193	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	
11351115	C4591001 1135 11351115	16-25	13AUG2020	48196	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	
11351120	C4591001 1135 11351120	16-25	13AUG2020	49213	Placebo	13AUG2020	Placebo	01SEP2020	Placebo	
11351139	C4591001 1135 11351139	16-25	17AUG2020	53117	Placebo	17AUG2020	Placebo	08SEP2020	Placebo	
11351154	C4591001 1135 11351154	16-25	18AUG2020	53679	Placebo	18AUG2020	Placebo	10SEP2020	Placebo	
11351165	C4591001 1135 11351165	16-25	20AUG2020	58667	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	
11351166	C4591001 1135 11351166	16-25	20AUG2020	58669	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	
11351175	C4591001 1135 11351175	16-25	21AUG2020	60770	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	
11351178	C4591001 1135 11351178	16-25	21AUG2020	60772	Placebo	21AUG2020	Placebo	10SEP2020	Placebo	
11351195	C4591001 1135 11351195	16-25	24AUG2020	64580	Placebo	24AUG2020	Placebo	14SEP2020	Placebo	
11351199	C4591001 1135 11351199	16-25	24AUG2020	64585	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)			

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11351203	C4591001 1135 11351203	16-25	25AUG2020	64979	Placebo	25AUG2020	Placebo	16SEP2020	Placebo
11351216	C4591001 1135 11351216	16-25	26AUG2020	68081	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11351234	C4591001 1135 11351234	16-25	31AUG2020	76037	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11351239	C4591001 1135 11351239	16-25	01SEP2020	76040	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11351253	C4591001 1135 11351253	16-25	01SEP2020	77615	Placebo	01SEP2020	Placebo	23SEP2020	Placebo
11351285	C4591001 1135 11351285	16-25	03SEP2020	80844	Placebo	03SEP2020	Placebo	25SEP2020	Placebo
11351301	C4591001 1135 11351301	16-25	04SEP2020	81658	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
11351323	C4591001 1135 11351323	16-25	08SEP2020	84133	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
11351350	C4591001 1135 11351350	16-25	14SEP2020	86042	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
11351355	C4591001 1135 11351355	16-25	15SEP2020	89962	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
11351361	C4591001 1135 11351361	16-25	17SEP2020	92523	Placebo	17SEP2020	Placebo	07OCT2020	Placebo
11351363	C4591001 1135 11351363	16-25	17SEP2020	92794	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11351367	C4591001 1135 11351367	16-25	17SEP2020	92800	Placebo	17SEP2020	Placebo	07OCT2020	Placebo
11351378	C4591001 1135 11351378	16-25	18SEP2020	94316	Placebo	18SEP2020	Placebo	09OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11351410	C4591001 1135 11351410	16-25	22SEP2020	95680	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11351412	C4591001 1135 11351412	16-25	22SEP2020	96797	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
11351414	C4591001 1135 11351414	16-25	22SEP2020	96801	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
11351428	C4591001 1135 11351428	16-25	23SEP2020	98406	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)		
11351461	C4591001 1135 11351461	16-25	21OCT2020	400316	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11351474	C4591001 1135 11351474	16-25	22OCT2020	400435	Placebo	22OCT2020	Placebo	10NOV2020	Placebo
11351486	C4591001 1135 11351486	16-25	23OCT2020	400499	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11351488	C4591001 1135 11351488	16-25	23OCT2020	400546	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11351489	C4591001 1135 11351489	16-25	23OCT2020	400567	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
11351491	C4591001 1135 11351491	16-25	23OCT2020	400574	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11351492	C4591001 1135 11351492	16-25	23OCT2020	400552	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
11351497	C4591001 1135 11351497	16-25	23OCT2020	400640	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
11351498	C4591001 1135 11351498	16-25	23OCT2020	400624	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11351513	C4591001 1135 11351513	16-25	24OCT2020	400710	BNT162b2 (30 µg)	24OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11351522	C4591001 1135 11351522	16-25	24OCT2020	400734	BNT162b2 (30 µg)	24OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11351529	C4591001 1135 11351529	16-25	24OCT2020	400756	BNT162b2 (30 µg)	24OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
11351547	C4591001 1135 11351547	16-25	26OCT2020	400999	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11351549	C4591001 1135 11351549	16-25	26OCT2020	401000	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11351552	C4591001 1135 11351552	16-25	27OCT2020	401039	Placebo	27OCT2020	Placebo	17NOV2020	Placebo
11351556	C4591001 1135 11351556	16-25	27OCT2020	401079	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
11361007	C4591001 1136 11361007	16-25	18AUG2020	54717	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11361034	C4591001 1136 11361034	16-25	20AUG2020	59779	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11361048	C4591001 1136 11361048	16-25	25AUG2020	65044	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11361049	C4591001 1136 11361049	16-25	25AUG2020	67073	Placebo	25AUG2020	Placebo	14SEP2020	Placebo
11361091	C4591001 1136 11361091	16-25	28OCT2020	114477	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
11391048	C4591001 1139 11391048	16-25	05AUG2020	42851	Placebo	05AUG2020	Placebo	27AUG2020	Placebo
11391049	C4591001 1139 11391049	16-25	05AUG2020	42850	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11391083	C4591001 1139 11391083	16-25	10AUG2020	44448	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391089	C4591001 1139 11391089	16-25	12AUG2020	45733	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11391116	C4591001 1139 11391116	16-25	20OCT2020	110233	Placebo	20OCT2020	Placebo	12NOV2020	Placebo
11391117	C4591001 1139 11391117	16-25	20OCT2020	110235	Placebo	20OCT2020	Placebo	12NOV2020	Placebo
11391130	C4591001 1139 11391130	16-25	10NOV2020	112273	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11391131	C4591001 1139 11391131	16-25	13NOV2020	112274	Placebo	13NOV2020	Placebo	04DEC2020	Placebo
11391132	C4591001 1139 11391132	16-25	17NOV2020	116334	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
11391133	C4591001 1139 11391133	16-25	17NOV2020	116335	Placebo	17NOV2020	Placebo	08DEC2020	Placebo
11391134	C4591001 1139 11391134	16-25	17NOV2020	116337	Placebo	17NOV2020	Placebo	08DEC2020	Placebo
11391135	C4591001 1139 11391135	16-25	17NOV2020	116344	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)
11391136	C4591001 1139 11391136	16-25	23NOV2020	116696	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11391137	C4591001 1139 11391137	16-25	23NOV2020	116697	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11391138	C4591001 1139 11391138	16-25	24NOV2020	116699	Placebo	24NOV2020	Placebo	17DEC2020	Placebo
11391139	C4591001 1139 11391139	16-25	24NOV2020	116704	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
11391140	C4591001 1139 11391140	16-25	24NOV2020	116801	Placebo	24NOV2020	Placebo	18DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11391141	C4591001 1139 11391141	16-25	24NOV2020	116806	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11391142	C4591001 1139 11391142	16-25	24NOV2020	116807	Placebo	24NOV2020	Placebo	18DEC2020	Placebo
11391143	C4591001 1139 11391143	16-25	11DEC2020	117758	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11391146	C4591001 1139 11391146	16-25	01DEC2020	116808	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
11391147	C4591001 1139 11391147	16-25	08DEC2020	117376	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11391148	C4591001 1139 11391148	16-25	18DEC2020	117919	Placebo	18DEC2020	Placebo	07JAN2021	Placebo
11391149	C4591001 1139 11391149	16-25	03DEC2020	117367	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11391150	C4591001 1139 11391150	16-25	04DEC2020	117369	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11391153	C4591001 1139 11391153	16-25	04DEC2020	117375	Placebo	04DEC2020	Placebo	28DEC2020	Placebo
11391160	C4591001 1139 11391160	16-25	08DEC2020	117750	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11391164	C4591001 1139 11391164	16-25	11DEC2020	117756	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)	30DEC2020	BNT162b2 (30 µg)
11391167	C4591001 1139 11391167	16-25	11DEC2020	117760	Placebo	11DEC2020	Placebo	30DEC2020	Placebo
11401006	C4591001 1140 11401006	16-25	30JUL2020	40103	BNT162b2 (30 µg)	30JUL2020	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)
11401030	C4591001 1140 11401030	16-25	04AUG2020	42153	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401046	C4591001 114011401046	16-25	05AUG2020	43010	Placebo	05AUG2020	Placebo	25AUG2020	Placebo
11401067	C4591001 114011401067	16-25	06AUG2020	43915	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
11401136	C4591001 114011401136	16-25	17AUG2020	50500	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11401206	C4591001 114011401206	16-25	27AUG2020	69514	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
11401211	C4591001 114011401211	16-25	28AUG2020	71598	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
11401259	C4591001 114011401259	16-25	04SEP2020	80647	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
11401262	C4591001 114011401262	16-25	07OCT2020	80653	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11401281	C4591001 114011401281	16-25	13OCT2020	104932	Placebo	13OCT2020	Placebo	02NOV2020	Placebo
11401309	C4591001 114011401309	16-25	23OCT2020	113082	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11401314	C4591001 114011401314	16-25	03NOV2020	113086	Placebo	03NOV2020	Placebo	23NOV2020	Placebo
11401316	C4591001 114011401316	16-25	25NOV2020	116910	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
11401317	C4591001 114011401317	16-25	02DEC2020	116913	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11401318	C4591001 114011401318	16-25	03DEC2020	116914	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11401319	C4591001 114011401319	16-25	03DEC2020	116915	Placebo	03DEC2020	Placebo	23DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11401320	C4591001 1140 11401320	16-25	03DEC2020	117330	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11401321	C4591001 1140 11401321	16-25	04DEC2020	117332	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11401322	C4591001 1140 11401322	16-25	04DEC2020	117334	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11411006	C4591001 1141 11411006	16-25	31JUL2020	40720	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)
11411010	C4591001 1141 11411010	16-25	31JUL2020	41077	Placebo	31JUL2020	Placebo	01SEP2020	Placebo
11411016	C4591001 1141 11411016	16-25	03AUG2020	41244	Placebo	03AUG2020	Placebo	24AUG2020	Placebo
11411021	C4591001 1141 11411021	16-25	04AUG2020	42137	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)
11411029	C4591001 1141 11411029	16-25	04AUG2020	42399	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11411032	C4591001 1141 11411032	16-25	05AUG2020	42836	Placebo	05AUG2020	Placebo	10SEP2020	Placebo
11411052	C4591001 1141 11411052	16-25	07AUG2020	44380	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
11411053	C4591001 1141 11411053	16-25	07AUG2020	44676	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11411056	C4591001 1141 11411056	16-25	10AUG2020	45282	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11411065	C4591001 1141 11411065	16-25	12AUG2020	46718	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11411067	C4591001 1141 11411067	16-25	12AUG2020	46719	Placebo	12AUG2020	Placebo	02SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11411070	C4591001 114114111411070	16-25	12AUG2020	47725	Placebo	12AUG2020	Placebo	31AUG2020	Placebo
11411072	C4591001 114114111411072	16-25	13AUG2020	47726	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11411074	C4591001 114114111411074	16-25	13AUG2020	48917	Placebo	13AUG2020	Placebo	03SEP2020	Placebo
11411077	C4591001 114114111411077	16-25	13AUG2020	48926	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
11411081	C4591001 114114111411081	16-25	14AUG2020	49501	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11411092	C4591001 114114111411092	16-25	17AUG2020	53334	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11411110	C4591001 114114111411110	16-25	20AUG2020	58078	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
11411122	C4591001 114114111411122	16-25	24AUG2020	60874	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11411123	C4591001 114114111411123	16-25	24AUG2020	63719	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11411125	C4591001 114114111411125	16-25	24AUG2020	63721	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11411127	C4591001 114114111411127	16-25	24AUG2020	63723	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
11411128	C4591001 114114111411128	16-25	24AUG2020	64496	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11411130	C4591001 114114111411130	16-25	25AUG2020	64503	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
11411131	C4591001 114114111411131	16-25	25AUG2020	64504	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11411133	C4591001 11411141 11411133	16-25	26AUG2020	66631	Placebo	26AUG2020	Placebo	25SEP2020	Placebo
11411135	C4591001 11411141 11411135	16-25	26AUG2020	66633	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11411139	C4591001 11411141 11411139	16-25	27AUG2020	68322	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
11411141	C4591001 11411141 11411141	16-25	27AUG2020	68327	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11411146	C4591001 11411141 11411146	16-25	28AUG2020	70595	Placebo	28AUG2020	Placebo		
11411161	C4591001 11411141 11411161	16-25	02SEP2020	77996	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
11411162	C4591001 11411141 11411162	16-25	02SEP2020	78000	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
11411167	C4591001 11411141 11411167	16-25	03SEP2020	78958	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
11411174	C4591001 11411141 11411174	16-25	04SEP2020	81308	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
11411182	C4591001 11411141 11411182	16-25	08SEP2020	82094	Placebo	08SEP2020	Placebo	01OCT2020	Placebo
11411187	C4591001 11411141 11411187	16-25	09SEP2020	85010	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11411192	C4591001 11411141 11411192	16-25	10SEP2020	85714	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11411202	C4591001 11411141 11411202	16-25	11SEP2020	88404	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11411203	C4591001 11411141 11411203	16-25	11SEP2020	88405	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11411204	C4591001 11411411204	16-25	11SEP2020	88408	Placebo	11SEP2020	Placebo	01OCT2020	Placebo
11411205	C4591001 11411411205	16-25	14SEP2020	89357	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
11411206	C4591001 11411411206	16-25	14SEP2020	89360	Placebo	14SEP2020	Placebo	08OCT2020	Placebo
11411211	C4591001 11411411211	16-25	15SEP2020	90260	Placebo	15SEP2020	Placebo	05OCT2020	Placebo
11411213	C4591001 11411411213	16-25	15SEP2020	90264	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11411215	C4591001 11411411215	16-25	16SEP2020	91002	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
11411217	C4591001 11411411217	16-25	16SEP2020	91004	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11411220	C4591001 11411411220	16-25	16SEP2020	91629	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11411226	C4591001 11411411226	16-25	17SEP2020	92384	Placebo	17SEP2020	Placebo	13OCT2020	Placebo
11411227	C4591001 11411411227	16-25	17SEP2020	92389	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11411228	C4591001 11411411228	16-25	17SEP2020	92391	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
11411234	C4591001 11411411234	16-25	18SEP2020	92919	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
11411235	C4591001 11411411235	16-25	18SEP2020	94027	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11411236	C4591001 11411411236	16-25	18SEP2020	94029	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11411238	C4591001 11411411238	16-25	21SEP2020	94036	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
11411239	C4591001 11411411239	16-25	21SEP2020	95597	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
11411242	C4591001 11411411242	16-25	24SEP2020	95608	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
11411250	C4591001 11411411250	16-25	05OCT2020	100285	Placebo	05OCT2020	Placebo	26OCT2020	Placebo
11411254	C4591001 11411411254	16-25	07OCT2020	104841	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11411255	C4591001 11411411255	16-25	08OCT2020	104844	Placebo	08OCT2020	Placebo	29OCT2020	Placebo
11411257	C4591001 11411411257	16-25	12OCT2020	104846	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
11411260	C4591001 11411411260	16-25	14OCT2020	104847	Placebo	14OCT2020	Placebo	11NOV2020	Placebo
11411262	C4591001 11411411262	16-25	16OCT2020	109013	Placebo	16OCT2020	Placebo	05NOV2020	Placebo
11411263	C4591001 11411411263	16-25	19OCT2020	109014	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11411267	C4591001 11411411267	16-25	23OCT2020	111529	Placebo	23OCT2020	Placebo	12NOV2020	Placebo
11411269	C4591001 11411411269	16-25	27OCT2020	111531	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
11411270	C4591001 11411411270	16-25	27OCT2020	111532	Placebo	27OCT2020	Placebo	17NOV2020	Placebo
11421028	C4591001 114211421028	16-25	03AUG2020	41533	Placebo	03AUG2020	Placebo	24AUG2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421037	C4591001 1142 11421037	16-25	04AUG2020	42437	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
11421045	C4591001 1142 11421045	16-25	05AUG2020	42789	Placebo	05AUG2020	Placebo	28AUG2020	Placebo
11421059	C4591001 1142 11421059	16-25	07AUG2020	44311	Placebo	07AUG2020	Placebo	28AUG2020	Placebo
11421078	C4591001 1142 11421078	16-25	11AUG2020	45525	Placebo	11AUG2020	Placebo	31AUG2020	Placebo
11421100	C4591001 1142 11421100	16-25	14AUG2020	49083	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
11421149	C4591001 1142 11421149	16-25	24AUG2020	60823	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
11421184	C4591001 1142 11421184	16-25	03SEP2020	79690	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
11421188	C4591001 1142 11421188	16-25	04SEP2020	80324	Placebo	04SEP2020	Placebo	24SEP2020	Placebo
11421202	C4591001 1142 11421202	16-25	08SEP2020	83837	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11421233	C4591001 1142 11421233	16-25	15SEP2020	90223	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
11421261	C4591001 1142 11421261	16-25	24SEP2020	96515	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
11421269	C4591001 1142 11421269	16-25	05OCT2020	98808	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11421270	C4591001 1142 11421270	16-25	05OCT2020	103829	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11421274	C4591001 1142 11421274	16-25	07OCT2020	103837	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421295	C4591001 1142 11421295	16-25	23OCT2020	111395	Placebo	23OCT2020	Placebo	12NOV2020	Placebo
11421310	C4591001 1142 11421310	16-25	29OCT2020	114456	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
11421313	C4591001 1142 11421313	16-25	29OCT2020	114458	Placebo	29OCT2020	Placebo	19NOV2020	Placebo
11421314	C4591001 1142 11421314	16-25	23NOV2020	114459	Placebo	23NOV2020	Placebo	15DEC2020	Placebo
11421315	C4591001 1142 11421315	16-25	24NOV2020	116779	Placebo	24NOV2020	Placebo	15DEC2020	Placebo
11421316	C4591001 1142 11421316	16-25	24NOV2020	116782	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11421317	C4591001 1142 11421317	16-25	25NOV2020	116786	Placebo	25NOV2020	Placebo	15DEC2020	Placebo
11421322	C4591001 1142 11421322	16-25	03DEC2020	116788	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11421328	C4591001 1142 11421328	16-25	04DEC2020	117521	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11421331	C4591001 1142 11421331	16-25	04DEC2020	117522	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11421332	C4591001 1142 11421332	16-25	04DEC2020	117525	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11421334	C4591001 1142 11421334	16-25	04DEC2020	117527	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11421336	C4591001 1142 11421336	16-25	04DEC2020	117606	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11421337	C4591001 1142 11421337	16-25	04DEC2020	117609	Placebo	04DEC2020	Placebo	23DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11421338	C4591001 1142 11421338	16-25	04DEC2020	117612	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11421339	C4591001 1142 11421339	16-25	04DEC2020	117615	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11421347	C4591001 1142 11421347	16-25	10DEC2020	117813	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11451026	C4591001 1145 11451026	16-25	18AUG2020	54823	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
11451059	C4591001 1145 11451059	16-25	28AUG2020	72415	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
11451071	C4591001 1145 11451071	16-25	04SEP2020	80090	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
11451079	C4591001 1145 11451079	16-25	04SEP2020	81723	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
11451080	C4591001 1145 11451080	16-25	08SEP2020	81724	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
11461063	C4591001 1146 11461063	16-25	19AUG2020	56433	Placebo	19AUG2020	Placebo	08SEP2020	Placebo
11461075	C4591001 1146 11461075	16-25	20AUG2020	58012	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11461077	C4591001 1146 11461077	16-25	20AUG2020	58745	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11461083	C4591001 1146 11461083	16-25	21AUG2020	59900	Placebo	21AUG2020	Placebo	10SEP2020	Placebo
11461096	C4591001 1146 11461096	16-25	21AUG2020	60612	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11461100	C4591001 1146 11461100	16-25	24AUG2020	60850	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11461110	C4591001 1146 11461110	16-25	25AUG2020	63482	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11461119	C4591001 1146 11461119	16-25	26AUG2020	67759	Placebo	26AUG2020	Placebo	18SEP2020	Placebo
11461140	C4591001 1146 11461140	16-25	27AUG2020	69710	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
11461142	C4591001 1146 11461142	16-25	28AUG2020	71495	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11461199	C4591001 1146 11461199	16-25	03SEP2020	79517	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
11461243	C4591001 1146 11461243	16-25	15SEP2020	90148	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
11461248	C4591001 1146 11461248	16-25	16SEP2020	90588	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
11461278	C4591001 1146 11461278	16-25	19OCT2020	400033	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11461280	C4591001 1146 11461280	16-25	20OCT2020	400040	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
11461285	C4591001 1146 11461285	16-25	20OCT2020	400066	Placebo	20OCT2020	Placebo	11NOV2020	Placebo
11461289	C4591001 1146 11461289	16-25	20OCT2020	400091	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11461292	C4591001 1146 11461292	16-25	20OCT2020	400128	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11461303	C4591001 1146 11461303	16-25	21OCT2020	400234	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
11461316	C4591001 1146 11461316	16-25	22OCT2020	400363	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11461327	C4591001 1146 11461327	16-25	23OCT2020	400469	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11461332	C4591001 1146 11461332	16-25	23OCT2020	400517	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11461333	C4591001 1146 11461333	16-25	23OCT2020	400518	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11461338	C4591001 1146 11461338	16-25	23OCT2020	400630	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
11461342	C4591001 1146 11461342	16-25	26OCT2020	400774	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11461343	C4591001 1146 11461343	16-25	26OCT2020	400777	Placebo	26OCT2020	Placebo	18NOV2020	Placebo
11461350	C4591001 1146 11461350	16-25	26OCT2020	400916	Placebo	26OCT2020	Placebo	17NOV2020	Placebo
11461351	C4591001 1146 11461351	16-25	26OCT2020	400922	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
11461358	C4591001 1146 11461358	16-25	27OCT2020	401054	Placebo	27OCT2020	Placebo	16NOV2020	Placebo
11461372	C4591001 1146 11461372	16-25	28OCT2020	401178	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
11461378	C4591001 1146 11461378	16-25	29OCT2020	401219	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
11461389	C4591001 1146 11461389	16-25	29OCT2020	401331	Placebo	29OCT2020	Placebo	18NOV2020	Placebo
11471166	C4591001 1147 11471166	16-25	20AUG2020	58972	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11471174	C4591001 1147 11471174	16-25	21AUG2020	59823	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11471176	C4591001 1147 11471176	16-25	21AUG2020	61110	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
11471209	C4591001 1147 11471209	16-25	01SEP2020	75650	Placebo	01SEP2020	Placebo	21SEP2020	Placebo
11471225	C4591001 1147 11471225	16-25	09SEP2020	81888	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11471255	C4591001 1147 11471255	16-25	14NOV2020	116261	BNT162b2 (30 µg)	14NOV2020	BNT162b2 (30 µg)	05DEC2020	BNT162b2 (30 µg)
11471256	C4591001 1147 11471256	16-25	14NOV2020	116263	Placebo	14NOV2020	Placebo	05DEC2020	Placebo
11471257	C4591001 1147 11471257	16-25	21NOV2020	116269	BNT162b2 (30 µg)	21NOV2020	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)
11471258	C4591001 1147 11471258	16-25	21NOV2020	116271	Placebo	21NOV2020	Placebo	12DEC2020	Placebo
11471259	C4591001 1147 11471259	16-25	21NOV2020	116650	BNT162b2 (30 µg)	21NOV2020	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)
11471260	C4591001 1147 11471260	16-25	21NOV2020	116653	BNT162b2 (30 µg)	21NOV2020	BNT162b2 (30 µg)	12DEC2020	BNT162b2 (30 µg)
11471265	C4591001 1147 11471265	16-25	05DEC2020	116654	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471266	C4591001 1147 11471266	16-25	05DEC2020	116656	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471267	C4591001 1147 11471267	16-25	05DEC2020	117642	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471272	C4591001 1147 11471272	16-25	05DEC2020	117644	Placebo	05DEC2020	Placebo	28DEC2020	Placebo
11471276	C4591001 1147 11471276	16-25	05DEC2020	117646	BNT162b2 (30 µg)	05DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11491021	C4591001 1149 11491021	16-25	07AUG2020	44743	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)
11491023	C4591001 1149 11491023	16-25	07AUG2020	44745	Placebo	07AUG2020	Placebo	27AUG2020	Placebo
11491024	C4591001 1149 11491024	16-25	07AUG2020	44752	Placebo	07AUG2020	Placebo	27AUG2020	Placebo
11491028	C4591001 1149 11491028	16-25	07AUG2020	44831	Placebo	07AUG2020	Placebo	27AUG2020	Placebo
11491035	C4591001 1149 11491035	16-25	10AUG2020	45754	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)
11491050	C4591001 1149 11491050	16-25	11AUG2020	46772	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11491061	C4591001 1149 11491061	16-25	12AUG2020	47906	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
11491079	C4591001 1149 11491079	16-25	17AUG2020	53383	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11491087	C4591001 1149 11491087	16-25	18AUG2020	55034	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
11491137	C4591001 1149 11491137	16-25	25AUG2020	66354	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
11491154	C4591001 1149 11491154	16-25	27AUG2020	70745	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11491173	C4591001 1149 11491173	16-25	28AUG2020	73018	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11491181	C4591001 1149 11491181	16-25	01SEP2020	77312	Placebo	01SEP2020	Placebo	21SEP2020	Placebo
11491202	C4591001 1149 11491202	16-25	04SEP2020	82374	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11491203	C4591001 1149 11491203	16-25	04SEP2020	82381	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
11491204	C4591001 1149 11491204	16-25	04SEP2020	82384	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
11491209	C4591001 1149 11491209	16-25	04SEP2020	82479	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11491218	C4591001 1149 11491218	16-25	08SEP2020	84291	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11491235	C4591001 1149 11491235	16-25	11SEP2020	88785	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11491255	C4591001 1149 11491255	16-25	18SEP2020	92774	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11491263	C4591001 1149 11491263	16-25	18SEP2020	94291	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11491271	C4591001 1149 11491271	16-25	21SEP2020	95458	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
11491294	C4591001 1149 11491294	16-25	23SEP2020	98266	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)
11491302	C4591001 1149 11491302	16-25	24SEP2020	98911	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
11491303	C4591001 1149 11491303	16-25	24SEP2020	98999	Placebo	24SEP2020	Placebo	16OCT2020	Placebo
11491315	C4591001 1149 11491315	16-25	24SEP2020	99079	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
11491321	C4591001 1149 11491321	16-25	25SEP2020	100362	Placebo	25SEP2020	Placebo	14OCT2020	Placebo
11491328	C4591001 1149 11491328	16-25	19OCT2020	100372	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11491331	C4591001 1149 11491331	16-25	20OCT2020	110446	Placebo	20OCT2020	Placebo	13NOV2020	Placebo
11491332	C4591001 1149 11491332	16-25	20OCT2020	110449	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11491335	C4591001 1149 11491335†	16-25	26OCT2020	113731	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
11501016	C4591001 1150 11501016	16-25	19AUG2020	55811	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11501017	C4591001 1150 11501017	16-25	19AUG2020	56405	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11501020	C4591001 1150 11501020	16-25	19AUG2020	57293	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
11501031	C4591001 1150 11501031	16-25	21AUG2020	60105	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
11501054	C4591001 1150 11501054	16-25	26AUG2020	67576	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
11501070	C4591001 1150 11501070	16-25	28AUG2020	71198	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
11501071	C4591001 1150 11501071	16-25	28AUG2020	71199	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
11501080	C4591001 1150 11501080	16-25	01SEP2020	76976	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
11501090	C4591001 1150 11501090	16-25	02SEP2020	78973	Placebo	02SEP2020	Placebo	24SEP2020	Placebo
11501096	C4591001 1150 11501096	16-25	03SEP2020	79805	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11501104	C4591001 1150 11501104	16-25	08SEP2020	84545	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501117	C4591001 11501150 11501117	16-25	25SEP2020	88490	Placebo	25SEP2020	Placebo	14OCT2020	Placebo
11501122	C4591001 11501150 11501122	16-25	15OCT2020	108475	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
11501142	C4591001 11501150 11501142	16-25	28OCT2020	114085	Placebo	28OCT2020	Placebo	24NOV2020	Placebo
11501144	C4591001 11501150 11501144	16-25	29OCT2020	114087	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
11501145	C4591001 11501150 11501145	16-25	29OCT2020	114786	Placebo	29OCT2020	Placebo	19NOV2020	Placebo
11501146	C4591001 11501150 11501146	16-25	05NOV2020	114788	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
11501147	C4591001 11501150 11501147	16-25	09NOV2020	114791	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)
11501148	C4591001 11501150 11501148	16-25	11NOV2020	114795	Placebo	11NOV2020	Placebo	03DEC2020	Placebo
11501149	C4591001 11501150 11501149	16-25	12NOV2020	116154	Placebo	12NOV2020	Placebo	02DEC2020	Placebo
11501150	C4591001 11501150 11501150	16-25	12NOV2020	116156	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)
11501151	C4591001 11501150 11501151	16-25	16NOV2020	116160	Placebo	16NOV2020	Placebo	08DEC2020	Placebo
11501152	C4591001 11501150 11501152	16-25	17NOV2020	116164	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11501153	C4591001 11501150 11501153	16-25	18NOV2020	116431	Placebo	18NOV2020	Placebo	11DEC2020	Placebo
11501154	C4591001 11501150 11501154	16-25	20NOV2020	116432	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501155	C4591001 11501155	16-25	23NOV2020	116433	Placebo	23NOV2020	Placebo	14DEC2020	Placebo
11501156	C4591001 11501156	16-25	23NOV2020	116434	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)
11501157	C4591001 11501157	16-25	23NOV2020	116733	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
11501158	C4591001 11501158	16-25	23NOV2020	116734	Placebo	23NOV2020	Placebo	16DEC2020	Placebo
11501159	C4591001 11501159	16-25	23NOV2020	116737	Placebo	23NOV2020	Placebo	16DEC2020	Placebo
11501160	C4591001 11501160	16-25	24NOV2020	116738	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11501161	C4591001 11501161	16-25	24NOV2020	116768	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
11501162	C4591001 11501162	16-25	24NOV2020	116769	Placebo	24NOV2020	Placebo	14DEC2020	Placebo
11501163	C4591001 11501163	16-25	24NOV2020	116772	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)
11501164	C4591001 11501164	16-25	24NOV2020	116776	Placebo	24NOV2020	Placebo	16DEC2020	Placebo
11501165	C4591001 11501165	16-25	30NOV2020	116995	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11501167	C4591001 11501167	16-25	02DEC2020	116998	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11501169	C4591001 11501169	16-25	02DEC2020	117000	Placebo	02DEC2020	Placebo	28DEC2020	Placebo
11501170	C4591001 11501170	16-25	03DEC2020	117004	Placebo	03DEC2020	Placebo	24DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11501174	C4591001 11501174	16-25	03DEC2020	117343	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11501175	C4591001 11501175	16-25	03DEC2020	117345	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11501177	C4591001 11501177	16-25	07DEC2020	117346	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11501181	C4591001 11501181	16-25	08DEC2020	117350	BNT162b2 (30 µg)	08DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11501184	C4591001 11501184	16-25	08DEC2020	117737	Placebo	08DEC2020	Placebo	30DEC2020	Placebo
11501188	C4591001 11501188	16-25	09DEC2020	117738	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
11521009	C4591001 11521009	16-25	12AUG2020	47497	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
11521011	C4591001 11521011	16-25	12AUG2020	47695	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11521019	C4591001 11521019	16-25	12AUG2020	48145	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11521024	C4591001 11521024	16-25	12AUG2020	48210	Placebo	12AUG2020	Placebo	02SEP2020	Placebo
11521030	C4591001 11521030	16-25	12AUG2020	48217	Placebo	12AUG2020	Placebo		
11521032	C4591001 11521032	16-25	12AUG2020	48245	Placebo	12AUG2020	Placebo	01SEP2020	Placebo
11521036	C4591001 11521036	16-25	12AUG2020	48253	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11521038	C4591001 11521038	16-25	13AUG2020	48644	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521044	C4591001 115211521044	16-25	13AUG2020	48989	Placebo	13AUG2020	Placebo	02SEP2020	Placebo
11521048	C4591001 115211521048	16-25	13AUG2020	48998	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
11521054	C4591001 115211521054	16-25	13AUG2020	49406	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
11521058	C4591001 115211521058	16-25	13AUG2020	49518	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
11521061	C4591001 115211521061	16-25	13AUG2020	49640	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
11521064	C4591001 115211521064	16-25	13AUG2020	49647	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11521066	C4591001 115211521066	16-25	13AUG2020	49701	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11521072	C4591001 115211521072	16-25	13AUG2020	49760	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11521075	C4591001 115211521075	16-25	13AUG2020	49766	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
11521086	C4591001 115211521086	16-25	19AUG2020	56375	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11521113	C4591001 1152111521113	16-25	19AUG2020	57724	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
11521114	C4591001 1152111521114	16-25	19AUG2020	57728	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11521115	C4591001 1152111521115	16-25	19AUG2020	57727	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11521118	C4591001 1152111521118	16-25	19AUG2020	57742	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521131	C4591001 1152 11521131	16-25	21AUG2020	60944	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
11521149	C4591001 1152 11521149	16-25	21AUG2020	61630	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11521158	C4591001 1152 11521158	16-25	24AUG2020	63851	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11521159	C4591001 1152 11521159	16-25	24AUG2020	64157	Placebo	24AUG2020	Placebo	15SEP2020	Placebo
11521164	C4591001 1152 11521164	16-25	24AUG2020	64158	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11521189	C4591001 1152 11521189	16-25	25AUG2020	66238	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11521208	C4591001 1152 11521208	16-25	26AUG2020	68249	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
11521220	C4591001 1152 11521220	16-25	26AUG2020	69303	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
11521222	C4591001 1152 11521222	16-25	26AUG2020	69330	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
11521224	C4591001 1152 11521224	16-25	26AUG2020	69337	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
11521255	C4591001 1152 11521255	16-25	31AUG2020	71447	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11521289	C4591001 1152 11521289	16-25	31AUG2020	76223	Placebo	31AUG2020	Placebo	24SEP2020	Placebo
11521296	C4591001 1152 11521296	16-25	31AUG2020	76265	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11521312	C4591001 1152 11521312	16-25	03SEP2020	80139	Placebo	03SEP2020	Placebo	22SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521322	C4591001 1152 11521322	16-25	03SEP2020	80797	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11521355	C4591001 1152 11521355	16-25	04SEP2020	82001	Placebo	04SEP2020	Placebo	24SEP2020	Placebo
11521357	C4591001 1152 11521357	16-25	04SEP2020	82008	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11521362	C4591001 1152 11521362	16-25	08SEP2020	83554	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
11521363	C4591001 1152 11521363	16-25	08SEP2020	83558	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
11521382	C4591001 1152 11521382	16-25	08SEP2020	84451	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
11521384	C4591001 1152 11521384	16-25	08SEP2020	84454	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
11521402	C4591001 1152 11521402	16-25	08SEP2020	84722	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
11521403	C4591001 1152 11521403	16-25	08SEP2020	84715	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
11521408	C4591001 1152 11521408	16-25	08SEP2020	84734	Placebo	08SEP2020	Placebo	14OCT2020	Placebo
11521416	C4591001 1152 11521416	16-25	09SEP2020	85256	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11521426	C4591001 1152 11521426	16-25	09SEP2020	85587	Placebo	09SEP2020	Placebo	09OCT2020	Placebo
11521436	C4591001 1152 11521436	16-25	09SEP2020	86201	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
11521439	C4591001 1152 11521439	16-25	09SEP2020	86207	Placebo	09SEP2020	Placebo	29SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521441	C4591001 1152 11521441	16-25	09SEP2020	86225	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
11521443	C4591001 1152 11521443	16-25	16SEP2020	86231	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11521451	C4591001 1152 11521451	16-25	16SEP2020	91858	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11521456	C4591001 1152 11521456	16-25	17SEP2020	93082	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11521460	C4591001 1152 11521460	16-25	18SEP2020	93848	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11521464	C4591001 1152 11521464	16-25	18SEP2020	94040	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11521470	C4591001 1152 11521470	16-25	23SEP2020	98028	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
11521474	C4591001 1152 11521474	16-25	24SEP2020	99139	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
11521481	C4591001 1152 11521481	16-25	25SEP2020	100099	Placebo	25SEP2020	Placebo	15OCT2020	Placebo
11521483	C4591001 1152 11521483	16-25	25SEP2020	100542	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
11521489	C4591001 1152 11521489	16-25	02OCT2020	100546	Placebo	02OCT2020	Placebo	21OCT2020	Placebo
11521505	C4591001 1152 11521505	16-25	09OCT2020	105531	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
11521508	C4591001 1152 11521508	16-25	09OCT2020	106211	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
11521511	C4591001 1152 11521511	16-25	09OCT2020	106215	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521519	C4591001 11521519	16-25	13OCT2020	106743	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
11521533	C4591001 11521533	16-25	15OCT2020	108594	Placebo	15OCT2020	Placebo	04NOV2020	Placebo
11521534	C4591001 11521534	16-25	16OCT2020	108596	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
11521537	C4591001 11521537	16-25	16OCT2020	108598	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
11521552	C4591001 11521552	16-25	21OCT2020	111200	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11521571	C4591001 11521571	16-25	26OCT2020	113794	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11521575	C4591001 11521575	16-25	28OCT2020	113795	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
11521583	C4591001 11521583	16-25	30OCT2020	115063	Placebo	30OCT2020	Placebo	18NOV2020	Placebo
11521587	C4591001 11521587	16-25	16NOV2020	115067	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11521588	C4591001 11521588	16-25	16NOV2020	115071	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11521589	C4591001 11521589	16-25	17NOV2020	116358	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11521590	C4591001 11521590	16-25	17NOV2020	116359	Placebo	17NOV2020	Placebo	07DEC2020	Placebo
11521591	C4591001 11521591	16-25	17NOV2020	116366	Placebo	17NOV2020	Placebo	07DEC2020	Placebo
11521592	C4591001 11521592	16-25	18NOV2020	116368	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
11521593	C4591001 11521521593	16-25	18NOV2020	116394	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	
11521594	C4591001 11521594	16-25	19NOV2020	116398	Placebo	19NOV2020	Placebo	08DEC2020	Placebo	
11521595	C4591001 11521595	16-25	19NOV2020	116399	Placebo	19NOV2020	Placebo	08DEC2020	Placebo	
11521596	C4591001 11521596	16-25	19NOV2020	116402	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)	
11521597	C4591001 11521597	16-25	23NOV2020	116742	Placebo	23NOV2020	Placebo	15DEC2020	Placebo	
11521598	C4591001 11521598	16-25	23NOV2020	116744	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	
11521599	C4591001 11521599	16-25	23NOV2020	116747	Placebo	23NOV2020	Placebo	14DEC2020	Placebo	
11521600	C4591001 11521600	16-25	24NOV2020	116748	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	
11521601	C4591001 11521601	16-25	24NOV2020	116861	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	
11521602	C4591001 11521602	16-25	24NOV2020	116867	Placebo	24NOV2020	Placebo	14DEC2020	Placebo	
11521603	C4591001 11521603	16-25	24NOV2020	116868	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	
11521606	C4591001 11521606	16-25	03DEC2020	117419	Placebo	03DEC2020	Placebo	22DEC2020	Placebo	
11521609	C4591001 11521609	16-25	03DEC2020	116871	Placebo	03DEC2020	Placebo	23DEC2020	Placebo	
11521610	C4591001 11521610	16-25	03DEC2020	117416	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11521616	C4591001 1152 11521616	16-25	03DEC2020	117423	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
11521618	C4591001 1152 11521618	16-25	03DEC2020	117424	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521620	C4591001 1152 11521620	16-25	03DEC2020	117486	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
11521621	C4591001 1152 11521621	16-25	03DEC2020	117487	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
11521622	C4591001 1152 11521622	16-25	04DEC2020	117492	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
11521623	C4591001 1152 11521623	16-25	04DEC2020	117570	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11521624	C4591001 1152 11521624	16-25	04DEC2020	117493	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11521627	C4591001 1152 11521627	16-25	04DEC2020	117574	Placebo	04DEC2020	Placebo	23DEC2020	Placebo
11521630	C4591001 1152 11521630	16-25	07DEC2020	117578	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521631	C4591001 1152 11521631	16-25	07DEC2020	117580	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521632	C4591001 1152 11521632	16-25	07DEC2020	117677	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521634	C4591001 1152 11521634	16-25	07DEC2020	117681	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
11521643	C4591001 1152 11521643	16-25	07DEC2020	117687	Placebo	07DEC2020	Placebo	28DEC2020	Placebo
11561007	C4591001 1156 11561007	16-25	20AUG2020	58521	Placebo	20AUG2020	Placebo	10SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561009	C4591001 1156 11561009	16-25	20AUG2020	58522	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11561011	C4591001 1156 11561011	16-25	21AUG2020	60329	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
11561012	C4591001 1156 11561012	16-25	21AUG2020	60332	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11561015	C4591001 1156 11561015	16-25	21AUG2020	61147	Placebo	21AUG2020	Placebo		
11561039	C4591001 1156 11561039	16-25	26AUG2020	68814	Placebo	26AUG2020	Placebo	17SEP2020	Placebo
11561040	C4591001 1156 11561040	16-25	26AUG2020	68815	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11561056	C4591001 1156 11561056	16-25	28AUG2020	71856	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
11561057	C4591001 1156 11561057	16-25	28AUG2020	71860	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11561063	C4591001 1156 11561063	16-25	29AUG2020	73473	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11561064	C4591001 1156 11561064	16-25	29AUG2020	73474	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11561075	C4591001 1156 11561075	16-25	01SEP2020	76549	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
11561081	C4591001 1156 11561081	16-25	02SEP2020	76947	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11561090	C4591001 1156 11561090	16-25	03SEP2020	79134	Placebo	03SEP2020	Placebo	02OCT2020	Placebo
11561097	C4591001 1156 11561097	16-25	03SEP2020	79141	Placebo	03SEP2020	Placebo	25SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561119	C4591001 1156 11561119	16-25	09SEP2020	83692	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
11561120	C4591001 1156 11561120	16-25	09SEP2020	85820	Placebo	09SEP2020	Placebo	02OCT2020	Placebo
11561126	C4591001 1156 11561126	16-25	10SEP2020	86976	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11561132	C4591001 1156 11561132	16-25	11SEP2020	88446	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
11561135	C4591001 1156 11561135	16-25	11SEP2020	88453	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
11561149	C4591001 1156 11561149	16-25	16SEP2020	91137	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
11561155	C4591001 1156 11561155	16-25	18SEP2020	91144	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11561156	C4591001 1156 11561156	16-25	18SEP2020	93622	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11561163	C4591001 1156 11561163	16-25	22SEP2020	96215	Placebo	22SEP2020	Placebo	14OCT2020	Placebo
11561164	C4591001 1156 11561164	16-25	23SEP2020	96218	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11561170	C4591001 1156 11561170	16-25	24SEP2020	98085	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11561175	C4591001 1156 11561175	16-25	25SEP2020	99965	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
11561186	C4591001 1156 11561186	16-25	30SEP2020	102197	Placebo	30SEP2020	Placebo	26OCT2020	Placebo
11561194	C4591001 1156 11561194	16-25	30SEP2020	102535	Placebo	30SEP2020	Placebo	21OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561203	C4591001 1156 11561203	16-25	02OCT2020	102993	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
11561206	C4591001 1156 11561206	16-25	02OCT2020	103289	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
11561213	C4591001 1156 11561213	16-25	08OCT2020	105317	Placebo	08OCT2020	Placebo	28OCT2020	Placebo
11561225	C4591001 1156 11561225	16-25	12OCT2020	105327	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
11561226	C4591001 1156 11561226	16-25	12OCT2020	106390	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
11561229	C4591001 1156 11561229	16-25	12OCT2020	106392	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
11561230	C4591001 1156 11561230	16-25	12OCT2020	106393	Placebo	12OCT2020	Placebo	04NOV2020	Placebo
11561233	C4591001 1156 11561233	16-25	12OCT2020	106617	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
11561258	C4591001 1156 11561258	16-25	20OCT2020	107294	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11561268	C4591001 1156 11561268	16-25	23OCT2020	112809	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11561270	C4591001 1156 11561270	16-25	23OCT2020	112811	Placebo	23OCT2020	Placebo	11NOV2020	Placebo
11561275	C4591001 1156 11561275	16-25	26OCT2020	113566	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11561276	C4591001 1156 11561276	16-25	27OCT2020	113569	Placebo	27OCT2020	Placebo	16NOV2020	Placebo
11561282	C4591001 1156 11561282	16-25	29OCT2020	114488	Placebo	29OCT2020	Placebo	17NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561288	C4591001 1156 11561288	16-25	30OCT2020	114969	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
11561291	C4591001 1156 11561291	16-25	30OCT2020	114975	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11561292	C4591001 1156 11561292	16-25	30OCT2020	115052	Placebo	30OCT2020	Placebo	20NOV2020	Placebo
11561293	C4591001 1156 11561293	16-25	30OCT2020	115054	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11561294	C4591001 1156 11561294	16-25	03NOV2020	115059	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
11561295	C4591001 1156 11561295	16-25	04NOV2020	115615	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)	27NOV2020	BNT162b2 (30 µg)
11561296	C4591001 1156 11561296	16-25	05NOV2020	115618	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
11561297	C4591001 1156 11561297	16-25	05NOV2020	115623	Placebo	05NOV2020	Placebo	25NOV2020	Placebo
11561298	C4591001 1156 11561298	16-25	11NOV2020	115624	Placebo	11NOV2020	Placebo	01DEC2020	Placebo
11561299	C4591001 1156 11561299	16-25	11NOV2020	116117	Placebo	11NOV2020	Placebo	01DEC2020	Placebo
11561300	C4591001 1156 11561300	16-25	17NOV2020	116122	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
11561301	C4591001 1156 11561301	16-25	18NOV2020	116125	Placebo	18NOV2020	Placebo	10DEC2020	Placebo
11561302	C4591001 1156 11561302	16-25	19NOV2020	116128	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
11561315	C4591001 1156 11561315	16-25	03DEC2020	117295	Placebo	03DEC2020	Placebo	23DEC2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11561326	C4591001 1156 11561326	16-25	10DEC2020	117299	Placebo	10DEC2020	Placebo	29DEC2020	Placebo
11561329	C4591001 1156 11561329	16-25	16DEC2020	117300	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	06JAN2021	BNT162b2 (30 µg)
11571002	C4591001 1157 11571002	16-25	12AUG2020	48129	Placebo	12AUG2020	Placebo	04SEP2020	Placebo
11571077	C4591001 1157 11571077	16-25	25AUG2020	66738	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
11571088	C4591001 1157 11571088	16-25	26AUG2020	67893	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
11571106	C4591001 1157 11571106	16-25	27AUG2020	69258	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
11571113	C4591001 1157 11571113	16-25	01SEP2020	70539	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11571114	C4591001 1157 11571114	16-25	01SEP2020	70540	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11611006	C4591001 1161 11611006	16-25	31JUL2020	41279	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)		
11611007	C4591001 1161 11611007	16-25	31JUL2020	41280	Placebo	31JUL2020	Placebo		
11611008	C4591001 1161 11611008	16-25	31JUL2020	41283	Placebo	31JUL2020	Placebo		
11611009	C4591001 1161 11611009	16-25	31JUL2020	41284	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
11611010	C4591001 1161 11611010	16-25	31JUL2020	41285	Placebo	31JUL2020	Placebo		
11611015	C4591001 1161 11611015	16-25	01AUG2020	41296	Placebo	01AUG2020	Placebo	19NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11611016	C4591001 1161 11611016	16-25	01AUG2020	41384	Placebo	01AUG2020	Placebo	19NOV2020	Placebo
11611018	C4591001 1161 11611018	16-25	01AUG2020	41386	Placebo	01AUG2020	Placebo		
11611019	C4591001 1161 11611019	16-25	03AUG2020	41855	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
11611023	C4591001 1161 11611023	16-25	03AUG2020	41857	Placebo	03AUG2020	Placebo		
11611024	C4591001 1161 11611024	16-25	03AUG2020	41856	Placebo	03AUG2020	Placebo		
11611026	C4591001 1161 11611026	16-25	04AUG2020	41859	BNT162b2 (30 µg)	04AUG2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
11611028	C4591001 1161 11611028	16-25	04AUG2020	42405	Placebo	04AUG2020	Placebo	12NOV2020	Placebo
11621001	C4591001 1162 11621001	16-25	31JUL2020	40962	Placebo	31JUL2020	Placebo	20AUG2020	Placebo
11621005	C4591001 1162 11621005	16-25	31JUL2020	40972	BNT162b2 (30 µg)	31JUL2020	BNT162b2 (30 µg)		
11621019	C4591001 1162 11621019	16-25	03AUG2020	41260	BNT162b2 (30 µg)	03AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
11621043	C4591001 1162 11621043	16-25	06AUG2020	43715	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
11621044	C4591001 1162 11621044	16-25	06AUG2020	43713	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
11621051	C4591001 1162 11621051	16-25	06AUG2020	43889	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)
11621055	C4591001 1162 11621055	16-25	06AUG2020	43896	Placebo	06AUG2020	Placebo	01SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11621074	C4591001 1162 11621074	16-25	11AUG2020	45556	Placebo	11AUG2020	Placebo	02SEP2020	Placebo
11621080	C4591001 1162 11621080	16-25	11AUG2020	46140	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11621081	C4591001 1162 11621081	16-25	11AUG2020	46141	Placebo	11AUG2020	Placebo	03SEP2020	Placebo
11621110	C4591001 1162 11621110	16-25	13AUG2020	48628	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11621130	C4591001 1162 11621130	16-25	17AUG2020	52567	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
11621141	C4591001 1162 11621141	16-25	17AUG2020	52828	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11621145	C4591001 1162 11621145	16-25	17AUG2020	52910	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
11621169	C4591001 1162 11621169	16-25	24AUG2020	63407	Placebo	24AUG2020	Placebo	16SEP2020	Placebo
11621187	C4591001 1162 11621187	16-25	24AUG2020	64040	Placebo	24AUG2020	Placebo	16SEP2020	Placebo
11621217	C4591001 1162 11621217	16-25	27AUG2020	70303	Placebo	27AUG2020	Placebo	09OCT2020	Placebo
11621226	C4591001 1162 11621226	16-25	31AUG2020	74753	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11621235	C4591001 1162 11621235	16-25	31AUG2020	74761	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11621249	C4591001 1162 11621249	16-25	01SEP2020	75619	Placebo	01SEP2020	Placebo	23SEP2020	Placebo
11621306	C4591001 1162 11621306	16-25	08SEP2020	83744	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11621310	C4591001 1162 11621310	16-25	08SEP2020	84005	Placebo	08SEP2020	Placebo		
11621320	C4591001 1162 11621320	16-25	17SEP2020	90026	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11621360	C4591001 1162 11621360	16-25	14SEP2020	89550	Placebo	14SEP2020	Placebo	22OCT2020	Placebo
11621374	C4591001 1162 11621374	16-25	14SEP2020	89819	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)		
11621388	C4591001 1162 11621388	16-25	17SEP2020	92195	Placebo	17SEP2020	Placebo	19OCT2020	Placebo
11621405	C4591001 1162 11621405	16-25	17SEP2020	92420	Placebo	17SEP2020	Placebo	13OCT2020	Placebo
11621418	C4591001 1162 11621418	16-25	21SEP2020	92847	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11621434	C4591001 1162 11621434	16-25	28SEP2020	96264	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
11621439	C4591001 1162 11621439	16-25	28SEP2020	101314	Placebo	28SEP2020	Placebo	21OCT2020	Placebo
11621456	C4591001 1162 11621456	16-25	28SEP2020	101537	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)
11621479	C4591001 1162 11621479	16-25	07OCT2020	104672	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
11621570	C4591001 1162 11621570	16-25	22OCT2020	112254	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
11621576	C4591001 1162 11621576	16-25	22OCT2020	112356	Placebo	22OCT2020	Placebo	23NOV2020	Placebo
11621583	C4591001 1162 11621583	16-25	28OCT2020	112471	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11621584	C4591001 1162 11621584	16-25	29OCT2020	112478	Placebo	29OCT2020	Placebo	19NOV2020	Placebo
11621585	C4591001 1162 11621585	16-25	29OCT2020	112472	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
11621586	C4591001 1162 11621586	16-25	04NOV2020	115638	Placebo	04NOV2020	Placebo	24NOV2020	Placebo
11621587	C4591001 1162 11621587	16-25	12NOV2020	115642	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
11621588	C4591001 1162 11621588	16-25	17NOV2020	115645	Placebo	17NOV2020	Placebo	10DEC2020	Placebo
11621589	C4591001 1162 11621589	16-25	17NOV2020	115644	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
11631048	C4591001 1163 11631048	16-25	06AUG2020	43787	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)
11631106	C4591001 1163 11631106	16-25	13AUG2020	49591	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
11631113	C4591001 1163 11631113	16-25	14AUG2020	50874	Placebo	14AUG2020	Placebo	02SEP2020	Placebo
11631138	C4591001 1163 11631138	16-25	20AUG2020	59861	Placebo	20AUG2020	Placebo	08SEP2020	Placebo
11661008	C4591001 1166 11661008	16-25	18AUG2020	54845	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11661032	C4591001 1166 11661032	16-25	20AUG2020	58484	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11661042	C4591001 1166 11661042	16-25	21AUG2020	60377	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11661048	C4591001 1166 11661048	16-25	31AUG2020	74656	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11661063	C4591001 1166 11661063	16-25	03SEP2020	80073	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
11661083	C4591001 1166 11661083	16-25	17SEP2020	92063	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
11661088	C4591001 1166 11661088	16-25	18SEP2020	92664	Placebo	18SEP2020	Placebo	07OCT2020	Placebo
11661096	C4591001 1166 11661096	16-25	24SEP2020	98791	Placebo	24SEP2020	Placebo	14OCT2020	Placebo
11671044	C4591001 1167 11671044	16-25	21AUG2020	60538	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
11671050	C4591001 1167 11671050	16-25	24AUG2020	63569	Placebo	24AUG2020	Placebo	15SEP2020	Placebo
11671111	C4591001 1167 11671111	16-25	01SEP2020	76279	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)		
11671112	C4591001 1167 11671112	16-25	01SEP2020	76282	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
11671129	C4591001 1167 11671129	16-25	02SEP2020	79098	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11671132	C4591001 1167 11671132	16-25	03SEP2020	79108	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11671140	C4591001 1167 11671140	16-25	03SEP2020	79842	Placebo	03SEP2020	Placebo	22SEP2020	Placebo
11671142	C4591001 1167 11671142	16-25	04SEP2020	79846	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
11671178	C4591001 1167 11671178	16-25	11SEP2020	87081	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
11671213	C4591001 1167 11671213	16-25	21SEP2020	95564	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11671223	C4591001 1167 11671223	16-25	23SEP2020	98189	Placebo	23SEP2020	Placebo	12NOV2020	Placebo
11671224	C4591001 1167 11671224	16-25	24SEP2020	98190	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11681013	C4591001 1168 11681013	16-25	13AUG2020	47888	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
11681014	C4591001 1168 11681014	16-25	13AUG2020	47893	Placebo	13AUG2020	Placebo	03SEP2020	Placebo
11681026	C4591001 1168 11681026	16-25	15AUG2020	51174	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
11681034	C4591001 1168 11681034	16-25	17AUG2020	53453	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11681035	C4591001 1168 11681035	16-25	17AUG2020	53457	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11681041	C4591001 1168 11681041	16-25	18AUG2020	54620	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
11681052	C4591001 1168 11681052	16-25	19AUG2020	56640	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
11681058	C4591001 1168 11681058	16-25	20AUG2020	59513	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
11681064	C4591001 1168 11681064	16-25	21AUG2020	60367	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
11681069	C4591001 1168 11681069	16-25	21AUG2020	60966	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11681071	C4591001 1168 11681071	16-25	21AUG2020	60971	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
11681076	C4591001 1168 11681076	16-25	24AUG2020	61485	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11681078	C4591001 1168 11681078	16-25	24AUG2020	64746	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
11681088	C4591001 1168 11681088	16-25	26AUG2020	68369	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
11681090	C4591001 1168 11681090	16-25	27AUG2020	68373	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
11681096	C4591001 1168 11681096	16-25	27AUG2020	70642	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11681098	C4591001 1168 11681098	16-25	27AUG2020	71369	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11681103	C4591001 1168 11681103	16-25	28AUG2020	72295	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
11681109	C4591001 1168 11681109	16-25	28AUG2020	73099	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
11681135	C4591001 1168 11681135	16-25	03SEP2020	79823	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11681145	C4591001 1168 11681145	16-25	08SEP2020	82239	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
11681154	C4591001 1168 11681154	16-25	10SEP2020	85225	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11681164	C4591001 1168 11681164	16-25	11SEP2020	88662	Placebo	11SEP2020	Placebo	01OCT2020	Placebo
11681176	C4591001 1168 11681176	16-25	16SEP2020	90087	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11681177	C4591001 1168 11681177	16-25	16SEP2020	91109	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
11681184	C4591001 1168 11681184	16-25	17SEP2020	91119	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11681195	C4591001 1168 11681195	16-25	22SEP2020	95416	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11681198	C4591001 1168 11681198	16-25	23SEP2020	97518	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
11681202	C4591001 1168 11681202	16-25	23SEP2020	97520	Placebo	23SEP2020	Placebo	13OCT2020	Placebo
11681212	C4591001 1168 11681212	16-25	25SEP2020	99516	Placebo	25SEP2020	Placebo	15OCT2020	Placebo
11681219	C4591001 1168 11681219	16-25	05OCT2020	103917	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
11681221	C4591001 1168 11681221	16-25	06OCT2020	103921	Placebo	06OCT2020	Placebo	29OCT2020	Placebo
11681224	C4591001 1168 11681224	16-25	08OCT2020	104938	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11681226	C4591001 1168 11681226	16-25	08OCT2020	104939	Placebo	08OCT2020	Placebo	28OCT2020	Placebo
11681227	C4591001 1168 11681227	16-25	12OCT2020	104943	Placebo	12OCT2020	Placebo		
11681228	C4591001 1168 11681228	16-25	13OCT2020	107277	Placebo	13OCT2020	Placebo	10NOV2020	Placebo
11681241	C4591001 1168 11681241	16-25	28OCT2020	113026	Placebo	28OCT2020	Placebo	16NOV2020	Placebo
11691014	C4591001 1169 11691014	16-25	04SEP2020	80110	Placebo	04SEP2020	Placebo	23SEP2020	Placebo
11691060	C4591001 1169 11691060	16-25	17SEP2020	92071	Placebo	17SEP2020	Placebo	13OCT2020	Placebo
11701009	C4591001 1170 11701009	16-25	13AUG2020	48068	Placebo	13AUG2020	Placebo	01SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11701022	C4591001 1170 11701022	16-25	17AUG2020	52770	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
11701042	C4591001 1170 11701042	16-25	20AUG2020	57252	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
11701043	C4591001 1170 11701043	16-25	20AUG2020	57255	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11701048	C4591001 1170 11701048	16-25	20AUG2020	58455	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
11701076	C4591001 1170 11701076	16-25	25AUG2020	65629	Placebo	25AUG2020	Placebo	14SEP2020	Placebo
11701089	C4591001 1170 11701089	16-25	26AUG2020	67538	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
11701095	C4591001 1170 11701095	16-25	26AUG2020	68197	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
11701096	C4591001 1170 11701096	16-25	26AUG2020	68948	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
11701107	C4591001 1170 11701107	16-25	27AUG2020	70612	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
11701111	C4591001 1170 11701111	16-25	27AUG2020	70965	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
11701118	C4591001 1170 11701118	16-25	28AUG2020	71775	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11701146	C4591001 1170 11701146	16-25	31AUG2020	75694	Placebo	31AUG2020	Placebo	23SEP2020	Placebo
11701154	C4591001 1170 11701154	16-25	01SEP2020	76521	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
11701164	C4591001 1170 11701164	16-25	01SEP2020	77151	Placebo	01SEP2020	Placebo	22SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11701191	C4591001 1170 11701191	16-25	03SEP2020	79251	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
11701261	C4591001 1170 11701261	16-25	10SEP2020	86297	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11701279	C4591001 1170 11701279	16-25	10SEP2020	87332	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11701311	C4591001 1170 11701311	16-25	14SEP2020	89324	Placebo	14SEP2020	Placebo		
11701361	C4591001 1170 11701361	16-25	21SEP2020	95623	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
11701373	C4591001 1170 11701373	16-25	25SEP2020	97587	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
11701392	C4591001 1170 11701392	16-25	20OCT2020	400141	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
11701407	C4591001 1170 11701407	16-25	21OCT2020	400245	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11701419	C4591001 1170 11701419	16-25	22OCT2020	400354	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
11701430	C4591001 1170 11701430	16-25	22OCT2020	400431	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11701444	C4591001 1170 11701444	16-25	23OCT2020	400664	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
11701477	C4591001 1170 11701477	16-25	28OCT2020	401135	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
11701487	C4591001 1170 11701487	16-25	29OCT2020	401261	Placebo	29OCT2020	Placebo	17NOV2020	Placebo
11701494	C4591001 1170 11701494	16-25	29OCT2020	401380	Placebo	29OCT2020	Placebo	17NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11711012	C4591001 1171 11711012	16-25	13AUG2020	48827	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
11711027	C4591001 1171 11711027	16-25	14AUG2020	50056	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
11711028	C4591001 1171 11711028	16-25	14AUG2020	50407	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
11711037	C4591001 1171 11711037	16-25	14AUG2020	50993	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
11711056	C4591001 1171 11711056	16-25	18AUG2020	53620	Placebo	18AUG2020	Placebo	14SEP2020	Placebo
11711068	C4591001 1171 11711068	16-25	18AUG2020	55320	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
11711088	C4591001 1171 11711088	16-25	20AUG2020	58760	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11711097	C4591001 1171 11711097	16-25	20AUG2020	59567	Placebo	20AUG2020	Placebo	14SEP2020	Placebo
11711101	C4591001 1171 11711101	16-25	24AUG2020	59570	Placebo	24AUG2020	Placebo	11SEP2020	Placebo
11711139	C4591001 1171 11711139	16-25	26AUG2020	68137	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11711152	C4591001 1171 11711152	16-25	31AUG2020	75057	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
11711194	C4591001 1171 11711194	16-25	08SEP2020	79900	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11711211	C4591001 1171 11711211	16-25	09SEP2020	85856	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11711221	C4591001 1171 11711221	16-25	10SEP2020	86644	Placebo	10SEP2020	Placebo	28SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11711223	C4591001 1171 11711223	16-25	10SEP2020	87019	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11711240	C4591001 1171 11711240	16-25	11SEP2020	88115	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11711252	C4591001 1171 11711252	16-25	11SEP2020	88768	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11711265	C4591001 1171 11711265	16-25	17SEP2020	92933	Placebo	17SEP2020	Placebo	07OCT2020	Placebo
11711279	C4591001 1171 11711279	16-25	21SEP2020	95046	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
11711287	C4591001 1171 11711287	16-25	22SEP2020	96296	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
11711299	C4591001 1171 11711299	16-25	28SEP2020	101586	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
11741005	C4591001 1174 11741005	16-25	01SEP2020	75504	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11741006	C4591001 1174 11741006	16-25	01SEP2020	75505	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
11741053	C4591001 1174 11741053	16-25	11SEP2020	88205	Placebo	11SEP2020	Placebo	01OCT2020	Placebo
11771081	C4591001 1177 11771081	16-25	19AUG2020	57370	Placebo	19AUG2020	Placebo	11SEP2020	Placebo
11771082	C4591001 1177 11771082	16-25	19AUG2020	57371	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
11771086	C4591001 1177 11771086	16-25	19AUG2020	57374	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
11771101	C4591001 1177 11771101	16-25	20AUG2020	59873	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11771113	C4591001 1177 11771113	16-25	21AUG2020	59878	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
11771170	C4591001 1177 11771170	16-25	27AUG2020	70698	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11771234	C4591001 1177 11771234	16-25	01SEP2020	77566	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
11771235	C4591001 1177 11771235	16-25	01SEP2020	77570	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
11771272	C4591001 1177 11771272	16-25	04SEP2020	81171	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
11771305	C4591001 1177 11771305	16-25	08SEP2020	84631	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
11771312	C4591001 1177 11771312	16-25	08SEP2020	84693	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
11771320	C4591001 1177 11771320	16-25	09SEP2020	85624	Placebo	09SEP2020	Placebo	30SEP2020	Placebo
11771341	C4591001 1177 11771341	16-25	11SEP2020	88973	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11771342	C4591001 1177 11771342	16-25	11SEP2020	88979	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11771345	C4591001 1177 11771345	16-25	11SEP2020	88980	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11771346	C4591001 1177 11771346	16-25	11SEP2020	88982	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
11771347	C4591001 1177 11771347	16-25	11SEP2020	89000	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
11771348	C4591001 1177 11771348	16-25	14SEP2020	89007	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11771351	C4591001 1177 11771351	16-25	14SEP2020	89008	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
11771368	C4591001 1177 11771368	16-25	16SEP2020	90614	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
11771393	C4591001 1177 11771393	16-25	18SEP2020	94142	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11771400	C4591001 1177 11771400	16-25	21SEP2020	94417	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
11771404	C4591001 1177 11771404	16-25	21SEP2020	95738	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11771418	C4591001 1177 11771418	16-25	22SEP2020	97125	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
11771428	C4591001 1177 11771428	16-25	23SEP2020	98219	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
11771432	C4591001 1177 11771432	16-25	24SEP2020	98223	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
11771435	C4591001 1177 11771435	16-25	24SEP2020	98877	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
11771439	C4591001 1177 11771439	16-25	24SEP2020	99106	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
11771442	C4591001 1177 11771442	16-25	24SEP2020	99110	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
11771443	C4591001 1177 11771443	16-25	24SEP2020	99163	Placebo	24SEP2020	Placebo	16OCT2020	Placebo
11771445	C4591001 1177 11771445	16-25	24SEP2020	99169	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
11771454	C4591001 1177 11771454	16-25	05OCT2020	103954	Placebo	05OCT2020	Placebo	26OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11771464	C4591001 1177 11771464	16-25	07OCT2020	104471	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
11771466	C4591001 1177 11771466	16-25	07OCT2020	104474	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
11771477	C4591001 1177 11771477	16-25	08OCT2020	105039	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
11771479	C4591001 1177 11771479	16-25	08OCT2020	105576	Placebo	08OCT2020	Placebo	29OCT2020	Placebo
11771487	C4591001 1177 11771487	16-25	09OCT2020	106222	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
11771488	C4591001 1177 11771488	16-25	09OCT2020	106223	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
11771490	C4591001 1177 11771490	16-25	12OCT2020	106227	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
11771506	C4591001 1177 11771506	16-25	14OCT2020	107254	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
11771516	C4591001 1177 11771516	16-25	15OCT2020	108302	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
11771529	C4591001 1177 11771529	16-25	19OCT2020	110540	Placebo	19OCT2020	Placebo	10NOV2020	Placebo
11771539	C4591001 1177 11771539	16-25	20OCT2020	111248	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
11771540	C4591001 1177 11771540	16-25	20OCT2020	111245	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
11771550	C4591001 1177 11771550	16-25	21OCT2020	111792	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11771564	C4591001 1177 11771564	16-25	27OCT2020	114259	Placebo	27OCT2020	Placebo	17NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11771565	C4591001 1177 11771565	16-25	29OCT2020	114260	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
11781067	C4591001 1178 11781067	16-25	01SEP2020	76654	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11781074	C4591001 1178 11781074	16-25	02SEP2020	77547	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
11781098	C4591001 1178 11781098	16-25	04SEP2020	80978	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
11781154	C4591001 1178 11781154	16-25	11SEP2020	87804	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11781156	C4591001 1178 11781156	16-25	11SEP2020	88184	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11781161	C4591001 1178 11781161	16-25	11SEP2020	88187	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
11781162	C4591001 1178 11781162	16-25	11SEP2020	88188	Placebo	11SEP2020	Placebo	01OCT2020	Placebo
11781170	C4591001 1178 11781170	16-25	14SEP2020	89427	Placebo	14SEP2020	Placebo	14OCT2020	Placebo
11781186	C4591001 1178 11781186	16-25	16SEP2020	90796	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
11781187	C4591001 1178 11781187	16-25	16SEP2020	91038	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
11781190	C4591001 1178 11781190	16-25	16SEP2020	91047	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
11781234	C4591001 1178 11781234	16-25	22SEP2020	96283	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
11781239	C4591001 1178 11781239	16-25	23SEP2020	96896	Placebo	23SEP2020	Placebo	13OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11781245	C4591001 1178 11781245	16-25	23SEP2020	96899	Placebo	23SEP2020	Placebo	13OCT2020	Placebo
11781247	C4591001 1178 11781247	16-25	24SEP2020	98565	Placebo	24SEP2020	Placebo	14OCT2020	Placebo
11781267	C4591001 1178 11781267	16-25	29SEP2020	101792	Placebo	29SEP2020	Placebo	19OCT2020	Placebo
11781284	C4591001 1178 11781284	16-25	06OCT2020	104168	Placebo	06OCT2020	Placebo	26OCT2020	Placebo
11781296	C4591001 1178 11781296	16-25	12OCT2020	104464	Placebo	12OCT2020	Placebo	03NOV2020	Placebo
11781301	C4591001 1178 11781301	16-25	14OCT2020	107532	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
11781309	C4591001 1178 11781309	16-25	20OCT2020	107534	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11781310	C4591001 1178 11781310	16-25	20OCT2020	111053	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11791021	C4591001 1179 11791021	16-25	29AUG2020	69443	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
11791030	C4591001 1179 11791030	16-25	02SEP2020	69446	Placebo	02SEP2020	Placebo	21SEP2020	Placebo
11791050	C4591001 1179 11791050	16-25	05SEP2020	77818	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
11791082	C4591001 1179 11791082	16-25	16SEP2020	90896	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
11791087	C4591001 1179 11791087	16-25	18SEP2020	93560	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
11791099	C4591001 1179 11791099	16-25	25SEP2020	94705	Placebo	25SEP2020	Placebo	14OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11791100	C4591001 1179 11791100	16-25	25SEP2020	99666	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
11791117	C4591001 1179 11791117	16-25	08OCT2020	104627	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
11791139	C4591001 1179 11791139	16-25	24OCT2020	113255	Placebo	24OCT2020	Placebo	12NOV2020	Placebo
11791143	C4591001 1179 11791143	16-25	24OCT2020	113258	Placebo	24OCT2020	Placebo	16NOV2020	Placebo
11791145	C4591001 1179 11791145	16-25	26OCT2020	113278	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
11791161	C4591001 1179 11791161	16-25	29OCT2020	114621	Placebo	29OCT2020	Placebo	18NOV2020	Placebo
11851024	C4591001 1185 11851024	16-25	27OCT2020	113942	Placebo	27OCT2020	Placebo	16NOV2020	Placebo
11851060	C4591001 1185 11851060	16-25	29OCT2020	114615	Placebo	29OCT2020	Placebo	18NOV2020	Placebo
11941044	C4591001 1194 11941044	16-25	17OCT2020	109439	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
11941045	C4591001 1194 11941045	16-25	17OCT2020	109440	Placebo	17OCT2020	Placebo	09NOV2020	Placebo
11941047	C4591001 1194 11941047	16-25	17OCT2020	109481	Placebo	17OCT2020	Placebo	09NOV2020	Placebo
11941057	C4591001 1194 11941057	16-25	19OCT2020	109801	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
11941062	C4591001 1194 11941062	16-25	20OCT2020	109932	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11941067	C4591001 1194 11941067	16-25	20OCT2020	110634	Placebo	20OCT2020	Placebo	11NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11941069	C4591001 1194 11941069	16-25	20OCT2020	110637	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11941082	C4591001 1194 11941082	16-25	21OCT2020	111275	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11941086	C4591001 1194 11941086	16-25	21OCT2020	111417	Placebo	21OCT2020	Placebo	12NOV2020	Placebo
11941091	C4591001 1194 11941091	16-25	22OCT2020	111945	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
11941092	C4591001 1194 11941092	16-25	22OCT2020	111946	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
11941103	C4591001 1194 11941103	16-25	22OCT2020	112233	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
11951015	C4591001 1195 11951015	16-25	15OCT2020	107910	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
11951019	C4591001 1195 11951019	16-25	15OCT2020	108005	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
11951029	C4591001 1195 11951029	16-25	16OCT2020	108654	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
11951061	C4591001 1195 11951061	16-25	17OCT2020	109400	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)		
11951063	C4591001 1195 11951063	16-25	17OCT2020	109402	Placebo	17OCT2020	Placebo	06NOV2020	Placebo
11951065	C4591001 1195 11951065	16-25	17OCT2020	109409	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
11951066	C4591001 1195 11951066	16-25	17OCT2020	109413	Placebo	17OCT2020	Placebo	05NOV2020	Placebo
11951080	C4591001 1195 11951080	16-25	17OCT2020	109548	Placebo	17OCT2020	Placebo	06NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
11951083	C4591001 119511951083	16-25	17OCT2020	109613	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)
11951084	C4591001 119511951084	16-25	17OCT2020	109615	Placebo	17OCT2020	Placebo	05NOV2020	Placebo
11951092	C4591001 119511951092	16-25	18OCT2020	109692	BNT162b2 (30 µg)	18OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)
11951100	C4591001 119511951100	16-25	18OCT2020	109718	Placebo	18OCT2020	Placebo	06NOV2020	Placebo
11951113	C4591001 119511951113	16-25	18OCT2020	109739	Placebo	18OCT2020	Placebo	07NOV2020	Placebo
11951148	C4591001 119511951148	16-25	20OCT2020	110649	Placebo	20OCT2020	Placebo	08NOV2020	Placebo
11971031	C4591001 119711971031	16-25	16OCT2020	108823	Placebo	16OCT2020	Placebo	06NOV2020	Placebo
12031026	C4591001 120312031026	16-25	20OCT2020	110623	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
12031047	C4591001 120312031047	16-25	23OCT2020	111292	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
12041029	C4591001 120412041029	16-25	02SEP2020	77434	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12041031	C4591001 120412041031	16-25	02SEP2020	78990	Placebo	02SEP2020	Placebo	23SEP2020	Placebo
12041061	C4591001 120412041061	16-25	08SEP2020	83915	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
12041080	C4591001 120412041080	16-25	10SEP2020	86277	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
12041088	C4591001 120412041088	16-25	10SEP2020	87146	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12041098	C4591001 1204 12041098	16-25	11SEP2020	88614	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)
12041112	C4591001 1204 12041112	16-25	16SEP2020	91036	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12041124	C4591001 1204 12041124	16-25	18SEP2020	93481	Placebo	18SEP2020	Placebo	08OCT2020	Placebo
12041129	C4591001 1204 12041129	16-25	18SEP2020	93760	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12041134	C4591001 1204 12041134	16-25	21SEP2020	94070	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
12041144	C4591001 1204 12041144	16-25	22SEP2020	96583	Placebo	22SEP2020	Placebo	14OCT2020	Placebo
12041147	C4591001 1204 12041147	16-25	23SEP2020	96588	Placebo	23SEP2020	Placebo	13OCT2020	Placebo
12041155	C4591001 1204 12041155	16-25	23SEP2020	98298	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
12041181	C4591001 1204 12041181	16-25	01OCT2020	101984	Placebo	01OCT2020	Placebo	22OCT2020	Placebo
12041192	C4591001 1204 12041192	16-25	06OCT2020	104294	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12041203	C4591001 1204 12041203	16-25	08OCT2020	105489	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12041220	C4591001 1204 12041220	16-25	12OCT2020	106631	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
12041247	C4591001 1204 12041247	16-25	15OCT2020	108182	Placebo	15OCT2020	Placebo	06NOV2020	Placebo
12041252	C4591001 1204 12041252	16-25	16OCT2020	108471	Placebo	16OCT2020	Placebo	05NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12041268	C4591001 1204 12041268	16-25	20OCT2020	110258	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
12041275	C4591001 1204 12041275	16-25	21OCT2020	111388	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12051079	C4591001 1205 12051079	16-25	11NOV2020	116081	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
12071009	C4591001 1207 12071009	16-25	26OCT2020	113356	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
12071049	C4591001 1207 12071049	16-25	04NOV2020	115396	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
12081032	C4591001 1208 12081032	16-25	04NOV2020	115519	Placebo	04NOV2020	Placebo	24NOV2020	Placebo
12081051	C4591001 1208 12081051	16-25	10NOV2020	116034	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)
12101008	C4591001 1210 12101008	16-25	26OCT2020	112724	Placebo	26OCT2020	Placebo	16NOV2020	Placebo
12101009	C4591001 1210 12101009	16-25	26OCT2020	112730	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
12101020	C4591001 1210 12101020	16-25	27OCT2020	113949	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
12101021	C4591001 1210 12101021	16-25	27OCT2020	113951	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
12101030	C4591001 1210 12101030	16-25	30OCT2020	114949	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)
12101040	C4591001 1210 12101040	16-25	03NOV2020	115414	Placebo	03NOV2020	Placebo	23NOV2020	Placebo
12101041	C4591001 1210 12101041	16-25	03NOV2020	115416	Placebo	03NOV2020	Placebo	23NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12101059	C4591001 1210 12101059	16-25	06NOV2020	115905	Placebo	06NOV2020	Placebo	27NOV2020	Placebo
12121007	C4591001 1212 12121007	16-25	26OCT2020	112641	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)
12121013	C4591001 1212 12121013	16-25	27OCT2020	113852	Placebo	27OCT2020	Placebo	18NOV2020	Placebo
12131003	C4591001 1213 12131003	16-25	22OCT2020	111959	Placebo	22OCT2020	Placebo	12NOV2020	Placebo
12131018	C4591001 1213 12131018	16-25	02NOV2020	115164	Placebo	02NOV2020	Placebo	24NOV2020	Placebo
12141012	C4591001 1214 12141012	16-25	30OCT2020	113422	Placebo	30OCT2020	Placebo	18NOV2020	Placebo
12141013	C4591001 1214 12141013	16-25	30OCT2020	113423	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)
12141022	C4591001 1214 12141022	16-25	03NOV2020	115216	Placebo	03NOV2020	Placebo	25NOV2020	Placebo
12141027	C4591001 1214 12141027	16-25	04NOV2020	115405	Placebo	04NOV2020	Placebo	25NOV2020	Placebo
12141053	C4591001 1214 12141053	16-25	10NOV2020	116032	Placebo	10NOV2020	Placebo	02DEC2020	Placebo
12171012	C4591001 1217 12171012	16-25	23OCT2020	112660	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	13NOV2020	BNT162b2 (30 µg)
12171032	C4591001 1217 12171032	16-25	02NOV2020	114925	Placebo	02NOV2020	Placebo	24NOV2020	Placebo
12171041	C4591001 1217 12171041	16-25	04NOV2020	115475	Placebo	04NOV2020	Placebo	25NOV2020	Placebo
12171047	C4591001 1217 12171047	16-25	05NOV2020	115583	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)	26NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12171053	C4591001 1217 12171053	16-25	06NOV2020	115855	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)	26NOV2020	BNT162b2 (30 µg)
12181011	C4591001 1218 12181011	16-25	02NOV2020	115290	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
12181014	C4591001 1218 12181014	16-25	11NOV2020	115300	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
12181030	C4591001 1218 12181030	16-25	20NOV2020	116510	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
12181047	C4591001 1218 12181047	16-25	02DEC2020	117236	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12181050	C4591001 1218 12181050	16-25	03DEC2020	117428	Placebo	03DEC2020	Placebo		
12181053	C4591001 1218 12181053	16-25	07DEC2020	117436	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12191004	C4591001 1219 12191004	16-25	01OCT2020	100559	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12191058	C4591001 1219 12191058	16-25	07DEC2020	117397	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12201012	C4591001 1220 12201012	16-25	07OCT2020	101533	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12201015	C4591001 1220 12201015	16-25	15OCT2020	105431	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12201017	C4591001 1220 12201017	16-25	15OCT2020	105432	Placebo	15OCT2020	Placebo	06NOV2020	Placebo
12201036	C4591001 1220 12201036	16-25	04NOV2020	115447	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)		
12201048	C4591001 1220 12201048	16-25	17NOV2020	116346	BNT162b2 (30 µg)	17NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12201057	C4591001 1220 12201057	16-25	20NOV2020	116543	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	11DEC2020	BNT162b2 (30 µg)
12211006	C4591001 1221 12211006	16-25	15OCT2020	107097	Placebo	15OCT2020	Placebo	04NOV2020	Placebo
12211012	C4591001 1221 12211012	16-25	22OCT2020	112199	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
12211025	C4591001 1221 12211025	16-25	05NOV2020	115608	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
12211036	C4591001 1221 12211036	16-25	16NOV2020	116287	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)
12211037	C4591001 1221 12211037	16-25	16NOV2020	116290	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
12211038	C4591001 1221 12211038	16-25	16NOV2020	116292	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
12211047	C4591001 1221 12211047	16-25	23NOV2020	116564	Placebo	23NOV2020	Placebo	15DEC2020	Placebo
12211054	C4591001 1221 12211054	16-25	20NOV2020	116561	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
12211056	C4591001 1221 12211056	16-25	23NOV2020	116569	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
12211062	C4591001 1221 12211062	16-25	24NOV2020	116851	Placebo	24NOV2020	Placebo	14DEC2020	Placebo
12211087	C4591001 1221 12211087	16-25	07DEC2020	117440	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12231005	C4591001 1223 12231005	16-25	27AUG2020	68440	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
12231008	C4591001 1223 12231008	16-25	27AUG2020	70097	Placebo	27AUG2020	Placebo	17SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12231025	C4591001 1223 12231025	16-25	28AUG2020	72426	Placebo	28AUG2020	Placebo	18SEP2020	Placebo
12231036	C4591001 1223 12231036	16-25	31AUG2020	73800	Placebo	31AUG2020	Placebo	22SEP2020	Placebo
12231053	C4591001 1223 12231053	16-25	01SEP2020	75479	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12231057	C4591001 1223 12231057	16-25	01SEP2020	76465	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12231061	C4591001 1223 12231061	16-25	01SEP2020	76466	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12231073	C4591001 1223 12231073	16-25	01SEP2020	77306	Placebo	01SEP2020	Placebo	22SEP2020	Placebo
12231082	C4591001 1223 12231082	16-25	02SEP2020	77848	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12231111	C4591001 1223 12231111	16-25	05SEP2020	79983	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
12231113	C4591001 1223 12231113	16-25	05SEP2020	82754	Placebo	05SEP2020	Placebo	28SEP2020	Placebo
12231117	C4591001 1223 12231117	16-25	05SEP2020	82755	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
12231118	C4591001 1223 12231118	16-25	05SEP2020	82756	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
12231120	C4591001 1223 12231120	16-25	05SEP2020	82869	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
12231161	C4591001 1223 12231161	16-25	14SEP2020	86353	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12231164	C4591001 1223 12231164	16-25	14SEP2020	89454	Placebo	14SEP2020	Placebo	06OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12231172	C4591001 1223 12231172	16-25	14SEP2020	89947	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
12231184	C4591001 1223 12231184	16-25	16SEP2020	91297	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12231186	C4591001 1223 12231186	16-25	16SEP2020	91298	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12231187	C4591001 1223 12231187	16-25	16SEP2020	91698	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
12231197	C4591001 1223 12231197	16-25	21SEP2020	95839	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
12241009	C4591001 1224 12241009	16-25	13AUG2020	47759	Placebo	13AUG2020	Placebo		
12241136	C4591001 1224 12241136	16-25	04SEP2020	81391	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12241165	C4591001 1224 12241165	16-25	19NOV2020	98785	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
12241166	C4591001 1224 12241166	16-25	20NOV2020	116554	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
12241167	C4591001 1224 12241167	16-25	20NOV2020	116556	Placebo	20NOV2020	Placebo		
12241168	C4591001 1224 12241168	16-25	20NOV2020	116558	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
12241169	C4591001 1224 12241169	16-25	23NOV2020	116559	Placebo	23NOV2020	Placebo	15DEC2020	Placebo
12241170	C4591001 1224 12241170	16-25	23NOV2020	116661	Placebo				
12241171	C4591001 1224 12241171	16-25	23NOV2020	116663	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12241172	C4591001 1224 12241172	16-25	23NOV2020	116665	Placebo	23NOV2020	Placebo	14DEC2020	Placebo
12241173	C4591001 1224 12241173	16-25	30NOV2020	116668	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12241174	C4591001 1224 12241174	16-25	30NOV2020	116981	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12241175	C4591001 1224 12241175	16-25	30NOV2020	116983	Placebo	30NOV2020	Placebo		
12241176	C4591001 1224 12241176	16-25	30NOV2020	116985	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)		
12241177	C4591001 1224 12241177	16-25	30NOV2020	116988	Placebo	30NOV2020	Placebo	21DEC2020	Placebo
12241178	C4591001 1224 12241178	16-25	30NOV2020	117042	BNT162b2 (30 µg)	30NOV2020	BNT162b2 (30 µg)	29DEC2020	BNT162b2 (30 µg)
12241179	C4591001 1224 12241179	16-25	30NOV2020	117043	Placebo	30NOV2020	Placebo	29DEC2020	Placebo
12241180	C4591001 1224 12241180	16-25	03DEC2020	117044	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
12241181	C4591001 1224 12241181	16-25	03DEC2020	117048	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
12241182	C4591001 1224 12241182	16-25	03DEC2020	117401	Placebo	03DEC2020	Placebo	22DEC2020	Placebo
12241183	C4591001 1224 12241183	16-25	04DEC2020	117403	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12241184	C4591001 1224 12241184	16-25	04DEC2020	117405	Placebo	04DEC2020	Placebo	28DEC2020	Placebo
12241185	C4591001 1224 12241185	16-25	04DEC2020	117408	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12241186	C4591001 1224 12241186	16-25	04DEC2020	117583	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12241187	C4591001 1224 12241187	16-25	04DEC2020	117586	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12261001	C4591001 1226 12261001	16-25	05AUG2020	42725	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)
12261006	C4591001 1226 12261006	16-25	05AUG2020	42743	Placebo	05AUG2020	Placebo	24AUG2020	Placebo
12261007	C4591001 1226 12261007	16-25	05AUG2020	42745	BNT162b2 (30 µg)	05AUG2020	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)
12261015	C4591001 1226 12261015	16-25	06AUG2020	42909	BNT162b2 (30 µg)	06AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
12261047	C4591001 1226 12261047	16-25	07AUG2020	44263	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12261049	C4591001 1226 12261049	16-25	07AUG2020	44270	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12261082	C4591001 1226 12261082	16-25	11AUG2020	46059	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
12261096	C4591001 1226 12261096	16-25	11AUG2020	46258	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
12261100	C4591001 1226 12261100	16-25	11AUG2020	46325	Placebo	11AUG2020	Placebo	31AUG2020	Placebo
12261103	C4591001 1226 12261103	16-25	11AUG2020	46330	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
12261113	C4591001 1226 12261113	16-25	12AUG2020	46942	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12261122	C4591001 1226 12261122	16-25	12AUG2020	47023	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12261124	C4591001 1226 12261124	16-25	12AUG2020	46992	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12261126	C4591001 1226 12261126	16-25	12AUG2020	46996	Placebo	12AUG2020	Placebo	21SEP2020	Placebo
12261133	C4591001 1226 12261133	16-25	12AUG2020	47026	Placebo	12AUG2020	Placebo	04SEP2020	Placebo
12261144	C4591001 1226 12261144	16-25	12AUG2020	47340	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12261158	C4591001 1226 12261158	16-25	13AUG2020	48381	Placebo	13AUG2020	Placebo	03SEP2020	Placebo
12261172	C4591001 1226 12261172	16-25	13AUG2020	48691	Placebo	13AUG2020	Placebo	03SEP2020	Placebo
12261175	C4591001 1226 12261175	16-25	13AUG2020	48692	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
12261204	C4591001 1226 12261204	16-25	17AUG2020	50204	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12261207	C4591001 1226 12261207	16-25	17AUG2020	52148	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12261230	C4591001 1226 12261230	16-25	17AUG2020	52508	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12261238	C4591001 1226 12261238	16-25	18AUG2020	52657	Placebo	18AUG2020	Placebo	07SEP2020	Placebo
12261249	C4591001 1226 12261249	16-25	27AUG2020	67932	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12261251	C4591001 1226 12261251	16-25	18AUG2020	53963	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
12261270	C4591001 1226 12261270	16-25	18AUG2020	54312	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12261275	C4591001 1226 12261275	16-25	19AUG2020	55645	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12261285	C4591001 1226 12261285	16-25	19AUG2020	55708	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12261292	C4591001 1226 12261292	16-25	19AUG2020	56105	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12261296	C4591001 1226 12261296	16-25	19AUG2020	56108	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12261327	C4591001 1226 12261327	16-25	20AUG2020	58364	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
12261332	C4591001 1226 12261332	16-25	20AUG2020	58572	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
12261343	C4591001 1226 12261343	16-25	21AUG2020	59970	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12261348	C4591001 1226 12261348	16-25	21AUG2020	60140	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12261434	C4591001 1226 12261434	16-25	26AUG2020	67488	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
12261443	C4591001 1226 12261443	16-25	26AUG2020	67611	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12261447	C4591001 1226 12261447	16-25	26AUG2020	67930	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
12261475	C4591001 1226 12261475	16-25	27AUG2020	70071	Placebo	27AUG2020	Placebo	19SEP2020	Placebo
12261543	C4591001 1226 12261543	16-25	05SEP2020	82665	BNT162b2 (30 µg)	05SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12261569	C4591001 1226 12261569	16-25	05SEP2020	82793	Placebo	05SEP2020	Placebo	25SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12261570	C4591001 1226 12261570	16-25	05SEP2020	82801	Placebo	05SEP2020	Placebo	25SEP2020	Placebo
12261579	C4591001 1226 12261579	16-25	05SEP2020	82851	Placebo	05SEP2020	Placebo	28SEP2020	Placebo
12261601	C4591001 1226 12261601	16-25	07SEP2020	83116	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
12261603	C4591001 1226 12261603	16-25	07SEP2020	83121	Placebo	07SEP2020	Placebo	02OCT2020	Placebo
12261631	C4591001 1226 12261631	16-25	08SEP2020	83630	Placebo	08SEP2020	Placebo	30SEP2020	Placebo
12261643	C4591001 1226 12261643	16-25	09SEP2020	85208	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
12261649	C4591001 1226 12261649	16-25	10SEP2020	86432	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
12261669	C4591001 1226 12261669	16-25	12SEP2020	89031	Placebo	12SEP2020	Placebo	01OCT2020	Placebo
12261709	C4591001 1226 12261709	16-25	14SEP2020	89447	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12261712	C4591001 1226 12261712	16-25	14SEP2020	89579	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12261746	C4591001 1226 12261746	16-25	16SEP2020	90978	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
12261768	C4591001 1226 12261768	16-25	17SEP2020	91947	Placebo	17SEP2020	Placebo	07OCT2020	Placebo
12261811	C4591001 1226 12261811	16-25	18SEP2020	93175	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12261818	C4591001 1226 12261818	16-25	18SEP2020	93196	Placebo	18SEP2020	Placebo	13OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12261827	C4591001 1226 12261827	16-25	18SEP2020	93245	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12261828	C4591001 1226 12261828	16-25	18SEP2020	93279	Placebo	18SEP2020	Placebo	08OCT2020	Placebo
12261831	C4591001 1226 12261831	16-25	18SEP2020	93249	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12261840	C4591001 1226 12261840	16-25	18SEP2020	93372	Placebo	18SEP2020	Placebo	08OCT2020	Placebo
12261844	C4591001 1226 12261844	16-25	18SEP2020	93465	Placebo	18SEP2020	Placebo	08OCT2020	Placebo
12261850	C4591001 1226 12261850	16-25	18SEP2020	93525	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12261881	C4591001 1226 12261881	16-25	25SEP2020	94490	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12261899	C4591001 1226 12261899	16-25	25SEP2020	99620	Placebo	25SEP2020	Placebo	14OCT2020	Placebo
12261911	C4591001 1226 12261911	16-25	28SEP2020	101266	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
12261918	C4591001 1226 12261918	16-25	28SEP2020	101345	Placebo	28SEP2020	Placebo	20OCT2020	Placebo
12261940	C4591001 1226 12261940	16-25	29SEP2020	101836	Placebo	29SEP2020	Placebo	20OCT2020	Placebo
12261941	C4591001 1226 12261941	16-25	29SEP2020	101846	Placebo	29SEP2020	Placebo	20OCT2020	Placebo
12261945	C4591001 1226 12261945	16-25	29SEP2020	101866	Placebo	29SEP2020	Placebo	19OCT2020	Placebo
12261950	C4591001 1226 12261950	16-25	29SEP2020	101904	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12261960	C4591001 1226 12261960	16-25	30SEP2020	102232	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12261967	C4591001 1226 12261967	16-25	30SEP2020	102377	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12261968	C4591001 1226 12261968	16-25	30SEP2020	102378	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
12261973	C4591001 1226 12261973	16-25	01OCT2020	102416	Placebo	01OCT2020	Placebo	22OCT2020	Placebo
12261975	C4591001 1226 12261975	16-25	01OCT2020	102419	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12261996	C4591001 1226 12261996	16-25	01OCT2020	102798	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12261999	C4591001 1226 12261999	16-25	01OCT2020	102821	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12262001	C4591001 1226 12262001	16-25	01OCT2020	102832	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12262021	C4591001 1226 12262021	16-25	02OCT2020	103185	Placebo	02OCT2020	Placebo	21OCT2020	Placebo
12262022	C4591001 1226 12262022	16-25	02OCT2020	103184	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
12262037	C4591001 1226 12262037	16-25	03OCT2020	103438	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12262044	C4591001 1226 12262044	16-25	03OCT2020	103461	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12262045	C4591001 1226 12262045	16-25	03OCT2020	103467	Placebo	03OCT2020	Placebo	26OCT2020	Placebo
12262049	C4591001 1226 12262049	16-25	03OCT2020	103469	Placebo	03OCT2020	Placebo	23OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12262058	C4591001 1226 12262058	16-25	03OCT2020	103493	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12262063	C4591001 1226 12262063	16-25	03OCT2020	103502	Placebo	03OCT2020	Placebo	23NOV2020	Placebo
12262068	C4591001 1226 12262068	16-25	05OCT2020	103514	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12262075	C4591001 1226 12262075	16-25	05OCT2020	103669	Placebo	05OCT2020	Placebo	27OCT2020	Placebo
12262080	C4591001 1226 12262080	16-25	05OCT2020	103705	Placebo	05OCT2020	Placebo	30OCT2020	Placebo
12262094	C4591001 1226 12262094	16-25	06OCT2020	104216	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12262099	C4591001 1226 12262099	16-25	07OCT2020	104317	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
12262115	C4591001 1226 12262115	16-25	08OCT2020	105360	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
12262116	C4591001 1226 12262116	16-25	08OCT2020	105362	Placebo	08OCT2020	Placebo	28OCT2020	Placebo
12262122	C4591001 1226 12262122	16-25	09OCT2020	105875	Placebo	09OCT2020	Placebo	29OCT2020	Placebo
12262143	C4591001 1226 12262143	16-25	13OCT2020	106782	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)
12262149	C4591001 1226 12262149	16-25	13OCT2020	106806	Placebo	13OCT2020	Placebo	04NOV2020	Placebo
12262181	C4591001 1226 12262181	16-25	13OCT2020	106971	Placebo	13OCT2020	Placebo	03NOV2020	Placebo
12262184	C4591001 1226 12262184	16-25	14OCT2020	107325	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12262189	C4591001 1226 12262189	16-25	14OCT2020	107368	Placebo	14OCT2020	Placebo		
12262197	C4591001 1226 12262197	16-25	15OCT2020	107882	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12262201	C4591001 1226 12262201	16-25	15OCT2020	107891	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
12262220	C4591001 1226 12262220	16-25	15OCT2020	108122	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
12262241	C4591001 1226 12262241	16-25	16OCT2020	108848	Placebo	16OCT2020	Placebo	04NOV2020	Placebo
12262245	C4591001 1226 12262245	16-25	16OCT2020	108957	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12262258	C4591001 1226 12262258	16-25	17OCT2020	109458	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12262270	C4591001 1226 12262270	16-25	17OCT2020	109500	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12262272	C4591001 1226 12262272	16-25	17OCT2020	109494	Placebo	17OCT2020	Placebo	07NOV2020	Placebo
12262274	C4591001 1226 12262274	16-25	17OCT2020	109506	Placebo	17OCT2020	Placebo	06NOV2020	Placebo
12262278	C4591001 1226 12262278	16-25	17OCT2020	109515	Placebo	17OCT2020	Placebo	20NOV2020	Placebo
12262279	C4591001 1226 12262279	16-25	17OCT2020	109529	Placebo	17OCT2020	Placebo	06NOV2020	Placebo
12262280	C4591001 1226 12262280	16-25	17OCT2020	109530	Placebo	17OCT2020	Placebo	05NOV2020	Placebo
12262290	C4591001 1226 12262290	16-25	17OCT2020	109593	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12262293	C4591001 1226 12262293	16-25	17OCT2020	109591	Placebo	17OCT2020	Placebo	06NOV2020	Placebo
12262299	C4591001 1226 12262299	16-25	17OCT2020	109602	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12262317	C4591001 1226 12262317	16-25	19OCT2020	109833	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12262322	C4591001 1226 12262322	16-25	19OCT2020	109870	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12262327	C4591001 1226 12262327	16-25	19OCT2020	109938	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)
12262329	C4591001 1226 12262329	16-25	19OCT2020	109940	Placebo	19OCT2020	Placebo	11NOV2020	Placebo
12262331	C4591001 1226 12262331	16-25	19OCT2020	109947	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)
12262334	C4591001 1226 12262334	16-25	19OCT2020	109997	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12262340	C4591001 1226 12262340	16-25	19OCT2020	110053	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)
12262348	C4591001 1226 12262348	16-25	19OCT2020	110180	Placebo	19OCT2020	Placebo	11NOV2020	Placebo
12262353	C4591001 1226 12262353	16-25	20OCT2020	110244	Placebo	23OCT2020	Placebo	11NOV2020	Placebo
12262354	C4591001 1226 12262354	16-25	20OCT2020	110245	Placebo	20OCT2020	Placebo	11NOV2020	Placebo
12291065	C4591001 1229 12291065	16-25	30SEP2020	102129	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12291077	C4591001 1229 12291077	16-25	01OCT2020	102135	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12291079	C4591001 1229 12291079	16-25	01OCT2020	102613	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
12291088	C4591001 1229 12291088	16-25	02OCT2020	103005	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
12291153	C4591001 1229 12291153	16-25	08OCT2020	105131	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12291158	C4591001 1229 12291158	16-25	08OCT2020	105096	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12291160	C4591001 1229 12291160	16-25	08OCT2020	105174	Placebo	08OCT2020	Placebo	29OCT2020	Placebo
12291169	C4591001 1229 12291169	16-25	09OCT2020	105663	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12291172	C4591001 1229 12291172	16-25	09OCT2020	105691	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12291180	C4591001 1229 12291180	16-25	12OCT2020	106279	Placebo	12OCT2020	Placebo	06NOV2020	Placebo
12291182	C4591001 1229 12291182	16-25	12OCT2020	106291	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
12291184	C4591001 1229 12291184	16-25	12OCT2020	106270	Placebo	12OCT2020	Placebo	04NOV2020	Placebo
12291187	C4591001 1229 12291187	16-25	12OCT2020	106296	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
12291192	C4591001 1229 12291192	16-25	13OCT2020	106752	Placebo	13OCT2020	Placebo	03NOV2020	Placebo
12291212	C4591001 1229 12291212	16-25	14OCT2020	106779	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
12291217	C4591001 1229 12291217	16-25	15OCT2020	107318	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12301005	C4591001 1230 12301005	16-25	23SEP2020	97144	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
12301009	C4591001 1230 12301009	16-25	23SEP2020	97237	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12301010	C4591001 1230 12301010	16-25	23SEP2020	97232	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12301012	C4591001 1230 12301012	16-25	23SEP2020	97556	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12301018	C4591001 1230 12301018	16-25	24SEP2020	98507	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
12301031	C4591001 1230 12301031	16-25	25SEP2020	99242	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
12301039	C4591001 1230 12301039	16-25	26SEP2020	100588	Placebo	26SEP2020	Placebo	17OCT2020	Placebo
12301044	C4591001 1230 12301044	16-25	26SEP2020	100598	BNT162b2 (30 µg)	26SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
12301052	C4591001 1230 12301052	16-25	28SEP2020	101225	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
12301053	C4591001 1230 12301053	16-25	28SEP2020	101199	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
12301056	C4591001 1230 12301056	16-25	28SEP2020	101234	Placebo	28SEP2020	Placebo	20OCT2020	Placebo
12301057	C4591001 1230 12301057	16-25	28SEP2020	101292	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
12301065	C4591001 1230 12301065	16-25	29SEP2020	101672	Placebo	29SEP2020	Placebo	26NOV2020	Placebo
12301078	C4591001 1230 12301078	16-25	30SEP2020	102019	Placebo	30SEP2020	Placebo	20OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12301079	C4591001 1230 12301079	16-25	30SEP2020	102020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
12301083	C4591001 1230 12301083	16-25	30SEP2020	102121	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12301085	C4591001 1230 12301085	16-25	30SEP2020	102262	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12301094	C4591001 1230 12301094	16-25	01OCT2020	102602	Placebo	01OCT2020	Placebo	21OCT2020	Placebo
12301102	C4591001 1230 12301102	16-25	02OCT2020	102772	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12301103	C4591001 1230 12301103	16-25	02OCT2020	103026	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12301104	C4591001 1230 12301104	16-25	02OCT2020	103030	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
12301109	C4591001 1230 12301109	16-25	02OCT2020	103058	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
12301114	C4591001 1230 12301114	16-25	03OCT2020	103116	Placebo	03OCT2020	Placebo	26OCT2020	Placebo
12301115	C4591001 1230 12301115	16-25	03OCT2020	103385	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)	24OCT2020	BNT162b2 (30 µg)
12301132	C4591001 1230 12301132	16-25	05OCT2020	103621	Placebo	05OCT2020	Placebo	26OCT2020	Placebo
12301133	C4591001 1230 12301133	16-25	05OCT2020	103622	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12301136	C4591001 1230 12301136	16-25	05OCT2020	103678	Placebo	05OCT2020	Placebo	26OCT2020	Placebo
12301151	C4591001 1230 12301151	16-25	06OCT2020	104101	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12301157	C4591001 1230 12301157	16-25	06OCT2020	104137	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12301166	C4591001 1230 12301166	16-25	07OCT2020	104522	Placebo	07OCT2020	Placebo	28OCT2020	Placebo
12301170	C4591001 1230 12301170	16-25	07OCT2020	104553	Placebo	07OCT2020	Placebo	28OCT2020	Placebo
12301175	C4591001 1230 12301175	16-25	07OCT2020	104607	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12301186	C4591001 1230 12301186	16-25	08OCT2020	105117	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12301195	C4591001 1230 12301195	16-25	08OCT2020	105195	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12301198	C4591001 1230 12301198	16-25	08OCT2020	105271	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12301202	C4591001 1230 12301202	16-25	09OCT2020	105633	Placebo	09OCT2020	Placebo	28OCT2020	Placebo
12301205	C4591001 1230 12301205	16-25	09OCT2020	105666	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301208	C4591001 1230 12301208	16-25	09OCT2020	105672	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301209	C4591001 1230 12301209	16-25	09OCT2020	105673	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12301210	C4591001 1230 12301210	16-25	09OCT2020	105730	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301213	C4591001 1230 12301213	16-25	09OCT2020	105738	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301215	C4591001 1230 12301215	16-25	09OCT2020	105739	Placebo	09OCT2020	Placebo	30OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12301216	C4591001 1230 12301216	16-25	09OCT2020	105742	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12301217	C4591001 1230 12301217	16-25	09OCT2020	105825	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301218	C4591001 1230 12301218	16-25	09OCT2020	105822	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301219	C4591001 1230 12301219	16-25	09OCT2020	105827	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12301220	C4591001 1230 12301220	16-25	09OCT2020	105830	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12301224	C4591001 1230 12301224	16-25	09OCT2020	105888	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301225	C4591001 1230 12301225	16-25	09OCT2020	106014	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12301226	C4591001 1230 12301226	16-25	09OCT2020	106018	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12311018	C4591001 1231 12311018	16-25	07AUG2020	44590	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)
12311024	C4591001 1231 12311024	16-25	10AUG2020	45234	BNT162b2 (30 µg)	10AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
12311031	C4591001 1231 12311031	16-25	10AUG2020	45500	Placebo	10AUG2020	Placebo		
12311042	C4591001 1231 12311042	16-25	11AUG2020	46036	Placebo	11AUG2020	Placebo	02SEP2020	Placebo
12311047	C4591001 1231 12311047	16-25	11AUG2020	46129	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
12311055	C4591001 1231 12311055	16-25	11AUG2020	46365	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311062	C4591001 1231 12311062	16-25	11AUG2020	46371	Placebo	11AUG2020	Placebo	01SEP2020	Placebo
12311088	C4591001 1231 12311088	16-25	12AUG2020	47159	Placebo	12AUG2020	Placebo		
12311091	C4591001 1231 12311091	16-25	12AUG2020	47283	Placebo	12AUG2020	Placebo	04SEP2020	Placebo
12311131	C4591001 1231 12311131	16-25	13AUG2020	48527	Placebo	13AUG2020	Placebo	01SEP2020	Placebo
12311137	C4591001 1231 12311137	16-25	13AUG2020	48634	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
12311138	C4591001 1231 12311138	16-25	13AUG2020	48638	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12311141	C4591001 1231 12311141	16-25	13AUG2020	48742	Placebo	13AUG2020	Placebo	02SEP2020	Placebo
12311142	C4591001 1231 12311142	16-25	13AUG2020	48748	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
12311151	C4591001 1231 12311151	16-25	13AUG2020	49253	Placebo	13AUG2020	Placebo	03SEP2020	Placebo
12311157	C4591001 1231 12311157	16-25	13AUG2020	49260	Placebo	13AUG2020	Placebo	04SEP2020	Placebo
12311162	C4591001 1231 12311162	16-25	13AUG2020	49299	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12311164	C4591001 1231 12311164	16-25	13AUG2020	49447	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12311170	C4591001 1231 12311170	16-25	13AUG2020	49510	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12311191	C4591001 1231 12311191	16-25	14AUG2020	49988	Placebo	14AUG2020	Placebo		

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311196	C4591001 1231 12311196	16-25	14AUG2020	50124	Placebo	14AUG2020	Placebo	02SEP2020	Placebo
12311199	C4591001 1231 12311199	16-25	14AUG2020	50126	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
12311229	C4591001 1231 12311229	16-25	14AUG2020	50366	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12311244	C4591001 1231 12311244	16-25	14AUG2020	50457	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
12311256	C4591001 1231 12311256	16-25	14AUG2020	50649	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
12311266	C4591001 1231 12311266	16-25	14AUG2020	50827	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12311268	C4591001 1231 12311268	16-25	14AUG2020	50754	BNT162b2 (30 µg)	14AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12311281	C4591001 1231 12311281	16-25	15AUG2020	51134	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12311283	C4591001 1231 12311283	16-25	15AUG2020	50987	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311306	C4591001 1231 12311306	16-25	15AUG2020	51164	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	06SEP2020	BNT162b2 (30 µg)
12311309	C4591001 1231 12311309	16-25	15AUG2020	51281	Placebo	15AUG2020	Placebo	03SEP2020	Placebo
12311322	C4591001 1231 12311322	16-25	15AUG2020	51200	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311350	C4591001 1231 12311350	16-25	15AUG2020	51373	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311359	C4591001 1231 12311359	16-25	15AUG2020	51370	Placebo	15AUG2020	Placebo	07SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311360	C4591001 1231 12311360	16-25	15AUG2020	51318	Placebo	15AUG2020	Placebo	07SEP2020	Placebo
12311366	C4591001 1231 12311366	16-25	15AUG2020	51378	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311368	C4591001 1231 12311368	16-25	15AUG2020	51382	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12311387	C4591001 1231 12311387	16-25	15AUG2020	51509	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311388	C4591001 1231 12311388	16-25	15AUG2020	51427	Placebo	15AUG2020	Placebo	03SEP2020	Placebo
12311392	C4591001 1231 12311392	16-25	15AUG2020	51491	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
12311431	C4591001 1231 12311431	16-25	15AUG2020	51526	Placebo	15AUG2020	Placebo		
12311432	C4591001 1231 12311432	16-25	15AUG2020	51528	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)
12311435	C4591001 1231 12311435	16-25	15AUG2020	51561	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311436	C4591001 1231 12311436	16-25	15AUG2020	51542	Placebo	15AUG2020	Placebo	03SEP2020	Placebo
12311447	C4591001 1231 12311447	16-25	15AUG2020	51569	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311454	C4591001 1231 12311454	16-25	15AUG2020	51583	BNT162b2 (30 µg)	15AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
12311463	C4591001 1231 12311463	16-25	15AUG2020	51606	Placebo	15AUG2020	Placebo	04SEP2020	Placebo
12311503	C4591001 1231 12311503	16-25	16AUG2020	51710	Placebo	16AUG2020	Placebo	07SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311534	C4591001 1231 12311534	16-25	16AUG2020	51768	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311535	C4591001 1231 12311535	16-25	16AUG2020	51773	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12311539	C4591001 1231 12311539	16-25	16AUG2020	51777	Placebo	16AUG2020	Placebo	08SEP2020	Placebo
12311547	C4591001 1231 12311547	16-25	16AUG2020	51796	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311551	C4591001 1231 12311551	16-25	16AUG2020	51851	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311556	C4591001 1231 12311556	16-25	16AUG2020	51808	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311566	C4591001 1231 12311566	16-25	16AUG2020	51853	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311567	C4591001 1231 12311567	16-25	16AUG2020	51857	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311570	C4591001 1231 12311570	16-25	16AUG2020	51885	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311593	C4591001 1231 12311593	16-25	16AUG2020	51895	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311597	C4591001 1231 12311597	16-25	16AUG2020	51959	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311604	C4591001 1231 12311604	16-25	16AUG2020	51949	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311609	C4591001 1231 12311609	16-25	16AUG2020	51937	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311623	C4591001 1231 12311623	16-25	16AUG2020	51998	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311627	C4591001 1231 12311627	16-25	16AUG2020	52026	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311631	C4591001 1231 12311631	16-25	16AUG2020	52097	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311633	C4591001 1231 12311633	16-25	16AUG2020	52036	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311641	C4591001 1231 12311641	16-25	16AUG2020	52068	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)		
12311643	C4591001 1231 12311643	16-25	16AUG2020	52039	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311644	C4591001 1231 12311644	16-25	16AUG2020	52063	Placebo	16AUG2020	Placebo	04SEP2020	Placebo
12311652	C4591001 1231 12311652	16-25	16AUG2020	52079	BNT162b2 (30 µg)	16AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311656	C4591001 1231 12311656	16-25	16AUG2020	52092	Placebo	16AUG2020	Placebo		
12311661	C4591001 1231 12311661	16-25	16AUG2020	52108	Placebo	16AUG2020	Placebo	07SEP2020	Placebo
12311666	C4591001 1231 12311666	16-25	17AUG2020	52161	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
12311683	C4591001 1231 12311683	16-25	17AUG2020	52272	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12311721	C4591001 1231 12311721	16-25	17AUG2020	52418	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12311765	C4591001 1231 12311765	16-25	17AUG2020	52648	Placebo	17AUG2020	Placebo	09SEP2020	Placebo
12311768	C4591001 1231 12311768	16-25	17AUG2020	52645	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311770	C4591001 1231 12311770	16-25	17AUG2020	52724	Placebo	17AUG2020	Placebo	07SEP2020	Placebo
12311773	C4591001 1231 12311773	16-25	17AUG2020	52794	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311774	C4591001 1231 12311774	16-25	17AUG2020	52722	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311783	C4591001 1231 12311783	16-25	17AUG2020	52803	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311788	C4591001 1231 12311788	16-25	17AUG2020	52917	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12311807	C4591001 1231 12311807	16-25	17AUG2020	53093	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311811	C4591001 1231 12311811	16-25	17AUG2020	53028	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311823	C4591001 1231 12311823	16-25	17AUG2020	53172	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12311838	C4591001 1231 12311838	16-25	17AUG2020	53322	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311841	C4591001 1231 12311841	16-25	17AUG2020	53249	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311846	C4591001 1231 12311846	16-25	17AUG2020	53379	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311849	C4591001 1231 12311849	16-25	17AUG2020	53421	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12311851	C4591001 1231 12311851	16-25	17AUG2020	53423	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311866	C4591001 1231 12311866	16-25	17AUG2020	53503	Placebo	17AUG2020	Placebo	07SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12311887	C4591001 1231 12311887	16-25	18AUG2020	53698	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12311890	C4591001 1231 12311890	16-25	18AUG2020	53870	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12311896	C4591001 1231 12311896	16-25	18AUG2020	53854	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12311928	C4591001 1231 12311928	16-25	18AUG2020	54053	Placebo	18AUG2020	Placebo	07SEP2020	Placebo
12311932	C4591001 1231 12311932	16-25	18AUG2020	54097	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311947	C4591001 1231 12311947	16-25	18AUG2020	54131	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12311998	C4591001 1231 12311998	16-25	18AUG2020	54485	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
12312008	C4591001 1231 12312008	16-25	18AUG2020	54496	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312011	C4591001 1231 12312011	16-25	18AUG2020	54523	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12312021	C4591001 1231 12312021	16-25	18AUG2020	54582	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12312033	C4591001 1231 12312033	16-25	18AUG2020	54703	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12312036	C4591001 1231 12312036	16-25	18AUG2020	54731	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312039	C4591001 1231 12312039	16-25	18AUG2020	54813	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12312041	C4591001 1231 12312041	16-25	18AUG2020	54943	Placebo	18AUG2020	Placebo	07SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312050	C4591001 1231 12312050	16-25	18AUG2020	54951	Placebo	18AUG2020	Placebo	07SEP2020	Placebo
12312069	C4591001 1231 12312069	16-25	18AUG2020	55103	Placebo	18AUG2020	Placebo	10SEP2020	Placebo
12312080	C4591001 1231 12312080	16-25	18AUG2020	55186	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312094	C4591001 1231 12312094	16-25	18AUG2020	55229	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12312097	C4591001 1231 12312097	16-25	18AUG2020	55286	Placebo	18AUG2020	Placebo	07SEP2020	Placebo
12312113	C4591001 1231 12312113	16-25	18AUG2020	55352	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12312120	C4591001 1231 12312120	16-25	18AUG2020	55426	Placebo	18AUG2020	Placebo	07SEP2020	Placebo
12312124	C4591001 1231 12312124	16-25	18AUG2020	55461	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312126	C4591001 1231 12312126	16-25	18AUG2020	55462	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312134	C4591001 1231 12312134	16-25	18AUG2020	55537	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
12312137	C4591001 1231 12312137	16-25	18AUG2020	55542	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312152	C4591001 1231 12312152	16-25	18AUG2020	55550	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12312159	C4591001 1231 12312159	16-25	18AUG2020	55582	Placebo	18AUG2020	Placebo	08SEP2020	Placebo
12312168	C4591001 1231 12312168	16-25	18AUG2020	55605	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312180	C4591001 1231 12312180	16-25	19AUG2020	55751	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	07SEP2020	BNT162b2 (30 µg)
12312184	C4591001 1231 12312184	16-25	19AUG2020	55671	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
12312192	C4591001 1231 12312192	16-25	19AUG2020	55723	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312193	C4591001 1231 12312193	16-25	19AUG2020	55749	Placebo	19AUG2020	Placebo	07SEP2020	Placebo
12312200	C4591001 1231 12312200	16-25	19AUG2020	55738	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312203	C4591001 1231 12312203	16-25	19AUG2020	55709	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
12312221	C4591001 1231 12312221	16-25	19AUG2020	55979	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
12312228	C4591001 1231 12312228	16-25	19AUG2020	55984	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312249	C4591001 1231 12312249	16-25	19AUG2020	56101	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312259	C4591001 1231 12312259	16-25	19AUG2020	56253	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312275	C4591001 1231 12312275	16-25	19AUG2020	56307	Placebo	19AUG2020	Placebo	08SEP2020	Placebo
12312282	C4591001 1231 12312282	16-25	19AUG2020	56534	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312283	C4591001 1231 12312283	16-25	19AUG2020	56571	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312298	C4591001 1231 12312298	16-25	19AUG2020	56539	Placebo	19AUG2020	Placebo	09SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312305	C4591001 1231 12312305	16-25	19AUG2020	56564	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312308	C4591001 1231 12312308	16-25	19AUG2020	56650	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
12312311	C4591001 1231 12312311	16-25	19AUG2020	56621	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
12312323	C4591001 1231 12312323	16-25	19AUG2020	56689	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
12312326	C4591001 1231 12312326	16-25	19AUG2020	56711	Placebo	19AUG2020	Placebo		
12312339	C4591001 1231 12312339	16-25	19AUG2020	56887	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)		
12312341	C4591001 1231 12312341	16-25	19AUG2020	56862	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312344	C4591001 1231 12312344	16-25	19AUG2020	56889	Placebo	19AUG2020	Placebo	24SEP2020	Placebo
12312346	C4591001 1231 12312346	16-25	19AUG2020	57282	Placebo	19AUG2020	Placebo	07SEP2020	Placebo
12312349	C4591001 1231 12312349	16-25	19AUG2020	56886	Placebo	19AUG2020	Placebo	08SEP2020	Placebo
12312352	C4591001 1231 12312352	16-25	19AUG2020	56894	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312359	C4591001 1231 12312359	16-25	19AUG2020	56928	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312364	C4591001 1231 12312364	16-25	19AUG2020	57002	Placebo	19AUG2020	Placebo	08SEP2020	Placebo
12312365	C4591001 1231 12312365	16-25	19AUG2020	57055	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)		

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312376	C4591001 1231 12312376	16-25	19AUG2020	57128	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
12312379	C4591001 1231 12312379	16-25	19AUG2020	57109	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312385	C4591001 1231 12312385	16-25	19AUG2020	57313	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312390	C4591001 1231 12312390	16-25	19AUG2020	57348	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312394	C4591001 1231 12312394	16-25	19AUG2020	57349	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312403	C4591001 1231 12312403	16-25	19AUG2020	57379	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)		
12312406	C4591001 1231 12312406	16-25	19AUG2020	57537	Placebo	19AUG2020	Placebo	07SEP2020	Placebo
12312438	C4591001 1231 12312438	16-25	19AUG2020	57636	Placebo	19AUG2020	Placebo	09SEP2020	Placebo
12312442	C4591001 1231 12312442	16-25	19AUG2020	57640	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312448	C4591001 1231 12312448	16-25	20AUG2020	57782	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
12312451	C4591001 1231 12312451	16-25	20AUG2020	57793	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)		
12312464	C4591001 1231 12312464	16-25	20AUG2020	57884	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
12312466	C4591001 1231 12312466	16-25	20AUG2020	57831	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312471	C4591001 1231 12312471	16-25	20AUG2020	57817	Placebo	20AUG2020	Placebo	10SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312516	C4591001 1231 12312516	16-25	20AUG2020	58241	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312520	C4591001 1231 12312520	16-25	20AUG2020	58157	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312528	C4591001 1231 12312528	16-25	20AUG2020	58357	Placebo	20AUG2020	Placebo	11SEP2020	Placebo
12312545	C4591001 1231 12312545	16-25	20AUG2020	58467	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
12312562	C4591001 1231 12312562	16-25	20AUG2020	58534	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
12312576	C4591001 1231 12312576	16-25	20AUG2020	58723	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
12312585	C4591001 1231 12312585	16-25	20AUG2020	58798	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
12312594	C4591001 1231 12312594	16-25	20AUG2020	58938	Placebo	20AUG2020	Placebo		
12312608	C4591001 1231 12312608	16-25	20AUG2020	59134	Placebo	20AUG2020	Placebo	08SEP2020	Placebo
12312615	C4591001 1231 12312615	16-25	20AUG2020	59060	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12312626	C4591001 1231 12312626	16-25	20AUG2020	59139	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312639	C4591001 1231 12312639	16-25	20AUG2020	59115	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312641	C4591001 1231 12312641	16-25	20AUG2020	59207	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
12312649	C4591001 1231 12312649	16-25	20AUG2020	59261	Placebo	20AUG2020	Placebo	11SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312652	C4591001 1231 12312652	16-25	20AUG2020	59361	Placebo	20AUG2020	Placebo	13SEP2020	Placebo
12312666	C4591001 1231 12312666	16-25	20AUG2020	59427	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
12312674	C4591001 1231 12312674	16-25	20AUG2020	59527	Placebo	20AUG2020	Placebo	09SEP2020	Placebo
12312684	C4591001 1231 12312684	16-25	20AUG2020	59577	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312690	C4591001 1231 12312690	16-25	20AUG2020	59627	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312710	C4591001 1231 12312710	16-25	20AUG2020	59732	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312716	C4591001 1231 12312716	16-25	20AUG2020	59763	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312725	C4591001 1231 12312725	16-25	20AUG2020	59775	Placebo	20AUG2020	Placebo	08SEP2020	Placebo
12312731	C4591001 1231 12312731	16-25	21AUG2020	59966	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12312741	C4591001 1231 12312741	16-25	21AUG2020	59952	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312750	C4591001 1231 12312750	16-25	21AUG2020	60038	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312757	C4591001 1231 12312757	16-25	21AUG2020	60004	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12312762	C4591001 1231 12312762	16-25	21AUG2020	60003	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312779	C4591001 1231 12312779	16-25	21AUG2020	60133	Placebo	21AUG2020	Placebo	13SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312790	C4591001 1231 12312790	16-25	21AUG2020	60185	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12312800	C4591001 1231 12312800	16-25	21AUG2020	60128	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312803	C4591001 1231 12312803	16-25	21AUG2020	60164	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312831	C4591001 1231 12312831	16-25	21AUG2020	60425	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
12312846	C4591001 1231 12312846	16-25	21AUG2020	60434	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12312857	C4591001 1231 12312857	16-25	21AUG2020	60523	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312859	C4591001 1231 12312859	16-25	21AUG2020	60526	Placebo	21AUG2020	Placebo	13SEP2020	Placebo
12312874	C4591001 1231 12312874	16-25	21AUG2020	60594	Placebo	21AUG2020	Placebo	10SEP2020	Placebo
12312882	C4591001 1231 12312882	16-25	21AUG2020	60619	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312883	C4591001 1231 12312883	16-25	21AUG2020	60719	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312891	C4591001 1231 12312891	16-25	21AUG2020	60723	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12312892	C4591001 1231 12312892	16-25	21AUG2020	60689	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312895	C4591001 1231 12312895	16-25	21AUG2020	60749	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12312896	C4591001 1231 12312896	16-25	21AUG2020	60694	Placebo	21AUG2020	Placebo	11SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312916	C4591001 1231 12312916	16-25	21AUG2020	60842	Placebo	21AUG2020	Placebo		
12312920	C4591001 1231 12312920	16-25	21AUG2020	61052	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312924	C4591001 1231 12312924	16-25	21AUG2020	61007	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12312930	C4591001 1231 12312930	16-25	21AUG2020	61036	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12312931	C4591001 1231 12312931	16-25	21AUG2020	61034	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
12312932	C4591001 1231 12312932	16-25	21AUG2020	61063	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312934	C4591001 1231 12312934	16-25	21AUG2020	61087	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
12312939	C4591001 1231 12312939	16-25	21AUG2020	61049	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12312941	C4591001 1231 12312941	16-25	21AUG2020	61069	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312953	C4591001 1231 12312953	16-25	21AUG2020	61184	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12312957	C4591001 1231 12312957	16-25	21AUG2020	61166	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312960	C4591001 1231 12312960	16-25	21AUG2020	61187	Placebo	21AUG2020	Placebo	09SEP2020	Placebo
12312972	C4591001 1231 12312972	16-25	21AUG2020	61270	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312983	C4591001 1231 12312983	16-25	21AUG2020	61332	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12312986	C4591001 1231 12312986	16-25	21AUG2020	61370	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312990	C4591001 1231 12312990	16-25	21AUG2020	61393	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12312992	C4591001 1231 12312992	16-25	21AUG2020	61372	Placebo	21AUG2020	Placebo	10SEP2020	Placebo
12312994	C4591001 1231 12312994	16-25	21AUG2020	61428	Placebo	21AUG2020	Placebo	01OCT2020	Placebo
12312996	C4591001 1231 12312996	16-25	21AUG2020	61429	Placebo	21AUG2020	Placebo	10SEP2020	Placebo
12313015	C4591001 1231 12313015	16-25	21AUG2020	61442	Placebo	21AUG2020	Placebo	10SEP2020	Placebo
12313031	C4591001 1231 12313031	16-25	21AUG2020	61541	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12313058	C4591001 1231 12313058	16-25	22AUG2020	61692	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313061	C4591001 1231 12313061	16-25	22AUG2020	61686	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12313062	C4591001 1231 12313062	16-25	22AUG2020	61728	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313066	C4591001 1231 12313066	16-25	22AUG2020	61717	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12313071	C4591001 1231 12313071	16-25	22AUG2020	61724	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313084	C4591001 1231 12313084	16-25	22AUG2020	61764	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12313085	C4591001 1231 12313085	16-25	22AUG2020	61759	Placebo	22AUG2020	Placebo	13SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313098	C4591001 1231 12313098	16-25	22AUG2020	61795	Placebo	22AUG2020	Placebo	09OCT2020	Placebo
12313116	C4591001 1231 12313116	16-25	22AUG2020	61819	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12313117	C4591001 1231 12313117	16-25	22AUG2020	61825	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313124	C4591001 1231 12313124	16-25	22AUG2020	61954	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12313130	C4591001 1231 12313130	16-25	22AUG2020	61865	Placebo	22AUG2020	Placebo	10SEP2020	Placebo
12313137	C4591001 1231 12313137	16-25	22AUG2020	61875	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12313141	C4591001 1231 12313141	16-25	22AUG2020	61924	Placebo	22AUG2020	Placebo	13SEP2020	Placebo
12313149	C4591001 1231 12313149	16-25	22AUG2020	61927	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12313168	C4591001 1231 12313168	16-25	22AUG2020	62016	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313177	C4591001 1231 12313177	16-25	22AUG2020	62045	Placebo	22AUG2020	Placebo	10SEP2020	Placebo
12313180	C4591001 1231 12313180	16-25	22AUG2020	62026	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12313186	C4591001 1231 12313186	16-25	22AUG2020	62039	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12313191	C4591001 1231 12313191	16-25	22AUG2020	62068	Placebo	22AUG2020	Placebo	14SEP2020	Placebo
12313203	C4591001 1231 12313203	16-25	22AUG2020	62098	Placebo	22AUG2020	Placebo	15SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313213	C4591001 1231 12313213	16-25	22AUG2020	62223	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313214	C4591001 1231 12313214	16-25	22AUG2020	62199	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12313229	C4591001 1231 12313229	16-25	22AUG2020	62201	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313231	C4591001 1231 12313231	16-25	22AUG2020	62244	Placebo	22AUG2020	Placebo	13SEP2020	Placebo
12313232	C4591001 1231 12313232	16-25	22AUG2020	62268	Placebo	22AUG2020	Placebo	14SEP2020	Placebo
12313243	C4591001 1231 12313243	16-25	22AUG2020	62254	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313244	C4591001 1231 12313244	16-25	22AUG2020	62260	Placebo	22AUG2020	Placebo	14SEP2020	Placebo
12313246	C4591001 1231 12313246	16-25	22AUG2020	62265	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313257	C4591001 1231 12313257	16-25	22AUG2020	62360	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12313258	C4591001 1231 12313258	16-25	22AUG2020	62272	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12313263	C4591001 1231 12313263	16-25	22AUG2020	62362	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12313288	C4591001 1231 12313288	16-25	22AUG2020	62453	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313297	C4591001 1231 12313297	16-25	22AUG2020	62480	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12313302	C4591001 1231 12313302	16-25	22AUG2020	62486	Placebo	22AUG2020	Placebo	13SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313308	C4591001 1231 12313308	16-25	22AUG2020	62505	BNT162b2 (30 µg)	22AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313317	C4591001 1231 12313317	16-25	22AUG2020	62509	Placebo	22AUG2020	Placebo	13SEP2020	Placebo
12313353	C4591001 1231 12313353	16-25	23AUG2020	62611	Placebo	23AUG2020	Placebo	11SEP2020	Placebo
12313372	C4591001 1231 12313372	16-25	23AUG2020	62650	Placebo	23AUG2020	Placebo	11SEP2020	Placebo
12313381	C4591001 1231 12313381	16-25	23AUG2020	62646	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313383	C4591001 1231 12313383	16-25	23AUG2020	62686	Placebo	23AUG2020	Placebo	11SEP2020	Placebo
12313384	C4591001 1231 12313384	16-25	23AUG2020	62658	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313408	C4591001 1231 12313408	16-25	23AUG2020	62721	Placebo	23AUG2020	Placebo	13SEP2020	Placebo
12313409	C4591001 1231 12313409	16-25	23AUG2020	62716	Placebo	23AUG2020	Placebo	11SEP2020	Placebo
12313412	C4591001 1231 12313412	16-25	23AUG2020	62722	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313430	C4591001 1231 12313430	16-25	23AUG2020	62782	Placebo	23AUG2020	Placebo	14SEP2020	Placebo
12313432	C4591001 1231 12313432	16-25	23AUG2020	62761	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12313434	C4591001 1231 12313434	16-25	23AUG2020	62817	Placebo	23AUG2020	Placebo	13SEP2020	Placebo
12313435	C4591001 1231 12313435	16-25	23AUG2020	62770	Placebo	23AUG2020	Placebo	13SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313443	C4591001 1231 12313443	16-25	23AUG2020	62897	Placebo				
12313460	C4591001 1231 12313460	16-25	23AUG2020	62845	Placebo	23AUG2020	Placebo	15SEP2020	Placebo
12313467	C4591001 1231 12313467	16-25	23AUG2020	62868	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)		
12313498	C4591001 1231 12313498	16-25	23AUG2020	62945	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)		
12313505	C4591001 1231 12313505	16-25	23AUG2020	62949	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12313515	C4591001 1231 12313515	16-25	23AUG2020	63015	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12313519	C4591001 1231 12313519	16-25	23AUG2020	62978	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)		
12313521	C4591001 1231 12313521	16-25	23AUG2020	62994	Placebo	23AUG2020	Placebo	15SEP2020	Placebo
12313527	C4591001 1231 12313527	16-25	23AUG2020	63011	Placebo				
12313533	C4591001 1231 12313533	16-25	23AUG2020	63021	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12313542	C4591001 1231 12313542	16-25	23AUG2020	63063	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12313546	C4591001 1231 12313546	16-25	23AUG2020	63074	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)		
12313553	C4591001 1231 12313553	16-25	23AUG2020	63076	BNT162b2 (30 µg)	23AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12313557	C4591001 1231 12313557	16-25	23AUG2020	63121	Placebo	23AUG2020	Placebo	13SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313558	C4591001 1231 12313558	16-25	23AUG2020	63093	Placebo	23AUG2020	Placebo	13SEP2020	Placebo
12313572	C4591001 1231 12313572	16-25	23AUG2020	63126	Placebo	23AUG2020	Placebo	13SEP2020	Placebo
12313613	C4591001 1231 12313613	16-25	23AUG2020	63192	Placebo	23AUG2020	Placebo	13SEP2020	Placebo
12313620	C4591001 1231 12313620	16-25	24AUG2020	64217	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313622	C4591001 1231 12313622	16-25	24AUG2020	64270	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)		
12313644	C4591001 1231 12313644	16-25	24AUG2020	64317	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313659	C4591001 1231 12313659	16-25	24AUG2020	64379	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313665	C4591001 1231 12313665	16-25	24AUG2020	64415	Placebo	24AUG2020	Placebo	13SEP2020	Placebo
12313669	C4591001 1231 12313669	16-25	24AUG2020	64488	Placebo	24AUG2020	Placebo	15SEP2020	Placebo
12313694	C4591001 1231 12313694	16-25	24AUG2020	64624	Placebo	24AUG2020	Placebo	13SEP2020	Placebo
12313705	C4591001 1231 12313705	16-25	24AUG2020	64684	Placebo	24AUG2020	Placebo	13SEP2020	Placebo
12313711	C4591001 1231 12313711	16-25	24AUG2020	64687	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313720	C4591001 1231 12313720	16-25	24AUG2020	64767	Placebo	24AUG2020	Placebo	13SEP2020	Placebo
12313722	C4591001 1231 12313722	16-25	24AUG2020	64788	Placebo	24AUG2020	Placebo	13SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313727	C4591001 1231 12313727	16-25	24AUG2020	64787	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12313758	C4591001 1231 12313758	16-25	24AUG2020	64935	Placebo	24AUG2020	Placebo		
12313778	C4591001 1231 12313778	16-25	24AUG2020	64997	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313830	C4591001 1231 12313830	16-25	25AUG2020	65243	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12313854	C4591001 1231 12313854	16-25	25AUG2020	65300	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
12313859	C4591001 1231 12313859	16-25	25AUG2020	65298	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313865	C4591001 1231 12313865	16-25	25AUG2020	65373	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12313868	C4591001 1231 12313868	16-25	25AUG2020	65326	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12313875	C4591001 1231 12313875	16-25	25AUG2020	65433	Placebo	25AUG2020	Placebo	13SEP2020	Placebo
12313876	C4591001 1231 12313876	16-25	25AUG2020	65436	Placebo	25AUG2020	Placebo	14SEP2020	Placebo
12313889	C4591001 1231 12313889	16-25	25AUG2020	65641	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313909	C4591001 1231 12313909	16-25	25AUG2020	65760	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313913	C4591001 1231 12313913	16-25	25AUG2020	65762	Placebo	25AUG2020	Placebo	13SEP2020	Placebo
12313917	C4591001 1231 12313917	16-25	25AUG2020	65821	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12313919	C4591001 1231 12313919	16-25	25AUG2020	65920	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12313921	C4591001 1231 12313921	16-25	25AUG2020	65967	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12313930	C4591001 1231 12313930	16-25	25AUG2020	65968	Placebo	25AUG2020	Placebo	13SEP2020	Placebo
12313948	C4591001 1231 12313948	16-25	25AUG2020	66089	Placebo	25AUG2020	Placebo	13SEP2020	Placebo
12313971	C4591001 1231 12313971	16-25	25AUG2020	66417	Placebo	25AUG2020	Placebo	16SEP2020	Placebo
12313981	C4591001 1231 12313981	16-25	25AUG2020	66381	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
12313999	C4591001 1231 12313999	16-25	25AUG2020	66588	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12314004	C4591001 1231 12314004	16-25	25AUG2020	66653	Placebo	25AUG2020	Placebo	22SEP2020	Placebo
12314007	C4591001 1231 12314007	16-25	25AUG2020	66680	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)
12314010	C4591001 1231 12314010	16-25	25AUG2020	66927	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
12314013	C4591001 1231 12314013	16-25	25AUG2020	66777	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12314021	C4591001 1231 12314021	16-25	25AUG2020	66760	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12314032	C4591001 1231 12314032	16-25	25AUG2020	66827	Placebo	25AUG2020	Placebo	14SEP2020	Placebo
12314033	C4591001 1231 12314033	16-25	25AUG2020	66826	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	13SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12314049	C4591001 1231 12314049	16-25	25AUG2020	66938	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12314062	C4591001 1231 12314062	16-25	25AUG2020	66977	Placebo	25AUG2020	Placebo	13SEP2020	Placebo
12314067	C4591001 1231 12314067	16-25	25AUG2020	66988	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314121	C4591001 1231 12314121	16-25	26AUG2020	67289	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
12314124	C4591001 1231 12314124	16-25	26AUG2020	67287	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314135	C4591001 1231 12314135	16-25	26AUG2020	67388	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314144	C4591001 1231 12314144	16-25	26AUG2020	67441	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314150	C4591001 1231 12314150	16-25	26AUG2020	67459	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314156	C4591001 1231 12314156	16-25	26AUG2020	67465	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
12314160	C4591001 1231 12314160	16-25	26AUG2020	67522	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314178	C4591001 1231 12314178	16-25	26AUG2020	67598	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314183	C4591001 1231 12314183	16-25	26AUG2020	67703	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314195	C4591001 1231 12314195	16-25	26AUG2020	67748	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314230	C4591001 1231 12314230	16-25	26AUG2020	68033	Placebo	26AUG2020	Placebo	14SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12314243	C4591001 1231 12314243	16-25	26AUG2020	68423	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314267	C4591001 1231 12314267	16-25	26AUG2020	68394	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314278	C4591001 1231 12314278	16-25	26AUG2020	68725	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314284	C4591001 1231 12314284	16-25	26AUG2020	68772	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314294	C4591001 1231 12314294	16-25	26AUG2020	68836	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
12314303	C4591001 1231 12314303	16-25	26AUG2020	68776	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
12314311	C4591001 1231 12314311	16-25	26AUG2020	68940	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314342	C4591001 1231 12314342	16-25	26AUG2020	69128	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314343	C4591001 1231 12314343	16-25	26AUG2020	69051	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314348	C4591001 1231 12314348	16-25	26AUG2020	69146	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
12314351	C4591001 1231 12314351	16-25	26AUG2020	69075	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314353	C4591001 1231 12314353	16-25	26AUG2020	69127	Placebo	26AUG2020	Placebo	14SEP2020	Placebo
12314356	C4591001 1231 12314356	16-25	26AUG2020	69190	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12314359	C4591001 1231 12314359	16-25	26AUG2020	69148	Placebo	26AUG2020	Placebo	14SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12314360	C4591001 1231 12314360	16-25	26AUG2020	69186	Placebo	26AUG2020	Placebo	16SEP2020	Placebo
12314396	C4591001 1231 12314396	16-25	27AUG2020	69471	Placebo	27AUG2020	Placebo	16SEP2020	Placebo
12314422	C4591001 1231 12314422	16-25	27AUG2020	69605	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
12314444	C4591001 1231 12314444	16-25	27AUG2020	69826	Placebo	27AUG2020	Placebo	18SEP2020	Placebo
12314459	C4591001 1231 12314459	16-25	27AUG2020	69932	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314482	C4591001 1231 12314482	16-25	27AUG2020	70055	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12314489	C4591001 1231 12314489	16-25	27AUG2020	70144	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12314492	C4591001 1231 12314492	16-25	27AUG2020	70185	Placebo	27AUG2020	Placebo		
12314497	C4591001 1231 12314497	16-25	27AUG2020	70250	Placebo	27AUG2020	Placebo	16SEP2020	Placebo
12314501	C4591001 1231 12314501	16-25	27AUG2020	70297	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314531	C4591001 1231 12314531	16-25	27AUG2020	70475	Placebo	27AUG2020	Placebo	28SEP2020	Placebo
12314534	C4591001 1231 12314534	16-25	27AUG2020	70479	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314535	C4591001 1231 12314535	16-25	27AUG2020	70586	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314553	C4591001 1231 12314553	16-25	27AUG2020	70666	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12314574	C4591001 1231 12314574	16-25	27AUG2020	70804	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314577	C4591001 1231 12314577	16-25	27AUG2020	70914	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314582	C4591001 1231 12314582	16-25	27AUG2020	70873	Placebo	27AUG2020	Placebo	17SEP2020	Placebo
12314583	C4591001 1231 12314583	16-25	27AUG2020	70872	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314596	C4591001 1231 12314596	16-25	27AUG2020	71032	Placebo	27AUG2020	Placebo	15SEP2020	Placebo
12314627	C4591001 1231 12314627	16-25	27AUG2020	71107	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12314629	C4591001 1231 12314629	16-25	27AUG2020	71111	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12314649	C4591001 1231 12314649	16-25	27AUG2020	71263	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12314672	C4591001 1231 12314672	16-25	28AUG2020	71478	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
12314684	C4591001 1231 12314684	16-25	28AUG2020	71507	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314697	C4591001 1231 12314697	16-25	28AUG2020	71550	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314698	C4591001 1231 12314698	16-25	28AUG2020	71575	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314709	C4591001 1231 12314709	16-25	28AUG2020	71592	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314742	C4591001 1231 12314742	16-25	28AUG2020	71761	Placebo	28AUG2020	Placebo	16SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12314746	C4591001 1231 12314746	16-25	28AUG2020	71790	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
12314757	C4591001 1231 12314757	16-25	28AUG2020	71814	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12314764	C4591001 1231 12314764	16-25	28AUG2020	71809	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314768	C4591001 1231 12314768	16-25	28AUG2020	71873	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12314774	C4591001 1231 12314774	16-25	28AUG2020	71874	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314783	C4591001 1231 12314783	16-25	28AUG2020	71936	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314800	C4591001 1231 12314800	16-25	28AUG2020	72096	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314814	C4591001 1231 12314814	16-25	28AUG2020	72149	Placebo	28AUG2020	Placebo	17SEP2020	Placebo
12314819	C4591001 1231 12314819	16-25	28AUG2020	72234	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314845	C4591001 1231 12314845	16-25	28AUG2020	72315	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314854	C4591001 1231 12314854	16-25	28AUG2020	72540	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314859	C4591001 1231 12314859	16-25	28AUG2020	72544	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314862	C4591001 1231 12314862	16-25	28AUG2020	72698	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314866	C4591001 1231 12314866	16-25	28AUG2020	72730	Placebo	28AUG2020	Placebo	17SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12314870	C4591001 1231 12314870	16-25	28AUG2020	72637	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314878	C4591001 1231 12314878	16-25	28AUG2020	72694	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314894	C4591001 1231 12314894	16-25	28AUG2020	72865	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314907	C4591001 1231 12314907	16-25	28AUG2020	72945	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314925	C4591001 1231 12314925	16-25	28AUG2020	72943	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12314936	C4591001 1231 12314936	16-25	28AUG2020	73039	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12314977	C4591001 1231 12314977	16-25	28AUG2020	73156	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12315013	C4591001 1231 12315013	16-25	28AUG2020	73200	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12315039	C4591001 1231 12315039	16-25	28AUG2020	73240	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12315062	C4591001 1231 12315062	16-25	29AUG2020	73288	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315080	C4591001 1231 12315080	16-25	29AUG2020	73337	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315089	C4591001 1231 12315089	16-25	29AUG2020	73361	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315100	C4591001 1231 12315100	16-25	29AUG2020	73423	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315136	C4591001 1231 12315136	16-25	29AUG2020	73501	Placebo	29AUG2020	Placebo	18SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12315169	C4591001 1231 12315169	16-25	29AUG2020	73497	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315175	C4591001 1231 12315175	16-25	29AUG2020	73525	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315177	C4591001 1231 12315177	16-25	29AUG2020	73530	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315180	C4591001 1231 12315180	16-25	29AUG2020	73571	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315182	C4591001 1231 12315182	16-25	29AUG2020	73536	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315185	C4591001 1231 12315185	16-25	29AUG2020	73531	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315194	C4591001 1231 12315194	16-25	29AUG2020	73588	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315195	C4591001 1231 12315195	16-25	29AUG2020	73552	Placebo	29AUG2020	Placebo	18SEP2020	Placebo
12315203	C4591001 1231 12315203	16-25	29AUG2020	73586	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315220	C4591001 1231 12315220	16-25	29AUG2020	73681	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315222	C4591001 1231 12315222	16-25	29AUG2020	73642	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315226	C4591001 1231 12315226	16-25	29AUG2020	73674	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315229	C4591001 1231 12315229	16-25	29AUG2020	73682	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315241	C4591001 1231 12315241	16-25	29AUG2020	73764	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12315259	C4591001 1231 12315259	16-25	29AUG2020	73809	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315265	C4591001 1231 12315265	16-25	29AUG2020	73815	Placebo	29AUG2020	Placebo	29SEP2020	Placebo
12315269	C4591001 1231 12315269	16-25	29AUG2020	73975	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)		
12315275	C4591001 1231 12315275	16-25	29AUG2020	73921	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315278	C4591001 1231 12315278	16-25	29AUG2020	73941	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315283	C4591001 1231 12315283	16-25	29AUG2020	73959	Placebo	29AUG2020	Placebo	18SEP2020	Placebo
12315299	C4591001 1231 12315299	16-25	29AUG2020	74027	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315309	C4591001 1231 12315309	16-25	29AUG2020	74026	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315318	C4591001 1231 12315318	16-25	29AUG2020	74123	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315326	C4591001 1231 12315326	16-25	29AUG2020	74132	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315337	C4591001 1231 12315337	16-25	29AUG2020	74153	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315357	C4591001 1231 12315357	16-25	29AUG2020	74189	Placebo	29AUG2020	Placebo		
12315358	C4591001 1231 12315358	16-25	29AUG2020	74186	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315361	C4591001 1231 12315361	16-25	29AUG2020	74202	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12315362	C4591001 1231 12315362	16-25	29AUG2020	74196	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12315364	C4591001 1231 12315364	16-25	29AUG2020	74206	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315371	C4591001 1231 12315371	16-25	29AUG2020	74231	Placebo	29AUG2020	Placebo	18SEP2020	Placebo
12315375	C4591001 1231 12315375	16-25	29AUG2020	74223	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315381	C4591001 1231 12315381	16-25	29AUG2020	74247	Placebo	29AUG2020	Placebo	17SEP2020	Placebo
12315406	C4591001 1231 12315406	16-25	30AUG2020	74307	Placebo	30AUG2020	Placebo	18SEP2020	Placebo
12315446	C4591001 1231 12315446	16-25	30AUG2020	74397	Placebo	30AUG2020	Placebo	19SEP2020	Placebo
12315461	C4591001 1231 12315461	16-25	30AUG2020	74410	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315462	C4591001 1231 12315462	16-25	30AUG2020	74419	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315465	C4591001 1231 12315465	16-25	30AUG2020	74443	Placebo	30AUG2020	Placebo	18SEP2020	Placebo
12315470	C4591001 1231 12315470	16-25	30AUG2020	74448	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315471	C4591001 1231 12315471	16-25	30AUG2020	74435	Placebo	30AUG2020	Placebo	18SEP2020	Placebo
12315480	C4591001 1231 12315480	16-25	30AUG2020	74462	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)
12315527	C4591001 1231 12315527	16-25	30AUG2020	74550	Placebo	30AUG2020	Placebo	19SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
12315529	C4591001 1231 12315529	16-25	30AUG2020	74581	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	
12315532	C4591001 1231 12315532	16-25	30AUG2020	74552	Placebo	30AUG2020	Placebo	19SEP2020	Placebo	
12315545	C4591001 1231 12315545	16-25	31AUG2020	74608	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315576	C4591001 1231 12315576	16-25	31AUG2020	74828	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315601	C4591001 1231 12315601	16-25	31AUG2020	75077	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	
12315609	C4591001 1231 12315609	16-25	31AUG2020	75081	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315621	C4591001 1231 12315621	16-25	31AUG2020	75436	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315622	C4591001 1231 12315622	16-25	31AUG2020	75546	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315644	C4591001 1231 12315644	16-25	31AUG2020	75706	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)	
12315647	C4591001 1231 12315647	16-25	31AUG2020	75759	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315648	C4591001 1231 12315648	16-25	31AUG2020	75789	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	19SEP2020	BNT162b2 (30 µg)	
12315674	C4591001 1231 12315674	16-25	31AUG2020	76020	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315678	C4591001 1231 12315678	16-25	31AUG2020	76055	Placebo	31AUG2020	Placebo	19SEP2020	Placebo	
12315680	C4591001 1231 12315680	16-25	31AUG2020	76060	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12321015	C4591001 1232 12321015	16-25	13AUG2020	48769	Placebo	13AUG2020	Placebo		
12321028	C4591001 1232 12321028	16-25	17AUG2020	50701	BNT162b2 (30 µg)	17AUG2020	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)
12321045	C4591001 1232 12321045	16-25	19AUG2020	55818	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12321056	C4591001 1232 12321056	16-25	19AUG2020	56549	Placebo	19AUG2020	Placebo	23SEP2020	Placebo
12321068	C4591001 1232 12321068	16-25	20AUG2020	58389	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12321100	C4591001 1232 12321100	16-25	26AUG2020	67541	Placebo	26AUG2020	Placebo		
12321101	C4591001 1232 12321101	16-25	26AUG2020	67543	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)		
12321120	C4591001 1232 12321120	16-25	27AUG2020	69667	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)
12321141	C4591001 1232 12321141	16-25	31AUG2020	75598	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
12321142	C4591001 1232 12321142	16-25	31AUG2020	74944	Placebo	31AUG2020	Placebo		
12321146	C4591001 1232 12321146	16-25	01SEP2020	75601	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12321159	C4591001 1232 12321159	16-25	02SEP2020	76558	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12321172	C4591001 1232 12321172	16-25	02SEP2020	78156	Placebo	02SEP2020	Placebo	22SEP2020	Placebo
12321210	C4591001 1232 12321210	16-25	09SEP2020	84977	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12321213	C4591001 1232 12321213	16-25	09SEP2020	84986	Placebo	09SEP2020	Placebo		
12321232	C4591001 1232 12321232	16-25	10SEP2020	86762	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
12321244	C4591001 1232 12321244	16-25	11SEP2020	87784	Placebo	11SEP2020	Placebo		
12321272	C4591001 1232 12321272	16-25	24SEP2020	98609	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
12321283	C4591001 1232 12321283	16-25	29SEP2020	101389	Placebo	29SEP2020	Placebo	21OCT2020	Placebo
12321294	C4591001 1232 12321294	16-25	02OCT2020	102839	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
12321302	C4591001 1232 12321302	16-25	06OCT2020	104237	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12321310	C4591001 1232 12321310	16-25	07OCT2020	104852	Placebo	07OCT2020	Placebo	25NOV2020	Placebo
12321313	C4591001 1232 12321313	16-25	08OCT2020	104853	Placebo	08OCT2020	Placebo	30OCT2020	Placebo
12321358	C4591001 1232 12321358	16-25	15OCT2020	108213	Placebo	15OCT2020	Placebo	03NOV2020	Placebo
12321408	C4591001 1232 12321408	16-25	26OCT2020	113604	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
12321412	C4591001 1232 12321412	16-25	27OCT2020	113605	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)		
12321424	C4591001 1232 12321424	16-25	27OCT2020	114176	Placebo	27OCT2020	Placebo	25NOV2020	Placebo
12321429	C4591001 1232 12321429	16-25	28OCT2020	114348	Placebo	28OCT2020	Placebo		

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12351003	C4591001 1235 12351003	16-25	03SEP2020	79709	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12351004	C4591001 1235 12351004	16-25	03SEP2020	79716	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12351006	C4591001 1235 12351006	16-25	03SEP2020	79719	Placebo	03SEP2020	Placebo	25SEP2020	Placebo
12351009	C4591001 1235 12351009	16-25	03SEP2020	80388	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
12351014	C4591001 1235 12351014	16-25	04SEP2020	81644	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12351015	C4591001 1235 12351015	16-25	04SEP2020	81648	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
12351016	C4591001 1235 12351016	16-25	04SEP2020	81651	Placebo	04SEP2020	Placebo	25SEP2020	Placebo
12351036	C4591001 1235 12351036	16-25	07SEP2020	83227	Placebo	07SEP2020	Placebo	29SEP2020	Placebo
12351040	C4591001 1235 12351040	16-25	08SEP2020	83235	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
12351049	C4591001 1235 12351049	16-25	09SEP2020	85797	Placebo	09SEP2020	Placebo	30SEP2020	Placebo
12351052	C4591001 1235 12351052	16-25	10SEP2020	85802	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
12351053	C4591001 1235 12351053	16-25	10SEP2020	86705	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
12351055	C4591001 1235 12351055	16-25	10SEP2020	86708	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
12351058	C4591001 1235 12351058	16-25	11SEP2020	87870	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12351063	C4591001 1235 12351063	16-25	11SEP2020	88374	Placebo	11SEP2020	Placebo	30SEP2020	Placebo
12351064	C4591001 1235 12351064	16-25	11SEP2020	88378	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
12351068	C4591001 1235 12351068	16-25	12SEP2020	88821	Placebo	12SEP2020	Placebo	02OCT2020	Placebo
12351073	C4591001 1235 12351073	16-25	14SEP2020	89563	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
12351092	C4591001 1235 12351092	16-25	16SEP2020	91353	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12351097	C4591001 1235 12351097	16-25	17SEP2020	91358	Placebo	17SEP2020	Placebo	09OCT2020	Placebo
12351098	C4591001 1235 12351098	16-25	17SEP2020	92129	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12351105	C4591001 1235 12351105	16-25	17SEP2020	92888	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
12351108	C4591001 1235 12351108	16-25	18SEP2020	92896	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12351112	C4591001 1235 12351112	16-25	18SEP2020	93550	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12351124	C4591001 1235 12351124	16-25	21SEP2020	94126	Placebo	21SEP2020	Placebo	13OCT2020	Placebo
12351125	C4591001 1235 12351125	16-25	21SEP2020	94129	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12351126	C4591001 1235 12351126	16-25	28SEP2020	99706	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)
12351127	C4591001 1235 12351127	16-25	21SEP2020	95201	Placebo	21SEP2020	Placebo	12OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12351128	C4591001 1235 12351128	16-25	21SEP2020	95202	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
12351146	C4591001 1235 12351146	16-25	23SEP2020	97963	Placebo	23SEP2020	Placebo	12OCT2020	Placebo
12351153	C4591001 1235 12351153	16-25	25SEP2020	99702	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12351156	C4591001 1235 12351156	16-25	28SEP2020	101405	Placebo	28SEP2020	Placebo	21OCT2020	Placebo
12351158	C4591001 1235 12351158	16-25	02OCT2020	101408	Placebo	02OCT2020	Placebo	21OCT2020	Placebo
12351159	C4591001 1235 12351159	16-25	02OCT2020	101414	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12351165	C4591001 1235 12351165	16-25	08OCT2020	103225	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
12351166	C4591001 1235 12351166	16-25	08OCT2020	103226	Placebo	08OCT2020	Placebo	29OCT2020	Placebo
12351171	C4591001 1235 12351171	16-25	09OCT2020	105940	Placebo	09OCT2020	Placebo	29OCT2020	Placebo
12351172	C4591001 1235 12351172	16-25	09OCT2020	106181	Placebo	09OCT2020	Placebo	28OCT2020	Placebo
12351181	C4591001 1235 12351181	16-25	15OCT2020	107999	Placebo	15OCT2020	Placebo	04NOV2020	Placebo
12351187	C4591001 1235 12351187	16-25	16OCT2020	108004	Placebo	16OCT2020	Placebo		
12351208	C4591001 1235 12351208	16-25	21OCT2020	111582	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
12351209	C4591001 1235 12351209	16-25	21OCT2020	111584	Placebo	21OCT2020	Placebo	09NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12351212	C4591001 1235 12351212	16-25	21OCT2020	111587	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12351217	C4591001 1235 12351217	16-25	23OCT2020	112425	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
12351219	C4591001 1235 12351219	16-25	23OCT2020	112430	Placebo	23OCT2020	Placebo	13NOV2020	Placebo
12351228	C4591001 1235 12351228	16-25	02NOV2020	114686	Placebo	02NOV2020	Placebo	23NOV2020	Placebo
12351230	C4591001 1235 12351230	16-25	03NOV2020	114687	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
12351231	C4591001 1235 12351231	16-25	03NOV2020	114688	BNT162b2 (30 µg)	03NOV2020	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)
12351237	C4591001 1235 12351237	16-25	07DEC2020	117653	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12351240	C4591001 1235 12351240	16-25	07DEC2020	117654	Placebo	07DEC2020	Placebo	30DEC2020	Placebo
12351241	C4591001 1235 12351241	16-25	07DEC2020	117659	BNT162b2 (30 µg)	07DEC2020	BNT162b2 (30 µg)	28DEC2020	BNT162b2 (30 µg)
12411010	C4591001 1241 12411010	16-25	07AUG2020	44717	Placebo	07AUG2020	Placebo	26AUG2020	Placebo
12411011	C4591001 1241 12411011	16-25	07AUG2020	44718	BNT162b2 (30 µg)	07AUG2020	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)
12411028	C4591001 1241 12411028	16-25	10AUG2020	45667	Placebo	10AUG2020	Placebo	31AUG2020	Placebo
12411034	C4591001 1241 12411034	16-25	11AUG2020	45820	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12411036	C4591001 1241 12411036	16-25	11AUG2020	46163	BNT162b2 (30 µg)	11AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411058	C4591001 1241 12411058	16-25	12AUG2020	47362	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12411061	C4591001 1241 12411061	16-25	12AUG2020	47478	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12411063	C4591001 1241 12411063	16-25	12AUG2020	47484	BNT162b2 (30 µg)	12AUG2020	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)
12411088	C4591001 1241 12411088	16-25	13AUG2020	48265	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)
12411095	C4591001 1241 12411095	16-25	13AUG2020	48906	BNT162b2 (30 µg)	13AUG2020	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)
12411127	C4591001 1241 12411127	16-25	14AUG2020	50329	Placebo	14AUG2020	Placebo	04SEP2020	Placebo
12411157	C4591001 1241 12411157	16-25	17AUG2020	52256	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12411171	C4591001 1241 12411171	16-25	17AUG2020	53071	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12411178	C4591001 1241 12411178	16-25	17AUG2020	53077	Placebo	17AUG2020	Placebo	08SEP2020	Placebo
12411205	C4591001 1241 12411205	16-25	18AUG2020	53754	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
12411215	C4591001 1241 12411215	16-25	18AUG2020	53918	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
12411220	C4591001 1241 12411220	16-25	18AUG2020	54074	Placebo	18AUG2020	Placebo	09SEP2020	Placebo
12411233	C4591001 1241 12411233	16-25	18AUG2020	54700	BNT162b2 (30 µg)	18AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12411294	C4591001 1241 12411294	16-25	19AUG2020	56696	Placebo	19AUG2020	Placebo	10SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411303	C4591001 1241 12411303	16-25	19AUG2020	56875	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
12411315	C4591001 1241 12411315	16-25	19AUG2020	57280	Placebo	19AUG2020	Placebo	10SEP2020	Placebo
12411317	C4591001 1241 12411317	16-25	19AUG2020	57475	BNT162b2 (30 µg)	19AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12411347	C4591001 1241 12411347	16-25	20AUG2020	58286	Placebo	20AUG2020	Placebo	10SEP2020	Placebo
12411366	C4591001 1241 12411366	16-25	20AUG2020	58995	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12411372	C4591001 1241 12411372	16-25	20AUG2020	59241	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12411374	C4591001 1241 12411374	16-25	20AUG2020	59247	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)
12411375	C4591001 1241 12411375	16-25	20AUG2020	59345	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12411393	C4591001 1241 12411393	16-25	21AUG2020	59886	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	11SEP2020	BNT162b2 (30 µg)
12411401	C4591001 1241 12411401	16-25	21AUG2020	60069	Placebo	21AUG2020	Placebo	11SEP2020	Placebo
12411415	C4591001 1241 12411415	16-25	24AUG2020	63214	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
12411427	C4591001 1241 12411427	16-25	24AUG2020	63341	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12411445	C4591001 1241 12411445	16-25	24AUG2020	64021	Placebo	24AUG2020	Placebo	14SEP2020	Placebo
12411450	C4591001 1241 12411450	16-25	24AUG2020	64199	Placebo	24AUG2020	Placebo	14SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411461	C4591001 1241 12411461	16-25	24AUG2020	64644	BNT162b2 (30 µg)	24AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12411476	C4591001 1241 12411476	16-25	25AUG2020	65192	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
12411501	C4591001 1241 12411501	16-25	25AUG2020	66563	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12411507	C4591001 1241 12411507	16-25	01SEP2020	76854	Placebo	01SEP2020	Placebo	24SEP2020	Placebo
12411509	C4591001 1241 12411509	16-25	01SEP2020	76860	Placebo	01SEP2020	Placebo	23SEP2020	Placebo
12411527	C4591001 1241 12411527	16-25	01SEP2020	77598	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12411539	C4591001 1241 12411539	16-25	02SEP2020	78405	Placebo	02SEP2020	Placebo	22SEP2020	Placebo
12411542	C4591001 1241 12411542	16-25	02SEP2020	78470	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12411543	C4591001 1241 12411543	16-25	02SEP2020	78463	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12411544	C4591001 1241 12411544	16-25	02SEP2020	78472	Placebo	02SEP2020	Placebo	22SEP2020	Placebo
12411555	C4591001 1241 12411555	16-25	02SEP2020	78754	Placebo	02SEP2020	Placebo	22SEP2020	Placebo
12411556	C4591001 1241 12411556	16-25	02SEP2020	78759	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12411566	C4591001 1241 12411566	16-25	02SEP2020	79117	Placebo	02SEP2020	Placebo	22SEP2020	Placebo
12411600	C4591001 1241 12411600	16-25	03SEP2020	80737	Placebo	03SEP2020	Placebo	25SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411624	C4591001 1241 12411624	16-25	04SEP2020	81632	Placebo	04SEP2020	Placebo	23SEP2020	Placebo
12411645	C4591001 1241 12411645	16-25	04SEP2020	82448	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12411648	C4591001 1241 12411648	16-25	04SEP2020	82455	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12411654	C4591001 1241 12411654	16-25	09SEP2020	85076	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
12411657	C4591001 1241 12411657	16-25	10SEP2020	85082	Placebo	10SEP2020	Placebo	29SEP2020	Placebo
12411662	C4591001 1241 12411662	16-25	10SEP2020	87058	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
12411664	C4591001 1241 12411664	16-25	10SEP2020	87062	Placebo	10SEP2020	Placebo	29SEP2020	Placebo
12411672	C4591001 1241 12411672	16-25	14SEP2020	87364	Placebo	14SEP2020	Placebo	06OCT2020	Placebo
12411673	C4591001 1241 12411673	16-25	14SEP2020	89372	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
12411674	C4591001 1241 12411674	16-25	14SEP2020	89370	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12411678	C4591001 1241 12411678	16-25	14SEP2020	89376	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12411680	C4591001 1241 12411680	16-25	15SEP2020	89646	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12411696	C4591001 1241 12411696	16-25	15SEP2020	90578	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12411698	C4591001 1241 12411698	16-25	15SEP2020	90645	Placebo	15SEP2020	Placebo	05OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411700	C4591001 1241 12411700	16-25	15SEP2020	90652	BNT162b2 (30 µg)	15SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12411725	C4591001 1241 12411725	16-25	16SEP2020	90962	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12411729	C4591001 1241 12411729	16-25	16SEP2020	91067	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12411735	C4591001 1241 12411735	16-25	16SEP2020	91239	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
12411757	C4591001 1241 12411757	16-25	16SEP2020	91592	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
12411773	C4591001 1241 12411773	16-25	16SEP2020	91819	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
12411776	C4591001 1241 12411776	16-25	16SEP2020	91830	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
12411777	C4591001 1241 12411777	16-25	16SEP2020	91832	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12411786	C4591001 1241 12411786	16-25	16SEP2020	91893	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12411791	C4591001 1241 12411791	16-25	17SEP2020	91929	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
12411800	C4591001 1241 12411800	16-25	17SEP2020	91992	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12411805	C4591001 1241 12411805	16-25	17SEP2020	92145	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12411808	C4591001 1241 12411808	16-25	17SEP2020	92151	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
12411827	C4591001 1241 12411827	16-25	17SEP2020	92626	Placebo	17SEP2020	Placebo	08OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411832	C4591001 1241 12411832	16-25	17SEP2020	92754	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12411833	C4591001 1241 12411833	16-25	17SEP2020	92759	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
12411839	C4591001 1241 12411839	16-25	17SEP2020	92810	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12411848	C4591001 1241 12411848	16-25	17SEP2020	92950	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12411850	C4591001 1241 12411850	16-25	17SEP2020	93005	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)
12411858	C4591001 1241 12411858	16-25	17SEP2020	93059	Placebo	17SEP2020	Placebo	06OCT2020	Placebo
12411860	C4591001 1241 12411860	16-25	17SEP2020	93092	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
12411865	C4591001 1241 12411865	16-25	17SEP2020	93131	Placebo	17SEP2020	Placebo	08OCT2020	Placebo
12411871	C4591001 1241 12411871	16-25	17SEP2020	93142	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)
12411880	C4591001 1241 12411880	16-25	18SEP2020	93168	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12411881	C4591001 1241 12411881	16-25	18SEP2020	93225	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12411884	C4591001 1241 12411884	16-25	18SEP2020	93228	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12411885	C4591001 1241 12411885	16-25	18SEP2020	93229	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12411886	C4591001 1241 12411886	16-25	18SEP2020	93284	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411887	C4591001 1241 12411887	16-25	18SEP2020	93311	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12411888	C4591001 1241 12411888	16-25	18SEP2020	93312	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12411889	C4591001 1241 12411889	16-25	18SEP2020	93313	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12411898	C4591001 1241 12411898	16-25	18SEP2020	93437	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12411913	C4591001 1241 12411913	16-25	18SEP2020	93874	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12411914	C4591001 1241 12411914	16-25	18SEP2020	93876	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12411917	C4591001 1241 12411917	16-25	18SEP2020	93930	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12411953	C4591001 1241 12411953	16-25	18SEP2020	94310	Placebo	18SEP2020	Placebo	08OCT2020	Placebo
12411960	C4591001 1241 12411960	16-25	18SEP2020	94365	Placebo	18SEP2020	Placebo	07OCT2020	Placebo
12411961	C4591001 1241 12411961	16-25	18SEP2020	94366	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12411974	C4591001 1241 12411974	16-25	21SEP2020	94640	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
12411975	C4591001 1241 12411975	16-25	21SEP2020	94642	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
12411985	C4591001 1241 12411985	16-25	21SEP2020	94755	Placebo	21SEP2020	Placebo	13OCT2020	Placebo
12411996	C4591001 1241 12411996	16-25	21SEP2020	95179	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12411997	C4591001 1241 12411997	16-25	21SEP2020	95182	Placebo	21SEP2020	Placebo	13OCT2020	Placebo
12412002	C4591001 1241 12412002	16-25	21SEP2020	95250	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
12412014	C4591001 1241 12412014	16-25	21SEP2020	95582	Placebo	21SEP2020	Placebo	14OCT2020	Placebo
12412027	C4591001 1241 12412027	16-25	30SEP2020	101939	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12412032	C4591001 1241 12412032	16-25	30SEP2020	102157	Placebo	30SEP2020	Placebo	19OCT2020	Placebo
12412049	C4591001 1241 12412049	16-25	30SEP2020	102304	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
12412058	C4591001 1241 12412058	16-25	30SEP2020	102453	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)
12412069	C4591001 1241 12412069	16-25	01OCT2020	102501	Placebo	01OCT2020	Placebo	22OCT2020	Placebo
12412072	C4591001 1241 12412072	16-25	01OCT2020	102643	Placebo	01OCT2020	Placebo	22OCT2020	Placebo
12412084	C4591001 1241 12412084	16-25	01OCT2020	102873	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12412090	C4591001 1241 12412090	16-25	01OCT2020	102915	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
12412103	C4591001 1241 12412103	16-25	02OCT2020	102987	Placebo	02OCT2020	Placebo	21OCT2020	Placebo
12412114	C4591001 1241 12412114	16-25	02OCT2020	103129	Placebo	02OCT2020	Placebo	22OCT2020	Placebo
12412135	C4591001 1241 12412135	16-25	02OCT2020	103311	BNT162b2 (30 µg)	02OCT2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12412136	C4591001 1241 12412136	16-25	02OCT2020	103376	Placebo	02OCT2020	Placebo	21OCT2020	Placebo
12412140	C4591001 1241 12412140	16-25	06OCT2020	104192	Placebo	06OCT2020	Placebo	26OCT2020	Placebo
12412141	C4591001 1241 12412141	16-25	06OCT2020	104195	Placebo	06OCT2020	Placebo	26OCT2020	Placebo
12412142	C4591001 1241 12412142	16-25	06OCT2020	104198	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12412159	C4591001 1241 12412159	16-25	07OCT2020	105019	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12412165	C4591001 1241 12412165	16-25	09OCT2020	106075	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12412172	C4591001 1241 12412172	16-25	13OCT2020	107138	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
12412175	C4591001 1241 12412175	16-25	14OCT2020	107185	Placebo	14OCT2020	Placebo	04NOV2020	Placebo
12412188	C4591001 1241 12412188	16-25	14OCT2020	107633	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
12412194	C4591001 1241 12412194	16-25	15OCT2020	108262	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12412198	C4591001 1241 12412198	16-25	15OCT2020	108268	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
12412199	C4591001 1241 12412199	16-25	15OCT2020	108284	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
12412211	C4591001 1241 12412211	16-25	15OCT2020	108407	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	04NOV2020	BNT162b2 (30 µg)
12412218	C4591001 1241 12412218	16-25	15OCT2020	108524	Placebo	15OCT2020	Placebo	06NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12412221	C4591001 1241 12412221	16-25	15OCT2020	108525	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12412227	C4591001 1241 12412227	16-25	16OCT2020	108676	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
12412229	C4591001 1241 12412229	16-25	16OCT2020	108682	Placebo	16OCT2020	Placebo	05NOV2020	Placebo
12412232	C4591001 1241 12412232	16-25	16OCT2020	108683	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
12412256	C4591001 1241 12412256	16-25	16OCT2020	108881	Placebo	16OCT2020	Placebo	05NOV2020	Placebo
12412257	C4591001 1241 12412257	16-25	16OCT2020	108882	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12412262	C4591001 1241 12412262	16-25	16OCT2020	108931	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12412267	C4591001 1241 12412267	16-25	16OCT2020	109097	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)
12412279	C4591001 1241 12412279	16-25	16OCT2020	109238	Placebo	16OCT2020	Placebo	05NOV2020	Placebo
12412294	C4591001 1241 12412294	16-25	16OCT2020	109333	Placebo	16OCT2020	Placebo	05NOV2020	Placebo
12412295	C4591001 1241 12412295	16-25	16OCT2020	109336	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)
12412327	C4591001 1241 12412327	16-25	19OCT2020	109991	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12412328	C4591001 1241 12412328	16-25	19OCT2020	110023	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
12412329	C4591001 1241 12412329	16-25	19OCT2020	110025	Placebo	19OCT2020	Placebo	09NOV2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12412339	C4591001 1241 12412339	16-25	19OCT2020	110174	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
12412344	C4591001 1241 12412344	16-25	19OCT2020	110294	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
12412351	C4591001 1241 12412351	16-25	19OCT2020	110349	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
12412352	C4591001 1241 12412352	16-25	19OCT2020	110350	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12412353	C4591001 1241 12412353	16-25	19OCT2020	110352	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
12412354	C4591001 1241 12412354	16-25	19OCT2020	110360	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
12412373	C4591001 1241 12412373	16-25	19OCT2020	110515	Placebo	19OCT2020	Placebo	09NOV2020	Placebo
12412377	C4591001 1241 12412377	16-25	19OCT2020	110523	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
12412382	C4591001 1241 12412382	16-25	20OCT2020	110669	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)
12412383	C4591001 1241 12412383	16-25	20OCT2020	110672	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
12412396	C4591001 1241 12412396	16-25	20OCT2020	110994	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
12412397	C4591001 1241 12412397	16-25	20OCT2020	110996	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
12412398	C4591001 1241 12412398	16-25	20OCT2020	110999	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
12412399	C4591001 1241 12412399	16-25	20OCT2020	111000	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12412413	C4591001 1241 12412413	16-25	20OCT2020	111151	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	10NOV2020	BNT162b2 (30 µg)
12412419	C4591001 1241 12412419	16-25	20OCT2020	111183	Placebo	20OCT2020	Placebo	10NOV2020	Placebo
12412421	C4591001 1241 12412421	16-25	21OCT2020	111475	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
12412423	C4591001 1241 12412423	16-25	21OCT2020	111479	Placebo	21OCT2020	Placebo	11NOV2020	Placebo
12412444	C4591001 1241 12412444	16-25	22OCT2020	112168	Placebo	22OCT2020	Placebo	11NOV2020	Placebo
12412482	C4591001 1241 12412482	16-25	23OCT2020	112619	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412485	C4591001 1241 12412485	16-25	23OCT2020	112620	Placebo	23OCT2020	Placebo	12NOV2020	Placebo
12412490	C4591001 1241 12412490	16-25	23OCT2020	112699	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12412505	C4591001 1241 12412505	16-25	23OCT2020	112784	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412517	C4591001 1241 12412517	16-25	23OCT2020	112964	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412523	C4591001 1241 12412523	16-25	23OCT2020	112968	Placebo	23OCT2020	Placebo	12NOV2020	Placebo
12412527	C4591001 1241 12412527	16-25	23OCT2020	113036	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412534	C4591001 1241 12412534	16-25	23OCT2020	113066	Placebo	23OCT2020	Placebo	19NOV2020	Placebo
12412537	C4591001 1241 12412537	16-25	23OCT2020	113120	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12412540	C4591001 1241 12412540	16-25	23OCT2020	113126	Placebo	23OCT2020	Placebo	11NOV2020	Placebo
12412546	C4591001 1241 12412546	16-25	23OCT2020	113143	Placebo	23OCT2020	Placebo	12NOV2020	Placebo
12412548	C4591001 1241 12412548	16-25	23OCT2020	113148	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412558	C4591001 1241 12412558	16-25	23OCT2020	113229	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412562	C4591001 1241 12412562	16-25	23OCT2020	113237	BNT162b2 (30 µg)	23OCT2020	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)
12412563	C4591001 1241 12412563	16-25	23OCT2020	113243	Placebo	23OCT2020	Placebo	12NOV2020	Placebo
12412565	C4591001 1241 12412565	16-25	23OCT2020	113248	Placebo	23OCT2020	Placebo	11NOV2020	Placebo
12461018	C4591001 1246 12461018	16-25	27SEP2020	100617	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)
12461019	C4591001 1246 12461019	16-25	27SEP2020	100618	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)
12461026	C4591001 1246 12461026	16-25	28SEP2020	101171	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
12461028	C4591001 1246 12461028	16-25	28SEP2020	101172	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
12461033	C4591001 1246 12461033	16-25	28SEP2020	101212	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
12461038	C4591001 1246 12461038	16-25	29SEP2020	101664	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
12461039	C4591001 1246 12461039	16-25	29SEP2020	101804	Placebo	29SEP2020	Placebo	20OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12461044	C4591001 1246 12461044	16-25	30SEP2020	101808	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)
12461059	C4591001 1246 12461059	16-25	01OCT2020	102667	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
12461065	C4591001 1246 12461065	16-25	02OCT2020	103021	Placebo	02OCT2020	Placebo	23OCT2020	Placebo
12461070	C4591001 1246 12461070	16-25	03OCT2020	103401	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)	24OCT2020	BNT162b2 (30 µg)
12461075	C4591001 1246 12461075	16-25	03OCT2020	103406	Placebo	03OCT2020	Placebo	23OCT2020	Placebo
12461079	C4591001 1246 12461079	16-25	05OCT2020	103530	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12461081	C4591001 1246 12461081	16-25	05OCT2020	103540	Placebo	05OCT2020	Placebo	24OCT2020	Placebo
12461082	C4591001 1246 12461082	16-25	05OCT2020	103579	Placebo	05OCT2020	Placebo	24OCT2020	Placebo
12461084	C4591001 1246 12461084	16-25	05OCT2020	103580	Placebo	05OCT2020	Placebo	26OCT2020	Placebo
12461092	C4591001 1246 12461092	16-25	06OCT2020	104045	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
12461094	C4591001 1246 12461094	16-25	06OCT2020	104050	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
12461095	C4591001 1246 12461095	16-25	06OCT2020	104055	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12461097	C4591001 1246 12461097	16-25	06OCT2020	104117	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
12461098	C4591001 1246 12461098	16-25	06OCT2020	104120	Placebo	06OCT2020	Placebo	27OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12461099	C4591001 1246 12461099	16-25	06OCT2020	104124	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
12461108	C4591001 1246 12461108	16-25	07OCT2020	104528	Placebo	07OCT2020	Placebo	28OCT2020	Placebo
12461109	C4591001 1246 12461109	16-25	07OCT2020	104533	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12461110	C4591001 1246 12461110	16-25	07OCT2020	104534	Placebo	07OCT2020	Placebo	28OCT2020	Placebo
12461112	C4591001 1246 12461112	16-25	08OCT2020	105058	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12461119	C4591001 1246 12461119	16-25	08OCT2020	105163	Placebo	08OCT2020	Placebo	29OCT2020	Placebo
12461121	C4591001 1246 12461121	16-25	09OCT2020	105168	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12461123	C4591001 1246 12461123	16-25	09OCT2020	105617	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12461126	C4591001 1246 12461126	16-25	09OCT2020	105620	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12461127	C4591001 1246 12461127	16-25	09OCT2020	105623	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12461128	C4591001 1246 12461128	16-25	09OCT2020	105624	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	31OCT2020	BNT162b2 (30 µg)
12461129	C4591001 1246 12461129	16-25	09OCT2020	105785	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12461130	C4591001 1246 12461130	16-25	10OCT2020	105786	BNT162b2 (30 µg)	10OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12461133	C4591001 1246 12461133	16-25	10OCT2020	105791	BNT162b2 (30 µg)	10OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12461135	C4591001 1246 12461135	16-25	10OCT2020	106236	BNT162b2 (30 µg)	10OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12461137	C4591001 1246 12461137	16-25	10OCT2020	106238	BNT162b2 (30 µg)	10OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
12461138	C4591001 1246 12461138	16-25	12OCT2020	106256	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
12461139	C4591001 1246 12461139	16-25	12OCT2020	106258	Placebo	12OCT2020	Placebo	02NOV2020	Placebo
12461140	C4591001 1246 12461140	16-25	12OCT2020	106262	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	02NOV2020	BNT162b2 (30 µg)
12471010	C4591001 1247 12471010	16-25	23SEP2020	97187	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
12471011	C4591001 1247 12471011	16-25	24SEP2020	97189	Placebo	24SEP2020	Placebo	14OCT2020	Placebo
12471013	C4591001 1247 12471013	16-25	24SEP2020	98441	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12471022	C4591001 1247 12471022	16-25	24SEP2020	98481	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
12471030	C4591001 1247 12471030	16-25	24SEP2020	98514	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
12471033	C4591001 1247 12471033	16-25	24SEP2020	98524	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
12471036	C4591001 1247 12471036	16-25	24SEP2020	98533	Placebo	24SEP2020	Placebo	15OCT2020	Placebo
12471051	C4591001 1247 12471051	16-25	25SEP2020	99211	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
12471075	C4591001 1247 12471075	16-25	28SEP2020	101298	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12471081	C4591001 1247 12471081	16-25	29SEP2020	101640	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)
12471087	C4591001 1247 12471087	16-25	28SEP2020	99312	Placebo	28SEP2020	Placebo	19OCT2020	Placebo
12471107	C4591001 1247 12471107	16-25	29SEP2020	101729	Placebo	29SEP2020	Placebo	20OCT2020	Placebo
12471121	C4591001 1247 12471121	16-25	30SEP2020	102046	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12471127	C4591001 1247 12471127	16-25	30SEP2020	102059	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12471139	C4591001 1247 12471139	16-25	30SEP2020	102146	Placebo	30SEP2020	Placebo	21OCT2020	Placebo
12471140	C4591001 1247 12471140	16-25	01OCT2020	102547	Placebo	01OCT2020	Placebo	22OCT2020	Placebo
12471143	C4591001 1247 12471143	16-25	01OCT2020	102562	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
12471145	C4591001 1247 12471145	16-25	01OCT2020	102560	Placebo	01OCT2020	Placebo	22OCT2020	Placebo
12471158	C4591001 1247 12471158	16-25	05OCT2020	102682	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12471174	C4591001 1247 12471174	16-25	05OCT2020	103609	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)
12471185	C4591001 1247 12471185	16-25	06OCT2020	104001	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
12471197	C4591001 1247 12471197	16-25	06OCT2020	104042	Placebo	06OCT2020	Placebo	27OCT2020	Placebo
12471198	C4591001 1247 12471198	16-25	06OCT2020	104083	Placebo	06OCT2020	Placebo	27OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12471199	C4591001 1247 12471199	16-25	06OCT2020	104084	BNT162b2 (30 µg)	06OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12471201	C4591001 1247 12471201	16-25	07OCT2020	104477	Placebo	07OCT2020	Placebo	28OCT2020	Placebo
12471203	C4591001 1247 12471203	16-25	07OCT2020	104486	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)	28OCT2020	BNT162b2 (30 µg)
12471218	C4591001 1247 12471218	16-25	08OCT2020	104588	Placebo	08OCT2020	Placebo	28OCT2020	Placebo
12471224	C4591001 1247 12471224	16-25	08OCT2020	105068	Placebo	08OCT2020	Placebo	29OCT2020	Placebo
12471230	C4591001 1247 12471230	16-25	08OCT2020	105072	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)
12471236	C4591001 1247 12471236	16-25	08OCT2020	105088	Placebo	08OCT2020	Placebo	30OCT2020	Placebo
12471237	C4591001 1247 12471237	16-25	08OCT2020	105138	BNT162b2 (30 µg)	08OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12471244	C4591001 1247 12471244	16-25	09OCT2020	105614	Placebo	09OCT2020	Placebo	29OCT2020	Placebo
12471245	C4591001 1247 12471245	16-25	09OCT2020	105616	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)
12471246	C4591001 1247 12471246	16-25	09OCT2020	105641	Placebo	09OCT2020	Placebo	29OCT2020	Placebo
12471248	C4591001 1247 12471248	16-25	09OCT2020	105647	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12471250	C4591001 1247 12471250	16-25	09OCT2020	105652	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
12471252	C4591001 1247 12471252	16-25	09OCT2020	105681	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)	30OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12471253	C4591001 1247 12471253	16-25	09OCT2020	105684	Placebo	09OCT2020	Placebo	30OCT2020	Placebo
12481001	C4591001 1248 12481001	16-25	26AUG2020	68729	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12481004	C4591001 1248 12481004	16-25	26AUG2020	68730	Placebo	26AUG2020	Placebo	15SEP2020	Placebo
12481025	C4591001 1248 12481025	16-25	29AUG2020	73294	BNT162b2 (30 µg)				
12481031	C4591001 1248 12481031	16-25	29AUG2020	73295	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	20SEP2020	BNT162b2 (30 µg)
12481033	C4591001 1248 12481033	16-25	29AUG2020	73889	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	20SEP2020	BNT162b2 (30 µg)
12481038	C4591001 1248 12481038	16-25	30AUG2020	74587	BNT162b2 (30 µg)	30AUG2020	BNT162b2 (30 µg)	20SEP2020	BNT162b2 (30 µg)
12481046	C4591001 1248 12481046	16-25	31AUG2020	74590	Placebo	31AUG2020	Placebo		
12481055	C4591001 1248 12481055	16-25	31AUG2020	75937	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	20SEP2020	BNT162b2 (30 µg)
12481062	C4591001 1248 12481062	16-25	02SEP2020	78224	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12481089	C4591001 1248 12481089	16-25	06SEP2020	82972	Placebo	06SEP2020	Placebo	25SEP2020	Placebo
12481099	C4591001 1248 12481099	16-25	08SEP2020	83030	Placebo	08SEP2020	Placebo	29SEP2020	Placebo
12481102	C4591001 1248 12481102	16-25	08SEP2020	83032	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
12481103	C4591001 1248 12481103	16-25	08SEP2020	84414	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12481106	C4591001 1248 12481106	16-25	09SEP2020	84418	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
12481110	C4591001 1248 12481110	16-25	09SEP2020	84420	Placebo	09SEP2020	Placebo		
12481138	C4591001 1248 12481138	16-25	12SEP2020	89174	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
12481153	C4591001 1248 12481153	16-25	13SEP2020	89283	Placebo	13SEP2020	Placebo	03OCT2020	Placebo
12481154	C4591001 1248 12481154	16-25	13SEP2020	89284	Placebo	13SEP2020	Placebo	03OCT2020	Placebo
12481165	C4591001 1248 12481165	16-25	14SEP2020	89918	Placebo	14SEP2020	Placebo	06OCT2020	Placebo
12481170	C4591001 1248 12481170	16-25	15SEP2020	90549	Placebo	15SEP2020	Placebo	03OCT2020	Placebo
12481178	C4591001 1248 12481178	16-25	15SEP2020	90822	Placebo	15SEP2020	Placebo	06OCT2020	Placebo
12481179	C4591001 1248 12481179	16-25	16SEP2020	90826	Placebo	16SEP2020	Placebo	09OCT2020	Placebo
12481189	C4591001 1248 12481189	16-25	16SEP2020	91716	Placebo	16SEP2020	Placebo	06OCT2020	Placebo
12481193	C4591001 1248 12481193	16-25	17SEP2020	91971	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12481206	C4591001 1248 12481206	16-25	18SEP2020	93859	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)	09OCT2020	BNT162b2 (30 µg)
12481227	C4591001 1248 12481227	16-25	22SEP2020	94596	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
12481234	C4591001 1248 12481234	16-25	22SEP2020	96488	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12481240	C4591001 1248 12481240	16-25	22SEP2020	96496	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
12481246	C4591001 1248 12481246	16-25	05OCT2020	97012	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)	24OCT2020	BNT162b2 (30 µg)
12511032	C4591001 1251 12511032	16-25	22AUG2020	61107	Placebo	22AUG2020	Placebo	11SEP2020	Placebo
12511051	C4591001 1251 12511051	16-25	25AUG2020	64555	BNT162b2 (30 µg)	25AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12511061	C4591001 1251 12511061	16-25	27AUG2020	68850	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)
12511115	C4591001 1251 12511115	16-25	03SEP2020	80600	BNT162b2 (30 µg)	03SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)
12511128	C4591001 1251 12511128	16-25	08SEP2020	83460	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
12511129	C4591001 1251 12511129	16-25	08SEP2020	83463	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	28SEP2020	BNT162b2 (30 µg)
12511140	C4591001 1251 12511140	16-25	09SEP2020	85323	Placebo	09SEP2020	Placebo	30SEP2020	Placebo
12511184	C4591001 1251 12511184	16-25	18SEP2020	92924	Placebo	18SEP2020	Placebo	12OCT2020	Placebo
12511221	C4591001 1251 12511221	16-25	29SEP2020	101885	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)
12521024	C4591001 1252 12521024	16-25	21AUG2020	58240	Placebo	21AUG2020	Placebo	10SEP2020	Placebo
12521036	C4591001 1252 12521036	16-25	08SEP2020	69478	Placebo	08SEP2020	Placebo	28SEP2020	Placebo
12541035	C4591001 1254 12541035	16-25	29AUG2020	74256	BNT162b2 (30 µg)	29AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12541057	C4591001 1254 12541057	16-25	31AUG2020	76258	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
12541104	C4591001 1254 12541104	16-25	05SEP2020	82616	Placebo	05SEP2020	Placebo	26SEP2020	Placebo
12541115	C4591001 1254 12541115	16-25	09SEP2020	84688	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
12541117	C4591001 1254 12541117	16-25	10SEP2020	85459	Placebo	10SEP2020	Placebo	30SEP2020	Placebo
12541121	C4591001 1254 12541121	16-25	10SEP2020	87692	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
12541133	C4591001 1254 12541133	16-25	11SEP2020	88985	Placebo	11SEP2020	Placebo	02OCT2020	Placebo
12541142	C4591001 1254 12541142	16-25	12SEP2020	89228	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)		
12541151	C4591001 1254 12541151	16-25	14SEP2020	89257	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)	03OCT2020	BNT162b2 (30 µg)
12541158	C4591001 1254 12541158	16-25	16SEP2020	91901	Placebo	16SEP2020	Placebo	07OCT2020	Placebo
12541159	C4591001 1254 12541159	16-25	16SEP2020	91904	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)	07OCT2020	BNT162b2 (30 µg)
12541162	C4591001 1254 12541162	16-25	18SEP2020	91905	Placebo	18SEP2020	Placebo	07OCT2020	Placebo
12541171	C4591001 1254 12541171	16-25	23SEP2020	98117	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
12541178	C4591001 1254 12541178	16-25	25SEP2020	100171	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
12541193	C4591001 1254 12541193	16-25	17OCT2020	109678	BNT162b2 (30 µg)	17OCT2020	BNT162b2 (30 µg)	07NOV2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12581022	C4591001 125812581022	16-25	09SEP2020	80355	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
12581023	C4591001 125812581023	16-25	09SEP2020	80356	BNT162b2 (30 µg)	09SEP2020	BNT162b2 (30 µg)	05OCT2020	BNT162b2 (30 µg)
12581034	C4591001 125812581034	16-25	18SEP2020	87769	Placebo	18SEP2020	Placebo	13OCT2020	Placebo
12581038	C4591001 125812581038	16-25	21SEP2020	94623	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
12581039	C4591001 125812581039	16-25	21SEP2020	95225	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
12581049	C4591001 125812581049	16-25	30SEP2020	102271	Placebo	30SEP2020	Placebo	20OCT2020	Placebo
12581060	C4591001 125812581060	16-25	09OCT2020	104268	Placebo	09OCT2020	Placebo	02NOV2020	Placebo
12581065	C4591001 125812581065	16-25	19OCT2020	110214	BNT162b2 (30 µg)	19OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
12581069	C4591001 125812581069	16-25	20OCT2020	110223	BNT162b2 (30 µg)	20OCT2020	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)
12581072	C4591001 125812581072	16-25	27OCT2020	113459	BNT162b2 (30 µg)	27OCT2020	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)
12581073	C4591001 125812581073	16-25	28OCT2020	113462	Placebo	28OCT2020	Placebo	18NOV2020	Placebo
12601004	C4591001 126012601004	16-25	26AUG2020	67234	Placebo	26AUG2020	Placebo	17SEP2020	Placebo
12601009	C4591001 126012601009	16-25	27AUG2020	68648	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	16SEP2020	BNT162b2 (30 µg)
12601017	C4591001 126012601017	16-25	28AUG2020	72252	BNT162b2 (30 µg)	28AUG2020	BNT162b2 (30 µg)	18SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12601022	C4591001 1260 12601022	16-25	28AUG2020	72255	Placebo	28AUG2020	Placebo	16SEP2020	Placebo
12601023	C4591001 1260 12601023	16-25	31AUG2020	74748	Placebo	31AUG2020	Placebo	21SEP2020	Placebo
12601032	C4591001 1260 12601032	16-25	31AUG2020	74752	BNT162b2 (30 µg)	31AUG2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
12601042	C4591001 1260 12601042	16-25	01SEP2020	75314	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)
12601045	C4591001 1260 12601045	16-25	01SEP2020	77025	BNT162b2 (30 µg)	01SEP2020	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)
12601099	C4591001 1260 12601099	16-25	10SEP2020	85935	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
12601126	C4591001 1260 12601126	16-25	17SEP2020	92117	BNT162b2 (30 µg)	17SEP2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
12601132	C4591001 1260 12601132	16-25	18SEP2020	93598	Placebo	18SEP2020	Placebo	09OCT2020	Placebo
12611033	C4591001 1261 12611033	16-25	03SEP2020	79334	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
12611036	C4591001 1261 12611036	16-25	03SEP2020	80364	Placebo	03SEP2020	Placebo	24SEP2020	Placebo
12611047	C4591001 1261 12611047	16-25	04SEP2020	82544	BNT162b2 (30 µg)	04SEP2020	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)
12611082	C4591001 1261 12611082	16-25	14SEP2020	88659	Placebo	14SEP2020	Placebo	05OCT2020	Placebo
12641009	C4591001 1264 12641009	16-25	21AUG2020	58982	BNT162b2 (30 µg)	21AUG2020	BNT162b2 (30 µg)	12SEP2020	BNT162b2 (30 µg)
12641037	C4591001 1264 12641037	16-25	24AUG2020	63862	Placebo	24AUG2020	Placebo	12SEP2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12641051	C4591001 1264 12641051	16-25	26AUG2020	66507	BNT162b2 (30 µg)	26AUG2020	BNT162b2 (30 µg)	14SEP2020	BNT162b2 (30 µg)
12641089	C4591001 1264 12641089	16-25	01SEP2020	75587	Placebo	01SEP2020	Placebo	21SEP2020	Placebo
12641095	C4591001 1264 12641095	16-25	02SEP2020	77258	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	24SEP2020	BNT162b2 (30 µg)
12641119	C4591001 1264 12641119	16-25	08SEP2020	82197	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	30SEP2020	BNT162b2 (30 µg)
12641120	C4591001 1264 12641120	16-25	08SEP2020	83766	BNT162b2 (30 µg)	08SEP2020	BNT162b2 (30 µg)	29SEP2020	BNT162b2 (30 µg)
12641184	C4591001 1264 12641184	16-25	21SEP2020	94288	Placebo	21SEP2020	Placebo	14OCT2020	Placebo
12641215	C4591001 1264 12641215	16-25	21OCT2020	111598	BNT162b2 (30 µg)	21OCT2020	BNT162b2 (30 µg)	09NOV2020	BNT162b2 (30 µg)
12641227	C4591001 1264 12641227	16-25	26OCT2020	113611	BNT162b2 (30 µg)	26OCT2020	BNT162b2 (30 µg)	16NOV2020	BNT162b2 (30 µg)
12651013	C4591001 1265 12651013	16-25	27AUG2020	70255	BNT162b2 (30 µg)	27AUG2020	BNT162b2 (30 µg)	01OCT2020	BNT162b2 (30 µg)
12651082	C4591001 1265 12651082	16-25	09SEP2020	85370	Placebo	09SEP2020	Placebo	28SEP2020	Placebo
12651083	C4591001 1265 12651083	16-25	09SEP2020	86141	Placebo	09SEP2020	Placebo	29SEP2020	Placebo
12691010	C4591001 1269 12691010	16-25	20AUG2020	57163	BNT162b2 (30 µg)	20AUG2020	BNT162b2 (30 µg)	10SEP2020	BNT162b2 (30 µg)
12691047	C4591001 1269 12691047	16-25	25AUG2020	62548	Placebo	25AUG2020	Placebo	15SEP2020	Placebo
12691106	C4591001 1269 12691106	16-25	02SEP2020	79380	BNT162b2 (30 µg)	02SEP2020	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12701048	C4591001 127012701048	16-25	02SEP2020	77702	Placebo	02SEP2020	Placebo	25SEP2020	Placebo
12701146	C4591001 127012701146	16-25	04NOV2020	115666	Placebo	04NOV2020	Placebo	23NOV2020	Placebo
12701147	C4591001 127012701147	16-25	04NOV2020	115667	Placebo	04NOV2020	Placebo	25NOV2020	Placebo
12701148	C4591001 127012701148	16-25	05NOV2020	115668	BNT162b2 (30 µg)	05NOV2020	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)
12701149	C4591001 127012701149	16-25	06NOV2020	115669	BNT162b2 (30 µg)	06NOV2020	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)
12701150	C4591001 127012701150	16-25	06NOV2020	115928	Placebo	06NOV2020	Placebo	25NOV2020	Placebo
12701151	C4591001 127012701151	16-25	11NOV2020	115932	BNT162b2 (30 µg)	11NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
12701152	C4591001 127012701152	16-25	11NOV2020	115933	Placebo	11NOV2020	Placebo	02DEC2020	Placebo
12701153	C4591001 127012701153	16-25	12NOV2020	115934	BNT162b2 (30 µg)	12NOV2020	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)
12701154	C4591001 127012701154	16-25	16NOV2020	116312	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
12701155	C4591001 127012701155	16-25	16NOV2020	116313	Placebo	16NOV2020	Placebo	07DEC2020	Placebo
12701156	C4591001 127012701156	16-25	18NOV2020	116316	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)
12701157	C4591001 127012701157	16-25	18NOV2020	116320	BNT162b2 (30 µg)	18NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)
12701158	C4591001 127012701158	16-25	19NOV2020	116526	BNT162b2 (30 µg)	19NOV2020	BNT162b2 (30 µg)	10DEC2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
12701159	C4591001 1270 12701159	16-25	19NOV2020	116527	Placebo	19NOV2020	Placebo	10DEC2020	Placebo	
12701160	C4591001 1270 12701160	16-25	19NOV2020	116532	Placebo	19NOV2020	Placebo	08DEC2020	Placebo	
12701161	C4591001 1270 12701161	16-25	20NOV2020	116536	BNT162b2 (30 µg)	20NOV2020	BNT162b2 (30 µg)	09DEC2020	BNT162b2 (30 µg)	
12701162	C4591001 1270 12701162	16-25	20NOV2020	116634	Placebo	20NOV2020	Placebo	11DEC2020	Placebo	
12701163	C4591001 1270 12701163	16-25	23NOV2020	116638	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	14DEC2020	BNT162b2 (30 µg)	
12701164	C4591001 1270 12701164	16-25	23NOV2020	116640	Placebo	23NOV2020	Placebo	14DEC2020	Placebo	
12701165	C4591001 1270 12701165	16-25	23NOV2020	116643	BNT162b2 (30 µg)	23NOV2020	BNT162b2 (30 µg)	15DEC2020	BNT162b2 (30 µg)	
12701166	C4591001 1270 12701166	16-25	24NOV2020	116840	Placebo	24NOV2020	Placebo	14DEC2020	Placebo	
12701167	C4591001 1270 12701167	16-25	24NOV2020	116844	Placebo	24NOV2020	Placebo	14DEC2020	Placebo	
12701168	C4591001 1270 12701168	16-25	24NOV2020	116847	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	
12701169	C4591001 1270 12701169	16-25	24NOV2020	116848	BNT162b2 (30 µg)	24NOV2020	BNT162b2 (30 µg)	16DEC2020	BNT162b2 (30 µg)	
12701170	C4591001 1270 12701170	16-25	25NOV2020	116945	Placebo	25NOV2020	Placebo	12JAN2021	Placebo	
12701171	C4591001 1270 12701171	16-25	25NOV2020	116947	Placebo	25NOV2020	Placebo	18DEC2020	Placebo	
12701172	C4591001 1270 12701172	16-25	25NOV2020	116950	BNT162b2 (30 µg)	25NOV2020	BNT162b2 (30 µg)	18DEC2020	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
12701175	C4591001 1270 12701175	16-25	01DEC2020	116952	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12701176	C4591001 1270 12701176	16-25	01DEC2020	117139	BNT162b2 (30 µg)	01DEC2020	BNT162b2 (30 µg)	21DEC2020	BNT162b2 (30 µg)
12701178	C4591001 1270 12701178	16-25	01DEC2020	117141	Placebo	01DEC2020	Placebo	22DEC2020	Placebo
12701179	C4591001 1270 12701179	16-25	02DEC2020	117146	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
12701182	C4591001 1270 12701182	16-25	02DEC2020	117147	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
12701183	C4591001 1270 12701183	16-25	02DEC2020	117270	Placebo	02DEC2020	Placebo	23DEC2020	Placebo
12701185	C4591001 1270 12701185	16-25	02DEC2020	117273	BNT162b2 (30 µg)	02DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
12701186	C4591001 1270 12701186	16-25	03DEC2020	117274	BNT162b2 (30 µg)	03DEC2020	BNT162b2 (30 µg)	22DEC2020	BNT162b2 (30 µg)
12701190	C4591001 1270 12701190	16-25	03DEC2020	117277	Placebo	03DEC2020	Placebo	23DEC2020	Placebo
12701193	C4591001 1270 12701193	16-25	04DEC2020	117619	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	23DEC2020	BNT162b2 (30 µg)
12701195	C4591001 1270 12701195	16-25	04DEC2020	117624	BNT162b2 (30 µg)	04DEC2020	BNT162b2 (30 µg)	24DEC2020	BNT162b2 (30 µg)
12701196	C4591001 1270 12701196	16-25	04DEC2020	117625	Placebo	04DEC2020	Placebo	24DEC2020	Placebo
12701197	C4591001 1270 12701197	16-25	07DEC2020	117626	Placebo	07DEC2020	Placebo	29DEC2020	Placebo
44441004	C4591001 4444 44441004	16-25	21SEP2020	94858	Placebo	21SEP2020	Placebo	13OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Date	Vaccine Received			
							Dose 1	Date	Dose 2	
44441016	C4591001 4444 44441016	16-25	21SEP2020	94859	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	
44441020	C4591001 4444 44441020	16-25	21SEP2020	94873	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	
44441023	C4591001 4444 44441023	16-25	21SEP2020	94905	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	
44441045	C4591001 4444 44441045	16-25	21SEP2020	95032	Placebo	21SEP2020	Placebo	13OCT2020	Placebo	
44441064	C4591001 4444 44441064	16-25	21SEP2020	95143	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	
44441065	C4591001 4444 44441065	16-25	21SEP2020	95213	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)	
44441106	C4591001 4444 44441106	16-25	21SEP2020	95398	Placebo	21SEP2020	Placebo	12OCT2020	Placebo	
44441115	C4591001 4444 44441115	16-25	21SEP2020	95445	Placebo	21SEP2020	Placebo	12OCT2020	Placebo	
44441147	C4591001 4444 44441147	16-25	21SEP2020	95620	Placebo	21SEP2020	Placebo	13OCT2020	Placebo	
44441150	C4591001 4444 44441150	16-25	21SEP2020	95662	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	
44441160	C4591001 4444 44441160	16-25	21SEP2020	95653	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	
44441171	C4591001 4444 44441171	16-25	21SEP2020	95692	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	
44441198	C4591001 4444 44441198	16-25	21SEP2020	95781	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	
44441203	C4591001 4444 44441203	16-25	21SEP2020	95755	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)	

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44441223	C4591001 4444 44441223	16-25	21SEP2020	95797	BNT162b2 (30 µg)	21SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
44441225	C4591001 4444 44441225	16-25	21SEP2020	95833	Placebo	21SEP2020	Placebo	12OCT2020	Placebo
44441278	C4591001 4444 44441278	16-25	22SEP2020	95947	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
44441284	C4591001 4444 44441284	16-25	22SEP2020	95954	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
44441304	C4591001 4444 44441304	16-25	22SEP2020	95996	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
44441329	C4591001 4444 44441329	16-25	22SEP2020	96030	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
44441334	C4591001 4444 44441334	16-25	22SEP2020	96060	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441353	C4591001 4444 44441353	16-25	22SEP2020	96157	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
44441360	C4591001 4444 44441360	16-25	22SEP2020	96173	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
44441365	C4591001 4444 44441365	16-25	22SEP2020	96224	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441388	C4591001 4444 44441388	16-25	22SEP2020	96464	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
44441395	C4591001 4444 44441395	16-25	22SEP2020	96401	Placebo	22SEP2020	Placebo	14OCT2020	Placebo
44441401	C4591001 4444 44441401	16-25	22SEP2020	96405	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
44441435	C4591001 4444 44441435	16-25	22SEP2020	96697	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44441444	C4591001 4444 44441444	16-25	22SEP2020	96692	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
44441446	C4591001 4444 44441446	16-25	22SEP2020	96672	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
44441485	C4591001 4444 44441485	16-25	22SEP2020	96843	Placebo	22SEP2020	Placebo	13OCT2020	Placebo
44441490	C4591001 4444 44441490	16-25	22SEP2020	96811	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
44441498	C4591001 4444 44441498	16-25	22SEP2020	96845	BNT162b2 (30 µg)	22SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
44441510	C4591001 4444 44441510	16-25	22SEP2020	96921	Placebo	22SEP2020	Placebo	12OCT2020	Placebo
44441524	C4591001 4444 44441524	16-25	22SEP2020	96954	Placebo	22SEP2020	Placebo	14OCT2020	Placebo
44441556	C4591001 4444 44441556	16-25	23SEP2020	97199	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441593	C4591001 4444 44441593	16-25	23SEP2020	97364	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
44441612	C4591001 4444 44441612	16-25	23SEP2020	97376	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441617	C4591001 4444 44441617	16-25	23SEP2020	97407	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441640	C4591001 4444 44441640	16-25	23SEP2020	97614	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	22OCT2020	BNT162b2 (30 µg)
44441654	C4591001 4444 44441654	16-25	23SEP2020	97633	Placebo	23SEP2020	Placebo	15OCT2020	Placebo
44441668	C4591001 4444 44441668	16-25	23SEP2020	97649	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44441686	C4591001 4444 44441686	16-25	23SEP2020	97726	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	12OCT2020	BNT162b2 (30 µg)
44441688	C4591001 4444 44441688	16-25	23SEP2020	97731	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	13OCT2020	BNT162b2 (30 µg)
44441699	C4591001 4444 44441699	16-25	23SEP2020	97945	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441705	C4591001 4444 44441705	16-25	23SEP2020	97816	Placebo	23SEP2020	Placebo	14OCT2020	Placebo
44441721	C4591001 4444 44441721	16-25	23SEP2020	97952	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441724	C4591001 4444 44441724	16-25	23SEP2020	97953	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441726	C4591001 4444 44441726	16-25	23SEP2020	98045	Placebo	23SEP2020	Placebo	12OCT2020	Placebo
44441779	C4591001 4444 44441779	16-25	23SEP2020	98356	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441782	C4591001 4444 44441782	16-25	23SEP2020	98346	Placebo	23SEP2020	Placebo	15OCT2020	Placebo
44441791	C4591001 4444 44441791	16-25	23SEP2020	98367	BNT162b2 (30 µg)	23SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441800	C4591001 4444 44441800	16-25	25SEP2020	99273	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44441807	C4591001 4444 44441807	16-25	25SEP2020	99320	Placebo	25SEP2020	Placebo	15OCT2020	Placebo
44441837	C4591001 4444 44441837	16-25	25SEP2020	99387	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44441851	C4591001 4444 44441851	16-25	25SEP2020	99417	Placebo	25SEP2020	Placebo	15OCT2020	Placebo

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44441857	C4591001 4444 44441857	16-25	25SEP2020	99525	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441874	C4591001 4444 44441874	16-25	25SEP2020	99527	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441878	C4591001 4444 44441878	16-25	25SEP2020	99528	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
44441885	C4591001 4444 44441885	16-25	25SEP2020	99596	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44441891	C4591001 4444 44441891	16-25	25SEP2020	99612	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
44441893	C4591001 4444 44441893	16-25	25SEP2020	99603	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
44441895	C4591001 4444 44441895	16-25	25SEP2020	99614	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441903	C4591001 4444 44441903	16-25	25SEP2020	99641	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441910	C4591001 4444 44441910	16-25	25SEP2020	99739	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441915	C4591001 4444 44441915	16-25	25SEP2020	99744	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441925	C4591001 4444 44441925	16-25	25SEP2020	99787	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
44441937	C4591001 4444 44441937	16-25	25SEP2020	99821	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44441956	C4591001 4444 44441956	16-25	25SEP2020	100092	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
44441965	C4591001 4444 44441965	16-25	25SEP2020	100166	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44441969	C4591001 4444 44441969	16-25	25SEP2020	100246	Placebo	25SEP2020	Placebo	14OCT2020	Placebo
44441973	C4591001 4444 44441973	16-25	25SEP2020	100158	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	29OCT2020	BNT162b2 (30 µg)
44441976	C4591001 4444 44441976	16-25	25SEP2020	100193	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441982	C4591001 4444 44441982	16-25	25SEP2020	100209	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44441997	C4591001 4444 44441997	16-25	25SEP2020	100271	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442006	C4591001 4444 44442006	16-25	25SEP2020	100304	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44442007	C4591001 4444 44442007	16-25	25SEP2020	100302	Placebo	25SEP2020	Placebo	16OCT2020	Placebo
44442025	C4591001 4444 44442025	16-25	25SEP2020	100433	Placebo	25SEP2020	Placebo	14OCT2020	Placebo
44442028	C4591001 4444 44442028	16-25	25SEP2020	100389	BNT162b2 (30 µg)	25SEP2020	BNT162b2 (30 µg)	14OCT2020	BNT162b2 (30 µg)
44442062	C4591001 4444 44442062	16-25	27SEP2020	100661	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442081	C4591001 4444 44442081	16-25	27SEP2020	100681	Placebo	27SEP2020	Placebo	15OCT2020	Placebo
44442135	C4591001 4444 44442135	16-25	27SEP2020	100777	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442155	C4591001 4444 44442155	16-25	27SEP2020	100796	Placebo	27SEP2020	Placebo	16OCT2020	Placebo
44442158	C4591001 4444 44442158	16-25	27SEP2020	100834	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)

**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44442186	C4591001 4444 44442186	16-25	27SEP2020	100868	Placebo	27SEP2020	Placebo	16OCT2020	Placebo
44442188	C4591001 4444 44442188	16-25	27SEP2020	100867	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442196	C4591001 4444 44442196	16-25	27SEP2020	100889	Placebo	27SEP2020	Placebo	15OCT2020	Placebo
44442203	C4591001 4444 44442203	16-25	27SEP2020	100904	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44442214	C4591001 4444 44442214	16-25	27SEP2020	100930	Placebo	27SEP2020	Placebo	16OCT2020	Placebo
44442217	C4591001 4444 44442217	16-25	27SEP2020	100932	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442219	C4591001 4444 44442219	16-25	27SEP2020	100947	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442230	C4591001 4444 44442230	16-25	27SEP2020	100948	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44442234	C4591001 4444 44442234	16-25	27SEP2020	100963	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44442236	C4591001 4444 44442236	16-25	27SEP2020	100975	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	15OCT2020	BNT162b2 (30 µg)
44442252	C4591001 4444 44442252	16-25	27SEP2020	101025	Placebo	27SEP2020	Placebo	16OCT2020	Placebo
44442256	C4591001 4444 44442256	16-25	27SEP2020	101020	Placebo	27SEP2020	Placebo	15OCT2020	Placebo
44442261	C4591001 4444 44442261	16-25	27SEP2020	101029	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44442263	C4591001 4444 44442263	16-25	27SEP2020	101027	Placebo	27SEP2020	Placebo		

090177e196ac3a63\Final\Final On: 31-Mar-2021 13:00 (GMT)



**16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Subjects 12 Through 25 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date	Dose 1	Date	Dose 2
44442284	C4591001 4444 44442284	16-25	27SEP2020	101074	Placebo	27SEP2020	Placebo	15OCT2020	Placebo
44442308	C4591001 4444 44442308	16-25	27SEP2020	101111	Placebo	27SEP2020	Placebo	15OCT2020	Placebo
44442312	C4591001 4444 44442312	16-25	27SEP2020	101131	BNT162b2 (30 µg)	27SEP2020	BNT162b2 (30 µg)	16OCT2020	BNT162b2 (30 µg)
44442321	C4591001 4444 44442321	16-25	27SEP2020	101152	Placebo	27SEP2020	Placebo	16OCT2020	Placebo

Note: † = Human immunodeficiency virus (HIV)-positive subject.

a. Subject Study Identifier = the subject study identifier is the current study 4-digit site number followed by unique 4-digit subject identifier.

PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (00:54)

(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2\_unblinded/C4591001\_BLA/adsl\_1003\_ped

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10011085	C4591001 1001 10011085	16-55	28JUL2020	40018	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011086	C4591001 1001 10011086	16-55	28JUL2020	40021	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10011087	C4591001 1001 10011087	16-55	28JUL2020	40032	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10011088	C4591001 1001 10011088	16-55	28JUL2020	40047	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10011089	C4591001 1001 10011089	16-55	28JUL2020	40070	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10011091	C4591001 1001 10011091	16-55	29JUL2020	40171	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011092	C4591001 1001 10011092	16-55	29JUL2020	40172	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10011095	C4591001 1001 10011095	16-55	29JUL2020	40178	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011101	C4591001 1001 10011101	16-55	30JUL2020	40180	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10011102	C4591001 1001 10011102	16-55	30JUL2020	40541	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031088	C4591001 1003 10031088	16-55	27JUL2020	40003	Placebo	27JUL2020/ Placebo	17AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10031090	C4591001 1003 10031090	16-55	27JUL2020	40006	BNT162b2 (30 µg)	27JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10031094	C4591001 1003 10031094	16-55	28JUL2020	40009	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10031096	C4591001 1003 10031096	16-55	28JUL2020	40013	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10031097	C4591001 1003 10031097	16-55	28JUL2020	40017	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10031100	C4591001 1003 10031100	16-55	28JUL2020	40037	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10031101	C4591001 1003 10031101	16-55	28JUL2020	40043	Placebo	28JUL2020/ Placebo	18AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10031104	C4591001 1003 10031104	16-55	29JUL2020	40145	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10031111	C4591001 1003 10031111	16-55	30JUL2020	40149	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10031115	C4591001 1003 10031115	16-55	30JUL2020	40151	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071080	C4591001 1007 10071080	16-55	28JUL2020	40012	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071082	C4591001 1007 10071082	16-55	28JUL2020	40035	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo		
10071083	C4591001 1007 10071083	16-55	28JUL2020	40026	Placebo	28JUL2020/ Placebo	17AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071087	C4591001 1007 10071087	16-55	29JUL2020	40111	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071089	C4591001 1007 10071089	16-55	29JUL2020	40113	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071092	C4591001 1007 10071092	16-55	29JUL2020	40117	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10071093	C4591001 1007 10071093	16-55	29JUL2020	40120	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10071095	C4591001 1007 10071095	16-55	30JUL2020	40422	Placebo	30JUL2020/ Placebo	17AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10071096	C4591001 1007 10071096	16-55	30JUL2020	40425	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10071097	C4591001 1007 10071097	16-55	30JUL2020	40427	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071100	C4591001 1007 10071100	16-55	30JUL2020	40430	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10071102	C4591001 1007 10071102	16-55	30JUL2020	40639	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10131002	C4591001 1013 10131002	16-55	28JUL2020	40033	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10131003	C4591001 1013 10131003	16-55	28JUL2020	40056	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131005	C4591001 1013 10131005	16-55	28JUL2020	40063	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10131006	C4591001 1013 10131006	16-55	28JUL2020	40057	Placebo	28JUL2020/ Placebo	19AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131007	C4591001 1013 10131007	16-55	28JUL2020	40044	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10131008	C4591001 1013 10131008	16-55	28JUL2020	40060	BNT162b2 (30 µg)	28JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10131009	C4591001 1013 10131009	16-55	28JUL2020	40050	Placebo	28JUL2020/ Placebo	17AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131010	C4591001 1013 10131010	16-55	29JUL2020	40087	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131011	C4591001 1013 10131011	16-55	29JUL2020	40085	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131012	C4591001 1013 10131012	16-55	29JUL2020	40129	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131013	C4591001 1013 10131013	16-55	29JUL2020	40123	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10131014	C4591001 1013 10131014	16-55	29JUL2020	40092	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131015	C4591001 1013 10131015	16-55	29JUL2020	40124	Placebo	29JUL2020/ Placebo	20AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131016	C4591001 1013 10131016	16-55	29JUL2020	40094	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10131018	C4591001 1013 10131018	16-55	30JUL2020	40402	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131019	C4591001 1013 10131019	16-55	30JUL2020	40398	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131020	C4591001 1013 10131020	16-55	30JUL2020	40404	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131021	C4591001 1013 10131021	16-55	30JUL2020	40407	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131022	C4591001 1013 10131022	16-55	30JUL2020	40417	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131023	C4591001 1013 10131023	16-55	30JUL2020	40413	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131024	C4591001 1013 10131024	16-55	30JUL2020	40416	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131025	C4591001 1013 10131025	16-55	30JUL2020	40419	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131026	C4591001 1013 10131026	16-55	30JUL2020	40493	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10131030	C4591001 1013 10131030	16-55	30JUL2020	40497	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10131031	C4591001 1013 10131031	16-55	30JUL2020	40500	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10131032	C4591001 1013 10131032	16-55	30JUL2020	40504	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10161003	C4591001 1016 10161003	16-55	29JUL2020	40137	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161004	C4591001 1016 10161004	16-55	29JUL2020	40139	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161005	C4591001 1016 10161005	16-55	29JUL2020	40142	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10161006	C4591001 1016 10161006	16-55	29JUL2020	40144	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10161009	C4591001 1016 10161009	16-55	30JUL2020	40433	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10161010	C4591001 1016 10161010	16-55	30JUL2020	40434	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10161014	C4591001 1016 10161014	16-55	30JUL2020	40440	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo		
10181001	C4591001 1018 10181001	16-55	29JUL2020	40193	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10181003	C4591001 1018 10181003	16-55	29JUL2020	40194	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	
10181007	C4591001 1018 10181007	16-55	29JUL2020	40199	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10421001	C4591001 1042 10421001	16-55	29JUL2020	40290	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10421003	C4591001 1042 10421003	16-55	29JUL2020	40293	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421004	C4591001 1042 10421004	16-55	29JUL2020	40295	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10421008	C4591001 1042 10421008	16-55	30JUL2020	40296	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10731006	C4591001 1073 10731006	16-55	30JUL2020	40529	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10731008	C4591001 1073 10731008	16-55	30JUL2020	40530	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10731009	C4591001 1073 10731009	16-55	30JUL2020	40535	Placebo	30JUL2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10731012	C4591001 1073 10731012	16-55	30JUL2020	40537	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10731013	C4591001 1073 10731013	16-55	30JUL2020	40722	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10791002	C4591001 1079 10791002	16-55	29JUL2020	40279	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791003	C4591001 1079 10791003	16-55	29JUL2020	40282	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
10791004	C4591001 1079 10791004	16-55	29JUL2020	40283	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791007	C4591001 1079 10791007	16-55	29JUL2020	40285	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10791008	C4591001 1079 10791008	16-55	29JUL2020	40301	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10791010	C4591001 1079 10791010	16-55	30JUL2020	40303	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10791013	C4591001 1079 10791013	16-55	30JUL2020	40306	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821003	C4591001 1082 10821003	16-55	30JUL2020	40519	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10821004	C4591001 1082 10821004	16-55	30JUL2020	40521	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10831001	C4591001 1083 10831001	16-55	29JUL2020	40326	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10831002	C4591001 1083 10831002	16-55	29JUL2020	40331	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10831004	C4591001 1083 10831004	16-55	29JUL2020	40333	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10831005	C4591001 1083 10831005	16-55	29JUL2020	40336	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831006	C4591001 1083 10831006	16-55	29JUL2020	40362	Placebo	29JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10841001	C4591001 1084 10841001	16-55	30JUL2020	40590	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10841003	C4591001 1084 10841003	16-55	30JUL2020	40591	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10851003	C4591001 1085 10851003	16-55	30JUL2020	40554	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo		
10851004	C4591001 1085 10851004	16-55	30JUL2020	40555	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10891011	C4591001 1089 10891011	16-55	30JUL2020	40567	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10891013	C4591001 1089 10891013	16-55	30JUL2020	40569	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10891015	C4591001 1089 10891015	16-55	30JUL2020	40572	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951001	C4591001 1095 10951001	16-55	30JUL2020	40449	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10951002	C4591001 1095 10951002	16-55	30JUL2020	40445	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951005	C4591001 1095 10951005	16-55	30JUL2020	40452	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10951006	C4591001 1095 10951006	16-55	30JUL2020	40455	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10951007	C4591001 1095 10951007	16-55	30JUL2020	40697	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071003	C4591001 1107 11071003	16-55	29JUL2020	40317	Placebo	29JUL2020/ Placebo	18AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11071006	C4591001 1107 11071006	16-55	30JUL2020	40319	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11071010	C4591001 1107 11071010	16-55	30JUL2020	40320	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
11091001	C4591001 1109 11091001	16-55	29JUL2020	40243	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11091002	C4591001 1109 11091002	16-55	29JUL2020	40249	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11091003	C4591001 1109 11091003	16-55	29JUL2020	40244	Placebo	29JUL2020/ Placebo	18AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091004	C4591001 1109 11091004	16-55	29JUL2020	40266	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091006	C4591001 1109 11091006	16-55	29JUL2020	40251	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091007	C4591001 1109 11091007	16-55	29JUL2020	40267	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091010	C4591001 1109 11091010	16-55	29JUL2020	40271	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11091011	C4591001 1109 11091011	16-55	29JUL2020	40270	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11091013	C4591001 1109 11091013	16-55	29JUL2020	40339	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091014	C4591001 1109 11091014	16-55	29JUL2020	40343	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091015	C4591001 1109 11091015	16-55	29JUL2020	40346	Placebo	29JUL2020/ Placebo	18AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091016	C4591001 1109 11091016	16-55	30JUL2020	40382	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11091017	C4591001 1109 11091017	16-55	30JUL2020	40348	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11091018	C4591001 1109 11091018	16-55	30JUL2020	40373	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091019	C4591001 1109 11091019	16-55	30JUL2020	40377	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091020	C4591001 1109 11091020	16-55	30JUL2020	40384	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11091021	C4591001 1109 11091021	16-55	30JUL2020	40387	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091022	C4591001 1109 11091022	16-55	30JUL2020	40388	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091023	C4591001 1109 11091023	16-55	30JUL2020	40394	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091024	C4591001 1109 11091024	16-55	30JUL2020	40396	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11091027	C4591001 1109 11091027	16-55	30JUL2020	40505	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091028	C4591001 1109 11091028	16-55	30JUL2020	40506	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091030	C4591001 1109 11091030	16-55	30JUL2020	40507	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		
11091033	C4591001 1109 11091033	16-55	30JUL2020	40515	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111001	C4591001 1111 11111001	16-55	30JUL2020	40473	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121004	C4591001 1112 11121004	16-55	29JUL2020	40208	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121006	C4591001 1112 11121006	16-55	29JUL2020	40214	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11121008	C4591001 1112 11121008	16-55	29JUL2020	40215	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo		
11121009	C4591001 1112 11121009	16-55	30JUL2020	40216	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11121011	C4591001 1112 11121011	16-55	30JUL2020	40482	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11121012	C4591001 1112 11121012	16-55	30JUL2020	40485	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121013	C4591001 1112 11121013	16-55	30JUL2020	40486	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121015	C4591001 1112 11121015	16-55	30JUL2020	40674	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121016	C4591001 1112 11121016	16-55	30JUL2020	40487	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201001	C4591001 1120 11201001	16-55	29JUL2020	40349	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11231001	C4591001 1123 11231001	16-55	29JUL2020	40221	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11231002	C4591001 1123 11231002	16-55	30JUL2020	40223	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		
11231003	C4591001 1123 11231003	16-55	30JUL2020	40225	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271004	C4591001 1127 11271004	16-55	29JUL2020	40230	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11271011	C4591001 1127 11271011	16-55	30JUL2020	40234	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271014	C4591001 1127 11271014	16-55	30JUL2020	40613	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271015	C4591001 1127 11271015	16-55	30JUL2020	40235	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271016	C4591001 1127 11271016	16-55	30JUL2020	40238	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271017	C4591001 1127 11271017	16-55	30JUL2020	40619	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291001	C4591001 1129 11291001	16-55	29JUL2020	40183	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11291005	C4591001 1129 11291005	16-55	29JUL2020	40184	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11291006	C4591001 1129 11291006	16-55	29JUL2020	40188	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11291010	C4591001 1129 11291010	16-55	30JUL2020	40192	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11291014	C4591001 1129 11291014	16-55	30JUL2020	40626	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11331001	C4591001 1133 11331001	16-55	30JUL2020	40463	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331003	C4591001 1133 11331003	16-55	30JUL2020	40466	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331004	C4591001 1133 11331004	16-55	30JUL2020	40465	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331011	C4591001 1133 11331011	16-55	30JUL2020	40467	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331014	C4591001 1133 11331014	16-55	30JUL2020	40650	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331016	C4591001 1133 11331016	16-55	30JUL2020	40651	Placebo	30JUL2020/ Placebo	24AUG2020/ Placebo		
11391001	C4591001 1139 11391001	16-55	29JUL2020	40075	Placebo	29JUL2020/ Placebo	20AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11391007	C4591001 1139 11391007	16-55	29JUL2020	40076	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11391010	C4591001 1139 11391010	16-55	29JUL2020	40078	Placebo	29JUL2020/ Placebo	20AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11391015	C4591001 1139 11391015	16-55	30JUL2020	40084	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11401001	C4591001 1140 11401001	16-55	29JUL2020	40099	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11401006	C4591001 1140 11401006	16-55	30JUL2020	40103	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11421001	C4591001 1142 11421001	16-55	29JUL2020	40157	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		
11421002	C4591001 1142 11421002	16-55	29JUL2020	40160	Placebo	29JUL2020/ Placebo	19AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11421004	C4591001 1142 11421004	16-55	29JUL2020	40167	BNT162b2 (30 µg)	29JUL2020/ BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421007	C4591001 1142 11421007	16-55	29JUL2020	40168	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421008	C4591001 1142 11421008	16-55	29JUL2020	40254	Placebo	29JUL2020/ Placebo	17AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11421010	C4591001 1142 11421010	16-55	30JUL2020	40259	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421011	C4591001 1142 11421011	16-55	30JUL2020	40261	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11421014	C4591001 1142 11421014	16-55	30JUL2020	40264	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11421015	C4591001 1142 11421015	16-55	30JUL2020	40607	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11421016	C4591001 1142 11421016	16-55	30JUL2020	40610	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11471001	C4591001 1147 11471001	16-55	30JUL2020	40577	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo		
10011083	C4591001 1001 10011083	16-55	31JUL2020	40545	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011105	C4591001 1001 10011105	16-55	31JUL2020	40547	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10011106	C4591001 1001 10011106	16-55	31JUL2020	40552	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10011107	C4591001 1001 10011107	16-55	31JUL2020	41035	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10011113	C4591001 1001 10011113	16-55	03AUG2020	41039	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10011125	C4591001 1001 10011125	16-55	04AUG2020	41040	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10011126	C4591001 1001 10011126	16-55	04AUG2020	41042	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10011129	C4591001 1001 10011129	16-55	05AUG2020	42967	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10011130	C4591001 1001 10011130	16-55	05AUG2020	42969	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10011131	C4591001 1001 10011131	16-55	05AUG2020	42976	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10011132	C4591001 1001 10011132	16-55	05AUG2020	42973	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10011135	C4591001 1001 10011135	16-55	05AUG2020	43218	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10011136	C4591001 1001 10011136	16-55	06AUG2020	43219	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10011138	C4591001 1001 10011138	16-55	06AUG2020	43225	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10011143	C4591001 1001 10011143	16-55	06AUG2020	43877	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10011145	C4591001 1001 10011145	16-55	07AUG2020	43878	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10011146	C4591001 1001 10011146	16-55	07AUG2020	43882	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10011149	C4591001 1001 10011149	16-55	07AUG2020	43887	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10031116	C4591001 1003 10031116	16-55	30JUL2020	40153	Placebo	30JUL2020/ Placebo	21AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10031122	C4591001 1003 10031122	16-55	31JUL2020	40819	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10031124	C4591001 1003 10031124	16-55	31JUL2020	40820	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10031125	C4591001 1003 10031125	16-55	31JUL2020	40823	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031137	C4591001 1003 10031137	16-55	04AUG2020	40828	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031138	C4591001 1003 10031138	16-55	04AUG2020	42130	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031141	C4591001 1003 10031141	16-55	04AUG2020	42133	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10031144	C4591001 1003 10031144	16-55	04AUG2020	42522	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031146	C4591001 1003 10031146	16-55	05AUG2020	42524	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10031147	C4591001 1003 10031147	16-55	05AUG2020	42526	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10031151	C4591001 1003 10031151	16-55	05AUG2020	42529	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10031155	C4591001 1003 10031155	16-55	06AUG2020	43470	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10031156	C4591001 1003 10031156	16-55	06AUG2020	43474	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10031158	C4591001 1003 10031158	16-55	06AUG2020	43479	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031160	C4591001 1003 10031160	16-55	06AUG2020	43480	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10031161	C4591001 1003 10031161	16-55	07AUG2020	44214	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10031162	C4591001 1003 10031162	16-55	07AUG2020	44217	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10031166	C4591001 1003 10031166	16-55	07AUG2020	44221	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10031170	C4591001 1003 10031170	16-55	10AUG2020	44224	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10031171	C4591001 1003 10031171	16-55	10AUG2020	45113	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10031174	C4591001 1003 10031174	16-55	10AUG2020	45115	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10031175	C4591001 1003 10031175	16-55	10AUG2020	45118	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10031177	C4591001 1003 10031177	16-55	10AUG2020	45122	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10031179	C4591001 1003 10031179	16-55	11AUG2020	46111	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031180	C4591001 1003 10031180	16-55	11AUG2020	46116	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10031183	C4591001 1003 10031183	16-55	11AUG2020	46117	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10031184	C4591001 1003 10031184	16-55	11AUG2020	46119	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10031186	C4591001 1003 10031186	16-55	12AUG2020	47001	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10031187	C4591001 1003 10031187	16-55	12AUG2020	47003	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10031190	C4591001 1003 10031190	16-55	12AUG2020	47004	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10031191	C4591001 1003 10031191	16-55	12AUG2020	47008	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10031194	C4591001 1003 10031194	16-55	13AUG2020	48774	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031196	C4591001 1003 10031196	16-55	13AUG2020	48776	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10031197	C4591001 1003 10031197	16-55	13AUG2020	48777	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031198	C4591001 1003 10031198	16-55	13AUG2020	48779	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031199	C4591001 1003 10031199	16-55	13AUG2020	49242	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031201	C4591001 1003 10031201	16-55	13AUG2020	49250	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10031203	C4591001 1003 10031203	16-55	14AUG2020	49251	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10031204	C4591001 1003 10031204	16-55	14AUG2020	49252	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10031205	C4591001 1003 10031205	16-55	14AUG2020	49868	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10031206	C4591001 1003 10031206	16-55	14AUG2020	49870	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10031207	C4591001 1003 10031207	16-55	14AUG2020	49872	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10051002	C4591001 1005 10051002	16-55	07AUG2020	44385	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10051003	C4591001 1005 10051003	16-55	07AUG2020	44387	Placebo	07AUG2020/ Placebo	30AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051004	C4591001 1005 10051004	16-55	10AUG2020	44389	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10051007	C4591001 1005 10051007	16-55	10AUG2020	44392	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10051008	C4591001 1005 10051008	16-55	10AUG2020	45368	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051015	C4591001 1005 10051015	16-55	10AUG2020	45372	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10051016	C4591001 1005 10051016	16-55	11AUG2020	45373	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10051017	C4591001 1005 10051017	16-55	11AUG2020	45374	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10051024	C4591001 1005 10051024	16-55	11AUG2020	46639	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10051026	C4591001 1005 10051026	16-55	11AUG2020	46641	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo		
10051027	C4591001 1005 10051027	16-55	11AUG2020	46642	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10051028	C4591001 1005 10051028	16-55	12AUG2020	47011	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051029	C4591001 1005 10051029	16-55	12AUG2020	46647	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051030	C4591001 1005 10051030	16-55	12AUG2020	47015	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051031	C4591001 1005 10051031	16-55	12AUG2020	47019	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051035	C4591001 1005 10051035	16-55	12AUG2020	47020	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051036	C4591001 1005 10051036	16-55	12AUG2020	47597	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10051041	C4591001 1005 10051041	16-55	12AUG2020	47921	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10051048	C4591001 1005 10051048	16-55	13AUG2020	47924	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051051	C4591001 1005 10051051	16-55	13AUG2020	47932	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051052	C4591001 1005 10051052	16-55	13AUG2020	47929	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051054	C4591001 1005 10051054	16-55	13AUG2020	48727	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051055	C4591001 1005 10051055	16-55	13AUG2020	48728	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10051057	C4591001 1005 10051057	16-55	13AUG2020	48729	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10051059	C4591001 1005 10051059	16-55	13AUG2020	48733	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051066	C4591001 1005 10051066	16-55	13AUG2020	49457	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10051067	C4591001 1005 10051067	16-55	13AUG2020	49463	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10051070	C4591001 1005 10051070	16-55	14AUG2020	49464	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051071	C4591001 1005 10051071	16-55	14AUG2020	49468	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10051073	C4591001 1005 10051073	16-55	14AUG2020	49998	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051075	C4591001 1005 10051075	16-55	14AUG2020	50002	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061005	C4591001 1006 10061005	16-55	10AUG2020	45485	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061007	C4591001 1006 10061007	16-55	10AUG2020	45487	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061008	C4591001 1006 10061008	16-55	10AUG2020	45490	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10061009	C4591001 1006 10061009	16-55	10AUG2020	45495	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10061011	C4591001 1006 10061011	16-55	11AUG2020	46289	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061012	C4591001 1006 10061012	16-55	11AUG2020	46292	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10061013	C4591001 1006 10061013	16-55	11AUG2020	46294	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10061014	C4591001 1006 10061014	16-55	11AUG2020	46296	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061015	C4591001 1006 10061015	16-55	11AUG2020	46865	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10061018	C4591001 1006 10061018	16-55	11AUG2020	46868	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10061019	C4591001 1006 10061019	16-55	12AUG2020	46869	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061021	C4591001 1006 10061021	16-55	12AUG2020	46874	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10061022	C4591001 1006 10061022	16-55	12AUG2020	47813	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10061023	C4591001 1006 10061023	16-55	12AUG2020	47819	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10061024	C4591001 1006 10061024	16-55	12AUG2020	47820	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10061028	C4591001 1006 10061028	16-55	13AUG2020	47823	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10061031	C4591001 1006 10061031	16-55	13AUG2020	49714	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10061032	C4591001 1006 10061032	16-55	13AUG2020	49718	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10061033	C4591001 1006 10061033	16-55	13AUG2020	49712	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10061036	C4591001 1006 10061036	16-55	14AUG2020	49719	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10061037	C4591001 1006 10061037	16-55	14AUG2020	50868	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071106	C4591001 1007 10071106	16-55	03AUG2020	40640	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071107	C4591001 1007 10071107	16-55	03AUG2020	40643	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10071108	C4591001 1007 10071108	16-55	03AUG2020	40648	Placebo	03AUG2020/ Placebo	27AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10071109	C4591001 1007 10071109	16-55	03AUG2020	41642	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10071110	C4591001 1007 10071110	16-55	03AUG2020	41636	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071111	C4591001 1007 10071111	16-55	03AUG2020	41643	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071112	C4591001 1007 10071112	16-55	03AUG2020	41644	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071117	C4591001 1007 10071117	16-55	03AUG2020	41898	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10071118	C4591001 1007 10071118	16-55	03AUG2020	41901	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10071119	C4591001 1007 10071119	16-55	05AUG2020	41902	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071123	C4591001 1007 10071123	16-55	05AUG2020	41903	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10071125	C4591001 1007 10071125	16-55	05AUG2020	42920	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10071129	C4591001 1007 10071129	16-55	05AUG2020	42924	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10071130	C4591001 1007 10071130	16-55	05AUG2020	42921	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10071131	C4591001 1007 10071131	16-55	05AUG2020	42926	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071132	C4591001 1007 10071132	16-55	05AUG2020	43159	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10071133	C4591001 1007 10071133	16-55	05AUG2020	43163	Placebo	05AUG2020/ Placebo	31AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071137	C4591001 1007 10071137	16-55	06AUG2020	43164	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071138	C4591001 1007 10071138	16-55	06AUG2020	43165	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071143	C4591001 1007 10071143	16-55	06AUG2020	43834	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071145	C4591001 1007 10071145	16-55	06AUG2020	43832	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10071146	C4591001 1007 10071146	16-55	06AUG2020	43838	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071148	C4591001 1007 10071148	16-55	06AUG2020	43839	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10071150	C4591001 1007 10071150	16-55	10AUG2020	45188	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071151	C4591001 1007 10071151	16-55	10AUG2020	45186	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10071152	C4591001 1007 10071152	16-55	10AUG2020	45191	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071153	C4591001 1007 10071153	16-55	10AUG2020	45270	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10071154	C4591001 1007 10071154	16-55	10AUG2020	45272	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071155	C4591001 1007 10071155	16-55	10AUG2020	45189	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071157	C4591001 1007 10071157	16-55	10AUG2020	45273	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071158	C4591001 1007 10071158	16-55	10AUG2020	45280	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071159	C4591001 1007 10071159	16-55	10AUG2020	45643	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10071162	C4591001 1007 10071162	16-55	10AUG2020	45644	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071171	C4591001 1007 10071171	16-55	12AUG2020	45645	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071172	C4591001 1007 10071172	16-55	12AUG2020	45647	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071175	C4591001 1007 10071175	16-55	12AUG2020	47633	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10071178	C4591001 1007 10071178	16-55	12AUG2020	47644	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071179	C4591001 1007 10071179	16-55	12AUG2020	47634	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
10071181	C4591001 1007 10071181	16-55	12AUG2020	47640	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10071184	C4591001 1007 10071184	16-55	13AUG2020	48452	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071185	C4591001 1007 10071185	16-55	13AUG2020	48455	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071186	C4591001 1007 10071186	16-55	13AUG2020	48459	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
10071193	C4591001 1007 10071193	16-55	13AUG2020	49097	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10071194	C4591001 1007 10071194	16-55	13AUG2020	49099	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071195	C4591001 1007 10071195	16-55	13AUG2020	49098	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10071196	C4591001 1007 10071196	16-55	13AUG2020	49103	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10071197	C4591001 1007 10071197	16-55	13AUG2020	49338	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10081006	C4591001 1008 10081006	16-55	10AUG2020	45761	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10081007	C4591001 1008 10081007	16-55	10AUG2020	45762	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10081011	C4591001 1008 10081011	16-55	11AUG2020	45768	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081013	C4591001 1008 10081013	16-55	11AUG2020	45771	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10081015	C4591001 1008 10081015	16-55	11AUG2020	46721	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081018	C4591001 1008 10081018	16-55	12AUG2020	46722	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10081019	C4591001 1008 10081019	16-55	12AUG2020	46728	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10081022	C4591001 1008 10081022	16-55	12AUG2020	46730	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10081024	C4591001 1008 10081024	16-55	12AUG2020	48101	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10081025	C4591001 1008 10081025	16-55	13AUG2020	48109	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10081028	C4591001 1008 10081028	16-55	13AUG2020	48110	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10081029	C4591001 1008 10081029	16-55	13AUG2020	48112	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10081030	C4591001 1008 10081030	16-55	13AUG2020	49435	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081031	C4591001 1008 10081031	16-55	13AUG2020	49441	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081033	C4591001 1008 10081033	16-55	14AUG2020	49443	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10081036	C4591001 1008 10081036	16-55	14AUG2020	49444	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10081037	C4591001 1008 10081037	16-55	14AUG2020	50633	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10081040	C4591001 1008 10081040	16-55	14AUG2020	50634	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10091002	C4591001 1009 10091002	16-55	07AUG2020	44552	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10091005	C4591001 1009 10091005	16-55	10AUG2020	44556	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10091006	C4591001 1009 10091006	16-55	10AUG2020	44558	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10091012	C4591001 1009 10091012	16-55	10AUG2020	44559	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10091021	C4591001 1009 10091021	16-55	11AUG2020	46841	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091023	C4591001 1009 10091023	16-55	11AUG2020	46842	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10091028	C4591001 1009 10091028	16-55	12AUG2020	46847	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10091031	C4591001 1009 10091031	16-55	12AUG2020	46850	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10091032	C4591001 1009 10091032	16-55	12AUG2020	48235	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10091042	C4591001 1009 10091042	16-55	14AUG2020	48238	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10091045	C4591001 1009 10091045	16-55	14AUG2020	48240	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10091049	C4591001 1009 10091049	16-55	14AUG2020	50934	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10091050	C4591001 1009 10091050	16-55	14AUG2020	50936	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10111001	C4591001 1011 10111001	16-55	11AUG2020	46499	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111004	C4591001 1011 10111004	16-55	12AUG2020	46500	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111005	C4591001 1011 10111005	16-55	12AUG2020	46501	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111006	C4591001 1011 10111006	16-55	12AUG2020	47094	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10111008	C4591001 1011 10111008	16-55	12AUG2020	47095	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10111009	C4591001 1011 10111009	16-55	12AUG2020	47103	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111013	C4591001 1011 10111013	16-55	12AUG2020	47104	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111016	C4591001 1011 10111016	16-55	13AUG2020	48308	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111017	C4591001 1011 10111017	16-55	13AUG2020	48313	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111021	C4591001 1011 10111021	16-55	13AUG2020	48314	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111024	C4591001 1011 10111024	16-55	13AUG2020	48315	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10111031	C4591001 1011 10111031	16-55	13AUG2020	49649	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111032	C4591001 1011 10111032	16-55	13AUG2020	49651	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10111034	C4591001 1011 10111034	16-55	14AUG2020	49652	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111035	C4591001 1011 10111035	16-55	14AUG2020	49653	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111038	C4591001 1011 10111038	16-55	14AUG2020	50273	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10111039	C4591001 1011 10111039	16-55	14AUG2020	50274	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10121001	C4591001 1012 10121001	16-55	03AUG2020	41719	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			
10121003	C4591001 1012 10121003	16-55	03AUG2020	41723	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10121005	C4591001 1012 10121005	16-55	03AUG2020	41725	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10121006	C4591001 1012 10121006	16-55	03AUG2020	41728	Placebo	03AUG2020/ Placebo	28AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10121013	C4591001 1012 10121013	16-55	05AUG2020	43014	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121014	C4591001 1012 10121014	16-55	05AUG2020	43017	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10121016	C4591001 1012 10121016	16-55	06AUG2020	43018	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10121020	C4591001 1012 10121020	16-55	07AUG2020	44658	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10121021	C4591001 1012 10121021	16-55	07AUG2020	43021	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10121022	C4591001 1012 10121022	16-55	10AUG2020	44659	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10121024	C4591001 1012 10121024	16-55	10AUG2020	44664	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121025	C4591001 1012 10121025	16-55	10AUG2020	44666	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121027	C4591001 1012 10121027	16-55	11AUG2020	46506	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10121030	C4591001 1012 10121030	16-55	12AUG2020	46509	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10121032	C4591001 1012 10121032	16-55	12AUG2020	46512	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121036	C4591001 1012 10121036	16-55	14AUG2020	46516	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10121037	C4591001 1012 10121037	16-55	14AUG2020	51058	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10131033	C4591001 1013 10131033	16-55	31JUL2020	40835	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131034	C4591001 1013 10131034	16-55	31JUL2020	40829	Placebo	31JUL2020/ Placebo	18AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131035	C4591001 1013 10131035	16-55	31JUL2020	40833	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131036	C4591001 1013 10131036	16-55	31JUL2020	40836	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131038	C4591001 1013 10131038	16-55	31JUL2020	40842	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131039	C4591001 1013 10131039	16-55	31JUL2020	40848	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131040	C4591001 1013 10131040	16-55	31JUL2020	40849	Placebo	31JUL2020/ Placebo	18AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131042	C4591001 1013 10131042	16-55	31JUL2020	40851	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131044	C4591001 1013 10131044	16-55	31JUL2020	40937	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131045	C4591001 1013 10131045	16-55	31JUL2020	40940	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131046	C4591001 1013 10131046	16-55	31JUL2020	40943	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10131047	C4591001 1013 10131047	16-55	31JUL2020	40942	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10131048	C4591001 1013 10131048	16-55	31JUL2020	41000	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10131049	C4591001 1013 10131049	16-55	31JUL2020	41006	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131050	C4591001 1013 10131050	16-55	31JUL2020	41003	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10131051	C4591001 1013 10131051	16-55	03AUG2020	41007	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10131052	C4591001 1013 10131052	16-55	03AUG2020	41462	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131054	C4591001 1013 10131054	16-55	03AUG2020	41456	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131055	C4591001 1013 10131055	16-55	03AUG2020	41455	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131056	C4591001 1013 10131056	16-55	03AUG2020	41463	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131057	C4591001 1013 10131057	16-55	03AUG2020	41537	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131058	C4591001 1013 10131058	16-55	03AUG2020	41542	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131059	C4591001 1013 10131059	16-55	03AUG2020	41544	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10131060	C4591001 1013 10131060	16-55	03AUG2020	41547	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131062	C4591001 1013 10131062	16-55	04AUG2020	42203	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131063	C4591001 1013 10131063	16-55	04AUG2020	42114	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131064	C4591001 1013 10131064	16-55	04AUG2020	42205	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo		
10131066	C4591001 1013 10131066	16-55	04AUG2020	42115	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131067	C4591001 1013 10131067	16-55	04AUG2020	42119	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131068	C4591001 1013 10131068	16-55	04AUG2020	42116	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131071	C4591001 1013 10131071	16-55	04AUG2020	42206	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131072	C4591001 1013 10131072	16-55	04AUG2020	42207	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10131074	C4591001 1013 10131074	16-55	04AUG2020	42309	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131076	C4591001 1013 10131076	16-55	04AUG2020	42305	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10131077	C4591001 1013 10131077	16-55	04AUG2020	42311	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131078	C4591001 1013 10131078	16-55	04AUG2020	42314	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10131079	C4591001 1013 10131079	16-55	04AUG2020	42473	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10131081	C4591001 1013 10131081	16-55	05AUG2020	42476	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131082	C4591001 1013 10131082	16-55	05AUG2020	42478	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10131083	C4591001 1013 10131083	16-55	05AUG2020	42484	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131084	C4591001 1013 10131084	16-55	05AUG2020	42812	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131087	C4591001 1013 10131087	16-55	06AUG2020	42813	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
10131089	C4591001 1013 10131089	16-55	06AUG2020	42820	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10131090	C4591001 1013 10131090	16-55	06AUG2020	42815	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10131093	C4591001 1013 10131093	16-55	06AUG2020	43639	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131094	C4591001 1013 10131094	16-55	06AUG2020	43637	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131098	C4591001 1013 10131098	16-55	06AUG2020	43645	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10131102	C4591001 1013 10131102	16-55	06AUG2020	43647	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131103	C4591001 1013 10131103	16-55	06AUG2020	44014	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10131105	C4591001 1013 10131105	16-55	10AUG2020	44017	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131106	C4591001 1013 10131106	16-55	10AUG2020	44018	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131107	C4591001 1013 10131107	16-55	10AUG2020	45343	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131108	C4591001 1013 10131108	16-55	10AUG2020	44019	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131109	C4591001 1013 10131109	16-55	10AUG2020	45349	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131111	C4591001 1013 10131111	16-55	10AUG2020	45348	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131113	C4591001 1013 10131113	16-55	10AUG2020	45351	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131115	C4591001 1013 10131115	16-55	10AUG2020	45534	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131116	C4591001 1013 10131116	16-55	10AUG2020	45533	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131117	C4591001 1013 10131117	16-55	10AUG2020	45542	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131118	C4591001 1013 10131118	16-55	10AUG2020	45541	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10131119	C4591001 1013 10131119	16-55	10AUG2020	45606	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131120	C4591001 1013 10131120	16-55	10AUG2020	45607	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131121	C4591001 1013 10131121	16-55	10AUG2020	45611	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10131122	C4591001 1013 10131122	16-55	10AUG2020	45614	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131124	C4591001 1013 10131124	16-55	11AUG2020	46088	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10131125	C4591001 1013 10131125	16-55	11AUG2020	46085	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10131126	C4591001 1013 10131126	16-55	11AUG2020	46090	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131127	C4591001 1013 10131127	16-55	11AUG2020	46092	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131128	C4591001 1013 10131128	16-55	11AUG2020	46146	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131131	C4591001 1013 10131131	16-55	11AUG2020	46148	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131132	C4591001 1013 10131132	16-55	11AUG2020	46147	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131135	C4591001 1013 10131135	16-55	11AUG2020	46154	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131136	C4591001 1013 10131136	16-55	11AUG2020	46459	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131137	C4591001 1013 10131137	16-55	11AUG2020	46460	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
10131138	C4591001 1013 10131138	16-55	11AUG2020	46461	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
10131139	C4591001 1013 10131139	16-55	11AUG2020	46465	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131143	C4591001 1013 10131143	16-55	12AUG2020	47033	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131145	C4591001 1013 10131145	16-55	12AUG2020	47035	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131146	C4591001 1013 10131146	16-55	12AUG2020	47129	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131147	C4591001 1013 10131147	16-55	12AUG2020	47130	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131148	C4591001 1013 10131148	16-55	12AUG2020	47036	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131149	C4591001 1013 10131149	16-55	12AUG2020	47039	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131155	C4591001 1013 10131155	16-55	12AUG2020	47134	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131156	C4591001 1013 10131156	16-55	12AUG2020	47132	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131158	C4591001 1013 10131158	16-55	12AUG2020	47347	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131159	C4591001 1013 10131159	16-55	12AUG2020	47349	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131163	C4591001 1013 10131163	16-55	13AUG2020	47355	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131165	C4591001 1013 10131165	16-55	13AUG2020	48413	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131166	C4591001 1013 10131166	16-55	13AUG2020	48419	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10131167	C4591001 1013 10131167	16-55	13AUG2020	48415	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10131169	C4591001 1013 10131169	16-55	13AUG2020	48420	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131171	C4591001 1013 10131171	16-55	13AUG2020	48549	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10131172	C4591001 1013 10131172	16-55	13AUG2020	48552	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131173	C4591001 1013 10131173	16-55	13AUG2020	48555	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131174	C4591001 1013 10131174	16-55	13AUG2020	48556	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10131177	C4591001 1013 10131177	16-55	13AUG2020	48718	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10131179	C4591001 1013 10131179	16-55	13AUG2020	48716	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131180	C4591001 1013 10131180	16-55	13AUG2020	48722	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131182	C4591001 1013 10131182	16-55	13AUG2020	48717	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131185	C4591001 1013 10131185	16-55	13AUG2020	49013	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151001	C4591001 1015 10151001	16-55	10AUG2020	45329	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10151005	C4591001 1015 10151005	16-55	12AUG2020	45331	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10151006	C4591001 1015 10151006	16-55	12AUG2020	45333	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151009	C4591001 1015 10151009	16-55	13AUG2020	45339	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151010	C4591001 1015 10151010	16-55	13AUG2020	48846	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151011	C4591001 1015 10151011	16-55	13AUG2020	48847	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151013	C4591001 1015 10151013	16-55	13AUG2020	48853	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151014	C4591001 1015 10151014	16-55	13AUG2020	48856	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151015	C4591001 1015 10151015	16-55	14AUG2020	49890	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151017	C4591001 1015 10151017	16-55	14AUG2020	49892	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10151018	C4591001 1015 10151018	16-55	14AUG2020	49895	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151021	C4591001 1015 10151021	16-55	14AUG2020	50793	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151023	C4591001 1015 10151023	16-55	14AUG2020	50790	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10151026	C4591001 1015 10151026	16-55	15AUG2020	50800	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10151027	C4591001 1015 10151027	16-55	15AUG2020	51187	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10161017	C4591001 1016 10161017	16-55	31JUL2020	40441	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10161018	C4591001 1016 10161018	16-55	31JUL2020	40901	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161019	C4591001 1016 10161019	16-55	31JUL2020	40909	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161020	C4591001 1016 10161020	16-55	31JUL2020	40908	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10161021	C4591001 1016 10161021	16-55	31JUL2020	40912	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161028	C4591001 1016 10161028	16-55	03AUG2020	41590	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161029	C4591001 1016 10161029	16-55	03AUG2020	41592	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10161030	C4591001 1016 10161030	16-55	03AUG2020	41587	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161031	C4591001 1016 10161031	16-55	03AUG2020	41594	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10161038	C4591001 1016 10161038	16-55	04AUG2020	42174	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10161043	C4591001 1016 10161043	16-55	04AUG2020	42176	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161045	C4591001 1016 10161045	16-55	04AUG2020	42182	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10161046	C4591001 1016 10161046	16-55	04AUG2020	42184	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161047	C4591001 1016 10161047	16-55	04AUG2020	42612	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10161048	C4591001 1016 10161048	16-55	04AUG2020	42614	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10161049	C4591001 1016 10161049	16-55	04AUG2020	42615	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10161051	C4591001 1016 10161051	16-55	05AUG2020	42616	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10161054	C4591001 1016 10161054	16-55	05AUG2020	42823	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10161057	C4591001 1016 10161057	16-55	05AUG2020	42824	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10161058	C4591001 1016 10161058	16-55	05AUG2020	42828	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo		
10161060	C4591001 1016 10161060	16-55	06AUG2020	43553	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161064	C4591001 1016 10161064	16-55	06AUG2020	43554	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10161065	C4591001 1016 10161065	16-55	06AUG2020	43561	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161069	C4591001 1016 10161069	16-55	06AUG2020	43562	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10161071	C4591001 1016 10161071	16-55	06AUG2020	44022	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10161073	C4591001 1016 10161073	16-55	06AUG2020	44023	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10161076	C4591001 1016 10161076	16-55	06AUG2020	44025	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10161077	C4591001 1016 10161077	16-55	07AUG2020	44028	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161078	C4591001 1016 10161078	16-55	07AUG2020	44280	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10161080	C4591001 1016 10161080	16-55	07AUG2020	44282	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10161081	C4591001 1016 10161081	16-55	07AUG2020	44281	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10161082	C4591001 1016 10161082	16-55	07AUG2020	44283	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10161084	C4591001 1016 10161084	16-55	07AUG2020	44491	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161085	C4591001 1016 10161085	16-55	10AUG2020	44492	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10161087	C4591001 1016 10161087	16-55	10AUG2020	44493	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			
10161091	C4591001 1016 10161091	16-55	10AUG2020	44495	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10161092	C4591001 1016 10161092	16-55	10AUG2020	45455	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161093	C4591001 1016 10161093	16-55	11AUG2020	45457	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10161094	C4591001 1016 10161094	16-55	11AUG2020	45460	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10161095	C4591001 1016 10161095	16-55	11AUG2020	45458	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161097	C4591001 1016 10161097	16-55	11AUG2020	46229	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161101	C4591001 1016 10161101	16-55	11AUG2020	46230	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10161102	C4591001 1016 10161102	16-55	12AUG2020	46234	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161103	C4591001 1016 10161103	16-55	12AUG2020	46237	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10161105	C4591001 1016 10161105	16-55	12AUG2020	47441	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161106	C4591001 1016 10161106	16-55	12AUG2020	47442	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161107	C4591001 1016 10161107	16-55	12AUG2020	47444	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10161109	C4591001 1016 10161109	16-55	12AUG2020	47448	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10161114	C4591001 1016 10161114	16-55	13AUG2020	48605	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161117	C4591001 1016 10161117	16-55	13AUG2020	48606	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
10161118	C4591001 1016 10161118	16-55	13AUG2020	48607	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161119	C4591001 1016 10161119	16-55	14AUG2020	48615	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10161120	C4591001 1016 10161120	16-55	14AUG2020	50034	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161122	C4591001 1016 10161122	16-55	14AUG2020	50036	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10161123	C4591001 1016 10161123	16-55	14AUG2020	50038	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10161125	C4591001 1016 10161125	16-55	14AUG2020	50042	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10181009	C4591001 1018 10181009	16-55	30JUL2020	40200	Placebo	30JUL2020/ Placebo	22AUG2020/ Placebo		
10181010	C4591001 1018 10181010	16-55	30JUL2020	40781	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181011	C4591001 1018 10181011	16-55	30JUL2020	40783	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10181012	C4591001 1018 10181012	16-55	30JUL2020	40790	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10181013	C4591001 1018 10181013	16-55	30JUL2020	40792	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181014	C4591001 1018 10181014	16-55	30JUL2020	40799	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10181015	C4591001 1018 10181015	16-55	31JUL2020	40800	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181016	C4591001 1018 10181016	16-55	31JUL2020	41014	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10181017	C4591001 1018 10181017	16-55	31JUL2020	40804	Placebo	31JUL2020/ Placebo	22AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10181018	C4591001 1018 10181018	16-55	31JUL2020	40802	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10181019	C4591001 1018 10181019	16-55	31JUL2020	41010	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10181020	C4591001 1018 10181020	16-55	31JUL2020	41015	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181021	C4591001 1018 10181021	16-55	31JUL2020	41013	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10181022	C4591001 1018 10181022	16-55	31JUL2020	41117	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181024	C4591001 1018 10181024	16-55	03AUG2020	41121	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
10181025	C4591001 1018 10181025	16-55	03AUG2020	41125	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			
10181026	C4591001 1018 10181026	16-55	03AUG2020	41694	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181027	C4591001 1018 10181027	16-55	03AUG2020	41127	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10181028	C4591001 1018 10181028	16-55	03AUG2020	41765	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181029	C4591001 1018 10181029	16-55	03AUG2020	41701	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181030	C4591001 1018 10181030	16-55	03AUG2020	41695	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181031	C4591001 1018 10181031	16-55	03AUG2020	41766	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181032	C4591001 1018 10181032	16-55	03AUG2020	41702	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10181033	C4591001 1018 10181033	16-55	03AUG2020	41768	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10181034	C4591001 1018 10181034	16-55	03AUG2020	41776	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181036	C4591001 1018 10181036	16-55	03AUG2020	41959	Placebo	03AUG2020/ Placebo			
10181037	C4591001 1018 10181037	16-55	03AUG2020	41961	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181038	C4591001 1018 10181038	16-55	03AUG2020	41964	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181039	C4591001 1018 10181039	16-55	03AUG2020	41994	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo		
10181040	C4591001 1018 10181040	16-55	03AUG2020	41965	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10181042	C4591001 1018 10181042	16-55	03AUG2020	41997	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10181045	C4591001 1018 10181045	16-55	03AUG2020	42000	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10181046	C4591001 1018 10181046	16-55	03AUG2020	42004	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181047	C4591001 1018 10181047	16-55	04AUG2020	42252	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181048	C4591001 1018 10181048	16-55	04AUG2020	42254	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181049	C4591001 1018 10181049	16-55	04AUG2020	42256	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181050	C4591001 1018 10181050	16-55	04AUG2020	42293	Placebo	04AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181051	C4591001 1018 10181051	16-55	04AUG2020	42253	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181052	C4591001 1018 10181052	16-55	04AUG2020	42295	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181053	C4591001 1018 10181053	16-55	04AUG2020	42298	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181054	C4591001 1018 10181054	16-55	04AUG2020	42304	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10181055	C4591001 1018 10181055	16-55	04AUG2020	42582	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181056	C4591001 1018 10181056	16-55	04AUG2020	42584	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181057	C4591001 1018 10181057	16-55	04AUG2020	42586	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10181058	C4591001 1018 10181058	16-55	04AUG2020	42589	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10181059	C4591001 1018 10181059	16-55	04AUG2020	42702	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10181062	C4591001 1018 10181062	16-55	05AUG2020	42703	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181064	C4591001 1018 10181064	16-55	05AUG2020	42709	Placebo	05AUG2020/ Placebo	29AUG2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181066	C4591001 1018 10181066	16-55	05AUG2020	42711	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181067	C4591001 1018 10181067	16-55	05AUG2020	43098	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10181071	C4591001 1018 10181071	16-55	05AUG2020	43100	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10181072	C4591001 1018 10181072	16-55	05AUG2020	43099	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10181074	C4591001 1018 10181074	16-55	05AUG2020	43101	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181076	C4591001 1018 10181076	16-55	05AUG2020	43289	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181077	C4591001 1018 10181077	16-55	05AUG2020	43290	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10181079	C4591001 1018 10181079	16-55	05AUG2020	43291	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10181081	C4591001 1018 10181081	16-55	05AUG2020	43293	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181083	C4591001 1018 10181083	16-55	06AUG2020	43675	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181084	C4591001 1018 10181084	16-55	06AUG2020	43622	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181085	C4591001 1018 10181085	16-55	06AUG2020	43613	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10181086	C4591001 1018 10181086	16-55	06AUG2020	43614	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181088	C4591001 1018 10181088	16-55	06AUG2020	43818	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181089	C4591001 1018 10181089	16-55	06AUG2020	43623	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10181090	C4591001 1018 10181090	16-55	06AUG2020	43680	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181091	C4591001 1018 10181091	16-55	06AUG2020	43676	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181093	C4591001 1018 10181093	16-55	06AUG2020	43678	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181094	C4591001 1018 10181094	16-55	07AUG2020	44739	Placebo	07AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181095	C4591001 1018 10181095	16-55	07AUG2020	43821	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10181098	C4591001 1018 10181098	16-55	07AUG2020	43827	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181100	C4591001 1018 10181100	16-55	07AUG2020	43824	Placebo	07AUG2020/ Placebo	02SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181103	C4591001 1018 10181103	16-55	07AUG2020	44733	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10181104	C4591001 1018 10181104	16-55	07AUG2020	44734	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10181105	C4591001 1018 10181105	16-55	07AUG2020	44737	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo		
10181106	C4591001 1018 10181106	16-55	07AUG2020	44901	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181107	C4591001 1018 10181107	16-55	10AUG2020	44902	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10181108	C4591001 1018 10181108	16-55	10AUG2020	44908	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181109	C4591001 1018 10181109	16-55	10AUG2020	44904	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181111	C4591001 1018 10181111	16-55	10AUG2020	45557	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
10181113	C4591001 1018 10181113	16-55	10AUG2020	45562	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10181114	C4591001 1018 10181114	16-55	10AUG2020	45558	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10181116	C4591001 1018 10181116	16-55	10AUG2020	45858	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181118	C4591001 1018 10181118	16-55	10AUG2020	45859	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10181119	C4591001 1018 10181119	16-55	10AUG2020	45564	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10181120	C4591001 1018 10181120	16-55	10AUG2020	45862	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10181125	C4591001 1018 10181125	16-55	11AUG2020	45868	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10181126	C4591001 1018 10181126	16-55	11AUG2020	46853	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10181127	C4591001 1018 10181127	16-55	12AUG2020	46856	Placebo	12AUG2020/ Placebo	12SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181128	C4591001 1018 10181128	16-55	12AUG2020	46858	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10181131	C4591001 1018 10181131	16-55	12AUG2020	47429	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181133	C4591001 1018 10181133	16-55	12AUG2020	46860	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181139	C4591001 1018 10181139	16-55	12AUG2020	47435	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10181141	C4591001 1018 10181141	16-55	13AUG2020	49002	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
10181142	C4591001 1018 10181142	16-55	13AUG2020	47439	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)			
10181143	C4591001 1018 10181143	16-55	13AUG2020	48799	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10181144	C4591001 1018 10181144	16-55	13AUG2020	47440	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181145	C4591001 1018 10181145	16-55	13AUG2020	49006	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181146	C4591001 1018 10181146	16-55	13AUG2020	48802	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181148	C4591001 1018 10181148	16-55	13AUG2020	48800	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181149	C4591001 1018 10181149	16-55	13AUG2020	49003	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181150	C4591001 1018 10181150	16-55	13AUG2020	48806	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181151	C4591001 1018 10181151	16-55	13AUG2020	49011	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	
10181152	C4591001 1018 10181152	16-55	14AUG2020	50251	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181154	C4591001 1018 10181154	16-55	13AUG2020	49221	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10181156	C4591001 1018 10181156	16-55	13AUG2020	49227	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10181157	C4591001 1018 10181157	16-55	13AUG2020	49222	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10181158	C4591001 1018 10181158	16-55	13AUG2020	49223	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181159	C4591001 1018 10181159	16-55	14AUG2020	50249	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181160	C4591001 1018 10181160	16-55	14AUG2020	50254	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10181162	C4591001 1018 10181162	16-55	14AUG2020	50909	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10181163	C4591001 1018 10181163	16-55	14AUG2020	50918	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181167	C4591001 1018 10181167	16-55	14AUG2020	50919	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10181186	C4591001 1018 10181186	16-55	19AUG2020	56266	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10191002	C4591001 1019 10191002	16-55	10AUG2020	45198	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10191005	C4591001 1019 10191005	16-55	10AUG2020	45204	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191006	C4591001 1019 10191006	16-55	10AUG2020	45205	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10191007	C4591001 1019 10191007	16-55	10AUG2020	45208	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10191015	C4591001 1019 10191015	16-55	11AUG2020	46555	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191018	C4591001 1019 10191018	16-55	12AUG2020	46556	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10191023	C4591001 1019 10191023	16-55	12AUG2020	46559	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10191027	C4591001 1019 10191027	16-55	13AUG2020	46561	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10191028	C4591001 1019 10191028	16-55	13AUG2020	227548	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10191032	C4591001 1019 10191032	16-55	13AUG2020	49054	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10191034	C4591001 1019 10191034	16-55	13AUG2020	49055	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10191036	C4591001 1019 10191036	16-55	13AUG2020	49056	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10191038	C4591001 1019 10191038	16-55	14AUG2020	49060	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10191041	C4591001 1019 10191041	16-55	14AUG2020	50393	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10211011	C4591001 1021 10211011	16-55	11AUG2020	225576	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211012	C4591001 1021 10211012	16-55	11AUG2020	46484	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10211016	C4591001 1021 10211016	16-55	11AUG2020	46490	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211032	C4591001 1021 10211032	16-55	13AUG2020	46491	Placebo	13AUG2020/ Placebo	16SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10211040	C4591001 1021 10211040	16-55	14AUG2020	46492	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10221004	C4591001 1022 10221004	16-55	14AUG2020	50525	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10241001	C4591001 1024 10241001	16-55	12AUG2020	47311	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10241002	C4591001 1024 10241002	16-55	12AUG2020	47313	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10241004	C4591001 1024 10241004	16-55	12AUG2020	47315	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10241005	C4591001 1024 10241005	16-55	12AUG2020	47316	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10241006	C4591001 1024 10241006	16-55	12AUG2020	47850	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241009	C4591001 1024 10241009	16-55	13AUG2020	47851	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10241011	C4591001 1024 10241011	16-55	13AUG2020	47855	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241012	C4591001 1024 10241012	16-55	13AUG2020	47858	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10241014	C4591001 1024 10241014	16-55	13AUG2020	49565	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10241015	C4591001 1024 10241015	16-55	13AUG2020	49568	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10241016	C4591001 1024 10241016	16-55	13AUG2020	49573	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10241020	C4591001 1024 10241020	16-55	14AUG2020	49574	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10241021	C4591001 1024 10241021	16-55	14AUG2020	50345	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10241023	C4591001 1024 10241023	16-55	14AUG2020	50349	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10271005	C4591001 1027 10271005	16-55	13AUG2020	48570	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271012	C4591001 1027 10271012	16-55	14AUG2020	48572	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10271017	C4591001 1027 10271017	16-55	14AUG2020	48574	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10271019	C4591001 1027 10271019	16-55	14AUG2020	48577	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10271021	C4591001 1027 10271021	16-55	14AUG2020	50599	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10281001	C4591001 1028 10281001	16-55	13AUG2020	48535	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10281002	C4591001 1028 10281002	16-55	13AUG2020	48538	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281003	C4591001 1028 10281003	16-55	14AUG2020	48540	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10421013	C4591001 1042 10421013	16-55	31JUL2020	40877	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421014	C4591001 1042 10421014	16-55	31JUL2020	40879	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421017	C4591001 1042 10421017	16-55	31JUL2020	40882	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421020	C4591001 1042 10421020	16-55	31JUL2020	40884	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10421021	C4591001 1042 10421021	16-55	03AUG2020	41621	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10421022	C4591001 1042 10421022	16-55	03AUG2020	41624	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421024	C4591001 1042 10421024	16-55	03AUG2020	41625	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421027	C4591001 1042 10421027	16-55	03AUG2020	41950	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421028	C4591001 1042 10421028	16-55	03AUG2020	41628	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo		
10421029	C4591001 1042 10421029	16-55	03AUG2020	41951	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421031	C4591001 1042 10421031	16-55	04AUG2020	41952	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10421034	C4591001 1042 10421034	16-55	04AUG2020	41955	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10421035	C4591001 1042 10421035	16-55	04AUG2020	42511	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421039	C4591001 1042 10421039	16-55	04AUG2020	42512	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10421041	C4591001 1042 10421041	16-55	04AUG2020	42516	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10421043	C4591001 1042 10421043	16-55	05AUG2020	42941	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10421044	C4591001 1042 10421044	16-55	05AUG2020	42517	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10421045	C4591001 1042 10421045	16-55	05AUG2020	42942	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10421050	C4591001 1042 10421050	16-55	05AUG2020	42949	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421051	C4591001 1042 10421051	16-55	06AUG2020	42951	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421057	C4591001 1042 10421057	16-55	06AUG2020	44082	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
10421059	C4591001 1042 10421059	16-55	07AUG2020	44083	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10421061	C4591001 1042 10421061	16-55	07AUG2020	44090	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421063	C4591001 1042 10421063	16-55	07AUG2020	44092	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10421065	C4591001 1042 10421065	16-55	07AUG2020	44838	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10421068	C4591001 1042 10421068	16-55	10AUG2020	44840	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421069	C4591001 1042 10421069	16-55	10AUG2020	44841	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			
10421070	C4591001 1042 10421070	16-55	10AUG2020	45439	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421071	C4591001 1042 10421071	16-55	10AUG2020	44848	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10421073	C4591001 1042 10421073	16-55	10AUG2020	45441	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
10421076	C4591001 1042 10421076	16-55	10AUG2020	45448	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421077	C4591001 1042 10421077	16-55	10AUG2020	45444	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10421079	C4591001 1042 10421079	16-55	10AUG2020	45966	Placebo	10AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421080	C4591001 1042 10421080	16-55	10AUG2020	45970	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421081	C4591001 1042 10421081	16-55	11AUG2020	45972	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421082	C4591001 1042 10421082	16-55	11AUG2020	45974	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10421083	C4591001 1042 10421083	16-55	11AUG2020	46391	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10421085	C4591001 1042 10421085	16-55	11AUG2020	46392	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10421088	C4591001 1042 10421088	16-55	11AUG2020	46395	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10421092	C4591001 1042 10421092	16-55	11AUG2020	46396	Placebo	11AUG2020/ Placebo	10SEP2020/ Placebo		
10421093	C4591001 1042 10421093	16-55	12AUG2020	47225	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421095	C4591001 1042 10421095	16-55	12AUG2020	47233	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421100	C4591001 1042 10421100	16-55	12AUG2020	47235	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421103	C4591001 1042 10421103	16-55	12AUG2020	47236	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421105	C4591001 1042 10421105	16-55	14AUG2020	50133	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421106	C4591001 1042 10421106	16-55	14AUG2020	50134	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
10421108	C4591001 1042 10421108	16-55	14AUG2020	50137	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10421109	C4591001 1042 10421109	16-55	14AUG2020	50140	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10441001	C4591001 1044 10441001	16-55	14AUG2020	50057	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461001	C4591001 1046 10461001	16-55	12AUG2020	47983	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10461002	C4591001 1046 10461002	16-55	12AUG2020	47985	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461005	C4591001 1046 10461005	16-55	13AUG2020	47987	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461006	C4591001 1046 10461006	16-55	13AUG2020	47991	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461010	C4591001 1046 10461010	16-55	13AUG2020	49111	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461011	C4591001 1046 10461011	16-55	13AUG2020	49113	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461014	C4591001 1046 10461014	16-55	13AUG2020	49118	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10461016	C4591001 1046 10461016	16-55	13AUG2020	49120	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10461018	C4591001 1046 10461018	16-55	14AUG2020	50081	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10461020	C4591001 1046 10461020	16-55	14AUG2020	50082	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10461023	C4591001 1046 10461023	16-55	14AUG2020	50089	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461024	C4591001 1046 10461024	16-55	14AUG2020	50092	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10461026	C4591001 1046 10461026	16-55	14AUG2020	50801	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10461027	C4591001 1046 10461027	16-55	14AUG2020	50805	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461028	C4591001 1046 10461028	16-55	14AUG2020	50806	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10461029	C4591001 1046 10461029	16-55	14AUG2020	50809	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10461030	C4591001 1046 10461030	16-55	14AUG2020	51018	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461031	C4591001 1046 10461031	16-55	14AUG2020	51019	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10461039	C4591001 1046 10461039	16-55	15AUG2020	51028	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo		
10481001	C4591001 1048 10481001	16-55	07AUG2020	44861	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10481004	C4591001 1048 10481004	16-55	14AUG2020	44866	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551001	C4591001 1055 10551001	16-55	06AUG2020	43751	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10551003	C4591001 1055 10551003	16-55	06AUG2020	43752	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10551007	C4591001 1055 10551007	16-55	07AUG2020	43753	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551012	C4591001 1055 10551012	16-55	10AUG2020	43756	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10551013	C4591001 1055 10551013	16-55	10AUG2020	45679	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10551016	C4591001 1055 10551016	16-55	10AUG2020	45680	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551020	C4591001 1055 10551020	16-55	11AUG2020	45681	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10551021	C4591001 1055 10551021	16-55	11AUG2020	45684	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551022	C4591001 1055 10551022	16-55	11AUG2020	46602	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551025	C4591001 1055 10551025	16-55	11AUG2020	46607	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10551026	C4591001 1055 10551026	16-55	11AUG2020	46608	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10551028	C4591001 1055 10551028	16-55	11AUG2020	46610	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10551029	C4591001 1055 10551029	16-55	12AUG2020	47502	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551032	C4591001 1055 10551032	16-55	12AUG2020	47504	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551034	C4591001 1055 10551034	16-55	12AUG2020	47505	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10551037	C4591001 1055 10551037	16-55	12AUG2020	47506	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10551040	C4591001 1055 10551040	16-55	13AUG2020	49230	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10551042	C4591001 1055 10551042	16-55	13AUG2020	49235	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10551043	C4591001 1055 10551043	16-55	13AUG2020	49238	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10551045	C4591001 1055 10551045	16-55	13AUG2020	49239	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10551046	C4591001 1055 10551046	16-55	13AUG2020	49615	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10561013	C4591001 1056 10561013	16-55	21AUG2020	60584	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10571001	C4591001 1057 10571001	16-55	12AUG2020	47742	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571002	C4591001 1057 10571002	16-55	12AUG2020	47746	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571005	C4591001 1057 10571005	16-55	13AUG2020	47748	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571006	C4591001 1057 10571006	16-55	13AUG2020	48429	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10571007	C4591001 1057 10571007	16-55	13AUG2020	47749	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571008	C4591001 1057 10571008	16-55	13AUG2020	48430	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
10571009	C4591001 1057 10571009	16-55	13AUG2020	48431	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571012	C4591001 1057 10571012	16-55	13AUG2020	48435	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571013	C4591001 1057 10571013	16-55	13AUG2020	48833	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571014	C4591001 1057 10571014	16-55	13AUG2020	48839	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571015	C4591001 1057 10571015	16-55	13AUG2020	48841	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571016	C4591001 1057 10571016	16-55	14AUG2020	48844	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571017	C4591001 1057 10571017	16-55	14AUG2020	49880	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10571018	C4591001 1057 10571018	16-55	14AUG2020	49884	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571019	C4591001 1057 10571019	16-55	14AUG2020	49887	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571024	C4591001 1057 10571024	16-55	14AUG2020	49888	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10661002	C4591001 1066 10661002	16-55	11AUG2020	46697	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10661015	C4591001 1066 10661015	16-55	12AUG2020	46702	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10661019	C4591001 1066 10661019	16-55	12AUG2020	46705	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661020	C4591001 1066 10661020	16-55	12AUG2020	46708	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10661022	C4591001 1066 10661022	16-55	13AUG2020	48786	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661025	C4591001 1066 10661025	16-55	13AUG2020	48789	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10661026	C4591001 1066 10661026	16-55	13AUG2020	48790	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10661027	C4591001 1066 10661027	16-55	13AUG2020	48791	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10661028	C4591001 1066 10661028	16-55	13AUG2020	49470	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10711004	C4591001 1071 10711004	16-55	10AUG2020	45871	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711005	C4591001 1071 10711005	16-55	10AUG2020	45876	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711006	C4591001 1071 10711006	16-55	10AUG2020	45877	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711008	C4591001 1071 10711008	16-55	10AUG2020	45880	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10711019	C4591001 1071 10711019	16-55	11AUG2020	46916	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10711020	C4591001 1071 10711020	16-55	12AUG2020	46918	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711021	C4591001 1071 10711021	16-55	12AUG2020	46917	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10711022	C4591001 1071 10711022	16-55	12AUG2020	46922	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10711026	C4591001 1071 10711026	16-55	12AUG2020	47933	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10711027	C4591001 1071 10711027	16-55	12AUG2020	47934	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10711028	C4591001 1071 10711028	16-55	12AUG2020	47936	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10711030	C4591001 1071 10711030	16-55	13AUG2020	47943	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10711034	C4591001 1071 10711034	16-55	13AUG2020	49680	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
10711036	C4591001 1071 10711036	16-55	13AUG2020	49682	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711037	C4591001 1071 10711037	16-55	14AUG2020	49683	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10711039	C4591001 1071 10711039	16-55	14AUG2020	49684	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711040	C4591001 1071 10711040	16-55	14AUG2020	50417	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711041	C4591001 1071 10711041	16-55	14AUG2020	50418	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711042	C4591001 1071 10711042	16-55	14AUG2020	50424	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24JAN2021/ BNT162b2 (30 µg)	14FEB2021/ BNT162b2 (30 µg)
10711045	C4591001 1071 10711045	16-55	14AUG2020	50425	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10711047	C4591001 1071 10711047	16-55	14AUG2020	51042	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10731016	C4591001 1073 10731016	16-55	31JUL2020	40728	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10731020	C4591001 1073 10731020	16-55	31JUL2020	40730	Placebo	31JUL2020/ Placebo	27AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10731021	C4591001 1073 10731021	16-55	31JUL2020	40732	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10731022	C4591001 1073 10731022	16-55	03AUG2020	41657	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo		
10731027	C4591001 1073 10731027	16-55	03AUG2020	41660	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731028	C4591001 1073 10731028	16-55	04AUG2020	41664	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10731029	C4591001 1073 10731029	16-55	04AUG2020	41665	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10731032	C4591001 1073 10731032	16-55	04AUG2020	42463	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10731034	C4591001 1073 10731034	16-55	04AUG2020	42464	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731036	C4591001 1073 10731036	16-55	05AUG2020	42465	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10731038	C4591001 1073 10731038	16-55	05AUG2020	42468	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)			
10731045	C4591001 1073 10731045	16-55	06AUG2020	43739	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10731048	C4591001 1073 10731048	16-55	06AUG2020	43741	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10731050	C4591001 1073 10731050	16-55	06AUG2020	43740	Placebo	06AUG2020/ Placebo	03SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10731056	C4591001 1073 10731056	16-55	10AUG2020	45655	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731057	C4591001 1073 10731057	16-55	10AUG2020	43742	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10731059	C4591001 1073 10731059	16-55	10AUG2020	45656	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10731062	C4591001 1073 10731062	16-55	11AUG2020	45660	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10731063	C4591001 1073 10731063	16-55	11AUG2020	45662	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10731064	C4591001 1073 10731064	16-55	11AUG2020	46350	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10731065	C4591001 1073 10731065	16-55	11AUG2020	46352	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10731067	C4591001 1073 10731067	16-55	11AUG2020	46353	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo		
10731068	C4591001 1073 10731068	16-55	11AUG2020	46360	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10731077	C4591001 1073 10731077	16-55	12AUG2020	47537	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10731079	C4591001 1073 10731079	16-55	12AUG2020	47538	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731081	C4591001 1073 10731081	16-55	12AUG2020	47541	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731083	C4591001 1073 10731083	16-55	13AUG2020	47545	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10731084	C4591001 1073 10731084	16-55	13AUG2020	48812	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10731085	C4591001 1073 10731085	16-55	13AUG2020	48813	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10771001	C4591001 1077 10771001	16-55	10AUG2020	45162	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771002	C4591001 1077 10771002	16-55	10AUG2020	45164	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10771003	C4591001 1077 10771003	16-55	10AUG2020	45165	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771004	C4591001 1077 10771004	16-55	10AUG2020	45170	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771007	C4591001 1077 10771007	16-55	10AUG2020	45356	Placebo	10AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10771008	C4591001 1077 10771008	16-55	10AUG2020	45358	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771009	C4591001 1077 10771009	16-55	10AUG2020	45361	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771010	C4591001 1077 10771010	16-55	10AUG2020	45363	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771013	C4591001 1077 10771013	16-55	10AUG2020	45801	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771014	C4591001 1077 10771014	16-55	10AUG2020	45802	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10771015	C4591001 1077 10771015	16-55	11AUG2020	45807	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771018	C4591001 1077 10771018	16-55	11AUG2020	45808	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771019	C4591001 1077 10771019	16-55	11AUG2020	46193	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771020	C4591001 1077 10771020	16-55	11AUG2020	46194	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771023	C4591001 1077 10771023	16-55	11AUG2020	46197	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10771027	C4591001 1077 10771027	16-55	11AUG2020	46201	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771028	C4591001 1077 10771028	16-55	11AUG2020	46788	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771029	C4591001 1077 10771029	16-55	11AUG2020	46782	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10771030	C4591001 1077 10771030	16-55	12AUG2020	46791	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10771031	C4591001 1077 10771031	16-55	12AUG2020	46792	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10771035	C4591001 1077 10771035	16-55	12AUG2020	47197	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10771036	C4591001 1077 10771036	16-55	12AUG2020	47198	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10771037	C4591001 1077 10771037	16-55	12AUG2020	47200	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10771038	C4591001 1077 10771038	16-55	12AUG2020	47577	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791017	C4591001 1079 10791017	16-55	31JUL2020	40307	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10791018	C4591001 1079 10791018	16-55	31JUL2020	41145	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791021	C4591001 1079 10791021	16-55	31JUL2020	41148	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10791022	C4591001 1079 10791022	16-55	31JUL2020	41150	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791037	C4591001 1079 10791037	16-55	03AUG2020	41151	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10791039	C4591001 1079 10791039	16-55	03AUG2020	41729	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791040	C4591001 1079 10791040	16-55	03AUG2020	41732	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10791046	C4591001 1079 10791046	16-55	04AUG2020	41733	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791047	C4591001 1079 10791047	16-55	04AUG2020	41734	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10791048	C4591001 1079 10791048	16-55	04AUG2020	42320	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791050	C4591001 1079 10791050	16-55	04AUG2020	42323	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791053	C4591001 1079 10791053	16-55	05AUG2020	42325	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791054	C4591001 1079 10791054	16-55	05AUG2020	42327	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10791058	C4591001 1079 10791058	16-55	05AUG2020	42978	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10791059	C4591001 1079 10791059	16-55	05AUG2020	42979	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791060	C4591001 1079 10791060	16-55	05AUG2020	42984	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10791061	C4591001 1079 10791061	16-55	05AUG2020	222967	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10791062	C4591001 1079 10791062	16-55	05AUG2020	222972	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10791063	C4591001 1079 10791063	16-55	05AUG2020	42985	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791072	C4591001 1079 10791072	16-55	06AUG2020	43939	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo		
10791073	C4591001 1079 10791073	16-55	06AUG2020	43941	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791075	C4591001 1079 10791075	16-55	07AUG2020	43944	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791077	C4591001 1079 10791077	16-55	07AUG2020	43948	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10791079	C4591001 1079 10791079	16-55	07AUG2020	44431	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10791082	C4591001 1079 10791082	16-55	07AUG2020	44432	Placebo	07AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791086	C4591001 1079 10791086	16-55	10AUG2020	44439	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10791087	C4591001 1079 10791087	16-55	10AUG2020	45461	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
10791089	C4591001 1079 10791089	16-55	10AUG2020	45467	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10791090	C4591001 1079 10791090	16-55	10AUG2020	45468	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10791091	C4591001 1079 10791091	16-55	10AUG2020	45472	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10791096	C4591001 1079 10791096	16-55	11AUG2020	46421	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10791097	C4591001 1079 10791097	16-55	11AUG2020	46423	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791098	C4591001 1079 10791098	16-55	11AUG2020	46428	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10791099	C4591001 1079 10791099	16-55	11AUG2020	46432	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10791102	C4591001 1079 10791102	16-55	12AUG2020	47179	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10791106	C4591001 1079 10791106	16-55	12AUG2020	47181	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791107	C4591001 1079 10791107	16-55	12AUG2020	47182	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791109	C4591001 1079 10791109	16-55	12AUG2020	47188	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
10791110	C4591001 1079 10791110	16-55	12AUG2020	47609	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791112	C4591001 1079 10791112	16-55	12AUG2020	47610	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791113	C4591001 1079 10791113	16-55	12AUG2020	47611	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791114	C4591001 1079 10791114	16-55	12AUG2020	47613	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791115	C4591001 1079 10791115	16-55	12AUG2020	48000	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10791116	C4591001 1079 10791116	16-55	12AUG2020	47996	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10791117	C4591001 1079 10791117	16-55	13AUG2020	48002	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10791118	C4591001 1079 10791118	16-55	13AUG2020	48003	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791120	C4591001 1079 10791120	16-55	13AUG2020	48658	Placebo	13AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10791124	C4591001 1079 10791124	16-55	13AUG2020	48660	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791125	C4591001 1079 10791125	16-55	13AUG2020	48663	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791126	C4591001 1079 10791126	16-55	13AUG2020	48662	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791127	C4591001 1079 10791127	16-55	13AUG2020	49410	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10791162	C4591001 1079 10791162	16-55	20AUG2020	56939	Placebo	20AUG2020/ Placebo	26AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801001	C4591001 1080 10801001	16-55	10AUG2020	45173	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801002	C4591001 1080 10801002	16-55	10AUG2020	45174	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10801003	C4591001 1080 10801003	16-55	10AUG2020	45176	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10801004	C4591001 1080 10801004	16-55	10AUG2020	45182	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10801009	C4591001 1080 10801009	16-55	11AUG2020	46038	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10801010	C4591001 1080 10801010	16-55	11AUG2020	46044	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10801017	C4591001 1080 10801017	16-55	12AUG2020	46045	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10801018	C4591001 1080 10801018	16-55	12AUG2020	46048	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10801019	C4591001 1080 10801019	16-55	12AUG2020	47382	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
10801022	C4591001 1080 10801022	16-55	12AUG2020	47389	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801023	C4591001 1080 10801023	16-55	13AUG2020	47391	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10801026	C4591001 1080 10801026	16-55	13AUG2020	47392	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10801027	C4591001 1080 10801027	16-55	13AUG2020	48666	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10801032	C4591001 1080 10801032	16-55	14AUG2020	48667	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801033	C4591001 1080 10801033	16-55	14AUG2020	48670	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10811001	C4591001 1081 10811001	16-55	10AUG2020	45066	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10811003	C4591001 1081 10811003	16-55	10AUG2020	45072	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10811006	C4591001 1081 10811006	16-55	10AUG2020	45073	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10811008	C4591001 1081 10811008	16-55	10AUG2020	45076	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10811009	C4591001 1081 10811009	16-55	10AUG2020	45596	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811010	C4591001 1081 10811010	16-55	10AUG2020	45598	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10811012	C4591001 1081 10811012	16-55	10AUG2020	45602	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10811013	C4591001 1081 10811013	16-55	11AUG2020	45604	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10811018	C4591001 1081 10811018	16-55	11AUG2020	46652	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10811020	C4591001 1081 10811020	16-55	11AUG2020	46655	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10811023	C4591001 1081 10811023	16-55	12AUG2020	46657	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
10811025	C4591001 1081 10811025	16-55	12AUG2020	46660	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10811032	C4591001 1081 10811032	16-55	12AUG2020	47782	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10811033	C4591001 1081 10811033	16-55	12AUG2020	47785	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10811036	C4591001 1081 10811036	16-55	13AUG2020	47787	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811038	C4591001 1081 10811038	16-55	13AUG2020	47788	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10821006	C4591001 1082 10821006	16-55	31JUL2020	40523	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10821008	C4591001 1082 10821008	16-55	31JUL2020	40526	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10821009	C4591001 1082 10821009	16-55	03AUG2020	41489	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821011	C4591001 1082 10821011	16-55	03AUG2020	41493	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821014	C4591001 1082 10821014	16-55	03AUG2020	41495	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821015	C4591001 1082 10821015	16-55	03AUG2020	41741	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10821016	C4591001 1082 10821016	16-55	03AUG2020	41743	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10821018	C4591001 1082 10821018	16-55	03AUG2020	41744	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821019	C4591001 1082 10821019	16-55	03AUG2020	41749	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821020	C4591001 1082108210821020	16-55	03AUG2020	41861	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821021	C4591001 1082108210821021	16-55	04AUG2020	41868	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10821022	C4591001 1082108210821022	16-55	04AUG2020	41865	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
10821023	C4591001 1082108210821023	16-55	04AUG2020	41866	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821024	C4591001 1082108210821024	16-55	04AUG2020	42209	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821025	C4591001 1082108210821025	16-55	04AUG2020	42217	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10821026	C4591001 1082108210821026	16-55	04AUG2020	42213	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821027	C4591001 1082108210821027	16-55	04AUG2020	42218	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821028	C4591001 1082108210821028	16-55	04AUG2020	42354	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10821031	C4591001 1082108210821031	16-55	04AUG2020	42357	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821034	C4591001 10821034	16-55	04AUG2020	42362	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821035	C4591001 10821035	16-55	04AUG2020	42363	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821036	C4591001 10821036	16-55	04AUG2020	42550	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10821037	C4591001 10821037	16-55	04AUG2020	42551	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821038	C4591001 10821038	16-55	05AUG2020	42555	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821039	C4591001 10821039	16-55	05AUG2020	42870	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821041	C4591001 10821041	16-55	05AUG2020	42556	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821043	C4591001 10821043	16-55	05AUG2020	42875	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821044	C4591001 10821044	16-55	05AUG2020	42877	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo		
10821045	C4591001 10821045	16-55	05AUG2020	42880	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821047	C4591001 10821047	16-55	05AUG2020	43040	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821049	C4591001 10821049	16-55	05AUG2020	43044	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821050	C4591001 10821050	16-55	05AUG2020	43046	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10821053	C4591001 10821053	16-55	05AUG2020	43047	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10821054	C4591001 10821054	16-55	05AUG2020	43181	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821056	C4591001 10821056	16-55	06AUG2020	43183	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10821060	C4591001 10821060	16-55	06AUG2020	43188	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821064	C4591001 10821064	16-55	06AUG2020	43191	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821065	C4591001 10821065	16-55	06AUG2020	43705	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10821066	C4591001 10821066	16-55	06AUG2020	43698	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821067	C4591001 1082 10821067	16-55	06AUG2020	43707	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10821069	C4591001 1082 10821069	16-55	06AUG2020	43708	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10821070	C4591001 1082 10821070	16-55	06AUG2020	43902	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821071	C4591001 1082 10821071	16-55	07AUG2020	43905	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821072	C4591001 1082 10821072	16-55	07AUG2020	43907	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821073	C4591001 1082 10821073	16-55	07AUG2020	43910	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821077	C4591001 1082 10821077	16-55	07AUG2020	44469	Placebo	07AUG2020/ Placebo			
10821078	C4591001 1082 10821078	16-55	07AUG2020	44468	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)			
10821080	C4591001 1082 10821080	16-55	07AUG2020	44474	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821081	C4591001 1082 10821081	16-55	07AUG2020	44476	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821082	C4591001 1082 10821082	16-55	07AUG2020	44621	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821083	C4591001 1082 10821083	16-55	07AUG2020	44629	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10821084	C4591001 1082 10821084	16-55	07AUG2020	44623	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821085	C4591001 1082 10821085	16-55	07AUG2020	44632	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10821088	C4591001 1082 10821088	16-55	10AUG2020	45636	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821089	C4591001 1082 10821089	16-55	10AUG2020	45638	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10821090	C4591001 1082 10821090	16-55	10AUG2020	45632	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821095	C4591001 1082 10821095	16-55	11AUG2020	226245	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821100	C4591001 1082 10821100	16-55	12AUG2020	45639	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10821102	C4591001 1082 10821102	16-55	13AUG2020	48870	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821104	C4591001 1082 10821104	16-55	14AUG2020	48876	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10821105	C4591001 1082 10821105	16-55	14AUG2020	48880	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10821106	C4591001 1082 10821106	16-55	14AUG2020	50238	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821107	C4591001 1082 10821107	16-55	14AUG2020	48879	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10821109	C4591001 1082 10821109	16-55	14AUG2020	50239	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10831007	C4591001 1083 10831007	16-55	30JUL2020	40367	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10831009	C4591001 1083 10831009	16-55	30JUL2020	40368	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10831011	C4591001 1083 10831011	16-55	30JUL2020	40369	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10831013	C4591001 1083 10831013	16-55	30JUL2020	40761	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831015	C4591001 1083 10831015	16-55	31JUL2020	40764	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831017	C4591001 1083 10831017	16-55	31JUL2020	40765	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10831018	C4591001 1083 10831018	16-55	31JUL2020	40766	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10831020	C4591001 1083 10831020	16-55	03AUG2020	41602	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10831025	C4591001 1083 10831025	16-55	04AUG2020	41605	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10831026	C4591001 1083 10831026	16-55	04AUG2020	41604	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10831029	C4591001 1083 10831029	16-55	04AUG2020	41608	Placebo	04AUG2020/ Placebo			
10831032	C4591001 1083 10831032	16-55	04AUG2020	42503	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831033	C4591001 1083 10831033	16-55	04AUG2020	42497	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10831034	C4591001 1083 10831034	16-55	04AUG2020	42499	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10831040	C4591001 1083 10831040	16-55	04AUG2020	42508	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831043	C4591001 1083 10831043	16-55	04AUG2020	42713	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831044	C4591001 1083 10831044	16-55	05AUG2020	42714	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831045	C4591001 1083 10831045	16-55	05AUG2020	42722	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10831046	C4591001 1083 10831046	16-55	05AUG2020	42715	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831047	C4591001 1083 10831047	16-55	05AUG2020	43073	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831052	C4591001 1083 10831052	16-55	05AUG2020	43077	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
10831054	C4591001 1083 10831054	16-55	05AUG2020	43079	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10831055	C4591001 1083 10831055	16-55	05AUG2020	43082	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831057	C4591001 1083 10831057	16-55	05AUG2020	43385	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10831060	C4591001 1083 10831060	16-55	06AUG2020	43386	Placebo	06AUG2020/ Placebo		06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831061	C4591001 1083 10831061	16-55	07AUG2020	43392	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10831062	C4591001 1083 10831062	16-55	07AUG2020	43395	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10831065	C4591001 1083 10831065	16-55	07AUG2020	44922	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10831067	C4591001 1083 10831067	16-55	07AUG2020	44923	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831068	C4591001 1083 10831068	16-55	10AUG2020	44924	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10831069	C4591001 1083 10831069	16-55	10AUG2020	44930	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831070	C4591001 1083 10831070	16-55	10AUG2020	45389	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10831074	C4591001 1083 10831074	16-55	10AUG2020	45393	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10831078	C4591001 1083 10831078	16-55	10AUG2020	45399	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831081	C4591001 1083 10831081	16-55	10AUG2020	45400	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831082	C4591001 1083 10831082	16-55	11AUG2020	46171	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831083	C4591001 1083 10831083	16-55	11AUG2020	46175	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831084	C4591001 1083 10831084	16-55	11AUG2020	46178	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10831086	C4591001 1083 10831086	16-55	11AUG2020	46179	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831090	C4591001 1083 10831090	16-55	13AUG2020	48478	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831091	C4591001 1083 10831091	16-55	13AUG2020	48482	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10831093	C4591001 1083 10831093	16-55	13AUG2020	48483	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10831094	C4591001 1083 10831094	16-55	13AUG2020	48484	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10831098	C4591001 1083 10831098	16-55	13AUG2020	49062	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10831099	C4591001 1083 10831099	16-55	13AUG2020	49065	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831101	C4591001 1083 10831101	16-55	13AUG2020	49071	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10831102	C4591001 1083 10831102	16-55	13AUG2020	49072	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10841004	C4591001 1084 10841004	16-55	07AUG2020	44454	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841008	C4591001 1084 10841008	16-55	30JUL2020	40596	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
10841009	C4591001 1084 10841009	16-55	30JUL2020	40598	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		
10841012	C4591001 1084 10841012	16-55	03AUG2020	41514	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841013	C4591001 1084 10841013	16-55	03AUG2020	41524	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841014	C4591001 1084 10841014	16-55	03AUG2020	41520	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841015	C4591001 1084 10841015	16-55	03AUG2020	41648	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10841016	C4591001 1084 10841016	16-55	03AUG2020	41516	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841017	C4591001 1084 10841017	16-55	03AUG2020	41651	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10841018	C4591001 1084 10841018	16-55	03AUG2020	41652	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841023	C4591001 1084 10841023	16-55	03AUG2020	41925	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo		
10841029	C4591001 1084 10841029	16-55	03AUG2020	41654	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10841031	C4591001 1084 10841031	16-55	03AUG2020	41930	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841033	C4591001 1084 10841033	16-55	03AUG2020	41928	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841035	C4591001 1084 10841035	16-55	03AUG2020	41931	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			
10841036	C4591001 1084 10841036	16-55	05AUG2020	42763	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841038	C4591001 1084 10841038	16-55	05AUG2020	42764	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841041	C4591001 1084 10841041	16-55	05AUG2020	42766	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841042	C4591001 1084 10841042	16-55	05AUG2020	42771	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10841044	C4591001 1084 10841044	16-55	05AUG2020	43086	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841047	C4591001 1084 10841047	16-55	05AUG2020	43092	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841054	C4591001 1084 10841054	16-55	05AUG2020	43093	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841055	C4591001 1084 10841055	16-55	05AUG2020	43275	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841056	C4591001 1084 10841056	16-55	05AUG2020	43095	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841057	C4591001 1084 10841057	16-55	05AUG2020	43274	Placebo	05AUG2020/ Placebo			
10841058	C4591001 1084 10841058	16-55	05AUG2020	43273	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841059	C4591001 1084 10841059	16-55	05AUG2020	43276	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10841060	C4591001 1084 10841060	16-55	07AUG2020	44334	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841061	C4591001 1084 10841061	16-55	07AUG2020	44336	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
10841062	C4591001 1084 10841062	16-55	07AUG2020	44463	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841064	C4591001 1084 10841064	16-55	07AUG2020	44340	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841066	C4591001 1084 10841066	16-55	07AUG2020	44544	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841068	C4591001 1084 10841068	16-55	07AUG2020	44459	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841069	C4591001 1084 10841069	16-55	07AUG2020	44344	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841071	C4591001 1084 10841071	16-55	07AUG2020	44539	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841072	C4591001 1084 10841072	16-55	07AUG2020	44461	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10841073	C4591001 1084 10841073	16-55	07AUG2020	44545	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841076	C4591001 1084 10841076	16-55	07AUG2020	44646	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841079	C4591001 1084 10841079	16-55	07AUG2020	44547	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841081	C4591001 1084 10841081	16-55	07AUG2020	44647	Placebo	07AUG2020/ Placebo	31AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841082	C4591001 1084 10841082	16-55	07AUG2020	44653	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841083	C4591001 1084 10841083	16-55	07AUG2020	44652	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841084	C4591001 1084 10841084	16-55	07AUG2020	44787	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841085	C4591001 1084 10841085	16-55	07AUG2020	44778	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841087	C4591001 1084 10841087	16-55	07AUG2020	44779	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841089	C4591001 1084 10841089	16-55	07AUG2020	44790	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841090	C4591001 1084 10841090	16-55	07AUG2020	44788	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841091	C4591001 1084 10841091	16-55	07AUG2020	44795	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841092	C4591001 1084 10841092	16-55	07AUG2020	44796	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841095	C4591001 1084 10841095	16-55	10AUG2020	45305	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841097	C4591001 1084 10841097	16-55	10AUG2020	44799	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841098	C4591001 1084 10841098	16-55	10AUG2020	45312	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841099	C4591001 1084 10841099	16-55	10AUG2020	45309	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841100	C4591001 1084 10841100	16-55	10AUG2020	45314	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10841101	C4591001 1084 10841101	16-55	10AUG2020	45509	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841102	C4591001 1084 10841102	16-55	10AUG2020	45511	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841104	C4591001 1084 10841104	16-55	10AUG2020	45513	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841107	C4591001 1084 10841107	16-55	10AUG2020	45515	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841111	C4591001 1084 10841111	16-55	10AUG2020	45618	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841113	C4591001 1084 10841113	16-55	10AUG2020	45620	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10841114	C4591001 1084 10841114	16-55	10AUG2020	45626	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841115	C4591001 1084 10841115	16-55	10AUG2020	45623	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841117	C4591001 1084 10841117	16-55	10AUG2020	45821	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841118	C4591001 1084 10841118	16-55	10AUG2020	45825	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10841119	C4591001 1084 10841119	16-55	10AUG2020	45889	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10841120	C4591001 1084 10841120	16-55	10AUG2020	45826	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841121	C4591001 1084 10841121	16-55	10AUG2020	45884	Placebo	10AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841122	C4591001 1084 10841122	16-55	10AUG2020	45832	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841123	C4591001 1084 10841123	16-55	10AUG2020	45886	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10841126	C4591001 1084 10841126	16-55	12AUG2020	45891	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841129	C4591001 1084 10841129	16-55	12AUG2020	47201	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841136	C4591001 1084 10841136	16-55	12AUG2020	47205	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841137	C4591001 1084 10841137	16-55	12AUG2020	47208	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
10841138	C4591001 1084 10841138	16-55	12AUG2020	47202	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841141	C4591001 1084 10841141	16-55	12AUG2020	47794	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841146	C4591001 1084 10841146	16-55	12AUG2020	47793	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10841148	C4591001 1084 10841148	16-55	12AUG2020	47797	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10841153	C4591001 1084 10841153	16-55	12AUG2020	48079	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841154	C4591001 1084 10841154	16-55	12AUG2020	47799	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841155	C4591001 1084 10841155	16-55	14AUG2020	48088	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841156	C4591001 1084 10841156	16-55	14AUG2020	48086	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10841159	C4591001 1084 10841159	16-55	14AUG2020	48084	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841163	C4591001 1084 10841163	16-55	14AUG2020	50300	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841164	C4591001 1084 10841164	16-55	14AUG2020	50303	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841181	C4591001 1084 10841181	16-55	14AUG2020	50308	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841182	C4591001 1084 10841182	16-55	14AUG2020	50889	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10841186	C4591001 1084 10841186	16-55	14AUG2020	50895	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10851013	C4591001 1085 10851013	16-55	30JUL2020	40738	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851014	C4591001 1085 10851014	16-55	30JUL2020	40742	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10851015	C4591001 1085 10851015	16-55	30JUL2020	40733	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10851016	C4591001 1085 10851016	16-55	01AUG2020	40743	Placebo	01AUG2020/ Placebo	22AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10851018	C4591001 1085 10851018	16-55	01AUG2020	41321	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
10851019	C4591001 1085 10851019	16-55	01AUG2020	41323	Placebo	01AUG2020/ Placebo	22AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10851022	C4591001 1085 10851022	16-55	01AUG2020	41330	Placebo	01AUG2020/ Placebo	22AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851023	C4591001 1085 10851023	16-55	01AUG2020	41328	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10851026	C4591001 1085 10851026	16-55	04AUG2020	42284	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10851027	C4591001 1085 10851027	16-55	04AUG2020	42286	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851029	C4591001 1085 10851029	16-55	04AUG2020	42287	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851032	C4591001 1085 10851032	16-55	05AUG2020	42290	Placebo	05AUG2020/ Placebo	02SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10851033	C4591001 1085 10851033	16-55	05AUG2020	43206	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10851034	C4591001 1085 10851034	16-55	05AUG2020	43210	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10851035	C4591001 1085 10851035	16-55	05AUG2020	43214	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10851039	C4591001 1085 10851039	16-55	05AUG2020	43216	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10851041	C4591001 1085 10851041	16-55	06AUG2020	43628	Placebo	06AUG2020/ Placebo	02SEP2020/ Placebo		
10851047	C4591001 1085 10851047	16-55	06AUG2020	43629	Placebo	06AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10851048	C4591001 1085 10851048	16-55	06AUG2020	43631	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10851049	C4591001 1085 10851049	16-55	06AUG2020	44156	Placebo	06AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10851050	C4591001 1085 10851050	16-55	06AUG2020	43636	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851051	C4591001 1085 10851051	16-55	07AUG2020	44159	Placebo	07AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10851058	C4591001 1085 10851058	16-55	07AUG2020	44160	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10851062	C4591001 1085 10851062	16-55	07AUG2020	44874	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10851063	C4591001 1085 10851063	16-55	07AUG2020	44162	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10851064	C4591001 1085 10851064	16-55	08AUG2020	44875	Placebo	08AUG2020/ Placebo	03SEP2020/ Placebo		
10851067	C4591001 1085 10851067	16-55	08AUG2020	44884	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
10851068	C4591001 1085 10851068	16-55	08AUG2020	44879	Placebo	08AUG2020/ Placebo	05SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10851069	C4591001 1085 10851069	16-55	08AUG2020	44986	Placebo	08AUG2020/ Placebo	03SEP2020/ Placebo		
10851070	C4591001 1085 10851070	16-55	08AUG2020	44990	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
10851075	C4591001 1085 10851075	16-55	08AUG2020	44991	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851079	C4591001 1085 10851079	16-55	10AUG2020	44992	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10851081	C4591001 1085 10851081	16-55	10AUG2020	45896	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
10851090	C4591001 1085 10851090	16-55	12AUG2020	45898	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10851098	C4591001 1085 10851098	16-55	13AUG2020	45900	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10851099	C4591001 1085 10851099	16-55	13AUG2020	45902	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10871007	C4591001 1087 10871007	16-55	07AUG2020	44230	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871010	C4591001 1087 10871010	16-55	07AUG2020	44231	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10871020	C4591001 1087 10871020	16-55	07AUG2020	44235	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10871021	C4591001 1087 10871021	16-55	07AUG2020	44233	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10871028	C4591001 1087 10871028	16-55	07AUG2020	44766	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871035	C4591001 1087 10871035	16-55	08AUG2020	44770	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10871041	C4591001 1087 10871041	16-55	10AUG2020	44772	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871042	C4591001 1087 10871042	16-55	10AUG2020	44776	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10871045	C4591001 1087 10871045	16-55	10AUG2020	45401	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871046	C4591001 1087 10871046	16-55	10AUG2020	45404	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871052	C4591001 1087 10871052	16-55	10AUG2020	45406	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871053	C4591001 1087 10871053	16-55	11AUG2020	45412	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871059	C4591001 1087 10871059	16-55	11AUG2020	46278	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871060	C4591001 1087 10871060	16-55	11AUG2020	46284	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10871061	C4591001 1087 10871061	16-55	11AUG2020	46286	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871062	C4591001 1087 10871062	16-55	11AUG2020	46281	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871064	C4591001 1087 10871064	16-55	11AUG2020	46400	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871065	C4591001 1087 10871065	16-55	11AUG2020	46402	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10871066	C4591001 1087 10871066	16-55	11AUG2020	46405	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871067	C4591001 1087 10871067	16-55	11AUG2020	46407	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10871068	C4591001 1087 10871068	16-55	11AUG2020	46570	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10871074	C4591001 1087 10871074	16-55	11AUG2020	46576	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10871076	C4591001 1087 10871076	16-55	11AUG2020	46879	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10871078	C4591001 1087 10871078	16-55	12AUG2020	46883	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10881005	C4591001 1088 10881005	16-55	12AUG2020	47047	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881009	C4591001 1088 10881009	16-55	12AUG2020	47051	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881010	C4591001 1088 10881010	16-55	12AUG2020	47053	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10881011	C4591001 1088 10881011	16-55	12AUG2020	47056	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10881012	C4591001 1088 10881012	16-55	12AUG2020	47945	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881016	C4591001 1088 10881016	16-55	13AUG2020	47948	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881017	C4591001 1088 10881017	16-55	13AUG2020	47951	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10881019	C4591001 1088 10881019	16-55	13AUG2020	47952	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10881021	C4591001 1088 10881021	16-55	13AUG2020	49386	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10881024	C4591001 1088 10881024	16-55	13AUG2020	49389	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10881025	C4591001 1088 10881025	16-55	14AUG2020	49391	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881036	C4591001 1088 10881036	16-55	14AUG2020	50683	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881037	C4591001 1088 10881037	16-55	15AUG2020	50684	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10881038	C4591001 1088 10881038	16-55	15AUG2020	50691	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10881039	C4591001 1088 10881039	16-55	15AUG2020	51276	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10881040	C4591001 1088 10881040	16-55	15AUG2020	51270	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10881128	C4591001 1088 10881128	16-55	01SEP2020	75393	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10891020	C4591001 1089 10891020	16-55	31JUL2020	40576	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10891022	C4591001 1089 10891022	16-55	31JUL2020	41059	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10891025	C4591001 1089 10891025	16-55	31JUL2020	41061	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10891027	C4591001 1089 10891027	16-55	31JUL2020	41067	Placebo	31JUL2020/ Placebo	25AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891029	C4591001 1089 10891029	16-55	03AUG2020	41068	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10891049	C4591001 1089 10891049	16-55	04AUG2020	42413	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10891050	C4591001 1089 10891050	16-55	04AUG2020	42419	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10891054	C4591001 1089 10891054	16-55	04AUG2020	42416	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10891055	C4591001 1089 10891055	16-55	04AUG2020	42422	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10891056	C4591001 1089 10891056	16-55	04AUG2020	42561	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10891057	C4591001 1089 10891057	16-55	04AUG2020	42562	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10891058	C4591001 1089 10891058	16-55	05AUG2020	42564	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10891059	C4591001 1089 10891059	16-55	05AUG2020	42566	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10891061	C4591001 1089 10891061	16-55	05AUG2020	42894	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891062	C4591001 1089 10891062	16-55	05AUG2020	42895	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10891064	C4591001 1089 10891064	16-55	05AUG2020	42897	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10891065	C4591001 1089 10891065	16-55	05AUG2020	42901	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10891067	C4591001 1089 10891067	16-55	06AUG2020	43508	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10891070	C4591001 1089 10891070	16-55	06AUG2020	43509	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10891072	C4591001 1089 10891072	16-55	06AUG2020	43513	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10891074	C4591001 1089 10891074	16-55	06AUG2020	43515	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10891076	C4591001 1089 10891076	16-55	06AUG2020	43844	Placebo	06AUG2020/ Placebo			
10891077	C4591001 1089 10891077	16-55	06AUG2020	43845	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10891078	C4591001 1089 10891078	16-55	06AUG2020	43849	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891079	C4591001 1089 10891079	16-55	06AUG2020	43850	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891080	C4591001 1089 10891080	16-55	06AUG2020	44057	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10891082	C4591001 1089 10891082	16-55	07AUG2020	44058	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10891084	C4591001 1089 10891084	16-55	07AUG2020	44060	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10891091	C4591001 1089 10891091	16-55	10AUG2020	44062	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10891100	C4591001 1089 10891100	16-55	11AUG2020	46242	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891101	C4591001 1089 10891101	16-55	11AUG2020	46245	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10891103	C4591001 1089 10891103	16-55	11AUG2020	46247	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo		
10891105	C4591001 1089 10891105	16-55	11AUG2020	46250	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10891106	C4591001 1089 10891106	16-55	11AUG2020	46794	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891107	C4591001 1089 10891107	16-55	12AUG2020	46796	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10891111	C4591001 1089 10891111	16-55	12AUG2020	46803	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10891113	C4591001 1089 10891113	16-55	12AUG2020	47861	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10891114	C4591001 1089 10891114	16-55	12AUG2020	47862	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10891115	C4591001 1089 10891115	16-55	13AUG2020	47863	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10891116	C4591001 1089 10891116	16-55	13AUG2020	47869	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891119	C4591001 1089 10891119	16-55	13AUG2020	49027	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10891120	C4591001 1089 10891120	16-55	13AUG2020	49030	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10891121	C4591001 1089 10891121	16-55	13AUG2020	49031	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10891123	C4591001 1089 10891123	16-55	14AUG2020	49036	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891130	C4591001 1089 10891130	16-55	14AUG2020	50622	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901001	C4591001 1090 10901001	16-55	31JUL2020	41045	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901002	C4591001 1090 10901002	16-55	31JUL2020	41051	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901005	C4591001 1090 10901005	16-55	31JUL2020	41189	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901006	C4591001 1090 10901006	16-55	31JUL2020	41052	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10901007	C4591001 1090 10901007	16-55	31JUL2020	41053	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		
10901008	C4591001 1090 10901008	16-55	31JUL2020	41192	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901009	C4591001 1090 10901009	16-55	31JUL2020	41199	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10901012	C4591001 1090 10901012	16-55	31JUL2020	41200	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10901014	C4591001 1090 10901014	16-55	03AUG2020	41501	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901015	C4591001 1090 10901015	16-55	03AUG2020	41503	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901016	C4591001 1090 10901016	16-55	03AUG2020	41507	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10901020	C4591001 1090 10901020	16-55	03AUG2020	41509	Placebo	03AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10901021	C4591001 1090 10901021	16-55	03AUG2020	41683	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10901022	C4591001 1090 10901022	16-55	03AUG2020	41682	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901023	C4591001 1090 10901023	16-55	03AUG2020	41691	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901024	C4591001 1090 10901024	16-55	03AUG2020	41684	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10901029	C4591001 1090 10901029	16-55	03AUG2020	41934	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10901031	C4591001 1090 10901031	16-55	03AUG2020	41935	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901034	C4591001 1090 10901034	16-55	04AUG2020	41936	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901035	C4591001 1090 10901035	16-55	04AUG2020	41942	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901037	C4591001 1090 10901037	16-55	04AUG2020	42236	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10901038	C4591001 1090 10901038	16-55	04AUG2020	42238	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901039	C4591001 1090 10901039	16-55	04AUG2020	42239	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901043	C4591001 1090 10901043	16-55	04AUG2020	42533	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901044	C4591001 1090 10901044	16-55	04AUG2020	42544	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10901045	C4591001 1090 10901045	16-55	04AUG2020	42244	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901046	C4591001 1090 10901046	16-55	04AUG2020	42541	Placebo	04AUG2020/ Placebo	31AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10901047	C4591001 1090 10901047	16-55	04AUG2020	42539	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901049	C4591001 1090 10901049	16-55	04AUG2020	42596	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901050	C4591001 1090 10901050	16-55	04AUG2020	42593	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901051	C4591001 1090 10901051	16-55	04AUG2020	42600	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901052	C4591001 1090 10901052	16-55	04AUG2020	42597	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo		
10901058	C4591001 1090 10901058	16-55	05AUG2020	43049	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10901061	C4591001 1090 10901061	16-55	05AUG2020	43057	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901065	C4591001 1090 10901065	16-55	05AUG2020	43060	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901067	C4591001 1090 10901067	16-55	05AUG2020	43059	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo		
10901068	C4591001 1090 10901068	16-55	05AUG2020	43301	Placebo	05AUG2020/ Placebo			
10901070	C4591001 1090 10901070	16-55	05AUG2020	43305	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901072	C4591001 1090 10901072	16-55	05AUG2020	43307	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901073	C4591001 1090 10901073	16-55	05AUG2020	43312	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10901074	C4591001 1090 10901074	16-55	05AUG2020	43397	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10901076	C4591001 1090 10901076	16-55	06AUG2020	43403	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10901079	C4591001 1090 10901079	16-55	06AUG2020	43405	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901081	C4591001 1090 10901081	16-55	06AUG2020	43406	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901086	C4591001 1090 10901086	16-55	06AUG2020	43949	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo		
10901088	C4591001 1090 10901088	16-55	06AUG2020	43954	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901090	C4591001 1090 10901090	16-55	06AUG2020	43951	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901094	C4591001 1090 10901094	16-55	07AUG2020	43955	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10901095	C4591001 1090 10901095	16-55	07AUG2020	44503	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901096	C4591001 1090 10901096	16-55	07AUG2020	44504	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901097	C4591001 1090 10901097	16-55	07AUG2020	44510	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901099	C4591001 1090 10901099	16-55	07AUG2020	44706	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10901101	C4591001 1090 10901101	16-55	07AUG2020	44505	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901103	C4591001 1090 10901103	16-55	07AUG2020	44713	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10901104	C4591001 1090 10901104	16-55	07AUG2020	44707	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901105	C4591001 1090 10901105	16-55	07AUG2020	44802	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10901106	C4591001 1090 10901106	16-55	07AUG2020	44936	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901109	C4591001 1090 10901109	16-55	07AUG2020	44710	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901111	C4591001 1090 10901111	16-55	07AUG2020	44803	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901112	C4591001 1090 10901112	16-55	07AUG2020	44806	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901114	C4591001 1090 10901114	16-55	07AUG2020	44937	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10901115	C4591001 1090 10901115	16-55	07AUG2020	44812	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10901116	C4591001 1090 10901116	16-55	10AUG2020	44939	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10901125	C4591001 1090 10901125	16-55	10AUG2020	44941	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901131	C4591001 1090 10901131	16-55	11AUG2020	46217	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901132	C4591001 1090 10901132	16-55	11AUG2020	46218	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901133	C4591001 1090 10901133	16-55	11AUG2020	46221	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901135	C4591001 1090 10901135	16-55	11AUG2020	46225	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901136	C4591001 1090 10901136	16-55	11AUG2020	46469	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901139	C4591001 1090 10901139	16-55	11AUG2020	46472	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901140	C4591001 1090 10901140	16-55	11AUG2020	46471	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10901147	C4591001 1090 10901147	16-55	12AUG2020	46478	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901154	C4591001 1090 10901154	16-55	12AUG2020	47958	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10901156	C4591001 1090 10901156	16-55	12AUG2020	47966	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
10901157	C4591001 1090 10901157	16-55	12AUG2020	47967	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10901160	C4591001 1090 10901160	16-55	13AUG2020	47968	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901161	C4591001 1090 10901161	16-55	13AUG2020	48559	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901163	C4591001 1090 10901163	16-55	13AUG2020	48561	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901167	C4591001 1090 10901167	16-55	13AUG2020	48565	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901169	C4591001 1090 10901169	16-55	13AUG2020	48568	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10901172	C4591001 1090 10901172	16-55	13AUG2020	49282	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10901174	C4591001 1090 10901174	16-55	13AUG2020	49285	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10901177	C4591001 1090 10901177	16-55	13AUG2020	49287	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10901178	C4591001 1090 10901178	16-55	13AUG2020	49286	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901185	C4591001 1090 10901185	16-55	14AUG2020	50227	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901193	C4591001 1090 10901193	16-55	14AUG2020	50234	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10901197	C4591001 1090 10901197	16-55	14AUG2020	50231	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901200	C4591001 1090 10901200	16-55	14AUG2020	50814	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10901201	C4591001 1090 10901201	16-55	14AUG2020	50815	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901245	C4591001 1090 10901245	16-55	18AUG2020	54088	Placebo	18AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10911005	C4591001 1091 10911005	16-55	30JUL2020	40686	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10911008	C4591001 1091 10911008	16-55	31JUL2020	40687	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10911011	C4591001 1091 10911011	16-55	31JUL2020	40688	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911013	C4591001 1091 10911013	16-55	31JUL2020	40689	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10911014	C4591001 1091 10911014	16-55	31JUL2020	40896	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911015	C4591001 1091 10911015	16-55	31JUL2020	40891	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10911017	C4591001 1091 10911017	16-55	03AUG2020	40898	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10911019	C4591001 1091 10911019	16-55	03AUG2020	41673	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911020	C4591001 1091 10911020	16-55	03AUG2020	40897	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911022	C4591001 1091 10911022	16-55	03AUG2020	41679	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10911025	C4591001 1091 10911025	16-55	03AUG2020	41680	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10911027	C4591001 1091 10911027	16-55	04AUG2020	42059	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911032	C4591001 1091 10911032	16-55	04AUG2020	42056	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911033	C4591001 1091 10911033	16-55	04AUG2020	42053	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911037	C4591001 1091 10911037	16-55	04AUG2020	42063	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911038	C4591001 1091 10911038	16-55	04AUG2020	42341	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10911039	C4591001 1091 10911039	16-55	04AUG2020	42348	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
10911042	C4591001 1091 10911042	16-55	04AUG2020	42346	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo		
10911043	C4591001 1091 10911043	16-55	04AUG2020	42452	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911046	C4591001 1091 10911046	16-55	04AUG2020	42349	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911051	C4591001 1091 10911051	16-55	05AUG2020	42456	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911052	C4591001 1091 10911052	16-55	05AUG2020	42458	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10911053	C4591001 1091 10911053	16-55	05AUG2020	43133	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10911054	C4591001 1091 10911054	16-55	05AUG2020	42459	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10911057	C4591001 1091 10911057	16-55	05AUG2020	43135	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911058	C4591001 1091 10911058	16-55	05AUG2020	43138	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10911061	C4591001 1091 10911061	16-55	05AUG2020	43316	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10911062	C4591001 1091 10911062	16-55	05AUG2020	43144	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911065	C4591001 1091 10911065	16-55	05AUG2020	43319	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911066	C4591001 1091 10911066	16-55	06AUG2020	43320	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10911067	C4591001 1091 10911067	16-55	06AUG2020	43324	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10911069	C4591001 1091 10911069	16-55	06AUG2020	43497	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10911070	C4591001 1091 10911070	16-55	06AUG2020	43495	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911072	C4591001 1091 10911072	16-55	06AUG2020	43496	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10911075	C4591001 1091 10911075	16-55	06AUG2020	43499	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10911077	C4591001 1091 10911077	16-55	06AUG2020	43723	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)			
10911078	C4591001 1091 10911078	16-55	06AUG2020	43724	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911079	C4591001 1091 10911079	16-55	06AUG2020	43727	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911082	C4591001 1091 10911082	16-55	06AUG2020	43729	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911083	C4591001 1091 10911083	16-55	06AUG2020	43855	Placebo	06AUG2020/ Placebo			
10911085	C4591001 1091 10911085	16-55	06AUG2020	43853	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10911087	C4591001 1091 10911087	16-55	10AUG2020	43861	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911088	C4591001 1091 10911088	16-55	10AUG2020	43862	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10911090	C4591001 1091 10911090	16-55	10AUG2020	45693	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10911091	C4591001 1091 10911091	16-55	10AUG2020	45698	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
10911093	C4591001 1091 10911093	16-55	10AUG2020	45700	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911095	C4591001 1091 10911095	16-55	11AUG2020	46184	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10911096	C4591001 1091 10911096	16-55	11AUG2020	46183	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911098	C4591001 1091 10911098	16-55	11AUG2020	46186	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911099	C4591001 1091 10911099	16-55	11AUG2020	46192	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
10911103	C4591001 1091 10911103	16-55	11AUG2020	46675	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911104	C4591001 1091 10911104	16-55	12AUG2020	46677	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911106	C4591001 1091 10911106	16-55	12AUG2020	46680	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10911107	C4591001 1091 10911107	16-55	12AUG2020	47266	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911108	C4591001 1091 10911108	16-55	12AUG2020	46682	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911111	C4591001 1091 10911111	16-55	12AUG2020	47268	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10911113	C4591001 1091 10911113	16-55	13AUG2020	47269	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10911116	C4591001 1091 10911116	16-55	13AUG2020	47272	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10911118	C4591001 1091 10911118	16-55	13AUG2020	48678	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911119	C4591001 1091 10911119	16-55	13AUG2020	48686	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10911120	C4591001 1091 10911120	16-55	13AUG2020	48681	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10911121	C4591001 1091 10911121	16-55	13AUG2020	49362	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10911122	C4591001 1091 10911122	16-55	13AUG2020	48683	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
10931001	C4591001 1093 10931001	16-55	15AUG2020	51223	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10931002	C4591001 1093 10931002	16-55	15AUG2020	51226	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10931003	C4591001 1093 10931003	16-55	15AUG2020	51229	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10931006	C4591001 1093 10931006	16-55	15AUG2020	51232	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10931007	C4591001 1093 10931007	16-55	15AUG2020	51438	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
10941004	C4591001 1094 10941004	16-55	12AUG2020	48018	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941010	C4591001 1094 10941010	16-55	13AUG2020	48020	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10941016	C4591001 1094 10941016	16-55	14AUG2020	48026	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10941017	C4591001 1094 10941017	16-55	14AUG2020	48028	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10951008	C4591001 1095 10951008	16-55	30JUL2020	40703	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
10951009	C4591001 1095 10951009	16-55	31JUL2020	40705	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10951011	C4591001 1095 10951011	16-55	31JUL2020	40708	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
10951014	C4591001 1095 10951014	16-55	31JUL2020	41177	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10951018	C4591001 1095 10951018	16-55	31JUL2020	41178	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
10951021	C4591001 1095 10951021	16-55	03AUG2020	41184	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10951022	C4591001 1095 10951022	16-55	03AUG2020	41550	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951023	C4591001 1095 10951023	16-55	03AUG2020	41179	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951024	C4591001 1095 10951024	16-55	03AUG2020	41551	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951025	C4591001 1095 10951025	16-55	03AUG2020	41552	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10951026	C4591001 1095 10951026	16-55	03AUG2020	41754	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951028	C4591001 1095 10951028	16-55	03AUG2020	41553	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951029	C4591001 1095 10951029	16-55	03AUG2020	41759	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10951030	C4591001 1095 10951030	16-55	03AUG2020	41756	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951031	C4591001 1095 10951031	16-55	03AUG2020	41764	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
10951033	C4591001 1095 10951033	16-55	03AUG2020	41910	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951034	C4591001 1095 10951034	16-55	03AUG2020	41909	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951036	C4591001 1095 10951036	16-55	03AUG2020	41914	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951038	C4591001 1095 10951038	16-55	03AUG2020	41918	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	
10951039	C4591001 1095 10951039	16-55	03AUG2020	42021	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
10951040	C4591001 1095 10951040	16-55	04AUG2020	42026	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
10951042	C4591001 1095 10951042	16-55	04AUG2020	42027	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951044	C4591001 1095 10951044	16-55	04AUG2020	42028	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951045	C4591001 1095 10951045	16-55	04AUG2020	42377	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951046	C4591001 1095 10951046	16-55	04AUG2020	42379	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
10951047	C4591001 1095 10951047	16-55	04AUG2020	42385	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951055	C4591001 1095 10951055	16-55	04AUG2020	42388	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951056	C4591001 1095 10951056	16-55	05AUG2020	42774	Placebo	05AUG2020/ Placebo			
10951057	C4591001 1095 10951057	16-55	05AUG2020	42780	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951058	C4591001 1095 10951058	16-55	05AUG2020	42782	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951059	C4591001 1095 10951059	16-55	05AUG2020	42781	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10951060	C4591001 1095 10951060	16-55	05AUG2020	42989	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10951061	C4591001 1095 10951061	16-55	05AUG2020	42992	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10951062	C4591001 1095 10951062	16-55	05AUG2020	42994	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951066	C4591001 1095 10951066	16-55	05AUG2020	42997	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951069	C4591001 1095 10951069	16-55	06AUG2020	43543	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951070	C4591001 1095 10951070	16-55	06AUG2020	43546	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951073	C4591001 1095 10951073	16-55	06AUG2020	43550	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951074	C4591001 1095 10951074	16-55	06AUG2020	43551	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10951076	C4591001 1095 10951076	16-55	06AUG2020	43793	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10951083	C4591001 1095 10951083	16-55	06AUG2020	43797	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951084	C4591001 1095 10951084	16-55	06AUG2020	43802	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
10951087	C4591001 1095 10951087	16-55	06AUG2020	43804	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951089	C4591001 1095 10951089	16-55	06AUG2020	44203	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951090	C4591001 1095 10951090	16-55	06AUG2020	44202	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10951091	C4591001 1095 10951091	16-55	06AUG2020	44207	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
10951092	C4591001 1095 10951092	16-55	06AUG2020	44211	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951093	C4591001 1095 10951093	16-55	07AUG2020	44290	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10951094	C4591001 1095 10951094	16-55	07AUG2020	44294	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
10951095	C4591001 1095 10951095	16-55	07AUG2020	44291	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951096	C4591001 1095 10951096	16-55	07AUG2020	44295	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10951106	C4591001 1095 10951106	16-55	07AUG2020	44850	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10961007	C4591001 1096 10961007	16-55	13AUG2020	48881	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10961010	C4591001 1096 10961010	16-55	13AUG2020	48883	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
10961011	C4591001 1096 10961011	16-55	13AUG2020	48888	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10961012	C4591001 1096 10961012	16-55	13AUG2020	48892	Placebo	13AUG2020/ Placebo	10SEP2020/ Placebo		
10961013	C4591001 1096 10961013	16-55	13AUG2020	49555	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961018	C4591001 1096 10961018	16-55	13AUG2020	49558	Placebo	13AUG2020/ Placebo	15SEP2020/ Placebo		
10961022	C4591001 1096 10961022	16-55	14AUG2020	49559	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10961023	C4591001 1096 10961023	16-55	14AUG2020	49564	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10961029	C4591001 1096 10961029	16-55	14AUG2020	50905	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
10961030	C4591001 1096 10961030	16-55	14AUG2020	50907	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11071012	C4591001 1107 11071012	16-55	03AUG2020	40321	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11071013	C4591001 1107 11071013	16-55	03AUG2020	41443	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
11071015	C4591001 1107 11071015	16-55	03AUG2020	41445	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11071016	C4591001 1107 11071016	16-55	03AUG2020	41449	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11071018	C4591001 1107 11071018	16-55	03AUG2020	41789	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071019	C4591001 1107 11071019	16-55	03AUG2020	41791	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071020	C4591001 1107 11071020	16-55	03AUG2020	41452	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071022	C4591001 1107 11071022	16-55	03AUG2020	41794	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071025	C4591001 1107 11071025	16-55	03AUG2020	41795	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11071026	C4591001 1107 11071026	16-55	04AUG2020	42098	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11071027	C4591001 1107 11071027	16-55	04AUG2020	42089	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071028	C4591001 1107 11071028	16-55	04AUG2020	42091	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071031	C4591001 1107 11071031	16-55	04AUG2020	42374	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071032	C4591001 1107 11071032	16-55	04AUG2020	42099	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071033	C4591001 1107 11071033	16-55	04AUG2020	42367	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071034	C4591001 1107 11071034	16-55	04AUG2020	42373	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11071039	C4591001 1107 11071039	16-55	05AUG2020	42376	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071046	C4591001 1107 11071046	16-55	05AUG2020	43029	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071049	C4591001 1107 11071049	16-55	05AUG2020	43031	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11071052	C4591001 1107 11071052	16-55	05AUG2020	43032	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071054	C4591001 1107 11071054	16-55	06AUG2020	43034	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071055	C4591001 1107 11071055	16-55	06AUG2020	43566	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071056	C4591001 1107 11071056	16-55	06AUG2020	43569	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071057	C4591001 1107 11071057	16-55	06AUG2020	43964	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071059	C4591001 1107 11071059	16-55	06AUG2020	43962	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071063	C4591001 1107 11071063	16-55	06AUG2020	43571	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo		
11071065	C4591001 1107 11071065	16-55	06AUG2020	43573	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo		
11071067	C4591001 1107 11071067	16-55	06AUG2020	43967	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11071069	C4591001 1107 11071069	16-55	06AUG2020	43968	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071070	C4591001 1107 11071070	16-55	06AUG2020	44045	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11071071	C4591001 1107 11071071	16-55	06AUG2020	44047	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11071072	C4591001 1107 11071072	16-55	10AUG2020	44049	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071074	C4591001 1107 11071074	16-55	10AUG2020	44054	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11071079	C4591001 1107 11071079	16-55	10AUG2020	45569	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11071083	C4591001 1107 11071083	16-55	10AUG2020	45572	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071086	C4591001 1107 11071086	16-55	11AUG2020	45575	Placebo	11AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071087	C4591001 1107 11071087	16-55	11AUG2020	45580	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11071089	C4591001 1107 11071089	16-55	11AUG2020	46313	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11071096	C4591001 1107 11071096	16-55	12AUG2020	46317	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071097	C4591001 1107 11071097	16-55	12AUG2020	46319	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071098	C4591001 1107 11071098	16-55	12AUG2020	46324	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11071102	C4591001 1107 11071102	16-55	13AUG2020	48317	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11071104	C4591001 1107 11071104	16-55	13AUG2020	48319	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11071105	C4591001 1107 11071105	16-55	13AUG2020	48323	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11071106	C4591001 1107 11071106	16-55	13AUG2020	48328	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071109	C4591001 1107 11071109	16-55	13AUG2020	48942	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11071110	C4591001 1107 11071110	16-55	13AUG2020	48943	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071111	C4591001 1107 11071111	16-55	13AUG2020	48946	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11071112	C4591001 1107 11071112	16-55	13AUG2020	48948	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11091041	C4591001 1109 11091041	16-55	31JUL2020	40805	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo		
11091043	C4591001 1109 11091043	16-55	31JUL2020	40806	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11091046	C4591001 1109 11091046	16-55	31JUL2020	40808	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11091047	C4591001 1109 11091047	16-55	31JUL2020	40816	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11091048	C4591001 1109 11091048	16-55	31JUL2020	40868	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11091052	C4591001 1109 11091052	16-55	31JUL2020	40872	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091054	C4591001 1109 11091054	16-55	31JUL2020	40873	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo		
11091055	C4591001 1109 11091055	16-55	31JUL2020	40875	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091056	C4591001 1109 11091056	16-55	31JUL2020	41027	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091057	C4591001 1109 11091057	16-55	31JUL2020	41028	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11091058	C4591001 1109 11091058	16-55	31JUL2020	220886	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091059	C4591001 1109 11091059	16-55	31JUL2020	41031	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11091060	C4591001 1109 11091060	16-55	31JUL2020	41032	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11091061	C4591001 1109 11091061	16-55	31JUL2020	41105	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091062	C4591001 1109 11091062	16-55	31JUL2020	41109	Placebo	31JUL2020/ Placebo	22AUG2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11091063	C4591001 1109 11091063	16-55	31JUL2020	41115	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091066	C4591001 1109 11091066	16-55	31JUL2020	41116	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo		
11091067	C4591001 1109 11091067	16-55	31JUL2020	41157	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11091068	C4591001 1109 11091068	16-55	31JUL2020	41153	Placebo	31JUL2020/ Placebo			
11091070	C4591001 1109 11091070	16-55	31JUL2020	41160	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091071	C4591001 1109 11091071	16-55	31JUL2020	41162	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091075	C4591001 1109 11091075	16-55	31JUL2020	41213	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
11091077	C4591001 1109 11091077	16-55	01AUG2020	41220	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091078	C4591001 1109 11091078	16-55	01AUG2020	41217	Placebo	01AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091080	C4591001 1109 11091080	16-55	01AUG2020	41221	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091082	C4591001 1109 11091082	16-55	01AUG2020	41297	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091083	C4591001 1109 11091083	16-55	01AUG2020	41299	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11091086	C4591001 1109 11091086	16-55	01AUG2020	41303	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11091092	C4591001 1109 11091092	16-55	01AUG2020	41308	Placebo	01AUG2020/ Placebo	23AUG2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091098	C4591001 1109 11091098	16-55	01AUG2020	41347	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11091099	C4591001 1109 11091099	16-55	01AUG2020	41350	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11091100	C4591001 1109 11091100	16-55	01AUG2020	41355	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11091102	C4591001 1109 11091102	16-55	01AUG2020	41356	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11091105	C4591001 1109 11091105	16-55	03AUG2020	41433	Placebo	03AUG2020/ Placebo	23AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11091106	C4591001 1109 11091106	16-55	03AUG2020	41430	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11091108	C4591001 1109 11091108	16-55	03AUG2020	41436	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091109	C4591001 1109 11091109	16-55	03AUG2020	41609	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091110	C4591001 1109 11091110	16-55	03AUG2020	41438	Placebo	03AUG2020/ Placebo	23AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11091112	C4591001 1109 11091112	16-55	03AUG2020	41612	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11091115	C4591001 1109 11091115	16-55	03AUG2020	41617	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
11091117	C4591001 1109 11091117	16-55	03AUG2020	41802	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11091122	C4591001 1109 11091122	16-55	03AUG2020	41618	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091126	C4591001 1109 11091126	16-55	03AUG2020	41803	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo		
11091127	C4591001 1109 11091127	16-55	03AUG2020	41808	Placebo	03AUG2020/ Placebo			
11091132	C4591001 1109 11091132	16-55	03AUG2020	41811	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091134	C4591001 1109 11091134	16-55	03AUG2020	41970	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091136	C4591001 1109 11091136	16-55	04AUG2020	41973	Placebo	04AUG2020/ Placebo	29AUG2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091145	C4591001 1109 11091145	16-55	04AUG2020	41977	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11091147	C4591001 1109 11091147	16-55	04AUG2020	41978	Placebo	04AUG2020/ Placebo	23AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11091148	C4591001 1109 11091148	16-55	04AUG2020	42187	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11091156	C4591001 1109 11091156	16-55	04AUG2020	42189	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091158	C4591001 1109 11091158	16-55	04AUG2020	42191	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091159	C4591001 1109 11091159	16-55	04AUG2020	42196	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)		
11091160	C4591001 1109 11091160	16-55	04AUG2020	42570	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11091176	C4591001 1109 11091176	16-55	08AUG2020	42576	Placebo	08AUG2020/ Placebo	31AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091178	C4591001 1109 11091178	16-55	08AUG2020	42579	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091180	C4591001 1109 11091180	16-55	08AUG2020	44958	Placebo	08AUG2020/ Placebo	27AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091183	C4591001 1109 11091183	16-55	08AUG2020	44961	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11091184	C4591001 1109 11091184	16-55	08AUG2020	44966	Placebo	08AUG2020/ Placebo	27AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11091185	C4591001 1109 11091185	16-55	10AUG2020	44967	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11091186	C4591001 1109 11091186	16-55	10AUG2020	45077	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11091187	C4591001 1109 11091187	16-55	10AUG2020	45084	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11091190	C4591001 1109 11091190	16-55	10AUG2020	45086	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11091197	C4591001 1109 11091197	16-55	10AUG2020	45087	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
11091199	C4591001 1109 11091199	16-55	11AUG2020	46002	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11091204	C4591001 1109 11091204	16-55	11AUG2020	46006	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091205	C4591001 1109 11091205	16-55	11AUG2020	46009	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11091211	C4591001 1109 11091211	16-55	13AUG2020	46010	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11091213	C4591001 1109 11091213	16-55	13AUG2020	48299	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11091214	C4591001 1109 11091214	16-55	13AUG2020	48300	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11091215	C4591001 1109 11091215	16-55	13AUG2020	48301	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11091216	C4591001 1109 11091216	16-55	14AUG2020	48303	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11091219	C4591001 1109 11091219	16-55	14AUG2020	49823	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091221	C4591001 1109 11091221	16-55	14AUG2020	49824	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091223	C4591001 1109 11091223	16-55	14AUG2020	49825	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11091228	C4591001 1109 11091228	16-55	15AUG2020	51092	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091230	C4591001 1109 11091230	16-55	15AUG2020	51097	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091231	C4591001 1109 11091231	16-55	15AUG2020	51098	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091232	C4591001 1109 11091232	16-55	15AUG2020	51099	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11091238	C4591001 1109 11091238	16-55	15AUG2020	51339	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091260	C4591001 1109 11091260	16-55	16AUG2020	51968	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11091266	C4591001 1109 11091266	16-55	16AUG2020	51971	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101001	C4591001 1110 11101001	16-55	31JUL2020	40856	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	
11101002	C4591001 1110 11101002	16-55	31JUL2020	40857	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11101006	C4591001 1110 11101006	16-55	31JUL2020	40859	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11101009	C4591001 1110 11101009	16-55	01AUG2020	40863	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101010	C4591001 1110 11101010	16-55	01AUG2020	41311	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo		
11101011	C4591001 1110 11101011	16-55	01AUG2020	41314	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11101012	C4591001 1110 11101012	16-55	01AUG2020	41318	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11101013	C4591001 1110 11101013	16-55	01AUG2020	41320	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11101019	C4591001 1110 11101019	16-55	01AUG2020	41360	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11101020	C4591001 1110 11101020	16-55	03AUG2020	41363	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11101021	C4591001 1110 11101021	16-55	03AUG2020	41364	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11101022	C4591001 1110 11101022	16-55	03AUG2020	41367	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11101025	C4591001 1110 11101025	16-55	03AUG2020	41887	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11101027	C4591001 1110 11101027	16-55	03AUG2020	41889	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101028	C4591001 1110 11101028	16-55	03AUG2020	41890	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11101030	C4591001 1110 11101030	16-55	04AUG2020	41892	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
11101032	C4591001 1110 11101032	16-55	05AUG2020	42860	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11101033	C4591001 1110 11101033	16-55	05AUG2020	42864	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11101034	C4591001 1110 11101034	16-55	05AUG2020	42862	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11101035	C4591001 1110 11101035	16-55	05AUG2020	42865	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo		
11101037	C4591001 1110 11101037	16-55	05AUG2020	43175	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11101038	C4591001 1110 11101038	16-55	05AUG2020	43169	Placebo	05AUG2020/ Placebo			
11101039	C4591001 1110 11101039	16-55	05AUG2020	43170	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)			
11101040	C4591001 1110 11101040	16-55	05AUG2020	43180	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101041	C4591001 1110 11101041	16-55	06AUG2020	43484	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11101042	C4591001 1110 11101042	16-55	06AUG2020	43489	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11101044	C4591001 1110 11101044	16-55	06AUG2020	43490	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11101045	C4591001 1110 11101045	16-55	06AUG2020	43491	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11101050	C4591001 1110 11101050	16-55	07AUG2020	44393	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11101052	C4591001 1110 11101052	16-55	07AUG2020	44400	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11101053	C4591001 1110 11101053	16-55	07AUG2020	44401	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo		
11101054	C4591001 1110 11101054	16-55	07AUG2020	44403	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101057	C4591001 1110 11101057	16-55	07AUG2020	44695	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11101058	C4591001 1110 11101058	16-55	07AUG2020	44699	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101059	C4591001 1110 11101059	16-55	07AUG2020	44701	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11101064	C4591001 1110 11101064	16-55	10AUG2020	44703	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11101065	C4591001 1110 11101065	16-55	10AUG2020	45247	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11101066	C4591001 1110 11101066	16-55	10AUG2020	45248	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11101069	C4591001 1110 11101069	16-55	11AUG2020	45249	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
11101072	C4591001 1110 11101072	16-55	11AUG2020	45254	Placebo	11AUG2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11101075	C4591001 1110 11101075	16-55	12AUG2020	47172	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11101076	C4591001 1110 11101076	16-55	12AUG2020	47167	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11101077	C4591001 1110 11101077	16-55	12AUG2020	47173	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11101078	C4591001 1110 11101078	16-55	12AUG2020	47176	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101080	C4591001 1110 11101080	16-55	12AUG2020	47658	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11101081	C4591001 1110 11101081	16-55	12AUG2020	47664	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11101082	C4591001 1110 11101082	16-55	12AUG2020	47668	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101083	C4591001 1110 11101083	16-55	12AUG2020	47665	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11101084	C4591001 1110 11101084	16-55	12AUG2020	48121	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11101085	C4591001 1110 11101085	16-55	12AUG2020	48120	Placebo	12AUG2020/ Placebo			
11101086	C4591001 1110 11101086	16-55	13AUG2020	48123	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
11101091	C4591001 1110 11101091	16-55	13AUG2020	48124	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11101092	C4591001 1110 11101092	16-55	13AUG2020	49038	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101095	C4591001 1110 11101095	16-55	14AUG2020	49041	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111009	C4591001 1111 11111009	16-55	31JUL2020	40477	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111012	C4591001 1111 11111012	16-55	03AUG2020	40478	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111018	C4591001 1111 11111018	16-55	03AUG2020	40479	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111022	C4591001 1111 11111022	16-55	04AUG2020	42079	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11111023	C4591001 1111 11111023	16-55	04AUG2020	42080	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11111024	C4591001 1111 11111024	16-55	04AUG2020	42084	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111029	C4591001 1111 11111029	16-55	05AUG2020	42088	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11111040	C4591001 1111 11111040	16-55	05AUG2020	43278	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111048	C4591001 1111 11111048	16-55	06AUG2020	43283	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111050	C4591001 1111 11111050	16-55	06AUG2020	43284	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111051	C4591001 1111 11111051	16-55	06AUG2020	43288	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo		
11111052	C4591001 1111 11111052	16-55	06AUG2020	44070	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11111053	C4591001 1111 11111053	16-55	06AUG2020	44071	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111054	C4591001 1111 11111054	16-55	06AUG2020	44076	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11111057	C4591001 1111 11111057	16-55	07AUG2020	44080	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111060	C4591001 1111 11111060	16-55	07AUG2020	44346	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111061	C4591001 1111 11111061	16-55	07AUG2020	44348	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11111064	C4591001 1111 11111064	16-55	07AUG2020	44350	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111068	C4591001 1111 11111068	16-55	08AUG2020	44354	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11111069	C4591001 1111 11111069	16-55	08AUG2020	44994	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111072	C4591001 1111 11111072	16-55	10AUG2020	44997	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111078	C4591001 1111 11111078	16-55	10AUG2020	45002	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111079	C4591001 1111 11111079	16-55	10AUG2020	45004	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111081	C4591001 1111 11111081	16-55	10AUG2020	45713	Placebo	10AUG2020/ Placebo	29AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111082	C4591001 1111 11111082	16-55	10AUG2020	45718	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111083	C4591001 1111 11111083	16-55	10AUG2020	45721	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111086	C4591001 1111 11111086	16-55	10AUG2020	45722	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111087	C4591001 1111 11111087	16-55	10AUG2020	45953	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11111089	C4591001 1111 11111089	16-55	11AUG2020	45961	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111090	C4591001 1111 11111090	16-55	11AUG2020	45956	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111097	C4591001 1111 11111097	16-55	11AUG2020	45964	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11111099	C4591001 1111 11111099	16-55	11AUG2020	46829	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
11111101	C4591001 1111 11111101	16-55	11AUG2020	46832	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11111104	C4591001 1111 11111104	16-55	14AUG2020	46834	Placebo	14AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111105	C4591001 1111 11111105	16-55	14AUG2020	46838	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11111113	C4591001 1111 11111113	16-55	14AUG2020	50851	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11111115	C4591001 1111 11111115	16-55	14AUG2020	50852	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11121014	C4591001 1112 11121014	16-55	30JUL2020	40675	Placebo	30JUL2020/ Placebo	20AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11121018	C4591001 1112 11121018	16-55	31JUL2020	40676	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11121019	C4591001 1112 11121019	16-55	31JUL2020	40679	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121020	C4591001 1112 11121020	16-55	31JUL2020	40974	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		
11121021	C4591001 1112 11121021	16-55	31JUL2020	40978	Placebo	31JUL2020/ Placebo	22AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121024	C4591001 1112 11121024	16-55	31JUL2020	40979	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121025	C4591001 1112 11121025	16-55	31JUL2020	40984	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121026	C4591001 1112 11121026	16-55	31JUL2020	41226	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121027	C4591001 1112 11121027	16-55	31JUL2020	41231	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121028	C4591001 1112 11121028	16-55	31JUL2020	41233	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11121031	C4591001 1112 11121031	16-55	31JUL2020	41235	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo		
11121033	C4591001 1112 11121033	16-55	03AUG2020	41467	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121035	C4591001 1112 11121035	16-55	03AUG2020	41468	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121038	C4591001 1112 11121038	16-55	03AUG2020	41476	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11121039	C4591001 1112 11121039	16-55	03AUG2020	41472	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121040	C4591001 1112 11121040	16-55	03AUG2020	41837	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11121042	C4591001 1112 11121042	16-55	03AUG2020	41842	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11121044	C4591001 1112 11121044	16-55	03AUG2020	41847	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121045	C4591001 1112 11121045	16-55	03AUG2020	41848	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11121046	C4591001 1112 11121046	16-55	03AUG2020	41982	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121047	C4591001 1112 11121047	16-55	03AUG2020	41984	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11121048	C4591001 1112 11121048	16-55	03AUG2020	41991	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121049	C4591001 1112 11121049	16-55	03AUG2020	41992	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121050	C4591001 1112 11121050	16-55	04AUG2020	42067	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121053	C4591001 1112 11121053	16-55	04AUG2020	42073	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121054	C4591001 1112 11121054	16-55	04AUG2020	42074	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo		
11121055	C4591001 1112 11121055	16-55	04AUG2020	42275	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11121056	C4591001 1112 11121056	16-55	04AUG2020	42075	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121058	C4591001 1112 11121058	16-55	04AUG2020	42276	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)			
11121062	C4591001 1112 11121062	16-55	04AUG2020	42278	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
11121064	C4591001 1112 11121064	16-55	04AUG2020	42279	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11121066	C4591001 1112 11121066	16-55	04AUG2020	42689	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121069	C4591001 1112 11121069	16-55	05AUG2020	42696	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121070	C4591001 1112 11121070	16-55	05AUG2020	42699	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11121071	C4591001 1112 11121071	16-55	05AUG2020	42700	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11121073	C4591001 1112 11121073	16-55	05AUG2020	42883	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11121077	C4591001 1112 11121077	16-55	05AUG2020	42885	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11121078	C4591001 1112 11121078	16-55	05AUG2020	42884	Placebo	05AUG2020/ Placebo	08SEP2020/ Placebo		
11121082	C4591001 1112 11121082	16-55	05AUG2020	42890	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11121083	C4591001 1112 11121083	16-55	05AUG2020	43363	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo		
11121085	C4591001 1112 11121085	16-55	10AUG2020	43366	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121087	C4591001 1112 11121087	16-55	10AUG2020	43370	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121088	C4591001 1112 11121088	16-55	10AUG2020	43372	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121090	C4591001 1112 11121090	16-55	10AUG2020	45378	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121091	C4591001 1112 11121091	16-55	10AUG2020	45384	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121092	C4591001 1112 11121092	16-55	10AUG2020	45387	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121098	C4591001 1112 11121098	16-55	10AUG2020	45388	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11121100	C4591001 1112 11121100	16-55	10AUG2020	45838	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11121101	C4591001 1112 11121101	16-55	10AUG2020	45839	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11121102	C4591001 1112 11121102	16-55	10AUG2020	45844	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121103	C4591001 1112 11121103	16-55	10AUG2020	45843	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121104	C4591001 1112 11121104	16-55	10AUG2020	45941	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121105	C4591001 1112 11121105	16-55	11AUG2020	45942	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121106	C4591001 1112 11121106	16-55	11AUG2020	45951	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121107	C4591001 1112 11121107	16-55	11AUG2020	45943	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121109	C4591001 1112 11121109	16-55	11AUG2020	46207	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121110	C4591001 1112 11121110	16-55	11AUG2020	46208	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11121114	C4591001 1112 11121114	16-55	11AUG2020	46210	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121115	C4591001 1112 11121115	16-55	11AUG2020	46216	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121117	C4591001 1112 11121117	16-55	11AUG2020	46628	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121119	C4591001 1112 11121119	16-55	11AUG2020	46631	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11121121	C4591001 1112 11121121	16-55	11AUG2020	46635	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11121122	C4591001 1112 11121122	16-55	11AUG2020	46901	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121123	C4591001 1112 11121123	16-55	11AUG2020	46636	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121124	C4591001 1112 11121124	16-55	11AUG2020	46904	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11141001	C4591001 1114 11141001	16-55	12AUG2020	47149	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141002	C4591001 1114 11141002	16-55	12AUG2020	47150	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141003	C4591001 1114 11141003	16-55	12AUG2020	47151	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141007	C4591001 1114 11141007	16-55	12AUG2020	47152	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141008	C4591001 1114 11141008	16-55	12AUG2020	47826	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11141009	C4591001 1114 11141009	16-55	12AUG2020	47827	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11141010	C4591001 1114 11141010	16-55	12AUG2020	47831	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141012	C4591001 1114 11141012	16-55	12AUG2020	48174	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141013	C4591001 1114 11141013	16-55	12AUG2020	47835	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141014	C4591001 1114 11141014	16-55	12AUG2020	48182	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11141015	C4591001 1114 11141015	16-55	12AUG2020	48178	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo		
11141016	C4591001 1114 11141016	16-55	12AUG2020	48176	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11141021	C4591001 1114 11141021	16-55	13AUG2020	48893	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11141024	C4591001 1114 11141024	16-55	13AUG2020	48894	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11181001	C4591001 1118 11181001	16-55	10AUG2020	45140	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11181002	C4591001 1118 11181002	16-55	10AUG2020	45144	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11181003	C4591001 1118 11181003	16-55	10AUG2020	45147	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181009	C4591001 1118 11181009	16-55	11AUG2020	45148	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181014	C4591001 1118 11181014	16-55	11AUG2020	46615	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11181016	C4591001 1118 11181016	16-55	12AUG2020	226194	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11181017	C4591001 1118 11181017	16-55	12AUG2020	46616	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11181018	C4591001 1118 11181018	16-55	13AUG2020	46621	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11181019	C4591001 1118 11181019	16-55	12AUG2020	46617	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181021	C4591001 1118 11181021	16-55	13AUG2020	48367	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181023	C4591001 1118 11181023	16-55	13AUG2020	48369	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11181025	C4591001 1118 11181025	16-55	13AUG2020	48374	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11181026	C4591001 1118 11181026	16-55	13AUG2020	48376	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11181027	C4591001 1118 11181027	16-55	13AUG2020	49265	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181028	C4591001 1118 11181028	16-55	13AUG2020	49268	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181030	C4591001 1118 11181030	16-55	14AUG2020	49270	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11181032	C4591001 1118 11181032	16-55	14AUG2020	49275	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11181033	C4591001 1118 11181033	16-55	14AUG2020	50110	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11181034	C4591001 1118 11181034	16-55	14AUG2020	50109	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11181035	C4591001 1118 11181035	16-55	14AUG2020	50112	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11181099	C4591001 1118 11181099	16-55	29AUG2020	73457	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11201005	C4591001 1120 11201005	16-55	30JUL2020	40351	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201013	C4591001 1120 11201013	16-55	30JUL2020	40353	Placebo	30JUL2020/ Placebo			
11201014	C4591001 1120 11201014	16-55	31JUL2020	41265	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201015	C4591001 1120 11201015	16-55	31JUL2020	40355	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11201016	C4591001 1120 11201016	16-55	31JUL2020	41266	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11201023	C4591001 1120 11201023	16-55	03AUG2020	41268	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11201024	C4591001 1120 11201024	16-55	03AUG2020	42032	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11201028	C4591001 1120 11201028	16-55	03AUG2020	41271	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11201029	C4591001 1120 11201029	16-55	04AUG2020	42036	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11201034	C4591001 1120 11201034	16-55	04AUG2020	42038	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11201037	C4591001 1120 11201037	16-55	04AUG2020	42040	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201039	C4591001 1120 11201039	16-55	04AUG2020	42488	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201042	C4591001 1120 11201042	16-55	04AUG2020	42491	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201044	C4591001 1120 11201044	16-55	06AUG2020	43650	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201045	C4591001 1120 11201045	16-55	04AUG2020	42492	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201053	C4591001 1120 11201053	16-55	05AUG2020	42749	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11201058	C4591001 1120 11201058	16-55	05AUG2020	42752	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201061	C4591001 1120 11201061	16-55	05AUG2020	42754	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201062	C4591001 1120 11201062	16-55	05AUG2020	43123	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11201063	C4591001 1120 11201063	16-55	05AUG2020	42757	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11201065	C4591001 1120 11201065	16-55	05AUG2020	43127	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201068	C4591001 1120 11201068	16-55	05AUG2020	43129	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201076	C4591001 1120 11201076	16-55	05AUG2020	43345	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201077	C4591001 1120 11201077	16-55	05AUG2020	43130	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201078	C4591001 1120 11201078	16-55	05AUG2020	43348	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11201079	C4591001 1120 11201079	16-55	05AUG2020	43346	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201081	C4591001 1120 11201081	16-55	05AUG2020	43445	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201082	C4591001 1120 11201082	16-55	05AUG2020	43347	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11201083	C4591001 1120 11201083	16-55	05AUG2020	43448	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201084	C4591001 1120 11201084	16-55	06AUG2020	43454	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201085	C4591001 1120 11201085	16-55	06AUG2020	43456	Placebo	06AUG2020/ Placebo			
11201096	C4591001 1120 11201096	16-55	06AUG2020	43651	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11201097	C4591001 1120 11201097	16-55	06AUG2020	43656	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201098	C4591001 1120 11201098	16-55	06AUG2020	43985	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11201100	C4591001 1120 11201100	16-55	06AUG2020	43988	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11201101	C4591001 1120 11201101	16-55	06AUG2020	43658	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11201103	C4591001 1120 11201103	16-55	06AUG2020	43990	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11201104	C4591001 1120 11201104	16-55	06AUG2020	43993	Placebo	06AUG2020/ Placebo			
11201105	C4591001 1120 11201105	16-55	06AUG2020	44169	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201106	C4591001 1120 11201106	16-55	07AUG2020	44170	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11201108	C4591001 1120 11201108	16-55	07AUG2020	44172	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11201110	C4591001 1120 11201110	16-55	07AUG2020	44174	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201112	C4591001 1120 11201112	16-55	07AUG2020	44638	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201113	C4591001 1120 11201113	16-55	07AUG2020	44639	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201115	C4591001 1120 11201115	16-55	07AUG2020	44641	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11201116	C4591001 1120 11201116	16-55	07AUG2020	44644	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11201119	C4591001 1120 11201119	16-55	07AUG2020	44815	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11201120	C4591001 1120 11201120	16-55	10AUG2020	44817	Placebo	10AUG2020/ Placebo	03SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11201130	C4591001 1120 11201130	16-55	11AUG2020	44822	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201133	C4591001 1120 11201133	16-55	11AUG2020	44824	Placebo	11AUG2020/ Placebo	08SEP2020/ Placebo		
11201135	C4591001 1120 11201135	16-55	11AUG2020	46735	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201139	C4591001 1120 11201139	16-55	11AUG2020	46736	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11201142	C4591001 1120 11201142	16-55	12AUG2020	46737	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201144	C4591001 1120 11201144	16-55	12AUG2020	46738	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11201148	C4591001 1120 11201148	16-55	12AUG2020	47393	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11201149	C4591001 1120 11201149	16-55	12AUG2020	47396	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11201154	C4591001 1120 11201154	16-55	12AUG2020	47399	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11201157	C4591001 1120 11201157	16-55	12AUG2020	47401	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11201161	C4591001 1120 11201161	16-55	12AUG2020	48164	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11201165	C4591001 1120 11201165	16-55	13AUG2020	48168	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201168	C4591001 1120 11201168	16-55	13AUG2020	48170	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201171	C4591001 1120 11201171	16-55	13AUG2020	48171	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201172	C4591001 1120 11201172	16-55	13AUG2020	48977	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201176	C4591001 1120 11201176	16-55	13AUG2020	48979	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201181	C4591001 1120 11201181	16-55	13AUG2020	48980	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11201191	C4591001 1120 11201191	16-55	14AUG2020	48987	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
11201194	C4591001 1120 11201194	16-55	14AUG2020	50430	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11201195	C4591001 1120 11201195	16-55	14AUG2020	50437	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11201196	C4591001 1120 11201196	16-55	14AUG2020	50439	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11201197	C4591001 1120 11201197	16-55	14AUG2020	50438	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11201198	C4591001 1120 11201198	16-55	14AUG2020	50574	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11201202	C4591001 1120 11201202	16-55	14AUG2020	50577	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11231005	C4591001 1123 11231005	16-55	30JUL2020	40226	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231007	C4591001 1123 11231007	16-55	30JUL2020	40751	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231009	C4591001 1123 11231009	16-55	30JUL2020	40752	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231019	C4591001 1123 11231019	16-55	03AUG2020	40754	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231022	C4591001 1123 11231022	16-55	03AUG2020	40756	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11231026	C4591001 1123 11231026	16-55	04AUG2020	42617	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11231028	C4591001 1123 11231028	16-55	04AUG2020	42654	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11231029	C4591001 1123 11231029	16-55	04AUG2020	42626	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231030	C4591001 1123 11231030	16-55	04AUG2020	42623	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231031	C4591001 1123 11231031	16-55	04AUG2020	42656	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231033	C4591001 1123 11231033	16-55	05AUG2020	43253	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231034	C4591001 1123 11231034	16-55	05AUG2020	42662	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11231035	C4591001 1123 11231035	16-55	05AUG2020	42661	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231038	C4591001 1123 11231038	16-55	05AUG2020	43258	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231041	C4591001 1123 11231041	16-55	05AUG2020	43259	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231042	C4591001 1123 11231042	16-55	06AUG2020	43264	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231043	C4591001 1123 11231043	16-55	06AUG2020	43975	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11231044	C4591001 1123 11231044	16-55	06AUG2020	43976	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231045	C4591001 1123 11231045	16-55	06AUG2020	43980	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11231046	C4591001 1123 11231046	16-55	06AUG2020	43984	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11231048	C4591001 1123 11231048	16-55	06AUG2020	44106	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231051	C4591001 1123 11231051	16-55	07AUG2020	44108	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo		
11231052	C4591001 1123 11231052	16-55	07AUG2020	44111	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231055	C4591001 1123 11231055	16-55	07AUG2020	44116	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11231057	C4591001 1123 11231057	16-55	10AUG2020	45473	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11231059	C4591001 1123 11231059	16-55	10AUG2020	45475	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11231060	C4591001 1123 11231060	16-55	10AUG2020	45481	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231062	C4591001 1123 11231062	16-55	10AUG2020	45484	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11231064	C4591001 1123 11231064	16-55	10AUG2020	45906	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231067	C4591001 1123 11231067	16-55	11AUG2020	45910	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231068	C4591001 1123 11231068	16-55	11AUG2020	45916	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231069	C4591001 1123 11231069	16-55	11AUG2020	45911	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
11231072	C4591001 1123 11231072	16-55	11AUG2020	46822	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11231073	C4591001 1123 11231073	16-55	11AUG2020	46820	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231074	C4591001 1123 11231074	16-55	11AUG2020	46827	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231075	C4591001 1123 11231075	16-55	11AUG2020	46825	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11231076	C4591001 1123 11231076	16-55	12AUG2020	47801	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11231077	C4591001 1123 11231077	16-55	12AUG2020	47802	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231078	C4591001 1123 11231078	16-55	12AUG2020	47805	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231081	C4591001 1123 11231081	16-55	12AUG2020	47808	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231082	C4591001 1123 11231082	16-55	12AUG2020	48043	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231083	C4591001 1123 11231083	16-55	12AUG2020	48044	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231084	C4591001 1123 11231084	16-55	13AUG2020	48045	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11231085	C4591001 1123 11231085	16-55	13AUG2020	48047	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231086	C4591001 1123 11231086	16-55	13AUG2020	49327	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231088	C4591001 1123 11231088	16-55	13AUG2020	49330	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231090	C4591001 1123 11231090	16-55	13AUG2020	49333	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231091	C4591001 1123 11231091	16-55	13AUG2020	49332	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11231092	C4591001 1123 11231092	16-55	13AUG2020	49529	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231094	C4591001 1123 11231094	16-55	13AUG2020	49530	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11231095	C4591001 1123 11231095	16-55	13AUG2020	49535	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231099	C4591001 1123 11231099	16-55	14AUG2020	50551	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231100	C4591001 1123 11231100	16-55	14AUG2020	50549	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11231101	C4591001 1123 11231101	16-55	14AUG2020	50559	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11231102	C4591001 1123 11231102	16-55	14AUG2020	50555	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11231104	C4591001 1123 11231104	16-55	14AUG2020	50777	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11241001	C4591001 1124 11241001	16-55	10AUG2020	45127	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
11241003	C4591001 1124 11241003	16-55	10AUG2020	45129	Placebo	10AUG2020/ Placebo	08OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241005	C4591001 1124 11241005	16-55	10AUG2020	45131	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241008	C4591001 1124 11241008	16-55	10AUG2020	45132	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241010	C4591001 1124 11241010	16-55	11AUG2020	46013	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241012	C4591001 1124 11241012	16-55	11AUG2020	46015	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11241017	C4591001 1124 11241017	16-55	11AUG2020	46016	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11241018	C4591001 1124 11241018	16-55	11AUG2020	46019	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241019	C4591001 1124 11241019	16-55	12AUG2020	46977	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11241020	C4591001 1124 11241020	16-55	12AUG2020	46978	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11241024	C4591001 1124 11241024	16-55	12AUG2020	46983	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11241025	C4591001 1124 11241025	16-55	12AUG2020	46981	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11241026	C4591001 1124 11241026	16-55	12AUG2020	47875	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11241027	C4591001 1124 11241027	16-55	12AUG2020	47878	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241028	C4591001 1124 11241028	16-55	13AUG2020	47883	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241030	C4591001 1124 11241030	16-55	13AUG2020	47884	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11241032	C4591001 1124 11241032	16-55	13AUG2020	48595	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11241036	C4591001 1124 11241036	16-55	13AUG2020	48597	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11241038	C4591001 1124 11241038	16-55	13AUG2020	48599	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11241039	C4591001 1124 11241039	16-55	13AUG2020	48600	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251004	C4591001 1125 11251004	16-55	12AUG2020	47408	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11251005	C4591001 1125 11251005	16-55	12AUG2020	47407	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251006	C4591001 1125 11251006	16-55	12AUG2020	47411	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251007	C4591001 1125 11251007	16-55	12AUG2020	47414	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	
11251009	C4591001 1125 11251009	16-55	12AUG2020	47682	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251010	C4591001 1125 11251010	16-55	12AUG2020	47683	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251014	C4591001 1125 11251014	16-55	12AUG2020	47690	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11251015	C4591001 1125 11251015	16-55	13AUG2020	47691	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251017	C4591001 1125 11251017	16-55	13AUG2020	48750	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251019	C4591001 1125 11251019	16-55	13AUG2020	48756	Placebo	13AUG2020/ Placebo			
11251020	C4591001 1125 11251020	16-55	13AUG2020	48757	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11251021	C4591001 1125 11251021	16-55	13AUG2020	48760	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251022	C4591001 1125 11251022	16-55	13AUG2020	49302	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11251023	C4591001 1125 11251023	16-55	13AUG2020	49305	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11251024	C4591001 1125 11251024	16-55	13AUG2020	49306	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251025	C4591001 1125 11251025	16-55	13AUG2020	49307	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251027	C4591001 1125 11251027	16-55	13AUG2020	49628	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11251028	C4591001 1125 11251028	16-55	13AUG2020	49630	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11251029	C4591001 1125 11251029	16-55	13AUG2020	49631	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11251030	C4591001 1125 11251030	16-55	13AUG2020	49633	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11251031	C4591001 1125 11251031	16-55	13AUG2020	49745	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11251032	C4591001 1125 11251032	16-55	14AUG2020	49755	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11251033	C4591001 1125 11251033	16-55	14AUG2020	49751	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11251034	C4591001 1125 11251034	16-55	14AUG2020	49756	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11251036	C4591001 1125 11251036	16-55	14AUG2020	50264	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251038	C4591001 1125 11251038	16-55	14AUG2020	50266	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
11251039	C4591001 1125 11251039	16-55	14AUG2020	50267	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251040	C4591001 1125 11251040	16-55	14AUG2020	50269	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11251043	C4591001 1125 11251043	16-55	14AUG2020	50732	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
11261002	C4591001 1126 11261002	16-55	10AUG2020	45787	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11261005	C4591001 1126 11261005	16-55	11AUG2020	45789	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11261006	C4591001 1126 11261006	16-55	11AUG2020	45795	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11261009	C4591001 1126 11261009	16-55	12AUG2020	45796	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261010	C4591001 1126 11261010	16-55	12AUG2020	47455	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261011	C4591001 1126 11261011	16-55	12AUG2020	47456	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261012	C4591001 1126 11261012	16-55	12AUG2020	47457	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11261013	C4591001 1126 11261013	16-55	12AUG2020	47460	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261014	C4591001 1126 11261014	16-55	12AUG2020	48225	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261017	C4591001 1126 11261017	16-55	13AUG2020	48228	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	
11261018	C4591001 1126 11261018	16-55	13AUG2020	48231	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11261019	C4591001 1126 11261019	16-55	13AUG2020	48232	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261021	C4591001 1126 11261021	16-55	13AUG2020	49734	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11261022	C4591001 1126 11261022	16-55	14AUG2020	49735	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11261024	C4591001 1126 11261024	16-55	14AUG2020	49739	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261025	C4591001 1126 11261025	16-55	14AUG2020	49741	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271021	C4591001 1127 11271021	16-55	30JUL2020	40622	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)		
11271022	C4591001 1127 11271022	16-55	30JUL2020	40769	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)			
11271024	C4591001 1127 11271024	16-55	30JUL2020	40624	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271025	C4591001 1127 11271025	16-55	30JUL2020	40770	Placebo	30JUL2020/ Placebo	18AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11271026	C4591001 1127 11271026	16-55	31JUL2020	40772	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271027	C4591001 1127 11271027	16-55	31JUL2020	40780	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271028	C4591001 1127 11271028	16-55	31JUL2020	40925	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11271029	C4591001 1127 11271029	16-55	31JUL2020	40929	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11271030	C4591001 1127 11271030	16-55	31JUL2020	40930	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271032	C4591001 1127 11271032	16-55	31JUL2020	40932	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271033	C4591001 1127 11271033	16-55	31JUL2020	41082	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271036	C4591001 1127 11271036	16-55	31JUL2020	41084	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271037	C4591001 1127 11271037	16-55	31JUL2020	41085	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11271040	C4591001 1127 11271040	16-55	31JUL2020	41088	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11271043	C4591001 1127 11271043	16-55	03AUG2020	41708	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11271044	C4591001 1127 11271044	16-55	03AUG2020	41707	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11271047	C4591001 1127 11271047	16-55	03AUG2020	41712	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)		
11271048	C4591001 1127 11271048	16-55	03AUG2020	41709	Placebo	03AUG2020/ Placebo	22AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11271052	C4591001 1127 11271052	16-55	04AUG2020	42227	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11271057	C4591001 1127 11271057	16-55	04AUG2020	42230	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271059	C4591001 1127 11271059	16-55	05AUG2020	42231	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11271068	C4591001 1127 11271068	16-55	05AUG2020	43349	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11271069	C4591001 1127 11271069	16-55	05AUG2020	42232	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271070	C4591001 1127 11271070	16-55	05AUG2020	43352	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271072	C4591001 1127 11271072	16-55	06AUG2020	43354	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11271073	C4591001 1127 11271073	16-55	06AUG2020	43356	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11271076	C4591001 1127 11271076	16-55	06AUG2020	43664	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11271077	C4591001 1127 11271077	16-55	06AUG2020	43666	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11271078	C4591001 1127 11271078	16-55	07AUG2020	43668	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
11271079	C4591001 1127 11271079	16-55	07AUG2020	43670	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271080	C4591001 1127 11271080	16-55	07AUG2020	44479	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11271084	C4591001 1127 11271084	16-55	11AUG2020	44483	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11271085	C4591001 1127 11271085	16-55	11AUG2020	44484	Placebo	11AUG2020/ Placebo	30AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11271086	C4591001 1127 11271086	16-55	11AUG2020	44486	Placebo	11AUG2020/ Placebo	30AUG2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271087	C4591001 1127 11271087	16-55	11AUG2020	46577	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)		
11281001	C4591001 1128 11281001	16-55	31JUL2020	40985	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11281002	C4591001 1128 11281002	16-55	31JUL2020	40990	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11281005	C4591001 1128 11281005	16-55	31JUL2020	40992	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11281012	C4591001 1128 11281012	16-55	31JUL2020	40995	Placebo	31JUL2020/ Placebo	25SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281017	C4591001 1128 11281017	16-55	01AUG2020	41334	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281018	C4591001 1128 11281018	16-55	01AUG2020	41335	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281020	C4591001 1128 11281020	16-55	01AUG2020	41337	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11281021	C4591001 1128 11281021	16-55	01AUG2020	41340	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11281024	C4591001 1128 11281024	16-55	01AUG2020	41376	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11281025	C4591001 1128 11281025	16-55	01AUG2020	41370	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11281026	C4591001 1128 11281026	16-55	01AUG2020	41377	Placebo	01AUG2020/ Placebo	20AUG2020/ Placebo		
11281028	C4591001 1128 11281028	16-55	01AUG2020	41380	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11281029	C4591001 1128 11281029	16-55	01AUG2020	41393	Placebo	01AUG2020/ Placebo	21AUG2020/ Placebo		
11281030	C4591001 1128 11281030	16-55	03AUG2020	41397	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281031	C4591001 1128 11281031	16-55	03AUG2020	41396	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281035	C4591001 1128 11281035	16-55	03AUG2020	41398	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11281038	C4591001 1128 11281038	16-55	05AUG2020	42954	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281042	C4591001 1128 11281042	16-55	05AUG2020	42957	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11281045	C4591001 1128 11281045	16-55	05AUG2020	42958	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11281047	C4591001 1128 11281047	16-55	05AUG2020	42961	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11281049	C4591001 1128 11281049	16-55	05AUG2020	43242	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281050	C4591001 1128 11281050	16-55	05AUG2020	43244	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11281054	C4591001 1128 11281054	16-55	05AUG2020	43247	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11281055	C4591001 1128 11281055	16-55	05AUG2020	43252	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo		
11281057	C4591001 1128 11281057	16-55	06AUG2020	44177	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281061	C4591001 1128 11281061	16-55	07AUG2020	44181	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281062	C4591001 1128 11281062	16-55	07AUG2020	44185	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11281064	C4591001 1128 11281064	16-55	07AUG2020	44188	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11281067	C4591001 1128 11281067	16-55	07AUG2020	44575	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11281070	C4591001 1128 11281070	16-55	07AUG2020	44578	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281071	C4591001 1128 11281071	16-55	07AUG2020	44577	Placebo	07AUG2020/ Placebo	31AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11281073	C4591001 1128 11281073	16-55	07AUG2020	44581	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11281074	C4591001 1128 11281074	16-55	07AUG2020	44890	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11281077	C4591001 1128 11281077	16-55	07AUG2020	44891	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11281078	C4591001 1128 11281078	16-55	07AUG2020	44892	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281080	C4591001 1128 11281080	16-55	10AUG2020	44895	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281083	C4591001 1128 11281083	16-55	10AUG2020	45850	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
11281086	C4591001 1128 11281086	16-55	10AUG2020	45852	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo		
11281092	C4591001 1128 11281092	16-55	11AUG2020	45853	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11281093	C4591001 1128 11281093	16-55	11AUG2020	46890	Placebo	11AUG2020/ Placebo	28AUG2020/ Placebo		
11281094	C4591001 1128 11281094	16-55	11AUG2020	46896	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11281095	C4591001 1128 11281095	16-55	11AUG2020	46899	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11281096	C4591001 1128 11281096	16-55	12AUG2020	46900	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11281098	C4591001 1128 11281098	16-55	12AUG2020	47468	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11281101	C4591001 1128 11281101	16-55	12AUG2020	47471	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281102	C4591001 1128 11281102	16-55	12AUG2020	47474	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11281103	C4591001 1128 11281103	16-55	12AUG2020	47476	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11281107	C4591001 1128 11281107	16-55	12AUG2020	48149	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281112	C4591001 1128 11281112	16-55	12AUG2020	48150	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11281113	C4591001 1128 11281113	16-55	14AUG2020	48154	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11281114	C4591001 1128 11281114	16-55	14AUG2020	50336	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11281115	C4591001 1128 11281115	16-55	14AUG2020	48156	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11281117	C4591001 1128 11281117	16-55	14AUG2020	50340	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11281118	C4591001 1128 11281118	16-55	14AUG2020	50343	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11281119	C4591001 1128 11281119	16-55	14AUG2020	50721	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281120	C4591001 1128 11281120	16-55	14AUG2020	50719	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11291017	C4591001 1129 11291017	16-55	30JUL2020	40628	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11291019	C4591001 1129 11291019	16-55	31JUL2020	40630	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11291020	C4591001 1129 11291020	16-55	31JUL2020	40635	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11291029	C4591001 1129 11291029	16-55	03AUG2020	41417	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11291030	C4591001 1129 11291030	16-55	03AUG2020	41420	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11291040	C4591001 1129 11291040	16-55	04AUG2020	41426	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11291041	C4591001 1129 11291041	16-55	04AUG2020	41428	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11291042	C4591001 1129 11291042	16-55	04AUG2020	42101	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11291045	C4591001 1129 11291045	16-55	04AUG2020	42102	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291047	C4591001 1129 11291047	16-55	04AUG2020	42104	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11291054	C4591001 1129 11291054	16-55	07AUG2020	44301	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11291055	C4591001 1129 11291055	16-55	07AUG2020	44298	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11291056	C4591001 1129 11291056	16-55	07AUG2020	44300	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11291058	C4591001 1129 11291058	16-55	07AUG2020	44308	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11291061	C4591001 1129 11291061	16-55	07AUG2020	44597	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11291063	C4591001 1129 11291063	16-55	07AUG2020	44598	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11291064	C4591001 1129 11291064	16-55	07AUG2020	44605	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
11291069	C4591001 1129 11291069	16-55	10AUG2020	44606	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11291070	C4591001 1129 11291070	16-55	10AUG2020	45092	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291071	C4591001 1129 11291071	16-55	10AUG2020	45093	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11291072	C4591001 1129 11291072	16-55	10AUG2020	45094	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
11291073	C4591001 1129 11291073	16-55	10AUG2020	45095	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11291088	C4591001 1129 11291088	16-55	11AUG2020	46061	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11291089	C4591001 1129 11291089	16-55	11AUG2020	46062	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11291092	C4591001 1129 11291092	16-55	11AUG2020	46065	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11291096	C4591001 1129 11291096	16-55	11AUG2020	46066	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11291097	C4591001 1129 11291097	16-55	11AUG2020	46436	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11291098	C4591001 1129 11291098	16-55	11AUG2020	46439	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11291104	C4591001 1129 11291104	16-55	11AUG2020	46442	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311002	C4591001 1131 11311002	16-55	13AUG2020	48701	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11311004	C4591001 1131 11311004	16-55	13AUG2020	48702	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11311011	C4591001 1131 11311011	16-55	14AUG2020	48708	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11311016	C4591001 1131 11311016	16-55	14AUG2020	50562	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11311020	C4591001 1131 11311020	16-55	14AUG2020	50571	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
11331019	C4591001 1133 11331019	16-55	30JUL2020	40653	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331023	C4591001 1133 11331023	16-55	31JUL2020	40654	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331028	C4591001 1133 11331028	16-55	31JUL2020	40949	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331030	C4591001 1133 11331030	16-55	31JUL2020	40953	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331037	C4591001 1133 11331037	16-55	31JUL2020	40958	Placebo	31JUL2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331041	C4591001 1133 11331041	16-55	31JUL2020	40960	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331042	C4591001 1133 11331042	16-55	31JUL2020	41165	Placebo	31JUL2020/ Placebo			
11331043	C4591001 1133 11331043	16-55	31JUL2020	41166	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331044	C4591001 1133 11331044	16-55	31JUL2020	41168	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331045	C4591001 1133 11331045	16-55	31JUL2020	41176	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11331047	C4591001 1133 11331047	16-55	03AUG2020	41485	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
11331048	C4591001 1133 11331048	16-55	03AUG2020	41482	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331050	C4591001 1133 11331050	16-55	03AUG2020	41479	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331051	C4591001 1133 11331051	16-55	03AUG2020	41562	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331052	C4591001 1133 11331052	16-55	03AUG2020	41486	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331054	C4591001 1133 11331054	16-55	03AUG2020	41567	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331058	C4591001 1133 11331058	16-55	03AUG2020	41572	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11331059	C4591001 1133 11331059	16-55	03AUG2020	41568	Placebo	03AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331060	C4591001 1133 11331060	16-55	03AUG2020	41875	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331062	C4591001 1133 11331062	16-55	03AUG2020	41876	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11331063	C4591001 1133 11331063	16-55	03AUG2020	41877	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331066	C4591001 1133 11331066	16-55	07AUG2020	41884	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11331069	C4591001 1133 11331069	16-55	07AUG2020	44358	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11331070	C4591001 1133 11331070	16-55	07AUG2020	44360	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331072	C4591001 1133 11331072	16-55	07AUG2020	44361	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331074	C4591001 1133 11331074	16-55	07AUG2020	44362	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331079	C4591001 1133 11331079	16-55	07AUG2020	44609	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11331083	C4591001 1133 11331083	16-55	07AUG2020	44612	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331087	C4591001 1133 11331087	16-55	08AUG2020	44616	Placebo	08AUG2020/ Placebo			
11331088	C4591001 1133 11331088	16-55	08AUG2020	44617	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331093	C4591001 1133 11331093	16-55	08AUG2020	44971	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331096	C4591001 1133 11331096	16-55	08AUG2020	44972	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331097	C4591001 1133 11331097	16-55	08AUG2020	44973	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331102	C4591001 1133 11331102	16-55	08AUG2020	44975	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331103	C4591001 1133 11331103	16-55	08AUG2020	45010	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331105	C4591001 1133 11331105	16-55	08AUG2020	45009	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11331106	C4591001 1133 11331106	16-55	08AUG2020	45012	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331108	C4591001 1133 11331108	16-55	08AUG2020	45016	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331111	C4591001 1133 11331111	16-55	08AUG2020	45019	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331113	C4591001 1133 11331113	16-55	08AUG2020	45021	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331115	C4591001 1133 11331115	16-55	08AUG2020	45022	Placebo	08AUG2020/ Placebo	29AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331117	C4591001 1133 11331117	16-55	08AUG2020	45028	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)		
11331119	C4591001 1133 11331119	16-55	12AUG2020	47081	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331120	C4591001 1133 11331120	16-55	12AUG2020	47086	Placebo	12AUG2020/ Placebo	30SEP2020/ Placebo		
11331121	C4591001 1133 11331121	16-55	12AUG2020	47088	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331122	C4591001 1133 11331122	16-55	12AUG2020	47285	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)			
11331123	C4591001 1133 11331123	16-55	12AUG2020	47092	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331125	C4591001 1133 11331125	16-55	12AUG2020	47291	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331129	C4591001 1133 11331129	16-55	12AUG2020	47290	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11331130	C4591001 1133 11331130	16-55	12AUG2020	47287	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11331131	C4591001 1133 11331131	16-55	12AUG2020	47550	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331132	C4591001 1133 11331132	16-55	12AUG2020	47555	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331135	C4591001 1133 11331135	16-55	12AUG2020	47556	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11331138	C4591001 1133 11331138	16-55	12AUG2020	47557	Placebo	12AUG2020/ Placebo			
11331139	C4591001 1133 11331139	16-55	14AUG2020	49962	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331140	C4591001 1133 11331140	16-55	14AUG2020	49969	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331142	C4591001 1133 11331142	16-55	14AUG2020	49964	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331144	C4591001 1133 11331144	16-55	14AUG2020	49970	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331145	C4591001 1133 11331145	16-55	14AUG2020	50070	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331149	C4591001 1133 11331149	16-55	14AUG2020	50071	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331150	C4591001 1133 11331150	16-55	14AUG2020	50073	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331151	C4591001 1133 11331151	16-55	14AUG2020	50078	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331158	C4591001 1133 11331158	16-55	14AUG2020	50179	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331166	C4591001 1133 11331166	16-55	14AUG2020	50188	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331175	C4591001 1133 11331175	16-55	14AUG2020	50663	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331177	C4591001 1133 11331177	16-55	14AUG2020	50666	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331178	C4591001 1133 11331178	16-55	14AUG2020	50668	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11341005	C4591001 1134 11341005	16-55	06AUG2020	44118	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11341007	C4591001 1134 11341007	16-55	07AUG2020	44121	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11341008	C4591001 1134 11341008	16-55	07AUG2020	44120	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11341012	C4591001 1134 11341012	16-55	07AUG2020	44122	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11341013	C4591001 1134 11341013	16-55	07AUG2020	44682	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11341018	C4591001 1134 11341018	16-55	10AUG2020	44685	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11341028	C4591001 1134 11341028	16-55	11AUG2020	44688	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11341031	C4591001 1134 11341031	16-55	11AUG2020	44689	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11341033	C4591001 1134 11341033	16-55	11AUG2020	46411	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341039	C4591001 1134 11341039	16-55	11AUG2020	46412	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11341041	C4591001 1134 11341041	16-55	11AUG2020	46417	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11341046	C4591001 1134 11341046	16-55	12AUG2020	46419	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11341054	C4591001 1134 11341054	16-55	12AUG2020	47585	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341060	C4591001 1134 11341060	16-55	13AUG2020	47586	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11341068	C4591001 1134 11341068	16-55	13AUG2020	47587	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
11341070	C4591001 1134 11341070	16-55	13AUG2020	47589	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11341072	C4591001 1134 11341072	16-55	14AUG2020	49949	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11341077	C4591001 1134 11341077	16-55	14AUG2020	49955	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351001	C4591001 1135 11351001	16-55	03AUG2020	41781	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351002	C4591001 1135 11351002	16-55	03AUG2020	41780	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11351004	C4591001 1135 11351004	16-55	03AUG2020	41787	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11351006	C4591001 1135 11351006	16-55	03AUG2020	41788	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351007	C4591001 1135 11351007	16-55	03AUG2020	42041	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11351008	C4591001 1135 11351008	16-55	03AUG2020	42047	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351009	C4591001 1135 11351009	16-55	04AUG2020	42048	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11351011	C4591001 1135 11351011	16-55	04AUG2020	42049	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351016	C4591001 1135 11351016	16-55	04AUG2020	42634	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351017	C4591001 1135 11351017	16-55	04AUG2020	42631	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11351018	C4591001 1135 11351018	16-55	04AUG2020	42636	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351020	C4591001 1135 11351020	16-55	04AUG2020	42680	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351021	C4591001 1135 11351021	16-55	04AUG2020	42638	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351022	C4591001 1135 11351022	16-55	04AUG2020	42683	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11351023	C4591001 1135 11351023	16-55	04AUG2020	42677	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351024	C4591001 1135 11351024	16-55	05AUG2020	42687	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11351025	C4591001 1135 11351025	16-55	05AUG2020	43064	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11351026	C4591001 1135 11351026	16-55	05AUG2020	43071	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351027	C4591001 1135 11351027	16-55	05AUG2020	43061	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351029	C4591001 1135 11351029	16-55	05AUG2020	43072	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo		
11351030	C4591001 1135 11351030	16-55	05AUG2020	43194	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351036	C4591001 1135 11351036	16-55	05AUG2020	43195	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11351037	C4591001 1135 11351037	16-55	05AUG2020	43200	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351038	C4591001 1135 11351038	16-55	05AUG2020	43203	Placebo	05AUG2020/ Placebo	02SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11351040	C4591001 1135 11351040	16-55	05AUG2020	43434	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11351041	C4591001 1135 11351041	16-55	06AUG2020	43443	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351042	C4591001 1135 11351042	16-55	06AUG2020	43439	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11351044	C4591001 1135 11351044	16-55	06AUG2020	43444	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11351050	C4591001 1135 11351050	16-55	06AUG2020	44144	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351052	C4591001 1135 11351052	16-55	07AUG2020	44761	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11351053	C4591001 1135 11351053	16-55	07AUG2020	44146	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351054	C4591001 1135 11351054	16-55	07AUG2020	44148	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11351057	C4591001 1135 11351057	16-55	07AUG2020	44755	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351058	C4591001 1135 11351058	16-55	07AUG2020	44149	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351059	C4591001 1135 11351059	16-55	07AUG2020	44757	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351060	C4591001 1135 11351060	16-55	07AUG2020	44758	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351061	C4591001 1135 11351061	16-55	07AUG2020	44909	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)			
11351065	C4591001 1135 11351065	16-55	07AUG2020	44945	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo		
11351067	C4591001 1135 11351067	16-55	07AUG2020	44911	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351068	C4591001 1135 11351068	16-55	07AUG2020	44912	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351069	C4591001 1135 11351069	16-55	07AUG2020	44916	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351072	C4591001 1135 11351072	16-55	08AUG2020	44946	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351073	C4591001 1135 11351073	16-55	08AUG2020	44950	Placebo	08AUG2020/ Placebo	28AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351075	C4591001 1135 11351075	16-55	08AUG2020	44952	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351080	C4591001 1135 11351080	16-55	08AUG2020	45029	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351082	C4591001 1135 11351082	16-55	08AUG2020	45036	Placebo	08AUG2020/ Placebo	28AUG2020/ Placebo		
11351083	C4591001 1135 11351083	16-55	08AUG2020	45030	Placebo	08AUG2020/ Placebo	31AUG2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11351084	C4591001 1135 11351084	16-55	08AUG2020	45037	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351085	C4591001 1135 11351085	16-55	08AUG2020	45047	Placebo	08AUG2020/ Placebo	28AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351088	C4591001 1135 11351088	16-55	08AUG2020	45041	BNT162b2 (30 µg)	08AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11351090	C4591001 1135 11351090	16-55	10AUG2020	45050	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351091	C4591001 1135 11351091	16-55	10AUG2020	45051	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351095	C4591001 1135 11351095	16-55	10AUG2020	45930	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351097	C4591001 1135 11351097	16-55	10AUG2020	45935	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351099	C4591001 1135 11351099	16-55	11AUG2020	45936	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351100	C4591001 1135 11351100	16-55	11AUG2020	45937	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351103	C4591001 1135 11351103	16-55	12AUG2020	47529	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351104	C4591001 1135 11351104	16-55	12AUG2020	47530	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
11351105	C4591001 1135 11351105	16-55	12AUG2020	47532	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11351109	C4591001 1135 11351109	16-55	12AUG2020	47536	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351111	C4591001 1135 11351111	16-55	12AUG2020	48189	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351112	C4591001 1135 11351112	16-55	13AUG2020	48190	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351113	C4591001 1135 11351113	16-55	13AUG2020	48193	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351114	C4591001 1135 11351114	16-55	13AUG2020	49205	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351115	C4591001 1135 11351115	16-55	13AUG2020	48196	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11351119	C4591001 1135 11351119	16-55	13AUG2020	49211	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11351120	C4591001 1135 11351120	16-55	13AUG2020	49213	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351121	C4591001 1135 11351121	16-55	13AUG2020	49208	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11351124	C4591001 1135 11351124	16-55	13AUG2020	49662	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11351126	C4591001 1135 11351126	16-55	13AUG2020	49664	Placebo	13AUG2020/ Placebo	11SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11351127	C4591001 1135 11351127	16-55	14AUG2020	49667	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351132	C4591001 1135 11351132	16-55	14AUG2020	50767	Placebo	14AUG2020/ Placebo	01SEP2020/ Placebo		
11351134	C4591001 1135 11351134	16-55	14AUG2020	50771	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11391016	C4591001 1139 11391016	16-55	30JUL2020	40661	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11391021	C4591001 1139 11391021	16-55	31JUL2020	40664	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11391023	C4591001 1139 11391023	16-55	31JUL2020	40666	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11391025	C4591001 1139 11391025	16-55	31JUL2020	40672	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11391027	C4591001 1139 11391027	16-55	03AUG2020	41410	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11391028	C4591001 1139 11391028	16-55	03AUG2020	41406	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11391029	C4591001 1139 11391029	16-55	06AUG2020	43111	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11391033	C4591001 1139 11391033	16-55	03AUG2020	41412	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391037	C4591001 1139 11391037	16-55	04AUG2020	41415	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11391038	C4591001 1139 11391038	16-55	04AUG2020	42257	Placebo	04AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11391041	C4591001 1139 11391041	16-55	04AUG2020	42259	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11391042	C4591001 1139 11391042	16-55	04AUG2020	42267	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo		
11391044	C4591001 1139 11391044	16-55	04AUG2020	42268	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11391047	C4591001 1139 11391047	16-55	05AUG2020	42846	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391048	C4591001 1139 11391048	16-55	05AUG2020	42851	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11391049	C4591001 1139 11391049	16-55	05AUG2020	42850	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391052	C4591001 1139 11391052	16-55	05AUG2020	42854	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11391053	C4591001 1139 11391053	16-55	05AUG2020	43109	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391058	C4591001 1139 11391058	16-55	06AUG2020	43115	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391062	C4591001 1139 11391062	16-55	06AUG2020	43120	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11391065	C4591001 1139 11391065	16-55	06AUG2020	43805	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11391070	C4591001 1139 11391070	16-55	07AUG2020	43809	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11391071	C4591001 1139 11391071	16-55	07AUG2020	43811	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11391072	C4591001 1139 11391072	16-55	07AUG2020	43814	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391073	C4591001 1139 11391073	16-55	07AUG2020	44441	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11391076	C4591001 1139 11391076	16-55	07AUG2020	44444	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11391081	C4591001 1139 11391081	16-55	10AUG2020	44451	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	
11391083	C4591001 1139 11391083	16-55	10AUG2020	44448	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391086	C4591001 1139 11391086	16-55	10AUG2020	45729	Placebo	10AUG2020/ Placebo	04SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11391087	C4591001 1139 11391087	16-55	12AUG2020	45732	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391089	C4591001 1139 11391089	16-55	12AUG2020	45733	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11391090	C4591001 1139 11391090	16-55	12AUG2020	47765	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11391091	C4591001 1139 11391091	16-55	12AUG2020	45734	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11401009	C4591001 1140 11401009	16-55	31JUL2020	40104	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)		
11401010	C4591001 1140 11401010	16-55	31JUL2020	40108	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11401011	C4591001 1140 11401011	16-55	31JUL2020	40914	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11401015	C4591001 1140 11401015	16-55	31JUL2020	40917	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11401016	C4591001 1140 11401016	16-55	31JUL2020	40918	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401017	C4591001 1140 11401017	16-55	31JUL2020	40921	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11401019	C4591001 1140 11401019	16-55	03AUG2020	41573	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401020	C4591001 1140 11401020	16-55	03AUG2020	41574	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401021	C4591001 1140 11401021	16-55	03AUG2020	41583	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401022	C4591001 1140 11401022	16-55	03AUG2020	41580	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401023	C4591001 1140 11401023	16-55	03AUG2020	41815	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11401024	C4591001 1140 11401024	16-55	03AUG2020	41816	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11401025	C4591001 1140 11401025	16-55	03AUG2020	41819	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401027	C4591001 1140 11401027	16-55	04AUG2020	41820	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401028	C4591001 1140 11401028	16-55	04AUG2020	42151	Placebo	04AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401030	C4591001 1140 11401030	16-55	04AUG2020	42153	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11401031	C4591001 1140 11401031	16-55	04AUG2020	42154	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11401032	C4591001 1140 11401032	16-55	04AUG2020	42157	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11401033	C4591001 1140 11401033	16-55	04AUG2020	42425	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11401037	C4591001 1140 11401037	16-55	04AUG2020	42426	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11401039	C4591001 1140 11401039	16-55	05AUG2020	42436	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401040	C4591001 1140 11401040	16-55	05AUG2020	42429	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11401044	C4591001 1140 11401044	16-55	05AUG2020	43004	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401045	C4591001 1140 11401045	16-55	05AUG2020	43005	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401046	C4591001 1140 11401046	16-55	05AUG2020	43010	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401048	C4591001 1140 11401048	16-55	05AUG2020	43007	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401049	C4591001 1140 11401049	16-55	05AUG2020	43149	Placebo	05AUG2020/ Placebo	27AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401050	C4591001 1140 11401050	16-55	05AUG2020	43148	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11401051	C4591001 1140 11401051	16-55	06AUG2020	43153	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401052	C4591001 1140 11401052	16-55	06AUG2020	43150	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11401053	C4591001 1140 11401053	16-55	06AUG2020	43536	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11401055	C4591001 1140 11401055	16-55	06AUG2020	43532	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11401057	C4591001 1140 11401057	16-55	06AUG2020	43539	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11401059	C4591001 1140 11401059	16-55	06AUG2020	43540	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11401061	C4591001 1140 11401061	16-55	06AUG2020	43685	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401062	C4591001 1140 11401062	16-55	06AUG2020	43686	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11401063	C4591001 1140 11401063	16-55	06AUG2020	43687	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11401065	C4591001 1140 11401065	16-55	06AUG2020	43693	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401067	C4591001 1140 11401067	16-55	06AUG2020	43915	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401068	C4591001 1140 11401068	16-55	06AUG2020	43917	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11401069	C4591001 1140 11401069	16-55	07AUG2020	43924	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11401070	C4591001 1140 11401070	16-55	07AUG2020	43922	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401071	C4591001 1140 11401071	16-55	07AUG2020	44250	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11401072	C4591001 1140 11401072	16-55	07AUG2020	44254	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11401073	C4591001 1140 11401073	16-55	07AUG2020	44258	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401074	C4591001 1140 11401074	16-55	07AUG2020	44260	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11401079	C4591001 1140 11401079	16-55	07AUG2020	44513	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401084	C4591001 1140 11401084	16-55	07AUG2020	44518	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11401085	C4591001 1140 11401085	16-55	07AUG2020	44521	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401088	C4591001 1140 11401088	16-55	10AUG2020	44523	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11401091	C4591001 1140 11401091	16-55	10AUG2020	45224	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11401092	C4591001 1140 11401092	16-55	10AUG2020	45227	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11401093	C4591001 1140 11401093	16-55	11AUG2020	45231	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11401094	C4591001 1140 11401094	16-55	11AUG2020	45232	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11401097	C4591001 1140 11401097	16-55	13AUG2020	48401	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401100	C4591001 1140 11401100	16-55	13AUG2020	48405	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11401101	C4591001 1140 11401101	16-55	13AUG2020	48406	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11401106	C4591001 1140 11401106	16-55	13AUG2020	48409	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11401108	C4591001 1140 11401108	16-55	13AUG2020	49145	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11401109	C4591001 1140 11401109	16-55	13AUG2020	49156	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11401110	C4591001 1140 11401110	16-55	13AUG2020	49147	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11401112	C4591001 1140 11401112	16-55	13AUG2020	49148	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11401115	C4591001 1140 11401115	16-55	14AUG2020	49905	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11401116	C4591001 1140 11401116	16-55	14AUG2020	49906	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11401118	C4591001 1140 11401118	16-55	14AUG2020	49908	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401124	C4591001 1140 11401124	16-55	14AUG2020	49912	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401127	C4591001 1140 11401127	16-55	14AUG2020	50489	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11411003	C4591001 1141 11411003	16-55	30JUL2020	40710	Placebo	30JUL2020/ Placebo	19AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411004	C4591001 1141 11411004	16-55	30JUL2020	40717	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11411005	C4591001 1141 11411005	16-55	31JUL2020	40719	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11411006	C4591001 1141 11411006	16-55	31JUL2020	40720	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11411007	C4591001 1141 11411007	16-55	31JUL2020	41070	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11411008	C4591001 1141 11411008	16-55	31JUL2020	41071	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11411010	C4591001 1141 11411010	16-55	31JUL2020	41077	Placebo	31JUL2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11411011	C4591001 1141 11411011	16-55	31JUL2020	41078	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411012	C4591001 1141 11411012	16-55	31JUL2020	41239	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11411013	C4591001 1141 11411013	16-55	03AUG2020	41240	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11411014	C4591001 1141 11411014	16-55	03AUG2020	41243	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11411016	C4591001 1141 11411016	16-55	03AUG2020	41244	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411017	C4591001 1141 11411017	16-55	03AUG2020	41828	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11411018	C4591001 1141 11411018	16-55	03AUG2020	41832	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11411019	C4591001 1141 11411019	16-55	03AUG2020	41829	Placebo	03AUG2020/ Placebo	25AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411020	C4591001 1141 11411020	16-55	03AUG2020	41833	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11411021	C4591001 1141 11411021	16-55	04AUG2020	42137	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11411022	C4591001 1141 11411022	16-55	04AUG2020	42142	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411023	C4591001 1141 11411023	16-55	04AUG2020	42144	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11411024	C4591001 1141 11411024	16-55	04AUG2020	42143	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411025	C4591001 1141 11411025	16-55	04AUG2020	42393	Placebo	04AUG2020/ Placebo	24AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11411026	C4591001 1141 11411026	16-55	04AUG2020	42394	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11411027	C4591001 1141 11411027	16-55	04AUG2020	42397	Placebo	04AUG2020/ Placebo	03SEP2020/ Placebo		
11411029	C4591001 1141 11411029	16-55	04AUG2020	42399	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411030	C4591001 1141 11411030	16-55	05AUG2020	42833	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411031	C4591001 1141 11411031	16-55	05AUG2020	42834	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo		
11411032	C4591001 1141 11411032	16-55	05AUG2020	42836	Placebo	05AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11411033	C4591001 1141 11411033	16-55	05AUG2020	42842	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411036	C4591001 1141 11411036	16-55	05AUG2020	43229	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411037	C4591001 1141 11411037	16-55	05AUG2020	43231	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411038	C4591001 1141 11411038	16-55	06AUG2020	43233	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411041	C4591001 1141 11411041	16-55	06AUG2020	43238	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411042	C4591001 1141 11411042	16-55	06AUG2020	43757	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411044	C4591001 1141 11411044	16-55	06AUG2020	43758	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11411045	C4591001 1141 11411045	16-55	06AUG2020	43766	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11411046	C4591001 1141 11411046	16-55	06AUG2020	43759	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411048	C4591001 1141 11411048	16-55	07AUG2020	44369	Placebo	07AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11411049	C4591001 1141 11411049	16-55	07AUG2020	44371	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411050	C4591001 1141 11411050	16-55	07AUG2020	44379	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11411051	C4591001 1141 11411051	16-55	07AUG2020	44674	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411052	C4591001 1141 11411052	16-55	07AUG2020	44380	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11411053	C4591001 1141 11411053	16-55	07AUG2020	44676	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11411054	C4591001 1141 11411054	16-55	07AUG2020	44677	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411055	C4591001 1141 11411055	16-55	10AUG2020	44680	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411056	C4591001 1141 11411056	16-55	10AUG2020	45282	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411057	C4591001 1141 11411057	16-55	10AUG2020	45281	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411060	C4591001 1141 11411060	16-55	10AUG2020	45287	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411061	C4591001 1141 11411061	16-55	11AUG2020	45288	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411062	C4591001 1141 11411062	16-55	11AUG2020	46715	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411064	C4591001 1141 11411064	16-55	12AUG2020	46717	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11411065	C4591001 1141 11411065	16-55	12AUG2020	46718	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11411067	C4591001 1141 11411067	16-55	12AUG2020	46719	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11411068	C4591001 1141 11411068	16-55	12AUG2020	47720	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11411070	C4591001 1141 11411070	16-55	12AUG2020	47725	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411072	C4591001 1141 11411072	16-55	13AUG2020	47726	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411073	C4591001 1141 11411073	16-55	13AUG2020	47727	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11411074	C4591001 1141 11411074	16-55	13AUG2020	48917	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11411075	C4591001 1141 11411075	16-55	13AUG2020	48921	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411076	C4591001 1141 11411076	16-55	13AUG2020	48922	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411078	C4591001 1141 11411078	16-55	13AUG2020	49496	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11411079	C4591001 1141 11411079	16-55	14AUG2020	49497	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11411080	C4591001 1141 11411080	16-55	14AUG2020	49500	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11411081	C4591001 1141 11411081	16-55	14AUG2020	49501	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11411084	C4591001 1141 11411084	16-55	14AUG2020	50370	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11421018	C4591001 1142 11421018	16-55	31JUL2020	40611	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11421020	C4591001 1142 11421020	16-55	31JUL2020	40612	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421021	C4591001 1142 11421021	16-55	31JUL2020	41101	Placebo	31JUL2020/ Placebo	21AUG2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11421022	C4591001 1142 11421022	16-55	31JUL2020	41102	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421023	C4591001 1142 11421023	16-55	31JUL2020	41103	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11421025	C4591001 1142 11421025	16-55	03AUG2020	41104	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11421026	C4591001 1142 11421026	16-55	03AUG2020	41526	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11421027	C4591001 1142 11421027	16-55	03AUG2020	41532	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11421028	C4591001 1142 11421028	16-55	03AUG2020	41533	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11421033	C4591001 1142 11421033	16-55	04AUG2020	41534	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11421037	C4591001 1142 11421037	16-55	04AUG2020	42437	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421040	C4591001 1142 11421040	16-55	04AUG2020	42438	Placebo	04AUG2020/ Placebo	28AUG2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11421041	C4591001 1142 11421041	16-55	05AUG2020	42446	Placebo	05AUG2020/ Placebo	29AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11421042	C4591001 1142 11421042	16-55	05AUG2020	42447	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421043	C4591001 1142 11421043	16-55	05AUG2020	42785	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11421045	C4591001 1142 11421045	16-55	05AUG2020	42789	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11421046	C4591001 1142 11421046	16-55	05AUG2020	42790	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421049	C4591001 1142 11421049	16-55	06AUG2020	42796	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421050	C4591001 1142 11421050	16-55	06AUG2020	43577	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421051	C4591001 1142 11421051	16-55	06AUG2020	43578	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11421052	C4591001 1142 11421052	16-55	06AUG2020	43580	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421056	C4591001 1142 11421056	16-55	06AUG2020	43583	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11421058	C4591001 1142 11421058	16-55	07AUG2020	44309	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421059	C4591001 1142 11421059	16-55	07AUG2020	44311	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421060	C4591001 1142 11421060	16-55	07AUG2020	44312	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11421062	C4591001 1142 11421062	16-55	07AUG2020	44313	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11421066	C4591001 1142 11421066	16-55	10AUG2020	45258	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11421067	C4591001 1142 11421067	16-55	10AUG2020	45262	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11421068	C4591001 1142 11421068	16-55	10AUG2020	45263	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11421070	C4591001 1142 11421070	16-55	10AUG2020	45267	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11421071	C4591001 1142 11421071	16-55	10AUG2020	45521	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11421072	C4591001 1142 11421072	16-55	11AUG2020	45523	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421078	C4591001 1142 11421078	16-55	11AUG2020	45525	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11421079	C4591001 1142 11421079	16-55	11AUG2020	45528	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421081	C4591001 1142 11421081	16-55	12AUG2020	47117	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421082	C4591001 1142 11421082	16-55	12AUG2020	47120	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11421084	C4591001 1142 11421084	16-55	12AUG2020	47124	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo		
11421085	C4591001 1142 11421085	16-55	12AUG2020	47127	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11421089	C4591001 1142 11421089	16-55	13AUG2020	48439	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421090	C4591001 1142 11421090	16-55	13AUG2020	48441	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421092	C4591001 1142 11421092	16-55	13AUG2020	48443	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421094	C4591001 1142 11421094	16-55	13AUG2020	48444	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11421096	C4591001 1142 11421096	16-55	13AUG2020	49079	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11421099	C4591001 1142 11421099	16-55	14AUG2020	49081	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421100	C4591001 1142 11421100	16-55	14AUG2020	49083	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11421101	C4591001 1142 11421101	16-55	14AUG2020	49084	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11451001	C4591001 1145 11451001	16-55	12AUG2020	47374	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451002	C4591001 1145 11451002	16-55	12AUG2020	47378	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11451003	C4591001 1145 11451003	16-55	13AUG2020	47380	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11451004	C4591001 1145 11451004	16-55	13AUG2020	47379	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11451007	C4591001 1145 11451007	16-55	13AUG2020	49134	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11451010	C4591001 1145 11451010	16-55	14AUG2020	49140	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11451011	C4591001 1145 11451011	16-55	14AUG2020	49142	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461002	C4591001 1146 11461002	16-55	11AUG2020	46591	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461004	C4591001 1146 11461004	16-55	12AUG2020	46594	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461007	C4591001 1146 11461007	16-55	12AUG2020	46595	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11461009	C4591001 1146 11461009	16-55	13AUG2020	46599	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11461010	C4591001 1146 11461010	16-55	13AUG2020	48353	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11461011	C4591001 1146 11461011	16-55	13AUG2020	48354	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461013	C4591001 1146 11461013	16-55	13AUG2020	48361	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11461020	C4591001 1146 11461020	16-55	14AUG2020	48362	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461021	C4591001 1146 11461021	16-55	14AUG2020	49929	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11461023	C4591001 1146 11461023	16-55	14AUG2020	49931	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471003	C4591001 1147 11471003	16-55	30JUL2020	40578	BNT162b2 (30 µg)	30JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471007	C4591001 1147 11471007	16-55	03AUG2020	40580	Placebo	03AUG2020/ Placebo	24AUG2020/ Placebo		
11471010	C4591001 1147 11471010	16-55	03AUG2020	40586	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11471011	C4591001 1147 11471011	16-55	04AUG2020	42162	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471013	C4591001 1147 11471013	16-55	04AUG2020	42167	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11471014	C4591001 1147 11471014	16-55	04AUG2020	42169	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471016	C4591001 1147 11471016	16-55	04AUG2020	42171	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11471017	C4591001 1147 11471017	16-55	05AUG2020	42935	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11471019	C4591001 1147 11471019	16-55	05AUG2020	42930	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11471021	C4591001 1147 11471021	16-55	05AUG2020	42938	Placebo	05AUG2020/ Placebo	28AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471025	C4591001 1147 11471025	16-55	05AUG2020	42940	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471026	C4591001 1147 11471026	16-55	05AUG2020	43373	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471027	C4591001 1147 11471027	16-55	05AUG2020	43376	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11471031	C4591001 1147 11471031	16-55	06AUG2020	43382	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11471033	C4591001 1147 11471033	16-55	06AUG2020	43383	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471035	C4591001 1147 11471035	16-55	06AUG2020	43777	Placebo	06AUG2020/ Placebo			
11471038	C4591001 1147 11471038	16-55	06AUG2020	43778	Placebo	06AUG2020/ Placebo	28AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471039	C4591001 1147 11471039	16-55	06AUG2020	43780	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471041	C4591001 1147 11471041	16-55	06AUG2020	43779	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11471045	C4591001 1147 11471045	16-55	06AUG2020	44190	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11471046	C4591001 1147 11471046	16-55	07AUG2020	44197	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471047	C4591001 1147 11471047	16-55	07AUG2020	44196	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11471048	C4591001 1147 11471048	16-55	07AUG2020	44198	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471049	C4591001 1147 11471049	16-55	07AUG2020	44409	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471051	C4591001 1147 11471051	16-55	07AUG2020	44408	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11471053	C4591001 1147 11471053	16-55	07AUG2020	44411	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11471054	C4591001 1147 11471054	16-55	07AUG2020	44416	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471056	C4591001 1147 11471056	16-55	07AUG2020	44562	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11471059	C4591001 1147 11471059	16-55	07AUG2020	44564	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471065	C4591001 1147 11471065	16-55	07AUG2020	44566	Placebo	07AUG2020/ Placebo	28AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471066	C4591001 1147 11471066	16-55	07AUG2020	44569	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471070	C4591001 1147 11471070	16-55	10AUG2020	45317	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471073	C4591001 1147 11471073	16-55	10AUG2020	45322	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471077	C4591001 1147 11471077	16-55	10AUG2020	45324	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471078	C4591001 1147 11471078	16-55	10AUG2020	45325	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471079	C4591001 1147 11471079	16-55	10AUG2020	45705	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471085	C4591001 1147 11471085	16-55	10AUG2020	45706	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471089	C4591001 1147 11471089	16-55	11AUG2020	45707	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471092	C4591001 1147 11471092	16-55	11AUG2020	45708	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11471094	C4591001 1147 11471094	16-55	11AUG2020	46449	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11471100	C4591001 1147 11471100	16-55	11AUG2020	46452	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471107	C4591001 1147 11471107	16-55	12AUG2020	46453	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471115	C4591001 1147 11471115	16-55	13AUG2020	46455	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471118	C4591001 1147 11471118	16-55	13AUG2020	49181	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471119	C4591001 1147 11471119	16-55	13AUG2020	49183	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471120	C4591001 1147 11471120	16-55	13AUG2020	49184	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11471121	C4591001 1147 11471121	16-55	13AUG2020	49185	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471122	C4591001 1147 11471122	16-55	13AUG2020	49579	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471123	C4591001 1147 11471123	16-55	13AUG2020	49582	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11471129	C4591001 1147 11471129	16-55	14AUG2020	49586	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471131	C4591001 1147 11471131	16-55	14AUG2020	49588	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471132	C4591001 1147 11471132	16-55	14AUG2020	50501	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471133	C4591001 1147 11471133	16-55	14AUG2020	50504	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471134	C4591001 1147 11471134	16-55	14AUG2020	50505	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471135	C4591001 1147 11471135	16-55	14AUG2020	50509	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491001	C4591001 1149 11491001	16-55	05AUG2020	43415	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11491005	C4591001 1149 11491005	16-55	05AUG2020	43417	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)			
11491006	C4591001 1149 11491006	16-55	05AUG2020	43418	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11491007	C4591001 1149 11491007	16-55	06AUG2020	43420	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11491008	C4591001 1149 11491008	16-55	06AUG2020	44037	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491011	C4591001 1149 11491011	16-55	06AUG2020	44039	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491012	C4591001 1149 11491012	16-55	06AUG2020	44008	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11491013	C4591001 1149 11491013	16-55	06AUG2020	43999	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11491014	C4591001 1149 11491014	16-55	06AUG2020	44002	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11491015	C4591001 1149 11491015	16-55	06AUG2020	44007	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11491016	C4591001 1149 11491016	16-55	07AUG2020	44042	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11491020	C4591001 1149 11491020	16-55	07AUG2020	44043	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11491021	C4591001 1149 11491021	16-55	07AUG2020	44743	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11491023	C4591001 1149 11491023	16-55	07AUG2020	44745	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491024	C4591001 1149 11491024	16-55	07AUG2020	44752	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11491025	C4591001 1149 11491025	16-55	07AUG2020	44751	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491027	C4591001 1149 11491027	16-55	07AUG2020	44828	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11491028	C4591001 1149 11491028	16-55	07AUG2020	44831	Placebo	07AUG2020/ Placebo	27AUG2020/ Placebo		
11491029	C4591001 1149 11491029	16-55	07AUG2020	44829	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11491030	C4591001 1149 11491030	16-55	10AUG2020	44834	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491031	C4591001 1149 11491031	16-55	10AUG2020	45753	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			
11491033	C4591001 1149 11491033	16-55	10AUG2020	45756	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11491034	C4591001 1149 11491034	16-55	10AUG2020	45759	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo		
11491035	C4591001 1149 11491035	16-55	10AUG2020	45754	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11491036	C4591001 1149 11491036	16-55	10AUG2020	45775	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491037	C4591001 1149 11491037	16-55	10AUG2020	45776	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491040	C4591001 1149 11491040	16-55	11AUG2020	45779	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
11491044	C4591001 1149 11491044	16-55	11AUG2020	45783	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11491045	C4591001 1149 11491045	16-55	11AUG2020	46686	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11491046	C4591001 1149 11491046	16-55	11AUG2020	46688	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11491047	C4591001 1149 11491047	16-55	11AUG2020	46689	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11491049	C4591001 1149 11491049	16-55	11AUG2020	46691	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11491050	C4591001 1149 11491050	16-55	11AUG2020	46772	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11491051	C4591001 1149 11491051	16-55	11AUG2020	46773	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11491054	C4591001 1149 11491054	16-55	12AUG2020	46775	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11491055	C4591001 1149 11491055	16-55	12AUG2020	46778	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491057	C4591001 1149 11491057	16-55	12AUG2020	47899	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11491059	C4591001 1149 11491059	16-55	12AUG2020	47905	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11491061	C4591001 1149 11491061	16-55	12AUG2020	47906	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11491062	C4591001 1149 11491062	16-55	12AUG2020	47908	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11491063	C4591001 1149 11491063	16-55	12AUG2020	48031	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11491065	C4591001 1149 11491065	16-55	12AUG2020	48032	Placebo	12AUG2020/ Placebo			
11491066	C4591001 1149 11491066	16-55	12AUG2020	48033	Placebo	12AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
11491067	C4591001 1149 11491067	16-55	12AUG2020	48035	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)			
11491068	C4591001 1149 11491068	16-55	13AUG2020	49169	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11491069	C4591001 1149 11491069	16-55	13AUG2020	49172	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491070	C4591001 1149 11491070	16-55	13AUG2020	49174	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11521001	C4591001 1152 11521001	16-55	12AUG2020	47251	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521002	C4591001 1152 11521002	16-55	12AUG2020	47253	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
11521003	C4591001 1152 11521003	16-55	12AUG2020	47258	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521005	C4591001 1152 11521005	16-55	12AUG2020	47260	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521007	C4591001 1152 11521007	16-55	12AUG2020	47492	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521008	C4591001 1152 11521008	16-55	12AUG2020	47496	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521009	C4591001 1152 11521009	16-55	12AUG2020	47497	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11521010	C4591001 1152 11521010	16-55	12AUG2020	47498	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521011	C4591001 1152 11521011	16-55	12AUG2020	47695	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521012	C4591001 1152 11521012	16-55	12AUG2020	47698	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521014	C4591001 1152 11521014	16-55	12AUG2020	47703	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11521015	C4591001 1152 11521015	16-55	12AUG2020	47704	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11521017	C4591001 1152 11521017	16-55	12AUG2020	48140	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521019	C4591001 1152 11521019	16-55	12AUG2020	48145	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521020	C4591001 1152 11521020	16-55	12AUG2020	48147	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11521022	C4591001 1152 11521022	16-55	12AUG2020	48148	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521024	C4591001 1152 11521024	16-55	12AUG2020	48210	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11521029	C4591001 1152 11521029	16-55	12AUG2020	48219	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521030	C4591001 1152 11521030	16-55	12AUG2020	48217	Placebo	12AUG2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521031	C4591001 1152 11521031	16-55	12AUG2020	48212	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521032	C4591001 1152 11521032	16-55	12AUG2020	48245	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo		
11521034	C4591001 1152 11521034	16-55	12AUG2020	48246	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)			
11521035	C4591001 1152 11521035	16-55	12AUG2020	48254	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521036	C4591001 1152 11521036	16-55	12AUG2020	48253	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521038	C4591001 1152 11521038	16-55	13AUG2020	48644	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521039	C4591001 1152 11521039	16-55	13AUG2020	48642	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo		
11521042	C4591001 1152 11521042	16-55	13AUG2020	48648	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
11521043	C4591001 1152 11521043	16-55	13AUG2020	48652	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521044	C4591001 1152 11521044	16-55	13AUG2020	48989	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521045	C4591001 1152 11521045	16-55	13AUG2020	48995	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11521046	C4591001 1152 11521046	16-55	13AUG2020	48996	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521048	C4591001 1152 11521048	16-55	13AUG2020	48998	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521051	C4591001 1152 11521051	16-55	13AUG2020	49399	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521052	C4591001 1152 11521052	16-55	13AUG2020	49400	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521053	C4591001 1152 11521053	16-55	13AUG2020	49402	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521054	C4591001 1152 11521054	16-55	13AUG2020	49406	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11521056	C4591001 1152 11521056	16-55	13AUG2020	49517	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521058	C4591001 1152 11521058	16-55	13AUG2020	49518	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521059	C4591001 1152 11521059	16-55	13AUG2020	49519	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521060	C4591001 1152 11521060	16-55	13AUG2020	49526	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521061	C4591001 1152 11521061	16-55	13AUG2020	49640	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521062	C4591001 1152 11521062	16-55	13AUG2020	49643	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521063	C4591001 1152 11521063	16-55	13AUG2020	49699	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521064	C4591001 1152 11521064	16-55	13AUG2020	49647	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521065	C4591001 1152 11521065	16-55	13AUG2020	49648	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521066	C4591001 1152 11521066	16-55	13AUG2020	49701	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521070	C4591001 1152 11521070	16-55	13AUG2020	49704	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11521071	C4591001 1152 11521071	16-55	13AUG2020	49702	Placebo	13AUG2020/ Placebo	11SEP2020/ Placebo		
11521072	C4591001 1152 11521072	16-55	13AUG2020	49760	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521073	C4591001 1152 11521073	16-55	13AUG2020	49761	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11521075	C4591001 1152 11521075	16-55	13AUG2020	49766	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11521076	C4591001 1152 11521076	16-55	13AUG2020	49768	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11521077	C4591001 1152 11521077	16-55	13AUG2020	49782	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11521078	C4591001 1152 11521078	16-55	14AUG2020	49783	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521081	C4591001 1152 11521081	16-55	14AUG2020	49784	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11571002	C4591001 1157 11571002	16-55	12AUG2020	48129	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11571003	C4591001 1157 11571003	16-55	12AUG2020	48130	Placebo	12AUG2020/ Placebo			
11571004	C4591001 1157 11571004	16-55	12AUG2020	48131	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571006	C4591001 1157 11571006	16-55	12AUG2020	48134	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571009	C4591001 1157 11571009	16-55	13AUG2020	49481	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571010	C4591001 1157 11571010	16-55	13AUG2020	49487	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571013	C4591001 1157 11571013	16-55	13AUG2020	49491	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571015	C4591001 1157 11571015	16-55	13AUG2020	49492	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571017	C4591001 1157 11571017	16-55	13AUG2020	49686	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571019	C4591001 1157 11571019	16-55	14AUG2020	49687	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571020	C4591001 1157 11571020	16-55	14AUG2020	49690	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11571021	C4591001 1157 11571021	16-55	14AUG2020	49695	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11611001	C4591001 1161 11611001	16-55	31JUL2020	41201	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11611002	C4591001 1161 11611002	16-55	31JUL2020	41202	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11611004	C4591001 1161 11611004	16-55	31JUL2020	41209	Placebo	31JUL2020/ Placebo	04NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11611006	C4591001 1161 11611006	16-55	31JUL2020	41279	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11611007	C4591001 1161 11611007	16-55	31JUL2020	41280	Placebo	31JUL2020/ Placebo			
11611008	C4591001 1161 11611008	16-55	31JUL2020	41283	Placebo	31JUL2020/ Placebo			
11611009	C4591001 1161 11611009	16-55	31JUL2020	41284	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11611010	C4591001 1161 11611010	16-55	31JUL2020	41285	Placebo	31JUL2020/ Placebo			
11611011	C4591001 1161 11611011	16-55	01AUG2020	41293	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11611014	C4591001 1161 11611014	16-55	01AUG2020	41294	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11611015	C4591001 1161 11611015	16-55	01AUG2020	41296	Placebo	01AUG2020/ Placebo	19NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11611016	C4591001 1161 11611016	16-55	01AUG2020	41384	Placebo	01AUG2020/ Placebo	19NOV2020/ Placebo		
11611017	C4591001 1161 11611017	16-55	01AUG2020	41390	BNT162b2 (30 µg)	01AUG2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11611018	C4591001 1161 11611018	16-55	01AUG2020	41386	Placebo	01AUG2020/ Placebo			
11611019	C4591001 1161 11611019	16-55	03AUG2020	41855	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11611020	C4591001 1161 11611020	16-55	03AUG2020	41392	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11611023	C4591001 1161 11611023	16-55	03AUG2020	41857	Placebo	03AUG2020/ Placebo			
11611024	C4591001 1161 11611024	16-55	03AUG2020	41856	Placebo	03AUG2020/ Placebo			
11611026	C4591001 1161 11611026	16-55	04AUG2020	41859	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11611027	C4591001 1161 11611027	16-55	04AUG2020	42404	Placebo	04AUG2020/ Placebo	02NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11611028	C4591001 1161 11611028	16-55	04AUG2020	42405	Placebo	04AUG2020/ Placebo	12NOV2020/ Placebo		
11611032	C4591001 1161 11611032	16-55	05AUG2020	42408	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11611033	C4591001 1161 11611033	16-55	05AUG2020	43326	Placebo	05AUG2020/ Placebo	20NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11611034	C4591001 1161 11611034	16-55	05AUG2020	42411	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11611040	C4591001 1161 11611040	16-55	05AUG2020	43335	Placebo	05AUG2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11611041	C4591001 1161 11611041	16-55	05AUG2020	43328	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11621001	C4591001 1162 11621001	16-55	31JUL2020	40962	Placebo	31JUL2020/ Placebo	20AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11621003	C4591001 1162 11621003	16-55	31JUL2020	40963	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)		
11621004	C4591001 1162 11621004	16-55	31JUL2020	40966	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621005	C4591001 1162 11621005	16-55	31JUL2020	40972	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)			
11621009	C4591001 1162 11621009	16-55	31JUL2020	41249	BNT162b2 (30 µg)	31JUL2020/ BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)		
11621010	C4591001 1162 11621010	16-55	03AUG2020	41252	Placebo	03AUG2020/ Placebo	26AUG2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11621018	C4591001 1162 11621018	16-55	03AUG2020	41258	Placebo	03AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11621019	C4591001 1162 11621019	16-55	03AUG2020	41260	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621021	C4591001 1162 11621021	16-55	03AUG2020	42006	BNT162b2 (30 µg)	03AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11621023	C4591001 1162 11621023	16-55	04AUG2020	42016	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo		
11621025	C4591001 1162 11621025	16-55	04AUG2020	42011	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621026	C4591001 1162 11621026	16-55	04AUG2020	42331	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11621028	C4591001 1162 11621028	16-55	04AUG2020	42335	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621031	C4591001 1162 11621031	16-55	04AUG2020	42337	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11621033	C4591001 1162 11621033	16-55	04AUG2020	42668	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11621034	C4591001 1162 11621034	16-55	04AUG2020	42666	Placebo	04AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621035	C4591001 1162 11621035	16-55	04AUG2020	42672	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621037	C4591001 1162 11621037	16-55	04AUG2020	42340	Placebo	04AUG2020/ Placebo	27AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621039	C4591001 1162 11621039	16-55	06AUG2020	42673	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo		
11621041	C4591001 1162 11621041	16-55	06AUG2020	43712	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11621042	C4591001 1162 11621042	16-55	06AUG2020	43714	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621043	C4591001 1162 11621043	16-55	06AUG2020	43715	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11621044	C4591001 1162 11621044	16-55	06AUG2020	43713	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11621051	C4591001 1162 11621051	16-55	06AUG2020	43889	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		
11621054	C4591001 1162 11621054	16-55	06AUG2020	43897	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11621055	C4591001 1162 11621055	16-55	06AUG2020	43896	Placebo	06AUG2020/ Placebo	01SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11621056	C4591001 1162 11621056	16-55	10AUG2020	43900	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11621061	C4591001 1162 11621061	16-55	10AUG2020	45413	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621062	C4591001 1162 11621062	16-55	10AUG2020	45414	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621064	C4591001 1162 11621064	16-55	10AUG2020	45419	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621066	C4591001 1162 11621066	16-55	10AUG2020	45424	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11621067	C4591001 1162 11621067	16-55	10AUG2020	45546	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621070	C4591001 1162 11621070	16-55	10AUG2020	45550	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11621072	C4591001 1162 11621072	16-55	10AUG2020	45555	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621074	C4591001 1162 11621074	16-55	11AUG2020	45556	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo		
11621075	C4591001 1162 11621075	16-55	11AUG2020	46137	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11621077	C4591001 1162 11621077	16-55	11AUG2020	46138	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621080	C4591001 1162 11621080	16-55	11AUG2020	46140	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621081	C4591001 1162 11621081	16-55	11AUG2020	46141	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11621083	C4591001 1162 11621083	16-55	11AUG2020	46345	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621084	C4591001 1162 11621084	16-55	11AUG2020	46337	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11621085	C4591001 1162 11621085	16-55	11AUG2020	46338	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621086	C4591001 1162 11621086	16-55	11AUG2020	46342	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621091	C4591001 1162 11621091	16-55	11AUG2020	46495	Placebo	11AUG2020/ Placebo	18SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621093	C4591001 1162 11621093	16-55	11AUG2020	46518	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11621094	C4591001 1162 11621094	16-55	11AUG2020	46519	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621096	C4591001 1162 11621096	16-55	13AUG2020	46522	Placebo	13AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621097	C4591001 1162 11621097	16-55	13AUG2020	46526	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621098	C4591001 1162 11621098	16-55	13AUG2020	48509	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621100	C4591001 1162 11621100	16-55	13AUG2020	48520	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621101	C4591001 1162 11621101	16-55	13AUG2020	48516	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11621103	C4591001 1162 11621103	16-55	13AUG2020	48517	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo		
11621104	C4591001 1162 11621104	16-55	13AUG2020	48618	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621106	C4591001 1162 11621106	16-55	13AUG2020	48620	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11621107	C4591001 1162 11621107	16-55	13AUG2020	48622	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11621108	C4591001 1162 11621108	16-55	13AUG2020	48865	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11621110	C4591001 1162 11621110	16-55	13AUG2020	48628	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621111	C4591001 1162 11621111	16-55	13AUG2020	48858	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621112	C4591001 1162 11621112	16-55	13AUG2020	48860	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11621114	C4591001 1162 11621114	16-55	13AUG2020	48861	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo		
11621115	C4591001 1162 11621115	16-55	13AUG2020	48954	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11621117	C4591001 1162 11621117	16-55	13AUG2020	48955	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11621118	C4591001 1162 11621118	16-55	13AUG2020	48958	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)			
11621120	C4591001 1162 11621120	16-55	13AUG2020	48963	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	
11621121	C4591001 1162 11621121	16-55	13AUG2020	49422	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11631004	C4591001 1163 11631004	16-55	31JUL2020	41130	Placebo	31JUL2020/ Placebo	19AUG2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11631006	C4591001 1163 11631006	16-55	31JUL2020	41132	BNT162b2 (30 µg)	31JUL2020/ 			
11631021	C4591001 1163 11631021	16-55	04AUG2020	42642	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631023	C4591001 1163 11631023	16-55	04AUG2020	41138	BNT162b2 (30 µg)	04AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11631028	C4591001 1163 11631028	16-55	05AUG2020	42645	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
11631029	C4591001 1163 11631029	16-55	05AUG2020	42647	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631036	C4591001 1163 11631036	16-55	05AUG2020	43421	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11631037	C4591001 1163 11631037	16-55	05AUG2020	42652	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631039	C4591001 1163 11631039	16-55	06AUG2020	43422	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11631040	C4591001 1163 11631040	16-55	06AUG2020	43429	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11631042	C4591001 1163 11631042	16-55	06AUG2020	43432	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11631046	C4591001 1163 11631046	16-55	06AUG2020	43783	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
11631048	C4591001 1163 11631048	16-55	06AUG2020	43787	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631049	C4591001 1163 11631049	16-55	06AUG2020	43788	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631050	C4591001 1163 11631050	16-55	06AUG2020	43790	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631052	C4591001 1163 11631052	16-55	06AUG2020	44131	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11631056	C4591001 1163 11631056	16-55	07AUG2020	44133	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11631059	C4591001 1163 11631059	16-55	07AUG2020	44137	Placebo	07AUG2020/ Placebo		19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11631060	C4591001 1163 11631060	16-55	07AUG2020	44529	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11631061	C4591001 1163 11631061	16-55	07AUG2020	44527	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
11631064	C4591001 1163 11631064	16-55	07AUG2020	44532	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11631066	C4591001 1163 11631066	16-55	07AUG2020	44535	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
11631069	C4591001 1163 11631069	16-55	10AUG2020	45427	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631072	C4591001 1163 11631072	16-55	10AUG2020	45428	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631074	C4591001 1163 11631074	16-55	10AUG2020	45921	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631075	C4591001 1163 11631075	16-55	10AUG2020	45435	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11631076	C4591001 1163 11631076	16-55	10AUG2020	45429	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11631077	C4591001 1163 11631077	16-55	10AUG2020	45917	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631081	C4591001 1163 11631081	16-55	11AUG2020	45923	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
11631087	C4591001 1163 11631087	16-55	11AUG2020	45928	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11631088	C4591001 1163 11631088	16-55	11AUG2020	46760	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11631093	C4591001 1163 11631093	16-55	12AUG2020	46761	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11631096	C4591001 1163 11631096	16-55	12AUG2020	46764	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631098	C4591001 1163 11631098	16-55	12AUG2020	46768	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11631102	C4591001 1163 11631102	16-55	12AUG2020	48198	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11631103	C4591001 1163 11631103	16-55	13AUG2020	48206	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11631104	C4591001 1163 11631104	16-55	13AUG2020	48205	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11631106	C4591001 1163 11631106	16-55	13AUG2020	49591	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11631107	C4591001 1163 11631107	16-55	13AUG2020	48204	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11631109	C4591001 1163 11631109	16-55	13AUG2020	49595	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11631110	C4591001 1163 11631110	16-55	14AUG2020	49600	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11631112	C4591001 1163 11631112	16-55	14AUG2020	49597	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11631113	C4591001 1163 11631113	16-55	14AUG2020	50874	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631114	C4591001 1163 11631114	16-55	14AUG2020	50877	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11631116	C4591001 1163 11631116	16-55	14AUG2020	50878	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11671001	C4591001 1167 11671001	16-55	14AUG2020	49809	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11671002	C4591001 1167 11671002	16-55	14AUG2020	49811	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11671004	C4591001 1167 11671004	16-55	14AUG2020	49816	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11671005	C4591001 1167 11671005	16-55	14AUG2020	50465	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11671006	C4591001 1167 11671006	16-55	14AUG2020	50466	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681001	C4591001 1168 11681001	16-55	11AUG2020	46667	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11681002	C4591001 1168 11681002	16-55	11AUG2020	46668	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11681003	C4591001 1168 11681003	16-55	12AUG2020	46669	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681004	C4591001 1168 11681004	16-55	12AUG2020	46672	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681005	C4591001 1168 11681005	16-55	12AUG2020	47567	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681006	C4591001 1168 11681006	16-55	12AUG2020	47568	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681007	C4591001 1168 11681007	16-55	12AUG2020	47571	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681008	C4591001 1168 11681008	16-55	12AUG2020	47572	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681009	C4591001 1168 11681009	16-55	12AUG2020	47885	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681011	C4591001 1168 11681011	16-55	13AUG2020	47886	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681013	C4591001 1168 11681013	16-55	13AUG2020	47888	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681014	C4591001 1168 11681014	16-55	13AUG2020	47893	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11681016	C4591001 1168 11681016	16-55	13AUG2020	49374	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681017	C4591001 1168 11681017	16-55	13AUG2020	49376	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681018	C4591001 1168 11681018	16-55	13AUG2020	49378	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681019	C4591001 1168 11681019	16-55	14AUG2020	49383	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681020	C4591001 1168 11681020	16-55	14AUG2020	50194	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11681022	C4591001 1168 11681022	16-55	14AUG2020	50195	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681023	C4591001 1168 11681023	16-55	14AUG2020	50198	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681024	C4591001 1168 11681024	16-55	14AUG2020	50200	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681025	C4591001 1168 11681025	16-55	15AUG2020	51173	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681026	C4591001 1168 11681026	16-55	15AUG2020	51174	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11681031	C4591001 1168 11681031	16-55	15AUG2020	51308	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701001	C4591001 1170 11701001	16-55	12AUG2020	47242	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701002	C4591001 1170 11701002	16-55	12AUG2020	47244	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11701003	C4591001 1170 11701003	16-55	12AUG2020	47246	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701006	C4591001 1170 11701006	16-55	12AUG2020	47247	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11701007	C4591001 1170 11701007	16-55	12AUG2020	48066	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701009	C4591001 1170 11701009	16-55	13AUG2020	48068	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701011	C4591001 1170 11701011	16-55	13AUG2020	48070	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11701012	C4591001 1170 11701012	16-55	13AUG2020	49314	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11701013	C4591001 1170 11701013	16-55	13AUG2020	226982	Placebo	13AUG2020/ Placebo	08SEP2020/ Placebo		
11701014	C4591001 1170 11701014	16-55	13AUG2020	49318	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701015	C4591001 1170 11701015	16-55	14AUG2020	49321	Placebo	14AUG2020/ Placebo	01SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11701016	C4591001 1170 11701016	16-55	14AUG2020	49323	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701018	C4591001 1170 11701018	16-55	14AUG2020	50610	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701019	C4591001 1170 11701019	16-55	14AUG2020	50611	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11701023	C4591001 1170 11701023	16-55	17AUG2020	52771	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11711001	C4591001 1171 11711001	16-55	12AUG2020	47321	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11711002	C4591001 1171 11711002	16-55	12AUG2020	47322	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11711003	C4591001 1171 11711003	16-55	12AUG2020	47325	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711004	C4591001 1171 11711004	16-55	12AUG2020	47327	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo		
11711005	C4591001 1171 11711005	16-55	12AUG2020	47706	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711006	C4591001 1171 11711006	16-55	12AUG2020	47710	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
11711008	C4591001 1171 11711008	16-55	12AUG2020	47713	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11711009	C4591001 1171 11711009	16-55	13AUG2020	47714	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11711010	C4591001 1171 11711010	16-55	13AUG2020	48826	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11711011	C4591001 1171 11711011	16-55	13AUG2020	48823	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11711012	C4591001 1171 11711012	16-55	13AUG2020	48827	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11711013	C4591001 1171 11711013	16-55	13AUG2020	48831	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11711014	C4591001 1171 11711014	16-55	13AUG2020	48965	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11711016	C4591001 1171 11711016	16-55	13AUG2020	48969	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
11711020	C4591001 1171 11711020	16-55	13AUG2020	48971	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711021	C4591001 1171 11711021	16-55	13AUG2020	48976	Placebo	13AUG2020/ Placebo	10SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11711023	C4591001 1171 11711023	16-55	14AUG2020	50045	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
11711024	C4591001 1171 11711024	16-55	14AUG2020	50048	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711026	C4591001 1171 11711026	16-55	14AUG2020	50052	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711028	C4591001 1171 11711028	16-55	14AUG2020	50407	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711029	C4591001 1171 11711029	16-55	14AUG2020	50408	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711030	C4591001 1171 11711030	16-55	14AUG2020	50414	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11711031	C4591001 1171 11711031	16-55	14AUG2020	50415	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11711033	C4591001 1171 11711033	16-55	14AUG2020	50516	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11711034	C4591001 1171 11711034	16-55	14AUG2020	50518	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711036	C4591001 1171 11711036	16-55	14AUG2020	50521	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711037	C4591001 1171 11711037	16-55	14AUG2020	50993	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11711039	C4591001 1171 11711039	16-55	14AUG2020	50995	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771001	C4591001 1177 11771001	16-55	12AUG2020	47622	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771003	C4591001 1177 11771003	16-55	12AUG2020	47627	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771004	C4591001 1177 11771004	16-55	12AUG2020	47624	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771005	C4591001 1177 11771005	16-55	12AUG2020	47631	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771007	C4591001 1177 11771007	16-55	12AUG2020	48090	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771009	C4591001 1177 11771009	16-55	12AUG2020	48092	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
11771010	C4591001 1177 11771010	16-55	12AUG2020	48093	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771013	C4591001 1177 11771013	16-55	13AUG2020	48099	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771014	C4591001 1177 11771014	16-55	13AUG2020	49158	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771017	C4591001 1177 11771017	16-55	13AUG2020	49160	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771018	C4591001 1177 11771018	16-55	13AUG2020	49167	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771021	C4591001 1177 11771021	16-55	13AUG2020	49168	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771022	C4591001 1177 11771022	16-55	13AUG2020	49546	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11771023	C4591001 1177 11771023	16-55	13AUG2020	49548	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771024	C4591001 1177 11771024	16-55	13AUG2020	49549	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771025	C4591001 1177 11771025	16-55	13AUG2020	49551	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771026	C4591001 1177 11771026	16-55	13AUG2020	49721	Placebo	13AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771027	C4591001 1177 11771027	16-55	13AUG2020	49728	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771028	C4591001 1177 11771028	16-55	13AUG2020	49729	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
11771030	C4591001 1177 11771030	16-55	13AUG2020	49730	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771032	C4591001 1177 11771032	16-55	13AUG2020	49769	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771038	C4591001 1177 11771038	16-55	14AUG2020	49772	Placebo	14AUG2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771039	C4591001 1177 11771039	16-55	14AUG2020	49776	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771043	C4591001 1177 11771043	16-55	14AUG2020	49778	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
11771047	C4591001 1177 11771047	16-55	14AUG2020	51077	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11791002	C4591001 1179 11791002	16-55	14AUG2020	50213	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12241005	C4591001 1224 12241005	16-55	12AUG2020	47753	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241008	C4591001 1224 12241008	16-55	12AUG2020	47755	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12241009	C4591001 1224 12241009	16-55	13AUG2020	47759	Placebo	13AUG2020/ Placebo			
12241010	C4591001 1224 12241010	16-55	13AUG2020	49085	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12241017	C4591001 1224 12241017	16-55	14AUG2020	49087	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12241021	C4591001 1224 12241021	16-55	14AUG2020	49091	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12241024	C4591001 1224 12241024	16-55	14AUG2020	49093	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12241026	C4591001 1224 12241026	16-55	14AUG2020	50971	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12241027	C4591001 1224 12241027	16-55	14AUG2020	50974	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12261001	C4591001 1226 12261001	16-55	05AUG2020	42725	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261002	C4591001 1226 12261002	16-55	05AUG2020	42729	Placebo	05AUG2020/ Placebo	25AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261003	C4591001 1226 12261003	16-55	05AUG2020	42731	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261004	C4591001 1226 12261004	16-55	05AUG2020	42733	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261005	C4591001 1226 12261005	16-55	05AUG2020	42737	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261006	C4591001 1226 12261006	16-55	05AUG2020	42743	Placebo	05AUG2020/ Placebo	24AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261007	C4591001 1226 12261007	16-55	05AUG2020	42745	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
12261008	C4591001 1226 12261008	16-55	05AUG2020	42803	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
12261010	C4591001 1226 12261010	16-55	05AUG2020	42804	Placebo	05AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261011	C4591001 1226 12261011	16-55	05AUG2020	42748	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)		
12261012	C4591001 1226 12261012	16-55	05AUG2020	42806	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261013	C4591001 1226 12261013	16-55	05AUG2020	42797	Placebo	05AUG2020/ Placebo	26AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261014	C4591001 1226 12261014	16-55	05AUG2020	42905	BNT162b2 (30 µg)	05AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261015	C4591001 1226 12261015	16-55	06AUG2020	42909	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261016	C4591001 1226 12261016	16-55	06AUG2020	42911	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261017	C4591001 1226 12261017	16-55	06AUG2020	42912	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261018	C4591001 1226 12261018	16-55	06AUG2020	43459	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261019	C4591001 1226 12261019	16-55	06AUG2020	43462	Placebo	06AUG2020/ Placebo	26AUG2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261020	C4591001 1226 12261020	16-55	06AUG2020	43465	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261021	C4591001 1226 12261021	16-55	06AUG2020	43468	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261022	C4591001 1226 12261022	16-55	06AUG2020	43522	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261024	C4591001 1226 12261024	16-55	06AUG2020	43524	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261025	C4591001 1226 12261025	16-55	06AUG2020	43604	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261026	C4591001 1226 12261026	16-55	06AUG2020	43528	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261027	C4591001 1226 12261027	16-55	06AUG2020	43525	Placebo	06AUG2020/ Placebo	12SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261029	C4591001 1226 12261029	16-55	06AUG2020	43606	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261030	C4591001 1226 12261030	16-55	06AUG2020	43608	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)		
12261031	C4591001 1226 12261031	16-55	06AUG2020	43611	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261032	C4591001 1226 12261032	16-55	06AUG2020	43865	Placebo	06AUG2020/ Placebo	25AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261036	C4591001 1226 12261036	16-55	07AUG2020	43870	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261037	C4591001 1226 12261037	16-55	07AUG2020	43873	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261038	C4591001 1226 12261038	16-55	07AUG2020	43875	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261041	C4591001 1226 12261041	16-55	07AUG2020	44237	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261043	C4591001 1226 12261043	16-55	07AUG2020	44238	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261044	C4591001 1226 12261044	16-55	07AUG2020	44246	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261045	C4591001 1226 12261045	16-55	07AUG2020	44248	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12261047	C4591001 1226 12261047	16-55	07AUG2020	44263	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261048	C4591001 1226 12261048	16-55	07AUG2020	44267	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261049	C4591001 1226 12261049	16-55	07AUG2020	44270	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261052	C4591001 1226 12261052	16-55	10AUG2020	44271	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261054	C4591001 1226 12261054	16-55	10AUG2020	45057	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261055	C4591001 1226 12261055	16-55	10AUG2020	45063	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261056	C4591001 1226 12261056	16-55	10AUG2020	45059	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	
12261057	C4591001 1226 12261057	16-55	10AUG2020	45060	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261058	C4591001 1226 12261058	16-55	10AUG2020	45103	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261060	C4591001 1226 12261060	16-55	10AUG2020	45105	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261061	C4591001 1226 12261061	16-55	10AUG2020	45106	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261065	C4591001 1226 12261065	16-55	10AUG2020	45107	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261066	C4591001 1226 12261066	16-55	10AUG2020	45209	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261067	C4591001 1226 12261067	16-55	10AUG2020	45215	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261068	C4591001 1226 12261068	16-55	10AUG2020	45212	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12261069	C4591001 1226 12261069	16-55	10AUG2020	45217	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261071	C4591001 1226 12261071	16-55	11AUG2020	45981	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261072	C4591001 1226 12261072	16-55	11AUG2020	45986	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)			
12261073	C4591001 1226 12261073	16-55	11AUG2020	45982	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261074	C4591001 1226 12261074	16-55	11AUG2020	45985	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261075	C4591001 1226 12261075	16-55	11AUG2020	45991	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261076	C4591001 1226 12261076	16-55	11AUG2020	45992	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261078	C4591001 1226 12261078	16-55	11AUG2020	45995	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261079	C4591001 1226 12261079	16-55	11AUG2020	46000	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261080	C4591001 1226 12261080	16-55	11AUG2020	46049	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12261081	C4591001 1226 12261081	16-55	11AUG2020	46058	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261082	C4591001 1226 12261082	16-55	11AUG2020	46059	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261083	C4591001 1226 12261083	16-55	11AUG2020	46104	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261084	C4591001 1226 12261084	16-55	11AUG2020	46060	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261085	C4591001 1226 12261085	16-55	11AUG2020	46084	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261086	C4591001 1226 12261086	16-55	11AUG2020	46073	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261087	C4591001 1226 12261087	16-55	11AUG2020	46078	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261088	C4591001 1226 12261088	16-55	11AUG2020	46082	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261089	C4591001 1226 12261089	16-55	11AUG2020	46105	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261091	C4591001 1226 12261091	16-55	11AUG2020	46107	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261092	C4591001 1226 12261092	16-55	11AUG2020	46108	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261093	C4591001 1226 12261093	16-55	11AUG2020	46256	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261094	C4591001 1226 12261094	16-55	11AUG2020	46257	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12261096	C4591001 1226 12261096	16-55	11AUG2020	46258	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261097	C4591001 1226 12261097	16-55	11AUG2020	46261	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261100	C4591001 1226 12261100	16-55	11AUG2020	46325	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261102	C4591001 1226 12261102	16-55	11AUG2020	46329	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261103	C4591001 1226 12261103	16-55	11AUG2020	46330	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261104	C4591001 1226 12261104	16-55	11AUG2020	46374	Placebo	11AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261105	C4591001 1226 12261105	16-55	11AUG2020	46332	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261106	C4591001 1226 12261106	16-55	11AUG2020	46377	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261107	C4591001 1226 12261107	16-55	11AUG2020	46378	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12261108	C4591001 1226 12261108	16-55	11AUG2020	46384	Placebo	11AUG2020/ Placebo	31AUG2020/ Placebo		
12261110	C4591001 1226 12261110	16-55	12AUG2020	46925	Placebo	12AUG2020/ Placebo	05SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261111	C4591001 1226 12261111	16-55	12AUG2020	46926	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261112	C4591001 1226 12261112	16-55	12AUG2020	46931	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12261113	C4591001 1226 12261113	16-55	12AUG2020	46942	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12261114	C4591001 1226 12261114	16-55	12AUG2020	46936	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261115	C4591001 1226 12261115	16-55	12AUG2020	46941	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261116	C4591001 1226 12261116	16-55	12AUG2020	46945	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261117	C4591001 1226 12261117	16-55	12AUG2020	46948	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261118	C4591001 1226 12261118	16-55	12AUG2020	46961	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261119	C4591001 1226 12261119	16-55	12AUG2020	46970	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261120	C4591001 1226 12261120	16-55	12AUG2020	46971	Placebo	12AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261121	C4591001 1226 12261121	16-55	12AUG2020	46968	Placebo	12AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261122	C4591001 1226 12261122	16-55	12AUG2020	47023	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261123	C4591001 1226 12261123	16-55	12AUG2020	46989	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261124	C4591001 1226 12261124	16-55	12AUG2020	46992	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261125	C4591001 1226 12261125	16-55	12AUG2020	46995	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261126	C4591001 1226 12261126	16-55	12AUG2020	46996	Placebo	12AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261127	C4591001 1226 12261127	16-55	12AUG2020	47025	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261130	C4591001 1226 12261130	16-55	12AUG2020	47105	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261132	C4591001 1226 12261132	16-55	12AUG2020	47029	Placebo	12AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261133	C4591001 1226 12261133	16-55	12AUG2020	47026	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261134	C4591001 1226 12261134	16-55	12AUG2020	47106	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261135	C4591001 1226 12261135	16-55	12AUG2020	47223	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261136	C4591001 1226 12261136	16-55	12AUG2020	47109	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261137	C4591001 1226 12261137	16-55	12AUG2020	47218	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261138	C4591001 1226 12261138	16-55	12AUG2020	47108	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261139	C4591001 1226 12261139	16-55	12AUG2020	47220	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261140	C4591001 1226 12261140	16-55	12AUG2020	47224	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261144	C4591001 1226 12261144	16-55	12AUG2020	47340	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261146	C4591001 1226 12261146	16-55	13AUG2020	47342	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261147	C4591001 1226 12261147	16-55	13AUG2020	47344	Placebo	13AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261148	C4591001 1226 12261148	16-55	13AUG2020	47341	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261150	C4591001 1226 12261150	16-55	13AUG2020	48330	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261151	C4591001 1226 12261151	16-55	13AUG2020	48274	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261152	C4591001 1226 12261152	16-55	13AUG2020	48269	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261153	C4591001 1226 12261153	16-55	13AUG2020	48275	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261154	C4591001 1226 12261154	16-55	13AUG2020	48279	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261155	C4591001 1226 12261155	16-55	13AUG2020	48336	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261156	C4591001 1226 12261156	16-55	13AUG2020	48331	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261157	C4591001 1226 12261157	16-55	13AUG2020	48339	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261158	C4591001 1226 12261158	16-55	13AUG2020	48381	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261159	C4591001 1226 12261159	16-55	13AUG2020	48388	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261160	C4591001 1226 12261160	16-55	13AUG2020	48383	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261161	C4591001 1226 12261161	16-55	13AUG2020	48382	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261163	C4591001 1226 12261163	16-55	13AUG2020	48506	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261164	C4591001 1226 12261164	16-55	13AUG2020	48497	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261165	C4591001 1226 12261165	16-55	13AUG2020	48583	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261166	C4591001 1226 12261166	16-55	13AUG2020	48507	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261167	C4591001 1226 12261167	16-55	13AUG2020	48508	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261168	C4591001 1226 12261168	16-55	13AUG2020	48589	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261170	C4591001 1226 12261170	16-55	13AUG2020	48582	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261172	C4591001 1226 12261172	16-55	13AUG2020	48691	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261174	C4591001 1226 12261174	16-55	13AUG2020	48592	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261175	C4591001 1226 12261175	16-55	13AUG2020	48692	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12261176	C4591001 1226 12261176	16-55	14AUG2020	48697	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261177	C4591001 1226 12261177	16-55	14AUG2020	49794	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261178	C4591001 1226 12261178	16-55	14AUG2020	48698	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261179	C4591001 1226 12261179	16-55	14AUG2020	49798	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261180	C4591001 1226 12261180	16-55	14AUG2020	49843	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261182	C4591001 1226 12261182	16-55	14AUG2020	49803	Placebo	14AUG2020/ Placebo	09SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261183	C4591001 1226 12261183	16-55	14AUG2020	49804	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261184	C4591001 1226 12261184	16-55	14AUG2020	49846	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261185	C4591001 1226 12261185	16-55	14AUG2020	49844	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261186	C4591001 1226 12261186	16-55	14AUG2020	49847	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261188	C4591001 1226 12261188	16-55	14AUG2020	49939	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261189	C4591001 1226 12261189	16-55	14AUG2020	49940	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261190	C4591001 1226 12261190	16-55	14AUG2020	50014	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261191	C4591001 1226 12261191	16-55	14AUG2020	49941	Placebo	14AUG2020/ Placebo	14SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261192	C4591001 1226 12261192	16-55	14AUG2020	49944	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261193	C4591001 1226 12261193	16-55	14AUG2020	50093	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261196	C4591001 1226 12261196	16-55	14AUG2020	50017	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261197	C4591001 1226 12261197	16-55	14AUG2020	50099	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261199	C4591001 1226 12261199	16-55	14AUG2020	50018	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261200	C4591001 1226 12261200	16-55	14AUG2020	50096	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261202	C4591001 1226 12261202	16-55	14AUG2020	50102	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12261203	C4591001 1226 12261203	16-55	14AUG2020	50203	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12311001	C4591001 1231 12311001	16-55	06AUG2020	43590	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311002	C4591001 1231 12311002	16-55	06AUG2020	43596	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311003	C4591001 1231 12311003	16-55	06AUG2020	43593	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311004	C4591001 1231 12311004	16-55	06AUG2020	43598	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
12311005	C4591001 1231 12311005	16-55	06AUG2020	43933	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12311006	C4591001 1231 12311006	16-55	06AUG2020	43928	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311008	C4591001 1231 12311008	16-55	06AUG2020	43934	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311009	C4591001 1231 12311009	16-55	06AUG2020	44094	Placebo	06AUG2020/ Placebo	27AUG2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311010	C4591001 1231 12311010	16-55	06AUG2020	43935	BNT162b2 (30 µg)	06AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311012	C4591001 1231 12311012	16-55	07AUG2020	44100	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		
12311013	C4591001 1231 12311013	16-55	07AUG2020	44099	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311018	C4591001 1231 12311018	16-55	07AUG2020	44590	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311019	C4591001 1231 12311019	16-55	07AUG2020	44101	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311021	C4591001 1231 12311021	16-55	07AUG2020	44593	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12311022	C4591001 1231 12311022	16-55	10AUG2020	44595	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311023	C4591001 1231 12311023	16-55	10AUG2020	44596	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311024	C4591001 1231 12311024	16-55	10AUG2020	45234	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311025	C4591001 1231 12311025	16-55	10AUG2020	45238	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311026	C4591001 1231 12311026	16-55	10AUG2020	45240	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311027	C4591001 1231 12311027	16-55	10AUG2020	45244	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12311029	C4591001 1231 12311029	16-55	10AUG2020	45499	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311030	C4591001 1231 12311030	16-55	10AUG2020	45508	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311031	C4591001 1231 12311031	16-55	10AUG2020	45500	Placebo	10AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311032	C4591001 1231 12311032	16-55	10AUG2020	45502	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311033	C4591001 1231 12311033	16-55	10AUG2020	45741	Placebo	10AUG2020/ Placebo	01SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311034	C4591001 1231 12311034	16-55	10AUG2020	45745	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311035	C4591001 1231 12311035	16-55	10AUG2020	45747	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311036	C4591001 1231 12311036	16-55	10AUG2020	45748	Placebo	10AUG2020/ Placebo	02SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12311039	C4591001 1231 12311039	16-55	11AUG2020	46033	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311040	C4591001 1231 12311040	16-55	11AUG2020	46027	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12311041	C4591001 1231 12311041	16-55	11AUG2020	46026	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311042	C4591001 1231 12311042	16-55	11AUG2020	46036	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311043	C4591001 1231 12311043	16-55	11AUG2020	46123	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311045	C4591001 1231 12311045	16-55	11AUG2020	46126	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311046	C4591001 1231 12311046	16-55	11AUG2020	46131	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311047	C4591001 1231 12311047	16-55	11AUG2020	46129	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311049	C4591001 1231 12311049	16-55	11AUG2020	46363	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311051	C4591001 1231 12311051	16-55	11AUG2020	46301	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311052	C4591001 1231 12311052	16-55	11AUG2020	46302	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311053	C4591001 1231 12311053	16-55	11AUG2020	46304	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311054	C4591001 1231 12311054	16-55	11AUG2020	46303	Placebo	11AUG2020/ Placebo			
12311055	C4591001 1231 12311055	16-55	11AUG2020	46365	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311058	C4591001 1231 12311058	16-55	11AUG2020	46370	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311062	C4591001 1231 12311062	16-55	11AUG2020	46371	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12311064	C4591001 1231 12311064	16-55	11AUG2020	46541	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311065	C4591001 1231 12311065	16-55	11AUG2020	46544	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311068	C4591001 1231 12311068	16-55	11AUG2020	46549	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311069	C4591001 1231 12311069	16-55	11AUG2020	46552	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311070	C4591001 1231 12311070	16-55	11AUG2020	46805	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311071	C4591001 1231 12311071	16-55	11AUG2020	46811	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo		
12311072	C4591001 1231 12311072	16-55	11AUG2020	46815	Placebo	11AUG2020/ Placebo	02SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311073	C4591001 1231 12311073	16-55	12AUG2020	46952	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311074	C4591001 1231 12311074	16-55	12AUG2020	46816	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311076	C4591001 1231 12311076	16-55	12AUG2020	46953	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311077	C4591001 1231 12311077	16-55	12AUG2020	46959	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311078	C4591001 1231 12311078	16-55	12AUG2020	46960	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311080	C4591001 1231 12311080	16-55	12AUG2020	47072	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311081	C4591001 1231 12311081	16-55	12AUG2020	47070	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311082	C4591001 1231 12311082	16-55	12AUG2020	47077	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311083	C4591001 1231 12311083	16-55	12AUG2020	47154	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311084	C4591001 1231 12311084	16-55	12AUG2020	47080	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311085	C4591001 1231 12311085	16-55	12AUG2020	47155	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311087	C4591001 1231 12311087	16-55	12AUG2020	47157	Placebo	12AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311088	C4591001 1231 12311088	16-55	12AUG2020	47159	Placebo	12AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311089	C4591001 1231 12311089	16-55	12AUG2020	47275	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311091	C4591001 1231 12311091	16-55	12AUG2020	47283	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311092	C4591001 1231 12311092	16-55	12AUG2020	47277	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311093	C4591001 1231 12311093	16-55	12AUG2020	47518	Placebo	12AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311094	C4591001 1231 12311094	16-55	12AUG2020	47284	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311095	C4591001 1231 12311095	16-55	12AUG2020	47513	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311096	C4591001 1231 12311096	16-55	12AUG2020	47521	Placebo	12AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311097	C4591001 1231 12311097	16-55	12AUG2020	47516	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311098	C4591001 1231 12311098	16-55	12AUG2020	47669	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311099	C4591001 1231 12311099	16-55	12AUG2020	47842	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311100	C4591001 1231 12311100	16-55	12AUG2020	47673	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo		
12311102	C4591001 1231 12311102	16-55	12AUG2020	47678	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311103	C4591001 1231 12311103	16-55	12AUG2020	47672	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311104	C4591001 1231 12311104	16-55	12AUG2020	47841	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311105	C4591001 1231 12311105	16-55	12AUG2020	47847	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311107	C4591001 1231 12311107	16-55	12AUG2020	48005	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311108	C4591001 1231 12311108	16-55	12AUG2020	47846	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311109	C4591001 1231 12311109	16-55	12AUG2020	48006	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311110	C4591001 1231 12311110	16-55	12AUG2020	48008	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311112	C4591001 1231 12311112	16-55	13AUG2020	48010	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311113	C4591001 1231 12311113	16-55	13AUG2020	48282	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311114	C4591001 1231 12311114	16-55	13AUG2020	48342	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311115	C4591001 1231 12311115	16-55	13AUG2020	48287	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311116	C4591001 1231 12311116	16-55	13AUG2020	48341	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311117	C4591001 1231 12311117	16-55	13AUG2020	48347	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311118	C4591001 1231 12311118	16-55	13AUG2020	48284	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311119	C4591001 1231 12311119	16-55	13AUG2020	48289	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311120	C4591001 1231 12311120	16-55	13AUG2020	48350	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311121	C4591001 1231 12311121	16-55	13AUG2020	48397	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311122	C4591001 1231 12311122	16-55	13AUG2020	48390	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311123	C4591001 1231 12311123	16-55	13AUG2020	48487	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311124	C4591001 1231 12311124	16-55	13AUG2020	48399	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311125	C4591001 1231 12311125	16-55	13AUG2020	48491	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)			
12311126	C4591001 1231 12311126	16-55	13AUG2020	48393	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311127	C4591001 1231 12311127	16-55	13AUG2020	48488	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311128	C4591001 1231 12311128	16-55	13AUG2020	48524	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311129	C4591001 1231 12311129	16-55	13AUG2020	48496	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311130	C4591001 1231 12311130	16-55	13AUG2020	48523	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311131	C4591001 1231 12311131	16-55	13AUG2020	48527	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311134	C4591001 1231 12311134	16-55	13AUG2020	48640	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311135	C4591001 1231 12311135	16-55	13AUG2020	48629	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311136	C4591001 1231 12311136	16-55	13AUG2020	48738	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311137	C4591001 1231 12311137	16-55	13AUG2020	48634	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311138	C4591001 1231 12311138	16-55	13AUG2020	48638	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311140	C4591001 1231 12311140	16-55	13AUG2020	48741	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311141	C4591001 1231 12311141	16-55	13AUG2020	48742	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311142	C4591001 1231 12311142	16-55	13AUG2020	48748	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311143	C4591001 1231 12311143	16-55	13AUG2020	48929	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311144	C4591001 1231 12311144	16-55	13AUG2020	48930	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311145	C4591001 1231 12311145	16-55	13AUG2020	48934	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
12311147	C4591001 1231 12311147	16-55	13AUG2020	48940	Placebo	13AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12311151	C4591001 1231 12311151	16-55	13AUG2020	49253	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12311152	C4591001 1231 12311152	16-55	13AUG2020	49255	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311153	C4591001 1231 12311153	16-55	13AUG2020	49258	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311156	C4591001 1231 12311156	16-55	13AUG2020	49289	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311157	C4591001 1231 12311157	16-55	13AUG2020	49260	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12311158	C4591001 1231 12311158	16-55	13AUG2020	49297	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311159	C4591001 1231 12311159	16-55	13AUG2020	49291	Placebo	13AUG2020/ Placebo	04SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311161	C4591001 1231 12311161	16-55	13AUG2020	49445	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12311162	C4591001 1231 12311162	16-55	13AUG2020	49299	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311164	C4591001 1231 12311164	16-55	13AUG2020	49447	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311166	C4591001 1231 12311166	16-55	13AUG2020	49454	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
12311167	C4591001 1231 12311167	16-55	13AUG2020	49449	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311168	C4591001 1231 12311168	16-55	13AUG2020	49506	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo		
12311169	C4591001 1231 12311169	16-55	13AUG2020	49508	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311170	C4591001 1231 12311170	16-55	13AUG2020	49510	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311171	C4591001 1231 12311171	16-55	13AUG2020	49512	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12311172	C4591001 1231 12311172	16-55	13AUG2020	49601	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311175	C4591001 1231 12311175	16-55	13AUG2020	49607	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311176	C4591001 1231 12311176	16-55	14AUG2020	49857	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311177	C4591001 1231 12311177	16-55	14AUG2020	49855	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311178	C4591001 1231 12311178	16-55	14AUG2020	49611	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311179	C4591001 1231 12311179	16-55	14AUG2020	49610	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311180	C4591001 1231 12311180	16-55	14AUG2020	49916	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311183	C4591001 1231 12311183	16-55	14AUG2020	49989	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311185	C4591001 1231 12311185	16-55	14AUG2020	49919	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311186	C4591001 1231 12311186	16-55	14AUG2020	49991	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311187	C4591001 1231 12311187	16-55	14AUG2020	49923	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311188	C4591001 1231 12311188	16-55	14AUG2020	49913	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311189	C4591001 1231 12311189	16-55	14AUG2020	49863	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)			
12311190	C4591001 1231 12311190	16-55	14AUG2020	49862	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311193	C4591001 1231 12311193	16-55	14AUG2020	49992	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311194	C4591001 1231 12311194	16-55	14AUG2020	50166	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311196	C4591001 1231 12311196	16-55	14AUG2020	50124	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311198	C4591001 1231 12311198	16-55	14AUG2020	50153	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311199	C4591001 1231 12311199	16-55	14AUG2020	50126	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311202	C4591001 1231 12311202	16-55	14AUG2020	50148	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo		
12311204	C4591001 1231 12311204	16-55	14AUG2020	50145	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311205	C4591001 1231 12311205	16-55	14AUG2020	50147	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311206	C4591001 1231 12311206	16-55	14AUG2020	50156	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311207	C4591001 1231 12311207	16-55	14AUG2020	50151	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311208	C4591001 1231 12311208	16-55	14AUG2020	50162	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311210	C4591001 1231 12311210	16-55	14AUG2020	50296	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311212	C4591001 1231 12311212	16-55	14AUG2020	50165	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311216	C4591001 1231 12311216	16-55	14AUG2020	50295	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311217	C4591001 1231 12311217	16-55	14AUG2020	50285	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311218	C4591001 1231 12311218	16-55	14AUG2020	50317	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311219	C4591001 1231 12311219	16-55	14AUG2020	50294	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311221	C4591001 1231 12311221	16-55	14AUG2020	50173	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311222	C4591001 1231 12311222	16-55	14AUG2020	50315	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311224	C4591001 1231 12311224	16-55	14AUG2020	50319	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311226	C4591001 1231 12311226	16-55	14AUG2020	50382	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311229	C4591001 1231 12311229	16-55	14AUG2020	50366	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311230	C4591001 1231 12311230	16-55	14AUG2020	50357	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
12311231	C4591001 1231 12311231	16-55	14AUG2020	50364	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311233	C4591001 1231 12311233	16-55	14AUG2020	50385	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311237	C4591001 1231 12311237	16-55	14AUG2020	50392	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo		
12311238	C4591001 1231 12311238	16-55	14AUG2020	50587	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311239	C4591001 1231 12311239	16-55	14AUG2020	50389	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311241	C4591001 1231 12311241	16-55	14AUG2020	50454	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311246	C4591001 1231 12311246	16-55	14AUG2020	50460	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311247	C4591001 1231 12311247	16-55	14AUG2020	50589	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311251	C4591001 1231 12311251	16-55	14AUG2020	50656	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311252	C4591001 1231 12311252	16-55	14AUG2020	50596	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311256	C4591001 1231 12311256	16-55	14AUG2020	50649	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311259	C4591001 1231 12311259	16-55	14AUG2020	50707	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311263	C4591001 1231 12311263	16-55	14AUG2020	50825	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311266	C4591001 1231 12311266	16-55	14AUG2020	50827	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311268	C4591001 1231 12311268	16-55	14AUG2020	50754	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311272	C4591001 1231 12311272	16-55	14AUG2020	50764	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12311273	C4591001 1231 12311273	16-55	14AUG2020	50835	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311279	C4591001 1231 12311279	16-55	15AUG2020	51121	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311281	C4591001 1231 12311281	16-55	15AUG2020	51134	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311282	C4591001 1231 12311282	16-55	15AUG2020	50984	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311283	C4591001 1231 12311283	16-55	15AUG2020	50987	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311284	C4591001 1231 12311284	16-55	15AUG2020	51155	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311288	C4591001 1231 12311288	16-55	15AUG2020	51104	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311289	C4591001 1231 12311289	16-55	15AUG2020	51115	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311290	C4591001 1231 12311290	16-55	15AUG2020	51116	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311291	C4591001 1231 12311291	16-55	15AUG2020	51136	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311293	C4591001 1231 12311293	16-55	15AUG2020	51146	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311295	C4591001 1231 12311295	16-55	15AUG2020	51154	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311296	C4591001 1231 12311296	16-55	15AUG2020	51142	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311303	C4591001 1231 12311303	16-55	15AUG2020	51161	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311307	C4591001 1231 12311307	16-55	15AUG2020	51261	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311308	C4591001 1231 12311308	16-55	15AUG2020	51170	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo		
12311309	C4591001 1231 12311309	16-55	15AUG2020	51281	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311312	C4591001 1231 12311312	16-55	15AUG2020	51257	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311315	C4591001 1231 12311315	16-55	15AUG2020	51255	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311321	C4591001 1231 12311321	16-55	15AUG2020	51251	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311322	C4591001 1231 12311322	16-55	15AUG2020	51200	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311327	C4591001 1231 12311327	16-55	15AUG2020	51202	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311330	C4591001 1231 12311330	16-55	15AUG2020	51203	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311331	C4591001 1231 12311331	16-55	15AUG2020	51301	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311333	C4591001 1231 12311333	16-55	15AUG2020	51236	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311336	C4591001 1231 12311336	16-55	15AUG2020	51217	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311337	C4591001 1231 12311337	16-55	15AUG2020	51233	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311340	C4591001 1231 12311340	16-55	15AUG2020	51220	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311341	C4591001 1231 12311341	16-55	15AUG2020	51327	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311342	C4591001 1231 12311342	16-55	15AUG2020	51267	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311343	C4591001 1231 12311343	16-55	15AUG2020	51286	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311344	C4591001 1231 12311344	16-55	15AUG2020	51249	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311347	C4591001 1231 12311347	16-55	15AUG2020	51300	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311348	C4591001 1231 12311348	16-55	15AUG2020	51292	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311349	C4591001 1231 12311349	16-55	15AUG2020	51299	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311350	C4591001 1231 12311350	16-55	15AUG2020	51373	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311358	C4591001 1231 12311358	16-55	15AUG2020	51347	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311365	C4591001 1231 12311365	16-55	15AUG2020	51323	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311366	C4591001 1231 12311366	16-55	15AUG2020	51378	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311368	C4591001 1231 12311368	16-55	15AUG2020	51382	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311370	C4591001 1231 12311370	16-55	15AUG2020	51361	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311372	C4591001 1231 12311372	16-55	15AUG2020	51389	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311375	C4591001 1231 12311375	16-55	15AUG2020	51401	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311377	C4591001 1231 12311377	16-55	15AUG2020	51350	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311380	C4591001 1231 12311380	16-55	15AUG2020	51399	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311381	C4591001 1231 12311381	16-55	15AUG2020	51358	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311383	C4591001 1231 12311383	16-55	15AUG2020	51403	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311384	C4591001 1231 12311384	16-55	15AUG2020	51404	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311386	C4591001 1231 12311386	16-55	15AUG2020	51408	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311388	C4591001 1231 12311388	16-55	15AUG2020	51427	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311392	C4591001 1231 12311392	16-55	15AUG2020	51491	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311393	C4591001 1231 12311393	16-55	15AUG2020	51436	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311395	C4591001 1231 12311395	16-55	15AUG2020	51485	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311396	C4591001 1231 12311396	16-55	15AUG2020	51508	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311397	C4591001 1231 12311397	16-55	15AUG2020	51452	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311398	C4591001 1231 12311398	16-55	15AUG2020	51449	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311399	C4591001 1231 12311399	16-55	15AUG2020	51471	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311401	C4591001 1231 12311401	16-55	15AUG2020	51502	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311411	C4591001 1231 12311411	16-55	15AUG2020	51489	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311413	C4591001 1231 12311413	16-55	15AUG2020	51476	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo		
12311414	C4591001 1231 12311414	16-55	15AUG2020	51478	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311418	C4591001 1231 12311418	16-55	15AUG2020	51515	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12311425	C4591001 1231 12311425	16-55	15AUG2020	51511	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311427	C4591001 1231 12311427	16-55	15AUG2020	51538	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311436	C4591001 1231 12311436	16-55	15AUG2020	51542	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311438	C4591001 1231 12311438	16-55	15AUG2020	51543	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311439	C4591001 1231 12311439	16-55	15AUG2020	51671	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311440	C4591001 1231 12311440	16-55	15AUG2020	51564	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311444	C4591001 1231 12311444	16-55	15AUG2020	51551	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311446	C4591001 1231 12311446	16-55	15AUG2020	51560	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311447	C4591001 1231 12311447	16-55	15AUG2020	51569	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311451	C4591001 1231 12311451	16-55	15AUG2020	51565	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311452	C4591001 1231 12311452	16-55	15AUG2020	51579	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311454	C4591001 1231 12311454	16-55	15AUG2020	51583	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311457	C4591001 1231 12311457	16-55	15AUG2020	51590	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311458	C4591001 1231 12311458	16-55	15AUG2020	51596	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311459	C4591001 1231 12311459	16-55	15AUG2020	51600	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311460	C4591001 1231 12311460	16-55	15AUG2020	51602	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311461	C4591001 1231 12311461	16-55	15AUG2020	51603	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311464	C4591001 1231 12311464	16-55	15AUG2020	51612	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311465	C4591001 1231 12311465	16-55	15AUG2020	51620	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311466	C4591001 1231 12311466	16-55	15AUG2020	51614	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311468	C4591001 1231 12311468	16-55	15AUG2020	51661	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311474	C4591001 1231 12311474	16-55	15AUG2020	51635	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311475	C4591001 1231 12311475	16-55	15AUG2020	51628	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311479	C4591001 1231 12311479	16-55	15AUG2020	51645	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311480	C4591001 1231 12311480	16-55	15AUG2020	51654	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311483	C4591001 1231 12311483	16-55	15AUG2020	51640	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311484	C4591001 1231 12311484	16-55	15AUG2020	51665	Placebo	15AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12311485	C4591001 1231 12311485	16-55	15AUG2020	51651	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311489	C4591001 1231 12311489	16-55	15AUG2020	51663	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311490	C4591001 1231 12311490	16-55	15AUG2020	51666	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12311544	C4591001 1231 12311544	16-55	16AUG2020	51795	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311560	C4591001 1231 12311560	16-55	16AUG2020	51842	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo		
12311635	C4591001 1231 12311635	16-55	16AUG2020	52037	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311644	C4591001 1231 12311644	16-55	16AUG2020	52063	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12321002	C4591001 1232 12321002	16-55	12AUG2020	47299	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
12321003	C4591001 1232 12321003	16-55	12AUG2020	47303	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321004	C4591001 1232 12321004	16-55	12AUG2020	47306	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321005	C4591001 1232 12321005	16-55	12AUG2020	47307	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12321006	C4591001 1232 12321006	16-55	12AUG2020	47418	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321007	C4591001 1232 12321007	16-55	12AUG2020	47419	Placebo	12AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321009	C4591001 1232 12321009	16-55	13AUG2020	47424	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo		
12321010	C4591001 1232 12321010	16-55	13AUG2020	47428	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12321012	C4591001 1232 12321012	16-55	13AUG2020	48764	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12321014	C4591001 1232 12321014	16-55	13AUG2020	48766	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321015	C4591001 1232 12321015	16-55	13AUG2020	48769	Placebo	13AUG2020/ Placebo			
12321018	C4591001 1232 12321018	16-55	13AUG2020	48770	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321019	C4591001 1232 12321019	16-55	14AUG2020	50022	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321022	C4591001 1232 12321022	16-55	14AUG2020	50024	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12321024	C4591001 1232 12321024	16-55	14AUG2020	50026	Placebo	14AUG2020/ Placebo	02SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321025	C4591001 1232 12321025	16-55	14AUG2020	50030	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12321026	C4591001 1232 12321026	16-55	14AUG2020	50697	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411001	C4591001 1241 12411001	16-55	07AUG2020	44322	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411002	C4591001 1241 12411002	16-55	07AUG2020	44325	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411003	C4591001 1241 12411003	16-55	07AUG2020	44329	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411004	C4591001 1241 12411004	16-55	07AUG2020	44331	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411005	C4591001 1241 12411005	16-55	07AUG2020	44419	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411006	C4591001 1241 12411006	16-55	07AUG2020	44421	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411007	C4591001 1241 12411007	16-55	07AUG2020	44422	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411009	C4591001 1241 12411009	16-55	07AUG2020	44424	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411010	C4591001 1241 12411010	16-55	07AUG2020	44717	Placebo	07AUG2020/ Placebo	26AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411011	C4591001 1241 12411011	16-55	07AUG2020	44718	BNT162b2 (30 µg)	07AUG2020/ BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)		
12411012	C4591001 1241 12411012	16-55	10AUG2020	44723	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12411013	C4591001 1241 12411013	16-55	10AUG2020	44726	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411014	C4591001 1241 12411014	16-55	10AUG2020	45149	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411016	C4591001 1241 12411016	16-55	10AUG2020	45150	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411017	C4591001 1241 12411017	16-55	10AUG2020	45154	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411018	C4591001 1241 12411018	16-55	10AUG2020	45155	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411019	C4591001 1241 12411019	16-55	10AUG2020	45297	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411020	C4591001 1241 12411020	16-55	10AUG2020	45299	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411021	C4591001 1241 12411021	16-55	10AUG2020	45300	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411022	C4591001 1241 12411022	16-55	10AUG2020	45302	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411023	C4591001 1241 12411023	16-55	10AUG2020	45588	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411024	C4591001 1241 12411024	16-55	10AUG2020	45589	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411025	C4591001 1241 12411025	16-55	10AUG2020	45590	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411026	C4591001 1241 12411026	16-55	10AUG2020	45591	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411027	C4591001 1241 12411027	16-55	10AUG2020	45666	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411028	C4591001 1241 12411028	16-55	10AUG2020	45667	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411029	C4591001 1241 12411029	16-55	10AUG2020	45668	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411030	C4591001 1241 12411030	16-55	10AUG2020	45673	BNT162b2 (30 µg)	10AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12411031	C4591001 1241 12411031	16-55	10AUG2020	45812	Placebo	10AUG2020/ Placebo	31AUG2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411032	C4591001 1241 12411032	16-55	11AUG2020	45818	Placebo	11AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411033	C4591001 1241 12411033	16-55	11AUG2020	45819	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411034	C4591001 1241 12411034	16-55	11AUG2020	45820	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411036	C4591001 1241 12411036	16-55	11AUG2020	46163	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411037	C4591001 1241 12411037	16-55	11AUG2020	46158	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411038	C4591001 1241 12411038	16-55	11AUG2020	46164	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411039	C4591001 1241 12411039	16-55	11AUG2020	46166	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411040	C4591001 1241 12411040	16-55	11AUG2020	46265	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411041	C4591001 1241 12411041	16-55	11AUG2020	46273	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411042	C4591001 1241 12411042	16-55	11AUG2020	46274	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411043	C4591001 1241 12411043	16-55	11AUG2020	46276	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411044	C4591001 1241 12411044	16-55	11AUG2020	46530	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411045	C4591001 1241 12411045	16-55	11AUG2020	46533	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411046	C4591001 1241 12411046	16-55	11AUG2020	46535	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411047	C4591001 1241 12411047	16-55	11AUG2020	46536	BNT162b2 (30 µg)	11AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411048	C4591001 1241 12411048	16-55	11AUG2020	46746	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411049	C4591001 1241 12411049	16-55	11AUG2020	46750	Placebo	11AUG2020/ Placebo	01SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411050	C4591001 1241 12411050	16-55	12AUG2020	46753	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411051	C4591001 1241 12411051	16-55	12AUG2020	46755	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411053	C4591001 1241 12411053	16-55	12AUG2020	47058	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411054	C4591001 1241 12411054	16-55	12AUG2020	47063	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411055	C4591001 1241 12411055	16-55	12AUG2020	47064	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411056	C4591001 1241 12411056	16-55	12AUG2020	47068	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411057	C4591001 1241 12411057	16-55	12AUG2020	47359	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411058	C4591001 1241 12411058	16-55	12AUG2020	47362	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411059	C4591001 1241 12411059	16-55	12AUG2020	47364	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411060	C4591001 1241 12411060	16-55	12AUG2020	47367	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411061	C4591001 1241 12411061	16-55	12AUG2020	47478	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411062	C4591001 1241 12411062	16-55	12AUG2020	47482	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411063	C4591001 1241 12411063	16-55	12AUG2020	47484	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411064	C4591001 1241 12411064	16-55	12AUG2020	47488	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411065	C4591001 1241 12411065	16-55	12AUG2020	47603	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411066	C4591001 1241 12411066	16-55	12AUG2020	47604	Placebo	12AUG2020/ Placebo	01SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411068	C4591001 1241 12411068	16-55	12AUG2020	47605	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo		
12411069	C4591001 1241 12411069	16-55	12AUG2020	47729	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411070	C4591001 1241 12411070	16-55	12AUG2020	47733	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411071	C4591001 1241 12411071	16-55	12AUG2020	47734	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411072	C4591001 1241 12411072	16-55	12AUG2020	47736	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411073	C4591001 1241 12411073	16-55	12AUG2020	47915	Placebo	12AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411074	C4591001 1241 12411074	16-55	12AUG2020	47916	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411075	C4591001 1241 12411075	16-55	12AUG2020	47918	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411076	C4591001 1241 12411076	16-55	12AUG2020	47920	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411077	C4591001 1241 12411077	16-55	12AUG2020	47973	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411078	C4591001 1241 12411078	16-55	12AUG2020	47975	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411079	C4591001 1241 12411079	16-55	12AUG2020	47976	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411080	C4591001 1241 12411080	16-55	12AUG2020	47979	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411081	C4591001 1241 12411081	16-55	12AUG2020	48055	Placebo	12AUG2020/ Placebo	02SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411082	C4591001 1241 12411082	16-55	12AUG2020	48059	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)		
12411083	C4591001 1241 12411083	16-55	13AUG2020	48063	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411084	C4591001 1241 12411084	16-55	13AUG2020	48064	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411085	C4591001 1241 12411085	16-55	13AUG2020	48262	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411087	C4591001 1241 12411087	16-55	13AUG2020	48263	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411088	C4591001 1241 12411088	16-55	13AUG2020	48265	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)		
12411089	C4591001 1241 12411089	16-55	13AUG2020	48267	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411090	C4591001 1241 12411090	16-55	13AUG2020	48462	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411091	C4591001 1241 12411091	16-55	13AUG2020	48464	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411093	C4591001 1241 12411093	16-55	13AUG2020	48470	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411094	C4591001 1241 12411094	16-55	13AUG2020	48471	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411095	C4591001 1241 12411095	16-55	13AUG2020	48906	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411096	C4591001 1241 12411096	16-55	13AUG2020	48907	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411097	C4591001 1241 12411097	16-55	13AUG2020	48910	Placebo	13AUG2020/ Placebo	02SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411098	C4591001 1241 12411098	16-55	13AUG2020	48911	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411099	C4591001 1241 12411099	16-55	13AUG2020	49121	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411100	C4591001 1241 12411100	16-55	13AUG2020	49122	Placebo	13AUG2020/ Placebo	01SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411101	C4591001 1241 12411101	16-55	13AUG2020	49123	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411102	C4591001 1241 12411102	16-55	13AUG2020	49132	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411103	C4591001 1241 12411103	16-55	13AUG2020	49195	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411106	C4591001 1241 12411106	16-55	13AUG2020	49197	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411108	C4591001 1241 12411108	16-55	13AUG2020	49200	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411109	C4591001 1241 12411109	16-55	13AUG2020	49202	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411110	C4591001 1241 12411110	16-55	13AUG2020	49350	BNT162b2 (30 µg)	13AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		
12411111	C4591001 1241 12411111	16-55	13AUG2020	49353	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411112	C4591001 1241 12411112	16-55	14AUG2020	49354	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411113	C4591001 1241 12411113	16-55	14AUG2020	49360	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411114	C4591001 1241 12411114	16-55	14AUG2020	49830	Placebo	14AUG2020/ Placebo	03SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411116	C4591001 1241 12411116	16-55	14AUG2020	49831	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411118	C4591001 1241 12411118	16-55	14AUG2020	49834	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411119	C4591001 1241 12411119	16-55	14AUG2020	49837	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411120	C4591001 1241 12411120	16-55	14AUG2020	49973	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411122	C4591001 1241 12411122	16-55	14AUG2020	49976	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411123	C4591001 1241 12411123	16-55	14AUG2020	49979	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411124	C4591001 1241 12411124	16-55	14AUG2020	49981	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411125	C4591001 1241 12411125	16-55	14AUG2020	50321	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411127	C4591001 1241 12411127	16-55	14AUG2020	50329	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411129	C4591001 1241 12411129	16-55	14AUG2020	50330	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411130	C4591001 1241 12411130	16-55	14AUG2020	50479	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411131	C4591001 1241 12411131	16-55	14AUG2020	50481	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411133	C4591001 1241 12411133	16-55	14AUG2020	50488	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411136	C4591001 1241 12411136	16-55	14AUG2020	50543	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411137	C4591001 1241 12411137	16-55	14AUG2020	50547	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12411138	C4591001 1241 12411138	16-55	14AUG2020	50669	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411139	C4591001 1241 12411139	16-55	14AUG2020	50670	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411141	C4591001 1241 12411141	16-55	14AUG2020	50680	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12521001	C4591001 1252 12521001	16-55	12AUG2020	47646	Placebo	12AUG2020/ Placebo	31AUG2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12521002	C4591001 1252 12521002	16-55	12AUG2020	47648	BNT162b2 (30 µg)	12AUG2020/ BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)		
12521004	C4591001 1252 12521004	16-55	13AUG2020	47652	Placebo	13AUG2020/ Placebo	03SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10031140	C4591001 1003 10031140	16-55	04AUG2020	42131	Placebo				
10031143	C4591001 1003 10031143	16-55	04AUG2020	42136	BNT162b2 (30 µg)				
10051076	C4591001 1005 10051076	16-55	17AUG2020	50006	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051077	C4591001 1005 10051077	16-55	17AUG2020	50008	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051079	C4591001 1005 10051079	16-55	19AUG2020	55901	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051081	C4591001 1005 10051081	16-55	19AUG2020	55904	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10051082	C4591001 1005 10051082	16-55	19AUG2020	55905	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051084	C4591001 1005 10051084	16-55	19AUG2020	55912	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10051085	C4591001 1005 10051085	16-55	19AUG2020	57222	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10051087	C4591001 1005 10051087	16-55	20AUG2020	57224	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051093	C4591001 1005 10051093	16-55	20AUG2020	57225	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10051094	C4591001 1005 10051094	16-55	20AUG2020	57229	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10051100	C4591001 1005 10051100	16-55	20AUG2020	59217	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10051101	C4591001 1005 10051101	16-55	20AUG2020	59214	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10051105	C4591001 1005 10051105	16-55	21AUG2020	59220	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10051106	C4591001 1005 10051106	16-55	21AUG2020	60019	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10051107	C4591001 1005 10051107	16-55	21AUG2020	60025	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10051108	C4591001 1005 10051108	16-55	21AUG2020	60024	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051115	C4591001 1005 10051115	16-55	21AUG2020	60026	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10051117	C4591001 1005 10051117	16-55	21AUG2020	60516	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051118	C4591001 1005 10051118	16-55	21AUG2020	60510	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10051119	C4591001 1005 10051119	16-55	24AUG2020	60517	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051123	C4591001 1005 10051123	16-55	24AUG2020	60518	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051125	C4591001 1005 10051125	16-55	24AUG2020	63763	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10051129	C4591001 1005 10051129	16-55	24AUG2020	63766	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10051134	C4591001 1005 10051134	16-55	24AUG2020	63769	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10051135	C4591001 1005 10051135	16-55	24AUG2020	63772	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051142	C4591001 1005 10051142	16-55	25AUG2020	65566	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10051144	C4591001 1005 10051144	16-55	25AUG2020	65570	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10051145	C4591001 1005 10051145	16-55	25AUG2020	65572	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051146	C4591001 1005 10051146	16-55	25AUG2020	65571	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051147	C4591001 1005 10051147	16-55	25AUG2020	66642	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10051148	C4591001 1005 10051148	16-55	25AUG2020	66646	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10051150	C4591001 1005 10051150	16-55	26AUG2020	66647	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051151	C4591001 1005 10051151	16-55	26AUG2020	66652	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10051153	C4591001 1005 10051153	16-55	26AUG2020	67421	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051161	C4591001 1005 10051161	16-55	26AUG2020	67422	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10051164	C4591001 1005 10051164	16-55	26AUG2020	67425	Placebo	26AUG2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10051165	C4591001 1005 10051165	16-55	26AUG2020	67427	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10051166	C4591001 1005 10051166	16-55	26AUG2020	68664	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051167	C4591001 1005 10051167	16-55	26AUG2020	68665	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10051168	C4591001 1005 10051168	16-55	27AUG2020	68666	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10051169	C4591001 1005 10051169	16-55	27AUG2020	68668	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10051170	C4591001 1005 10051170	16-55	27AUG2020	69678	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10051171	C4591001 1005 10051171	16-55	27AUG2020	69684	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10051175	C4591001 1005 10051175	16-55	27AUG2020	69686	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10051178	C4591001 1005 10051178	16-55	28AUG2020	69688	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10051179	C4591001 1005 10051179	16-55	28AUG2020	71693	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051181	C4591001 1005 10051181	16-55	28AUG2020	71695	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10051182	C4591001 1005 10051182	16-55	28AUG2020	71703	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051183	C4591001 1005 10051183	16-55	31AUG2020	71704	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10051187	C4591001 1005 10051187	16-55	31AUG2020	76003	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10051188	C4591001 1005 10051188	16-55	01SEP2020	76004	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051189	C4591001 1005 10051189	16-55	01SEP2020	76005	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051192	C4591001 1005 10051192	16-55	02SEP2020	76009	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10051198	C4591001 1005 10051198	16-55	03SEP2020	79548	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051199	C4591001 1005 10051199	16-55	03SEP2020	79545	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051200	C4591001 1005 10051200	16-55	03SEP2020	79549	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10051203	C4591001 1005 10051203	16-55	03SEP2020	79551	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10051210	C4591001 1005 10051210	16-55	03SEP2020	79914	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051212	C4591001 1005 10051212	16-55	03SEP2020	79915	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051215	C4591001 1005 10051215	16-55	10SEP2020	80877	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10051216	C4591001 1005 10051216	16-55	03SEP2020	79923	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10051217	C4591001 1005 10051217	16-55	03SEP2020	79916	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051219	C4591001 1005 10051219	16-55	03SEP2020	80873	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10051220	C4591001 1005 10051220	16-55	12OCT2020	80882	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051221	C4591001 1005 10051221	16-55	12OCT2020	106314	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10051222	C4591001 1005 10051222	16-55	12OCT2020	80878	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051223	C4591001 1005 10051223	16-55	12OCT2020	106316	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051224	C4591001 1005 10051224	16-55	12OCT2020	106315	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051225	C4591001 1005 10051225	16-55	12OCT2020	106322	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051226	C4591001 1005 10051226	16-55	12OCT2020	106409	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10051228	C4591001 1005 10051228	16-55	12OCT2020	106414	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051232	C4591001 1005 10051232	16-55	12OCT2020	106416	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10051233	C4591001 1005 10051233	16-55	12OCT2020	106418	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051235	C4591001 1005 10051235	16-55	12OCT2020	106685	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10051236	C4591001 1005 10051236	16-55	13OCT2020	106687	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051237	C4591001 1005 10051237	16-55	13OCT2020	106691	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051238	C4591001 1005 10051238	16-55	13OCT2020	106696	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		
10051240	C4591001 1005 10051240	16-55	13OCT2020	107157	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051241	C4591001 1005 10051241	16-55	13OCT2020	107153	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051242	C4591001 1005 10051242	16-55	13OCT2020	107159	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10051243	C4591001 1005 10051243	16-55	13OCT2020	107160	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051244	C4591001 1005 10051244	16-55	13OCT2020	107246	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051245	C4591001 1005 10051245	16-55	13OCT2020	107245	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10051246	C4591001 1005 10051246	16-55	13OCT2020	107241	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10051248	C4591001 1005 10051248	16-55	14OCT2020	107248	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10051251	C4591001 1005 10051251	16-55	14OCT2020	107406	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10051254	C4591001 1005 10051254	16-55	14OCT2020	107409	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10051257	C4591001 1005 10051257	16-55	14OCT2020	107410	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051259	C4591001 1005 10051259	16-55	14OCT2020	107414	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051260	C4591001 1005 10051260	16-55	14OCT2020	107790	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051264	C4591001 1005 10051264	16-55	15OCT2020	107793	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051267	C4591001 1005 10051267	16-55	15OCT2020	107796	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051268	C4591001 1005 10051268	16-55	15OCT2020	107797	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10051270	C4591001 1005 10051270	16-55	15OCT2020	108269	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051273	C4591001 1005 10051273	16-55	15OCT2020	108272	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10051274	C4591001 1005 10051274	16-55	15OCT2020	108277	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10051276	C4591001 1005 10051276	16-55	15OCT2020	108425	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10051277	C4591001 1005 10051277	16-55	15OCT2020	108278	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051280	C4591001 1005 10051280	16-55	16OCT2020	108428	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10051281	C4591001 1005 10051281	16-55	16OCT2020	108429	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10051283	C4591001 1005 10051283	16-55	16OCT2020	108430	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10051285	C4591001 1005 10051285	16-55	16OCT2020	109004	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10051288	C4591001 1005 10051288	16-55	16OCT2020	109006	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10051289	C4591001 1005 10051289	16-55	16OCT2020	109010	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10051290	C4591001 1005 10051290	16-55	16OCT2020	109012	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10051291	C4591001 1005 10051291	16-55	19OCT2020	109823	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051292	C4591001 1005 10051292	16-55	19OCT2020	109825	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051294	C4591001 1005 10051294	16-55	19OCT2020	109827	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051295	C4591001 1005 10051295	16-55	19OCT2020	109828	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10051301	C4591001 1005 10051301	16-55	19OCT2020	110106	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051302	C4591001 1005 10051302	16-55	19OCT2020	110107	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051308	C4591001 1005 10051308	16-55	19OCT2020	110110	Placebo	19OCT2020/ Placebo			
10051310	C4591001 1005 10051310	16-55	19OCT2020	110114	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
10051311	C4591001 1005 10051311	16-55	19OCT2020	110432	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10051314	C4591001 1005 10051314	16-55	19OCT2020	110435	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051315	C4591001 1005 10051315	16-55	20OCT2020	110436	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10051316	C4591001 1005 10051316	16-55	20OCT2020	110440	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10051318	C4591001 1005 10051318	16-55	20OCT2020	110705	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051322	C4591001 1005 10051322	16-55	20OCT2020	110707	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10051323	C4591001 1005 10051323	16-55	20OCT2020	110712	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10051326	C4591001 1005 10051326	16-55	20OCT2020	110716	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10051331	C4591001 1005 10051331	16-55	20OCT2020	110911	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10051332	C4591001 1005 10051332	16-55	20OCT2020	110913	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10051335	C4591001 1005 10051335	16-55	21OCT2020	110915	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10051340	C4591001 1005 10051340	16-55	21OCT2020	110919	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051341	C4591001 1005 10051341	16-55	21OCT2020	111573	Placebo	21OCT2020/ Placebo		12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10051343	C4591001 1005 10051343	16-55	21OCT2020	111578	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051345	C4591001 1005 10051345	16-55	21OCT2020	111579	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051346	C4591001 1005 10051346	16-55	21OCT2020	111580	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10051349	C4591001 1005 10051349	16-55	22OCT2020	112037	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051350	C4591001 1005 10051350	16-55	22OCT2020	112038	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051354	C4591001 1005 10051354	16-55	22OCT2020	112040	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10051356	C4591001 1005 10051356	16-55	22OCT2020	112042	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10051357	C4591001 1005 10051357	16-55	22OCT2020	112290	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10051358	C4591001 1005 10051358	16-55	22OCT2020	112295	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051361	C4591001 1005 10051361	16-55	22OCT2020	112297	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051362	C4591001 1005 10051362	16-55	23OCT2020	112300	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10051363	C4591001 1005 10051363	16-55	23OCT2020	112711	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051364	C4591001 1005 10051364	16-55	23OCT2020	112714	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10051365	C4591001 1005 10051365	16-55	23OCT2020	112715	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10051366	C4591001 1005 10051366	16-55	23OCT2020	112717	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10051368	C4591001 1005 10051368	16-55	23OCT2020	112976	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10051369	C4591001 1005 10051369	16-55	26OCT2020	112979	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10051370	C4591001 1005 10051370	16-55	26OCT2020	112984	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051371	C4591001 1005 10051371	16-55	26OCT2020	112983	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10051377	C4591001 1005 10051377	16-55	27OCT2020	113982	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051378	C4591001 1005 10051378	16-55	27OCT2020	113984	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10051380	C4591001 1005 10051380	16-55	27OCT2020	113991	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051381	C4591001 1005 10051381	16-55	28OCT2020	113992	BNT162b2 (30 µg)				
10051385	C4591001 1005 10051385	16-55	28OCT2020	114463	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10051386	C4591001 1005 10051386	16-55	28OCT2020	114465	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051390	C4591001 1005 10051390	16-55	30OCT2020	273647	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051393	C4591001 1005 10051393	16-55	30OCT2020	114466	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10051394	C4591001 1005 10051394	16-55	02NOV2020	114472	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051396	C4591001 1005 10051396	16-55	02NOV2020	115315	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10051397	C4591001 1005 10051397	16-55	02NOV2020	115317	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10051398	C4591001 1005 10051398	16-55	03NOV2020	115318	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051400	C4591001 1005 10051400	16-55	03NOV2020	115320	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051407	C4591001 1005 10051407	16-55	11NOV2020	116093	Placebo	11NOV2020/ Placebo	03DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10051408	C4591001 1005 10051408	16-55	11NOV2020	116096	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10051409	C4591001 1005 10051409	16-55	09DEC2020	116098	Placebo	09DEC2020/ Placebo	29DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051411	C4591001 1005 10051411	16-55	08JAN2021	117970	BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)		
10051416	C4591001 1005 10051416	16-55	16DEC2020	116101	BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)		
10051423	C4591001 1005 10051423	16-55	17DEC2020	117906	Placebo	17DEC2020/ Placebo	07JAN2021/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10051426	C4591001 1005 10051426	16-55	21DEC2020	117907	BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)		
10051432	C4591001 1005 10051432	16-55	22DEC2020	117910	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)		
10051433	C4591001 1005 10051433	16-55	22DEC2020	117911	Placebo	22DEC2020/ Placebo	13JAN2021/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10051434	C4591001 1005 10051434	16-55	22DEC2020	117954	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10051435	C4591001 1005 10051435	16-55	22DEC2020	117955	Placebo	22DEC2020/ Placebo	12JAN2021/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10051442	C4591001 1005 10051442	16-55	22DEC2020	117959	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)		
10051443	C4591001 1005 10051443	16-55	22DEC2020	117962	Placebo	22DEC2020/ Placebo	13JAN2021/ Placebo		
10051446	C4591001 1005 10051446	16-55	22DEC2020	117967	Placebo	22DEC2020/ Placebo	12JAN2021/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10061040	C4591001 1006 10061040	16-55	14AUG2020	50870	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10061041	C4591001 1006 10061041	16-55	14AUG2020	50871	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10061043	C4591001 1006 10061043	16-55	17AUG2020	50872	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061050	C4591001 1006 10061050	16-55	17AUG2020	53731	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10061052	C4591001 1006 10061052	16-55	18AUG2020	53735	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10061053	C4591001 1006 10061053	16-55	18AUG2020	53737	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061054	C4591001 1006 10061054	16-55	18AUG2020	53738	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10061055	C4591001 1006 10061055	16-55	18AUG2020	54787	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061056	C4591001 1006 10061056	16-55	18AUG2020	54791	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10061057	C4591001 1006 10061057	16-55	18AUG2020	54788	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061061	C4591001 1006 10061061	16-55	18AUG2020	54792	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10061062	C4591001 1006 10061062	16-55	18AUG2020	55590	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10061066	C4591001 1006 10061066	16-55	19AUG2020	55592	Placebo	19AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10061067	C4591001 1006 10061067	16-55	19AUG2020	55593	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061068	C4591001 1006 10061068	16-55	19AUG2020	55595	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10061070	C4591001 1006 10061070	16-55	19AUG2020	57392	Placebo	19AUG2020/ Placebo	02OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061071	C4591001 1006 10061071	16-55	19AUG2020	57393	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10061073	C4591001 1006 10061073	16-55	19AUG2020	57394	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061074	C4591001 1006 10061074	16-55	19AUG2020	57395	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10061075	C4591001 1006 10061075	16-55	20AUG2020	58337	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
10061078	C4591001 1006 10061078	16-55	20AUG2020	58342	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10061079	C4591001 1006 10061079	16-55	20AUG2020	58343	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10061081	C4591001 1006 10061081	16-55	20AUG2020	58344	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10061084	C4591001 1006 10061084	16-55	20AUG2020	59827	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061088	C4591001 1006 10061088	16-55	21AUG2020	59828	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10061089	C4591001 1006 10061089	16-55	21AUG2020	59831	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061090	C4591001 1006 10061090	16-55	21AUG2020	59835	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10061091	C4591001 1006 10061091	16-55	21AUG2020	61613	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10061092	C4591001 1006 10061092	16-55	21AUG2020	61614	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10061093	C4591001 1006 10061093	16-55	24AUG2020	61616	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061094	C4591001 1006 10061094	16-55	24AUG2020	61617	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061095	C4591001 1006 10061095	16-55	24AUG2020	63883	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061096	C4591001 1006 10061096	16-55	24AUG2020	63885	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10061099	C4591001 1006 10061099	16-55	24AUG2020	63886	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10061100	C4591001 1006 10061100	16-55	24AUG2020	63892	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10061102	C4591001 1006 10061102	16-55	24AUG2020	64939	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061103	C4591001 1006 10061103	16-55	24AUG2020	64940	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10061104	C4591001 1006 10061104	16-55	25AUG2020	64944	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10061106	C4591001 1006 10061106	16-55	25AUG2020	64947	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10061107	C4591001 1006 10061107	16-55	25AUG2020	66439	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10061108	C4591001 1006 10061108	16-55	25AUG2020	66442	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061109	C4591001 1006 10061109	16-55	25AUG2020	66446	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10061110	C4591001 1006 10061110	16-55	25AUG2020	66447	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10061112	C4591001 1006 10061112	16-55	26AUG2020	67556	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10061113	C4591001 1006 10061113	16-55	26AUG2020	67557	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10061114	C4591001 1006 10061114	16-55	26AUG2020	67561	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061116	C4591001 1006 10061116	16-55	26AUG2020	67562	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061117	C4591001 1006 10061117	16-55	26AUG2020	69344	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10061118	C4591001 1006 10061118	16-55	27AUG2020	69346	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10061122	C4591001 1006 10061122	16-55	27AUG2020	69348	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061124	C4591001 1006 10061124	16-55	28AUG2020	69350	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10061128	C4591001 1006 10061128	16-55	28AUG2020	73077	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10061129	C4591001 1006 10061129	16-55	28AUG2020	73076	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10061130	C4591001 1006 10061130	16-55	28AUG2020	73081	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10061131	C4591001 1006 10061131	16-55	28AUG2020	73083	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10061133	C4591001 1006 10061133	16-55	31AUG2020	74861	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061134	C4591001 1006 10061134	16-55	01SEP2020	74865	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10061136	C4591001 1006 10061136	16-55	01SEP2020	74866	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10061137	C4591001 1006 10061137	16-55	01SEP2020	74868	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10061138	C4591001 1006 10061138	16-55	02SEP2020	78067	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061140	C4591001 1006 10061140	16-55	02SEP2020	78074	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10061141	C4591001 1006 10061141	16-55	03SEP2020	78076	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10061142	C4591001 1006 10061142	16-55	03SEP2020	80753	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10061144	C4591001 1006 10061144	16-55	03SEP2020	80757	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10061148	C4591001 1006 10061148	16-55	11SEP2020	80761	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10061151	C4591001 1006 10061151	16-55	22SEP2020	80763	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061152	C4591001 1006 10061152	16-55	22SEP2020	97097	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10061153	C4591001 1006 10061153	16-55	23SEP2020	97102	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10061154	C4591001 1006 10061154	16-55	23SEP2020	97105	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061155	C4591001 1006 10061155	16-55	29SEP2020	101552	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10061156	C4591001 1006 10061156	16-55	24SEP2020	97108	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061159	C4591001 1006 10061159	16-55	24SEP2020	99089	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10061160	C4591001 1006 10061160	16-55	25SEP2020	99094	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10061161	C4591001 1006 10061161	16-55	25SEP2020	99095	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo		
10061162	C4591001 1006 10061162	16-55	25SEP2020	99100	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10061163	C4591001 1006 10061163	16-55	25SEP2020	100532	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061164	C4591001 1006 10061164	16-55	25SEP2020	100535	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10061165	C4591001 1006 10061165	16-55	25SEP2020	100536	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10061166	C4591001 1006 10061166	16-55	25SEP2020	100538	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10061167	C4591001 1006 10061167	16-55	28SEP2020	101549	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10061169	C4591001 1006 10061169	16-55	02OCT2020	101554	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10061170	C4591001 1006 10061170	16-55	05OCT2020	101559	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10061171	C4591001 1006 10061171	16-55	08OCT2020	105593	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10061173	C4591001 1006 10061173	16-55	09OCT2020	105598	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10061174	C4591001 1006 10061174	16-55	12OCT2020	105601	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10061176	C4591001 1006 10061176	16-55	27OCT2020	105602	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061179	C4591001 1006 10061179	16-55	30OCT2020	115137	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10061180	C4591001 1006 10061180	16-55	06NOV2020	115140	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10061181	C4591001 1006 10061181	16-55	13NOV2020	115141	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10061182	C4591001 1006 10061182	16-55	30NOV2020	115143	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)		
10061185	C4591001 1006 10061185	16-55	30NOV2020	117101	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10061186	C4591001 1006 10061186	16-55	01DEC2020	117109	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo		
10061187	C4591001 1006 10061187	16-55	01DEC2020	117110	Placebo	01DEC2020/ Placebo	28DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10061192	C4591001 1006 10061192	16-55	02DEC2020	117112	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10061193	C4591001 1006 10061193	16-55	02DEC2020	117245	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10061194	C4591001 1006 10061194	16-55	02DEC2020	117248	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061195	C4591001 1006 10061195	16-55	02DEC2020	117251	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10061197	C4591001 1006 10061197	16-55	03DEC2020	117252	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10061199	C4591001 1006 10061199	16-55	03DEC2020	117378	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10061202	C4591001 1006 10061202	16-55	03DEC2020	117380	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10061204	C4591001 1006 10061204	16-55	03DEC2020	117381	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061205	C4591001 1006 10061205	16-55	03DEC2020	117383	Placebo	03DEC2020/ Placebo	24DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061208	C4591001 1006 10061208	16-55	04DEC2020	117557	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10061210	C4591001 1006 10061210	16-55	04DEC2020	117561	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10061211	C4591001 1006 10061211	16-55	04DEC2020	117562	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10061215	C4591001 1006 10061215	16-55	04DEC2020	117563	Placebo	04DEC2020/ Placebo	22JAN2021/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10061216	C4591001 1006 10061216	16-55	04DEC2020	117629	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10061217	C4591001 1006 10061217	16-55	04DEC2020	117633	Placebo	04DEC2020/ Placebo	24DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10061218	C4591001 1006 10061218	16-55	07DEC2020	117634	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10061222	C4591001 1006 10061222	16-55	07DEC2020	117639	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10061225	C4591001 1006 10061225	16-55	07DEC2020	117713	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10061238	C4591001 1006 10061238	16-55	09DEC2020	117719	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10061240	C4591001 1006 10061240	16-55	09DEC2020	117722	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)		
10061246	C4591001 1006 10061246	16-55	10DEC2020	117724	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10061255	C4591001 1006 10061255	16-55	11DEC2020	117895	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10071203	C4591001 1007 10071203	16-55	17AUG2020	49345	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071204	C4591001 1007 10071204	16-55	17AUG2020	49347	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10071206	C4591001 1007 10071206	16-55	17AUG2020	49348	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071207	C4591001 1007 10071207	16-55	17AUG2020	52985	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071208	C4591001 1007 10071208	16-55	17AUG2020	52986	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071211	C4591001 1007 10071211	16-55	17AUG2020	52987	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10071212	C4591001 1007 10071212	16-55	17AUG2020	52994	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
10071214	C4591001 1007 10071214	16-55	17AUG2020	53133	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10071217	C4591001 1007 10071217	16-55	19AUG2020	53135	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10071218	C4591001 1007 10071218	16-55	19AUG2020	53136	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10071219	C4591001 1007 10071219	16-55	19AUG2020	53139	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071221	C4591001 1007 10071221	16-55	19AUG2020	56214	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071225	C4591001 1007 10071225	16-55	19AUG2020	56220	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
10071227	C4591001 1007 10071227	16-55	19AUG2020	56224	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10071228	C4591001 1007 10071228	16-55	19AUG2020	56853	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071229	C4591001 1007 10071229	16-55	19AUG2020	56854	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071230	C4591001 1007 10071230	16-55	19AUG2020	56857	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071231	C4591001 1007 10071231	16-55	19AUG2020	56855	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071232	C4591001 1007 10071232	16-55	20AUG2020	58098	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071233	C4591001 1007 10071233	16-55	20AUG2020	58099	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10071235	C4591001 1007 10071235	16-55	20AUG2020	58101	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071236	C4591001 1007 10071236	16-55	20AUG2020	58108	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071238	C4591001 1007 10071238	16-55	20AUG2020	58474	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071240	C4591001 1007 10071240	16-55	20AUG2020	58478	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10071243	C4591001 1007 10071243	16-55	20AUG2020	58475	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
10071246	C4591001 1007 10071246	16-55	20AUG2020	58480	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071250	C4591001 1007 10071250	16-55	24AUG2020	63416	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071251	C4591001 1007 10071251	16-55	24AUG2020	63418	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10071252	C4591001 1007 10071252	16-55	24AUG2020	63420	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071253	C4591001 1007 10071253	16-55	24AUG2020	63422	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071256	C4591001 1007 10071256	16-55	24AUG2020	63989	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071258	C4591001 1007 10071258	16-55	24AUG2020	63993	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10071264	C4591001 1007 10071264	16-55	26AUG2020	63997	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071266	C4591001 1007 10071266	16-55	26AUG2020	63999	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10071269	C4591001 1007 10071269	16-55	26AUG2020	67664	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10071270	C4591001 1007 10071270	16-55	26AUG2020	67667	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071272	C4591001 1007 10071272	16-55	26AUG2020	67668	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10071275	C4591001 1007 10071275	16-55	26AUG2020	67671	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10071276	C4591001 1007 10071276	16-55	26AUG2020	68489	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
10071278	C4591001 1007 10071278	16-55	26AUG2020	68492	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10071280	C4591001 1007 10071280	16-55	27AUG2020	68493	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071281	C4591001 1007 10071281	16-55	27AUG2020	68495	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10071284	C4591001 1007 10071284	16-55	27AUG2020	69885	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10071285	C4591001 1007 10071285	16-55	27AUG2020	69888	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10071286	C4591001 1007 10071286	16-55	27AUG2020	69889	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
10071289	C4591001 1007 10071289	16-55	27AUG2020	69892	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10071295	C4591001 1007 10071295	16-55	27AUG2020	70845	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
10071296	C4591001 1007 10071296	16-55	27AUG2020	70844	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071307	C4591001 1007 10071307	16-55	12OCT2020	70846	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10071309	C4591001 1007 10071309	16-55	12OCT2020	70848	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10071334	C4591001 1007 10071334	16-55	14OCT2020	107694	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071337	C4591001 1007 10071337	16-55	14OCT2020	107700	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071339	C4591001 1007 10071339	16-55	14OCT2020	107702	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10071340	C4591001 1007 10071340	16-55	14OCT2020	107703	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10071341	C4591001 1007 10071341	16-55	14OCT2020	107807	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071342	C4591001 1007 10071342	16-55	15OCT2020	107809	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10071350	C4591001 1007 10071350	16-55	15OCT2020	107810	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10071352	C4591001 1007 10071352	16-55	15OCT2020	108452	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10071353	C4591001 1007 10071353	16-55	15OCT2020	107811	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10071358	C4591001 1007 10071358	16-55	19OCT2020	108457	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10071362	C4591001 1007 10071362	16-55	19OCT2020	108459	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071363	C4591001 1007 10071363	16-55	19OCT2020	108458	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10071365	C4591001 1007 10071365	16-55	19OCT2020	110369	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10071366	C4591001 1007 10071366	16-55	19OCT2020	110371	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071367	C4591001 1007 10071367	16-55	19OCT2020	110489	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071368	C4591001 1007 10071368	16-55	19OCT2020	110375	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071369	C4591001 1007 10071369	16-55	19OCT2020	110377	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10071370	C4591001 1007 10071370	16-55	20OCT2020	110490	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10071373	C4591001 1007 10071373	16-55	20OCT2020	110500	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071374	C4591001 1007 10071374	16-55	20OCT2020	110496	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071376	C4591001 1007 10071376	16-55	20OCT2020	110825	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071377	C4591001 1007 10071377	16-55	20OCT2020	110831	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071378	C4591001 1007 10071378	16-55	20OCT2020	110827	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10071380	C4591001 1007 10071380	16-55	20OCT2020	110833	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo		
10071381	C4591001 1007 10071381	16-55	20OCT2020	111017	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071382	C4591001 1007 10071382	16-55	20OCT2020	111021	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10071385	C4591001 1007 10071385	16-55	20OCT2020	111025	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10071386	C4591001 1007 10071386	16-55	21OCT2020	111027	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071387	C4591001 1007 10071387	16-55	21OCT2020	111347	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
10071388	C4591001 1007 10071388	16-55	21OCT2020	111342	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071389	C4591001 1007 10071389	16-55	21OCT2020	111350	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071390	C4591001 1007 10071390	16-55	21OCT2020	111351	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071391	C4591001 1007 10071391	16-55	21OCT2020	111492	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071392	C4591001 1007 10071392	16-55	21OCT2020	111493	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071397	C4591001 1007 10071397	16-55	21OCT2020	111494	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10071398	C4591001 1007 10071398	16-55	21OCT2020	111766	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071399	C4591001 1007 10071399	16-55	21OCT2020	111495	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10071400	C4591001 1007 10071400	16-55	21OCT2020	111769	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071401	C4591001 1007 10071401	16-55	21OCT2020	111812	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071402	C4591001 1007 10071402	16-55	21OCT2020	111771	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071403	C4591001 1007 10071403	16-55	21OCT2020	111772	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071404	C4591001 1007 10071404	16-55	21OCT2020	111814	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10071405	C4591001 1007 10071405	16-55	22OCT2020	111816	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
10071406	C4591001 1007 10071406	16-55	22OCT2020	112064	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071407	C4591001 1007 10071407	16-55	22OCT2020	111820	Placebo	22OCT2020/ Placebo		12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10071408	C4591001 1007 10071408	16-55	22OCT2020	112068	Placebo	22OCT2020/ Placebo	03DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10071410	C4591001 1007 10071410	16-55	22OCT2020	112069	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071416	C4591001 1007 10071416	16-55	22OCT2020	112072	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071418	C4591001 1007 10071418	16-55	22OCT2020	112331	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071419	C4591001 1007 10071419	16-55	22OCT2020	112326	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10071420	C4591001 1007 10071420	16-55	22OCT2020	112327	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071421	C4591001 1007 10071421	16-55	22OCT2020	112336	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071422	C4591001 1007 10071422	16-55	22OCT2020	112376	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
10071423	C4591001 1007 10071423	16-55	22OCT2020	112378	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071424	C4591001 1007 10071424	16-55	22OCT2020	112379	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071425	C4591001 1007 10071425	16-55	22OCT2020	112382	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071426	C4591001 1007 10071426	16-55	22OCT2020	112535	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10071427	C4591001 1007 10071427	16-55	22OCT2020	112530	Placebo	22OCT2020/ Placebo	23NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10071431	C4591001 1007 10071431	16-55	26OCT2020	112537	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10071433	C4591001 1007 10071433	16-55	27OCT2020	112540	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
10071434	C4591001 1007 10071434	16-55	27OCT2020	114209	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071435	C4591001 1007 10071435	16-55	28OCT2020	114213	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071436	C4591001 1007 10071436	16-55	28OCT2020	114214	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10071437	C4591001 1007 10071437	16-55	16NOV2020	116279	Placebo	16NOV2020/ Placebo	22DEC2020/ Placebo		
10071438	C4591001 1007 10071438	16-55	29OCT2020	114220	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10071439	C4591001 1007 10071439	16-55	29OCT2020	114777	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10071440	C4591001 1007 10071440	16-55	29OCT2020	114773	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10071441	C4591001 1007 10071441	16-55	29OCT2020	114775	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071442	C4591001 1007 10071442	16-55	03NOV2020	114784	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071443	C4591001 1007 10071443	16-55	04NOV2020	115649	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10071444	C4591001 1007 10071444	16-55	04NOV2020	115652	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071445	C4591001 1007 10071445	16-55	10NOV2020	115654	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
10071446	C4591001 1007 10071446	16-55	18NOV2020	116405	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
10071447	C4591001 1007 10071447	16-55	11NOV2020	115659	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
10071448	C4591001 1007 10071448	16-55	11NOV2020	116136	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10071449	C4591001 1007 10071449	16-55	11NOV2020	116137	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071450	C4591001 1007 10071450	16-55	12NOV2020	116138	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071451	C4591001 1007 10071451	16-55	12NOV2020	116140	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071452	C4591001 1007 10071452	16-55	12NOV2020	116167	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071454	C4591001 1007 10071454	16-55	12NOV2020	116168	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10071455	C4591001 1007 10071455	16-55	12NOV2020	116170	Placebo	12NOV2020/ Placebo	09DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071456	C4591001 1007 10071456	16-55	16NOV2020	116174	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10071457	C4591001 1007 10071457	16-55	16NOV2020	116275	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
10071458	C4591001 1007 10071458	16-55	16NOV2020	116277	Placebo	16NOV2020/ Placebo	09DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071459	C4591001 1007 10071459	16-55	17NOV2020	116281	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10071461	C4591001 1007 10071461	16-55	18NOV2020	116406	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071462	C4591001 1007 10071462	16-55	18NOV2020	116409	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10071463	C4591001 1007 10071463	16-55	18NOV2020	116489	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10071464	C4591001 1007 10071464	16-55	18NOV2020	116415	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10071465	C4591001 1007 10071465	16-55	19NOV2020	116492	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo		
10071466	C4591001 1007 10071466	16-55	19NOV2020	116494	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071468	C4591001 1007 10071468	16-55	30NOV2020	116497	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10071470	C4591001 1007 10071470	16-55	30NOV2020	117030	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10071473	C4591001 1007 10071473	16-55	07DEC2020	117471	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10071474	C4591001 1007 10071474	16-55	30NOV2020	117032	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10071477	C4591001 1007 10071477	16-55	30NOV2020	117036	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10071479	C4591001 1007 10071479	16-55	30NOV2020	117038	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10071486	C4591001 1007 10071486	16-55	01DEC2020	117126	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071487	C4591001 1007 10071487	16-55	01DEC2020	117129	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071489	C4591001 1007 10071489	16-55	01DEC2020	117130	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071491	C4591001 1007 10071491	16-55	01DEC2020	117135	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071493	C4591001 1007 10071493	16-55	01DEC2020	117173	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071498	C4591001 1007 10071498	16-55	02DEC2020	117175	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071501	C4591001 1007 10071501	16-55	03DEC2020	117176	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10071502	C4591001 1007 10071502	16-55	03DEC2020	117180	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071503	C4591001 1007 10071503	16-55	03DEC2020	117464	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10071510	C4591001 1007 10071510	16-55	07DEC2020	117466	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10071513	C4591001 1007 10071513	16-55	07DEC2020	117472	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10071532	C4591001 1007 10071532	16-55	09DEC2020	117799	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10071534	C4591001 1007 10071534	16-55	09DEC2020	117805	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10071538	C4591001 1007 10071538	16-55	09DEC2020	117806	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10071548	C4591001 1007 10071548	16-55	10DEC2020	117808	Placebo	10DEC2020/ Placebo	30DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10071549	C4591001 1007 10071549	16-55	10DEC2020	117847	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10071553	C4591001 1007 10071553	16-55	10DEC2020	117849	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10071556	C4591001 1007 10071556	16-55	10DEC2020	117850	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo		
10081032	C4591001 1008 10081032	16-55	24AUG2020	63515	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10081042	C4591001 1008 10081042	16-55	17AUG2020	50636	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081043	C4591001 1008 10081043	16-55	17AUG2020	50640	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10081046	C4591001 1008 10081046	16-55	17AUG2020	53141	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10081047	C4591001 1008 10081047	16-55	17AUG2020	53142	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10081048	C4591001 1008 10081048	16-55	17AUG2020	53144	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081049	C4591001 1008 10081049	16-55	17AUG2020	53151	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10081051	C4591001 1008 10081051	16-55	18AUG2020	54390	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10081052	C4591001 1008 10081052	16-55	18AUG2020	54393	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10081053	C4591001 1008 10081053	16-55	18AUG2020	54398	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081054	C4591001 1008 10081054	16-55	18AUG2020	54400	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081059	C4591001 1008 10081059	16-55	18AUG2020	55206	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081064	C4591001 1008 10081064	16-55	19AUG2020	55210	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10081065	C4591001 1008 10081065	16-55	19AUG2020	55216	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10081066	C4591001 1008 10081066	16-55	19AUG2020	55213	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10081067	C4591001 1008 10081067	16-55	19AUG2020	57176	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081068	C4591001 1008 10081068	16-55	20AUG2020	57177	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10081071	C4591001 1008 10081071	16-55	20AUG2020	57178	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081072	C4591001 1008 10081072	16-55	20AUG2020	57184	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081077	C4591001 1008 10081077	16-55	21AUG2020	60452	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081078	C4591001 1008 10081078	16-55	21AUG2020	60453	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10081079	C4591001 1008 10081079	16-55	21AUG2020	60455	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081080	C4591001 1008 10081080	16-55	21AUG2020	60456	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10081086	C4591001 1008 10081086	16-55	24AUG2020	63518	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081087	C4591001 1008 10081087	16-55	24AUG2020	63519	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10081088	C4591001 1008 10081088	16-55	24AUG2020	63520	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081089	C4591001 1008 10081089	16-55	25AUG2020	65489	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10081091	C4591001 1008 10081091	16-55	25AUG2020	65490	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10081095	C4591001 1008 10081095	16-55	25AUG2020	65495	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081099	C4591001 1008 10081099	16-55	25AUG2020	65498	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081101	C4591001 1008 10081101	16-55	26AUG2020	67614	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081102	C4591001 1008 10081102	16-55	26AUG2020	67615	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10081103	C4591001 1008 10081103	16-55	26AUG2020	67622	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081113	C4591001 1008 10081113	16-55	26AUG2020	67623	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10081116	C4591001 1008 10081116	16-55	27AUG2020	69968	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081121	C4591001 1008 10081121	16-55	27AUG2020	69970	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081122	C4591001 1008 10081122	16-55	27AUG2020	69975	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10081129	C4591001 1008 10081129	16-55	28AUG2020	69976	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081130	C4591001 1008 10081130	16-55	28AUG2020	72020	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
10081136	C4591001 1008 10081136	16-55	28AUG2020	72021	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081137	C4591001 1008 10081137	16-55	28AUG2020	72027	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10081138	C4591001 1008 10081138	16-55	28AUG2020	72028	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081140	C4591001 1008 10081140	16-55	28AUG2020	72785	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081142	C4591001 1008 10081142	16-55	28AUG2020	72788	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10081143	C4591001 1008 10081143	16-55	28AUG2020	72789	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081147	C4591001 1008 10081147	16-55	31AUG2020	72790	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081148	C4591001 1008 10081148	16-55	31AUG2020	75737	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081149	C4591001 1008 10081149	16-55	31AUG2020	75738	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10081150	C4591001 1008 10081150	16-55	31AUG2020	75746	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10081151	C4591001 1008 10081151	16-55	31AUG2020	75747	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081152	C4591001 1008 10081152	16-55	31AUG2020	75850	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10081153	C4591001 1008 10081153	16-55	01SEP2020	75851	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10081155	C4591001 1008 10081155	16-55	01SEP2020	75853	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10081156	C4591001 1008 10081156	16-55	01SEP2020	75854	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081158	C4591001 1008 10081158	16-55	01SEP2020	76685	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081159	C4591001 1008 10081159	16-55	01SEP2020	76689	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081160	C4591001 1008 10081160	16-55	01SEP2020	76695	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081166	C4591001 1008 10081166	16-55	02SEP2020	76696	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10081183	C4591001 1008 10081183	16-55	03SEP2020	80622	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10081187	C4591001 1008 10081187	16-55	03SEP2020	80626	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10081191	C4591001 1008 10081191	16-55	04SEP2020	80628	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10081193	C4591001 1008 10081193	16-55	04SEP2020	81559	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10081194	C4591001 1008 10081194	16-55	04SEP2020	80631	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10081197	C4591001 1008 10081197	16-55	04SEP2020	81565	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081198	C4591001 1008 10081198	16-55	04SEP2020	81566	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10081199	C4591001 1008 10081199	16-55	04SEP2020	81568	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081200	C4591001 1008 10081200	16-55	04SEP2020	82148	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081202	C4591001 1008 10081202	16-55	04SEP2020	82149	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10081212	C4591001 1008 10081212	16-55	08SEP2020	82153	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081215	C4591001 1008 10081215	16-55	08SEP2020	82155	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10081217	C4591001 1008 10081217	16-55	08SEP2020	84102	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081218	C4591001 1008 10081218	16-55	08SEP2020	84106	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10081220	C4591001 1008 10081220	16-55	08SEP2020	84109	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10081221	C4591001 1008 10081221	16-55	08SEP2020	84112	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10081224	C4591001 1008 10081224	16-55	08SEP2020	84320	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081225	C4591001 1008 10081225	16-55	08SEP2020	84317	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081232	C4591001 1008 10081232	16-55	08SEP2020	84322	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10081233	C4591001 1008 10081233	16-55	08SEP2020	84326	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081234	C4591001 1008 10081234	16-55	08SEP2020	84648	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10081235	C4591001 1008 10081235	16-55	08SEP2020	84647	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10081238	C4591001 1008 10081238	16-55	09SEP2020	84650	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081239	C4591001 1008 10081239	16-55	09SEP2020	84652	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081240	C4591001 1008 10081240	16-55	09SEP2020	85037	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10081244	C4591001 1008 10081244	16-55	09SEP2020	85038	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10081251	C4591001 1008 10081251	16-55	09SEP2020	85039	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081253	C4591001 1008 10081253	16-55	09SEP2020	85043	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081256	C4591001 1008 10081256	16-55	09SEP2020	86071	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081257	C4591001 1008 10081257	16-55	09SEP2020	86072	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10081258	C4591001 1008 10081258	16-55	09SEP2020	86075	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081260	C4591001 1008 10081260	16-55	09SEP2020	86079	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10081261	C4591001 1008 10081261	16-55	09SEP2020	86166	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081263	C4591001 1008 10081263	16-55	09SEP2020	86169	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081265	C4591001 1008 10081265	16-55	10SEP2020	86172	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081271	C4591001 1008 10081271	16-55	10SEP2020	86175	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081274	C4591001 1008 10081274	16-55	10SEP2020	87270	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081281	C4591001 1008 10081281	16-55	10SEP2020	87273	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081286	C4591001 1008 10081286	16-55	10SEP2020	87274	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081289	C4591001 1008 10081289	16-55	10SEP2020	87280	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10081290	C4591001 1008 10081290	16-55	11SEP2020	87977	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081292	C4591001 1008 10081292	16-55	11SEP2020	87982	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081293	C4591001 1008 10081293	16-55	11SEP2020	87983	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081295	C4591001 1008 10081295	16-55	11SEP2020	87988	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081297	C4591001 1008 10081297	16-55	11SEP2020	88170	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081300	C4591001 1008 10081300	16-55	11SEP2020	88172	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081304	C4591001 1008 10081304	16-55	11SEP2020	88174	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10081306	C4591001 1008 10081306	16-55	11SEP2020	88177	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081310	C4591001 1008 10081310	16-55	14SEP2020	89467	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081312	C4591001 1008 10081312	16-55	14SEP2020	89469	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081313	C4591001 1008 10081313	16-55	14SEP2020	89472	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081314	C4591001 1008 10081314	16-55	14SEP2020	89476	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081315	C4591001 1008 10081315	16-55	14SEP2020	89611	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081316	C4591001 1008 10081316	16-55	14SEP2020	89612	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081320	C4591001 1008 10081320	16-55	14SEP2020	89615	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081321	C4591001 1008 10081321	16-55	14SEP2020	89904	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081325	C4591001 1008 10081325	16-55	14SEP2020	89619	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081326	C4591001 1008 10081326	16-55	14SEP2020	89898	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081327	C4591001 1008 10081327	16-55	14SEP2020	89903	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10081328	C4591001 1008 10081328	16-55	14SEP2020	89905	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081333	C4591001 1008 10081333	16-55	15SEP2020	90305	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081336	C4591001 1008 10081336	16-55	15SEP2020	90312	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081337	C4591001 1008 10081337	16-55	15SEP2020	90313	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081338	C4591001 1008 10081338	16-55	15SEP2020	90316	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081341	C4591001 1008 10081341	16-55	15SEP2020	90499	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081343	C4591001 1008 10081343	16-55	15SEP2020	90500	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081344	C4591001 1008 10081344	16-55	15SEP2020	90501	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081346	C4591001 1008 10081346	16-55	15SEP2020	90503	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081347	C4591001 1008 10081347	16-55	16SEP2020	91051	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081348	C4591001 1008 10081348	16-55	16SEP2020	91055	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081349	C4591001 1008 10081349	16-55	16SEP2020	91056	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081350	C4591001 1008 10081350	16-55	16SEP2020	91059	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081351	C4591001 1008 10081351	16-55	16SEP2020	91277	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081352	C4591001 1008 10081352	16-55	16SEP2020	91280	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081354	C4591001 1008 10081354	16-55	16SEP2020	91282	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081357	C4591001 1008 10081357	16-55	16SEP2020	91403	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10081358	C4591001 1008 10081358	16-55	16SEP2020	91397	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10081359	C4591001 1008 10081359	16-55	16SEP2020	91288	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081360	C4591001 1008 10081360	16-55	16SEP2020	91405	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081361	C4591001 1008 10081361	16-55	16SEP2020	91408	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10081364	C4591001 1008 10081364	16-55	16SEP2020	91613	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081365	C4591001 1008 10081365	16-55	16SEP2020	91618	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081366	C4591001 1008 10081366	16-55	16SEP2020	91621	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081367	C4591001 1008 10081367	16-55	16SEP2020	91622	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10081368	C4591001 1008 10081368	16-55	16SEP2020	91733	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081370	C4591001 1008 10081370	16-55	17SEP2020	91735	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081372	C4591001 1008 10081372	16-55	17SEP2020	91737	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081374	C4591001 1008 10081374	16-55	17SEP2020	91743	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081379	C4591001 1008 10081379	16-55	17SEP2020	92489	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081382	C4591001 1008 10081382	16-55	17SEP2020	92491	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081383	C4591001 1008 10081383	16-55	17SEP2020	92494	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081384	C4591001 1008 10081384	16-55	17SEP2020	92497	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081385	C4591001 1008 10081385	16-55	17SEP2020	92573	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081388	C4591001 1008 10081388	16-55	17SEP2020	92575	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081391	C4591001 1008 10081391	16-55	17SEP2020	92578	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081392	C4591001 1008 10081392	16-55	18SEP2020	92582	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081393	C4591001 1008 10081393	16-55	18SEP2020	93486	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081394	C4591001 1008 10081394	16-55	18SEP2020	93487	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081395	C4591001 1008 10081395	16-55	18SEP2020	93489	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081396	C4591001 1008 10081396	16-55	18SEP2020	93493	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081397	C4591001 1008 10081397	16-55	18SEP2020	93656	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081398	C4591001 1008 10081398	16-55	18SEP2020	93658	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081401	C4591001 1008 10081401	16-55	18SEP2020	93659	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10081402	C4591001 1008 10081402	16-55	18SEP2020	93663	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081404	C4591001 1008 10081404	16-55	18SEP2020	93810	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081407	C4591001 1008 10081407	16-55	18SEP2020	93815	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081408	C4591001 1008 10081408	16-55	18SEP2020	93811	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081410	C4591001 1008 10081410	16-55	18SEP2020	93817	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081411	C4591001 1008 10081411	16-55	18SEP2020	94109	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081413	C4591001 1008 10081413	16-55	18SEP2020	94110	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10081416	C4591001 1008 10081416	16-55	21SEP2020	94115	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081418	C4591001 1008 10081418	16-55	21SEP2020	94118	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081419	C4591001 1008 10081419	16-55	21SEP2020	94821	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10081420	C4591001 1008 10081420	16-55	21SEP2020	94824	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081421	C4591001 1008 10081421	16-55	21SEP2020	94825	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081422	C4591001 1008 10081422	16-55	21SEP2020	94826	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081423	C4591001 1008 10081423	16-55	21SEP2020	94974	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081425	C4591001 1008 10081425	16-55	21SEP2020	94977	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081426	C4591001 1008 10081426	16-55	21SEP2020	94979	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081427	C4591001 1008 10081427	16-55	21SEP2020	94980	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081429	C4591001 1008 10081429	16-55	21SEP2020	95129	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081430	C4591001 1008 10081430	16-55	21SEP2020	95130	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081432	C4591001 1008 10081432	16-55	21SEP2020	95134	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081433	C4591001 1008 10081433	16-55	21SEP2020	95136	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081435	C4591001 1008 10081435	16-55	21SEP2020	95299	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081436	C4591001 1008 10081436	16-55	21SEP2020	95301	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081437	C4591001 1008 10081437	16-55	21SEP2020	95302	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10081438	C4591001 1008 10081438	16-55	21SEP2020	262615	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081439	C4591001 1008 10081439	16-55	21SEP2020	95306	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081440	C4591001 1008 10081440	16-55	21SEP2020	95513	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081441	C4591001 1008 10081441	16-55	21SEP2020	95514	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10081442	C4591001 1008 10081442	16-55	22SEP2020	95515	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081444	C4591001 1008 10081444	16-55	22SEP2020	95521	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081447	C4591001 1008 10081447	16-55	22SEP2020	96163	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081449	C4591001 1008 10081449	16-55	22SEP2020	96167	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081450	C4591001 1008 10081450	16-55	22SEP2020	96170	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081452	C4591001 1008 10081452	16-55	22SEP2020	96171	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10081453	C4591001 1008 10081453	16-55	22SEP2020	96330	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081456	C4591001 1008 10081456	16-55	22SEP2020	96335	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081457	C4591001 1008 10081457	16-55	22SEP2020	96331	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081462	C4591001 1008 10081462	16-55	22SEP2020	96336	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081463	C4591001 1008 10081463	16-55	22SEP2020	96571	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081464	C4591001 1008 10081464	16-55	22SEP2020	96573	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081466	C4591001 1008 10081466	16-55	22SEP2020	96578	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081467	C4591001 1008 10081467	16-55	22SEP2020	96580	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081468	C4591001 1008 10081468	16-55	22SEP2020	96702	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10081469	C4591001 1008 10081469	16-55	22SEP2020	96708	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10081470	C4591001 1008 10081470	16-55	22SEP2020	96710	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081471	C4591001 1008 10081471	16-55	22SEP2020	96711	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10081472	C4591001 1008 10081472	16-55	23SEP2020	97448	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081473	C4591001 1008 10081473	16-55	23SEP2020	97449	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081474	C4591001 1008 10081474	16-55	23SEP2020	97450	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081475	C4591001 1008 10081475	16-55	23SEP2020	97452	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081476	C4591001 1008 10081476	16-55	23SEP2020	97567	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081477	C4591001 1008 10081477	16-55	23SEP2020	97569	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081479	C4591001 1008 10081479	16-55	23SEP2020	97572	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081480	C4591001 1008 10081480	16-55	23SEP2020	97573	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10081481	C4591001 1008 10081481	16-55	23SEP2020	97697	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081485	C4591001 1008 10081485	16-55	23SEP2020	97698	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081487	C4591001 1008 10081487	16-55	23SEP2020	97699	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081492	C4591001 1008 10081492	16-55	23SEP2020	98011	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10081493	C4591001 1008 10081493	16-55	23SEP2020	97702	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081496	C4591001 1008 10081496	16-55	23SEP2020	98012	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081497	C4591001 1008 10081497	16-55	23SEP2020	98018	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10081499	C4591001 1008 10081499	16-55	24SEP2020	98019	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081500	C4591001 1008 10081500	16-55	24SEP2020	98672	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081504	C4591001 1008 10081504	16-55	24SEP2020	98673	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081505	C4591001 1008 10081505	16-55	24SEP2020	98677	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081506	C4591001 1008 10081506	16-55	24SEP2020	98680	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081507	C4591001 1008 10081507	16-55	24SEP2020	98743	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081509	C4591001 1008 10081509	16-55	24SEP2020	98746	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081512	C4591001 1008 10081512	16-55	24SEP2020	98749	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10081513	C4591001 1008 10081513	16-55	24SEP2020	98752	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081514	C4591001 1008 10081514	16-55	24SEP2020	98826	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10081518	C4591001 1008 10081518	16-55	24SEP2020	98827	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081520	C4591001 1008 10081520	16-55	24SEP2020	98831	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081521	C4591001 1008 10081521	16-55	24SEP2020	98832	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081524	C4591001 1008 10081524	16-55	24SEP2020	98949	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081525	C4591001 1008 10081525	16-55	24SEP2020	98950	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10081527	C4591001 1008 10081527	16-55	25SEP2020	98953	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081528	C4591001 1008 10081528	16-55	25SEP2020	98954	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081529	C4591001 1008 10081529	16-55	25SEP2020	99584	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
10081532	C4591001 1008 10081532	16-55	25SEP2020	99586	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081533	C4591001 1008 10081533	16-55	25SEP2020	99588	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081534	C4591001 1008 10081534	16-55	25SEP2020	99592	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10081541	C4591001 1008 10081541	16-55	25SEP2020	100229	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081542	C4591001 1008 10081542	16-55	25SEP2020	100230	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
10081543	C4591001 1008 10081543	16-55	25SEP2020	100236	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081544	C4591001 1008 10081544	16-55	25SEP2020	100239	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10081547	C4591001 1008 10081547	16-55	28SEP2020	101362	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081548	C4591001 1008 10081548	16-55	28SEP2020	101363	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10081549	C4591001 1008 10081549	16-55	28SEP2020	101364	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10081551	C4591001 1008 10081551	16-55	30SEP2020	102317	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081552	C4591001 1008 10081552	16-55	30SEP2020	101367	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081553	C4591001 1008 10081553	16-55	30SEP2020	102318	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10081554	C4591001 1008 10081554	16-55	30SEP2020	102322	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10081555	C4591001 1008 10081555	16-55	30SEP2020	102323	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081556	C4591001 1008 10081556	16-55	01OCT2020	102929	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081557	C4591001 1008 10081557	16-55	01OCT2020	102930	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081558	C4591001 1008 10081558	16-55	02OCT2020	102932	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10081559	C4591001 1008 10081559	16-55	02OCT2020	102937	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10081567	C4591001 1008 10081567	16-55	06OCT2020	104406	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10081568	C4591001 1008 10081568	16-55	06OCT2020	104407	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10081572	C4591001 1008 10081572	16-55	07OCT2020	104412	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10081573	C4591001 1008 10081573	16-55	08OCT2020	104413	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081574	C4591001 1008 10081574	16-55	09OCT2020	105894	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10081576	C4591001 1008 10081576	16-55	09OCT2020	105895	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081577	C4591001 1008 10081577	16-55	09OCT2020	105903	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081578	C4591001 1008 10081578	16-55	09OCT2020	105904	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081579	C4591001 1008 10081579	16-55	09OCT2020	105991	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10081580	C4591001 1008 10081580	16-55	09OCT2020	105992	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10081581	C4591001 1008 10081581	16-55	09OCT2020	105996	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10081582	C4591001 1008 10081582	16-55	09OCT2020	105999	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081583	C4591001 1008 10081583	16-55	09OCT2020	106112	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081584	C4591001 1008 10081584	16-55	12OCT2020	106114	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10081590	C4591001 1008 10081590	16-55	13OCT2020	106115	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10081594	C4591001 1008 10081594	16-55	13OCT2020	106118	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10081595	C4591001 1008 10081595	16-55	13OCT2020	107166	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081596	C4591001 1008 10081596	16-55	13OCT2020	107167	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081598	C4591001 1008 10081598	16-55	13OCT2020	107170	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081600	C4591001 1008 10081600	16-55	14OCT2020	107174	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10081604	C4591001 1008 10081604	16-55	14OCT2020	107717	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081605	C4591001 1008 10081605	16-55	14OCT2020	107719	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10081606	C4591001 1008 10081606	16-55	14OCT2020	107721	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10081607	C4591001 1008 10081607	16-55	14OCT2020	107727	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081608	C4591001 1008 10081608	16-55	14OCT2020	107777	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10081611	C4591001 1008 10081611	16-55	15OCT2020	107785	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081612	C4591001 1008 10081612	16-55	15OCT2020	107784	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081617	C4591001 1008 10081617	16-55	15OCT2020	107787	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10081618	C4591001 1008 10081618	16-55	15OCT2020	108535	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10081620	C4591001 1008 10081620	16-55	16OCT2020	108540	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081623	C4591001 1008 10081623	16-55	16OCT2020	108542	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10081628	C4591001 1008 10081628	16-55	16OCT2020	108544	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10081629	C4591001 1008 10081629	16-55	16OCT2020	109281	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
10081630	C4591001 1008 10081630	16-55	16OCT2020	109279	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10081631	C4591001 1008 10081631	16-55	16OCT2020	109284	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10081632	C4591001 1008 10081632	16-55	19OCT2020	109285	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10081633	C4591001 1008 10081633	16-55	19OCT2020	110083	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081637	C4591001 1008 10081637	16-55	19OCT2020	110089	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10081638	C4591001 1008 10081638	16-55	19OCT2020	110090	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10081643	C4591001 1008 10081643	16-55	20OCT2020	110092	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081647	C4591001 1008 10081647	16-55	20OCT2020	111080	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10081648	C4591001 1008 10081648	16-55	20OCT2020	111081	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10081649	C4591001 1008 10081649	16-55	20OCT2020	111082	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10081653	C4591001 1008 10081653	16-55	21OCT2020	111550	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10081654	C4591001 1008 10081654	16-55	21OCT2020	111087	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10081655	C4591001 1008 10081655	16-55	21OCT2020	111551	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081657	C4591001 1008 10081657	16-55	21OCT2020	111555	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081659	C4591001 1008 10081659	16-55	21OCT2020	111556	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081663	C4591001 1008 10081663	16-55	21OCT2020	111821	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10081664	C4591001 1008 10081664	16-55	22OCT2020	111825	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10081665	C4591001 1008 10081665	16-55	22OCT2020	111826	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081668	C4591001 1008 10081668	16-55	22OCT2020	111829	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10081669	C4591001 1008 10081669	16-55	22OCT2020	112458	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081670	C4591001 1008 10081670	16-55	22OCT2020	112459	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10081672	C4591001 1008 10081672	16-55	22OCT2020	112465	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10081673	C4591001 1008 10081673	16-55	22OCT2020	112464	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10081674	C4591001 1008 10081674	16-55	22OCT2020	112567	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081675	C4591001 1008 10081675	16-55	23OCT2020	112569	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081676	C4591001 1008 10081676	16-55	23OCT2020	112572	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081677	C4591001 1008 10081677	16-55	23OCT2020	112576	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10081678	C4591001 1008 10081678	16-55	23OCT2020	112890	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081680	C4591001 1008 10081680	16-55	23OCT2020	112895	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10081682	C4591001 1008 10081682	16-55	23OCT2020	112897	Placebo	23OCT2020/ Placebo	11DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081683	C4591001 1008 10081683	16-55	23OCT2020	112899	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10081688	C4591001 1008 10081688	16-55	26OCT2020	113587	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10081692	C4591001 1008 10081692	16-55	26OCT2020	113590	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10081693	C4591001 1008 10081693	16-55	26OCT2020	113591	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081695	C4591001 1008 10081695	16-55	26OCT2020	113765	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10081696	C4591001 1008 10081696	16-55	26OCT2020	113593	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081698	C4591001 1008 10081698	16-55	27OCT2020	113768	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo		
10081700	C4591001 1008 10081700	16-55	27OCT2020	113773	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10081703	C4591001 1008 10081703	16-55	27OCT2020	113774	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10081704	C4591001 1008 10081704	16-55	27OCT2020	114152	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10081706	C4591001 1008 10081706	16-55	27OCT2020	114155	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10081710	C4591001 1008 10081710	16-55	28OCT2020	114159	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10081712	C4591001 1008 10081712	16-55	28OCT2020	114160	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081713	C4591001 1008 10081713	16-55	28OCT2020	114403	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081715	C4591001 1008 10081715	16-55	28OCT2020	114405	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10081716	C4591001 1008 10081716	16-55	28OCT2020	114409	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10081717	C4591001 1008 10081717	16-55	28OCT2020	114412	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10081719	C4591001 1008 10081719	16-55	28OCT2020	114509	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10081720	C4591001 1008 10081720	16-55	28OCT2020	114512	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10081721	C4591001 1008 10081721	16-55	29OCT2020	114513	Placebo	29OCT2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10081722	C4591001 1008 10081722	16-55	29OCT2020	114514	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10081727	C4591001 1008 10081727	16-55	29OCT2020	114798	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10081728	C4591001 1008 10081728	16-55	29OCT2020	114801	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081731	C4591001 1008 10081731	16-55	30OCT2020	114804	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081733	C4591001 1008 10081733	16-55	30OCT2020	114807	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081736	C4591001 1008 10081736	16-55	30OCT2020	115099	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10081737	C4591001 1008 10081737	16-55	30OCT2020	115106	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10081738	C4591001 1008 10081738	16-55	30OCT2020	115100	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10081739	C4591001 1008 10081739	16-55	30OCT2020	115107	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081741	C4591001 1008 10081741	16-55	02NOV2020	115277	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10081742	C4591001 1008 10081742	16-55	03NOV2020	115279	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10081743	C4591001 1008 10081743	16-55	04NOV2020	115283	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
10081744	C4591001 1008 10081744	16-55	04NOV2020	115288	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10081745	C4591001 1008 10081745	16-55	12NOV2020	116194	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081746	C4591001 1008 10081746	16-55	13NOV2020	116195	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10081747	C4591001 1008 10081747	16-55	20NOV2020	116197	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
10081748	C4591001 1008 10081748	16-55	20NOV2020	116199	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10081749	C4591001 1008 10081749	16-55	24NOV2020	116818	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10081750	C4591001 1008 10081750	16-55	24NOV2020	116821	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo		
10081762	C4591001 1008 10081762	16-55	07DEC2020	116822	Placebo	07DEC2020/ Placebo	30DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10081765	C4591001 1008 10081765	16-55	08DEC2020	116823	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10081766	C4591001 1008 10081766	16-55	08DEC2020	117763	Placebo	08DEC2020/ Placebo	29DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10081772	C4591001 1008 10081772	16-55	09DEC2020	117765	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10081776	C4591001 1008 10081776	16-55	09DEC2020	117767	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10081778	C4591001 1008 10081778	16-55	10DEC2020	117771	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	31DEC2020/ BNT162b2 (30 µg)		
10081779	C4591001 1008 10081779	16-55	10DEC2020	117857	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081782	C4591001 1008 10081782	16-55	11DEC2020	117858	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10081783	C4591001 1008 10081783	16-55	11DEC2020	117864	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10081784	C4591001 1008 10081784	16-55	11DEC2020	117868	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	31DEC2020/ BNT162b2 (30 µg)		
10081786	C4591001 1008 10081786	16-55	11DEC2020	117882	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10091030	C4591001 1009 10091030	16-55	02SEP2020	76250	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10091046	C4591001 1009 10091046	16-55	14AUG2020	48242	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10091053	C4591001 1009 10091053	16-55	14AUG2020	50938	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10091056	C4591001 1009 10091056	16-55	17AUG2020	50939	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091058	C4591001 1009 10091058	16-55	17AUG2020	53621	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10091059	C4591001 1009 10091059	16-55	17AUG2020	53625	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10091061	C4591001 1009 10091061	16-55	17AUG2020	53628	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10091063	C4591001 1009 10091063	16-55	18AUG2020	53631	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10091066	C4591001 1009 10091066	16-55	18AUG2020	55508	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10091068	C4591001 1009 10091068	16-55	18AUG2020	55512	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10091070	C4591001 1009 10091070	16-55	19AUG2020	55515	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10091073	C4591001 1009 10091073	16-55	19AUG2020	55516	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10091075	C4591001 1009 10091075	16-55	19AUG2020	57658	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10091079	C4591001 1009 10091079	16-55	20AUG2020	57660	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091080	C4591001 1009 10091080	16-55	20AUG2020	57661	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10091081	C4591001 1009 10091081	16-55	20AUG2020	57662	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10091082	C4591001 1009 10091082	16-55	20AUG2020	58649	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10091084	C4591001 1009 10091084	16-55	20AUG2020	58650	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10091085	C4591001 1009 10091085	16-55	20AUG2020	58657	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10091086	C4591001 1009 10091086	16-55	20AUG2020	58659	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10091088	C4591001 1009 10091088	16-55	20AUG2020	59553	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10091091	C4591001 1009 10091091	16-55	21AUG2020	59555	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10091092	C4591001 1009 10091092	16-55	21AUG2020	59558	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10091095	C4591001 1009 10091095	16-55	21AUG2020	59559	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091097	C4591001 1009 10091097	16-55	24AUG2020	63810	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10091098	C4591001 1009 10091098	16-55	24AUG2020	63811	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10091102	C4591001 1009 10091102	16-55	24AUG2020	63814	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10091103	C4591001 1009 10091103	16-55	24AUG2020	63819	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10091105	C4591001 1009 10091105	16-55	25AUG2020	66044	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10091106	C4591001 1009 10091106	16-55	25AUG2020	66046	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10091108	C4591001 1009 10091108	16-55	25AUG2020	66050	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10091109	C4591001 1009 10091109	16-55	25AUG2020	66051	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10091110	C4591001 1009 10091110	16-55	25AUG2020	67052	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10091112	C4591001 1009 10091112	16-55	26AUG2020	67053	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091113	C4591001 1009 10091113	16-55	26AUG2020	67054	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10091116	C4591001 1009 10091116	16-55	26AUG2020	67060	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10091117	C4591001 1009 10091117	16-55	26AUG2020	69306	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10091118	C4591001 1009 10091118	16-55	27AUG2020	69307	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091124	C4591001 1009 10091124	16-55	27AUG2020	69315	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10091128	C4591001 1009 10091128	16-55	28AUG2020	69316	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10091129	C4591001 1009 10091129	16-55	28AUG2020	72716	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10091131	C4591001 1009 10091131	16-55	28AUG2020	72717	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10091133	C4591001 1009 10091133	16-55	28AUG2020	72718	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
10091134	C4591001 1009 10091134	16-55	31AUG2020	72724	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091138	C4591001 1009 10091138	16-55	31AUG2020	76244	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10091140	C4591001 1009 10091140	16-55	01SEP2020	76246	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10091142	C4591001 1009 10091142	16-55	01SEP2020	76247	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10091147	C4591001 1009 10091147	16-55	02SEP2020	79001	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10091158	C4591001 1009 10091158	16-55	08SEP2020	79002	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10091159	C4591001 1009 10091159	16-55	08SEP2020	79005	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10091163	C4591001 1009 10091163	16-55	09SEP2020	79006	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10091164	C4591001 1009 10091164	16-55	10SEP2020	86589	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10091166	C4591001 1009 10091166	16-55	10SEP2020	86590	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091171	C4591001 1009 10091171	16-55	11SEP2020	86595	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091172	C4591001 1009 10091172	16-55	11SEP2020	86596	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10091174	C4591001 1009 10091174	16-55	14SEP2020	89841	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091175	C4591001 1009 10091175	16-55	14SEP2020	89846	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10091177	C4591001 1009 10091177	16-55	15SEP2020	89847	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10091178	C4591001 1009 10091178	16-55	15SEP2020	89848	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10091183	C4591001 1009 10091183	16-55	17SEP2020	92897	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10091184	C4591001 1009 10091184	16-55	18SEP2020	92898	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10091185	C4591001 1009 10091185	16-55	18SEP2020	92902	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10091186	C4591001 1009 10091186	16-55	21SEP2020	92908	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10091187	C4591001 1009 10091187	16-55	21SEP2020	95765	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091188	C4591001 1009 10091188	16-55	21SEP2020	95767	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10091192	C4591001 1009 10091192	16-55	24SEP2020	95769	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10091194	C4591001 1009 10091194	16-55	24SEP2020	95775	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10091197	C4591001 1009 10091197	16-55	28SEP2020	101600	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10091198	C4591001 1009 10091198	16-55	28SEP2020	101601	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10091200	C4591001 1009 10091200	16-55	29SEP2020	101604	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10091201	C4591001 1009 10091201	16-55	13OCT2020	101607	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091202	C4591001 1009 10091202	16-55	13OCT2020	107262	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091203	C4591001 1009 10091203	16-55	15OCT2020	107269	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10091206	C4591001 1009 10091206	16-55	15OCT2020	107270	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091207	C4591001 1009 10091207	16-55	15OCT2020	107271	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
10091210	C4591001 1009 10091210	16-55	16OCT2020	108980	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10091211	C4591001 1009 10091211	16-55	16OCT2020	108983	Placebo	16OCT2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
10091214	C4591001 1009 10091214	16-55	16OCT2020	108984	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10091217	C4591001 1009 10091217	16-55	16OCT2020	108985	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10091219	C4591001 1009 10091219	16-55	16OCT2020	109074	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10091222	C4591001 1009 10091222	16-55	19OCT2020	109075	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo		
10091224	C4591001 1009 10091224	16-55	19OCT2020	109076	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10091225	C4591001 1009 10091225	16-55	20OCT2020	109081	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091228	C4591001 1009 10091228	16-55	20OCT2020	111210	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091230	C4591001 1009 10091230	16-55	20OCT2020	111213	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10091232	C4591001 1009 10091232	16-55	21OCT2020	111216	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10091235	C4591001 1009 10091235	16-55	21OCT2020	111217	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
10091236	C4591001 1009 10091236	16-55	21OCT2020	111799	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10091239	C4591001 1009 10091239	16-55	21OCT2020	111803	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10091241	C4591001 1009 10091241	16-55	21OCT2020	111805	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10091242	C4591001 1009 10091242	16-55	22OCT2020	111807	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10091243	C4591001 1009 10091243	16-55	22OCT2020	112520	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10091244	C4591001 1009 10091244	16-55	22OCT2020	112521	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10091252	C4591001 1009 10091252	16-55	23OCT2020	112522	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091253	C4591001 1009 10091253	16-55	26OCT2020	112525	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10091254	C4591001 1009 10091254	16-55	26OCT2020	113802	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10091255	C4591001 1009 10091255	16-55	26OCT2020	113805	Placebo	26OCT2020/ Placebo	23NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091256	C4591001 1009 10091256	16-55	27OCT2020	113808	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10091257	C4591001 1009 10091257	16-55	27OCT2020	113810	Placebo	27OCT2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	
10091258	C4591001 1009 10091258	16-55	03NOV2020	115462	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10091259	C4591001 1009 10091259	16-55	03NOV2020	115463	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10091260	C4591001 1009 10091260	16-55	11NOV2020	115465	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
10091261	C4591001 1009 10091261	16-55	11NOV2020	115467	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo		
10091262	C4591001 1009 10091262	16-55	13NOV2020	116238	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091263	C4591001 1009 10091263	16-55	30NOV2020	116242	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091264	C4591001 1009 10091264	16-55	30NOV2020	116243	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10091271	C4591001 1009 10091271	16-55	01DEC2020	116248	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10091276	C4591001 1009 10091276	16-55	03DEC2020	117306	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10091278	C4591001 1009 10091278	16-55	03DEC2020	117308	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10091279	C4591001 1009 10091279	16-55	03DEC2020	117310	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10091285	C4591001 1009 10091285	16-55	03DEC2020	117313	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10091286	C4591001 1009 10091286	16-55	04DEC2020	117510	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10091290	C4591001 1009 10091290	16-55	04DEC2020	117513	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10091291	C4591001 1009 10091291	16-55	04DEC2020	117517	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10091299	C4591001 1009 10091299	16-55	07DEC2020	117520	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10111042	C4591001 1011 10111042	16-55	14AUG2020	50282	Placebo	14AUG2020/ Placebo	08SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10111043	C4591001 1011 10111043	16-55	17AUG2020	50284	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10111044	C4591001 1011 10111044	16-55	17AUG2020	52421	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10111046	C4591001 1011 10111046	16-55	17AUG2020	52425	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10111052	C4591001 1011 10111052	16-55	18AUG2020	52428	Placebo	18AUG2020/ Placebo	18SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10111053	C4591001 1011 10111053	16-55	18AUG2020	52432	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111070	C4591001 1011 10111070	16-55	19AUG2020	56777	Placebo	19AUG2020/ Placebo	01OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111071	C4591001 1011 10111071	16-55	20AUG2020	56778	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10111072	C4591001 1011 10111072	16-55	20AUG2020	56784	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111074	C4591001 1011 10111074	16-55	20AUG2020	56787	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10111077	C4591001 1011 10111077	16-55	20AUG2020	59742	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10111078	C4591001 1011 10111078	16-55	20AUG2020	59744	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111079	C4591001 1011 10111079	16-55	20AUG2020	59746	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10111082	C4591001 1011 10111082	16-55	21AUG2020	59747	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111087	C4591001 1011 10111087	16-55	24AUG2020	63546	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10111088	C4591001 1011 10111088	16-55	24AUG2020	63547	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10111089	C4591001 1011 10111089	16-55	24AUG2020	63551	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10111090	C4591001 1011 10111090	16-55	24AUG2020	63554	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10111091	C4591001 1011 10111091	16-55	25AUG2020	65145	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111092	C4591001 1011 10111092	16-55	25AUG2020	65146	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10111093	C4591001 1011 10111093	16-55	25AUG2020	65151	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10111094	C4591001 1011 10111094	16-55	25AUG2020	65152	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111095	C4591001 1011 10111095	16-55	25AUG2020	66281	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10111097	C4591001 1011 10111097	16-55	25AUG2020	66283	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111098	C4591001 1011 10111098	16-55	26AUG2020	66289	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10111102	C4591001 1011 10111102	16-55	26AUG2020	66292	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10111104	C4591001 1011 10111104	16-55	26AUG2020	68070	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10111106	C4591001 1011 10111106	16-55	27AUG2020	68073	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111107	C4591001 1011 10111107	16-55	27AUG2020	68075	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111111	C4591001 1011 10111111	16-55	27AUG2020	68078	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10111115	C4591001 1011 10111115	16-55	27AUG2020	71009	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10111116	C4591001 1011 10111116	16-55	27AUG2020	71014	Placebo	27AUG2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111117	C4591001 1011 10111117	16-55	27AUG2020	71016	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10111118	C4591001 1011 10111118	16-55	28AUG2020	71017	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10111119	C4591001 1011 10111119	16-55	28AUG2020	71561	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111122	C4591001 1011 10111122	16-55	28AUG2020	71565	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10111123	C4591001 1011 10111123	16-55	28AUG2020	71566	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10111124	C4591001 1011 10111124	16-55	28AUG2020	71571	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10111125	C4591001 1011 10111125	16-55	28AUG2020	72355	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111129	C4591001 1011 10111129	16-55	31AUG2020	72356	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10111130	C4591001 1011 10111130	16-55	31AUG2020	72357	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10111134	C4591001 1011 10111134	16-55	01SEP2020	72363	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10111135	C4591001 1011 10111135	16-55	01SEP2020	76374	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10111141	C4591001 1011 10111141	16-55	01SEP2020	76376	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10111142	C4591001 1011 10111142	16-55	01SEP2020	76378	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10111143	C4591001 1011 10111143	16-55	02SEP2020	76379	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10111144	C4591001 1011 10111144	16-55	02SEP2020	77864	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10111148	C4591001 1011 10111148	16-55	02SEP2020	77867	Placebo	02SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111150	C4591001 1011 10111150	16-55	02SEP2020	77869	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111151	C4591001 1011 10111151	16-55	02SEP2020	77871	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10111154	C4591001 1011 10111154	16-55	03SEP2020	79578	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10111159	C4591001 1011 10111159	16-55	03SEP2020	79581	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111164	C4591001 1011 10111164	16-55	03SEP2020	79586	Placebo	03SEP2020/ Placebo	01OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10111166	C4591001 1011 10111166	16-55	03SEP2020	79588	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10111168	C4591001 1011 10111168	16-55	16SEP2020	91495	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10111169	C4591001 1011 10111169	16-55	06OCT2020	91500	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10111170	C4591001 1011 10111170	16-55	06OCT2020	91502	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10111173	C4591001 1011 10111173	16-55	07OCT2020	91503	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111174	C4591001 1011 10111174	16-55	07OCT2020	104711	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111175	C4591001 1011 10111175	16-55	13OCT2020	105540	Placebo	13OCT2020/ Placebo	30OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10111176	C4591001 1011 10111176	16-55	07OCT2020	104712	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10111179	C4591001 1011 10111179	16-55	08OCT2020	104714	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10111182	C4591001 1011 10111182	16-55	08OCT2020	104716	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111183	C4591001 1011 10111183	16-55	08OCT2020	105533	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10111184	C4591001 1011 10111184	16-55	08OCT2020	105536	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10111186	C4591001 1011 10111186	16-55	27OCT2020	112924	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10111190	C4591001 1011 10111190	16-55	13OCT2020	105542	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10111193	C4591001 1011 10111193	16-55	14OCT2020	107442	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10111195	C4591001 1011 10111195	16-55	14OCT2020	107444	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111197	C4591001 1011 10111197	16-55	14OCT2020	107450	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10111199	C4591001 1011 10111199	16-55	15OCT2020	107452	Placebo	15OCT2020/ Placebo	12NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10111203	C4591001 1011 10111203	16-55	15OCT2020	108137	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10111210	C4591001 1011 10111210	16-55	15OCT2020	108138	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10111211	C4591001 1011 10111211	16-55	26OCT2020	112915	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10111212	C4591001 1011 10111212	16-55	16OCT2020	108141	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10111213	C4591001 1011 10111213	16-55	16OCT2020	108143	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10111214	C4591001 1011 10111214	16-55	19OCT2020	110096	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111215	C4591001 1011 10111215	16-55	19OCT2020	110094	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10111216	C4591001 1011 10111216	16-55	19OCT2020	110098	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111219	C4591001 1011 10111219	16-55	20OCT2020	110099	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10111220	C4591001 1011 10111220	16-55	20OCT2020	111221	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10111222	C4591001 1011 10111222	16-55	21OCT2020	111226	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111224	C4591001 1011 10111224	16-55	21OCT2020	111227	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10111227	C4591001 1011 10111227	16-55	23OCT2020	112913	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10111228	C4591001 1011 10111228	16-55	23OCT2020	111231	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10111232	C4591001 1011 10111232	16-55	27OCT2020	112916	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10111233	C4591001 1011 10111233	16-55	29OCT2020	114594	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10111234	C4591001 1011 10111234	16-55	29OCT2020	114597	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10111235	C4591001 1011 10111235	16-55	30OCT2020	114601	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10111236	C4591001 1011 10111236	16-55	30OCT2020	114604	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10111237	C4591001 1011 10111237	16-55	30OCT2020	115027	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10121043	C4591001 1012 10121043	16-55	18AUG2020	51059	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121046	C4591001 1012 10121046	16-55	19AUG2020	51061	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10121051	C4591001 1012 10121051	16-55	20AUG2020	51062	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10121053	C4591001 1012 10121053	16-55	20AUG2020	58915	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10121055	C4591001 1012 10121055	16-55	20AUG2020	58918	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	23JAN2021/ BNT162b2 (30 µg)
10121058	C4591001 1012 10121058	16-55	21AUG2020	58919	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10121059	C4591001 1012 10121059	16-55	21AUG2020	58924	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10121061	C4591001 1012 10121061	16-55	24AUG2020	63906	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121065	C4591001 1012 10121065	16-55	24AUG2020	63910	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10121066	C4591001 1012 10121066	16-55	25AUG2020	63914	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10121072	C4591001 1012 10121072	16-55	26AUG2020	63916	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
10121073	C4591001 1012 10121073	16-55	26AUG2020	68274	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10121074	C4591001 1012 10121074	16-55	26AUG2020	68277	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10121076	C4591001 1012 10121076	16-55	26AUG2020	68280	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10121078	C4591001 1012 10121078	16-55	27AUG2020	68281	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10121079	C4591001 1012 10121079	16-55	27AUG2020	70481	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10121082	C4591001 1012 10121082	16-55	27AUG2020	70486	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10121083	C4591001 1012 10121083	16-55	27AUG2020	70487	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121085	C4591001 1012 10121085	16-55	28AUG2020	70492	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10121087	C4591001 1012 10121087	16-55	28AUG2020	72953	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10121089	C4591001 1012 10121089	16-55	28AUG2020	72957	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10121090	C4591001 1012 10121090	16-55	28AUG2020	72959	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10121091	C4591001 1012 10121091	16-55	31AUG2020	72964	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121092	C4591001 1012 10121092	16-55	31AUG2020	75138	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121095	C4591001 1012 10121095	16-55	31AUG2020	75144	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10121096	C4591001 1012 10121096	16-55	31AUG2020	75145	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10121101	C4591001 1012 10121101	16-55	01SEP2020	75146	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10121102	C4591001 1012 10121102	16-55	01SEP2020	76842	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121103	C4591001 1012 10121103	16-55	01SEP2020	76845	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ Placebo		
10121104	C4591001 1012 10121104	16-55	01SEP2020	76849	Placebo	01SEP2020/ Placebo	02OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10121105	C4591001 1012 10121105	16-55	01SEP2020	76848	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10121107	C4591001 1012 10121107	16-55	01SEP2020	77444	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10121108	C4591001 1012 10121108	16-55	01SEP2020	77446	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10121110	C4591001 1012 10121110	16-55	01SEP2020	77450	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
10121111	C4591001 1012 10121111	16-55	02SEP2020	77452	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121116	C4591001 1012 10121116	16-55	02SEP2020	79291	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10121117	C4591001 1012 10121117	16-55	02SEP2020	79290	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10121118	C4591001 1012 10121118	16-55	02SEP2020	79296	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121119	C4591001 1012 10121119	16-55	02SEP2020	79300	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10121121	C4591001 1012 10121121	16-55	02SEP2020	79471	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10121124	C4591001 1012 10121124	16-55	03SEP2020	79472	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10121130	C4591001 1012 10121130	16-55	03SEP2020	79477	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	23JAN2021/ BNT162b2 (30 µg)
10121131	C4591001 1012 10121131	16-55	04SEP2020	79478	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10121132	C4591001 1012 10121132	16-55	04SEP2020	81703	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10121133	C4591001 1012 10121133	16-55	04SEP2020	81706	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10121134	C4591001 1012 10121134	16-55	04SEP2020	81707	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10121136	C4591001 1012 10121136	16-55	04SEP2020	81709	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10121137	C4591001 1012 10121137	16-55	04SEP2020	82553	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121138	C4591001 1012 10121138	16-55	05SEP2020	82559	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo		
10121141	C4591001 1012 10121141	16-55	05SEP2020	82560	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10121143	C4591001 1012 10121143	16-55	05SEP2020	82563	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10121144	C4591001 1012 10121144	16-55	05SEP2020	82878	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10121145	C4591001 1012 10121145	16-55	05SEP2020	82881	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10121146	C4591001 1012 10121146	16-55	05SEP2020	82883	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10121151	C4591001 1012 10121151	16-55	08SEP2020	83975	Placebo	08SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	
10121153	C4591001 1012 10121153	16-55	08SEP2020	84197	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10121154	C4591001 1012 10121154	16-55	08SEP2020	84198	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10121155	C4591001 1012 10121155	16-55	08SEP2020	84202	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121156	C4591001 1012 10121156	16-55	09SEP2020	84203	Placebo	09SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10121157	C4591001 1012 10121157	16-55	11SEP2020	88155	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10121158	C4591001 1012 10121158	16-55	09SEP2020	85506	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10121162	C4591001 1012 10121162	16-55	09SEP2020	85509	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10121163	C4591001 1012 10121163	16-55	09SEP2020	85512	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)			
10121164	C4591001 1012 10121164	16-55	10SEP2020	85515	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10121166	C4591001 1012 10121166	16-55	10SEP2020	86849	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
10121172	C4591001 1012 10121172	16-55	10SEP2020	86852	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10121173	C4591001 1012 10121173	16-55	10SEP2020	86850	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10121174	C4591001 1012 10121174	16-55	10SEP2020	86859	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10121178	C4591001 1012 10121178	16-55	11SEP2020	88145	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10121180	C4591001 1012 10121180	16-55	11SEP2020	88146	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10121181	C4591001 1012 10121181	16-55	11SEP2020	88147	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10121182	C4591001 1012 10121182	16-55	11SEP2020	88517	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10121183	C4591001 1012 10121183	16-55	11SEP2020	88519	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10121185	C4591001 1012 10121185	16-55	11SEP2020	88521	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		
10121187	C4591001 1012 10121187	16-55	11SEP2020	88525	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10121188	C4591001 1012 10121188	16-55	11SEP2020	88926	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10131017	C4591001 1013 10131017	16-55	30JUL2020	40132	Placebo				
10131027	C4591001 1013 10131027	16-55	17AUG2020	52443	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131112	C4591001 1013 10131112	16-55	02SEP2020	76876	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131134	C4591001 1013 10131134	16-55	18AUG2020	52895	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131187	C4591001 1013 10131187	16-55	17AUG2020	49015	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131188	C4591001 1013 10131188	16-55	17AUG2020	49017	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131190	C4591001 1013 10131190	16-55	17AUG2020	49018	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131195	C4591001 1013 10131195	16-55	17AUG2020	52439	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131196	C4591001 1013 10131196	16-55	17AUG2020	52435	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131197	C4591001 1013 10131197	16-55	17AUG2020	52437	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10131199	C4591001 1013 10131199	16-55	17AUG2020	52613	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131200	C4591001 1013 10131200	16-55	17AUG2020	52614	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131204	C4591001 1013 10131204	16-55	17AUG2020	52622	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131205	C4591001 1013 10131205	16-55	17AUG2020	52620	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131207	C4591001 1013 10131207	16-55	17AUG2020	52890	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131209	C4591001 1013 10131209	16-55	18AUG2020	54017	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131210	C4591001 1013 10131210	16-55	18AUG2020	54020	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10131211	C4591001 1013 10131211	16-55	18AUG2020	52898	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131214	C4591001 1013 10131214	16-55	18AUG2020	54022	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131215	C4591001 1013 10131215	16-55	18AUG2020	54026	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10131216	C4591001 1013 10131216	16-55	18AUG2020	52900	Placebo	18AUG2020/ Placebo			
10131218	C4591001 1013 10131218	16-55	18AUG2020	54118	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131219	C4591001 1013 10131219	16-55	18AUG2020	54116	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131220	C4591001 1013 10131220	16-55	18AUG2020	54114	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131221	C4591001 1013 10131221	16-55	18AUG2020	54117	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131223	C4591001 1013 10131223	16-55	18AUG2020	54281	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131224	C4591001 1013 10131224	16-55	18AUG2020	54289	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10131225	C4591001 1013 10131225	16-55	18AUG2020	54288	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131228	C4591001 1013 10131228	16-55	19AUG2020	54292	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131229	C4591001 1013 10131229	16-55	19AUG2020	55842	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
10131231	C4591001 1013 10131231	16-55	19AUG2020	55845	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131237	C4591001 1013 10131237	16-55	19AUG2020	55849	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131238	C4591001 1013 10131238	16-55	19AUG2020	55846	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
10131239	C4591001 1013 10131239	16-55	19AUG2020	56085	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131241	C4591001 1013 10131241	16-55	19AUG2020	56086	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131245	C4591001 1013 10131245	16-55	19AUG2020	56088	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131246	C4591001 1013 10131246	16-55	19AUG2020	56092	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131250	C4591001 1013 10131250	16-55	20AUG2020	58019	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131251	C4591001 1013 10131251	16-55	20AUG2020	58014	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10131252	C4591001 1013 10131252	16-55	20AUG2020	58018	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131254	C4591001 1013 10131254	16-55	20AUG2020	58021	Placebo	20AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131255	C4591001 1013 10131255	16-55	20AUG2020	58170	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131256	C4591001 1013 10131256	16-55	20AUG2020	58172	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131258	C4591001 1013 10131258	16-55	20AUG2020	58177	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131259	C4591001 1013 10131259	16-55	20AUG2020	58179	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131263	C4591001 1013 10131263	16-55	20AUG2020	58558	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10131264	C4591001 1013 10131264	16-55	20AUG2020	58563	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131266	C4591001 1013 10131266	16-55	20AUG2020	58561	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10131267	C4591001 1013 10131267	16-55	20AUG2020	58688	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131268	C4591001 1013 10131268	16-55	20AUG2020	58690	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131269	C4591001 1013 10131269	16-55	20AUG2020	58564	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131271	C4591001 1013 10131271	16-55	24AUG2020	58691	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131275	C4591001 1013 10131275	16-55	24AUG2020	63462	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131276	C4591001 1013 10131276	16-55	24AUG2020	58695	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131280	C4591001 1013 10131280	16-55	24AUG2020	63464	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131281	C4591001 1013 10131281	16-55	24AUG2020	63467	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10131283	C4591001 1013 10131283	16-55	24AUG2020	63465	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131285	C4591001 1013 10131285	16-55	24AUG2020	63617	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131287	C4591001 1013 10131287	16-55	24AUG2020	63618	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131288	C4591001 1013 10131288	16-55	24AUG2020	63624	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131290	C4591001 1013 10131290	16-55	24AUG2020	63626	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131291	C4591001 1013 10131291	16-55	24AUG2020	63801	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131292	C4591001 1013 10131292	16-55	25AUG2020	63802	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131293	C4591001 1013 10131293	16-55	25AUG2020	63804	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131296	C4591001 1013 10131296	16-55	25AUG2020	63808	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131299	C4591001 1013 10131299	16-55	25AUG2020	65537	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131302	C4591001 1013 10131302	16-55	25AUG2020	65547	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131303	C4591001 1013 10131303	16-55	25AUG2020	65804	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10131304	C4591001 1013 10131304	16-55	25AUG2020	65543	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131305	C4591001 1013 10131305	16-55	25AUG2020	65548	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
10131307	C4591001 1013 10131307	16-55	25AUG2020	65899	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	
10131308	C4591001 1013 10131308	16-55	25AUG2020	65839	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131309	C4591001 1013 10131309	16-55	25AUG2020	65900	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131311	C4591001 1013 10131311	16-55	25AUG2020	65903	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131312	C4591001 1013 10131312	16-55	25AUG2020	65904	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131313	C4591001 1013 10131313	16-55	26AUG2020	67248	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131315	C4591001 1013 10131315	16-55	26AUG2020	67244	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10131316	C4591001 1013 10131316	16-55	26AUG2020	67242	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131317	C4591001 1013 10131317	16-55	26AUG2020	67321	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131318	C4591001 1013 10131318	16-55	26AUG2020	67316	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131319	C4591001 1013 10131319	16-55	26AUG2020	67251	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131321	C4591001 1013 10131321	16-55	26AUG2020	67323	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131322	C4591001 1013 10131322	16-55	26AUG2020	67322	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131325	C4591001 1013 10131325	16-55	26AUG2020	67505	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131332	C4591001 1013 10131332	16-55	26AUG2020	67506	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10131338	C4591001 1013 10131338	16-55	27AUG2020	67514	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10131339	C4591001 1013 10131339	16-55	27AUG2020	67516	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131340	C4591001 1013 10131340	16-55	27AUG2020	69813	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131343	C4591001 1013 10131343	16-55	27AUG2020	69815	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131348	C4591001 1013 10131348	16-55	27AUG2020	69818	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10131349	C4591001 1013 10131349	16-55	27AUG2020	70088	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10131351	C4591001 1013 10131351	16-55	27AUG2020	69819	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131352	C4591001 1013 10131352	16-55	27AUG2020	70089	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10131353	C4591001 1013 10131353	16-55	27AUG2020	70093	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131355	C4591001 1013 10131355	16-55	31AUG2020	70096	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131357	C4591001 1013 10131357	16-55	31AUG2020	74730	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131361	C4591001 1013 10131361	16-55	31AUG2020	74731	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131364	C4591001 1013 10131364	16-55	31AUG2020	74739	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10131365	C4591001 1013 10131365	16-55	31AUG2020	74921	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131366	C4591001 1013 10131366	16-55	31AUG2020	74737	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131370	C4591001 1013 10131370	16-55	31AUG2020	74925	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131371	C4591001 1013 10131371	16-55	31AUG2020	74926	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131373	C4591001 1013 10131373	16-55	31AUG2020	75188	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10131375	C4591001 1013 10131375	16-55	31AUG2020	74931	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10131376	C4591001 1013 10131376	16-55	09SEP2020	84956	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131377	C4591001 1013 10131377	16-55	31AUG2020	75191	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131379	C4591001 1013 10131379	16-55	01SEP2020	75194	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131381	C4591001 1013 10131381	16-55	01SEP2020	75195	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131383	C4591001 1013 10131383	16-55	01SEP2020	76399	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131385	C4591001 1013 10131385	16-55	01SEP2020	76400	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131388	C4591001 1013 10131388	16-55	01SEP2020	76403	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131389	C4591001 1013 10131389	16-55	01SEP2020	76717	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131391	C4591001 1013 10131391	16-55	01SEP2020	76404	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131394	C4591001 1013 10131394	16-55	01SEP2020	76718	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131395	C4591001 1013 10131395	16-55	01SEP2020	76719	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131396	C4591001 1013 10131396	16-55	01SEP2020	76720	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131397	C4591001 1013 10131397	16-55	01SEP2020	76865	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131398	C4591001 1013 10131398	16-55	02SEP2020	76867	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
10131400	C4591001 1013 10131400	16-55	02SEP2020	77937	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131401	C4591001 1013 10131401	16-55	02SEP2020	76875	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131403	C4591001 1013 10131403	16-55	02SEP2020	77941	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10131405	C4591001 1013 10131405	16-55	02SEP2020	77944	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131406	C4591001 1013 10131406	16-55	02SEP2020	77942	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131407	C4591001 1013 10131407	16-55	02SEP2020	78185	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131408	C4591001 1013 10131408	16-55	02SEP2020	78193	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10131409	C4591001 1013 10131409	16-55	02SEP2020	78187	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131411	C4591001 1013 10131411	16-55	02SEP2020	78269	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131412	C4591001 1013 10131412	16-55	02SEP2020	78272	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10131413	C4591001 1013 10131413	16-55	02SEP2020	78196	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131416	C4591001 1013 10131416	16-55	02SEP2020	78347	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131417	C4591001 1013 10131417	16-55	02SEP2020	78275	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131418	C4591001 1013 10131418	16-55	02SEP2020	78276	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131419	C4591001 1013 10131419	16-55	02SEP2020	78349	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131420	C4591001 1013 10131420	16-55	02SEP2020	78343	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131421	C4591001 1013 10131421	16-55	02SEP2020	78345	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131422	C4591001 1013 10131422	16-55	03SEP2020	79590	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131423	C4591001 1013 10131423	16-55	03SEP2020	79597	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131424	C4591001 1013 10131424	16-55	03SEP2020	79593	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131425	C4591001 1013 10131425	16-55	03SEP2020	79641	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131426	C4591001 1013 10131426	16-55	03SEP2020	79595	Placebo	03SEP2020/ Placebo			
10131427	C4591001 1013 10131427	16-55	03SEP2020	79645	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131430	C4591001 1013 10131430	16-55	03SEP2020	79646	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131432	C4591001 1013 10131432	16-55	03SEP2020	79648	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131436	C4591001 1013 10131436	16-55	03SEP2020	79856	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10131437	C4591001 1013 10131437	16-55	03SEP2020	79859	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131438	C4591001 1013 10131438	16-55	03SEP2020	79864	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10131439	C4591001 1013 10131439	16-55	03SEP2020	79860	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
10131440	C4591001 1013 10131440	16-55	03SEP2020	80011	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131441	C4591001 1013 10131441	16-55	03SEP2020	80014	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131442	C4591001 1013 10131442	16-55	03SEP2020	80015	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10131444	C4591001 1013 10131444	16-55	03SEP2020	80020	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10131445	C4591001 1013 10131445	16-55	08SEP2020	83393	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131446	C4591001 1013 10131446	16-55	08SEP2020	83311	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131447	C4591001 1013 10131447	16-55	08SEP2020	83315	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131448	C4591001 1013 10131448	16-55	08SEP2020	83318	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131449	C4591001 1013 10131449	16-55	08SEP2020	83317	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131451	C4591001 1013 10131451	16-55	08SEP2020	83403	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131452	C4591001 1013 10131452	16-55	08SEP2020	83402	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131454	C4591001 1013 10131454	16-55	08SEP2020	83397	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10131458	C4591001 1013 10131458	16-55	08SEP2020	83516	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131459	C4591001 1013 10131459	16-55	08SEP2020	83515	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131463	C4591001 1013 10131463	16-55	08SEP2020	83518	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131464	C4591001 1013 10131464	16-55	08SEP2020	83520	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131467	C4591001 1013 10131467	16-55	08SEP2020	83711	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131468	C4591001 1013 10131468	16-55	08SEP2020	83714	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131469	C4591001 1013 10131469	16-55	08SEP2020	83715	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131470	C4591001 1013 10131470	16-55	08SEP2020	83709	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
10131471	C4591001 1013 10131471	16-55	08SEP2020	83790	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131472	C4591001 1013 10131472	16-55	09SEP2020	83798	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131473	C4591001 1013 10131473	16-55	09SEP2020	83799	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131474	C4591001 1013 10131474	16-55	09SEP2020	83795	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131475	C4591001 1013 10131475	16-55	09SEP2020	84846	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131476	C4591001 1013 10131476	16-55	09SEP2020	84852	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131477	C4591001 1013 10131477	16-55	09SEP2020	84850	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131478	C4591001 1013 10131478	16-55	09SEP2020	84849	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10131484	C4591001 1013 10131484	16-55	09SEP2020	84955	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131486	C4591001 1013 10131486	16-55	09SEP2020	84959	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131487	C4591001 1013 10131487	16-55	09SEP2020	84957	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131492	C4591001 1013 10131492	16-55	09SEP2020	85230	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131493	C4591001 1013 10131493	16-55	09SEP2020	85233	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10131498	C4591001 1013 10131498	16-55	09SEP2020	85235	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131499	C4591001 1013 10131499	16-55	10SEP2020	86408	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131500	C4591001 1013 10131500	16-55	10SEP2020	86405	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131501	C4591001 1013 10131501	16-55	10SEP2020	85240	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10131502	C4591001 1013 10131502	16-55	10SEP2020	86409	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10131503	C4591001 1013 10131503	16-55	10SEP2020	86477	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131504	C4591001 1013 10131504	16-55	10SEP2020	86416	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131507	C4591001 1013 10131507	16-55	10SEP2020	86480	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10131513	C4591001 1013 10131513	16-55	10SEP2020	86487	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131514	C4591001 1013 10131514	16-55	10SEP2020	86488	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10131515	C4591001 1013 10131515	16-55	10SEP2020	86813	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10131518	C4591001 1013 10131518	16-55	10SEP2020	86820	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131522	C4591001 1013 10131522	16-55	14SEP2020	86821	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131524	C4591001 1013 10131524	16-55	14SEP2020	86824	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131526	C4591001 1013 10131526	16-55	14SEP2020	89601	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131529	C4591001 1013 10131529	16-55	14SEP2020	89604	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131530	C4591001 1013 10131530	16-55	15SEP2020	89607	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
10131531	C4591001 1013 10131531	16-55	15SEP2020	89605	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131532	C4591001 1013 10131532	16-55	15SEP2020	90155	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131533	C4591001 1013 10131533	16-55	15SEP2020	90153	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131534	C4591001 1013 10131534	16-55	15SEP2020	90149	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131535	C4591001 1013 10131535	16-55	15SEP2020	90152	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131538	C4591001 1013 10131538	16-55	15SEP2020	90213	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131541	C4591001 1013 10131541	16-55	15SEP2020	90218	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10131542	C4591001 1013 10131542	16-55	15SEP2020	90214	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131544	C4591001 1013 10131544	16-55	15SEP2020	90437	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10131545	C4591001 1013 10131545	16-55	15SEP2020	90440	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131546	C4591001 1013 10131546	16-55	15SEP2020	90220	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131550	C4591001 1013 10131550	16-55	16SEP2020	90446	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10131552	C4591001 1013 10131552	16-55	16SEP2020	90992	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10131553	C4591001 1013 10131553	16-55	16SEP2020	90448	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131556	C4591001 1013 10131556	16-55	16SEP2020	90997	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131557	C4591001 1013 10131557	16-55	16SEP2020	90998	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10131559	C4591001 1013 10131559	16-55	16SEP2020	91000	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10131562	C4591001 1013 10131562	16-55	16SEP2020	91220	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131563	C4591001 1013 10131563	16-55	16SEP2020	91223	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131564	C4591001 1013 10131564	16-55	16SEP2020	91222	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10131565	C4591001 1013 10131565	16-55	16SEP2020	91226	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131567	C4591001 1013 10131567	16-55	17SEP2020	92030	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131568	C4591001 1013 10131568	16-55	17SEP2020	92021	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131569	C4591001 1013 10131569	16-55	17SEP2020	92022	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131570	C4591001 1013 10131570	16-55	17SEP2020	92023	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131571	C4591001 1013 10131571†	16-55	17SEP2020	92110	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131572	C4591001 1013 10131572†	16-55	17SEP2020	92111	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10131573	C4591001 1013 10131573	16-55	17SEP2020	92112	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
10131575	C4591001 1013 10131575	16-55	17SEP2020	92321	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131576	C4591001 1013 10131576	16-55	17SEP2020	92114	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		
10131580	C4591001 1013 10131580	16-55	17SEP2020	92325	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10131581	C4591001 1013 10131581	16-55	17SEP2020	92329	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131582	C4591001 1013 10131582	16-55	17SEP2020	92331	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131585	C4591001 1013 10131585	16-55	17SEP2020	92465	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10131586	C4591001 1013 10131586	16-55	17SEP2020	92468	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131587	C4591001 1013 10131587	16-55	21SEP2020	94689	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10131588	C4591001 1013 10131588	16-55	21SEP2020	92470	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131589	C4591001 1013 10131589	16-55	21SEP2020	92476	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131591	C4591001 1013 10131591	16-55	21SEP2020	94688	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131592	C4591001 1013 10131592	16-55	21SEP2020	94693	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10131593	C4591001 1013 10131593	16-55	21SEP2020	94762	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10131594	C4591001 1013 10131594	16-55	21SEP2020	94760	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10131595	C4591001 1013 10131595	16-55	21SEP2020	94696	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131597	C4591001 1013 10131597	16-55	21SEP2020	94764	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10131598	C4591001 1013 10131598	16-55	21SEP2020	94944	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131599	C4591001 1013 10131599	16-55	21SEP2020	94768	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131600	C4591001 1013 10131600	16-55	21SEP2020	94943	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131601	C4591001 1013 10131601	16-55	21SEP2020	94937	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10131603	C4591001 1013 10131603	16-55	22SEP2020	94948	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131605	C4591001 1013 10131605	16-55	22SEP2020	96234	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10131606	C4591001 1013 10131606	16-55	22SEP2020	96241	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10131607	C4591001 1013 10131607	16-55	22SEP2020	96240	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10131608	C4591001 1013 10131608	16-55	22SEP2020	96236	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131611	C4591001 1013 10131611	16-55	22SEP2020	96368	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131612	C4591001 1013 10131612	16-55	22SEP2020	96370	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131613	C4591001 1013 10131613	16-55	23SEP2020	96373	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10131614	C4591001 1013 10131614†	16-55	23SEP2020	97433	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10131616	C4591001 1013 10131616	16-55	23SEP2020	96375	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131619	C4591001 1013 10131619	16-55	23SEP2020	97435	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10131621	C4591001 1013 10131621	16-55	24SEP2020	97442	Placebo	24SEP2020/ Placebo	19OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131622	C4591001 1013 10131622	16-55	24SEP2020	97443	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10131624	C4591001 1013 10131624	16-55	24SEP2020	98729	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131625	C4591001 1013 10131625	16-55	24SEP2020	98730	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131626	C4591001 1013 10131626	16-55	24SEP2020	98731	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10131628	C4591001 1013 10131628	16-55	05OCT2020	103712	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131629	C4591001 1013 10131629	16-55	05OCT2020	98739	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131630	C4591001 1013 10131630	16-55	05OCT2020	103716	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131632	C4591001 1013 10131632	16-55	05OCT2020	103714	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131633	C4591001 1013 10131633	16-55	05OCT2020	103717	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131634	C4591001 1013 10131634	16-55	05OCT2020	103781	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo		
10131635	C4591001 1013 10131635	16-55	06OCT2020	103783	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10131636	C4591001 1013 10131636	16-55	06OCT2020	103782	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131637	C4591001 1013 10131637	16-55	06OCT2020	103787	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131638	C4591001 1013 10131638	16-55	06OCT2020	104185	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131639	C4591001 1013 10131639	16-55	06OCT2020	104186	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131642	C4591001 1013 10131642	16-55	06OCT2020	104178	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		
10131643	C4591001 1013 10131643	16-55	06OCT2020	104188	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131644	C4591001 1013 10131644	16-55	06OCT2020	104302	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10131645	C4591001 1013 10131645	16-55	06OCT2020	104303	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10131647	C4591001 1013 10131647	16-55	06OCT2020	104304	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131651	C4591001 1013 10131651	16-55	07OCT2020	104305	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10131652	C4591001 1013 10131652	16-55	07OCT2020	104645	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131653	C4591001 1013 10131653	16-55	07OCT2020	104654	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131654	C4591001 1013 10131654	16-55	07OCT2020	104756	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131656	C4591001 1013 10131656	16-55	07OCT2020	104650	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131657	C4591001 1013 10131657	16-55	07OCT2020	104758	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10131658	C4591001 1013 10131658	16-55	07OCT2020	104653	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131660	C4591001 1013 10131660	16-55	07OCT2020	104762	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131663	C4591001 1013 10131663	16-55	08OCT2020	104764	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10131664	C4591001 1013 10131664	16-55	08OCT2020	105199	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10131665	C4591001 1013 10131665	16-55	08OCT2020	105197	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10131666	C4591001 1013 10131666	16-55	08OCT2020	105202	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10131667	C4591001 1013 10131667	16-55	08OCT2020	105205	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131668	C4591001 1013 10131668	16-55	08OCT2020	105224	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131669	C4591001 1013 10131669	16-55	08OCT2020	105226	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131670	C4591001 1013 10131670†	16-55	08OCT2020	105229	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)			
10131671	C4591001 1013 10131671	16-55	08OCT2020	105231	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131673	C4591001 1013 10131673†	16-55	08OCT2020	105308	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10131675	C4591001 1013 10131675	16-55	08OCT2020	105310	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10131676	C4591001 1013 10131676	16-55	12OCT2020	105312	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10131677	C4591001 1013 10131677	16-55	12OCT2020	106349	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131678	C4591001 1013 10131678	16-55	12OCT2020	105314	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10131680	C4591001 1013 10131680	16-55	12OCT2020	106353	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131681	C4591001 1013 10131681	16-55	12OCT2020	106359	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10131682	C4591001 1013 10131682	16-55	12OCT2020	106360	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131683	C4591001 1013 10131683	16-55	12OCT2020	106402	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10131685	C4591001 1013 10131685	16-55	12OCT2020	106404	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131688	C4591001 1013 10131688	16-55	12OCT2020	106407	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131689	C4591001 1013 10131689	16-55	12OCT2020	106507	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131691	C4591001 1013 10131691	16-55	12OCT2020	106408	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10131693	C4591001 1013 10131693	16-55	13OCT2020	106512	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131696	C4591001 1013 10131696	16-55	13OCT2020	106515	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131697	C4591001 1013 10131697	16-55	13OCT2020	106509	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10131700	C4591001 1013 10131700	16-55	13OCT2020	106926	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131701	C4591001 1013 10131701	16-55	13OCT2020	106933	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131703	C4591001 1013 10131703	16-55	13OCT2020	106934	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131708	C4591001 1013 10131708	16-55	13OCT2020	106935	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131709	C4591001 1013 10131709	16-55	14OCT2020	107371	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131710	C4591001 1013 10131710	16-55	14OCT2020	107376	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131713	C4591001 1013 10131713	16-55	14OCT2020	107372	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10131716	C4591001 1013 10131716	16-55	14OCT2020	107377	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10131717	C4591001 1013 10131717	16-55	14OCT2020	107469	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10131718	C4591001 1013 10131718	16-55	14OCT2020	107472	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131720	C4591001 1013 10131720	16-55	14OCT2020	107539	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131721	C4591001 1013 10131721	16-55	14OCT2020	107473	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131722	C4591001 1013 10131722	16-55	14OCT2020	107537	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131723	C4591001 1013 10131723	16-55	14OCT2020	107474	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131724	C4591001 1013 10131724	16-55	14OCT2020	107546	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10131729	C4591001 1013 10131729	16-55	15OCT2020	107951	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10131730	C4591001 1013 10131730	16-55	15OCT2020	107548	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131731	C4591001 1013 10131731	16-55	15OCT2020	107948	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10131733	C4591001 1013 10131733	16-55	15OCT2020	107954	Placebo	15OCT2020/ Placebo	09NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10131734	C4591001 1013 10131734	16-55	15OCT2020	107956	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131736	C4591001 1013 10131736	16-55	15OCT2020	108024	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10131737	C4591001 1013 10131737	16-55	15OCT2020	108021	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131738	C4591001 1013 10131738	16-55	15OCT2020	108197	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131739	C4591001 1013 10131739	16-55	15OCT2020	108025	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10131740	C4591001 1013 10131740	16-55	15OCT2020	108026	Placebo				
10131744	C4591001 1013 10131744	16-55	19OCT2020	108204	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131745	C4591001 1013 10131745	16-55	19OCT2020	108205	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10131746	C4591001 1013 10131746	16-55	19OCT2020	108207	Placebo	19OCT2020/ Placebo			
10131748	C4591001 1013 10131748	16-55	19OCT2020	109961	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131749	C4591001 1013 10131749	16-55	19OCT2020	109966	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10131752	C4591001 1013 10131752	16-55	19OCT2020	109970	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131756	C4591001 1013 10131756	16-55	19OCT2020	109972	Placebo	19OCT2020/ Placebo	12NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131757	C4591001 1013 10131757	16-55	19OCT2020	110154	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10131759	C4591001 1013 10131759	16-55	19OCT2020	110156	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131760	C4591001 1013 10131760	16-55	20OCT2020	110733	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131761	C4591001 1013 10131761	16-55	20OCT2020	110730	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131762	C4591001 1013 10131762	16-55	20OCT2020	110162	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10131763	C4591001 1013 10131763	16-55	20OCT2020	110163	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10131767	C4591001 1013 10131767	16-55	20OCT2020	110736	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo		
10131769	C4591001 1013 10131769	16-55	20OCT2020	110740	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131770	C4591001 1013 10131770	16-55	20OCT2020	110804	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131771	C4591001 1013 10131771	16-55	20OCT2020	110802	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131772	C4591001 1013 10131772	16-55	20OCT2020	110808	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131774	C4591001 1013 10131774	16-55	20OCT2020	110807	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10131777	C4591001 1013 10131777	16-55	20OCT2020	110866	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131778	C4591001 1013 10131778	16-55	20OCT2020	110861	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10131779	C4591001 1013 10131779	16-55	20OCT2020	110867	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
10131780	C4591001 1013 10131780	16-55	20OCT2020	110870	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
10131783	C4591001 1013 10131783	16-55	21OCT2020	111330	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10131785	C4591001 1013 10131785	16-55	21OCT2020	111334	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10131790	C4591001 1013 10131790	16-55	21OCT2020	111338	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131791	C4591001 1013 10131791	16-55	21OCT2020	111339	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131792	C4591001 1013 10131792	16-55	21OCT2020	111438	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10131793	C4591001 1013 10131793	16-55	21OCT2020	111441	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131794	C4591001 1013 10131794	16-55	21OCT2020	111444	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131796	C4591001 1013 10131796	16-55	21OCT2020	111447	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131797	C4591001 1013 10131797	16-55	22OCT2020	112049	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131800	C4591001 1013 10131800	16-55	22OCT2020	112050	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131801	C4591001 1013 10131801	16-55	22OCT2020	112052	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131802	C4591001 1013 10131802	16-55	22OCT2020	112058	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10131803	C4591001 1013 10131803	16-55	22OCT2020	112086	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo		
10131804	C4591001 1013 10131804	16-55	22OCT2020	112096	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131806	C4591001 1013 10131806	16-55	22OCT2020	112085	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131807	C4591001 1013 10131807	16-55	22OCT2020	112174	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10131808	C4591001 1013 10131808	16-55	22OCT2020	112091	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10131809	C4591001 1013 10131809	16-55	22OCT2020	112172	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10131810	C4591001 1013 10131810	16-55	22OCT2020	112245	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10131811	C4591001 1013 10131811	16-55	22OCT2020	112171	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo		
10131813	C4591001 1013 10131813	16-55	22OCT2020	112177	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10131815	C4591001 1013 10131815	16-55	22OCT2020	112250	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10131817	C4591001 1013 10131817	16-55	22OCT2020	112251	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10131818	C4591001 1013 10131818	16-55	30NOV2020	112252	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131819	C4591001 1013 10131819	16-55	30NOV2020	117007	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10131820	C4591001 1013 10131820	16-55	30NOV2020	20327	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10131825	C4591001 1013 10131825	16-55	01DEC2020	117009	Placebo	01DEC2020/ Placebo	23DEC2020/ Placebo		
10131829	C4591001 1013 10131829	16-55	02DEC2020	117010	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10131831	C4591001 1013 10131831	16-55	02DEC2020	117199	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo		
10131832	C4591001 1013 10131832	16-55	02DEC2020	117198	Placebo	02DEC2020/ Placebo	23JAN2021/ Placebo		
10131833	C4591001 1013 10131833	16-55	02DEC2020	117207	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10131834	C4591001 1013 10131834	16-55	02DEC2020	117016	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)		
10131837	C4591001 1013 10131837	16-55	02DEC2020	117200	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10131838	C4591001 1013 10131838	16-55	02DEC2020	117222	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10131840	C4591001 1013 10131840	16-55	02DEC2020	117224	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10131847	C4591001 1013 10131847	16-55	03DEC2020	117226	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10131849	C4591001 1013 10131849	16-55	03DEC2020	117231	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo		
10131853	C4591001 1013 10131853	16-55	07DEC2020	117701	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo		
10131854	C4591001 1013 10131854	16-55	08DEC2020	117705	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10131857	C4591001 1013 10131857	16-55	09DEC2020	117707	Placebo	09DEC2020/ Placebo	30DEC2020/ Placebo		
10131864	C4591001 1013 10131864	16-55	10DEC2020	117710	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
10151020	C4591001 1015 10151020	16-55	14AUG2020	49898	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151022	C4591001 1015 10151022	16-55	14AUG2020	50795	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151028	C4591001 1015 10151028	16-55	15AUG2020	51188	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151029	C4591001 1015 10151029	16-55	15AUG2020	51189	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151030	C4591001 1015 10151030	16-55	15AUG2020	51193	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151031	C4591001 1015 10151031	16-55	15AUG2020	51416	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151034	C4591001 1015 10151034	16-55	16AUG2020	51422	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151035	C4591001 1015 10151035	16-55	16AUG2020	51423	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10151038	C4591001 1015 10151038	16-55	17AUG2020	51424	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151039	C4591001 1015 10151039	16-55	17AUG2020	52343	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
10151041	C4591001 1015 10151041	16-55	17AUG2020	52344	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151044	C4591001 1015 10151044	16-55	17AUG2020	52348	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
10151045	C4591001 1015 10151045	16-55	17AUG2020	52346	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151046	C4591001 1015 10151046	16-55	17AUG2020	53299	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151047	C4591001 1015 10151047	16-55	17AUG2020	53307	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151048	C4591001 1015 10151048	16-55	17AUG2020	53308	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151049	C4591001 1015 10151049	16-55	18AUG2020	53999	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10151050	C4591001 1015 10151050	16-55	18AUG2020	53996	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151051	C4591001 1015 10151051	16-55	18AUG2020	54004	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151052	C4591001 1015 10151052	16-55	18AUG2020	54000	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151053	C4591001 1015 10151053	16-55	18AUG2020	54740	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10151054	C4591001 1015 10151054	16-55	18AUG2020	54741	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151055	C4591001 1015 10151055	16-55	18AUG2020	54744	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10151056	C4591001 1015 10151056	16-55	18AUG2020	54746	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151058	C4591001 1015 10151058	16-55	19AUG2020	55998	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151061	C4591001 1015 10151061	16-55	19AUG2020	56000	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10151062	C4591001 1015 10151062	16-55	19AUG2020	56006	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151063	C4591001 1015 10151063	16-55	19AUG2020	56002	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151064	C4591001 1015 10151064	16-55	19AUG2020	56898	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151066	C4591001 1015 10151066	16-55	19AUG2020	56901	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151067	C4591001 1015 10151067	16-55	19AUG2020	56904	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151068	C4591001 1015 10151068	16-55	19AUG2020	56907	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151069	C4591001 1015 10151069	16-55	20AUG2020	57967	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10151070	C4591001 1015 10151070	16-55	20AUG2020	57972	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151071	C4591001 1015 10151071	16-55	20AUG2020	57976	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151072	C4591001 1015 10151072	16-55	20AUG2020	57974	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151073	C4591001 1015 10151073	16-55	20AUG2020	58505	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151074	C4591001 1015 10151074	16-55	20AUG2020	58513	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151075	C4591001 1015 10151075	16-55	20AUG2020	58508	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151076	C4591001 1015 10151076	16-55	20AUG2020	58515	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10151077	C4591001 1015 10151077	16-55	20AUG2020	59096	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10151080	C4591001 1015 10151080	16-55	20AUG2020	59099	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10151081	C4591001 1015 10151081	16-55	21AUG2020	59103	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151082	C4591001 1015 10151082	16-55	21AUG2020	59104	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151083	C4591001 1015 10151083	16-55	21AUG2020	60281	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151084	C4591001 1015 10151084	16-55	21AUG2020	60282	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151085	C4591001 1015 10151085	16-55	21AUG2020	60285	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151086	C4591001 1015 10151086	16-55	21AUG2020	60291	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151087	C4591001 1015 10151087	16-55	24AUG2020	61315	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151088	C4591001 1015 10151088	16-55	21AUG2020	60864	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10151089	C4591001 1015 10151089	16-55	21AUG2020	60865	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151092	C4591001 1015 10151092	16-55	21AUG2020	60867	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151093	C4591001 1015 10151093	16-55	21AUG2020	61314	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10151094	C4591001 1015 10151094	16-55	24AUG2020	61319	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151097	C4591001 1015 10151097	16-55	24AUG2020	61320	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151098	C4591001 1015 10151098	16-55	24AUG2020	63919	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151099	C4591001 1015 10151099	16-55	24AUG2020	63921	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151100	C4591001 1015 10151100	16-55	24AUG2020	63922	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151101	C4591001 1015 10151101	16-55	25AUG2020	66729	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10151102	C4591001 1015 10151102	16-55	24AUG2020	63923	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10151103	C4591001 1015 10151103	16-55	24AUG2020	64518	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10151104	C4591001 1015 10151104	16-55	24AUG2020	64517	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10151105	C4591001 1015 10151105	16-55	24AUG2020	64522	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151107	C4591001 1015 10151107	16-55	26AUG2020	66731	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151108	C4591001 1015 10151108	16-55	01SEP2020	75460	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151112	C4591001 1015 10151112	16-55	25AUG2020	66726	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10151113	C4591001 1015 10151113	16-55	25AUG2020	64525	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10151115	C4591001 1015 10151115	16-55	26AUG2020	66733	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151116	C4591001 1015 10151116	16-55	26AUG2020	67301	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151117	C4591001 1015 10151117	16-55	26AUG2020	67303	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10151118	C4591001 1015 10151118	16-55	26AUG2020	67308	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151119	C4591001 1015 10151119	16-55	26AUG2020	67307	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10151120	C4591001 1015 10151120	16-55	26AUG2020	68310	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151121	C4591001 1015 10151121	16-55	24SEP2020	97608	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151122	C4591001 1015 10151122	16-55	26AUG2020	68314	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10151123	C4591001 1015 10151123	16-55	26AUG2020	68315	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10151124	C4591001 1015 10151124	16-55	26AUG2020	68318	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151125	C4591001 1015 10151125	16-55	27AUG2020	69557	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151126	C4591001 1015 10151126	16-55	27AUG2020	69560	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151128	C4591001 1015 10151128	16-55	27AUG2020	69561	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10151130	C4591001 1015 10151130	16-55	27AUG2020	69568	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10151131	C4591001 1015 10151131	16-55	27AUG2020	70270	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151132	C4591001 1015 10151132	16-55	27AUG2020	70272	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10151133	C4591001 1015 10151133	16-55	27AUG2020	70273	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151134	C4591001 1015 10151134	16-55	27AUG2020	70275	Placebo	27AUG2020/ Placebo		21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151135	C4591001 1015 10151135	16-55	27AUG2020	70709	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10151136	C4591001 1015 10151136	16-55	27AUG2020	70715	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10151137	C4591001 1015 10151137	16-55	27AUG2020	70714	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151138	C4591001 1015 10151138	16-55	28AUG2020	70719	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10151139	C4591001 1015 10151139	16-55	28AUG2020	71729	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151143	C4591001 1015 10151143	16-55	28AUG2020	71731	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151146	C4591001 1015 10151146	16-55	31AUG2020	71733	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151147	C4591001 1015 10151147	16-55	31AUG2020	71732	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151148	C4591001 1015 10151148	16-55	31AUG2020	75018	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151149	C4591001 1015 10151149	16-55	31AUG2020	75017	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151150	C4591001 1015 10151150	16-55	31AUG2020	75023	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151151	C4591001 1015 10151151	16-55	31AUG2020	75451	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151152	C4591001 1015 10151152	16-55	31AUG2020	75028	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151153	C4591001 1015 10151153	16-55	31AUG2020	75453	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151154	C4591001 1015 10151154	16-55	31AUG2020	75454	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151157	C4591001 1015 10151157	16-55	01SEP2020	76697	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10151159	C4591001 1015 10151159	16-55	01SEP2020	76700	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151160	C4591001 1015 10151160	16-55	01SEP2020	76701	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10151161	C4591001 1015 10151161	16-55	01SEP2020	76705	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151162	C4591001 1015 10151162	16-55	01SEP2020	77186	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151163	C4591001 1015 10151163	16-55	01SEP2020	77187	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151164	C4591001 1015 10151164	16-55	01SEP2020	77188	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10151165	C4591001 1015 10151165	16-55	02SEP2020	77875	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151166	C4591001 1015 10151166	16-55	02SEP2020	77877	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151167	C4591001 1015 10151167	16-55	02SEP2020	77879	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151170	C4591001 1015 10151170	16-55	02SEP2020	77882	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10151171	C4591001 1015 10151171	16-55	03SEP2020	79530	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151172	C4591001 1015 10151172	16-55	03SEP2020	79533	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151174	C4591001 1015 10151174	16-55	03SEP2020	79537	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151175	C4591001 1015 10151175	16-55	03SEP2020	79540	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10151176	C4591001 1015 10151176	16-55	03SEP2020	80694	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10151177	C4591001 1015 10151177	16-55	03SEP2020	80695	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10151179	C4591001 1015 10151179	16-55	04SEP2020	80703	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151180	C4591001 1015 10151180	16-55	04SEP2020	80700	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10151182	C4591001 1015 10151182	16-55	04SEP2020	81766	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10151183	C4591001 1015 10151183	16-55	04SEP2020	81768	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151184	C4591001 1015 10151184	16-55	04SEP2020	81770	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10151185	C4591001 1015 10151185	16-55	04SEP2020	81772	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10151187	C4591001 1015 10151187	16-55	07SEP2020	83060	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151188	C4591001 1015 10151188	16-55	07SEP2020	83061	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10151189	C4591001 1015 10151189	16-55	07SEP2020	83065	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151191	C4591001 1015 10151191	16-55	07SEP2020	83066	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151192	C4591001 1015 10151192	16-55	07SEP2020	83168	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10151193	C4591001 1015 10151193	16-55	07SEP2020	83169	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151196	C4591001 1015 10151196	16-55	08SEP2020	83171	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151197	C4591001 1015 10151197	16-55	08SEP2020	83172	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10151198	C4591001 1015 10151198	16-55	08SEP2020	84029	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151199	C4591001 1015 10151199	16-55	08SEP2020	84031	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)			
10151200	C4591001 1015 10151200	16-55	08SEP2020	84033	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151201	C4591001 1015 10151201	16-55	08SEP2020	84034	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10151202	C4591001 1015 10151202	16-55	09SEP2020	84824	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151203	C4591001 1015 10151203	16-55	09SEP2020	84827	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151204	C4591001 1015 10151204	16-55	09SEP2020	84830	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151205	C4591001 1015 10151205	16-55	09SEP2020	84832	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10151206	C4591001 1015 10151206	16-55	09SEP2020	85679	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10151207	C4591001 1015 10151207	16-55	10SEP2020	85680	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151208	C4591001 1015 10151208	16-55	10SEP2020	85681	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10151209	C4591001 1015 10151209	16-55	10SEP2020	86780	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151210	C4591001 1015 10151210	16-55	10SEP2020	85682	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151211	C4591001 1015 10151211	16-55	10SEP2020	86781	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10151212	C4591001 1015 10151212	16-55	10SEP2020	86784	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151214	C4591001 1015 10151214	16-55	11SEP2020	86787	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10151217	C4591001 1015 10151217	16-55	11SEP2020	88544	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151218	C4591001 1015 10151218	16-55	11SEP2020	88541	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10151220	C4591001 1015 10151220	16-55	11SEP2020	88546	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10151221	C4591001 1015 10151221	16-55	11SEP2020	88552	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10151222	C4591001 1015 10151222	16-55	14SEP2020	89717	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10151223	C4591001 1015 10151223	16-55	14SEP2020	89726	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10151224	C4591001 1015 10151224	16-55	23SEP2020	97605	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151225	C4591001 1015 10151225	16-55	15SEP2020	89727	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10151226	C4591001 1015 10151226	16-55	16SEP2020	89728	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10151227	C4591001 1015 10151227	16-55	17SEP2020	92862	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10151228	C4591001 1015 10151228	16-55	17SEP2020	92866	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151229	C4591001 1015 10151229	16-55	18SEP2020	92868	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151230	C4591001 1015 10151230	16-55	21SEP2020	92872	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10151231	C4591001 1015 10151231	16-55	23SEP2020	97603	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151232	C4591001 1015 10151232	16-55	23SEP2020	97606	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151233	C4591001 1015 10151233	16-55	24SEP2020	98599	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10151234	C4591001 1015 10151234	16-55	25SEP2020	98601	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151235	C4591001 1015 10151235	16-55	30SEP2020	98603	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10151236	C4591001 1015 10151236	16-55	01OCT2020	98608	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151239	C4591001 1015 10151239	16-55	02OCT2020	103282	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10151240	C4591001 1015 10151240	16-55	07OCT2020	103284	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10151241	C4591001 1015 10151241	16-55	07OCT2020	103286	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10151242	C4591001 1015 10151242	16-55	08OCT2020	103288	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10151243	C4591001 1015 10151243	16-55	08OCT2020	105475	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10151245	C4591001 1015 10151245	16-55	14OCT2020	105479	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10151246	C4591001 1015 10151246	16-55	15OCT2020	105480	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10151248	C4591001 1015 10151248	16-55	16OCT2020	105482	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151249	C4591001 1015 10151249	16-55	19OCT2020	109913	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10151250	C4591001 1015 10151250	16-55	20OCT2020	109914	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151252	C4591001 1015 10151252	16-55	21OCT2020	109922	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10151254	C4591001 1015 10151254	16-55	22OCT2020	109923	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10151255	C4591001 1015 10151255	16-55	23OCT2020	112763	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10151256	C4591001 1015 10151256	16-55	23OCT2020	112757	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10151257	C4591001 1015 10151257	16-55	26OCT2020	112764	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10151259	C4591001 1015 10151259	16-55	27OCT2020	112766	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10151260	C4591001 1015 10151260	16-55	27OCT2020	114067	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10151261	C4591001 1015 10151261	16-55	27OCT2020	114070	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10151262	C4591001 1015 10151262	16-55	28OCT2020	114071	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10151263	C4591001 1015 10151263	16-55	28OCT2020	114076	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151265	C4591001 1015 10151265	16-55	29OCT2020	114633	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10151266	C4591001 1015 10151266	16-55	29OCT2020	114634	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10151267	C4591001 1015 10151267	16-55	30OCT2020	114636	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10151268	C4591001 1015 10151268	16-55	30OCT2020	114639	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10161126	C4591001 1016 10161126	16-55	14AUG2020	50442	Placebo	14AUG2020/ Placebo			
10161128	C4591001 1016 10161128	16-55	17AUG2020	50444	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10161130	C4591001 1016 10161130	16-55	17AUG2020	50447	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10161133	C4591001 1016 10161133	16-55	17AUG2020	50451	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161136	C4591001 1016 10161136	16-55	18AUG2020	54138	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10161139	C4591001 1016 10161139	16-55	18AUG2020	54140	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161140	C4591001 1016 10161140	16-55	18AUG2020	54144	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10161143	C4591001 1016 10161143	16-55	19AUG2020	54147	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161144	C4591001 1016 10161144	16-55	19AUG2020	56069	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10161145	C4591001 1016 10161145	16-55	19AUG2020	56072	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10161147	C4591001 1016 10161147	16-55	19AUG2020	56079	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10161148	C4591001 1016 10161148	16-55	19AUG2020	56080	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10161152	C4591001 1016 10161152	16-55	20AUG2020	58085	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10161154	C4591001 1016 10161154	16-55	20AUG2020	58086	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161155	C4591001 1016 10161155	16-55	20AUG2020	58088	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10161156	C4591001 1016 10161156	16-55	20AUG2020	58095	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
10161159	C4591001 1016 10161159	16-55	20AUG2020	59430	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10161160	C4591001 1016 10161160	16-55	21AUG2020	59432	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10161163	C4591001 1016 10161163	16-55	21AUG2020	59434	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10161164	C4591001 1016 10161164	16-55	21AUG2020	59438	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10161167	C4591001 1016 10161167	16-55	21AUG2020	61289	Placebo	21AUG2020/ Placebo	08SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10161168	C4591001 1016 10161168	16-55	24AUG2020	61291	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10161170	C4591001 1016 10161170	16-55	24AUG2020	61296	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10161171	C4591001 1016 10161171	16-55	24AUG2020	219978	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161172	C4591001 1016 10161172	16-55	24AUG2020	61299	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161176	C4591001 1016 10161176	16-55	25AUG2020	65717	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10161177	C4591001 1016 10161177	16-55	25AUG2020	65721	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
10161178	C4591001 1016 10161178	16-55	25AUG2020	65719	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10161181	C4591001 1016 10161181	16-55	25AUG2020	65725	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161183	C4591001 1016 10161183	16-55	25AUG2020	66690	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10161184	C4591001 1016 10161184	16-55	26AUG2020	66695	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10161185	C4591001 1016 10161185	16-55	26AUG2020	66697	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161186	C4591001 1016 10161186	16-55	26AUG2020	66699	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161189	C4591001 1016 10161189	16-55	26AUG2020	68553	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161190	C4591001 1016 10161190	16-55	26AUG2020	68554	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10161192	C4591001 1016 10161192	16-55	27AUG2020	68556	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10161193	C4591001 1016 10161193	16-55	27AUG2020	68560	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10161196	C4591001 1016 10161196	16-55	27AUG2020	70015	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10161204	C4591001 1016 10161204	16-55	28AUG2020	70018	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161205	C4591001 1016 10161205	16-55	28AUG2020	70021	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10161206	C4591001 1016 10161206	16-55	28AUG2020	70023	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10161208	C4591001 1016 10161208	16-55	31AUG2020	74694	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10161209	C4591001 1016 10161209	16-55	31AUG2020	74697	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
10161210	C4591001 1016 10161210	16-55	31AUG2020	74700	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161213	C4591001 1016 10161213	16-55	31AUG2020	74703	Placebo	31AUG2020/ Placebo	29SEP2020/ Placebo		
10161215	C4591001 1016 10161215	16-55	31AUG2020	75727	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161216	C4591001 1016 10161216	16-55	01SEP2020	75733	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161217	C4591001 1016 10161217	16-55	01SEP2020	75731	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161218	C4591001 1016 10161218	16-55	01SEP2020	75736	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161223	C4591001 1016 10161223	16-55	01SEP2020	77397	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10161225	C4591001 1016 10161225	16-55	02SEP2020	77398	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10161226	C4591001 1016 10161226	16-55	02SEP2020	77400	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161228	C4591001 1016 10161228	16-55	02SEP2020	77401	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10161229	C4591001 1016 10161229	16-55	02SEP2020	78221	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161230	C4591001 1016 10161230	16-55	02SEP2020	78654	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161231	C4591001 1016 10161231	16-55	02SEP2020	78656	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161232	C4591001 1016 10161232	16-55	02SEP2020	78661	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10161233	C4591001 1016 10161233	16-55	02SEP2020	78662	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10161234	C4591001 1016 10161234	16-55	02SEP2020	79025	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10161235	C4591001 1016 10161235	16-55	03SEP2020	79031	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10161237	C4591001 1016 10161237	16-55	03SEP2020	79032	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10161242	C4591001 1016 10161242	16-55	03SEP2020	79036	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10161243	C4591001 1016 10161243	16-55	03SEP2020	80657	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161244	C4591001 1016 10161244	16-55	03SEP2020	80666	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161245	C4591001 1016 10161245	16-55	04SEP2020	80667	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10161248	C4591001 1016 10161248	16-55	04SEP2020	80668	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10161249	C4591001 1016 10161249	16-55	04SEP2020	82121	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10161252	C4591001 1016 10161252	16-55	08SEP2020	82129	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10161253	C4591001 1016 10161253	16-55	08SEP2020	82130	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10161255	C4591001 1016 10161255	16-55	08SEP2020	82131	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10161258	C4591001 1016 10161258	16-55	09SEP2020	219977	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10161259	C4591001 1016 10161259	16-55	09SEP2020	219987	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161261	C4591001 1016 10161261	16-55	09SEP2020	219988	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10161265	C4591001 1016 10161265	16-55	09SEP2020	85158	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161268	C4591001 1016 10161268	16-55	10SEP2020	85163	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10161269	C4591001 1016 10161269	16-55	10SEP2020	85166	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10161272	C4591001 1016 10161272	16-55	10SEP2020	85168	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10161273	C4591001 1016 10161273	16-55	10SEP2020	87177	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10161275	C4591001 1016 10161275	16-55	10SEP2020	87178	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10161276	C4591001 1016 10161276	16-55	10SEP2020	87179	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10161277	C4591001 1016 10161277	16-55	11SEP2020	87181	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10161279	C4591001 1016 10161279	16-55	11SEP2020	88016	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10161280	C4591001 1016 10161280	16-55	11SEP2020	88015	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
10161281	C4591001 1016 10161281	16-55	11SEP2020	88020	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161284	C4591001 1016 10161284	16-55	11SEP2020	88023	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10161285	C4591001 1016 10161285	16-55	17SEP2020	92153	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
10161286	C4591001 1016 10161286	16-55	17SEP2020	92160	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10161287	C4591001 1016 10161287	16-55	17SEP2020	92163	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo		
10161288	C4591001 1016 10161288	16-55	17SEP2020	92164	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10161289	C4591001 1016 10161289	16-55	18SEP2020	93329	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10161290	C4591001 1016 10161290	16-55	18SEP2020	93331	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10161291	C4591001 1016 10161291	16-55	18SEP2020	93334	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10161292	C4591001 1016 10161292	16-55	18SEP2020	93336	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10161293	C4591001 1016 10161293	16-55	21SEP2020	94675	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10161294	C4591001 1016 10161294	16-55	21SEP2020	94679	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161295	C4591001 1016 10161295	16-55	22SEP2020	94681	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10161296	C4591001 1016 10161296	16-55	22SEP2020	94684	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10161297	C4591001 1016 10161297	16-55	22SEP2020	96606	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
10161298	C4591001 1016 10161298	16-55	22SEP2020	96611	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10161299	C4591001 1016 10161299	16-55	23SEP2020	96613	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
10161300	C4591001 1016 10161300	16-55	23SEP2020	96615	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10161301	C4591001 1016 10161301	16-55	24SEP2020	98576	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
10161302	C4591001 1016 10161302	16-55	24SEP2020	98577	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10161303	C4591001 1016 10161303	16-55	07OCT2020	98580	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10161304	C4591001 1016 10161304	16-55	12OCT2020	98583	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161305	C4591001 1016 10161305	16-55	13OCT2020	106865	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10161306	C4591001 1016 10161306	16-55	13OCT2020	106871	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10161312	C4591001 1016 10161312	16-55	15OCT2020	106873	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10161313	C4591001 1016 10161313	16-55	16OCT2020	106874	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10161317	C4591001 1016 10161317	16-55	16OCT2020	109196	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10161321	C4591001 1016 10161321	16-55	19OCT2020	109199	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10161328	C4591001 1016 10161328	16-55	20OCT2020	109202	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo		
10161333	C4591001 1016 10161333	16-55	21OCT2020	109203	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10161341	C4591001 1016 10161341	16-55	22OCT2020	112505	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)			
10161342	C4591001 1016 10161342	16-55	22OCT2020	112506	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10161345	C4591001 1016 10161345	16-55	28OCT2020	112513	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10161346	C4591001 1016 10161346	16-55	28OCT2020	112515	Placebo	28OCT2020/ Placebo	20NOV2020/ Placebo		
10161347	C4591001 1016 10161347	16-55	02NOV2020	115301	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10161348	C4591001 1016 10161348	16-55	05NOV2020	115302	Placebo	05NOV2020/ Placebo		11MAR2021/ BNT162b2 (30 µg)	
10161349	C4591001 1016 10161349	16-55	06NOV2020	115304	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
10161355	C4591001 1016 10161355	16-55	02DEC2020	115310	Placebo	02DEC2020/ Placebo	04JAN2021/ Placebo		
10161359	C4591001 1016 10161359	16-55	03DEC2020	117322	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10161360	C4591001 1016 10161360	16-55	04DEC2020	117323	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	07MAR2021/ BNT162b2 (30 µg)
10181161	C4591001 1018 10181161	16-55	14AUG2020	50259	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181164	C4591001 1018 10181164	16-55	14AUG2020	50916	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10181165	C4591001 1018 10181165	16-55	14AUG2020	50960	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181166	C4591001 1018 10181166	16-55	14AUG2020	50961	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10181170	C4591001 1018 10181170	16-55	17AUG2020	50964	Placebo	17AUG2020/ Placebo	11SEP2020/ Placebo		
10181171	C4591001 1018 10181171	16-55	17AUG2020	50966	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10181173	C4591001 1018 10181173	16-55	17AUG2020	53393	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10181174	C4591001 1018 10181174	16-55	17AUG2020	53397	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10181176	C4591001 1018 10181176	16-55	17AUG2020	53402	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181178	C4591001 1018 10181178	16-55	18AUG2020	53404	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10181180	C4591001 1018 10181180	16-55	18AUG2020	54881	Placebo	18AUG2020/ Placebo	12SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181181	C4591001 1018 10181181	16-55	18AUG2020	54884	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181182	C4591001 1018 10181182	16-55	18AUG2020	54892	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181183	C4591001 1018 10181183	16-55	18AUG2020	54887	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181184	C4591001 1018 10181184	16-55	19AUG2020	56261	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181185	C4591001 1018 10181185	16-55	19AUG2020	56262	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10181187	C4591001 1018 10181187	16-55	19AUG2020	56269	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10181188	C4591001 1018 10181188	16-55	19AUG2020	57498	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181189	C4591001 1018 10181189	16-55	19AUG2020	57503	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10181191	C4591001 1018 10181191	16-55	20AUG2020	57505	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10181193	C4591001 1018 10181193	16-55	20AUG2020	59684	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181194	C4591001 1018 10181194	16-55	20AUG2020	57506	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10181195	C4591001 1018 10181195	16-55	21AUG2020	59685	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181196	C4591001 1018 10181196	16-55	21AUG2020	59689	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181197	C4591001 1018 10181197	16-55	21AUG2020	59690	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181198	C4591001 1018 10181198	16-55	21AUG2020	60977	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181199	C4591001 1018 10181199	16-55	21AUG2020	60980	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181200	C4591001 1018 10181200	16-55	21AUG2020	60986	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10181201	C4591001 1018 10181201	16-55	21AUG2020	60981	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181202	C4591001 1018 10181202	16-55	21AUG2020	61447	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181204	C4591001 1018 10181204	16-55	22AUG2020	61450	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
10181205	C4591001 1018 10181205	16-55	22AUG2020	61452	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181206	C4591001 1018 10181206	16-55	22AUG2020	61453	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181207	C4591001 1018 10181207	16-55	22AUG2020	62277	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181208	C4591001 1018 10181208	16-55	22AUG2020	62279	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10181211	C4591001 1018 10181211	16-55	24AUG2020	62280	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181214	C4591001 1018 10181214	16-55	24AUG2020	62283	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
10181215	C4591001 1018 10181215	16-55	24AUG2020	64808	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10181216	C4591001 1018 10181216	16-55	25AUG2020	64809	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10181218	C4591001 1018 10181218	16-55	26AUG2020	64810	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181219	C4591001 1018 10181219	16-55	26AUG2020	64811	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181221	C4591001 1018 10181221	16-55	29AUG2020	73698	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo		
10181222	C4591001 1018 10181222	16-55	29AUG2020	73700	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181223	C4591001 1018 10181223	16-55	29AUG2020	73704	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo		
10181224	C4591001 1018 10181224	16-55	29AUG2020	73708	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10181225	C4591001 1018 10181225	16-55	29AUG2020	74081	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181226	C4591001 1018 10181226	16-55	29AUG2020	74084	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10181227	C4591001 1018 10181227	16-55	29AUG2020	74082	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181228	C4591001 1018 10181228	16-55	31AUG2020	74090	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10181230	C4591001 1018 10181230	16-55	31AUG2020	75067	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10181232	C4591001 1018 10181232	16-55	31AUG2020	75071	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10181233	C4591001 1018 10181233	16-55	31AUG2020	75073	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10181234	C4591001 1018 10181234	16-55	01SEP2020	76600	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181235	C4591001 1018 10181235	16-55	01SEP2020	76593	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181236	C4591001 1018 10181236	16-55	01SEP2020	76591	Placebo	01SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181237	C4591001 1018 10181237	16-55	01SEP2020	75074	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10181238	C4591001 1018 10181238	16-55	01SEP2020	76598	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10181240	C4591001 1018 10181240	16-55	01SEP2020	76997	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10181241	C4591001 1018 10181241	16-55	01SEP2020	77001	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181242	C4591001 1018 10181242	16-55	01SEP2020	77004	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181244	C4591001 1018 10181244	16-55	01SEP2020	77006	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181245	C4591001 1018 10181245	16-55	01SEP2020	77734	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10181246	C4591001 1018 10181246	16-55	01SEP2020	77738	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181247	C4591001 1018 10181247	16-55	01SEP2020	77736	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10181251	C4591001 1018 10181251	16-55	02SEP2020	78390	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10181252	C4591001 1018 10181252	16-55	02SEP2020	77740	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10181254	C4591001 1018 10181254	16-55	02SEP2020	78391	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10181255	C4591001 1018 10181255	16-55	02SEP2020	78393	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181256	C4591001 1018 10181256	16-55	02SEP2020	78399	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10181257	C4591001 1018 10181257	16-55	03SEP2020	79758	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181259	C4591001 1018 10181259	16-55	03SEP2020	79759	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10181260	C4591001 1018 10181260	16-55	03SEP2020	79762	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10181261	C4591001 1018 10181261	16-55	03SEP2020	79766	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181262	C4591001 1018 10181262	16-55	04SEP2020	81443	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181263	C4591001 1018 10181263	16-55	04SEP2020	81440	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181264	C4591001 1018 10181264	16-55	04SEP2020	81444	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10181266	C4591001 1018 10181266	16-55	04SEP2020	81445	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)			
10181267	C4591001 1018 10181267	16-55	04SEP2020	81967	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10181268	C4591001 1018 10181268	16-55	04SEP2020	81968	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10181269	C4591001 1018 10181269	16-55	04SEP2020	81971	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181272	C4591001 1018 10181272	16-55	09SEP2020	81974	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181275	C4591001 1018 10181275	16-55	09SEP2020	86046	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10181276	C4591001 1018 10181276	16-55	10SEP2020	86047	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181277	C4591001 1018 10181277	16-55	10SEP2020	86050	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181279	C4591001 1018 10181279	16-55	11SEP2020	86052	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181282	C4591001 1018 10181282	16-55	12SEP2020	89144	Placebo	12SEP2020/ Placebo	07OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10181283	C4591001 1018 10181283	16-55	12SEP2020	89149	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181284	C4591001 1018 10181284	16-55	12SEP2020	89150	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10181286	C4591001 1018 10181286	16-55	12SEP2020	89152	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10181287	C4591001 1018 10181287	16-55	14SEP2020	89789	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10181288	C4591001 1018 10181288	16-55	14SEP2020	89793	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10181289	C4591001 1018 10181289	16-55	14SEP2020	89794	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10181290	C4591001 1018 10181290	16-55	15SEP2020	89796	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181292	C4591001 1018 10181292	16-55	15SEP2020	90678	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10181293	C4591001 1018 10181293	16-55	15SEP2020	90686	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10181294	C4591001 1018 10181294	16-55	15SEP2020	90679	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181295	C4591001 1018 10181295	16-55	16SEP2020	90687	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10181298	C4591001 1018 10181298	16-55	17SEP2020	92333	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181299	C4591001 1018 10181299	16-55	17SEP2020	92335	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10181301	C4591001 1018 10181301	16-55	18SEP2020	92344	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10181302	C4591001 1018 10181302	16-55	18SEP2020	92342	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10181304	C4591001 1018 10181304	16-55	21SEP2020	95275	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10181305	C4591001 1018 10181305	16-55	21SEP2020	95279	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181306	C4591001 1018 10181306	16-55	21SEP2020	95280	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10181307	C4591001 1018 10181307	16-55	23SEP2020	95284	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10181309	C4591001 1018 10181309	16-55	25SEP2020	100313	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181310	C4591001 1018 10181310	16-55	12OCT2020	100320	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)			
10181311	C4591001 1018 10181311	16-55	12OCT2020	100321	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)			
10181313	C4591001 1018 10181313	16-55	12OCT2020	100324	Placebo	12OCT2020/ Placebo			
10181314	C4591001 1018 10181314	16-55	13OCT2020	106949	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10181315	C4591001 1018 10181315	16-55	13OCT2020	106952	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181316	C4591001 1018 10181316	16-55	13OCT2020	106953	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10181317	C4591001 1018 10181317	16-55	13OCT2020	106957	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181319	C4591001 1018 10181319	16-55	13OCT2020	107109	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		
10181320	C4591001 1018 10181320	16-55	13OCT2020	107111	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10181321	C4591001 1018 10181321	16-55	13OCT2020	107114	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10181322	C4591001 1018 10181322	16-55	13OCT2020	107116	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10181323	C4591001 1018 10181323	16-55	14OCT2020	107549	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10181324	C4591001 1018 10181324	16-55	14OCT2020	107552	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10181326	C4591001 1018 10181326	16-55	14OCT2020	107556	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10181327	C4591001 1018 10181327	16-55	14OCT2020	107559	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10181329	C4591001 1018 10181329	16-55	14OCT2020	107741	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181333	C4591001 1018 10181333	16-55	15OCT2020	107742	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181334	C4591001 1018 10181334	16-55	15OCT2020	107743	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10181335	C4591001 1018 10181335	16-55	15OCT2020	107748	Placebo	15OCT2020/ Placebo	13NOV2020/ Placebo		
10181336	C4591001 1018 10181336	16-55	19OCT2020	110309	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181337	C4591001 1018 10181337	16-55	19OCT2020	110311	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181338	C4591001 1018 10181338	16-55	19OCT2020	110318	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181340	C4591001 1018 10181340	16-55	19OCT2020	110320	Placebo	19OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10181341	C4591001 1018 10181341	16-55	19OCT2020	110502	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10181342	C4591001 1018 10181342	16-55	20OCT2020	110503	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181344	C4591001 1018 10181344	16-55	20OCT2020	110506	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10181345	C4591001 1018 10181345	16-55	30OCT2020	111875	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10181346	C4591001 1018 10181346	16-55	20OCT2020	110510	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10181347	C4591001 1018 10181347	16-55	20OCT2020	111127	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10181349	C4591001 1018 10181349	16-55	21OCT2020	111129	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10181351	C4591001 1018 10181351	16-55	21OCT2020	111130	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10181352	C4591001 1018 10181352	16-55	21OCT2020	111135	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10181353	C4591001 1018 10181353	16-55	21OCT2020	111870	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10191044	C4591001 1019 10191044	16-55	17AUG2020	50396	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10191047	C4591001 1019 10191047	16-55	17AUG2020	50398	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10191050	C4591001 1019 10191050	16-55	17AUG2020	50403	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10191056	C4591001 1019 10191056	16-55	18AUG2020	54466	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191058	C4591001 1019 10191058	16-55	18AUG2020	54461	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10191059	C4591001 1019 10191059	16-55	18AUG2020	54469	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191063	C4591001 1019 10191063	16-55	19AUG2020	54471	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10191068	C4591001 1019 10191068	16-55	19AUG2020	57077	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10191073	C4591001 1019 10191073	16-55	20AUG2020	58221	Placebo	20AUG2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191074	C4591001 1019 10191074	16-55	20AUG2020	58223	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10191076	C4591001 1019 10191076	16-55	20AUG2020	58226	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10191077	C4591001 1019 10191077	16-55	20AUG2020	58228	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10191081	C4591001 1019 10191081	16-55	21AUG2020	60049	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10191083	C4591001 1019 10191083	16-55	21AUG2020	60050	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191085	C4591001 1019 10191085	16-55	21AUG2020	60051	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10191090	C4591001 1019 10191090	16-55	24AUG2020	60052	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10191098	C4591001 1019 10191098	16-55	25AUG2020	65807	Placebo	25AUG2020/ Placebo			
10191100	C4591001 1019 10191100	16-55	25AUG2020	65811	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10191101	C4591001 1019 10191101	16-55	25AUG2020	65812	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10191102	C4591001 1019 10191102	16-55	25AUG2020	66478	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10191106	C4591001 1019 10191106	16-55	26AUG2020	66480	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191108	C4591001 1019 10191108	16-55	26AUG2020	66483	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10191110	C4591001 1019 10191110	16-55	26AUG2020	66484	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10191113	C4591001 1019 10191113	16-55	26AUG2020	68562	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191116	C4591001 1019 10191116	16-55	26AUG2020	68563	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10191123	C4591001 1019 10191123	16-55	27AUG2020	68565	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10191124	C4591001 1019 10191124	16-55	27AUG2020	68572	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10191125	C4591001 1019 10191125	16-55	27AUG2020	71250	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10191127	C4591001 1019 10191127	16-55	27AUG2020	71251	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10191128	C4591001 1019 10191128	16-55	27AUG2020	71258	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10191129	C4591001 1019 10191129	16-55	27AUG2020	71260	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10191133	C4591001 1019 10191133	16-55	28AUG2020	71911	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10191137	C4591001 1019 10191137	16-55	28AUG2020	71912	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10191138	C4591001 1019 10191138	16-55	28AUG2020	71914	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191140	C4591001 1019 10191140	16-55	31AUG2020	71915	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10191141	C4591001 1019 10191141	16-55	31AUG2020	75485	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10191145	C4591001 1019 10191145	16-55	01SEP2020	75488	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
10191147	C4591001 1019 10191147	16-55	01SEP2020	75489	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10191154	C4591001 1019 10191154	16-55	03SEP2020	75495	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10191156	C4591001 1019 10191156	16-55	03SEP2020	80933	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10191157	C4591001 1019 10191157	16-55	03SEP2020	80936	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10191159	C4591001 1019 10191159	16-55	04SEP2020	80943	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10191161	C4591001 1019 10191161	16-55	04SEP2020	80944	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191164	C4591001 1019 10191164	16-55	04SEP2020	81862	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191165	C4591001 1019 10191165	16-55	04SEP2020	81866	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191166	C4591001 1019 10191166	16-55	04SEP2020	81867	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)			
10191168	C4591001 1019 10191168	16-55	08SEP2020	81868	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10191171	C4591001 1019 10191171	16-55	08SEP2020	84138	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10191172	C4591001 1019 10191172	16-55	08SEP2020	84141	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191173	C4591001 1019 10191173	16-55	08SEP2020	84142	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10191174	C4591001 1019 10191174	16-55	09SEP2020	84145	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191175	C4591001 1019 10191175	16-55	09SEP2020	84941	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10191181	C4591001 1019 10191181	16-55	09SEP2020	84948	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10191184	C4591001 1019 10191184	16-55	10SEP2020	84951	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191186	C4591001 1019 10191186	16-55	10SEP2020	86962	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10191187	C4591001 1019 10191187	16-55	10SEP2020	84952	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10191188	C4591001 1019 10191188	16-55	10SEP2020	86965	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10191189	C4591001 1019 10191189	16-55	10SEP2020	86967	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10191192	C4591001 1019 10191192	16-55	10SEP2020	86968	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10191193	C4591001 1019 10191193	16-55	11SEP2020	87809	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10191194	C4591001 1019 10191194	16-55	11SEP2020	87810	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10191195	C4591001 1019 10191195	16-55	11SEP2020	87815	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191196	C4591001 1019 10191196	16-55	11SEP2020	87820	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10191197	C4591001 1019 10191197	16-55	11SEP2020	88097	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191198	C4591001 1019 10191198	16-55	11SEP2020	88098	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10191205	C4591001 1019 10191205	16-55	14SEP2020	88101	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10191206	C4591001 1019 10191206	16-55	14SEP2020	88105	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10191208	C4591001 1019 10191208	16-55	14SEP2020	89935	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10191209	C4591001 1019 10191209	16-55	15SEP2020	89936	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10191211	C4591001 1019 10191211	16-55	15SEP2020	89938	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10191212	C4591001 1019 10191212	16-55	15SEP2020	89944	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191213	C4591001 1019 10191213	16-55	15SEP2020	90765	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191214	C4591001 1019 10191214	16-55	16SEP2020	90766	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10191215	C4591001 1019 10191215	16-55	02OCT2020	103238	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191216	C4591001 1019 10191216	16-55	16SEP2020	90767	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10191217	C4591001 1019 10191217	16-55	18SEP2020	90770	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10191218	C4591001 1019 10191218	16-55	18SEP2020	93537	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10191220	C4591001 1019 10191220	16-55	21SEP2020	93539	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10191222	C4591001 1019 10191222	16-55	22SEP2020	93541	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10191225	C4591001 1019 10191225	16-55	23SEP2020	93543	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10191226	C4591001 1019 10191226	16-55	23SEP2020	97847	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10191227	C4591001 1019 10191227	16-55	24SEP2020	97848	Placebo	24SEP2020/ Placebo	23OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10191230	C4591001 1019 10191230	16-55	24SEP2020	97849	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10191232	C4591001 1019 10191232	16-55	25SEP2020	97850	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191234	C4591001 1019 10191234	16-55	25SEP2020	99848	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10191235	C4591001 1019 10191235	16-55	25SEP2020	99849	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10191236	C4591001 1019 10191236	16-55	25SEP2020	99850	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10191238	C4591001 1019 10191238	16-55	25SEP2020	99854	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10191242	C4591001 1019 10191242	16-55	30SEP2020	102245	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10191245	C4591001 1019 10191245	16-55	01OCT2020	102251	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
10191246	C4591001 1019 10191246	16-55	01OCT2020	102254	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10191247	C4591001 1019 10191247	16-55	01OCT2020	102255	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10191249	C4591001 1019 10191249	16-55	02OCT2020	103231	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10191251	C4591001 1019 10191251	16-55	02OCT2020	103236	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191252	C4591001 1019 10191252	16-55	02OCT2020	103237	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10191254	C4591001 1019 10191254	16-55	05OCT2020	103925	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10191255	C4591001 1019 10191255	16-55	06OCT2020	103927	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10191256	C4591001 1019 10191256	16-55	08OCT2020	103931	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10191257	C4591001 1019 10191257	16-55	09OCT2020	103936	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10191260	C4591001 1019 10191260	16-55	12OCT2020	106363	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10191262	C4591001 1019 10191262	16-55	12OCT2020	106364	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10191264	C4591001 1019 10191264	16-55	12OCT2020	106370	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10191265	C4591001 1019 10191265	16-55	13OCT2020	106371	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10191267	C4591001 1019 10191267	16-55	13OCT2020	107143	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191268	C4591001 1019 10191268	16-55	13OCT2020	107144	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10191269	C4591001 1019 10191269	16-55	13OCT2020	107145	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191270	C4591001 1019 10191270	16-55	13OCT2020	107149	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10191273	C4591001 1019 10191273	16-55	14OCT2020	107574	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10191276	C4591001 1019 10191276	16-55	14OCT2020	107575	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10191279	C4591001 1019 10191279	16-55	15OCT2020	107579	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10191280	C4591001 1019 10191280	16-55	15OCT2020	107581	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10191281	C4591001 1019 10191281	16-55	15OCT2020	108329	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10191288	C4591001 1019 10191288	16-55	20OCT2020	108332	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10191289	C4591001 1019 10191289	16-55	20OCT2020	108334	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191290	C4591001 1019 10191290	16-55	20OCT2020	108340	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10191292	C4591001 1019 10191292	16-55	21OCT2020	111401	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10191293	C4591001 1019 10191293	16-55	21OCT2020	111402	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10191295	C4591001 1019 10191295	16-55	21OCT2020	111404	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10191296	C4591001 1019 10191296	16-55	21OCT2020	111411	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10191301	C4591001 1019 10191301	16-55	23OCT2020	112775	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10191304	C4591001 1019 10191304	16-55	23OCT2020	112776	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
10191305	C4591001 1019 10191305	16-55	23OCT2020	112777	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10191306	C4591001 1019 10191306	16-55	23OCT2020	112778	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10191312	C4591001 1019 10191312	16-55	27OCT2020	113994	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10191315	C4591001 1019 10191315	16-55	28OCT2020	113996	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10191318	C4591001 1019 10191318	16-55	29OCT2020	113999	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10191321	C4591001 1019 10191321	16-55	30OCT2020	114001	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10211042	C4591001 1021 10211042	16-55	17AUG2020	52374	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10211061	C4591001 1021 10211061	16-55	19AUG2020	52377	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10211066	C4591001 1021 10211066	16-55	20AUG2020	52379	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10211069	C4591001 1021 10211069	16-55	20AUG2020	52381	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10211083	C4591001 1021 10211083	16-55	24AUG2020	63329	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211092	C4591001 1021 10211092	16-55	25AUG2020	63332	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10211097	C4591001 1021 10211097	16-55	26AUG2020	63336	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211099	C4591001 1021 10211099	16-55	26AUG2020	63337	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10211101	C4591001 1021 10211101	16-55	26AUG2020	68058	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211104	C4591001 1021 10211104	16-55	26AUG2020	68065	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10211112	C4591001 1021 10211112	16-55	27AUG2020	68067	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10211117	C4591001 1021 10211117	16-55	28AUG2020	68068	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10211119	C4591001 1021 10211119	16-55	28AUG2020	72762	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10211123	C4591001 1021 10211123	16-55	31AUG2020	72764	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10211127	C4591001 1021 10211127	16-55	31AUG2020	72769	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10211130	C4591001 1021 10211130	16-55	01SEP2020	72770	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10211137	C4591001 1021 10211137	16-55	02SEP2020	77921	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211142	C4591001 1021 10211142	16-55	02SEP2020	77923	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10211146	C4591001 1021 10211146	16-55	03SEP2020	77929	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10211147	C4591001 1021 10211147	16-55	03SEP2020	77930	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10211149	C4591001 1021 10211149	16-55	03SEP2020	79949	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10211152	C4591001 1021 10211152	16-55	03SEP2020	79950	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10211154	C4591001 1021 10211154	16-55	04SEP2020	79957	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211156	C4591001 1021 10211156	16-55	04SEP2020	81500	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211157	C4591001 1021 10211157	16-55	04SEP2020	79960	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10211158	C4591001 1021 10211158	16-55	04SEP2020	81501	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10211168	C4591001 1021 10211168	16-55	08SEP2020	81503	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211182	C4591001 1021 10211182	16-55	10SEP2020	81504	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10211185	C4591001 1021 10211185	16-55	10SEP2020	86949	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211202	C4591001 1021 10211202	16-55	14SEP2020	86951	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10211210	C4591001 1021 10211210	16-55	15SEP2020	86954	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10211211	C4591001 1021 10211211	16-55	15SEP2020	90162	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10211212	C4591001 1021 10211212	16-55	15SEP2020	86956	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10211213	C4591001 1021 10211213	16-55	15SEP2020	90165	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10211216	C4591001 1021 10211216	16-55	15SEP2020	90166	Placebo	15SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10211219	C4591001 1021 10211219	16-55	16SEP2020	90172	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10211220	C4591001 1021 10211220	16-55	16SEP2020	91073	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211223	C4591001 1021 10211223	16-55	16SEP2020	91075	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10211224	C4591001 1021 10211224	16-55	17SEP2020	91079	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10211230	C4591001 1021 10211230	16-55	17SEP2020	91080	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10211235	C4591001 1021 10211235	16-55	18SEP2020	93677	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10211239	C4591001 1021 10211239	16-55	21SEP2020	93679	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211240	C4591001 1021 10211240	16-55	21SEP2020	93681	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10211242	C4591001 1021 10211242	16-55	21SEP2020	93682	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10211244	C4591001 1021 10211244	16-55	21SEP2020	95504	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10211245	C4591001 1021 10211245	16-55	22SEP2020	95507	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10211246	C4591001 1021 10211246	16-55	22SEP2020	95510	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10211247	C4591001 1021 10211247	16-55	22SEP2020	95511	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10211248	C4591001 1021 10211248	16-55	22SEP2020	96451	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10211252	C4591001 1021 10211252	16-55	21OCT2020	96453	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10221010	C4591001 1022 10221010	16-55	17AUG2020	50526	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221013	C4591001 1022 10221013	16-55	17AUG2020	50532	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10221017	C4591001 1022 10221017	16-55	17AUG2020	50535	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10221018	C4591001 1022 10221018	16-55	17AUG2020	53407	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10221019	C4591001 1022 10221019	16-55	18AUG2020	53409	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221020	C4591001 1022 10221020	16-55	18AUG2020	53410	Placebo	18AUG2020/ Placebo	11SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10221023	C4591001 1022 10221023	16-55	18AUG2020	53416	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221024	C4591001 1022 10221024	16-55	18AUG2020	54833	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10221025	C4591001 1022 10221025	16-55	18AUG2020	54839	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10221027	C4591001 1022 10221027	16-55	18AUG2020	54841	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10221028	C4591001 1022 10221028	16-55	19AUG2020	54843	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221030	C4591001 1022 10221030	16-55	19AUG2020	56599	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10221031	C4591001 1022 10221031	16-55	19AUG2020	56602	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221033	C4591001 1022 10221033	16-55	20AUG2020	56603	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10221035	C4591001 1022 10221035	16-55	20AUG2020	56606	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10221040	C4591001 1022 10221040	16-55	21AUG2020	60682	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10221043	C4591001 1022 10221043	16-55	11SEP2020	88893	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221048	C4591001 1022 10221048	16-55	21AUG2020	60683	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10221049	C4591001 1022 10221049	16-55	21AUG2020	60685	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10221051	C4591001 1022 10221051	16-55	24AUG2020	60687	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221052	C4591001 1022 10221052	16-55	24AUG2020	63954	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10221054	C4591001 1022 10221054	16-55	24AUG2020	63955	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10221055	C4591001 1022 10221055	16-55	24AUG2020	63958	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10221062	C4591001 1022 10221062	16-55	25AUG2020	63962	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221064	C4591001 1022 10221064	16-55	25AUG2020	66786	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10221066	C4591001 1022 10221066	16-55	26AUG2020	66787	Placebo	26AUG2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10221069	C4591001 1022 10221069	16-55	26AUG2020	66794	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221070	C4591001 1022 10221070	16-55	26AUG2020	66796	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10221074	C4591001 1022 10221074	16-55	26AUG2020	68969	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10221076	C4591001 1022 10221076	16-55	27AUG2020	68970	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221078	C4591001 1022 10221078	16-55	27AUG2020	68971	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10221080	C4591001 1022 10221080	16-55	27AUG2020	68972	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10221081	C4591001 1022 10221081	16-55	27AUG2020	70626	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10221083	C4591001 1022 10221083	16-55	27AUG2020	70628	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10221084	C4591001 1022 10221084	16-55	27AUG2020	70630	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10221087	C4591001 1022 10221087	16-55	28AUG2020	72389	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10221088	C4591001 1022 10221088	16-55	28AUG2020	70634	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221093	C4591001 1022 10221093	16-55	31AUG2020	72390	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10221094	C4591001 1022 10221094	16-55	31AUG2020	72397	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10221098	C4591001 1022 10221098	16-55	31AUG2020	72399	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10221100	C4591001 1022 10221100	16-55	31AUG2020	76113	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10221101	C4591001 1022 10221101	16-55	01SEP2020	76114	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10221105	C4591001 1022 10221105	16-55	01SEP2020	76115	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221106	C4591001 1022 10221106	16-55	01SEP2020	76120	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10221108	C4591001 1022 10221108	16-55	02SEP2020	78321	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10221110	C4591001 1022 10221110	16-55	02SEP2020	78324	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10221111	C4591001 1022 10221111	16-55	02SEP2020	78325	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221112	C4591001 1022 10221112	16-55	02SEP2020	78328	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10221115	C4591001 1022 10221115	16-55	02SEP2020	79062	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10221117	C4591001 1022 10221117	16-55	02SEP2020	79063	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221120	C4591001 1022 10221120	16-55	03SEP2020	79068	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221122	C4591001 1022 10221122	16-55	03SEP2020	79070	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10221123	C4591001 1022 10221123	16-55	03SEP2020	80333	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221125	C4591001 1022 10221125	16-55	03SEP2020	80334	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10221126	C4591001 1022 10221126	16-55	03SEP2020	80335	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10221127	C4591001 1022 10221127	16-55	03SEP2020	80341	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221128	C4591001 1022 10221128	16-55	04SEP2020	81461	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221129	C4591001 1022 10221129	16-55	04SEP2020	81463	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10221131	C4591001 1022 10221131	16-55	04SEP2020	81466	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10221133	C4591001 1022 10221133	16-55	04SEP2020	81471	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10221134	C4591001 1022 10221134	16-55	04SEP2020	82319	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10221136	C4591001 1022 10221136	16-55	08SEP2020	82320	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10221137	C4591001 1022 10221137	16-55	08SEP2020	82322	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10221138	C4591001 1022 10221138	16-55	08SEP2020	82324	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10221139	C4591001 1022 10221139	16-55	08SEP2020	84175	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10221142	C4591001 1022 10221142	16-55	08SEP2020	84176	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10221143	C4591001 1022 10221143	16-55	08SEP2020	254977	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10221144	C4591001 1022 10221144	16-55	09SEP2020	84181	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10221147	C4591001 1022 10221147	16-55	09SEP2020	84183	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10221156	C4591001 1022 10221156	16-55	15SEP2020	88897	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10221164	C4591001 1022 10221164	16-55	17SEP2020	88898	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10221179	C4591001 1022 10221179	16-55	28SEP2020	88900	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10241026	C4591001 1024 10241026	16-55	17AUG2020	50352	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10241027	C4591001 1024 10241027	16-55	17AUG2020	50356	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10241029	C4591001 1024 10241029	16-55	17AUG2020	52674	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10241030	C4591001 1024 10241030	16-55	17AUG2020	52679	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241032	C4591001 1024 10241032	16-55	17AUG2020	52681	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241033	C4591001 1024 10241033	16-55	18AUG2020	52684	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10241036	C4591001 1024 10241036	16-55	18AUG2020	54929	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10241038	C4591001 1024 10241038	16-55	18AUG2020	54934	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10241039	C4591001 1024 10241039	16-55	18AUG2020	54935	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10241040	C4591001 1024 10241040	16-55	18AUG2020	54939	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10241042	C4591001 1024 10241042	16-55	19AUG2020	55793	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10241043	C4591001 1024 10241043	16-55	19AUG2020	55797	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10241044	C4591001 1024 10241044	16-55	19AUG2020	55799	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10241045	C4591001 1024 10241045	16-55	19AUG2020	55804	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10241046	C4591001 1024 10241046	16-55	19AUG2020	56813	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241051	C4591001 1024 10241051	16-55	20AUG2020	56815	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241052	C4591001 1024 10241052	16-55	20AUG2020	56820	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10241054	C4591001 1024 10241054	16-55	20AUG2020	56822	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10241055	C4591001 1024 10241055	16-55	20AUG2020	59717	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10241056	C4591001 1024 10241056	16-55	20AUG2020	59721	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10241058	C4591001 1024 10241058	16-55	21AUG2020	59722	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241061	C4591001 1024 10241061	16-55	21AUG2020	59726	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10241063	C4591001 1024 10241063	16-55	24AUG2020	63257	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10241064	C4591001 1024 10241064	16-55	24AUG2020	63258	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10241066	C4591001 1024 10241066	16-55	24AUG2020	63264	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241067	C4591001 1024 10241067	16-55	24AUG2020	63266	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10241070	C4591001 1024 10241070	16-55	24AUG2020	64604	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10241071	C4591001 1024 10241071	16-55	24AUG2020	64605	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10241072	C4591001 1024 10241072	16-55	25AUG2020	64608	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10241073	C4591001 1024 10241073	16-55	25AUG2020	64609	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10241074	C4591001 1024 10241074	16-55	25AUG2020	65466	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10241075	C4591001 1024 10241075	16-55	25AUG2020	65468	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10241078	C4591001 1024 10241078	16-55	26AUG2020	65471	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10241080	C4591001 1024 10241080	16-55	26AUG2020	65476	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10241084	C4591001 1024 10241084	16-55	27AUG2020	69761	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241085	C4591001 1024 10241085	16-55	27AUG2020	69765	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10241086	C4591001 1024 10241086	16-55	27AUG2020	69767	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10241088	C4591001 1024 10241088	16-55	27AUG2020	69772	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10241090	C4591001 1024 10241090	16-55	28AUG2020	244293	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10241091	C4591001 1024 10241091	16-55	28AUG2020	71777	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10241092	C4591001 1024 10241092	16-55	28AUG2020	71781	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10241094	C4591001 1024 10241094	16-55	28AUG2020	71782	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10241095	C4591001 1024 10241095	16-55	28AUG2020	71784	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10241098	C4591001 1024 10241098	16-55	28AUG2020	72618	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10241100	C4591001 1024 10241100	16-55	31AUG2020	72619	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241101	C4591001 1024 10241101	16-55	31AUG2020	72622	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	
10241102	C4591001 1024 10241102	16-55	31AUG2020	72624	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10241104	C4591001 1024 10241104	16-55	01SEP2020	76387	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10241106	C4591001 1024 10241106	16-55	01SEP2020	76388	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10241107	C4591001 1024 10241107	16-55	02SEP2020	76390	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10241108	C4591001 1024 10241108	16-55	02SEP2020	76391	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10241109	C4591001 1024 10241109	16-55	02SEP2020	79399	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10241112	C4591001 1024 10241112	16-55	03SEP2020	79401	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10241114	C4591001 1024 10241114	16-55	08SEP2020	79406	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10241117	C4591001 1024 10241117	16-55	16SEP2020	79407	Placebo	16SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10241118	C4591001 1024 10241118†	16-55	21SEP2020	95073	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10241121	C4591001 1024 10241121†	16-55	08OCT2020	95074	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10241123	C4591001 1024 10241123†	16-55	14OCT2020	95075	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10241124	C4591001 1024 10241124†	16-55	14OCT2020	95077	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10241129	C4591001 1024 10241129	16-55	19OCT2020	108549	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10241131	C4591001 1024 10241131	16-55	20OCT2020	108552	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10241132	C4591001 1024 10241132	16-55	26OCT2020	108553	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10271026	C4591001 1027 10271026	16-55	17AUG2020	50601	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10271028	C4591001 1027 10271028	16-55	17AUG2020	50607	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10271029	C4591001 1027 10271029	16-55	17AUG2020	50608	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271032	C4591001 1027 10271032	16-55	18AUG2020	54164	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10271033	C4591001 1027 10271033	16-55	18AUG2020	54166	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10271037	C4591001 1027 10271037	16-55	18AUG2020	54168	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10271040	C4591001 1027 10271040	16-55	19AUG2020	54172	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10271041	C4591001 1027 10271041	16-55	19AUG2020	56489	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10271046	C4591001 1027 10271046	16-55	19AUG2020	56495	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10271049	C4591001 1027 10271049	16-55	20AUG2020	56499	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10271058	C4591001 1027 10271058	16-55	21AUG2020	56500	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10271059	C4591001 1027 10271059	16-55	21AUG2020	60234	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10271061	C4591001 1027 10271061	16-55	21AUG2020	60237	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271079	C4591001 1027 10271079	16-55	25AUG2020	60240	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10271083	C4591001 1027 10271083	16-55	26AUG2020	60243	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10271086	C4591001 1027 10271086	16-55	26AUG2020	67817	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10271091	C4591001 1027 10271091	16-55	26AUG2020	67819	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10271094	C4591001 1027 10271094	16-55	27AUG2020	67823	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10271104	C4591001 1027 10271104	16-55	28AUG2020	67825	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10271105	C4591001 1027 10271105	16-55	28AUG2020	72609	Placebo	28AUG2020/ Placebo			
10271107	C4591001 1027 10271107	16-55	31AUG2020	72611	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10271108	C4591001 1027 10271108	16-55	31AUG2020	72612	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10271119	C4591001 1027 10271119	16-55	01SEP2020	72614	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271126	C4591001 1027 10271126	16-55	01SEP2020	77239	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10271127	C4591001 1027 10271127	16-55	01SEP2020	77240	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10271129	C4591001 1027 10271129	16-55	02SEP2020	77243	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10271145	C4591001 1027 10271145	16-55	03SEP2020	77248	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10271152	C4591001 1027 10271152	16-55	04SEP2020	82098	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10271155	C4591001 1027 10271155	16-55	08SEP2020	82100	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10271157	C4591001 1027 10271157	16-55	08SEP2020	82103	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10271158	C4591001 1027 10271158	16-55	08SEP2020	82104	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10271162	C4591001 1027 10271162	16-55	09SEP2020	84761	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271163	C4591001 1027 10271163	16-55	09SEP2020	84762	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271172	C4591001 1027 10271172	16-55	09SEP2020	84763	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271173	C4591001 1027 10271173	16-55	10SEP2020	84765	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10271182	C4591001 1027 10271182	16-55	10SEP2020	87209	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10271183	C4591001 1027 10271183	16-55	10SEP2020	87215	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271192	C4591001 1027 10271192	16-55	11SEP2020	87216	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10271193	C4591001 1027 10271193	16-55	11SEP2020	87219	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10271197	C4591001 1027 10271197	16-55	16SEP2020	91457	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10271199	C4591001 1027 10271199	16-55	22SEP2020	91459	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10271203	C4591001 1027 10271203	16-55	24SEP2020	91462	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10271207	C4591001 1027 10271207†	16-55	01OCT2020	91468	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10271208	C4591001 1027 10271208†	16-55	01OCT2020	102790	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10271212	C4591001 1027 10271212†	16-55	08OCT2020	102791	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10271214	C4591001 1027 10271214	16-55	14OCT2020	102792	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10271215	C4591001 1027 10271215	16-55	15OCT2020	102794	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10271216	C4591001 1027 10271216	16-55	15OCT2020	108306	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10281005	C4591001 1028 10281005	16-55	17AUG2020	48543	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10281007	C4591001 1028 10281007	16-55	17AUG2020	53349	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281009	C4591001 1028 10281009	16-55	17AUG2020	53298	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
10281010	C4591001 1028 10281010	16-55	18AUG2020	53350	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10281013	C4591001 1028 10281013	16-55	18AUG2020	53354	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281017	C4591001 1028 10281017	16-55	18AUG2020	53355	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10281018	C4591001 1028 10281018	16-55	19AUG2020	55987	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10281019	C4591001 1028 10281019	16-55	19AUG2020	55990	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281022	C4591001 1028 10281022	16-55	19AUG2020	55995	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10281023	C4591001 1028 10281023	16-55	19AUG2020	55991	Placebo	19AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10281024	C4591001 1028 10281024	16-55	19AUG2020	57006	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10281025	C4591001 1028 10281025	16-55	19AUG2020	57005	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281026	C4591001 1028 10281026	16-55	20AUG2020	57011	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281027	C4591001 1028 10281027	16-55	20AUG2020	57015	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10281028	C4591001 1028 10281028	16-55	20AUG2020	58265	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281029	C4591001 1028 10281029	16-55	20AUG2020	58266	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281030	C4591001 1028 10281030	16-55	20AUG2020	58272	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10281031	C4591001 1028 10281031	16-55	20AUG2020	58267	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10281033	C4591001 1028 10281033	16-55	20AUG2020	59313	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10281035	C4591001 1028 10281035	16-55	21AUG2020	59317	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10281036	C4591001 1028 10281036	16-55	21AUG2020	59315	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10281038	C4591001 1028 10281038	16-55	21AUG2020	59319	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10281043	C4591001 1028 10281043	16-55	24AUG2020	63378	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10281044	C4591001 1028 10281044	16-55	24AUG2020	63384	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10281047	C4591001 1028 10281047	16-55	24AUG2020	63387	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281048	C4591001 1028 10281048	16-55	24AUG2020	63385	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10281049	C4591001 1028 10281049	16-55	24AUG2020	64301	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10281050	C4591001 1028 10281050	16-55	24AUG2020	64302	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10281052	C4591001 1028 10281052	16-55	25AUG2020	64304	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10281053	C4591001 1028 10281053	16-55	25AUG2020	64310	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10281054	C4591001 1028 10281054	16-55	25AUG2020	66521	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10281055	C4591001 1028 10281055	16-55	25AUG2020	66522	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10281059	C4591001 1028 10281059	16-55	26AUG2020	66525	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10281060	C4591001 1028 10281060	16-55	26AUG2020	66529	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10281061	C4591001 1028 10281061	16-55	26AUG2020	68681	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281062	C4591001 1028 10281062	16-55	26AUG2020	68684	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281065	C4591001 1028 10281065	16-55	27AUG2020	68690	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10281066	C4591001 1028 10281066	16-55	27AUG2020	68691	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10281069	C4591001 1028 10281069	16-55	27AUG2020	70343	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10281070	C4591001 1028 10281070	16-55	27AUG2020	70344	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10281072	C4591001 1028 10281072	16-55	27AUG2020	70345	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
10281075	C4591001 1028 10281075	16-55	28AUG2020	70348	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10281077	C4591001 1028 10281077	16-55	28AUG2020	71898	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10281078	C4591001 1028 10281078	16-55	28AUG2020	71903	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10281079	C4591001 1028 10281079	16-55	28AUG2020	71906	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281080	C4591001 1028 10281080	16-55	28AUG2020	71907	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281085	C4591001 1028 10281085	16-55	31AUG2020	75029	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281086	C4591001 1028 10281086	16-55	31AUG2020	75035	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281087	C4591001 1028 10281087	16-55	31AUG2020	75037	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10281088	C4591001 1028 10281088	16-55	31AUG2020	75036	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10281089	C4591001 1028 10281089	16-55	31AUG2020	75809	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10281090	C4591001 1028 10281090	16-55	01SEP2020	75811	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10281094	C4591001 1028 10281094	16-55	01SEP2020	75817	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10281095	C4591001 1028 10281095	16-55	01SEP2020	75820	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10281096	C4591001 1028 10281096	16-55	01SEP2020	77288	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281097	C4591001 1028 10281097	16-55	01SEP2020	77286	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281098	C4591001 1028 10281098	16-55	01SEP2020	77293	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281100	C4591001 1028 10281100	16-55	02SEP2020	77295	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10281101	C4591001 1028 10281101	16-55	02SEP2020	78055	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10281103	C4591001 1028 10281103	16-55	02SEP2020	78057	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281104	C4591001 1028 10281104	16-55	02SEP2020	78060	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281105	C4591001 1028 10281105	16-55	02SEP2020	78931	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10281106	C4591001 1028 10281106	16-55	02SEP2020	78063	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10281110	C4591001 1028 10281110	16-55	03SEP2020	78934	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281112	C4591001 1028 10281112	16-55	03SEP2020	78932	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281114	C4591001 1028 10281114	16-55	03SEP2020	78935	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281116	C4591001 1028 10281116	16-55	03SEP2020	80705	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281118	C4591001 1028 10281118	16-55	03SEP2020	80706	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10281119	C4591001 1028 10281119	16-55	04SEP2020	80709	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10281120	C4591001 1028 10281120	16-55	04SEP2020	80707	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10281121	C4591001 1028 10281121	16-55	04SEP2020	81283	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281122	C4591001 1028 10281122	16-55	04SEP2020	81287	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10281124	C4591001 1028 10281124	16-55	04SEP2020	81288	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10281125	C4591001 1028 10281125	16-55	04SEP2020	81291	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281126	C4591001 1028 10281126	16-55	04SEP2020	81750	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281130	C4591001 1028 10281130	16-55	05SEP2020	81751	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10281131	C4591001 1028 10281131	16-55	05SEP2020	81754	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10281133	C4591001 1028 10281133	16-55	05SEP2020	82782	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281134	C4591001 1028 10281134	16-55	05SEP2020	82784	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10281135	C4591001 1028 10281135	16-55	05SEP2020	81759	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo		
10281138	C4591001 1028 10281138	16-55	07SEP2020	82789	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10281141	C4591001 1028 10281141	16-55	07SEP2020	82790	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10281143	C4591001 1028 10281143	16-55	08SEP2020	83357	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10281144	C4591001 1028 10281144	16-55	08SEP2020	83360	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10281146	C4591001 1028 10281146	16-55	08SEP2020	83361	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281150	C4591001 1028 10281150	16-55	10SEP2020	86390	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10281152	C4591001 1028 10281152	16-55	09SEP2020	83362	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10281153	C4591001 1028 10281153	16-55	09SEP2020	84965	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281154	C4591001 1028 10281154	16-55	09SEP2020	84971	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10281155	C4591001 1028 10281155	16-55	09SEP2020	84966	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10281156	C4591001 1028 10281156	16-55	09SEP2020	84974	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10281158	C4591001 1028 10281158	16-55	10SEP2020	86381	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10281159	C4591001 1028 10281159	16-55	10SEP2020	86387	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10281161	C4591001 1028 10281161	16-55	10SEP2020	86392	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281162	C4591001 1028 10281162	16-55	10SEP2020	87162	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281165	C4591001 1028 10281165	16-55	10SEP2020	87164	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281167	C4591001 1028 10281167	16-55	11SEP2020	87165	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10281170	C4591001 1028 10281170	16-55	11SEP2020	87168	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10281172	C4591001 1028 10281172	16-55	11SEP2020	88410	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10281174	C4591001 1028 10281174	16-55	14SEP2020	88416	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281176	C4591001 1028 10281176	16-55	14SEP2020	88417	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281177	C4591001 1028 10281177	16-55	14SEP2020	88420	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10281183	C4591001 1028 10281183	16-55	15SEP2020	90620	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10281184	C4591001 1028 10281184	16-55	15SEP2020	90622	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10281186	C4591001 1028 10281186	16-55	15SEP2020	90625	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281188	C4591001 1028 10281188	16-55	16SEP2020	90628	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10281190	C4591001 1028 10281190	16-55	16SEP2020	91208	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10281191	C4591001 1028 10281191	16-55	16SEP2020	91212	Placebo	16SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281192	C4591001 1028 10281192	16-55	16SEP2020	91214	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10281197	C4591001 1028 10281197	16-55	17SEP2020	91216	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10281198	C4591001 1028 10281198	16-55	17SEP2020	92240	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10281200	C4591001 1028 10281200	16-55	17SEP2020	92244	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10281202	C4591001 1028 10281202	16-55	18SEP2020	92245	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10281203	C4591001 1028 10281203	16-55	18SEP2020	92247	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10281205	C4591001 1028 10281205	16-55	18SEP2020	93797	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281207	C4591001 1028 10281207	16-55	18SEP2020	93804	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10281208	C4591001 1028 10281208	16-55	21SEP2020	93806	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10281209	C4591001 1028 10281209	16-55	21SEP2020	93807	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10281211	C4591001 1028 10281211	16-55	21SEP2020	94841	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10281213	C4591001 1028 10281213	16-55	30SEP2020	99755	Placebo	30SEP2020/ Placebo	30OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10281216	C4591001 1028 10281216	16-55	22SEP2020	94843	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281221	C4591001 1028 10281221	16-55	22SEP2020	94845	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10281222	C4591001 1028 10281222	16-55	23SEP2020	94851	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10281223	C4591001 1028 10281223	16-55	23SEP2020	97338	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281224	C4591001 1028 10281224	16-55	23SEP2020	97343	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281225	C4591001 1028 10281225	16-55	23SEP2020	97347	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10281226	C4591001 1028 10281226	16-55	23SEP2020	97344	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281227	C4591001 1028 10281227	16-55	23SEP2020	98021	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10281228	C4591001 1028 10281228	16-55	23SEP2020	98177	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10281229	C4591001 1028 10281229	16-55	24SEP2020	98183	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10281231	C4591001 1028 10281231	16-55	24SEP2020	98184	Placebo	24SEP2020/ Placebo	26OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281236	C4591001 1028 10281236	16-55	25SEP2020	98186	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10281237	C4591001 1028 10281237	16-55	25SEP2020	99751	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10281240	C4591001 1028 10281240	16-55	30SEP2020	99752	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10281241	C4591001 1028 10281241	16-55	01OCT2020	99758	Placebo	01OCT2020/ Placebo	29OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281242	C4591001 1028 10281242	16-55	01OCT2020	102919	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10281243	C4591001 1028 10281243	16-55	02OCT2020	102922	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10281244	C4591001 1028 10281244	16-55	05OCT2020	102924	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10281246	C4591001 1028 10281246	16-55	06OCT2020	102927	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10281247	C4591001 1028 10281247	16-55	07OCT2020	104634	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10281248	C4591001 1028 10281248	16-55	07OCT2020	104639	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10281249	C4591001 1028 10281249	16-55	07OCT2020	104642	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10281250	C4591001 1028 10281250	16-55	08OCT2020	104644	Placebo	08OCT2020/ Placebo	03NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10281251	C4591001 1028 10281251	16-55	09OCT2020	105800	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10281253	C4591001 1028 10281253	16-55	13OCT2020	105803	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281254	C4591001 1028 10281254	16-55	14OCT2020	105805	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10281255	C4591001 1028 10281255	16-55	14OCT2020	105806	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10281256	C4591001 1028 10281256	16-55	14OCT2020	107659	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10281257	C4591001 1028 10281257	16-55	14OCT2020	107661	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10281258	C4591001 1028 10281258	16-55	14OCT2020	107664	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281259	C4591001 1028 10281259	16-55	15OCT2020	107665	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10281261	C4591001 1028 10281261	16-55	19OCT2020	109975	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10281262	C4591001 1028 10281262	16-55	19OCT2020	109977	Placebo	19OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10281265	C4591001 1028 10281265	16-55	20OCT2020	109979	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10281267	C4591001 1028 10281267	16-55	21OCT2020	111318	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281269	C4591001 1028 10281269	16-55	20OCT2020	109980	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10281271	C4591001 1028 10281271	16-55	21OCT2020	111320	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10281274	C4591001 1028 10281274	16-55	22OCT2020	111327	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10281275	C4591001 1028 10281275	16-55	22OCT2020	111324	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10281276	C4591001 1028 10281276	16-55	22OCT2020	112447	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10281279	C4591001 1028 10281279	16-55	26OCT2020	112448	Placebo	26OCT2020/ Placebo	19NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10281280	C4591001 1028 10281280	16-55	26OCT2020	112453	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10281282	C4591001 1028 10281282	16-55	27OCT2020	112455	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10281284	C4591001 1028 10281284	16-55	27OCT2020	114162	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
10281285	C4591001 1028 10281285	16-55	27OCT2020	114164	Placebo	27OCT2020/ Placebo		17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10281286	C4591001 1028 10281286	16-55	27OCT2020	114169	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10281287	C4591001 1028 10281287	16-55	28OCT2020	114171	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10281290	C4591001 1028 10281290	16-55	28OCT2020	114497	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10281291	C4591001 1028 10281291	16-55	28OCT2020	114502	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10281294	C4591001 1028 10281294	16-55	29OCT2020	114504	Placebo	29OCT2020/ Placebo		02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10301001	C4591001 1030 10301001	16-55	26AUG2020	67361	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301002	C4591001 1030 10301002	16-55	26AUG2020	67362	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10301003	C4591001 1030 10301003	16-55	26AUG2020	67369	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10301004	C4591001 1030 10301004	16-55	27AUG2020	67372	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10301005	C4591001 1030 10301005	16-55	27AUG2020	69500	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301008	C4591001 1030 10301008	16-55	27AUG2020	69502	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10301010	C4591001 1030 10301010	16-55	28AUG2020	69503	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10301011	C4591001 1030 10301011	16-55	28AUG2020	69505	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10301012	C4591001 1030 10301012	16-55	28AUG2020	72558	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10301013	C4591001 1030 10301013	16-55	28AUG2020	72559	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301014	C4591001 1030 10301014	16-55	28AUG2020	72564	Placebo	28AUG2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10301015	C4591001 1030 10301015	16-55	28AUG2020	72568	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10301018	C4591001 1030 10301018	16-55	31AUG2020	74886	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10301019	C4591001 1030 10301019	16-55	31AUG2020	74887	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10301021	C4591001 1030 10301021	16-55	31AUG2020	74890	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301022	C4591001 1030 10301022	16-55	31AUG2020	74893	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10301023	C4591001 1030 10301023	16-55	31AUG2020	75909	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10301026	C4591001 1030 10301026	16-55	01SEP2020	75913	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10301027	C4591001 1030 10301027	16-55	01SEP2020	75914	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10301028	C4591001 1030 10301028	16-55	01SEP2020	77072	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10301029	C4591001 1030 10301029	16-55	01SEP2020	77074	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10301030	C4591001 1030 10301030	16-55	01SEP2020	77075	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301032	C4591001 1030 10301032	16-55	02SEP2020	77080	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10301038	C4591001 1030 10301038	16-55	03SEP2020	78774	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10301039	C4591001 1030 10301039	16-55	03SEP2020	78777	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301040	C4591001 1030 10301040	16-55	03SEP2020	78782	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10301041	C4591001 1030 10301041	16-55	03SEP2020	79877	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10301042	C4591001 1030 10301042	16-55	03SEP2020	79880	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10301043	C4591001 1030 10301043	16-55	03SEP2020	79886	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10301044	C4591001 1030 10301044	16-55	03SEP2020	79888	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10301045	C4591001 1030 10301045	16-55	04SEP2020	81245	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10301048	C4591001 1030 10301048	16-55	04SEP2020	81247	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10301049	C4591001 1030 10301049	16-55	04SEP2020	81251	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10301050	C4591001 1030 10301050	16-55	08SEP2020	81252	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10301053	C4591001 1030 10301053	16-55	08SEP2020	83946	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301054	C4591001 1030 10301054	16-55	08SEP2020	83948	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10301055	C4591001 1030 10301055	16-55	08SEP2020	83950	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10301056	C4591001 1030 10301056	16-55	08SEP2020	83956	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10301057	C4591001 1030 10301057	16-55	09SEP2020	84857	Placebo	09SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10301060	C4591001 1030 10301060	16-55	09SEP2020	84862	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10301061	C4591001 1030 10301061	16-55	09SEP2020	84863	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10301063	C4591001 1030 10301063	16-55	10SEP2020	84867	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10301065	C4591001 1030 10301065	16-55	10SEP2020	86669	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10301069	C4591001 1030 10301069	16-55	10SEP2020	86673	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301070	C4591001 1030 10301070	16-55	11SEP2020	86674	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301071	C4591001 1030 10301071	16-55	11SEP2020	86677	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10301072	C4591001 1030 10301072	16-55	11SEP2020	87751	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10301075	C4591001 1030 10301075	16-55	11SEP2020	87752	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10301077	C4591001 1030 10301077	16-55	11SEP2020	87753	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301080	C4591001 1030 10301080	16-55	11SEP2020	87758	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10301081	C4591001 1030 10301081	16-55	14SEP2020	89315	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301082	C4591001 1030 10301082	16-55	14SEP2020	89317	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10301083	C4591001 1030 10301083	16-55	14SEP2020	89318	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301087	C4591001 1030 10301087	16-55	15SEP2020	89319	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301088	C4591001 1030 10301088	16-55	15SEP2020	90115	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301093	C4591001 1030 10301093	16-55	15SEP2020	90116	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301095	C4591001 1030 10301095	16-55	15SEP2020	90119	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10301097	C4591001 1030 10301097	16-55	16SEP2020	90122	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10301099	C4591001 1030 10301099	16-55	16SEP2020	91328	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10301100	C4591001 1030 10301100	16-55	16SEP2020	91331	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10301101	C4591001 1030 10301101	16-55	17SEP2020	91332	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10301102	C4591001 1030 10301102	16-55	17SEP2020	91334	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10301104	C4591001 1030 10301104	16-55	17SEP2020	92825	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10301106	C4591001 1030 10301106	16-55	18SEP2020	92827	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10301107	C4591001 1030 10301107	16-55	18SEP2020	92829	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301110	C4591001 1030 10301110	16-55	18SEP2020	92835	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10301113	C4591001 1030 10301113	16-55	18SEP2020	94050	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10301120	C4591001 1030 10301120	16-55	22SEP2020	94053	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10301122	C4591001 1030 10301122	16-55	22SEP2020	94054	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10301123	C4591001 1030 10301123	16-55	22SEP2020	94055	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10301124	C4591001 1030 10301124	16-55	22SEP2020	96821	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10301127	C4591001 1030 10301127	16-55	23SEP2020	96824	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10301128	C4591001 1030 10301128	16-55	23SEP2020	96827	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10301130	C4591001 1030 10301130	16-55	24SEP2020	96832	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10301134	C4591001 1030 10301134	16-55	24SEP2020	98897	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301136	C4591001 1030 10301136	16-55	25SEP2020	98901	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10301137	C4591001 1030 10301137	16-55	25SEP2020	98903	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10301139	C4591001 1030 10301139	16-55	25SEP2020	98904	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10301142	C4591001 1030 10301142	16-55	06OCT2020	104144	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10301143	C4591001 1030 10301143	16-55	07OCT2020	104145	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10301145	C4591001 1030 10301145	16-55	09OCT2020	104147	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10301146	C4591001 1030 10301146	16-55	12OCT2020	104152	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10301148	C4591001 1030 10301148	16-55	12OCT2020	106493	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10301152	C4591001 1030 10301152	16-55	15OCT2020	106497	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10301153	C4591001 1030 10301153	16-55	16OCT2020	106500	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10301154	C4591001 1030 10301154	16-55	19OCT2020	106501	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10301155	C4591001 1030 10301155	16-55	19OCT2020	110120	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10361004	C4591001 1036 10361004	16-55	19AUG2020	56323	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10361006	C4591001 1036 10361006	16-55	19AUG2020	56327	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10361009	C4591001 1036 10361009	16-55	19AUG2020	56328	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10361011	C4591001 1036 10361011	16-55	20AUG2020	56329	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
10361012	C4591001 1036 10361012	16-55	20AUG2020	58902	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10361014	C4591001 1036 10361014	16-55	20AUG2020	58903	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10361017	C4591001 1036 10361017	16-55	21AUG2020	58908	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10361018	C4591001 1036 10361018	16-55	21AUG2020	58910	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361020	C4591001 1036 10361020	16-55	21AUG2020	61075	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10361021	C4591001 1036 10361021	16-55	21AUG2020	61078	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10361022	C4591001 1036 10361022	16-55	24AUG2020	61079	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10361023	C4591001 1036 10361023	16-55	25AUG2020	61084	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10361026	C4591001 1036 10361026	16-55	25AUG2020	66606	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10361027	C4591001 1036 10361027	16-55	25AUG2020	66608	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10361029	C4591001 1036 10361029	16-55	25AUG2020	66612	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10361030	C4591001 1036 10361030	16-55	25AUG2020	66613	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10361032	C4591001 1036 10361032	16-55	26AUG2020	68384	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
10361033	C4591001 1036 10361033	16-55	26AUG2020	68389	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361038	C4591001 1036 10361038	16-55	27AUG2020	68391	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10361039	C4591001 1036 10361039	16-55	27AUG2020	68392	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361040	C4591001 1036 10361040	16-55	27AUG2020	70831	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361042	C4591001 1036 10361042	16-55	28AUG2020	70832	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10361043	C4591001 1036 10361043	16-55	28AUG2020	70834	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10361047	C4591001 1036 10361047	16-55	29AUG2020	70837	Placebo	29AUG2020/ Placebo	22SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
10361048	C4591001 1036 10361048	16-55	29AUG2020	73867	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361050	C4591001 1036 10361050	16-55	31AUG2020	73868	BNT162b2 (30 µg)				
10361053	C4591001 1036 10361053	16-55	31AUG2020	73871	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10361055	C4591001 1036 10361055	16-55	31AUG2020	75823	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361056	C4591001 1036 10361056	16-55	31AUG2020	75828	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10361060	C4591001 1036 10361060	16-55	01SEP2020	75829	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10361061	C4591001 1036 10361061	16-55	01SEP2020	75832	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10361062	C4591001 1036 10361062	16-55	01SEP2020	76949	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10361064	C4591001 1036 10361064	16-55	02SEP2020	76951	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10361065	C4591001 1036 10361065	16-55	02SEP2020	76959	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10361068	C4591001 1036 10361068	16-55	02SEP2020	76960	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10361069	C4591001 1036 10361069	16-55	02SEP2020	79221	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361070	C4591001 1036 10361070	16-55	02SEP2020	79223	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10361072	C4591001 1036 10361072	16-55	03SEP2020	79224	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361073	C4591001 1036 10361073	16-55	04SEP2020	79227	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10361074	C4591001 1036 10361074	16-55	04SEP2020	81619	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361075	C4591001 1036 10361075	16-55	04SEP2020	81622	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10361076	C4591001 1036 10361076	16-55	04SEP2020	81623	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10361078	C4591001 1036 10361078	16-55	08SEP2020	81628	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo		
10361084	C4591001 1036 10361084	16-55	09SEP2020	86084	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10361086	C4591001 1036 10361086	16-55	10SEP2020	86085	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10361088	C4591001 1036 10361088	16-55	11SEP2020	86086	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10361093	C4591001 1036 10361093	16-55	12SEP2020	86091	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10361094	C4591001 1036 10361094	16-55	12SEP2020	89192	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361095	C4591001 1036 10361095	16-55	12SEP2020	89197	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361096	C4591001 1036 10361096	16-55	12SEP2020	89199	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo		
10361097	C4591001 1036 10361097	16-55	12SEP2020	89200	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10361098	C4591001 1036 10361098	16-55	12SEP2020	89214	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
10361099	C4591001 1036 10361099	16-55	12SEP2020	89217	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
10361100	C4591001 1036 10361100	16-55	12SEP2020	89219	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo		
10361102	C4591001 1036 10361102	16-55	15SEP2020	89221	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361103	C4591001 1036 10361103	16-55	19SEP2020	94446	Placebo	19SEP2020/ Placebo	10OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361104	C4591001 1036 10361104	16-55	19SEP2020	94447	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
10361105	C4591001 1036 10361105	16-55	28SEP2020	94451	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361107	C4591001 1036 10361107	16-55	24SEP2020	264862	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10361110	C4591001 1036 10361110	16-55	02OCT2020	94454	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10361112	C4591001 1036 10361112	16-55	05OCT2020	103733	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10361117	C4591001 1036 10361117	16-55	16OCT2020	108965	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10361118	C4591001 1036 10361118	16-55	10OCT2020	103735	Placebo	10OCT2020/ Placebo	02NOV2020/ Placebo		
10361119	C4591001 1036 10361119	16-55	10OCT2020	103736	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10361125	C4591001 1036 10361125	16-55	13OCT2020	103741	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361126	C4591001 1036 10361126	16-55	16OCT2020	108967	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10361127	C4591001 1036 10361127	16-55	16OCT2020	108974	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)			
10361128	C4591001 1036 10361128	16-55	16OCT2020	108975	Placebo	16OCT2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10361129	C4591001 1036 10361129	16-55	16OCT2020	109145	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10361131	C4591001 1036 10361131	16-55	16OCT2020	109146	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10361135	C4591001 1036 10361135	16-55	19OCT2020	109147	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10361137	C4591001 1036 10361137	16-55	20OCT2020	109154	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10361141	C4591001 1036 10361141	16-55	23OCT2020	112988	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10361144	C4591001 1036 10361144	16-55	26OCT2020	112989	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10361145	C4591001 1036 10361145	16-55	26OCT2020	112990	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10371007	C4591001 1037 10371007	16-55	18AUG2020	54153	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371008	C4591001 1037 10371008	16-55	18AUG2020	54154	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371010	C4591001 1037 10371010	16-55	18AUG2020	54157	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371017	C4591001 1037 10371017	16-55	19AUG2020	56129	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371018	C4591001 1037 10371018	16-55	19AUG2020	54158	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10371024	C4591001 1037 10371024	16-55	19AUG2020	56133	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371026	C4591001 1037 10371026	16-55	20AUG2020	56138	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10371028	C4591001 1037 10371028	16-55	20AUG2020	58301	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10371029	C4591001 1037 10371029	16-55	20AUG2020	56140	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371037	C4591001 1037 10371037	16-55	21AUG2020	58304	Placebo	21AUG2020/ Placebo	15SEP2020/ Placebo		
10371038	C4591001 1037 10371038	16-55	21AUG2020	58308	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371041	C4591001 1037 10371041	16-55	21AUG2020	58311	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10371042	C4591001 1037 10371042	16-55	21AUG2020	60773	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371043	C4591001 1037 10371043	16-55	21AUG2020	60775	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10371044	C4591001 1037 10371044	16-55	21AUG2020	60778	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10371045	C4591001 1037 10371045	16-55	21AUG2020	60784	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10371046	C4591001 1037 10371046	16-55	21AUG2020	60990	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371047	C4591001 1037 10371047	16-55	21AUG2020	60992	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10371050	C4591001 1037 10371050	16-55	24AUG2020	60994	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10371051	C4591001 1037 10371051	16-55	24AUG2020	60996	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10371052	C4591001 1037 10371052	16-55	24AUG2020	63425	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10371054	C4591001 1037 10371054	16-55	24AUG2020	63426	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10371056	C4591001 1037 10371056	16-55	24AUG2020	63428	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371058	C4591001 1037 10371058	16-55	24AUG2020	63435	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371060	C4591001 1037 10371060	16-55	24AUG2020	64662	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10371061	C4591001 1037 10371061	16-55	25AUG2020	64665	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10371065	C4591001 1037 10371065	16-55	25AUG2020	64668	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10371067	C4591001 1037 10371067	16-55	25AUG2020	64669	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10371068	C4591001 1037 10371068	16-55	25AUG2020	65705	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10371072	C4591001 1037 10371072	16-55	26AUG2020	65709	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10371073	C4591001 1037 10371073	16-55	26AUG2020	65713	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10371074	C4591001 1037 10371074	16-55	26AUG2020	65716	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371076	C4591001 1037 10371076	16-55	26AUG2020	67686	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371077	C4591001 1037 10371077	16-55	26AUG2020	67689	Placebo	26AUG2020/ Placebo			
10371078	C4591001 1037 10371078	16-55	26AUG2020	67690	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10371081	C4591001 1037 10371081	16-55	27AUG2020	67692	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10371082	C4591001 1037 10371082	16-55	27AUG2020	70037	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10371083	C4591001 1037 10371083	16-55	28AUG2020	70041	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10371087	C4591001 1037 10371087	16-55	31AUG2020	70046	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10371088	C4591001 1037 10371088	16-55	31AUG2020	70042	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10371092	C4591001 1037 10371092	16-55	31AUG2020	74962	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371096	C4591001 1037 10371096	16-55	31AUG2020	74964	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
10371097	C4591001 1037 10371097	16-55	01SEP2020	74966	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371104	C4591001 1037 10371104	16-55	01SEP2020	76601	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371109	C4591001 1037 10371109	16-55	01SEP2020	76605	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371110	C4591001 1037 10371110	16-55	01SEP2020	76608	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371115	C4591001 1037 10371115	16-55	02SEP2020	76612	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10371116	C4591001 1037 10371116	16-55	02SEP2020	78079	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10371124	C4591001 1037 10371124	16-55	02SEP2020	78081	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371125	C4591001 1037 10371125	16-55	02SEP2020	78085	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10371126	C4591001 1037 10371126	16-55	03SEP2020	78088	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10371130	C4591001 1037 10371130	16-55	03SEP2020	79628	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10371131	C4591001 1037 10371131	16-55	03SEP2020	79630	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371138	C4591001 1037 10371138	16-55	03SEP2020	79631	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10371140	C4591001 1037 10371140	16-55	03SEP2020	79636	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371142	C4591001 1037 10371142	16-55	04SEP2020	81833	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10371145	C4591001 1037 10371145	16-55	04SEP2020	81836	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10371148	C4591001 1037 10371148	16-55	04SEP2020	81838	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10371152	C4591001 1037 10371152	16-55	04SEP2020	81841	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10371154	C4591001 1037 10371154	16-55	15SEP2020	90249	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371155	C4591001 1037 10371155	16-55	08SEP2020	83297	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10371157	C4591001 1037 10371157	16-55	08SEP2020	83298	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10371168	C4591001 1037 10371168	16-55	09SEP2020	83301	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371169	C4591001 1037 10371169	16-55	09SEP2020	84905	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10371170	C4591001 1037 10371170	16-55	09SEP2020	83305	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10371172	C4591001 1037 10371172	16-55	09SEP2020	84907	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10371176	C4591001 1037 10371176	16-55	09SEP2020	84909	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10371179	C4591001 1037 10371179	16-55	10SEP2020	84911	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10371180	C4591001 1037 10371180	16-55	10SEP2020	86360	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10371183	C4591001 1037 10371183	16-55	10SEP2020	86363	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10371192	C4591001 1037 10371192	16-55	11SEP2020	86365	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10371198	C4591001 1037 10371198	16-55	11SEP2020	86368	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371199	C4591001 1037 10371199	16-55	14SEP2020	89339	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371200	C4591001 1037 10371200	16-55	14SEP2020	89334	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10371201	C4591001 1037 10371201	16-55	14SEP2020	89340	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371202	C4591001 1037 10371202	16-55	14SEP2020	89342	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371208	C4591001 1037 10371208	16-55	14SEP2020	89622	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371209	C4591001 1037 10371209	16-55	14SEP2020	89623	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10371210	C4591001 1037 10371210	16-55	15SEP2020	89624	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371214	C4591001 1037 10371214	16-55	15SEP2020	89626	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10371215	C4591001 1037 10371215	16-55	15SEP2020	90252	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10371216	C4591001 1037 10371216	16-55	15SEP2020	90255	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371219	C4591001 1037 10371219	16-55	16SEP2020	90256	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371220	C4591001 1037 10371220	16-55	16SEP2020	90965	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10371221	C4591001 1037 10371221	16-55	16SEP2020	90971	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10371222	C4591001 1037 10371222	16-55	16SEP2020	90973	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371223	C4591001 1037 10371223	16-55	16SEP2020	90976	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10371230	C4591001 1037 10371230	16-55	17SEP2020	92045	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371231	C4591001 1037 10371231	16-55	17SEP2020	92046	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371232	C4591001 1037 10371232	16-55	17SEP2020	92052	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371236	C4591001 1037 10371236	16-55	18SEP2020	92053	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371237	C4591001 1037 10371237	16-55	18SEP2020	93714	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10371238	C4591001 1037 10371238	16-55	18SEP2020	93715	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371240	C4591001 1037 10371240	16-55	18SEP2020	93713	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10371241	C4591001 1037 10371241	16-55	18SEP2020	93720	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10371245	C4591001 1037 10371245	16-55	21SEP2020	94662	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371246	C4591001 1037 10371246	16-55	21SEP2020	94667	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10371249	C4591001 1037 10371249	16-55	05OCT2020	103687	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10371250	C4591001 1037 10371250	16-55	21SEP2020	94668	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371253	C4591001 1037 10371253	16-55	21SEP2020	94669	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371254	C4591001 1037 10371254	16-55	21SEP2020	95167	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371255	C4591001 1037 10371255	16-55	22SEP2020	95169	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371256	C4591001 1037 10371256	16-55	22SEP2020	95173	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371257	C4591001 1037 10371257	16-55	22SEP2020	95175	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo		
10371258	C4591001 1037 10371258	16-55	22SEP2020	96113	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371259	C4591001 1037 10371259	16-55	22SEP2020	96117	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10371262	C4591001 1037 10371262	16-55	22SEP2020	96120	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10371265	C4591001 1037 10371265	16-55	22SEP2020	96123	Placebo	22SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10371266	C4591001 1037 10371266	16-55	22SEP2020	96415	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371269	C4591001 1037 10371269	16-55	23SEP2020	96417	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10371271	C4591001 1037 10371271	16-55	23SEP2020	96419	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10371272	C4591001 1037 10371272	16-55	23SEP2020	96420	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10371277	C4591001 1037 10371277	16-55	23SEP2020	97483	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371284	C4591001 1037 10371284	16-55	24SEP2020	97489	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10371285	C4591001 1037 10371285	16-55	24SEP2020	97484	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10371286	C4591001 1037 10371286	16-55	24SEP2020	97487	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10371287	C4591001 1037 10371287	16-55	24SEP2020	98648	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10371288	C4591001 1037 10371288	16-55	24SEP2020	98649	Placebo	24SEP2020/ Placebo	22OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10371290	C4591001 1037 10371290	16-55	25SEP2020	98651	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371291	C4591001 1037 10371291	16-55	25SEP2020	98652	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10371296	C4591001 1037 10371296	16-55	25SEP2020	100075	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10371298	C4591001 1037 10371298	16-55	29SEP2020	100077	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371300	C4591001 1037 10371300	16-55	29SEP2020	100083	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371301	C4591001 1037 10371301	16-55	29SEP2020	100084	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10371302	C4591001 1037 10371302	16-55	29SEP2020	101850	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10371306	C4591001 1037 10371306	16-55	30SEP2020	101851	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10371307	C4591001 1037 10371307	16-55	30SEP2020	101853	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10371308	C4591001 1037 10371308	16-55	30SEP2020	101858	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10371309	C4591001 1037 10371309	16-55	30SEP2020	102521	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10371310	C4591001 1037 10371310	16-55	01OCT2020	102524	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371312	C4591001 1037 10371312	16-55	01OCT2020	102527	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371313	C4591001 1037 10371313	16-55	01OCT2020	102810	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371314	C4591001 1037 10371314	16-55	01OCT2020	102528	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371315	C4591001 1037 10371315	16-55	02OCT2020	102814	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10371316	C4591001 1037 10371316	16-55	02OCT2020	102817	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371317	C4591001 1037 10371317	16-55	02OCT2020	102820	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10371319	C4591001 1037 10371319	16-55	05OCT2020	103689	Placebo	05OCT2020/ Placebo	09NOV2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10371321	C4591001 1037 10371321	16-55	07OCT2020	103691	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10371323	C4591001 1037 10371323	16-55	07OCT2020	103694	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371324	C4591001 1037 10371324	16-55	07OCT2020	104744	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10371325	C4591001 1037 10371325	16-55	08OCT2020	104749	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10371327	C4591001 1037 10371327	16-55	08OCT2020	104750	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10371328	C4591001 1037 10371328	16-55	08OCT2020	104752	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371330	C4591001 1037 10371330	16-55	08OCT2020	105437	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10371331	C4591001 1037 10371331	16-55	08OCT2020	105444	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10371332	C4591001 1037 10371332	16-55	09OCT2020	105446	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10371336	C4591001 1037 10371336	16-55	13OCT2020	105447	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10371337	C4591001 1037 10371337	16-55	02NOV2020	115266	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
10371340	C4591001 1037 10371340	16-55	13OCT2020	107189	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10371341	C4591001 1037 10371341	16-55	13OCT2020	107194	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10371342	C4591001 1037 10371342	16-55	14OCT2020	107196	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10371343	C4591001 1037 10371343	16-55	14OCT2020	107198	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10371344	C4591001 1037 10371344	16-55	14OCT2020	107599	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371347	C4591001 1037 10371347	16-55	15OCT2020	107600	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10371349	C4591001 1037 10371349	16-55	15OCT2020	107602	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10371350	C4591001 1037 10371350	16-55	15OCT2020	107605	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10371351	C4591001 1037 10371351	16-55	16OCT2020	109085	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10371352	C4591001 1037 10371352	16-55	19OCT2020	109086	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10371353	C4591001 1037 10371353	16-55	19OCT2020	109090	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10371355	C4591001 1037 10371355	16-55	19OCT2020	109093	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10371357	C4591001 1037 10371357	16-55	20OCT2020	111161	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10371358	C4591001 1037 10371358	16-55	20OCT2020	111164	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10371359	C4591001 1037 10371359	16-55	21OCT2020	111165	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10371360	C4591001 1037 10371360	16-55	23OCT2020	111172	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10381001	C4591001 1038 10381001	16-55	18AUG2020	54797	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10381002	C4591001 1038 10381002	16-55	18AUG2020	54798	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381003	C4591001 1038 10381003	16-55	18AUG2020	54806	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381004	C4591001 1038 10381004	16-55	19AUG2020	54808	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10381005	C4591001 1038 10381005	16-55	19AUG2020	55869	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381006	C4591001 1038 10381006	16-55	19AUG2020	55870	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381008	C4591001 1038 10381008	16-55	19AUG2020	55873	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10381010	C4591001 1038 10381010	16-55	19AUG2020	55876	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10381012	C4591001 1038 10381012	16-55	20AUG2020	57954	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381013	C4591001 1038 10381013	16-55	20AUG2020	57956	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10381014	C4591001 1038 10381014	16-55	20AUG2020	57959	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381016	C4591001 1038 10381016	16-55	20AUG2020	57960	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10381018	C4591001 1038 10381018	16-55	20AUG2020	59325	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10381020	C4591001 1038 10381020	16-55	21AUG2020	59327	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10381022	C4591001 1038 10381022	16-55	21AUG2020	59328	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381023	C4591001 1038 10381023	16-55	21AUG2020	61193	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381024	C4591001 1038 10381024	16-55	21AUG2020	59330	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10381027	C4591001 1038 10381027	16-55	24AUG2020	61197	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10381028	C4591001 1038 10381028	16-55	24AUG2020	61198	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381029	C4591001 1038 10381029	16-55	24AUG2020	61201	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10381036	C4591001 1038 10381036	16-55	25AUG2020	66130	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10381038	C4591001 1038 10381038	16-55	25AUG2020	66133	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10381042	C4591001 1038 10381042	16-55	26AUG2020	66134	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10381043	C4591001 1038 10381043	16-55	26AUG2020	66136	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381044	C4591001 1038 10381044	16-55	26AUG2020	68789	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10381045	C4591001 1038 10381045	16-55	27AUG2020	68790	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10381048	C4591001 1038 10381048	16-55	27AUG2020	68792	Placebo	27AUG2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10381049	C4591001 1038 10381049	16-55	27AUG2020	68796	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10381052	C4591001 1038 10381052	16-55	27AUG2020	71069	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381053	C4591001 1038 10381053	16-55	28AUG2020	71070	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10381057	C4591001 1038 10381057	16-55	28AUG2020	71074	Placebo	28AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10381059	C4591001 1038 10381059	16-55	28AUG2020	71075	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10381061	C4591001 1038 10381061	16-55	31AUG2020	74658	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10381063	C4591001 1038 10381063	16-55	21SEP2020	93518	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10381065	C4591001 1038 10381065	16-55	31AUG2020	74659	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10381067	C4591001 1038 10381067	16-55	31AUG2020	74661	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10381069	C4591001 1038 10381069	16-55	01SEP2020	74665	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10381070	C4591001 1038 10381070	16-55	01SEP2020	76325	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10381075	C4591001 1038 10381075	16-55	01SEP2020	76333	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381076	C4591001 1038 10381076	16-55	01SEP2020	76334	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10381077	C4591001 1038 10381077	16-55	02SEP2020	76335	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10381078	C4591001 1038 10381078	16-55	02SEP2020	77825	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10381079	C4591001 1038 10381079	16-55	02SEP2020	77827	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10381080	C4591001 1038 10381080	16-55	02SEP2020	77829	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10381082	C4591001 1038 10381082	16-55	02SEP2020	77833	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381083	C4591001 1038 10381083	16-55	02SEP2020	78691	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10381085	C4591001 1038 10381085	16-55	02SEP2020	78692	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10381088	C4591001 1038 10381088	16-55	03SEP2020	78694	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381091	C4591001 1038 10381091	16-55	03SEP2020	78695	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381093	C4591001 1038 10381093	16-55	03SEP2020	80863	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10381094	C4591001 1038 10381094	16-55	03SEP2020	80867	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10381095	C4591001 1038 10381095	16-55	04SEP2020	80868	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10381096	C4591001 1038 10381096	16-55	04SEP2020	80870	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10381097	C4591001 1038 10381097	16-55	04SEP2020	81570	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10381098	C4591001 1038 10381098	16-55	04SEP2020	81571	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10381102	C4591001 1038 10381102	16-55	08SEP2020	81573	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10381103	C4591001 1038 10381103	16-55	08SEP2020	81577	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10381105	C4591001 1038 10381105	16-55	08SEP2020	84342	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10381109	C4591001 1038 10381109	16-55	10SEP2020	84343	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381111	C4591001 1038 10381111	16-55	10SEP2020	84344	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10381112	C4591001 1038 10381112	16-55	10SEP2020	84352	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10381115	C4591001 1038 10381115	16-55	11SEP2020	88003	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10381116	C4591001 1038 10381116	16-55	11SEP2020	88009	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10381117	C4591001 1038 10381117	16-55	11SEP2020	88010	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10381118	C4591001 1038 10381118	16-55	11SEP2020	88012	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10381119	C4591001 1038 10381119	16-55	11SEP2020	88674	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10381120	C4591001 1038 10381120	16-55	11SEP2020	88675	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10381121	C4591001 1038 10381121	16-55	14SEP2020	88676	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10381127	C4591001 1038 10381127	16-55	17SEP2020	88679	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10381128	C4591001 1038 10381128	16-55	17SEP2020	92874	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10381129	C4591001 1038 10381129	16-55	17SEP2020	92878	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10381130	C4591001 1038 10381130	16-55	18SEP2020	92881	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10381131	C4591001 1038 10381131	16-55	18SEP2020	92884	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10381133	C4591001 1038 10381133	16-55	18SEP2020	93509	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10381136	C4591001 1038 10381136	16-55	21SEP2020	93510	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10381137	C4591001 1038 10381137	16-55	21SEP2020	93519	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10381138	C4591001 1038 10381138	16-55	23SEP2020	97902	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10381140	C4591001 1038 10381140	16-55	24SEP2020	97907	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10381141	C4591001 1038 10381141	16-55	25SEP2020	97909	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391002	C4591001 1039 10391002	16-55	20AUG2020	58061	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10391003	C4591001 1039 10391003	16-55	09SEP2020	85376	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391004	C4591001 1039 10391004	16-55	20AUG2020	58063	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10391009	C4591001 1039 10391009	16-55	21AUG2020	58071	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391011	C4591001 1039 10391011	16-55	21AUG2020	58072	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391014	C4591001 1039 10391014	16-55	15SEP2020	89808	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10391016	C4591001 1039 10391016	16-55	24AUG2020	63593	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10391017	C4591001 1039 10391017	16-55	24AUG2020	63594	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391021	C4591001 1039 10391021	16-55	25AUG2020	63599	Placebo	25AUG2020/ Placebo			
10391022	C4591001 1039 10391022	16-55	25AUG2020	63602	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391025	C4591001 1039 10391025	16-55	25AUG2020	66174	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391026	C4591001 1039 10391026	16-55	25AUG2020	66177	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10391036	C4591001 1039 10391036	16-55	26AUG2020	66181	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10391045	C4591001 1039 10391045	16-55	28AUG2020	66182	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10391057	C4591001 1039 10391057	16-55	31AUG2020	75533	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391058	C4591001 1039 10391058	16-55	31AUG2020	75534	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10391065	C4591001 1039 10391065	16-55	01SEP2020	75537	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10391067	C4591001 1039 10391067	16-55	01SEP2020	75544	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10391068	C4591001 1039 10391068	16-55	02SEP2020	77900	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10391071	C4591001 1039 10391071	16-55	02SEP2020	77902	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391076	C4591001 1039 10391076	16-55	02SEP2020	77904	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10391080	C4591001 1039 10391080	16-55	03SEP2020	77906	Placebo	03SEP2020/ Placebo			
10391085	C4591001 1039 10391085	16-55	03SEP2020	80477	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391086	C4591001 1039 10391086	16-55	03SEP2020	80478	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10391087	C4591001 1039 10391087	16-55	03SEP2020	80484	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10391088	C4591001 1039 10391088	16-55	04SEP2020	251445	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10391090	C4591001 1039 10391090	16-55	04SEP2020	252354	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391091	C4591001 1039 10391091	16-55	04SEP2020	80485	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391093	C4591001 1039 10391093	16-55	04SEP2020	81822	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10391096	C4591001 1039 10391096	16-55	04SEP2020	81826	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391097	C4591001 1039 10391097	16-55	04SEP2020	81829	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10391099	C4591001 1039 10391099	16-55	08SEP2020	81831	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10391104	C4591001 1039 10391104	16-55	08SEP2020	84065	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10391108	C4591001 1039 10391108	16-55	09SEP2020	84068	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391109	C4591001 1039 10391109	16-55	09SEP2020	84069	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10391110	C4591001 1039 10391110	16-55	09SEP2020	84933	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391112	C4591001 1039 10391112	16-55	09SEP2020	84938	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10391114	C4591001 1039 10391114	16-55	09SEP2020	84940	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10391115	C4591001 1039 10391115	16-55	09SEP2020	84939	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10391118	C4591001 1039 10391118	16-55	09SEP2020	85380	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391119	C4591001 1039 10391119	16-55	10SEP2020	85382	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10391120	C4591001 1039 10391120	16-55	15SEP2020	89807	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391124	C4591001 1039 10391124	16-55	10SEP2020	85383	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10391127	C4591001 1039 10391127	16-55	10SEP2020	87282	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10391128	C4591001 1039 10391128	16-55	10SEP2020	87283	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10391133	C4591001 1039 10391133	16-55	11SEP2020	87286	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10391134	C4591001 1039 10391134	16-55	11SEP2020	257764	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10391136	C4591001 1039 10391136	16-55	11SEP2020	87290	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391140	C4591001 1039 10391140	16-55	14SEP2020	89801	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391145	C4591001 1039 10391145	16-55	17SEP2020	89809	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391150	C4591001 1039 10391150	16-55	18SEP2020	93377	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10391151	C4591001 1039 10391151	16-55	18SEP2020	93380	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10391152	C4591001 1039 10391152	16-55	18SEP2020	93381	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10391153	C4591001 1039 10391153	16-55	21SEP2020	93384	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10391156	C4591001 1039 10391156	16-55	25SEP2020	99727	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10391157	C4591001 1039 10391157	16-55	25SEP2020	99728	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10391162	C4591001 1039 10391162	16-55	29SEP2020	99731	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391165	C4591001 1039 10391165	16-55	30SEP2020	99732	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10391166	C4591001 1039 10391166	16-55	30SEP2020	102366	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391167	C4591001 1039 10391167	16-55	30SEP2020	102371	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391168	C4591001 1039 10391168	16-55	01OCT2020	102373	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391171	C4591001 1039 10391171	16-55	01OCT2020	102374	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10391172	C4591001 1039 10391172	16-55	02OCT2020	103135	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10391175	C4591001 1039 10391175	16-55	05OCT2020	103136	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10391176	C4591001 1039 10391176	16-55	05OCT2020	103138	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391177	C4591001 1039 10391177	16-55	05OCT2020	103142	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10391178	C4591001 1039 10391178	16-55	05OCT2020	103891	Placebo	05OCT2020/ Placebo	10NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10391179	C4591001 1039 10391179	16-55	06OCT2020	103892	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10391180	C4591001 1039 10391180	16-55	07OCT2020	103894	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391181	C4591001 1039 10391181	16-55	07OCT2020	103895	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391182	C4591001 1039 10391182	16-55	07OCT2020	104874	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391183	C4591001 1039 10391183	16-55	08OCT2020	104876	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10391185	C4591001 1039 10391185	16-55	08OCT2020	104883	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10391186	C4591001 1039 10391186	16-55	09OCT2020	104884	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo		
10391187	C4591001 1039 10391187	16-55	09OCT2020	106085	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10391190	C4591001 1039 10391190	16-55	12OCT2020	106088	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10391196	C4591001 1039 10391196	16-55	15OCT2020	106091	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo		
10391198	C4591001 1039 10391198	16-55	16OCT2020	106094	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10391199	C4591001 1039 10391199	16-55	16OCT2020	109157	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10391200	C4591001 1039 10391200	16-55	16OCT2020	109164	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391203	C4591001 1039 10391203	16-55	19OCT2020	109166	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10391205	C4591001 1039 10391205	16-55	20OCT2020	109167	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10391207	C4591001 1039 10391207	16-55	20OCT2020	110838	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10391208	C4591001 1039 10391208	16-55	20OCT2020	110841	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391209	C4591001 1039 10391209	16-55	20OCT2020	110840	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10391212	C4591001 1039 10391212	16-55	21OCT2020	110844	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391214	C4591001 1039 10391214	16-55	21OCT2020	111715	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391218	C4591001 1039 10391218†	16-55	22OCT2020	111717	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10391220	C4591001 1039 10391220	16-55	23OCT2020	111719	Placebo	23OCT2020/ Placebo	16NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391222	C4591001 1039 10391222	16-55	23OCT2020	111722	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391224	C4591001 1039 10391224	16-55	26OCT2020	113466	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10391225	C4591001 1039 10391225	16-55	26OCT2020	113468	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10391226	C4591001 1039 10391226	16-55	26OCT2020	113470	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10391232	C4591001 1039 10391232	16-55	27OCT2020	113471	Placebo	27OCT2020/ Placebo	02DEC2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391233	C4591001 1039 10391233	16-55	28OCT2020	114317	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10391234	C4591001 1039 10391234†	16-55	28OCT2020	114319	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10391235	C4591001 1039 10391235	16-55	29OCT2020	114323	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391237	C4591001 1039 10391237	16-55	29OCT2020	114326	Placebo	29OCT2020/ Placebo	30NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10391239	C4591001 1039 10391239	16-55	29OCT2020	114704	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10391240	C4591001 1039 10391240	16-55	30OCT2020	114707	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10391241	C4591001 1039 10391241	16-55	02NOV2020	114708	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10391242	C4591001 1039 10391242	16-55	02NOV2020	114711	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10391243	C4591001 1039 10391243	16-55	09NOV2020	116010	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10391244	C4591001 1039 10391244	16-55	11NOV2020	116012	Placebo	11NOV2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10391245	C4591001 1039 10391245	16-55	30NOV2020	116013	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10391248	C4591001 1039 10391248	16-55	01DEC2020	116020	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10391249	C4591001 1039 10391249	16-55	04DEC2020	117535	Placebo	04DEC2020/ Placebo	28DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10391254	C4591001 1039 10391254	16-55	07DEC2020	117538	Placebo	07DEC2020/ Placebo	29DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10391257	C4591001 1039 10391257	16-55	07DEC2020	117542	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10391261	C4591001 1039 10391261	16-55	07DEC2020	117543	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421111	C4591001 1042 10421111	16-55	17AUG2020	52517	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421112	C4591001 1042 10421112	16-55	17AUG2020	52520	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10421114	C4591001 1042 10421114	16-55	17AUG2020	52522	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421115	C4591001 1042 10421115	16-55	17AUG2020	52523	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10421120	C4591001 1042 10421120	16-55	17AUG2020	53515	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421121	C4591001 1042 10421121	16-55	17AUG2020	53519	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10421123	C4591001 1042 10421123	16-55	17AUG2020	53523	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10421124	C4591001 1042 10421124	16-55	18AUG2020	53524	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421125	C4591001 1042 10421125	16-55	18AUG2020	54990	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10421126	C4591001 1042 10421126	16-55	18AUG2020	54995	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421128	C4591001 1042 10421128	16-55	19AUG2020	54999	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10421129	C4591001 1042 10421129	16-55	19AUG2020	55000	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421130	C4591001 1042 10421130	16-55	19AUG2020	56456	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10421131	C4591001 1042 10421131	16-55	19AUG2020	56459	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10421140	C4591001 1042 10421140	16-55	19AUG2020	56461	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421142	C4591001 1042 10421142	16-55	19AUG2020	57677	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10421143	C4591001 1042 10421143	16-55	19AUG2020	56464	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10421144	C4591001 1042 10421144	16-55	24AUG2020	57681	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10421148	C4591001 1042 10421148	16-55	24AUG2020	57682	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421151	C4591001 1042 10421151	16-55	24AUG2020	57683	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421155	C4591001 1042 10421155	16-55	24AUG2020	64890	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10421157	C4591001 1042 10421157	16-55	26AUG2020	64893	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10421158	C4591001 1042 10421158	16-55	26AUG2020	64896	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421161	C4591001 1042 10421161	16-55	26AUG2020	64900	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421162	C4591001 1042 10421162	16-55	26AUG2020	68155	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421163	C4591001 1042 10421163	16-55	26AUG2020	68157	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10421165	C4591001 1042 10421165	16-55	26AUG2020	68161	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10421169	C4591001 1042 10421169	16-55	27AUG2020	68163	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421170	C4591001 1042 10421170	16-55	28AUG2020	72930	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10421175	C4591001 1042 10421175	16-55	31AUG2020	72931	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421176	C4591001 1042 10421176	16-55	31AUG2020	72935	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10421177	C4591001 1042 10421177	16-55	31AUG2020	72939	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10421180	C4591001 1042 10421180	16-55	31AUG2020	76173	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10421181	C4591001 1042 10421181	16-55	01SEP2020	76174	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10421185	C4591001 1042 10421185	16-55	02SEP2020	76175	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10421188	C4591001 1042 10421188	16-55	02SEP2020	76180	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10421190	C4591001 1042 10421190	16-55	02SEP2020	79339	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10421193	C4591001 1042 10421193	16-55	08SEP2020	79341	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10421194	C4591001 1042 10421194	16-55	08SEP2020	79346	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10421196	C4591001 1042 10421196	16-55	08SEP2020	79348	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421197	C4591001 1042 10421197	16-55	08SEP2020	83825	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10421198	C4591001 1042 10421198	16-55	08SEP2020	83828	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10421204	C4591001 1042 10421204	16-55	08SEP2020	83833	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421205	C4591001 1042 10421205	16-55	08SEP2020	83836	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10421206	C4591001 1042 10421206	16-55	08SEP2020	84608	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10421207	C4591001 1042 10421207	16-55	08SEP2020	84612	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421209	C4591001 1042 10421209	16-55	09SEP2020	84615	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10421210	C4591001 1042 10421210	16-55	09SEP2020	84616	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10421213	C4591001 1042 10421213	16-55	09SEP2020	85784	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421216	C4591001 1042 10421216	16-55	10SEP2020	85786	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421217	C4591001 1042 10421217	16-55	10SEP2020	85789	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10421219	C4591001 1042 10421219	16-55	10SEP2020	85791	Placebo	10SEP2020/ Placebo	05OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10421222	C4591001 1042 10421222	16-55	10SEP2020	87293	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10421228	C4591001 1042 10421228	16-55	10SEP2020	87294	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10421229	C4591001 1042 10421229	16-55	10SEP2020	87295	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	
10421231	C4591001 1042 10421231	16-55	11SEP2020	87298	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10421232	C4591001 1042 10421232	16-55	11SEP2020	87908	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421233	C4591001 1042 10421233	16-55	11SEP2020	87912	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421234	C4591001 1042 10421234	16-55	11SEP2020	87913	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10421235	C4591001 1042 10421235	16-55	11SEP2020	87916	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421237	C4591001 1042 10421237	16-55	11SEP2020	88337	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10421238	C4591001 1042 10421238	16-55	11SEP2020	88338	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10421239	C4591001 1042 10421239	16-55	11SEP2020	88340	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421243	C4591001 1042 10421243	16-55	11SEP2020	88344	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421245	C4591001 1042 10421245	16-55	11SEP2020	88844	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10421246	C4591001 1042 10421246	16-55	11SEP2020	88847	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10421247	C4591001 1042 10421247	16-55	11SEP2020	88849	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421249	C4591001 1042 10421249	16-55	17SEP2020	88850	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10421250	C4591001 1042 10421250	16-55	17SEP2020	92301	Placebo	17SEP2020/ Placebo			
10421251	C4591001 1042 10421251	16-55	17SEP2020	92302	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421252	C4591001 1042 10421252	16-55	18SEP2020	92306	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421253	C4591001 1042 10421253	16-55	18SEP2020	92307	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10421255	C4591001 1042 10421255	16-55	18SEP2020	94385	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10421256	C4591001 1042 10421256	16-55	22SEP2020	94391	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10421259	C4591001 1042 10421259	16-55	05OCT2020	94394	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10421260	C4591001 1042 10421260	16-55	05OCT2020	94395	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10421261	C4591001 1042 10421261	16-55	07OCT2020	104816	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10421262	C4591001 1042 10421262	16-55	14OCT2020	104821	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10421264	C4591001 1042 10421264	16-55	16OCT2020	104822	Placebo	16OCT2020/ Placebo	13NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10421265	C4591001 1042 10421265	16-55	20OCT2020	104823	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10421266	C4591001 1042 10421266	16-55	20OCT2020	110789	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10421267	C4591001 1042 10421267	16-55	20OCT2020	110792	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10441009	C4591001 1044 10441009	16-55	17AUG2020	50058	Placebo	17AUG2020/ Placebo	06SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10441011	C4591001 1044 10441011	16-55	18AUG2020	50064	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10441015	C4591001 1044 10441015	16-55	19AUG2020	50067	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10441019	C4591001 1044 10441019	16-55	20AUG2020	59285	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10441021	C4591001 1044 10441021	16-55	21AUG2020	59286	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10441024	C4591001 1044 10441024	16-55	21AUG2020	59293	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10441028	C4591001 1044 10441028	16-55	25AUG2020	65391	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10441029	C4591001 1044 10441029	16-55	25AUG2020	59294	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441030	C4591001 1044 10441030	16-55	25AUG2020	65383	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10441031	C4591001 1044 10441031	16-55	25AUG2020	65390	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10441034	C4591001 1044 10441034	16-55	26AUG2020	67918	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441035	C4591001 1044 10441035	16-55	26AUG2020	65392	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10441037	C4591001 1044 10441037	16-55	26AUG2020	67915	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441038	C4591001 1044 10441038	16-55	26AUG2020	67919	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10441042	C4591001 1044 10441042	16-55	26AUG2020	67923	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10441043	C4591001 1044 10441043	16-55	27AUG2020	69653	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441044	C4591001 1044 10441044	16-55	27AUG2020	69655	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441045	C4591001 1044 10441045	16-55	27AUG2020	69663	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441048	C4591001 1044 10441048	16-55	28AUG2020	72641	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441050	C4591001 1044 10441050	16-55	27AUG2020	69664	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441051	C4591001 1044 10441051	16-55	28AUG2020	71705	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10441052	C4591001 1044 10441052	16-55	28AUG2020	71708	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441053	C4591001 1044 10441053	16-55	28AUG2020	71709	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10441054	C4591001 1044 10441054	16-55	28AUG2020	71716	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10441056	C4591001 1044 10441056	16-55	29AUG2020	72644	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo		
10441057	C4591001 1044 10441057	16-55	29AUG2020	72645	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10441058	C4591001 1044 10441058	16-55	29AUG2020	72649	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441059	C4591001 1044 10441059	16-55	29AUG2020	73879	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441060	C4591001 1044 10441060	16-55	31AUG2020	73885	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10441061	C4591001 1044 10441061	16-55	31AUG2020	73887	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441063	C4591001 1044 10441063	16-55	01SEP2020	73888	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10441065	C4591001 1044 10441065	16-55	01SEP2020	76568	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10441068	C4591001 1044 10441068	16-55	01SEP2020	76571	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10441069	C4591001 1044 10441069	16-55	02SEP2020	76573	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10441071	C4591001 1044 10441071	16-55	02SEP2020	76575	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10441076	C4591001 1044 10441076	16-55	03SEP2020	80255	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10441077	C4591001 1044 10441077	16-55	03SEP2020	80256	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441079	C4591001 1044 10441079	16-55	04SEP2020	80257	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441081	C4591001 1044 10441081	16-55	04SEP2020	80260	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10441084	C4591001 1044 10441084	16-55	05SEP2020	82650	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441086	C4591001 1044 10441086	16-55	05SEP2020	82651	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441088	C4591001 1044 10441088	16-55	06SEP2020	82653	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10441089	C4591001 1044 10441089	16-55	06SEP2020	82657	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10441099	C4591001 1044 10441099	16-55	09SEP2020	85554	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10441101	C4591001 1044 10441101	16-55	09SEP2020	85558	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10441102	C4591001 1044 10441102	16-55	09SEP2020	85561	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10441103	C4591001 1044 10441103	16-55	10SEP2020	85564	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10441107	C4591001 1044 10441107	16-55	10SEP2020	86865	Placebo	10SEP2020/ Placebo	06OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441112	C4591001 1044 10441112	16-55	11SEP2020	86866	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10441119	C4591001 1044 10441119	16-55	21SEP2020	86867	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441121	C4591001 1044 10441121	16-55	22SEP2020	86870	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441122	C4591001 1044 10441122	16-55	22SEP2020	96066	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10441123	C4591001 1044 10441123	16-55	22SEP2020	96070	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441126	C4591001 1044 10441126	16-55	22SEP2020	96072	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441127	C4591001 1044 10441127	16-55	22SEP2020	96074	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441129	C4591001 1044 10441129	16-55	22SEP2020	97062	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10441132	C4591001 1044 10441132	16-55	23SEP2020	97063	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10441133	C4591001 1044 10441133	16-55	23SEP2020	97068	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441136	C4591001 1044 10441136	16-55	23SEP2020	97070	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10441137	C4591001 1044 10441137	16-55	23SEP2020	98394	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10441139	C4591001 1044 10441139	16-55	23SEP2020	98399	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10441140	C4591001 1044 10441140	16-55	24SEP2020	98403	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441141	C4591001 1044 10441141	16-55	24SEP2020	98404	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10441142	C4591001 1044 10441142	16-55	24SEP2020	98754	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10441143	C4591001 1044 10441143	16-55	24SEP2020	98755	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10441144	C4591001 1044 10441144	16-55	24SEP2020	98757	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10441146	C4591001 1044 10441146	16-55	24SEP2020	98759	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10441151	C4591001 1044 10441151	16-55	25SEP2020	100148	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441152	C4591001 1044 10441152†	16-55	28SEP2020	100149	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
10441153	C4591001 1044 10441153	16-55	30SEP2020	100151	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10441155	C4591001 1044 10441155	16-55	01OCT2020	100155	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10441156	C4591001 1044 10441156	16-55	01OCT2020	102776	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10441157	C4591001 1044 10441157	16-55	01OCT2020	102777	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10441158	C4591001 1044 10441158	16-55	01OCT2020	102780	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10441159	C4591001 1044 10441159	16-55	02OCT2020	102782	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10441162	C4591001 1044 10441162	16-55	05OCT2020	103878	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10441163	C4591001 1044 10441163	16-55	05OCT2020	103880	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10441164	C4591001 1044 10441164	16-55	06OCT2020	103884	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441165	C4591001 1044 10441165	16-55	06OCT2020	104394	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10441166	C4591001 1044 10441166	16-55	06OCT2020	103885	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10441167	C4591001 1044 10441167	16-55	06OCT2020	104393	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10441168	C4591001 1044 10441168	16-55	07OCT2020	104400	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10441170	C4591001 1044 10441170	16-55	07OCT2020	104404	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441171	C4591001 1044 10441171	16-55	07OCT2020	104889	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10441173	C4591001 1044 10441173	16-55	08OCT2020	104893	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441174	C4591001 1044 10441174	16-55	08OCT2020	104895	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10441176	C4591001 1044 10441176	16-55	08OCT2020	104896	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10441177	C4591001 1044 10441177	16-55	08OCT2020	105497	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441181	C4591001 1044 10441181	16-55	16OCT2020	105500	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441185	C4591001 1044 10441185	16-55	17OCT2020	105503	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10441186	C4591001 1044 10441186	16-55	17OCT2020	109555	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441187	C4591001 1044 10441187	16-55	17OCT2020	105504	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10441188	C4591001 1044 10441188	16-55	17OCT2020	109559	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441190	C4591001 1044 10441190	16-55	17OCT2020	109557	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10441191	C4591001 1044 10441191	16-55	17OCT2020	109665	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441192	C4591001 1044 10441192	16-55	17OCT2020	109662	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10441193	C4591001 1044 10441193	16-55	17OCT2020	109563	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10441197	C4591001 1044 10441197	16-55	18OCT2020	109667	Placebo	18OCT2020/ Placebo	10NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441198	C4591001 1044 10441198	16-55	18OCT2020	109672	Placebo	18OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10441199	C4591001 1044 10441199	16-55	19OCT2020	110381	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10441200	C4591001 1044 10441200	16-55	20OCT2020	110385	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10441203	C4591001 1044 10441203	16-55	20OCT2020	110386	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10441204	C4591001 1044 10441204	16-55	20OCT2020	110389	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10441207	C4591001 1044 10441207	16-55	21OCT2020	111353	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10441210	C4591001 1044 10441210	16-55	21OCT2020	111356	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10441211	C4591001 1044 10441211	16-55	21OCT2020	111357	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441212	C4591001 1044 10441212	16-55	21OCT2020	111361	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10441213	C4591001 1044 10441213	16-55	22OCT2020	112077	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441215	C4591001 1044 10441215	16-55	22OCT2020	112078	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441218	C4591001 1044 10441218	16-55	22OCT2020	112082	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10441219	C4591001 1044 10441219	16-55	22OCT2020	112083	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10441224	C4591001 1044 10441224	16-55	23OCT2020	112999	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10441227	C4591001 1044 10441227	16-55	23OCT2020	113000	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10441228	C4591001 1044 10441228	16-55	16NOV2020	113002	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441229	C4591001 1044 10441229	16-55	17NOV2020	113007	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10441230	C4591001 1044 10441230	16-55	18NOV2020	116384	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
10441231	C4591001 1044 10441231	16-55	18NOV2020	116387	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10441232	C4591001 1044 10441232	16-55	18NOV2020	116389	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441233	C4591001 1044 10441233	16-55	18NOV2020	116390	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
10441234	C4591001 1044 10441234	16-55	19NOV2020	116517	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10441235	C4591001 1044 10441235	16-55	19NOV2020	116523	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	17DEC2020/ BNT162b2 (30 µg)		
10441236	C4591001 1044 10441236	16-55	19NOV2020	116522	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10441237	C4591001 1044 10441237	16-55	20NOV2020	116524	Placebo	20NOV2020/ Placebo	09DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10441238	C4591001 1044 10441238	16-55	20NOV2020	116574	Placebo	20NOV2020/ Placebo	09DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441239	C4591001 1044 10441239	16-55	20NOV2020	116577	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10441240	C4591001 1044 10441240	16-55	23NOV2020	116579	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10441241	C4591001 1044 10441241	16-55	23NOV2020	116582	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10441242	C4591001 1044 10441242	16-55	24NOV2020	116825	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441243	C4591001 1044 10441243	16-55	24NOV2020	116827	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10441244	C4591001 1044 10441244	16-55	24NOV2020	116832	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10441245	C4591001 1044 10441245	16-55	24NOV2020	116828	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10441246	C4591001 1044 10441246	16-55	25NOV2020	116925	BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)		
10441247	C4591001 1044 10441247	16-55	25NOV2020	116922	Placebo	25NOV2020/ Placebo	14DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441248	C4591001 1044 10441248	16-55	25NOV2020	116923	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
10441249	C4591001 1044 10441249	16-55	30NOV2020	20352	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10441250	C4591001 1044 10441250	16-55	30NOV2020	20353	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
10441254	C4591001 1044 10441254	16-55	30NOV2020	20437	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10441258	C4591001 1044 10441258	16-55	01DEC2020	20568	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10441262	C4591001 1044 10441262	16-55	07DEC2020	20620	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10441269	C4591001 1044 10441269	16-55	08DEC2020	116927	Placebo	08DEC2020/ Placebo	30DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10441272	C4591001 1044 10441272	16-55	08DEC2020	117787	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10441287	C4591001 1044 10441287	16-55	11DEC2020	117788	Placebo	11DEC2020/ Placebo		30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10461034	C4591001 1046 10461034	16-55	15AUG2020	51027	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)		
10461040	C4591001 1046 10461040	16-55	17AUG2020	52544	Placebo	17AUG2020/ Placebo			
10461042	C4591001 1046 10461042	16-55	17AUG2020	52548	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10461043	C4591001 1046 10461043	16-55	17AUG2020	52549	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461044	C4591001 1046 10461044	16-55	17AUG2020	52551	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461046	C4591001 1046 10461046	16-55	17AUG2020	53287	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461049	C4591001 1046 10461049	16-55	18AUG2020	53291	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10461050	C4591001 1046 10461050	16-55	18AUG2020	53292	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10461051	C4591001 1046 10461051	16-55	18AUG2020	53296	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461052	C4591001 1046 10461052	16-55	18AUG2020	54970	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10461053	C4591001 1046 10461053	16-55	18AUG2020	54973	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461054	C4591001 1046 10461054	16-55	18AUG2020	54974	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10461055	C4591001 1046 10461055	16-55	18AUG2020	54976	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461058	C4591001 1046 10461058	16-55	19AUG2020	56981	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461063	C4591001 1046 10461063	16-55	19AUG2020	56990	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461066	C4591001 1046 10461066	16-55	20AUG2020	56991	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461067	C4591001 1046 10461067	16-55	20AUG2020	56992	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10461068	C4591001 1046 10461068	16-55	20AUG2020	59638	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461069	C4591001 1046 10461069	16-55	20AUG2020	59639	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10461070	C4591001 1046 10461070	16-55	20AUG2020	59640	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10461071	C4591001 1046 10461071	16-55	20AUG2020	59644	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10461072	C4591001 1046 10461072	16-55	21AUG2020	60381	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10461081	C4591001 1046 10461081	16-55	24AUG2020	60383	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10461089	C4591001 1046 10461089	16-55	24AUG2020	60388	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10461091	C4591001 1046 10461091	16-55	25AUG2020	65358	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10461092	C4591001 1046 10461092	16-55	25AUG2020	65360	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461093	C4591001 1046 10461093	16-55	25AUG2020	65366	Placebo	25AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10461097	C4591001 1046 10461097	16-55	25AUG2020	65368	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10461098	C4591001 1046 10461098	16-55	25AUG2020	66797	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10461099	C4591001 1046 10461099	16-55	25AUG2020	66798	Placebo	25AUG2020/ Placebo			
10461100	C4591001 1046 10461100	16-55	25AUG2020	66801	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461101	C4591001 1046 10461101	16-55	26AUG2020	66802	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461102	C4591001 1046 10461102	16-55	26AUG2020	67410	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461104	C4591001 1046 10461104	16-55	26AUG2020	67413	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461105	C4591001 1046 10461105	16-55	26AUG2020	67414	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461107	C4591001 1046 10461107	16-55	26AUG2020	67417	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461108	C4591001 1046 10461108	16-55	26AUG2020	68525	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461109	C4591001 1046 10461109	16-55	26AUG2020	68528	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461111	C4591001 1046 10461111	16-55	26AUG2020	68530	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461112	C4591001 1046 10461112	16-55	27AUG2020	68535	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461113	C4591001 1046 10461113	16-55	27AUG2020	69725	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461115	C4591001 1046 10461115	16-55	27AUG2020	69729	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10461116	C4591001 1046 10461116	16-55	27AUG2020	69731	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461117	C4591001 1046 10461117	16-55	27AUG2020	69733	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10461118	C4591001 1046 10461118	16-55	27AUG2020	70566	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461119	C4591001 1046 10461119	16-55	27AUG2020	70567	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461120	C4591001 1046 10461120	16-55	27AUG2020	70568	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10461123	C4591001 1046 10461123	16-55	27AUG2020	70569	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10461124	C4591001 1046 10461124	16-55	27AUG2020	71394	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10461125	C4591001 1046 10461125	16-55	27AUG2020	71397	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461127	C4591001 1046 10461127	16-55	28AUG2020	71402	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10461130	C4591001 1046 10461130	16-55	28AUG2020	71404	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10461131	C4591001 1046 10461131	16-55	28AUG2020	72329	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10461133	C4591001 1046 10461133	16-55	28AUG2020	72334	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10461134	C4591001 1046 10461134	16-55	28AUG2020	72336	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461135	C4591001 1046 10461135	16-55	28AUG2020	72338	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461137	C4591001 1046 10461137	16-55	29AUG2020	73410	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10461139	C4591001 1046 10461139	16-55	29AUG2020	73416	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461140	C4591001 1046 10461140	16-55	29AUG2020	73417	Placebo	29AUG2020/ Placebo			
10461142	C4591001 1046 10461142	16-55	31AUG2020	73420	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10461143	C4591001 1046 10461143	16-55	31AUG2020	74790	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461145	C4591001 1046 10461145	16-55	31AUG2020	74791	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461146	C4591001 1046 10461146	16-55	31AUG2020	74793	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10461147	C4591001 1046 10461147	16-55	31AUG2020	74797	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461148	C4591001 1046 10461148	16-55	31AUG2020	76025	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10461149	C4591001 1046 10461149	16-55	31AUG2020	76026	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461150	C4591001 1046 10461150	16-55	31AUG2020	245714	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461151	C4591001 1046 10461151	16-55	01SEP2020	76028	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10461152	C4591001 1046 10461152	16-55	01SEP2020	76031	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461153	C4591001 1046 10461153	16-55	01SEP2020	76507	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461154	C4591001 1046 10461154	16-55	01SEP2020	76509	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10461155	C4591001 1046 10461155	16-55	01SEP2020	76511	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10461159	C4591001 1046 10461159	16-55	01SEP2020	77417	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10461162	C4591001 1046 10461162	16-55	02SEP2020	77419	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10461163	C4591001 1046 10461163	16-55	02SEP2020	77421	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461164	C4591001 1046 10461164	16-55	02SEP2020	77428	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461167	C4591001 1046 10461167	16-55	02SEP2020	78308	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10461168	C4591001 1046 10461168	16-55	02SEP2020	78310	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461170	C4591001 1046 10461170	16-55	02SEP2020	78312	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10461171	C4591001 1046 10461171	16-55	02SEP2020	78316	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461172	C4591001 1046 10461172	16-55	02SEP2020	79253	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461174	C4591001 1046 10461174	16-55	03SEP2020	79257	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10461175	C4591001 1046 10461175	16-55	03SEP2020	79261	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
10461176	C4591001 1046 10461176	16-55	03SEP2020	79263	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461177	C4591001 1046 10461177	16-55	03SEP2020	79865	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461186	C4591001 1046 10461186	16-55	04SEP2020	79867	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461188	C4591001 1046 10461188	16-55	04SEP2020	79870	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461191	C4591001 1046 10461191	16-55	04SEP2020	79874	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10461192	C4591001 1046 10461192	16-55	04SEP2020	82387	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461193	C4591001 1046 10461193	16-55	04SEP2020	82388	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10461194	C4591001 1046 10461194	16-55	04SEP2020	82390	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
10461196	C4591001 1046 10461196	16-55	04SEP2020	82394	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10461197	C4591001 1046 10461197	16-55	05SEP2020	82675	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10461198	C4591001 1046 10461198	16-55	05SEP2020	82676	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461199	C4591001 1046 10461199	16-55	05SEP2020	82677	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10461200	C4591001 1046 10461200	16-55	05SEP2020	82678	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461201	C4591001 1046 10461201	16-55	05SEP2020	82854	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10461202	C4591001 1046 10461202	16-55	07SEP2020	82857	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461203	C4591001 1046 10461203	16-55	07SEP2020	82859	Placebo	07SEP2020/ Placebo	02OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461204	C4591001 1046 10461204	16-55	07SEP2020	82861	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10461209	C4591001 1046 10461209	16-55	08SEP2020	83646	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10461210	C4591001 1046 10461210	16-55	08SEP2020	83649	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10461211	C4591001 1046 10461211	16-55	08SEP2020	83651	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10461217	C4591001 1046 10461217	16-55	08SEP2020	83656	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461218	C4591001 1046 10461218	16-55	08SEP2020	84560	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461219	C4591001 1046 10461219	16-55	08SEP2020	84563	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461221	C4591001 1046 10461221	16-55	09SEP2020	84564	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461223	C4591001 1046 10461223	16-55	09SEP2020	84568	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10461224	C4591001 1046 10461224	16-55	09SEP2020	85101	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10461227	C4591001 1046 10461227	16-55	09SEP2020	85105	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10461232	C4591001 1046 10461232	16-55	09SEP2020	85107	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10461233	C4591001 1046 10461233	16-55	09SEP2020	85108	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10461234	C4591001 1046 10461234	16-55	09SEP2020	86093	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10461236	C4591001 1046 10461236	16-55	10SEP2020	86097	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10461237	C4591001 1046 10461237	16-55	10SEP2020	86099	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10461240	C4591001 1046 10461240	16-55	10SEP2020	86104	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461242	C4591001 1046 10461242	16-55	10SEP2020	87152	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10461246	C4591001 1046 10461246	16-55	11SEP2020	87156	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10461247	C4591001 1046 10461247	16-55	11SEP2020	87157	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10461248	C4591001 1046 10461248	16-55	11SEP2020	87158	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10461252	C4591001 1046 10461252	16-55	11SEP2020	88733	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10461254	C4591001 1046 10461254	16-55	11SEP2020	88734	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10461255	C4591001 1046 10461255	16-55	12SEP2020	88737	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10461256	C4591001 1046 10461256	16-55	12SEP2020	88740	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10461257	C4591001 1046 10461257	16-55	12SEP2020	89153	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10461261	C4591001 1046 10461261	16-55	16SEP2020	89155	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461263	C4591001 1046 10461263	16-55	18SEP2020	89162	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10461265	C4591001 1046 10461265	16-55	19SEP2020	89163	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10461266	C4591001 1046 10461266	16-55	21SEP2020	94879	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10461268	C4591001 1046 10461268	16-55	23SEP2020	94883	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461269	C4591001 1046 10461269	16-55	24SEP2020	94884	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10461270	C4591001 1046 10461270	16-55	24SEP2020	94886	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
10461271	C4591001 1046 10461271	16-55	24SEP2020	98922	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10461272	C4591001 1046 10461272	16-55	25SEP2020	98926	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10461273	C4591001 1046 10461273	16-55	25SEP2020	98932	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10461274	C4591001 1046 10461274	16-55	25SEP2020	98927	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461275	C4591001 1046 10461275	16-55	29SEP2020	101958	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10461276	C4591001 1046 10461276	16-55	02OCT2020	101963	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10461280	C4591001 1046 10461280	16-55	06OCT2020	101967	Placebo	06OCT2020/ Placebo	03NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10461281	C4591001 1046 10461281	16-55	06OCT2020	101968	Placebo	06OCT2020/ Placebo	03NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461284	C4591001 1046 10461284	16-55	08OCT2020	105365	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10461285	C4591001 1046 10461285	16-55	08OCT2020	105369	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10461287	C4591001 1046 10461287	16-55	09OCT2020	105374	Placebo	09OCT2020/ Placebo	03NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10461288	C4591001 1046 10461288	16-55	09OCT2020	105375	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10461289	C4591001 1046 10461289	16-55	09OCT2020	106049	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10461290	C4591001 1046 10461290	16-55	09OCT2020	106053	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461291	C4591001 1046 10461291	16-55	09OCT2020	106058	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10461292	C4591001 1046 10461292	16-55	12OCT2020	267853	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10461294	C4591001 1046 10461294	16-55	12OCT2020	106059	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10461295	C4591001 1046 10461295	16-55	13OCT2020	106901	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10461297	C4591001 1046 10461297	16-55	14OCT2020	106905	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10461298	C4591001 1046 10461298	16-55	14OCT2020	106906	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10461300	C4591001 1046 10461300	16-55	14OCT2020	106912	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10461302	C4591001 1046 10461302	16-55	15OCT2020	108150	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10461303	C4591001 1046 10461303	16-55	15OCT2020	108151	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10461304	C4591001 1046 10461304	16-55	15OCT2020	108153	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461306	C4591001 1046 10461306	16-55	16OCT2020	108154	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10461307	C4591001 1046 10461307	16-55	16OCT2020	108943	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10461308	C4591001 1046 10461308	16-55	16OCT2020	108944	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10461311	C4591001 1046 10461311	16-55	17OCT2020	108947	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10461312	C4591001 1046 10461312	16-55	17OCT2020	108950	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10461313	C4591001 1046 10461313	16-55	17OCT2020	109625	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
10461314	C4591001 1046 10461314	16-55	17OCT2020	109626	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10461315	C4591001 1046 10461315	16-55	17OCT2020	109629	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10461318	C4591001 1046 10461318	16-55	19OCT2020	109636	Placebo	19OCT2020/ Placebo	03NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10461319	C4591001 1046 10461319	16-55	26OCT2020	113489	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461321	C4591001 1046 10461321	16-55	26OCT2020	113493	Placebo	26OCT2020/ Placebo	19NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10461323	C4591001 1046 10461323	16-55	26OCT2020	113495	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10461324	C4591001 1046 10461324	16-55	26OCT2020	113500	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10461325	C4591001 1046 10461325	16-55	27OCT2020	114006	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10461327	C4591001 1046 10461327	16-55	28OCT2020	114008	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10461329	C4591001 1046 10461329	16-55	28OCT2020	114011	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10461330	C4591001 1046 10461330	16-55	29OCT2020	114015	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10461331	C4591001 1046 10461331	16-55	29OCT2020	114653	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10461332	C4591001 1046 10461332	16-55	29OCT2020	114654	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10461333	C4591001 1046 10461333	16-55	29OCT2020	114659	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461334	C4591001 1046 10461334	16-55	29OCT2020	114660	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10461336	C4591001 1046 10461336	16-55	30OCT2020	114992	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10461337	C4591001 1046 10461337	16-55	30OCT2020	114993	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10461338	C4591001 1046 10461338	16-55	30OCT2020	114995	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10461339	C4591001 1046 10461339	16-55	30OCT2020	114996	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10461340	C4591001 1046 10461340	16-55	30OCT2020	115110	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10461341	C4591001 1046 10461341	16-55	19NOV2020	115114	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10461342	C4591001 1046 10461342	16-55	19NOV2020	115115	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10461343	C4591001 1046 10461343	16-55	20NOV2020	115118	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10461344	C4591001 1046 10461344	16-55	20NOV2020	116609	Placebo	20NOV2020/ Placebo	21DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10461345	C4591001 1046 10461345	16-55	24NOV2020	116614	Placebo	24NOV2020/ Placebo	17DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10461346	C4591001 1046 10461346	16-55	01DEC2020	116615	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10461347	C4591001 1046 10461347	16-55	03DEC2020	116617	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10461348	C4591001 1046 10461348	16-55	04DEC2020	117595	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10471009	C4591001 1047 10471009	16-55	20AUG2020	58289	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10471010	C4591001 1047 10471010	16-55	20AUG2020	58290	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10471015	C4591001 1047 10471015	16-55	20AUG2020	58297	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10471017	C4591001 1047 10471017	16-55	21AUG2020	58299	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10471018	C4591001 1047 10471018	16-55	21AUG2020	60642	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10471020	C4591001 1047 10471020	16-55	21AUG2020	60644	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471021	C4591001 1047 10471021	16-55	21AUG2020	60647	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10471025	C4591001 1047 10471025	16-55	21AUG2020	60652	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10471028	C4591001 1047 10471028	16-55	22AUG2020	61891	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10471029	C4591001 1047 10471029	16-55	22AUG2020	61898	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10471030	C4591001 1047 10471030	16-55	22AUG2020	61899	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo		
10471033	C4591001 1047 10471033	16-55	22AUG2020	62393	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10471034	C4591001 1047 10471034	16-55	22AUG2020	61900	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo		
10471035	C4591001 1047 10471035	16-55	24AUG2020	62396	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10471036	C4591001 1047 10471036	16-55	24AUG2020	62397	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10471037	C4591001 1047 10471037	16-55	24AUG2020	62403	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10471038	C4591001 1047 10471038	16-55	24AUG2020	64253	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471040	C4591001 1047 10471040	16-55	24AUG2020	64258	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471041	C4591001 1047 10471041	16-55	25AUG2020	64264	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471042	C4591001 1047 10471042	16-55	25AUG2020	64263	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10471046	C4591001 1047 10471046	16-55	25AUG2020	66077	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10471047	C4591001 1047 10471047	16-55	25AUG2020	66082	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471048	C4591001 1047 10471048	16-55	25AUG2020	66085	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471049	C4591001 1047 10471049	16-55	25AUG2020	66087	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10471051	C4591001 1047 10471051	16-55	25AUG2020	66906	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471052	C4591001 1047 10471052	16-55	26AUG2020	66909	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10471053	C4591001 1047 10471053	16-55	26AUG2020	66912	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471054	C4591001 1047 10471054	16-55	26AUG2020	66914	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
10471056	C4591001 1047 10471056	16-55	26AUG2020	68340	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471057	C4591001 1047 10471057	16-55	26AUG2020	68336	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471058	C4591001 1047 10471058	16-55	26AUG2020	68342	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10471059	C4591001 1047 10471059	16-55	26AUG2020	68344	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
10471061	C4591001 1047 10471061	16-55	27AUG2020	69835	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471064	C4591001 1047 10471064	16-55	27AUG2020	69837	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471065	C4591001 1047 10471065	16-55	27AUG2020	69843	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10471067	C4591001 1047 10471067	16-55	27AUG2020	69844	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471068	C4591001 1047 10471068	16-55	27AUG2020	71047	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471069	C4591001 1047 10471069	16-55	27AUG2020	71051	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471070	C4591001 1047 10471070	16-55	27AUG2020	243124	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10471071	C4591001 1047 10471071	16-55	27AUG2020	71048	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471074	C4591001 1047 10471074	16-55	28AUG2020	71055	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10471075	C4591001 1047 10471075	16-55	28AUG2020	72161	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10471076	C4591001 1047 10471076	16-55	28AUG2020	72166	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10471077	C4591001 1047 10471077	16-55	28AUG2020	72168	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471078	C4591001 1047 10471078	16-55	28AUG2020	72171	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471079	C4591001 1047 10471079	16-55	28AUG2020	72653	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10471080	C4591001 1047 10471080	16-55	28AUG2020	72654	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471081	C4591001 1047 10471081	16-55	28AUG2020	72658	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471082	C4591001 1047 10471082	16-55	28AUG2020	72656	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10471083	C4591001 1047 10471083	16-55	28AUG2020	73170	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10471084	C4591001 1047 10471084	16-55	28AUG2020	73172	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10471085	C4591001 1047 10471085	16-55	31AUG2020	73178	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471086	C4591001 1047 10471086	16-55	31AUG2020	73179	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10471087	C4591001 1047 10471087	16-55	31AUG2020	75149	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471088	C4591001 1047 10471088	16-55	31AUG2020	75151	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10471089	C4591001 1047 10471089	16-55	31AUG2020	75154	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10471093	C4591001 1047 10471093	16-55	31AUG2020	75157	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471094	C4591001 1047 10471094	16-55	01SEP2020	76484	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10471095	C4591001 1047 10471095	16-55	01SEP2020	76486	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10471100	C4591001 1047 10471100	16-55	01SEP2020	76487	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10471106	C4591001 1047 10471106	16-55	02SEP2020	76490	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10471107	C4591001 1047 10471107	16-55	02SEP2020	78065	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10471109	C4591001 1047 10471109	16-55	02SEP2020	78236	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10471111	C4591001 1047 10471111	16-55	02SEP2020	78237	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10471112	C4591001 1047 10471112	16-55	02SEP2020	78238	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10471115	C4591001 1047 10471115	16-55	02SEP2020	78239	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471116	C4591001 1047 10471116	16-55	02SEP2020	79265	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471117	C4591001 1047 10471117	16-55	03SEP2020	79268	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10471118	C4591001 1047 10471118	16-55	03SEP2020	79269	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10471119	C4591001 1047 10471119	16-55	03SEP2020	79273	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10471120	C4591001 1047 10471120	16-55	03SEP2020	80166	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10471124	C4591001 1047 10471124	16-55	03SEP2020	80171	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10471125	C4591001 1047 10471125	16-55	03SEP2020	80172	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471126	C4591001 1047 10471126	16-55	03SEP2020	80921	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10471127	C4591001 1047 10471127	16-55	03SEP2020	80175	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10471128	C4591001 1047 10471128	16-55	03SEP2020	80922	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10471129	C4591001 1047 10471129	16-55	03SEP2020	80927	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471131	C4591001 1047 10471131	16-55	04SEP2020	80929	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471133	C4591001 1047 10471133	16-55	04SEP2020	81401	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10471134	C4591001 1047 10471134	16-55	04SEP2020	81406	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10471143	C4591001 1047 10471143	16-55	04SEP2020	81409	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10471144	C4591001 1047 10471144	16-55	04SEP2020	81410	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10471146	C4591001 1047 10471146	16-55	07SEP2020	83146	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10471147	C4591001 1047 10471147	16-55	07SEP2020	83141	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10471148	C4591001 1047 10471148	16-55	07SEP2020	83147	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471149	C4591001 1047 10471149	16-55	07SEP2020	83149	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471150	C4591001 1047 10471150	16-55	07SEP2020	83214	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471151	C4591001 1047 10471151	16-55	07SEP2020	83216	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471153	C4591001 1047 10471153	16-55	08SEP2020	83219	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471155	C4591001 1047 10471155	16-55	08SEP2020	83221	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471159	C4591001 1047 10471159	16-55	08SEP2020	84307	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471162	C4591001 1047 10471162	16-55	08SEP2020	84311	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471163	C4591001 1047 10471163	16-55	09SEP2020	84314	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10471164	C4591001 1047 10471164	16-55	09SEP2020	84316	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471166	C4591001 1047 10471166	16-55	09SEP2020	85172	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471167	C4591001 1047 10471167	16-55	09SEP2020	85173	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10471168	C4591001 1047 10471168	16-55	09SEP2020	85176	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471171	C4591001 1047 10471171	16-55	09SEP2020	85179	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10471172	C4591001 1047 10471172	16-55	10SEP2020	86508	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471174	C4591001 1047 10471174	16-55	10SEP2020	86510	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10471176	C4591001 1047 10471176	16-55	10SEP2020	86511	Placebo	10SEP2020/ Placebo	23OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10471179	C4591001 1047 10471179	16-55	10SEP2020	86512	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471180	C4591001 1047 10471180	16-55	10SEP2020	87526	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10471181	C4591001 1047 10471181	16-55	10SEP2020	87528	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10471186	C4591001 1047 10471186	16-55	11SEP2020	87529	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10471189	C4591001 1047 10471189	16-55	11SEP2020	87532	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10471192	C4591001 1047 10471192	16-55	11SEP2020	88797	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471198	C4591001 1047 10471198	16-55	12SEP2020	88799	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10471199	C4591001 1047 10471199	16-55	12SEP2020	88801	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10471201	C4591001 1047 10471201	16-55	12SEP2020	89237	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10471202	C4591001 1047 10471202	16-55	12SEP2020	88804	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10471203	C4591001 1047 10471203	16-55	14SEP2020	89242	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471207	C4591001 1047 10471207	16-55	14SEP2020	89247	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10471210	C4591001 1047 10471210	16-55	15SEP2020	89248	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
10471211	C4591001 1047 10471211	16-55	15SEP2020	90377	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
10471212	C4591001 1047 10471212	16-55	15SEP2020	90378	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10471217	C4591001 1047 10471217	16-55	16SEP2020	90379	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471219	C4591001 1047 10471219	16-55	16SEP2020	90382	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10471220	C4591001 1047 10471220	16-55	16SEP2020	91193	Placebo	16SEP2020/ Placebo	20OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10471221	C4591001 1047 10471221	16-55	16SEP2020	91195	Placebo	16SEP2020/ Placebo			
10471223	C4591001 1047 10471223	16-55	16SEP2020	91198	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471225	C4591001 1047 10471225	16-55	16SEP2020	91199	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10471226	C4591001 1047 10471226	16-55	16SEP2020	91687	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471227	C4591001 1047 10471227	16-55	16SEP2020	91691	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10471229	C4591001 1047 10471229	16-55	17SEP2020	91693	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471231	C4591001 1047 10471231	16-55	17SEP2020	91696	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10471232	C4591001 1047 10471232	16-55	17SEP2020	92454	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471233	C4591001 1047 10471233	16-55	17SEP2020	92459	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471234	C4591001 1047 10471234	16-55	17SEP2020	92461	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		
10471236	C4591001 1047 10471236	16-55	17SEP2020	92462	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471237	C4591001 1047 10471237	16-55	17SEP2020	92970	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10471238	C4591001 1047 10471238	16-55	18SEP2020	92971	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10471240	C4591001 1047 10471240	16-55	18SEP2020	92976	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10471241	C4591001 1047 10471241	16-55	18SEP2020	92979	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10471243	C4591001 1047 10471243	16-55	18SEP2020	94198	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10471244	C4591001 1047 10471244	16-55	18SEP2020	94200	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10471245	C4591001 1047 10471245	16-55	21SEP2020	94201	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471246	C4591001 1047 10471246	16-55	21SEP2020	94203	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471251	C4591001 1047 10471251	16-55	21SEP2020	95311	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10471253	C4591001 1047 10471253	16-55	21SEP2020	95312	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471254	C4591001 1047 10471254	16-55	21SEP2020	95316	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10471255	C4591001 1047 10471255	16-55	21SEP2020	95318	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471256	C4591001 1047 10471256	16-55	21SEP2020	95494	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10471257	C4591001 1047 10471257	16-55	21SEP2020	95496	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471258	C4591001 1047 10471258	16-55	22SEP2020	95498	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10471259	C4591001 1047 10471259	16-55	22SEP2020	95500	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10471262	C4591001 1047 10471262	16-55	22SEP2020	96390	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471264	C4591001 1047 10471264	16-55	22SEP2020	96391	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10471266	C4591001 1047 10471266	16-55	22SEP2020	96392	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10471267	C4591001 1047 10471267	16-55	22SEP2020	96400	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471270	C4591001 1047 10471270	16-55	22SEP2020	96930	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471271	C4591001 1047 10471271	16-55	23SEP2020	96934	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10471275	C4591001 1047 10471275	16-55	23SEP2020	96936	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471278	C4591001 1047 10471278	16-55	23SEP2020	98285	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10471279	C4591001 1047 10471279	16-55	23SEP2020	96937	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471284	C4591001 1047 10471284	16-55	24SEP2020	98286	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
10471285	C4591001 1047 10471285	16-55	24SEP2020	98287	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471286	C4591001 1047 10471286	16-55	24SEP2020	98296	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471287	C4591001 1047 10471287	16-55	24SEP2020	98765	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10471288	C4591001 1047 10471288	16-55	24SEP2020	98767	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471289	C4591001 1047 10471289	16-55	24SEP2020	98774	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10471291	C4591001 1047 10471291	16-55	24SEP2020	98776	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10471292	C4591001 1047 10471292	16-55	24SEP2020	98985	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10471293	C4591001 1047 10471293	16-55	25SEP2020	98991	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
10471294	C4591001 1047 10471294	16-55	25SEP2020	98987	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471295	C4591001 1047 10471295	16-55	25SEP2020	98992	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10471296	C4591001 1047 10471296	16-55	25SEP2020	99983	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471297	C4591001 1047 10471297	16-55	25SEP2020	99984	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10471301	C4591001 1047 10471301	16-55	28SEP2020	99985	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
10471303	C4591001 1047 10471303	16-55	29SEP2020	99986	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		
10471304	C4591001 1047 10471304	16-55	30SEP2020	102341	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
10471305	C4591001 1047 10471305	16-55	30SEP2020	102342	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10471306	C4591001 1047 10471306	16-55	02OCT2020	102349	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10471307	C4591001 1047 10471307	16-55	05OCT2020	102352	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10471308	C4591001 1047 10471308	16-55	05OCT2020	103868	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10471310	C4591001 1047 10471310	16-55	07OCT2020	103874	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10471312	C4591001 1047 10471312	16-55	09OCT2020	103875	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471314	C4591001 1047 10471314	16-55	12OCT2020	103876	Placebo	12OCT2020/ Placebo			
10471316	C4591001 1047 10471316	16-55	13OCT2020	107229	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10471317	C4591001 1047 10471317	16-55	13OCT2020	107232	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10471318	C4591001 1047 10471318	16-55	14OCT2020	107233	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10471319	C4591001 1047 10471319	16-55	15OCT2020	107236	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10471321	C4591001 1047 10471321	16-55	19OCT2020	110057	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10471322	C4591001 1047 10471322	16-55	19OCT2020	110059	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo		
10471325	C4591001 1047 10471325	16-55	20OCT2020	110065	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10471326	C4591001 1047 10471326	16-55	21OCT2020	110068	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo		
10471327	C4591001 1047 10471327	16-55	21OCT2020	111725	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo		
10471328	C4591001 1047 10471328	16-55	21OCT2020	111730	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10471329	C4591001 1047 10471329	16-55	21OCT2020	111731	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10471331	C4591001 1047 10471331	16-55	22OCT2020	111736	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10471332	C4591001 1047 10471332	16-55	23OCT2020	112865	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10481011	C4591001 1048 10481011	16-55	17AUG2020	44867	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10481017	C4591001 1048 10481017	16-55	18AUG2020	44870	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10481019	C4591001 1048 10481019	16-55	18AUG2020	55289	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10481020	C4591001 1048 10481020	16-55	18AUG2020	55290	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10481021	C4591001 1048 10481021	16-55	24AUG2020	55292	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10481024	C4591001 1048 10481024	16-55	24AUG2020	55299	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10481025	C4591001 1048 10481025	16-55	24AUG2020	64818	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481027	C4591001 1048 10481027	16-55	25AUG2020	64819	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10481030	C4591001 1048 10481030	16-55	25AUG2020	64821	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10481032	C4591001 1048 10481032	16-55	25AUG2020	64823	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10481035	C4591001 1048 10481035	16-55	26AUG2020	67949	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10481037	C4591001 1048 10481037	16-55	26AUG2020	67952	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10481040	C4591001 1048 10481040	16-55	27AUG2020	67953	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10481044	C4591001 1048 10481044	16-55	27AUG2020	67955	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10481046	C4591001 1048 10481046	16-55	27AUG2020	71310	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10481048	C4591001 1048 10481048	16-55	28AUG2020	71312	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10481052	C4591001 1048 10481052	16-55	28AUG2020	71317	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481054	C4591001 1048 10481054	16-55	28AUG2020	71319	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10481055	C4591001 1048 10481055	16-55	31AUG2020	74945	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10481056	C4591001 1048 10481056	16-55	31AUG2020	74951	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10481057	C4591001 1048 10481057	16-55	31AUG2020	74953	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10481061	C4591001 1048 10481061	16-55	01SEP2020	74956	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10481064	C4591001 1048 10481064	16-55	01SEP2020	77409	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10481065	C4591001 1048 10481065	16-55	01SEP2020	77405	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10481070	C4591001 1048 10481070	16-55	02SEP2020	77410	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
10481075	C4591001 1048 10481075	16-55	02SEP2020	77416	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10481079	C4591001 1048 10481079	16-55	03SEP2020	80287	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481080	C4591001 1048 10481080	16-55	03SEP2020	80289	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10481083	C4591001 1048 10481083	16-55	03SEP2020	80291	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10481085	C4591001 1048 10481085	16-55	03SEP2020	80295	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10481086	C4591001 1048 10481086	16-55	03SEP2020	81140	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10481088	C4591001 1048 10481088	16-55	04SEP2020	81142	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10481092	C4591001 1048 10481092	16-55	04SEP2020	81143	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10481094	C4591001 1048 10481094	16-55	04SEP2020	81144	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
10481095	C4591001 1048 10481095	16-55	08SEP2020	83853	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10481097	C4591001 1048 10481097	16-55	08SEP2020	83858	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10481098	C4591001 1048 10481098	16-55	08SEP2020	83859	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481101	C4591001 1048 10481101	16-55	08SEP2020	83860	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10481103	C4591001 1048 10481103	16-55	08SEP2020	84670	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10481106	C4591001 1048 10481106	16-55	09SEP2020	84671	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10481107	C4591001 1048 10481107	16-55	09SEP2020	84672	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10481108	C4591001 1048 10481108	16-55	09SEP2020	84674	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
10481109	C4591001 1048 10481109	16-55	09SEP2020	86193	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10481110	C4591001 1048 10481110	16-55	09SEP2020	86195	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10481114	C4591001 1048 10481114	16-55	10SEP2020	86197	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10481116	C4591001 1048 10481116	16-55	10SEP2020	86200	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10481125	C4591001 1048 10481125	16-55	11SEP2020	88230	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10481126	C4591001 1048 10481126	16-55	11SEP2020	88235	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10481131	C4591001 1048 10481131	16-55	11SEP2020	88238	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10481132	C4591001 1048 10481132	16-55	11SEP2020	88937	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10521003	C4591001 1052 10521003	16-55	18AUG2020	232263	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10521004	C4591001 1052 10521004	16-55	19AUG2020	56720	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10521005	C4591001 1052 10521005	16-55	19AUG2020	56721	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10521006	C4591001 1052 10521006	16-55	19AUG2020	56722	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10521007	C4591001 1052 10521007	16-55	19AUG2020	56724	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10521011	C4591001 1052 10521011	16-55	19AUG2020	57569	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10521013	C4591001 1052 10521013	16-55	20AUG2020	57572	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521015	C4591001 10521015	16-55	20AUG2020	57573	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10521016	C4591001 10521016	16-55	20AUG2020	57574	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	
10521017	C4591001 10521017	16-55	21AUG2020	61042	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10521021	C4591001 10521021	16-55	21AUG2020	61043	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10521022	C4591001 10521022	16-55	21AUG2020	61045	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
10521026	C4591001 10521026	16-55	24AUG2020	61046	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10521028	C4591001 10521028	16-55	25AUG2020	66490	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10521030	C4591001 10521030	16-55	25AUG2020	66492	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10521031	C4591001 10521031	16-55	26AUG2020	66494	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10521032	C4591001 10521032	16-55	26AUG2020	66496	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521035	C4591001 1052 10521035	16-55	26AUG2020	68623	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
10521036	C4591001 1052 10521036	16-55	26AUG2020	68626	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10521040	C4591001 1052 10521040	16-55	26AUG2020	68630	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10521041	C4591001 1052 10521041	16-55	26AUG2020	69078	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10521043	C4591001 1052 10521043	16-55	27AUG2020	69082	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10521044	C4591001 1052 10521044	16-55	27AUG2020	69084	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10521046	C4591001 1052 10521046	16-55	27AUG2020	69087	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10521049	C4591001 1052 10521049	16-55	27AUG2020	71185	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10521051	C4591001 1052 10521051	16-55	28AUG2020	71186	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10521052	C4591001 1052 10521052	16-55	28AUG2020	71187	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521053	C4591001 1052 10521053	16-55	28AUG2020	71188	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10521054	C4591001 1052 10521054	16-55	28AUG2020	72584	Placebo	28AUG2020/ Placebo			
10521055	C4591001 1052 10521055	16-55	28AUG2020	72585	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10521056	C4591001 1052 10521056	16-55	28AUG2020	72587	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10521057	C4591001 1052 10521057	16-55	28AUG2020	72591	Placebo	28AUG2020/ Placebo			
10521058	C4591001 1052 10521058	16-55	28AUG2020	73110	Placebo	28AUG2020/ Placebo			
10521063	C4591001 1052 10521063	16-55	31AUG2020	73112	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10521064	C4591001 1052 10521064	16-55	31AUG2020	73115	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)			
10521065	C4591001 1052 10521065	16-55	31AUG2020	73119	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521066	C4591001 1052 10521066	16-55	31AUG2020	76126	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521068	C4591001 1052 10521068	16-55	01SEP2020	76127	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10521070	C4591001 1052 10521070	16-55	01SEP2020	76128	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10521071	C4591001 1052 10521071	16-55	01SEP2020	76131	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10521073	C4591001 1052 10521073	16-55	01SEP2020	77374	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10521075	C4591001 1052 10521075	16-55	01SEP2020	77370	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10521076	C4591001 1052 10521076	16-55	02SEP2020	77377	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10521079	C4591001 1052 10521079	16-55	02SEP2020	77378	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10521080	C4591001 1052 10521080	16-55	02SEP2020	78907	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)			
10521081	C4591001 1052 10521081	16-55	02SEP2020	78909	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10521082	C4591001 1052 10521082	16-55	02SEP2020	78913	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521083	C4591001 1052 10521083	16-55	03SEP2020	80370	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10521084	C4591001 1052 10521084	16-55	03SEP2020	78915	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521086	C4591001 1052 10521086	16-55	03SEP2020	80373	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10521087	C4591001 1052 10521087	16-55	03SEP2020	80376	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521090	C4591001 1052 10521090	16-55	03SEP2020	80377	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521091	C4591001 1052 10521091	16-55	03SEP2020	81030	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10521092	C4591001 1052 10521092	16-55	04SEP2020	81034	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521093	C4591001 1052 10521093	16-55	04SEP2020	81035	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10521096	C4591001 1052 10521096	16-55	04SEP2020	81038	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10521100	C4591001 1052 10521100	16-55	04SEP2020	82054	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521101	C4591001 1052 10521101	16-55	04SEP2020	82055	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10521104	C4591001 1052 10521104	16-55	04SEP2020	82056	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521105	C4591001 1052 10521105	16-55	04SEP2020	82057	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10521106	C4591001 1052 10521106	16-55	04SEP2020	82410	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521109	C4591001 1052 10521109	16-55	04SEP2020	82413	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521110	C4591001 1052 10521110	16-55	04SEP2020	82415	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
10521111	C4591001 1052 10521111	16-55	04SEP2020	82420	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10521113	C4591001 1052 10521113	16-55	04SEP2020	82581	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10521114	C4591001 1052 10521114	16-55	16SEP2020	82585	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10521116	C4591001 1052 10521116	16-55	16SEP2020	82586	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521117	C4591001 1052 10521117	16-55	16SEP2020	82587	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521120	C4591001 1052 10521120	16-55	17SEP2020	92816	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10521121	C4591001 1052 10521121	16-55	17SEP2020	92815	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
10521123	C4591001 1052 10521123	16-55	18SEP2020	92823	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521125	C4591001 1052 10521125	16-55	18SEP2020	93966	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521126	C4591001 1052 10521126	16-55	18SEP2020	92824	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521129	C4591001 1052 10521129	16-55	18SEP2020	93971	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10521131	C4591001 1052 10521131	16-55	19SEP2020	93972	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10521132	C4591001 1052 10521132	16-55	19SEP2020	93974	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521133	C4591001 1052 10521133	16-55	19SEP2020	94506	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521134	C4591001 1052 10521134	16-55	19SEP2020	94510	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521135	C4591001 1052 10521135	16-55	19SEP2020	94511	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521139	C4591001 1052 10521139	16-55	19SEP2020	94515	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)			
10521140	C4591001 1052 10521140	16-55	19SEP2020	94555	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10521141	C4591001 1052 10521141	16-55	21SEP2020	94559	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10521143	C4591001 1052 10521143	16-55	21SEP2020	94563	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10521145	C4591001 1052 10521145	16-55	22SEP2020	94564	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10521148	C4591001 1052 10521148	16-55	22SEP2020	96735	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10521149	C4591001 1052 10521149	16-55	22SEP2020	96728	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10521150	C4591001 1052 10521150	16-55	22SEP2020	96729	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521152	C4591001 1052 10521152	16-55	22SEP2020	96736	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521154	C4591001 1052 10521154	16-55	23SEP2020	97769	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521155	C4591001 1052 10521155	16-55	23SEP2020	97770	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	
10521157	C4591001 1052 10521157	16-55	23SEP2020	97771	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10521158	C4591001 1052 10521158	16-55	23SEP2020	97779	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521159	C4591001 1052 10521159	16-55	23SEP2020	97865	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10521160	C4591001 1052 10521160	16-55	23SEP2020	97870	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10521161	C4591001 1052 10521161	16-55	23SEP2020	97872	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10521162	C4591001 1052 10521162	16-55	23SEP2020	97873	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10521163	C4591001 1052 10521163	16-55	23SEP2020	98240	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521164	C4591001 1052 10521164	16-55	23SEP2020	98241	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10521165	C4591001 1052 10521165	16-55	23SEP2020	98243	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10521166	C4591001 1052 10521166	16-55	23SEP2020	98246	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10521167	C4591001 1052 10521167	16-55	24SEP2020	99067	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10521168	C4591001 1052 10521168	16-55	25SEP2020	99069	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10521169	C4591001 1052 10521169	16-55	25SEP2020	99070	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10521170	C4591001 1052 10521170	16-55	25SEP2020	99074	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10521172	C4591001 1052 10521172	16-55	25SEP2020	100135	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10521173	C4591001 1052 10521173	16-55	25SEP2020	100137	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10521174	C4591001 1052 10521174	16-55	25SEP2020	100139	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10521175	C4591001 1052 10521175	16-55	25SEP2020	100142	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10521176	C4591001 1052 10521176	16-55	25SEP2020	100409	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10521177	C4591001 1052 10521177	16-55	25SEP2020	100417	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10521178	C4591001 1052 10521178	16-55	25SEP2020	100418	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10541001	C4591001 1054 10541001	16-55	19AUG2020	56513	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10541002	C4591001 1054 10541002	16-55	19AUG2020	56515	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10541003	C4591001 1054 10541003	16-55	19AUG2020	56518	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10541005	C4591001 1054 10541005	16-55	19AUG2020	56523	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541006	C4591001 1054 10541006	16-55	19AUG2020	57210	Placebo	19AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10541007	C4591001 1054 10541007	16-55	19AUG2020	57209	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541008	C4591001 1054 10541008	16-55	19AUG2020	57211	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541011	C4591001 1054 10541011	16-55	20AUG2020	57213	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10541012	C4591001 1054 10541012	16-55	20AUG2020	58541	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10541013	C4591001 1054 10541013	16-55	20AUG2020	58543	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10541014	C4591001 1054 10541014	16-55	20AUG2020	58549	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541016	C4591001 1054 10541016	16-55	20AUG2020	58551	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
10541017	C4591001 1054 10541017	16-55	20AUG2020	59071	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10541018	C4591001 1054 10541018	16-55	20AUG2020	59075	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10541019	C4591001 1054 10541019	16-55	20AUG2020	59076	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10541022	C4591001 1054 10541022	16-55	21AUG2020	59079	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541023	C4591001 1054 10541023	16-55	21AUG2020	60741	Placebo	21AUG2020/ Placebo			
10541025	C4591001 1054 10541025	16-55	21AUG2020	60743	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541026	C4591001 1054 10541026	16-55	21AUG2020	60744	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541027	C4591001 1054 10541027	16-55	21AUG2020	60746	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541028	C4591001 1054 10541028	16-55	21AUG2020	61206	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10541032	C4591001 1054 10541032	16-55	22AUG2020	61213	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10541033	C4591001 1054 10541033	16-55	22AUG2020	61214	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
10541034	C4591001 1054 10541034	16-55	22AUG2020	61215	Placebo	22AUG2020/ Placebo	15SEP2020/ Placebo		
10541035	C4591001 1054 10541035	16-55	22AUG2020	62370	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10541037	C4591001 1054 10541037	16-55	24AUG2020	62375	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541038	C4591001 1054 10541038	16-55	24AUG2020	62377	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10541039	C4591001 1054 10541039	16-55	24AUG2020	62378	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10541041	C4591001 1054 10541041	16-55	24AUG2020	64111	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10541042	C4591001 1054 10541042	16-55	24AUG2020	64110	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541043	C4591001 1054 10541043	16-55	24AUG2020	64112	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10541044	C4591001 1054 10541044	16-55	25AUG2020	64116	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541047	C4591001 1054 10541047	16-55	25AUG2020	65888	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10541048	C4591001 1054 10541048	16-55	25AUG2020	65891	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10541049	C4591001 1054 10541049	16-55	25AUG2020	65893	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo		
10541050	C4591001 1054 10541050	16-55	26AUG2020	65894	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541051	C4591001 1054 10541051	16-55	26AUG2020	67810	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541052	C4591001 1054 10541052	16-55	26AUG2020	67814	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10541053	C4591001 1054 10541053	16-55	26AUG2020	67815	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10541054	C4591001 1054 10541054	16-55	26AUG2020	67901	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541055	C4591001 1054 10541055	16-55	26AUG2020	67903	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10541057	C4591001 1054 10541057	16-55	26AUG2020	67908	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10541058	C4591001 1054 10541058	16-55	26AUG2020	67912	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10541060	C4591001 1054 10541060	16-55	27AUG2020	69992	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10541061	C4591001 1054 10541061	16-55	27AUG2020	69993	Placebo	27AUG2020/ Placebo	28SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10541064	C4591001 1054 10541064	16-55	27AUG2020	69994	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541065	C4591001 1054 10541065	16-55	27AUG2020	69996	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10541066	C4591001 1054 10541066	16-55	28AUG2020	71998	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10541067	C4591001 1054 10541067	16-55	28AUG2020	71999	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10541068	C4591001 1054 10541068	16-55	28AUG2020	72001	Placebo	28AUG2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541069	C4591001 1054 10541069	16-55	28AUG2020	72004	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10541070	C4591001 1054 10541070	16-55	28AUG2020	72197	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10541073	C4591001 1054 10541073	16-55	28AUG2020	72204	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541074	C4591001 1054 10541074	16-55	28AUG2020	72198	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
10541076	C4591001 1054 10541076	16-55	31AUG2020	72207	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10541078	C4591001 1054 10541078	16-55	31AUG2020	75116	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541080	C4591001 1054 10541080	16-55	31AUG2020	75114	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10541081	C4591001 1054 10541081	16-55	31AUG2020	75117	Placebo	31AUG2020/ Placebo	02OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541084	C4591001 1054 10541084	16-55	31AUG2020	75557	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541085	C4591001 1054 10541085	16-55	31AUG2020	75122	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10541086	C4591001 1054 10541086	16-55	31AUG2020	75561	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10541087	C4591001 1054 10541087	16-55	01SEP2020	75566	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541088	C4591001 1054 10541088	16-55	01SEP2020	75568	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541089	C4591001 1054 10541089	16-55	01SEP2020	76785	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541090	C4591001 1054 10541090	16-55	01SEP2020	76786	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10541091	C4591001 1054 10541091	16-55	01SEP2020	76788	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541092	C4591001 1054 10541092	16-55	01SEP2020	76791	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10541094	C4591001 1054 10541094	16-55	02SEP2020	77386	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10541096	C4591001 1054 10541096	16-55	02SEP2020	77389	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10541097	C4591001 1054 10541097	16-55	02SEP2020	77391	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10541098	C4591001 1054 10541098	16-55	02SEP2020	78666	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541100	C4591001 1054 10541100	16-55	02SEP2020	78669	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10541101	C4591001 1054 10541101	16-55	02SEP2020	78671	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10541104	C4591001 1054 10541104	16-55	03SEP2020	78672	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541106	C4591001 1054 10541106	16-55	03SEP2020	79939	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10541107	C4591001 1054 10541107	16-55	03SEP2020	79941	Placebo	03SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541108	C4591001 1054 10541108	16-55	03SEP2020	79946	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541109	C4591001 1054 10541109	16-55	03SEP2020	80563	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10541110	C4591001 1054 10541110	16-55	03SEP2020	80567	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10541111	C4591001 1054 10541111	16-55	03SEP2020	80570	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541113	C4591001 1054 10541113	16-55	03SEP2020	80571	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10541115	C4591001 1054 10541115	16-55	04SEP2020	81608	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10541119	C4591001 1054 10541119	16-55	04SEP2020	81610	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10541120	C4591001 1054 10541120	16-55	04SEP2020	81611	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10541121	C4591001 1054 10541121	16-55	04SEP2020	81614	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10541122	C4591001 1054 10541122	16-55	08SEP2020	83657	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541123	C4591001 1054 10541123	16-55	08SEP2020	83659	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10541125	C4591001 1054 10541125	16-55	08SEP2020	83660	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10541130	C4591001 1054 10541130	16-55	09SEP2020	83663	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
10541131	C4591001 1054 10541131	16-55	09SEP2020	85293	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541135	C4591001 1054 10541135	16-55	09SEP2020	85294	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10541137	C4591001 1054 10541137	16-55	10SEP2020	85295	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10541138	C4591001 1054 10541138	16-55	10SEP2020	85298	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)			
10541140	C4591001 1054 10541140	16-55	10SEP2020	87234	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10541141	C4591001 1054 10541141	16-55	10SEP2020	87235	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10541144	C4591001 1054 10541144	16-55	11SEP2020	87238	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541145	C4591001 1054 10541145	16-55	11SEP2020	87244	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541148	C4591001 1054 10541148	16-55	11SEP2020	88506	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10541150	C4591001 1054 10541150	16-55	14SEP2020	88510	Placebo	14SEP2020/ Placebo			
10541152	C4591001 1054 10541152	16-55	14SEP2020	88513	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10541153	C4591001 1054 10541153	16-55	15SEP2020	88516	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10541154	C4591001 1054 10541154	16-55	15SEP2020	90414	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10541155	C4591001 1054 10541155	16-55	15SEP2020	90415	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541157	C4591001 1054 10541157	16-55	15SEP2020	90423	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10541158	C4591001 1054 10541158	16-55	15SEP2020	90424	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10541160	C4591001 1054 10541160	16-55	16SEP2020	91158	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541161	C4591001 1054 10541161	16-55	16SEP2020	91161	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
10541165	C4591001 1054 10541165	16-55	17SEP2020	91164	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10541170	C4591001 1054 10541170	16-55	18SEP2020	91168	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10541171	C4591001 1054 10541171	16-55	18SEP2020	93762	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541174	C4591001 1054 10541174	16-55	18SEP2020	93766	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10541176	C4591001 1054 10541176	16-55	21SEP2020	93770	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10541178	C4591001 1054 10541178	16-55	22SEP2020	93771	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10541179	C4591001 1054 10541179	16-55	22SEP2020	96751	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10541182	C4591001 1054 10541182	16-55	23SEP2020	96752	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10541184	C4591001 1054 10541184	16-55	23SEP2020	96758	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541190	C4591001 1054 10541190	16-55	12OCT2020	106543	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
10541191	C4591001 1054 10541191	16-55	13OCT2020	106544	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10541192	C4591001 1054 10541192	16-55	13OCT2020	106548	Placebo	13OCT2020/ Placebo	20NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541193	C4591001 1054 10541193	16-55	14OCT2020	106550	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10541197	C4591001 1054 10541197	16-55	19OCT2020	110408	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10541200	C4591001 1054 10541200	16-55	22OCT2020	110411	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10541201	C4591001 1054 10541201	16-55	22OCT2020	110412	Placebo	22OCT2020/ Placebo	20NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10541203	C4591001 1054 10541203	16-55	23OCT2020	110415	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10541204	C4591001 1054 10541204†	16-55	26OCT2020	113637	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
10541206	C4591001 1054 10541206	16-55	26OCT2020	113743	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10541207	C4591001 1054 10541207	16-55	27OCT2020	113745	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10541208	C4591001 1054 10541208	16-55	28OCT2020	113750	Placebo	28OCT2020/ Placebo	23NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10541212	C4591001 1054 10541212†	16-55	29OCT2020	113751	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10541214	C4591001 1054 10541214	16-55	29OCT2020	114749	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
10541215	C4591001 1054 10541215	16-55	29OCT2020	114750	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551050	C4591001 1055 10551050	16-55	17AUG2020	49616	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551051	C4591001 1055 10551051	16-55	17AUG2020	49617	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551054	C4591001 1055 10551054	16-55	17AUG2020	49620	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10551056	C4591001 1055 10551056	16-55	17AUG2020	53153	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551057	C4591001 1055 10551057	16-55	17AUG2020	53157	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551058	C4591001 1055 10551058	16-55	17AUG2020	53162	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551061	C4591001 1055 10551061	16-55	18AUG2020	53164	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551063	C4591001 1055 10551063	16-55	18AUG2020	55051	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10551067	C4591001 1055 10551067	16-55	18AUG2020	55055	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551071	C4591001 1055 10551071	16-55	19AUG2020	55056	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10551072	C4591001 1055 10551072	16-55	19AUG2020	55060	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10551073	C4591001 1055 10551073	16-55	19AUG2020	56970	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551074	C4591001 1055 10551074	16-55	19AUG2020	56974	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10551075	C4591001 1055 10551075	16-55	19AUG2020	56976	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10551076	C4591001 1055 10551076	16-55	19AUG2020	56979	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551077	C4591001 1055 10551077	16-55	19AUG2020	57509	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10551078	C4591001 1055 10551078	16-55	19AUG2020	57511	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10551080	C4591001 1055 10551080	16-55	20AUG2020	57518	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10551082	C4591001 1055 10551082	16-55	20AUG2020	57520	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10551084	C4591001 1055 10551084	16-55	20AUG2020	59409	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10551085	C4591001 1055 10551085	16-55	20AUG2020	59413	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551086	C4591001 1055 10551086	16-55	20AUG2020	59415	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10551087	C4591001 1055 10551087	16-55	21AUG2020	59416	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551089	C4591001 1055 10551089	16-55	21AUG2020	61278	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10551090	C4591001 1055 10551090	16-55	24AUG2020	61279	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551092	C4591001 1055 10551092	16-55	24AUG2020	61282	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551097	C4591001 1055 10551097	16-55	24AUG2020	61284	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10551099	C4591001 1055 10551099	16-55	24AUG2020	64697	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551103	C4591001 1055 10551103	16-55	25AUG2020	64702	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551104	C4591001 1055 10551104	16-55	25AUG2020	64703	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551105	C4591001 1055 10551105	16-55	25AUG2020	64707	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551115	C4591001 1055 10551115	16-55	26AUG2020	68226	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10551116	C4591001 1055 10551116	16-55	26AUG2020	68227	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10551117	C4591001 1055 10551117	16-55	26AUG2020	68229	Placebo	26AUG2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551118	C4591001 1055 10551118	16-55	26AUG2020	68235	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551121	C4591001 1055 10551121	16-55	26AUG2020	69055	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10551125	C4591001 1055 10551125	16-55	27AUG2020	69058	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10551128	C4591001 1055 10551128	16-55	27AUG2020	69060	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551131	C4591001 1055 10551131	16-55	27AUG2020	69063	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10551133	C4591001 1055 10551133	16-55	27AUG2020	71302	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10551134	C4591001 1055 10551134	16-55	27AUG2020	71305	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10551135	C4591001 1055 10551135	16-55	28AUG2020	71306	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10551136	C4591001 1055 10551136	16-55	28AUG2020	71308	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10551138	C4591001 1055 10551138	16-55	28AUG2020	72365	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10551139	C4591001 1055 10551139	16-55	28AUG2020	72367	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551143	C4591001 1055 10551143	16-55	28AUG2020	72373	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10551144	C4591001 1055 10551144	16-55	28AUG2020	72372	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10551145	C4591001 1055 10551145	16-55	28AUG2020	73002	Placebo	28AUG2020/ Placebo			
10551146	C4591001 1055 10551146	16-55	28AUG2020	73004	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10551151	C4591001 1055 10551151	16-55	31AUG2020	73006	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10551152	C4591001 1055 10551152	16-55	31AUG2020	73011	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	
10551157	C4591001 1055 10551157	16-55	01SEP2020	76985	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10551161	C4591001 1055 10551161	16-55	01SEP2020	76986	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10551162	C4591001 1055 10551162	16-55	01SEP2020	76991	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551165	C4591001 1055 10551165	16-55	02SEP2020	76992	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551168	C4591001 1055 10551168	16-55	02SEP2020	78858	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10551169	C4591001 1055 10551169	16-55	02SEP2020	78857	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551171	C4591001 1055 10551171	16-55	02SEP2020	78859	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10551173	C4591001 1055 10551173	16-55	03SEP2020	78861	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551174	C4591001 1055 10551174	16-55	03SEP2020	80226	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10551175	C4591001 1055 10551175	16-55	03SEP2020	80231	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10551176	C4591001 1055 10551176	16-55	03SEP2020	80233	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10551177	C4591001 1055 10551177	16-55	03SEP2020	80236	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10551179	C4591001 1055 10551179	16-55	03SEP2020	80805	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10551181	C4591001 1055 10551181	16-55	03SEP2020	80807	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551184	C4591001 1055 10551184	16-55	03SEP2020	80808	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551186	C4591001 1055 10551186	16-55	04SEP2020	80810	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10551190	C4591001 1055 10551190	16-55	04SEP2020	82172	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10551193	C4591001 1055 10551193	16-55	04SEP2020	82173	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10551195	C4591001 1055 10551195	16-55	04SEP2020	82176	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551198	C4591001 1055 10551198	16-55	08SEP2020	82179	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10551200	C4591001 1055 10551200	16-55	08SEP2020	84618	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10551202	C4591001 1055 10551202	16-55	09SEP2020	84623	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10551203	C4591001 1055 10551203	16-55	09SEP2020	84625	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10551204	C4591001 1055 10551204	16-55	09SEP2020	84627	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551206	C4591001 1055 10551206	16-55	09SEP2020	85901	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10551207	C4591001 1055 10551207	16-55	09SEP2020	85906	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10551208	C4591001 1055 10551208	16-55	09SEP2020	85907	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10551211	C4591001 1055 10551211	16-55	10SEP2020	85912	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10551215	C4591001 1055 10551215	16-55	10SEP2020	87558	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10551219	C4591001 1055 10551219	16-55	11SEP2020	87562	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10551220	C4591001 1055 10551220	16-55	11SEP2020	87564	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10551221	C4591001 1055 10551221	16-55	11SEP2020	87566	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10551222	C4591001 1055 10551222	16-55	11SEP2020	88589	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10551223	C4591001 1055 10551223	16-55	11SEP2020	88591	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551224	C4591001 1055 10551224	16-55	11SEP2020	88594	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10551225	C4591001 1055 10551225	16-55	11SEP2020	88598	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10551226	C4591001 1055 10551226	16-55	11SEP2020	88855	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10551228	C4591001 1055 10551228	16-55	14SEP2020	88856	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10551229	C4591001 1055 10551229	16-55	14SEP2020	88858	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551230	C4591001 1055 10551230	16-55	14SEP2020	88861	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551231	C4591001 1055 10551231	16-55	15SEP2020	90450	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10551232	C4591001 1055 10551232	16-55	15SEP2020	90452	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10551233	C4591001 1055 10551233	16-55	15SEP2020	90455	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10551234	C4591001 1055 10551234	16-55	15SEP2020	90456	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551235	C4591001 1055 10551235	16-55	15SEP2020	90749	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551237	C4591001 1055 10551237	16-55	16SEP2020	90753	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10551238	C4591001 1055 10551238	16-55	17SEP2020	90754	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10551239	C4591001 1055 10551239	16-55	17SEP2020	90760	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551240	C4591001 1055 10551240	16-55	17SEP2020	92744	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10551243	C4591001 1055 10551243	16-55	24SEP2020	92745	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10551244	C4591001 1055 10551244	16-55	19OCT2020	92748	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10551245	C4591001 1055 10551245	16-55	21OCT2020	92750	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10551246	C4591001 1055 10551246	16-55	21OCT2020	111749	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10551247	C4591001 1055 10551247	16-55	21OCT2020	111750	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10551249	C4591001 1055 10551249	16-55	21OCT2020	111755	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10561001	C4591001 1056 10561001	16-55	19AUG2020	57139	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10561002	C4591001 1056 10561002	16-55	19AUG2020	57141	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10561003	C4591001 1056 10561003	16-55	19AUG2020	57143	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561004	C4591001 1056 10561004	16-55	19AUG2020	57145	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561006	C4591001 1056 10561006	16-55	20AUG2020	58629	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10561007	C4591001 1056 10561007	16-55	20AUG2020	58632	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10561009	C4591001 1056 10561009	16-55	20AUG2020	58634	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10561010	C4591001 1056 10561010	16-55	20AUG2020	58636	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
10561016	C4591001 1056 10561016	16-55	21AUG2020	60588	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561019	C4591001 1056 10561019	16-55	22AUG2020	62107	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10561020	C4591001 1056 10561020	16-55	22AUG2020	60591	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo		
10561021	C4591001 1056 10561021	16-55	22AUG2020	60592	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10561022	C4591001 1056 10561022	16-55	22AUG2020	62110	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10561025	C4591001 1056 10561025	16-55	22AUG2020	62112	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10561026	C4591001 1056 10561026	16-55	22AUG2020	62116	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10561027	C4591001 1056 10561027	16-55	22AUG2020	62310	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
10561028	C4591001 1056 10561028	16-55	24AUG2020	62316	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561029	C4591001 1056 10561029	16-55	24AUG2020	62319	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561031	C4591001 1056 10561031	16-55	24AUG2020	62320	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561039	C4591001 1056 10561039	16-55	25AUG2020	65347	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561041	C4591001 1056 10561041	16-55	25AUG2020	65351	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10561042	C4591001 1056 10561042	16-55	25AUG2020	65353	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10561046	C4591001 1056 10561046	16-55	25AUG2020	65355	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561050	C4591001 1056 10561050	16-55	26AUG2020	67985	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
10561053	C4591001 1056 10561053	16-55	27AUG2020	67986	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10561058	C4591001 1056 10561058	16-55	27AUG2020	67990	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561059	C4591001 1056 10561059	16-55	27AUG2020	67994	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561060	C4591001 1056 10561060	16-55	27AUG2020	70723	Placebo	27AUG2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561061	C4591001 1056 10561061	16-55	27AUG2020	70724	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561065	C4591001 1056 10561065	16-55	27AUG2020	70725	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10561069	C4591001 1056 10561069	16-55	28AUG2020	70729	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10561071	C4591001 1056 10561071	16-55	28AUG2020	71826	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10561072	C4591001 1056 10561072	16-55	28AUG2020	71829	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10561073	C4591001 1056 10561073	16-55	28AUG2020	71831	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10561076	C4591001 1056 10561076	16-55	28AUG2020	71834	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561077	C4591001 1056 10561077	16-55	28AUG2020	72678	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10561081	C4591001 1056 10561081	16-55	28AUG2020	72683	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561082	C4591001 1056 10561082	16-55	28AUG2020	72687	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561087	C4591001 1056 10561087	16-55	29AUG2020	73555	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561088	C4591001 1056 10561088	16-55	29AUG2020	73559	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10561089	C4591001 1056 10561089	16-55	29AUG2020	73562	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10561090	C4591001 1056 10561090	16-55	29AUG2020	73783	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
10561092	C4591001 1056 10561092	16-55	29AUG2020	73564	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
10561097	C4591001 1056 10561097	16-55	31AUG2020	73789	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561098	C4591001 1056 10561098	16-55	31AUG2020	73790	Placebo	31AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10561100	C4591001 1056 10561100	16-55	31AUG2020	73791	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10561102	C4591001 1056 10561102	16-55	31AUG2020	75609	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10561103	C4591001 1056 10561103	16-55	31AUG2020	75610	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10561108	C4591001 1056 10561108	16-55	01SEP2020	75615	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561110	C4591001 1056 10561110	16-55	01SEP2020	76494	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561111	C4591001 1056 10561111	16-55	01SEP2020	76498	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561112	C4591001 1056 10561112	16-55	01SEP2020	76503	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10561113	C4591001 1056 10561113	16-55	01SEP2020	76504	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10561115	C4591001 1056 10561115	16-55	01SEP2020	76637	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10561116	C4591001 1056 10561116	16-55	01SEP2020	76638	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561118	C4591001 1056 10561118	16-55	01SEP2020	76640	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10561119	C4591001 1056 10561119	16-55	01SEP2020	76642	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561121	C4591001 1056 10561121	16-55	01SEP2020	77249	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561126	C4591001 1056 10561126	16-55	02SEP2020	78102	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561129	C4591001 1056 10561129	16-55	02SEP2020	78106	Placebo	02SEP2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561130	C4591001 1056 10561130	16-55	02SEP2020	78107	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10561131	C4591001 1056 10561131	16-55	02SEP2020	78109	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10561132	C4591001 1056 10561132	16-55	02SEP2020	78836	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561135	C4591001 1056 10561135	16-55	03SEP2020	78837	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo		
10561145	C4591001 1056 10561145	16-55	03SEP2020	78841	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561146	C4591001 1056 10561146	16-55	03SEP2020	78844	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10561147	C4591001 1056 10561147	16-55	03SEP2020	80442	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10561149	C4591001 1056 10561149	16-55	03SEP2020	80444	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561152	C4591001 1056 10561152	16-55	03SEP2020	80890	Placebo	03SEP2020/ Placebo			
10561153	C4591001 1056 10561153	16-55	03SEP2020	80895	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561154	C4591001 1056 10561154	16-55	03SEP2020	81069	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561155	C4591001 1056 10561155	16-55	03SEP2020	80449	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10561156	C4591001 1056 10561156	16-55	03SEP2020	80452	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561157	C4591001 1056 10561157	16-55	03SEP2020	80886	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10561158	C4591001 1056 10561158	16-55	03SEP2020	80889	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561160	C4591001 1056 10561160	16-55	04SEP2020	81070	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561161	C4591001 1056 10561161	16-55	04SEP2020	81074	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561165	C4591001 1056 10561165	16-55	04SEP2020	81076	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10561169	C4591001 1056 10561169	16-55	04SEP2020	82182	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10561170	C4591001 1056 10561170	16-55	04SEP2020	82183	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561171	C4591001 1056 10561171	16-55	04SEP2020	82188	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561172	C4591001 1056 10561172	16-55	04SEP2020	82191	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561173	C4591001 1056 10561173	16-55	04SEP2020	82351	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561174	C4591001 1056 10561174	16-55	04SEP2020	82352	Placebo	04SEP2020/ Placebo	30SEP2020/ Placebo		
10561177	C4591001 1056 10561177	16-55	08SEP2020	82354	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561178	C4591001 1056 10561178	16-55	08SEP2020	82356	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561182	C4591001 1056 10561182	16-55	08SEP2020	84389	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561185	C4591001 1056 10561185	16-55	08SEP2020	84395	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561186	C4591001 1056 10561186	16-55	09SEP2020	84396	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561187	C4591001 1056 10561187	16-55	09SEP2020	84400	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561188	C4591001 1056 10561188	16-55	09SEP2020	85051	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561189	C4591001 1056 10561189	16-55	09SEP2020	85052	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561190	C4591001 1056 10561190	16-55	09SEP2020	85055	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo		
10561191	C4591001 1056 10561191	16-55	09SEP2020	85059	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10561192	C4591001 1056 10561192	16-55	09SEP2020	85281	Placebo	09SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561193	C4591001 1056 10561193	16-55	09SEP2020	85282	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10561194	C4591001 1056 10561194	16-55	09SEP2020	85284	Placebo	09SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561195	C4591001 1056 10561195	16-55	09SEP2020	85287	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10561196	C4591001 1056 10561196	16-55	09SEP2020	85493	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561197	C4591001 1056 10561197	16-55	09SEP2020	85500	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561203	C4591001 1056 10561203	16-55	09SEP2020	85501	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561205	C4591001 1056 10561205	16-55	09SEP2020	86012	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
10561206	C4591001 1056 10561206	16-55	09SEP2020	85502	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561208	C4591001 1056 10561208	16-55	10SEP2020	86013	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561210	C4591001 1056 10561210	16-55	10SEP2020	86015	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10561212	C4591001 1056 10561212	16-55	10SEP2020	86017	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561213	C4591001 1056 10561213	16-55	10SEP2020	86915	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561214	C4591001 1056 10561214	16-55	10SEP2020	86916	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
10561215	C4591001 1056 10561215	16-55	10SEP2020	86918	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561217	C4591001 1056 10561217	16-55	11SEP2020	86920	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561218	C4591001 1056 10561218	16-55	11SEP2020	88253	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561219	C4591001 1056 10561219	16-55	11SEP2020	88259	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10561226	C4591001 1056 10561226	16-55	11SEP2020	88261	Placebo	11SEP2020/ Placebo	28SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561227	C4591001 1056 10561227	16-55	14SEP2020	88262	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561228	C4591001 1056 10561228	16-55	14SEP2020	89429	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10561230	C4591001 1056 10561230	16-55	14SEP2020	89431	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561233	C4591001 1056 10561233	16-55	14SEP2020	89434	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10561234	C4591001 1056 10561234	16-55	14SEP2020	89437	Placebo	14SEP2020/ Placebo	09OCT2020/ Placebo		
10561235	C4591001 1056 10561235	16-55	14SEP2020	89994	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561240	C4591001 1056 10561240	16-55	15SEP2020	89997	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561241	C4591001 1056 10561241	16-55	15SEP2020	90001	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561243	C4591001 1056 10561243	16-55	15SEP2020	90002	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
10561244	C4591001 1056 10561244	16-55	15SEP2020	90475	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo		
10561245	C4591001 1056 10561245	16-55	15SEP2020	90480	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10561246	C4591001 1056 10561246	16-55	15SEP2020	90482	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561251	C4591001 1056 10561251	16-55	16SEP2020	90483	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561252	C4591001 1056 10561252	16-55	16SEP2020	91241	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561253	C4591001 1056 10561253	16-55	16SEP2020	91243	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561255	C4591001 1056 10561255	16-55	16SEP2020	91250	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561256	C4591001 1056 10561256	16-55	16SEP2020	91248	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561262	C4591001 1056 10561262	16-55	16SEP2020	91769	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10561263	C4591001 1056 10561263	16-55	16SEP2020	91770	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561264	C4591001 1056 10561264	16-55	16SEP2020	91775	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561268	C4591001 1056 10561268	16-55	17SEP2020	91777	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10561271	C4591001 1056 10561271	16-55	17SEP2020	92405	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10561272	C4591001 1056 10561272	16-55	17SEP2020	92407	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561273	C4591001 1056 10561273	16-55	17SEP2020	92412	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561274	C4591001 1056 10561274	16-55	17SEP2020	92414	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10561277	C4591001 1056 10561277	16-55	18SEP2020	93455	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561278	C4591001 1056 10561278	16-55	18SEP2020	93456	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561282	C4591001 105610561282	16-55	18SEP2020	93457	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10561284	C4591001 105610561284	16-55	18SEP2020	93460	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561286	C4591001 105610561286	16-55	18SEP2020	93835	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10561288	C4591001 105610561288	16-55	18SEP2020	93839	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561289	C4591001 105610561289	16-55	18SEP2020	93840	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561290	C4591001 105610561290	16-55	18SEP2020	93842	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561291	C4591001 105610561291	16-55	18SEP2020	93941	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10561292	C4591001 105610561292	16-55	18SEP2020	93942	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10561293	C4591001 105610561293	16-55	18SEP2020	93950	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)			
10561295	C4591001 105610561295	16-55	18SEP2020	93951	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10561299	C4591001 105610561299	16-55	18SEP2020	94244	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561300	C4591001 1056 10561300	16-55	21SEP2020	94247	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10561304	C4591001 1056 10561304	16-55	21SEP2020	94249	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561307	C4591001 1056 10561307	16-55	21SEP2020	94250	Placebo	21SEP2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561308	C4591001 1056 10561308	16-55	21SEP2020	95058	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561309	C4591001 1056 10561309	16-55	21SEP2020	95059	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561312	C4591001 1056 10561312	16-55	21SEP2020	95061	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10561313	C4591001 1056 10561313	16-55	22SEP2020	95066	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561314	C4591001 1056 10561314	16-55	22SEP2020	96475	Placebo	22SEP2020/ Placebo	16OCT2020/ Placebo		
10561315	C4591001 1056 10561315	16-55	22SEP2020	96477	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561316	C4591001 1056 10561316	16-55	22SEP2020	96480	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561317	C4591001 1056 10561317	16-55	22SEP2020	96483	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10561319	C4591001 1056 10561319	16-55	22SEP2020	96968	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561320	C4591001 1056 10561320	16-55	22SEP2020	96972	Placebo	22SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561321	C4591001 1056 10561321	16-55	22SEP2020	96973	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10561322	C4591001 1056 10561322	16-55	23SEP2020	96974	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo		
10561325	C4591001 1056 10561325	16-55	23SEP2020	97817	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10561327	C4591001 1056 10561327	16-55	24SEP2020	97825	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561330	C4591001 1056 10561330	16-55	24SEP2020	97826	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10561331	C4591001 1056 10561331	16-55	24SEP2020	97827	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10561332	C4591001 1056 10561332	16-55	24SEP2020	98706	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561333	C4591001 1056 10561333	16-55	24SEP2020	98707	Placebo	24SEP2020/ Placebo	28OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	
10561335	C4591001 1056 10561335	16-55	24SEP2020	98709	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10561336	C4591001 1056 10561336	16-55	24SEP2020	98715	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
10561338	C4591001 1056 10561338	16-55	25SEP2020	99451	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10561340	C4591001 1056 10561340	16-55	25SEP2020	99456	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10561341	C4591001 1056 10561341	16-55	25SEP2020	99457	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10561344	C4591001 1056 10561344	16-55	25SEP2020	99458	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561345	C4591001 1056 10561345	16-55	25SEP2020	100013	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561347	C4591001 1056 10561347	16-55	28SEP2020	100014	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
10561348	C4591001 1056 10561348	16-55	28SEP2020	100017	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561350	C4591001 1056 10561350	16-55	28SEP2020	100024	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10561352	C4591001 1056 10561352	16-55	28SEP2020	101465	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10561354	C4591001 1056 10561354	16-55	28SEP2020	101466	Placebo	28SEP2020/ Placebo	16OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561358	C4591001 1056 10561358	16-55	28SEP2020	101468	Placebo	28SEP2020/ Placebo	29OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561359	C4591001 1056 10561359	16-55	29SEP2020	101814	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561360	C4591001 1056 10561360	16-55	29SEP2020	101470	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561361	C4591001 1056 10561361	16-55	29SEP2020	101819	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)			
10561363	C4591001 1056 10561363	16-55	29SEP2020	101823	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561364	C4591001 1056 10561364	16-55	29SEP2020	101824	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561365	C4591001 1056 10561365	16-55	29SEP2020	101948	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561366	C4591001 1056 10561366	16-55	29SEP2020	101949	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10561367	C4591001 1056 10561367	16-55	29SEP2020	101952	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10561369	C4591001 1056 10561369	16-55	30SEP2020	101954	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561372	C4591001 1056 10561372	16-55	30SEP2020	102329	Placebo	30SEP2020/ Placebo			
10561373	C4591001 1056 10561373	16-55	30SEP2020	102330	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561375	C4591001 1056 10561375	16-55	30SEP2020	102334	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10561376	C4591001 1056 10561376	16-55	30SEP2020	102339	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561377	C4591001 1056 10561377	16-55	30SEP2020	102465	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561378	C4591001 1056 10561378	16-55	30SEP2020	102467	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10561383	C4591001 1056 10561383	16-55	02OCT2020	102471	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561384	C4591001 1056 10561384	16-55	02OCT2020	102472	Placebo	02OCT2020/ Placebo	02DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10561385	C4591001 1056 10561385	16-55	02OCT2020	103266	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
10561386	C4591001 1056 10561386	16-55	02OCT2020	103267	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
10561388	C4591001 1056 10561388	16-55	02OCT2020	103272	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10561391	C4591001 1056 10561391	16-55	02OCT2020	103274	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10561392	C4591001 1056 10561392	16-55	02OCT2020	103362	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561393	C4591001 1056 10561393	16-55	05OCT2020	103367	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561394	C4591001 1056 10561394	16-55	05OCT2020	103369	Placebo	05OCT2020/ Placebo	03NOV2020/ Placebo		
10561395	C4591001 1056 10561395	16-55	05OCT2020	103372	Placebo	05OCT2020/ Placebo			
10561396	C4591001 1056 10561396	16-55	05OCT2020	103818	Placebo	05OCT2020/ Placebo	23OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561397	C4591001 1056 10561397	16-55	05OCT2020	103819	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561398	C4591001 1056 10561398	16-55	05OCT2020	103820	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561400	C4591001 1056 10561400	16-55	05OCT2020	103826	Placebo	05OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561401	C4591001 1056 10561401	16-55	05OCT2020	103961	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561402	C4591001 1056 10561402	16-55	05OCT2020	103938	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10561403	C4591001 1056 10561403	16-55	05OCT2020	103939	Placebo	05OCT2020/ Placebo	23OCT2020/ Placebo		
10561405	C4591001 1056 10561405	16-55	05OCT2020	103947	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561406	C4591001 1056 10561406	16-55	05OCT2020	103941	Placebo	05OCT2020/ Placebo	29OCT2020/ Placebo		
10561407	C4591001 1056 10561407	16-55	05OCT2020	103965	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561408	C4591001 1056 10561408	16-55	06OCT2020	103970	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561411	C4591001 1056 10561411	16-55	06OCT2020	103972	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561413	C4591001 1056 10561413	16-55	06OCT2020	104226	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561414	C4591001 1056 10561414	16-55	06OCT2020	104231	Placebo	06OCT2020/ Placebo			
10561417	C4591001 1056 10561417	16-55	06OCT2020	104235	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10561419	C4591001 1056 10561419	16-55	06OCT2020	104236	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10561421	C4591001 1056 10561421	16-55	06OCT2020	104417	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10561422	C4591001 1056 10561422	16-55	06OCT2020	104419	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10561425	C4591001 1056 10561425	16-55	06OCT2020	104421	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561427	C4591001 1056 10561427	16-55	07OCT2020	104426	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
10561432	C4591001 1056 10561432	16-55	07OCT2020	104792	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
10561434	C4591001 1056 10561434	16-55	07OCT2020	104797	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561437	C4591001 1056 10561437	16-55	08OCT2020	104798	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10561440	C4591001 1056 10561440	16-55	08OCT2020	104800	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561441	C4591001 1056 10561441	16-55	08OCT2020	105415	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561442	C4591001 1056 10561442	16-55	08OCT2020	105417	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561443	C4591001 1056 10561443	16-55	08OCT2020	105423	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
10561444	C4591001 1056 10561444	16-55	08OCT2020	105424	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561445	C4591001 1056 10561445	16-55	08OCT2020	105450	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10561448	C4591001 1056 10561448	16-55	08OCT2020	105452	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10561451	C4591001 1056 10561451	16-55	08OCT2020	105456	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10561452	C4591001 1056 10561452	16-55	08OCT2020	105457	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561453	C4591001 1056 10561453	16-55	09OCT2020	105857	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo		
10561456	C4591001 1056 10561456	16-55	09OCT2020	105859	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10561466	C4591001 1056 10561466	16-55	09OCT2020	105865	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10561467	C4591001 1056 10561467	16-55	09OCT2020	105868	Placebo	09OCT2020/ Placebo	05NOV2020/ Placebo		
10561468	C4591001 1056 10561468	16-55	09OCT2020	106169	Placebo	09OCT2020/ Placebo	03NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10561469	C4591001 1056 10561469	16-55	09OCT2020	106173	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10561471	C4591001 1056 10561471	16-55	09OCT2020	106180	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10561472	C4591001 1056 10561472	16-55	09OCT2020	106193	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561473	C4591001 1056 10561473	16-55	09OCT2020	106176	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10561474	C4591001 1056 10561474	16-55	12OCT2020	106197	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561475	C4591001 1056 10561475	16-55	12OCT2020	106201	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10561476	C4591001 1056 10561476	16-55	12OCT2020	106203	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561477	C4591001 1056 10561477	16-55	12OCT2020	106472	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10561480	C4591001 1056 10561480	16-55	12OCT2020	106473	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10561482	C4591001 1056 10561482	16-55	12OCT2020	106475	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561484	C4591001 1056 10561484	16-55	12OCT2020	106478	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561488	C4591001 1056 10561488	16-55	12OCT2020	106601	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
10561489	C4591001 1056 10561489	16-55	12OCT2020	106602	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10561490	C4591001 1056 10561490	16-55	12OCT2020	106607	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561491	C4591001 1056 10561491	16-55	12OCT2020	106610	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561493	C4591001 1056 10561493	16-55	12OCT2020	106663	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10561494	C4591001 1056 10561494	16-55	13OCT2020	106664	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561495	C4591001 1056 10561495	16-55	13OCT2020	106667	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561499	C4591001 1056 10561499	16-55	13OCT2020	107009	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561503	C4591001 1056 10561503	16-55	13OCT2020	106668	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10561505	C4591001 1056 10561505	16-55	13OCT2020	107010	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
10561506	C4591001 1056 10561506	16-55	13OCT2020	107011	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10561507	C4591001 1056 10561507	16-55	13OCT2020	107020	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10561508	C4591001 1056 10561508	16-55	14OCT2020	107478	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561510	C4591001 1056 10561510	16-55	14OCT2020	107480	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561511	C4591001 1056 10561511	16-55	14OCT2020	107485	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10561512	C4591001 1056 10561512	16-55	14OCT2020	107487	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561513	C4591001 1056 10561513	16-55	14OCT2020	107684	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561514	C4591001 1056 10561514	16-55	14OCT2020	107688	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10561516	C4591001 1056 10561516	16-55	14OCT2020	107691	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10561517	C4591001 1056 10561517	16-55	15OCT2020	107692	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10561518	C4591001 1056 10561518	16-55	15OCT2020	108090	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561519	C4591001 1056 10561519	16-55	15OCT2020	108091	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10561520	C4591001 1056 10561520	16-55	15OCT2020	108092	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
10561521	C4591001 1056 10561521	16-55	15OCT2020	108096	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561525	C4591001 1056 10561525	16-55	16OCT2020	108989	Placebo	16OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561526	C4591001 1056 10561526	16-55	16OCT2020	108990	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561528	C4591001 1056 10561528	16-55	16OCT2020	108995	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo		
10561529	C4591001 1056 10561529	16-55	16OCT2020	108997	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10561531	C4591001 1056 10561531	16-55	16OCT2020	109169	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561532	C4591001 1056 10561532	16-55	16OCT2020	109172	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10561533	C4591001 1056 10561533	16-55	16OCT2020	109174	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561534	C4591001 1056 10561534	16-55	16OCT2020	109179	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10561539	C4591001 1056 10561539	16-55	19OCT2020	110201	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
10561540	C4591001 1056 10561540	16-55	19OCT2020	110203	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561541	C4591001 1056 10561541	16-55	19OCT2020	110204	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
10561542	C4591001 1056 10561542	16-55	19OCT2020	110212	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10561543	C4591001 1056 10561543	16-55	19OCT2020	110334	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo		
10561544	C4591001 1056 10561544	16-55	19OCT2020	110336	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561545	C4591001 1056 10561545	16-55	19OCT2020	110339	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10561547	C4591001 1056 10561547	16-55	19OCT2020	110344	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10561548	C4591001 1056 10561548	16-55	20OCT2020	110770	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561549	C4591001 1056 10561549	16-55	20OCT2020	110772	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10561550	C4591001 1056 10561550	16-55	20OCT2020	110774	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)			
10561553	C4591001 1056 10561553	16-55	20OCT2020	110775	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561554	C4591001 1056 10561554	16-55	20OCT2020	110969	Placebo	20OCT2020/ Placebo			
10561555	C4591001 1056 10561555	16-55	20OCT2020	110972	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10561558	C4591001 1056 10561558	16-55	20OCT2020	110980	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561559	C4591001 1056 10561559	16-55	20OCT2020	111189	Placebo	20OCT2020/ Placebo	13NOV2020/ Placebo		
10561560	C4591001 1056 10561560	16-55	20OCT2020	111190	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561562	C4591001 1056 10561562	16-55	21OCT2020	111192	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561563	C4591001 1056 10561563	16-55	21OCT2020	111196	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo		
10561564	C4591001 1056 10561564	16-55	21OCT2020	111692	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561565	C4591001 1056 10561565	16-55	21OCT2020	111693	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561566	C4591001 1056 10561566	16-55	21OCT2020	111697	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561567	C4591001 1056 10561567	16-55	21OCT2020	111698	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10561569	C4591001 1056 10561569	16-55	21OCT2020	111833	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)			
10561570	C4591001 1056 10561570	16-55	21OCT2020	111835	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561572	C4591001 1056 10561572	16-55	22OCT2020	111837	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
10561575	C4591001 1056 10561575	16-55	22OCT2020	111843	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10561576	C4591001 1056 10561576	16-55	22OCT2020	112362	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10561579	C4591001 1056 10561579	16-55	22OCT2020	112363	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10561581	C4591001 1056 10561581	16-55	23OCT2020	112878	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		
10561582	C4591001 1056 10561582	16-55	23OCT2020	112366	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		
10561583	C4591001 1056 10561583	16-55	23OCT2020	112364	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561585	C4591001 1056 10561585	16-55	23OCT2020	112880	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		
10561586	C4591001 1056 10561586	16-55	23OCT2020	112884	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10561587	C4591001 1056 10561587	16-55	26OCT2020	112886	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561588	C4591001 1056 10561588	16-55	26OCT2020	113672	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561590	C4591001 1056 10561590	16-55	26OCT2020	113678	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561591	C4591001 1056 10561591	16-55	26OCT2020	113679	Placebo	26OCT2020/ Placebo			
10561592	C4591001 1056 10561592	16-55	26OCT2020	113680	Placebo	26OCT2020/ Placebo	30NOV2020/ Placebo		
10561593	C4591001 1056 10561593	16-55	26OCT2020	113682	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561594	C4591001 1056 10561594	16-55	26OCT2020	113683	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561595	C4591001 1056 10561595	16-55	26OCT2020	113691	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10561596	C4591001 1056 10561596	16-55	26OCT2020	113692	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561599	C4591001 1056 10561599	16-55	27OCT2020	114018	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561600	C4591001 1056 10561600	16-55	27OCT2020	114020	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10561601	C4591001 1056 10561601	16-55	27OCT2020	114023	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo		
10561602	C4591001 1056 10561602	16-55	27OCT2020	114027	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561606	C4591001 1056 10561606	16-55	27OCT2020	114107	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561608	C4591001 1056 10561608	16-55	27OCT2020	114110	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10561609	C4591001 1056 10561609	16-55	27OCT2020	114112	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo		
10561610	C4591001 1056 10561610	16-55	27OCT2020	114191	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10561611	C4591001 1056 10561611	16-55	27OCT2020	114194	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10561612	C4591001 1056 10561612	16-55	27OCT2020	114195	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561613	C4591001 1056 10561613	16-55	27OCT2020	114196	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10561614	C4591001 1056 10561614	16-55	27OCT2020	114234	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561617	C4591001 1056 10561617	16-55	27OCT2020	114238	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
10561618	C4591001 1056 10561618	16-55	28OCT2020	114241	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561621	C4591001 1056 10561621	16-55	28OCT2020	114244	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561622	C4591001 1056 10561622	16-55	28OCT2020	114394	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10561623	C4591001 1056 10561623	16-55	28OCT2020	114395	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo		
10561626	C4591001 1056 10561626	16-55	28OCT2020	114398	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10561627	C4591001 1056 10561627	16-55	28OCT2020	114400	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo		
10561629	C4591001 1056 10561629	16-55	28OCT2020	114521	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10561632	C4591001 1056 10561632	16-55	28OCT2020	114524	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10561633	C4591001 1056 10561633	16-55	28OCT2020	114528	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561634	C4591001 1056 10561634	16-55	29OCT2020	114530	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10561635	C4591001 1056 10561635	16-55	29OCT2020	114642	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10561636	C4591001 1056 10561636	16-55	29OCT2020	114644	Placebo	29OCT2020/ Placebo		11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561638	C4591001 1056 10561638	16-55	29OCT2020	114647	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10561639	C4591001 1056 10561639	16-55	29OCT2020	114652	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10561642	C4591001 1056 10561642	16-55	29OCT2020	114809	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
10561643	C4591001 1056 10561643	16-55	30OCT2020	114815	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10571025	C4591001 1057 10571025	16-55	17AUG2020	52289	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571027	C4591001 1057 10571027	16-55	17AUG2020	52292	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571028	C4591001 1057 10571028	16-55	17AUG2020	52294	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10571030	C4591001 1057 10571030	16-55	17AUG2020	52297	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571031	C4591001 1057 10571031	16-55	18AUG2020	53876	Placebo				
10571032	C4591001 1057 10571032	16-55	18AUG2020	53878	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10571033	C4591001 1057 10571033	16-55	18AUG2020	53879	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571035	C4591001 1057 10571035	16-55	18AUG2020	53884	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571036	C4591001 1057 10571036	16-55	18AUG2020	54041	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10571037	C4591001 1057 10571037	16-55	18AUG2020	54047	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571042	C4591001 1057 10571042	16-55	19AUG2020	54048	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571043	C4591001 1057 10571043	16-55	19AUG2020	54052	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571044	C4591001 1057 10571044	16-55	19AUG2020	55856	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571045	C4591001 1057 10571045	16-55	19AUG2020	55853	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571046	C4591001 1057 10571046	16-55	19AUG2020	55860	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571048	C4591001 1057 10571048	16-55	19AUG2020	233180	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10571049	C4591001 1057 10571049	16-55	19AUG2020	55862	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571050	C4591001 1057 10571050	16-55	19AUG2020	56352	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10571051	C4591001 1057 10571051	16-55	19AUG2020	56354	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571054	C4591001 1057 10571054	16-55	20AUG2020	56355	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10571056	C4591001 1057 10571056	16-55	20AUG2020	56356	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571058	C4591001 1057 10571058	16-55	20AUG2020	58399	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10571059	C4591001 1057 10571059	16-55	20AUG2020	58403	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10571060	C4591001 1057 10571060	16-55	20AUG2020	58405	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571065	C4591001 1057 10571065	16-55	21AUG2020	58406	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571067	C4591001 1057 10571067	16-55	21AUG2020	60461	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10571068	C4591001 1057 10571068	16-55	21AUG2020	60463	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10571070	C4591001 1057 10571070	16-55	21AUG2020	60468	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10571071	C4591001 1057 10571071	16-55	24AUG2020	60472	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10571074	C4591001 1057 10571074	16-55	24AUG2020	63498	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571075	C4591001 1057 10571075	16-55	24AUG2020	63506	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571078	C4591001 1057 10571078	16-55	24AUG2020	63507	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571079	C4591001 1057 10571079	16-55	24AUG2020	63508	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571080	C4591001 1057 10571080	16-55	24AUG2020	64121	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571081	C4591001 1057 10571081	16-55	24AUG2020	64125	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10571082	C4591001 1057 10571082	16-55	25AUG2020	64127	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10571083	C4591001 1057 10571083	16-55	25AUG2020	64129	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571085	C4591001 1057 10571085	16-55	25AUG2020	65585	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10571088	C4591001 1057 10571088	16-55	25AUG2020	65587	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571089	C4591001 1057 10571089	16-55	25AUG2020	65594	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10571090	C4591001 1057 10571090	16-55	25AUG2020	65595	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571091	C4591001 1057 10571091	16-55	25AUG2020	66137	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571092	C4591001 1057 10571092	16-55	26AUG2020	66138	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10571093	C4591001 1057 10571093	16-55	26AUG2020	66145	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10571095	C4591001 1057 10571095	16-55	26AUG2020	66147	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10571100	C4591001 1057 10571100	16-55	26AUG2020	68454	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10571103	C4591001 1057 10571103	16-55	27AUG2020	68455	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571104	C4591001 1057 10571104	16-55	27AUG2020	68461	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10571106	C4591001 1057 10571106	16-55	27AUG2020	68463	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10571109	C4591001 1057 10571109	16-55	27AUG2020	69907	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10571111	C4591001 1057 10571111	16-55	27AUG2020	69909	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571113	C4591001 1057 10571113	16-55	28AUG2020	69911	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10571117	C4591001 1057 10571117	16-55	28AUG2020	69915	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10571118	C4591001 1057 10571118	16-55	28AUG2020	71659	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10571120	C4591001 1057 10571120	16-55	28AUG2020	71660	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10571121	C4591001 1057 10571121	16-55	28AUG2020	71662	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10571122	C4591001 1057 10571122	16-55	28AUG2020	71666	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10571123	C4591001 1057 10571123	16-55	31AUG2020	74669	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10571124	C4591001 1057 10571124	16-55	31AUG2020	74671	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10571125	C4591001 1057 10571125	16-55	31AUG2020	74673	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10571127	C4591001 1057 10571127	16-55	31AUG2020	74677	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571129	C4591001 1057 10571129	16-55	31AUG2020	74969	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10571132	C4591001 1057 10571132	16-55	01SEP2020	74970	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10571136	C4591001 1057 10571136	16-55	01SEP2020	74979	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571137	C4591001 1057 10571137	16-55	01SEP2020	74980	Placebo	01SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571139	C4591001 1057 10571139	16-55	02SEP2020	78126	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10571140	C4591001 1057 10571140	16-55	02SEP2020	78130	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10571142	C4591001 1057 10571142	16-55	03SEP2020	78135	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10571144	C4591001 1057 10571144	16-55	03SEP2020	78136	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10571145	C4591001 1057 10571145	16-55	03SEP2020	79565	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571146	C4591001 1057 10571146	16-55	03SEP2020	79566	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571147	C4591001 1057 10571147	16-55	03SEP2020	79572	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10571148	C4591001 1057 10571148	16-55	03SEP2020	79573	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
10571152	C4591001 1057 10571152	16-55	03SEP2020	80430	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10571153	C4591001 1057 10571153	16-55	04SEP2020	80433	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10571154	C4591001 1057 10571154	16-55	04SEP2020	80435	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571155	C4591001 1057 10571155	16-55	04SEP2020	81269	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10571156	C4591001 1057 10571156	16-55	04SEP2020	80439	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10571158	C4591001 1057 10571158	16-55	04SEP2020	81273	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10571160	C4591001 1057 10571160	16-55	08SEP2020	81274	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571161	C4591001 1057 10571161	16-55	08SEP2020	81280	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571162	C4591001 1057 10571162	16-55	08SEP2020	83288	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571163	C4591001 1057 10571163	16-55	08SEP2020	83290	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10571164	C4591001 1057 10571164	16-55	08SEP2020	83292	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10571165	C4591001 1057 10571165	16-55	08SEP2020	83294	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10571169	C4591001 1057 10571169	16-55	09SEP2020	85112	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571170	C4591001 1057 10571170	16-55	09SEP2020	85116	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10571171	C4591001 1057 10571171	16-55	09SEP2020	85117	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10571173	C4591001 1057 10571173	16-55	10SEP2020	85120	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10571176	C4591001 1057 10571176	16-55	10SEP2020	86659	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10571177	C4591001 1057 10571177	16-55	10SEP2020	86660	Placebo	10SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571182	C4591001 1057 10571182	16-55	11SEP2020	86665	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571185	C4591001 1057 10571185	16-55	14SEP2020	86667	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10571186	C4591001 1057 10571186	16-55	14SEP2020	89514	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10571187	C4591001 1057 10571187	16-55	14SEP2020	89515	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571188	C4591001 1057 10571188	16-55	14SEP2020	89518	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10571191	C4591001 1057 10571191	16-55	15SEP2020	89523	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo		
10571193	C4591001 1057 10571193	16-55	15SEP2020	90331	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10571194	C4591001 1057 10571194	16-55	15SEP2020	90332	Placebo	15SEP2020/ Placebo	08OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10571195	C4591001 1057 10571195	16-55	16SEP2020	90336	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10571198	C4591001 1057 10571198	16-55	17SEP2020	92206	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571200	C4591001 1057 10571200	16-55	17SEP2020	90340	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571201	C4591001 1057 10571201	16-55	17SEP2020	92207	Placebo	17SEP2020/ Placebo	14OCT2020/ Placebo		
10571202	C4591001 1057 10571202	16-55	17SEP2020	92208	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10571203	C4591001 1057 10571203	16-55	17SEP2020	92211	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571204	C4591001 1057 10571204	16-55	17SEP2020	92538	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10571205	C4591001 1057 10571205	16-55	17SEP2020	92543	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10571206	C4591001 1057 10571206	16-55	17SEP2020	92545	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571207	C4591001 1057 10571207	16-55	17SEP2020	92548	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10571208	C4591001 1057 10571208	16-55	18SEP2020	93235	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10571210	C4591001 1057 10571210	16-55	18SEP2020	93239	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571211	C4591001 1057 10571211	16-55	18SEP2020	93241	Placebo				
10571212	C4591001 1057 10571212	16-55	18SEP2020	93242	BNT162b2 (30 µg)				
10571215	C4591001 1057 10571215	16-55	18SEP2020	93703	Placebo				
10571216	C4591001 1057 10571216	16-55	21SEP2020	93709	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
10571217	C4591001 1057 10571217	16-55	21SEP2020	93710	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10571218	C4591001 1057 10571218	16-55	21SEP2020	93711	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10571219	C4591001 1057 10571219	16-55	21SEP2020	95322	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571220	C4591001 1057 10571220	16-55	21SEP2020	95328	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571222	C4591001 1057 10571222	16-55	22SEP2020	95329	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
10571223	C4591001 1057 10571223	16-55	22SEP2020	95330	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10571226	C4591001 1057 10571226	16-55	22SEP2020	96769	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571227	C4591001 1057 10571227	16-55	22SEP2020	96766	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
10571229	C4591001 1057 10571229	16-55	23SEP2020	96770	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571230	C4591001 1057 10571230	16-55	23SEP2020	96772	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10571232	C4591001 1057 10571232	16-55	23SEP2020	97531	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571233	C4591001 1057 10571233	16-55	23SEP2020	97536	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10571234	C4591001 1057 10571234	16-55	23SEP2020	97538	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571235	C4591001 1057 10571235	16-55	23SEP2020	97540	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
10571236	C4591001 1057 10571236	16-55	23SEP2020	97877	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
10571238	C4591001 1057 10571238	16-55	24SEP2020	97878	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10571239	C4591001 1057 10571239	16-55	24SEP2020	97883	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571240	C4591001 1057 10571240	16-55	24SEP2020	98658	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10571241	C4591001 1057 10571241	16-55	24SEP2020	97885	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571243	C4591001 1057 10571243	16-55	24SEP2020	98665	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
10571244	C4591001 1057 10571244	16-55	25SEP2020	98666	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10571245	C4591001 1057 10571245	16-55	25SEP2020	98668	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10571246	C4591001 1057 10571246	16-55	25SEP2020	99557	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10571247	C4591001 1057 10571247	16-55	25SEP2020	99560	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571248	C4591001 1057 10571248	16-55	25SEP2020	99562	Placebo	25SEP2020/ Placebo			
10571249	C4591001 1057 10571249	16-55	25SEP2020	99567	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10571252	C4591001 1057 10571252	16-55	28SEP2020	101336	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571253	C4591001 1057 10571253	16-55	28SEP2020	101339	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
10571257	C4591001 1057 10571257	16-55	01OCT2020	101340	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571258	C4591001 1057 10571258	16-55	01OCT2020	101343	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10571259	C4591001 1057 10571259	16-55	01OCT2020	102885	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10571261	C4591001 1057 10571261	16-55	02OCT2020	102888	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10571262	C4591001 1057 10571262	16-55	02OCT2020	266890	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10571263	C4591001 1057 10571263	16-55	02OCT2020	102889	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
10571265	C4591001 1057 10571265	16-55	02OCT2020	102890	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10571266	C4591001 1057 10571266	16-55	05OCT2020	103843	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10571267	C4591001 1057 10571267	16-55	05OCT2020	103845	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo		
10571268	C4591001 1057 10571268	16-55	06OCT2020	103848	Placebo				



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571269	C4591001 1057 10571269	16-55	06OCT2020	103851	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10571270	C4591001 1057 10571270	16-55	06OCT2020	104207	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10571271	C4591001 1057 10571271	16-55	06OCT2020	104208	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
10571272	C4591001 1057 10571272	16-55	06OCT2020	104209	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10571273	C4591001 1057 10571273	16-55	07OCT2020	104211	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10571274	C4591001 1057 10571274	16-55	07OCT2020	104693	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571276	C4591001 1057 10571276	16-55	08OCT2020	104694	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10571277	C4591001 1057 10571277	16-55	08OCT2020	104696	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10571278	C4591001 1057 10571278	16-55	08OCT2020	104700	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10571279	C4591001 1057 10571279	16-55	08OCT2020	105297	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571280	C4591001 1057 10571280	16-55	08OCT2020	105299	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10571281	C4591001 1057 10571281	16-55	08OCT2020	105301	Placebo	08OCT2020/ Placebo	02NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571282	C4591001 1057 10571282	16-55	08OCT2020	105304	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10571283	C4591001 1057 10571283	16-55	09OCT2020	105750	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10571284	C4591001 1057 10571284	16-55	09OCT2020	105753	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571286	C4591001 1057 10571286	16-55	09OCT2020	105754	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10571287	C4591001 1057 10571287	16-55	09OCT2020	105756	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10571288	C4591001 1057 10571288	16-55	09OCT2020	105920	Placebo	09OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10571291	C4591001 1057 10571291	16-55	09OCT2020	105921	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10571293	C4591001 1057 10571293	16-55	12OCT2020	105923	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571294	C4591001 1057 10571294	16-55	12OCT2020	105927	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571295	C4591001 1057 10571295	16-55	12OCT2020	106421	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo		
10571298	C4591001 1057 10571298	16-55	12OCT2020	106424	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10571299	C4591001 1057 10571299	16-55	12OCT2020	106429	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10571301	C4591001 1057 10571301	16-55	13OCT2020	106430	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo		
10571304	C4591001 1057 10571304	16-55	13OCT2020	107201	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10571305	C4591001 1057 10571305	16-55	14OCT2020	107206	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10571309	C4591001 1057 10571309	16-55	14OCT2020	107207	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10571311	C4591001 1057 10571311	16-55	14OCT2020	107210	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10571312	C4591001 1057 10571312	16-55	14OCT2020	107648	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571313	C4591001 1057 10571313	16-55	14OCT2020	107649	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10571314	C4591001 1057 10571314	16-55	14OCT2020	107652	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10571315	C4591001 1057 10571315	16-55	14OCT2020	107653	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10571316	C4591001 1057 10571316	16-55	15OCT2020	107897	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10571317	C4591001 1057 10571317	16-55	15OCT2020	107898	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571318	C4591001 1057 10571318	16-55	15OCT2020	107901	Placebo	15OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10571319	C4591001 1057 10571319	16-55	15OCT2020	107902	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10571320	C4591001 1057 10571320	16-55	15OCT2020	108054	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10571322	C4591001 1057 10571322	16-55	15OCT2020	108057	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
10571324	C4591001 1057 10571324	16-55	15OCT2020	108062	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571325	C4591001 1057 10571325	16-55	16OCT2020	108063	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10571326	C4591001 1057 10571326	16-55	16OCT2020	108761	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10571328	C4591001 1057 10571328	16-55	19OCT2020	108764	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
10571329	C4591001 1057 10571329	16-55	19OCT2020	108769	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571331	C4591001 1057 10571331	16-55	20OCT2020	108770	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10571332	C4591001 1057 10571332†	16-55	20OCT2020	110721	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571333	C4591001 1057 10571333	16-55	20OCT2020	110722	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571336	C4591001 1057 10571336	16-55	20OCT2020	110726	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
10571337	C4591001 1057 10571337	16-55	20OCT2020	110728	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571338	C4591001 1057 10571338	16-55	20OCT2020	110982	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571339	C4591001 1057 10571339	16-55	20OCT2020	110985	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571340	C4591001 1057 10571340	16-55	20OCT2020	110986	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo		
10571341	C4591001 1057 10571341	16-55	21OCT2020	110989	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571342	C4591001 1057 10571342	16-55	21OCT2020	111451	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571343	C4591001 1057 10571343	16-55	21OCT2020	111454	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571344	C4591001 1057 10571344†	16-55	21OCT2020	111457	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10571345	C4591001 1057 10571345†	16-55	21OCT2020	111458	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10571347	C4591001 1057 10571347†	16-55	21OCT2020	111742	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10571348	C4591001 1057 10571348†	16-55	21OCT2020	111743	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10571352	C4591001 1057 10571352†	16-55	22OCT2020	111744	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571353	C4591001 1057 10571353	16-55	22OCT2020	111745	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10571355	C4591001 1057 10571355†	16-55	23OCT2020	112829	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571356	C4591001 1057 10571356	16-55	23OCT2020	112831	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10571357	C4591001 1057 10571357	16-55	26OCT2020	112834	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10571358	C4591001 1057 10571358	16-55	26OCT2020	112835	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo		
10571362	C4591001 1057 10571362†	16-55	30OCT2020	115015	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10571363	C4591001 1057 10571363	16-55	18NOV2020	115021	Placebo	18NOV2020/ Placebo	08DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10571364	C4591001 1057 10571364	16-55	18NOV2020	115022	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
10571365	C4591001 1057 10571365	16-55	23NOV2020	116717	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10571366	C4591001 1057 10571366	16-55	23NOV2020	115024	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10571367	C4591001 1057 10571367	16-55	23NOV2020	116721	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
10571368	C4591001 1057 10571368	16-55	23NOV2020	116723	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10571369	C4591001 1057 10571369	16-55	30NOV2020	116727	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10571370	C4591001 1057 10571370	16-55	30NOV2020	117053	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10571371	C4591001 1057 10571371	16-55	30NOV2020	117056	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10571372	C4591001 1057 10571372	16-55	02DEC2020	117060	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10571373	C4591001 1057 10571373	16-55	02DEC2020	117063	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10571374	C4591001 1057 10571374	16-55	03DEC2020	117354	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10571375	C4591001 1057 10571375	16-55	03DEC2020	117358	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
10571381	C4591001 1057 10571381	16-55	08DEC2020	117359	Placebo	08DEC2020/ Placebo	28DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661035	C4591001 1066 10661035	16-55	17AUG2020	49472	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10661036	C4591001 1066 10661036	16-55	17AUG2020	49475	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10661037	C4591001 1066 10661037	16-55	17AUG2020	49478	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10661044	C4591001 1066 10661044	16-55	18AUG2020	54875	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10661059	C4591001 1066 10661059	16-55	19AUG2020	54876	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10661060	C4591001 1066 10661060	16-55	19AUG2020	54877	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10661062	C4591001 1066 10661062	16-55	19AUG2020	54878	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10661064	C4591001 1066 10661064	16-55	20AUG2020	58193	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10661071	C4591001 1066 10661071	16-55	20AUG2020	58196	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661072	C4591001 1066 10661072	16-55	20AUG2020	58198	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661073	C4591001 1066 10661073	16-55	20AUG2020	58199	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10661075	C4591001 1066 10661075	16-55	20AUG2020	59853	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10661078	C4591001 1066 10661078	16-55	21AUG2020	59854	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10661081	C4591001 1066 10661081	16-55	24AUG2020	59856	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10661082	C4591001 1066 10661082	16-55	24AUG2020	59858	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10661085	C4591001 1066 10661085	16-55	24AUG2020	64205	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10661086	C4591001 1066 10661086	16-55	24AUG2020	64211	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10661090	C4591001 1066 10661090	16-55	24AUG2020	64214	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10661095	C4591001 1066 10661095	16-55	25AUG2020	64215	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661097	C4591001 1066 10661097	16-55	25AUG2020	66548	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661098	C4591001 1066 10661098	16-55	25AUG2020	66549	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10661101	C4591001 1066 10661101	16-55	25AUG2020	66550	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10661106	C4591001 1066 10661106	16-55	26AUG2020	66552	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10661115	C4591001 1066 10661115	16-55	26AUG2020	69317	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10661116	C4591001 1066 10661116	16-55	26AUG2020	69321	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10661121	C4591001 1066 10661121	16-55	27AUG2020	69325	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
10661123	C4591001 1066 10661123	16-55	27AUG2020	69327	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10661129	C4591001 1066 10661129	16-55	28AUG2020	71969	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10661130	C4591001 1066 10661130	16-55	28AUG2020	71975	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10661132	C4591001 1066 10661132	16-55	28AUG2020	71978	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661133	C4591001 1066 10661133	16-55	28AUG2020	71979	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10661136	C4591001 1066 10661136	16-55	28AUG2020	72774	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10661137	C4591001 1066 10661137	16-55	28AUG2020	72781	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10661138	C4591001 1066 10661138	16-55	28AUG2020	72783	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10661139	C4591001 1066 10661139	16-55	28AUG2020	72784	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10661142	C4591001 1066 10661142	16-55	31AUG2020	74779	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10661147	C4591001 1066 10661147	16-55	31AUG2020	74784	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10661149	C4591001 1066 10661149	16-55	31AUG2020	74786	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10661151	C4591001 1066 10661151	16-55	31AUG2020	74787	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10661152	C4591001 1066 10661152	16-55	01SEP2020	76433	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661160	C4591001 1066 10661160	16-55	01SEP2020	76436	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10661163	C4591001 1066 10661163	16-55	01SEP2020	76438	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10661166	C4591001 1066 10661166	16-55	02SEP2020	76441	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10661167	C4591001 1066 10661167	16-55	02SEP2020	78512	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10661168	C4591001 1066 10661168	16-55	02SEP2020	78514	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10661173	C4591001 1066 10661173	16-55	03SEP2020	78517	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10661178	C4591001 1066 10661178	16-55	03SEP2020	78518	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10661182	C4591001 1066 10661182	16-55	03SEP2020	81007	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10661183	C4591001 1066 10661183	16-55	03SEP2020	81008	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10661184	C4591001 1066 10661184	16-55	04SEP2020	81012	Placebo	04SEP2020/ Placebo	13OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661185	C4591001 1066 10661185	16-55	04SEP2020	81016	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661186	C4591001 1066 10661186	16-55	04SEP2020	81414	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10661187	C4591001 1066 10661187	16-55	04SEP2020	81417	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10661190	C4591001 1066 10661190	16-55	04SEP2020	81419	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661192	C4591001 1066 10661192	16-55	04SEP2020	81421	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10661193	C4591001 1066 10661193	16-55	04SEP2020	82206	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10661194	C4591001 1066 10661194	16-55	04SEP2020	82210	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10661195	C4591001 1066 10661195	16-55	04SEP2020	82211	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10661197	C4591001 1066 10661197	16-55	07SEP2020	82212	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10661198	C4591001 1066 10661198	16-55	07SEP2020	83095	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661202	C4591001 1066 10661202	16-55	07SEP2020	83098	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10661203	C4591001 1066 10661203	16-55	07SEP2020	83101	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10661214	C4591001 1066 10661214	16-55	08SEP2020	83103	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10661217	C4591001 1066 10661217	16-55	09SEP2020	85148	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10661219	C4591001 1066 10661219	16-55	09SEP2020	85150	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10661226	C4591001 1066 10661226	16-55	09SEP2020	85153	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10661233	C4591001 1066 10661233	16-55	10SEP2020	87619	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10661235	C4591001 1066 10661235	16-55	11SEP2020	87622	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10661242	C4591001 1066 10661242	16-55	11SEP2020	87623	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10661243	C4591001 1066 10661243	16-55	11SEP2020	87627	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661246	C4591001 1066 10661246	16-55	14SEP2020	90090	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10661247	C4591001 1066 10661247	16-55	14SEP2020	90089	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10661251	C4591001 1066 10661251	16-55	15SEP2020	90093	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10661253	C4591001 1066 10661253	16-55	15SEP2020	90098	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10661259	C4591001 1066 10661259	16-55	16SEP2020	91758	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10661260	C4591001 1066 10661260	16-55	16SEP2020	91761	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10661261	C4591001 1066 10661261	16-55	16SEP2020	91762	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661262	C4591001 1066 10661262	16-55	16SEP2020	91764	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10661264	C4591001 1066 10661264	16-55	17SEP2020	92442	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10661265	C4591001 1066 10661265	16-55	17SEP2020	92443	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661267	C4591001 1066 10661267	16-55	17SEP2020	92448	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10661270	C4591001 1066 10661270	16-55	17SEP2020	92451	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10661272	C4591001 1066 10661272	16-55	18SEP2020	93641	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10661273	C4591001 1066 10661273	16-55	18SEP2020	93644	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10661275	C4591001 1066 10661275	16-55	18SEP2020	93646	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10661276	C4591001 1066 10661276	16-55	18SEP2020	93647	Placebo	18SEP2020/ Placebo	27OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10661277	C4591001 1066 10661277	16-55	18SEP2020	94326	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661278	C4591001 1066 10661278	16-55	21SEP2020	94327	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10661279	C4591001 1066 10661279	16-55	21SEP2020	94332	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10661280	C4591001 1066 10661280	16-55	21SEP2020	94336	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661282	C4591001 1066 10661282	16-55	21SEP2020	95801	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10661284	C4591001 1066 10661284	16-55	22SEP2020	95803	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10661285	C4591001 1066 10661285	16-55	22SEP2020	95806	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10661287	C4591001 1066 10661287	16-55	22SEP2020	95808	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10661289	C4591001 1066 10661289	16-55	22SEP2020	97025	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
10661290	C4591001 1066 10661290	16-55	22SEP2020	97029	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10661291	C4591001 1066 10661291	16-55	23SEP2020	97032	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10661293	C4591001 1066 10661293	16-55	23SEP2020	97034	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10661294	C4591001 1066 10661294	16-55	23SEP2020	98312	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10661295	C4591001 1066 10661295	16-55	23SEP2020	98316	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661296	C4591001 1066 10661296	16-55	23SEP2020	98318	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10661299	C4591001 1066 10661299	16-55	24SEP2020	98320	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10661300	C4591001 1066 10661300	16-55	24SEP2020	98624	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10661301	C4591001 1066 10661301	16-55	24SEP2020	98627	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10661305	C4591001 1066 10661305	16-55	24SEP2020	98629	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10661307	C4591001 1066 10661307	16-55	06OCT2020	99995	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10661308	C4591001 1066 10661308	16-55	01OCT2020	99991	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10661309	C4591001 1066 10661309	16-55	25SEP2020	98631	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10661310	C4591001 1066 10661310	16-55	25SEP2020	265017	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10661312	C4591001 1066 10661312	16-55	25SEP2020	99989	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661315	C4591001 1066 10661315	16-55	05OCT2020	99992	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10661317	C4591001 1066 10661317	16-55	08OCT2020	105213	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10661321	C4591001 1066 10661321	16-55	09OCT2020	105215	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10661322	C4591001 1066 10661322	16-55	12OCT2020	105218	Placebo	12OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10661323	C4591001 1066 10661323	16-55	12OCT2020	105219	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10661324	C4591001 1066 10661324	16-55	12OCT2020	106722	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10661330	C4591001 1066 10661330	16-55	13OCT2020	106723	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10661331	C4591001 1066 10661331	16-55	14OCT2020	106726	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661332	C4591001 1066 10661332	16-55	14OCT2020	106732	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10661333	C4591001 1066 10661333	16-55	20OCT2020	111036	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661335	C4591001 1066 10661335	16-55	14OCT2020	107674	BNT162b2 (30 µg)				
10661336	C4591001 1066 10661336	16-55	14OCT2020	107676	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10661337	C4591001 1066 10661337	16-55	19OCT2020	109368	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10661338	C4591001 1066 10661338	16-55	15OCT2020	107677	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
10661340	C4591001 1066 10661340	16-55	15OCT2020	107680	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661341	C4591001 1066 10661341	16-55	15OCT2020	108581	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10661342	C4591001 1066 10661342	16-55	16OCT2020	108582	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10661344	C4591001 1066 10661344	16-55	16OCT2020	108586	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661345	C4591001 1066 10661345	16-55	16OCT2020	108591	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10661346	C4591001 1066 10661346	16-55	16OCT2020	109365	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661348	C4591001 1066 10661348	16-55	19OCT2020	109367	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10661355	C4591001 1066 10661355	16-55	20OCT2020	109372	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10661358	C4591001 1066 10661358	16-55	04NOV2020	113704	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10661360	C4591001 1066 10661360	16-55	20OCT2020	111038	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10661363	C4591001 1066 10661363	16-55	21OCT2020	111039	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10661364	C4591001 1066 10661364	16-55	21OCT2020	111040	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10661366	C4591001 1066 10661366	16-55	22OCT2020	112109	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10661372	C4591001 1066 10661372	16-55	22OCT2020	112112	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10661379	C4591001 1066 10661379	16-55	23OCT2020	112113	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10661386	C4591001 1066 10661386	16-55	26OCT2020	112116	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661388	C4591001 1066 10661388	16-55	26OCT2020	113695	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10661389	C4591001 1066 10661389	16-55	26OCT2020	113698	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10661390	C4591001 1066 10661390	16-55	30OCT2020	113701	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10661391	C4591001 1066 10661391	16-55	04NOV2020	115688	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
10661392	C4591001 1066 10661392	16-55	19NOV2020	115689	Placebo	19NOV2020/ Placebo	09DEC2020/ Placebo		
10661393	C4591001 1066 10661393	16-55	24NOV2020	115691	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10661396	C4591001 1066 10661396	16-55	01DEC2020	115695	Placebo	01DEC2020/ Placebo		22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10661398	C4591001 1066 10661398	16-55	02DEC2020	117187	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo		
10661399	C4591001 1066 10661399	16-55	02DEC2020	117188	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo		
10661400	C4591001 1066 10661400	16-55	02DEC2020	117189	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10661406	C4591001 1066 10661406	16-55	04DEC2020	117194	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10661413	C4591001 1066 10661413	16-55	10DEC2020	117836	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10681002	C4591001 1068 10681002	16-55	18AUG2020	55553	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681003	C4591001 1068 10681003	16-55	19AUG2020	55554	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10681006	C4591001 1068 10681006	16-55	19AUG2020	55557	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681010	C4591001 1068 10681010	16-55	19AUG2020	55560	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681011	C4591001 1068 10681011	16-55	19AUG2020	57666	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681012	C4591001 1068 10681012	16-55	20AUG2020	57670	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10681013	C4591001 1068 10681013	16-55	20AUG2020	57674	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10681016	C4591001 1068 10681016	16-55	20AUG2020	57675	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681017	C4591001 1068 10681017	16-55	20AUG2020	59480	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681018	C4591001 1068 10681018	16-55	20AUG2020	59485	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10681021	C4591001 1068 10681021	16-55	21AUG2020	59486	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10681024	C4591001 1068 10681024	16-55	21AUG2020	59488	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10681025	C4591001 1068 10681025	16-55	21AUG2020	61244	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681026	C4591001 1068 10681026	16-55	21AUG2020	61248	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10681027	C4591001 1068 10681027	16-55	21AUG2020	61249	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10681028	C4591001 1068 10681028	16-55	24AUG2020	61252	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10681031	C4591001 1068 10681031	16-55	24AUG2020	63728	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681034	C4591001 1068 10681034	16-55	24AUG2020	63733	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681035	C4591001 1068 10681035	16-55	24AUG2020	63732	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10681036	C4591001 1068 10681036	16-55	24AUG2020	63734	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681037	C4591001 1068 10681037	16-55	24AUG2020	64962	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10681038	C4591001 1068 10681038	16-55	26AUG2020	64964	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10681042	C4591001 1068 10681042	16-55	26AUG2020	64967	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10681046	C4591001 1068 10681046	16-55	26AUG2020	64972	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10681047	C4591001 1068 10681047	16-55	26AUG2020	69285	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10681052	C4591001 1068 10681052	16-55	27AUG2020	69288	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10681053	C4591001 1068 10681053	16-55	27AUG2020	69289	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10681058	C4591001 1068 10681058	16-55	27AUG2020	69291	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681060	C4591001 1068 10681060	16-55	28AUG2020	71717	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10681061	C4591001 1068 10681061	16-55	28AUG2020	71718	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10681064	C4591001 1068 10681064	16-55	28AUG2020	71719	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681066	C4591001 1068 10681066	16-55	28AUG2020	71724	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681071	C4591001 1068 10681071	16-55	31AUG2020	74766	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10681072	C4591001 1068 10681072	16-55	31AUG2020	74769	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10681073	C4591001 1068 10681073	16-55	31AUG2020	74770	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10681074	C4591001 1068 10681074	16-55	31AUG2020	74775	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10681076	C4591001 1068 10681076	16-55	31AUG2020	75368	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681077	C4591001 1068 10681077	16-55	31AUG2020	75370	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681080	C4591001 1068 10681080	16-55	31AUG2020	75371	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681081	C4591001 1068 10681081	16-55	31AUG2020	75372	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10681083	C4591001 1068 10681083	16-55	01SEP2020	76421	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681086	C4591001 1068 10681086	16-55	01SEP2020	76424	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10681087	C4591001 1068 10681087	16-55	02SEP2020	76426	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681089	C4591001 1068 10681089	16-55	02SEP2020	76431	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10681097	C4591001 1068 10681097	16-55	03SEP2020	79661	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681098	C4591001 1068 10681098	16-55	03SEP2020	79662	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10681099	C4591001 1068 10681099	16-55	03SEP2020	79667	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10681100	C4591001 1068 10681100	16-55	03SEP2020	79670	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681102	C4591001 1068 10681102	16-55	03SEP2020	80898	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681106	C4591001 1068 10681106	16-55	04SEP2020	80902	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10681109	C4591001 1068 10681109	16-55	04SEP2020	80904	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10681110	C4591001 1068 10681110	16-55	04SEP2020	80907	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10681112	C4591001 1068 10681112	16-55	04SEP2020	82571	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10681113	C4591001 1068 10681113	16-55	08SEP2020	82573	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10681114	C4591001 1068 10681114	16-55	08SEP2020	82574	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10681115	C4591001 1068 10681115	16-55	08SEP2020	82575	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10681116	C4591001 1068 10681116	16-55	10SEP2020	86793	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10681117	C4591001 1068 10681117	16-55	10SEP2020	86797	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10681119	C4591001 1068 10681119	16-55	10SEP2020	86799	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10681121	C4591001 1068 10681121	16-55	23SEP2020	86800	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10711018	C4591001 1071 10711018	16-55	04SEP2020	81555	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10711055	C4591001 1071 10711055	16-55	17AUG2020	51049	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10711056	C4591001 1071 10711056	16-55	18AUG2020	51050	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10711057	C4591001 1071 10711057	16-55	18AUG2020	54629	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	14FEB2021/ BNT162b2 (30 µg)
10711061	C4591001 1071 10711061	16-55	18AUG2020	54630	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10711062	C4591001 1071 10711062	16-55	18AUG2020	54633	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10711065	C4591001 1071 10711065	16-55	19AUG2020	54635	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10711079	C4591001 1071 10711079	16-55	22AUG2020	62083	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711080	C4591001 1071 10711080	16-55	22AUG2020	62086	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10711081	C4591001 1071 10711081	16-55	23AUG2020	62090	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo		
10711082	C4591001 1071 10711082	16-55	23AUG2020	62091	Placebo	23AUG2020/ Placebo	12SEP2020/ Placebo		
10711083	C4591001 1071 10711083	16-55	24AUG2020	63705	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10711086	C4591001 1071 10711086	16-55	24AUG2020	63706	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10711087	C4591001 1071 10711087	16-55	24AUG2020	63707	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10711092	C4591001 1071 10711092	16-55	25AUG2020	63712	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711094	C4591001 1071 10711094	16-55	25AUG2020	67042	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10711095	C4591001 1071 10711095	16-55	25AUG2020	67045	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10711097	C4591001 1071 10711097	16-55	26AUG2020	67047	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711098	C4591001 1071 10711098	16-55	26AUG2020	67048	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711100	C4591001 1071 10711100	16-55	26AUG2020	69222	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711102	C4591001 1071 10711102	16-55	27AUG2020	69227	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10711107	C4591001 1071 10711107	16-55	27AUG2020	69231	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10711113	C4591001 1071 10711113	16-55	29AUG2020	69232	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711114	C4591001 1071 10711114	16-55	29AUG2020	73844	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10711115	C4591001 1071 10711115	16-55	29AUG2020	73847	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10711116	C4591001 1071 10711116	16-55	29AUG2020	73850	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711118	C4591001 1071 10711118	16-55	31AUG2020	73851	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10711119	C4591001 1071 10711119	16-55	01SEP2020	77742	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711124	C4591001 1071 10711124	16-55	03SEP2020	77749	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711125	C4591001 1071 10711125	16-55	03SEP2020	77744	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10711127	C4591001 1071 10711127	16-55	03SEP2020	77750	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711128	C4591001 1071 10711128	16-55	04SEP2020	81547	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10711131	C4591001 1071 10711131	16-55	04SEP2020	81548	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711133	C4591001 1071 10711133	16-55	04SEP2020	81554	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10711136	C4591001 1071 10711136	16-55	04SEP2020	82592	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711137	C4591001 1071 10711137	16-55	04SEP2020	82594	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711138	C4591001 1071 10711138	16-55	08SEP2020	82595	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10711140	C4591001 1071 10711140	16-55	08SEP2020	82596	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711148	C4591001 1071 10711148	16-55	09SEP2020	86177	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10711149	C4591001 1071 10711149	16-55	09SEP2020	86179	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	16JAN2021/ BNT162b2 (30 µg)
10711150	C4591001 1071 10711150	16-55	10SEP2020	86180	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10711151	C4591001 1071 10711151	16-55	10SEP2020	86188	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10711152	C4591001 1071 10711152	16-55	10SEP2020	87380	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711153	C4591001 1071 10711153	16-55	10SEP2020	87383	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10711156	C4591001 1071 10711156	16-55	10SEP2020	87384	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	13MAR2021/ BNT162b2 (30 µg)
10711157	C4591001 1071 10711157	16-55	10SEP2020	87388	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10711159	C4591001 1071 10711159	16-55	11SEP2020	88350	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10711160	C4591001 1071 10711160	16-55	11SEP2020	88351	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711161	C4591001 1071 10711161	16-55	11SEP2020	88352	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10711162	C4591001 1071 10711162	16-55	11SEP2020	88357	Placebo				
10711164	C4591001 1071 10711164	16-55	14SEP2020	89777	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo		
10711166	C4591001 1071 10711166	16-55	15SEP2020	89784	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10711167	C4591001 1071 10711167	16-55	15SEP2020	89785	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10711170	C4591001 1071 10711170	16-55	15SEP2020	89786	Placebo	15SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711171	C4591001 1071 10711171	16-55	15SEP2020	90848	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10711173	C4591001 1071 10711173	16-55	16SEP2020	90850	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
10711175	C4591001 1071 10711175	16-55	17SEP2020	90851	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
10711176	C4591001 1071 10711176	16-55	17SEP2020	90855	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10711182	C4591001 1071 10711182	16-55	17SEP2020	93115	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711183	C4591001 1071 10711183	16-55	17SEP2020	93120	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10711185	C4591001 1071 10711185	16-55	18SEP2020	93122	Placebo	18SEP2020/ Placebo			
10711189	C4591001 1071 10711189	16-55	21SEP2020	93124	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10711193	C4591001 1071 10711193	16-55	23SEP2020	97738	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10711194	C4591001 1071 10711194	16-55	23SEP2020	97739	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711198	C4591001 1071 10711198	16-55	24SEP2020	97743	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10711199	C4591001 1071 10711199	16-55	24SEP2020	97744	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10711200	C4591001 1071 10711200	16-55	24SEP2020	99042	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10711202	C4591001 1071 10711202	16-55	26SEP2020	99045	Placebo	26SEP2020/ Placebo	16OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711203	C4591001 1071 10711203	16-55	26SEP2020	99047	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711204	C4591001 1071 10711204	16-55	26SEP2020	99050	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10711205	C4591001 1071 10711205	16-55	26SEP2020	100602	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
10711206	C4591001 1071 10711206	16-55	26SEP2020	100604	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	24JAN2021/ BNT162b2 (30 µg)	14FEB2021/ BNT162b2 (30 µg)
10711208	C4591001 1071 10711208	16-55	02OCT2020	100606	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711209	C4591001 1071 10711209	16-55	02OCT2020	100607	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10711210	C4591001 1071 10711210	16-55	05OCT2020	103793	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10711211	C4591001 1071 10711211	16-55	05OCT2020	103796	Placebo	05OCT2020/ Placebo			
10711212	C4591001 1071 10711212	16-55	05OCT2020	103799	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
10711215	C4591001 1071 10711215	16-55	09OCT2020	105845	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	31OCT2020/ BNT162b2 (30 µg)		
10711217	C4591001 1071 10711217	16-55	09OCT2020	105847	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	31OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711218	C4591001 1071 10711218	16-55	09OCT2020	105853	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10711219	C4591001 1071 10711219	16-55	12OCT2020	105855	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	
10711222	C4591001 1071 10711222	16-55	14OCT2020	107627	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10711223	C4591001 1071 10711223	16-55	14OCT2020	107630	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	13MAR2021/ BNT162b2 (30 µg)
10711224	C4591001 1071 10711224	16-55	15OCT2020	107631	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo		
10711225	C4591001 1071 10711225	16-55	15OCT2020	107632	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10711227	C4591001 1071 10711227	16-55	15OCT2020	108498	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
10711229	C4591001 1071 10711229	16-55	16OCT2020	108505	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10711230	C4591001 1071 10711230	16-55	16OCT2020	108506	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10711231	C4591001 1071 10711231	16-55	16OCT2020	108507	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711232	C4591001 1071 10711232	16-55	19OCT2020	110191	Placebo	19OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10711233	C4591001 1071 10711233	16-55	19OCT2020	110195	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10711234	C4591001 1071 10711234	16-55	19OCT2020	110198	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
10711235	C4591001 1071 10711235	16-55	20OCT2020	110199	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)			
10711236	C4591001 1071 10711236	16-55	20OCT2020	110851	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10711237	C4591001 1071 10711237	16-55	23OCT2020	110853	Placebo	23OCT2020/ Placebo			
10711239	C4591001 1071 10711239	16-55	24OCT2020	110855	Placebo	24OCT2020/ Placebo	14NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	16JAN2021/ BNT162b2 (30 µg)
10711241	C4591001 1071 10711241	16-55	24OCT2020	110858	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
10711242	C4591001 1071 10711242	16-55	24OCT2020	113292	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
10711244	C4591001 1071 10711244	16-55	27OCT2020	113293	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10711246	C4591001 1071 10711246	16-55	27OCT2020	113294	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10711247	C4591001 1071 10711247	16-55	27OCT2020	113296	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10711249	C4591001 1071 10711249	16-55	30OCT2020	115122	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo		
10711250	C4591001 1071 10711250	16-55	30OCT2020	115123	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10721001	C4591001 1072 10721001	16-55	17AUG2020	52445	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10721008	C4591001 1072 10721008	16-55	17AUG2020	52446	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10721009	C4591001 1072 10721009	16-55	18AUG2020	52448	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10721012	C4591001 1072 10721012	16-55	18AUG2020	52453	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
10721013	C4591001 1072 10721013	16-55	19AUG2020	56791	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10721022	C4591001 1072 10721022	16-55	20AUG2020	56796	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721023	C4591001 1072 10721023	16-55	20AUG2020	56797	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10721024	C4591001 1072 10721024	16-55	21AUG2020	56798	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10721029	C4591001 1072 10721029	16-55	21AUG2020	61412	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo		
10721030	C4591001 1072 10721030	16-55	22AUG2020	61413	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10721031	C4591001 1072 10721031	16-55	22AUG2020	61417	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10721033	C4591001 1072 10721033	16-55	22AUG2020	61418	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10721034	C4591001 1072 10721034	16-55	22AUG2020	62347	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10721035	C4591001 1072 10721035	16-55	24AUG2020	62348	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10721040	C4591001 1072 10721040	16-55	24AUG2020	62352	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10721046	C4591001 1072 10721046	16-55	25AUG2020	62353	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721047	C4591001 1072 10721047	16-55	25AUG2020	66835	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10721049	C4591001 1072 10721049	16-55	26AUG2020	66836	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10721050	C4591001 1072 10721050	16-55	26AUG2020	66839	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10721051	C4591001 1072 10721051	16-55	26AUG2020	66840	Placebo	26AUG2020/ Placebo		08MAR2021/ BNT162b2 (30 µg)	
10721052	C4591001 1072 10721052	16-55	26AUG2020	68202	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10721058	C4591001 1072 10721058	16-55	27AUG2020	68203	Placebo	27AUG2020/ Placebo	25SEP2020/ Placebo		
10721063	C4591001 1072 10721063	16-55	28AUG2020	68205	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10721069	C4591001 1072 10721069	16-55	31AUG2020	68212	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10721070	C4591001 1072 10721070	16-55	31AUG2020	75882	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10721071	C4591001 1072 10721071	16-55	01SEP2020	75887	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721072	C4591001 1072 10721072	16-55	01SEP2020	75888	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10721074	C4591001 1072 10721074	16-55	01SEP2020	75890	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10721077	C4591001 1072 10721077	16-55	02SEP2020	78920	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10721083	C4591001 1072 10721083	16-55	03SEP2020	78921	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10721084	C4591001 1072 10721084	16-55	03SEP2020	78924	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10721085	C4591001 1072 10721085	16-55	04SEP2020	78925	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10721086	C4591001 1072 10721086	16-55	04SEP2020	81426	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10721087	C4591001 1072 10721087	16-55	04SEP2020	81430	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10721089	C4591001 1072 10721089	16-55	04SEP2020	81432	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
10721090	C4591001 1072 10721090	16-55	04SEP2020	81436	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10721091	C4591001 1072 10721091	16-55	08SEP2020	83539	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10721093	C4591001 1072 10721093	16-55	08SEP2020	83542	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10721094	C4591001 1072 10721094	16-55	08SEP2020	83543	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10721099	C4591001 1072 10721099	16-55	10SEP2020	83548	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
10721100	C4591001 1072 10721100	16-55	11SEP2020	88289	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10731091	C4591001 1073 10731091	16-55	19AUG2020	48816	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10731093	C4591001 1073 10731093	16-55	19AUG2020	48818	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10731101	C4591001 1073 10731101	16-55	20AUG2020	58710	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10731103	C4591001 1073 10731103	16-55	20AUG2020	58713	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10731106	C4591001 1073 10731106	16-55	24AUG2020	58714	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10731109	C4591001 1073 10731109	16-55	24AUG2020	58716	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10731110	C4591001 1073 10731110	16-55	24AUG2020	64133	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731112	C4591001 1073 10731112	16-55	25AUG2020	64137	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10731113	C4591001 1073 10731113	16-55	25AUG2020	64140	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10731114	C4591001 1073 10731114	16-55	25AUG2020	64143	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10731116	C4591001 1073 10731116	16-55	25AUG2020	66222	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10731117	C4591001 1073 10731117	16-55	25AUG2020	66227	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10731120	C4591001 1073 10731120	16-55	26AUG2020	66228	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10771041	C4591001 1077 10771041	16-55	17AUG2020	47579	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10771042	C4591001 1077 10771042	16-55	17AUG2020	226551	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771044	C4591001 1077 10771044	16-55	17AUG2020	47580	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771045	C4591001 1077 10771045	16-55	17AUG2020	47584	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771054	C4591001 1077 10771054	16-55	17AUG2020	53201	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10771058	C4591001 1077 10771058	16-55	17AUG2020	53205	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10771061	C4591001 1077 10771061	16-55	18AUG2020	53210	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10771067	C4591001 1077 10771067	16-55	18AUG2020	53211	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10771068	C4591001 1077 10771068	16-55	18AUG2020	54473	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10771069	C4591001 1077 10771069	16-55	18AUG2020	54474	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10771071	C4591001 1077 10771071	16-55	18AUG2020	54478	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10771073	C4591001 1077 10771073	16-55	18AUG2020	54479	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771074	C4591001 1077 10771074	16-55	18AUG2020	55217	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10771076	C4591001 1077 10771076	16-55	19AUG2020	55219	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10771077	C4591001 1077 10771077	16-55	19AUG2020	55221	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10771079	C4591001 1077 10771079	16-55	19AUG2020	55224	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10771080	C4591001 1077 10771080	16-55	19AUG2020	56241	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10771082	C4591001 1077 10771082	16-55	19AUG2020	56242	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10771083	C4591001 1077 10771083	16-55	24AUG2020	56244	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10771084	C4591001 1077 10771084	16-55	24AUG2020	56245	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771085	C4591001 1077 10771085	16-55	24AUG2020	63301	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10771086	C4591001 1077 10771086	16-55	24AUG2020	63303	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771087	C4591001 1077 10771087	16-55	24AUG2020	63302	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10771089	C4591001 1077 10771089	16-55	24AUG2020	63582	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771096	C4591001 1077 10771096	16-55	24AUG2020	63586	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10771097	C4591001 1077 10771097	16-55	24AUG2020	63589	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10771100	C4591001 1077 10771100	16-55	25AUG2020	63592	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771108	C4591001 1077 10771108	16-55	25AUG2020	65923	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10771114	C4591001 1077 10771114	16-55	25AUG2020	65926	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10771117	C4591001 1077 10771117	16-55	26AUG2020	65928	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10771118	C4591001 1077 10771118	16-55	26AUG2020	65932	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771120	C4591001 1077 10771120	16-55	26AUG2020	67495	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771122	C4591001 1077 10771122	16-55	26AUG2020	67493	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10771123	C4591001 1077 10771123	16-55	26AUG2020	67496	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10771124	C4591001 1077 10771124	16-55	26AUG2020	67999	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10771125	C4591001 1077 10771125	16-55	26AUG2020	67501	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10771126	C4591001 1077 10771126	16-55	26AUG2020	68002	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10771128	C4591001 1077 10771128	16-55	26AUG2020	68006	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771129	C4591001 1077 10771129	16-55	26AUG2020	68008	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10771131	C4591001 1077 10771131	16-55	26AUG2020	69113	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10771132	C4591001 1077 10771132	16-55	27AUG2020	69117	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771133	C4591001 1077 10771133	16-55	27AUG2020	69118	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771134	C4591001 1077 10771134	16-55	27AUG2020	69124	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10771136	C4591001 1077 10771136	16-55	27AUG2020	69584	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771137	C4591001 1077 10771137	16-55	27AUG2020	69585	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771138	C4591001 1077 10771138	16-55	27AUG2020	69587	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10771139	C4591001 1077 10771139	16-55	27AUG2020	69592	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10771140	C4591001 1077 10771140	16-55	27AUG2020	70218	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10771142	C4591001 1077 10771142	16-55	27AUG2020	70220	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10771150	C4591001 1077 10771150	16-55	01SEP2020	70224	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10771152	C4591001 1077 10771152	16-55	01SEP2020	70227	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771153	C4591001 1077 10771153	16-55	01SEP2020	76679	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771156	C4591001 1077 10771156	16-55	01SEP2020	76680	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771157	C4591001 1077 10771157	16-55	01SEP2020	76682	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10771158	C4591001 1077 10771158	16-55	01SEP2020	76683	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10771159	C4591001 1077 10771159	16-55	01SEP2020	77587	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10771165	C4591001 1077 10771165	16-55	02SEP2020	77590	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10771166	C4591001 1077 10771166	16-55	02SEP2020	77593	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10771169	C4591001 1077 10771169	16-55	02SEP2020	77594	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10771171	C4591001 1077 10771171	16-55	02SEP2020	79147	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771178	C4591001 1077 10771178	16-55	03SEP2020	79148	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771181	C4591001 1077 10771181	16-55	03SEP2020	79149	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771183	C4591001 1077 10771183	16-55	03SEP2020	79152	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771184	C4591001 1077 10771184	16-55	03SEP2020	80501	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10771186	C4591001 1077 10771186	16-55	03SEP2020	80505	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771188	C4591001 1077 10771188	16-55	03SEP2020	80510	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771189	C4591001 1077 10771189	16-55	03SEP2020	80511	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10771190	C4591001 1077 10771190	16-55	03SEP2020	80945	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10771192	C4591001 1077 10771192	16-55	03SEP2020	80950	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10771193	C4591001 1077 10771193	16-55	04SEP2020	80952	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10771198	C4591001 1077 10771198	16-55	04SEP2020	80955	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10771200	C4591001 1077 10771200	16-55	04SEP2020	81810	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771201	C4591001 1077 10771201	16-55	04SEP2020	81812	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10771202	C4591001 1077 10771202	16-55	08SEP2020	81813	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10771203	C4591001 1077 10771203	16-55	08SEP2020	81820	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10771204	C4591001 1077 10771204	16-55	08SEP2020	83333	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10771209	C4591001 1077 10771209	16-55	08SEP2020	83334	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10771212	C4591001 1077 10771212	16-55	08SEP2020	83336	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10771213	C4591001 1077 10771213	16-55	08SEP2020	83343	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771214	C4591001 1077 10771214	16-55	09SEP2020	84775	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10771218	C4591001 1077 10771218	16-55	09SEP2020	84779	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo		
10771222	C4591001 1077 10771222	16-55	10SEP2020	84780	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771234	C4591001 1077 10771234	16-55	17SEP2020	84782	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10771235	C4591001 1077 10771235	16-55	17SEP2020	92250	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10771236	C4591001 1077 10771236	16-55	18SEP2020	92253	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10771237	C4591001 1077 10771237	16-55	18SEP2020	92259	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10771238	C4591001 1077 10771238	16-55	18SEP2020	92260	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10771240	C4591001 1077 10771240	16-55	18SEP2020	93608	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10771242	C4591001 1077 10771242	16-55	12OCT2020	93609	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10771243	C4591001 1077 10771243	16-55	13OCT2020	93612	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10771244	C4591001 1077 10771244	16-55	14OCT2020	93615	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10771245	C4591001 1077 10771245	16-55	15OCT2020	107983	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771246	C4591001 1077 10771246	16-55	19OCT2020	107985	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771247	C4591001 1077 10771247	16-55	19OCT2020	107989	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10771248	C4591001 1077 10771248	16-55	19OCT2020	107991	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10771250	C4591001 1077 10771250	16-55	19OCT2020	110276	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10771253	C4591001 1077 10771253	16-55	20OCT2020	110278	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10771254	C4591001 1077 10771254	16-55	20OCT2020	110280	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10771258	C4591001 1077 10771258	16-55	20OCT2020	110281	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10771260	C4591001 1077 10771260	16-55	20OCT2020	110957	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10771261	C4591001 1077 10771261	16-55	20OCT2020	110958	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10771262	C4591001 1077 10771262	16-55	20OCT2020	110961	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10771268	C4591001 1077 10771268	16-55	22OCT2020	110965	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10771269	C4591001 1077 10771269	16-55	22OCT2020	112339	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10771272	C4591001 1077 10771272	16-55	29OCT2020	112340	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10771273	C4591001 1077 10771273	16-55	02DEC2020	112345	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
10771276	C4591001 1077 10771276	16-55	04DEC2020	112346	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10791129	C4591001 1079 10791129	16-55	17AUG2020	49412	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10791130	C4591001 1079 10791130	16-55	17AUG2020	49417	Placebo	17AUG2020/ BNT162b2 (30 µg)			
10791133	C4591001 1079 10791133	16-55	17AUG2020	49420	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791134	C4591001 1079 10791134	16-55	17AUG2020	53213	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10791135	C4591001 1079 10791135	16-55	17AUG2020	53215	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791137	C4591001 1079 10791137	16-55	18AUG2020	53221	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10791142	C4591001 1079 10791142	16-55	18AUG2020	55158	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791143	C4591001 1079 10791143	16-55	18AUG2020	53224	Placebo	18AUG2020/ Placebo	06NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791144	C4591001 1079 10791144	16-55	19AUG2020	55162	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10791146	C4591001 1079 10791146	16-55	19AUG2020	55163	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791147	C4591001 1079 10791147	16-55	19AUG2020	55168	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791153	C4591001 1079 10791153	16-55	19AUG2020	56933	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791154	C4591001 1079 10791154	16-55	19AUG2020	56937	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791157	C4591001 1079 10791157	16-55	20AUG2020	56938	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791164	C4591001 1079 10791164	16-55	20AUG2020	59273	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791166	C4591001 1079 10791166	16-55	21AUG2020	59279	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10791169	C4591001 1079 10791169	16-55	21AUG2020	59280	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10791170	C4591001 1079 10791170	16-55	24AUG2020	59283	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10791171	C4591001 1079 10791171	16-55	24AUG2020	63929	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791172	C4591001 1079 10791172	16-55	24AUG2020	63936	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10791173	C4591001 1079 10791173	16-55	24AUG2020	63938	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791174	C4591001 1079 10791174	16-55	25AUG2020	63939	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10791175	C4591001 1079 10791175	16-55	25AUG2020	65418	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10791176	C4591001 1079 10791176	16-55	25AUG2020	65421	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791177	C4591001 1079 10791177	16-55	25AUG2020	65425	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791178	C4591001 1079 10791178	16-55	25AUG2020	65428	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791179	C4591001 1079 10791179	16-55	25AUG2020	66030	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791181	C4591001 1079 10791181	16-55	25AUG2020	66039	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791182	C4591001 1079 10791182	16-55	25AUG2020	66035	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10791184	C4591001 1079 10791184	16-55	26AUG2020	66040	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10791186	C4591001 1079 10791186	16-55	26AUG2020	68107	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791187	C4591001 1079 10791187	16-55	26AUG2020	68108	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10791188	C4591001 1079 10791188	16-55	26AUG2020	68110	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10791192	C4591001 1079 10791192	16-55	27AUG2020	68116	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791195	C4591001 1079 10791195	16-55	27AUG2020	70446	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791197	C4591001 1079 10791197	16-55	27AUG2020	70450	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791199	C4591001 1079 10791199	16-55	27AUG2020	70454	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791202	C4591001 1079 10791202	16-55	28AUG2020	70455	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791203	C4591001 1079 10791203	16-55	28AUG2020	72103	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10791205	C4591001 1079 10791205	16-55	28AUG2020	72105	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10791206	C4591001 1079 10791206	16-55	28AUG2020	72107	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10791211	C4591001 1079 10791211	16-55	31AUG2020	72111	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791224	C4591001 1079 10791224	16-55	01SEP2020	77157	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791230	C4591001 1079 10791230	16-55	02SEP2020	77158	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
10791232	C4591001 1079 10791232	16-55	03SEP2020	77164	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791235	C4591001 1079 10791235	16-55	03SEP2020	80201	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10791238	C4591001 1079 10791238	16-55	03SEP2020	80202	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10791239	C4591001 1079 10791239	16-55	03SEP2020	80203	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791241	C4591001 1079 10791241	16-55	04SEP2020	80209	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10791244	C4591001 1079 10791244	16-55	04SEP2020	82013	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10791245	C4591001 1079 10791245	16-55	04SEP2020	82017	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10791249	C4591001 1079 10791249	16-55	08SEP2020	84209	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791250	C4591001 1079 10791250	16-55	08SEP2020	82023	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791251	C4591001 1079 10791251	16-55	08SEP2020	82022	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10791252	C4591001 1079 10791252	16-55	08SEP2020	84212	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791253	C4591001 1079 10791253	16-55	08SEP2020	84216	Placebo	08SEP2020/ Placebo			
10791256	C4591001 1079 10791256	16-55	09SEP2020	84219	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10791257	C4591001 1079 10791257	16-55	09SEP2020	85413	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10791262	C4591001 1079 10791262	16-55	09SEP2020	85415	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10791263	C4591001 1079 10791263	16-55	09SEP2020	85414	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791265	C4591001 1079 10791265	16-55	09SEP2020	85420	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10791267	C4591001 1079 10791267	16-55	10SEP2020	86611	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10791272	C4591001 1079 10791272	16-55	11SEP2020	86612	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10791275	C4591001 1079 10791275	16-55	11SEP2020	86617	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10791277	C4591001 1079 10791277	16-55	11SEP2020	86620	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791281	C4591001 1079 10791281	16-55	15SEP2020	90177	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10791288	C4591001 1079 10791288	16-55	16SEP2020	90180	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10791289	C4591001 1079 10791289	16-55	16SEP2020	90182	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10791290	C4591001 1079 10791290	16-55	16SEP2020	90184	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10791291	C4591001 1079 10791291	16-55	16SEP2020	91505	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10791293	C4591001 1079 10791293	16-55	21SEP2020	91506	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10791294	C4591001 1079 10791294	16-55	21SEP2020	91507	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10791296	C4591001 1079 10791296	16-55	09OCT2020	106039	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10791297	C4591001 1079 10791297	16-55	22SEP2020	91515	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10791298	C4591001 1079 10791298	16-55	22SEP2020	96441	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10791300	C4591001 1079 10791300	16-55	05OCT2020	96442	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10791303	C4591001 1079 10791303	16-55	07OCT2020	96444	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10791304	C4591001 1079 10791304	16-55	09OCT2020	96446	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10791305	C4591001 1079 10791305	16-55	12OCT2020	106042	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10791311	C4591001 1079 10791311	16-55	14OCT2020	106045	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10791313	C4591001 1079 10791313	16-55	16OCT2020	106047	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10791315	C4591001 1079 10791315	16-55	20OCT2020	110933	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10791316	C4591001 1079 10791316	16-55	23OCT2020	110934	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801036	C4591001 1080 10801036	16-55	14AUG2020	48674	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10801040	C4591001 1080 10801040	16-55	14AUG2020	50746	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801041	C4591001 1080 10801041	16-55	14AUG2020	50748	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10801042	C4591001 1080 10801042	16-55	17AUG2020	50749	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10801043	C4591001 1080 10801043	16-55	17AUG2020	50752	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10801045	C4591001 1080 10801045	16-55	17AUG2020	52829	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10801050	C4591001 1080 10801050	16-55	17AUG2020	52834	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10801051	C4591001 1080 10801051	16-55	17AUG2020	52838	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10801053	C4591001 1080 10801053	16-55	18AUG2020	52839	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801054	C4591001 1080 10801054	16-55	18AUG2020	54237	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801055	C4591001 1080 10801055	16-55	18AUG2020	54240	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
10801057	C4591001 1080 10801057	16-55	18AUG2020	54241	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801058	C4591001 1080 10801058	16-55	19AUG2020	54243	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10801059	C4591001 1080 10801059	16-55	19AUG2020	55829	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10801065	C4591001 1080 10801065	16-55	19AUG2020	55832	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10801068	C4591001 1080 10801068	16-55	20AUG2020	55837	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10801072	C4591001 1080 10801072	16-55	20AUG2020	55838	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801078	C4591001 1080 10801078	16-55	21AUG2020	60665	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10801079	C4591001 1080 10801079	16-55	21AUG2020	60670	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10801081	C4591001 1080 10801081	16-55	21AUG2020	60666	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10801082	C4591001 1080 10801082	16-55	24AUG2020	60672	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10801087	C4591001 1080 10801087	16-55	24AUG2020	64361	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801089	C4591001 1080 10801089	16-55	25AUG2020	64363	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10801092	C4591001 1080 10801092	16-55	25AUG2020	64365	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10801096	C4591001 1080 10801096	16-55	26AUG2020	64368	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10801100	C4591001 1080 10801100	16-55	26AUG2020	67781	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801102	C4591001 1080 10801102	16-55	26AUG2020	67782	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10801104	C4591001 1080 10801104	16-55	27AUG2020	67784	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10801107	C4591001 1080 10801107	16-55	27AUG2020	70901	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10801108	C4591001 1080 10801108	16-55	27AUG2020	67787	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10801109	C4591001 1080 10801109	16-55	28AUG2020	70902	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10801111	C4591001 1080 10801111	16-55	28AUG2020	70904	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801114	C4591001 1080 10801114	16-55	28AUG2020	70905	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10801115	C4591001 1080 10801115	16-55	28AUG2020	72224	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10801117	C4591001 1080 10801117	16-55	28AUG2020	72225	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10801119	C4591001 1080 10801119	16-55	28AUG2020	72230	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10801120	C4591001 1080 10801120	16-55	28AUG2020	72845	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10801122	C4591001 1080 10801122	16-55	28AUG2020	72232	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10801131	C4591001 1080 10801131	16-55	01SEP2020	72852	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10801132	C4591001 1080 10801132	16-55	02SEP2020	72853	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10801135	C4591001 1080 10801135	16-55	02SEP2020	72855	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10801136	C4591001 1080 10801136	16-55	02SEP2020	78799	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801137	C4591001 1080 10801137	16-55	02SEP2020	78800	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10801140	C4591001 1080 10801140	16-55	03SEP2020	78808	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10801141	C4591001 1080 10801141	16-55	03SEP2020	78801	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10801142	C4591001 1080 10801142	16-55	03SEP2020	79721	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10801144	C4591001 1080 10801144	16-55	03SEP2020	79723	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10801145	C4591001 1080 10801145	16-55	03SEP2020	79729	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10801149	C4591001 1080 10801149	16-55	03SEP2020	79732	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10801151	C4591001 1080 10801151	16-55	04SEP2020	81257	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10801153	C4591001 1080 10801153	16-55	04SEP2020	81259	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10801155	C4591001 1080 10801155	16-55	04SEP2020	81261	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801159	C4591001 1080 10801159	16-55	04SEP2020	81264	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10801160	C4591001 1080 10801160	16-55	04SEP2020	82306	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10801162	C4591001 1080 10801162	16-55	04SEP2020	82307	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		
10801163	C4591001 1080 10801163	16-55	08SEP2020	82310	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10801179	C4591001 1080 10801179	16-55	11SEP2020	82311	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10801180	C4591001 1080 10801180	16-55	11SEP2020	87835	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801182	C4591001 1080 10801182	16-55	11SEP2020	87837	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10801183	C4591001 1080 10801183	16-55	11SEP2020	87838	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10801185	C4591001 1080 10801185	16-55	14SEP2020	87841	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10801187	C4591001 1080 10801187	16-55	14SEP2020	89924	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801192	C4591001 1080 10801192	16-55	15SEP2020	89926	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10801193	C4591001 1080 10801193	16-55	16SEP2020	89927	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10801194	C4591001 1080 10801194	16-55	16SEP2020	89932	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10801195	C4591001 1080 10801195	16-55	16SEP2020	91481	Placebo	16SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10801196	C4591001 1080 10801196	16-55	17SEP2020	91488	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10801197	C4591001 1080 10801197	16-55	17SEP2020	91483	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10801201	C4591001 1080 10801201	16-55	17SEP2020	91489	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10801202	C4591001 1080 10801202	16-55	17SEP2020	92588	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10801205	C4591001 1080 10801205	16-55	18SEP2020	92589	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10801212	C4591001 1080 10801212	16-55	18SEP2020	92591	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10801213	C4591001 1080 10801213	16-55	21SEP2020	92592	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10801214	C4591001 1080 10801214	16-55	21SEP2020	94713	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10801219	C4591001 1080 10801219	16-55	21SEP2020	94716	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10801221	C4591001 1080 10801221	16-55	22SEP2020	94719	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10811042	C4591001 1081 10811042	16-55	17AUG2020	52194	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
10811044	C4591001 1081 10811044	16-55	17AUG2020	52197	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811046	C4591001 1081 10811046	16-55	17AUG2020	52203	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10811047	C4591001 1081 10811047	16-55	17AUG2020	52204	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10811062	C4591001 1081 10811062	16-55	19AUG2020	55650	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10811066	C4591001 1081 10811066	16-55	19AUG2020	55652	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811067	C4591001 1081 10811067	16-55	19AUG2020	55659	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10811070	C4591001 1081 10811070	16-55	19AUG2020	55660	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811071	C4591001 1081 10811071	16-55	19AUG2020	56839	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
10811074	C4591001 1081 10811074	16-55	20AUG2020	56844	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10811075	C4591001 1081 10811075	16-55	20AUG2020	56848	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10811077	C4591001 1081 10811077	16-55	20AUG2020	59034	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811079	C4591001 1081 10811079	16-55	21AUG2020	59037	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811081	C4591001 1081 10811081	16-55	24AUG2020	59040	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811085	C4591001 1081 10811085	16-55	24AUG2020	59043	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10811086	C4591001 1081 10811086	16-55	24AUG2020	63523	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811087	C4591001 1081 10811087	16-55	24AUG2020	63524	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10811089	C4591001 1081 10811089	16-55	24AUG2020	63528	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10811092	C4591001 1081 10811092	16-55	24AUG2020	63532	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811094	C4591001 1081 10811094	16-55	25AUG2020	65573	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10811095	C4591001 1081 10811095	16-55	25AUG2020	65575	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10811096	C4591001 1081 10811096	16-55	25AUG2020	65582	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10811098	C4591001 1081 10811098	16-55	25AUG2020	66161	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10811104	C4591001 1081 10811104	16-55	26AUG2020	66163	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811105	C4591001 1081 10811105	16-55	26AUG2020	66167	BNT162b2 (30 µg)				
10811106	C4591001 1081 10811106	16-55	26AUG2020	67267	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10811108	C4591001 1081 10811108	16-55	26AUG2020	67269	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811109	C4591001 1081 10811109	16-55	26AUG2020	67274	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10811114	C4591001 1081 10811114	16-55	26AUG2020	67275	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10811118	C4591001 1081 10811118	16-55	26AUG2020	68758	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10811119	C4591001 1081 10811119	16-55	26AUG2020	68759	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10811121	C4591001 1081 10811121	16-55	27AUG2020	68760	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10811126	C4591001 1081 10811126	16-55	27AUG2020	68763	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10811127	C4591001 1081 10811127	16-55	27AUG2020	70542	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811130	C4591001 1081 10811130	16-55	27AUG2020	70545	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811131	C4591001 1081 10811131	16-55	27AUG2020	70546	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10811133	C4591001 1081 10811133	16-55	31AUG2020	70547	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811134	C4591001 1081 10811134	16-55	31AUG2020	75005	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10811135	C4591001 1081 10811135	16-55	31AUG2020	75008	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
10811141	C4591001 1081 10811141	16-55	01SEP2020	75010	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10811143	C4591001 1081 10811143	16-55	01SEP2020	75012	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10811145	C4591001 1081 10811145	16-55	01SEP2020	76361	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10811146	C4591001 1081 10811146	16-55	01SEP2020	76362	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10811147	C4591001 1081 10811147	16-55	01SEP2020	76367	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10811148	C4591001 1081 10811148	16-55	01SEP2020	76369	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10811160	C4591001 1081 10811160	16-55	02SEP2020	78498	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10811161	C4591001 1081 10811161	16-55	02SEP2020	78499	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811164	C4591001 1081 10811164	16-55	02SEP2020	78507	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10811172	C4591001 1081 10811172	16-55	03SEP2020	78508	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10811185	C4591001 1081 10811185	16-55	08SEP2020	83671	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10811186	C4591001 1081 10811186	16-55	08SEP2020	83673	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10811187	C4591001 1081 10811187	16-55	09SEP2020	83674	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10811190	C4591001 1081 10811190	16-55	10SEP2020	83675	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10811192	C4591001 1081 10811192	16-55	10SEP2020	86540	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10811193	C4591001 1081 10811193	16-55	10SEP2020	86542	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10811194	C4591001 1081 10811194	16-55	10SEP2020	86545	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
10811196	C4591001 1081 10811196	16-55	10SEP2020	86546	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10811197	C4591001 1081 10811197	16-55	11SEP2020	87714	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10811198	C4591001 1081 10811198	16-55	14SEP2020	87716	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10811199	C4591001 1081 10811199	16-55	14SEP2020	87722	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10811200	C4591001 1081 10811200	16-55	15SEP2020	87723	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10811206	C4591001 1081 10811206	16-55	17SEP2020	92214	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10811207	C4591001 1081 10811207	16-55	17SEP2020	92218	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10811209	C4591001 1081 10811209	16-55	17SEP2020	92220	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10811210	C4591001 1081 10811210	16-55	17SEP2020	92222	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10821013	C4591001 1082 10821013	16-55	03AUG2020	41498	Placebo				
10821111	C4591001 1082 10821111	16-55	17AUG2020	50247	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821113	C4591001 10821113	16-55	17AUG2020	50248	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821115	C4591001 10821115	16-55	18AUG2020	54595	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10821116	C4591001 10821116	16-55	18AUG2020	54596	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10821120	C4591001 10821120	16-55	20AUG2020	54600	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10821123	C4591001 10821123	16-55	21AUG2020	54604	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10821127	C4591001 10821127	16-55	24AUG2020	63453	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821128	C4591001 10821128	16-55	24AUG2020	63454	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10821129	C4591001 10821129	16-55	24AUG2020	63455	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10821130	C4591001 10821130	16-55	24AUG2020	63459	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10821136	C4591001 10821136	16-55	27AUG2020	70399	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821139	C4591001 1082 10821139	16-55	28AUG2020	70400	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10821140	C4591001 1082 10821140	16-55	28AUG2020	70402	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10821143	C4591001 1082 10821143	16-55	01SEP2020	70407	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10821145	C4591001 1082 10821145	16-55	02SEP2020	78007	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		
10821148	C4591001 1082 10821148	16-55	03SEP2020	78009	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10821149	C4591001 1082 10821149	16-55	03SEP2020	78011	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
10821150	C4591001 1082 10821150	16-55	03SEP2020	80552	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10821151	C4591001 1082 10821151	16-55	03SEP2020	78012	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10821154	C4591001 1082 10821154	16-55	08SEP2020	80554	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821156	C4591001 1082 10821156	16-55	10SEP2020	80557	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821158	C4591001 1082 10821158	16-55	14SEP2020	80560	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10821161	C4591001 1082 10821161	16-55	18SEP2020	93425	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821163	C4591001 1082 10821163	16-55	18SEP2020	93426	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10821168	C4591001 1082 10821168	16-55	21SEP2020	93431	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10821171	C4591001 1082 10821171	16-55	21SEP2020	93435	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo		
10821172	C4591001 1082 10821172	16-55	22SEP2020	96090	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821175	C4591001 1082 10821175	16-55	23SEP2020	96093	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10821178	C4591001 1082 10821178	16-55	24SEP2020	96095	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10821180	C4591001 1082 10821180	16-55	24SEP2020	96100	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10821183	C4591001 1082 10821183	16-55	25SEP2020	99631	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821185	C4591001 1082 10821185	16-55	25SEP2020	99633	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821186	C4591001 1082 10821186	16-55	25SEP2020	99635	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10821187	C4591001 1082 10821187	16-55	25SEP2020	99640	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10821188	C4591001 1082 10821188	16-55	08OCT2020	105281	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821194	C4591001 1082 10821194	16-55	09OCT2020	106025	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10821195	C4591001 1082 10821195	16-55	09OCT2020	105284	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10821196	C4591001 1082 10821196	16-55	09OCT2020	105290	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10821197	C4591001 1082 10821197	16-55	12OCT2020	106026	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10821198	C4591001 1082 10821198	16-55	14OCT2020	106032	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10821199	C4591001 1082 10821199	16-55	15OCT2020	106036	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821201	C4591001 10821082 10821201	16-55	19OCT2020	110299	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10821202	C4591001 10821082 10821202	16-55	19OCT2020	110297	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10821203	C4591001 10821082 10821203	16-55	20OCT2020	110304	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10821204	C4591001 10821082 10821204	16-55	20OCT2020	110306	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10821207	C4591001 10821082 10821207	16-55	20OCT2020	111089	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821208	C4591001 10821082 10821208	16-55	21OCT2020	111092	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10821210	C4591001 10821082 10821210	16-55	22OCT2020	111095	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10821211	C4591001 10821082 10821211	16-55	27OCT2020	111097	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10821212	C4591001 10821082 10821212	16-55	28OCT2020	114332	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10821215	C4591001 10821082 10821215	16-55	29OCT2020	114336	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10821216	C4591001 1082 10821216	16-55	29OCT2020	114338	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10821217	C4591001 1082 10821217	16-55	30OCT2020	114340	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10821218	C4591001 1082 10821218	16-55	30OCT2020	115038	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10821220	C4591001 1082 10821220	16-55	30OCT2020	115040	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10821221	C4591001 1082 10821221	16-55	30OCT2020	115044	Placebo	30OCT2020/ Placebo		12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10821224	C4591001 1082 10821224	16-55	30OCT2020	115046	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo		
10831105	C4591001 1083 10831105	16-55	17AUG2020	52365	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831106	C4591001 1083 10831106	16-55	17AUG2020	52368	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10831112	C4591001 1083 10831112	16-55	17AUG2020	52369	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10831113	C4591001 1083 10831113	16-55	18AUG2020	52371	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831118	C4591001 1083 10831118	16-55	18AUG2020	54641	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10831119	C4591001 1083 10831119	16-55	18AUG2020	54642	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831122	C4591001 1083 10831122	16-55	19AUG2020	54650	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831123	C4591001 1083 10831123	16-55	19AUG2020	54652	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10831124	C4591001 1083 10831124	16-55	19AUG2020	57487	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831127	C4591001 1083 10831127	16-55	20AUG2020	57494	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10831128	C4591001 1083 10831128	16-55	20AUG2020	57495	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831130	C4591001 1083 10831130	16-55	20AUG2020	57496	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831132	C4591001 1083 10831132	16-55	20AUG2020	58577	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10831133	C4591001 1083 10831133	16-55	20AUG2020	58584	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831136	C4591001 1083 10831136	16-55	20AUG2020	58585	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831139	C4591001 1083 10831139	16-55	21AUG2020	61233	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10831140	C4591001 1083 10831140	16-55	21AUG2020	58587	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10831141	C4591001 1083 10831141	16-55	21AUG2020	61236	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			
10831142	C4591001 1083 10831142	16-55	24AUG2020	61238	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831143	C4591001 1083 10831143	16-55	24AUG2020	61240	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831145	C4591001 1083 10831145	16-55	24AUG2020	64061	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831148	C4591001 1083 10831148	16-55	24AUG2020	64066	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831152	C4591001 1083 10831152	16-55	25AUG2020	64067	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10831153	C4591001 1083 10831153	16-55	25AUG2020	64069	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831154	C4591001 1083 10831154	16-55	25AUG2020	66297	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
10831160	C4591001 1083 10831160	16-55	26AUG2020	66298	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10831161	C4591001 1083 10831161	16-55	26AUG2020	66301	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831162	C4591001 1083 10831162	16-55	26AUG2020	66304	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10831163	C4591001 1083 10831163	16-55	26AUG2020	68505	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10831164	C4591001 1083 10831164	16-55	26AUG2020	68508	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10831166	C4591001 1083 10831166	16-55	26AUG2020	68510	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10831169	C4591001 1083 10831169	16-55	27AUG2020	68512	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10831170	C4591001 1083 10831170	16-55	27AUG2020	70457	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10831171	C4591001 1083 10831171	16-55	27AUG2020	70464	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831174	C4591001 1083 10831174	16-55	27AUG2020	70466	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10831178	C4591001 1083 10831178	16-55	31AUG2020	70468	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831179	C4591001 1083 10831179	16-55	31AUG2020	75463	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10831181	C4591001 1083 10831181	16-55	31AUG2020	75465	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10831183	C4591001 1083 10831183	16-55	01SEP2020	75466	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10831185	C4591001 1083 10831185	16-55	01SEP2020	75467	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10831186	C4591001 1083 10831186	16-55	02SEP2020	77957	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10831187	C4591001 1083 10831187	16-55	02SEP2020	77963	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10831188	C4591001 1083 10831188	16-55	03SEP2020	77965	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10831191	C4591001 1083 10831191	16-55	04SEP2020	77967	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831194	C4591001 1083 10831194	16-55	04SEP2020	81918	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10831197	C4591001 1083 10831197	16-55	04SEP2020	81921	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10831198	C4591001 1083 10831198	16-55	09SEP2020	81922	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10831201	C4591001 1083 10831201	16-55	09SEP2020	81928	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo		
10831203	C4591001 1083 10831203	16-55	09SEP2020	86153	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10831205	C4591001 1083 10831205	16-55	09SEP2020	86158	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10831207	C4591001 1083 10831207	16-55	10SEP2020	86161	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831210	C4591001 1083 10831210	16-55	10SEP2020	86164	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831212	C4591001 1083 10831212	16-55	10SEP2020	87069	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10831214	C4591001 1083 10831214	16-55	10SEP2020	87072	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831219	C4591001 1083 10831219	16-55	10SEP2020	87074	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831221	C4591001 1083 10831221	16-55	10SEP2020	87076	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831222	C4591001 1083 10831222	16-55	10SEP2020	87701	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831223	C4591001 1083 10831223	16-55	10SEP2020	87705	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831227	C4591001 1083 10831227	16-55	11SEP2020	87707	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10831232	C4591001 1083 10831232	16-55	11SEP2020	87712	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831235	C4591001 1083 10831235	16-55	11SEP2020	88709	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831240	C4591001 1083 10831240	16-55	11SEP2020	88711	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831241	C4591001 1083 10831241	16-55	11SEP2020	88717	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10831242	C4591001 1083 10831242	16-55	11SEP2020	88714	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831244	C4591001 1083 10831244	16-55	11SEP2020	88954	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831245	C4591001 1083 10831245	16-55	11SEP2020	88953	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10831247	C4591001 1083 10831247	16-55	11SEP2020	88957	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831249	C4591001 1083 10831249	16-55	11SEP2020	88959	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831250	C4591001 1083 10831250	16-55	11SEP2020	89009	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10831252	C4591001 1083 10831252	16-55	22SEP2020	89016	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
10831253	C4591001 1083 10831253	16-55	22SEP2020	89011	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10831254	C4591001 1083 10831254	16-55	22SEP2020	89017	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10831255	C4591001 1083 10831255	16-55	22SEP2020	97039	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10831256	C4591001 1083 10831256	16-55	23SEP2020	97040	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831259	C4591001 1083 10831259	16-55	24SEP2020	97042	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10831262	C4591001 1083 10831262	16-55	24SEP2020	97045	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10831264	C4591001 1083 10831264	16-55	24SEP2020	99114	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10831265	C4591001 1083 10831265	16-55	24SEP2020	99115	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831266	C4591001 1083 10831266	16-55	25SEP2020	99117	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10831267	C4591001 1083 10831267	16-55	25SEP2020	99122	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10831268	C4591001 1083 10831268	16-55	25SEP2020	100422	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10831270	C4591001 1083 10831270	16-55	21OCT2020	100424	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10831271	C4591001 1083 10831271	16-55	21OCT2020	100431	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10831272	C4591001 1083 10831272	16-55	21OCT2020	100429	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10831273	C4591001 1083 10831273	16-55	21OCT2020	111657	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10831276	C4591001 1083 10831276	16-55	21OCT2020	111658	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10831278	C4591001 1083 10831278	16-55	21OCT2020	111659	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10831279	C4591001 1083 10831279	16-55	22OCT2020	111660	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
10831281	C4591001 1083 10831281	16-55	22OCT2020	112399	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10831282	C4591001 1083 10831282	16-55	22OCT2020	112400	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10831284	C4591001 1083 10831284	16-55	22OCT2020	112402	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10841170	C4591001 1084 10841170	16-55	14AUG2020	50306	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10841185	C4591001 1084 10841185	16-55	14AUG2020	50886	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
10841187	C4591001 1084 10841187	16-55	14AUG2020	50894	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841188	C4591001 1084 10841188	16-55	14AUG2020	50948	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841189	C4591001 1084 10841189	16-55	17AUG2020	50952	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10841197	C4591001 1084 10841197	16-55	17AUG2020	50955	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10841199	C4591001 1084 10841199	16-55	17AUG2020	52687	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10841200	C4591001 1084 10841200	16-55	17AUG2020	50956	Placebo	17AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10841201	C4591001 1084 10841201	16-55	17AUG2020	52689	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841208	C4591001 1084 10841208	16-55	17AUG2020	52693	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841209	C4591001 1084 10841209	16-55	17AUG2020	52692	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10841214	C4591001 1084 10841214	16-55	17AUG2020	53277	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841215	C4591001 1084 10841215	16-55	17AUG2020	53274	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841220	C4591001 1084 10841220	16-55	17AUG2020	53278	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841222	C4591001 1084 10841222	16-55	19AUG2020	53282	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841223	C4591001 1084 10841223	16-55	19AUG2020	56166	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841228	C4591001 1084 10841228	16-55	19AUG2020	56167	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841234	C4591001 1084 10841234	16-55	19AUG2020	56170	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841241	C4591001 1084 10841241	16-55	19AUG2020	56173	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10841249	C4591001 1084 10841249	16-55	22AUG2020	61857	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841251	C4591001 1084 10841251	16-55	22AUG2020	61858	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841254	C4591001 1084 10841254	16-55	22AUG2020	61864	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841255	C4591001 1084 10841255	16-55	22AUG2020	61855	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841259	C4591001 1084 10841259	16-55	22AUG2020	61999	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841262	C4591001 1084 10841262	16-55	22AUG2020	62001	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10841267	C4591001 1084 10841267	16-55	22AUG2020	62178	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10841268	C4591001 1084 10841268	16-55	22AUG2020	62006	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10841269	C4591001 1084 10841269	16-55	22AUG2020	62002	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841270	C4591001 1084 10841270	16-55	22AUG2020	62184	Placebo	22AUG2020/ Placebo	18SEP2020/ Placebo		
10841272	C4591001 1084 10841272	16-55	22AUG2020	62337	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
10841273	C4591001 1084 10841273	16-55	22AUG2020	62185	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841274	C4591001 1084 10841274	16-55	22AUG2020	62340	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841275	C4591001 1084 10841275	16-55	22AUG2020	62339	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841277	C4591001 1084 10841277	16-55	22AUG2020	62187	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10841279	C4591001 1084 10841279	16-55	24AUG2020	63822	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10841280	C4591001 1084 10841280	16-55	24AUG2020	62344	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841281	C4591001 1084 10841281	16-55	24AUG2020	63828	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841283	C4591001 1084 10841283	16-55	24AUG2020	63830	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841285	C4591001 1084 10841285	16-55	24AUG2020	64505	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841286	C4591001 1084 10841286	16-55	24AUG2020	64631	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841287	C4591001 1084 10841287	16-55	24AUG2020	64506	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841288	C4591001 1084 10841288	16-55	24AUG2020	64513	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841290	C4591001 1084 10841290	16-55	24AUG2020	63832	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841291	C4591001 1084 10841291	16-55	24AUG2020	64509	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841292	C4591001 1084 10841292	16-55	24AUG2020	64627	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10841294	C4591001 1084 10841294	16-55	26AUG2020	64633	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10841301	C4591001 1084 10841301	16-55	26AUG2020	64635	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841303	C4591001 1084 10841303	16-55	26AUG2020	68873	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10841306	C4591001 1084 10841306	16-55	26AUG2020	68882	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
10841307	C4591001 1084 10841307	16-55	26AUG2020	68877	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10841308	C4591001 1084 10841308	16-55	28AUG2020	72057	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10841309	C4591001 1084 10841309	16-55	28AUG2020	68883	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10841311	C4591001 1084 10841311	16-55	28AUG2020	72058	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841312	C4591001 1084 10841312	16-55	28AUG2020	72062	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10841315	C4591001 1084 10841315	16-55	28AUG2020	72473	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10841316	C4591001 1084 10841316	16-55	28AUG2020	72064	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841317	C4591001 1084 10841317	16-55	28AUG2020	72478	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841318	C4591001 1084 10841318	16-55	28AUG2020	72481	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10841321	C4591001 1084 10841321	16-55	31AUG2020	72482	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841322	C4591001 1084 10841322	16-55	31AUG2020	74911	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10841324	C4591001 1084 10841324	16-55	31AUG2020	74912	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841327	C4591001 1084 10841327	16-55	31AUG2020	74913	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10841328	C4591001 1084 10841328	16-55	31AUG2020	74916	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841330	C4591001 1084 10841330	16-55	31AUG2020	75527	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10841333	C4591001 1084 10841333	16-55	31AUG2020	75528	Placebo	31AUG2020/ Placebo	02OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841334	C4591001 1084 10841334	16-55	31AUG2020	75529	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10841338	C4591001 1084 10841338	16-55	02SEP2020	78426	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10841339	C4591001 1084 10841339	16-55	02SEP2020	75530	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841342	C4591001 1084 10841342	16-55	02SEP2020	78429	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10841344	C4591001 1084 10841344	16-55	02SEP2020	78430	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841346	C4591001 1084 10841346	16-55	04SEP2020	78436	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10841348	C4591001 1084 10841348	16-55	04SEP2020	81773	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841350	C4591001 1084 10841350	16-55	04SEP2020	81774	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841351	C4591001 1084 10841351	16-55	04SEP2020	81784	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841352	C4591001 1084 10841352	16-55	04SEP2020	81778	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841353	C4591001 1084 10841353	16-55	04SEP2020	82266	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841355	C4591001 1084 10841355	16-55	04SEP2020	82272	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10841356	C4591001 1084 10841356	16-55	04SEP2020	82269	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841358	C4591001 1084 10841358	16-55	09SEP2020	82276	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
10841359	C4591001 1084 10841359	16-55	09SEP2020	85013	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841365	C4591001 1084 10841365	16-55	09SEP2020	85017	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841371	C4591001 1084 10841371	16-55	09SEP2020	85020	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
10841372	C4591001 1084 10841372	16-55	11SEP2020	85023	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841373	C4591001 1084 10841373	16-55	11SEP2020	88044	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10841374	C4591001 1084 10841374	16-55	11SEP2020	88041	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841375	C4591001 1084 10841375	16-55	11SEP2020	88046	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10841376	C4591001 1084 10841376	16-55	11SEP2020	88048	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10841378	C4591001 1084 10841378	16-55	11SEP2020	88325	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841381	C4591001 1084 10841381	16-55	11SEP2020	88336	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10841382	C4591001 1084 10841382	16-55	11SEP2020	88329	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
10841384	C4591001 1084 10841384	16-55	11SEP2020	88331	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841385	C4591001 1084 10841385	16-55	11SEP2020	88722	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841386	C4591001 1084 10841386	16-55	11SEP2020	88727	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841388	C4591001 1084 10841388	16-55	11SEP2020	88729	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10841390	C4591001 1084 10841390	16-55	14SEP2020	88732	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841391	C4591001 1084 10841391	16-55	14SEP2020	89525	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841393	C4591001 1084 10841393	16-55	14SEP2020	89528	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10841394	C4591001 1084 10841394	16-55	14SEP2020	89534	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841396	C4591001 1084 10841396	16-55	14SEP2020	89536	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841402	C4591001 1084 10841402	16-55	14SEP2020	89969	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10841404	C4591001 1084 10841404	16-55	14SEP2020	89971	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841405	C4591001 1084 10841405	16-55	23SEP2020	97472	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10841407	C4591001 1084 10841407	16-55	16SEP2020	89975	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841409	C4591001 1084 10841409	16-55	16SEP2020	89977	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
10841410	C4591001 1084 10841410	16-55	16SEP2020	91409	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10841413	C4591001 1084 10841413	16-55	16SEP2020	91414	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10841416	C4591001 1084 10841416	16-55	18SEP2020	91419	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841417	C4591001 1084 10841417	16-55	18SEP2020	93633	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10841418	C4591001 1084 10841418	16-55	18SEP2020	91420	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10841420	C4591001 1084 10841420	16-55	18SEP2020	93634	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841422	C4591001 1084 10841422	16-55	18SEP2020	93635	Placebo	18SEP2020/ Placebo	21OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841423	C4591001 1084 10841423	16-55	18SEP2020	93977	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10841425	C4591001 1084 10841425	16-55	18SEP2020	93639	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841426	C4591001 1084 10841426	16-55	18SEP2020	93982	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10841428	C4591001 1084 10841428	16-55	18SEP2020	93984	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841429	C4591001 1084 10841429	16-55	21SEP2020	93985	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841431	C4591001 1084 10841431	16-55	21SEP2020	95121	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10841432	C4591001 1084 10841432	16-55	21SEP2020	95120	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10841433	C4591001 1084 10841433	16-55	21SEP2020	95433	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841434	C4591001 1084 10841434	16-55	21SEP2020	95126	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841435	C4591001 1084 10841435	16-55	21SEP2020	95124	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10841436	C4591001 1084 10841436	16-55	21SEP2020	95435	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841437	C4591001 1084 10841437	16-55	21SEP2020	95438	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841438	C4591001 1084 10841438	16-55	21SEP2020	95440	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10841439	C4591001 1084 10841439	16-55	23SEP2020	97469	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo		
10841441	C4591001 1084 10841441	16-55	23SEP2020	97473	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841442	C4591001 1084 10841442	16-55	23SEP2020	97476	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10841448	C4591001 1084 10841448	16-55	23SEP2020	98156	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841449	C4591001 1084 10841449	16-55	23SEP2020	98153	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841450	C4591001 1084 10841450	16-55	25SEP2020	98164	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
10841452	C4591001 1084 10841452	16-55	25SEP2020	98157	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841454	C4591001 1084 10841454	16-55	25SEP2020	99941	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841456	C4591001 1084 10841456	16-55	25SEP2020	99945	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841457	C4591001 1084 10841457	16-55	25SEP2020	99943	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841458	C4591001 1084 10841458	16-55	25SEP2020	99950	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10841461	C4591001 1084 10841461	16-55	25SEP2020	100508	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
10841462	C4591001 1084 10841462	16-55	28SEP2020	100509	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10841464	C4591001 1084 10841464	16-55	28SEP2020	100515	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841465	C4591001 1084 10841465	16-55	28SEP2020	100511	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10841466	C4591001 1084 10841466	16-55	28SEP2020	101479	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10841468	C4591001 1084 10841468	16-55	28SEP2020	101482	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10841469	C4591001 1084 10841469	16-55	28SEP2020	101486	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841474	C4591001 1084 10841474	16-55	12OCT2020	101487	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841479	C4591001 1084 10841479	16-55	14OCT2020	107513	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841480	C4591001 1084 10841480	16-55	14OCT2020	107519	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
10841481	C4591001 1084 10841481	16-55	14OCT2020	107514	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10841484	C4591001 1084 10841484	16-55	14OCT2020	107730	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841486	C4591001 1084 10841486	16-55	14OCT2020	107522	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841488	C4591001 1084 10841488	16-55	16OCT2020	107734	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841489	C4591001 1084 10841489	16-55	16OCT2020	107736	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10841492	C4591001 1084 10841492	16-55	16OCT2020	109184	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10841493	C4591001 1084 10841493	16-55	16OCT2020	109192	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10841494	C4591001 1084 10841494	16-55	16OCT2020	107740	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841495	C4591001 1084 10841495	16-55	16OCT2020	109187	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841496	C4591001 1084 10841496	16-55	16OCT2020	109186	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841499	C4591001 1084 10841499	16-55	16OCT2020	109307	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10841500	C4591001 1084 10841500	16-55	16OCT2020	109308	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10841502	C4591001 1084 10841502	16-55	19OCT2020	109309	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10841503	C4591001 1084 10841503	16-55	19OCT2020	109312	Placebo	19OCT2020/ Placebo	16NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10841506	C4591001 1084 10841506	16-55	19OCT2020	110550	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841509	C4591001 1084 10841509	16-55	19OCT2020	110558	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841511	C4591001 1084 10841511	16-55	19OCT2020	110551	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841512	C4591001 1084 10841512	16-55	21OCT2020	110560	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841513	C4591001 1084 10841513	16-55	21OCT2020	111510	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841514	C4591001 1084 10841514	16-55	21OCT2020	111515	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10841517	C4591001 1084 10841517	16-55	21OCT2020	111516	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10841518	C4591001 1084 10841518	16-55	21OCT2020	111629	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841519	C4591001 1084 10841519	16-55	21OCT2020	111518	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841520	C4591001 1084 10841520	16-55	23OCT2020	111630	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10841521	C4591001 1084 10841521	16-55	23OCT2020	111631	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10841522	C4591001 1084 10841522	16-55	19NOV2020	272881	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10841526	C4591001 1084 10841526	16-55	23OCT2020	111633	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10841530	C4591001 1084 10841530	16-55	23OCT2020	113219	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10841532	C4591001 1084 10841532	16-55	23OCT2020	113221	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10841533	C4591001 1084 10841533	16-55	26OCT2020	113222	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10841535	C4591001 1084 10841535	16-55	26OCT2020	113223	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10841536	C4591001 1084 10841536	16-55	28OCT2020	114546	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10841537	C4591001 1084 10841537	16-55	30OCT2020	114549	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10841538	C4591001 1084 10841538	16-55	06NOV2020	114554	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
10841539	C4591001 1084 10841539	16-55	11NOV2020	114555	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10841540	C4591001 1084 10841540	16-55	20NOV2020	116598	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
10851104	C4591001 1085 10851104	16-55	17AUG2020	52866	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10851108	C4591001 1085 10851108	16-55	17AUG2020	52875	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851109	C4591001 1085 10851109	16-55	17AUG2020	52874	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10851110	C4591001 1085 10851110	16-55	17AUG2020	52876	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10851112	C4591001 1085 10851112	16-55	17AUG2020	53586	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10851114	C4591001 1085 10851114	16-55	18AUG2020	53588	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851124	C4591001 1085 10851124	16-55	18AUG2020	53592	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851125	C4591001 1085 10851125	16-55	18AUG2020	55269	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10851127	C4591001 1085 10851127	16-55	18AUG2020	55270	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10851128	C4591001 1085 10851128	16-55	18AUG2020	53596	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10851129	C4591001 1085 10851129	16-55	18AUG2020	55274	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10851132	C4591001 1085 10851132	16-55	20AUG2020	55276	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851136	C4591001 1085 10851136	16-55	21AUG2020	60488	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10851137	C4591001 1085 10851137	16-55	21AUG2020	60493	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
10851140	C4591001 1085 10851140	16-55	24AUG2020	60495	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10851141	C4591001 1085 10851141	16-55	24AUG2020	60496	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10851142	C4591001 1085 10851142	16-55	24AUG2020	63643	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851143	C4591001 1085 10851143	16-55	24AUG2020	63642	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10851153	C4591001 1085 10851153	16-55	10SEP2020	87009	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851155	C4591001 1085 10851155	16-55	24AUG2020	63646	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10851157	C4591001 1085 10851157	16-55	24AUG2020	64770	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10851158	C4591001 1085 10851158	16-55	24AUG2020	64771	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851159	C4591001 1085 10851159	16-55	25AUG2020	64775	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851163	C4591001 1085 10851163	16-55	25AUG2020	65971	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851164	C4591001 1085 10851164	16-55	25AUG2020	64777	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851165	C4591001 1085 10851165	16-55	25AUG2020	65972	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10851170	C4591001 1085 10851170	16-55	25AUG2020	65976	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10851175	C4591001 1085 10851175	16-55	25AUG2020	66848	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851178	C4591001 1085 10851178	16-55	26AUG2020	66849	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	
10851179	C4591001 1085 10851179	16-55	26AUG2020	66850	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851180	C4591001 1085 10851180	16-55	26AUG2020	66854	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10851188	C4591001 1085 10851188	16-55	26AUG2020	69103	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851189	C4591001 1085 10851189	16-55	26AUG2020	69101	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851191	C4591001 1085 10851191	16-55	26AUG2020	69105	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10851193	C4591001 1085 10851193	16-55	27AUG2020	69111	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10851195	C4591001 1085 10851195	16-55	27AUG2020	70651	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10851196	C4591001 1085 10851196	16-55	27AUG2020	70653	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851200	C4591001 1085 10851200	16-55	29AUG2020	70659	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10851203	C4591001 1085 10851203	16-55	29AUG2020	73855	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10851206	C4591001 1085 10851206	16-55	31AUG2020	73857	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10851210	C4591001 1085 10851210	16-55	31AUG2020	73858	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		
10851211	C4591001 1085 10851211	16-55	31AUG2020	73861	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851212	C4591001 1085 10851212	16-55	31AUG2020	75317	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10851217	C4591001 1085 10851217	16-55	31AUG2020	75318	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10851219	C4591001 1085 10851219	16-55	31AUG2020	75325	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10851221	C4591001 1085 10851221	16-55	01SEP2020	75327	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10851225	C4591001 1085 10851225	16-55	01SEP2020	76891	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10851229	C4591001 1085 10851229	16-55	01SEP2020	76892	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10851231	C4591001 1085 10851231	16-55	01SEP2020	76893	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10851236	C4591001 1085 10851236	16-55	01SEP2020	76897	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10851237	C4591001 1085 10851237	16-55	01SEP2020	77709	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10851238	C4591001 1085 10851238	16-55	02SEP2020	77710	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851239	C4591001 1085 10851239	16-55	02SEP2020	77712	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851240	C4591001 1085 10851240	16-55	02SEP2020	77713	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851242	C4591001 1085 10851242	16-55	02SEP2020	78295	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851244	C4591001 1085 10851244	16-55	02SEP2020	78298	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10851245	C4591001 1085 10851245	16-55	02SEP2020	78301	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10851246	C4591001 1085 10851246	16-55	02SEP2020	78304	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10851248	C4591001 1085 10851248	16-55	02SEP2020	79207	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10851249	C4591001 1085 10851249	16-55	02SEP2020	79213	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10851250	C4591001 1085 10851250	16-55	03SEP2020	79214	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10851252	C4591001 1085 10851252	16-55	03SEP2020	79215	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851253	C4591001 1085 10851253	16-55	03SEP2020	80491	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10851256	C4591001 1085 10851256	16-55	03SEP2020	80493	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10851259	C4591001 1085 10851259	16-55	03SEP2020	80496	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10851261	C4591001 1085 10851261	16-55	04SEP2020	80499	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851264	C4591001 1085 10851264	16-55	08SEP2020	83477	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10851265	C4591001 1085 10851265	16-55	08SEP2020	83478	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851269	C4591001 1085 10851269	16-55	08SEP2020	83482	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851270	C4591001 1085 10851270	16-55	08SEP2020	83485	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851276	C4591001 1085 10851276	16-55	08SEP2020	84047	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851277	C4591001 1085 10851277	16-55	08SEP2020	84048	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851280	C4591001 1085 10851280	16-55	08SEP2020	84595	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851281	C4591001 1085 10851281	16-55	08SEP2020	84052	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851283	C4591001 1085 10851283	16-55	09SEP2020	84596	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10851284	C4591001 1085 10851284	16-55	09SEP2020	84602	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851285	C4591001 1085 10851285	16-55	09SEP2020	84604	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10851286	C4591001 1085 10851286	16-55	09SEP2020	85518	Placebo	09SEP2020/ Placebo			
10851287	C4591001 1085 10851287	16-55	09SEP2020	85520	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo		
10851290	C4591001 1085 10851290	16-55	09SEP2020	85522	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10851291	C4591001 1085 10851291	16-55	09SEP2020	85528	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10851294	C4591001 1085 10851294	16-55	09SEP2020	86021	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851296	C4591001 1085 10851296	16-55	09SEP2020	86024	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10851298	C4591001 1085 10851298	16-55	10SEP2020	86027	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851299	C4591001 1085 10851299	16-55	10SEP2020	86031	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10851300	C4591001 1085 10851300	16-55	10SEP2020	87007	Placebo	10SEP2020/ Placebo	12OCT2020/ Placebo		
10851302	C4591001 1085 10851302	16-55	10SEP2020	87011	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10851304	C4591001 1085 10851304	16-55	10SEP2020	87014	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10851305	C4591001 1085 10851305	16-55	10SEP2020	87583	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10851307	C4591001 1085 10851307	16-55	10SEP2020	87586	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10851308	C4591001 1085 10851308	16-55	11SEP2020	87587	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10851309	C4591001 1085 10851309	16-55	11SEP2020	87930	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851310	C4591001 1085 10851310	16-55	11SEP2020	87589	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851312	C4591001 1085 10851312	16-55	11SEP2020	87931	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851314	C4591001 1085 10851314	16-55	11SEP2020	87937	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10851316	C4591001 1085 10851316	16-55	11SEP2020	87935	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10851320	C4591001 1085 10851320	16-55	11SEP2020	88702	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10851321	C4591001 1085 10851321	16-55	11SEP2020	88703	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10851323	C4591001 1085 10851323	16-55	11SEP2020	88704	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851325	C4591001 1085 10851325	16-55	14SEP2020	88707	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851327	C4591001 1085 10851327	16-55	14SEP2020	89741	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10851328	C4591001 1085 10851328	16-55	14SEP2020	89744	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851330	C4591001 1085 10851330	16-55	14SEP2020	89745	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851332	C4591001 1085 10851332	16-55	14SEP2020	89750	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
10851336	C4591001 1085 10851336	16-55	15SEP2020	90432	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851337	C4591001 1085 10851337	16-55	15SEP2020	90426	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10851339	C4591001 1085 10851339	16-55	15SEP2020	90435	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10851341	C4591001 1085 10851341	16-55	15SEP2020	90436	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10851342	C4591001 1085 10851342	16-55	15SEP2020	90836	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851343	C4591001 1085 10851343	16-55	15SEP2020	90838	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10851344	C4591001 1085 10851344	16-55	16SEP2020	90842	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851345	C4591001 1085 10851345	16-55	16SEP2020	90843	Placebo	16SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851346	C4591001 1085 10851346	16-55	16SEP2020	91579	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10851349	C4591001 1085 10851349	16-55	16SEP2020	91583	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10851350	C4591001 1085 10851350	16-55	16SEP2020	91584	Placebo	16SEP2020/ Placebo	19OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10851352	C4591001 1085 10851352	16-55	17SEP2020	91585	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10851354	C4591001 1085 10851354	16-55	28SEP2020	101430	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10851355	C4591001 1085 10851355	16-55	29SEP2020	101432	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10851356	C4591001 1085 10851356	16-55	29SEP2020	101436	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10851357	C4591001 1085 10851357	16-55	30SEP2020	101437	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10851358	C4591001 1085 10851358	16-55	05OCT2020	103747	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10851359	C4591001 1085 10851359	16-55	05OCT2020	103752	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851361	C4591001 1085 10851361	16-55	05OCT2020	103753	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10851362	C4591001 1085 10851362	16-55	05OCT2020	103756	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10851363	C4591001 1085 10851363	16-55	06OCT2020	104357	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10851364	C4591001 1085 10851364	16-55	06OCT2020	104361	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10851365	C4591001 1085 10851365	16-55	06OCT2020	104363	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851366	C4591001 1085 10851366	16-55	08OCT2020	104365	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10851367	C4591001 1085 10851367	16-55	08OCT2020	105557	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10851368	C4591001 1085 10851368	16-55	12OCT2020	105558	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10851369	C4591001 1085 10851369	16-55	12OCT2020	105563	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10851370	C4591001 1085 10851370	16-55	12OCT2020	105566	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10851371	C4591001 1085 10851371	16-55	13OCT2020	107034	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
10851372	C4591001 1085 10851372	16-55	13OCT2020	107037	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10851373	C4591001 1085 10851373	16-55	29OCT2020	107039	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10851374	C4591001 1085 10851374	16-55	29OCT2020	107041	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
10851375	C4591001 1085 10851375	16-55	29OCT2020	114857	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10871083	C4591001 1087 10871083	16-55	17AUG2020	46887	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10871084	C4591001 1087 10871084	16-55	17AUG2020	46886	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871085	C4591001 1087 10871085	16-55	17AUG2020	52403	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
10871086	C4591001 1087 10871086	16-55	17AUG2020	52407	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871087	C4591001 1087 10871087	16-55	17AUG2020	52408	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871088	C4591001 1087 10871088	16-55	17AUG2020	52406	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871089	C4591001 1087 10871089	16-55	17AUG2020	52589	Placebo	17AUG2020/ Placebo			
10871092	C4591001 1087 10871092	16-55	17AUG2020	52590	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871094	C4591001 1087 10871094	16-55	18AUG2020	52599	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871095	C4591001 1087 10871095	16-55	18AUG2020	52597	Placebo	18AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871096	C4591001 1087 10871096	16-55	18AUG2020	53837	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10871102	C4591001 1087 10871102	16-55	18AUG2020	53840	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871103	C4591001 1087 10871103	16-55	18AUG2020	53841	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871104	C4591001 1087 10871104	16-55	18AUG2020	53842	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871107	C4591001 1087 10871107	16-55	18AUG2020	54655	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871108	C4591001 1087 10871108	16-55	18AUG2020	54654	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
10871109	C4591001 1087 10871109	16-55	18AUG2020	54657	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871110	C4591001 1087 10871110	16-55	18AUG2020	54659	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871111	C4591001 1087 10871111	16-55	18AUG2020	54954	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
10871113	C4591001 1087 10871113	16-55	18AUG2020	54956	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10871114	C4591001 1087 10871114	16-55	19AUG2020	54957	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871118	C4591001 1087 10871118	16-55	19AUG2020	54961	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10871119	C4591001 1087 10871119	16-55	19AUG2020	56576	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10871120	C4591001 1087 10871120	16-55	19AUG2020	56574	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871127	C4591001 1087 10871127	16-55	20AUG2020	56577	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871135	C4591001 1087 10871135	16-55	20AUG2020	56583	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10871138	C4591001 1087 10871138	16-55	20AUG2020	58613	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871146	C4591001 1087 10871146	16-55	20AUG2020	58614	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871148	C4591001 1087 10871148	16-55	20AUG2020	58618	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10871149	C4591001 1087 10871149	16-55	21AUG2020	58622	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10871151	C4591001 1087 10871151	16-55	21AUG2020	60319	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10871152	C4591001 1087 10871152	16-55	21AUG2020	60317	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10871153	C4591001 1087 10871153	16-55	21AUG2020	60318	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871160	C4591001 1087 10871160	16-55	21AUG2020	60321	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10871166	C4591001 1087 10871166	16-55	24AUG2020	63318	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871171	C4591001 1087 10871171	16-55	24AUG2020	63321	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871172	C4591001 1087 10871172	16-55	24AUG2020	63322	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10871179	C4591001 1087 10871179	16-55	24AUG2020	63328	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10871180	C4591001 1087 10871180	16-55	24AUG2020	64399	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10871181	C4591001 1087 10871181	16-55	24AUG2020	64402	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10871182	C4591001 1087 10871182	16-55	24AUG2020	64403	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871186	C4591001 1087 10871186	16-55	25AUG2020	64407	Placebo	25AUG2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871189	C4591001 1087 10871189	16-55	25AUG2020	65288	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10871191	C4591001 1087 10871191	16-55	25AUG2020	65289	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871194	C4591001 1087 10871194	16-55	25AUG2020	65295	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871195	C4591001 1087 10871195	16-55	25AUG2020	65293	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10871196	C4591001 1087 10871196	16-55	25AUG2020	65768	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10871201	C4591001 1087 10871201	16-55	25AUG2020	65770	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10871205	C4591001 1087 10871205	16-55	25AUG2020	65772	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10871209	C4591001 1087 10871209	16-55	25AUG2020	66389	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10871212	C4591001 1087 10871212	16-55	25AUG2020	66391	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10871213	C4591001 1087 10871213	16-55	26AUG2020	66394	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871214	C4591001 1087 10871214	16-55	26AUG2020	66396	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10871215	C4591001 1087 10871215	16-55	26AUG2020	67256	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10871225	C4591001 1087 10871225	16-55	26AUG2020	67260	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871230	C4591001 1087 10871230	16-55	26AUG2020	67261	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871231	C4591001 1087 10871231	16-55	26AUG2020	67264	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10871235	C4591001 1087 10871235	16-55	26AUG2020	68298	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
10871239	C4591001 1087 10871239	16-55	26AUG2020	68302	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10871241	C4591001 1087 10871241	16-55	26AUG2020	68305	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10871243	C4591001 1087 10871243	16-55	26AUG2020	68308	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10871244	C4591001 1087 10871244	16-55	26AUG2020	68993	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871247	C4591001 1087 10871247	16-55	27AUG2020	68996	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10871248	C4591001 1087 10871248	16-55	27AUG2020	69001	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10871252	C4591001 1087 10871252	16-55	28AUG2020	69003	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871265	C4591001 1087 10871265	16-55	31AUG2020	75992	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10871267	C4591001 1087 10871267	16-55	31AUG2020	75993	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10871276	C4591001 1087 10871276	16-55	01SEP2020	75994	Placebo	01SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871279	C4591001 1087 10871279	16-55	01SEP2020	75995	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10871282	C4591001 1087 10871282	16-55	01SEP2020	76759	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10871285	C4591001 1087 10871285	16-55	01SEP2020	76763	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10871293	C4591001 1087 10871293	16-55	01SEP2020	76765	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10871296	C4591001 1087 10871296	16-55	01SEP2020	249020	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10871297	C4591001 1087 10871297	16-55	02SEP2020	76766	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871299	C4591001 1087 10871299	16-55	02SEP2020	77802	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871301	C4591001 1087 10871301	16-55	02SEP2020	77803	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10871308	C4591001 1087 10871308	16-55	02SEP2020	77809	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10871310	C4591001 1087 10871310	16-55	02SEP2020	77812	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871314	C4591001 1087 10871314	16-55	02SEP2020	79038	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10871316	C4591001 1087 10871316	16-55	02SEP2020	79041	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871323	C4591001 1087 10871323	16-55	03SEP2020	79044	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10871325	C4591001 1087 10871325	16-55	03SEP2020	79046	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo		
10871330	C4591001 1087 10871330	16-55	03SEP2020	79986	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10871332	C4591001 1087 10871332	16-55	03SEP2020	79993	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10871333	C4591001 1087 10871333	16-55	03SEP2020	79994	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871336	C4591001 1087 10871336	16-55	03SEP2020	79996	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
10871338	C4591001 1087 10871338	16-55	04SEP2020	81377	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10871342	C4591001 1087 10871342	16-55	04SEP2020	81380	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871343	C4591001 1087 10871343	16-55	08SEP2020	81382	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10871348	C4591001 1087 10871348	16-55	08SEP2020	83466	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10871349	C4591001 1087 10871349	16-55	08SEP2020	81383	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10871354	C4591001 1087 10871354	16-55	08SEP2020	83469	Placebo	08SEP2020/ Placebo			
10871355	C4591001 1087 10871355	16-55	08SEP2020	83474	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10871356	C4591001 1087 10871356	16-55	08SEP2020	83475	Placebo	08SEP2020/ Placebo			
10871357	C4591001 1087 10871357	16-55	08SEP2020	83878	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871359	C4591001 1087 10871359	16-55	08SEP2020	83879	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10871360	C4591001 1087 10871360	16-55	08SEP2020	83881	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871361	C4591001 1087 10871361	16-55	08SEP2020	83883	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10871363	C4591001 1087 10871363	16-55	08SEP2020	84246	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10871372	C4591001 1087 10871372	16-55	09SEP2020	84247	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10871377	C4591001 1087 10871377	16-55	09SEP2020	84254	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10871378	C4591001 1087 10871378	16-55	09SEP2020	84255	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871387	C4591001 1087 10871387	16-55	09SEP2020	85873	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
10871389	C4591001 1087 10871389	16-55	09SEP2020	85866	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871391	C4591001 1087 10871391	16-55	09SEP2020	85872	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871393	C4591001 1087 10871393	16-55	09SEP2020	85871	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10871394	C4591001 1087 10871394	16-55	10SEP2020	86253	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871395	C4591001 1087 10871395	16-55	10SEP2020	86250	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10871398	C4591001 1087 10871398	16-55	10SEP2020	86252	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871399	C4591001 1087 10871399	16-55	10SEP2020	86259	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10871401	C4591001 1087 10871401	16-55	10SEP2020	86552	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10871404	C4591001 1087 10871404	16-55	10SEP2020	86554	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871412	C4591001 1087 10871412	16-55	10SEP2020	86556	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10871414	C4591001 1087 10871414	16-55	10SEP2020	87438	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10871415	C4591001 1087 10871415	16-55	10SEP2020	87444	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871420	C4591001 1087 10871420	16-55	11SEP2020	87446	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871426	C4591001 1087 10871426	16-55	11SEP2020	87447	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871427	C4591001 1087 10871427	16-55	11SEP2020	88195	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10871435	C4591001 1087 10871435	16-55	11SEP2020	88197	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871436	C4591001 1087 10871436	16-55	11SEP2020	88201	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10871443	C4591001 1087 10871443	16-55	14SEP2020	88204	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10871454	C4591001 1087 10871454	16-55	15SEP2020	90776	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10871457	C4591001 1087 10871457	16-55	16SEP2020	90778	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10871468	C4591001 1087 10871468	16-55	16SEP2020	90780	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10871469	C4591001 1087 10871469	16-55	16SEP2020	90783	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871471	C4591001 1087 10871471	16-55	17SEP2020	91975	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10871473	C4591001 1087 10871473	16-55	17SEP2020	91979	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871474	C4591001 1087 10871474	16-55	17SEP2020	91980	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10871480	C4591001 1087 10871480	16-55	17SEP2020	91981	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10871484	C4591001 1087 10871484	16-55	18SEP2020	93200	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10871486	C4591001 1087 10871486	16-55	18SEP2020	93204	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10871487	C4591001 1087 10871487	16-55	18SEP2020	93201	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10871490	C4591001 1087 10871490	16-55	18SEP2020	93207	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871491	C4591001 1087 10871491	16-55	18SEP2020	93917	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871493	C4591001 1087 10871493	16-55	18SEP2020	93923	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871494	C4591001 1087 10871494	16-55	18SEP2020	93924	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10871499	C4591001 1087 10871499	16-55	21SEP2020	93927	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10871504	C4591001 1087 10871504	16-55	21SEP2020	95370	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10871506	C4591001 1087 10871506	16-55	21SEP2020	95371	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10871510	C4591001 1087 10871510	16-55	22SEP2020	95375	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10871513	C4591001 1087 10871513	16-55	22SEP2020	95376	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10871520	C4591001 1087 10871520	16-55	25SEP2020	99681	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871525	C4591001 1087 10871525	16-55	25SEP2020	99684	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
10871527	C4591001 1087 10871527	16-55	28SEP2020	99685	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10871529	C4591001 1087 10871529	16-55	29SEP2020	99688	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871530	C4591001 1087 10871530	16-55	01OCT2020	102847	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10871531	C4591001 1087 10871531	16-55	06OCT2020	102851	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
10871533	C4591001 1087 10871533	16-55	08OCT2020	102852	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10871535	C4591001 1087 10871535	16-55	09OCT2020	102854	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10871541	C4591001 1087 10871541	16-55	12OCT2020	106637	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10871543	C4591001 1087 10871543	16-55	12OCT2020	106638	Placebo	12OCT2020/ Placebo	09NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
10871544	C4591001 1087 10871544	16-55	13OCT2020	106640	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871545	C4591001 1087 10871545	16-55	13OCT2020	106793	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871546	C4591001 1087 10871546	16-55	13OCT2020	106643	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10871550	C4591001 1087 10871550	16-55	13OCT2020	106799	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871551	C4591001 1087 10871551	16-55	13OCT2020	106797	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871552	C4591001 1087 10871552	16-55	13OCT2020	106801	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10871553	C4591001 1087 10871553	16-55	14OCT2020	107346	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
10871554	C4591001 1087 10871554	16-55	14OCT2020	107350	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10871555	C4591001 1087 10871555	16-55	14OCT2020	107353	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10871556	C4591001 1087 10871556	16-55	14OCT2020	107355	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871557	C4591001 1087 10871557	16-55	14OCT2020	107612	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10871558	C4591001 1087 10871558	16-55	14OCT2020	107613	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10871562	C4591001 1087 10871562	16-55	14OCT2020	107614	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)			
10871563	C4591001 1087 10871563	16-55	15OCT2020	107620	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871565	C4591001 1087 10871565	16-55	15OCT2020	107921	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10871568	C4591001 1087 10871568	16-55	15OCT2020	107923	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10871571	C4591001 1087 10871571	16-55	15OCT2020	107927	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10871572	C4591001 1087 10871572	16-55	15OCT2020	107931	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871573	C4591001 1087 10871573	16-55	16OCT2020	108739	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10871576	C4591001 1087 10871576	16-55	21OCT2020	108742	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10871579	C4591001 1087 10871579	16-55	21OCT2020	108744	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10871581	C4591001 1087 10871581	16-55	22OCT2020	108745	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10871582	C4591001 1087 10871582	16-55	26OCT2020	113478	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10871583	C4591001 1087 10871583	16-55	26OCT2020	113481	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10871584	C4591001 1087 10871584	16-55	26OCT2020	113484	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10871586	C4591001 1087 10871586	16-55	26OCT2020	113487	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10871588	C4591001 1087 10871588	16-55	27OCT2020	113957	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10871593	C4591001 1087 10871593	16-55	28OCT2020	113959	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10871594	C4591001 1087 10871594	16-55	28OCT2020	113961	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10871595	C4591001 1087 10871595	16-55	28OCT2020	113962	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10871596	C4591001 1087 10871596	16-55	28OCT2020	114356	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10871597	C4591001 1087 10871597	16-55	28OCT2020	114359	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10871599	C4591001 1087 10871599	16-55	29OCT2020	114362	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10871601	C4591001 1087 10871601	16-55	29OCT2020	114364	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881030	C4591001 1088 10881030	16-55	14AUG2020	49396	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881033	C4591001 1088 10881033	16-55	14AUG2020	50682	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10881044	C4591001 1088 10881044	16-55	17AUG2020	51277	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10881045	C4591001 1088 10881045	16-55	17AUG2020	51279	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10881048	C4591001 1088 10881048	16-55	17AUG2020	53600	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881050	C4591001 1088 10881050	16-55	18AUG2020	53604	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10881053	C4591001 1088 10881053	16-55	18AUG2020	53605	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10881054	C4591001 1088 10881054	16-55	18AUG2020	53607	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10881059	C4591001 1088 10881059	16-55	19AUG2020	56441	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10881060	C4591001 1088 10881060	16-55	19AUG2020	56446	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881064	C4591001 1088 10881064	16-55	19AUG2020	56449	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10881065	C4591001 1088 10881065	16-55	20AUG2020	56451	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10881067	C4591001 1088 10881067	16-55	20AUG2020	58699	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10881074	C4591001 1088 10881074	16-55	21AUG2020	58703	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10881077	C4591001 1088 10881077	16-55	21AUG2020	58705	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ Placebo		
10881079	C4591001 1088 10881079	16-55	21AUG2020	58707	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10881080	C4591001 1088 10881080	16-55	21AUG2020	61253	Placebo	21AUG2020/ Placebo	12OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10881081	C4591001 1088 10881081	16-55	24AUG2020	61258	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10881082	C4591001 1088 10881082	16-55	24AUG2020	61263	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10881084	C4591001 1088 10881084	16-55	24AUG2020	61264	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881087	C4591001 1088 10881087	16-55	24AUG2020	64470	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10881094	C4591001 1088 10881094	16-55	25AUG2020	64474	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10881095	C4591001 1088 10881095	16-55	25AUG2020	64475	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10881098	C4591001 1088 10881098	16-55	26AUG2020	64479	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10881100	C4591001 1088 10881100	16-55	26AUG2020	68285	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881101	C4591001 1088 10881101	16-55	26AUG2020	68286	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10881102	C4591001 1088 10881102	16-55	26AUG2020	68293	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10881103	C4591001 1088 10881103	16-55	26AUG2020	68295	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881107	C4591001 1088 10881107	16-55	27AUG2020	69953	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10881109	C4591001 1088 10881109	16-55	27AUG2020	69958	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881111	C4591001 1088 10881111	16-55	27AUG2020	69960	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10881112	C4591001 1088 10881112	16-55	27AUG2020	69962	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10881114	C4591001 1088 10881114	16-55	28AUG2020	72011	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881116	C4591001 1088 10881116	16-55	28AUG2020	72012	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10881117	C4591001 1088 10881117	16-55	28AUG2020	72014	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
10881123	C4591001 1088 10881123	16-55	31AUG2020	72015	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10881125	C4591001 1088 10881125	16-55	31AUG2020	75389	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10881130	C4591001 1088 10881130	16-55	01SEP2020	75397	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10881134	C4591001 1088 10881134	16-55	01SEP2020	75400	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10881137	C4591001 1088 10881137	16-55	02SEP2020	78608	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881143	C4591001 1088 10881143	16-55	03SEP2020	78612	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10881148	C4591001 1088 10881148	16-55	03SEP2020	78615	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10881151	C4591001 1088 10881151	16-55	04SEP2020	78616	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10881153	C4591001 1088 10881153	16-55	04SEP2020	81595	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10881158	C4591001 1088 10881158	16-55	04SEP2020	81596	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10881159	C4591001 1088 10881159	16-55	04SEP2020	81598	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10881160	C4591001 1088 10881160	16-55	04SEP2020	81600	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10881161	C4591001 1088 10881161	16-55	04SEP2020	82362	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10881162	C4591001 1088 10881162	16-55	04SEP2020	82364	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10881166	C4591001 1088 10881166	16-55	08SEP2020	82369	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881169	C4591001 1088 10881169	16-55	08SEP2020	82370	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10881171	C4591001 1088 10881171	16-55	08SEP2020	84509	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881175	C4591001 1088 10881175	16-55	09SEP2020	84513	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10881176	C4591001 1088 10881176	16-55	09SEP2020	84514	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10881177	C4591001 1088 10881177	16-55	09SEP2020	84519	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10881180	C4591001 1088 10881180	16-55	09SEP2020	85652	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10881183	C4591001 1088 10881183	16-55	10SEP2020	85653	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881185	C4591001 1088 10881185	16-55	10SEP2020	85658	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881187	C4591001 1088 10881187	16-55	10SEP2020	85660	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10881189	C4591001 1088 10881189	16-55	10SEP2020	87511	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881192	C4591001 1088 10881192	16-55	11SEP2020	87514	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881193	C4591001 1088 10881193	16-55	11SEP2020	87515	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10881194	C4591001 1088 10881194	16-55	11SEP2020	87516	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10881196	C4591001 1088 10881196	16-55	11SEP2020	88559	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10881197	C4591001 1088 10881197	16-55	11SEP2020	88557	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10881200	C4591001 1088 10881200	16-55	11SEP2020	88560	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10881201	C4591001 1088 10881201	16-55	14SEP2020	88562	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10881213	C4591001 1088 10881213	16-55	16SEP2020	91745	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10881214	C4591001 1088 10881214	16-55	17SEP2020	91746	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10881217	C4591001 1088 10881217	16-55	17SEP2020	91749	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881218	C4591001 1088 10881218	16-55	17SEP2020	91755	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10881220	C4591001 1088 10881220	16-55	18SEP2020	93296	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10881221	C4591001 1088 10881221	16-55	18SEP2020	93294	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10881222	C4591001 1088 10881222	16-55	18SEP2020	93300	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10881224	C4591001 1088 10881224	16-55	21SEP2020	93303	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10881225	C4591001 1088 10881225	16-55	21SEP2020	95191	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10881227	C4591001 1088 10881227	16-55	21SEP2020	95193	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10881232	C4591001 1088 10881232	16-55	25SEP2020	95196	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10881233	C4591001 1088 10881233	16-55	25SEP2020	95199	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10881235	C4591001 1088 10881235	16-55	25SEP2020	99858	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881238	C4591001 1088 10881238	16-55	25SEP2020	99863	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10881239	C4591001 1088 10881239	16-55	25SEP2020	99866	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10881240	C4591001 1088 10881240	16-55	25SEP2020	99868	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10881245	C4591001 1088 10881245	16-55	06OCT2020	104429	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10881246	C4591001 1088 10881246	16-55	08OCT2020	104430	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10881248	C4591001 1088 10881248	16-55	13OCT2020	104432	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10881251	C4591001 1088 10881251	16-55	13OCT2020	104439	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10881254	C4591001 1088 10881254	16-55	15OCT2020	108185	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10881255	C4591001 1088 10881255	16-55	15OCT2020	108187	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10881256	C4591001 1088 10881256	16-55	16OCT2020	108195	Placebo	16OCT2020/ Placebo	09NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10881258	C4591001 1088 10881258	16-55	16OCT2020	108196	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10881259	C4591001 1088 10881259	16-55	19OCT2020	110129	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10891097	C4591001 1089 10891097	16-55	02SEP2020	77777	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo		
10891131	C4591001 1089 10891131	16-55	17AUG2020	50626	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891132	C4591001 1089 10891132	16-55	17AUG2020	50627	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10891134	C4591001 1089 10891134	16-55	17AUG2020	50628	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10891135	C4591001 1089 10891135	16-55	17AUG2020	52759	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10891138	C4591001 1089 10891138	16-55	17AUG2020	52761	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891139	C4591001 1089 10891139	16-55	18AUG2020	52762	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10891140	C4591001 1089 10891140	16-55	18AUG2020	52766	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891141	C4591001 1089 10891141	16-55	18AUG2020	54188	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891147	C4591001 1089 10891147	16-55	19AUG2020	54193	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10891149	C4591001 1089 10891149	16-55	19AUG2020	54196	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891151	C4591001 1089 10891151	16-55	19AUG2020	56058	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891152	C4591001 1089 10891152	16-55	19AUG2020	56062	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10891153	C4591001 1089 10891153	16-55	19AUG2020	56064	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10891155	C4591001 1089 10891155	16-55	20AUG2020	56068	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891156	C4591001 1089 10891156	16-55	20AUG2020	58050	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10891158	C4591001 1089 10891158	16-55	20AUG2020	58055	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
10891162	C4591001 1089 10891162	16-55	20AUG2020	58056	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891165	C4591001 1089 10891165	16-55	21AUG2020	58058	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10891166	C4591001 1089 10891166	16-55	21AUG2020	60800	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891168	C4591001 1089 10891168	16-55	21AUG2020	60804	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10891173	C4591001 1089 10891173	16-55	24AUG2020	60807	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10891176	C4591001 1089 10891176	16-55	24AUG2020	60808	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10891179	C4591001 1089 10891179	16-55	25AUG2020	65226	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10891180	C4591001 1089 10891180	16-55	25AUG2020	65229	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10891181	C4591001 1089 10891181	16-55	25AUG2020	65230	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10891182	C4591001 1089 10891182	16-55	25AUG2020	65233	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10891183	C4591001 1089 10891183	16-55	25AUG2020	66248	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891185	C4591001 1089 10891185	16-55	25AUG2020	66251	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10891186	C4591001 1089 10891186	16-55	25AUG2020	66253	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891192	C4591001 1089 10891192	16-55	26AUG2020	66254	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10891193	C4591001 1089 10891193	16-55	26AUG2020	68612	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10891194	C4591001 1089 10891194	16-55	26AUG2020	68611	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10891196	C4591001 1089 10891196	16-55	27AUG2020	68615	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10891197	C4591001 1089 10891197	16-55	27AUG2020	68617	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10891198	C4591001 1089 10891198	16-55	27AUG2020	70112	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10891199	C4591001 1089 10891199	16-55	27AUG2020	70113	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10891200	C4591001 1089 10891200	16-55	27AUG2020	70115	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891201	C4591001 1089 10891201	16-55	27AUG2020	70116	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10891204	C4591001 1089 10891204	16-55	27AUG2020	71001	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10891205	C4591001 1089 10891205	16-55	28AUG2020	71003	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10891206	C4591001 1089 10891206	16-55	28AUG2020	71007	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891207	C4591001 1089 10891207	16-55	28AUG2020	71008	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891209	C4591001 1089 10891209	16-55	28AUG2020	72270	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10891212	C4591001 1089 10891212	16-55	31AUG2020	72275	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10891213	C4591001 1089 10891213	16-55	31AUG2020	72279	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10891215	C4591001 1089 10891215	16-55	31AUG2020	72280	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10891220	C4591001 1089 10891220	16-55	01SEP2020	76338	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891221	C4591001 1089 10891221	16-55	01SEP2020	76339	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10891225	C4591001 1089 10891225	16-55	01SEP2020	76344	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891226	C4591001 1089 10891226	16-55	01SEP2020	76348	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10891227	C4591001 1089 10891227	16-55	02SEP2020	77782	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
10891228	C4591001 1089 10891228	16-55	02SEP2020	77786	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10891230	C4591001 1089 10891230	16-55	02SEP2020	77788	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10891231	C4591001 1089 10891231	16-55	02SEP2020	78174	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10891232	C4591001 1089 10891232	16-55	02SEP2020	78177	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10891233	C4591001 1089 10891233	16-55	02SEP2020	78180	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891234	C4591001 1089 10891234	16-55	02SEP2020	78181	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891235	C4591001 1089 10891235	16-55	02SEP2020	79049	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10891238	C4591001 1089 10891238	16-55	03SEP2020	79050	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891239	C4591001 1089 10891239	16-55	03SEP2020	79053	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891241	C4591001 1089 10891241	16-55	03SEP2020	79060	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10891246	C4591001 1089 10891246	16-55	04SEP2020	81354	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891253	C4591001 1089 10891253	16-55	04SEP2020	81359	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10891257	C4591001 1089 10891257	16-55	08SEP2020	81360	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10891259	C4591001 1089 10891259	16-55	08SEP2020	81362	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10891261	C4591001 1089 10891261	16-55	08SEP2020	83885	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10891268	C4591001 1089 10891268	16-55	09SEP2020	83888	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891271	C4591001 1089 10891271	16-55	09SEP2020	83889	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10891272	C4591001 1089 10891272	16-55	09SEP2020	83894	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10891273	C4591001 1089 10891273	16-55	09SEP2020	85566	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891275	C4591001 1089 10891275	16-55	09SEP2020	85570	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10891277	C4591001 1089 10891277	16-55	10SEP2020	85576	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10891278	C4591001 1089 10891278	16-55	10SEP2020	86393	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10891279	C4591001 1089 10891279	16-55	10SEP2020	85571	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10891280	C4591001 1089 10891280	16-55	10SEP2020	86400	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10891283	C4591001 1089 10891283	16-55	10SEP2020	86402	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10891285	C4591001 1089 10891285	16-55	10SEP2020	256802	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891287	C4591001 1089 10891287	16-55	11SEP2020	86404	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10891288	C4591001 1089 10891288	16-55	11SEP2020	87738	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891289	C4591001 1089 10891289	16-55	11SEP2020	87740	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891291	C4591001 1089 10891291	16-55	11SEP2020	87744	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10891293	C4591001 1089 10891293	16-55	11SEP2020	87747	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10891294	C4591001 1089 10891294	16-55	11SEP2020	88075	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10891296	C4591001 1089 10891296	16-55	11SEP2020	88076	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10891299	C4591001 1089 10891299	16-55	14SEP2020	88080	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10891306	C4591001 1089 10891306	16-55	14SEP2020	88081	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10891309	C4591001 1089 10891309	16-55	15SEP2020	90273	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891310	C4591001 1089 10891310	16-55	15SEP2020	90274	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10891311	C4591001 1089 10891311	16-55	15SEP2020	90275	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10891313	C4591001 1089 10891313	16-55	15SEP2020	90280	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10891315	C4591001 1089 10891315	16-55	16SEP2020	90929	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10891317	C4591001 1089 10891317	16-55	16SEP2020	90933	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
10891318	C4591001 1089 10891318	16-55	16SEP2020	90937	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10891323	C4591001 1089 10891323	16-55	17SEP2020	90938	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10891330	C4591001 1089 10891330	16-55	17SEP2020	92982	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10891332	C4591001 1089 10891332	16-55	18SEP2020	92985	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
10891334	C4591001 1089 10891334	16-55	18SEP2020	92991	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891335	C4591001 1089 10891335	16-55	18SEP2020	92987	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10891336	C4591001 1089 10891336	16-55	18SEP2020	93726	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10891337	C4591001 1089 10891337	16-55	18SEP2020	93728	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10891338	C4591001 1089 10891338	16-55	18SEP2020	93733	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
10891339	C4591001 1089 10891339	16-55	21SEP2020	93734	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10891340	C4591001 1089 10891340	16-55	21SEP2020	94805	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10891342	C4591001 1089 10891342	16-55	21SEP2020	94808	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10891343	C4591001 1089 10891343	16-55	21SEP2020	94811	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10891346	C4591001 1089 10891346	16-55	22SEP2020	94814	BNT162b2 (30 µg)				
10891347	C4591001 1089 10891347	16-55	22SEP2020	96427	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10891348	C4591001 1089 10891348	16-55	22SEP2020	96431	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10891349	C4591001 1089 10891349	16-55	22SEP2020	96433	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10891350	C4591001 1089 10891350	16-55	25SEP2020	96435	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
10891351	C4591001 1089 10891351	16-55	25SEP2020	100061	BNT162b2 (30 µg)				
10891352	C4591001 1089 10891352	16-55	25SEP2020	100069	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10891353	C4591001 1089 10891353	16-55	25SEP2020	100070	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10901187	C4591001 1090 10901187	16-55	14AUG2020	50229	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10901206	C4591001 1090 10901206	16-55	17AUG2020	50820	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901210	C4591001 1090 10901210	16-55	17AUG2020	50824	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901212	C4591001 1090 10901212	16-55	17AUG2020	52661	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901216	C4591001 1090 10901216	16-55	17AUG2020	52665	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901220	C4591001 1090 10901220	16-55	17AUG2020	52669	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10901222	C4591001 1090 10901222	16-55	17AUG2020	52672	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10901226	C4591001 1090 10901226	16-55	18AUG2020	54081	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10901239	C4591001 1090 10901239	16-55	18AUG2020	54086	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901244	C4591001 1090 10901244	16-55	18AUG2020	54087	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10901251	C4591001 1090 10901251	16-55	19AUG2020	56143	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901253	C4591001 1090 10901253	16-55	19AUG2020	56145	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901256	C4591001 1090 10901256	16-55	19AUG2020	56150	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901260	C4591001 1090 10901260	16-55	19AUG2020	56151	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901262	C4591001 1090 10901262	16-55	19AUG2020	56947	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10901264	C4591001 1090 10901264	16-55	19AUG2020	57414	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10901266	C4591001 1090 10901266	16-55	19AUG2020	56948	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
10901267	C4591001 1090 10901267	16-55	19AUG2020	56950	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10901268	C4591001 1090 10901268	16-55	19AUG2020	56954	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901269	C4591001 1090 10901269	16-55	19AUG2020	57418	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10901270	C4591001 1090 10901270	16-55	19AUG2020	57422	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10901271	C4591001 1090 10901271	16-55	19AUG2020	57423	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10901277	C4591001 1090 10901277	16-55	01SEP2020	77131	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10901278	C4591001 1090 10901278	16-55	01SEP2020	77129	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901281	C4591001 1090 10901281	16-55	01SEP2020	77130	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
10901283	C4591001 1090 10901283	16-55	01SEP2020	77133	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901288	C4591001 1090 10901288	16-55	01SEP2020	77482	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10901289	C4591001 1090 10901289	16-55	01SEP2020	77483	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10901290	C4591001 1090 10901290	16-55	02SEP2020	77487	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10901291	C4591001 1090 10901291	16-55	02SEP2020	77488	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10901294	C4591001 1090 10901294	16-55	02SEP2020	78115	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10901295	C4591001 1090 10901295	16-55	02SEP2020	78118	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10901297	C4591001 1090 10901297	16-55	02SEP2020	78121	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
10901304	C4591001 1090 10901304	16-55	02SEP2020	78122	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10901312	C4591001 1090 10901312	16-55	02SEP2020	79125	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901314	C4591001 1090 10901314	16-55	02SEP2020	79127	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10901315	C4591001 1090 10901315	16-55	02SEP2020	79130	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10901316	C4591001 1090 10901316	16-55	03SEP2020	79132	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901318	C4591001 1090 10901318	16-55	03SEP2020	79781	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10901319	C4591001 1090 10901319	16-55	03SEP2020	79783	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901320	C4591001 1090 10901320	16-55	03SEP2020	79792	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901321	C4591001 1090 10901321	16-55	03SEP2020	79791	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901323	C4591001 1090 10901323	16-55	03SEP2020	80396	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10901325	C4591001 1090 10901325	16-55	03SEP2020	80394	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10901326	C4591001 1090 10901326	16-55	03SEP2020	80398	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901328	C4591001 1090 10901328	16-55	03SEP2020	80915	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901329	C4591001 1090 10901329	16-55	03SEP2020	80404	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10901330	C4591001 1090 10901330	16-55	03SEP2020	80909	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10901334	C4591001 1090 10901334	16-55	03SEP2020	80918	Placebo	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901335	C4591001 1090 10901335	16-55	03SEP2020	80919	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10901336	C4591001 1090 10901336	16-55	08SEP2020	83322	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10901339	C4591001 1090 10901339	16-55	08SEP2020	83324	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10901341	C4591001 1090 10901341	16-55	08SEP2020	83327	Placebo	08SEP2020/ Placebo	06OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10901343	C4591001 1090 10901343	16-55	08SEP2020	83331	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10901346	C4591001 1090 10901346	16-55	08SEP2020	83721	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901347	C4591001 1090 10901347	16-55	08SEP2020	83723	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10901348	C4591001 1090 10901348	16-55	08SEP2020	83725	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10901349	C4591001 1090 10901349	16-55	08SEP2020	83728	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10901350	C4591001 1090 10901350	16-55	08SEP2020	84260	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10901355	C4591001 1090 10901355	16-55	09SEP2020	84262	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10901356	C4591001 1090 10901356	16-55	09SEP2020	84265	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901357	C4591001 1090 10901357	16-55	09SEP2020	85085	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10901358	C4591001 1090 10901358	16-55	09SEP2020	84266	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901360	C4591001 1090 10901360	16-55	09SEP2020	85090	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10901362	C4591001 1090 10901362	16-55	09SEP2020	85094	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901363	C4591001 1090 10901363	16-55	09SEP2020	85096	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901365	C4591001 1090 10901365	16-55	09SEP2020	85625	Placebo	09SEP2020/ Placebo	06OCT2020/ Placebo		
10901366	C4591001 1090 10901366	16-55	09SEP2020	85626	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10901367	C4591001 1090 10901367	16-55	10SEP2020	85630	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10901369	C4591001 1090 10901369	16-55	10SEP2020	85632	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901370	C4591001 1090 10901370	16-55	10SEP2020	86466	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901371	C4591001 1090 10901371	16-55	10SEP2020	86468	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
10901372	C4591001 1090 10901372	16-55	10SEP2020	86467	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10901373	C4591001 1090 10901373	16-55	10SEP2020	86472	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10901374	C4591001 1090 10901374	16-55	10SEP2020	86741	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901375	C4591001 1090 10901375	16-55	10SEP2020	86744	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901377	C4591001 1090 10901377	16-55	10SEP2020	86746	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		
10901378	C4591001 1090 10901378	16-55	10SEP2020	86750	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10901379	C4591001 1090 10901379	16-55	10SEP2020	87103	Placebo	10SEP2020/ Placebo			
10901380	C4591001 1090 10901380	16-55	10SEP2020	87104	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10901382	C4591001 1090 10901382	16-55	10SEP2020	87106	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10901383	C4591001 1090 10901383	16-55	14SEP2020	87109	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901384	C4591001 1090 10901384	16-55	14SEP2020	89539	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo		
10901386	C4591001 1090 10901386	16-55	14SEP2020	89542	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10901387	C4591001 1090 10901387	16-55	14SEP2020	89543	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901391	C4591001 1090 10901391	16-55	15SEP2020	90234	Placebo	15SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10901392	C4591001 1090 10901392	16-55	15SEP2020	89545	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901393	C4591001 1090 10901393	16-55	15SEP2020	90236	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10901394	C4591001 1090 10901394	16-55	15SEP2020	90238	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10901395	C4591001 1090 10901395	16-55	15SEP2020	90239	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901397	C4591001 1090 10901397	16-55	15SEP2020	90558	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901398	C4591001 1090 10901398	16-55	15SEP2020	90560	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901399	C4591001 1090 10901399	16-55	16SEP2020	90567	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10901400	C4591001 1090 10901400	16-55	16SEP2020	90568	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10901401	C4591001 1090 10901401	16-55	16SEP2020	91145	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901402	C4591001 1090 10901402	16-55	16SEP2020	91154	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10901407	C4591001 1090 10901407	16-55	16SEP2020	91155	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901408	C4591001 1090 10901408	16-55	16SEP2020	91156	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901410	C4591001 1090 10901410	16-55	17SEP2020	92035	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10901413	C4591001 1090 10901413	16-55	17SEP2020	92041	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901416	C4591001 1090 10901416	16-55	17SEP2020	92043	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901417	C4591001 1090 10901417	16-55	17SEP2020	92044	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10901418	C4591001 1090 10901418	16-55	17SEP2020	92502	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10901419	C4591001 1090 10901419	16-55	17SEP2020	92503	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10901422	C4591001 1090 10901422	16-55	17SEP2020	92505	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901423	C4591001 1090 10901423	16-55	17SEP2020	92729	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo		
10901424	C4591001 1090 10901424	16-55	17SEP2020	92507	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901426	C4591001 1090 10901426	16-55	21SEP2020	92731	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10901427	C4591001 1090 10901427	16-55	21SEP2020	92737	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901429	C4591001 1090 10901429	16-55	21SEP2020	92740	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901431	C4591001 1090 10901431	16-55	21SEP2020	95082	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901432	C4591001 1090 10901432	16-55	21SEP2020	95087	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10901435	C4591001 1090 10901435	16-55	22SEP2020	95088	Placebo	22SEP2020/ Placebo	16OCT2020/ Placebo		
10901437	C4591001 1090 10901437	16-55	22SEP2020	95089	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901440	C4591001 1090 10901440	16-55	22SEP2020	96344	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901441	C4591001 1090 10901441	16-55	22SEP2020	96346	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10901443	C4591001 1090 10901443	16-55	22SEP2020	96345	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10901451	C4591001 1090 10901451	16-55	23SEP2020	96347	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
10901452	C4591001 1090 10901452	16-55	23SEP2020	97675	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
10901457	C4591001 1090 10901457	16-55	23SEP2020	97676	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10901461	C4591001 1090 10901461	16-55	23SEP2020	97677	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10901463	C4591001 1090 10901463	16-55	24SEP2020	97684	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo		
10901464	C4591001 1090 10901464	16-55	24SEP2020	98694	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10901465	C4591001 1090 10901465	16-55	24SEP2020	98695	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10901470	C4591001 1090 10901470	16-55	25SEP2020	98699	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901473	C4591001 1090 10901473	16-55	25SEP2020	98703	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10901474	C4591001 1090 10901474	16-55	25SEP2020	99810	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10901476	C4591001 1090 10901476	16-55	25SEP2020	99811	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10901477	C4591001 1090 10901477	16-55	25SEP2020	99817	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10901479	C4591001 1090 10901479	16-55	25SEP2020	99818	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901480	C4591001 1090 10901480	16-55	25SEP2020	100122	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10901481	C4591001 1090 10901481	16-55	25SEP2020	100124	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10901482	C4591001 1090 10901482	16-55	25SEP2020	100126	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
10901484	C4591001 1090 10901484	16-55	07OCT2020	100132	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10901489	C4591001 1090 10901489	16-55	09OCT2020	105837	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901491	C4591001 1090 10901491	16-55	09OCT2020	105839	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10901496	C4591001 1090 10901496	16-55	14OCT2020	105841	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10901497	C4591001 1090 10901497	16-55	14OCT2020	105843	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10901498	C4591001 1090 10901498	16-55	14OCT2020	107561	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10901502	C4591001 1090 10901502	16-55	15OCT2020	107562	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
10901503	C4591001 1090 10901503	16-55	15OCT2020	107566	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10901507	C4591001 1090 10901507	16-55	16OCT2020	107570	Placebo	16OCT2020/ Placebo		11MAR2021/ BNT162b2 (30 µg)	
10901508	C4591001 1090 10901508	16-55	16OCT2020	109037	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10901509	C4591001 1090 10901509	16-55	19OCT2020	109041	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901510	C4591001 1090 10901510	16-55	19OCT2020	109045	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901513	C4591001 1090 10901513	16-55	19OCT2020	109046	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10901516	C4591001 1090 10901516	16-55	20OCT2020	110693	Placebo	20OCT2020/ Placebo	06NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10901517	C4591001 1090 10901517	16-55	20OCT2020	110697	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10901518	C4591001 1090 10901518	16-55	20OCT2020	110699	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10901520	C4591001 1090 10901520	16-55	20OCT2020	110703	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10901524	C4591001 1090 10901524	16-55	21OCT2020	111431	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10901526	C4591001 1090 10901526	16-55	21OCT2020	111432	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901527	C4591001 1090 10901527	16-55	21OCT2020	111433	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901528	C4591001 1090 10901528	16-55	22OCT2020	111436	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10901529	C4591001 1090 10901529	16-55	22OCT2020	112152	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901530	C4591001 1090 10901530	16-55	22OCT2020	112150	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901535	C4591001 1090 10901535	16-55	23OCT2020	112155	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10901536	C4591001 1090 10901536	16-55	23OCT2020	112156	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901537	C4591001 1090 10901537	16-55	23OCT2020	112927	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10901538	C4591001 1090 10901538	16-55	23OCT2020	112930	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901539	C4591001 1090 10901539	16-55	23OCT2020	112933	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
10901540	C4591001 1090 10901540	16-55	23OCT2020	112934	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10901543	C4591001 1090 10901543	16-55	23OCT2020	113107	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10901544	C4591001 1090 10901544	16-55	23OCT2020	113109	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10901546	C4591001 1090 10901546	16-55	26OCT2020	113113	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10901547	C4591001 1090 10901547	16-55	26OCT2020	113116	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10901548	C4591001 1090 10901548	16-55	26OCT2020	113527	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10901550	C4591001 1090 10901550	16-55	26OCT2020	113529	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10901551	C4591001 1090 10901551	16-55	26OCT2020	113530	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo		
10901557	C4591001 1090 10901557	16-55	27OCT2020	113535	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10901558	C4591001 1090 10901558	16-55	27OCT2020	114029	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10901559	C4591001 1090 10901559	16-55	27OCT2020	114032	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10901565	C4591001 1090 10901565	16-55	29OCT2020	114036	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10901566	C4591001 1090 10901566	16-55	30OCT2020	114040	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10911123	C4591001 1091 10911123	16-55	17AUG2020	49366	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911125	C4591001 1091 10911125	16-55	17AUG2020	49370	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911130	C4591001 1091 10911130	16-55	17AUG2020	49372	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10911132	C4591001 1091 10911132	16-55	18AUG2020	54223	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10911133	C4591001 1091 10911133	16-55	18AUG2020	54228	Placebo	18AUG2020/ Placebo	15SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911134	C4591001 1091 10911134	16-55	18AUG2020	54227	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10911137	C4591001 1091 10911137	16-55	18AUG2020	54229	Placebo	18AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911138	C4591001 1091 10911138	16-55	18AUG2020	54977	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10911139	C4591001 1091 10911139	16-55	18AUG2020	54986	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10911140	C4591001 1091 10911140	16-55	18AUG2020	54985	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10911141	C4591001 1091 10911141	16-55	19AUG2020	54988	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911142	C4591001 1091 10911142	16-55	19AUG2020	56189	Placebo	19AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10911143	C4591001 1091 10911143	16-55	19AUG2020	56199	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
10911144	C4591001 1091 10911144	16-55	19AUG2020	56195	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10911145	C4591001 1091 10911145	16-55	19AUG2020	56289	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10911146	C4591001 1091 10911146	16-55	19AUG2020	56190	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10911149	C4591001 1091 10911149	16-55	19AUG2020	56290	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911150	C4591001 1091 10911150	16-55	19AUG2020	56292	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10911151	C4591001 1091 10911151	16-55	19AUG2020	57089	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10911152	C4591001 1091 10911152	16-55	19AUG2020	56296	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10911156	C4591001 1091 10911156	16-55	20AUG2020	57090	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911157	C4591001 1091 10911157	16-55	20AUG2020	57095	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10911160	C4591001 1091 10911160	16-55	20AUG2020	57096	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10911162	C4591001 1091 10911162	16-55	20AUG2020	59154	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10911164	C4591001 1091 10911164	16-55	24AUG2020	59161	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911165	C4591001 1091 10911165	16-55	24AUG2020	59162	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911166	C4591001 1091 10911166	16-55	24AUG2020	59157	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10911169	C4591001 1091 10911169	16-55	25AUG2020	65478	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10911172	C4591001 1091 10911172	16-55	25AUG2020	65483	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10911174	C4591001 1091 10911174	16-55	25AUG2020	65485	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911175	C4591001 1091 10911175	16-55	25AUG2020	65486	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911176	C4591001 1091 10911176	16-55	26AUG2020	67681	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911177	C4591001 1091 10911177	16-55	26AUG2020	67675	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911179	C4591001 1091 10911179	16-55	26AUG2020	67682	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10911182	C4591001 1091 10911182	16-55	26AUG2020	67684	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10911183	C4591001 1091 10911183	16-55	27AUG2020	69871	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911185	C4591001 1091 10911185	16-55	27AUG2020	69872	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10911186	C4591001 1091 10911186	16-55	27AUG2020	69880	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10911188	C4591001 1091 10911188	16-55	27AUG2020	69877	Placebo	27AUG2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10911189	C4591001 1091 10911189	16-55	27AUG2020	70805	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10911192	C4591001 1091 10911192	16-55	28AUG2020	70811	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911196	C4591001 1091 10911196	16-55	28AUG2020	70812	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911197	C4591001 1091 10911197	16-55	28AUG2020	71958	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10911198	C4591001 1091 10911198	16-55	28AUG2020	70816	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
10911200	C4591001 1091 10911200	16-55	31AUG2020	71968	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911202	C4591001 1091 10911202	16-55	31AUG2020	71966	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911203	C4591001 1091 10911203	16-55	31AUG2020	71965	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		
10911206	C4591001 1091 10911206	16-55	31AUG2020	75575	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911207	C4591001 1091 10911207	16-55	31AUG2020	75578	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10911208	C4591001 1091 10911208	16-55	31AUG2020	75571	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911210	C4591001 1091 10911210	16-55	01SEP2020	75580	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911215	C4591001 1091 10911215	16-55	01SEP2020	77189	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10911218	C4591001 1091 10911218	16-55	01SEP2020	77191	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911219	C4591001 1091 10911219	16-55	01SEP2020	77636	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911220	C4591001 1091 10911220	16-55	01SEP2020	77196	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911221	C4591001 1091 10911221	16-55	01SEP2020	77638	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10911223	C4591001 1091 10911223	16-55	01SEP2020	77198	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10911226	C4591001 1091 10911226	16-55	02SEP2020	77641	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10911229	C4591001 1091 10911229	16-55	02SEP2020	77643	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10911232	C4591001 1091 10911232	16-55	02SEP2020	78881	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10911233	C4591001 1091 10911233	16-55	02SEP2020	78882	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911236	C4591001 1091 10911236	16-55	02SEP2020	78887	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10911237	C4591001 1091 10911237	16-55	02SEP2020	79308	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911238	C4591001 1091 10911238	16-55	02SEP2020	79301	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10911239	C4591001 1091 10911239	16-55	02SEP2020	78888	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911240	C4591001 1091 10911240	16-55	02SEP2020	79311	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10911241	C4591001 1091 10911241	16-55	02SEP2020	79312	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
10911245	C4591001 1091 10911245	16-55	03SEP2020	79776	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10911246	C4591001 1091 10911246	16-55	03SEP2020	79771	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10911250	C4591001 1091 10911250	16-55	03SEP2020	79778	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10911252	C4591001 1091 10911252	16-55	08SEP2020	79779	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911255	C4591001 1091 10911255	16-55	08SEP2020	84165	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10911256	C4591001 1091 10911256	16-55	08SEP2020	84167	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10911257	C4591001 1091 10911257	16-55	08SEP2020	84168	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10911260	C4591001 1091 10911260	16-55	09SEP2020	85326	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911261	C4591001 1091 10911261	16-55	09SEP2020	84170	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911270	C4591001 1091 10911270	16-55	09SEP2020	85331	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911271	C4591001 1091 10911271	16-55	09SEP2020	85327	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911276	C4591001 1091 10911276	16-55	10SEP2020	85336	Placebo	10SEP2020/ Placebo	05OCT2020/ Placebo		
10911277	C4591001 1091 10911277	16-55	10SEP2020	87252	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911279	C4591001 1091 10911279	16-55	10SEP2020	87246	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911281	C4591001 1091 10911281	16-55	10SEP2020	87255	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10911282	C4591001 1091 10911282	16-55	10SEP2020	87251	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10911283	C4591001 1091 10911283	16-55	10SEP2020	87535	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911284	C4591001 1091 10911284	16-55	10SEP2020	87539	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10911286	C4591001 1091 10911286	16-55	11SEP2020	87540	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911288	C4591001 1091 10911288	16-55	11SEP2020	87544	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10911289	C4591001 1091 10911289	16-55	11SEP2020	88030	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911290	C4591001 1091 10911290	16-55	11SEP2020	88031	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10911291	C4591001 1091 10911291	16-55	11SEP2020	88028	Placebo	11SEP2020/ Placebo	04NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10911293	C4591001 1091 10911293	16-55	14SEP2020	88034	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911297	C4591001 1091 10911297	16-55	14SEP2020	89862	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911298	C4591001 1091 10911298	16-55	14SEP2020	89863	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10911300	C4591001 1091 10911300	16-55	15SEP2020	89865	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10911301	C4591001 1091 10911301	16-55	15SEP2020	89870	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10911302	C4591001 1091 10911302	16-55	15SEP2020	90389	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10911303	C4591001 1091 10911303	16-55	15SEP2020	90391	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911304	C4591001 1091 10911304	16-55	15SEP2020	90394	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10911306	C4591001 1091 10911306	16-55	15SEP2020	90399	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911309	C4591001 1091 10911309	16-55	16SEP2020	91187	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911310	C4591001 1091 10911310	16-55	16SEP2020	91184	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911311	C4591001 1091 10911311	16-55	16SEP2020	91185	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911313	C4591001 1091 10911313	16-55	16SEP2020	91565	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911314	C4591001 1091 10911314	16-55	16SEP2020	91190	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911315	C4591001 1091 10911315	16-55	17SEP2020	91570	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911317	C4591001 1091 10911317	16-55	17SEP2020	91572	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10911319	C4591001 1091 10911319	16-55	17SEP2020	91575	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10911320	C4591001 1091 10911320	16-55	17SEP2020	92634	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10911321	C4591001 1091 10911321	16-55	17SEP2020	92640	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10911322	C4591001 1091 10911322	16-55	17SEP2020	92635	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
10911324	C4591001 1091 10911324	16-55	17SEP2020	92641	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911325	C4591001 1091 10911325	16-55	21SEP2020	94832	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911327	C4591001 1091 10911327	16-55	21SEP2020	94834	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10911328	C4591001 1091 10911328	16-55	21SEP2020	94838	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10911331	C4591001 1091 10911331	16-55	22SEP2020	94840	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911333	C4591001 1091 10911333	16-55	22SEP2020	97089	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911334	C4591001 1091 10911334	16-55	23SEP2020	97091	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10911336	C4591001 1091 10911336	16-55	23SEP2020	97095	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10911338	C4591001 1091 10911338	16-55	24SEP2020	97096	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10911339	C4591001 1091 10911339	16-55	25SEP2020	99426	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10911340	C4591001 1091 10911340	16-55	25SEP2020	99433	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911341	C4591001 1091 10911341	16-55	25SEP2020	99545	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10911342	C4591001 1091 10911342	16-55	25SEP2020	99430	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10911343	C4591001 1091 10911343	16-55	25SEP2020	99432	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10911344	C4591001 1091 10911344	16-55	29SEP2020	99549	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		
10911348	C4591001 1091 10911348	16-55	01OCT2020	99551	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10911350	C4591001 1091 10911350	16-55	05OCT2020	99554	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10911351	C4591001 1091 10911351	16-55	05OCT2020	103902	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10911352	C4591001 1091 10911352	16-55	06OCT2020	103906	Placebo	06OCT2020/ Placebo			
10911353	C4591001 1091 10911353	16-55	06OCT2020	103911	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10911355	C4591001 1091 10911355	16-55	08OCT2020	103912	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911356	C4591001 1091 10911356	16-55	08OCT2020	105342	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10911357	C4591001 1091 10911357	16-55	08OCT2020	105345	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10911358	C4591001 1091 10911358	16-55	08OCT2020	105347	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10911360	C4591001 1091 10911360	16-55	09OCT2020	105351	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10911361	C4591001 1091 10911361	16-55	12OCT2020	106596	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10911362	C4591001 1091 10911362	16-55	12OCT2020	106590	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10911363	C4591001 1091 10911363	16-55	12OCT2020	106593	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10911366	C4591001 1091 10911366	16-55	14OCT2020	106600	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10911368	C4591001 1091 10911368	16-55	15OCT2020	108365	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
10911371	C4591001 1091 10911371	16-55	19OCT2020	108366	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911372	C4591001 1091 10911372	16-55	19OCT2020	108368	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
10911373	C4591001 1091 10911373	16-55	20OCT2020	108373	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10911375	C4591001 1091 10911375	16-55	21OCT2020	111605	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10911376	C4591001 1091 10911376	16-55	04NOV2020	114763	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10911378	C4591001 1091 10911378	16-55	23OCT2020	111607	Placebo	23OCT2020/ Placebo	03DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
10911379	C4591001 1091 10911379	16-55	26OCT2020	111608	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10911380	C4591001 1091 10911380	16-55	26OCT2020	111616	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10911381	C4591001 1091 10911381	16-55	27OCT2020	114199	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10911382	C4591001 1091 10911382	16-55	28OCT2020	114200	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10911383	C4591001 1091 10911383	16-55	28OCT2020	114204	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911384	C4591001 1091 10911384	16-55	29OCT2020	114207	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10911385	C4591001 1091 10911385	16-55	29OCT2020	114761	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10911386	C4591001 1091 10911386	16-55	03NOV2020	114762	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10911387	C4591001 1091 10911387	16-55	05NOV2020	114767	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)			
10911388	C4591001 1091 10911388	16-55	16NOV2020	116297	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10911389	C4591001 1091 10911389	16-55	18NOV2020	116298	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
10911390	C4591001 1091 10911390	16-55	18NOV2020	116302	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10911391	C4591001 1091 10911391	16-55	25NOV2020	116303	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
10911392	C4591001 1091 10911392	16-55	30NOV2020	117066	Placebo	30NOV2020/ Placebo	22DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10911393	C4591001 1091 10911393	16-55	01DEC2020	20577	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10911397	C4591001 1091 10911397	16-55	03DEC2020	117073	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10911398	C4591001 1091 10911398	16-55	03DEC2020	117075	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)		
10911401	C4591001 1091 10911401	16-55	04DEC2020	117547	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
10921001	C4591001 1092 10921001	16-55	18AUG2020	54917	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921002	C4591001 1092 10921002	16-55	18AUG2020	54918	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10921003	C4591001 1092 10921003	16-55	18AUG2020	54921	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10921008	C4591001 1092 10921008	16-55	19AUG2020	54922	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10921020	C4591001 1092 10921020	16-55	20AUG2020	57858	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10921024	C4591001 1092 10921024	16-55	20AUG2020	57862	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10921026	C4591001 1092 10921026	16-55	20AUG2020	57863	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921027	C4591001 1092 10921027	16-55	20AUG2020	57864	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921029	C4591001 1092 10921029	16-55	20AUG2020	58844	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10921033	C4591001 1092 10921033	16-55	20AUG2020	58847	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10921035	C4591001 1092 10921035	16-55	21AUG2020	58848	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10921036	C4591001 1092 10921036	16-55	21AUG2020	58851	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921042	C4591001 1092 10921042	16-55	24AUG2020	63223	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10921045	C4591001 1092 10921045	16-55	24AUG2020	63226	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10921053	C4591001 1092 10921053	16-55	24AUG2020	63228	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10921055	C4591001 1092 10921055	16-55	24AUG2020	63229	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
10921056	C4591001 1092 10921056	16-55	25AUG2020	65118	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921064	C4591001 10921064	16-55	25AUG2020	65120	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921065	C4591001 10921065	16-55	25AUG2020	65121	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921066	C4591001 10921066	16-55	25AUG2020	65128	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
10921075	C4591001 10921075	16-55	26AUG2020	67127	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921076	C4591001 10921076	16-55	26AUG2020	67128	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921080	C4591001 10921080	16-55	26AUG2020	67129	Placebo	26AUG2020/ Placebo			
10921081	C4591001 10921081	16-55	26AUG2020	67132	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921082	C4591001 10921082	16-55	26AUG2020	67627	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921083	C4591001 10921083	16-55	26AUG2020	67629	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10921084	C4591001 10921084	16-55	26AUG2020	67631	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921085	C4591001 1092 10921085	16-55	26AUG2020	67632	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10921091	C4591001 1092 10921091	16-55	26AUG2020	68900	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10921097	C4591001 1092 10921097	16-55	27AUG2020	68903	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10921098	C4591001 1092 10921098	16-55	27AUG2020	68906	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921099	C4591001 1092 10921099	16-55	27AUG2020	68907	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10921101	C4591001 1092 10921101	16-55	27AUG2020	71098	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10921106	C4591001 1092 10921106	16-55	31AUG2020	71100	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10921109	C4591001 1092 10921109	16-55	31AUG2020	71103	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10921112	C4591001 1092 10921112	16-55	31AUG2020	71104	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921113	C4591001 1092 10921113	16-55	31AUG2020	75406	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921118	C4591001 1092 10921118	16-55	31AUG2020	75408	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10921122	C4591001 1092 10921122	16-55	01SEP2020	75411	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921125	C4591001 1092 10921125	16-55	01SEP2020	75412	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921127	C4591001 1092 10921127	16-55	01SEP2020	76961	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921128	C4591001 1092 10921128	16-55	01SEP2020	76964	BNT162b2 (30 µg)				
10921130	C4591001 1092 10921130	16-55	01SEP2020	76968	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10921131	C4591001 1092 10921131	16-55	01SEP2020	76970	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921132	C4591001 1092 10921132	16-55	01SEP2020	77204	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10921133	C4591001 1092 10921133	16-55	01SEP2020	77207	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921139	C4591001 1092 10921139	16-55	02SEP2020	77209	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921142	C4591001 1092 10921142	16-55	02SEP2020	77212	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921143	C4591001 1092 10921143	16-55	02SEP2020	78809	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921144	C4591001 1092 10921144	16-55	02SEP2020	78814	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921146	C4591001 1092 10921146	16-55	02SEP2020	78815	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921147	C4591001 1092 10921147	16-55	03SEP2020	78820	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921153	C4591001 1092 10921153	16-55	03SEP2020	79901	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921157	C4591001 1092 10921157	16-55	03SEP2020	79902	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10921158	C4591001 1092 10921158	16-55	03SEP2020	79904	Placebo	03SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10921160	C4591001 1092 10921160	16-55	03SEP2020	79908	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10921161	C4591001 1092 10921161	16-55	04SEP2020	81224	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921162	C4591001 1092 10921162	16-55	04SEP2020	81225	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10921168	C4591001 1092 10921168	16-55	08SEP2020	81231	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10921175	C4591001 1092 10921175	16-55	09SEP2020	81232	Placebo	09SEP2020/ Placebo	04NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921177	C4591001 1092 10921177	16-55	10SEP2020	86239	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10921179	C4591001 1092 10921179	16-55	10SEP2020	86240	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10921181	C4591001 1092 10921181	16-55	11SEP2020	86244	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921183	C4591001 1092 10921183	16-55	11SEP2020	86245	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10921184	C4591001 1092 10921184	16-55	11SEP2020	87893	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10921186	C4591001 1092 10921186	16-55	14SEP2020	87900	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10921188	C4591001 1092 10921188	16-55	15SEP2020	87903	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921189	C4591001 1092 10921189	16-55	15SEP2020	87904	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10921192	C4591001 1092 10921192	16-55	16SEP2020	91530	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10921197	C4591001 1092 10921197	16-55	05OCT2020	91532	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10921198	C4591001 1092 10921198	16-55	05OCT2020	91535	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10921200	C4591001 1092 10921200	16-55	06OCT2020	91540	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10921201	C4591001 1092 10921201	16-55	06OCT2020	104345	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10921203	C4591001 1092 10921203	16-55	06OCT2020	104347	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10921204	C4591001 1092 10921204	16-55	06OCT2020	104348	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921205	C4591001 1092 10921205	16-55	07OCT2020	104349	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10921208	C4591001 1092 10921208	16-55	07OCT2020	104657	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921209	C4591001 1092 10921209	16-55	07OCT2020	104658	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
10921210	C4591001 1092 10921210	16-55	07OCT2020	104662	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921211	C4591001 1092 10921211	16-55	07OCT2020	104664	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10921218	C4591001 1092 10921218	16-55	09OCT2020	105765	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921219	C4591001 1092 10921219	16-55	09OCT2020	105766	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10921223	C4591001 1092 10921223	16-55	12OCT2020	105769	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10921225	C4591001 1092 10921225	16-55	12OCT2020	105770	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921227	C4591001 1092 10921227	16-55	12OCT2020	106568	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
10921228	C4591001 1092 10921228	16-55	12OCT2020	106572	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10921229	C4591001 1092 10921229	16-55	12OCT2020	106573	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921236	C4591001 1092 10921236	16-55	13OCT2020	106575	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10921237	C4591001 1092 10921237	16-55	13OCT2020	107118	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10921239	C4591001 1092 10921239	16-55	14OCT2020	107120	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10921245	C4591001 1092 10921245	16-55	15OCT2020	107124	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo		
10921246	C4591001 1092 10921246	16-55	19OCT2020	107128	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10921247	C4591001 1092 10921247	16-55	19OCT2020	109854	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10921248	C4591001 1092 10921248	16-55	19OCT2020	109858	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10921249	C4591001 1092 10921249	16-55	20OCT2020	109859	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)			
10921260	C4591001 1092 10921260	16-55	20OCT2020	109864	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10921271	C4591001 1092 10921271	16-55	27OCT2020	113924	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10921272	C4591001 1092 10921272	16-55	27OCT2020	113925	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10921274	C4591001 1092 10921274	16-55	27OCT2020	113929	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10921276	C4591001 1092 10921276	16-55	29OCT2020	113931	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10931009	C4591001 1093 10931009	16-55	17AUG2020	51440	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10931011	C4591001 1093 10931011	16-55	17AUG2020	51443	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931013	C4591001 1093 10931013	16-55	18AUG2020	51448	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
10931017	C4591001 1093 10931017	16-55	18AUG2020	54365	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10931018	C4591001 1093 10931018	16-55	18AUG2020	54368	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10931019	C4591001 1093 10931019	16-55	18AUG2020	54370	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10931020	C4591001 1093 10931020	16-55	18AUG2020	54372	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931022	C4591001 1093 10931022	16-55	19AUG2020	55878	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10931027	C4591001 1093 10931027	16-55	20AUG2020	55885	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10931028	C4591001 1093 10931028	16-55	20AUG2020	55879	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10931030	C4591001 1093 10931030	16-55	03SEP2020	78898	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10931031	C4591001 1093 10931031	16-55	21AUG2020	60149	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10931032	C4591001 1093 10931032	16-55	21AUG2020	55887	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10931033	C4591001 1093 10931033	16-55	21AUG2020	60152	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931039	C4591001 1093 10931039	16-55	21AUG2020	60155	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10931040	C4591001 1093 10931040	16-55	21AUG2020	60157	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931041	C4591001 1093 10931041	16-55	21AUG2020	61577	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931042	C4591001 1093 10931042	16-55	22AUG2020	61582	Placebo	22AUG2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931043	C4591001 1093 10931043	16-55	22AUG2020	61581	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10931049	C4591001 1093 10931049	16-55	24AUG2020	61587	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10931052	C4591001 1093 10931052	16-55	25AUG2020	65659	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10931053	C4591001 1093 10931053	16-55	25AUG2020	65660	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10931055	C4591001 1093 10931055	16-55	25AUG2020	65667	BNT162b2 (30 µg)				
10931056	C4591001 1093 10931056	16-55	25AUG2020	65668	Placebo	25AUG2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931058	C4591001 1093 10931058	16-55	25AUG2020	67013	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
10931061	C4591001 1093 10931061	16-55	26AUG2020	67017	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10931063	C4591001 1093 10931063	16-55	26AUG2020	67019	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931065	C4591001 1093 10931065	16-55	26AUG2020	67023	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10931066	C4591001 1093 10931066	16-55	26AUG2020	68477	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10931067	C4591001 1093 10931067	16-55	26AUG2020	68478	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10931068	C4591001 1093 10931068	16-55	26AUG2020	68479	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10931070	C4591001 1093 10931070	16-55	26AUG2020	68484	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931071	C4591001 1093 10931071	16-55	26AUG2020	69018	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10931072	C4591001 1093 10931072	16-55	26AUG2020	69019	Placebo	26AUG2020/ Placebo			
10931073	C4591001 1093 10931073	16-55	27AUG2020	69021	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10931074	C4591001 1093 10931074	16-55	27AUG2020	69026	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10931078	C4591001 1093 10931078	16-55	27AUG2020	71129	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931084	C4591001 1093 10931084	16-55	28AUG2020	71130	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10931085	C4591001 1093 10931085	16-55	28AUG2020	71132	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10931087	C4591001 1093 10931087	16-55	28AUG2020	71137	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931088	C4591001 1093 10931088	16-55	31AUG2020	74722	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10931089	C4591001 1093 10931089	16-55	31AUG2020	74725	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10931090	C4591001 1093 10931090	16-55	31AUG2020	74726	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10931091	C4591001 1093 10931091	16-55	31AUG2020	74727	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
10931093	C4591001 1093 10931093	16-55	31AUG2020	76073	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10931094	C4591001 1093 10931094	16-55	31AUG2020	76074	Placebo	31AUG2020/ Placebo			
10931095	C4591001 1093 10931095	16-55	31AUG2020	76076	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931096	C4591001 1093 10931096	16-55	01SEP2020	76082	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931098	C4591001 1093 10931098	16-55	01SEP2020	76829	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10931099	C4591001 1093 10931099	16-55	01SEP2020	76830	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10931100	C4591001 1093 10931100	16-55	01SEP2020	76831	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
10931101	C4591001 1093 10931101	16-55	02SEP2020	76832	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10931103	C4591001 1093 10931103	16-55	02SEP2020	78893	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10931108	C4591001 1093 10931108	16-55	04SEP2020	78901	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10931111	C4591001 1093 10931111	16-55	08SEP2020	84428	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10931113	C4591001 1093 10931113	16-55	08SEP2020	84429	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
10931115	C4591001 1093 10931115	16-55	10SEP2020	84430	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931117	C4591001 1093 10931117	16-55	10SEP2020	84431	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931118	C4591001 1093 10931118	16-55	10SEP2020	87629	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10931121	C4591001 1093 10931121	16-55	11SEP2020	87635	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10931123	C4591001 1093 10931123	16-55	11SEP2020	87636	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10931124	C4591001 1093 10931124	16-55	11SEP2020	87639	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10931126	C4591001 1093 10931126	16-55	11SEP2020	88626	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10931127	C4591001 1093 10931127	16-55	11SEP2020	88627	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931129	C4591001 1093 10931129	16-55	15SEP2020	88631	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
10931131	C4591001 1093 10931131	16-55	17SEP2020	88634	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10931132	C4591001 1093 10931132	16-55	18SEP2020	93260	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931133	C4591001 1093 10931133	16-55	18SEP2020	93263	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931134	C4591001 1093 10931134	16-55	22SEP2020	93266	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931135	C4591001 1093 10931135	16-55	22SEP2020	93267	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10931136	C4591001 1093 10931136	16-55	22SEP2020	96199	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10931137	C4591001 1093 10931137	16-55	22SEP2020	96202	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
10931138	C4591001 1093 10931138	16-55	22SEP2020	96203	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10931139	C4591001 1093 10931139	16-55	22SEP2020	96204	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10931145	C4591001 1093 10931145	16-55	22SEP2020	97052	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10931146	C4591001 1093 10931146	16-55	22SEP2020	97053	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10931147	C4591001 1093 10931147	16-55	22SEP2020	97055	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931148	C4591001 1093 10931148	16-55	22SEP2020	97109	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
10931149	C4591001 1093 10931149	16-55	22SEP2020	97057	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931150	C4591001 1093 10931150	16-55	22SEP2020	97113	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10931152	C4591001 1093 10931152	16-55	23SEP2020	97115	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10931155	C4591001 1093 10931155	16-55	23SEP2020	97119	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10931158	C4591001 1093 10931158	16-55	23SEP2020	97917	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
10931168	C4591001 1093 10931168	16-55	02OCT2020	97920	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
10931169	C4591001 1093 10931169	16-55	02OCT2020	97922	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
10931170	C4591001 1093 10931170	16-55	07OCT2020	97924	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10931171	C4591001 1093 10931171	16-55	07OCT2020	104981	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931173	C4591001 1093 10931173	16-55	12OCT2020	104984	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
10931174	C4591001 1093 10931174	16-55	12OCT2020	104985	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10931175	C4591001 1093 10931175	16-55	14OCT2020	104991	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo		
10931177	C4591001 1093 10931177	16-55	19OCT2020	109895	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10931178	C4591001 1093 10931178	16-55	19OCT2020	109896	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10931179	C4591001 1093 10931179	16-55	19OCT2020	109897	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10931180	C4591001 1093 10931180	16-55	19OCT2020	109898	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10931183	C4591001 1093 10931183	16-55	20OCT2020	110876	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10931185	C4591001 1093 10931185	16-55	20OCT2020	110880	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10931186	C4591001 1093 10931186	16-55	20OCT2020	110878	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931187	C4591001 1093 10931187	16-55	20OCT2020	110881	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10931188	C4591001 1093 10931188	16-55	20OCT2020	111233	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10931194	C4591001 1093 10931194	16-55	22OCT2020	111241	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10931195	C4591001 1093 10931195	16-55	22OCT2020	111243	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
10931196	C4591001 1093 10931196	16-55	23OCT2020	111244	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
10931197	C4591001 1093 10931197	16-55	23OCT2020	112818	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10931199	C4591001 1093 10931199	16-55	23OCT2020	112821	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10931200	C4591001 1093 10931200	16-55	23OCT2020	112823	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931201	C4591001 1093 10931201	16-55	23OCT2020	112826	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931202	C4591001 1093 10931202	16-55	23OCT2020	113167	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931203	C4591001 1093 10931203	16-55	23OCT2020	113171	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10931204	C4591001 1093 10931204	16-55	23OCT2020	113175	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931205	C4591001 1093 10931205	16-55	23OCT2020	113176	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
10931208	C4591001 1093 10931208	16-55	26OCT2020	113575	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10931209	C4591001 1093 10931209	16-55	26OCT2020	113583	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10931210	C4591001 1093 10931210	16-55	26OCT2020	113576	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
10931211	C4591001 1093 10931211	16-55	26OCT2020	113582	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)			
10931214	C4591001 1093 10931214	16-55	26OCT2020	113721	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10931215	C4591001 1093 10931215	16-55	26OCT2020	113723	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
10931216	C4591001 1093 10931216	16-55	26OCT2020	113726	Placebo	26OCT2020/ Placebo	20NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10931217	C4591001 1093 10931217	16-55	26OCT2020	113780	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
10931218	C4591001 1093 10931218	16-55	26OCT2020	113727	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
10931219	C4591001 1093 10931219	16-55	27OCT2020	113784	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10931222	C4591001 1093 10931222	16-55	27OCT2020	113785	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10931223	C4591001 1093 10931223	16-55	28OCT2020	113788	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
10931224	C4591001 1093 10931224	16-55	28OCT2020	114378	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10931226	C4591001 1093 10931226	16-55	28OCT2020	114379	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10941025	C4591001 1094 10941025	16-55	18AUG2020	231522	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10941030	C4591001 1094 10941030	16-55	18AUG2020	55259	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10941031	C4591001 1094 10941031	16-55	18AUG2020	55256	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941040	C4591001 1094 10941040	16-55	20AUG2020	55260	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10941043	C4591001 1094 10941043	16-55	21AUG2020	55264	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
10941048	C4591001 1094 10941048	16-55	24AUG2020	64794	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941049	C4591001 1094 10941049	16-55	24AUG2020	64793	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941055	C4591001 1094 10941055	16-55	25AUG2020	64796	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10941066	C4591001 1094 10941066	16-55	28AUG2020	64798	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10941067	C4591001 1094 10941067	16-55	28AUG2020	72043	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10941068	C4591001 1094 10941068	16-55	28AUG2020	72049	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10941069	C4591001 1094 10941069	16-55	28AUG2020	72051	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10941070	C4591001 1094 10941070	16-55	28AUG2020	72052	Placebo	28AUG2020/ Placebo	28SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941075	C4591001 1094 10941075	16-55	01SEP2020	77681	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941076	C4591001 1094 10941076	16-55	01SEP2020	77686	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10941077	C4591001 1094 10941077	16-55	01SEP2020	77688	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941082	C4591001 1094 10941082	16-55	02SEP2020	77690	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10941084	C4591001 1094 10941084	16-55	03SEP2020	80180	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10941087	C4591001 1094 10941087	16-55	03SEP2020	80184	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941090	C4591001 1094 10941090	16-55	03SEP2020	80186	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10941091	C4591001 1094 10941091	16-55	03SEP2020	80188	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941095	C4591001 1094 10941095	16-55	04SEP2020	82029	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10941098	C4591001 1094 10941098	16-55	04SEP2020	82031	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941100	C4591001 1094 10941100	16-55	05SEP2020	82034	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10941104	C4591001 1094 10941104	16-55	07SEP2020	82035	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10941107	C4591001 1094 10941107	16-55	07SEP2020	83254	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10941108	C4591001 1094 10941108	16-55	07SEP2020	83256	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10941109	C4591001 1094 10941109	16-55	07SEP2020	83258	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10941117	C4591001 1094 10941117	16-55	09SEP2020	83259	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10941124	C4591001 1094 10941124	16-55	11SEP2020	88219	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941129	C4591001 1094 10941129	16-55	15SEP2020	88226	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10941131	C4591001 1094 10941131	16-55	15SEP2020	88227	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10941132	C4591001 1094 10941132	16-55	15SEP2020	88228	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941137	C4591001 1094 10941137	16-55	17SEP2020	92708	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
10941143	C4591001 1094 10941143	16-55	18SEP2020	262044	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10941144	C4591001 1094 10941144	16-55	18SEP2020	92709	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941150	C4591001 1094 10941150	16-55	07OCT2020	103975	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10941153	C4591001 1094 10941153	16-55	24SEP2020	92711	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10941155	C4591001 1094 10941155	16-55	25SEP2020	92715	Placebo	25SEP2020/ Placebo	10NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10941156	C4591001 1094 10941156	16-55	25SEP2020	100025	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10941163	C4591001 1094 10941163	16-55	01OCT2020	100030	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941166	C4591001 1094 10941166	16-55	02OCT2020	100031	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
10941167	C4591001 1094 10941167	16-55	02OCT2020	100035	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10941169	C4591001 1094 10941169	16-55	05OCT2020	103974	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo		
10941176	C4591001 1094 10941176	16-55	12OCT2020	103978	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10941179	C4591001 1094 10941179	16-55	19OCT2020	103981	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10941181	C4591001 1094 10941181	16-55	21OCT2020	111463	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
10941182	C4591001 1094 10941182	16-55	22OCT2020	111467	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10941186	C4591001 1094 10941186	16-55	29OCT2020	111468	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10941188	C4591001 1094 10941188	16-55	29OCT2020	111469	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
10941189	C4591001 1094 10941189	16-55	29OCT2020	114821	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10941192	C4591001 1094 10941192	16-55	30OCT2020	114825	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
10951110	C4591001 1095 10951110	16-55	19AUG2020	44853	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951112	C4591001 1095 10951112	16-55	25AUG2020	65406	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10951114	C4591001 1095 10951114	16-55	20AUG2020	44858	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10951116	C4591001 1095 10951116	16-55	21AUG2020	44859	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10951119	C4591001 1095 10951119	16-55	28AUG2020	72343	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	
10951121	C4591001 1095 10951121	16-55	21AUG2020	61398	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10951122	C4591001 1095 10951122	16-55	24AUG2020	61401	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951124	C4591001 1095 10951124	16-55	24AUG2020	61405	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10951128	C4591001 1095 10951128	16-55	25AUG2020	65405	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10951129	C4591001 1095 10951129	16-55	25AUG2020	61408	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10951132	C4591001 1095 10951132	16-55	04SEP2020	81485	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951137	C4591001 1095 10951137	16-55	26AUG2020	65416	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951138	C4591001 1095 10951138	16-55	26AUG2020	65414	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10951141	C4591001 1095 10951141	16-55	26AUG2020	68046	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10951142	C4591001 1095 10951142	16-55	26AUG2020	68050	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10951143	C4591001 1095 10951143	16-55	26AUG2020	68052	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10951144	C4591001 1095 10951144	16-55	26AUG2020	68053	Placebo	26AUG2020/ Placebo	30NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
10951147	C4591001 1095 10951147	16-55	27AUG2020	69713	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951148	C4591001 1095 10951148	16-55	27AUG2020	69715	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951149	C4591001 1095 10951149	16-55	27AUG2020	69717	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951150	C4591001 1095 10951150	16-55	27AUG2020	69722	Placebo	27AUG2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951152	C4591001 1095 10951152	16-55	27AUG2020	71214	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10951153	C4591001 1095 10951153	16-55	28AUG2020	71218	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951154	C4591001 1095 10951154	16-55	28AUG2020	71222	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10951155	C4591001 1095 10951155	16-55	28AUG2020	72341	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951156	C4591001 1095 10951156	16-55	28AUG2020	71224	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10951159	C4591001 1095 10951159	16-55	29AUG2020	72345	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10951160	C4591001 1095 10951160	16-55	29AUG2020	72347	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10951161	C4591001 1095 10951161	16-55	29AUG2020	73663	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10951163	C4591001 1095 10951163	16-55	29AUG2020	73666	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951166	C4591001 1095 10951166	16-55	29AUG2020	73668	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951168	C4591001 1095 10951168	16-55	29AUG2020	73669	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			
10951169	C4591001 1095 10951169	16-55	29AUG2020	74070	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10951170	C4591001 1095 10951170	16-55	29AUG2020	74018	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10951171	C4591001 1095 10951171	16-55	29AUG2020	74015	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951172	C4591001 1095 10951172	16-55	29AUG2020	74012	Placebo	29AUG2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10951173	C4591001 1095 10951173	16-55	29AUG2020	74020	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			
10951174	C4591001 1095 10951174	16-55	31AUG2020	74075	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10951176	C4591001 1095 10951176	16-55	31AUG2020	74072	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10951177	C4591001 1095 10951177	16-55	03SEP2020	79466	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951178	C4591001 1095 10951178	16-55	31AUG2020	74076	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951182	C4591001 1095 10951182	16-55	31AUG2020	75221	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951183	C4591001 1095 10951183	16-55	31AUG2020	75223	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951184	C4591001 1095 10951184	16-55	31AUG2020	75224	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10951185	C4591001 1095 10951185	16-55	31AUG2020	75227	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10951186	C4591001 1095 10951186	16-55	31AUG2020	76149	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10951188	C4591001 1095 10951188	16-55	01SEP2020	76150	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951191	C4591001 1095 10951191	16-55	01SEP2020	76151	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10951194	C4591001 1095 10951194	16-55	01SEP2020	76152	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951196	C4591001 1095 10951196	16-55	01SEP2020	77333	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10951197	C4591001 1095 10951197	16-55	01SEP2020	77334	Placebo	01SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951198	C4591001 1095 10951198	16-55	01SEP2020	77343	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951199	C4591001 1095 10951199	16-55	01SEP2020	77344	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10951201	C4591001 1095 10951201	16-55	02SEP2020	78091	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10951202	C4591001 1095 10951202	16-55	02SEP2020	78095	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
10951203	C4591001 1095 10951203	16-55	02SEP2020	78099	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10951207	C4591001 1095 10951207	16-55	02SEP2020	78100	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10951208	C4591001 1095 10951208	16-55	02SEP2020	78525	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10951214	C4591001 1095 10951214	16-55	02SEP2020	78527	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10951215	C4591001 1095 10951215	16-55	02SEP2020	78528	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10951216	C4591001 1095 10951216	16-55	02SEP2020	78531	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951217	C4591001 1095 10951217	16-55	02SEP2020	79461	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951218	C4591001 1095 10951218	16-55	02SEP2020	79465	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10951222	C4591001 1095 10951222	16-55	03SEP2020	79467	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951223	C4591001 1095 10951223	16-55	04SEP2020	81487	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951225	C4591001 1095 10951225	16-55	04SEP2020	81488	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10951231	C4591001 1095 10951231	16-55	25SEP2020	81490	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
10951233	C4591001 1095 10951233	16-55	25SEP2020	99896	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10951236	C4591001 1095 10951236	16-55	25SEP2020	99899	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10951241	C4591001 1095 10951241	16-55	30SEP2020	102489	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
10951243	C4591001 1095 10951243	16-55	25SEP2020	99901	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951244	C4591001 1095 10951244	16-55	28SEP2020	99902	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951245	C4591001 1095 10951245	16-55	28SEP2020	101369	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951248	C4591001 1095 10951248	16-55	28SEP2020	101371	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10951250	C4591001 1095 10951250	16-55	28SEP2020	101372	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
10951251	C4591001 1095 10951251	16-55	28SEP2020	101375	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10951253	C4591001 1095 10951253	16-55	28SEP2020	101573	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10951254	C4591001 1095 10951254	16-55	28SEP2020	101577	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10951255	C4591001 1095 10951255	16-55	29SEP2020	101579	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10951257	C4591001 1095 10951257	16-55	30SEP2020	101580	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10951259	C4591001 1095 10951259	16-55	06OCT2020	102490	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951260	C4591001 1095 10951260	16-55	07OCT2020	102493	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10951262	C4591001 1095 10951262	16-55	07OCT2020	102496	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10951266	C4591001 1095 10951266	16-55	08OCT2020	105333	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10951267	C4591001 1095 10951267	16-55	08OCT2020	105334	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10951268	C4591001 1095 10951268	16-55	08OCT2020	105339	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10951269	C4591001 1095 10951269	16-55	08OCT2020	105338	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
10951270	C4591001 1095 10951270	16-55	08OCT2020	105512	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo		
10951271	C4591001 1095 10951271	16-55	08OCT2020	105511	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10951274	C4591001 1095 10951274	16-55	12OCT2020	105515	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
10951277	C4591001 1095 10951277	16-55	12OCT2020	106578	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951278	C4591001 1095 10951278	16-55	12OCT2020	105516	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10951280	C4591001 1095 10951280	16-55	12OCT2020	106587	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951281	C4591001 1095 10951281	16-55	12OCT2020	106581	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951282	C4591001 1095 10951282	16-55	12OCT2020	106585	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10951283	C4591001 1095 10951283	16-55	12OCT2020	106697	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10951284	C4591001 1095 10951284	16-55	13OCT2020	106701	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10951285	C4591001 1095 10951285	16-55	13OCT2020	106706	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10951286	C4591001 1095 10951286	16-55	13OCT2020	106707	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10951288	C4591001 1095 10951288	16-55	14OCT2020	107754	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
10951290	C4591001 1095 10951290	16-55	14OCT2020	107756	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951291	C4591001 1095 10951291	16-55	14OCT2020	107758	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10951292	C4591001 1095 10951292	16-55	16OCT2020	107762	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo		
10951293	C4591001 1095 10951293	16-55	16OCT2020	109053	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951294	C4591001 1095 10951294	16-55	16OCT2020	109054	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
10951295	C4591001 1095 10951295	16-55	16OCT2020	109058	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10951296	C4591001 1095 10951296	16-55	19OCT2020	109059	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10951298	C4591001 1095 10951298	16-55	19OCT2020	110561	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
10951299	C4591001 1095 10951299	16-55	20OCT2020	110565	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo		
10951301	C4591001 1095 10951301	16-55	21OCT2020	110566	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
10951304	C4591001 1095 10951304	16-55	22OCT2020	110567	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951305	C4591001 1095 10951305	16-55	23OCT2020	113201	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
10951306	C4591001 1095 10951306	16-55	23OCT2020	113203	Placebo	23OCT2020/ Placebo	17NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10951307	C4591001 1095 10951307	16-55	30OCT2020	113207	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
10951308	C4591001 1095 10951308	16-55	17NOV2020	113212	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
10951309	C4591001 1095 10951309	16-55	18NOV2020	116456	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo		
10951310	C4591001 1095 10951310	16-55	19NOV2020	116457	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10951311	C4591001 1095 10951311	16-55	19NOV2020	116458	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
10951312	C4591001 1095 10951312	16-55	20NOV2020	116464	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951313	C4591001 1095 10951313	16-55	23NOV2020	116671	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
10951314	C4591001 1095 10951314	16-55	23NOV2020	116676	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10951315	C4591001 1095 10951315	16-55	23NOV2020	116677	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
10951316	C4591001 1095 10951316	16-55	23NOV2020	116678	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10951317	C4591001 1095 10951317	16-55	24NOV2020	116876	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10951318	C4591001 1095 10951318	16-55	30NOV2020	116879	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10951319	C4591001 1095 10951319	16-55	01DEC2020	116881	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
10961026	C4591001 1096 10961026	16-55	14AUG2020	50902	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
10961027	C4591001 1096 10961027	16-55	14AUG2020	50900	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10961031	C4591001 1096 10961031	16-55	14AUG2020	51006	Placebo	14AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
10961032	C4591001 1096 10961032	16-55	14AUG2020	51007	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
10961035	C4591001 1096 10961035	16-55	17AUG2020	51015	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961036	C4591001 1096 10961036	16-55	17AUG2020	51014	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
10961042	C4591001 1096 10961042	16-55	17AUG2020	53688	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961049	C4591001 1096 10961049	16-55	18AUG2020	53689	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10961052	C4591001 1096 10961052	16-55	18AUG2020	53690	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961053	C4591001 1096 10961053	16-55	18AUG2020	55568	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10961057	C4591001 1096 10961057	16-55	18AUG2020	53691	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
10961059	C4591001 1096 10961059	16-55	19AUG2020	55573	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961060	C4591001 1096 10961060	16-55	19AUG2020	55570	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10961061	C4591001 1096 10961061	16-55	19AUG2020	55574	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961062	C4591001 1096 10961062	16-55	19AUG2020	56745	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961063	C4591001 1096 10961063	16-55	19AUG2020	56748	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961064	C4591001 1096 10961064	16-55	19AUG2020	56749	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961067	C4591001 1096 10961067	16-55	19AUG2020	56751	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10961072	C4591001 1096 10961072	16-55	20AUG2020	58782	Placebo	20AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10961074	C4591001 1096 10961074	16-55	20AUG2020	58784	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961075	C4591001 1096 10961075	16-55	20AUG2020	58787	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961076	C4591001 1096 10961076	16-55	20AUG2020	58785	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
10961077	C4591001 1096 10961077	16-55	20AUG2020	58949	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961078	C4591001 1096 10961078	16-55	20AUG2020	58951	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10961081	C4591001 1096 10961081	16-55	20AUG2020	58958	Placebo	20AUG2020/ Placebo			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961083	C4591001 1096 10961083	16-55	20AUG2020	59843	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10961084	C4591001 1096 10961084	16-55	20AUG2020	59844	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10961085	C4591001 1096 10961085	16-55	20AUG2020	58960	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961087	C4591001 1096 10961087	16-55	21AUG2020	61016	Placebo	21AUG2020/ Placebo	12SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10961088	C4591001 1096 10961088	16-55	21AUG2020	59846	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961089	C4591001 1096 10961089	16-55	21AUG2020	59845	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961090	C4591001 1096 10961090	16-55	22AUG2020	61019	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10961093	C4591001 1096 10961093	16-55	22AUG2020	61988	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10961096	C4591001 1096 10961096	16-55	22AUG2020	61024	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10961097	C4591001 1096 10961097	16-55	22AUG2020	61020	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961098	C4591001 1096 10961098	16-55	22AUG2020	61991	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961099	C4591001 1096 10961099	16-55	22AUG2020	61992	Placebo	22AUG2020/ Placebo	19SEP2020/ Placebo		
10961100	C4591001 1096 10961100	16-55	22AUG2020	61996	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10961101	C4591001 1096 10961101	16-55	22AUG2020	62233	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10961102	C4591001 1096 10961102	16-55	22AUG2020	62226	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961103	C4591001 1096 10961103	16-55	22AUG2020	62225	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961105	C4591001 1096 10961105	16-55	22AUG2020	62236	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10961109	C4591001 1096 10961109	16-55	22AUG2020	62291	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo		
10961110	C4591001 1096 10961110	16-55	22AUG2020	62290	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961111	C4591001 1096 10961111	16-55	22AUG2020	62288	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961112	C4591001 1096 10961112	16-55	22AUG2020	62292	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10961113	C4591001 1096 10961113	16-55	22AUG2020	62381	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
10961114	C4591001 1096 10961114	16-55	24AUG2020	62384	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961115	C4591001 1096 10961115	16-55	24AUG2020	62386	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961122	C4591001 1096 10961122	16-55	24AUG2020	62391	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10961125	C4591001 1096 10961125	16-55	25AUG2020	66150	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10961130	C4591001 1096 10961130	16-55	25AUG2020	66152	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10961137	C4591001 1096 10961137	16-55	26AUG2020	68095	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961138	C4591001 1096 10961138	16-55	26AUG2020	68104	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
10961139	C4591001 1096 10961139	16-55	26AUG2020	66154	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961140	C4591001 1096 10961140	16-55	26AUG2020	66159	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10961141	C4591001 1096 10961141	16-55	26AUG2020	68100	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
10961142	C4591001 1096 10961142	16-55	26AUG2020	68103	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
10961145	C4591001 1096 10961145	16-55	26AUG2020	69029	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
10961147	C4591001 1096 10961147	16-55	26AUG2020	69032	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961148	C4591001 1096 10961148	16-55	26AUG2020	69031	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961150	C4591001 1096 10961150	16-55	27AUG2020	69033	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961151	C4591001 1096 10961151	16-55	27AUG2020	70443	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10961152	C4591001 1096 10961152	16-55	27AUG2020	70434	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961154	C4591001 1096 10961154	16-55	27AUG2020	70442	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961158	C4591001 1096 10961158	16-55	27AUG2020	70444	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961168	C4591001 1096 10961168	16-55	28AUG2020	72569	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10961169	C4591001 1096 10961169	16-55	28AUG2020	72573	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
10961170	C4591001 1096 10961170	16-55	29AUG2020	72575	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961172	C4591001 1096 10961172	16-55	29AUG2020	73649	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10961173	C4591001 1096 10961173	16-55	29AUG2020	73733	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961175	C4591001 1096 10961175	16-55	29AUG2020	73659	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10961176	C4591001 1096 10961176	16-55	29AUG2020	73735	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10961177	C4591001 1096 10961177	16-55	29AUG2020	73740	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961178	C4591001 1096 10961178	16-55	29AUG2020	73739	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961179	C4591001 1096 10961179	16-55	29AUG2020	73651	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961180	C4591001 1096 10961180	16-55	29AUG2020	73658	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10961185	C4591001 1096 10961185	16-55	29AUG2020	73926	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961186	C4591001 1096 10961186	16-55	29AUG2020	73930	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10961187	C4591001 1096 10961187	16-55	29AUG2020	73933	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10961195	C4591001 1096 10961195	16-55	31AUG2020	73936	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
10961196	C4591001 1096 10961196	16-55	31AUG2020	75212	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
10961197	C4591001 1096 10961197	16-55	31AUG2020	75213	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961199	C4591001 1096 10961199	16-55	31AUG2020	75216	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961200	C4591001 1096 10961200	16-55	31AUG2020	75218	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961205	C4591001 1096 10961205	16-55	01SEP2020	77053	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
10961206	C4591001 1096 10961206	16-55	01SEP2020	77045	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961207	C4591001 1096 10961207	16-55	01SEP2020	77055	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10961208	C4591001 1096 10961208	16-55	01SEP2020	77650	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10961209	C4591001 1096 10961209	16-55	01SEP2020	77645	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961210	C4591001 1096 10961210	16-55	01SEP2020	77054	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10961211	C4591001 1096 10961211	16-55	01SEP2020	77655	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961213	C4591001 1096 10961213	16-55	02SEP2020	77656	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961214	C4591001 1096 10961214	16-55	02SEP2020	78458	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961215	C4591001 1096 10961215	16-55	02SEP2020	78460	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961216	C4591001 1096 10961216	16-55	02SEP2020	78452	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
10961217	C4591001 1096 10961217	16-55	02SEP2020	78451	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10961218	C4591001 1096 10961218	16-55	02SEP2020	78643	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961219	C4591001 1096 10961219	16-55	02SEP2020	78652	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10961220	C4591001 1096 10961220	16-55	02SEP2020	79363	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961222	C4591001 1096 10961222	16-55	02SEP2020	78645	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10961223	C4591001 1096 10961223	16-55	02SEP2020	78648	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961225	C4591001 1096 10961225	16-55	03SEP2020	79372	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10961226	C4591001 1096 10961226	16-55	03SEP2020	79365	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10961227	C4591001 1096 10961227	16-55	03SEP2020	79364	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961229	C4591001 1096 10961229	16-55	03SEP2020	80405	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961230	C4591001 1096 10961230	16-55	03SEP2020	80412	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
10961231	C4591001 1096 10961231	16-55	03SEP2020	80409	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961236	C4591001 1096 10961236	16-55	03SEP2020	80416	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10961238	C4591001 1096 10961238	16-55	04SEP2020	81473	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10961239	C4591001 1096 10961239	16-55	04SEP2020	81474	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961240	C4591001 1096 10961240	16-55	04SEP2020	81477	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961242	C4591001 1096 10961242	16-55	04SEP2020	81478	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961243	C4591001 1096 10961243	16-55	04SEP2020	81791	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961244	C4591001 1096 10961244	16-55	04SEP2020	81796	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961245	C4591001 1096 10961245	16-55	04SEP2020	81790	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961246	C4591001 1096 10961246	16-55	04SEP2020	81788	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
10961249	C4591001 1096 10961249	16-55	04SEP2020	82329	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961251	C4591001 1096 10961251	16-55	04SEP2020	82330	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10961254	C4591001 1096 10961254	16-55	04SEP2020	82333	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10961255	C4591001 1096 10961255	16-55	04SEP2020	82334	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961256	C4591001 1096 10961256	16-55	04SEP2020	82406	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
10961257	C4591001 1096 10961257	16-55	04SEP2020	82405	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961258	C4591001 1096 10961258	16-55	04SEP2020	82401	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10961261	C4591001 1096 10961261	16-55	05SEP2020	82735	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961262	C4591001 1096 10961262	16-55	05SEP2020	82736	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
10961264	C4591001 1096 10961264	16-55	05SEP2020	82737	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10961265	C4591001 1096 10961265	16-55	05SEP2020	82738	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961266	C4591001 1096 10961266	16-55	05SEP2020	82769	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10961267	C4591001 1096 10961267	16-55	05SEP2020	82770	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961268	C4591001 1096 10961268	16-55	05SEP2020	82774	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
10961271	C4591001 1096 10961271	16-55	05SEP2020	82775	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10961275	C4591001 1096 10961275	16-55	05SEP2020	82937	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10961276	C4591001 1096 10961276	16-55	05SEP2020	82939	Placebo	05SEP2020/ Placebo			
10961277	C4591001 1096 10961277	16-55	05SEP2020	82938	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961278	C4591001 1096 10961278	16-55	05SEP2020	82945	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
10961279	C4591001 1096 10961279	16-55	05SEP2020	82979	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
10961280	C4591001 1096 10961280	16-55	05SEP2020	82976	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
10961284	C4591001 1096 10961284	16-55	05SEP2020	82991	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10961286	C4591001 1096 10961286	16-55	05SEP2020	82982	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
10961287	C4591001 1096 10961287	16-55	05SEP2020	82993	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961288	C4591001 1096 10961288	16-55	05SEP2020	82984	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10961289	C4591001 1096 10961289	16-55	08SEP2020	82995	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961291	C4591001 1096 10961291	16-55	08SEP2020	82996	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
10961293	C4591001 1096 10961293	16-55	08SEP2020	84570	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961299	C4591001 1096 10961299	16-55	08SEP2020	84574	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10961301	C4591001 1096 10961301	16-55	08SEP2020	84578	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10961303	C4591001 1096 10961303	16-55	09SEP2020	84579	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961305	C4591001 1096 10961305	16-55	09SEP2020	86058	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
10961306	C4591001 1096 10961306	16-55	10SEP2020	86061	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10961307	C4591001 1096 10961307	16-55	10SEP2020	86065	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
10961309	C4591001 1096 10961309	16-55	10SEP2020	86066	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961313	C4591001 1096 10961313	16-55	10SEP2020	87642	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10961317	C4591001 1096 10961317	16-55	12SEP2020	87645	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
10961318	C4591001 1096 10961318	16-55	12SEP2020	87649	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961319	C4591001 1096 10961319	16-55	12SEP2020	87652	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10961321	C4591001 1096 10961321	16-55	12SEP2020	89179	Placebo	12SEP2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10961322	C4591001 1096 10961322	16-55	14SEP2020	89182	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10961323	C4591001 1096 10961323	16-55	14SEP2020	89187	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10961328	C4591001 1096 10961328	16-55	14SEP2020	89188	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
10961330	C4591001 1096 10961330	16-55	15SEP2020	90522	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10961331	C4591001 1096 10961331	16-55	15SEP2020	90523	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10961335	C4591001 1096 10961335	16-55	15SEP2020	90525	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
10961336	C4591001 1096 10961336	16-55	15SEP2020	90530	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10961340	C4591001 1096 10961340	16-55	15SEP2020	90810	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961341	C4591001 1096 10961341	16-55	15SEP2020	90814	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10961342	C4591001 1096 10961342	16-55	15SEP2020	90816	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10961343	C4591001 1096 10961343	16-55	16SEP2020	90817	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
10961344	C4591001 1096 10961344	16-55	16SEP2020	91363	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)			
10961345	C4591001 1096 10961345	16-55	16SEP2020	91368	Placebo	16SEP2020/ Placebo	06NOV2020/ Placebo		
10961348	C4591001 1096 10961348	16-55	16SEP2020	91369	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10961350	C4591001 1096 10961350	16-55	17SEP2020	91371	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10961351	C4591001 1096 10961351	16-55	17SEP2020	92671	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
10961357	C4591001 1096 10961357	16-55	17SEP2020	92673	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
10961358	C4591001 1096 10961358	16-55	17SEP2020	92675	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961359	C4591001 1096 10961359	16-55	17SEP2020	261564	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10961360	C4591001 1096 10961360	16-55	17SEP2020	92678	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10961362	C4591001 1096 10961362	16-55	17SEP2020	93108	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
10961366	C4591001 1096 10961366	16-55	28SEP2020	93110	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
10961367	C4591001 1096 10961367	16-55	28SEP2020	93111	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10961370	C4591001 1096 10961370	16-55	29SEP2020	93112	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10961372	C4591001 1096 10961372	16-55	06OCT2020	104371	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
10961373	C4591001 1096 10961373	16-55	06OCT2020	104370	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		
10961374	C4591001 1096 10961374	16-55	06OCT2020	104377	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
10961375	C4591001 1096 10961375	16-55	07OCT2020	104380	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961376	C4591001 1096 10961376	16-55	07OCT2020	104950	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
10961378	C4591001 1096 10961378	16-55	08OCT2020	104954	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10961379	C4591001 1096 10961379	16-55	08OCT2020	104953	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
10961382	C4591001 1096 10961382	16-55	09OCT2020	104956	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
10961385	C4591001 1096 10961385	16-55	09OCT2020	106161	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10961387	C4591001 1096 10961387	16-55	09OCT2020	106163	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
10961388	C4591001 1096 10961388	16-55	09OCT2020	106165	Placebo	09OCT2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
10961390	C4591001 1096 10961390	16-55	02NOV2020	106167	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo		
10961391	C4591001 1096 10961391	16-55	05NOV2020	115819	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
10961392	C4591001 1096 10961392	16-55	23NOV2020	115821	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10961393	C4591001 1096 10961393	16-55	02DEC2020	115827	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
10971007	C4591001 1097 10971007	16-55	20AUG2020	57896	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
10971018	C4591001 1097 10971018	16-55	22AUG2020	57898	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
10971041	C4591001 1097 10971041	16-55	26AUG2020	57899	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10971069	C4591001 1097 10971069	16-55	31AUG2020	57900	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10971081	C4591001 1097 10971081	16-55	01SEP2020	248315	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10971083	C4591001 1097 10971083	16-55	01SEP2020	77226	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
10971085	C4591001 1097 10971085	16-55	01SEP2020	77227	Placebo	01SEP2020/ Placebo	15OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
10971086	C4591001 1097 10971086	16-55	02SEP2020	77228	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10971096	C4591001 1097 10971096	16-55	04SEP2020	77236	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10971116	C4591001 1097 10971116	16-55	18SEP2020	93573	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
10971117	C4591001 1097 10971117	16-55	21SEP2020	93576	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10971119	C4591001 1097 10971119	16-55	28SEP2020	93578	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
10971120	C4591001 1097 10971120	16-55	15OCT2020	93580	Placebo	15OCT2020/ Placebo	17NOV2020/ Placebo		
10981001	C4591001 1098 10981001	16-55	18AUG2020	54332	Placebo	18AUG2020/ Placebo			
10981004	C4591001 1098 10981004	16-55	18AUG2020	54333	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
10981006	C4591001 1098 10981006	16-55	18AUG2020	54334	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
10981009	C4591001 1098 10981009	16-55	19AUG2020	54338	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10981011	C4591001 1098 10981011	16-55	19AUG2020	56201	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10981014	C4591001 1098 10981014	16-55	19AUG2020	56203	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981015	C4591001 1098 10981015	16-55	19AUG2020	56209	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
10981018	C4591001 1098 10981018	16-55	20AUG2020	56211	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981020	C4591001 1098 10981020	16-55	20AUG2020	59249	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981023	C4591001 1098 10981023	16-55	21AUG2020	59257	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
10981025	C4591001 1098 10981025	16-55	21AUG2020	59259	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
10981027	C4591001 1098 10981027	16-55	21AUG2020	59260	Placebo	21AUG2020/ Placebo	15SEP2020/ Placebo		
10981029	C4591001 1098 10981029	16-55	21AUG2020	61171	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			
10981031	C4591001 1098 10981031	16-55	24AUG2020	61173	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
10981032	C4591001 1098 10981032	16-55	24AUG2020	61175	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10981035	C4591001 1098 10981035	16-55	24AUG2020	61180	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981043	C4591001 1098 10981043	16-55	25AUG2020	66593	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981048	C4591001 1098 10981048	16-55	26AUG2020	66597	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10981052	C4591001 1098 10981052	16-55	27AUG2020	66599	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
10981054	C4591001 1098 10981054	16-55	27AUG2020	66602	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981055	C4591001 1098 10981055	16-55	27AUG2020	70892	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
10981056	C4591001 1098 10981056	16-55	27AUG2020	70896	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
10981057	C4591001 1098 10981057	16-55	28AUG2020	70898	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981060	C4591001 1098 10981060	16-55	28AUG2020	70900	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981064	C4591001 1098 10981064	16-55	31AUG2020	74837	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981065	C4591001 1098 10981065	16-55	31AUG2020	74841	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981067	C4591001 1098 10981067	16-55	31AUG2020	74845	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981068	C4591001 1098 10981068	16-55	31AUG2020	74848	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981069	C4591001 1098 10981069	16-55	31AUG2020	75295	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981073	C4591001 1098 10981073	16-55	01SEP2020	75296	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10981074	C4591001 1098 10981074	16-55	01SEP2020	75301	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981075	C4591001 1098 10981075	16-55	01SEP2020	75303	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981076	C4591001 1098 10981076	16-55	01SEP2020	77165	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
10981077	C4591001 1098 10981077	16-55	02SEP2020	77166	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
10981079	C4591001 1098 10981079	16-55	02SEP2020	77169	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
10981084	C4591001 1098 10981084	16-55	02SEP2020	77171	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981085	C4591001 1098 10981085	16-55	02SEP2020	78473	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
10981086	C4591001 1098 10981086	16-55	02SEP2020	78474	Placebo	02SEP2020/ Placebo	29SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
10981089	C4591001 1098 10981089	16-55	03SEP2020	78476	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981091	C4591001 1098 10981091	16-55	03SEP2020	78480	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981095	C4591001 1098 10981095	16-55	03SEP2020	80221	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981096	C4591001 1098 10981096	16-55	03SEP2020	80223	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
10981097	C4591001 1098 10981097	16-55	03SEP2020	80214	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10981100	C4591001 1098 10981100	16-55	03SEP2020	80224	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981101	C4591001 1098 10981101	16-55	03SEP2020	80828	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10981103	C4591001 1098 10981103	16-55	04SEP2020	80829	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981106	C4591001 1098 10981106	16-55	04SEP2020	80833	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
10981111	C4591001 1098 10981111	16-55	05SEP2020	80835	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981117	C4591001 1098 10981117	16-55	05SEP2020	82711	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981120	C4591001 1098 10981120	16-55	08SEP2020	82712	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
10981121	C4591001 1098 10981121	16-55	08SEP2020	82714	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10981122	C4591001 1098 10981122	16-55	08SEP2020	82718	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
10981125	C4591001 1098 10981125	16-55	08SEP2020	84269	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
10981126	C4591001 1098 10981126	16-55	08SEP2020	84270	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10981129	C4591001 1098 10981129	16-55	09SEP2020	84271	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981132	C4591001 1098 10981132	16-55	09SEP2020	84276	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981134	C4591001 1098 10981134	16-55	10SEP2020	86565	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
10981136	C4591001 1098 10981136	16-55	10SEP2020	86567	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10981137	C4591001 1098 10981137	16-55	10SEP2020	86568	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981138	C4591001 1098 10981138	16-55	10SEP2020	86570	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981140	C4591001 1098 10981140	16-55	10SEP2020	87317	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981141	C4591001 1098 10981141	16-55	10SEP2020	87319	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981142	C4591001 1098 10981142	16-55	10SEP2020	87324	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10981143	C4591001 1098 10981143	16-55	11SEP2020	87328	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10981144	C4591001 1098 10981144	16-55	11SEP2020	88110	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981145	C4591001 1098 10981145	16-55	11SEP2020	88122	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981146	C4591001 1098 10981146	16-55	11SEP2020	88124	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981147	C4591001 1098 10981147	16-55	11SEP2020	88130	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10981151	C4591001 1098 10981151	16-55	11SEP2020	88132	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
10981152	C4591001 1098 10981152	16-55	11SEP2020	88903	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
10981153	C4591001 1098 10981153	16-55	11SEP2020	88908	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981154	C4591001 1098 10981154	16-55	14SEP2020	88909	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10981155	C4591001 1098 10981155	16-55	14SEP2020	88911	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
10981156	C4591001 1098 10981156	16-55	14SEP2020	89657	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
10981160	C4591001 1098 10981160	16-55	14SEP2020	89660	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981161	C4591001 1098 10981161	16-55	14SEP2020	89661	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981163	C4591001 1098 10981163	16-55	14SEP2020	89662	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
10981166	C4591001 1098 10981166	16-55	15SEP2020	90353	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10981168	C4591001 1098 10981168†	16-55	15SEP2020	90360	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
10981169	C4591001 1098 10981169†	16-55	15SEP2020	90361	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
10981170	C4591001 1098 10981170	16-55	15SEP2020	90362	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10981176	C4591001 1098 10981176	16-55	16SEP2020	91100	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981177	C4591001 1098 10981177	16-55	16SEP2020	91103	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10981180	C4591001 1098 10981180	16-55	16SEP2020	91106	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
10981181	C4591001 1098 10981181	16-55	16SEP2020	91108	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981183	C4591001 1098 10981183	16-55	16SEP2020	91795	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981185	C4591001 1098 10981185	16-55	16SEP2020	91796	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
10981186	C4591001 1098 10981186	16-55	16SEP2020	91799	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10981187	C4591001 1098 10981187	16-55	16SEP2020	91803	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
10981188	C4591001 1098 10981188	16-55	24SEP2020	98636	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10981189	C4591001 1098 10981189	16-55	08OCT2020	105245	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
10981191	C4591001 1098 10981191	16-55	18SEP2020	93894	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10981192	C4591001 1098 10981192	16-55	18SEP2020	93896	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
10981194	C4591001 1098 10981194	16-55	18SEP2020	93902	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
10981196	C4591001 1098 10981196	16-55	21SEP2020	93903	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
10981197	C4591001 1098 10981197	16-55	21SEP2020	94963	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981198	C4591001 1098 10981198	16-55	21SEP2020	94965	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
10981199	C4591001 1098 10981199	16-55	21SEP2020	94971	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10981200	C4591001 1098 10981200	16-55	21SEP2020	94970	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)			
10981205	C4591001 1098 10981205	16-55	22SEP2020	96138	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10981206	C4591001 1098 10981206	16-55	22SEP2020	96144	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981207	C4591001 1098 10981207	16-55	22SEP2020	96145	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
10981210	C4591001 1098 10981210	16-55	22SEP2020	96146	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
10981216	C4591001 1098 10981216	16-55	23SEP2020	97830	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
10981217	C4591001 1098 10981217	16-55	23SEP2020	97834	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
10981218	C4591001 1098 10981218	16-55	23SEP2020	97836	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981219	C4591001 1098 10981219	16-55	24SEP2020	97839	Placebo	24SEP2020/ Placebo			
10981220	C4591001 1098 10981220	16-55	24SEP2020	98635	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10981224	C4591001 1098 10981224	16-55	25SEP2020	98638	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
10981226	C4591001 1098 10981226	16-55	25SEP2020	98640	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10981229	C4591001 1098 10981229	16-55	25SEP2020	99953	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
10981230	C4591001 1098 10981230	16-55	25SEP2020	99960	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
10981231	C4591001 1098 10981231	16-55	25SEP2020	99961	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
10981232	C4591001 1098 10981232	16-55	25SEP2020	99964	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
10981234	C4591001 1098 10981234	16-55	28SEP2020	101443	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10981235	C4591001 1098 10981235	16-55	28SEP2020	101444	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981236	C4591001 1098 10981236	16-55	29SEP2020	101449	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10981238	C4591001 1098 10981238	16-55	29SEP2020	101452	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
10981240	C4591001 1098 10981240	16-55	30SEP2020	102509	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
10981241	C4591001 1098 10981241	16-55	01OCT2020	102510	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
10981243	C4591001 1098 10981243	16-55	02OCT2020	102511	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10981244	C4591001 1098 10981244	16-55	02OCT2020	102512	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
10981246	C4591001 1098 10981246	16-55	02OCT2020	103207	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
10981247	C4591001 1098 10981247	16-55	02OCT2020	103208	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
10981251	C4591001 1098 10981251	16-55	07OCT2020	103213	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
10981252	C4591001 1098 10981252	16-55	07OCT2020	103215	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
10981253	C4591001 1098 10981253	16-55	08OCT2020	105249	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo		
10981254	C4591001 1098 10981254	16-55	09OCT2020	105252	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
10981258	C4591001 1098 10981258	16-55	16OCT2020	105253	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10981259	C4591001 1098 10981259	16-55	16OCT2020	109241	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
10981260	C4591001 1098 10981260	16-55	16OCT2020	109247	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
10981262	C4591001 1098 10981262	16-55	20OCT2020	109248	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
10981263	C4591001 1098 10981263	16-55	22OCT2020	109250	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
10981265	C4591001 1098 10981265	16-55	23OCT2020	112853	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
10981266	C4591001 1098 10981266	16-55	23OCT2020	112858	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11011001	C4591001 1101 11011001	16-55	28AUG2020	71947	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011004	C4591001 1101 11011004	16-55	01SEP2020	71950	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11011005	C4591001 1101 11011005	16-55	02SEP2020	71952	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11011007	C4591001 1101 11011007	16-55	02SEP2020	71956	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11011010	C4591001 1101 11011010	16-55	02SEP2020	78705	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11011012	C4591001 1101 11011012	16-55	03SEP2020	78708	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11011013	C4591001 1101 11011013	16-55	03SEP2020	78711	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11011014	C4591001 1101 11011014	16-55	03SEP2020	78712	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11011015	C4591001 1101 11011015	16-55	04SEP2020	82338	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11011016	C4591001 1101 11011016	16-55	04SEP2020	82342	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11011018	C4591001 1101 11011018	16-55	08SEP2020	82343	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011020	C4591001 1101 11011020	16-55	08SEP2020	82344	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11011021	C4591001 1101 11011021	16-55	08SEP2020	84536	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11011022	C4591001 1101 11011022	16-55	09SEP2020	84539	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11011024	C4591001 1101 11011024	16-55	09SEP2020	84540	Placebo	09SEP2020/ Placebo		28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11011026	C4591001 1101 11011026	16-55	09SEP2020	84543	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11011028	C4591001 1101 11011028	16-55	09SEP2020	85843	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11011029	C4591001 1101 11011029	16-55	09SEP2020	85846	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11011030	C4591001 1101 11011030	16-55	10SEP2020	85847	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11011033	C4591001 1101 11011033	16-55	10SEP2020	85852	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11011034	C4591001 1101 11011034	16-55	10SEP2020	86923	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011038	C4591001 1101 11011038	16-55	10SEP2020	86925	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11011039	C4591001 1101 11011039	16-55	10SEP2020	86926	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11011040	C4591001 1101 11011040	16-55	10SEP2020	86927	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11011041	C4591001 1101 11011041	16-55	10SEP2020	87666	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11011042	C4591001 1101 11011042	16-55	11SEP2020	87667	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11011044	C4591001 1101 11011044	16-55	11SEP2020	87674	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11011045	C4591001 1101 11011045	16-55	11SEP2020	87676	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11011046	C4591001 1101 11011046	16-55	14SEP2020	89407	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11011048	C4591001 1101 11011048	16-55	14SEP2020	89408	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11011051	C4591001 1101 11011051	16-55	14SEP2020	89410	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011052	C4591001 1101 11011052	16-55	14SEP2020	89412	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11011053	C4591001 1101 11011053	16-55	14SEP2020	90065	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11011056	C4591001 1101 11011056	16-55	15SEP2020	90068	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11011057	C4591001 1101 11011057	16-55	15SEP2020	90067	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
11011058	C4591001 1101 11011058	16-55	15SEP2020	90074	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11011059	C4591001 1101 11011059	16-55	15SEP2020	90730	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11011060	C4591001 1101 11011060	16-55	15SEP2020	90732	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11011061	C4591001 1101 11011061	16-55	15SEP2020	90733	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11011062	C4591001 1101 11011062	16-55	16SEP2020	90735	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11011065	C4591001 1101 11011065	16-55	16SEP2020	91301	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011067	C4591001 1101 11011067	16-55	16SEP2020	91304	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11011069	C4591001 1101 11011069	16-55	16SEP2020	91306	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11011070	C4591001 1101 11011070	16-55	16SEP2020	91308	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11011071	C4591001 1101 11011071	16-55	16SEP2020	91841	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11011072	C4591001 1101 11011072	16-55	16SEP2020	91846	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11011073	C4591001 1101 11011073	16-55	17SEP2020	91847	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11011074	C4591001 1101 11011074	16-55	17SEP2020	91851	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11011075	C4591001 1101 11011075	16-55	17SEP2020	93042	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11011076	C4591001 1101 11011076	16-55	18SEP2020	93044	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11011079	C4591001 1101 11011079	16-55	18SEP2020	93050	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011080	C4591001 1101 11011080	16-55	18SEP2020	93051	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11011084	C4591001 1101 11011084	16-55	21SEP2020	95334	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11011085	C4591001 1101 11011085	16-55	21SEP2020	95336	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11011087	C4591001 1101 11011087	16-55	22SEP2020	95340	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11011088	C4591001 1101 11011088	16-55	22SEP2020	95344	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11011089	C4591001 1101 11011089	16-55	23SEP2020	97329	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11011090	C4591001 1101 11011090	16-55	23SEP2020	97331	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11011091	C4591001 1101 11011091	16-55	23SEP2020	97333	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11011094	C4591001 1101 11011094	16-55	24SEP2020	97336	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11011096	C4591001 1101 11011096	16-55	24SEP2020	99053	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011097	C4591001 1101 11011097	16-55	24SEP2020	99054	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11011100	C4591001 1101 11011100	16-55	01OCT2020	99056	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11011101	C4591001 1101 11011101	16-55	07OCT2020	99062	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11011105	C4591001 1101 11011105	16-55	12OCT2020	106460	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11011106	C4591001 1101 11011106	16-55	12OCT2020	106463	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11011107	C4591001 1101 11011107	16-55	13OCT2020	106464	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11011108	C4591001 1101 11011108	16-55	13OCT2020	106467	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11011110	C4591001 1101 11011110	16-55	17NOV2020	113542	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11011111	C4591001 1101 11011111	16-55	19OCT2020	110264	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11011113	C4591001 1101 11011113	16-55	20OCT2020	110265	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11011114	C4591001 1101 11011114	16-55	20OCT2020	110267	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11011115	C4591001 1101 11011115	16-55	20OCT2020	110270	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
11011118	C4591001 1101 11011118	16-55	26OCT2020	113537	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11071114	C4591001 1107 11071114	16-55	17AUG2020	52787	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071118	C4591001 1107 11071118	16-55	17AUG2020	52786	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071122	C4591001 1107 11071122	16-55	17AUG2020	52781	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11071123	C4591001 1107 11071123	16-55	18AUG2020	53949	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071124	C4591001 1107 11071124	16-55	17AUG2020	52792	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071125	C4591001 1107 11071125	16-55	18AUG2020	53951	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071126	C4591001 1107 11071126	16-55	18AUG2020	53952	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071129	C4591001 1107 11071129	16-55	18AUG2020	53956	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11071130	C4591001 1107 11071130	16-55	18AUG2020	54509	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071134	C4591001 1107 11071134	16-55	18AUG2020	54510	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11071136	C4591001 1107 11071136	16-55	18AUG2020	54515	Placebo	18AUG2020/ Placebo	14SEP2020/ Placebo		
11071138	C4591001 1107 11071138	16-55	19AUG2020	54519	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071139	C4591001 1107 11071139	16-55	19AUG2020	56022	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11071144	C4591001 1107 11071144	16-55	02SEP2020	78420	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11071145	C4591001 1107 11071145	16-55	20AUG2020	56026	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11071146	C4591001 1107 11071146	16-55	20AUG2020	56030	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071151	C4591001 1107 11071151	16-55	20AUG2020	56031	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071154	C4591001 1107 11071154	16-55	20AUG2020	58929	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11071155	C4591001 1107 11071155	16-55	20AUG2020	58931	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071156	C4591001 1107 11071156	16-55	20AUG2020	58934	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11071157	C4591001 1107 11071157	16-55	20AUG2020	58933	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11071160	C4591001 1107 11071160	16-55	24AUG2020	63390	Placebo	24AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071162	C4591001 1107 11071162	16-55	24AUG2020	63394	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11071163	C4591001 1107 11071163	16-55	24AUG2020	63396	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071164	C4591001 1107 11071164	16-55	24AUG2020	63397	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071165	C4591001 1107 11071165	16-55	24AUG2020	64241	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11071168	C4591001 1107 11071168	16-55	25AUG2020	64248	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071171	C4591001 1107 11071171	16-55	25AUG2020	64250	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11071174	C4591001 1107 11071174	16-55	26AUG2020	64252	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11071178	C4591001 1107 11071178	16-55	27AUG2020	69774	Placebo	27AUG2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11071179	C4591001 1107 11071179	16-55	27AUG2020	69775	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11071180	C4591001 1107 11071180	16-55	27AUG2020	69779	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11071181	C4591001 1107 11071181	16-55	27AUG2020	69781	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071184	C4591001 1107 11071184	16-55	31AUG2020	74854	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11071186	C4591001 1107 11071186	16-55	31AUG2020	74856	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11071188	C4591001 1107 11071188	16-55	01SEP2020	74858	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11071190	C4591001 1107 11071190	16-55	02SEP2020	74860	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071193	C4591001 1107 11071193	16-55	02SEP2020	78419	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11071195	C4591001 1107 11071195	16-55	03SEP2020	78423	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11071200	C4591001 1107 11071200	16-55	03SEP2020	78424	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11071203	C4591001 1107 11071203	16-55	03SEP2020	80688	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11071204	C4591001 1107 11071204	16-55	08SEP2020	80689	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11071209	C4591001 1107 11071209	16-55	08SEP2020	80690	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11071211	C4591001 1107 11071211	16-55	10SEP2020	80692	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11071212	C4591001 1107 11071212	16-55	10SEP2020	87452	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11071213	C4591001 1107 11071213	16-55	14SEP2020	87454	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11071215	C4591001 1107 11071215	16-55	14SEP2020	87457	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11071222	C4591001 1107 11071222	16-55	13OCT2020	87460	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
11091226	C4591001 1109 11091226	16-55	15AUG2020	49827	Placebo	15AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
11091234	C4591001 1109 11091234	16-55	15AUG2020	51329	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)			
11091236	C4591001 1109 11091236	16-55	15AUG2020	51336	Placebo	15AUG2020/ Placebo	12SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091242	C4591001 1109 11091242	16-55	16AUG2020	51340	Placebo	16AUG2020/ Placebo	06SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091245	C4591001 1109 11091245	16-55	16AUG2020	51691	Placebo	16AUG2020/ Placebo	06SEP2020/ Placebo		
11091246	C4591001 1109 11091246	16-55	16AUG2020	51693	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11091249	C4591001 1109 11091249	16-55	16AUG2020	51695	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11091250	C4591001 1109 11091250	16-55	16AUG2020	51699	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11091251	C4591001 1109 11091251	16-55	16AUG2020	51813	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091252	C4591001 1109 11091252	16-55	16AUG2020	51810	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
11091256	C4591001 1109 11091256	16-55	16AUG2020	51814	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091258	C4591001 1109 11091258	16-55	16AUG2020	51819	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11091261	C4591001 1109 11091261	16-55	16AUG2020	51969	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11091267	C4591001 1109 11091267	16-55	16AUG2020	51976	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo		
11091275	C4591001 1109 11091275	16-55	21AUG2020	60006	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11091278	C4591001 1109 11091278	16-55	21AUG2020	60008	Placebo	21AUG2020/ Placebo	18SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11091287	C4591001 1109 11091287	16-55	21AUG2020	60012	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11091288	C4591001 1109 11091288	16-55	21AUG2020	60014	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11091303	C4591001 1109 11091303	16-55	22AUG2020	61877	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091304	C4591001 1109 11091304	16-55	22AUG2020	61882	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11091308	C4591001 1109 11091308	16-55	22AUG2020	61883	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11091309	C4591001 1109 11091309	16-55	22AUG2020	61887	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11091311	C4591001 1109 11091311	16-55	23AUG2020	62732	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091314	C4591001 1109 11091314	16-55	23AUG2020	62733	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11091315	C4591001 1109 11091315	16-55	23AUG2020	62737	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
11091316	C4591001 1109 11091316	16-55	23AUG2020	62740	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091319	C4591001 1109 11091319	16-55	23AUG2020	62933	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091320	C4591001 1109 11091320	16-55	23AUG2020	62939	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091321	C4591001 1109 11091321	16-55	25AUG2020	62941	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091324	C4591001 1109 11091324	16-55	25AUG2020	62942	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11091326	C4591001 1109 11091326	16-55	25AUG2020	66211	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091329	C4591001 1109 11091329	16-55	26AUG2020	66218	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11091330	C4591001 1109 11091330	16-55	26AUG2020	66219	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091331	C4591001 1109 11091331	16-55	26AUG2020	66220	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11091332	C4591001 1109 11091332	16-55	26AUG2020	67831	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11091333	C4591001 1109 11091333	16-55	26AUG2020	67835	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11091335	C4591001 1109 11091335	16-55	26AUG2020	67839	Placebo	26AUG2020/ Placebo			
11091337	C4591001 1109 11091337	16-55	27AUG2020	67840	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11091338	C4591001 1109 11091338	16-55	27AUG2020	69521	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091340	C4591001 1109 11091340	16-55	27AUG2020	69525	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091343	C4591001 1109 11091343	16-55	28AUG2020	69530	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11091349	C4591001 1109 11091349	16-55	28AUG2020	69532	BNT162b2 (30 µg)				
11091350	C4591001 1109 11091350	16-55	28AUG2020	72895	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11091352	C4591001 1109 11091352	16-55	29AUG2020	72896	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo		
11091353	C4591001 1109 11091353	16-55	29AUG2020	72904	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
11091355	C4591001 1109 11091355	16-55	29AUG2020	72898	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11091361	C4591001 1109 11091361	16-55	29AUG2020	73964	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091362	C4591001 1109 11091362	16-55	29AUG2020	73965	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11091370	C4591001 1109 11091370	16-55	29AUG2020	73972	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091372	C4591001 1109 11091372	16-55	29AUG2020	74142	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11091373	C4591001 1109 11091373	16-55	29AUG2020	73969	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11091375	C4591001 1109 11091375	16-55	29AUG2020	74143	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
11091378	C4591001 1109 11091378	16-55	31AUG2020	74149	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11091382	C4591001 1109 11091382	16-55	31AUG2020	74150	Placebo	31AUG2020/ Placebo	25SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11091383	C4591001 1109 11091383	16-55	31AUG2020	75862	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11091391	C4591001 1109 11091391	16-55	01SEP2020	75866	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11091392	C4591001 1109 11091392	16-55	01SEP2020	75865	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11091393	C4591001 1109 11091393	16-55	01SEP2020	75868	Placebo	01SEP2020/ Placebo	29SEP2020/ Placebo		
11091395	C4591001 1109 11091395	16-55	02SEP2020	78792	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091396	C4591001 1109 11091396	16-55	02SEP2020	78788	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091397	C4591001 1109 11091397	16-55	02SEP2020	78794	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091400	C4591001 1109 11091400	16-55	02SEP2020	78795	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11091403	C4591001 1109 11091403	16-55	02SEP2020	79170	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
11091406	C4591001 1109 11091406	16-55	03SEP2020	79171	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11091412	C4591001 1109 11091412	16-55	05SEP2020	79172	Placebo	05SEP2020/ Placebo	05OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11091414	C4591001 1109 11091414	16-55	05SEP2020	79177	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091415	C4591001 1109 11091415	16-55	05SEP2020	82829	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11091416	C4591001 1109 11091416	16-55	05SEP2020	82830	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091417	C4591001 1109 11091417	16-55	05SEP2020	82833	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091418	C4591001 1109 11091418	16-55	05SEP2020	82839	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
11091419	C4591001 1109 11091419	16-55	05SEP2020	82930	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo		
11091422	C4591001 1109 11091422	16-55	05SEP2020	82928	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11091424	C4591001 1109 11091424	16-55	05SEP2020	82933	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11091425	C4591001 1109 11091425	16-55	05SEP2020	82936	Placebo	05SEP2020/ Placebo	07OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091426	C4591001 1109 11091426	16-55	05SEP2020	82951	Placebo	05SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11091427	C4591001 1109 11091427	16-55	06SEP2020	82956	Placebo	06SEP2020/ Placebo	26SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
11091428	C4591001 1109 11091428	16-55	06SEP2020	82958	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	04OCT2020/ BNT162b2 (30 µg)		
11091432	C4591001 1109 11091432	16-55	06SEP2020	82959	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
11091434	C4591001 1109 11091434	16-55	07SEP2020	83201	Placebo	07SEP2020/ Placebo	26SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091435	C4591001 1109 11091435	16-55	07SEP2020	83204	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11091436	C4591001 1109 11091436	16-55	07SEP2020	83207	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
11091439	C4591001 1109 11091439	16-55	07SEP2020	83210	Placebo	07SEP2020/ Placebo	01OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091440	C4591001 1109 11091440	16-55	07SEP2020	83239	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091441	C4591001 1109 11091441	16-55	07SEP2020	83242	Placebo	07SEP2020/ Placebo	03OCT2020/ Placebo		
11091442	C4591001 1109 11091442	16-55	07SEP2020	83244	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091444	C4591001 1109 11091444	16-55	08SEP2020	253742	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091448	C4591001 1109 11091448	16-55	08SEP2020	84116	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11091450	C4591001 1109 11091450	16-55	08SEP2020	83246	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091453	C4591001 1109 11091453	16-55	08SEP2020	84120	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091455	C4591001 1109 11091455	16-55	08SEP2020	84123	Placebo	08SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11091457	C4591001 1109 11091457	16-55	08SEP2020	84124	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091459	C4591001 1109 11091459	16-55	08SEP2020	84463	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11091465	C4591001 1109 11091465	16-55	09SEP2020	84472	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11091466	C4591001 1109 11091466	16-55	09SEP2020	84466	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11091467	C4591001 1109 11091467	16-55	09SEP2020	84470	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11091468	C4591001 1109 11091468	16-55	09SEP2020	85640	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091472	C4591001 1109 11091472	16-55	09SEP2020	85641	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11091473	C4591001 1109 11091473	16-55	09SEP2020	85645	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091476	C4591001 1109 11091476	16-55	09SEP2020	85648	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091477	C4591001 1109 11091477	16-55	09SEP2020	85973	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11091478	C4591001 1109 11091478	16-55	09SEP2020	85976	Placebo	09SEP2020/ Placebo			
11091479	C4591001 1109 11091479	16-55	09SEP2020	85977	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091483	C4591001 1109 11091483	16-55	10SEP2020	85981	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11091484	C4591001 1109 11091484	16-55	10SEP2020	86998	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091485	C4591001 1109 11091485	16-55	10SEP2020	87000	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091488	C4591001 1109 11091488	16-55	10SEP2020	87002	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11091489	C4591001 1109 11091489	16-55	10SEP2020	87003	Placebo	10SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11091492	C4591001 1109 11091492	16-55	10SEP2020	87427	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11091495	C4591001 1109 11091495	16-55	11SEP2020	87429	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091496	C4591001 1109 11091496	16-55	11SEP2020	87431	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11091497	C4591001 1109 11091497	16-55	11SEP2020	87433	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091498	C4591001 1109 11091498	16-55	11SEP2020	88745	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11091499	C4591001 1109 11091499	16-55	11SEP2020	88749	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11091502	C4591001 1109 11091502	16-55	11SEP2020	88750	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091506	C4591001 1109 11091506	16-55	12SEP2020	88752	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11091507	C4591001 1109 11091507	16-55	12SEP2020	89201	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
11091508	C4591001 1109 11091508	16-55	12SEP2020	89202	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11091511	C4591001 1109 11091511	16-55	13SEP2020	89203	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	04OCT2020/ BNT162b2 (30 µg)		
11091512	C4591001 1109 11091512	16-55	13SEP2020	89209	Placebo	13SEP2020/ Placebo	06OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091513	C4591001 1109 11091513	16-55	13SEP2020	89285	Placebo	13SEP2020/ Placebo	06OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11091514	C4591001 1109 11091514	16-55	13SEP2020	89286	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11091515	C4591001 1109 11091515	16-55	15SEP2020	89287	Placebo	15SEP2020/ Placebo			
11091516	C4591001 1109 11091516	16-55	15SEP2020	89290	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11091517	C4591001 1109 11091517	16-55	15SEP2020	90701	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11091518	C4591001 1109 11091518	16-55	16SEP2020	90702	Placebo	16SEP2020/ Placebo	03OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091520	C4591001 1109 11091520	16-55	17SEP2020	90710	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11091521	C4591001 1109 11091521	16-55	18SEP2020	90711	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11091522	C4591001 1109 11091522	16-55	18SEP2020	94098	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11091523	C4591001 1109 11091523	16-55	18SEP2020	94099	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091524	C4591001 1109 11091524	16-55	18SEP2020	94103	Placebo	18SEP2020/ Placebo	10OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11091525	C4591001 1109 11091525	16-55	18SEP2020	94108	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
11091526	C4591001 1109 11091526	16-55	18SEP2020	94158	Placebo	18SEP2020/ Placebo	05OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091528	C4591001 1109 11091528	16-55	19SEP2020	94161	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11091529	C4591001 1109 11091529	16-55	19SEP2020	94159	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
11091530	C4591001 1109 11091530	16-55	21SEP2020	94890	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091531	C4591001 1109 11091531	16-55	21SEP2020	94163	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11091532	C4591001 1109 11091532	16-55	21SEP2020	94893	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11091534	C4591001 1109 11091534	16-55	21SEP2020	94894	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11091535	C4591001 1109 11091535	16-55	22SEP2020	94900	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091536	C4591001 1109 11091536	16-55	22SEP2020	96788	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11091539	C4591001 1109 11091539	16-55	23SEP2020	96790	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11091540	C4591001 1109 11091540	16-55	23SEP2020	96793	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11091541	C4591001 1109 11091541	16-55	24SEP2020	96795	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11091545	C4591001 1109 11091545	16-55	29SEP2020	101971	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11091546	C4591001 1109 11091546	16-55	30SEP2020	101974	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11091547	C4591001 1109 11091547	16-55	30SEP2020	101976	Placebo	30SEP2020/ Placebo			
11091548	C4591001 1109 11091548	16-55	01OCT2020	101978	Placebo	01OCT2020/ Placebo	24OCT2020/ Placebo		
11091549	C4591001 1109 11091549	16-55	01OCT2020	102896	Placebo	01OCT2020/ Placebo	24OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11091550	C4591001 1109 11091550	16-55	01OCT2020	102897	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11091553	C4591001 1109 11091553	16-55	02OCT2020	102899	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11091554	C4591001 1109 11091554	16-55	02OCT2020	102903	Placebo	02OCT2020/ Placebo	26OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11091555	C4591001 1109 11091555	16-55	04OCT2020	103517	BNT162b2 (30 µg)	04OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11091556	C4591001 1109 11091556	16-55	04OCT2020	103522	Placebo	04OCT2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	
11091557	C4591001 1109 11091557	16-55	05OCT2020	103525	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
11091563	C4591001 1109 11091563	16-55	06OCT2020	103528	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo		
11101096	C4591001 1110 11101096	16-55	14AUG2020	49043	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11101099	C4591001 1110 11101099	16-55	17AUG2020	49046	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101100	C4591001 1110 11101100	16-55	17AUG2020	53181	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11101102	C4591001 1110 11101102	16-55	18AUG2020	53185	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101106	C4591001 1110 11101106	16-55	18AUG2020	53187	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
11101110	C4591001 1110 11101110	16-55	18AUG2020	53188	Placebo	18AUG2020/ Placebo			
11101111	C4591001 1110 11101111	16-55	18AUG2020	55362	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11101113	C4591001 1110 11101113	16-55	19AUG2020	55364	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11101116	C4591001 1110 11101116	16-55	19AUG2020	55365	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11101117	C4591001 1110 11101117	16-55	19AUG2020	55370	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11101122	C4591001 1110 11101122	16-55	20AUG2020	59142	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101125	C4591001 1110 11101125	16-55	21AUG2020	59147	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11101126	C4591001 1110 11101126	16-55	21AUG2020	59151	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11101127	C4591001 1110 11101127	16-55	21AUG2020	60569	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101131	C4591001 1110 11101131	16-55	24AUG2020	60571	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11101132	C4591001 1110 11101132	16-55	24AUG2020	60573	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11101139	C4591001 1110 11101139	16-55	25AUG2020	60580	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11101141	C4591001 1110 11101141	16-55	26AUG2020	67709	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo		
11101144	C4591001 1110 11101144	16-55	27AUG2020	67713	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11101145	C4591001 1110 11101145	16-55	27AUG2020	67714	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11101148	C4591001 1110 11101148	16-55	27AUG2020	67717	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11101149	C4591001 1110 11101149	16-55	27AUG2020	70772	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11101151	C4591001 1110 11101151	16-55	28AUG2020	70775	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11101154	C4591001 1110 11101154	16-55	28AUG2020	72377	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
11101155	C4591001 1110 11101155	16-55	28AUG2020	70779	Placebo	28AUG2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101156	C4591001 1110 11101156	16-55	28AUG2020	70776	Placebo	28AUG2020/ Placebo			
11101157	C4591001 1110 11101157	16-55	28AUG2020	72379	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
11101158	C4591001 1110 11101158	16-55	29AUG2020	72380	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11101161	C4591001 1110 11101161	16-55	29AUG2020	72386	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101162	C4591001 1110 11101162	16-55	29AUG2020	73631	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101163	C4591001 1110 11101163	16-55	29AUG2020	73630	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11101164	C4591001 1110 11101164	16-55	29AUG2020	73633	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11101165	C4591001 1110 11101165	16-55	29AUG2020	73635	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11101167	C4591001 1110 11101167	16-55	29AUG2020	73817	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101168	C4591001 1110 11101168	16-55	29AUG2020	73821	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101174	C4591001 1110 11101174	16-55	29AUG2020	73823	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101175	C4591001 1110 11101175	16-55	31AUG2020	73828	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101177	C4591001 1110 11101177	16-55	31AUG2020	75246	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
11101180	C4591001 1110 11101180	16-55	31AUG2020	75252	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11101181	C4591001 1110 11101181	16-55	01SEP2020	75253	Placebo	01SEP2020/ Placebo	08OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11101182	C4591001 1110 11101182	16-55	01SEP2020	76913	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101183	C4591001 1110 11101183	16-55	01SEP2020	75255	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11101186	C4591001 1110 11101186	16-55	01SEP2020	76917	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11101187	C4591001 1110 11101187	16-55	01SEP2020	76918	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11101189	C4591001 1110 11101189	16-55	11SEP2020	87971	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101194	C4591001 1110 11101194	16-55	02SEP2020	76921	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101196	C4591001 1110 11101196	16-55	02SEP2020	79157	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11101198	C4591001 1110 11101198	16-55	02SEP2020	79163	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11101199	C4591001 1110 11101199	16-55	02SEP2020	79166	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11101200	C4591001 1110 11101200	16-55	03SEP2020	79167	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11101203	C4591001 1110 11101203	16-55	03SEP2020	80765	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101204	C4591001 1110 11101204	16-55	03SEP2020	80775	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11101205	C4591001 1110 11101205	16-55	03SEP2020	80773	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11101211	C4591001 1110 11101211	16-55	04SEP2020	80776	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11101212	C4591001 1110 11101212	16-55	04SEP2020	81738	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101213	C4591001 1110 11101213	16-55	04SEP2020	81744	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101214	C4591001 1110 11101214	16-55	04SEP2020	81745	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11101217	C4591001 1110 11101217	16-55	04SEP2020	81748	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11101219	C4591001 1110 11101219	16-55	04SEP2020	82243	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11101220	C4591001 1110 11101220	16-55	04SEP2020	82241	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11101221	C4591001 1110 11101221	16-55	04SEP2020	82247	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11101223	C4591001 1110 11101223	16-55	08SEP2020	82248	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11101224	C4591001 1110 11101224	16-55	08SEP2020	84402	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11101226	C4591001 1110 11101226	16-55	09SEP2020	84403	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11101227	C4591001 1110 11101227	16-55	09SEP2020	84406	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101229	C4591001 1110 11101229	16-55	10SEP2020	84410	Placebo	10SEP2020/ Placebo		23FEB2021/ BNT162b2 (30 µg)	
11101231	C4591001 1110 11101231	16-55	11SEP2020	87966	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11101234	C4591001 1110 11101234	16-55	15SEP2020	89760	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
11101235	C4591001 1110 11101235	16-55	11SEP2020	87972	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101236	C4591001 1110 11101236	16-55	11SEP2020	87974	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11101237	C4591001 1110 11101237	16-55	14SEP2020	89393	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101238	C4591001 1110 11101238	16-55	14SEP2020	89399	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11101240	C4591001 1110 11101240	16-55	14SEP2020	89395	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11101242	C4591001 1110 11101242	16-55	14SEP2020	89402	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11101243	C4591001 1110 11101243	16-55	14SEP2020	89753	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11101244	C4591001 1110 11101244	16-55	14SEP2020	89758	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101246	C4591001 1110 11101246	16-55	15SEP2020	89761	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101247	C4591001 1110 11101247	16-55	15SEP2020	90293	Placebo	15SEP2020/ Placebo			
11101250	C4591001 1110 11101250	16-55	15SEP2020	90296	Placebo	15SEP2020/ Placebo			
11101261	C4591001 1110 11101261	16-55	15SEP2020	90299	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101264	C4591001 1110 11101264	16-55	16SEP2020	90302	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11101266	C4591001 1110 11101266	16-55	16SEP2020	91376	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11101268	C4591001 1110 11101268	16-55	16SEP2020	91649	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11101269	C4591001 1110 11101269	16-55	17SEP2020	91651	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11101271	C4591001 1110 11101271	16-55	29SEP2020	101399	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11101273	C4591001 1110 11101273	16-55	17SEP2020	91658	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101274	C4591001 1110 11101274	16-55	17SEP2020	91660	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11101275	C4591001 1110 11101275	16-55	18SEP2020	93318	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11101278	C4591001 1110 11101278	16-55	18SEP2020	93322	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11101282	C4591001 1110 11101282	16-55	21SEP2020	93324	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11101283	C4591001 1110 11101283	16-55	12OCT2020	105556	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11101286	C4591001 1110 11101286	16-55	21SEP2020	95477	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11101287	C4591001 1110 11101287	16-55	21SEP2020	93328	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
11101290	C4591001 1110 11101290	16-55	13OCT2020	107084	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11101292	C4591001 1110 11101292	16-55	22SEP2020	95478	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11101293	C4591001 1110 11101293	16-55	23SEP2020	95480	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101294	C4591001 1110 11101294	16-55	23SEP2020	95487	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11101298	C4591001 1110 11101298	16-55	23SEP2020	98225	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11101300	C4591001 1110 11101300	16-55	24SEP2020	98229	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11101305	C4591001 1110 11101305	16-55	24SEP2020	98233	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11101308	C4591001 1110 11101308	16-55	25SEP2020	98235	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101311	C4591001 1110 11101311	16-55	28SEP2020	101393	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11101313	C4591001 1110 11101313	16-55	28SEP2020	101394	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11101314	C4591001 1110 11101314	16-55	29SEP2020	101403	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11101316	C4591001 1110 11101316	16-55	29SEP2020	101931	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11101317	C4591001 1110 11101317	16-55	29SEP2020	101928	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101318	C4591001 1110 11101318	16-55	29SEP2020	101929	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11101319	C4591001 1110 11101319	16-55	29SEP2020	101932	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11101320	C4591001 1110 11101320	16-55	30SEP2020	102235	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101321	C4591001 1110 11101321	16-55	30SEP2020	102238	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11101322	C4591001 1110 11101322	16-55	30SEP2020	102241	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo		
11101323	C4591001 1110 11101323	16-55	30SEP2020	102243	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11101325	C4591001 1110 11101325	16-55	01OCT2020	102705	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11101326	C4591001 1110 11101326	16-55	01OCT2020	102707	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
11101327	C4591001 1110 11101327	16-55	01OCT2020	102711	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11101328	C4591001 1110 11101328	16-55	01OCT2020	102712	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101329	C4591001 1110 11101329	16-55	02OCT2020	103193	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11101330	C4591001 1110 11101330	16-55	02OCT2020	103201	Placebo	02OCT2020/ Placebo	26OCT2020/ Placebo		
11101331	C4591001 1110 11101331	16-55	02OCT2020	103195	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11101333	C4591001 1110 11101333	16-55	02OCT2020	103202	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)			
11101337	C4591001 1110 11101337	16-55	02OCT2020	103326	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11101338	C4591001 1110 11101338	16-55	02OCT2020	103327	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11101341	C4591001 1110 11101341	16-55	05OCT2020	103330	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11101342	C4591001 1110 11101342	16-55	06OCT2020	103332	Placebo	06OCT2020/ Placebo			
11101343	C4591001 1110 11101343	16-55	06OCT2020	104321	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11101344	C4591001 1110 11101344	16-55	08OCT2020	104331	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101345	C4591001 1110 11101345	16-55	08OCT2020	104322	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11101346	C4591001 1110 11101346	16-55	08OCT2020	104326	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11101347	C4591001 1110 11101347	16-55	08OCT2020	105547	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11101348	C4591001 1110 11101348	16-55	09OCT2020	105548	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
11101349	C4591001 1110 11101349	16-55	09OCT2020	105551	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11101350	C4591001 1110 11101350	16-55	13OCT2020	107081	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11101352	C4591001 1110 11101352	16-55	14OCT2020	107091	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11101354	C4591001 1110 11101354	16-55	15OCT2020	107092	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11101356	C4591001 1110 11101356	16-55	15OCT2020	108379	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11101360	C4591001 1110 11101360	16-55	19OCT2020	108382	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11101361	C4591001 1110 11101361	16-55	19OCT2020	108387	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11101365	C4591001 1110 11101365	16-55	21OCT2020	108388	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101371	C4591001 1110 11101371	16-55	26OCT2020	113638	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11101372	C4591001 1110 11101372	16-55	27OCT2020	113641	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11101374	C4591001 1110 11101374	16-55	28OCT2020	113644	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11101375	C4591001 1110 11101375	16-55	28OCT2020	114417	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo		
11101377	C4591001 1110 11101377	16-55	29OCT2020	114420	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo		
11101379	C4591001 1110 11101379	16-55	13NOV2020	114421	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11101380	C4591001 1110 11101380	16-55	04DEC2020	114422	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11111117	C4591001 1111 11111117	16-55	17AUG2020	50855	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111121	C4591001 1111 11111121	16-55	17AUG2020	50856	Placebo	17AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111130	C4591001 1111 11111130	16-55	18AUG2020	55002	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11111132	C4591001 1111 11111132	16-55	19AUG2020	55003	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11111138	C4591001 1111 11111138	16-55	20AUG2020	55008	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11111139	C4591001 1111 11111139	16-55	21AUG2020	55011	Placebo	21AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11111142	C4591001 1111 11111142	16-55	27AUG2020	70076	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11111143	C4591001 1111 11111143	16-55	27AUG2020	70081	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11111144	C4591001 1111 11111144	16-55	28AUG2020	72437	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11111145	C4591001 1111 11111145	16-55	28AUG2020	70082	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11111146	C4591001 1111 11111146	16-55	28AUG2020	70083	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111148	C4591001 1111 11111148	16-55	28AUG2020	72438	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11111151	C4591001 1111 11111151	16-55	28AUG2020	72440	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11111155	C4591001 1111 11111155	16-55	02SEP2020	77789	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111156	C4591001 1111 11111156	16-55	02SEP2020	72442	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111159	C4591001 1111 11111159	16-55	02SEP2020	77790	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11111166	C4591001 1111 11111166	16-55	02SEP2020	77794	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111169	C4591001 1111 11111169	16-55	02SEP2020	77795	Placebo	02SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111170	C4591001 1111 11111170	16-55	02SEP2020	79352	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11111171	C4591001 1111 11111171	16-55	04SEP2020	79353	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111172	C4591001 1111 11111172	16-55	04SEP2020	79356	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111176	C4591001 1111 11111176	16-55	08SEP2020	79357	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111177	C4591001 1111 11111177	16-55	08SEP2020	83976	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111179	C4591001 1111 11111179	16-55	09SEP2020	83978	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111180	C4591001 1111 11111180	16-55	09SEP2020	83979	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11111183	C4591001 1111 11111183	16-55	21SEP2020	94626	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111184	C4591001 1111 11111184	16-55	21SEP2020	94628	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111188	C4591001 1111 11111188	16-55	21SEP2020	94629	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111189	C4591001 1111 11111189	16-55	21SEP2020	94630	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11111191	C4591001 1111 11111191	16-55	30SEP2020	102440	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11111192	C4591001 1111 11111192	16-55	15OCT2020	102442	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11111200	C4591001 1111 11111200	16-55	21OCT2020	102447	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11111203	C4591001 1111 11111203	16-55	21OCT2020	102448	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11121081	C4591001 1112 11121081	16-55	02SEP2020	78848	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121125	C4591001 1112 11121125	16-55	17AUG2020	46906	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11121126	C4591001 1112 11121126	16-55	17AUG2020	46911	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121127	C4591001 1112 11121127	16-55	17AUG2020	52937	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121128	C4591001 1112 11121128	16-55	17AUG2020	52944	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11121130	C4591001 1112 11121130	16-55	18AUG2020	52945	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11121132	C4591001 1112 11121132	16-55	18AUG2020	52948	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121135	C4591001 1112 11121135	16-55	18AUG2020	55086	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121136	C4591001 1112 11121136	16-55	18AUG2020	55088	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121137	C4591001 1112 11121137	16-55	18AUG2020	55092	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121138	C4591001 1112 11121138	16-55	18AUG2020	55093	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121139	C4591001 1112 11121139	16-55	19AUG2020	56047	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11121146	C4591001 1112 11121146	16-55	20AUG2020	56049	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11121147	C4591001 1112 11121147	16-55	20AUG2020	56050	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11121148	C4591001 1112 11121148	16-55	20AUG2020	56052	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11121151	C4591001 1112 11121151	16-55	20AUG2020	59457	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121152	C4591001 1112 11121152	16-55	20AUG2020	59458	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11121154	C4591001 1112 11121154	16-55	21AUG2020	59459	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121155	C4591001 1112 11121155	16-55	21AUG2020	59462	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121156	C4591001 1112 11121156	16-55	21AUG2020	60933	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11121157	C4591001 1112 11121157	16-55	21AUG2020	60934	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11121158	C4591001 1112 11121158	16-55	21AUG2020	60937	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121159	C4591001 1112 11121159	16-55	24AUG2020	60938	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121160	C4591001 1112 11121160	16-55	24AUG2020	63738	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121161	C4591001 1112 11121161	16-55	24AUG2020	63742	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11121162	C4591001 1112 11121162	16-55	24AUG2020	63743	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11121163	C4591001 1112 11121163	16-55	24AUG2020	63746	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11121165	C4591001 1112 11121165	16-55	24AUG2020	64547	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121169	C4591001 1112 11121169	16-55	25AUG2020	64550	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11121171	C4591001 1112 11121171	16-55	25AUG2020	64551	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11121173	C4591001 1112 11121173	16-55	25AUG2020	64552	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11121174	C4591001 1112 11121174	16-55	25AUG2020	66809	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121175	C4591001 1112 11121175	16-55	26AUG2020	66817	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11121177	C4591001 1112 11121177	16-55	26AUG2020	66818	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11121180	C4591001 1112 11121180	16-55	26AUG2020	66819	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121183	C4591001 1112 11121183	16-55	27AUG2020	70149	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11121184	C4591001 1112 11121184	16-55	27AUG2020	70152	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121185	C4591001 1112 11121185	16-55	27AUG2020	70151	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121187	C4591001 1112 11121187	16-55	27AUG2020	70156	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11121188	C4591001 1112 11121188	16-55	27AUG2020	71273	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121189	C4591001 1112 11121189	16-55	28AUG2020	71277	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121190	C4591001 1112 11121190	16-55	28AUG2020	71278	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11121191	C4591001 1112 11121191	16-55	28AUG2020	71280	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11121192	C4591001 1112 11121192	16-55	28AUG2020	72740	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
11121193	C4591001 1112 11121193	16-55	28AUG2020	72739	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11121194	C4591001 1112 11121194	16-55	28AUG2020	72745	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121197	C4591001 1112 11121197	16-55	31AUG2020	72747	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11121198	C4591001 1112 11121198	16-55	31AUG2020	75334	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121199	C4591001 1112 11121199	16-55	31AUG2020	75335	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121200	C4591001 1112 11121200	16-55	31AUG2020	75336	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11121201	C4591001 1112 11121201	16-55	31AUG2020	75337	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11121204	C4591001 1112 11121204	16-55	01SEP2020	76661	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121207	C4591001 1112 11121207	16-55	01SEP2020	76663	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11121208	C4591001 1112 11121208	16-55	01SEP2020	76664	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11121213	C4591001 1112 11121213	16-55	02SEP2020	76672	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11121214	C4591001 1112 11121214	16-55	02SEP2020	78845	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11121215	C4591001 1112 11121215	16-55	02SEP2020	78854	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121216	C4591001 1112 11121216	16-55	02SEP2020	78856	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121217	C4591001 1112 11121217	16-55	03SEP2020	79604	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121218	C4591001 1112 11121218	16-55	03SEP2020	79608	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121224	C4591001 1112 11121224	16-55	03SEP2020	79609	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11121225	C4591001 1112 11121225	16-55	04SEP2020	79611	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11121226	C4591001 1112 11121226	16-55	04SEP2020	81668	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11121228	C4591001 1112 11121228	16-55	04SEP2020	81670	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	
11121229	C4591001 1112 11121229	16-55	04SEP2020	81671	BNT162b2 (30 µg)				
11121231	C4591001 1112 11121231	16-55	08SEP2020	81673	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11121234	C4591001 1112 11121234	16-55	08SEP2020	84476	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121237	C4591001 1112 11121237	16-55	09SEP2020	84478	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121239	C4591001 1112 11121239	16-55	09SEP2020	84482	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11121240	C4591001 1112 11121240	16-55	09SEP2020	84483	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11121242	C4591001 1112 11121242	16-55	10SEP2020	86445	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11121243	C4591001 1112 11121243	16-55	10SEP2020	86448	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11121244	C4591001 1112 11121244	16-55	10SEP2020	86446	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11121245	C4591001 1112 11121245	16-55	10SEP2020	86451	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11121246	C4591001 1112 11121246	16-55	10SEP2020	87595	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11121249	C4591001 1112 11121249	16-55	11SEP2020	87596	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11121250	C4591001 1112 11121250	16-55	11SEP2020	87599	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11121253	C4591001 1112 11121253	16-55	11SEP2020	87604	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121254	C4591001 1112 11121254	16-55	06OCT2020	104155	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11121256	C4591001 1112 11121256	16-55	06OCT2020	104156	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121258	C4591001 1112 11121258	16-55	06OCT2020	104160	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
11121259	C4591001 1112 11121259	16-55	06OCT2020	104161	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
11121260	C4591001 1112 11121260	16-55	06OCT2020	104441	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11121261	C4591001 1112 11121261	16-55	07OCT2020	104444	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121263	C4591001 1112 11121263	16-55	07OCT2020	104448	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11121264	C4591001 1112 11121264	16-55	07OCT2020	104452	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11121265	C4591001 1112 11121265†	16-55	07OCT2020	104960	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
11121266	C4591001 1112 11121266	16-55	19OCT2020	107464	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121268	C4591001 1112 11121268	16-55	08OCT2020	104961	Placebo	08OCT2020/ Placebo	02NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121269	C4591001 1112 11121269	16-55	08OCT2020	104967	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121270	C4591001 1112 11121270†	16-55	08OCT2020	104968	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)			
11121271	C4591001 1112 11121271	16-55	08OCT2020	105401	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11121272	C4591001 1112 11121272	16-55	08OCT2020	105405	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11121273	C4591001 1112 11121273	16-55	08OCT2020	105406	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121275	C4591001 1112 11121275	16-55	08OCT2020	105408	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121281	C4591001 1112 11121281	16-55	09OCT2020	105966	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11121282	C4591001 1112 11121282	16-55	09OCT2020	105972	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11121283	C4591001 1112 11121283	16-55	09OCT2020	105974	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121284	C4591001 1112 11121284	16-55	09OCT2020	105975	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11121286	C4591001 1112 11121286	16-55	09OCT2020	106148	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11121289	C4591001 1112 11121289	16-55	09OCT2020	106149	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11121290	C4591001 1112 11121290	16-55	12OCT2020	106151	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121291	C4591001 1112 11121291	16-55	12OCT2020	106156	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11121293	C4591001 1112 11121293	16-55	12OCT2020	106530	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11121296	C4591001 1112 11121296	16-55	12OCT2020	106533	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11121297	C4591001 1112 11121297	16-55	12OCT2020	106538	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121298	C4591001 1112 11121298	16-55	12OCT2020	106535	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121299	C4591001 1112 11121299	16-55	12OCT2020	106674	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121300	C4591001 1112 11121300	16-55	12OCT2020	106679	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11121301	C4591001 1112 11121301	16-55	12OCT2020	106682	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121303	C4591001 1112 11121303	16-55	13OCT2020	106683	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11121304	C4591001 1112 11121304	16-55	13OCT2020	106853	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121305	C4591001 1112 11121305	16-55	13OCT2020	106854	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11121307	C4591001 1112 11121307	16-55	13OCT2020	106856	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11121308	C4591001 1112 11121308	16-55	13OCT2020	106858	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11121310	C4591001 1112 11121310	16-55	14OCT2020	107457	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11121313	C4591001 1112 11121313	16-55	19OCT2020	107460	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
11121315	C4591001 1112 11121315	16-55	19OCT2020	107462	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121317	C4591001 1112 11121317	16-55	19OCT2020	110465	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11121318	C4591001 1112 11121318†	16-55	19OCT2020	110474	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121319	C4591001 1112 11121319	16-55	19OCT2020	110466	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11121322	C4591001 1112 11121322	16-55	19OCT2020	110475	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11121323	C4591001 1112 11121323	16-55	20OCT2020	110753	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121324	C4591001 1112 11121324	16-55	20OCT2020	110754	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121326	C4591001 1112 11121326	16-55	20OCT2020	110760	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121328	C4591001 1112 11121328	16-55	20OCT2020	110763	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11121331	C4591001 1112 11121331	16-55	20OCT2020	111139	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11121332	C4591001 1112 11121332	16-55	20OCT2020	111141	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11121333	C4591001 1112 11121333	16-55	21OCT2020	111143	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11121335	C4591001 1112 11121335	16-55	21OCT2020	111148	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11121339	C4591001 1112 11121339	16-55	21OCT2020	111857	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11121341	C4591001 1112 11121341	16-55	22OCT2020	111862	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121342	C4591001 1112 11121342	16-55	22OCT2020	111868	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11121343	C4591001 1112 11121343	16-55	22OCT2020	111864	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121345	C4591001 1112 11121345	16-55	22OCT2020	112218	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11121346	C4591001 1112 11121346	16-55	22OCT2020	112219	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11121351	C4591001 1112 11121351	16-55	22OCT2020	112225	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11141027	C4591001 1114 11141027	16-55	17AUG2020	48900	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141029	C4591001 1114 11141029	16-55	17AUG2020	48903	Placebo	17AUG2020/ Placebo	15SEP2020/ Placebo		
11141033	C4591001 1114 11141033	16-55	17AUG2020	53432	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11141034	C4591001 1114 11141034	16-55	17AUG2020	53435	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11141037	C4591001 1114 11141037	16-55	17AUG2020	53437	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11141038	C4591001 1114 11141038	16-55	17AUG2020	53705	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141039	C4591001 1114 11141039	16-55	17AUG2020	53438	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141040	C4591001 1114 11141040	16-55	17AUG2020	53711	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11141041	C4591001 1114 11141041	16-55	18AUG2020	53715	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11141042	C4591001 1114 11141042	16-55	18AUG2020	53714	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11141051	C4591001 1114 11141051	16-55	18AUG2020	55449	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141053	C4591001 1114 11141053	16-55	18AUG2020	55453	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141054	C4591001 1114 11141054	16-55	19AUG2020	55454	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11141061	C4591001 1114 11141061	16-55	19AUG2020	55455	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11141062	C4591001 1114 11141062	16-55	19AUG2020	57427	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141063	C4591001 1114 11141063	16-55	19AUG2020	57429	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141064	C4591001 1114 11141064	16-55	20AUG2020	57430	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141065	C4591001 1114 11141065	16-55	20AUG2020	57436	Placebo	20AUG2020/ Placebo	22OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11141068	C4591001 1114 11141068	16-55	21AUG2020	60222	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141069	C4591001 1114 11141069	16-55	21AUG2020	60223	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141070	C4591001 1114 11141070	16-55	21AUG2020	60229	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141072	C4591001 1114 11141072	16-55	21AUG2020	60232	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11141074	C4591001 1114 11141074	16-55	21AUG2020	61497	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11141075	C4591001 1114 11141075	16-55	21AUG2020	61498	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
11141076	C4591001 1114 11141076	16-55	24AUG2020	61499	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11141079	C4591001 1114 11141079	16-55	24AUG2020	61504	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141081	C4591001 1114 11141081	16-55	24AUG2020	64349	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141083	C4591001 1114 11141083	16-55	24AUG2020	64351	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141084	C4591001 1114 11141084	16-55	24AUG2020	64358	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141085	C4591001 1114 11141085	16-55	24AUG2020	64359	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11141087	C4591001 1114 11141087	16-55	25AUG2020	65309	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141089	C4591001 1114 11141089	16-55	25AUG2020	65313	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11141093	C4591001 1114 11141093	16-55	25AUG2020	65318	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11141095	C4591001 1114 11141095	16-55	25AUG2020	65320	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11141096	C4591001 1114 11141096	16-55	25AUG2020	66714	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11141097	C4591001 1114 11141097	16-55	25AUG2020	66718	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11141098	C4591001 1114 11141098	16-55	25AUG2020	66721	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141100	C4591001 1114 11141100	16-55	25AUG2020	66723	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11141103	C4591001 1114 11141103	16-55	26AUG2020	68777	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11141105	C4591001 1114 11141105	16-55	26AUG2020	68781	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11141106	C4591001 1114 11141106	16-55	27AUG2020	68782	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11141109	C4591001 1114 11141109	16-55	29AUG2020	68784	Placebo	29AUG2020/ Placebo	26SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11141111	C4591001 1114 11141111	16-55	29AUG2020	74037	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11141113	C4591001 1114 11141113	16-55	29AUG2020	74039	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11141115	C4591001 1114 11141115	16-55	29AUG2020	74042	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11141117	C4591001 1114 11141117	16-55	29AUG2020	74044	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11141118	C4591001 1114 11141118	16-55	29AUG2020	74277	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11141119	C4591001 1114 11141119	16-55	31AUG2020	74279	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	
11141121	C4591001 1114 11141121	16-55	03SEP2020	74281	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11141123	C4591001 1114 11141123	16-55	11SEP2020	74283	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11161002	C4591001 1116 11161002	16-55	25AUG2020	65946	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161003	C4591001 1116 11161003	16-55	25AUG2020	65950	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161006	C4591001 1116 11161006	16-55	25AUG2020	65951	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161007	C4591001 1116 11161007	16-55	25AUG2020	66368	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161008	C4591001 1116 11161008	16-55	25AUG2020	65953	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
11161009	C4591001 1116 11161009	16-55	25AUG2020	66369	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11161012	C4591001 1116 11161012	16-55	25AUG2020	66370	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
11161014	C4591001 1116 11161014	16-55	26AUG2020	66372	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11161015	C4591001 1116 11161015	16-55	26AUG2020	67973	BNT162b2 (30 µg)				
11161022	C4591001 1116 11161022	16-55	26AUG2020	67976	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11161023	C4591001 1116 11161023	16-55	26AUG2020	67978	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo		
11161029	C4591001 1116 11161029	16-55	27AUG2020	67983	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161036	C4591001 1116 11161036	16-55	27AUG2020	71407	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11161041	C4591001 1116 11161041	16-55	28AUG2020	71413	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11161043	C4591001 1116 11161043	16-55	28AUG2020	71415	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11161044	C4591001 1116 11161044	16-55	28AUG2020	71416	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11161047	C4591001 1116 11161047	16-55	28AUG2020	72463	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11161049	C4591001 1116 11161049	16-55	28AUG2020	72464	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11161053	C4591001 1116 11161053	16-55	28AUG2020	72467	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11161054	C4591001 1116 11161054	16-55	28AUG2020	72469	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11161058	C4591001 1116 11161058	16-55	31AUG2020	75041	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11161059	C4591001 1116 11161059	16-55	31AUG2020	75043	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161065	C4591001 1116 11161065	16-55	31AUG2020	75044	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11161066	C4591001 1116 11161066	16-55	31AUG2020	75046	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11161068	C4591001 1116 11161068	16-55	31AUG2020	75776	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11161071	C4591001 1116 11161071	16-55	31AUG2020	75777	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11161072	C4591001 1116 11161072	16-55	31AUG2020	75778	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11161076	C4591001 1116 11161076	16-55	01SEP2020	75784	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11161082	C4591001 1116 11161082	16-55	01SEP2020	77577	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161083	C4591001 1116 11161083	16-55	01SEP2020	77578	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161085	C4591001 1116 11161085	16-55	01SEP2020	77581	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11161091	C4591001 1116 11161091	16-55	02SEP2020	77582	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161099	C4591001 1116 11161099	16-55	02SEP2020	79016	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11161100	C4591001 1116 11161100	16-55	02SEP2020	79018	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11161101	C4591001 1116 11161101	16-55	02SEP2020	79022	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11161103	C4591001 1116 11161103	16-55	02SEP2020	79024	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11161104	C4591001 1116 11161104	16-55	02SEP2020	79409	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
11161105	C4591001 1116 11161105	16-55	03SEP2020	79411	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11161107	C4591001 1116 11161107	16-55	03SEP2020	79414	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161108	C4591001 1116 11161108	16-55	03SEP2020	79416	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11161110	C4591001 1116 11161110	16-55	03SEP2020	80095	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11161113	C4591001 1116 11161113	16-55	03SEP2020	80099	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161115	C4591001 1116 11161115	16-55	03SEP2020	80100	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11161119	C4591001 1116 11161119	16-55	03SEP2020	80103	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161129	C4591001 1116 11161129	16-55	04SEP2020	81942	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11161138	C4591001 1116 11161138	16-55	04SEP2020	81944	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11161139	C4591001 1116 11161139	16-55	04SEP2020	81946	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11161140	C4591001 1116 11161140	16-55	04SEP2020	81952	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11161143	C4591001 1116 11161143	16-55	08SEP2020	83586	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)			
11161148	C4591001 1116 11161148	16-55	08SEP2020	83587	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161154	C4591001 1116 11161154	16-55	08SEP2020	83593	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11161157	C4591001 1116 11161157	16-55	08SEP2020	83594	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161158	C4591001 1116 11161158	16-55	09SEP2020	84917	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11161159	C4591001 1116 11161159	16-55	09SEP2020	84918	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11161160	C4591001 1116 11161160	16-55	09SEP2020	84922	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11161164	C4591001 1116 11161164	16-55	09SEP2020	255639	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11161171	C4591001 1116 11161171	16-55	09SEP2020	85950	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161172	C4591001 1116 11161172	16-55	09SEP2020	84924	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)			
11161175	C4591001 1116 11161175	16-55	09SEP2020	85951	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11161176	C4591001 1116 11161176	16-55	09SEP2020	85952	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11161178	C4591001 1116 11161178	16-55	10SEP2020	85958	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11161179	C4591001 1116 11161179	16-55	10SEP2020	86515	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161180	C4591001 1116 11161180	16-55	10SEP2020	86516	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11161185	C4591001 1116 11161185	16-55	10SEP2020	86519	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161186	C4591001 1116 11161186	16-55	10SEP2020	86522	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161196	C4591001 1116 11161196	16-55	10SEP2020	87545	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11161200	C4591001 1116 11161200	16-55	11SEP2020	87550	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11161203	C4591001 1116 11161203	16-55	11SEP2020	87553	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161204	C4591001 1116 11161204	16-55	11SEP2020	87556	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11161205	C4591001 1116 11161205	16-55	11SEP2020	88065	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11161206	C4591001 1116 11161206	16-55	11SEP2020	88063	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		
11161214	C4591001 1116 11161214	16-55	11SEP2020	88069	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161216	C4591001 1116 11161216	16-55	11SEP2020	88070	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11161217	C4591001 1116 11161217	16-55	11SEP2020	88692	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11161220	C4591001 1116 11161220	16-55	11SEP2020	88694	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11161224	C4591001 1116 11161224	16-55	11SEP2020	88695	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11161225	C4591001 1116 11161225	16-55	11SEP2020	88917	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11161226	C4591001 1116 11161226	16-55	11SEP2020	88696	BNT162b2 (30 µg)	11SEP2020/ Placebo	02OCT2020/ Placebo		
11161228	C4591001 1116 11161228	16-55	17SEP2020	88918	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161230	C4591001 1116 11161230	16-55	17SEP2020	88919	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161235	C4591001 1116 11161235	16-55	17SEP2020	88923	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161239	C4591001 1116 11161239	16-55	18SEP2020	93404	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161240	C4591001 1116 11161240	16-55	18SEP2020	93405	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161245	C4591001 1116 11161245	16-55	18SEP2020	93406	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11161249	C4591001 1116 11161249	16-55	18SEP2020	93411	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11161252	C4591001 1116 11161252	16-55	18SEP2020	94253	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11161256	C4591001 1116 11161256	16-55	19SEP2020	94255	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11161259	C4591001 1116 11161259	16-55	19SEP2020	94260	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11161260	C4591001 1116 11161260	16-55	19SEP2020	94261	Placebo	19SEP2020/ Placebo	12OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11161261	C4591001 1116 11161261	16-55	19SEP2020	94518	Placebo	19SEP2020/ Placebo	12OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11161268	C4591001 1116 11161268	16-55	22SEP2020	94522	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11161274	C4591001 1116 11161274	16-55	22SEP2020	94526	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161276	C4591001 1116 11161276	16-55	23SEP2020	94527	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161277	C4591001 1116 11161277	16-55	23SEP2020	97589	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161284	C4591001 1116 11161284	16-55	23SEP2020	97590	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11161286	C4591001 1116 11161286	16-55	23SEP2020	97593	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11161288	C4591001 1116 11161288	16-55	24SEP2020	97596	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161292	C4591001 1116 11161292	16-55	24SEP2020	98815	Placebo	24SEP2020/ Placebo			
11161293	C4591001 1116 11161293	16-55	24SEP2020	98817	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11161299	C4591001 1116 11161299	16-55	24SEP2020	98822	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11161301	C4591001 1116 11161301	16-55	24SEP2020	98823	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161305	C4591001 1116 11161305	16-55	25SEP2020	99500	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161307	C4591001 1116 11161307	16-55	25SEP2020	99501	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161308	C4591001 1116 11161308	16-55	25SEP2020	99504	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161309	C4591001 1116 11161309	16-55	25SEP2020	99505	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11161310	C4591001 1116 11161310	16-55	25SEP2020	99653	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11161312	C4591001 1116 11161312	16-55	25SEP2020	99654	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11161315	C4591001 1116 11161315	16-55	25SEP2020	99655	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161317	C4591001 1116 11161317	16-55	25SEP2020	100295	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161318	C4591001 1116 11161318	16-55	25SEP2020	99661	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11161320	C4591001 1116 11161320	16-55	25SEP2020	100296	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11161321	C4591001 1116 11161321	16-55	25SEP2020	100300	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11161322	C4591001 1116 11161322	16-55	25SEP2020	100297	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
11161323	C4591001 1116 11161323	16-55	25SEP2020	100517	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
11161324	C4591001 1116 11161324	16-55	09OCT2020	100522	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11161326	C4591001 1116 11161326	16-55	09OCT2020	100525	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo		
11161329	C4591001 1116 11161329	16-55	09OCT2020	100527	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11171011	C4591001 1117 11171011	16-55	17AUG2020	53717	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11171014	C4591001 1117 11171014	16-55	18AUG2020	53720	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11171015	C4591001 1117 11171015	16-55	18AUG2020	53722	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11171017	C4591001 1117 11171017	16-55	18AUG2020	53725	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11171021	C4591001 1117 11171021	16-55	19AUG2020	57114	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11171029	C4591001 1117 11171029	16-55	19AUG2020	57115	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171030	C4591001 1117 11171030	16-55	19AUG2020	57119	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11171035	C4591001 1117 11171035	16-55	20AUG2020	59601	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11171036	C4591001 1117 11171036	16-55	20AUG2020	57122	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11171038	C4591001 1117 11171038	16-55	20AUG2020	59602	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11171045	C4591001 1117 11171045	16-55	24AUG2020	59608	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11171050	C4591001 1117 11171050	16-55	24AUG2020	64842	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11171053	C4591001 1117 11171053	16-55	25AUG2020	64844	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11171058	C4591001 1117 11171058	16-55	25AUG2020	64846	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11171061	C4591001 1117 11171061	16-55	25AUG2020	64847	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11171062	C4591001 1117 11171062	16-55	26AUG2020	68406	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171063	C4591001 1117 11171063	16-55	26AUG2020	68407	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171064	C4591001 1117 11171064	16-55	26AUG2020	68412	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11171065	C4591001 1117 11171065	16-55	26AUG2020	68405	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11171066	C4591001 1117 11171066	16-55	26AUG2020	68922	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11171067	C4591001 1117 11171067	16-55	26AUG2020	68927	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171068	C4591001 1117 11171068	16-55	26AUG2020	68925	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11171069	C4591001 1117 11171069	16-55	26AUG2020	68928	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11171070	C4591001 1117 11171070	16-55	26AUG2020	69274	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11171073	C4591001 1117 11171073	16-55	27AUG2020	69277	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171074	C4591001 1117 11171074	16-55	27AUG2020	69279	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171075	C4591001 1117 11171075	16-55	27AUG2020	71141	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11171077	C4591001 1117 11171077	16-55	27AUG2020	69280	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11171078	C4591001 1117 11171078	16-55	27AUG2020	71142	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo		
11171083	C4591001 1117 11171083	16-55	02SEP2020	71145	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11171084	C4591001 1117 11171084	16-55	02SEP2020	71148	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11171085	C4591001 1117 11171085	16-55	02SEP2020	79387	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11171087	C4591001 1117 11171087	16-55	03SEP2020	79389	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11171089	C4591001 1117 11171089	16-55	03SEP2020	79391	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11171090	C4591001 1117 11171090	16-55	03SEP2020	79393	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11171091	C4591001 1117 11171091	16-55	03SEP2020	81089	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171093	C4591001 1117 11171093	16-55	04SEP2020	81092	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11171095	C4591001 1117 11171095	16-55	04SEP2020	81095	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11171096	C4591001 1117 11171096	16-55	04SEP2020	81090	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11171099	C4591001 1117 11171099	16-55	04SEP2020	81368	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11171100	C4591001 1117 11171100	16-55	04SEP2020	81372	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11171101	C4591001 1117 11171101	16-55	04SEP2020	81373	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11171102	C4591001 1117 11171102	16-55	04SEP2020	81374	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11171103	C4591001 1117 11171103	16-55	10SEP2020	87221	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11171107	C4591001 1117 11171107	16-55	10SEP2020	87227	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11171108	C4591001 1117 11171108	16-55	10SEP2020	87228	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171109	C4591001 1117 11171109	16-55	11SEP2020	87230	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11171111	C4591001 1117 11171111	16-55	11SEP2020	88134	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11171113	C4591001 1117 11171113	16-55	14SEP2020	88140	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11171119	C4591001 1117 11171119	16-55	15SEP2020	88143	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11171121	C4591001 1117 11171121	16-55	15SEP2020	88144	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11171126	C4591001 1117 11171126	16-55	16SEP2020	91807	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11171127	C4591001 1117 11171127	16-55	17SEP2020	91809	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
11171129	C4591001 1117 11171129	16-55	17SEP2020	91811	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11171131	C4591001 1117 11171131	16-55	17SEP2020	91816	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11171132	C4591001 1117 11171132	16-55	21SEP2020	95034	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171134	C4591001 1117 11171134	16-55	21SEP2020	95037	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11171137	C4591001 1117 11171137	16-55	21SEP2020	95041	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11171138	C4591001 1117 11171138	16-55	15OCT2020	108571	Placebo	15OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11171140	C4591001 1117 11171140	16-55	22SEP2020	95042	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11171143	C4591001 1117 11171143	16-55	22SEP2020	96379	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11171144	C4591001 1117 11171144	16-55	22SEP2020	96378	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11171145	C4591001 1117 11171145	16-55	22SEP2020	96381	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11171150	C4591001 1117 11171150	16-55	23SEP2020	96386	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11171154	C4591001 1117 11171154	16-55	23SEP2020	98141	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11171156	C4591001 1117 11171156	16-55	24SEP2020	98144	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171158	C4591001 1117 11171158	16-55	24SEP2020	98148	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11171161	C4591001 1117 11171161	16-55	29SEP2020	101278	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11171169	C4591001 1117 11171169	16-55	25SEP2020	98149	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11171170	C4591001 1117 11171170	16-55	25SEP2020	100327	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11171171	C4591001 1117 11171171	16-55	25SEP2020	100332	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11171172	C4591001 1117 11171172	16-55	25SEP2020	100329	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11171174	C4591001 1117 11171174	16-55	25SEP2020	100335	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11171178	C4591001 1117 11171178	16-55	28SEP2020	101273	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11171180	C4591001 1117 11171180	16-55	29SEP2020	101276	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11171181	C4591001 1117 11171181	16-55	29SEP2020	101280	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11171183	C4591001 1117 11171183	16-55	29SEP2020	101912	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11171184	C4591001 1117 11171184	16-55	30SEP2020	101913	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11171186	C4591001 1117 11171186	16-55	06OCT2020	101915	Placebo	06OCT2020/ Placebo			
11171187	C4591001 1117 11171187	16-55	06OCT2020	101919	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11171189	C4591001 1117 11171189	16-55	07OCT2020	104898	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11171190	C4591001 1117 11171190	16-55	08OCT2020	104899	Placebo	08OCT2020/ Placebo		11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11171192	C4591001 1117 11171192	16-55	09OCT2020	104900	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11171196	C4591001 1117 11171196	16-55	15OCT2020	104907	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11171197	C4591001 1117 11171197	16-55	20OCT2020	108572	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11181040	C4591001 1118 11181040	16-55	17AUG2020	50116	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181042	C4591001 1118 11181042	16-55	17AUG2020	52709	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11181046	C4591001 1118 11181046	16-55	17AUG2020	52712	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11181047	C4591001 1118 11181047	16-55	18AUG2020	52715	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11181048	C4591001 1118 11181048	16-55	18AUG2020	52720	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11181049	C4591001 1118 11181049	16-55	18AUG2020	53935	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11181054	C4591001 1118 11181054	16-55	18AUG2020	53936	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11181059	C4591001 1118 11181059	16-55	19AUG2020	53942	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11181060	C4591001 1118 11181060	16-55	19AUG2020	53944	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11181061	C4591001 1118 11181061	16-55	19AUG2020	55965	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11181062	C4591001 1118 11181062	16-55	19AUG2020	55962	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181063	C4591001 1118 11181063	16-55	19AUG2020	55967	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11181064	C4591001 1118 11181064	16-55	19AUG2020	55971	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
11181070	C4591001 1118 11181070	16-55	20AUG2020	58258	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11181076	C4591001 1118 11181076	16-55	20AUG2020	58259	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181079	C4591001 1118 11181079	16-55	20AUG2020	58262	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11181080	C4591001 1118 11181080	16-55	20AUG2020	59239	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11181081	C4591001 1118 11181081	16-55	20AUG2020	58263	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11181082	C4591001 1118 11181082	16-55	25AUG2020	65695	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11181083	C4591001 1118 11181083	16-55	25AUG2020	65699	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11181084	C4591001 1118 11181084	16-55	25AUG2020	65702	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181085	C4591001 1118 11181085	16-55	26AUG2020	65703	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11181086	C4591001 1118 11181086	16-55	26AUG2020	68601	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11181089	C4591001 1118 11181089	16-55	27AUG2020	68603	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11181096	C4591001 1118 11181096	16-55	29AUG2020	68604	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11181097	C4591001 1118 11181097	16-55	29AUG2020	68607	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11181100	C4591001 1118 11181100	16-55	29AUG2020	73459	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11181101	C4591001 1118 11181101	16-55	29AUG2020	73461	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11181103	C4591001 1118 11181103	16-55	09SEP2020	73462	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11181104	C4591001 1118 11181104	16-55	10SEP2020	86309	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11181106	C4591001 1118 11181106	16-55	11SEP2020	86311	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181107	C4591001 1118 11181107	16-55	11SEP2020	86316	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11181108	C4591001 1118 11181108	16-55	17SEP2020	86317	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11181109	C4591001 1118 11181109	16-55	13OCT2020	107022	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11181110	C4591001 1118 11181110	16-55	19OCT2020	107026	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
11181111	C4591001 1118 11181111	16-55	20OCT2020	107029	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11181112	C4591001 1118 11181112	16-55	20OCT2020	107030	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11181115	C4591001 1118 11181115	16-55	21OCT2020	111309	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11181116	C4591001 1118 11181116	16-55	21OCT2020	111312	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11181117	C4591001 1118 11181117	16-55	21OCT2020	111314	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11181121	C4591001 1118 11181121	16-55	22OCT2020	111315	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11181122	C4591001 1118 11181122	16-55	22OCT2020	112206	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11201038	C4591001 1120 11201038	16-55	04AUG2020	42486	Placebo				
11201203	C4591001 1120 11201203	16-55	17AUG2020	50579	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201205	C4591001 1120 11201205	16-55	17AUG2020	50583	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201207	C4591001 1120 11201207	16-55	17AUG2020	52956	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11201220	C4591001 1120 11201220	16-55	18AUG2020	52957	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201223	C4591001 1120 11201223	16-55	18AUG2020	52959	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11201230	C4591001 1120 11201230	16-55	18AUG2020	52960	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201231	C4591001 1120 11201231	16-55	18AUG2020	55376	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11201234	C4591001 1120 11201234	16-55	19AUG2020	55377	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201236	C4591001 1120 11201236	16-55	21AUG2020	55384	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo		
11201237	C4591001 1120 11201237	16-55	21AUG2020	55380	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11201238	C4591001 1120 11201238	16-55	21AUG2020	60353	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11201240	C4591001 1120 11201240	16-55	21AUG2020	60354	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11201241	C4591001 1120 11201241	16-55	21AUG2020	60359	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201244	C4591001 1120 11201244	16-55	21AUG2020	60363	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11201249	C4591001 1120 11201249	16-55	21AUG2020	60811	Placebo	21AUG2020/ Placebo			
11201250	C4591001 1120 11201250	16-55	21AUG2020	60812	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11201252	C4591001 1120 11201252	16-55	09SEP2020	60814	Placebo				
11201259	C4591001 1120 11201259	16-55	09SEP2020	60818	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11201261	C4591001 1120 11201261	16-55	10SEP2020	86578	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201265	C4591001 1120 11201265	16-55	10SEP2020	86584	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201266	C4591001 1120 11201266	16-55	10SEP2020	86582	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11201270	C4591001 1120 11201270	16-55	11SEP2020	88088	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201274	C4591001 1120 11201274	16-55	11SEP2020	88092	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11201275	C4591001 1120 11201275	16-55	11SEP2020	88091	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11201277	C4591001 1120 11201277	16-55	11SEP2020	88096	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11201278	C4591001 1120 11201278	16-55	11SEP2020	88832	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11201279	C4591001 1120 11201279	16-55	11SEP2020	88837	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11201280	C4591001 1120 11201280	16-55	11SEP2020	88835	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11201281	C4591001 1120 11201281	16-55	21SEP2020	88839	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201284	C4591001 1120 11201284	16-55	21SEP2020	95814	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11201286	C4591001 1120 11201286	16-55	22SEP2020	95817	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11201288	C4591001 1120 11201288	16-55	22SEP2020	95822	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11201289	C4591001 1120 11201289	16-55	22SEP2020	95824	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201291	C4591001 1120 11201291	16-55	22SEP2020	96678	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11201293	C4591001 1120 11201293	16-55	22SEP2020	96681	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11201297	C4591001 1120 11201297	16-55	23SEP2020	96685	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11201298	C4591001 1120 11201298	16-55	23SEP2020	96687	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11201299	C4591001 1120 11201299	16-55	23SEP2020	97508	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11201300	C4591001 1120 11201300	16-55	23SEP2020	97509	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201303	C4591001 1120 11201303	16-55	23SEP2020	97513	Placebo	23SEP2020/ Placebo	19OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201305	C4591001 1120 11201305	16-55	23SEP2020	97514	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11201306	C4591001 1120 11201306	16-55	23SEP2020	97987	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11201311	C4591001 1120 11201311	16-55	14OCT2020	97991	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11201315	C4591001 1120 11201315	16-55	14OCT2020	97992	Placebo	14OCT2020/ Placebo	06NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11201318	C4591001 1120 11201318	16-55	15OCT2020	97995	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11201320	C4591001 1120 11201320	16-55	15OCT2020	108066	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201322	C4591001 1120 11201322	16-55	15OCT2020	108075	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11201323	C4591001 1120 11201323	16-55	15OCT2020	108068	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201325	C4591001 1120 11201325	16-55	15OCT2020	108076	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201326	C4591001 1120 11201326	16-55	15OCT2020	108320	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11201331	C4591001 1120 11201331	16-55	16OCT2020	108321	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11201334	C4591001 1120 11201334	16-55	16OCT2020	108325	Placebo	16OCT2020/ Placebo	10NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201337	C4591001 1120 11201337	16-55	16OCT2020	108328	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11201339	C4591001 1120 11201339	16-55	16OCT2020	109205	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11201340	C4591001 1120 11201340	16-55	19OCT2020	109207	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201342	C4591001 1120 11201342	16-55	20OCT2020	109209	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11201343	C4591001 1120 11201343	16-55	20OCT2020	109208	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201346	C4591001 1120 11201346	16-55	20OCT2020	111009	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11201348	C4591001 1120 11201348	16-55	20OCT2020	111012	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201352	C4591001 1120 11201352	16-55	21OCT2020	111014	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201356	C4591001 1120 11201356	16-55	21OCT2020	111015	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201357	C4591001 1120 11201357	16-55	21OCT2020	111533	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11201363	C4591001 1120 11201363	16-55	21OCT2020	111538	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11201364	C4591001 1120 11201364	16-55	21OCT2020	111542	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11201367	C4591001 1120 11201367	16-55	21OCT2020	111544	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11201371	C4591001 1120 11201371	16-55	22OCT2020	112138	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11201386	C4591001 1120 11201386	16-55	22OCT2020	112140	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11201388	C4591001 1120 11201388	16-55	23OCT2020	112141	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11201392	C4591001 1120 11201392	16-55	23OCT2020	113047	Placebo	23OCT2020/ Placebo	01DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201393	C4591001 1120 11201393	16-55	23OCT2020	112143	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11201395	C4591001 1120 11201395	16-55	23OCT2020	113051	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11201398	C4591001 1120 11201398	16-55	27OCT2020	113053	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201404	C4591001 1120 11201404	16-55	28OCT2020	113056	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201405	C4591001 1120 11201405	16-55	28OCT2020	114368	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo		
11201406	C4591001 1120 11201406	16-55	28OCT2020	114369	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201407	C4591001 1120 11201407	16-55	28OCT2020	114373	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201409	C4591001 1120 11201409	16-55	28OCT2020	114370	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11201416	C4591001 1120 11201416	16-55	28OCT2020	114557	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201417	C4591001 1120 11201417	16-55	29OCT2020	114562	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11201418	C4591001 1120 11201418	16-55	29OCT2020	114567	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11201420	C4591001 1120 11201420	16-55	29OCT2020	114564	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11201425	C4591001 1120 11201425	16-55	29OCT2020	114738	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11201427	C4591001 1120 11201427	16-55	29OCT2020	114741	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11201430	C4591001 1120 11201430	16-55	29OCT2020	114746	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11201431	C4591001 1120 11201431	16-55	29OCT2020	114747	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11201433	C4591001 1120 11201433	16-55	30OCT2020	115085	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11211001	C4591001 1121 11211001	16-55	24AUG2020	63486	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211002	C4591001 1121 11211002	16-55	24AUG2020	63490	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211003	C4591001 1121 11211003	16-55	24AUG2020	63493	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211004	C4591001 1121 11211004	16-55	24AUG2020	63496	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		
11211005	C4591001 1121 11211005	16-55	24AUG2020	63689	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211006	C4591001 1121 11211006	16-55	24AUG2020	63694	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11211008	C4591001 1121 11211008	16-55	24AUG2020	63699	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211009	C4591001 1121 11211009	16-55	24AUG2020	63700	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211010	C4591001 1121 11211010	16-55	24AUG2020	63944	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		
11211012	C4591001 1121 11211012	16-55	24AUG2020	63948	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211013	C4591001 1121 11211013	16-55	24AUG2020	63951	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
11211014	C4591001 1121 11211014	16-55	25AUG2020	63952	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211015	C4591001 1121 11211015	16-55	25AUG2020	65454	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211018	C4591001 1121 11211018	16-55	26AUG2020	65455	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
11211022	C4591001 1121 11211022	16-55	26AUG2020	65457	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11211023	C4591001 1121 11211023	16-55	26AUG2020	65463	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11211024	C4591001 1121 11211024	16-55	26AUG2020	67883	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11211025	C4591001 1121 11211025	16-55	26AUG2020	67885	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
11211026	C4591001 1121 11211026	16-55	26AUG2020	67886	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211027	C4591001 1121 11211027	16-55	27AUG2020	67887	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211028	C4591001 1121 11211028	16-55	27AUG2020	69630	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211029	C4591001 1121 11211029	16-55	27AUG2020	69632	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11211030	C4591001 1121 11211030	16-55	27AUG2020	69637	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211033	C4591001 1121 11211033	16-55	27AUG2020	69640	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211034	C4591001 1121 11211034	16-55	27AUG2020	70173	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11211035	C4591001 1121 11211035	16-55	27AUG2020	70176	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211036	C4591001 1121 11211036	16-55	27AUG2020	70178	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211038	C4591001 1121 11211038	16-55	27AUG2020	70180	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11211039	C4591001 1121 11211039	16-55	27AUG2020	70506	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211041	C4591001 1121 11211041	16-55	27AUG2020	70510	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211044	C4591001 1121 11211044	16-55	31AUG2020	70513	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211050	C4591001 1121 11211050	16-55	01SEP2020	70516	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211052	C4591001 1121 11211052	16-55	01SEP2020	76577	Placebo	01SEP2020/ Placebo	20SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211053	C4591001 1121 11211053	16-55	01SEP2020	76578	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211054	C4591001 1121 11211054	16-55	01SEP2020	76581	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
11211057	C4591001 1121 11211057	16-55	02SEP2020	76587	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
11211059	C4591001 1121 11211059	16-55	02SEP2020	78247	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
11211060	C4591001 1121 11211060	16-55	02SEP2020	78249	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211061	C4591001 1121 11211061	16-55	02SEP2020	78251	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211064	C4591001 1121 11211064	16-55	02SEP2020	78255	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
11211065	C4591001 1121 11211065	16-55	02SEP2020	78533	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211066	C4591001 1121 11211066	16-55	03SEP2020	78534	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11211067	C4591001 1121 11211067	16-55	03SEP2020	78535	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11211069	C4591001 1121 11211069	16-55	03SEP2020	78540	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211070	C4591001 1121 11211070	16-55	03SEP2020	79697	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211076	C4591001 1121 11211076	16-55	03SEP2020	79698	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211078	C4591001 1121 11211078	16-55	03SEP2020	79699	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211080	C4591001 1121 11211080	16-55	03SEP2020	251734	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11211081	C4591001 1121 11211081	16-55	04SEP2020	79706	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211082	C4591001 1121 11211082	16-55	04SEP2020	81534	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211084	C4591001 1121 11211084	16-55	04SEP2020	81537	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211085	C4591001 1121 11211085	16-55	04SEP2020	81541	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11211087	C4591001 1121 11211087	16-55	08SEP2020	81542	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11211091	C4591001 1121 11211091	16-55	08SEP2020	83635	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211093	C4591001 1121 11211093	16-55	08SEP2020	83636	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211094	C4591001 1121 11211094	16-55	08SEP2020	83640	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
11211095	C4591001 1121 11211095	16-55	08SEP2020	83643	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211096	C4591001 1121 11211096	16-55	08SEP2020	83862	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo		
11211097	C4591001 1121 11211097	16-55	08SEP2020	83863	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211099	C4591001 1121 11211099	16-55	09SEP2020	83864	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211100	C4591001 1121 11211100	16-55	09SEP2020	83867	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211105	C4591001 1121 11211105	16-55	09SEP2020	85337	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
11211106	C4591001 1121 11211106	16-55	09SEP2020	85338	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211108	C4591001 1121 11211108	16-55	09SEP2020	85341	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
11211109	C4591001 1121 11211109	16-55	09SEP2020	85342	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211110	C4591001 1121 11211110	16-55	09SEP2020	85589	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11211111	C4591001 1121 11211111	16-55	10SEP2020	85590	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211112	C4591001 1121 11211112	16-55	10SEP2020	85592	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11211113	C4591001 1121 11211113	16-55	10SEP2020	85600	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211114	C4591001 1121 11211114	16-55	10SEP2020	86681	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11211115	C4591001 1121 11211115	16-55	10SEP2020	86684	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211116	C4591001 1121 11211116	16-55	10SEP2020	86685	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211117	C4591001 1121 11211117	16-55	10SEP2020	86692	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11211118	C4591001 1121 11211118	16-55	10SEP2020	86891	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11211121	C4591001 1121 11211121	16-55	10SEP2020	86892	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11211123	C4591001 1121 11211123	16-55	10SEP2020	86893	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11221001	C4591001 1122 11221001	16-55	31AUG2020	75270	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11221003	C4591001 1122 11221003	16-55	02SEP2020	75278	Placebo	02SEP2020/ Placebo	29SEP2020/ Placebo		
11221004	C4591001 1122 11221004	16-55	02SEP2020	75279	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11221005	C4591001 1122 11221005	16-55	03SEP2020	75280	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11221006	C4591001 1122 11221006	16-55	03SEP2020	79925	Placebo				
11221008	C4591001 1122 11221008	16-55	03SEP2020	79929	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11221009	C4591001 1122 11221009	16-55	04SEP2020	79931	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11221012	C4591001 1122 11221012	16-55	08SEP2020	79936	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11221014	C4591001 1122 11221014	16-55	09SEP2020	84234	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11221016	C4591001 1122 11221016	16-55	08SEP2020	84233	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11221023	C4591001 1122 11221023	16-55	10SEP2020	84240	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221024	C4591001 1122 11221024	16-55	10SEP2020	84242	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11221025	C4591001 1122 11221025	16-55	10SEP2020	87402	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11221026	C4591001 1122 11221026	16-55	11SEP2020	87404	BNT162b2 (30 µg)				
11221027	C4591001 1122 11221027	16-55	11SEP2020	87406	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11221028	C4591001 1122 11221028	16-55	11SEP2020	87408	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221030	C4591001 1122 11221030	16-55	11SEP2020	88472	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221031	C4591001 1122 11221031	16-55	11SEP2020	88475	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11221032	C4591001 1122 11221032	16-55	14SEP2020	88477	Placebo	14SEP2020/ Placebo	23OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11221033	C4591001 1122 11221033	16-55	15SEP2020	88479	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11221038	C4591001 1122 11221038	16-55	25SEP2020	100373	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
11221040	C4591001 1122 11221040	16-55	05OCT2020	100376	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11221041	C4591001 1122 11221041	16-55	07OCT2020	100378	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11221042	C4591001 1122 11221042	16-55	07OCT2020	100381	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11221045	C4591001 1122 11221045	16-55	08OCT2020	266907	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11221047	C4591001 1122 11221047	16-55	08OCT2020	105237	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11221048	C4591001 1122 11221048	16-55	08OCT2020	105239	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11221051	C4591001 1122 11221051	16-55	09OCT2020	105243	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11221052	C4591001 1122 11221052	16-55	09OCT2020	106121	Placebo	09OCT2020/ Placebo	13NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11221053	C4591001 1122 11221053	16-55	13OCT2020	106126	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11221054	C4591001 1122 11221054	16-55	15OCT2020	106127	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11221059	C4591001 1122 11221059	16-55	22OCT2020	106132	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231027	C4591001 1123 11231027	16-55	04AUG2020	42620	BNT162b2 (30 µg)				
11231098	C4591001 1123 11231098	16-55	14AUG2020	49536	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11231106	C4591001 1123 11231106	16-55	17AUG2020	50783	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11231108	C4591001 1123 11231108	16-55	17AUG2020	50785	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231109	C4591001 1123 11231109	16-55	17AUG2020	52966	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11231114	C4591001 1123 11231114	16-55	17AUG2020	52968	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231115	C4591001 1123 11231115	16-55	17AUG2020	52970	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231116	C4591001 1123 11231116	16-55	17AUG2020	52972	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231117	C4591001 1123 11231117	16-55	18AUG2020	54500	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231118	C4591001 1123 11231118	16-55	18AUG2020	54503	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231119	C4591001 1123 11231119	16-55	18AUG2020	54504	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231120	C4591001 1123 11231120	16-55	18AUG2020	54506	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231121	C4591001 1123 11231121	16-55	18AUG2020	55078	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231122	C4591001 1123 11231122	16-55	18AUG2020	55080	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231123	C4591001 1123 11231123	16-55	19AUG2020	55081	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11231124	C4591001 1123 11231124	16-55	19AUG2020	55082	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11231127	C4591001 1123 11231127	16-55	19AUG2020	57037	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231128	C4591001 1123 11231128	16-55	19AUG2020	57038	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231130	C4591001 1123 11231130	16-55	19AUG2020	57039	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11231132	C4591001 1123 11231132	16-55	20AUG2020	57040	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231134	C4591001 1123 11231134	16-55	20AUG2020	58817	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11231135	C4591001 1123 11231135	16-55	20AUG2020	58822	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11231136	C4591001 1123 11231136	16-55	20AUG2020	58825	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231137	C4591001 1123 11231137	16-55	20AUG2020	58828	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231138	C4591001 1123 11231138	16-55	20AUG2020	59003	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11231142	C4591001 1123 11231142	16-55	20AUG2020	59005	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11231143	C4591001 1123 11231143	16-55	20AUG2020	59008	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231144	C4591001 1123 11231144	16-55	20AUG2020	59658	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
11231145	C4591001 1123 11231145	16-55	24AUG2020	59663	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
11231151	C4591001 1123 11231151	16-55	24AUG2020	59668	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11231152	C4591001 1123 11231152	16-55	24AUG2020	64050	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231153	C4591001 1123 11231153	16-55	24AUG2020	59665	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231154	C4591001 1123 11231154	16-55	24AUG2020	64052	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11231155	C4591001 1123 11231155	16-55	24AUG2020	64055	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11231156	C4591001 1123 11231156	16-55	24AUG2020	64056	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11231157	C4591001 1123 11231157	16-55	24AUG2020	64386	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11231159	C4591001 1123 11231159	16-55	24AUG2020	64387	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231160	C4591001 1123 11231160	16-55	25AUG2020	64394	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11231161	C4591001 1123 11231161	16-55	25AUG2020	64391	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231162	C4591001 1123 11231162	16-55	25AUG2020	66269	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231163	C4591001 1123 11231163	16-55	25AUG2020	66271	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231164	C4591001 1123 11231164	16-55	25AUG2020	66278	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11231165	C4591001 1123 11231165	16-55	25AUG2020	66280	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231168	C4591001 1123 11231168	16-55	25AUG2020	66666	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
11231170	C4591001 1123 11231170	16-55	25AUG2020	66668	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11231171	C4591001 1123 11231171	16-55	25AUG2020	66670	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11231172	C4591001 1123 11231172	16-55	25AUG2020	66676	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231173	C4591001 1123 11231173	16-55	25AUG2020	66965	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231175	C4591001 1123 11231175	16-55	26AUG2020	66966	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11231176	C4591001 1123 11231176	16-55	26AUG2020	66967	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231177	C4591001 1123 11231177	16-55	26AUG2020	66970	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231178	C4591001 1123 11231178	16-55	26AUG2020	68168	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231179	C4591001 1123 11231179	16-55	26AUG2020	68169	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231183	C4591001 1123 11231183	16-55	26AUG2020	68176	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11231184	C4591001 1123 11231184	16-55	26AUG2020	68173	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11231187	C4591001 1123 11231187	16-55	26AUG2020	68741	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11231188	C4591001 1123 11231188	16-55	26AUG2020	68742	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231189	C4591001 1123 11231189	16-55	26AUG2020	68745	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231190	C4591001 1123 11231190	16-55	26AUG2020	68748	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231191	C4591001 1123 11231191	16-55	26AUG2020	69089	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11231194	C4591001 1123 11231194	16-55	27AUG2020	69091	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231195	C4591001 1123 11231195	16-55	27AUG2020	69096	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231197	C4591001 1123 11231197	16-55	27AUG2020	69098	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11231199	C4591001 1123 11231199	16-55	27AUG2020	71057	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231200	C4591001 1123 11231200	16-55	27AUG2020	71066	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231201	C4591001 1123 11231201	16-55	27AUG2020	71065	Placebo	27AUG2020/ Placebo	01OCT2020/ Placebo		
11231202	C4591001 1123 11231202	16-55	27AUG2020	71068	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231204	C4591001 1123 11231204	16-55	27AUG2020	71165	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11231207	C4591001 1123 11231207	16-55	27AUG2020	71170	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11231208	C4591001 1123 11231208	16-55	28AUG2020	71175	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11231209	C4591001 1123 11231209	16-55	04SEP2020	71176	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231210	C4591001 1123 11231210	16-55	04SEP2020	81846	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231212	C4591001 1123 11231212	16-55	04SEP2020	81849	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231215	C4591001 1123 11231215	16-55	08SEP2020	81851	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231216	C4591001 1123 11231216	16-55	08SEP2020	81852	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231217	C4591001 1123 11231217	16-55	09SEP2020	84882	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11231218	C4591001 1123 11231218	16-55	09SEP2020	84885	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231220	C4591001 1123 11231220	16-55	09SEP2020	84890	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11231221	C4591001 1123 11231221	16-55	09SEP2020	84892	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231222	C4591001 1123 11231222	16-55	09SEP2020	85830	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11231228	C4591001 1123 11231228	16-55	10SEP2020	85831	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231229	C4591001 1123 11231229	16-55	10SEP2020	85833	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11231230	C4591001 1123 11231230	16-55	10SEP2020	85839	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231232	C4591001 1123 11231232	16-55	10SEP2020	87497	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11231233	C4591001 1123 11231233	16-55	10SEP2020	87504	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11231234	C4591001 1123 11231234	16-55	11SEP2020	87506	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11231235	C4591001 1123 11231235	16-55	11SEP2020	87507	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231236	C4591001 1123 11231236	16-55	11SEP2020	88054	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11231237	C4591001 1123 11231237	16-55	11SEP2020	88050	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11231238	C4591001 1123 11231238	16-55	11SEP2020	88057	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11231239	C4591001 1123 11231239	16-55	11SEP2020	88059	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11231240	C4591001 1123 11231240	16-55	11SEP2020	88426	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11231243	C4591001 1123 11231243	16-55	14SEP2020	88428	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231245	C4591001 1123 11231245	16-55	14SEP2020	88431	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231246	C4591001 1123 11231246	16-55	14SEP2020	88432	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11231248	C4591001 1123 11231248	16-55	15SEP2020	90595	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231249	C4591001 1123 11231249	16-55	15SEP2020	90596	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231251	C4591001 1123 11231251	16-55	15SEP2020	90598	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11231252	C4591001 1123 11231252	16-55	15SEP2020	90604	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11231253	C4591001 1123 11231253	16-55	16SEP2020	91256	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11231260	C4591001 1123 11231260	16-55	16SEP2020	91259	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231261	C4591001 1123 11231261	16-55	16SEP2020	91262	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11231262	C4591001 1123 11231262	16-55	17SEP2020	91264	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11231263	C4591001 1123 11231263	16-55	17SEP2020	92553	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11231264	C4591001 1123 11231264	16-55	17SEP2020	92554	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11231265	C4591001 1123 11231265	16-55	17SEP2020	92556	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231266	C4591001 1123 11231266	16-55	17SEP2020	92560	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231267	C4591001 1123 11231267	16-55	17SEP2020	92720	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11231268	C4591001 1123 11231268	16-55	17SEP2020	92719	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11231269	C4591001 1123 11231269	16-55	17SEP2020	92721	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11231272	C4591001 1123 11231272	16-55	18SEP2020	93884	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231275	C4591001 1123 11231275	16-55	18SEP2020	92724	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11231276	C4591001 1123 11231276	16-55	18SEP2020	93887	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11231280	C4591001 1123 11231280	16-55	21SEP2020	93888	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231281	C4591001 1123 11231281	16-55	22SEP2020	93890	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231283	C4591001 1123 11231283	16-55	22SEP2020	96353	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11231286	C4591001 1123 11231286	16-55	23SEP2020	96356	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231287	C4591001 1123 11231287	16-55	23SEP2020	96359	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11231289	C4591001 1123 11231289	16-55	23SEP2020	97783	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11231290	C4591001 1123 11231290	16-55	23SEP2020	96360	Placebo	23SEP2020/ Placebo			
11231291	C4591001 1123 11231291	16-55	23SEP2020	97787	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231292	C4591001 1123 11231292	16-55	23SEP2020	97789	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11231293	C4591001 1123 11231293	16-55	23SEP2020	97791	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231294	C4591001 1123 11231294	16-55	23SEP2020	97997	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11231295	C4591001 1123 11231295	16-55	23SEP2020	98003	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11231298	C4591001 1123 11231298	16-55	23SEP2020	98004	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11231299	C4591001 1123 11231299	16-55	23SEP2020	98006	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231300	C4591001 1123 11231300	16-55	24SEP2020	98585	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11231301	C4591001 1123 11231301	16-55	24SEP2020	98586	BNT162b2 (30 µg)				
11231302	C4591001 1123 11231302	16-55	24SEP2020	98588	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231303	C4591001 1123 11231303	16-55	24SEP2020	98589	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231304	C4591001 1123 11231304	16-55	24SEP2020	98838	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231305	C4591001 1123 11231305	16-55	24SEP2020	98845	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231306	C4591001 1123 11231306	16-55	24SEP2020	98848	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11231307	C4591001 1123 11231307	16-55	24SEP2020	98847	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11231308	C4591001 1123 11231308	16-55	24SEP2020	98888	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
11231309	C4591001 1123 11231309	16-55	24SEP2020	98891	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231313	C4591001 1123 11231313	16-55	24SEP2020	98894	Placebo	24SEP2020/ Placebo		12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231317	C4591001 1123 11231317	16-55	24SEP2020	98896	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231320	C4591001 1123 11231320	16-55	24SEP2020	99130	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11231321	C4591001 1123 11231321	16-55	25SEP2020	99132	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231322	C4591001 1123 11231322	16-55	25SEP2020	99134	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231323	C4591001 1123 11231323	16-55	25SEP2020	99135	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231324	C4591001 1123 11231324	16-55	25SEP2020	99869	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11231325	C4591001 1123 11231325	16-55	25SEP2020	99870	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11231326	C4591001 1123 11231326	16-55	25SEP2020	99871	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231327	C4591001 1123 11231327	16-55	25SEP2020	99879	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231328	C4591001 1123 11231328	16-55	25SEP2020	100001	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11231329	C4591001 1123 11231329	16-55	25SEP2020	100004	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11231330	C4591001 1123 11231330	16-55	25SEP2020	100005	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11231334	C4591001 1123 11231334	16-55	25SEP2020	100012	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11231336	C4591001 1123 11231336	16-55	02OCT2020	103313	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11231337	C4591001 1123 11231337	16-55	02OCT2020	103314	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
11231338	C4591001 1123 11231338	16-55	06OCT2020	103316	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11231339	C4591001 1123 11231339	16-55	06OCT2020	103317	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		
11231346	C4591001 1123 11231346	16-55	07OCT2020	104969	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11231350	C4591001 1123 11231350	16-55	08OCT2020	104971	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231351	C4591001 1123 11231351	16-55	08OCT2020	104978	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo		
11231352	C4591001 1123 11231352	16-55	08OCT2020	104980	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11231353	C4591001 1123 11231353	16-55	08OCT2020	105583	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11231357	C4591001 1123 11231357	16-55	09OCT2020	105585	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11231358	C4591001 1123 11231358	16-55	09OCT2020	105587	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11231359	C4591001 1123 11231359	16-55	12OCT2020	105588	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231360	C4591001 1123 11231360	16-55	12OCT2020	106375	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11231361	C4591001 1123 11231361	16-55	12OCT2020	106377	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11231362	C4591001 1123 11231362	16-55	12OCT2020	106378	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231364	C4591001 1123 11231364	16-55	12OCT2020	106384	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231365	C4591001 1123 11231365	16-55	12OCT2020	106522	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11231366	C4591001 1123 11231366	16-55	12OCT2020	106523	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11231369	C4591001 1123 11231369	16-55	12OCT2020	106526	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231372	C4591001 1123 11231372	16-55	13OCT2020	106528	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo		
11231375	C4591001 1123 11231375	16-55	13OCT2020	107058	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11231377	C4591001 1123 11231377	16-55	14OCT2020	107060	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11231381	C4591001 1123 11231381	16-55	15OCT2020	107068	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11231382	C4591001 1123 11231382	16-55	15OCT2020	108486	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11231383	C4591001 1123 11231383	16-55	15OCT2020	108488	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11231384	C4591001 1123 11231384	16-55	15OCT2020	108487	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231386	C4591001 1123 11231386	16-55	19OCT2020	108491	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
11231387	C4591001 1123 11231387	16-55	19OCT2020	110526	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11231389	C4591001 1123 11231389	16-55	20OCT2020	110531	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11231392	C4591001 1123 11231392	16-55	21OCT2020	110533	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11231395	C4591001 1123 11231395	16-55	22OCT2020	110535	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11231397	C4591001 1123 11231397	16-55	22OCT2020	112304	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo		
11231398	C4591001 1123 11231398	16-55	22OCT2020	112305	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231399	C4591001 1123 11231399	16-55	23OCT2020	112307	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11231403	C4591001 1123 11231403	16-55	26OCT2020	112312	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11231404	C4591001 1123 11231404	16-55	26OCT2020	113645	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231405	C4591001 1123 11231405	16-55	26OCT2020	113647	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11231407	C4591001 1123 11231407	16-55	28OCT2020	113649	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11231408	C4591001 1123 11231408	16-55	28OCT2020	113656	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11231409	C4591001 1123 11231409	16-55	29OCT2020	114716	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231410	C4591001 1123 11231410	16-55	29OCT2020	114718	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11231411	C4591001 1123 11231411	16-55	30OCT2020	114722	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11231412	C4591001 1123 11231412	16-55	17NOV2020	114724	Placebo	17NOV2020/ Placebo	09DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11231413	C4591001 1123 11231413	16-55	18NOV2020	116442	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11231414	C4591001 1123 11231414	16-55	19NOV2020	116445	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
11231415	C4591001 1123 11231415	16-55	19NOV2020	116446	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231416	C4591001 1123 11231416	16-55	19NOV2020	116452	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11231417	C4591001 1123 11231417	16-55	23NOV2020	116684	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
11231418	C4591001 1123 11231418	16-55	23NOV2020	116687	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231419	C4591001 1123 11231419	16-55	24NOV2020	116688	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231420	C4591001 1123 11231420	16-55	25NOV2020	116692	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
11231421	C4591001 1123 11231421	16-55	30NOV2020	117017	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11231423	C4591001 1123 11231423	16-55	01DEC2020	117018	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11231426	C4591001 1123 11231426	16-55	03DEC2020	117024	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231427	C4591001 1123 11231427	16-55	03DEC2020	117028	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11231429	C4591001 1123 11231429	16-55	03DEC2020	117450	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11231430	C4591001 1123 11231430	16-55	03DEC2020	117451	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231433	C4591001 1123 11231433	16-55	07DEC2020	117455	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11231435	C4591001 1123 11231435	16-55	07DEC2020	117459	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
11231436	C4591001 1123 11231436	16-55	07DEC2020	117665	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
11231437	C4591001 1123 11231437	16-55	08DEC2020	117669	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)		
11231464	C4591001 1123 11231464	16-55	18DEC2020	117672	Placebo	18DEC2020/ Placebo	07JAN2021/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11231471	C4591001 1123 11231471	16-55	21DEC2020	117673	Placebo	21DEC2020/ Placebo	12JAN2021/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11231480	C4591001 1123 11231480	16-55	21DEC2020	117943	BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)		
11231490	C4591001 1123 11231490	16-55	22DEC2020	117945	BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)		
11231498	C4591001 1123 11231498	16-55	23DEC2020	117950	Placebo	23DEC2020/ Placebo	20JAN2021/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241041	C4591001 1124 11241041	16-55	17AUG2020	52243	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11241042	C4591001 1124 11241042	16-55	17AUG2020	52246	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11241043	C4591001 1124 11241043	16-55	17AUG2020	52248	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11241047	C4591001 1124 11241047	16-55	17AUG2020	52251	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241049	C4591001 1124 11241049	16-55	17AUG2020	53046	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11241050	C4591001 1124 11241050	16-55	17AUG2020	53051	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11241052	C4591001 1124 11241052	16-55	18AUG2020	53054	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11241053	C4591001 1124 11241053	16-55	18AUG2020	53055	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11241054	C4591001 1124 11241054	16-55	18AUG2020	54005	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241055	C4591001 1124 11241055	16-55	18AUG2020	54009	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241057	C4591001 1124 11241057	16-55	18AUG2020	54010	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241058	C4591001 1124 11241058	16-55	18AUG2020	54016	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241059	C4591001 1124 11241059	16-55	18AUG2020	54893	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241060	C4591001 1124 11241060	16-55	18AUG2020	54894	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241061	C4591001 1124 11241061	16-55	19AUG2020	54896	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11241065	C4591001 1124 11241065	16-55	19AUG2020	54902	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11241066	C4591001 1124 11241066	16-55	19AUG2020	57019	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11241067	C4591001 1124 11241067	16-55	19AUG2020	57020	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11241068	C4591001 1124 11241068	16-55	19AUG2020	57028	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11241069	C4591001 1124 11241069	16-55	19AUG2020	57021	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241071	C4591001 1124 11241071	16-55	19AUG2020	57450	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241072	C4591001 1124 11241072	16-55	19AUG2020	57452	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
11241075	C4591001 1124 11241075	16-55	20AUG2020	57453	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11241076	C4591001 1124 11241076	16-55	20AUG2020	58877	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11241077	C4591001 1124 11241077	16-55	20AUG2020	57459	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11241078	C4591001 1124 11241078	16-55	20AUG2020	58881	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11241081	C4591001 1124 11241081	16-55	24AUG2020	58887	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241083	C4591001 1124 11241083	16-55	24AUG2020	58888	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241084	C4591001 1124 11241084	16-55	24AUG2020	63665	Placebo	24AUG2020/ Placebo			
11241086	C4591001 1124 11241086	16-55	24AUG2020	63667	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241087	C4591001 1124 11241087	16-55	24AUG2020	63671	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11241090	C4591001 1124 11241090	16-55	25AUG2020	63675	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241092	C4591001 1124 11241092	16-55	25AUG2020	65442	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11241093	C4591001 1124 11241093	16-55	25AUG2020	65444	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11241094	C4591001 1124 11241094	16-55	25AUG2020	65450	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11241095	C4591001 1124 11241095	16-55	25AUG2020	65452	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241096	C4591001 1124 11241096	16-55	25AUG2020	66257	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11241097	C4591001 1124 11241097	16-55	25AUG2020	66260	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11241099	C4591001 1124 11241099	16-55	26AUG2020	66267	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241100	C4591001 1124 11241100	16-55	26AUG2020	67338	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241102	C4591001 1124 11241102	16-55	26AUG2020	67340	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11241103	C4591001 1124 11241103	16-55	26AUG2020	67347	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11241104	C4591001 1124 11241104	16-55	26AUG2020	67348	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241105	C4591001 1124 11241105	16-55	26AUG2020	68359	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11241106	C4591001 1124 11241106	16-55	26AUG2020	68357	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241108	C4591001 1124 11241108	16-55	26AUG2020	68364	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11241109	C4591001 1124 11241109	16-55	26AUG2020	68365	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241111	C4591001 1124 11241111	16-55	26AUG2020	69163	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11241112	C4591001 1124 11241112	16-55	27AUG2020	69168	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11241113	C4591001 1124 11241113	16-55	27AUG2020	69169	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241118	C4591001 1124 11241118	16-55	27AUG2020	69172	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11241120	C4591001 1124 11241120	16-55	27AUG2020	70821	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11241122	C4591001 1124 11241122	16-55	27AUG2020	70822	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11241125	C4591001 1124 11241125	16-55	31AUG2020	70824	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241127	C4591001 1124 11241127	16-55	31AUG2020	70825	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11241129	C4591001 1124 11241129	16-55	31AUG2020	75356	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11241137	C4591001 1124 11241137	16-55	01SEP2020	75357	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241141	C4591001 1124 11241141	16-55	01SEP2020	75361	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11241142	C4591001 1124 11241142	16-55	02SEP2020	75364	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11241149	C4591001 1124 11241149	16-55	02SEP2020	78979	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241152	C4591001 1124 11241152	16-55	02SEP2020	78985	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11241153	C4591001 1124 11241153	16-55	02SEP2020	78986	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11241167	C4591001 1124 11241167	16-55	03SEP2020	78988	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11241168	C4591001 1124 11241168	16-55	03SEP2020	80959	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11241170	C4591001 1124 11241170	16-55	04SEP2020	80962	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11241174	C4591001 1124 11241174	16-55	04SEP2020	80963	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11241176	C4591001 1124 11241176	16-55	04SEP2020	80967	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241178	C4591001 1124 11241178	16-55	08SEP2020	83274	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11241179	C4591001 1124 11241179	16-55	08SEP2020	83277	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11241180	C4591001 1124 11241180	16-55	08SEP2020	83280	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241183	C4591001 1124 11241183	16-55	08SEP2020	83284	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11241184	C4591001 1124 11241184	16-55	08SEP2020	83957	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241185	C4591001 1124 11241185	16-55	08SEP2020	83961	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11241186	C4591001 1124 11241186	16-55	08SEP2020	83963	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11241187	C4591001 1124 11241187	16-55	08SEP2020	83964	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11241188	C4591001 1124 11241188	16-55	09SEP2020	84786	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11241189	C4591001 1124 11241189	16-55	09SEP2020	84787	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241190	C4591001 1124 11241190	16-55	09SEP2020	84793	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11241194	C4591001 1124 11241194	16-55	09SEP2020	84794	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11241195	C4591001 1124 11241195	16-55	09SEP2020	85435	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241196	C4591001 1124 11241196	16-55	10SEP2020	86374	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11241197	C4591001 1124 11241197	16-55	09SEP2020	85439	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11241198	C4591001 1124 11241198	16-55	09SEP2020	85440	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11241199	C4591001 1124 11241199	16-55	10SEP2020	85442	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11241200	C4591001 1124 11241200	16-55	10SEP2020	86370	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11241202	C4591001 1124 11241202	16-55	10SEP2020	86373	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241207	C4591001 1124 11241207	16-55	10SEP2020	87187	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11241208	C4591001 1124 11241208	16-55	10SEP2020	86378	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11241212	C4591001 1124 11241212	16-55	11SEP2020	87189	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11241213	C4591001 1124 11241213	16-55	11SEP2020	87192	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241214	C4591001 1124 11241214	16-55	11SEP2020	87196	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241216	C4591001 1124 11241216	16-55	11SEP2020	87959	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241217	C4591001 1124 11241217	16-55	11SEP2020	87958	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11241218	C4591001 1124 11241218	16-55	11SEP2020	87961	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11241219	C4591001 1124 11241219	16-55	11SEP2020	87963	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11241222	C4591001 1124 11241222	16-55	11SEP2020	88313	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11241223	C4591001 1124 11241223	16-55	14SEP2020	88314	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11241224	C4591001 1124 11241224	16-55	14SEP2020	88316	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11241225	C4591001 1124 11241225	16-55	16SEP2020	88323	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11241226	C4591001 1124 11241226	16-55	16SEP2020	91270	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11241227	C4591001 1124 11241227	16-55	17SEP2020	91271	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11241228	C4591001 1124 11241228	16-55	17SEP2020	91274	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo		
11241232	C4591001 1124 11241232	16-55	23SEP2020	91276	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11241233	C4591001 1124 11241233	16-55	30SEP2020	98977	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11241234	C4591001 1124 11241234	16-55	24SEP2020	98969	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11241235	C4591001 1124 11241235	16-55	24SEP2020	98972	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11251044	C4591001 1125 11251044	16-55	17AUG2020	50737	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11251045	C4591001 1125 11251045	16-55	17AUG2020	50734	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11251049	C4591001 1125 11251049	16-55	17AUG2020	53081	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251050	C4591001 1125 11251050	16-55	17AUG2020	50739	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251051	C4591001 1125 11251051	16-55	17AUG2020	53083	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11251053	C4591001 1125 11251053	16-55	18AUG2020	53087	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11251058	C4591001 1125 11251058	16-55	18AUG2020	53091	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11251059	C4591001 1125 11251059	16-55	18AUG2020	55115	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo		
11251061	C4591001 1125 11251061	16-55	18AUG2020	55116	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11251062	C4591001 1125 11251062	16-55	21AUG2020	55118	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11251067	C4591001 1125 11251067	16-55	21AUG2020	55120	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251075	C4591001 1125 11251075	16-55	22AUG2020	61774	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251078	C4591001 1125 11251078	16-55	22AUG2020	61777	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11251080	C4591001 1125 11251080	16-55	22AUG2020	61778	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251081	C4591001 1125 11251081	16-55	22AUG2020	61780	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11251086	C4591001 1125 11251086	16-55	24AUG2020	64183	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
11251087	C4591001 1125 11251087	16-55	24AUG2020	64185	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251091	C4591001 1125 11251091	16-55	25AUG2020	64186	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11251094	C4591001 1125 11251094	16-55	25AUG2020	64191	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11251095	C4591001 1125 11251095	16-55	25AUG2020	66405	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11251096	C4591001 1125 11251096	16-55	25AUG2020	66406	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11251097	C4591001 1125 11251097	16-55	25AUG2020	66411	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11251098	C4591001 1125 11251098	16-55	25AUG2020	66412	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11251099	C4591001 1125 11251099	16-55	26AUG2020	67470	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251101	C4591001 1125 11251101	16-55	26AUG2020	67471	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11251102	C4591001 1125 11251102	16-55	26AUG2020	67472	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11251105	C4591001 1125 11251105	16-55	26AUG2020	67474	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11251106	C4591001 1125 11251106	16-55	26AUG2020	69245	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11251108	C4591001 1125 11251108	16-55	27AUG2020	69246	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11251109	C4591001 1125 11251109	16-55	27AUG2020	69249	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11251112	C4591001 1125 11251112	16-55	27AUG2020	69253	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11251117	C4591001 1125 11251117	16-55	27AUG2020	71333	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11251119	C4591001 1125 11251119	16-55	28AUG2020	71334	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11251124	C4591001 1125 11251124	16-55	28AUG2020	71338	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251126	C4591001 1125 11251126	16-55	28AUG2020	71341	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251127	C4591001 1125 11251127	16-55	28AUG2020	72884	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11251128	C4591001 1125 11251128	16-55	31AUG2020	72885	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251131	C4591001 1125 11251131	16-55	31AUG2020	72887	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11251132	C4591001 1125 11251132	16-55	31AUG2020	72888	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251134	C4591001 1125 11251134	16-55	31AUG2020	75677	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
11251135	C4591001 1125 11251135	16-55	31AUG2020	75680	Placebo	31AUG2020/ Placebo	28SEP2020/ Placebo		
11251136	C4591001 1125 11251136	16-55	31AUG2020	75682	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11251138	C4591001 1125 11251138	16-55	01SEP2020	75683	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251139	C4591001 1125 11251139	16-55	01SEP2020	76811	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251140	C4591001 1125 11251140	16-55	01SEP2020	76812	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11251142	C4591001 1125 11251142	16-55	01SEP2020	76813	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo		
11251144	C4591001 1125 11251144	16-55	02SEP2020	76816	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11251146	C4591001 1125 11251146	16-55	02SEP2020	78211	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251148	C4591001 1125 11251148	16-55	02SEP2020	78213	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)			
11251149	C4591001 1125 11251149	16-55	02SEP2020	78216	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11251150	C4591001 1125 11251150	16-55	02SEP2020	78220	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11251151	C4591001 1125 11251151	16-55	02SEP2020	79483	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251152	C4591001 1125 11251152	16-55	02SEP2020	79484	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251155	C4591001 1125 11251155	16-55	03SEP2020	79487	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251156	C4591001 1125 11251156	16-55	03SEP2020	80021	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251158	C4591001 1125 11251158	16-55	03SEP2020	79488	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11251159	C4591001 1125 11251159	16-55	03SEP2020	80023	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
11251160	C4591001 1125 11251160	16-55	03SEP2020	80026	Placebo	03SEP2020/ Placebo			
11251162	C4591001 1125 11251162	16-55	03SEP2020	80032	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo		
11251166	C4591001 1125 11251166	16-55	04SEP2020	81318	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		
11251167	C4591001 1125 11251167	16-55	04SEP2020	81319	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251168	C4591001 1125 11251168	16-55	04SEP2020	81320	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11251169	C4591001 1125 11251169	16-55	04SEP2020	81321	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11251170	C4591001 1125 11251170	16-55	04SEP2020	81581	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251173	C4591001 1125 11251173	16-55	04SEP2020	81583	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11251174	C4591001 1125 11251174	16-55	04SEP2020	81585	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251175	C4591001 1125 11251175	16-55	04SEP2020	81588	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251176	C4591001 1125 11251176	16-55	04SEP2020	82159	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11251177	C4591001 1125 11251177	16-55	04SEP2020	82161	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251178	C4591001 1125 11251178	16-55	04SEP2020	82165	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11251179	C4591001 1125 11251179	16-55	04SEP2020	82166	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11251180	C4591001 1125 11251180	16-55	04SEP2020	82434	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11251181	C4591001 1125 11251181	16-55	08SEP2020	82437	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
11251182	C4591001 1125 11251182	16-55	08SEP2020	82438	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251183	C4591001 1125 11251183	16-55	08SEP2020	82440	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11251184	C4591001 1125 11251184	16-55	08SEP2020	83574	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11251193	C4591001 1125 11251193	16-55	09SEP2020	83576	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11251194	C4591001 1125 11251194	16-55	09SEP2020	83582	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11251195	C4591001 1125 11251195	16-55	09SEP2020	83583	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11251197	C4591001 1125 11251197	16-55	10SEP2020	86599	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11251198	C4591001 1125 11251198	16-55	10SEP2020	86600	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11251200	C4591001 1125 11251200	16-55	10SEP2020	86602	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11251201	C4591001 1125 11251201	16-55	10SEP2020	86607	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
11251202	C4591001 1125 11251202	16-55	10SEP2020	87032	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251203	C4591001 1125 11251203	16-55	10SEP2020	87038	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11251207	C4591001 1125 11251207	16-55	10SEP2020	87039	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11251208	C4591001 1125 11251208	16-55	11SEP2020	87040	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11251212	C4591001 1125 11251212	16-55	11SEP2020	88566	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11251213	C4591001 1125 11251213	16-55	16SEP2020	88569	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo		
11251214	C4591001 1125 11251214	16-55	17SEP2020	88572	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11251215	C4591001 1125 11251215	16-55	22SEP2020	88574	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11251218	C4591001 1125 11251218	16-55	24SEP2020	98684	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11251219	C4591001 1125 11251219	16-55	24SEP2020	98685	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11251221	C4591001 1125 11251221	16-55	24SEP2020	98689	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11251237	C4591001 1125 11251237	16-55	21OCT2020	98690	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11251238	C4591001 1125 11251238	16-55	22OCT2020	112414	Placebo	22OCT2020/ Placebo			
11251239	C4591001 1125 11251239	16-55	18NOV2020	112418	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo		
11251240	C4591001 1125 11251240	16-55	20NOV2020	112419	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
11251243	C4591001 1125 11251243	16-55	08DEC2020	112420	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)			
11251247	C4591001 1125 11251247	16-55	11DEC2020	117872	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		
11261028	C4591001 1126 11261028	16-55	14AUG2020	51029	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11261029	C4591001 1126 11261029	16-55	17AUG2020	51030	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261030	C4591001 1126 11261030	16-55	17AUG2020	51032	Placebo	17AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11261033	C4591001 1126 11261033	16-55	17AUG2020	51035	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261034	C4591001 1126 11261034	16-55	17AUG2020	53743	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11261035	C4591001 1126 11261035	16-55	18AUG2020	53745	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261037	C4591001 1126 11261037	16-55	18AUG2020	53749	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261039	C4591001 1126 11261039	16-55	18AUG2020	53751	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11261040	C4591001 1126 11261040	16-55	18AUG2020	55614	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11261041	C4591001 1126 11261041	16-55	19AUG2020	55616	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261043	C4591001 1126 11261043	16-55	19AUG2020	55618	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261044	C4591001 1126 11261044	16-55	19AUG2020	55623	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261045	C4591001 1126 11261045	16-55	19AUG2020	57618	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11261046	C4591001 1126 11261046	16-55	19AUG2020	57690	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261047	C4591001 1126 11261047	16-55	19AUG2020	57695	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261048	C4591001 1126 11261048	16-55	20AUG2020	57698	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11261053	C4591001 1126 11261053	16-55	20AUG2020	57700	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11261055	C4591001 1126 11261055	16-55	21AUG2020	60419	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261056	C4591001 1126 11261056	16-55	21AUG2020	60421	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11261060	C4591001 1126 11261060	16-55	21AUG2020	60422	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11261061	C4591001 1126 11261061	16-55	21AUG2020	60424	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11261062	C4591001 1126 11261062	16-55	21AUG2020	61589	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11261063	C4591001 1126 11261063	16-55	24AUG2020	61594	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11261064	C4591001 1126 11261064	16-55	24AUG2020	61596	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261068	C4591001 1126 11261068	16-55	24AUG2020	61598	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11261074	C4591001 1126 11261074	16-55	25AUG2020	67065	Placebo				
11261075	C4591001 1126 11261075	16-55	25AUG2020	67063	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261076	C4591001 1126 11261076	16-55	26AUG2020	67066	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11261078	C4591001 1126 11261078	16-55	26AUG2020	67071	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11261080	C4591001 1126 11261080	16-55	26AUG2020	68981	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11261081	C4591001 1126 11261081	16-55	26AUG2020	68986	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11261082	C4591001 1126 11261082	16-55	26AUG2020	68990	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11261083	C4591001 1126 11261083	16-55	26AUG2020	68992	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11261085	C4591001 1126 11261085	16-55	27AUG2020	70361	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261086	C4591001 1126 11261086	16-55	27AUG2020	70362	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261092	C4591001 1126 11261092	16-55	27AUG2020	70371	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261093	C4591001 1126 11261093	16-55	28AUG2020	70372	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11261099	C4591001 1126 11261099	16-55	28AUG2020	73085	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11261101	C4591001 1126 11261101	16-55	28AUG2020	73207	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11261103	C4591001 1126 11261103	16-55	31AUG2020	73208	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11261104	C4591001 1126 11261104	16-55	31AUG2020	73212	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261105	C4591001 1126 11261105	16-55	31AUG2020	73209	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11261109	C4591001 1126 11261109	16-55	31AUG2020	76181	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11261111	C4591001 1126 11261111	16-55	01SEP2020	76182	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261113	C4591001 1126 11261113	16-55	01SEP2020	77108	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11261114	C4591001 1126 11261114	16-55	01SEP2020	76185	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261115	C4591001 1126 11261115	16-55	01SEP2020	76190	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11261116	C4591001 1126 11261116	16-55	01SEP2020	77112	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261121	C4591001 1126 11261121	16-55	02SEP2020	77113	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11261122	C4591001 1126 11261122	16-55	02SEP2020	77116	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11261124	C4591001 1126 11261124	16-55	02SEP2020	79314	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11261126	C4591001 1126 11261126	16-55	03SEP2020	79323	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11261128	C4591001 1126 11261128	16-55	03SEP2020	79315	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11261131	C4591001 1126 11261131	16-55	03SEP2020	79320	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261134	C4591001 1126 11261134	16-55	03SEP2020	81174	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11261135	C4591001 1126 11261135	16-55	03SEP2020	81175	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo		
11261141	C4591001 1126 11261141	16-55	04SEP2020	81177	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11261142	C4591001 1126 11261142	16-55	04SEP2020	81184	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11261143	C4591001 1126 11261143	16-55	08SEP2020	83609	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11261144	C4591001 1126 11261144	16-55	08SEP2020	83610	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11261145	C4591001 1126 11261145	16-55	08SEP2020	83611	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11261148	C4591001 1126 11261148	16-55	08SEP2020	83612	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261149	C4591001 1126 11261149	16-55	09SEP2020	85302	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11261150	C4591001 1126 11261150	16-55	09SEP2020	85307	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261151	C4591001 1126 11261151	16-55	09SEP2020	85308	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11261157	C4591001 1126 11261157	16-55	09SEP2020	85309	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11261158	C4591001 1126 11261158	16-55	10SEP2020	86838	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261161	C4591001 1126 11261161	16-55	10SEP2020	86841	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11261166	C4591001 1126 11261166	16-55	11SEP2020	86844	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11261170	C4591001 1126 11261170	16-55	11SEP2020	88640	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11261171	C4591001 1126 11261171	16-55	11SEP2020	86847	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261172	C4591001 1126 11261172	16-55	11SEP2020	88639	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261173	C4591001 1126 11261173	16-55	11SEP2020	88645	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11261177	C4591001 1126 11261177	16-55	11SEP2020	88646	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261178	C4591001 1126 11261178	16-55	15SEP2020	90799	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11261182	C4591001 1126 11261182	16-55	16SEP2020	90800	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11261183	C4591001 1126 11261183	16-55	16SEP2020	90801	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261184	C4591001 1126 11261184	16-55	16SEP2020	90805	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11261185	C4591001 1126 11261185	16-55	17SEP2020	92561	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11261186	C4591001 1126 11261186	16-55	17SEP2020	92564	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11261187	C4591001 1126 11261187	16-55	17SEP2020	92565	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11261189	C4591001 1126 11261189	16-55	18SEP2020	92570	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11261190	C4591001 1126 11261190	16-55	18SEP2020	93991	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11261191	C4591001 1126 11261191	16-55	18SEP2020	93995	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261192	C4591001 1126 11261192	16-55	18SEP2020	93998	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11261193	C4591001 1126 11261193	16-55	18SEP2020	93999	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11261194	C4591001 1126 11261194	16-55	18SEP2020	94402	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11261195	C4591001 1126 11261195	16-55	18SEP2020	94404	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11261196	C4591001 1126 11261196	16-55	21SEP2020	94405	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11261197	C4591001 1126 11261197	16-55	21SEP2020	94407	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11261198	C4591001 1126 11261198	16-55	21SEP2020	95358	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11261199	C4591001 1126 11261199	16-55	21SEP2020	95360	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11261200	C4591001 1126 11261200	16-55	29OCT2020	95364	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11261201	C4591001 1126 11261201	16-55	30OCT2020	95368	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261202	C4591001 1126 11261202	16-55	30OCT2020	115150	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11261203	C4591001 1126 11261203	16-55	02NOV2020	115153	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11261204	C4591001 1126 11261204	16-55	04NOV2020	115154	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11261205	C4591001 1126 11261205	16-55	11NOV2020	115156	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
11261206	C4591001 1126 11261206	16-55	11NOV2020	116141	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261207	C4591001 1126 11261207	16-55	13NOV2020	116145	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11261208	C4591001 1126 11261208	16-55	13NOV2020	116147	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11261209	C4591001 1126 11261209	16-55	16NOV2020	116152	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11261210	C4591001 1126 11261210	16-55	16NOV2020	116324	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11261211	C4591001 1126 11261211	16-55	17NOV2020	116326	Placebo	17NOV2020/ Placebo	09DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261212	C4591001 1126 11261212	16-55	18NOV2020	116329	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11261213	C4591001 1126 11261213	16-55	18NOV2020	116331	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11261214	C4591001 1126 11261214	16-55	20NOV2020	116623	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261215	C4591001 1126 11261215	16-55	20NOV2020	116626	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11261216	C4591001 1126 11261216	16-55	23NOV2020	116629	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11261217	C4591001 1126 11261217	16-55	23NOV2020	116630	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11261218	C4591001 1126 11261218	16-55	23NOV2020	116759	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11261219	C4591001 1126 11261219	16-55	24NOV2020	116760	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
11261220	C4591001 1126 11261220	16-55	24NOV2020	116761	Placebo	24NOV2020/ Placebo	16DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11261221	C4591001 1126 11261221	16-55	24NOV2020	116764	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261222	C4591001 1126 11261222	16-55	24NOV2020	116897	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11261223	C4591001 1126 11261223	16-55	25NOV2020	116899	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261224	C4591001 1126 11261224	16-55	25NOV2020	116900	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261225	C4591001 1126 11261225	16-55	25NOV2020	116907	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	17DEC2020/ BNT162b2 (30 µg)		
11261226	C4591001 1126 11261226	16-55	25NOV2020	116957	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
11261227	C4591001 1126 11261227	16-55	25NOV2020	116958	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11261228	C4591001 1126 11261228	16-55	25NOV2020	116963	Placebo	25NOV2020/ Placebo	16DEC2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261231	C4591001 1126 11261231	16-55	30NOV2020	116968	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11261232	C4591001 1126 11261232	16-55	01DEC2020	117118	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11261234	C4591001 1126 11261234	16-55	01DEC2020	117119	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261236	C4591001 1126 11261236	16-55	01DEC2020	117120	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11261237	C4591001 1126 11261237	16-55	01DEC2020	117122	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11261238	C4591001 1126 11261238	16-55	02DEC2020	117211	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261242	C4591001 1126 11261242	16-55	02DEC2020	117212	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11261244	C4591001 1126 11261244	16-55	02DEC2020	117216	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11261245	C4591001 1126 11261245	16-55	02DEC2020	117218	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11261247	C4591001 1126 11261247	16-55	02DEC2020	117283	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261248	C4591001 1126 11261248	16-55	02DEC2020	117285	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261252	C4591001 1126 11261252	16-55	03DEC2020	117287	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11261256	C4591001 1126 11261256	16-55	03DEC2020	117288	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11261257	C4591001 1126 11261257	16-55	03DEC2020	117479	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11261259	C4591001 1126 11261259	16-55	03DEC2020	117481	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11261260	C4591001 1126 11261260	16-55	04DEC2020	117482	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11261261	C4591001 1126 11261261	16-55	04DEC2020	117484	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11271096	C4591001 1127 11271096	16-55	19AUG2020	46581	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11271097	C4591001 1127 11271097	16-55	19AUG2020	46585	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11271099	C4591001 1127 11271099	16-55	19AUG2020	46586	Placebo	19AUG2020/ Placebo		03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11271101	C4591001 1127 11271101	16-55	20AUG2020	58207	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271102	C4591001 1127 11271102	16-55	20AUG2020	58208	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11271105	C4591001 1127 11271105	16-55	20AUG2020	58211	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11271106	C4591001 1127 11271106	16-55	20AUG2020	58216	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11271107	C4591001 1127 11271107	16-55	20AUG2020	58854	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
11271109	C4591001 1127 11271109	16-55	20AUG2020	58856	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11271112	C4591001 1127 11271112	16-55	20AUG2020	58862	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11281116	C4591001 1128 11281116	16-55	14AUG2020	50338	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11281123	C4591001 1128 11281123	16-55	17AUG2020	50728	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11281124	C4591001 1128 11281124	16-55	17AUG2020	52809	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281125	C4591001 1128 11281125	16-55	17AUG2020	50726	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11281126	C4591001 1128 11281126	16-55	17AUG2020	52806	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11281128	C4591001 1128 11281128	16-55	17AUG2020	52810	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281129	C4591001 1128 11281129	16-55	17AUG2020	52812	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11281132	C4591001 1128 11281132	16-55	17AUG2020	53574	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281134	C4591001 1128 11281134	16-55	18AUG2020	53575	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281135	C4591001 1128 11281135	16-55	18AUG2020	53577	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11281137	C4591001 1128 11281137	16-55	18AUG2020	53581	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11281143	C4591001 1128 11281143	16-55	18AUG2020	55327	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11281145	C4591001 1128 11281145	16-55	18AUG2020	55328	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281146	C4591001 1128 11281146	16-55	19AUG2020	55331	Placebo	19AUG2020/ Placebo			
11281147	C4591001 1128 11281147	16-55	19AUG2020	55336	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281151	C4591001 1128 11281151	16-55	19AUG2020	57607	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281152	C4591001 1128 11281152	16-55	19AUG2020	57611	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11281153	C4591001 1128 11281153	16-55	19AUG2020	57612	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281154	C4591001 1128 11281154	16-55	20AUG2020	57613	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281155	C4591001 1128 11281155	16-55	20AUG2020	58829	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11281156	C4591001 1128 11281156	16-55	20AUG2020	58837	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11281157	C4591001 1128 11281157	16-55	20AUG2020	58836	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11281159	C4591001 1128 11281159	16-55	20AUG2020	58840	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
11281162	C4591001 1128 11281162	16-55	20AUG2020	59646	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11281164	C4591001 1128 11281164	16-55	20AUG2020	59655	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11281165	C4591001 1128 11281165	16-55	24AUG2020	59656	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281167	C4591001 1128 11281167	16-55	24AUG2020	63870	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281168	C4591001 1128 11281168	16-55	24AUG2020	63874	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281169	C4591001 1128 11281169	16-55	24AUG2020	63873	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281170	C4591001 1128 11281170	16-55	24AUG2020	64169	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11281171	C4591001 1128 11281171	16-55	24AUG2020	63880	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11281173	C4591001 1128 11281173	16-55	24AUG2020	64180	Placebo	24AUG2020/ Placebo	30SEP2020/ Placebo		
11281174	C4591001 1128 11281174	16-55	24AUG2020	64171	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11281175	C4591001 1128 11281175	16-55	24AUG2020	64170	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281176	C4591001 1128 11281176	16-55	24AUG2020	64738	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281177	C4591001 1128 11281177	16-55	24AUG2020	64740	Placebo	24AUG2020/ Placebo	29SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281178	C4591001 1128 11281178	16-55	24AUG2020	64741	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11281181	C4591001 1128 11281181	16-55	25AUG2020	64743	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11281183	C4591001 1128 11281183	16-55	25AUG2020	65982	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11281184	C4591001 1128 11281184	16-55	25AUG2020	65985	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11281187	C4591001 1128 11281187	16-55	25AUG2020	65986	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11281188	C4591001 1128 11281188	16-55	25AUG2020	66895	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11281190	C4591001 1128 11281190	16-55	25AUG2020	65989	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11281195	C4591001 1128 11281195	16-55	25AUG2020	66900	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281196	C4591001 1128 11281196	16-55	25AUG2020	66902	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281197	C4591001 1128 11281197	16-55	25AUG2020	66903	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281198	C4591001 1128 11281198	16-55	26AUG2020	67721	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11281199	C4591001 1128 11281199	16-55	26AUG2020	67722	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281200	C4591001 1128 11281200	16-55	26AUG2020	68213	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11281201	C4591001 1128 11281201	16-55	26AUG2020	67729	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281202	C4591001 1128 11281202	16-55	26AUG2020	67723	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281204	C4591001 1128 11281204	16-55	26AUG2020	68214	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281208	C4591001 1128 11281208	16-55	26AUG2020	68220	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281209	C4591001 1128 11281209	16-55	27AUG2020	68224	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11281210	C4591001 1128 11281210	16-55	27AUG2020	70157	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11281216	C4591001 1128 11281216	16-55	27AUG2020	70158	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281217	C4591001 1128 11281217	16-55	27AUG2020	70167	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11281218	C4591001 1128 11281218	16-55	27AUG2020	70163	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11281219	C4591001 1128 11281219	16-55	28AUG2020	72137	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11281220	C4591001 1128 11281220	16-55	28AUG2020	72144	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281222	C4591001 1128 11281222	16-55	28AUG2020	72141	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo		
11281224	C4591001 1128 11281224	16-55	28AUG2020	72665	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281225	C4591001 1128 11281225	16-55	28AUG2020	72674	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11281227	C4591001 1128 11281227	16-55	28AUG2020	72675	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
11281228	C4591001 1128 11281228	16-55	31AUG2020	72676	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281230	C4591001 1128 11281230	16-55	31AUG2020	75104	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281231	C4591001 1128 11281231	16-55	31AUG2020	75101	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281232	C4591001 1128 11281232	16-55	31AUG2020	75105	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11281235	C4591001 1128 11281235	16-55	31AUG2020	75112	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281239	C4591001 1128 11281239	16-55	31AUG2020	75977	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11281240	C4591001 1128 11281240	16-55	31AUG2020	75980	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281241	C4591001 1128 11281241	16-55	31AUG2020	75978	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11281243	C4591001 1128 11281243	16-55	31AUG2020	75985	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281244	C4591001 1128 11281244	16-55	01SEP2020	76625	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281245	C4591001 1128 11281245	16-55	01SEP2020	76628	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11281246	C4591001 1128 11281246	16-55	02SEP2020	78029	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281247	C4591001 1128 11281247	16-55	01SEP2020	76632	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281248	C4591001 1128 11281248	16-55	01SEP2020	76636	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281249	C4591001 1128 11281249	16-55	01SEP2020	77179	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281252	C4591001 1128 11281252	16-55	01SEP2020	77457	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281255	C4591001 1128 11281255	16-55	01SEP2020	77463	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281257	C4591001 1128 11281257	16-55	01SEP2020	77462	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11281261	C4591001 1128 11281261	16-55	01SEP2020	77464	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281262	C4591001 1128 11281262	16-55	17SEP2020	91725	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281263	C4591001 1128 11281263	16-55	02SEP2020	78032	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11281265	C4591001 1128 11281265	16-55	02SEP2020	78033	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281267	C4591001 1128 11281267	16-55	02SEP2020	78035	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281268	C4591001 1128 11281268	16-55	02SEP2020	78821	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281269	C4591001 1128 11281269	16-55	02SEP2020	78827	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11281272	C4591001 1128 11281272	16-55	02SEP2020	78828	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281274	C4591001 1128 11281274	16-55	03SEP2020	78830	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11281275	C4591001 1128 11281275	16-55	03SEP2020	80417	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11281276	C4591001 1128 11281276	16-55	03SEP2020	80422	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11281279	C4591001 1128 11281279	16-55	03SEP2020	80424	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281281	C4591001 1128 11281281	16-55	03SEP2020	80427	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11281282	C4591001 1128 11281282	16-55	03SEP2020	81129	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281283	C4591001 1128 11281283	16-55	03SEP2020	81125	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11281285	C4591001 1128 11281285	16-55	04SEP2020	81134	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11281286	C4591001 1128 11281286	16-55	04SEP2020	81131	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11281287	C4591001 1128 11281287	16-55	02OCT2020	103354	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281288	C4591001 1128 11281288	16-55	04SEP2020	81978	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11281289	C4591001 1128 11281289	16-55	04SEP2020	81983	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11281291	C4591001 1128 11281291	16-55	04SEP2020	81986	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11281292	C4591001 1128 11281292	16-55	04SEP2020	81987	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11281294	C4591001 1128 11281294	16-55	08SEP2020	83695	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281297	C4591001 1128 11281297	16-55	08SEP2020	83697	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281299	C4591001 1128 11281299	16-55	08SEP2020	83701	Placebo	08SEP2020/ Placebo	07OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11281300	C4591001 1128 11281300	16-55	08SEP2020	83703	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11281301	C4591001 1128 11281301	16-55	08SEP2020	84490	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11281302	C4591001 1128 11281302	16-55	08SEP2020	84492	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11281304	C4591001 1128 11281304	16-55	08SEP2020	84493	Placebo	08SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281305	C4591001 1128 11281305	16-55	08SEP2020	84496	Placebo	08SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281306	C4591001 1128 11281306	16-55	09SEP2020	85265	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11281309	C4591001 1128 11281309	16-55	09SEP2020	85268	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
11281311	C4591001 1128 11281311	16-55	09SEP2020	85269	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281312	C4591001 1128 11281312	16-55	09SEP2020	85273	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281317	C4591001 1128 11281317	16-55	11SEP2020	87685	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11281319	C4591001 1128 11281319	16-55	09SEP2020	86213	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11281323	C4591001 1128 11281323	16-55	10SEP2020	86217	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11281324	C4591001 1128 11281324	16-55	10SEP2020	86220	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281326	C4591001 1128 11281326	16-55	10SEP2020	87682	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11281327	C4591001 1128 11281327	16-55	10SEP2020	86221	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281328	C4591001 1128 11281328	16-55	10SEP2020	87677	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11281331	C4591001 1128 11281331	16-55	11SEP2020	88386	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11281332	C4591001 1128 11281332	16-55	11SEP2020	87686	Placebo	11SEP2020/ Placebo	03OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11281334	C4591001 1128 11281334	16-55	11SEP2020	88390	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281337	C4591001 1128 11281337	16-55	11SEP2020	88391	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11281338	C4591001 1128 11281338	16-55	11SEP2020	88881	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11281339	C4591001 1128 11281339	16-55	11SEP2020	88394	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281341	C4591001 1128 11281341	16-55	11SEP2020	88882	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11281342	C4591001 1128 11281342	16-55	11SEP2020	88883	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281343	C4591001 1128 11281343	16-55	12SEP2020	89129	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
11281345	C4591001 1128 11281345	16-55	12SEP2020	88886	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281347	C4591001 1128 11281347	16-55	12SEP2020	89130	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11281352	C4591001 1128 11281352	16-55	12SEP2020	89131	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11281355	C4591001 1128 11281355	16-55	14SEP2020	89139	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281357	C4591001 1128 11281357	16-55	15SEP2020	90282	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11281358	C4591001 1128 11281358	16-55	15SEP2020	90288	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11281359	C4591001 1128 11281359	16-55	15SEP2020	90289	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11281363	C4591001 1128 11281363	16-55	15SEP2020	90716	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11281364	C4591001 1128 11281364	16-55	15SEP2020	90292	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11281366	C4591001 1128 11281366	16-55	15SEP2020	90718	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11281367	C4591001 1128 11281367	16-55	16SEP2020	90721	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11281368	C4591001 1128 11281368	16-55	16SEP2020	90719	Placebo	16SEP2020/ Placebo			
11281373	C4591001 1128 11281373	16-55	16SEP2020	91722	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11281384	C4591001 1128 11281384	16-55	23SEP2020	91726	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11281385	C4591001 1128 11281385	16-55	25SEP2020	91730	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11291048	C4591001 1129 11291048	16-55	04AUG2020	42108	Placebo				
11291106	C4591001 1129 11291106	16-55	17AUG2020	46444	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11291120	C4591001 1129 11291120	16-55	18AUG2020	53922	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11291129	C4591001 1129 11291129	16-55	18AUG2020	53927	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11291135	C4591001 1129 11291135	16-55	25AUG2020	53928	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11291141	C4591001 1129 11291141	16-55	25AUG2020	53931	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11291142	C4591001 1129 11291142	16-55	25AUG2020	66185	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11291143	C4591001 1129 11291143	16-55	25AUG2020	66191	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11291145	C4591001 1129 11291145	16-55	25AUG2020	66193	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291148	C4591001 1129 11291148	16-55	25AUG2020	66195	Placebo	25AUG2020/ Placebo	18SEP2020/ Placebo		
11291153	C4591001 1129 11291153	16-55	31AUG2020	75893	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11291157	C4591001 1129 11291157	16-55	01SEP2020	75896	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11291163	C4591001 1129 11291163	16-55	01SEP2020	75898	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11291164	C4591001 1129 11291164	16-55	08SEP2020	83261	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11291165	C4591001 1129 11291165	16-55	08SEP2020	75901	Placebo	08SEP2020/ Placebo	27OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11291168	C4591001 1129 11291168	16-55	08SEP2020	83263	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11291171	C4591001 1129 11291171	16-55	14SEP2020	83265	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11291178	C4591001 1129 11291178	16-55	14SEP2020	83271	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11291181	C4591001 1129 11291181	16-55	14SEP2020	89981	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291185	C4591001 1129 11291185	16-55	15SEP2020	89987	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11291187	C4591001 1129 11291187	16-55	15SEP2020	89985	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11291189	C4591001 1129 11291189	16-55	15SEP2020	89992	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11291190	C4591001 1129 11291190	16-55	21SEP2020	94722	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11291192	C4591001 1129 11291192	16-55	21SEP2020	94723	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11291193	C4591001 1129 11291193	16-55	21SEP2020	94728	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
11291196	C4591001 1129 11291196	16-55	22SEP2020	96018	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11291197	C4591001 1129 11291197	16-55	22SEP2020	94730	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11291201	C4591001 1129 11291201	16-55	22SEP2020	96019	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11291202	C4591001 1129 11291202	16-55	22SEP2020	96021	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291209	C4591001 1129 11291209	16-55	29SEP2020	96022	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11291210	C4591001 1129 11291210	16-55	29SEP2020	101874	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11291211	C4591001 1129 11291211	16-55	29SEP2020	266504	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11291212	C4591001 1129 11291212	16-55	29SEP2020	101881	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11291213	C4591001 1129 11291213	16-55	05OCT2020	101882	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11291216	C4591001 1129 11291216	16-55	06OCT2020	101884	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
11291220	C4591001 1129 11291220	16-55	07OCT2020	104777	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11291223	C4591001 1129 11291223	16-55	12OCT2020	104778	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
11291224	C4591001 1129 11291224	16-55	12OCT2020	104782	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11291228	C4591001 1129 11291228	16-55	13OCT2020	104783	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291229	C4591001 1129 11291229	16-55	13OCT2020	106817	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo		
11291238	C4591001 1129 11291238	16-55	19OCT2020	106818	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11291244	C4591001 1129 11291244	16-55	21OCT2020	106820	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11291245	C4591001 1129 11291245	16-55	24OCT2020	106823	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11291249	C4591001 1129 11291249	16-55	24OCT2020	113263	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)			
11291252	C4591001 1129 11291252	16-55	24OCT2020	113261	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11291255	C4591001 1129 11291255	16-55	13NOV2020	113264	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo		
11291256	C4591001 1129 11291256	16-55	16NOV2020	113271	Placebo	16NOV2020/ Placebo	23DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11291257	C4591001 1129 11291257	16-55	18NOV2020	116477	Placebo	18NOV2020/ Placebo	09DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11291258	C4591001 1129 11291258	16-55	30NOV2020	117080	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11291260	C4591001 1129 11291260	16-55	20NOV2020	116482	Placebo	20NOV2020/ Placebo	15DEC2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	
11291261	C4591001 1129 11291261	16-55	23NOV2020	116485	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11291262	C4591001 1129 11291262	16-55	23NOV2020	116487	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11291263	C4591001 1129 11291263	16-55	03DEC2020	117081	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11291264	C4591001 1129 11291264	16-55	03DEC2020	117082	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11291265	C4591001 1129 11291265	16-55	03DEC2020	117087	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
11301001	C4591001 1130 11301001	16-55	24AUG2020	64101	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11301002	C4591001 1130 11301002	16-55	24AUG2020	64103	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11301014	C4591001 1130 11301014	16-55	27AUG2020	64105	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11301015	C4591001 1130 11301015	16-55	27AUG2020	64106	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301021	C4591001 1130 11301021	16-55	31AUG2020	76210	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11301026	C4591001 1130 11301026	16-55	01SEP2020	76211	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11301028	C4591001 1130 11301028	16-55	02SEP2020	76214	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11301032	C4591001 1130 11301032	16-55	02SEP2020	76216	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11301033	C4591001 1130 11301033	16-55	02SEP2020	79496	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11301043	C4591001 1130 11301043	16-55	04SEP2020	79498	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11301044	C4591001 1130 11301044	16-55	04SEP2020	79502	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11301045	C4591001 1130 11301045	16-55	04SEP2020	79503	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11301046	C4591001 1130 11301046	16-55	04SEP2020	82460	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11301047	C4591001 1130 11301047	16-55	04SEP2020	82464	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301049	C4591001 1130 11301049	16-55	04SEP2020	82465	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11301051	C4591001 1130 11301051	16-55	08SEP2020	82467	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11301052	C4591001 1130 11301052	16-55	08SEP2020	83993	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11301054	C4591001 1130 11301054	16-55	08SEP2020	84000	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11301056	C4591001 1130 11301056	16-55	08SEP2020	84001	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11301058	C4591001 1130 11301058	16-55	09SEP2020	84004	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11301059	C4591001 1130 11301059	16-55	09SEP2020	85603	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11301063	C4591001 1130 11301063	16-55	10SEP2020	85605	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11301064	C4591001 1130 11301064	16-55	10SEP2020	85606	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11301068	C4591001 1130 11301068	16-55	11SEP2020	85611	Placebo	11SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301069	C4591001 1130 11301069	16-55	14SEP2020	89706	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11301072	C4591001 1130 11301072	16-55	16SEP2020	89708	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11301073	C4591001 1130 11301073	16-55	17SEP2020	89713	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11301074	C4591001 1130 11301074	16-55	22SEP2020	89715	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11301075	C4591001 1130 11301075	16-55	22SEP2020	96618	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11301077	C4591001 1130 11301077	16-55	23SEP2020	96622	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11301078	C4591001 1130 11301078	16-55	23SEP2020	96623	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11301079	C4591001 1130 11301079	16-55	24SEP2020	96626	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11301081	C4591001 1130 11301081	16-55	16OCT2020	109109	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11301082	C4591001 1130 11301082	16-55	16OCT2020	109110	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301083	C4591001 1130 11301083	16-55	16OCT2020	109118	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11301084	C4591001 1130 11301084	16-55	19OCT2020	109120	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11301085	C4591001 1130 11301085	16-55	20OCT2020	110900	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11301086	C4591001 1130 11301086	16-55	20OCT2020	110901	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11301087	C4591001 1130 11301087	16-55	20OCT2020	110902	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11301088	C4591001 1130 11301088	16-55	21OCT2020	110905	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11301089	C4591001 1130 11301089	16-55	21OCT2020	111669	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11301090	C4591001 1130 11301090	16-55	22OCT2020	111670	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11301091	C4591001 1130 11301091	16-55	26OCT2020	111671	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11301092	C4591001 1130 11301092	16-55	26OCT2020	111675	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11301093	C4591001 1130 11301093	16-55	26OCT2020	113816	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11301094	C4591001 1130 11301094	16-55	27OCT2020	260487	Placebo	27OCT2020/ Placebo	03DEC2020/ Placebo		
11301097	C4591001 1130 11301097	16-55	27OCT2020	113820	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11301099	C4591001 1130 11301099	16-55	30OCT2020	113822	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11311015	C4591001 1131 11311015	16-55	14AUG2020	48710	Placebo	14AUG2020/ Placebo	08SEP2020/ Placebo		
11311017	C4591001 1131 11311017	16-55	14AUG2020	50566	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11311018	C4591001 1131 11311018	16-55	14AUG2020	50569	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11311024	C4591001 1131 11311024	16-55	17AUG2020	52927	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11311026	C4591001 1131 11311026	16-55	17AUG2020	52928	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11311031	C4591001 1131 11311031	16-55	18AUG2020	52930	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311032	C4591001 1131 11311032	16-55	18AUG2020	52936	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311035	C4591001 1131 11311035	16-55	18AUG2020	54781	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11311038	C4591001 1131 11311038	16-55	18AUG2020	54782	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311041	C4591001 1131 11311041	16-55	19AUG2020	54783	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11311042	C4591001 1131 11311042	16-55	19AUG2020	54784	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11311045	C4591001 1131 11311045	16-55	19AUG2020	57198	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
11311046	C4591001 1131 11311046	16-55	19AUG2020	57199	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311048	C4591001 1131 11311048	16-55	19AUG2020	57204	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11311049	C4591001 1131 11311049	16-55	19AUG2020	57208	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11311050	C4591001 1131 11311050	16-55	19AUG2020	57642	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311051	C4591001 1131 11311051	16-55	20AUG2020	57646	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11311053	C4591001 1131 11311053	16-55	20AUG2020	57647	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311061	C4591001 1131 11311061	16-55	20AUG2020	57652	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311062	C4591001 1131 11311062	16-55	21AUG2020	60174	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11311064	C4591001 1131 11311064	16-55	21AUG2020	60176	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11311065	C4591001 1131 11311065	16-55	21AUG2020	60179	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311069	C4591001 1131 11311069	16-55	21AUG2020	60184	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11311071	C4591001 1131 11311071	16-55	21AUG2020	61351	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11311073	C4591001 1131 11311073	16-55	24AUG2020	61353	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11311076	C4591001 1131 11311076	16-55	24AUG2020	61356	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311078	C4591001 1131 11311078	16-55	24AUG2020	61359	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11311079	C4591001 1131 11311079	16-55	25AUG2020	65502	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11311080	C4591001 1131 11311080	16-55	25AUG2020	65510	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11311081	C4591001 1131 11311081	16-55	25AUG2020	65508	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11311083	C4591001 1131 11311083	16-55	25AUG2020	65512	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11311085	C4591001 1131 11311085	16-55	25AUG2020	66857	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11311086	C4591001 1131 11311086	16-55	27AUG2020	66859	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311087	C4591001 1131 11311087	16-55	27AUG2020	66862	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311090	C4591001 1131 11311090	16-55	27AUG2020	66865	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11311091	C4591001 1131 11311091	16-55	27AUG2020	70493	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311092	C4591001 1131 11311092	16-55	27AUG2020	70494	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311093	C4591001 1131 11311093	16-55	27AUG2020	70500	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311094	C4591001 1131 11311094	16-55	27AUG2020	70504	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11311097	C4591001 1131 11311097	16-55	27AUG2020	71382	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11311099	C4591001 1131 11311099	16-55	28AUG2020	71386	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11311102	C4591001 1131 11311102	16-55	28AUG2020	71388	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11311103	C4591001 1131 11311103	16-55	28AUG2020	71391	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11311104	C4591001 1131 11311104	16-55	28AUG2020	72821	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11311106	C4591001 1131 11311106	16-55	28AUG2020	72823	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11311107	C4591001 1131 11311107	16-55	31AUG2020	72826	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311109	C4591001 1131 11311109	16-55	31AUG2020	72827	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311111	C4591001 1131 11311111	16-55	01SEP2020	76448	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11311112	C4591001 1131 11311112	16-55	01SEP2020	76450	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11311113	C4591001 1131 11311113	16-55	01SEP2020	76451	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11311116	C4591001 1131 11311116	16-55	01SEP2020	76456	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11311117	C4591001 1131 11311117	16-55	01SEP2020	77754	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11311124	C4591001 1131 11311124	16-55	02SEP2020	77755	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11311129	C4591001 1131 11311129	16-55	03SEP2020	77759	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11311131	C4591001 1131 11311131	16-55	03SEP2020	77762	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11311132	C4591001 1131 11311132	16-55	03SEP2020	80986	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311134	C4591001 1131 11311134	16-55	03SEP2020	80987	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311136	C4591001 1131 11311136	16-55	03SEP2020	80990	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11311138	C4591001 1131 11311138	16-55	04SEP2020	80992	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11311142	C4591001 1131 11311142	16-55	04SEP2020	81899	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11311143	C4591001 1131 11311143	16-55	04SEP2020	81900	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11311144	C4591001 1131 11311144	16-55	04SEP2020	81901	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311147	C4591001 1131 11311147	16-55	08SEP2020	81902	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11311148	C4591001 1131 11311148	16-55	08SEP2020	84329	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11311152	C4591001 1131 11311152	16-55	09SEP2020	84330	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11311153	C4591001 1131 11311153	16-55	09SEP2020	84337	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311157	C4591001 1131 11311157	16-55	09SEP2020	84338	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11311158	C4591001 1131 11311158	16-55	09SEP2020	85771	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11311160	C4591001 1131 11311160	16-55	09SEP2020	85772	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11311161	C4591001 1131 11311161	16-55	09SEP2020	85775	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11311162	C4591001 1131 11311162	16-55	10SEP2020	85776	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11311167	C4591001 1131 11311167	16-55	10SEP2020	87389	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11311172	C4591001 1131 11311172	16-55	11SEP2020	87390	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11311173	C4591001 1131 11311173	16-55	11SEP2020	87392	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11311178	C4591001 1131 11311178	16-55	15SEP2020	87393	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11311181	C4591001 1131 11311181	16-55	16SEP2020	91435	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311182	C4591001 1131 11311182	16-55	16SEP2020	91437	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11311183	C4591001 1131 11311183	16-55	16SEP2020	91441	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11311184	C4591001 1131 11311184	16-55	16SEP2020	91444	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11311190	C4591001 1131 11311190	16-55	18SEP2020	93343	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11311193	C4591001 1131 11311193	16-55	18SEP2020	93346	Placebo	18SEP2020/ Placebo			
11311201	C4591001 1131 11311201	16-55	21SEP2020	93349	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11311205	C4591001 1131 11311205	16-55	22SEP2020	93351	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11311209	C4591001 1131 11311209	16-55	24SEP2020	98849	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11311219	C4591001 1131 11311219	16-55	25SEP2020	98855	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11311220	C4591001 1131 11311220	16-55	25SEP2020	98857	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311221	C4591001 1131 11311221	16-55	25SEP2020	98860	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11311228	C4591001 1131 11311228	16-55	30SEP2020	102356	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11311229	C4591001 1131 11311229	16-55	02OCT2020	102357	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
11311230	C4591001 1131 11311230	16-55	06OCT2020	102361	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11311232	C4591001 1131 11311232	16-55	08OCT2020	102362	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11311233	C4591001 1131 11311233	16-55	09OCT2020	106062	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11311241	C4591001 1131 11311241	16-55	12OCT2020	106063	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11311243	C4591001 1131 11311243	16-55	13OCT2020	106064	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11311246	C4591001 1131 11311246	16-55	19OCT2020	106065	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11311252	C4591001 1131 11311252	16-55	23OCT2020	113098	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311253	C4591001 1131 11311253	16-55	23OCT2020	113100	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11311254	C4591001 1131 11311254	16-55	23OCT2020	113101	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11311257	C4591001 1131 11311257	16-55	29OCT2020	113104	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11311260	C4591001 1131 11311260	16-55	29OCT2020	114848	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11311263	C4591001 1131 11311263	16-55	13NOV2020	114849	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11311264	C4591001 1131 11311264	16-55	16NOV2020	114851	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11311265	C4591001 1131 11311265	16-55	17NOV2020	114855	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11311266	C4591001 1131 11311266	16-55	18NOV2020	116470	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11311267	C4591001 1131 11311267	16-55	23NOV2020	116472	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11311268	C4591001 1131 11311268	16-55	23NOV2020	116476	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11311269	C4591001 1131 11311269	16-55	23NOV2020	116474	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11311270	C4591001 1131 11311270	16-55	24NOV2020	116790	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11311271	C4591001 1131 11311271	16-55	24NOV2020	116792	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo		
11311272	C4591001 1131 11311272	16-55	02DEC2020	116794	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11311273	C4591001 1131 11311273	16-55	02DEC2020	116795	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11311274	C4591001 1131 11311274	16-55	04DEC2020	117498	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11311276	C4591001 1131 11311276	16-55	04DEC2020	117500	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11311279	C4591001 1131 11311279	16-55	21DEC2020	117502	BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)		
11331152	C4591001 1133 11331152	16-55	14AUG2020	50178	Placebo	14AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331162	C4591001 1133 11331162	16-55	14AUG2020	50182	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331170	C4591001 1133 11331170	16-55	14AUG2020	50660	Placebo	14AUG2020/ Placebo			
11331180	C4591001 1133 11331180	16-55	14AUG2020	50921	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11331185	C4591001 1133 11331185	16-55	19AUG2020	50927	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331186	C4591001 1133 11331186	16-55	19AUG2020	50923	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331188	C4591001 1133 11331188	16-55	19AUG2020	50929	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11331193	C4591001 1133 11331193	16-55	19AUG2020	56661	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331195	C4591001 1133 11331195	16-55	19AUG2020	56663	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331198	C4591001 1133 11331198	16-55	19AUG2020	56666	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331202	C4591001 1133 11331202	16-55	19AUG2020	56667	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331203	C4591001 1133 11331203	16-55	19AUG2020	56912	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331206	C4591001 1133 11331206	16-55	19AUG2020	56914	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331207	C4591001 1133 11331207	16-55	19AUG2020	56917	Placebo	19AUG2020/ Placebo			
11331208	C4591001 1133 11331208	16-55	19AUG2020	56916	Placebo	19AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331209	C4591001 1133 11331209	16-55	19AUG2020	57522	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11331210	C4591001 1133 11331210	16-55	19AUG2020	57525	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11331216	C4591001 1133 11331216	16-55	24AUG2020	57530	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331226	C4591001 1133 11331226	16-55	24AUG2020	64005	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331228	C4591001 1133 11331228	16-55	24AUG2020	64010	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331230	C4591001 1133 11331230	16-55	24AUG2020	64009	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331236	C4591001 1133 11331236	16-55	26AUG2020	64011	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331240	C4591001 1133 11331240	16-55	26AUG2020	67577	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331246	C4591001 1133 11331246	16-55	26AUG2020	67583	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331248	C4591001 1133 11331248	16-55	26AUG2020	67578	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331252	C4591001 1133 11331252	16-55	26AUG2020	67579	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331255	C4591001 1133 11331255	16-55	26AUG2020	67970	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331256	C4591001 1133 11331256	16-55	26AUG2020	67962	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11331257	C4591001 1133 11331257	16-55	26AUG2020	67966	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331258	C4591001 1133 11331258	16-55	26AUG2020	68117	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331259	C4591001 1133 11331259	16-55	26AUG2020	67969	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331263	C4591001 1133 11331263	16-55	26AUG2020	68125	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331264	C4591001 1133 11331264	16-55	26AUG2020	68126	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11331265	C4591001 1133 11331265	16-55	26AUG2020	68128	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331266	C4591001 1133 11331266	16-55	26AUG2020	68589	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331267	C4591001 1133 11331267	16-55	26AUG2020	68590	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331272	C4591001 1133 11331272	16-55	27AUG2020	68596	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331273	C4591001 1133 11331273	16-55	27AUG2020	69787	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331274	C4591001 1133 11331274	16-55	27AUG2020	68594	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331275	C4591001 1133 11331275	16-55	27AUG2020	69788	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331276	C4591001 1133 11331276	16-55	27AUG2020	69795	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331278	C4591001 1133 11331278	16-55	27AUG2020	69796	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331282	C4591001 1133 11331282	16-55	27AUG2020	70315	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331283	C4591001 1133 11331283	16-55	27AUG2020	70313	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331291	C4591001 1133 11331291	16-55	27AUG2020	70554	Placebo	27AUG2020/ Placebo			
11331292	C4591001 1133 11331292	16-55	27AUG2020	70561	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331293	C4591001 1133 11331293	16-55	27AUG2020	70322	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331294	C4591001 1133 11331294	16-55	27AUG2020	70323	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11331295	C4591001 1133 11331295	16-55	27AUG2020	70558	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
11331296	C4591001 1133 11331296	16-55	27AUG2020	70564	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331301	C4591001 1133 11331301	16-55	27AUG2020	70857	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331303	C4591001 1133 11331303	16-55	01OCT2020	99918	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331307	C4591001 1133 11331307	16-55	28AUG2020	244327	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331308	C4591001 1133 11331308	16-55	28AUG2020	70858	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331313	C4591001 1133 11331313	16-55	28AUG2020	70861	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331316	C4591001 1133 11331316	16-55	28AUG2020	72320	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331317	C4591001 1133 11331317	16-55	28AUG2020	70859	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331320	C4591001 1133 11331320	16-55	28AUG2020	72323	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331321	C4591001 1133 11331321	16-55	28AUG2020	72327	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11331322	C4591001 1133 11331322	16-55	28AUG2020	72449	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331324	C4591001 1133 11331324	16-55	28AUG2020	72451	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331328	C4591001 1133 11331328	16-55	29AUG2020	72455	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331329	C4591001 1133 11331329	16-55	29AUG2020	72458	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11331332	C4591001 1133 11331332	16-55	29AUG2020	73447	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331333	C4591001 1133 11331333	16-55	29AUG2020	73450	Placebo	29AUG2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331334	C4591001 1133 11331334	16-55	29AUG2020	73452	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331335	C4591001 1133 11331335	16-55	29AUG2020	73453	Placebo	29AUG2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331336	C4591001 1133 11331336	16-55	29AUG2020	73685	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11331337	C4591001 1133 11331337	16-55	29AUG2020	73689	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331338	C4591001 1133 11331338	16-55	29AUG2020	73829	Placebo	29AUG2020/ Placebo			
11331340	C4591001 1133 11331340	16-55	29AUG2020	73696	Placebo	29AUG2020/ Placebo	25SEP2020/ Placebo		
11331341	C4591001 1133 11331341	16-55	29AUG2020	73691	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331346	C4591001 1133 11331346	16-55	29AUG2020	73831	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11331348	C4591001 1133 11331348	16-55	29AUG2020	73834	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11331350	C4591001 1133 11331350	16-55	02SEP2020	73836	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331351	C4591001 1133 11331351	16-55	02SEP2020	77969	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331352	C4591001 1133 11331352	16-55	02SEP2020	77970	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331354	C4591001 1133 11331354	16-55	02SEP2020	77975	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331355	C4591001 1133 11331355	16-55	02SEP2020	78137	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331357	C4591001 1133 11331357	16-55	02SEP2020	77980	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331360	C4591001 1133 11331360	16-55	02SEP2020	78143	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331363	C4591001 1133 11331363	16-55	02SEP2020	78138	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331365	C4591001 1133 11331365	16-55	02SEP2020	78140	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331367	C4591001 1133 11331367	16-55	02SEP2020	78377	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331370	C4591001 1133 11331370	16-55	02SEP2020	78379	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331374	C4591001 1133 11331374	16-55	02SEP2020	78380	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331376	C4591001 1133 11331376	16-55	02SEP2020	78726	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11331378	C4591001 1133 11331378	16-55	02SEP2020	78727	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331379	C4591001 1133 11331379	16-55	02SEP2020	78381	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331385	C4591001 1133 11331385	16-55	02SEP2020	79078	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11331387	C4591001 1133 11331387	16-55	02SEP2020	78734	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331388	C4591001 1133 11331388	16-55	02SEP2020	79077	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331389	C4591001 1133 11331389	16-55	02SEP2020	79081	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11331393	C4591001 1133 11331393	16-55	02SEP2020	79083	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331395	C4591001 1133 11331395	16-55	09SEP2020	84896	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331397	C4591001 1133 11331397	16-55	09SEP2020	84898	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331398	C4591001 1133 11331398	16-55	09SEP2020	85062	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331401	C4591001 1133 11331401	16-55	09SEP2020	85071	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331404	C4591001 1133 11331404	16-55	09SEP2020	84901	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331406	C4591001 1133 11331406	16-55	09SEP2020	84900	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331408	C4591001 1133 11331408	16-55	09SEP2020	85064	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331409	C4591001 1133 11331409	16-55	09SEP2020	85134	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331410	C4591001 1133 11331410	16-55	09SEP2020	85136	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331411	C4591001 1133 11331411	16-55	09SEP2020	85350	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331413	C4591001 1133 11331413	16-55	09SEP2020	85143	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331414	C4591001 1133 11331414	16-55	09SEP2020	85140	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331418	C4591001 1133 11331418	16-55	09SEP2020	85352	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11331419	C4591001 1133 11331419	16-55	09SEP2020	85357	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331422	C4591001 1133 11331422	16-55	09SEP2020	85358	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331423	C4591001 1133 11331423	16-55	09SEP2020	85759	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331427	C4591001 1133 11331427	16-55	09SEP2020	85765	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11331428	C4591001 1133 11331428	16-55	09SEP2020	85767	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331432	C4591001 1133 11331432	16-55	09SEP2020	85768	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331435	C4591001 1133 11331435	16-55	09SEP2020	85889	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11331438	C4591001 1133 11331438	16-55	09SEP2020	85899	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11331439	C4591001 1133 11331439	16-55	09SEP2020	85893	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11331440	C4591001 1133 11331440	16-55	09SEP2020	85900	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331441	C4591001 1133 11331441	16-55	09SEP2020	86117	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11331448	C4591001 1133 11331448	16-55	16SEP2020	86118	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331450	C4591001 1133 11331450	16-55	16SEP2020	86121	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331456	C4591001 1133 11331456	16-55	16SEP2020	86126	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331460	C4591001 1133 11331460	16-55	18SEP2020	93353	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331461	C4591001 1133 11331461	16-55	18SEP2020	93354	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331462	C4591001 1133 11331462	16-55	18SEP2020	93356	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331463	C4591001 1133 11331463	16-55	18SEP2020	93363	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331465	C4591001 1133 11331465	16-55	18SEP2020	93738	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11331467	C4591001 1133 11331467	16-55	18SEP2020	93744	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331468	C4591001 1133 11331468	16-55	18SEP2020	93740	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331473	C4591001 1133 11331473	16-55	18SEP2020	93748	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331474	C4591001 1133 11331474	16-55	18SEP2020	94077	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11331475	C4591001 1133 11331475	16-55	21SEP2020	94081	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331476	C4591001 1133 11331476	16-55	21SEP2020	94084	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331478	C4591001 1133 11331478	16-55	21SEP2020	94082	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331479	C4591001 1133 11331479	16-55	21SEP2020	94927	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331480	C4591001 1133 11331480	16-55	21SEP2020	94928	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11331483	C4591001 1133 11331483	16-55	21SEP2020	94936	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo		
11331484	C4591001 1133 11331484	16-55	21SEP2020	95285	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
11331485	C4591001 1133 11331485	16-55	21SEP2020	94930	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331489	C4591001 1133 11331489	16-55	21SEP2020	95293	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331490	C4591001 1133 11331490	16-55	21SEP2020	95292	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331491	C4591001 1133 11331491	16-55	21SEP2020	95294	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331492	C4591001 1133 11331492	16-55	23SEP2020	97388	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331495	C4591001 1133 11331495	16-55	23SEP2020	97389	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331496	C4591001 1133 11331496†	16-55	23SEP2020	97393	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331497	C4591001 1133 11331497	16-55	23SEP2020	97390	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331498	C4591001 1133 11331498	16-55	23SEP2020	97745	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11331499	C4591001 1133 11331499	16-55	23SEP2020	97752	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11331501	C4591001 1133 11331501	16-55	23SEP2020	97751	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331502	C4591001 1133 11331502	16-55	23SEP2020	97756	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331504	C4591001 1133 11331504	16-55	23SEP2020	98058	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331505	C4591001 1133 11331505	16-55	23SEP2020	98063	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331506	C4591001 1133 11331506	16-55	23SEP2020	98062	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331508	C4591001 1133 11331508	16-55	25SEP2020	98068	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331509	C4591001 1133 11331509	16-55	25SEP2020	99461	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
11331510	C4591001 1133 11331510	16-55	25SEP2020	99464	Placebo	25SEP2020/ Placebo			
11331511	C4591001 1133 11331511	16-55	25SEP2020	99463	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331512	C4591001 1133 11331512	16-55	25SEP2020	99468	Placebo	25SEP2020/ Placebo		12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331515	C4591001 1133 11331515	16-55	25SEP2020	99917	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11331521	C4591001 1133 11331521	16-55	23OCT2020	400487	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331522	C4591001 1133 11331522	16-55	23OCT2020	400484	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331523	C4591001 1133 11331523	16-55	23OCT2020	400489	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331524	C4591001 1133 11331524	16-55	23OCT2020	400491	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331525	C4591001 1133 11331525	16-55	23OCT2020	400529	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331526	C4591001 1133 11331526	16-55	23OCT2020	400532	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331527	C4591001 1133 11331527	16-55	23OCT2020	400538	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331528	C4591001 1133 11331528	16-55	23OCT2020	400539	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331529	C4591001 1133 11331529	16-55	23OCT2020	400583	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331530	C4591001 1133 11331530	16-55	23OCT2020	400584	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331531	C4591001 1133 11331531	16-55	23OCT2020	400588	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331532	C4591001 1133 11331532	16-55	23OCT2020	400606	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11331533	C4591001 1133 11331533	16-55	23OCT2020	400657	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331534	C4591001 1133 11331534	16-55	23OCT2020	400603	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331535	C4591001 1133 11331535	16-55	23OCT2020	400585	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331536	C4591001 1133 11331536	16-55	23OCT2020	400655	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331537	C4591001 1133 11331537	16-55	23OCT2020	400610	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331538	C4591001 1133 11331538	16-55	23OCT2020	400609	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11331539	C4591001 1133 11331539	16-55	23OCT2020	400654	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331540	C4591001 1133 11331540	16-55	26OCT2020	400658	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331541	C4591001 1133 11331541	16-55	26OCT2020	400784	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11331542	C4591001 1133 11331542	16-55	26OCT2020	400799	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
11331543	C4591001 1133 11331543	16-55	26OCT2020	400798	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331544	C4591001 1133 11331544	16-55	26OCT2020	400781	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331545	C4591001 1133 11331545	16-55	26OCT2020	400786	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331546	C4591001 1133 11331546	16-55	26OCT2020	400792	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331547	C4591001 1133 11331547	16-55	26OCT2020	400800	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331548	C4591001 1133 11331548	16-55	26OCT2020	400803	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331549	C4591001 1133 11331549	16-55	26OCT2020	400832	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331550	C4591001 1133 11331550	16-55	26OCT2020	400835	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331551	C4591001 1133 11331551	16-55	26OCT2020	400830	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11331552	C4591001 1133 11331552	16-55	26OCT2020	400847	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331553	C4591001 1133 11331553	16-55	26OCT2020	400839	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11331554	C4591001 1133 11331554	16-55	26OCT2020	400850	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331555	C4591001 1133 11331555	16-55	26OCT2020	400851	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11331556	C4591001 1133 11331556	16-55	26OCT2020	400852	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331557	C4591001 1133 11331557	16-55	26OCT2020	400892	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331558	C4591001 1133 11331558	16-55	26OCT2020	400894	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331559	C4591001 1133 11331559	16-55	26OCT2020	400897	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331560	C4591001 1133 11331560	16-55	26OCT2020	400899	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331561	C4591001 1133 11331561	16-55	26OCT2020	400978	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11331562	C4591001 1133 11331562	16-55	26OCT2020	400952	Placebo	26OCT2020/ Placebo		05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331563	C4591001 1133 11331563	16-55	26OCT2020	400949	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331564	C4591001 1133 11331564	16-55	26OCT2020	400951	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331565	C4591001 1133 11331565	16-55	26OCT2020	400983	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331566	C4591001 1133 11331566	16-55	26OCT2020	400989	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11331567	C4591001 1133 11331567	16-55	26OCT2020	400984	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331568	C4591001 1133 11331568	16-55	26OCT2020	400960	Placebo	26OCT2020/ Placebo			
11331569	C4591001 1133 11331569	16-55	26OCT2020	400974	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331570	C4591001 1133 11331570	16-55	26OCT2020	400990	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331571	C4591001 1133 11331571	16-55	26OCT2020	401012	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331572	C4591001 1133 11331572	16-55	26OCT2020	400995	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11331573	C4591001 1133 11331573	16-55	26OCT2020	400993	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11331574	C4591001 1133 11331574	16-55	26OCT2020	401014	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331575	C4591001 1133 11331575	16-55	29OCT2020	401015	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331577	C4591001 1133 11331577	16-55	29OCT2020	401243	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331578	C4591001 1133 11331578	16-55	29OCT2020	401242	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11331579	C4591001 1133 11331579	16-55	29OCT2020	401020	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331580	C4591001 1133 11331580	16-55	29OCT2020	401237	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331581	C4591001 1133 11331581	16-55	29OCT2020	401251	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331582	C4591001 1133 11331582†	16-55	29OCT2020	401252	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331583	C4591001 1133 11331583	16-55	29OCT2020	401258	Placebo	29OCT2020/ Placebo			
11331584	C4591001 1133 11331584	16-55	29OCT2020	401247	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331585	C4591001 1133 11331585	16-55	29OCT2020	401259	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331586	C4591001 1133 11331586	16-55	29OCT2020	401277	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331587	C4591001 1133 11331587	16-55	29OCT2020	401280	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331588	C4591001 1133 11331588	16-55	29OCT2020	401282	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331589	C4591001 1133 11331589	16-55	29OCT2020	401284	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331590	C4591001 1133 11331590	16-55	29OCT2020	401289	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331591	C4591001 1133 11331591	16-55	29OCT2020	401305	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331592	C4591001 1133 11331592	16-55	29OCT2020	401296	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331593	C4591001 1133 11331593	16-55	29OCT2020	401293	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331594	C4591001 1133 11331594	16-55	29OCT2020	401291	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331595	C4591001 1133 11331595	16-55	29OCT2020	401298	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331596	C4591001 1133 11331596	16-55	29OCT2020	401309	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331598	C4591001 1133 11331598	16-55	29OCT2020	401307	Placebo	29OCT2020/ Placebo			
11331600	C4591001 1133 11331600	16-55	29OCT2020	401317	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11331601	C4591001 1133 11331601	16-55	29OCT2020	401299	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331602	C4591001 1133 11331602	16-55	29OCT2020	401315	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331603	C4591001 1133 11331603	16-55	29OCT2020	401318	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331604	C4591001 1133 11331604	16-55	29OCT2020	401335	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331605	C4591001 1133 11331605	16-55	29OCT2020	401336	Placebo	29OCT2020/ Placebo	24NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331606	C4591001 1133 11331606	16-55	29OCT2020	401339	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331609	C4591001 1133 11331609	16-55	29OCT2020	401341	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331610	C4591001 1133 11331610	16-55	29OCT2020	401358	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11331612	C4591001 1133 11331612	16-55	29OCT2020	401385	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331613	C4591001 1133 11331613	16-55	29OCT2020	401362	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331614	C4591001 1133 11331614	16-55	29OCT2020	401382	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331615	C4591001 1133 11331615	16-55	29OCT2020	401365	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331616	C4591001 1133 11331616	16-55	29OCT2020	401388	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331617	C4591001 1133 11331617	16-55	29OCT2020	401364	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331618	C4591001 1133 11331618†	16-55	29OCT2020	401390	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331619	C4591001 1133 11331619	16-55	29OCT2020	401407	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11331621	C4591001 1133 11331621	16-55	29OCT2020	401409	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331622	C4591001 1133 11331622	16-55	29OCT2020	401413	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331624	C4591001 1133 11331624	16-55	29OCT2020	401416	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331625	C4591001 1133 11331625	16-55	29OCT2020	401418	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331626	C4591001 1133 11331626	16-55	29OCT2020	401419	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331627	C4591001 1133 11331627	16-55	29OCT2020	401428	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331628	C4591001 1133 11331628	16-55	29OCT2020	401424	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331629	C4591001 1133 11331629	16-55	29OCT2020	401445	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331630	C4591001 1133 11331630	16-55	29OCT2020	401441	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331631	C4591001 1133 11331631	16-55	29OCT2020	401444	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11331632	C4591001 1133 11331632	16-55	29OCT2020	401456	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331633	C4591001 1133 11331633	16-55	29OCT2020	401453	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
11331634	C4591001 1133 11331634	16-55	29OCT2020	401451	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11331635	C4591001 1133 11331635	16-55	30OCT2020	401458	Placebo	30OCT2020/ Placebo			
11331636	C4591001 1133 11331636	16-55	30OCT2020	401460	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331637	C4591001 1133 11331637	16-55	30OCT2020	401470	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331638	C4591001 1133 11331638	16-55	30OCT2020	401468	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331639	C4591001 1133 11331639	16-55	30OCT2020	401471	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331640	C4591001 1133 11331640	16-55	30OCT2020	401483	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331641	C4591001 1133 11331641	16-55	30OCT2020	401473	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11331642	C4591001 1133 11331642	16-55	30OCT2020	401482	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11331643	C4591001 1133 11331643	16-55	30OCT2020	401486	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11331644	C4591001 1133 11331644	16-55	30OCT2020	401477	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo		
11331645	C4591001 1133 11331645	16-55	30OCT2020	401490	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11331646	C4591001 1133 11331646	16-55	02NOV2020	401495	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11331647	C4591001 1133 11331647	16-55	02NOV2020	401497	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo		
11331648	C4591001 1133 11331648	16-55	02NOV2020	401499	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11341086	C4591001 1134 11341086	16-55	17AUG2020	49956	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341088	C4591001 1134 11341088	16-55	17AUG2020	49960	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11341089	C4591001 1134 11341089	16-55	17AUG2020	52738	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11341093	C4591001 1134 11341093	16-55	18AUG2020	52740	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341102	C4591001 1134 11341102	16-55	18AUG2020	52741	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11341104	C4591001 1134 11341104	16-55	19AUG2020	52744	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11341106	C4591001 1134 11341106	16-55	20AUG2020	56284	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11341107	C4591001 1134 11341107	16-55	19AUG2020	56280	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11341111	C4591001 1134 11341111	16-55	19AUG2020	56282	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341112	C4591001 1134 11341112	16-55	19AUG2020	56281	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341116	C4591001 1134 11341116	16-55	20AUG2020	57992	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11341117	C4591001 1134 11341117	16-55	20AUG2020	57993	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11341118	C4591001 1134 11341118	16-55	20AUG2020	57997	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11341129	C4591001 1134 11341129	16-55	20AUG2020	58000	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341134	C4591001 1134 11341134	16-55	21AUG2020	60293	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11341147	C4591001 1134 11341147	16-55	24AUG2020	60294	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11341149	C4591001 1134 11341149	16-55	24AUG2020	60298	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11341151	C4591001 1134 11341151	16-55	24AUG2020	60301	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11341153	C4591001 1134 11341153	16-55	24AUG2020	64342	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11341154	C4591001 1134 11341154	16-55	24AUG2020	64339	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341157	C4591001 1134 11341157	16-55	24AUG2020	64346	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11341169	C4591001 1134 11341169	16-55	25AUG2020	64348	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11341173	C4591001 1134 11341173	16-55	26AUG2020	67446	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11341174	C4591001 1134 11341174	16-55	26AUG2020	67450	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341176	C4591001 1134 11341176	16-55	26AUG2020	67451	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11341177	C4591001 1134 11341177	16-55	26AUG2020	67455	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11341180	C4591001 1134 11341180	16-55	26AUG2020	68181	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341183	C4591001 1134 11341183	16-55	26AUG2020	68185	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11341184	C4591001 1134 11341184	16-55	26AUG2020	68186	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11341186	C4591001 1134 11341186	16-55	27AUG2020	68188	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11341188	C4591001 1134 11341188	16-55	27AUG2020	69594	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341190	C4591001 1134 11341190	16-55	27AUG2020	69600	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341192	C4591001 1134 11341192	16-55	27AUG2020	69602	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11341195	C4591001 1134 11341195	16-55	27AUG2020	69603	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341203	C4591001 1134 11341203	16-55	27AUG2020	70987	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11341204	C4591001 1134 11341204	16-55	27AUG2020	70988	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341210	C4591001 1134 11341210	16-55	28AUG2020	70994	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341211	C4591001 1134 11341211	16-55	28AUG2020	70995	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341213	C4591001 1134 11341213	16-55	28AUG2020	72549	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11341222	C4591001 1134 11341222	16-55	31AUG2020	72550	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11341224	C4591001 1134 11341224	16-55	31AUG2020	72553	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11341225	C4591001 1134 11341225	16-55	31AUG2020	72556	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11341226	C4591001 1134 11341226	16-55	31AUG2020	75874	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11341228	C4591001 1134 11341228	16-55	01SEP2020	75876	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341230	C4591001 1134 11341230	16-55	01SEP2020	75877	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11341232	C4591001 1134 11341232	16-55	01SEP2020	75878	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11341234	C4591001 1134 11341234	16-55	01SEP2020	77489	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341235	C4591001 1134 11341235	16-55	01SEP2020	77498	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341236	C4591001 1134 11341236	16-55	01SEP2020	77490	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11341237	C4591001 1134 11341237	16-55	01SEP2020	77492	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11341241	C4591001 1134 11341241	16-55	02SEP2020	78021	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11341242	C4591001 1134 11341242	16-55	02SEP2020	78024	Placebo	02SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341244	C4591001 1134 11341244	16-55	02SEP2020	78025	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341247	C4591001 1134 11341247	16-55	02SEP2020	78027	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341248	C4591001 1134 11341248	16-55	02SEP2020	79185	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11341249	C4591001 1134 11341249	16-55	02SEP2020	79186	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341253	C4591001 1134 11341253	16-55	03SEP2020	79188	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11341254	C4591001 1134 11341254	16-55	03SEP2020	79189	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11341259	C4591001 1134 11341259	16-55	03SEP2020	80782	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11341260	C4591001 1134 11341260	16-55	03SEP2020	80779	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341263	C4591001 1134 11341263	16-55	03SEP2020	80784	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11341268	C4591001 1134 11341268	16-55	04SEP2020	80785	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341269	C4591001 1134 11341269	16-55	04SEP2020	81692	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11341276	C4591001 1134 11341276	16-55	04SEP2020	81696	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341280	C4591001 1134 11341280	16-55	08SEP2020	81697	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11341281	C4591001 1134 11341281	16-55	08SEP2020	81699	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341282	C4591001 1134 11341282	16-55	08SEP2020	83376	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341283	C4591001 1134 11341283	16-55	08SEP2020	83373	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11341286	C4591001 1134 11341286	16-55	08SEP2020	83378	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341290	C4591001 1134 11341290	16-55	08SEP2020	83380	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341292	C4591001 1134 11341292	16-55	08SEP2020	84078	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341295	C4591001 1134 11341295	16-55	08SEP2020	84083	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11341296	C4591001 1134 11341296	16-55	08SEP2020	84084	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11341299	C4591001 1134 11341299	16-55	09SEP2020	84087	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341301	C4591001 1134 11341301	16-55	09SEP2020	85482	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341303	C4591001 1134 11341303	16-55	09SEP2020	85490	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11341304	C4591001 1134 11341304	16-55	09SEP2020	85484	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
11341308	C4591001 1134 11341308	16-55	09SEP2020	85491	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341313	C4591001 1134 11341313	16-55	10SEP2020	86286	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11341314	C4591001 1134 11341314	16-55	10SEP2020	86290	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11341315	C4591001 1134 11341315	16-55	10SEP2020	86291	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341317	C4591001 1134 11341317	16-55	10SEP2020	86295	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11341321	C4591001 1134 11341321	16-55	10SEP2020	86933	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341322	C4591001 1134 11341322	16-55	10SEP2020	86935	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341323	C4591001 1134 11341323	16-55	10SEP2020	86939	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11341324	C4591001 1134 11341324	16-55	10SEP2020	86942	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341325	C4591001 1134 11341325	16-55	11SEP2020	87725	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341326	C4591001 1134 11341326	16-55	11SEP2020	87726	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11341327	C4591001 1134 11341327	16-55	11SEP2020	87727	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341328	C4591001 1134 11341328	16-55	11SEP2020	87728	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11341330	C4591001 1134 11341330	16-55	11SEP2020	87825	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11341332	C4591001 1134 11341332	16-55	11SEP2020	87826	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11341335	C4591001 1134 11341335	16-55	11SEP2020	87830	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341336	C4591001 1134 11341336	16-55	11SEP2020	88608	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341337	C4591001 1134 11341337	16-55	11SEP2020	88603	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11341338	C4591001 1134 11341338	16-55	11SEP2020	87832	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11341340	C4591001 1134 11341340	16-55	14SEP2020	88609	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11341344	C4591001 1134 11341344	16-55	14SEP2020	88611	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11341348	C4591001 1134 11341348	16-55	14SEP2020	89887	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11341351	C4591001 1134 11341351	16-55	15SEP2020	89890	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11341352	C4591001 1134 11341352	16-55	15SEP2020	89891	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11341355	C4591001 1134 11341355	16-55	16SEP2020	89896	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11341356	C4591001 1134 11341356	16-55	16SEP2020	91521	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11341363	C4591001 1134 11341363	16-55	18SEP2020	91522	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341364	C4591001 1134 11341364	16-55	18SEP2020	91523	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11341365	C4591001 1134 11341365	16-55	18SEP2020	91525	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11341370	C4591001 1134 11341370	16-55	25SEP2020	99716	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341372	C4591001 1134 11341372	16-55	25SEP2020	99719	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11341373	C4591001 1134 11341373	16-55	25SEP2020	99721	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341378	C4591001 1134 11341378	16-55	06OCT2020	99723	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11341379	C4591001 1134 11341379	16-55	06OCT2020	104273	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11341381	C4591001 1134 11341381	16-55	07OCT2020	104274	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11341385	C4591001 1134 11341385	16-55	08OCT2020	104277	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11341389	C4591001 1134 11341389	16-55	08OCT2020	104281	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341392	C4591001 1134 11341392	16-55	09OCT2020	105775	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11341393	C4591001 1134 11341393	16-55	09OCT2020	105776	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341397	C4591001 1134 11341397	16-55	09OCT2020	105779	Placebo	09OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11341399	C4591001 1134 11341399	16-55	09OCT2020	105780	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11341404	C4591001 1134 11341404	16-55	12OCT2020	106557	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11341406	C4591001 1134 11341406	16-55	12OCT2020	106561	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11341407	C4591001 1134 11341407	16-55	12OCT2020	106562	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11341408	C4591001 1134 11341408	16-55	13OCT2020	106564	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341413	C4591001 1134 11341413	16-55	14OCT2020	107420	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11341416	C4591001 1134 11341416	16-55	15OCT2020	107424	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341417	C4591001 1134 11341417	16-55	15OCT2020	107425	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341420	C4591001 1134 11341420	16-55	15OCT2020	107428	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11341421	C4591001 1134 11341421	16-55	15OCT2020	108233	Placebo	15OCT2020/ Placebo	11NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341424	C4591001 1134 11341424	16-55	15OCT2020	108242	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11341425	C4591001 1134 11341425	16-55	15OCT2020	108235	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11341426	C4591001 1134 11341426	16-55	15OCT2020	108243	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11341428	C4591001 1134 11341428	16-55	16OCT2020	108838	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11341433	C4591001 1134 11341433	16-55	19OCT2020	108840	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11341435	C4591001 1134 11341435	16-55	21OCT2020	108841	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11341436	C4591001 1134 11341436	16-55	21OCT2020	108843	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11341437	C4591001 1134 11341437	16-55	22OCT2020	112481	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11341438	C4591001 1134 11341438	16-55	28OCT2020	112482	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351129	C4591001 1135 11351129	16-55	14AUG2020	49669	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351136	C4591001 1135 11351136	16-55	17AUG2020	50773	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351137	C4591001 1135 11351137	16-55	17AUG2020	50776	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351139	C4591001 1135 11351139	16-55	17AUG2020	53117	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11351142	C4591001 1135 11351142	16-55	17AUG2020	53120	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11351144	C4591001 1135 11351144	16-55	17AUG2020	53124	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11351145	C4591001 1135 11351145	16-55	17AUG2020	53125	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351148	C4591001 1135 11351148	16-55	17AUG2020	53669	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351151	C4591001 1135 11351151	16-55	18AUG2020	53675	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351152	C4591001 1135 11351152	16-55	18AUG2020	53677	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11351154	C4591001 1135 11351154	16-55	18AUG2020	53679	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11351155	C4591001 1135 11351155	16-55	18AUG2020	55434	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351156	C4591001 1135 11351156	16-55	19AUG2020	55437	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351158	C4591001 1135 11351158	16-55	19AUG2020	55440	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351163	C4591001 1135 11351163	16-55	19AUG2020	55443	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11351164	C4591001 1135 11351164	16-55	20AUG2020	58663	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351165	C4591001 1135 11351165	16-55	20AUG2020	58667	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11351166	C4591001 1135 11351166	16-55	20AUG2020	58669	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351168	C4591001 1135 11351168	16-55	20AUG2020	59381	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11351169	C4591001 1135 11351169	16-55	20AUG2020	58671	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
11351170	C4591001 1135 11351170	16-55	20AUG2020	59388	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351171	C4591001 1135 11351171	16-55	20AUG2020	59386	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351172	C4591001 1135 11351172	16-55	21AUG2020	59390	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11351173	C4591001 1135 11351173	16-55	21AUG2020	60766	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11351175	C4591001 1135 11351175	16-55	21AUG2020	60770	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11351176	C4591001 1135 11351176	16-55	21AUG2020	61373	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351177	C4591001 1135 11351177	16-55	21AUG2020	60767	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351178	C4591001 1135 11351178	16-55	21AUG2020	60772	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351179	C4591001 1135 11351179	16-55	21AUG2020	61377	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11351184	C4591001 1135 11351184	16-55	24AUG2020	238320	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351190	C4591001 1135 11351190	16-55	24AUG2020	61383	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11351191	C4591001 1135 11351191	16-55	24AUG2020	61379	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11351194	C4591001 1135 11351194	16-55	24AUG2020	64581	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11351195	C4591001 1135 11351195	16-55	24AUG2020	64580	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351198	C4591001 1135 11351198	16-55	24AUG2020	64584	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351199	C4591001 1135 11351199	16-55	24AUG2020	64585	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11351200	C4591001 1135 11351200	16-55	24AUG2020	64974	Placebo	24AUG2020/ Placebo			
11351201	C4591001 1135 11351201	16-55	25AUG2020	64978	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351203	C4591001 1135 11351203	16-55	25AUG2020	64979	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11351205	C4591001 1135 11351205	16-55	25AUG2020	64980	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11351206	C4591001 1135 11351206	16-55	25AUG2020	66425	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351207	C4591001 1135 11351207	16-55	25AUG2020	66435	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351208	C4591001 1135 11351208	16-55	25AUG2020	66427	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11351210	C4591001 1135 11351210	16-55	25AUG2020	66436	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11351211	C4591001 1135 11351211	16-55	25AUG2020	66958	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11351212	C4591001 1135 11351212	16-55	25AUG2020	66960	Placebo	25AUG2020/ Placebo			
11351213	C4591001 1135 11351213	16-55	25AUG2020	66954	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11351214	C4591001 1135 11351214	16-55	25AUG2020	66963	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351216	C4591001 1135 11351216	16-55	26AUG2020	68081	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11351217	C4591001 1135 11351217	16-55	26AUG2020	68087	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351220	C4591001 1135 11351220	16-55	27AUG2020	68089	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351221	C4591001 1135 11351221	16-55	28AUG2020	68092	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11351222	C4591001 1135 11351222	16-55	31AUG2020	75177	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351225	C4591001 1135 11351225	16-55	31AUG2020	75183	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351226	C4591001 1135 11351226	16-55	31AUG2020	75178	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351227	C4591001 1135 11351227	16-55	31AUG2020	75179	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11351228	C4591001 1135 11351228	16-55	31AUG2020	75630	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351229	C4591001 1135 11351229	16-55	31AUG2020	75638	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351230	C4591001 1135 11351230	16-55	31AUG2020	75635	Placebo	31AUG2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351231	C4591001 1135 11351231	16-55	31AUG2020	75639	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351234	C4591001 1135 11351234	16-55	31AUG2020	76037	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351235	C4591001 1135 11351235	16-55	31AUG2020	76038	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11351239	C4591001 1135 11351239	16-55	01SEP2020	76040	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351241	C4591001 1135 11351241	16-55	01SEP2020	76048	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11351242	C4591001 1135 11351242	16-55	01SEP2020	76819	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351243	C4591001 1135 11351243	16-55	01SEP2020	76822	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351244	C4591001 1135 11351244	16-55	01SEP2020	76825	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11351245	C4591001 1135 11351245	16-55	01SEP2020	76827	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351247	C4591001 1135 11351247	16-55	01SEP2020	77363	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351248	C4591001 1135 11351248	16-55	01SEP2020	77357	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11351250	C4591001 1135 11351250	16-55	01SEP2020	77361	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351251	C4591001 1135 11351251	16-55	01SEP2020	77358	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11351253	C4591001 1135 11351253	16-55	01SEP2020	77615	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351256	C4591001 1135 11351256	16-55	01SEP2020	77617	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351259	C4591001 1135 11351259	16-55	01SEP2020	77619	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351262	C4591001 1135 11351262	16-55	02SEP2020	78369	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351263	C4591001 1135 11351263	16-55	02SEP2020	77620	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351264	C4591001 1135 11351264	16-55	02SEP2020	78373	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351265	C4591001 1135 11351265	16-55	02SEP2020	78372	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351267	C4591001 1135 11351267	16-55	02SEP2020	78374	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351268	C4591001 1135 11351268	16-55	02SEP2020	78678	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351269	C4591001 1135 11351269	16-55	02SEP2020	78684	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351274	C4591001 1135 11351274	16-55	02SEP2020	78685	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351276	C4591001 1135 11351276	16-55	03SEP2020	78686	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351279	C4591001 1135 11351279	16-55	03SEP2020	80241	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11351281	C4591001 1135 11351281	16-55	03SEP2020	80242	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351282	C4591001 1135 11351282	16-55	03SEP2020	80243	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11351284	C4591001 1135 11351284	16-55	03SEP2020	80244	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351285	C4591001 1135 11351285	16-55	03SEP2020	80844	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
11351286	C4591001 1135 11351286	16-55	03SEP2020	80842	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11351287	C4591001 1135 11351287	16-55	03SEP2020	80848	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351288	C4591001 1135 11351288	16-55	03SEP2020	80837	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11351290	C4591001 1135 11351290	16-55	03SEP2020	81042	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351291	C4591001 1135 11351291	16-55	03SEP2020	81044	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11351292	C4591001 1135 11351292	16-55	03SEP2020	81045	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351293	C4591001 1135 11351293	16-55	04SEP2020	81052	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351294	C4591001 1135 11351294	16-55	04SEP2020	81653	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11351295	C4591001 1135 11351295	16-55	04SEP2020	81654	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351297	C4591001 1135 11351297	16-55	04SEP2020	81656	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11351301	C4591001 1135 11351301	16-55	04SEP2020	81658	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo		
11351304	C4591001 1135 11351304	16-55	04SEP2020	82533	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11351307	C4591001 1135 11351307	16-55	15SEP2020	89961	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351308	C4591001 1135 11351308	16-55	08SEP2020	82537	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11351310	C4591001 1135 11351310	16-55	08SEP2020	82538	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11351313	C4591001 1135 11351313	16-55	08SEP2020	82539	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351315	C4591001 1135 11351315	16-55	08SEP2020	84130	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11351322	C4591001 1135 11351322	16-55	08SEP2020	84131	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo		
11351323	C4591001 1135 11351323	16-55	08SEP2020	84133	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351326	C4591001 1135 11351326	16-55	08SEP2020	84136	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351327	C4591001 1135 11351327	16-55	08SEP2020	84583	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351328	C4591001 1135 11351328	16-55	08SEP2020	84587	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351330	C4591001 1135 11351330	16-55	09SEP2020	84589	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11351331	C4591001 1135 11351331	16-55	09SEP2020	84591	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11351332	C4591001 1135 11351332	16-55	09SEP2020	85398	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
11351334	C4591001 1135 11351334	16-55	09SEP2020	85406	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11351335	C4591001 1135 11351335	16-55	09SEP2020	85700	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11351336	C4591001 1135 11351336	16-55	09SEP2020	85401	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351338	C4591001 1135 11351338	16-55	09SEP2020	85408	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351341	C4591001 1135 11351341	16-55	09SEP2020	85702	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11351342	C4591001 1135 11351342	16-55	09SEP2020	85706	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11351343	C4591001 1135 11351343	16-55	09SEP2020	85708	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11351346	C4591001 1135 11351346	16-55	09SEP2020	86038	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11351347	C4591001 1135 11351347	16-55	09SEP2020	86034	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11351349	C4591001 1135 11351349	16-55	11SEP2020	86040	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11351350	C4591001 1135 11351350	16-55	14SEP2020	86042	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11351351	C4591001 1135 11351351	16-55	14SEP2020	89957	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11351355	C4591001 1135 11351355	16-55	15SEP2020	89962	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11351356	C4591001 1135 11351356	16-55	16SEP2020	89966	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351359	C4591001 1135 11351359	16-55	17SEP2020	92514	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11351360	C4591001 1135 11351360	16-55	17SEP2020	92520	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11351361	C4591001 1135 11351361	16-55	17SEP2020	92523	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351362	C4591001 1135 11351362	16-55	17SEP2020	92522	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11351363	C4591001 1135 11351363	16-55	17SEP2020	92794	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11351365	C4591001 1135 11351365	16-55	17SEP2020	92797	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11351366	C4591001 1135 11351366	16-55	17SEP2020	92799	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351367	C4591001 1135 11351367	16-55	17SEP2020	92800	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11351368	C4591001 1135 11351368	16-55	18SEP2020	93670	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11351369	C4591001 1135 11351369	16-55	18SEP2020	93673	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351370	C4591001 1135 11351370	16-55	18SEP2020	93667	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351373	C4591001 1135 11351373	16-55	18SEP2020	93676	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351374	C4591001 1135 11351374	16-55	18SEP2020	93908	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11351375	C4591001 1135 11351375	16-55	18SEP2020	93909	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11351376	C4591001 1135 11351376	16-55	18SEP2020	93910	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
11351377	C4591001 1135 11351377	16-55	18SEP2020	93911	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11351378	C4591001 1135 11351378	16-55	18SEP2020	94316	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351379	C4591001 1135 11351379	16-55	18SEP2020	94319	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11351381	C4591001 1135 11351381	16-55	19SEP2020	94324	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351382	C4591001 1135 11351382	16-55	19SEP2020	94320	Placebo	19SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351383	C4591001 1135 11351383	16-55	19SEP2020	94502	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11351384	C4591001 1135 11351384	16-55	19SEP2020	94498	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351387	C4591001 1135 11351387	16-55	19SEP2020	94500	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351389	C4591001 1135 11351389	16-55	19SEP2020	94503	BNT162b2 (30 µg)				
11351391	C4591001 1135 11351391	16-55	19SEP2020	94547	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351392	C4591001 1135 11351392	16-55	19SEP2020	94541	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351393	C4591001 1135 11351393	16-55	19SEP2020	94544	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11351394	C4591001 1135 11351394	16-55	19SEP2020	94550	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo		
11351399	C4591001 1135 11351399	16-55	21SEP2020	95550	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351400	C4591001 1135 11351400	16-55	21SEP2020	95552	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351401	C4591001 1135 11351401	16-55	21SEP2020	95556	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351403	C4591001 1135 11351403	16-55	21SEP2020	95676	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
11351404	C4591001 1135 11351404	16-55	21SEP2020	95558	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11351405	C4591001 1135 11351405	16-55	21SEP2020	95677	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351408	C4591001 1135 11351408	16-55	22SEP2020	95679	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
11351410	C4591001 1135 11351410	16-55	22SEP2020	95680	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351411	C4591001 1135 11351411	16-55	22SEP2020	96800	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351412	C4591001 1135 11351412	16-55	22SEP2020	96797	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351414	C4591001 1135 11351414	16-55	22SEP2020	96801	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11351415	C4591001 1135 11351415	16-55	22SEP2020	96804	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351416	C4591001 1135 11351416	16-55	22SEP2020	97016	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351417	C4591001 1135 11351417	16-55	23SEP2020	97017	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351418	C4591001 1135 11351418	16-55	23SEP2020	97018	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351420	C4591001 1135 11351420	16-55	23SEP2020	97023	Placebo	23SEP2020/ Placebo			
11351421	C4591001 1135 11351421	16-55	23SEP2020	98070	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
11351422	C4591001 1135 11351422	16-55	23SEP2020	98072	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11351423	C4591001 1135 11351423	16-55	23SEP2020	98071	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11351425	C4591001 1135 11351425	16-55	23SEP2020	98077	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351428	C4591001 1135 11351428	16-55	23SEP2020	98406	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)			
11351429	C4591001 1135 11351429	16-55	24SEP2020	98408	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351430	C4591001 1135 11351430	16-55	24SEP2020	98409	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)			
11351431	C4591001 1135 11351431	16-55	24SEP2020	98413	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351432	C4591001 1135 11351432	16-55	24SEP2020	99020	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11351433	C4591001 1135 11351433	16-55	24SEP2020	99021	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo		
11351434	C4591001 1135 11351434	16-55	24SEP2020	99022	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11351435	C4591001 1135 11351435	16-55	24SEP2020	99026	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11351436	C4591001 1135 11351436	16-55	24SEP2020	99149	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11351437	C4591001 1135 11351437	16-55	25SEP2020	99150	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351438	C4591001 1135 11351438	16-55	25SEP2020	99155	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
11351439	C4591001 1135 11351439	16-55	25SEP2020	99156	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351440	C4591001 1135 11351440	16-55	21OCT2020	400193	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351441	C4591001 1135 11351441	16-55	21OCT2020	400194	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351442	C4591001 1135 11351442	16-55	21OCT2020	400202	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351443	C4591001 1135 11351443	16-55	21OCT2020	400201	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351444	C4591001 1135 11351444	16-55	21OCT2020	400221	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351445	C4591001 1135 11351445	16-55	21OCT2020	400222	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351446	C4591001 1135 11351446	16-55	21OCT2020	400223	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351448	C4591001 1135 11351448	16-55	21OCT2020	400228	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11351449	C4591001 1135 11351449	16-55	21OCT2020	400257	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351450	C4591001 1135 11351450	16-55	21OCT2020	400254	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351451	C4591001 1135 11351451	16-55	21OCT2020	400263	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351452	C4591001 1135 11351452	16-55	21OCT2020	400264	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11351453	C4591001 1135 11351453	16-55	21OCT2020	400295	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351454	C4591001 1135 11351454	16-55	21OCT2020	400298	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351455	C4591001 1135 11351455	16-55	21OCT2020	400297	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351456	C4591001 1135 11351456	16-55	21OCT2020	400296	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351457	C4591001 1135 11351457	16-55	21OCT2020	400317	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351458	C4591001 1135 11351458	16-55	21OCT2020	400321	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11351459	C4591001 1135 11351459	16-55	21OCT2020	400313	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11351460	C4591001 1135 11351460	16-55	21OCT2020	400326	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351461	C4591001 1135 11351461	16-55	21OCT2020	400316	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351462	C4591001 1135 11351462	16-55	21OCT2020	400327	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351463	C4591001 1135 11351463	16-55	21OCT2020	400328	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11351464	C4591001 1135 11351464	16-55	22OCT2020	400329	Placebo	22OCT2020/ Placebo	16NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351465	C4591001 1135 11351465	16-55	22OCT2020	400386	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351466	C4591001 1135 11351466	16-55	22OCT2020	400388	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351467	C4591001 1135 11351467	16-55	22OCT2020	400392	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11351468	C4591001 1135 11351468	16-55	22OCT2020	400395	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351469	C4591001 1135 11351469	16-55	22OCT2020	400411	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351470	C4591001 1135 11351470	16-55	22OCT2020	400413	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351471	C4591001 1135 11351471	16-55	22OCT2020	400433	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351472	C4591001 1135 11351472	16-55	22OCT2020	400414	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351473	C4591001 1135 11351473	16-55	22OCT2020	400419	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11351474	C4591001 1135 11351474	16-55	22OCT2020	400435	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo		
11351475	C4591001 1135 11351475	16-55	22OCT2020	400442	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351476	C4591001 1135 11351476	16-55	22OCT2020	400437	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11351477	C4591001 1135 11351477	16-55	22OCT2020	400459	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351479	C4591001 1135 11351479	16-55	22OCT2020	400462	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351480	C4591001 1135 11351480	16-55	22OCT2020	400467	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351482	C4591001 1135 11351482	16-55	22OCT2020	400468	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351483	C4591001 1135 11351483	16-55	23OCT2020	400495	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351484	C4591001 1135 11351484	16-55	23OCT2020	400496	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11351485	C4591001 1135 11351485	16-55	23OCT2020	400504	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11351486	C4591001 1135 11351486	16-55	23OCT2020	400499	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351487	C4591001 1135 11351487	16-55	23OCT2020	400541	Placebo	23OCT2020/ Placebo	14NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11351488	C4591001 1135 11351488	16-55	23OCT2020	400546	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351489	C4591001 1135 11351489	16-55	23OCT2020	400567	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351490	C4591001 1135 11351490	16-55	23OCT2020	400551	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351491	C4591001 1135 11351491	16-55	23OCT2020	400574	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351492	C4591001 1135 11351492	16-55	23OCT2020	400552	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351493	C4591001 1135 11351493	16-55	23OCT2020	400568	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351494	C4591001 1135 11351494	16-55	23OCT2020	400575	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351495	C4591001 1135 11351495	16-55	23OCT2020	400616	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351496	C4591001 1135 11351496	16-55	23OCT2020	400614	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351497	C4591001 1135 11351497	16-55	23OCT2020	400640	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
11351498	C4591001 1135 11351498	16-55	23OCT2020	400624	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351499	C4591001 1135 11351499	16-55	23OCT2020	400638	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351500	C4591001 1135 11351500	16-55	23OCT2020	400618	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11351501	C4591001 1135 11351501	16-55	23OCT2020	400696	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11351502	C4591001 1135 11351502	16-55	23OCT2020	400695	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351503	C4591001 1135 11351503	16-55	23OCT2020	400644	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351505	C4591001 1135 11351505	16-55	23OCT2020	400641	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351506	C4591001 1135 11351506	16-55	23OCT2020	400689	Placebo	23OCT2020/ Placebo	16NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11351508	C4591001 1135 11351508	16-55	23OCT2020	400688	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351509	C4591001 1135 11351509	16-55	23OCT2020	400698	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351510	C4591001 1135 11351510	16-55	24OCT2020	400704	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351511	C4591001 1135 11351511	16-55	24OCT2020	400703	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351512	C4591001 1135 11351512	16-55	24OCT2020	400700	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351513	C4591001 1135 11351513	16-55	24OCT2020	400710	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351514	C4591001 1135 11351514	16-55	24OCT2020	400725	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351516	C4591001 1135 11351516	16-55	24OCT2020	400720	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351517	C4591001 1135 11351517	16-55	24OCT2020	400716	Placebo	24OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351518	C4591001 1135 11351518	16-55	24OCT2020	400712	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351519	C4591001 1135 11351519	16-55	24OCT2020	400731	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351520	C4591001 1135 11351520	16-55	24OCT2020	400723	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351521	C4591001 1135 11351521	16-55	24OCT2020	400728	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351522	C4591001 1135 11351522	16-55	24OCT2020	400734	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351523	C4591001 1135 11351523	16-55	24OCT2020	400738	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)			
11351524	C4591001 1135 11351524	16-55	24OCT2020	400735	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11351525	C4591001 1135 11351525	16-55	24OCT2020	400742	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351526	C4591001 1135 11351526	16-55	24OCT2020	400750	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11351527	C4591001 1135 11351527	16-55	24OCT2020	400751	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo		
11351528	C4591001 1135 11351528	16-55	24OCT2020	400757	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351529	C4591001 1135 11351529	16-55	24OCT2020	400756	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351530	C4591001 1135 11351530	16-55	24OCT2020	400752	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11351531	C4591001 1135 11351531	16-55	24OCT2020	400763	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11351532	C4591001 1135 11351532	16-55	24OCT2020	400758	Placebo	24OCT2020/ Placebo	13NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351533	C4591001 1135 11351533	16-55	24OCT2020	400768	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo		
11351534	C4591001 1135 11351534	16-55	26OCT2020	400858	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11351535	C4591001 1135 11351535	16-55	26OCT2020	400854	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351536	C4591001 1135 11351536	16-55	26OCT2020	400859	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351537	C4591001 1135 11351537	16-55	26OCT2020	400867	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351538	C4591001 1135 11351538	16-55	26OCT2020	400876	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11351539	C4591001 1135 11351539	16-55	26OCT2020	400861	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351540	C4591001 1135 11351540	16-55	26OCT2020	400902	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351541	C4591001 1135 11351541	16-55	26OCT2020	400869	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351542	C4591001 1135 11351542	16-55	26OCT2020	400872	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11351543	C4591001 1135 11351543	16-55	26OCT2020	400903	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11351544	C4591001 1135 11351544	16-55	26OCT2020	400904	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351545	C4591001 1135 11351545	16-55	26OCT2020	400910	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351546	C4591001 1135 11351546	16-55	26OCT2020	400998	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351547	C4591001 1135 11351547	16-55	26OCT2020	400999	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11351548	C4591001 1135 11351548	16-55	26OCT2020	401005	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11351549	C4591001 1135 11351549	16-55	26OCT2020	401000	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11351550	C4591001 1135 11351550	16-55	26OCT2020	401033	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351551	C4591001 1135 11351551	16-55	27OCT2020	401035	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11351552	C4591001 1135 11351552	16-55	27OCT2020	401039	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11351553	C4591001 1135 11351553	16-55	27OCT2020	401043	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11351554	C4591001 1135 11351554	16-55	27OCT2020	401073	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351555	C4591001 1135 11351555	16-55	27OCT2020	401074	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351556	C4591001 1135 11351556	16-55	27OCT2020	401079	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351557	C4591001 1135 11351557	16-55	27OCT2020	401080	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11351558	C4591001 1135 11351558	16-55	27OCT2020	401097	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
11351559	C4591001 1135 11351559	16-55	27OCT2020	401099	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351560	C4591001 1135 11351560	16-55	27OCT2020	401101	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351561	C4591001 1135 11351561	16-55	27OCT2020	401100	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11351562	C4591001 1135 11351562	16-55	27OCT2020	401105	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351563	C4591001 1135 11351563	16-55	27OCT2020	401109	Placebo	27OCT2020/ Placebo	20NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11351564	C4591001 1135 11351564	16-55	27OCT2020	401110	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo		
11351565	C4591001 1135 11351565	16-55	27OCT2020	401112	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11351566	C4591001 1135 11351566	16-55	27OCT2020	401146	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11351567	C4591001 1135 11351567	16-55	27OCT2020	401141	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11351568	C4591001 1135 11351568	16-55	27OCT2020	401144	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351569	C4591001 1135 11351569	16-55	27OCT2020	401147	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351571	C4591001 1135 11351571	16-55	27OCT2020	401154	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351572	C4591001 1135 11351572	16-55	27OCT2020	401153	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11351573	C4591001 1135 11351573	16-55	27OCT2020	401158	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11361001	C4591001 1136 11361001	16-55	18AUG2020	54536	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11361002	C4591001 1136 11361002	16-55	18AUG2020	54540	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11361003	C4591001 1136 11361003	16-55	18AUG2020	54544	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361004	C4591001 1136 11361004	16-55	18AUG2020	54537	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11361006	C4591001 1136 11361006	16-55	18AUG2020	54713	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11361007	C4591001 1136 11361007	16-55	18AUG2020	54717	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361010	C4591001 1136 11361010	16-55	18AUG2020	54718	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361012	C4591001 1136 11361012	16-55	18AUG2020	54722	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11361013	C4591001 1136 11361013	16-55	18AUG2020	55304	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11361018	C4591001 1136 11361018	16-55	20AUG2020	55305	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361020	C4591001 1136 11361020	16-55	20AUG2020	55308	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11361021	C4591001 1136 11361021	16-55	20AUG2020	55309	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11361024	C4591001 1136 11361024	16-55	20AUG2020	59083	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361026	C4591001 1136 11361026	16-55	20AUG2020	59091	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361027	C4591001 1136 11361027	16-55	20AUG2020	59092	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11361028	C4591001 1136 11361028	16-55	20AUG2020	59444	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361029	C4591001 1136 11361029	16-55	20AUG2020	59449	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11361030	C4591001 1136 11361030	16-55	20AUG2020	59450	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11361031	C4591001 1136 11361031	16-55	20AUG2020	59451	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11361032	C4591001 1136 11361032	16-55	20AUG2020	59778	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11361034	C4591001 1136 11361034	16-55	20AUG2020	59779	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11361035	C4591001 1136 11361035	16-55	20AUG2020	59781	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11361036	C4591001 1136 11361036	16-55	21AUG2020	59785	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361039	C4591001 1136 11361039	16-55	21AUG2020	61602	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11361040	C4591001 1136 11361040	16-55	21AUG2020	61605	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11361042	C4591001 1136 11361042	16-55	24AUG2020	61609	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361043	C4591001 1136 11361043	16-55	24AUG2020	61610	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
11361045	C4591001 1136 11361045	16-55	24AUG2020	65036	Placebo	24AUG2020/ Placebo			
11361046	C4591001 1136 11361046	16-55	24AUG2020	65033	Placebo	24AUG2020/ Placebo	01OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11361047	C4591001 1136 11361047	16-55	25AUG2020	65040	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361048	C4591001 1136 11361048	16-55	25AUG2020	65044	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11361049	C4591001 1136 11361049	16-55	25AUG2020	67073	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11361054	C4591001 1136 11361054	16-55	28AUG2020	67075	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361058	C4591001 1136 11361058	16-55	14SEP2020	67077	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
11361060	C4591001 1136 11361060	16-55	14SEP2020	67084	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11361062	C4591001 1136 11361062	16-55	14SEP2020	89826	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11361063	C4591001 1136 11361063	16-55	14SEP2020	89829	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11361064	C4591001 1136 11361064	16-55	14SEP2020	89831	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11361065	C4591001 1136 11361065	16-55	14SEP2020	89835	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11361067	C4591001 1136 11361067	16-55	21OCT2020	111560	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11361072	C4591001 1136 11361072	16-55	21OCT2020	111564	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11361073	C4591001 1136 11361073	16-55	21OCT2020	111562	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11361076	C4591001 1136 11361076	16-55	22OCT2020	111565	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361082	C4591001 1136 11361082	16-55	27OCT2020	114248	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11361083	C4591001 1136 11361083	16-55	27OCT2020	114249	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11361084	C4591001 1136 11361084	16-55	28OCT2020	114250	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11361086	C4591001 1136 11361086	16-55	28OCT2020	114252	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11361087	C4591001 1136 11361087	16-55	28OCT2020	114474	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11361090	C4591001 1136 11361090	16-55	28OCT2020	114476	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo		
11361091	C4591001 1136 11361091	16-55	28OCT2020	114477	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11361092	C4591001 1136 11361092	16-55	28OCT2020	114479	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11361094	C4591001 1136 11361094	16-55	29OCT2020	114692	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11361095	C4591001 1136 11361095	16-55	29OCT2020	114696	Placebo	29OCT2020/ Placebo	16NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11361098	C4591001 1136 11361098	16-55	29OCT2020	114697	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11361099	C4591001 1136 11361099	16-55	29OCT2020	114700	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11361100	C4591001 1136 11361100	16-55	29OCT2020	114726	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11361101	C4591001 1136 11361101	16-55	29OCT2020	114728	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11361108	C4591001 1136 11361108	16-55	29OCT2020	114730	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11361109	C4591001 1136 11361109	16-55	29OCT2020	114834	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11361111	C4591001 1136 11361111	16-55	29OCT2020	114735	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)			
11391094	C4591001 1139 11391094	16-55	06OCT2020	47767	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391099	C4591001 1139 11391099	16-55	08OCT2020	47771	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11391100	C4591001 1139 11391100	16-55	08OCT2020	47775	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391101	C4591001 1139 11391101	16-55	08OCT2020	105464	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11391102	C4591001 1139 11391102	16-55	15OCT2020	107075	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11391103	C4591001 1139 11391103	16-55	09OCT2020	105465	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11391105	C4591001 1139 11391105	16-55	13OCT2020	105469	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11391106	C4591001 1139 11391106	16-55	13OCT2020	107069	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11391107	C4591001 1139 11391107	16-55	13OCT2020	107072	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11391108	C4591001 1139 11391108	16-55	13OCT2020	105472	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11391109	C4591001 1139 11391109	16-55	15OCT2020	107079	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo		
11391110	C4591001 1139 11391110	16-55	15OCT2020	108227	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11391112	C4591001 1139 11391112	16-55	16OCT2020	108228	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391113	C4591001 1139 11391113	16-55	16OCT2020	108229	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11391114	C4591001 1139 11391114	16-55	19OCT2020	108230	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11391116	C4591001 1139 11391116	16-55	20OCT2020	110233	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11391117	C4591001 1139 11391117	16-55	20OCT2020	110235	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11391119	C4591001 1139 11391119	16-55	19OCT2020	110231	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11391120	C4591001 1139 11391120	16-55	19OCT2020	110225	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11391125	C4591001 1139 11391125	16-55	22OCT2020	112265	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11391127	C4591001 1139 11391127	16-55	23OCT2020	112270	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11391130	C4591001 1139 11391130	16-55	10NOV2020	112273	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11391131	C4591001 1139 11391131	16-55	13NOV2020	112274	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391132	C4591001 1139 11391132	16-55	17NOV2020	116334	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11391133	C4591001 1139 11391133	16-55	17NOV2020	116335	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11391134	C4591001 1139 11391134	16-55	17NOV2020	116337	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	
11391135	C4591001 1139 11391135	16-55	17NOV2020	116344	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
11391136	C4591001 1139 11391136	16-55	23NOV2020	116696	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11391137	C4591001 1139 11391137	16-55	23NOV2020	116697	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11391138	C4591001 1139 11391138	16-55	24NOV2020	116699	Placebo	24NOV2020/ Placebo	17DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11391139	C4591001 1139 11391139	16-55	24NOV2020	116704	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11391140	C4591001 1139 11391140	16-55	24NOV2020	116801	Placebo	24NOV2020/ Placebo	18DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11391141	C4591001 1139 11391141	16-55	24NOV2020	116806	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391142	C4591001 1139 11391142	16-55	24NOV2020	116807	Placebo	24NOV2020/ Placebo	18DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11391143	C4591001 1139 11391143	16-55	11DEC2020	117758	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11391146	C4591001 1139 11391146	16-55	01DEC2020	116808	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
11391147	C4591001 1139 11391147	16-55	08DEC2020	117376	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11391148	C4591001 1139 11391148	16-55	18DEC2020	117919	Placebo	18DEC2020/ Placebo	07JAN2021/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11391149	C4591001 1139 11391149	16-55	03DEC2020	117367	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11391150	C4591001 1139 11391150	16-55	04DEC2020	117369	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11391153	C4591001 1139 11391153	16-55	04DEC2020	117375	Placebo	04DEC2020/ Placebo	28DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11391160	C4591001 1139 11391160	16-55	08DEC2020	117750	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11391164	C4591001 1139 11391164	16-55	11DEC2020	117756	BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)	30DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11391167	C4591001 1139 11391167	16-55	11DEC2020	117760	Placebo	11DEC2020/ Placebo	30DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11401054	C4591001 1140 11401054	16-55	25AUG2020	65613	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11401129	C4591001 1140 11401129	16-55	17AUG2020	50495	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11401130	C4591001 1140 11401130	16-55	17AUG2020	229998	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11401135	C4591001 1140 11401135	16-55	17AUG2020	50497	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401136	C4591001 1140 11401136	16-55	17AUG2020	50500	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11401137	C4591001 1140 11401137	16-55	17AUG2020	53003	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401144	C4591001 1140 11401144	16-55	04SEP2020	80651	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11401148	C4591001 1140 11401148	16-55	18AUG2020	53004	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11401149	C4591001 1140 11401149	16-55	18AUG2020	53005	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401150	C4591001 1140 11401150	16-55	18AUG2020	54858	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401151	C4591001 1140 11401151	16-55	18AUG2020	53008	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401153	C4591001 1140 11401153	16-55	19AUG2020	54861	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401154	C4591001 1140 11401154	16-55	19AUG2020	54863	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11401157	C4591001 1140 11401157	16-55	19AUG2020	54866	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11401158	C4591001 1140 11401158	16-55	19AUG2020	56731	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401159	C4591001 1140 11401159	16-55	19AUG2020	56733	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11401160	C4591001 1140 11401160	16-55	19AUG2020	56736	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401164	C4591001 1140 11401164	16-55	20AUG2020	56738	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11401166	C4591001 1140 11401166	16-55	20AUG2020	58433	Placebo	20AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401170	C4591001 1140 11401170	16-55	20AUG2020	58436	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11401176	C4591001 1140 11401176	16-55	21AUG2020	58437	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11401177	C4591001 1140 11401177	16-55	21AUG2020	58438	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11401178	C4591001 1140 11401178	16-55	24AUG2020	63309	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11401180	C4591001 1140 11401180	16-55	24AUG2020	63310	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11401184	C4591001 1140 11401184	16-55	24AUG2020	63312	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401187	C4591001 1140 11401187	16-55	25AUG2020	65611	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11401188	C4591001 1140 11401188	16-55	25AUG2020	63316	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11401198	C4591001 1140 11401198	16-55	26AUG2020	65618	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401201	C4591001 1140 11401201	16-55	27AUG2020	69511	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401202	C4591001 1140 11401202	16-55	27AUG2020	65619	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11401203	C4591001 1140 11401203	16-55	27AUG2020	69509	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11401206	C4591001 1140 11401206	16-55	27AUG2020	69514	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11401209	C4591001 1140 11401209	16-55	28AUG2020	69518	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401210	C4591001 1140 11401210	16-55	28AUG2020	71597	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11401211	C4591001 1140 11401211	16-55	28AUG2020	71598	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11401214	C4591001 1140 11401214	16-55	28AUG2020	71606	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11401215	C4591001 1140 11401215	16-55	28AUG2020	71608	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11401216	C4591001 1140 11401216	16-55	31AUG2020	74621	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11401219	C4591001 1140 11401219	16-55	31AUG2020	74627	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401224	C4591001 1140 11401224	16-55	31AUG2020	74628	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11401231	C4591001 1140 11401231	16-55	01SEP2020	74630	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11401232	C4591001 1140 11401232	16-55	01SEP2020	76740	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401239	C4591001 1140 11401239	16-55	02SEP2020	76741	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11401240	C4591001 1140 11401240	16-55	02SEP2020	76743	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11401241	C4591001 1140 11401241	16-55	02SEP2020	76744	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11401243	C4591001 1140 11401243	16-55	02SEP2020	78356	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11401246	C4591001 1140 11401246	16-55	02SEP2020	78360	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11401249	C4591001 1140 11401249	16-55	03SEP2020	78361	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11401250	C4591001 1140 11401250	16-55	03SEP2020	78362	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401251	C4591001 1140 11401251	16-55	03SEP2020	80157	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11401252	C4591001 1140 11401252	16-55	03SEP2020	80159	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11401255	C4591001 1140 11401255	16-55	03SEP2020	80164	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11401257	C4591001 1140 11401257	16-55	03SEP2020	80645	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11401259	C4591001 1140 11401259	16-55	04SEP2020	80647	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11401262	C4591001 1140 11401262	16-55	07OCT2020	80653	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11401264	C4591001 1140 11401264	16-55	07OCT2020	104923	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11401272	C4591001 1140 11401272	16-55	09OCT2020	104924	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11401279	C4591001 1140 11401279	16-55	13OCT2020	104926	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11401281	C4591001 1140 11401281	16-55	13OCT2020	104932	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401282	C4591001 1140 11401282	16-55	13OCT2020	107214	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11401284	C4591001 1140 11401284	16-55	14OCT2020	107215	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11401285	C4591001 1140 11401285	16-55	14OCT2020	107216	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401290	C4591001 1140 11401290	16-55	15OCT2020	107218	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11401294	C4591001 1140 11401294	16-55	15OCT2020	108414	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11401298	C4591001 1140 11401298	16-55	16OCT2020	108417	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401299	C4591001 1140 11401299	16-55	16OCT2020	108419	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11401301	C4591001 1140 11401301	16-55	19OCT2020	108424	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
11401303	C4591001 1140 11401303	16-55	20OCT2020	110681	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11401304	C4591001 1140 11401304	16-55	20OCT2020	110682	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401306	C4591001 1140 11401306	16-55	22OCT2020	110686	Placebo	22OCT2020/ Placebo			
11401308	C4591001 1140 11401308	16-55	23OCT2020	110691	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11401309	C4591001 1140 11401309	16-55	23OCT2020	113082	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11401310	C4591001 1140 11401310	16-55	23OCT2020	113083	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11401311	C4591001 1140 11401311	16-55	26OCT2020	113085	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11401314	C4591001 1140 11401314	16-55	03NOV2020	113086	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11401316	C4591001 1140 11401316	16-55	25NOV2020	116910	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11401317	C4591001 1140 11401317	16-55	02DEC2020	116913	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11401318	C4591001 1140 11401318	16-55	03DEC2020	116914	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11401319	C4591001 1140 11401319	16-55	03DEC2020	116915	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11401320	C4591001 1140 11401320	16-55	03DEC2020	117330	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11401321	C4591001 1140 11401321	16-55	04DEC2020	117332	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11401322	C4591001 1140 11401322	16-55	04DEC2020	117334	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11411077	C4591001 1141 11411077	16-55	13AUG2020	48926	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11411082	C4591001 1141 11411082	16-55	14AUG2020	50369	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411085	C4591001 1141 11411085	16-55	14AUG2020	50373	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411087	C4591001 1141 11411087	16-55	17AUG2020	50380	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411088	C4591001 1141 11411088	16-55	17AUG2020	52697	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411089	C4591001 1141 11411089	16-55	17AUG2020	52701	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11411090	C4591001 1141 11411090	16-55	17AUG2020	52708	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411091	C4591001 1141 11411091	16-55	17AUG2020	52707	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411092	C4591001 1141 11411092	16-55	17AUG2020	53334	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11411093	C4591001 1141 11411093	16-55	18AUG2020	53336	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11411094	C4591001 1141 11411094	16-55	18AUG2020	53339	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411096	C4591001 1141 11411096	16-55	18AUG2020	53342	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411097	C4591001 1141 11411097	16-55	18AUG2020	54753	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11411098	C4591001 1141 11411098	16-55	18AUG2020	54755	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11411099	C4591001 1141 11411099	16-55	19AUG2020	54758	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11411102	C4591001 1141 11411102	16-55	19AUG2020	54760	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11411103	C4591001 1141 11411103	16-55	19AUG2020	56586	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411104	C4591001 1141 11411104	16-55	19AUG2020	56590	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411106	C4591001 1141 11411106	16-55	19AUG2020	56593	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11411107	C4591001 1141 11411107	16-55	19AUG2020	56594	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11411108	C4591001 1141 11411108	16-55	20AUG2020	58073	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411109	C4591001 1141 11411109	16-55	20AUG2020	58076	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411110	C4591001 1141 11411110	16-55	20AUG2020	58078	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11411112	C4591001 1141 11411112	16-55	20AUG2020	58082	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411113	C4591001 1141 11411113	16-55	20AUG2020	59610	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411114	C4591001 1141 11411114	16-55	21AUG2020	59612	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411116	C4591001 1141 11411116	16-55	21AUG2020	59613	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411118	C4591001 1141 11411118	16-55	21AUG2020	59619	Placebo	21AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11411119	C4591001 1141 11411119	16-55	21AUG2020	60869	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411120	C4591001 1141 11411120	16-55	21AUG2020	60871	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11411121	C4591001 1141 11411121	16-55	21AUG2020	60872	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411122	C4591001 1141 11411122	16-55	24AUG2020	60874	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11411123	C4591001 1141 11411123	16-55	24AUG2020	63719	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411124	C4591001 1141 11411124	16-55	24AUG2020	63716	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411125	C4591001 1141 11411125	16-55	24AUG2020	63721	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11411127	C4591001 1141 11411127	16-55	24AUG2020	63723	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11411128	C4591001 1141 11411128	16-55	24AUG2020	64496	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411129	C4591001 1141 11411129	16-55	25AUG2020	64497	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11411130	C4591001 1141 11411130	16-55	25AUG2020	64503	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11411131	C4591001 1141 11411131	16-55	25AUG2020	64504	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11411132	C4591001 1141 11411132	16-55	25AUG2020	66630	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11411133	C4591001 1141 11411133	16-55	26AUG2020	66631	Placebo	26AUG2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11411135	C4591001 1141 11411135	16-55	26AUG2020	66633	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11411136	C4591001 1141 11411136	16-55	26AUG2020	68321	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11411137	C4591001 1141 11411137	16-55	26AUG2020	66640	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11411139	C4591001 1141 11411139	16-55	27AUG2020	68322	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11411140	C4591001 1141 11411140	16-55	27AUG2020	68326	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411141	C4591001 1141 11411141	16-55	27AUG2020	68327	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11411142	C4591001 1141 11411142	16-55	27AUG2020	70592	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11411144	C4591001 1141 11411144	16-55	27AUG2020	70593	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11411146	C4591001 1141 11411146	16-55	28AUG2020	70595	Placebo	28AUG2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411148	C4591001 1141 11411148	16-55	28AUG2020	70597	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11411149	C4591001 1141 11411149	16-55	28AUG2020	72509	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11411151	C4591001 1141 11411151	16-55	31AUG2020	72513	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11411152	C4591001 1141 11411152	16-55	31AUG2020	72512	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411153	C4591001 1141 11411153	16-55	31AUG2020	75258	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11411154	C4591001 1141 11411154	16-55	31AUG2020	72514	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411156	C4591001 1141 11411156	16-55	31AUG2020	75259	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11411158	C4591001 1141 11411158	16-55	01SEP2020	75260	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411159	C4591001 1141 11411159	16-55	01SEP2020	75262	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11411161	C4591001 1141 11411161	16-55	02SEP2020	77996	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411162	C4591001 1141 11411162	16-55	02SEP2020	78000	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411163	C4591001 1141 11411163	16-55	02SEP2020	78001	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11411164	C4591001 1141 11411164	16-55	02SEP2020	78004	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)			
11411165	C4591001 1141 11411165	16-55	02SEP2020	78956	Placebo	02SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11411166	C4591001 1141 11411166	16-55	02SEP2020	78957	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11411167	C4591001 1141 11411167	16-55	03SEP2020	78958	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411168	C4591001 1141 11411168	16-55	03SEP2020	78962	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11411169	C4591001 1141 11411169	16-55	03SEP2020	79962	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11411170	C4591001 1141 11411170	16-55	03SEP2020	79963	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11411171	C4591001 1141 11411171	16-55	03SEP2020	79969	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11411172	C4591001 1141 11411172	16-55	03SEP2020	79972	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411173	C4591001 1141 11411173	16-55	04SEP2020	81305	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11411174	C4591001 1141 11411174	16-55	04SEP2020	81308	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11411175	C4591001 1141 11411175	16-55	04SEP2020	81310	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11411176	C4591001 1141 11411176	16-55	04SEP2020	81309	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411177	C4591001 1141 11411177	16-55	04SEP2020	82085	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411179	C4591001 1141 11411179	16-55	08SEP2020	82088	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11411181	C4591001 1141 11411181	16-55	08SEP2020	82089	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11411182	C4591001 1141 11411182	16-55	08SEP2020	82094	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11411184	C4591001 1141 11411184	16-55	09SEP2020	85001	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11411185	C4591001 1141 11411185	16-55	09SEP2020	85007	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11411186	C4591001 1141 11411186	16-55	09SEP2020	85004	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11411187	C4591001 1141 11411187	16-55	09SEP2020	85010	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11411188	C4591001 1141 11411188	16-55	09SEP2020	85710	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11411192	C4591001 1141 11411192	16-55	10SEP2020	85714	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11411193	C4591001 1141 11411193	16-55	10SEP2020	85717	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411194	C4591001 1141 11411194	16-55	10SEP2020	85718	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11411195	C4591001 1141 11411195	16-55	10SEP2020	87259	Placebo	10SEP2020/ Placebo	14OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11411197	C4591001 1141 11411197	16-55	10SEP2020	87260	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11411198	C4591001 1141 11411198	16-55	11SEP2020	87262	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11411199	C4591001 1141 11411199	16-55	11SEP2020	87267	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11411201	C4591001 1141 11411201	16-55	11SEP2020	88401	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11411202	C4591001 1141 11411202	16-55	11SEP2020	88404	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11411203	C4591001 1141 11411203	16-55	11SEP2020	88405	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11411204	C4591001 1141 11411204	16-55	11SEP2020	88408	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11411205	C4591001 1141 11411205	16-55	14SEP2020	89357	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411206	C4591001 1141 11411206	16-55	14SEP2020	89360	Placebo	14SEP2020/ Placebo	08OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11411208	C4591001 1141 11411208	16-55	14SEP2020	89364	Placebo	14SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11411209	C4591001 1141 11411209	16-55	14SEP2020	89365	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11411211	C4591001 1141 11411211	16-55	15SEP2020	90260	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11411212	C4591001 1141 11411212	16-55	15SEP2020	90261	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11411213	C4591001 1141 11411213	16-55	15SEP2020	90264	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411214	C4591001 1141 11411214	16-55	15SEP2020	90265	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11411215	C4591001 1141 11411215	16-55	16SEP2020	91002	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11411217	C4591001 1141 11411217	16-55	16SEP2020	91004	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11411218	C4591001 1141 11411218	16-55	16SEP2020	91005	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411219	C4591001 1141 11411219	16-55	16SEP2020	91010	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11411220	C4591001 1141 11411220	16-55	16SEP2020	91629	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411221	C4591001 1141 11411221	16-55	16SEP2020	91630	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11411222	C4591001 1141 11411222	16-55	16SEP2020	91635	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11411223	C4591001 1141 11411223	16-55	16SEP2020	91636	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo		
11411224	C4591001 1141 11411224	16-55	17SEP2020	92383	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11411226	C4591001 1141 11411226	16-55	17SEP2020	92384	Placebo	17SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11411227	C4591001 1141 11411227	16-55	17SEP2020	92389	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411228	C4591001 1141 11411228	16-55	17SEP2020	92391	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11411229	C4591001 1141 11411229	16-55	17SEP2020	92912	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411230	C4591001 1141 11411230	16-55	18SEP2020	92917	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11411231	C4591001 1141 11411231	16-55	18SEP2020	92918	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11411234	C4591001 1141 11411234	16-55	18SEP2020	92919	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11411235	C4591001 1141 11411235	16-55	18SEP2020	94027	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411236	C4591001 1141 11411236	16-55	18SEP2020	94029	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11411237	C4591001 1141 11411237	16-55	21SEP2020	94032	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11411238	C4591001 1141 11411238	16-55	21SEP2020	94036	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11411239	C4591001 1141 11411239	16-55	21SEP2020	95597	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11411240	C4591001 1141 11411240	16-55	22SEP2020	95600	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411241	C4591001 1141 11411241	16-55	22SEP2020	95605	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411242	C4591001 1141 11411242	16-55	24SEP2020	95608	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11411243	C4591001 1141 11411243	16-55	24SEP2020	98935	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11411245	C4591001 1141 11411245	16-55	25SEP2020	98938	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11411246	C4591001 1141 11411246	16-55	25SEP2020	100279	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11411247	C4591001 1141 11411247	16-55	25SEP2020	98941	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11411248	C4591001 1141 11411248	16-55	25SEP2020	98943	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11411249	C4591001 1141 11411249	16-55	25SEP2020	100282	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11411250	C4591001 1141 11411250	16-55	05OCT2020	100285	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11411251	C4591001 1141 11411251	16-55	06OCT2020	100287	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11411254	C4591001 1141 11411254	16-55	07OCT2020	104841	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411255	C4591001 1141 11411255	16-55	08OCT2020	104844	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11411256	C4591001 1141 11411256	16-55	04NOV2020	115677	Placebo	04NOV2020/ Placebo	04DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11411257	C4591001 1141 11411257	16-55	12OCT2020	104846	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11411260	C4591001 1141 11411260	16-55	14OCT2020	104847	Placebo	14OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11411262	C4591001 1141 11411262	16-55	16OCT2020	109013	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11411263	C4591001 1141 11411263	16-55	19OCT2020	109014	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11411264	C4591001 1141 11411264	16-55	20OCT2020	109017	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11411265	C4591001 1141 11411265	16-55	20OCT2020	109020	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11411266	C4591001 1141 11411266	16-55	21OCT2020	111526	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11411267	C4591001 1141 11411267	16-55	23OCT2020	111529	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11411269	C4591001 1141 11411269	16-55	27OCT2020	111531	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11411270	C4591001 1141 11411270	16-55	27OCT2020	111532	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11421029	C4591001 1142 11421029	16-55	19AUG2020	56670	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11421063	C4591001 1142 11421063	16-55	01SEP2020	75243	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11421106	C4591001 1142 11421106	16-55	17AUG2020	52472	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11421107	C4591001 1142 11421107	16-55	17AUG2020	52476	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11421110	C4591001 1142 11421110	16-55	17AUG2020	52477	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11421112	C4591001 1142 11421112	16-55	17AUG2020	52479	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11421113	C4591001 1142 11421113	16-55	18AUG2020	54187	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421115	C4591001 1142 11421115	16-55	18AUG2020	54259	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421119	C4591001 1142 11421119	16-55	18AUG2020	54260	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421123	C4591001 1142 11421123	16-55	19AUG2020	54261	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11421124	C4591001 1142 11421124	16-55	19AUG2020	54267	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11421126	C4591001 1142 11421126	16-55	19AUG2020	56669	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11421129	C4591001 1142 11421129	16-55	20AUG2020	56674	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11421130	C4591001 1142 11421130	16-55	20AUG2020	56680	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11421131	C4591001 1142 11421131	16-55	20AUG2020	58147	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11421132	C4591001 1142 11421132	16-55	20AUG2020	58151	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11421138	C4591001 1142 11421138	16-55	21AUG2020	58153	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11421141	C4591001 1142 11421141	16-55	21AUG2020	58155	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421142	C4591001 1142 11421142	16-55	21AUG2020	60822	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11421149	C4591001 1142 11421149	16-55	24AUG2020	60823	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11421150	C4591001 1142 11421150	16-55	24AUG2020	60826	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11421153	C4591001 1142 11421153	16-55	24AUG2020	60830	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11421155	C4591001 1142 11421155	16-55	24AUG2020	63980	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11421157	C4591001 1142 11421157	16-55	31AUG2020	63984	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11421158	C4591001 1142 11421158	16-55	31AUG2020	63986	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11421161	C4591001 1142 11421161	16-55	31AUG2020	63987	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11421163	C4591001 1142 11421163	16-55	31AUG2020	75238	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11421164	C4591001 1142 11421164	16-55	01SEP2020	75239	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421166	C4591001 1142 11421166	16-55	01SEP2020	75241	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11421173	C4591001 1142 11421173	16-55	02SEP2020	77982	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421175	C4591001 1142 11421175	16-55	02SEP2020	77985	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11421178	C4591001 1142 11421178	16-55	10SEP2020	85451	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11421179	C4591001 1142 11421179	16-55	02SEP2020	77991	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11421181	C4591001 1142 11421181	16-55	03SEP2020	77992	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11421182	C4591001 1142 11421182	16-55	03SEP2020	79687	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421183	C4591001 1142 11421183	16-55	03SEP2020	79688	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11421184	C4591001 1142 11421184	16-55	03SEP2020	79690	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11421185	C4591001 1142 11421185	16-55	03SEP2020	79691	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421187	C4591001 1142 11421187	16-55	03SEP2020	80322	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11421188	C4591001 1142 11421188	16-55	04SEP2020	80324	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11421190	C4591001 1142 11421190	16-55	04SEP2020	80328	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11421194	C4591001 1142 11421194	16-55	04SEP2020	80330	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11421197	C4591001 1142 11421197	16-55	08SEP2020	83441	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11421198	C4591001 1142 11421198	16-55	08SEP2020	83442	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11421199	C4591001 1142 11421199	16-55	08SEP2020	83445	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11421200	C4591001 1142 11421200	16-55	08SEP2020	83447	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11421202	C4591001 1142 11421202	16-55	08SEP2020	83837	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11421203	C4591001 1142 11421203	16-55	09SEP2020	83842	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421204	C4591001 1142 11421204	16-55	09SEP2020	83846	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11421205	C4591001 1142 11421205	16-55	09SEP2020	83847	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421206	C4591001 1142 11421206	16-55	09SEP2020	85450	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11421212	C4591001 1142 11421212	16-55	10SEP2020	85454	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421214	C4591001 1142 11421214	16-55	10SEP2020	85456	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11421216	C4591001 1142 11421216	16-55	11SEP2020	87919	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11421218	C4591001 1142 11421218	16-55	11SEP2020	87925	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11421219	C4591001 1142 11421219	16-55	11SEP2020	87926	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11421220	C4591001 1142 11421220	16-55	11SEP2020	87927	Placebo	11SEP2020/ Placebo	20OCT2020/ Placebo		
11421222	C4591001 1142 11421222	16-55	14SEP2020	89489	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421223	C4591001 1142 11421223	16-55	14SEP2020	89491	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11421229	C4591001 1142 11421229	16-55	14SEP2020	89494	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11421230	C4591001 1142 11421230	16-55	15SEP2020	89500	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11421231	C4591001 1142 11421231	16-55	15SEP2020	90221	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11421233	C4591001 1142 11421233	16-55	15SEP2020	90223	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11421234	C4591001 1142 11421234	16-55	16SEP2020	90228	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11421235	C4591001 1142 11421235	16-55	16SEP2020	90229	Placebo	16SEP2020/ Placebo	12OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11421239	C4591001 1142 11421239	16-55	17SEP2020	92527	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11421242	C4591001 1142 11421242	16-55	18SEP2020	92530	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11421244	C4591001 1142 11421244	16-55	18SEP2020	92533	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421245	C4591001 1142 11421245	16-55	18SEP2020	92535	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11421248	C4591001 1142 11421248	16-55	21SEP2020	94769	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11421250	C4591001 1142 11421250	16-55	21SEP2020	94772	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11421251	C4591001 1142 11421251	16-55	21SEP2020	94774	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421253	C4591001 1142 11421253	16-55	22SEP2020	94775	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11421255	C4591001 1142 11421255	16-55	22SEP2020	96509	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11421256	C4591001 1142 11421256	16-55	23SEP2020	96511	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11421258	C4591001 1142 11421258	16-55	23SEP2020	96514	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11421261	C4591001 1142 11421261	16-55	24SEP2020	96515	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11421262	C4591001 1142 11421262	16-55	24SEP2020	98801	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421264	C4591001 1142 11421264	16-55	25SEP2020	98803	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421265	C4591001 1142 11421265	16-55	25SEP2020	98806	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11421269	C4591001 1142 11421269	16-55	05OCT2020	98808	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11421270	C4591001 1142 11421270	16-55	05OCT2020	103829	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11421271	C4591001 1142 11421271	16-55	05OCT2020	103836	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11421274	C4591001 1142 11421274	16-55	07OCT2020	103837	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11421275	C4591001 1142 11421275	16-55	07OCT2020	103838	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421276	C4591001 1142 11421276	16-55	07OCT2020	104825	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421277	C4591001 1142 11421277	16-55	08OCT2020	104828	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11421280	C4591001 1142 11421280	16-55	09OCT2020	104829	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421281	C4591001 1142 11421281	16-55	13OCT2020	104832	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11421282	C4591001 1142 11421282	16-55	15OCT2020	108077	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
11421283	C4591001 1142 11421283	16-55	15OCT2020	108082	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11421284	C4591001 1142 11421284	16-55	15OCT2020	108086	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11421286	C4591001 1142 11421286	16-55	16OCT2020	108088	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11421287	C4591001 1142 11421287	16-55	16OCT2020	108870	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11421289	C4591001 1142 11421289	16-55	19OCT2020	108871	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11421290	C4591001 1142 11421290	16-55	20OCT2020	108878	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11421292	C4591001 1142 11421292	16-55	20OCT2020	108879	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11421293	C4591001 1142 11421293	16-55	21OCT2020	111392	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421295	C4591001 1142 11421295	16-55	23OCT2020	111395	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11421298	C4591001 1142 11421298	16-55	23OCT2020	111396	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11421299	C4591001 1142 11421299	16-55	26OCT2020	111400	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11421300	C4591001 1142 11421300	16-55	26OCT2020	113514	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11421303	C4591001 1142 11421303	16-55	27OCT2020	113520	Placebo	27OCT2020/ Placebo	12NOV2020/ Placebo		
11421306	C4591001 1142 11421306	16-55	28OCT2020	113522	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11421307	C4591001 1142 11421307	16-55	28OCT2020	113524	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11421308	C4591001 1142 11421308	16-55	28OCT2020	114452	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11421310	C4591001 1142 11421310	16-55	29OCT2020	114456	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11421313	C4591001 1142 11421313	16-55	29OCT2020	114458	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421314	C4591001 1142 11421314	16-55	23NOV2020	114459	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo		
11421315	C4591001 1142 11421315	16-55	24NOV2020	116779	Placebo	24NOV2020/ Placebo	15DEC2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11421316	C4591001 1142 11421316	16-55	24NOV2020	116782	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11421317	C4591001 1142 11421317	16-55	25NOV2020	116786	Placebo	25NOV2020/ Placebo	15DEC2020/ Placebo		
11421322	C4591001 1142 11421322	16-55	03DEC2020	116788	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11421328	C4591001 1142 11421328	16-55	04DEC2020	117521	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421331	C4591001 1142 11421331	16-55	04DEC2020	117522	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11421332	C4591001 1142 11421332	16-55	04DEC2020	117525	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421334	C4591001 1142 11421334	16-55	04DEC2020	117527	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11421336	C4591001 1142 11421336	16-55	04DEC2020	117606	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11421337	C4591001 1142 11421337	16-55	04DEC2020	117609	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11421338	C4591001 1142 11421338	16-55	04DEC2020	117612	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421339	C4591001 1142 11421339	16-55	04DEC2020	117615	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11421347	C4591001 1142 11421347	16-55	10DEC2020	117813	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11451017	C4591001 1145 11451017	16-55	17AUG2020	49143	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451019	C4591001 1145 11451019	16-55	17AUG2020	53034	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451020	C4591001 1145 11451020	16-55	17AUG2020	53035	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11451021	C4591001 1145 11451021	16-55	18AUG2020	53037	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11451022	C4591001 1145 11451022	16-55	18AUG2020	53042	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451025	C4591001 1145 11451025	16-55	18AUG2020	54821	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11451026	C4591001 1145 11451026	16-55	18AUG2020	54823	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451030	C4591001 1145 11451030	16-55	21AUG2020	54829	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11451031	C4591001 1145 11451031	16-55	21AUG2020	54831	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451033	C4591001 1145 11451033	16-55	21AUG2020	60881	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451034	C4591001 1145 11451034	16-55	24AUG2020	60884	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451036	C4591001 1145 11451036	16-55	24AUG2020	60891	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451037	C4591001 1145 11451037	16-55	24AUG2020	60892	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
11451039	C4591001 1145 11451039	16-55	24AUG2020	64087	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11451042	C4591001 1145 11451042	16-55	25AUG2020	64092	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451043	C4591001 1145 11451043	16-55	25AUG2020	64093	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451044	C4591001 1145 11451044	16-55	25AUG2020	64094	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451051	C4591001 1145 11451051	16-55	26AUG2020	68262	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11451053	C4591001 1145 11451053	16-55	27AUG2020	68265	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11451054	C4591001 1145 11451054	16-55	27AUG2020	68267	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451057	C4591001 1145 11451057	16-55	28AUG2020	68269	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451059	C4591001 1145 11451059	16-55	28AUG2020	72415	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451060	C4591001 1145 11451060	16-55	28AUG2020	72414	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11451063	C4591001 1145 11451063	16-55	31AUG2020	72416	Placebo	31AUG2020/ Placebo	24NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451064	C4591001 1145 11451064	16-55	02SEP2020	72418	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11451067	C4591001 1145 11451067	16-55	03SEP2020	80084	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451068	C4591001 1145 11451068	16-55	03SEP2020	80088	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451071	C4591001 1145 11451071	16-55	04SEP2020	80090	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451074	C4591001 1145 11451074	16-55	04SEP2020	81713	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451075	C4591001 1145 11451075	16-55	04SEP2020	80091	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451077	C4591001 1145 11451077	16-55	04SEP2020	81720	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11451079	C4591001 1145 11451079	16-55	04SEP2020	81723	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11451080	C4591001 1145 11451080	16-55	08SEP2020	81724	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11451081	C4591001 1145 11451081	16-55	09SEP2020	85025	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451082	C4591001 1145 11451082	16-55	09SEP2020	85033	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451085	C4591001 1145 11451085	16-55	09SEP2020	85034	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11451086	C4591001 1145 11451086	16-55	09SEP2020	85036	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451087	C4591001 1145 11451087	16-55	09SEP2020	85532	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11451088	C4591001 1145 11451088	16-55	09SEP2020	85534	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451090	C4591001 1145 11451090	16-55	10SEP2020	85540	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451091	C4591001 1145 11451091	16-55	10SEP2020	85537	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451093	C4591001 1145 11451093	16-55	10SEP2020	86802	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11451094	C4591001 1145 11451094	16-55	10SEP2020	86804	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11451097	C4591001 1145 11451097	16-55	10SEP2020	86807	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11451101	C4591001 1145 11451101	16-55	11SEP2020	86811	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11451103	C4591001 1145 11451103	16-55	11SEP2020	88582	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11451104	C4591001 1145 11451104	16-55	11SEP2020	88585	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11451106	C4591001 1145 11451106	16-55	18SEP2020	88588	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451107	C4591001 1145 11451107	16-55	18SEP2020	88586	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11451108	C4591001 1145 11451108	16-55	13OCT2020	106988	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11451110	C4591001 1145 11451110	16-55	15OCT2020	106989	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11451112	C4591001 1145 11451112	16-55	22OCT2020	106990	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11451115	C4591001 1145 11451115	16-55	28OCT2020	106992	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461028	C4591001 1146 11461028	16-55	17AUG2020	49932	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461030	C4591001 1146 11461030	16-55	17AUG2020	49935	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461031	C4591001 1146 11461031	16-55	17AUG2020	52325	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461033	C4591001 1146 11461033	16-55	17AUG2020	52327	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461034	C4591001 1146 11461034	16-55	17AUG2020	52328	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461038	C4591001 1146 11461038	16-55	17AUG2020	52330	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461041	C4591001 1146 11461041	16-55	18AUG2020	53789	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461043	C4591001 1146 11461043	16-55	18AUG2020	53793	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461044	C4591001 1146 11461044	16-55	18AUG2020	53794	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461046	C4591001 1146 11461046	16-55	18AUG2020	53800	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461049	C4591001 1146 11461049	16-55	18AUG2020	54762	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461050	C4591001 1146 11461050	16-55	19AUG2020	54766	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461052	C4591001 1146 11461052	16-55	19AUG2020	54767	Placebo	19AUG2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461053	C4591001 1146 11461053	16-55	19AUG2020	54771	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461054	C4591001 1146 11461054	16-55	19AUG2020	55950	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461055	C4591001 1146 11461055	16-55	19AUG2020	55952	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11461056	C4591001 1146 11461056	16-55	19AUG2020	55953	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461058	C4591001 1146 11461058	16-55	19AUG2020	55956	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461059	C4591001 1146 11461059	16-55	19AUG2020	56429	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461061	C4591001 1146 11461061	16-55	19AUG2020	56430	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461063	C4591001 1146 11461063	16-55	19AUG2020	56433	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11461069	C4591001 1146 11461069	16-55	20AUG2020	56436	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461070	C4591001 1146 11461070	16-55	20AUG2020	58006	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461071	C4591001 1146 11461071	16-55	20AUG2020	58007	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461075	C4591001 1146 11461075	16-55	20AUG2020	58012	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461076	C4591001 1146 11461076	16-55	20AUG2020	58011	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461077	C4591001 1146 11461077	16-55	20AUG2020	58745	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11461078	C4591001 1146 11461078	16-55	20AUG2020	58748	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11461080	C4591001 1146 11461080	16-55	20AUG2020	58751	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461081	C4591001 1146 11461081	16-55	20AUG2020	58756	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461082	C4591001 1146 11461082	16-55	21AUG2020	59899	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461083	C4591001 1146 11461083	16-55	21AUG2020	59900	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11461084	C4591001 1146 11461084	16-55	21AUG2020	59907	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11461085	C4591001 1146 11461085	16-55	21AUG2020	59903	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461086	C4591001 1146 11461086	16-55	21AUG2020	60090	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461090	C4591001 1146 11461090	16-55	21AUG2020	60093	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461091	C4591001 1146 11461091	16-55	21AUG2020	60098	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461092	C4591001 1146 11461092	16-55	21AUG2020	60100	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461093	C4591001 1146 11461093	16-55	21AUG2020	60605	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461094	C4591001 1146 11461094	16-55	21AUG2020	60607	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461096	C4591001 1146 11461096	16-55	21AUG2020	60612	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11461097	C4591001 1146 11461097	16-55	21AUG2020	60613	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11461098	C4591001 1146 11461098	16-55	21AUG2020	60849	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11461100	C4591001 1146 11461100	16-55	24AUG2020	60850	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461102	C4591001 1146 11461102	16-55	24AUG2020	60852	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	
11461103	C4591001 1146 11461103	16-55	24AUG2020	60854	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461104	C4591001 1146 11461104	16-55	24AUG2020	63476	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461108	C4591001 1146 11461108	16-55	25AUG2020	63478	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461110	C4591001 1146 11461110	16-55	25AUG2020	63482	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11461111	C4591001 1146 11461111	16-55	26AUG2020	63483	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461112	C4591001 1146 11461112	16-55	26AUG2020	67194	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11461113	C4591001 1146 11461113	16-55	26AUG2020	67193	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461116	C4591001 1146 11461116	16-55	26AUG2020	67199	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461117	C4591001 1146 11461117	16-55	26AUG2020	67200	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461118	C4591001 1146 11461118	16-55	26AUG2020	67757	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461119	C4591001 1146 11461119	16-55	26AUG2020	67759	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461122	C4591001 1146 11461122	16-55	26AUG2020	67766	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11461123	C4591001 1146 11461123	16-55	26AUG2020	67768	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11461124	C4591001 1146 11461124	16-55	27AUG2020	69398	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461125	C4591001 1146 11461125	16-55	27AUG2020	69392	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461126	C4591001 1146 11461126	16-55	27AUG2020	69395	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11461129	C4591001 1146 11461129	16-55	27AUG2020	69703	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11461130	C4591001 1146 11461130	16-55	27AUG2020	69399	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11461133	C4591001 1146 11461133	16-55	27AUG2020	69706	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461140	C4591001 1146 11461140	16-55	27AUG2020	69710	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11461141	C4591001 1146 11461141	16-55	28AUG2020	71494	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11461142	C4591001 1146 11461142	16-55	28AUG2020	71495	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11461144	C4591001 1146 11461144	16-55	28AUG2020	71496	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11461145	C4591001 1146 11461145	16-55	28AUG2020	71681	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11461146	C4591001 1146 11461146	16-55	28AUG2020	71497	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461147	C4591001 1146 11461147	16-55	28AUG2020	71684	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11461150	C4591001 1146 11461150	16-55	28AUG2020	71689	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461155	C4591001 1146 11461155	16-55	28AUG2020	72500	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11461157	C4591001 1146 11461157	16-55	28AUG2020	71692	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461158	C4591001 1146 11461158	16-55	31AUG2020	72501	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461159	C4591001 1146 11461159	16-55	31AUG2020	72507	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461160	C4591001 1146 11461160	16-55	31AUG2020	72504	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461163	C4591001 1146 11461163	16-55	31AUG2020	74803	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11461166	C4591001 1146 11461166	16-55	31AUG2020	74804	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461167	C4591001 1146 11461167	16-55	31AUG2020	74805	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461168	C4591001 1146 11461168	16-55	01SEP2020	74811	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11461170	C4591001 1146 11461170	16-55	01SEP2020	76289	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461172	C4591001 1146 11461172	16-55	01SEP2020	76290	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11461176	C4591001 1146 11461176	16-55	01SEP2020	76299	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461177	C4591001 1146 11461177	16-55	01SEP2020	76298	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461179	C4591001 1146 11461179	16-55	01SEP2020	76925	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461183	C4591001 1146 11461183	16-55	02SEP2020	76927	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461184	C4591001 1146 11461184	16-55	02SEP2020	76935	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461185	C4591001 1146 11461185	16-55	02SEP2020	76936	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461186	C4591001 1146 11461186	16-55	02SEP2020	77949	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461187	C4591001 1146 11461187	16-55	02SEP2020	77951	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11461190	C4591001 1146 11461190	16-55	02SEP2020	77952	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461192	C4591001 1146 11461192	16-55	02SEP2020	77954	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11461193	C4591001 1146 11461193	16-55	02SEP2020	78584	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461195	C4591001 1146 11461195	16-55	03SEP2020	78587	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11461196	C4591001 1146 11461196	16-55	03SEP2020	78589	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11461197	C4591001 1146 11461197	16-55	03SEP2020	78592	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11461198	C4591001 1146 11461198	16-55	03SEP2020	79520	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11461199	C4591001 1146 11461199	16-55	03SEP2020	79517	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461200	C4591001 1146 11461200	16-55	03SEP2020	79525	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461201	C4591001 1146 11461201	16-55	03SEP2020	79528	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461202	C4591001 1146 11461202	16-55	03SEP2020	79829	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11461204	C4591001 1146 11461204	16-55	03SEP2020	79832	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461205	C4591001 1146 11461205	16-55	03SEP2020	79838	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461206	C4591001 1146 11461206	16-55	03SEP2020	79836	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461207	C4591001 1146 11461207	16-55	03SEP2020	80275	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461210	C4591001 1146 11461210	16-55	04SEP2020	80282	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461211	C4591001 1146 11461211	16-55	04SEP2020	80283	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461212	C4591001 1146 11461212	16-55	04SEP2020	80284	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11461216	C4591001 1146 11461216	16-55	04SEP2020	81330	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461218	C4591001 1146 11461218	16-55	04SEP2020	81333	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461219	C4591001 1146 11461219	16-55	04SEP2020	81335	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461220	C4591001 1146 11461220	16-55	04SEP2020	81340	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11461221	C4591001 1146 11461221	16-55	04SEP2020	81521	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461225	C4591001 1146 11461225	16-55	04SEP2020	81522	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11461227	C4591001 1146 11461227	16-55	04SEP2020	81529	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461229	C4591001 1146 11461229	16-55	11SEP2020	81531	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461234	C4591001 1146 11461234	16-55	14SEP2020	89586	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11461236	C4591001 1146 11461236	16-55	14SEP2020	89587	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461237	C4591001 1146 11461237	16-55	15SEP2020	89594	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11461238	C4591001 1146 11461238	16-55	15SEP2020	89596	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11461239	C4591001 1146 11461239	16-55	15SEP2020	90139	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11461240	C4591001 1146 11461240	16-55	15SEP2020	90143	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
11461241	C4591001 1146 11461241	16-55	15SEP2020	90147	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461243	C4591001 1146 11461243	16-55	15SEP2020	90148	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461245	C4591001 1146 11461245	16-55	15SEP2020	90584	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11461246	C4591001 1146 11461246†	16-55	16SEP2020	90585	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461248	C4591001 1146 11461248	16-55	16SEP2020	90588	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11461249	C4591001 1146 11461249	16-55	17SEP2020	90589	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11461250	C4591001 1146 11461250	16-55	17SEP2020	92172	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11461251	C4591001 1146 11461251	16-55	17SEP2020	92173	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11461255	C4591001 1146 11461255	16-55	18SEP2020	92175	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11461258	C4591001 1146 11461258	16-55	18SEP2020	92176	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11461263	C4591001 1146 11461263	16-55	25SEP2020	99935	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461265	C4591001 1146 11461265	16-55	25SEP2020	99933	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11461267	C4591001 1146 11461267	16-55	19OCT2020	400002	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461268	C4591001 1146 11461268	16-55	19OCT2020	400004	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11461269	C4591001 1146 11461269	16-55	19OCT2020	400003	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11461270	C4591001 1146 11461270	16-55	19OCT2020	400006	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461271	C4591001 1146 11461271	16-55	19OCT2020	400015	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461272	C4591001 1146 11461272	16-55	19OCT2020	400017	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461273	C4591001 1146 11461273	16-55	19OCT2020	400022	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11461274	C4591001 1146 11461274	16-55	19OCT2020	400023	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461275	C4591001 1146 11461275	16-55	19OCT2020	400026	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461276	C4591001 1146 11461276	16-55	19OCT2020	400030	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11461277	C4591001 1146 11461277	16-55	19OCT2020	400032	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461278	C4591001 1146 11461278	16-55	19OCT2020	400033	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461279	C4591001 1146 11461279	16-55	20OCT2020	400038	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461280	C4591001 1146 11461280	16-55	20OCT2020	400040	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461281	C4591001 1146 11461281	16-55	20OCT2020	400046	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11461282	C4591001 1146 11461282	16-55	20OCT2020	400044	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461283	C4591001 1146 11461283	16-55	20OCT2020	400065	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461284	C4591001 1146 11461284	16-55	20OCT2020	400064	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461285	C4591001 1146 11461285	16-55	20OCT2020	400066	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461286	C4591001 1146 11461286	16-55	20OCT2020	400085	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461287	C4591001 1146 11461287	16-55	20OCT2020	400069	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461288	C4591001 1146 11461288	16-55	20OCT2020	400086	Placebo	20OCT2020/ Placebo	19NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461289	C4591001 1146 11461289	16-55	20OCT2020	400091	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461290	C4591001 1146 11461290	16-55	20OCT2020	400094	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461291	C4591001 1146 11461291	16-55	20OCT2020	400121	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11461292	C4591001 1146 11461292	16-55	20OCT2020	400128	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461293	C4591001 1146 11461293	16-55	20OCT2020	400127	Placebo	20OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461294	C4591001 1146 11461294	16-55	21OCT2020	400131	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461295	C4591001 1146 11461295	16-55	21OCT2020	400145	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461296	C4591001 1146 11461296	16-55	21OCT2020	400150	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461297	C4591001 1146 11461297	16-55	21OCT2020	400152	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11461298	C4591001 1146 11461298	16-55	21OCT2020	400153	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461299	C4591001 1146 11461299	16-55	21OCT2020	400169	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461300	C4591001 1146 11461300	16-55	21OCT2020	400179	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461301	C4591001 1146 11461301	16-55	21OCT2020	400174	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11461302	C4591001 1146 11461302	16-55	21OCT2020	400180	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11461303	C4591001 1146 11461303	16-55	21OCT2020	400234	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11461304	C4591001 1146 11461304	16-55	21OCT2020	400237	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461305	C4591001 1146 11461305	16-55	21OCT2020	400235	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461306	C4591001 1146 11461306	16-55	21OCT2020	400240	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11461307	C4591001 1146 11461307	16-55	21OCT2020	400279	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461308	C4591001 1146 11461308	16-55	22OCT2020	400281	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461309	C4591001 1146 11461309	16-55	22OCT2020	400283	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11461310	C4591001 1146 11461310	16-55	22OCT2020	400282	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461311	C4591001 1146 11461311	16-55	22OCT2020	400339	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11461312	C4591001 1146 11461312	16-55	22OCT2020	400344	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11461313	C4591001 1146 11461313	16-55	22OCT2020	400345	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461314	C4591001 1146 11461314	16-55	22OCT2020	400348	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11461315	C4591001 1146 11461315	16-55	22OCT2020	400362	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461316	C4591001 1146 11461316	16-55	22OCT2020	400363	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461317	C4591001 1146 11461317	16-55	22OCT2020	400372	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461318	C4591001 1146 11461318	16-55	22OCT2020	400369	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461319	C4591001 1146 11461319	16-55	22OCT2020	400399	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461320	C4591001 1146 11461320	16-55	22OCT2020	400401	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461321	C4591001 1146 11461321	16-55	22OCT2020	400403	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11461322	C4591001 1146 11461322	16-55	22OCT2020	400406	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
11461323	C4591001 1146 11461323	16-55	22OCT2020	400445	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461324	C4591001 1146 11461324	16-55	22OCT2020	400446	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461325	C4591001 1146 11461325	16-55	23OCT2020	400449	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461326	C4591001 1146 11461326	16-55	23OCT2020	400455	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461327	C4591001 1146 11461327	16-55	23OCT2020	400469	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461328	C4591001 1146 11461328	16-55	23OCT2020	400475	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461329	C4591001 1146 11461329	16-55	23OCT2020	400471	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461331	C4591001 1146 11461331	16-55	23OCT2020	400480	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461332	C4591001 1146 11461332	16-55	23OCT2020	400517	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11461333	C4591001 1146 11461333	16-55	23OCT2020	400518	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461334	C4591001 1146 11461334	16-55	23OCT2020	400521	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461335	C4591001 1146 11461335	16-55	23OCT2020	400523	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11461336	C4591001 1146 11461336	16-55	23OCT2020	400627	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461337	C4591001 1146 11461337	16-55	23OCT2020	400628	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11461338	C4591001 1146 11461338	16-55	23OCT2020	400630	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461339	C4591001 1146 11461339	16-55	26OCT2020	400634	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461340	C4591001 1146 11461340	16-55	26OCT2020	400771	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11461341	C4591001 1146 11461341	16-55	26OCT2020	400773	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461342	C4591001 1146 11461342	16-55	26OCT2020	400774	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11461343	C4591001 1146 11461343	16-55	26OCT2020	400777	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461344	C4591001 1146 11461344	16-55	26OCT2020	400806	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461345	C4591001 1146 11461345	16-55	26OCT2020	400807	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461346	C4591001 1146 11461346	16-55	26OCT2020	400808	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461347	C4591001 1146 11461347	16-55	26OCT2020	400812	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11461348	C4591001 1146 11461348	16-55	26OCT2020	400913	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461349	C4591001 1146 11461349	16-55	26OCT2020	400914	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11461350	C4591001 1146 11461350	16-55	26OCT2020	400916	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461351	C4591001 1146 11461351	16-55	26OCT2020	400922	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461352	C4591001 1146 11461352	16-55	26OCT2020	400942	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11461353	C4591001 1146 11461353	16-55	26OCT2020	400944	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11461354	C4591001 1146 11461354	16-55	26OCT2020	400946	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461355	C4591001 1146 11461355	16-55	27OCT2020	400947	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461356	C4591001 1146 11461356	16-55	27OCT2020	401045	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461357	C4591001 1146 11461357	16-55	27OCT2020	401050	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461358	C4591001 1146 11461358	16-55	27OCT2020	401054	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11461359	C4591001 1146 11461359	16-55	27OCT2020	401055	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461360	C4591001 1146 11461360	16-55	27OCT2020	401057	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461361	C4591001 1146 11461361	16-55	27OCT2020	401061	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461363	C4591001 1146 11461363	16-55	27OCT2020	401062	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461364	C4591001 1146 11461364	16-55	27OCT2020	401118	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461365	C4591001 1146 11461365	16-55	27OCT2020	401068	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461366	C4591001 1146 11461366	16-55	28OCT2020	401119	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11461367	C4591001 1146 11461367	16-55	28OCT2020	401121	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461368	C4591001 1146 11461368	16-55	28OCT2020	401124	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461369	C4591001 1146 11461369	16-55	28OCT2020	401165	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461370	C4591001 1146 11461370	16-55	28OCT2020	401168	Placebo	28OCT2020/ Placebo	19NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461371	C4591001 1146 11461371	16-55	28OCT2020	401166	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461372	C4591001 1146 11461372	16-55	28OCT2020	401178	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11461373	C4591001 1146 11461373	16-55	28OCT2020	401174	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11461374	C4591001 1146 11461374	16-55	28OCT2020	401180	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461375	C4591001 1146 11461375	16-55	29OCT2020	401183	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11461376	C4591001 1146 11461376	16-55	29OCT2020	401218	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11461377	C4591001 1146 11461377	16-55	29OCT2020	401188	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461378	C4591001 1146 11461378	16-55	29OCT2020	401219	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461379	C4591001 1146 11461379	16-55	29OCT2020	401221	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11461380	C4591001 1146 11461380	16-55	29OCT2020	401224	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
11461381	C4591001 1146 11461381	16-55	29OCT2020	401226	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461382	C4591001 1146 11461382	16-55	29OCT2020	401232	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461384	C4591001 1146 11461384	16-55	29OCT2020	401231	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11461385	C4591001 1146 11461385	16-55	29OCT2020	401234	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11461386	C4591001 1146 11461386	16-55	29OCT2020	401323	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461387	C4591001 1146 11461387	16-55	29OCT2020	401325	Placebo	29OCT2020/ Placebo	20NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11461388	C4591001 1146 11461388	16-55	29OCT2020	401332	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11461389	C4591001 1146 11461389	16-55	29OCT2020	401331	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11461390	C4591001 1146 11461390	16-55	29OCT2020	401351	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461391	C4591001 1146 11461391	16-55	29OCT2020	401353	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11461393	C4591001 1146 11461393	16-55	29OCT2020	401355	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11461394	C4591001 1146 11461394	16-55	29OCT2020	401356	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11461395	C4591001 1146 11461395	16-55	29OCT2020	401393	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11461397	C4591001 1146 11461397	16-55	29OCT2020	401404	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11461398	C4591001 1146 11461398	16-55	29OCT2020	401397	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11461399	C4591001 1146 11461399	16-55	29OCT2020	401403	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11471112	C4591001 1147 11471112	16-55	24AUG2020	61112	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471136	C4591001 1147 11471136	16-55	14AUG2020	50838	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11471140	C4591001 1147 11471140	16-55	17AUG2020	50839	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11471142	C4591001 1147 11471142	16-55	18AUG2020	50842	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471144	C4591001 1147 11471144	16-55	19AUG2020	50847	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471145	C4591001 1147 11471145	16-55	19AUG2020	56122	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
11471147	C4591001 1147 11471147	16-55	19AUG2020	56123	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11471149	C4591001 1147 11471149	16-55	19AUG2020	56124	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471150	C4591001 1147 11471150	16-55	19AUG2020	56125	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11471151	C4591001 1147 11471151	16-55	19AUG2020	57043	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471152	C4591001 1147 11471152	16-55	19AUG2020	57046	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471153	C4591001 1147 11471153	16-55	19AUG2020	57047	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471160	C4591001 1147 11471160	16-55	20AUG2020	57051	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471163	C4591001 1147 11471163	16-55	20AUG2020	58964	Placebo	20AUG2020/ Placebo	17SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11471164	C4591001 1147 11471164	16-55	20AUG2020	58967	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11471165	C4591001 1147 11471165	16-55	20AUG2020	58971	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471166	C4591001 1147 11471166	16-55	20AUG2020	58972	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471168	C4591001 1147 11471168	16-55	20AUG2020	59813	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471171	C4591001 1147 11471171	16-55	21AUG2020	59815	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11471173	C4591001 1147 11471173	16-55	21AUG2020	59817	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471174	C4591001 1147 11471174	16-55	21AUG2020	59823	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471176	C4591001 1147 11471176	16-55	21AUG2020	61110	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471180	C4591001 1147 11471180	16-55	24AUG2020	61116	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11471182	C4591001 1147 11471182	16-55	24AUG2020	61120	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471183	C4591001 1147 11471183	16-55	24AUG2020	64326	Placebo	24AUG2020/ Placebo	18SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471184	C4591001 1147 11471184	16-55	24AUG2020	64331	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11471186	C4591001 1147 11471186	16-55	25AUG2020	64334	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11471188	C4591001 1147 11471188	16-55	25AUG2020	64336	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11471189	C4591001 1147 11471189	16-55	25AUG2020	66463	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11471191	C4591001 1147 11471191	16-55	26AUG2020	66466	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11471194	C4591001 1147 11471194	16-55	27AUG2020	66469	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471195	C4591001 1147 11471195	16-55	27AUG2020	66472	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11471197	C4591001 1147 11471197	16-55	28AUG2020	72030	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11471201	C4591001 1147 11471201	16-55	28AUG2020	72034	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11471202	C4591001 1147 11471202	16-55	28AUG2020	72039	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471203	C4591001 1147 11471203	16-55	31AUG2020	72040	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11471204	C4591001 1147 11471204	16-55	31AUG2020	75641	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11471206	C4591001 1147 11471206	16-55	31AUG2020	75643	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471207	C4591001 1147 11471207	16-55	31AUG2020	75649	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11471209	C4591001 1147 11471209	16-55	01SEP2020	75650	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471210	C4591001 1147 11471210	16-55	02SEP2020	78437	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471211	C4591001 1147 11471211	16-55	02SEP2020	78438	Placebo	02SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11471212	C4591001 1147 11471212	16-55	03SEP2020	78442	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
11471213	C4591001 1147 11471213	16-55	03SEP2020	78443	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471216	C4591001 1147 11471216	16-55	03SEP2020	80453	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471217	C4591001 1147 11471217	16-55	03SEP2020	80456	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471219	C4591001 1147 11471219	16-55	03SEP2020	80458	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11471220	C4591001 1147 11471220	16-55	03SEP2020	80464	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11471222	C4591001 1147 11471222	16-55	04SEP2020	81886	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471223	C4591001 1147 11471223	16-55	04SEP2020	81887	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11471225	C4591001 1147 11471225	16-55	09SEP2020	81888	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471226	C4591001 1147 11471226	16-55	09SEP2020	81889	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11471227	C4591001 1147 11471227	16-55	09SEP2020	85388	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11471231	C4591001 1147 11471231	16-55	09SEP2020	85389	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11471234	C4591001 1147 11471234	16-55	10SEP2020	85392	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11471235	C4591001 1147 11471235	16-55	10SEP2020	86648	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11471236	C4591001 1147 11471236	16-55	10SEP2020	86645	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11471237	C4591001 1147 11471237	16-55	10SEP2020	85395	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11471243	C4591001 1147 11471243	16-55	10SEP2020	86649	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11471245	C4591001 1147 11471245	16-55	11SEP2020	86651	Placebo	11SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11471246	C4591001 1147 11471246	16-55	11SEP2020	88244	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471252	C4591001 1147 11471252	16-55	11SEP2020	88249	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11471253	C4591001 1147 11471253	16-55	11SEP2020	88251	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11471254	C4591001 1147 11471254	16-55	11SEP2020	88252	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11471255	C4591001 1147 11471255	16-55	14NOV2020	116261	BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)	05DEC2020/ BNT162b2 (30 µg)		
11471256	C4591001 1147 11471256	16-55	14NOV2020	116263	Placebo	14NOV2020/ Placebo	05DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471257	C4591001 1147 11471257	16-55	21NOV2020	116269	BNT162b2 (30 µg)	21NOV2020/ BNT162b2 (30 µg)	12DEC2020/ BNT162b2 (30 µg)		
11471258	C4591001 1147 11471258	16-55	21NOV2020	116271	Placebo	21NOV2020/ Placebo	12DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471259	C4591001 1147 11471259	16-55	21NOV2020	116650	BNT162b2 (30 µg)	21NOV2020/ BNT162b2 (30 µg)	12DEC2020/ BNT162b2 (30 µg)		
11471260	C4591001 1147 11471260	16-55	21NOV2020	116653	BNT162b2 (30 µg)	21NOV2020/ BNT162b2 (30 µg)	12DEC2020/ BNT162b2 (30 µg)		
11471265	C4591001 1147 11471265	16-55	05DEC2020	116654	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11471266	C4591001 1147 11471266	16-55	05DEC2020	116656	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471267	C4591001 1147 11471267	16-55	05DEC2020	117642	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471272	C4591001 1147 11471272	16-55	05DEC2020	117644	Placebo	05DEC2020/ Placebo	28DEC2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11471276	C4591001 1147 11471276	16-55	05DEC2020	117646	BNT162b2 (30 µg)	05DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11491073	C4591001 1149 11491073	16-55	17AUG2020	53237	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491074	C4591001 1149 11491074	16-55	17AUG2020	53243	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491075	C4591001 1149 11491075	16-55	17AUG2020	53246	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11491076	C4591001 1149 11491076	16-55	17AUG2020	53247	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11491077	C4591001 1149 11491077	16-55	17AUG2020	53381	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491079	C4591001 1149 11491079	16-55	17AUG2020	53383	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491083	C4591001 1149 11491083	16-55	18AUG2020	53386	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491084	C4591001 1149 11491084	16-55	18AUG2020	53392	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11491085	C4591001 1149 11491085	16-55	18AUG2020	55025	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11491086	C4591001 1149 11491086	16-55	18AUG2020	55028	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11491087	C4591001 1149 11491087	16-55	18AUG2020	55034	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11491088	C4591001 1149 11491088	16-55	18AUG2020	55035	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11491089	C4591001 1149 11491089	16-55	19AUG2020	57079	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11491092	C4591001 1149 11491092	16-55	19AUG2020	57088	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11491093	C4591001 1149 11491093	16-55	19AUG2020	57086	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11491096	C4591001 1149 11491096	16-55	19AUG2020	57326	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491097	C4591001 1149 11491097	16-55	19AUG2020	57327	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491098	C4591001 1149 11491098	16-55	19AUG2020	57319	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11491099	C4591001 1149 11491099	16-55	20AUG2020	57328	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
11491108	C4591001 1149 11491108	16-55	20AUG2020	59790	Placebo				
11491109	C4591001 1149 11491109	16-55	20AUG2020	59192	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11491110	C4591001 1149 11491110	16-55	20AUG2020	59194	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11491114	C4591001 1149 11491114	16-55	20AUG2020	59189	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491115	C4591001 1149 11491115	16-55	20AUG2020	59132	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11491116	C4591001 1149 11491116	16-55	20AUG2020	59195	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11491119	C4591001 1149 11491119	16-55	21AUG2020	59791	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491120	C4591001 1149 11491120	16-55	21AUG2020	59795	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11491121	C4591001 1149 11491121	16-55	21AUG2020	59796	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11491125	C4591001 1149 11491125	16-55	21AUG2020	61121	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491128	C4591001 1149 11491128	16-55	24AUG2020	61129	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11491129	C4591001 1149 11491129	16-55	24AUG2020	61122	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11491133	C4591001 1149 11491133	16-55	24AUG2020	61131	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11491136	C4591001 1149 11491136	16-55	25AUG2020	66355	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11491137	C4591001 1149 11491137	16-55	25AUG2020	66354	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11491140	C4591001 1149 11491140	16-55	25AUG2020	66534	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491141	C4591001 1149 11491141	16-55	25AUG2020	66362	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491142	C4591001 1149 11491142	16-55	25AUG2020	66363	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11491145	C4591001 1149 11491145	16-55	26AUG2020	66537	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491146	C4591001 1149 11491146	16-55	26AUG2020	66538	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11491147	C4591001 1149 11491147	16-55	26AUG2020	66543	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491148	C4591001 1149 11491148	16-55	26AUG2020	68839	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491149	C4591001 1149 11491149	16-55	26AUG2020	68842	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491150	C4591001 1149 11491150	16-55	26AUG2020	68846	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11491151	C4591001 1149 11491151	16-55	26AUG2020	68848	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11491154	C4591001 1149 11491154	16-55	27AUG2020	70745	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491155	C4591001 1149 11491155	16-55	27AUG2020	70746	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491156	C4591001 1149 11491156	16-55	27AUG2020	70747	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491157	C4591001 1149 11491157	16-55	27AUG2020	71227	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491158	C4591001 1149 11491158	16-55	27AUG2020	70753	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11491160	C4591001 1149 11491160	16-55	27AUG2020	71226	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11491162	C4591001 1149 11491162	16-55	27AUG2020	71234	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491163	C4591001 1149 11491163	16-55	27AUG2020	71230	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11491164	C4591001 1149 11491164	16-55	27AUG2020	71346	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11491165	C4591001 1149 11491165	16-55	28AUG2020	71347	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11491166	C4591001 1149 11491166	16-55	28AUG2020	71352	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491169	C4591001 1149 11491169	16-55	28AUG2020	71356	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491170	C4591001 1149 11491170	16-55	28AUG2020	73017	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11491172	C4591001 1149 11491172	16-55	28AUG2020	73020	Placebo	28AUG2020/ Placebo	20NOV2020/ Placebo		
11491173	C4591001 1149 11491173	16-55	28AUG2020	73018	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11491174	C4591001 1149 11491174	16-55	01SEP2020	73021	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491175	C4591001 1149 11491175	16-55	01SEP2020	77261	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11491176	C4591001 1149 11491176	16-55	01SEP2020	77263	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491178	C4591001 1149 11491178	16-55	01SEP2020	77266	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11491179	C4591001 1149 11491179	16-55	01SEP2020	77268	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491180	C4591001 1149 11491180	16-55	01SEP2020	77310	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491181	C4591001 1149 11491181	16-55	01SEP2020	77312	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491182	C4591001 1149 11491182	16-55	01SEP2020	77314	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11491183	C4591001 1149 11491183	16-55	02SEP2020	77317	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491186	C4591001 1149 11491186	16-55	02SEP2020	78871	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11491187	C4591001 1149 11491187	16-55	02SEP2020	78869	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11491188	C4591001 1149 11491188	16-55	02SEP2020	78874	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11491191	C4591001 1149 11491191	16-55	02SEP2020	78875	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11491194	C4591001 1149 11491194	16-55	03SEP2020	80721	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11491197	C4591001 1149 11491197	16-55	03SEP2020	80724	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11491198	C4591001 1149 11491198	16-55	03SEP2020	80725	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11491201	C4591001 1149 11491201	16-55	04SEP2020	80728	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491202	C4591001 1149 11491202	16-55	04SEP2020	82374	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491203	C4591001 1149 11491203	16-55	04SEP2020	82381	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491204	C4591001 1149 11491204	16-55	04SEP2020	82384	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491205	C4591001 1149 11491205	16-55	04SEP2020	82383	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491206	C4591001 1149 11491206	16-55	04SEP2020	82470	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491207	C4591001 1149 11491207	16-55	04SEP2020	82477	Placebo	04SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11491208	C4591001 1149 11491208	16-55	04SEP2020	82480	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
11491209	C4591001 1149 11491209	16-55	04SEP2020	82479	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11491210	C4591001 1149 11491210	16-55	04SEP2020	82507	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11491211	C4591001 1149 11491211	16-55	04SEP2020	82512	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491212	C4591001 1149 11491212	16-55	04SEP2020	82514	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491213	C4591001 1149 11491213	16-55	08SEP2020	82516	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491215	C4591001 1149 11491215	16-55	08SEP2020	84282	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491216	C4591001 1149 11491216	16-55	08SEP2020	84287	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491217	C4591001 1149 11491217	16-55	08SEP2020	84289	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491218	C4591001 1149 11491218	16-55	08SEP2020	84291	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491219	C4591001 1149 11491219	16-55	08SEP2020	84355	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11491220	C4591001 1149 11491220	16-55	08SEP2020	84357	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11491221	C4591001 1149 11491221	16-55	10SEP2020	84359	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11491223	C4591001 1149 11491223	16-55	10SEP2020	84362	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491227	C4591001 1149 11491227	16-55	10SEP2020	87473	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11491228	C4591001 1149 11491228	16-55	11SEP2020	87474	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11491230	C4591001 1149 11491230	16-55	11SEP2020	87475	Placebo	11SEP2020/ Placebo			
11491233	C4591001 1149 11491233	16-55	11SEP2020	87480	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11491234	C4591001 1149 11491234	16-55	11SEP2020	88781	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11491235	C4591001 1149 11491235	16-55	11SEP2020	88785	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11491238	C4591001 1149 11491238	16-55	15SEP2020	88788	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11491241	C4591001 1149 11491241	16-55	15SEP2020	88791	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11491242	C4591001 1149 11491242	16-55	16SEP2020	91558	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11491246	C4591001 1149 11491246	16-55	16SEP2020	91563	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491247	C4591001 1149 11491247	16-55	16SEP2020	91562	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11491248	C4591001 1149 11491248	16-55	17SEP2020	91564	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11491249	C4591001 1149 11491249	16-55	17SEP2020	92766	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11491250	C4591001 1149 11491250	16-55	18SEP2020	92768	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11491252	C4591001 1149 11491252	16-55	18SEP2020	92769	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11491254	C4591001 1149 11491254	16-55	18SEP2020	94010	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11491255	C4591001 1149 11491255	16-55	18SEP2020	92774	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11491256	C4591001 1149 11491256	16-55	18SEP2020	94001	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11491258	C4591001 1149 11491258	16-55	18SEP2020	94006	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11491259	C4591001 1149 11491259	16-55	18SEP2020	94011	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491263	C4591001 1149 11491263	16-55	18SEP2020	94291	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11491266	C4591001 1149 11491266	16-55	21SEP2020	94293	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11491268	C4591001 1149 11491268	16-55	21SEP2020	94297	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491269	C4591001 1149 11491269	16-55	21SEP2020	95456	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11491270	C4591001 1149 11491270	16-55	21SEP2020	94298	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11491271	C4591001 1149 11491271	16-55	21SEP2020	95458	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11491273	C4591001 1149 11491273	16-55	22SEP2020	95463	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11491274	C4591001 1149 11491274	16-55	22SEP2020	95464	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491275	C4591001 1149 11491275	16-55	22SEP2020	96857	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491276	C4591001 1149 11491276	16-55	22SEP2020	96862	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491277	C4591001 1149 11491277	16-55	22SEP2020	96865	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11491280	C4591001 1149 11491280	16-55	22SEP2020	96866	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11491281	C4591001 1149 11491281	16-55	22SEP2020	96907	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11491282	C4591001 1149 11491282	16-55	22SEP2020	96909	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11491284	C4591001 1149 11491284	16-55	23SEP2020	96911	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11491285	C4591001 1149 11491285	16-55	23SEP2020	96914	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11491286	C4591001 1149 11491286	16-55	23SEP2020	98105	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11491289	C4591001 1149 11491289	16-55	23SEP2020	98113	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491290	C4591001 1149 11491290	16-55	23SEP2020	98108	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11491292	C4591001 1149 11491292	16-55	23SEP2020	98115	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491293	C4591001 1149 11491293	16-55	23SEP2020	98265	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11491294	C4591001 1149 11491294	16-55	23SEP2020	98266	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11491295	C4591001 1149 11491295	16-55	23SEP2020	98270	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11491302	C4591001 1149 11491302	16-55	24SEP2020	98911	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491303	C4591001 1149 11491303	16-55	24SEP2020	98999	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11491304	C4591001 1149 11491304	16-55	24SEP2020	98912	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11491305	C4591001 1149 11491305	16-55	24SEP2020	98272	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11491307	C4591001 1149 11491307	16-55	24SEP2020	99000	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
11491308	C4591001 1149 11491308	16-55	24SEP2020	98916	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491310	C4591001 1149 11491310	16-55	24SEP2020	98996	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491311	C4591001 1149 11491311	16-55	24SEP2020	98913	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491314	C4591001 1149 11491314	16-55	24SEP2020	99002	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491315	C4591001 1149 11491315	16-55	24SEP2020	99079	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11491316	C4591001 1149 11491316	16-55	24SEP2020	99081	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11491320	C4591001 1149 11491320	16-55	25SEP2020	99086	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491321	C4591001 1149 11491321	16-55	25SEP2020	100362	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11491322	C4591001 1149 11491322	16-55	25SEP2020	100364	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11491324	C4591001 1149 11491324	16-55	25SEP2020	99085	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11491327	C4591001 1149 11491327	16-55	25SEP2020	100367	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11491328	C4591001 1149 11491328	16-55	19OCT2020	100372	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491329	C4591001 1149 11491329	16-55	19OCT2020	110441	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11491331	C4591001 1149 11491331	16-55	20OCT2020	110446	Placebo	20OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11491332	C4591001 1149 11491332	16-55	20OCT2020	110449	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11491334	C4591001 1149 11491334†	16-55	26OCT2020	113729	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11491335	C4591001 1149 11491335†	16-55	26OCT2020	113731	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11491337	C4591001 1149 11491337†	16-55	26OCT2020	110451	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491339	C4591001 1149 11491339†	16-55	26OCT2020	113733	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11491340	C4591001 1149 11491340	16-55	27OCT2020	113735	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11491341	C4591001 1149 11491341	16-55	27OCT2020	114138	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11491343	C4591001 1149 11491343	16-55	27OCT2020	114139	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11491344	C4591001 1149 11491344†	16-55	27OCT2020	114145	Placebo	27OCT2020/ Placebo			
11501001	C4591001 1150 11501001	16-55	17AUG2020	52855	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501002	C4591001 1150 11501002	16-55	17AUG2020	52856	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501003	C4591001 1150 11501003	16-55	17AUG2020	52857	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501004	C4591001 1150 11501004	16-55	17AUG2020	52858	Placebo	17AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11501005	C4591001 1150 11501005	16-55	18AUG2020	53887	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501006	C4591001 1150 11501006	16-55	18AUG2020	53892	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501007	C4591001 1150 11501007	16-55	18AUG2020	53895	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501008	C4591001 1150 11501008	16-55	18AUG2020	53896	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501009	C4591001 1150 11501009	16-55	18AUG2020	54678	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501010	C4591001 1150 11501010	16-55	18AUG2020	54682	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501011	C4591001 1150 11501011	16-55	18AUG2020	54683	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501012	C4591001 1150 11501012	16-55	19AUG2020	54684	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501013	C4591001 1150 11501013	16-55	19AUG2020	55805	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11501014	C4591001 1150 11501014	16-55	19AUG2020	55807	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501015	C4591001 1150 11501015	16-55	19AUG2020	55809	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501016	C4591001 1150 11501016	16-55	19AUG2020	55811	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11501017	C4591001 1150 11501017	16-55	19AUG2020	56405	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11501018	C4591001 1150 11501018	16-55	19AUG2020	56409	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501019	C4591001 1150 11501019	16-55	19AUG2020	56413	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501020	C4591001 1150 11501020	16-55	19AUG2020	57293	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501021	C4591001 1150 11501021	16-55	19AUG2020	56416	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11501022	C4591001 1150 11501022	16-55	19AUG2020	57299	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11501023	C4591001 1150 11501023	16-55	20AUG2020	57301	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501024	C4591001 1150 11501024	16-55	20AUG2020	57304	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501025	C4591001 1150 11501025	16-55	20AUG2020	58675	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11501026	C4591001 1150 11501026	16-55	20AUG2020	58677	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501027	C4591001 1150 11501027	16-55	20AUG2020	58680	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11501028	C4591001 1150 11501028	16-55	20AUG2020	58681	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11501029	C4591001 1150 11501029	16-55	21AUG2020	60104	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501031	C4591001 1150 11501031	16-55	21AUG2020	60105	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11501032	C4591001 1150 11501032	16-55	24AUG2020	60107	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11501033	C4591001 1150 11501033	16-55	24AUG2020	60112	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11501034	C4591001 1150 11501034	16-55	24AUG2020	63896	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501035	C4591001 1150 11501035	16-55	24AUG2020	63899	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11501036	C4591001 1150 11501036	16-55	24AUG2020	63900	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501037	C4591001 1150 11501037	16-55	24AUG2020	63901	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11501038	C4591001 1150 11501038	16-55	25AUG2020	65165	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11501039	C4591001 1150 11501039	16-55	25AUG2020	65167	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501040	C4591001 1150 11501040	16-55	25AUG2020	65172	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501041	C4591001 1150 11501041	16-55	25AUG2020	65174	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11501043	C4591001 1150 11501043	16-55	25AUG2020	66008	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11501044	C4591001 1150 11501044	16-55	25AUG2020	66009	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501045	C4591001 1150 11501045	16-55	25AUG2020	66011	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501046	C4591001 1150 11501046	16-55	25AUG2020	66012	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501047	C4591001 1150 11501047	16-55	25AUG2020	66763	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11501048	C4591001 1150 11501048	16-55	25AUG2020	66764	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11501049	C4591001 1150 11501049	16-55	25AUG2020	66767	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11501050	C4591001 1150 11501050	16-55	26AUG2020	66768	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11501051	C4591001 1150 11501051	16-55	26AUG2020	67569	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501052	C4591001 1150 11501052	16-55	26AUG2020	67571	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501053	C4591001 1150 11501053	16-55	26AUG2020	67573	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11501054	C4591001 1150 11501054	16-55	26AUG2020	67576	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11501055	C4591001 1150 11501055	16-55	26AUG2020	68469	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501056	C4591001 1150 11501056	16-55	26AUG2020	68470	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501057	C4591001 1150 11501057	16-55	26AUG2020	68472	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11501058	C4591001 1150 11501058	16-55	26AUG2020	68474	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11501059	C4591001 1150 11501059	16-55	26AUG2020	69197	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11501060	C4591001 1150 11501060	16-55	27AUG2020	69199	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11501061	C4591001 1150 11501061	16-55	27AUG2020	69203	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501062	C4591001 1150 11501062	16-55	27AUG2020	69208	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11501063	C4591001 1150 11501063	16-55	27AUG2020	70424	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11501064	C4591001 1150 11501064	16-55	27AUG2020	70428	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11501065	C4591001 1150 11501065	16-55	27AUG2020	70431	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11501067	C4591001 1150 11501067	16-55	27AUG2020	70432	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501068	C4591001 1150 11501068	16-55	27AUG2020	71194	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11501069	C4591001 1150 11501069	16-55	28AUG2020	71195	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11501070	C4591001 1150 11501070	16-55	28AUG2020	71198	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11501071	C4591001 1150 11501071	16-55	28AUG2020	71199	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11501072	C4591001 1150 11501072	16-55	28AUG2020	71887	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501073	C4591001 1150 11501073	16-55	31AUG2020	71888	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11501074	C4591001 1150 11501074	16-55	31AUG2020	71893	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501075	C4591001 1150 11501075	16-55	31AUG2020	71894	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501076	C4591001 1150 11501076	16-55	31AUG2020	75920	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11501077	C4591001 1150 11501077	16-55	01SEP2020	75923	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501078	C4591001 1150 11501078	16-55	01SEP2020	75924	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11501079	C4591001 1150 11501079	16-55	01SEP2020	75928	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501080	C4591001 1150 11501080	16-55	01SEP2020	76976	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11501081	C4591001 1150 11501081	16-55	01SEP2020	76980	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11501082	C4591001 1150 11501082	16-55	01SEP2020	76981	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501083	C4591001 1150 11501083	16-55	01SEP2020	76984	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11501084	C4591001 1150 11501084	16-55	01SEP2020	77669	Placebo	01SEP2020/ Placebo	01OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11501085	C4591001 1150 11501085	16-55	02SEP2020	77670	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501086	C4591001 1150 11501086	16-55	02SEP2020	77675	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11501087	C4591001 1150 11501087	16-55	02SEP2020	77676	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11501088	C4591001 1150 11501088	16-55	02SEP2020	78969	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501089	C4591001 1150 11501089	16-55	02SEP2020	78971	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501090	C4591001 1150 11501090	16-55	02SEP2020	78973	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501091	C4591001 1150 11501091	16-55	02SEP2020	78974	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11501092	C4591001 1150 11501092	16-55	02SEP2020	79436	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501093	C4591001 1150 11501093	16-55	03SEP2020	79438	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11501094	C4591001 1150 11501094	16-55	03SEP2020	79439	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501095	C4591001 1150 11501095	16-55	03SEP2020	79441	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11501096	C4591001 1150 11501096	16-55	03SEP2020	79805	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501097	C4591001 1150 11501097	16-55	03SEP2020	79809	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11501098	C4591001 1150 11501098	16-55	03SEP2020	79810	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11501099	C4591001 1150 11501099	16-55	03SEP2020	79814	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11501100	C4591001 1150 11501100	16-55	03SEP2020	80586	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11501101	C4591001 1150 11501101	16-55	03SEP2020	80587	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11501102	C4591001 1150 11501102	16-55	03SEP2020	80594	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501103	C4591001 1150 11501103	16-55	08SEP2020	80596	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11501104	C4591001 1150 11501104	16-55	08SEP2020	84545	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11501105	C4591001 1150 11501105	16-55	09SEP2020	84549	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11501106	C4591001 1150 11501106	16-55	09SEP2020	84550	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11501107	C4591001 1150 11501107	16-55	10SEP2020	84555	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11501110	C4591001 1150 11501110	16-55	11SEP2020	87845	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11501111	C4591001 1150 11501111	16-55	11SEP2020	87846	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11501112	C4591001 1150 11501112	16-55	11SEP2020	87852	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501113	C4591001 1150 11501113	16-55	11SEP2020	87853	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11501114	C4591001 1150 11501114	16-55	11SEP2020	88485	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501115	C4591001 1150 11501115	16-55	24SEP2020	88486	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11501116	C4591001 1150 11501116	16-55	24SEP2020	88488	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11501117	C4591001 1150 11501117	16-55	25SEP2020	88490	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501122	C4591001 1150 11501122	16-55	15OCT2020	108475	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11501137	C4591001 1150 11501137	16-55	22OCT2020	108477	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11501138	C4591001 1150 11501138	16-55	26OCT2020	108482	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11501139	C4591001 1150 11501139	16-55	27OCT2020	108484	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11501140	C4591001 1150 11501140	16-55	27OCT2020	114081	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11501141	C4591001 1150 11501141	16-55	27OCT2020	114082	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501142	C4591001 1150 11501142	16-55	28OCT2020	114085	Placebo	28OCT2020/ Placebo	24NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501144	C4591001 1150 11501144	16-55	29OCT2020	114087	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11501145	C4591001 1150 11501145	16-55	29OCT2020	114786	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11501146	C4591001 1150 11501146	16-55	05NOV2020	114788	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11501147	C4591001 1150 11501147	16-55	09NOV2020	114791	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
11501148	C4591001 1150 11501148	16-55	11NOV2020	114795	Placebo	11NOV2020/ Placebo	03DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11501149	C4591001 1150 11501149	16-55	12NOV2020	116154	Placebo	12NOV2020/ Placebo	02DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501150	C4591001 1150 11501150	16-55	12NOV2020	116156	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
11501151	C4591001 1150 11501151	16-55	16NOV2020	116160	Placebo	16NOV2020/ Placebo	08DEC2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11501152	C4591001 1150 11501152	16-55	17NOV2020	116164	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11501153	C4591001 1150 11501153	16-55	18NOV2020	116431	Placebo	18NOV2020/ Placebo	11DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501154	C4591001 1150 11501154	16-55	20NOV2020	116432	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11501155	C4591001 1150 11501155	16-55	23NOV2020	116433	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11501156	C4591001 1150 11501156	16-55	23NOV2020	116434	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11501157	C4591001 1150 11501157	16-55	23NOV2020	116733	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
11501158	C4591001 1150 11501158	16-55	23NOV2020	116734	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501159	C4591001 1150 11501159	16-55	23NOV2020	116737	Placebo	23NOV2020/ Placebo	16DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501160	C4591001 1150 11501160	16-55	24NOV2020	116738	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11501161	C4591001 1150 11501161	16-55	24NOV2020	116768	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11501162	C4591001 1150 11501162	16-55	24NOV2020	116769	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11501163	C4591001 1150 11501163	16-55	24NOV2020	116772	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501164	C4591001 1150 11501164	16-55	24NOV2020	116776	Placebo	24NOV2020/ Placebo	16DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501165	C4591001 1150 11501165	16-55	30NOV2020	116995	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11501167	C4591001 1150 11501167	16-55	02DEC2020	116998	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11501169	C4591001 1150 11501169	16-55	02DEC2020	117000	Placebo	02DEC2020/ Placebo	28DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501170	C4591001 1150 11501170	16-55	03DEC2020	117004	Placebo	03DEC2020/ Placebo	24DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11501174	C4591001 1150 11501174	16-55	03DEC2020	117343	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11501175	C4591001 1150 11501175	16-55	03DEC2020	117345	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11501177	C4591001 1150 11501177	16-55	07DEC2020	117346	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11501181	C4591001 1150 11501181	16-55	08DEC2020	117350	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11501184	C4591001 1150 11501184	16-55	08DEC2020	117737	Placebo	08DEC2020/ Placebo	30DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11501188	C4591001 1150 11501188	16-55	09DEC2020	117738	BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
11521084	C4591001 1152 11521084	16-55	19AUG2020	49788	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11521085	C4591001 1152 11521085	16-55	19AUG2020	56371	Placebo	19AUG2020/ Placebo			
11521086	C4591001 1152 11521086	16-55	19AUG2020	56375	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521089	C4591001 1152 11521089	16-55	19AUG2020	56378	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521090	C4591001 1152 11521090	16-55	19AUG2020	56380	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521098	C4591001 1152 11521098	16-55	19AUG2020	57355	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521100	C4591001 1152 11521100	16-55	19AUG2020	57358	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
11521105	C4591001 1152 11521105	16-55	19AUG2020	57363	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521108	C4591001 1152 11521108	16-55	19AUG2020	57364	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521110	C4591001 1152 11521110	16-55	19AUG2020	57716	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11521111	C4591001 1152 11521111	16-55	19AUG2020	57720	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521112	C4591001 1152 11521112	16-55	19AUG2020	57722	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521113	C4591001 1152 11521113	16-55	19AUG2020	57724	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521114	C4591001 1152 11521114	16-55	19AUG2020	57728	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521115	C4591001 1152 11521115	16-55	19AUG2020	57727	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521116	C4591001 1152 11521116	16-55	19AUG2020	57732	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521117	C4591001 1152 11521117	16-55	19AUG2020	57734	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521118	C4591001 1152 11521118	16-55	19AUG2020	57742	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521120	C4591001 1152 11521120	16-55	20AUG2020	57743	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521121	C4591001 1152 11521121	16-55	20AUG2020	57746	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521126	C4591001 1152 11521126	16-55	21AUG2020	57747	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521129	C4591001 1152 11521129	16-55	21AUG2020	60943	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521131	C4591001 1152 11521131	16-55	21AUG2020	60944	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521137	C4591001 1152 11521137	16-55	21AUG2020	60945	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11521138	C4591001 1152 11521138	16-55	21AUG2020	60950	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11521139	C4591001 1152 11521139	16-55	21AUG2020	61530	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
11521140	C4591001 1152 11521140	16-55	21AUG2020	61532	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521142	C4591001 1152 11521142	16-55	21AUG2020	61534	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521143	C4591001 1152 11521143	16-55	21AUG2020	61539	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521144	C4591001 1152 11521144	16-55	21AUG2020	61570	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11521145	C4591001 1152 11521145	16-55	21AUG2020	61569	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521146	C4591001 1152 11521146	16-55	21AUG2020	61572	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11521147	C4591001 1152 11521147	16-55	21AUG2020	61575	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521148	C4591001 1152 11521148	16-55	21AUG2020	61629	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11521149	C4591001 1152 11521149	16-55	21AUG2020	61630	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11521150	C4591001 1152 11521150	16-55	21AUG2020	61631	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521153	C4591001 1152 11521153	16-55	24AUG2020	61632	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
11521154	C4591001 1152 11521154	16-55	24AUG2020	63846	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521156	C4591001 1152 11521156	16-55	24AUG2020	63850	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521157	C4591001 1152 11521157	16-55	24AUG2020	63852	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11521158	C4591001 1152 11521158	16-55	24AUG2020	63851	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521159	C4591001 1152 11521159	16-55	24AUG2020	64157	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521164	C4591001 1152 11521164	16-55	24AUG2020	64158	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521165	C4591001 1152 11521165	16-55	24AUG2020	64160	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521166	C4591001 1152 11521166	16-55	24AUG2020	64857	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo		
11521167	C4591001 1152 11521167	16-55	24AUG2020	64165	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11521168	C4591001 1152 11521168	16-55	24AUG2020	64859	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521169	C4591001 1152 11521169	16-55	24AUG2020	64861	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521173	C4591001 1152 11521173	16-55	24AUG2020	64864	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521176	C4591001 1152 11521176	16-55	24AUG2020	65022	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521177	C4591001 1152 11521177	16-55	24AUG2020	65024	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521180	C4591001 1152 11521180	16-55	24AUG2020	65026	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521182	C4591001 1152 11521182	16-55	24AUG2020	65027	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521183	C4591001 1152 11521183	16-55	24AUG2020	65045	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11521184	C4591001 1152 11521184	16-55	24AUG2020	65047	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521185	C4591001 1152 11521185	16-55	25AUG2020	65049	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521186	C4591001 1152 11521186	16-55	25AUG2020	65054	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11521187	C4591001 1152 11521187	16-55	25AUG2020	66235	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11521188	C4591001 1152 11521188	16-55	25AUG2020	66236	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521189	C4591001 1152 11521189	16-55	25AUG2020	66238	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521192	C4591001 1152 11521192	16-55	25AUG2020	66244	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521195	C4591001 1152 11521195	16-55	25AUG2020	66994	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11521196	C4591001 1152 11521196	16-55	25AUG2020	66992	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11521197	C4591001 1152 11521197	16-55	25AUG2020	66995	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521199	C4591001 1152 11521199	16-55	25AUG2020	66998	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521204	C4591001 1152 11521204	16-55	25AUG2020	67086	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521205	C4591001 1152 11521205	16-55	25AUG2020	67091	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11521206	C4591001 1152 11521206	16-55	26AUG2020	67095	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521207	C4591001 1152 11521207	16-55	26AUG2020	67094	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521208	C4591001 1152 11521208	16-55	26AUG2020	68249	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11521209	C4591001 1152 11521209	16-55	26AUG2020	68253	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
11521211	C4591001 1152 11521211	16-55	26AUG2020	68254	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521212	C4591001 1152 11521212	16-55	26AUG2020	68258	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521213	C4591001 1152 11521213	16-55	26AUG2020	68697	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
11521214	C4591001 1152 11521214	16-55	26AUG2020	68698	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11521215	C4591001 1152 11521215	16-55	26AUG2020	68699	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11521216	C4591001 1152 11521216	16-55	26AUG2020	68703	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521218	C4591001 1152 11521218	16-55	26AUG2020	69294	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11521219	C4591001 1152 11521219	16-55	26AUG2020	69299	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521220	C4591001 1152 11521220	16-55	26AUG2020	69303	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11521221	C4591001 1152 11521221	16-55	26AUG2020	69304	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11521222	C4591001 1152 11521222	16-55	26AUG2020	69330	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521223	C4591001 1152 11521223	16-55	26AUG2020	69334	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521224	C4591001 1152 11521224	16-55	26AUG2020	69337	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521225	C4591001 1152 11521225	16-55	26AUG2020	69339	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11521226	C4591001 1152 11521226	16-55	26AUG2020	69378	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521227	C4591001 1152 11521227	16-55	26AUG2020	69380	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
11521228	C4591001 1152 11521228	16-55	27AUG2020	69381	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521229	C4591001 1152 11521229	16-55	27AUG2020	69387	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521231	C4591001 1152 11521231	16-55	27AUG2020	70677	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11521234	C4591001 1152 11521234	16-55	27AUG2020	70681	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521235	C4591001 1152 11521235	16-55	27AUG2020	70682	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521236	C4591001 1152 11521236	16-55	27AUG2020	70684	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521239	C4591001 1152 11521239	16-55	27AUG2020	71034	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521240	C4591001 1152 11521240	16-55	27AUG2020	71037	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11521248	C4591001 1152 11521248	16-55	27AUG2020	71038	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521249	C4591001 1152 11521249	16-55	27AUG2020	71041	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11521253	C4591001 1152 11521253	16-55	27AUG2020	71443	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521254	C4591001 1152 11521254	16-55	27AUG2020	71444	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521255	C4591001 1152 11521255	16-55	31AUG2020	71447	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11521256	C4591001 1152 11521256	16-55	31AUG2020	71451	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521261	C4591001 1152 11521261	16-55	31AUG2020	75282	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521263	C4591001 1152 11521263	16-55	31AUG2020	75284	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521264	C4591001 1152 11521264	16-55	31AUG2020	75290	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11521269	C4591001 1152 11521269	16-55	31AUG2020	75291	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521270	C4591001 1152 11521270	16-55	31AUG2020	75766	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521271	C4591001 1152 11521271	16-55	31AUG2020	75768	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521274	C4591001 1152 11521274	16-55	31AUG2020	75769	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11521275	C4591001 1152 11521275	16-55	31AUG2020	75770	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521276	C4591001 1152 11521276	16-55	31AUG2020	76098	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521277	C4591001 1152 11521277	16-55	31AUG2020	76099	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11521282	C4591001 1152 11521282	16-55	31AUG2020	76100	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521283	C4591001 1152 11521283	16-55	31AUG2020	76104	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521284	C4591001 1152 11521284	16-55	31AUG2020	76202	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521285	C4591001 1152 11521285	16-55	31AUG2020	76195	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521286	C4591001 1152 11521286	16-55	31AUG2020	76203	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
11521287	C4591001 1152 11521287	16-55	31AUG2020	76204	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521288	C4591001 1152 11521288	16-55	31AUG2020	76220	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521289	C4591001 1152 11521289	16-55	31AUG2020	76223	Placebo	31AUG2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521291	C4591001 1152 11521291	16-55	31AUG2020	76225	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11521295	C4591001 1152 11521295	16-55	31AUG2020	76226	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11521296	C4591001 1152 11521296	16-55	31AUG2020	76265	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11521297	C4591001 1152 11521297	16-55	31AUG2020	76268	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521298	C4591001 1152 11521298	16-55	31AUG2020	76274	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521302	C4591001 1152 11521302	16-55	03SEP2020	76275	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521308	C4591001 1152 11521308	16-55	03SEP2020	80132	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521309	C4591001 1152 11521309	16-55	03SEP2020	80133	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521312	C4591001 1152 11521312	16-55	03SEP2020	80139	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11521316	C4591001 1152 11521316	16-55	03SEP2020	80140	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521318	C4591001 1152 11521318	16-55	03SEP2020	80791	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521319	C4591001 1152 11521319	16-55	03SEP2020	80796	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521322	C4591001 1152 11521322	16-55	03SEP2020	80797	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11521323	C4591001 1152 11521323	16-55	03SEP2020	81083	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521325	C4591001 1152 11521325	16-55	03SEP2020	80799	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521327	C4591001 1152 11521327	16-55	03SEP2020	81086	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521328	C4591001 1152 11521328	16-55	03SEP2020	81084	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11521329	C4591001 1152 11521329	16-55	03SEP2020	81088	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521332	C4591001 1152 11521332	16-55	03SEP2020	81153	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521333	C4591001 1152 11521333	16-55	03SEP2020	81154	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521335	C4591001 1152 11521335	16-55	03SEP2020	81159	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521336	C4591001 1152 11521336	16-55	03SEP2020	81158	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
11521338	C4591001 1152 11521338	16-55	03SEP2020	81188	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521339	C4591001 1152 11521339	16-55	03SEP2020	81185	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11521340	C4591001 1152 11521340	16-55	03SEP2020	81191	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521341	C4591001 1152 11521341	16-55	03SEP2020	81194	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521344	C4591001 1152 11521344	16-55	03SEP2020	81197	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521345	C4591001 1152 11521345	16-55	03SEP2020	81199	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521346	C4591001 1152 11521346	16-55	03SEP2020	81202	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11521347	C4591001 1152 11521347	16-55	03SEP2020	81206	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521348	C4591001 1152 11521348	16-55	03SEP2020	81209	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11521352	C4591001 1152 11521352	16-55	04SEP2020	81218	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11521353	C4591001 1152 11521353	16-55	04SEP2020	81219	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		
11521354	C4591001 1152 11521354	16-55	04SEP2020	81220	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11521355	C4591001 1152 11521355	16-55	04SEP2020	82001	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11521356	C4591001 1152 11521356	16-55	04SEP2020	82007	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11521357	C4591001 1152 11521357	16-55	04SEP2020	82008	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11521361	C4591001 1152 11521361	16-55	08SEP2020	83551	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521362	C4591001 1152 11521362	16-55	08SEP2020	83554	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11521363	C4591001 1152 11521363	16-55	08SEP2020	83558	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11521365	C4591001 1152 11521365	16-55	08SEP2020	83560	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521366	C4591001 1152 11521366	16-55	08SEP2020	83730	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521367	C4591001 1152 11521367	16-55	08SEP2020	83731	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521369	C4591001 1152 11521369	16-55	08SEP2020	83738	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521371	C4591001 1152 11521371	16-55	08SEP2020	83740	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521372	C4591001 1152 11521372	16-55	08SEP2020	83937	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11521373	C4591001 1152 11521373	16-55	08SEP2020	83936	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521374	C4591001 1152 11521374	16-55	08SEP2020	83940	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11521376	C4591001 1152 11521376	16-55	08SEP2020	83943	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521377	C4591001 1152 11521377	16-55	08SEP2020	84150	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521378	C4591001 1152 11521378	16-55	08SEP2020	84151	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521379	C4591001 1152 11521379	16-55	08SEP2020	84155	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521381	C4591001 1152 11521381	16-55	08SEP2020	84158	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521382	C4591001 1152 11521382	16-55	08SEP2020	84451	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521383	C4591001 1152 11521383	16-55	08SEP2020	84449	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11521384	C4591001 1152 11521384	16-55	08SEP2020	84454	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521390	C4591001 1152 11521390	16-55	08SEP2020	84455	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
11521391	C4591001 1152 11521391	16-55	08SEP2020	84653	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521393	C4591001 1152 11521393	16-55	08SEP2020	84656	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521394	C4591001 1152 11521394	16-55	08SEP2020	84661	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521396	C4591001 1152 11521396	16-55	08SEP2020	84663	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521397	C4591001 1152 11521397	16-55	08SEP2020	84703	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521399	C4591001 1152 11521399	16-55	08SEP2020	84704	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521400	C4591001 1152 11521400	16-55	08SEP2020	84705	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521401	C4591001 1152 11521401	16-55	08SEP2020	84709	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521402	C4591001 1152 11521402	16-55	08SEP2020	84722	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521403	C4591001 1152 11521403	16-55	08SEP2020	84715	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521404	C4591001 1152 11521404	16-55	08SEP2020	84724	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521405	C4591001 1152 11521405	16-55	08SEP2020	84723	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521406	C4591001 1152 11521406	16-55	08SEP2020	84725	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521407	C4591001 1152 11521407	16-55	08SEP2020	84733	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521408	C4591001 1152 11521408	16-55	08SEP2020	84734	Placebo	08SEP2020/ Placebo	14OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521409	C4591001 1152 11521409	16-55	08SEP2020	84736	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521410	C4591001 1152 11521410	16-55	08SEP2020	84737	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521412	C4591001 1152 11521412	16-55	09SEP2020	84741	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521413	C4591001 1152 11521413	16-55	09SEP2020	84744	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521414	C4591001 1152 11521414	16-55	09SEP2020	84747	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11521415	C4591001 1152 11521415	16-55	09SEP2020	85255	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521416	C4591001 1152 11521416	16-55	09SEP2020	85256	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521419	C4591001 1152 11521419	16-55	09SEP2020	85258	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521421	C4591001 1152 11521421	16-55	09SEP2020	85263	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521422	C4591001 1152 11521422	16-55	09SEP2020	85578	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521423	C4591001 1152 11521423	16-55	09SEP2020	85584	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521424	C4591001 1152 11521424	16-55	09SEP2020	85586	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521426	C4591001 1152 11521426	16-55	09SEP2020	85587	Placebo	09SEP2020/ Placebo	09OCT2020/ Placebo		
11521427	C4591001 1152 11521427	16-55	09SEP2020	85805	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11521429	C4591001 1152 11521429	16-55	09SEP2020	85806	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11521430	C4591001 1152 11521430	16-55	09SEP2020	85808	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521431	C4591001 1152 11521431	16-55	09SEP2020	85813	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521432	C4591001 1152 11521432	16-55	09SEP2020	86105	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521433	C4591001 1152 11521433	16-55	09SEP2020	86107	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521434	C4591001 1152 11521434	16-55	09SEP2020	86113	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521435	C4591001 1152 11521435	16-55	09SEP2020	86114	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521436	C4591001 1152 11521436	16-55	09SEP2020	86201	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521437	C4591001 1152 11521437	16-55	09SEP2020	86202	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11521439	C4591001 1152 11521439	16-55	09SEP2020	86207	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521440	C4591001 1152 11521440	16-55	09SEP2020	86208	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521441	C4591001 1152 11521441	16-55	09SEP2020	86225	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11521442	C4591001 1152 11521442	16-55	16SEP2020	86226	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521443	C4591001 1152 11521443	16-55	16SEP2020	86231	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521444	C4591001 1152 11521444	16-55	16SEP2020	86234	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11521445	C4591001 1152 11521445	16-55	16SEP2020	91603	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521446	C4591001 1152 11521446	16-55	16SEP2020	91605	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521447	C4591001 1152 11521447	16-55	16SEP2020	91606	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521449	C4591001 1152 11521449	16-55	16SEP2020	91612	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521450	C4591001 1152 11521450	16-55	16SEP2020	91854	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11521451	C4591001 1152 11521451	16-55	16SEP2020	91858	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521452	C4591001 1152 11521452	16-55	16SEP2020	91861	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11521453	C4591001 1152 11521453	16-55	16SEP2020	91862	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11521454	C4591001 1152 11521454	16-55	17SEP2020	93077	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521455	C4591001 1152 11521455	16-55	17SEP2020	93080	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
11521456	C4591001 1152 11521456	16-55	17SEP2020	93082	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521457	C4591001 1152 11521457	16-55	17SEP2020	93087	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521459	C4591001 1152 11521459	16-55	18SEP2020	93847	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521460	C4591001 1152 11521460	16-55	18SEP2020	93848	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11521461	C4591001 1152 11521461	16-55	18SEP2020	93850	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11521462	C4591001 1152 11521462	16-55	18SEP2020	93856	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11521464	C4591001 1152 11521464	16-55	18SEP2020	94040	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521465	C4591001 1152 11521465	16-55	18SEP2020	94042	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11521467	C4591001 1152 11521467	16-55	22SEP2020	94045	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521468	C4591001 1152 11521468	16-55	22SEP2020	94048	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521469	C4591001 1152 11521469	16-55	23SEP2020	98023	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521470	C4591001 1152 11521470	16-55	23SEP2020	98028	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
11521472	C4591001 1152 11521472	16-55	24SEP2020	98029	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
11521474	C4591001 1152 11521474	16-55	24SEP2020	99139	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521475	C4591001 1152 11521475	16-55	24SEP2020	99140	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11521477	C4591001 1152 11521477	16-55	25SEP2020	99147	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11521478	C4591001 1152 11521478	16-55	25SEP2020	99148	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
11521479	C4591001 1152 11521479	16-55	25SEP2020	100098	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11521480	C4591001 1152 11521480	16-55	25SEP2020	100100	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11521481	C4591001 1152 11521481	16-55	25SEP2020	100099	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
11521482	C4591001 1152 11521482	16-55	25SEP2020	100105	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
11521483	C4591001 1152 11521483	16-55	25SEP2020	100542	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521489	C4591001 1152 11521489	16-55	02OCT2020	100546	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
11521490	C4591001 1152 11521490	16-55	02OCT2020	100549	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11521492	C4591001 1152 11521492	16-55	06OCT2020	100551	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11521493	C4591001 1152 11521493	16-55	06OCT2020	104385	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11521496	C4591001 1152 11521496	16-55	07OCT2020	104386	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo		
11521498	C4591001 1152 11521498	16-55	07OCT2020	104387	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11521499	C4591001 1152 11521499	16-55	07OCT2020	104388	Placebo	07OCT2020/ Placebo	06NOV2020/ Placebo		
11521500	C4591001 1152 11521500	16-55	08OCT2020	105522	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11521501	C4591001 1152 11521501	16-55	09OCT2020	105526	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11521504	C4591001 1152 11521504	16-55	09OCT2020	105530	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521505	C4591001 1152 11521505	16-55	09OCT2020	105531	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11521506	C4591001 1152 11521506	16-55	09OCT2020	106207	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11521508	C4591001 1152 11521508	16-55	09OCT2020	106211	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
11521509	C4591001 1152 11521509	16-55	09OCT2020	106213	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11521511	C4591001 1152 11521511	16-55	09OCT2020	106215	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11521512	C4591001 1152 11521512	16-55	12OCT2020	106738	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11521515	C4591001 1152 11521515	16-55	13OCT2020	106739	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11521517	C4591001 1152 11521517	16-55	13OCT2020	106740	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521519	C4591001 1152 11521519	16-55	13OCT2020	106743	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521520	C4591001 1152 11521520	16-55	14OCT2020	107815	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521521	C4591001 1152 11521521	16-55	15OCT2020	107817	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11521522	C4591001 1152 11521522	16-55	15OCT2020	107819	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11521529	C4591001 1152 11521529	16-55	15OCT2020	107824	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521533	C4591001 1152 11521533	16-55	15OCT2020	108594	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11521534	C4591001 1152 11521534	16-55	16OCT2020	108596	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11521537	C4591001 1152 11521537	16-55	16OCT2020	108598	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11521541	C4591001 1152 11521541	16-55	19OCT2020	108601	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11521549	C4591001 1152 11521549	16-55	20OCT2020	111198	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11521551	C4591001 1152 11521551	16-55	21OCT2020	111199	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521552	C4591001 1152 11521552	16-55	21OCT2020	111200	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521557	C4591001 1152 11521557	16-55	22OCT2020	111207	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11521560	C4591001 1152 11521560	16-55	22OCT2020	112589	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11521566	C4591001 1152 11521566	16-55	26OCT2020	112595	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11521568	C4591001 1152 11521568	16-55	26OCT2020	112598	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11521569	C4591001 1152 11521569	16-55	26OCT2020	112599	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11521570	C4591001 1152 11521570	16-55	26OCT2020	113790	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521571	C4591001 1152 11521571	16-55	26OCT2020	113794	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11521575	C4591001 1152 11521575	16-55	28OCT2020	113795	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11521577	C4591001 1152 11521577	16-55	29OCT2020	113798	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11521583	C4591001 1152 11521583	16-55	30OCT2020	115063	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521584	C4591001 1152 11521584	16-55	30OCT2020	115065	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11521587	C4591001 1152 11521587	16-55	16NOV2020	115067	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521588	C4591001 1152 11521588	16-55	16NOV2020	115071	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521589	C4591001 1152 11521589	16-55	17NOV2020	116358	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521590	C4591001 1152 11521590	16-55	17NOV2020	116359	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo		
11521591	C4591001 1152 11521591	16-55	17NOV2020	116366	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521592	C4591001 1152 11521592	16-55	18NOV2020	116368	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521593	C4591001 1152 11521593	16-55	18NOV2020	116394	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11521594	C4591001 1152 11521594	16-55	19NOV2020	116398	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo		
11521595	C4591001 1152 11521595	16-55	19NOV2020	116399	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521596	C4591001 1152 11521596	16-55	19NOV2020	116402	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
11521597	C4591001 1152 11521597	16-55	23NOV2020	116742	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo		
11521598	C4591001 1152 11521598	16-55	23NOV2020	116744	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11521599	C4591001 1152 11521599	16-55	23NOV2020	116747	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo		
11521600	C4591001 1152 11521600	16-55	24NOV2020	116748	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11521601	C4591001 1152 11521601	16-55	24NOV2020	116861	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
11521602	C4591001 1152 11521602	16-55	24NOV2020	116867	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11521603	C4591001 1152 11521603	16-55	24NOV2020	116868	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
11521606	C4591001 1152 11521606	16-55	03DEC2020	117419	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
11521609	C4591001 1152 11521609	16-55	03DEC2020	116871	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo		
11521610	C4591001 1152 11521610	16-55	03DEC2020	117416	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521616	C4591001 1152 11521616	16-55	03DEC2020	117423	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo		
11521618	C4591001 1152 11521618	16-55	03DEC2020	117424	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521620	C4591001 1152 11521620	16-55	03DEC2020	117486	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo		
11521621	C4591001 1152 11521621	16-55	03DEC2020	117487	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
11521622	C4591001 1152 11521622	16-55	04DEC2020	117492	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
11521623	C4591001 1152 11521623	16-55	04DEC2020	117570	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11521624	C4591001 1152 11521624	16-55	04DEC2020	117493	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11521627	C4591001 1152 11521627	16-55	04DEC2020	117574	Placebo	04DEC2020/ Placebo	23DEC2020/ Placebo		
11521630	C4591001 1152 11521630	16-55	07DEC2020	117578	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521631	C4591001 1152 11521631	16-55	07DEC2020	117580	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521632	C4591001 1152 11521632	16-55	07DEC2020	117677	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11521634	C4591001 1152 11521634	16-55	07DEC2020	117681	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
11521643	C4591001 1152 11521643	16-55	07DEC2020	117687	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo		
11561002	C4591001 1156 11561002	16-55	19AUG2020	57067	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11561003	C4591001 1156 11561003	16-55	19AUG2020	57066	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11561004	C4591001 1156 11561004	16-55	19AUG2020	57071	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11561005	C4591001 1156 11561005	16-55	20AUG2020	57073	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11561006	C4591001 1156 11561006	16-55	20AUG2020	58517	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
11561007	C4591001 1156 11561007	16-55	20AUG2020	58521	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11561008	C4591001 1156 11561008	16-55	20AUG2020	58519	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11561009	C4591001 1156 11561009	16-55	20AUG2020	58522	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561010	C4591001 1156 11561010	16-55	25AUG2020	64238	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11561011	C4591001 1156 11561011	16-55	21AUG2020	60329	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11561012	C4591001 1156 11561012	16-55	21AUG2020	60332	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11561013	C4591001 1156 11561013	16-55	21AUG2020	60334	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11561014	C4591001 1156 11561014	16-55	21AUG2020	60337	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561015	C4591001 1156 11561015	16-55	21AUG2020	61147	Placebo	21AUG2020/ Placebo			
11561016	C4591001 1156 11561016	16-55	21AUG2020	61149	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11561018	C4591001 1156 11561018	16-55	24AUG2020	61150	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11561019	C4591001 1156 11561019	16-55	24AUG2020	61154	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11561021	C4591001 1156 11561021	16-55	24AUG2020	64234	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561023	C4591001 1156 11561023	16-55	24AUG2020	64229	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
11561026	C4591001 1156 11561026	16-55	25AUG2020	64236	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11561028	C4591001 1156 11561028	16-55	25AUG2020	65598	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11561029	C4591001 1156 11561029	16-55	25AUG2020	65601	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561030	C4591001 1156 11561030	16-55	25AUG2020	65603	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11561031	C4591001 1156 11561031	16-55	25AUG2020	65602	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561032	C4591001 1156 11561032	16-55	25AUG2020	66703	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561033	C4591001 1156 11561033	16-55	26AUG2020	66704	Placebo	26AUG2020/ Placebo			
11561034	C4591001 1156 11561034	16-55	26AUG2020	66706	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561036	C4591001 1156 11561036	16-55	26AUG2020	66711	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561039	C4591001 1156 11561039	16-55	26AUG2020	68814	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
11561040	C4591001 1156 11561040	16-55	26AUG2020	68815	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561041	C4591001 1156 11561041	16-55	26AUG2020	68813	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11561042	C4591001 1156 11561042	16-55	27AUG2020	68820	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11561043	C4591001 1156 11561043	16-55	27AUG2020	69797	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561045	C4591001 1156 11561045	16-55	27AUG2020	69802	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
11561046	C4591001 1156 11561046	16-55	27AUG2020	69807	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11561048	C4591001 1156 11561048	16-55	27AUG2020	69808	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11561049	C4591001 1156 11561049	16-55	27AUG2020	70878	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo		
11561050	C4591001 1156 11561050	16-55	27AUG2020	70884	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11561053	C4591001 1156 11561053	16-55	28AUG2020	70888	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561054	C4591001 1156 11561054	16-55	28AUG2020	71849	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11561055	C4591001 1156 11561055	16-55	28AUG2020	71850	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
11561056	C4591001 1156 11561056	16-55	28AUG2020	71856	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11561057	C4591001 1156 11561057	16-55	28AUG2020	71860	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561058	C4591001 1156 11561058	16-55	28AUG2020	72523	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561060	C4591001 1156 11561060	16-55	29AUG2020	72526	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
11561061	C4591001 1156 11561061	16-55	29AUG2020	72529	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11561062	C4591001 1156 11561062	16-55	29AUG2020	72531	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
11561063	C4591001 1156 11561063	16-55	29AUG2020	73473	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11561064	C4591001 1156 11561064	16-55	29AUG2020	73474	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11561065	C4591001 1156 11561065	16-55	29AUG2020	73475	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561071	C4591001 1156 11561071	16-55	31AUG2020	73477	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11561072	C4591001 1156 11561072	16-55	01SEP2020	76541	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11561073	C4591001 1156 11561073	16-55	01SEP2020	76544	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11561074	C4591001 1156 11561074	16-55	01SEP2020	76545	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11561075	C4591001 1156 11561075	16-55	01SEP2020	76549	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11561076	C4591001 1156 11561076	16-55	01SEP2020	76938	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11561077	C4591001 1156 11561077	16-55	01SEP2020	76941	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11561078	C4591001 1156 11561078	16-55	01SEP2020	76942	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11561081	C4591001 1156 11561081	16-55	02SEP2020	76947	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11561082	C4591001 1156 11561082	16-55	02SEP2020	78041	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561085	C4591001 1156 11561085	16-55	02SEP2020	78046	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11561086	C4591001 1156 11561086	16-55	02SEP2020	78051	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11561087	C4591001 1156 11561087	16-55	02SEP2020	78052	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561089	C4591001 1156 11561089	16-55	02SEP2020	79133	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11561090	C4591001 1156 11561090	16-55	03SEP2020	79134	Placebo	03SEP2020/ Placebo	02OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11561093	C4591001 1156 11561093	16-55	03SEP2020	79139	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561097	C4591001 1156 11561097	16-55	03SEP2020	79141	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11561105	C4591001 1156 11561105	16-55	04SEP2020	82037	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561107	C4591001 1156 11561107	16-55	04SEP2020	82042	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11561108	C4591001 1156 11561108	16-55	04SEP2020	82043	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561109	C4591001 1156 11561109	16-55	08SEP2020	82045	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11561111	C4591001 1156 11561111	16-55	08SEP2020	83684	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11561113	C4591001 1156 11561113	16-55	08SEP2020	83685	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11561115	C4591001 1156 11561115	16-55	08SEP2020	83687	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11561119	C4591001 1156 11561119	16-55	09SEP2020	83692	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11561120	C4591001 1156 11561120	16-55	09SEP2020	85820	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo		
11561121	C4591001 1156 11561121	16-55	09SEP2020	85822	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11561123	C4591001 1156 11561123	16-55	10SEP2020	85825	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11561124	C4591001 1156 11561124	16-55	10SEP2020	85827	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11561126	C4591001 1156 11561126	16-55	10SEP2020	86976	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11561128	C4591001 1156 11561128	16-55	10SEP2020	86977	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561129	C4591001 1156 11561129	16-55	11SEP2020	86979	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11561131	C4591001 1156 11561131	16-55	11SEP2020	86980	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561132	C4591001 1156 11561132	16-55	11SEP2020	88446	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo		
11561134	C4591001 1156 11561134	16-55	11SEP2020	88447	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11561135	C4591001 1156 11561135	16-55	11SEP2020	88453	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11561136	C4591001 1156 11561136	16-55	11SEP2020	88455	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11561137	C4591001 1156 11561137	16-55	14SEP2020	89477	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11561145	C4591001 1156 11561145	16-55	15SEP2020	89481	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11561146	C4591001 1156 11561146	16-55	15SEP2020	89482	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11561147	C4591001 1156 11561147	16-55	16SEP2020	89487	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561148	C4591001 1156 11561148	16-55	16SEP2020	91133	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11561149	C4591001 1156 11561149	16-55	16SEP2020	91137	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo		
11561154	C4591001 1156 11561154	16-55	17SEP2020	91140	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11561155	C4591001 1156 11561155	16-55	18SEP2020	91144	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11561156	C4591001 1156 11561156	16-55	18SEP2020	93622	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11561158	C4591001 1156 11561158	16-55	21SEP2020	93624	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11561159	C4591001 1156 11561159	16-55	21SEP2020	93626	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561161	C4591001 1156 11561161	16-55	21SEP2020	93628	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11561162	C4591001 1156 11561162	16-55	22SEP2020	96214	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11561163	C4591001 1156 11561163	16-55	22SEP2020	96215	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561164	C4591001 1156 11561164	16-55	23SEP2020	96218	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11561165	C4591001 1156 11561165	16-55	23SEP2020	96219	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
11561166	C4591001 1156 11561166	16-55	23SEP2020	98083	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11561170	C4591001 1156 11561170	16-55	24SEP2020	98085	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11561172	C4591001 1156 11561172	16-55	25SEP2020	98089	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11561174	C4591001 1156 11561174	16-55	25SEP2020	98092	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11561175	C4591001 1156 11561175	16-55	25SEP2020	99965	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11561176	C4591001 1156 11561176	16-55	25SEP2020	99973	Placebo	25SEP2020/ Placebo	20OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561177	C4591001 1156 11561177	16-55	25SEP2020	99975	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11561178	C4591001 1156 11561178	16-55	25SEP2020	99976	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561179	C4591001 1156 11561179	16-55	28SEP2020	101324	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11561180	C4591001 1156 11561180	16-55	28SEP2020	101325	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11561185	C4591001 1156 11561185	16-55	30SEP2020	101330	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11561186	C4591001 1156 11561186	16-55	30SEP2020	102197	Placebo	30SEP2020/ Placebo	26OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11561187	C4591001 1156 11561187	16-55	30SEP2020	102203	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11561188	C4591001 1156 11561188	16-55	30SEP2020	101332	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11561189	C4591001 1156 11561189	16-55	30SEP2020	102204	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561190	C4591001 1156 11561190	16-55	30SEP2020	102207	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11561194	C4591001 1156 11561194	16-55	30SEP2020	102535	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11561196	C4591001 1156 11561196	16-55	01OCT2020	102539	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561198	C4591001 1156 11561198	16-55	01OCT2020	102540	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11561199	C4591001 1156 11561199	16-55	01OCT2020	102543	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561200	C4591001 1156 11561200	16-55	01OCT2020	102989	Placebo	01OCT2020/ Placebo	24NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11561201	C4591001 1156 11561201	16-55	02OCT2020	102990	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561203	C4591001 1156 11561203	16-55	02OCT2020	102993	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo		
11561205	C4591001 1156 11561205	16-55	02OCT2020	102994	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561206	C4591001 1156 11561206	16-55	02OCT2020	103289	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11561208	C4591001 1156 11561208	16-55	05OCT2020	103292	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561209	C4591001 1156 11561209	16-55	06OCT2020	103299	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11561210	C4591001 1156 11561210	16-55	06OCT2020	103300	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561213	C4591001 1156 11561213	16-55	08OCT2020	105317	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561214	C4591001 1156 11561214	16-55	08OCT2020	105323	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561216	C4591001 1156 11561216	16-55	08OCT2020	105324	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11561225	C4591001 1156 11561225	16-55	12OCT2020	105327	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11561226	C4591001 1156 11561226	16-55	12OCT2020	106390	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561227	C4591001 1156 11561227	16-55	12OCT2020	106391	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11561229	C4591001 1156 11561229	16-55	12OCT2020	106392	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11561230	C4591001 1156 11561230	16-55	12OCT2020	106393	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11561231	C4591001 1156 11561231	16-55	12OCT2020	106613	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11561233	C4591001 1156 11561233	16-55	12OCT2020	106617	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561234	C4591001 1156 11561234	16-55	12OCT2020	106622	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11561235	C4591001 1156 11561235	16-55	13OCT2020	106624	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11561239	C4591001 1156 11561239	16-55	13OCT2020	107286	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11561251	C4591001 1156 11561251	16-55	16OCT2020	107289	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11561252	C4591001 1156 11561252	16-55	16OCT2020	107292	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		
11561258	C4591001 1156 11561258	16-55	20OCT2020	107294	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11561268	C4591001 1156 11561268	16-55	23OCT2020	112809	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11561270	C4591001 1156 11561270	16-55	23OCT2020	112811	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11561272	C4591001 1156 11561272	16-55	26OCT2020	112815	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11561273	C4591001 1156 11561273	16-55	26OCT2020	112816	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561274	C4591001 1156 11561274	16-55	26OCT2020	113565	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11561275	C4591001 1156 11561275	16-55	26OCT2020	113566	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
11561276	C4591001 1156 11561276	16-55	27OCT2020	113569	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561277	C4591001 1156 11561277	16-55	27OCT2020	113572	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11561281	C4591001 1156 11561281	16-55	28OCT2020	114487	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561282	C4591001 1156 11561282	16-55	29OCT2020	114488	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11561283	C4591001 1156 11561283	16-55	29OCT2020	114491	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11561286	C4591001 1156 11561286	16-55	29OCT2020	114492	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11561287	C4591001 1156 11561287	16-55	30OCT2020	114966	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo		
11561288	C4591001 1156 11561288	16-55	30OCT2020	114969	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561289	C4591001 1156 11561289	16-55	30OCT2020	114974	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561290	C4591001 1156 11561290	16-55	30OCT2020	115049	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11561291	C4591001 1156 11561291	16-55	30OCT2020	114975	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11561292	C4591001 1156 11561292	16-55	30OCT2020	115052	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo		
11561293	C4591001 1156 11561293	16-55	30OCT2020	115054	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11561294	C4591001 1156 11561294	16-55	03NOV2020	115059	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11561295	C4591001 1156 11561295	16-55	04NOV2020	115615	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
11561296	C4591001 1156 11561296	16-55	05NOV2020	115618	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11561297	C4591001 1156 11561297	16-55	05NOV2020	115623	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo		
11561298	C4591001 1156 11561298	16-55	11NOV2020	115624	Placebo	11NOV2020/ Placebo	01DEC2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11561299	C4591001 1156 11561299	16-55	11NOV2020	116117	Placebo	11NOV2020/ Placebo	01DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561300	C4591001 1156 11561300	16-55	17NOV2020	116122	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
11561301	C4591001 1156 11561301	16-55	18NOV2020	116125	Placebo	18NOV2020/ Placebo	10DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11561302	C4591001 1156 11561302	16-55	19NOV2020	116128	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
11561315	C4591001 1156 11561315	16-55	03DEC2020	117295	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11561326	C4591001 1156 11561326	16-55	10DEC2020	117299	Placebo	10DEC2020/ Placebo	29DEC2020/ Placebo		
11561329	C4591001 1156 11561329	16-55	16DEC2020	117300	BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)		
11571026	C4591001 1157 11571026	16-55	14AUG2020	51069	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11571034	C4591001 1157 11571034	16-55	17AUG2020	51070	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11571040	C4591001 1157 11571040	16-55	18AUG2020	51071	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571042	C4591001 1157 11571042	16-55	18AUG2020	51076	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11571052	C4591001 1157 11571052	16-55	19AUG2020	57332	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11571054	C4591001 1157 11571054	16-55	19AUG2020	57333	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571057	C4591001 1157 11571057	16-55	19AUG2020	57335	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571070	C4591001 1157 11571070	16-55	25AUG2020	57338	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
11571077	C4591001 1157 11571077	16-55	25AUG2020	66738	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11571081	C4591001 1157 11571081	16-55	25AUG2020	66743	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11571082	C4591001 1157 11571082	16-55	25AUG2020	66746	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11571083	C4591001 1157 11571083	16-55	25AUG2020	66744	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571088	C4591001 1157 11571088	16-55	26AUG2020	67893	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571090	C4591001 1157 11571090	16-55	26AUG2020	67894	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11571092	C4591001 1157 11571092	16-55	26AUG2020	67899	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
11571093	C4591001 1157 11571093	16-55	26AUG2020	67896	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11571103	C4591001 1157 11571103	16-55	26AUG2020	69257	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11571106	C4591001 1157 11571106	16-55	27AUG2020	69258	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571108	C4591001 1157 11571108	16-55	27AUG2020	69259	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11571109	C4591001 1157 11571109	16-55	27AUG2020	69264	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		
11571111	C4591001 1157 11571111	16-55	27AUG2020	70530	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11571112	C4591001 1157 11571112	16-55	01SEP2020	70532	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571113	C4591001 1157 11571113	16-55	01SEP2020	70539	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571114	C4591001 1157 11571114	16-55	01SEP2020	70540	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571115	C4591001 1157 11571115	16-55	01SEP2020	76902	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571117	C4591001 1157 11571117	16-55	01SEP2020	76903	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571118	C4591001 1157 11571118	16-55	01SEP2020	76904	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11571121	C4591001 1157 11571121	16-55	01SEP2020	76911	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
11571124	C4591001 1157 11571124	16-55	01SEP2020	77507	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
11571125	C4591001 1157 11571125	16-55	01SEP2020	77510	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11571126	C4591001 1157 11571126	16-55	01SEP2020	77511	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571127	C4591001 1157 11571127	16-55	01SEP2020	77512	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
11571130	C4591001 1157 11571130	16-55	01SEP2020	77765	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571132	C4591001 1157 11571132	16-55	02SEP2020	77773	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571135	C4591001 1157 11571135	16-55	02SEP2020	77774	Placebo	02SEP2020/ Placebo			
11571136	C4591001 1157 11571136	16-55	02SEP2020	77775	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11571137	C4591001 1157 11571137	16-55	02SEP2020	78560	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571140	C4591001 1157 11571140	16-55	02SEP2020	78561	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11571141	C4591001 1157 11571141	16-55	05OCT2020	78565	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11571145	C4591001 1157 11571145	16-55	08OCT2020	78567	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11571154	C4591001 1157 11571154	16-55	10OCT2020	106241	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11571156	C4591001 1157 11571156	16-55	10OCT2020	106247	Placebo	10OCT2020/ Placebo	30NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11571166	C4591001 1157 11571166	16-55	19OCT2020	106248	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11571168	C4591001 1157 11571168	16-55	19OCT2020	106252	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11571169	C4591001 1157 11571169	16-55	19OCT2020	110573	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
11571170	C4591001 1157 11571170	16-55	19OCT2020	110579	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11571174	C4591001 1157 11571174	16-55	20OCT2020	110582	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo		
11571176	C4591001 1157 11571176	16-55	20OCT2020	110584	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11611005	C4591001 1161 11611005	16-55	31JUL2020	41211	Placebo	31JUL2020/ Placebo			
11621024	C4591001 1162 11621024	16-55	04AUG2020	42014	Placebo				
11621124	C4591001 1162 11621124	16-55	17AUG2020	49424	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621128	C4591001 1162 11621128	16-55	17AUG2020	52825	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621129	C4591001 1162 11621129	16-55	17AUG2020	49429	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621130	C4591001 1162 11621130	16-55	17AUG2020	52567	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11621131	C4591001 1162 11621131	16-55	17AUG2020	49431	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621132	C4591001 1162 11621132	16-55	17AUG2020	52565	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621133	C4591001 1162 11621133	16-55	17AUG2020	52569	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621135	C4591001 1162 11621135	16-55	17AUG2020	52574	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621137	C4591001 1162 11621137	16-55	17AUG2020	52824	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11621140	C4591001 1162 11621140	16-55	17AUG2020	52826	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621141	C4591001 1162 11621141	16-55	17AUG2020	52828	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621142	C4591001 1162 11621142	16-55	17AUG2020	52902	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621143	C4591001 1162 11621143	16-55	17AUG2020	52901	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11621144	C4591001 1162 11621144	16-55	17AUG2020	52905	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11621145	C4591001 1162 11621145	16-55	17AUG2020	52910	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621146	C4591001 1162 11621146	16-55	18AUG2020	53988	Placebo	18AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11621147	C4591001 1162 11621147	16-55	18AUG2020	53983	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621150	C4591001 1162 11621150	16-55	18AUG2020	53989	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621151	C4591001 1162 11621151	16-55	18AUG2020	53991	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621152	C4591001 1162 11621152	16-55	18AUG2020	54272	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621153	C4591001 1162 11621153	16-55	18AUG2020	54275	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621154	C4591001 1162 11621154	16-55	18AUG2020	54273	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621155	C4591001 1162 11621155	16-55	18AUG2020	54425	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621156	C4591001 1162 11621156	16-55	18AUG2020	54428	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621158	C4591001 1162 11621158	16-55	18AUG2020	54435	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621159	C4591001 1162 11621159	16-55	18AUG2020	54431	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11621162	C4591001 1162 11621162	16-55	18AUG2020	54671	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621163	C4591001 1162 11621163	16-55	18AUG2020	54669	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11621164	C4591001 1162 11621164	16-55	18AUG2020	54666	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
11621166	C4591001 1162 11621166	16-55	24AUG2020	63401	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
11621168	C4591001 1162 11621168	16-55	24AUG2020	54673	Placebo	24AUG2020/ Placebo	21SEP2020/ Placebo		
11621169	C4591001 1162 11621169	16-55	24AUG2020	63407	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621170	C4591001 1162 11621170	16-55	24AUG2020	63403	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621171	C4591001 1162 11621171	16-55	24AUG2020	63412	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621172	C4591001 1162 11621172	16-55	24AUG2020	63558	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621175	C4591001 1162 11621175	16-55	24AUG2020	63564	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621177	C4591001 1162 11621177	16-55	24AUG2020	63565	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo		
11621178	C4591001 1162 11621178	16-55	24AUG2020	63568	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621180	C4591001 1162 11621180	16-55	24AUG2020	63837	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621181	C4591001 1162 11621181	16-55	24AUG2020	63840	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11621182	C4591001 1162 11621182	16-55	24AUG2020	63843	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621183	C4591001 1162 11621183	16-55	24AUG2020	63842	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621187	C4591001 1162 11621187	16-55	24AUG2020	64040	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11621188	C4591001 1162 11621188	16-55	24AUG2020	64045	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621190	C4591001 1162 11621190	16-55	24AUG2020	64046	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621193	C4591001 1162 11621193	16-55	25AUG2020	64047	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11621195	C4591001 1162 11621195	16-55	25AUG2020	65790	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621202	C4591001 1162 11621202	16-55	25AUG2020	65792	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621203	C4591001 1162 11621203	16-55	25AUG2020	65794	Placebo	25AUG2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11621204	C4591001 1162 11621204	16-55	25AUG2020	65796	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621205	C4591001 1162 11621205	16-55	27AUG2020	69848	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621206	C4591001 1162 11621206	16-55	27AUG2020	69853	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11621207	C4591001 1162 11621207	16-55	27AUG2020	69850	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621208	C4591001 1162 11621208	16-55	27AUG2020	69846	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11621210	C4591001 1162 11621210	16-55	27AUG2020	70301	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621216	C4591001 1162 11621216	16-55	27AUG2020	70308	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11621217	C4591001 1162 11621217	16-55	27AUG2020	70303	Placebo	27AUG2020/ Placebo	09OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621219	C4591001 1162 11621219	16-55	27AUG2020	70311	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11621220	C4591001 1162 11621220	16-55	27AUG2020	70519	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11621222	C4591001 1162 11621222	16-55	27AUG2020	70522	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11621223	C4591001 1162 11621223	16-55	27AUG2020	70528	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11621224	C4591001 1162 11621224	16-55	27AUG2020	70526	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621226	C4591001 1162 11621226	16-55	31AUG2020	74753	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621227	C4591001 1162 11621227	16-55	31AUG2020	74755	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11621234	C4591001 1162 11621234	16-55	31AUG2020	74764	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621235	C4591001 1162 11621235	16-55	31AUG2020	74761	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621239	C4591001 1162 11621239	16-55	31AUG2020	75162	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621243	C4591001 1162 11621243	16-55	31AUG2020	75166	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11621244	C4591001 1162 11621244	16-55	31AUG2020	75163	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621245	C4591001 1162 11621245	16-55	31AUG2020	75172	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621247	C4591001 1162 11621247	16-55	31AUG2020	75618	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621249	C4591001 1162 11621249	16-55	01SEP2020	75619	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11621251	C4591001 1162 11621251	16-55	01SEP2020	75621	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621252	C4591001 1162 11621252	16-55	01SEP2020	76615	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621254	C4591001 1162 11621254	16-55	01SEP2020	75623	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621255	C4591001 1162 11621255	16-55	01SEP2020	76623	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11621256	C4591001 1162 11621256	16-55	01SEP2020	76617	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621259	C4591001 1162 11621259	16-55	01SEP2020	76624	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11621260	C4591001 1162 11621260	16-55	01SEP2020	76793	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621267	C4591001 1162 11621267	16-55	01SEP2020	76796	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621268	C4591001 1162 11621268	16-55	01SEP2020	76803	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11621269	C4591001 1162 11621269	16-55	01SEP2020	76801	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11621273	C4591001 1162 11621273	16-55	03SEP2020	79752	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621274	C4591001 1162 11621274	16-55	03SEP2020	79753	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621275	C4591001 1162 11621275	16-55	03SEP2020	79747	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621279	C4591001 1162 11621279	16-55	03SEP2020	79754	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621282	C4591001 1162 11621282	16-55	03SEP2020	80297	Placebo	03SEP2020/ Placebo	02OCT2020/ Placebo		
11621283	C4591001 1162 11621283	16-55	03SEP2020	80300	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11621284	C4591001 1162 11621284	16-55	03SEP2020	80301	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621285	C4591001 1162 11621285	16-55	03SEP2020	80526	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621286	C4591001 1162 11621286	16-55	03SEP2020	80307	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11621287	C4591001 1162 11621287	16-55	03SEP2020	80527	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621289	C4591001 1162 11621289	16-55	08SEP2020	83501	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11621290	C4591001 1162 11621290	16-55	08SEP2020	80528	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11621291	C4591001 1162 11621291	16-55	08SEP2020	80532	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621294	C4591001 1162 11621294	16-55	08SEP2020	83508	Placebo	08SEP2020/ Placebo			
11621295	C4591001 1162 11621295	16-55	08SEP2020	83504	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621296	C4591001 1162 11621296	16-55	08SEP2020	83502	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621302	C4591001 1162 11621302	16-55	08SEP2020	83741	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11621304	C4591001 1162 11621304	16-55	08SEP2020	83748	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621306	C4591001 1162 11621306	16-55	08SEP2020	83744	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11621308	C4591001 1162 11621308	16-55	08SEP2020	83752	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621310	C4591001 1162 11621310	16-55	08SEP2020	84005	Placebo	08SEP2020/ Placebo			
11621311	C4591001 1162 11621311	16-55	08SEP2020	84006	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11621313	C4591001 1162 11621313	16-55	08SEP2020	84012	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621314	C4591001 1162 11621314	16-55	08SEP2020	84014	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
11621315	C4591001 1162 11621315	16-55	08SEP2020	84366	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11621316	C4591001 1162 11621316	16-55	08SEP2020	84367	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11621320	C4591001 1162 11621320	16-55	17SEP2020	90026	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11621321	C4591001 1162 11621321	16-55	10SEP2020	84373	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11621322	C4591001 1162 11621322	16-55	10SEP2020	86697	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11621323	C4591001 1162 11621323	16-55	10SEP2020	84375	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621324	C4591001 1162 11621324	16-55	10SEP2020	86699	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11621325	C4591001 1162 11621325	16-55	10SEP2020	86702	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11621326	C4591001 1162 11621326	16-55	10SEP2020	87050	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621328	C4591001 1162 11621328	16-55	10SEP2020	86703	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621331	C4591001 1162 11621331	16-55	10SEP2020	86873	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11621334	C4591001 1162 11621334	16-55	10SEP2020	86875	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621335	C4591001 1162 11621335	16-55	10SEP2020	86876	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11621336	C4591001 1162 11621336	16-55	10SEP2020	86879	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
11621338	C4591001 1162 11621338	16-55	10SEP2020	87051	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621339	C4591001 1162 11621339	16-55	10SEP2020	87044	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo		
11621340	C4591001 1162 11621340	16-55	10SEP2020	87049	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11621344	C4591001 1162 11621344	16-55	10SEP2020	87312	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11621346	C4591001 1162 11621346	16-55	10SEP2020	87313	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
11621350	C4591001 1162 11621350	16-55	14SEP2020	87315	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621351	C4591001 1162 11621351	16-55	14SEP2020	89502	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621352	C4591001 1162 11621352	16-55	14SEP2020	87316	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621354	C4591001 1162 11621354	16-55	14SEP2020	89511	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621355	C4591001 1162 11621355	16-55	14SEP2020	89503	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621356	C4591001 1162 11621356	16-55	14SEP2020	89509	Placebo	14SEP2020/ Placebo			
11621358	C4591001 1162 11621358	16-55	14SEP2020	89555	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
11621360	C4591001 1162 11621360	16-55	14SEP2020	89550	Placebo	14SEP2020/ Placebo	22OCT2020/ Placebo		
11621361	C4591001 1162 11621361	16-55	14SEP2020	89558	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621362	C4591001 1162 11621362	16-55	14SEP2020	89559	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621363	C4591001 1162 11621363	16-55	14SEP2020	89686	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621366	C4591001 1162 11621366	16-55	14SEP2020	89690	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621367	C4591001 1162 11621367	16-55	14SEP2020	89691	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11621370	C4591001 1162 11621370	16-55	14SEP2020	89692	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621372	C4591001 1162 11621372	16-55	14SEP2020	89815	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11621374	C4591001 1162 11621374	16-55	14SEP2020	89819	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
11621375	C4591001 1162 11621375	16-55	14SEP2020	89820	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11621376	C4591001 1162 11621376	16-55	14SEP2020	89823	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo		
11621377	C4591001 1162 11621377	16-55	14SEP2020	89873	Placebo	14SEP2020/ Placebo	15OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621378	C4591001 1162 11621378	16-55	14SEP2020	89877	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11621379	C4591001 1162 11621379	16-55	14SEP2020	89880	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621381	C4591001 1162 11621381	16-55	14SEP2020	90019	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
11621382	C4591001 1162 11621382	16-55	14SEP2020	89881	Placebo	14SEP2020/ Placebo	09OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621383	C4591001 1162 11621383	16-55	17SEP2020	90027	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621384	C4591001 1162 11621384	16-55	17SEP2020	90021	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621386	C4591001 1162 11621386	16-55	17SEP2020	92192	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621387	C4591001 1162 11621387	16-55	17SEP2020	92194	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621388	C4591001 1162 11621388	16-55	17SEP2020	92195	Placebo	17SEP2020/ Placebo	19OCT2020/ Placebo		
11621389	C4591001 1162 11621389	16-55	17SEP2020	92198	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11621391	C4591001 1162 11621391	16-55	17SEP2020	92345	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)			
11621392	C4591001 1162 11621392	16-55	17SEP2020	92418	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621393	C4591001 1162 11621393	16-55	17SEP2020	92347	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo		
11621394	C4591001 1162 11621394	16-55	17SEP2020	92353	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621396	C4591001 1162 11621396	16-55	17SEP2020	92354	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621401	C4591001 1162 11621401	16-55	17SEP2020	92425	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621404	C4591001 1162 11621404	16-55	17SEP2020	92427	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621405	C4591001 1162 11621405	16-55	17SEP2020	92420	Placebo	17SEP2020/ Placebo	13OCT2020/ Placebo		
11621406	C4591001 1162 11621406	16-55	17SEP2020	92683	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11621408	C4591001 1162 11621408	16-55	17SEP2020	92684	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11621410	C4591001 1162 11621410	16-55	17SEP2020	92687	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11621413	C4591001 1162 11621413	16-55	17SEP2020	92692	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621414	C4591001 1162 11621414	16-55	17SEP2020	92837	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11621416	C4591001 1162 11621416	16-55	21SEP2020	92848	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621417	C4591001 1162 11621417	16-55	21SEP2020	92846	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621418	C4591001 1162 11621418	16-55	21SEP2020	92847	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11621421	C4591001 1162 11621421	16-55	21SEP2020	95097	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11621422	C4591001 1162 11621422	16-55	21SEP2020	95095	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621423	C4591001 1162 11621423	16-55	21SEP2020	95098	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11621427	C4591001 1162 11621427	16-55	21SEP2020	95104	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo		
11621429	C4591001 1162 11621429	16-55	22SEP2020	96258	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11621430	C4591001 1162 11621430	16-55	22SEP2020	96259	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621434	C4591001 1162 11621434	16-55	28SEP2020	96264	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621435	C4591001 1162 11621435	16-55	28SEP2020	101309	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11621436	C4591001 1162 11621436	16-55	28SEP2020	96266	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621437	C4591001 1162 11621437	16-55	28SEP2020	101310	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621439	C4591001 1162 11621439	16-55	28SEP2020	101314	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo		
11621442	C4591001 1162 11621442	16-55	28SEP2020	101316	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11621443	C4591001 1162 11621443	16-55	28SEP2020	101420	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11621445	C4591001 1162 11621445	16-55	28SEP2020	101419	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621446	C4591001 1162 11621446	16-55	28SEP2020	101421	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
11621448	C4591001 1162 11621448	16-55	28SEP2020	101498	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11621450	C4591001 1162 11621450	16-55	28SEP2020	101490	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621451	C4591001 1162 11621451	16-55	28SEP2020	101428	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621452	C4591001 1162 11621452	16-55	28SEP2020	101496	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621454	C4591001 1162 11621454	16-55	28SEP2020	101548	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11621455	C4591001 1162 11621455	16-55	28SEP2020	101500	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621456	C4591001 1162 11621456	16-55	28SEP2020	101537	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621457	C4591001 1162 11621457	16-55	28SEP2020	101561	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621458	C4591001 1162 11621458	16-55	28SEP2020	101544	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621459	C4591001 1162 11621459	16-55	28SEP2020	101545	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621460	C4591001 1162 11621460	16-55	30SEP2020	101564	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621463	C4591001 1162 11621463	16-55	30SEP2020	101567	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621464	C4591001 1162 11621464	16-55	30SEP2020	101570	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo		
11621466	C4591001 1162 11621466	16-55	30SEP2020	102310	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621467	C4591001 1162 11621467	16-55	30SEP2020	102306	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11621468	C4591001 1162 11621468	16-55	30SEP2020	102313	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11621469	C4591001 1162 11621469	16-55	30SEP2020	102309	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11621471	C4591001 1162 11621471	16-55	30SEP2020	102390	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621472	C4591001 1162 11621472	16-55	30SEP2020	102393	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11621476	C4591001 1162 11621476	16-55	30SEP2020	102396	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621477	C4591001 1162 11621477	16-55	30SEP2020	102398	BNT162b2 (30 µg)				
11621479	C4591001 1162 11621479	16-55	07OCT2020	104672	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621480	C4591001 1162 11621480	16-55	07OCT2020	104671	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
11621483	C4591001 1162 11621483	16-55	07OCT2020	104673	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11621484	C4591001 1162 11621484	16-55	07OCT2020	104680	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11621486	C4591001 1162 11621486	16-55	07OCT2020	104803	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11621488	C4591001 1162 11621488	16-55	07OCT2020	104801	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621489	C4591001 1162 11621489	16-55	07OCT2020	104806	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
11621490	C4591001 1162 11621490	16-55	07OCT2020	104865	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
11621491	C4591001 1162 11621491	16-55	07OCT2020	104808	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11621492	C4591001 1162 11621492	16-55	07OCT2020	104867	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11621494	C4591001 1162 11621494	16-55	07OCT2020	104868	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621496	C4591001 1162 11621496	16-55	13OCT2020	106914	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11621499	C4591001 1162 11621499	16-55	13OCT2020	106920	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11621500	C4591001 1162 11621500	16-55	13OCT2020	106924	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621502	C4591001 1162 11621502	16-55	13OCT2020	106922	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11621504	C4591001 1162 11621504	16-55	13OCT2020	107047	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621505	C4591001 1162 11621505	16-55	13OCT2020	107046	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11621510	C4591001 1162 11621510	16-55	13OCT2020	107052	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11621513	C4591001 1162 11621513	16-55	15OCT2020	107054	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621514	C4591001 1162 11621514	16-55	15OCT2020	108029	Placebo	15OCT2020/ Placebo			
11621515	C4591001 1162 11621515	16-55	15OCT2020	108031	Placebo	15OCT2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621518	C4591001 1162 11621518	16-55	15OCT2020	108033	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11621519	C4591001 1162 11621519	16-55	15OCT2020	108125	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621520	C4591001 1162 11621520	16-55	15OCT2020	108034	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11621522	C4591001 1162 11621522	16-55	15OCT2020	108127	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621524	C4591001 1162 11621524	16-55	15OCT2020	108132	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)			
11621526	C4591001 1162 11621526	16-55	15OCT2020	108136	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11621530	C4591001 1162 11621530	16-55	15OCT2020	108346	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11621532	C4591001 1162 11621532	16-55	15OCT2020	108341	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11621534	C4591001 1162 11621534	16-55	15OCT2020	108347	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11621535	C4591001 1162 11621535	16-55	15OCT2020	108350	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621537	C4591001 1162 11621537	16-55	15OCT2020	108509	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11621538	C4591001 1162 11621538	16-55	21OCT2020	108519	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo		
11621539	C4591001 1162 11621539	16-55	21OCT2020	108516	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621540	C4591001 1162 11621540	16-55	21OCT2020	108520	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621541	C4591001 1162 11621541	16-55	21OCT2020	111497	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11621543	C4591001 1162 11621543	16-55	21OCT2020	111501	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo		
11621545	C4591001 1162 11621545	16-55	21OCT2020	111503	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
11621548	C4591001 1162 11621548	16-55	21OCT2020	111505	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621549	C4591001 1162 11621549	16-55	21OCT2020	111644	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11621551	C4591001 1162 11621551	16-55	21OCT2020	111646	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621553	C4591001 1162 11621553	16-55	21OCT2020	111648	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11621554	C4591001 1162 11621554	16-55	21OCT2020	111647	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11621559	C4591001 1162 11621559	16-55	22OCT2020	112097	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11621563	C4591001 1162 11621563	16-55	22OCT2020	112104	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo		
11621566	C4591001 1162 11621566	16-55	22OCT2020	112102	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)			
11621569	C4591001 1162 11621569	16-55	22OCT2020	112107	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11621570	C4591001 1162 11621570	16-55	22OCT2020	112254	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo		
11621571	C4591001 1162 11621571	16-55	22OCT2020	112259	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621572	C4591001 1162 11621572	16-55	22OCT2020	112256	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo		
11621573	C4591001 1162 11621573	16-55	22OCT2020	112263	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621574	C4591001 1162 11621574	16-55	22OCT2020	112354	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621576	C4591001 1162 11621576	16-55	22OCT2020	112356	Placebo	22OCT2020/ Placebo	23NOV2020/ Placebo		
11621579	C4591001 1162 11621579	16-55	22OCT2020	112357	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11621580	C4591001 1162 11621580	16-55	22OCT2020	112358	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo		
11621582	C4591001 1162 11621582	16-55	22OCT2020	112469	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11621583	C4591001 1162 11621583	16-55	28OCT2020	112471	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11621584	C4591001 1162 11621584	16-55	29OCT2020	112478	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
11621585	C4591001 1162 11621585	16-55	29OCT2020	112472	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11621586	C4591001 1162 11621586	16-55	04NOV2020	115638	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo		
11621587	C4591001 1162 11621587	16-55	12NOV2020	115642	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11621588	C4591001 1162 11621588	16-55	17NOV2020	115645	Placebo	17NOV2020/ Placebo	10DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11621589	C4591001 1162 11621589	16-55	17NOV2020	115644	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
11631117	C4591001 1163 11631117	16-55	17AUG2020	50881	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631121	C4591001 1163 11631121	16-55	17AUG2020	53636	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11631122	C4591001 1163 11631122	16-55	17AUG2020	53638	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11631123	C4591001 1163 11631123	16-55	17AUG2020	53640	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11631124	C4591001 1163 11631124	16-55	17AUG2020	53642	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631127	C4591001 1163 11631127	16-55	18AUG2020	55482	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631129	C4591001 1163 11631129	16-55	19AUG2020	55488	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11631135	C4591001 1163 11631135	16-55	20AUG2020	55491	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11631136	C4591001 1163 11631136	16-55	20AUG2020	55492	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11631138	C4591001 1163 11631138	16-55	20AUG2020	59861	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11631142	C4591001 1163 11631142	16-55	21AUG2020	59868	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11631143	C4591001 1163 11631143	16-55	21AUG2020	59867	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11631145	C4591001 1163 11631145	16-55	21AUG2020	59871	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661002	C4591001 1166 11661002	16-55	18AUG2020	54353	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11661003	C4591001 1166 11661003	16-55	18AUG2020	54355	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661004	C4591001 1166 11661004	16-55	18AUG2020	54357	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11661005	C4591001 1166 11661005	16-55	18AUG2020	54358	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11661008	C4591001 1166 11661008	16-55	18AUG2020	54845	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661009	C4591001 1166 11661009	16-55	18AUG2020	54847	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11661011	C4591001 1166 11661011	16-55	19AUG2020	54848	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
11661014	C4591001 1166 11661014	16-55	19AUG2020	54854	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11661016	C4591001 1166 11661016	16-55	19AUG2020	56384	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11661017	C4591001 1166 11661017	16-55	19AUG2020	56386	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11661019	C4591001 1166 11661019	16-55	19AUG2020	56387	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11661022	C4591001 1166 11661022	16-55	20AUG2020	56390	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11661023	C4591001 1166 11661023	16-55	20AUG2020	57906	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11661024	C4591001 1166 11661024	16-55	20AUG2020	57911	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661025	C4591001 1166 11661025	16-55	20AUG2020	57912	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661028	C4591001 1166 11661028	16-55	20AUG2020	57915	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11661030	C4591001 1166 11661030	16-55	20AUG2020	58482	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11661032	C4591001 1166 11661032	16-55	20AUG2020	58484	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11661033	C4591001 1166 11661033	16-55	20AUG2020	58488	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11661035	C4591001 1166 11661035	16-55	20AUG2020	58490	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11661036	C4591001 1166 11661036	16-55	20AUG2020	59009	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11661037	C4591001 1166 11661037	16-55	20AUG2020	59012	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
11661039	C4591001 1166 11661039	16-55	21AUG2020	59015	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11661041	C4591001 1166 11661041	16-55	21AUG2020	59020	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11661042	C4591001 1166 11661042	16-55	21AUG2020	60377	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661044	C4591001 1166 11661044	16-55	31AUG2020	74645	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11661046	C4591001 1166 11661046	16-55	31AUG2020	74646	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661047	C4591001 1166 11661047	16-55	31AUG2020	74652	Placebo	31AUG2020/ Placebo			
11661048	C4591001 1166 11661048	16-55	31AUG2020	74656	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11661049	C4591001 1166 11661049	16-55	01SEP2020	76301	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11661051	C4591001 1166 11661051	16-55	01SEP2020	76304	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
11661052	C4591001 1166 11661052	16-55	01SEP2020	76305	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11661055	C4591001 1166 11661055	16-55	03SEP2020	76306	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661056	C4591001 1166 11661056	16-55	03SEP2020	79613	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661060	C4591001 1166 11661060	16-55	03SEP2020	79616	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661061	C4591001 1166 11661061	16-55	03SEP2020	79617	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661062	C4591001 1166 11661062	16-55	03SEP2020	79624	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11661063	C4591001 1166 11661063	16-55	03SEP2020	80073	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11661064	C4591001 1166 11661064	16-55	03SEP2020	80074	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11661065	C4591001 1166 11661065	16-55	03SEP2020	80076	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661066	C4591001 1166 11661066	16-55	03SEP2020	80078	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11661067	C4591001 1166 11661067	16-55	03SEP2020	80741	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11661068	C4591001 1166 11661068	16-55	04SEP2020	80748	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661069	C4591001 1166 11661069	16-55	04SEP2020	80749	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661070	C4591001 1166 11661070	16-55	04SEP2020	80752	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661071	C4591001 1166 11661071	16-55	10SEP2020	86453	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11661072	C4591001 1166 11661072	16-55	10SEP2020	86456	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11661073	C4591001 1166 11661073	16-55	11SEP2020	86459	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11661076	C4591001 1166 11661076	16-55	15SEP2020	86463	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661077	C4591001 1166 11661077	16-55	15SEP2020	90629	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661078	C4591001 1166 11661078	16-55	15SEP2020	90631	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
11661079	C4591001 1166 11661079	16-55	16SEP2020	90634	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11661080	C4591001 1166 11661080	16-55	17SEP2020	90638	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11661081	C4591001 1166 11661081	16-55	17SEP2020	92058	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11661082	C4591001 1166 11661082	16-55	17SEP2020	92061	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661083	C4591001 1166 11661083	16-55	17SEP2020	92063	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661084	C4591001 1166 11661084	16-55	17SEP2020	92065	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11661085	C4591001 1166 11661085	16-55	17SEP2020	92658	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11661086	C4591001 1166 11661086	16-55	18SEP2020	92659	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11661087	C4591001 1166 11661087	16-55	18SEP2020	92660	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11661088	C4591001 1166 11661088	16-55	18SEP2020	92664	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661090	C4591001 1166 11661090	16-55	22SEP2020	96185	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11661091	C4591001 1166 11661091	16-55	22SEP2020	96186	Placebo	22SEP2020/ Placebo	04NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11661092	C4591001 1166 11661092	16-55	23SEP2020	96192	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11661094	C4591001 1166 11661094	16-55	23SEP2020	96194	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11661095	C4591001 1166 11661095	16-55	24SEP2020	98790	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11661096	C4591001 1166 11661096	16-55	24SEP2020	98791	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661097	C4591001 1166 11661097	16-55	23OCT2020	98793	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11661099	C4591001 1166 11661099	16-55	26OCT2020	98794	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11661103	C4591001 1166 11661103	16-55	26OCT2020	113706	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11661104	C4591001 1166 11661104	16-55	26OCT2020	113707	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11661106	C4591001 1166 11661106	16-55	29OCT2020	113713	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11661109	C4591001 1166 11661109	16-55	30OCT2020	113715	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11661110	C4591001 1166 11661110	16-55	30OCT2020	115001	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11661112	C4591001 1166 11661112	16-55	30OCT2020	115004	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671003	C4591001 1167 11671003	16-55	14AUG2020	49812	Placebo				
11671007	C4591001 1167 11671007	16-55	17AUG2020	50468	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671009	C4591001 1167 11671009	16-55	17AUG2020	50474	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11671010	C4591001 1167 11671010	16-55	17AUG2020	53011	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11671011	C4591001 1167 11671011	16-55	17AUG2020	53017	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671013	C4591001 1167 11671013	16-55	17AUG2020	53018	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11671017	C4591001 1167 11671017	16-55	18AUG2020	53019	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11671019	C4591001 1167 11671019	16-55	18AUG2020	55121	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11671020	C4591001 1167 11671020	16-55	19AUG2020	55123	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671021	C4591001 1167 11671021	16-55	19AUG2020	55126	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671023	C4591001 1167 11671023	16-55	19AUG2020	55132	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11671025	C4591001 1167 11671025	16-55	19AUG2020	57257	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11671026	C4591001 1167 11671026	16-55	20AUG2020	57261	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11671028	C4591001 1167 11671028	16-55	20AUG2020	57263	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11671029	C4591001 1167 11671029	16-55	20AUG2020	57266	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11671030	C4591001 1167 11671030	16-55	20AUG2020	58327	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11671032	C4591001 1167 11671032	16-55	20AUG2020	58328	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671034	C4591001 1167 11671034	16-55	20AUG2020	58333	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11671035	C4591001 1167 11671035	16-55	20AUG2020	58335	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671036	C4591001 1167 11671036	16-55	21AUG2020	59986	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671038	C4591001 1167 11671038	16-55	21AUG2020	59988	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11671039	C4591001 1167 11671039	16-55	21AUG2020	59990	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671040	C4591001 1167 11671040	16-55	21AUG2020	59991	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11671041	C4591001 1167 11671041	16-55	21AUG2020	60534	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11671044	C4591001 1167 11671044	16-55	21AUG2020	60538	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11671045	C4591001 1167 11671045	16-55	21AUG2020	60539	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671046	C4591001 1167 11671046	16-55	21AUG2020	60541	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671050	C4591001 1167 11671050	16-55	24AUG2020	63569	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671051	C4591001 1167 11671051	16-55	24AUG2020	63570	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671053	C4591001 1167 11671053	16-55	24AUG2020	63571	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671054	C4591001 1167 11671054	16-55	24AUG2020	63578	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11671055	C4591001 1167 11671055	16-55	25AUG2020	65214	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11671057	C4591001 1167 11671057	16-55	25AUG2020	65216	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11671058	C4591001 1167 11671058	16-55	25AUG2020	65217	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11671060	C4591001 1167 11671060	16-55	25AUG2020	65222	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671061	C4591001 1167 11671061	16-55	25AUG2020	65840	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11671065	C4591001 1167 11671065	16-55	25AUG2020	65846	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11671066	C4591001 1167 11671066	16-55	26AUG2020	65848	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671070	C4591001 1167 11671070	16-55	26AUG2020	67637	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11671071	C4591001 1167 11671071	16-55	26AUG2020	67645	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671073	C4591001 1167 11671073	16-55	26AUG2020	67646	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11671078	C4591001 1167 11671078	16-55	27AUG2020	67647	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11671082	C4591001 1167 11671082	16-55	27AUG2020	70937	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671083	C4591001 1167 11671083	16-55	27AUG2020	70943	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11671086	C4591001 1167 11671086	16-55	28AUG2020	70946	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11671089	C4591001 1167 11671089	16-55	28AUG2020	70948	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11671092	C4591001 1167 11671092	16-55	28AUG2020	72486	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11671095	C4591001 1167 11671095	16-55	31AUG2020	72489	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11671096	C4591001 1167 11671096	16-55	31AUG2020	72495	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11671097	C4591001 1167 11671097	16-55	31AUG2020	72496	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671099	C4591001 1167 11671099	16-55	31AUG2020	74981	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11671102	C4591001 1167 11671102	16-55	31AUG2020	74983	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11671103	C4591001 1167 11671103	16-55	31AUG2020	74986	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671105	C4591001 1167 11671105	16-55	01SEP2020	74991	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11671106	C4591001 1167 11671106	16-55	01SEP2020	76277	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11671111	C4591001 1167 11671111	16-55	01SEP2020	76279	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)			
11671112	C4591001 1167 11671112	16-55	01SEP2020	76282	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11671113	C4591001 1167 11671113	16-55	01SEP2020	76286	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11671114	C4591001 1167 11671114	16-55	01SEP2020	77121	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11671117	C4591001 1167 11671117	16-55	02SEP2020	77122	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671118	C4591001 1167 11671118	16-55	02SEP2020	77123	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11671119	C4591001 1167 11671119	16-55	02SEP2020	77127	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671120	C4591001 1167 11671120	16-55	02SEP2020	77885	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11671124	C4591001 1167 11671124	16-55	02SEP2020	77891	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671125	C4591001 1167 11671125	16-55	02SEP2020	77893	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11671128	C4591001 1167 11671128	16-55	02SEP2020	77896	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671129	C4591001 1167 11671129	16-55	02SEP2020	79098	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671130	C4591001 1167 11671130	16-55	03SEP2020	79101	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671131	C4591001 1167 11671131	16-55	03SEP2020	79104	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11671132	C4591001 1167 11671132	16-55	03SEP2020	79108	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671134	C4591001 1167 11671134	16-55	03SEP2020	79841	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11671140	C4591001 1167 11671140	16-55	03SEP2020	79842	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11671142	C4591001 1167 11671142	16-55	04SEP2020	79846	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671144	C4591001 1167 11671144	16-55	04SEP2020	79847	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11671146	C4591001 1167 11671146	16-55	04SEP2020	81451	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11671149	C4591001 1167 11671149	16-55	04SEP2020	81453	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11671150	C4591001 1167 11671150	16-55	04SEP2020	81454	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11671151	C4591001 1167 11671151	16-55	04SEP2020	81458	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11671152	C4591001 1167 11671152	16-55	04SEP2020	82133	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671160	C4591001 1167 11671160	16-55	08SEP2020	82134	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671162	C4591001 1167 11671162	16-55	09SEP2020	254067	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11671164	C4591001 1167 11671164	16-55	09SEP2020	82135	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11671166	C4591001 1167 11671166	16-55	09SEP2020	82143	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671167	C4591001 1167 11671167	16-55	09SEP2020	85544	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11671169	C4591001 1167 11671169	16-55	10SEP2020	85545	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11671170	C4591001 1167 11671170	16-55	10SEP2020	85547	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11671173	C4591001 1167 11671173	16-55	10SEP2020	85550	Placebo	10SEP2020/ Placebo	19OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671174	C4591001 1167 11671174	16-55	10SEP2020	87079	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11671175	C4591001 1167 11671175	16-55	10SEP2020	87080	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11671178	C4591001 1167 11671178	16-55	11SEP2020	87081	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671179	C4591001 1167 11671179	16-55	11SEP2020	87082	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11671181	C4591001 1167 11671181	16-55	11SEP2020	88436	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11671185	C4591001 1167 11671185	16-55	14SEP2020	88437	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671187	C4591001 1167 11671187	16-55	15SEP2020	88438	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11671188	C4591001 1167 11671188	16-55	15SEP2020	88443	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11671189	C4591001 1167 11671189	16-55	16SEP2020	90941	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11671191	C4591001 1167 11671191	16-55	16SEP2020	90946	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11671192	C4591001 1167 11671192	16-55	16SEP2020	90951	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671193	C4591001 1167 11671193	16-55	16SEP2020	90952	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11671194	C4591001 1167 11671194	16-55	16SEP2020	91445	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671195	C4591001 1167 11671195	16-55	16SEP2020	91449	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671199	C4591001 1167 11671199	16-55	17SEP2020	91450	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11671200	C4591001 1167 11671200	16-55	17SEP2020	91452	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11671201	C4591001 1167 11671201	16-55	17SEP2020	92312	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11671202	C4591001 1167 11671202	16-55	17SEP2020	92315	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671205	C4591001 1167 11671205	16-55	18SEP2020	92318	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11671206	C4591001 1167 11671206	16-55	18SEP2020	92320	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11671208	C4591001 1167 11671208	16-55	18SEP2020	94086	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11671210	C4591001 1167 11671210	16-55	21SEP2020	94087	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11671211	C4591001 1167 11671211	16-55	21SEP2020	94091	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671212	C4591001 1167 11671212	16-55	21SEP2020	94092	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11671213	C4591001 1167 11671213	16-55	21SEP2020	95564	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11671214	C4591001 1167 11671214	16-55	21SEP2020	95561	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11671216	C4591001 1167 11671216	16-55	22SEP2020	95565	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11671217	C4591001 1167 11671217	16-55	22SEP2020	95572	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11671218	C4591001 1167 11671218	16-55	22SEP2020	96560	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11671219	C4591001 1167 11671219	16-55	22SEP2020	96563	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11671220	C4591001 1167 11671220	16-55	22SEP2020	96566	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11671222	C4591001 1167 11671222	16-55	23SEP2020	96568	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11671223	C4591001 1167 11671223	16-55	23SEP2020	98189	Placebo	23SEP2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11671224	C4591001 1167 11671224	16-55	24SEP2020	98190	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11671230	C4591001 1167 11671230	16-55	25SEP2020	98196	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11671231	C4591001 1167 11671231	16-55	25SEP2020	98200	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11681027	C4591001 1168 11681027	16-55	15AUG2020	51175	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681028	C4591001 1168 11681028	16-55	15AUG2020	51182	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11681030	C4591001 1168 11681030	16-55	15AUG2020	51307	BNT162b2 (30 µg)				
11681032	C4591001 1168 11681032	16-55	17AUG2020	51314	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
11681033	C4591001 1168 11681033	16-55	17AUG2020	51316	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681034	C4591001 1168 11681034	16-55	17AUG2020	53453	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11681035	C4591001 1168 11681035	16-55	17AUG2020	53457	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681036	C4591001 1168 11681036	16-55	19AUG2020	55342	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681038	C4591001 1168 11681038	16-55	18AUG2020	53461	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11681039	C4591001 1168 11681039	16-55	18AUG2020	53462	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
11681040	C4591001 1168 11681040	16-55	18AUG2020	54617	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11681041	C4591001 1168 11681041	16-55	18AUG2020	54620	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681042	C4591001 1168 11681042	16-55	18AUG2020	54625	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681045	C4591001 1168 11681045	16-55	18AUG2020	55338	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681046	C4591001 1168 11681046	16-55	18AUG2020	54628	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681047	C4591001 1168 11681047	16-55	19AUG2020	55343	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681048	C4591001 1168 11681048	16-55	19AUG2020	55348	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681050	C4591001 1168 11681050	16-55	19AUG2020	56637	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681052	C4591001 1168 11681052	16-55	19AUG2020	56640	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681053	C4591001 1168 11681053	16-55	19AUG2020	56642	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681054	C4591001 1168 11681054	16-55	20AUG2020	56643	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681058	C4591001 1168 11681058	16-55	20AUG2020	59513	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681059	C4591001 1168 11681059	16-55	20AUG2020	59518	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11681060	C4591001 1168 11681060	16-55	20AUG2020	59522	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681062	C4591001 1168 11681062	16-55	21AUG2020	59523	Placebo	21AUG2020/ Placebo	16SEP2020/ Placebo		
11681063	C4591001 1168 11681063	16-55	21AUG2020	60366	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11681064	C4591001 1168 11681064	16-55	21AUG2020	60367	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681065	C4591001 1168 11681065	16-55	21AUG2020	60369	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681068	C4591001 1168 11681068	16-55	21AUG2020	60376	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11681069	C4591001 1168 11681069	16-55	21AUG2020	60966	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11681070	C4591001 1168 11681070	16-55	21AUG2020	60968	Placebo	21AUG2020/ Placebo	05OCT2020/ Placebo		
11681071	C4591001 1168 11681071	16-55	21AUG2020	60971	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681072	C4591001 1168 11681072	16-55	21AUG2020	61482	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11681073	C4591001 1168 11681073	16-55	21AUG2020	60974	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11681074	C4591001 1168 11681074	16-55	24AUG2020	61484	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681076	C4591001 1168 11681076	16-55	24AUG2020	61485	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11681077	C4591001 1168 11681077	16-55	24AUG2020	61487	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681078	C4591001 1168 11681078	16-55	24AUG2020	64746	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11681079	C4591001 1168 11681079	16-55	25AUG2020	64749	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11681080	C4591001 1168 11681080	16-55	25AUG2020	64751	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11681081	C4591001 1168 11681081	16-55	25AUG2020	64755	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11681084	C4591001 1168 11681084	16-55	25AUG2020	66331	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11681085	C4591001 1168 11681085	16-55	25AUG2020	66338	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11681086	C4591001 1168 11681086	16-55	25AUG2020	66332	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681087	C4591001 1168 11681087	16-55	26AUG2020	66339	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11681088	C4591001 1168 11681088	16-55	26AUG2020	68369	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11681089	C4591001 1168 11681089	16-55	26AUG2020	68370	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681090	C4591001 1168 11681090	16-55	27AUG2020	68373	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11681093	C4591001 1168 11681093	16-55	27AUG2020	68374	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11681094	C4591001 1168 11681094	16-55	27AUG2020	70637	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11681095	C4591001 1168 11681095	16-55	27AUG2020	70639	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11681096	C4591001 1168 11681096	16-55	27AUG2020	70642	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11681097	C4591001 1168 11681097	16-55	27AUG2020	70646	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11681098	C4591001 1168 11681098	16-55	27AUG2020	71369	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11681100	C4591001 1168 11681100	16-55	28AUG2020	71372	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681101	C4591001 1168 11681101	16-55	28AUG2020	71379	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681102	C4591001 1168 11681102	16-55	28AUG2020	71380	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681103	C4591001 1168 11681103	16-55	28AUG2020	72295	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681104	C4591001 1168 11681104	16-55	28AUG2020	72297	Placebo	28AUG2020/ Placebo			
11681105	C4591001 1168 11681105	16-55	28AUG2020	72298	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11681107	C4591001 1168 11681107	16-55	28AUG2020	72299	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11681109	C4591001 1168 11681109	16-55	28AUG2020	73099	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681112	C4591001 1168 11681112	16-55	31AUG2020	73100	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11681114	C4591001 1168 11681114	16-55	31AUG2020	73101	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681115	C4591001 1168 11681115	16-55	31AUG2020	73107	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11681116	C4591001 1168 11681116	16-55	31AUG2020	75655	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11681117	C4591001 1168 11681117	16-55	31AUG2020	75656	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681118	C4591001 1168 11681118	16-55	01SEP2020	75662	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11681121	C4591001 1168 11681121	16-55	01SEP2020	75663	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11681125	C4591001 1168 11681125	16-55	01SEP2020	77465	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681126	C4591001 1168 11681126	16-55	01SEP2020	77468	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
11681127	C4591001 1168 11681127	16-55	02SEP2020	77473	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11681128	C4591001 1168 11681128	16-55	02SEP2020	77476	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11681130	C4591001 1168 11681130	16-55	03SEP2020	79818	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681132	C4591001 1168 11681132	16-55	03SEP2020	79819	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11681134	C4591001 1168 11681134	16-55	03SEP2020	79821	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681135	C4591001 1168 11681135	16-55	03SEP2020	79823	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681136	C4591001 1168 11681136	16-55	03SEP2020	81057	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11681137	C4591001 1168 11681137	16-55	03SEP2020	81059	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681138	C4591001 1168 11681138	16-55	03SEP2020	81060	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11681141	C4591001 1168 11681141	16-55	04SEP2020	81063	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681142	C4591001 1168 11681142	16-55	04SEP2020	82231	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11681143	C4591001 1168 11681143	16-55	04SEP2020	82232	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11681145	C4591001 1168 11681145	16-55	08SEP2020	82239	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681146	C4591001 1168 11681146	16-55	08SEP2020	82240	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11681148	C4591001 1168 11681148	16-55	09SEP2020	85218	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11681153	C4591001 1168 11681153	16-55	10SEP2020	85221	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681154	C4591001 1168 11681154	16-55	10SEP2020	85225	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11681157	C4591001 1168 11681157	16-55	10SEP2020	85228	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11681158	C4591001 1168 11681158	16-55	11SEP2020	87858	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11681159	C4591001 1168 11681159	16-55	11SEP2020	87863	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11681160	C4591001 1168 11681160	16-55	11SEP2020	87866	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11681162	C4591001 1168 11681162	16-55	11SEP2020	87868	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681163	C4591001 1168 11681163	16-55	11SEP2020	88661	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11681164	C4591001 1168 11681164	16-55	11SEP2020	88662	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo		
11681166	C4591001 1168 11681166	16-55	14SEP2020	88672	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681167	C4591001 1168 11681167	16-55	14SEP2020	88668	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681168	C4591001 1168 11681168	16-55	14SEP2020	90077	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11681169	C4591001 1168 11681169	16-55	15SEP2020	90084	Placebo	15SEP2020/ Placebo	13OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681175	C4591001 1168 11681175	16-55	15SEP2020	90086	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681176	C4591001 1168 11681176	16-55	16SEP2020	90087	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11681177	C4591001 1168 11681177	16-55	16SEP2020	91109	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11681178	C4591001 1168 11681178	16-55	16SEP2020	91115	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo		
11681182	C4591001 1168 11681182	16-55	17SEP2020	91117	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11681184	C4591001 1168 11681184	16-55	17SEP2020	91119	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11681185	C4591001 1168 11681185	16-55	17SEP2020	93020	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11681186	C4591001 1168 11681186	16-55	17SEP2020	93026	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681187	C4591001 1168 11681187	16-55	18SEP2020	93027	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681188	C4591001 1168 11681188	16-55	18SEP2020	93028	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11681192	C4591001 1168 11681192	16-55	21SEP2020	95407	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11681193	C4591001 1168 11681193	16-55	21SEP2020	95411	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681194	C4591001 1168 11681194	16-55	22SEP2020	95415	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11681195	C4591001 1168 11681195	16-55	22SEP2020	95416	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11681197	C4591001 1168 11681197	16-55	23SEP2020	97494	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11681198	C4591001 1168 11681198	16-55	23SEP2020	97518	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11681202	C4591001 1168 11681202	16-55	23SEP2020	97520	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11681203	C4591001 1168 11681203	16-55	23SEP2020	97521	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681206	C4591001 1168 11681206	16-55	24SEP2020	97526	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11681207	C4591001 1168 11681207	16-55	25SEP2020	99510	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11681210	C4591001 1168 11681210	16-55	25SEP2020	99513	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11681212	C4591001 1168 11681212	16-55	25SEP2020	99516	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681213	C4591001 1168 11681213	16-55	25SEP2020	99517	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11681215	C4591001 1168 11681215	16-55	29SEP2020	102005	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
11681216	C4591001 1168 11681216	16-55	02OCT2020	102008	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11681217	C4591001 1168 11681217	16-55	05OCT2020	102013	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11681218	C4591001 1168 11681218	16-55	05OCT2020	103913	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11681219	C4591001 1168 11681219	16-55	05OCT2020	103917	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681220	C4591001 1168 11681220	16-55	05OCT2020	102016	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
11681221	C4591001 1168 11681221	16-55	06OCT2020	103921	Placebo	06OCT2020/ Placebo	29OCT2020/ Placebo		
11681222	C4591001 1168 11681222	16-55	06OCT2020	103922	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11681223	C4591001 1168 11681223	16-55	07OCT2020	104936	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11681224	C4591001 1168 11681224	16-55	08OCT2020	104938	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11681226	C4591001 1168 11681226	16-55	08OCT2020	104939	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11681227	C4591001 1168 11681227	16-55	12OCT2020	104943	Placebo	12OCT2020/ Placebo			
11681228	C4591001 1168 11681228	16-55	13OCT2020	107277	Placebo	13OCT2020/ Placebo	10NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681229	C4591001 1168 11681229	16-55	15OCT2020	107279	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11681231	C4591001 1168 11681231	16-55	20OCT2020	107280	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11681234	C4591001 1168 11681234	16-55	21OCT2020	107281	Placebo	21OCT2020/ Placebo	02DEC2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
11681239	C4591001 1168 11681239	16-55	23OCT2020	113022	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11681241	C4591001 1168 11681241	16-55	28OCT2020	113026	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11691001	C4591001 1169 11691001	16-55	01SEP2020	76411	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11691002	C4591001 1169 11691002	16-55	01SEP2020	76413	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11691007	C4591001 1169 11691007	16-55	03SEP2020	76414	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11691010	C4591001 1169 11691010	16-55	03SEP2020	76419	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11691011	C4591001 1169 11691011	16-55	03SEP2020	80106	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11691012	C4591001 1169 11691012	16-55	04SEP2020	80108	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11691014	C4591001 1169 11691014	16-55	04SEP2020	80110	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691017	C4591001 1169 11691017	16-55	08SEP2020	80114	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691018	C4591001 1169 11691018	16-55	08SEP2020	83345	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11691019	C4591001 1169 11691019	16-55	08SEP2020	83347	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11691020	C4591001 1169 11691020	16-55	08SEP2020	83348	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11691021	C4591001 1169 11691021	16-55	08SEP2020	83355	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11691022	C4591001 1169 11691022	16-55	08SEP2020	83801	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691023	C4591001 1169 11691023	16-55	08SEP2020	83802	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11691024	C4591001 1169 11691024	16-55	09SEP2020	83807	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11691025	C4591001 1169 11691025	16-55	09SEP2020	83812	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11691026	C4591001 1169 11691026	16-55	09SEP2020	85125	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691027	C4591001 1169 11691027	16-55	09SEP2020	85128	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691029	C4591001 1169 11691029	16-55	09SEP2020	85130	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11691030	C4591001 1169 11691030	16-55	10SEP2020	85132	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11691031	C4591001 1169 11691031	16-55	10SEP2020	86418	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11691033	C4591001 1169 11691033	16-55	10SEP2020	86419	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11691034	C4591001 1169 11691034	16-55	10SEP2020	86423	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
11691036	C4591001 1169 11691036	16-55	11SEP2020	86425	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11691038	C4591001 1169 11691038	16-55	11SEP2020	87943	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11691039	C4591001 1169 11691039	16-55	11SEP2020	87945	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11691040	C4591001 1169 11691040	16-55	11SEP2020	87951	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691041	C4591001 1169 11691041	16-55	11SEP2020	87952	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11691043	C4591001 1169 11691043	16-55	14SEP2020	89346	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11691044	C4591001 1169 11691044	16-55	14SEP2020	89347	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11691046	C4591001 1169 11691046	16-55	15SEP2020	89353	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691047	C4591001 1169 11691047	16-55	15SEP2020	89355	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691048	C4591001 1169 11691048	16-55	15SEP2020	90341	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11691049	C4591001 1169 11691049	16-55	15SEP2020	90342	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11691053	C4591001 1169 11691053	16-55	16SEP2020	90343	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11691054	C4591001 1169 11691054	16-55	16SEP2020	90346	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11691055	C4591001 1169 11691055	16-55	16SEP2020	91122	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691056	C4591001 1169 11691056	16-55	16SEP2020	91124	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691057	C4591001 1169 11691057	16-55	16SEP2020	91127	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691058	C4591001 1169 11691058	16-55	16SEP2020	91131	Placebo	16SEP2020/ Placebo		07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11691059	C4591001 1169 11691059	16-55	17SEP2020	92070	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11691060	C4591001 1169 11691060	16-55	17SEP2020	92071	Placebo	17SEP2020/ Placebo	13OCT2020/ Placebo		
11691062	C4591001 1169 11691062	16-55	17SEP2020	92075	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11691063	C4591001 1169 11691063	16-55	17SEP2020	92077	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691064	C4591001 1169 11691064	16-55	17SEP2020	92597	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11691065	C4591001 1169 11691065	16-55	18SEP2020	92600	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11691067	C4591001 1169 11691067	16-55	18SEP2020	92602	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11691069	C4591001 1169 11691069	16-55	18SEP2020	92608	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11691072	C4591001 1169 11691072	16-55	22SEP2020	95983	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11691073	C4591001 1169 11691073†	16-55	01OCT2020	95984	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11691075	C4591001 1169 11691075†	16-55	02OCT2020	95987	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11701020	C4591001 1170 11701020	16-55	17AUG2020	50616	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701021	C4591001 1170 11701021	16-55	17AUG2020	50617	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701022	C4591001 1170 11701022	16-55	17AUG2020	52770	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11701024	C4591001 1170 11701024	16-55	17AUG2020	52772	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701025	C4591001 1170 11701025	16-55	17AUG2020	52780	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701026	C4591001 1170 11701026	16-55	17AUG2020	53645	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701029	C4591001 1170 11701029	16-55	18AUG2020	53648	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701031	C4591001 1170 11701031	16-55	18AUG2020	53649	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701034	C4591001 1170 11701034	16-55	19AUG2020	53654	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701035	C4591001 1170 11701035	16-55	19AUG2020	56309	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701036	C4591001 1170 11701036	16-55	19AUG2020	56311	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11701037	C4591001 1170 11701037	16-55	19AUG2020	56316	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701038	C4591001 1170 11701038	16-55	19AUG2020	56317	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11701040	C4591001 1170 11701040	16-55	19AUG2020	57250	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
11701041	C4591001 1170 11701041	16-55	19AUG2020	57251	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11701042	C4591001 1170 11701042	16-55	20AUG2020	57252	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701043	C4591001 1170 11701043	16-55	20AUG2020	57255	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701044	C4591001 1170 11701044	16-55	20AUG2020	58446	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701045	C4591001 1170 11701045	16-55	20AUG2020	58447	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
11701047	C4591001 1170 11701047	16-55	20AUG2020	58450	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701048	C4591001 1170 11701048	16-55	20AUG2020	58455	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
11701049	C4591001 1170 11701049	16-55	20AUG2020	59372	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701052	C4591001 1170 11701052	16-55	21AUG2020	59375	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701054	C4591001 1170 11701054	16-55	21AUG2020	59378	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701055	C4591001 1170 11701055	16-55	21AUG2020	59379	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11701057	C4591001 1170 11701057	16-55	21AUG2020	60727	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701059	C4591001 1170 11701059	16-55	21AUG2020	60733	Placebo	21AUG2020/ Placebo	08SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701060	C4591001 1170 11701060	16-55	21AUG2020	60734	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11701063	C4591001 1170 11701063	16-55	24AUG2020	60736	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701064	C4591001 1170 11701064	16-55	24AUG2020	63629	Placebo	24AUG2020/ Placebo	11SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701065	C4591001 1170 11701065	16-55	24AUG2020	63630	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701069	C4591001 1170 11701069	16-55	24AUG2020	63636	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701072	C4591001 1170 11701072	16-55	25AUG2020	63639	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701073	C4591001 1170 11701073	16-55	25AUG2020	65622	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11701074	C4591001 1170 11701074	16-55	25AUG2020	65623	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701075	C4591001 1170 11701075	16-55	25AUG2020	65625	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701076	C4591001 1170 11701076	16-55	25AUG2020	65629	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11701077	C4591001 1170 11701077	16-55	25AUG2020	66102	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
11701079	C4591001 1170 11701079	16-55	25AUG2020	66105	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11701081	C4591001 1170 11701081	16-55	25AUG2020	66106	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
11701085	C4591001 1170 11701085	16-55	26AUG2020	66112	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701086	C4591001 1170 11701086	16-55	26AUG2020	67535	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701087	C4591001 1170 11701087	16-55	26AUG2020	67536	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701089	C4591001 1170 11701089	16-55	26AUG2020	67538	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11701091	C4591001 1170 11701091	16-55	26AUG2020	67540	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701092	C4591001 1170 11701092	16-55	26AUG2020	68192	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701093	C4591001 1170 11701093	16-55	26AUG2020	68195	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701094	C4591001 1170 11701094	16-55	26AUG2020	68196	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701095	C4591001 1170 11701095	16-55	26AUG2020	68197	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11701096	C4591001 1170 11701096	16-55	26AUG2020	68948	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701097	C4591001 1170 11701097	16-55	27AUG2020	68949	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701098	C4591001 1170 11701098	16-55	27AUG2020	68950	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701099	C4591001 1170 11701099	16-55	27AUG2020	68952	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701100	C4591001 1170 11701100	16-55	27AUG2020	70330	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701101	C4591001 1170 11701101	16-55	27AUG2020	70332	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701102	C4591001 1170 11701102	16-55	27AUG2020	70335	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11701103	C4591001 1170 11701103	16-55	27AUG2020	70336	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701104	C4591001 1170 11701104	16-55	27AUG2020	70601	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701105	C4591001 1170 11701105	16-55	27AUG2020	70605	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701106	C4591001 1170 11701106	16-55	27AUG2020	70607	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701107	C4591001 1170 11701107	16-55	27AUG2020	70612	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701108	C4591001 1170 11701108	16-55	27AUG2020	70961	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701110	C4591001 1170 11701110	16-55	27AUG2020	70964	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
11701111	C4591001 1170 11701111	16-55	27AUG2020	70965	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701112	C4591001 1170 11701112	16-55	28AUG2020	70967	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11701115	C4591001 1170 11701115	16-55	28AUG2020	71767	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701116	C4591001 1170 11701116	16-55	28AUG2020	71771	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701117	C4591001 1170 11701117	16-55	28AUG2020	71773	Placebo	28AUG2020/ Placebo	15SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701118	C4591001 1170 11701118	16-55	28AUG2020	71775	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701119	C4591001 1170 11701119	16-55	28AUG2020	71925	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701120	C4591001 1170 11701120	16-55	28AUG2020	71928	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701121	C4591001 1170 11701121	16-55	28AUG2020	71930	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11701122	C4591001 1170 11701122	16-55	28AUG2020	71931	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701123	C4591001 1170 11701123	16-55	28AUG2020	72259	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11701125	C4591001 1170 11701125	16-55	28AUG2020	72261	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701126	C4591001 1170 11701126	16-55	28AUG2020	72262	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11701127	C4591001 1170 11701127	16-55	28AUG2020	72264	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701128	C4591001 1170 11701128	16-55	28AUG2020	72701	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11701129	C4591001 1170 11701129	16-55	28AUG2020	72703	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701131	C4591001 1170 11701131	16-55	31AUG2020	72704	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701136	C4591001 1170 11701136	16-55	31AUG2020	72708	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701137	C4591001 1170 11701137	16-55	31AUG2020	75092	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701138	C4591001 1170 11701138	16-55	31AUG2020	75095	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701139	C4591001 1170 11701139	16-55	31AUG2020	75097	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11701143	C4591001 1170 11701143	16-55	31AUG2020	75098	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701144	C4591001 1170 11701144	16-55	31AUG2020	75690	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701145	C4591001 1170 11701145	16-55	31AUG2020	75691	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701146	C4591001 1170 11701146	16-55	31AUG2020	75694	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo		
11701149	C4591001 1170 11701149	16-55	01SEP2020	75697	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11701150	C4591001 1170 11701150	16-55	01SEP2020	76316	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701151	C4591001 1170 11701151	16-55	01SEP2020	76321	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701152	C4591001 1170 11701152	16-55	01SEP2020	76322	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701153	C4591001 1170 11701153	16-55	01SEP2020	76324	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701154	C4591001 1170 11701154	16-55	01SEP2020	76521	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701156	C4591001 1170 11701156	16-55	01SEP2020	76523	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701158	C4591001 1170 11701158	16-55	01SEP2020	76525	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701159	C4591001 1170 11701159	16-55	01SEP2020	76528	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701162	C4591001 1170 11701162	16-55	01SEP2020	77142	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11701163	C4591001 1170 11701163	16-55	01SEP2020	77146	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701164	C4591001 1170 11701164	16-55	01SEP2020	77151	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11701165	C4591001 1170 11701165	16-55	01SEP2020	77152	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701166	C4591001 1170 11701166	16-55	01SEP2020	77347	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701167	C4591001 1170 11701167	16-55	01SEP2020	77348	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701170	C4591001 1170 11701170	16-55	02SEP2020	77351	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11701171	C4591001 1170 11701171	16-55	02SEP2020	77352	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11701174	C4591001 1170 11701174	16-55	02SEP2020	78332	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701178	C4591001 1170 11701178	16-55	02SEP2020	78333	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701179	C4591001 1170 11701179	16-55	02SEP2020	78335	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701180	C4591001 1170 11701180	16-55	02SEP2020	78340	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701181	C4591001 1170 11701181	16-55	02SEP2020	78767	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701182	C4591001 1170 11701182	16-55	02SEP2020	78768	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701183	C4591001 1170 11701183	16-55	02SEP2020	78769	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701184	C4591001 1170 11701184	16-55	02SEP2020	78770	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11701185	C4591001 1170 11701185	16-55	02SEP2020	79243	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11701187	C4591001 1170 11701187	16-55	02SEP2020	79247	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701190	C4591001 1170 11701190	16-55	03SEP2020	79250	Placebo	03SEP2020/ Placebo	28SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	
11701191	C4591001 1170 11701191	16-55	03SEP2020	79251	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701192	C4591001 1170 11701192	16-55	03SEP2020	79651	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701193	C4591001 1170 11701193	16-55	03SEP2020	79653	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701195	C4591001 1170 11701195	16-55	03SEP2020	79655	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11701196	C4591001 1170 11701196	16-55	03SEP2020	79658	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701199	C4591001 1170 11701199	16-55	03SEP2020	80576	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701201	C4591001 1170 11701201	16-55	03SEP2020	80578	Placebo	03SEP2020/ Placebo	21SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11701203	C4591001 1170 11701203	16-55	03SEP2020	80581	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701204	C4591001 1170 11701204	16-55	03SEP2020	80582	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11701205	C4591001 1170 11701205	16-55	03SEP2020	81020	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11701206	C4591001 1170 11701206	16-55	04SEP2020	81021	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701207	C4591001 1170 11701207	16-55	04SEP2020	81022	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11701208	C4591001 1170 11701208	16-55	04SEP2020	81024	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701209	C4591001 1170 11701209	16-55	04SEP2020	81678	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
11701210	C4591001 1170 11701210	16-55	08SEP2020	81679	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11701211	C4591001 1170 11701211	16-55	08SEP2020	81680	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701212	C4591001 1170 11701212	16-55	08SEP2020	81686	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701213	C4591001 1170 11701213	16-55	08SEP2020	83419	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701215	C4591001 1170 11701215	16-55	08SEP2020	83420	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701221	C4591001 1170 11701221	16-55	08SEP2020	83423	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701222	C4591001 1170 11701222	16-55	08SEP2020	83426	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701223	C4591001 1170 11701223	16-55	08SEP2020	83902	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701225	C4591001 1170 11701225	16-55	08SEP2020	83903	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701226	C4591001 1170 11701226	16-55	08SEP2020	83906	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11701227	C4591001 1170 11701227	16-55	08SEP2020	83907	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701228	C4591001 1170 11701228	16-55	08SEP2020	84225	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701229	C4591001 1170 11701229	16-55	08SEP2020	84229	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701230	C4591001 1170 11701230	16-55	08SEP2020	84231	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701231	C4591001 1170 11701231	16-55	08SEP2020	84232	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo		
11701232	C4591001 1170 11701232	16-55	08SEP2020	84378	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11701233	C4591001 1170 11701233	16-55	08SEP2020	84380	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701234	C4591001 1170 11701234	16-55	09SEP2020	84381	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701235	C4591001 1170 11701235	16-55	09SEP2020	84388	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701236	C4591001 1170 11701236	16-55	09SEP2020	84874	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701237	C4591001 1170 11701237	16-55	09SEP2020	84875	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701241	C4591001 1170 11701241	16-55	09SEP2020	84877	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701243	C4591001 1170 11701243	16-55	09SEP2020	84880	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701244	C4591001 1170 11701244	16-55	09SEP2020	85472	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701245	C4591001 1170 11701245	16-55	09SEP2020	85473	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701249	C4591001 1170 11701249	16-55	09SEP2020	85478	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701250	C4591001 1170 11701250	16-55	09SEP2020	85480	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701251	C4591001 1170 11701251	16-55	09SEP2020	85747	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701252	C4591001 1170 11701252	16-55	09SEP2020	85749	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701253	C4591001 1170 11701253	16-55	09SEP2020	85751	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701255	C4591001 1170 11701255	16-55	09SEP2020	85755	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701256	C4591001 1170 11701256	16-55	09SEP2020	256211	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701257	C4591001 1170 11701257	16-55	09SEP2020	85961	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701258	C4591001 1170 11701258	16-55	09SEP2020	85965	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11701259	C4591001 1170 11701259	16-55	09SEP2020	85967	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701260	C4591001 1170 11701260	16-55	09SEP2020	85969	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701261	C4591001 1170 11701261	16-55	10SEP2020	86297	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701262	C4591001 1170 11701262	16-55	10SEP2020	86298	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701263	C4591001 1170 11701263	16-55	10SEP2020	86300	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701264	C4591001 1170 11701264	16-55	10SEP2020	86305	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701268	C4591001 1170 11701268	16-55	10SEP2020	86768	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701269	C4591001 1170 11701269	16-55	10SEP2020	86772	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701271	C4591001 1170 11701271	16-55	10SEP2020	86775	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701274	C4591001 1170 11701274	16-55	10SEP2020	86776	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701279	C4591001 1170 11701279	16-55	10SEP2020	87332	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701280	C4591001 1170 11701280	16-55	10SEP2020	87334	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701281	C4591001 1170 11701281	16-55	10SEP2020	87337	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701283	C4591001 1170 11701283	16-55	10SEP2020	87340	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701284	C4591001 1170 11701284	16-55	10SEP2020	87466	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11701285	C4591001 1170 11701285	16-55	10SEP2020	87467	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701286	C4591001 1170 11701286	16-55	10SEP2020	87468	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11701287	C4591001 1170 11701287	16-55	10SEP2020	87472	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11701288	C4591001 1170 11701288	16-55	10SEP2020	87569	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701289	C4591001 1170 11701289	16-55	11SEP2020	87575	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701290	C4591001 1170 11701290	16-55	11SEP2020	87576	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11701291	C4591001 1170 11701291	16-55	11SEP2020	87579	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701292	C4591001 1170 11701292	16-55	11SEP2020	87992	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701293	C4591001 1170 11701293	16-55	11SEP2020	87994	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701296	C4591001 1170 11701296	16-55	11SEP2020	87995	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		
11701297	C4591001 1170 11701297	16-55	11SEP2020	87996	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701298	C4591001 1170 11701298	16-55	11SEP2020	88457	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701300	C4591001 1170 11701300	16-55	11SEP2020	88461	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701302	C4591001 1170 11701302	16-55	11SEP2020	88463	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11701303	C4591001 1170 11701303	16-55	11SEP2020	88464	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701304	C4591001 1170 11701304	16-55	11SEP2020	88770	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701306	C4591001 1170 11701306	16-55	11SEP2020	88774	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701307	C4591001 1170 11701307	16-55	11SEP2020	88779	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701308	C4591001 1170 11701308	16-55	11SEP2020	88780	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11701310	C4591001 1170 11701310	16-55	14SEP2020	89321	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701311	C4591001 1170 11701311	16-55	14SEP2020	89324	Placebo	14SEP2020/ Placebo			
11701312	C4591001 1170 11701312	16-55	14SEP2020	89327	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701313	C4591001 1170 11701313	16-55	14SEP2020	89330	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11701314	C4591001 1170 11701314	16-55	14SEP2020	89852	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11701315	C4591001 1170 11701315	16-55	14SEP2020	89853	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11701316	C4591001 1170 11701316	16-55	14SEP2020	89855	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11701317	C4591001 1170 11701317	16-55	15SEP2020	89856	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701318	C4591001 1170 11701318	16-55	15SEP2020	90317	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701319	C4591001 1170 11701319	16-55	15SEP2020	90321	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701320	C4591001 1170 11701320	16-55	15SEP2020	90322	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701321	C4591001 1170 11701321	16-55	15SEP2020	90324	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701322	C4591001 1170 11701322	16-55	15SEP2020	90510	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701323	C4591001 1170 11701323	16-55	15SEP2020	90511	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701324	C4591001 1170 11701324	16-55	15SEP2020	90513	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701325	C4591001 1170 11701325†	16-55	15SEP2020	90517	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11701326	C4591001 1170 11701326†	16-55	16SEP2020	91019	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11701334	C4591001 1170 11701334†	16-55	16SEP2020	91021	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11701337	C4591001 1170 11701337	16-55	16SEP2020	91022	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701338	C4591001 1170 11701338	16-55	17SEP2020	91024	Placebo	17SEP2020/ Placebo	15OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701340	C4591001 1170 11701340	16-55	17SEP2020	92265	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11701341	C4591001 1170 11701341	16-55	17SEP2020	92267	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701342	C4591001 1170 11701342	16-55	17SEP2020	92270	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11701343	C4591001 1170 11701343	16-55	17SEP2020	92272	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11701344	C4591001 1170 11701344†	16-55	17SEP2020	92777	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11701346	C4591001 1170 11701346	16-55	17SEP2020	92779	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701348	C4591001 1170 11701348	16-55	17SEP2020	92780	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11701349	C4591001 1170 11701349	16-55	17SEP2020	92785	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701350	C4591001 1170 11701350	16-55	18SEP2020	93285	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701352	C4591001 1170 11701352†	16-55	18SEP2020	93286	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11701355	C4591001 1170 11701355†	16-55	18SEP2020	93287	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11701357	C4591001 1170 11701357	16-55	21SEP2020	94735	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11701358	C4591001 1170 11701358	16-55	21SEP2020	94736	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11701359	C4591001 1170 11701359	16-55	21SEP2020	94740	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
11701360	C4591001 1170 11701360	16-55	21SEP2020	94744	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701361	C4591001 1170 11701361	16-55	21SEP2020	95623	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701362	C4591001 1170 11701362	16-55	22SEP2020	95628	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11701364	C4591001 1170 11701364	16-55	22SEP2020	95629	Placebo	22SEP2020/ Placebo	17NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11701365	C4591001 1170 11701365	16-55	22SEP2020	95630	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701370	C4591001 1170 11701370	16-55	23SEP2020	97582	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11701372	C4591001 1170 11701372	16-55	25SEP2020	97585	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701373	C4591001 1170 11701373	16-55	25SEP2020	97587	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11701374	C4591001 1170 11701374	16-55	20OCT2020	400049	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo		
11701375	C4591001 1170 11701375	16-55	20OCT2020	400051	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701376	C4591001 1170 11701376	16-55	20OCT2020	400053	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701377	C4591001 1170 11701377	16-55	20OCT2020	400057	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701378	C4591001 1170 11701378	16-55	20OCT2020	400074	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701379	C4591001 1170 11701379	16-55	20OCT2020	400076	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701380	C4591001 1170 11701380	16-55	20OCT2020	400081	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701381	C4591001 1170 11701381	16-55	20OCT2020	400083	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701382	C4591001 1170 11701382	16-55	20OCT2020	400100	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701383	C4591001 1170 11701383	16-55	20OCT2020	400101	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701384	C4591001 1170 11701384	16-55	20OCT2020	400106	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701385	C4591001 1170 11701385†	16-55	20OCT2020	400108	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701386	C4591001 1170 11701386	16-55	20OCT2020	400109	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701387	C4591001 1170 11701387	16-55	20OCT2020	400111	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11701388	C4591001 1170 11701388	16-55	20OCT2020	400115	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701389	C4591001 1170 11701389	16-55	20OCT2020	400117	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11701390	C4591001 1170 11701390	16-55	20OCT2020	400139	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701391	C4591001 1170 11701391	16-55	20OCT2020	400140	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701392	C4591001 1170 11701392	16-55	20OCT2020	400141	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11701393	C4591001 1170 11701393	16-55	21OCT2020	400144	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
11701394	C4591001 1170 11701394†	16-55	21OCT2020	400157	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701395	C4591001 1170 11701395	16-55	21OCT2020	400159	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701396	C4591001 1170 11701396	16-55	21OCT2020	400161	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701397	C4591001 1170 11701397	16-55	21OCT2020	400162	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11701398	C4591001 1170 11701398	16-55	21OCT2020	400182	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701399	C4591001 1170 11701399	16-55	21OCT2020	400183	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701400	C4591001 1170 11701400	16-55	21OCT2020	400184	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701401	C4591001 1170 11701401	16-55	21OCT2020	400189	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11701402	C4591001 1170 11701402	16-55	21OCT2020	400205	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701403	C4591001 1170 11701403	16-55	21OCT2020	400211	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11701404	C4591001 1170 11701404	16-55	21OCT2020	400213	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
11701405	C4591001 1170 11701405	16-55	21OCT2020	400215	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11701406	C4591001 1170 11701406	16-55	21OCT2020	400243	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701407	C4591001 1170 11701407	16-55	21OCT2020	400245	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701408	C4591001 1170 11701408†	16-55	21OCT2020	400246	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701410	C4591001 1170 11701410	16-55	21OCT2020	400265	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701411	C4591001 1170 11701411	16-55	21OCT2020	400270	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701412	C4591001 1170 11701412	16-55	21OCT2020	400272	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701413	C4591001 1170 11701413	16-55	21OCT2020	400273	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
11701414	C4591001 1170 11701414	16-55	21OCT2020	400304	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
11701416	C4591001 1170 11701416	16-55	22OCT2020	400309	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11701417	C4591001 1170 11701417	16-55	22OCT2020	400311	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701418	C4591001 1170 11701418	16-55	22OCT2020	400312	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701419	C4591001 1170 11701419	16-55	22OCT2020	400354	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11701420	C4591001 1170 11701420	16-55	22OCT2020	400355	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701421	C4591001 1170 11701421	16-55	22OCT2020	400356	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701422	C4591001 1170 11701422†	16-55	22OCT2020	400358	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701423	C4591001 1170 11701423	16-55	22OCT2020	400378	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701424	C4591001 1170 11701424	16-55	22OCT2020	400379	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701425	C4591001 1170 11701425	16-55	22OCT2020	400380	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701426	C4591001 1170 11701426	16-55	22OCT2020	400381	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701427	C4591001 1170 11701427†	16-55	22OCT2020	400421	Placebo	22OCT2020/ Placebo			
11701428	C4591001 1170 11701428	16-55	22OCT2020	400426	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701429	C4591001 1170 11701429	16-55	22OCT2020	400428	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11701430	C4591001 1170 11701430	16-55	22OCT2020	400431	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11701431	C4591001 1170 11701431	16-55	23OCT2020	400505	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701432	C4591001 1170 11701432	16-55	23OCT2020	400508	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701433	C4591001 1170 11701433	16-55	23OCT2020	400511	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701434	C4591001 1170 11701434	16-55	23OCT2020	400514	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11701435	C4591001 1170 11701435	16-55	23OCT2020	400554	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701436	C4591001 1170 11701436	16-55	23OCT2020	400555	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11701437	C4591001 1170 11701437	16-55	23OCT2020	400556	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701438	C4591001 1170 11701438	16-55	23OCT2020	400557	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11701439	C4591001 1170 11701439	16-55	23OCT2020	400594	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11701440	C4591001 1170 11701440	16-55	23OCT2020	400595	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701441	C4591001 1170 11701441	16-55	23OCT2020	400596	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11701442	C4591001 1170 11701442	16-55	23OCT2020	400598	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701443	C4591001 1170 11701443	16-55	23OCT2020	400663	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11701444	C4591001 1170 11701444	16-55	23OCT2020	400664	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701445	C4591001 1170 11701445	16-55	23OCT2020	400669	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11701446	C4591001 1170 11701446	16-55	23OCT2020	400671	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11701447	C4591001 1170 11701447	16-55	23OCT2020	400673	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701449	C4591001 1170 11701449	16-55	26OCT2020	400677	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701450	C4591001 1170 11701450	16-55	26OCT2020	400678	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701451	C4591001 1170 11701451	16-55	26OCT2020	400818	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701452	C4591001 1170 11701452	16-55	26OCT2020	400825	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11701453	C4591001 1170 11701453	16-55	26OCT2020	400827	Placebo	26OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701455	C4591001 1170 11701455	16-55	26OCT2020	400877	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11701456	C4591001 1170 11701456†	16-55	26OCT2020	400879	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701457	C4591001 1170 11701457†	16-55	26OCT2020	400880	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701458	C4591001 1170 11701458	16-55	26OCT2020	400881	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701459	C4591001 1170 11701459	16-55	26OCT2020	400928	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701460	C4591001 1170 11701460	16-55	26OCT2020	400931	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701461	C4591001 1170 11701461	16-55	26OCT2020	400934	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701462	C4591001 1170 11701462	16-55	26OCT2020	400936	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701463	C4591001 1170 11701463†	16-55	26OCT2020	400964	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701464	C4591001 1170 11701464	16-55	26OCT2020	400965	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701465	C4591001 1170 11701465	16-55	26OCT2020	400968	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11701466	C4591001 1170 11701466	16-55	26OCT2020	400969	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701467	C4591001 1170 11701467	16-55	26OCT2020	401021	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11701468	C4591001 1170 11701468	16-55	27OCT2020	401023	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701469	C4591001 1170 11701469	16-55	27OCT2020	401025	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701470	C4591001 1170 11701470	16-55	27OCT2020	401030	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11701471	C4591001 1170 11701471	16-55	27OCT2020	401081	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11701472	C4591001 1170 11701472	16-55	27OCT2020	401084	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701473	C4591001 1170 11701473	16-55	27OCT2020	401086	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11701474	C4591001 1170 11701474†	16-55	27OCT2020	401087	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701475	C4591001 1170 11701475	16-55	27OCT2020	401129	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701476	C4591001 1170 11701476	16-55	27OCT2020	401133	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701477	C4591001 1170 11701477	16-55	28OCT2020	401135	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11701478	C4591001 1170 11701478	16-55	28OCT2020	401139	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701479	C4591001 1170 11701479	16-55	28OCT2020	401189	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11701480	C4591001 1170 11701480	16-55	28OCT2020	401193	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701481	C4591001 1170 11701481	16-55	28OCT2020	401194	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11701482	C4591001 1170 11701482	16-55	28OCT2020	401200	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo		
11701483	C4591001 1170 11701483	16-55	28OCT2020	401206	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11701484	C4591001 1170 11701484	16-55	28OCT2020	401209	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701485	C4591001 1170 11701485	16-55	28OCT2020	401210	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
11701486	C4591001 1170 11701486	16-55	29OCT2020	401211	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11701487	C4591001 1170 11701487	16-55	29OCT2020	401261	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		
11701488	C4591001 1170 11701488	16-55	29OCT2020	401266	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11701489	C4591001 1170 11701489	16-55	29OCT2020	401267	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
11701490	C4591001 1170 11701490	16-55	29OCT2020	401271	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11701491	C4591001 1170 11701491	16-55	29OCT2020	401369	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701492	C4591001 1170 11701492	16-55	29OCT2020	401377	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11701493	C4591001 1170 11701493	16-55	29OCT2020	401378	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701494	C4591001 1170 11701494	16-55	29OCT2020	401380	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11701495	C4591001 1170 11701495	16-55	29OCT2020	401433	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11701496	C4591001 1170 11701496	16-55	30OCT2020	401434	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11701497	C4591001 1170 11701497†	16-55	30OCT2020	401436	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11701498	C4591001 1170 11701498	16-55	30OCT2020	401440	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701499	C4591001 1170 11701499	16-55	30OCT2020	401504	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11701500	C4591001 1170 11701500	16-55	30OCT2020	401506	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11701501	C4591001 1170 11701501	16-55	30OCT2020	401509	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11711027	C4591001 1171 11711027	16-55	14AUG2020	50056	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
11711042	C4591001 1171 11711042	16-55	17AUG2020	50996	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)			
11711043	C4591001 1171 11711043	16-55	17AUG2020	53444	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711044	C4591001 1171 11711044	16-55	17AUG2020	50997	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11711046	C4591001 1171 11711046	16-55	17AUG2020	53447	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
11711047	C4591001 1171 11711047	16-55	17AUG2020	53449	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11711050	C4591001 1171 11711050	16-55	17AUG2020	53450	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11711052	C4591001 1171 11711052	16-55	17AUG2020	53609	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711053	C4591001 1171 11711053	16-55	18AUG2020	53612	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11711055	C4591001 1171 11711055	16-55	18AUG2020	53619	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711056	C4591001 1171 11711056	16-55	18AUG2020	53620	Placebo	18AUG2020/ Placebo	14SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11711058	C4591001 1171 11711058	16-55	18AUG2020	54546	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11711060	C4591001 1171 11711060	16-55	18AUG2020	54548	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711062	C4591001 1171 11711062	16-55	18AUG2020	54553	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11711065	C4591001 1171 11711065	16-55	18AUG2020	54556	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711066	C4591001 1171 11711066	16-55	18AUG2020	55315	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11711067	C4591001 1171 11711067	16-55	18AUG2020	55316	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711068	C4591001 1171 11711068	16-55	18AUG2020	55320	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11711069	C4591001 1171 11711069	16-55	18AUG2020	55322	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711070	C4591001 1171 11711070	16-55	19AUG2020	56334	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11711071	C4591001 1171 11711071	16-55	19AUG2020	56336	Placebo	19AUG2020/ Placebo	16SEP2020/ Placebo		
11711072	C4591001 1171 11711072	16-55	19AUG2020	56340	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
11711073	C4591001 1171 11711073	16-55	19AUG2020	56343	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711074	C4591001 1171 11711074	16-55	19AUG2020	56825	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11711076	C4591001 1171 11711076	16-55	19AUG2020	56831	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11711077	C4591001 1171 11711077	16-55	19AUG2020	56828	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11711079	C4591001 1171 11711079	16-55	19AUG2020	56836	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711080	C4591001 1171 11711080	16-55	19AUG2020	57561	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11711081	C4591001 1171 11711081	16-55	19AUG2020	57562	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11711082	C4591001 1171 11711082	16-55	20AUG2020	57564	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11711083	C4591001 1171 11711083	16-55	20AUG2020	57567	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711084	C4591001 1171 11711084	16-55	20AUG2020	58589	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11711085	C4591001 1171 11711085	16-55	20AUG2020	58590	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711087	C4591001 1171 11711087	16-55	20AUG2020	58592	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711088	C4591001 1171 11711088	16-55	20AUG2020	58760	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711089	C4591001 1171 11711089	16-55	20AUG2020	58600	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711091	C4591001 1171 11711091	16-55	20AUG2020	58765	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711092	C4591001 1171 11711092	16-55	20AUG2020	58767	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11711093	C4591001 1171 11711093	16-55	20AUG2020	58768	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11711095	C4591001 1171 11711095	16-55	20AUG2020	59562	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711096	C4591001 1171 11711096	16-55	20AUG2020	59565	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11711097	C4591001 1171 11711097	16-55	20AUG2020	59567	Placebo	20AUG2020/ Placebo	14SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11711100	C4591001 1171 11711100	16-55	24AUG2020	63656	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711101	C4591001 1171 11711101	16-55	24AUG2020	59570	Placebo	24AUG2020/ Placebo	11SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11711103	C4591001 1171 11711103	16-55	24AUG2020	63657	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11711104	C4591001 1171 11711104	16-55	24AUG2020	63660	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711105	C4591001 1171 11711105	16-55	24AUG2020	63664	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711106	C4591001 1171 11711106	16-55	24AUG2020	64436	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711109	C4591001 1171 11711109	16-55	24AUG2020	64437	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11711110	C4591001 1171 11711110	16-55	25AUG2020	65646	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11711111	C4591001 1171 11711111	16-55	25AUG2020	64438	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11711112	C4591001 1171 11711112	16-55	25AUG2020	64439	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11711113	C4591001 1171 11711113	16-55	25AUG2020	65647	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711114	C4591001 1171 11711114	16-55	25AUG2020	65649	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711115	C4591001 1171 11711115	16-55	25AUG2020	65650	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11711116	C4591001 1171 11711116	16-55	25AUG2020	65853	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11711118	C4591001 1171 11711118	16-55	25AUG2020	65856	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11711119	C4591001 1171 11711119	16-55	25AUG2020	65859	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11711121	C4591001 1171 11711121	16-55	25AUG2020	66574	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11711122	C4591001 1171 11711122	16-55	25AUG2020	65860	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711124	C4591001 1171 11711124	16-55	25AUG2020	66575	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11711125	C4591001 1171 11711125	16-55	25AUG2020	66578	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11711126	C4591001 1171 11711126	16-55	25AUG2020	66580	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711127	C4591001 1171 11711127	16-55	26AUG2020	67770	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711128	C4591001 1171 11711128	16-55	26AUG2020	67771	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11711129	C4591001 1171 11711129	16-55	26AUG2020	67775	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711130	C4591001 1171 11711130	16-55	26AUG2020	67772	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711131	C4591001 1171 11711131	16-55	26AUG2020	68013	Placebo	26AUG2020/ Placebo			
11711133	C4591001 1171 11711133	16-55	26AUG2020	68018	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711134	C4591001 1171 11711134	16-55	26AUG2020	68015	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711135	C4591001 1171 11711135	16-55	26AUG2020	68017	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711136	C4591001 1171 11711136	16-55	26AUG2020	68129	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11711137	C4591001 1171 11711137	16-55	26AUG2020	68131	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711138	C4591001 1171 11711138	16-55	26AUG2020	68136	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11711139	C4591001 1171 11711139	16-55	26AUG2020	68137	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11711141	C4591001 1171 11711141	16-55	26AUG2020	68909	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711142	C4591001 1171 11711142	16-55	26AUG2020	68920	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11711143	C4591001 1171 11711143	16-55	26AUG2020	68912	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711144	C4591001 1171 11711144	16-55	26AUG2020	68911	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711145	C4591001 1171 11711145	16-55	26AUG2020	69237	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11711146	C4591001 1171 11711146	16-55	26AUG2020	69241	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11711147	C4591001 1171 11711147	16-55	27AUG2020	69243	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11711151	C4591001 1171 11711151	16-55	31AUG2020	69244	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711152	C4591001 1171 11711152	16-55	31AUG2020	75057	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		
11711153	C4591001 1171 11711153	16-55	31AUG2020	75058	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11711154	C4591001 1171 11711154	16-55	31AUG2020	75061	Placebo	31AUG2020/ Placebo	18SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11711156	C4591001 1171 11711156	16-55	01SEP2020	75803	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711158	C4591001 1171 11711158	16-55	31AUG2020	75063	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11711159	C4591001 1171 11711159	16-55	31AUG2020	75799	Placebo	31AUG2020/ Placebo			
11711161	C4591001 1171 11711161	16-55	31AUG2020	75802	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711163	C4591001 1171 11711163	16-55	01SEP2020	75807	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711164	C4591001 1171 11711164	16-55	01SEP2020	76726	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711166	C4591001 1171 11711166	16-55	01SEP2020	76728	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711167	C4591001 1171 11711167	16-55	01SEP2020	76727	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711169	C4591001 1171 11711169	16-55	01SEP2020	76730	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711171	C4591001 1171 11711171	16-55	01SEP2020	77275	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11711172	C4591001 1171 11711172	16-55	01SEP2020	77279	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11711174	C4591001 1171 11711174	16-55	01SEP2020	77280	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11711175	C4591001 1171 11711175	16-55	02SEP2020	77284	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711176	C4591001 1171 11711176	16-55	02SEP2020	78200	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711177	C4591001 1171 11711177	16-55	02SEP2020	78204	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711181	C4591001 1171 11711181	16-55	02SEP2020	78205	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11711183	C4591001 1171 11711183	16-55	02SEP2020	78206	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711184	C4591001 1171 11711184	16-55	02SEP2020	79085	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711185	C4591001 1171 11711185	16-55	02SEP2020	79090	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711186	C4591001 1171 11711186	16-55	02SEP2020	79091	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo		
11711187	C4591001 1171 11711187	16-55	02SEP2020	79096	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11711189	C4591001 1171 11711189	16-55	03SEP2020	79890	Placebo	03SEP2020/ Placebo	21SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711191	C4591001 1171 11711191	16-55	08SEP2020	79896	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711192	C4591001 1171 11711192	16-55	08SEP2020	79897	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711194	C4591001 1171 11711194	16-55	08SEP2020	79900	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711195	C4591001 1171 11711195	16-55	08SEP2020	83925	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11711196	C4591001 1171 11711196	16-55	08SEP2020	83926	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711198	C4591001 1171 11711198	16-55	08SEP2020	83928	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11711200	C4591001 1171 11711200	16-55	08SEP2020	83932	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711203	C4591001 1171 11711203	16-55	09SEP2020	85195	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711206	C4591001 1171 11711206	16-55	09SEP2020	85199	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11711207	C4591001 1171 11711207	16-55	09SEP2020	85200	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo		
11711209	C4591001 1171 11711209	16-55	09SEP2020	85201	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711210	C4591001 1171 11711210	16-55	09SEP2020	85855	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711211	C4591001 1171 11711211	16-55	09SEP2020	85856	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711212	C4591001 1171 11711212	16-55	09SEP2020	85864	Placebo	09SEP2020/ Placebo	16OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711213	C4591001 1171 11711213	16-55	09SEP2020	85857	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711214	C4591001 1171 11711214	16-55	10SEP2020	86636	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711216	C4591001 1171 11711216	16-55	10SEP2020	86637	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11711219	C4591001 1171 11711219	16-55	10SEP2020	86638	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711221	C4591001 1171 11711221	16-55	10SEP2020	86644	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11711223	C4591001 1171 11711223	16-55	10SEP2020	87019	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11711224	C4591001 1171 11711224	16-55	10SEP2020	87024	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo		
11711225	C4591001 1171 11711225	16-55	10SEP2020	87027	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11711226	C4591001 1171 11711226	16-55	10SEP2020	87026	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11711228	C4591001 1171 11711228	16-55	10SEP2020	87369	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
11711229	C4591001 1171 11711229	16-55	10SEP2020	87366	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711231	C4591001 1171 11711231	16-55	10SEP2020	87373	Placebo	10SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11711234	C4591001 1171 11711234	16-55	10SEP2020	87376	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11711236	C4591001 1171 11711236	16-55	11SEP2020	88111	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711239	C4591001 1171 11711239	16-55	11SEP2020	88112	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11711240	C4591001 1171 11711240	16-55	11SEP2020	88115	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11711241	C4591001 1171 11711241	16-55	11SEP2020	88302	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11711242	C4591001 1171 11711242	16-55	11SEP2020	88303	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711245	C4591001 1171 11711245	16-55	11SEP2020	88308	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11711246	C4591001 1171 11711246	16-55	11SEP2020	88311	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11711247	C4591001 1171 11711247	16-55	11SEP2020	88759	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711248	C4591001 1171 11711248	16-55	11SEP2020	88760	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11711249	C4591001 1171 11711249	16-55	11SEP2020	88765	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11711250	C4591001 1171 11711250	16-55	11SEP2020	88869	Placebo	11SEP2020/ Placebo	29SEP2020/ Placebo		
11711251	C4591001 1171 11711251	16-55	11SEP2020	88865	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11711252	C4591001 1171 11711252	16-55	11SEP2020	88768	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11711256	C4591001 1171 11711256	16-55	15SEP2020	88871	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	
11711258	C4591001 1171 11711258	16-55	16SEP2020	88873	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11711260	C4591001 1171 11711260	16-55	16SEP2020	91314	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11711261	C4591001 1171 11711261	16-55	17SEP2020	91318	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
11711262	C4591001 1171 11711262	16-55	17SEP2020	91323	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711263	C4591001 1171 11711263	16-55	17SEP2020	91322	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11711265	C4591001 1171 11711265	16-55	17SEP2020	92933	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11711266	C4591001 1171 11711266	16-55	17SEP2020	92934	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11711267	C4591001 1171 11711267	16-55	17SEP2020	92938	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11711271	C4591001 1171 11711271	16-55	18SEP2020	92943	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11711272	C4591001 1171 11711272	16-55	18SEP2020	93790	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11711273	C4591001 1171 11711273	16-55	18SEP2020	93791	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11711274	C4591001 1171 11711274	16-55	18SEP2020	93794	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11711278	C4591001 1171 11711278	16-55	21SEP2020	93795	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
11711279	C4591001 1171 11711279	16-55	21SEP2020	95046	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711280	C4591001 1171 11711280	16-55	21SEP2020	95047	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11711281	C4591001 1171 11711281	16-55	21SEP2020	95050	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11711286	C4591001 1171 11711286	16-55	22SEP2020	95056	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11711287	C4591001 1171 11711287	16-55	22SEP2020	96296	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
11711288	C4591001 1171 11711288	16-55	23SEP2020	96298	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11711289	C4591001 1171 11711289	16-55	23SEP2020	96300	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11711290	C4591001 1171 11711290	16-55	23SEP2020	96304	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11711292	C4591001 1171 11711292	16-55	23SEP2020	97762	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11711293	C4591001 1171 11711293	16-55	24SEP2020	97764	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11711294	C4591001 1171 11711294	16-55	24SEP2020	97766	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11711298	C4591001 1171 11711298	16-55	28SEP2020	97767	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11711299	C4591001 1171 11711299	16-55	28SEP2020	101586	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
11711301	C4591001 1171 11711301	16-55	30SEP2020	101592	Placebo	30SEP2020/ Placebo			
11711303	C4591001 1171 11711303	16-55	07OCT2020	101593	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11711305	C4591001 1171 11711305	16-55	09OCT2020	101595	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11711306	C4591001 1171 11711306	16-55	12OCT2020	106445	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11741003	C4591001 1174 11741003	16-55	31AUG2020	75500	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11741004	C4591001 1174 11741004	16-55	31AUG2020	75501	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11741005	C4591001 1174 11741005	16-55	01SEP2020	75504	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11741006	C4591001 1174 11741006	16-55	01SEP2020	75505	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741008	C4591001 1174 11741008	16-55	01SEP2020	77082	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11741011	C4591001 1174 11741011	16-55	01SEP2020	77086	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11741013	C4591001 1174 11741013	16-55	02SEP2020	77088	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11741015	C4591001 1174 11741015	16-55	02SEP2020	77089	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11741020	C4591001 1174 11741020	16-55	03SEP2020	79673	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11741023	C4591001 1174 11741023	16-55	03SEP2020	79674	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11741024	C4591001 1174 11741024	16-55	04SEP2020	79676	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11741026	C4591001 1174 11741026	16-55	04SEP2020	79684	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11741027	C4591001 1174 11741027	16-55	04SEP2020	81953	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11741030	C4591001 1174 11741030	16-55	04SEP2020	81959	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741031	C4591001 1174 11741031	16-55	04SEP2020	81955	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11741032	C4591001 1174 11741032	16-55	04SEP2020	81960	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11741034	C4591001 1174 11741034	16-55	08SEP2020	83492	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11741038	C4591001 1174 11741038	16-55	08SEP2020	83494	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11741045	C4591001 1174 11741045	16-55	09SEP2020	83498	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11741046	C4591001 1174 11741046	16-55	10SEP2020	86490	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11741049	C4591001 1174 11741049	16-55	10SEP2020	86496	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11741050	C4591001 1174 11741050	16-55	10SEP2020	86498	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11741051	C4591001 1174 11741051	16-55	10SEP2020	86500	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11741053	C4591001 1174 11741053	16-55	11SEP2020	88205	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741055	C4591001 1174 11741055	16-55	11SEP2020	88206	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11741056	C4591001 1174 11741056	16-55	11SEP2020	88211	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11741057	C4591001 1174 11741057	16-55	28SEP2020	93420	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11741058	C4591001 1174 11741058	16-55	15SEP2020	88214	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11741060	C4591001 1174 11741060	16-55	15SEP2020	90665	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11741061	C4591001 1174 11741061	16-55	16SEP2020	90666	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11741063	C4591001 1174 11741063	16-55	17SEP2020	90669	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11741065	C4591001 1174 11741065	16-55	17SEP2020	90672	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11741066	C4591001 1174 11741066†	16-55	18SEP2020	93413	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11741071	C4591001 1174 11741071	16-55	28SEP2020	93414	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11741072	C4591001 1174 11741072	16-55	28SEP2020	93418	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11771048	C4591001 1177 11771048	16-55	14AUG2020	51080	Placebo	14AUG2020/ Placebo	05SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11771049	C4591001 1177 11771049	16-55	17AUG2020	51088	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11771050	C4591001 1177 11771050	16-55	17AUG2020	53057	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11771051	C4591001 1177 11771051	16-55	17AUG2020	51086	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
11771054	C4591001 1177 11771054	16-55	17AUG2020	53061	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11771056	C4591001 1177 11771056	16-55	17AUG2020	53067	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771057	C4591001 1177 11771057	16-55	17AUG2020	53068	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771058	C4591001 1177 11771058	16-55	17AUG2020	53550	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771066	C4591001 1177 11771066	16-55	18AUG2020	53555	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771070	C4591001 1177 11771070	16-55	18AUG2020	53559	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771075	C4591001 1177 11771075	16-55	19AUG2020	53560	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771076	C4591001 1177 11771076	16-55	19AUG2020	56804	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
11771078	C4591001 1177 11771078	16-55	19AUG2020	56807	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771079	C4591001 1177 11771079	16-55	19AUG2020	56811	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771080	C4591001 1177 11771080	16-55	19AUG2020	56812	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771081	C4591001 1177 11771081	16-55	19AUG2020	57370	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771082	C4591001 1177 11771082	16-55	19AUG2020	57371	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771086	C4591001 1177 11771086	16-55	19AUG2020	57374	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771087	C4591001 1177 11771087	16-55	19AUG2020	57376	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771088	C4591001 1177 11771088	16-55	19AUG2020	57703	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771090	C4591001 1177 11771090	16-55	19AUG2020	57704	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11771092	C4591001 1177 11771092	16-55	20AUG2020	57706	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771093	C4591001 1177 11771093	16-55	20AUG2020	57708	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771095	C4591001 1177 11771095	16-55	20AUG2020	59333	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771096	C4591001 1177 11771096	16-55	20AUG2020	59340	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11771097	C4591001 1177 11771097	16-55	20AUG2020	59341	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771100	C4591001 1177 11771100	16-55	20AUG2020	59344	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11771101	C4591001 1177 11771101	16-55	20AUG2020	59873	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
11771103	C4591001 1177 11771103	16-55	20AUG2020	59876	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771105	C4591001 1177 11771105	16-55	21AUG2020	59877	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771111	C4591001 1177 11771111	16-55	21AUG2020	61521	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11771113	C4591001 1177 11771113	16-55	21AUG2020	59878	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771114	C4591001 1177 11771114	16-55	21AUG2020	61518	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771116	C4591001 1177 11771116	16-55	21AUG2020	61522	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11771117	C4591001 1177 11771117	16-55	24AUG2020	61526	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11771118	C4591001 1177 11771118	16-55	24AUG2020	64026	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771119	C4591001 1177 11771119	16-55	24AUG2020	64032	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11771122	C4591001 1177 11771122	16-55	24AUG2020	64033	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11771124	C4591001 1177 11771124	16-55	24AUG2020	64035	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771128	C4591001 1177 11771128	16-55	24AUG2020	65011	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11771134	C4591001 1177 11771134	16-55	25AUG2020	65012	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11771135	C4591001 1177 11771135	16-55	25AUG2020	65018	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11771137	C4591001 1177 11771137	16-55	25AUG2020	65020	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771138	C4591001 1177 11771138	16-55	25AUG2020	66881	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771139	C4591001 1177 11771139	16-55	25AUG2020	66885	Placebo	25AUG2020/ Placebo		05MAR2021/ BNT162b2 (30 µg)	
11771145	C4591001 1177 11771145	16-55	25AUG2020	66887	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771153	C4591001 1177 11771153	16-55	26AUG2020	66888	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11771154	C4591001 1177 11771154	16-55	26AUG2020	69153	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11771155	C4591001 1177 11771155	16-55	26AUG2020	69154	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771156	C4591001 1177 11771156	16-55	26AUG2020	69156	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771157	C4591001 1177 11771157	16-55	26AUG2020	69158	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
11771159	C4591001 1177 11771159	16-55	26AUG2020	69358	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11771160	C4591001 1177 11771160	16-55	26AUG2020	69359	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11771161	C4591001 1177 11771161	16-55	26AUG2020	69363	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771162	C4591001 1177 11771162	16-55	26AUG2020	69364	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
11771163	C4591001 1177 11771163	16-55	26AUG2020	69366	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11771165	C4591001 1177 11771165	16-55	27AUG2020	69369	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771166	C4591001 1177 11771166	16-55	27AUG2020	69371	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771167	C4591001 1177 11771167	16-55	27AUG2020	69375	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771170	C4591001 1177 11771170	16-55	27AUG2020	70698	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771171	C4591001 1177 11771171	16-55	27AUG2020	70700	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771172	C4591001 1177 11771172	16-55	27AUG2020	70706	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771173	C4591001 1177 11771173	16-55	27AUG2020	70707	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771174	C4591001 1177 11771174	16-55	27AUG2020	71124	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771176	C4591001 1177 11771176	16-55	27AUG2020	71126	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11771177	C4591001 1177 11771177	16-55	27AUG2020	71127	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771179	C4591001 1177 11771179	16-55	27AUG2020	71128	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771181	C4591001 1177 11771181	16-55	27AUG2020	71419	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11771182	C4591001 1177 11771182	16-55	27AUG2020	71423	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771183	C4591001 1177 11771183	16-55	27AUG2020	71424	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771184	C4591001 1177 11771184	16-55	27AUG2020	71428	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771185	C4591001 1177 11771185	16-55	27AUG2020	71429	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11771186	C4591001 1177 11771186	16-55	28AUG2020	71438	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771187	C4591001 1177 11771187	16-55	28AUG2020	71431	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771192	C4591001 1177 11771192	16-55	28AUG2020	71439	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11771194	C4591001 1177 11771194	16-55	28AUG2020	73121	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11771195	C4591001 1177 11771195	16-55	28AUG2020	73127	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11771196	C4591001 1177 11771196	16-55	28AUG2020	73128	Placebo	28AUG2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11771197	C4591001 1177 11771197	16-55	28AUG2020	73130	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771198	C4591001 1177 11771198	16-55	28AUG2020	73256	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771200	C4591001 1177 11771200	16-55	31AUG2020	73259	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771207	C4591001 1177 11771207	16-55	31AUG2020	73262	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771209	C4591001 1177 11771209	16-55	31AUG2020	76087	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771210	C4591001 1177 11771210	16-55	31AUG2020	73263	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771212	C4591001 1177 11771212	16-55	31AUG2020	76089	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771216	C4591001 1177 11771216	16-55	31AUG2020	76091	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771218	C4591001 1177 11771218	16-55	31AUG2020	76093	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771219	C4591001 1177 11771219	16-55	31AUG2020	76229	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771220	C4591001 1177 11771220	16-55	31AUG2020	76230	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771221	C4591001 1177 11771221	16-55	31AUG2020	76233	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771222	C4591001 1177 11771222	16-55	01SEP2020	77093	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11771223	C4591001 1177 11771223	16-55	01SEP2020	76239	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771224	C4591001 1177 11771224	16-55	01SEP2020	77096	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771225	C4591001 1177 11771225	16-55	01SEP2020	77098	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11771226	C4591001 1177 11771226	16-55	01SEP2020	77102	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771228	C4591001 1177 11771228	16-55	01SEP2020	77562	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11771234	C4591001 1177 11771234	16-55	01SEP2020	77566	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771235	C4591001 1177 11771235	16-55	01SEP2020	77570	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11771236	C4591001 1177 11771236	16-55	02SEP2020	77571	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771237	C4591001 1177 11771237	16-55	02SEP2020	78596	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11771238	C4591001 1177 11771238	16-55	02SEP2020	78600	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771241	C4591001 1177 11771241	16-55	02SEP2020	78601	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771242	C4591001 1177 11771242	16-55	02SEP2020	250293	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771245	C4591001 1177 11771245	16-55	02SEP2020	78602	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771246	C4591001 1177 11771246	16-55	02SEP2020	79423	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771248	C4591001 1177 11771248	16-55	02SEP2020	79425	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11771251	C4591001 1177 11771251	16-55	02SEP2020	79426	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771254	C4591001 1177 11771254	16-55	02SEP2020	79431	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11771257	C4591001 1177 11771257	16-55	03SEP2020	80515	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771258	C4591001 1177 11771258	16-55	03SEP2020	80518	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
11771259	C4591001 1177 11771259	16-55	03SEP2020	80520	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771260	C4591001 1177 11771260	16-55	03SEP2020	80849	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771261	C4591001 1177 11771261	16-55	03SEP2020	80524	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771262	C4591001 1177 11771262	16-55	03SEP2020	80850	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771265	C4591001 1177 11771265	16-55	03SEP2020	80853	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771266	C4591001 1177 11771266	16-55	03SEP2020	80857	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771267	C4591001 1177 11771267	16-55	03SEP2020	81161	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771270	C4591001 1177 11771270	16-55	03SEP2020	81167	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11771271	C4591001 1177 11771271	16-55	03SEP2020	81169	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771272	C4591001 1177 11771272	16-55	04SEP2020	81171	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771278	C4591001 1177 11771278	16-55	04SEP2020	82495	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771281	C4591001 1177 11771281	16-55	04SEP2020	82498	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11771282	C4591001 1177 11771282	16-55	04SEP2020	82601	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11771283	C4591001 1177 11771283	16-55	04SEP2020	82500	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11771284	C4591001 1177 11771284	16-55	04SEP2020	82503	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771285	C4591001 1177 11771285	16-55	04SEP2020	82604	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11771289	C4591001 1177 11771289	16-55	05SEP2020	82608	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11771292	C4591001 1177 11771292	16-55	05SEP2020	82612	Placebo	05SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771294	C4591001 1177 11771294	16-55	05SEP2020	82902	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771295	C4591001 1177 11771295	16-55	05SEP2020	82904	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11771296	C4591001 1177 11771296	16-55	05SEP2020	82906	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
11771297	C4591001 1177 11771297	16-55	05SEP2020	82912	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771300	C4591001 1177 11771300	16-55	08SEP2020	83981	Placebo	08SEP2020/ Placebo	05OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771302	C4591001 1177 11771302	16-55	08SEP2020	83984	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11771303	C4591001 1177 11771303	16-55	08SEP2020	83986	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771304	C4591001 1177 11771304	16-55	08SEP2020	83992	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11771305	C4591001 1177 11771305	16-55	08SEP2020	84631	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771306	C4591001 1177 11771306	16-55	08SEP2020	84632	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771307	C4591001 1177 11771307	16-55	08SEP2020	84630	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771309	C4591001 1177 11771309	16-55	08SEP2020	84638	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771310	C4591001 1177 11771310	16-55	08SEP2020	84691	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771312	C4591001 1177 11771312	16-55	08SEP2020	84693	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11771313	C4591001 1177 11771313	16-55	09SEP2020	85615	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771314	C4591001 1177 11771314	16-55	09SEP2020	84697	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771315	C4591001 1177 11771315	16-55	09SEP2020	84698	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771318	C4591001 1177 11771318	16-55	09SEP2020	85618	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11771319	C4591001 1177 11771319	16-55	09SEP2020	85620	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11771320	C4591001 1177 11771320	16-55	09SEP2020	85624	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
11771321	C4591001 1177 11771321	16-55	09SEP2020	86000	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771322	C4591001 1177 11771322	16-55	09SEP2020	86005	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771323	C4591001 1177 11771323	16-55	09SEP2020	86007	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11771324	C4591001 1177 11771324	16-55	09SEP2020	86008	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11771328	C4591001 1177 11771328	16-55	10SEP2020	87342	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11771329	C4591001 1177 11771329	16-55	10SEP2020	87346	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11771330	C4591001 1177 11771330	16-55	10SEP2020	87347	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771331	C4591001 1177 11771331	16-55	10SEP2020	87348	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11771332	C4591001 1177 11771332	16-55	10SEP2020	87606	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771333	C4591001 1177 11771333	16-55	10SEP2020	87608	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
11771334	C4591001 1177 11771334	16-55	10SEP2020	87609	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771335	C4591001 1177 11771335	16-55	10SEP2020	87614	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11771341	C4591001 1177 11771341	16-55	11SEP2020	88973	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771342	C4591001 1177 11771342	16-55	11SEP2020	88979	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771343	C4591001 1177 11771343	16-55	11SEP2020	89006	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11771345	C4591001 1177 11771345	16-55	11SEP2020	88980	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771346	C4591001 1177 11771346	16-55	11SEP2020	88982	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771347	C4591001 1177 11771347	16-55	11SEP2020	89000	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11771348	C4591001 1177 11771348	16-55	14SEP2020	89007	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11771351	C4591001 1177 11771351	16-55	14SEP2020	89008	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771354	C4591001 1177 11771354	16-55	14SEP2020	90029	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771355	C4591001 1177 11771355	16-55	14SEP2020	90031	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11771357	C4591001 1177 11771357	16-55	14SEP2020	90035	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771360	C4591001 1177 11771360	16-55	15SEP2020	90038	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11771361	C4591001 1177 11771361	16-55	15SEP2020	90605	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11771366	C4591001 1177 11771366	16-55	15SEP2020	90611	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11771367	C4591001 1177 11771367	16-55	16SEP2020	90613	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11771368	C4591001 1177 11771368	16-55	16SEP2020	90614	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
11771369	C4591001 1177 11771369	16-55	16SEP2020	91638	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		
11771371	C4591001 1177 11771371	16-55	16SEP2020	91639	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11771374	C4591001 1177 11771374	16-55	16SEP2020	91641	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771375	C4591001 1177 11771375	16-55	16SEP2020	91647	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11771377	C4591001 1177 11771377	16-55	17SEP2020	92645	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11771383	C4591001 1177 11771383	16-55	17SEP2020	92650	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11771385	C4591001 1177 11771385	16-55	18SEP2020	92652	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
11771386	C4591001 1177 11771386	16-55	18SEP2020	92655	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
11771389	C4591001 1177 11771389	16-55	18SEP2020	94133	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11771391	C4591001 1177 11771391	16-55	18SEP2020	94139	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771392	C4591001 1177 11771392	16-55	18SEP2020	94141	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771393	C4591001 1177 11771393	16-55	18SEP2020	94142	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11771394	C4591001 1177 11771394	16-55	18SEP2020	94411	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771397	C4591001 1177 11771397	16-55	18SEP2020	94412	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11771400	C4591001 1177 11771400	16-55	21SEP2020	94417	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771401	C4591001 1177 11771401	16-55	21SEP2020	94420	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11771402	C4591001 1177 11771402	16-55	21SEP2020	95733	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771403	C4591001 1177 11771403	16-55	21SEP2020	95737	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11771404	C4591001 1177 11771404	16-55	21SEP2020	95738	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11771405	C4591001 1177 11771405	16-55	21SEP2020	95739	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11771410	C4591001 1177 11771410	16-55	22SEP2020	96656	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11771411	C4591001 1177 11771411	16-55	22SEP2020	96657	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
11771415	C4591001 1177 11771415	16-55	22SEP2020	96659	Placebo	22SEP2020/ Placebo	20OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771416	C4591001 1177 11771416	16-55	22SEP2020	96663	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11771418	C4591001 1177 11771418	16-55	22SEP2020	97125	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11771420	C4591001 1177 11771420	16-55	22SEP2020	97126	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771422	C4591001 1177 11771422	16-55	23SEP2020	97127	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11771423	C4591001 1177 11771423	16-55	23SEP2020	97129	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771424	C4591001 1177 11771424	16-55	23SEP2020	98214	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
11771428	C4591001 1177 11771428	16-55	23SEP2020	98219	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11771429	C4591001 1177 11771429	16-55	23SEP2020	98216	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11771432	C4591001 1177 11771432	16-55	24SEP2020	98223	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
11771433	C4591001 1177 11771433	16-55	24SEP2020	98874	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771434	C4591001 1177 11771434	16-55	24SEP2020	98878	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11771435	C4591001 1177 11771435	16-55	24SEP2020	98877	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771438	C4591001 1177 11771438	16-55	24SEP2020	98884	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771439	C4591001 1177 11771439	16-55	24SEP2020	99106	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11771440	C4591001 1177 11771440	16-55	24SEP2020	99107	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11771441	C4591001 1177 11771441	16-55	24SEP2020	99108	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771442	C4591001 1177 11771442	16-55	24SEP2020	99110	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11771443	C4591001 1177 11771443	16-55	24SEP2020	99163	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771444	C4591001 1177 11771444	16-55	24SEP2020	99167	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11771445	C4591001 1177 11771445	16-55	24SEP2020	99169	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771446	C4591001 1177 11771446	16-55	25SEP2020	99171	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
11771449	C4591001 1177 11771449	16-55	25SEP2020	100458	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	
11771450	C4591001 1177 11771450	16-55	25SEP2020	100462	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
11771452	C4591001 1177 11771452	16-55	05OCT2020	100465	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11771453	C4591001 1177 11771453	16-55	05OCT2020	100467	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11771454	C4591001 1177 11771454	16-55	05OCT2020	103954	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771455	C4591001 1177 11771455	16-55	05OCT2020	103956	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11771456	C4591001 1177 11771456	16-55	05OCT2020	103958	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11771458	C4591001 1177 11771458	16-55	05OCT2020	103959	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11771463	C4591001 1177 11771463	16-55	06OCT2020	104466	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771464	C4591001 1177 11771464	16-55	07OCT2020	104471	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11771465	C4591001 1177 11771465	16-55	07OCT2020	104473	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11771466	C4591001 1177 11771466	16-55	07OCT2020	104474	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11771472	C4591001 1177 11771472	16-55	07OCT2020	105031	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771473	C4591001 1177 11771473	16-55	08OCT2020	105034	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11771475	C4591001 1177 11771475	16-55	08OCT2020	105035	Placebo	08OCT2020/ Placebo	05NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771477	C4591001 1177 11771477	16-55	08OCT2020	105039	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11771478	C4591001 1177 11771478	16-55	08OCT2020	105571	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11771479	C4591001 1177 11771479	16-55	08OCT2020	105576	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
11771482	C4591001 1177 11771482	16-55	09OCT2020	105577	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771484	C4591001 1177 11771484	16-55	09OCT2020	105580	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771485	C4591001 1177 11771485	16-55	09OCT2020	106221	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11771487	C4591001 1177 11771487	16-55	09OCT2020	106222	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11771488	C4591001 1177 11771488	16-55	09OCT2020	106223	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11771490	C4591001 1177 11771490	16-55	12OCT2020	106227	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
11771491	C4591001 1177 11771491	16-55	12OCT2020	106653	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
11771493	C4591001 1177 11771493	16-55	12OCT2020	106652	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771494	C4591001 1177 11771494	16-55	12OCT2020	106656	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771496	C4591001 1177 11771496	16-55	12OCT2020	106658	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
11771497	C4591001 1177 11771497	16-55	12OCT2020	106709	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771499	C4591001 1177 11771499	16-55	12OCT2020	106712	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771500	C4591001 1177 11771500	16-55	13OCT2020	106714	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11771501	C4591001 1177 11771501	16-55	13OCT2020	106716	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11771502	C4591001 1177 11771502	16-55	13OCT2020	107249	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11771503	C4591001 1177 11771503	16-55	13OCT2020	107250	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11771504	C4591001 1177 11771504	16-55	13OCT2020	107252	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11771506	C4591001 1177 11771506	16-55	14OCT2020	107254	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771509	C4591001 1177 11771509	16-55	14OCT2020	107766	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11771510	C4591001 1177 11771510	16-55	14OCT2020	107771	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11771511	C4591001 1177 11771511	16-55	14OCT2020	107775	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771513	C4591001 1177 11771513	16-55	14OCT2020	107776	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771514	C4591001 1177 11771514	16-55	15OCT2020	108294	Placebo	15OCT2020/ Placebo	12NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11771515	C4591001 1177 11771515	16-55	15OCT2020	108295	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771516	C4591001 1177 11771516	16-55	15OCT2020	108302	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11771517	C4591001 1177 11771517	16-55	15OCT2020	108304	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11771520	C4591001 1177 11771520	16-55	16OCT2020	109313	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11771521	C4591001 1177 11771521	16-55	16OCT2020	109314	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11771524	C4591001 1177 11771524	16-55	19OCT2020	109316	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11771525	C4591001 1177 11771525	16-55	19OCT2020	109320	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771526	C4591001 1177 11771526	16-55	19OCT2020	110537	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771528	C4591001 1177 11771528	16-55	19OCT2020	110538	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771529	C4591001 1177 11771529	16-55	19OCT2020	110540	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771531	C4591001 1177 11771531	16-55	19OCT2020	110542	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771532	C4591001 1177 11771532	16-55	19OCT2020	110611	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11771533	C4591001 1177 11771533	16-55	19OCT2020	110612	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11771534	C4591001 1177 11771534	16-55	20OCT2020	110618	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11771537	C4591001 1177 11771537	16-55	20OCT2020	110620	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11771539	C4591001 1177 11771539	16-55	20OCT2020	111248	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771540	C4591001 1177 11771540	16-55	20OCT2020	111245	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11771541	C4591001 1177 11771541	16-55	21OCT2020	111250	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771543	C4591001 1177 11771543	16-55	21OCT2020	111255	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11771544	C4591001 1177 11771544	16-55	21OCT2020	111788	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11771548	C4591001 1177 11771548	16-55	21OCT2020	111789	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11771549	C4591001 1177 11771549	16-55	21OCT2020	111791	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11771550	C4591001 1177 11771550	16-55	21OCT2020	111792	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11771551	C4591001 1177 11771551	16-55	21OCT2020	111882	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
11771552	C4591001 1177 11771552	16-55	21OCT2020	111885	Placebo	21OCT2020/ Placebo	16NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11771554	C4591001 1177 11771554	16-55	22OCT2020	111887	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11771555	C4591001 1177 11771555	16-55	22OCT2020	111888	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11771556	C4591001 1177 11771556	16-55	22OCT2020	112577	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11771557	C4591001 1177 11771557	16-55	22OCT2020	112578	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11771562	C4591001 1177 11771562	16-55	23OCT2020	112580	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11771563	C4591001 1177 11771563	16-55	23OCT2020	112588	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11771564	C4591001 1177 11771564	16-55	27OCT2020	114259	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
11771565	C4591001 1177 11771565	16-55	29OCT2020	114260	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11781001	C4591001 1178 11781001	16-55	21AUG2020	60245	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11781010	C4591001 1178 11781010	16-55	24AUG2020	60247	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11781014	C4591001 1178 11781014	16-55	25AUG2020	60248	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11781019	C4591001 1178 11781019	16-55	25AUG2020	60255	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
11781020	C4591001 1178 11781020	16-55	26AUG2020	67375	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781029	C4591001 1178 11781029	16-55	27AUG2020	67378	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
11781030	C4591001 1178 11781030	16-55	27AUG2020	67383	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11781036	C4591001 1178 11781036	16-55	27AUG2020	67384	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11781040	C4591001 1178 11781040	16-55	28AUG2020	71838	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11781041	C4591001 1178 11781041	16-55	28AUG2020	71840	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11781043	C4591001 1178 11781043	16-55	28AUG2020	71842	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
11781044	C4591001 1178 11781044	16-55	28AUG2020	71841	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11781050	C4591001 1178 11781050	16-55	31AUG2020	75515	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781051	C4591001 1178 11781051	16-55	31AUG2020	75510	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11781052	C4591001 1178 11781052	16-55	31AUG2020	75511	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781053	C4591001 1178 11781053	16-55	31AUG2020	75517	Placebo	31AUG2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781054	C4591001 1178 11781054	16-55	31AUG2020	75957	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
11781055	C4591001 1178 11781055	16-55	31AUG2020	75958	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781058	C4591001 1178 11781058	16-55	01SEP2020	75960	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781061	C4591001 1178 11781061	16-55	01SEP2020	75963	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781062	C4591001 1178 11781062	16-55	01SEP2020	76651	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781065	C4591001 1178 11781065	16-55	01SEP2020	76653	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
11781067	C4591001 1178 11781067	16-55	01SEP2020	76654	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781069	C4591001 1178 11781069	16-55	01SEP2020	76658	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11781070	C4591001 1178 11781070	16-55	01SEP2020	77538	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781072	C4591001 1178 11781072	16-55	02SEP2020	77542	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781073	C4591001 1178 11781073	16-55	02SEP2020	77541	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
11781074	C4591001 1178 11781074	16-55	02SEP2020	77547	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781077	C4591001 1178 11781077	16-55	02SEP2020	78714	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781078	C4591001 1178 11781078	16-55	02SEP2020	78716	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11781079	C4591001 1178 11781079	16-55	02SEP2020	78723	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11781082	C4591001 1178 11781082	16-55	02SEP2020	78724	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11781084	C4591001 1178 11781084	16-55	02SEP2020	79277	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
11781087	C4591001 1178 11781087	16-55	03SEP2020	79279	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781089	C4591001 1178 11781089	16-55	03SEP2020	79280	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781092	C4591001 1178 11781092	16-55	03SEP2020	79282	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781095	C4591001 1178 11781095	16-55	03SEP2020	80970	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11781096	C4591001 1178 11781096	16-55	03SEP2020	80971	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781097	C4591001 1178 11781097	16-55	04SEP2020	81344	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11781098	C4591001 1178 11781098	16-55	04SEP2020	80978	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
11781100	C4591001 1178 11781100	16-55	04SEP2020	80979	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11781104	C4591001 1178 11781104	16-55	04SEP2020	81347	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11781105	C4591001 1178 11781105	16-55	04SEP2020	81349	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11781106	C4591001 1178 11781106	16-55	04SEP2020	81351	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781107	C4591001 1178 11781107	16-55	04SEP2020	82074	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781110	C4591001 1178 11781110	16-55	08SEP2020	82075	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781113	C4591001 1178 11781113	16-55	08SEP2020	82077	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11781114	C4591001 1178 11781114	16-55	08SEP2020	82080	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11781120	C4591001 1178 11781120	16-55	08SEP2020	84522	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
11781121	C4591001 1178 11781121	16-55	08SEP2020	84525	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11781127	C4591001 1178 11781127	16-55	09SEP2020	84529	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781128	C4591001 1178 11781128	16-55	09SEP2020	84530	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11781129	C4591001 1178 11781129	16-55	09SEP2020	85692	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781130	C4591001 1178 11781130	16-55	09SEP2020	85691	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
11781131	C4591001 1178 11781131	16-55	09SEP2020	85685	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781133	C4591001 1178 11781133	16-55	09SEP2020	85693	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
11781135	C4591001 1178 11781135	16-55	09SEP2020	85987	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11781137	C4591001 1178 11781137	16-55	10SEP2020	85988	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781144	C4591001 1178 11781144	16-55	10SEP2020	85991	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781145	C4591001 1178 11781145	16-55	10SEP2020	85993	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11781149	C4591001 1178 11781149	16-55	11SEP2020	87798	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781150	C4591001 1178 11781150	16-55	11SEP2020	87802	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11781153	C4591001 1178 11781153	16-55	11SEP2020	87799	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781154	C4591001 1178 11781154	16-55	11SEP2020	87804	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781155	C4591001 1178 11781155	16-55	11SEP2020	88182	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781156	C4591001 1178 11781156	16-55	11SEP2020	88184	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781161	C4591001 1178 11781161	16-55	11SEP2020	88187	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
11781162	C4591001 1178 11781162	16-55	11SEP2020	88188	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781163	C4591001 1178 11781163	16-55	14SEP2020	89421	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781168	C4591001 1178 11781168	16-55	14SEP2020	89426	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781170	C4591001 1178 11781170	16-55	14SEP2020	89427	Placebo	14SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781171	C4591001 1178 11781171	16-55	15SEP2020	90189	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11781175	C4591001 1178 11781175	16-55	15SEP2020	90190	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11781179	C4591001 1178 11781179	16-55	15SEP2020	90191	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781181	C4591001 1178 11781181	16-55	15SEP2020	90786	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781182	C4591001 1178 11781182	16-55	15SEP2020	90196	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781183	C4591001 1178 11781183	16-55	15SEP2020	90788	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
11781185	C4591001 1178 11781185	16-55	16SEP2020	90789	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11781186	C4591001 1178 11781186	16-55	16SEP2020	90796	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781187	C4591001 1178 11781187	16-55	16SEP2020	91038	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11781188	C4591001 1178 11781188	16-55	16SEP2020	91043	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11781189	C4591001 1178 11781189	16-55	16SEP2020	91045	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781190	C4591001 1178 11781190	16-55	16SEP2020	91047	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781194	C4591001 1178 11781194	16-55	16SEP2020	91661	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11781197	C4591001 1178 11781197	16-55	16SEP2020	91665	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781198	C4591001 1178 11781198	16-55	17SEP2020	91666	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
11781208	C4591001 1178 11781208	16-55	17SEP2020	92993	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
11781209	C4591001 1178 11781209	16-55	17SEP2020	91669	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11781210	C4591001 1178 11781210	16-55	18SEP2020	92998	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11781211	C4591001 1178 11781211	16-55	18SEP2020	93001	Placebo	18SEP2020/ Placebo	12OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781213	C4591001 1178 11781213	16-55	18SEP2020	93004	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11781214	C4591001 1178 11781214	16-55	18SEP2020	93822	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781216	C4591001 1178 11781216	16-55	21SEP2020	93828	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781217	C4591001 1178 11781217	16-55	21SEP2020	93826	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781218	C4591001 1178 11781218	16-55	21SEP2020	93832	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781219	C4591001 1178 11781219	16-55	21SEP2020	94949	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781221	C4591001 1178 11781221	16-55	21SEP2020	94950	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11781222	C4591001 1178 11781222	16-55	21SEP2020	94952	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781223	C4591001 1178 11781223	16-55	21SEP2020	94953	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781224	C4591001 1178 11781224	16-55	21SEP2020	95528	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11781226	C4591001 1178 11781226	16-55	21SEP2020	95530	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781227	C4591001 1178 11781227	16-55	22SEP2020	95535	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
11781228	C4591001 1178 11781228	16-55	22SEP2020	95536	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781230	C4591001 1178 11781230	16-55	22SEP2020	96282	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781233	C4591001 1178 11781233	16-55	22SEP2020	96284	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781234	C4591001 1178 11781234	16-55	22SEP2020	96283	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
11781236	C4591001 1178 11781236	16-55	22SEP2020	96291	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781237	C4591001 1178 11781237	16-55	22SEP2020	96894	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781239	C4591001 1178 11781239	16-55	23SEP2020	96896	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11781244	C4591001 1178 11781244	16-55	23SEP2020	96898	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
11781245	C4591001 1178 11781245	16-55	23SEP2020	96899	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781247	C4591001 1178 11781247	16-55	24SEP2020	98565	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
11781248	C4591001 1178 11781248	16-55	24SEP2020	98569	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11781249	C4591001 1178 11781249	16-55	24SEP2020	98570	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11781251	C4591001 1178 11781251	16-55	24SEP2020	98571	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781253	C4591001 1178 11781253	16-55	24SEP2020	99007	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11781254	C4591001 1178 11781254	16-55	24SEP2020	99008	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
11781257	C4591001 1178 11781257	16-55	25SEP2020	99014	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11781258	C4591001 1178 11781258	16-55	25SEP2020	99016	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11781260	C4591001 1178 11781260	16-55	25SEP2020	99773	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781262	C4591001 1178 11781262	16-55	28SEP2020	99775	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781263	C4591001 1178 11781263	16-55	28SEP2020	99776	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11781266	C4591001 1178 11781266	16-55	29SEP2020	99782	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11781267	C4591001 1178 11781267	16-55	29SEP2020	101792	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781268	C4591001 1178 11781268	16-55	29SEP2020	101793	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781269	C4591001 1178 11781269	16-55	29SEP2020	101795	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781270	C4591001 1178 11781270	16-55	29SEP2020	101797	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
11781271	C4591001 1178 11781271	16-55	29SEP2020	101994	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
11781275	C4591001 1178 11781275	16-55	01OCT2020	101999	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11781277	C4591001 1178 11781277	16-55	02OCT2020	102002	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11781279	C4591001 1178 11781279	16-55	02OCT2020	102000	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11781284	C4591001 1178 11781284	16-55	06OCT2020	104168	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
11781285	C4591001 1178 11781285	16-55	06OCT2020	104169	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
11781286	C4591001 1178 11781286	16-55	06OCT2020	104171	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11781288	C4591001 1178 11781288	16-55	06OCT2020	104176	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781290	C4591001 1178 11781290	16-55	06OCT2020	104455	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11781291	C4591001 1178 11781291	16-55	07OCT2020	104458	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
11781295	C4591001 1178 11781295	16-55	08OCT2020	104462	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
11781296	C4591001 1178 11781296	16-55	12OCT2020	104464	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11781298	C4591001 1178 11781298	16-55	14OCT2020	107525	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo		
11781300	C4591001 1178 11781300	16-55	14OCT2020	107527	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
11781301	C4591001 1178 11781301	16-55	14OCT2020	107532	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11781309	C4591001 1178 11781309	16-55	20OCT2020	107534	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11781310	C4591001 1178 11781310	16-55	20OCT2020	111053	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11781311	C4591001 1178 11781311	16-55	21OCT2020	111054	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11781312	C4591001 1178 11781312	16-55	21OCT2020	111060	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781314	C4591001 1178 11781314	16-55	22OCT2020	111063	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11781316	C4591001 1178 11781316	16-55	26OCT2020	113621	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11791008	C4591001 1179 11791008	16-55	20AUG2020	50214	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
11791009	C4591001 1179 11791009	16-55	21AUG2020	50218	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11791010	C4591001 1179 11791010	16-55	21AUG2020	50219	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
11791014	C4591001 1179 11791014	16-55	27AUG2020	69442	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11791021	C4591001 1179 11791021	16-55	29AUG2020	69443	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
11791023	C4591001 1179 11791023	16-55	31AUG2020	69444	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11791030	C4591001 1179 11791030	16-55	02SEP2020	69446	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791033	C4591001 1179 11791033	16-55	02SEP2020	77813	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
11791050	C4591001 1179 11791050	16-55	05SEP2020	77818	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
11791054	C4591001 1179 11791054	16-55	05SEP2020	77820	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791058	C4591001 1179 11791058	16-55	08SEP2020	77823	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
11791061	C4591001 1179 11791061	16-55	08SEP2020	84438	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
11791064	C4591001 1179 11791064	16-55	09SEP2020	84441	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
11791066	C4591001 1179 11791066	16-55	09SEP2020	84443	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11791067	C4591001 1179 11791067	16-55	10SEP2020	84444	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11791069	C4591001 1179 11791069	16-55	10SEP2020	86265	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11791075	C4591001 1179 11791075	16-55	11SEP2020	86266	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791076	C4591001 1179 11791076	16-55	11SEP2020	86267	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
11791079	C4591001 1179 11791079	16-55	11SEP2020	86268	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
11791081	C4591001 1179 11791081	16-55	16SEP2020	90895	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11791082	C4591001 1179 11791082	16-55	16SEP2020	90896	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
11791083	C4591001 1179 11791083	16-55	16SEP2020	90900	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11791085	C4591001 1179 11791085	16-55	17SEP2020	90901	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
11791086	C4591001 1179 11791086	16-55	18SEP2020	93559	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
11791087	C4591001 1179 11791087	16-55	18SEP2020	93560	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
11791090	C4591001 1179 11791090	16-55	18SEP2020	93561	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
11791091	C4591001 1179 11791091	16-55	18SEP2020	93566	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791093	C4591001 1179 11791093	16-55	21SEP2020	94700	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11791098	C4591001 1179 11791098	16-55	25SEP2020	94704	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
11791099	C4591001 1179 11791099	16-55	25SEP2020	94705	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
11791100	C4591001 1179 11791100	16-55	25SEP2020	99666	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791101	C4591001 1179 11791101	16-55	25SEP2020	99670	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11791104	C4591001 1179 11791104	16-55	26SEP2020	99673	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11791106	C4591001 1179 11791106	16-55	26SEP2020	99674	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
11791107	C4591001 1179 11791107	16-55	01OCT2020	102725	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11791109	C4591001 1179 11791109	16-55	01OCT2020	102726	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
11791112	C4591001 1179 11791112	16-55	02OCT2020	102730	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791114	C4591001 1179 11791114	16-55	02OCT2020	102736	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
11791115	C4591001 1179 11791115	16-55	07OCT2020	104626	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
11791117	C4591001 1179 11791117	16-55	08OCT2020	104627	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
11791118	C4591001 1179 11791118	16-55	08OCT2020	104628	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
11791119	C4591001 1179 11791119	16-55	08OCT2020	104629	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11791122	C4591001 1179 11791122	16-55	09OCT2020	106099	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
11791123	C4591001 1179 11791123	16-55	15OCT2020	106103	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11791125	C4591001 1179 11791125	16-55	16OCT2020	106104	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11791126	C4591001 1179 11791126	16-55	19OCT2020	106108	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11791130	C4591001 1179 11791130	16-55	21OCT2020	111293	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791131	C4591001 1179 11791131	16-55	21OCT2020	111294	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11791133	C4591001 1179 11791133	16-55	21OCT2020	111295	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11791136	C4591001 1179 11791136	16-55	23OCT2020	111304	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11791137	C4591001 1179 11791137	16-55	24OCT2020	113251	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791138	C4591001 1179 11791138	16-55	24OCT2020	113252	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)			
11791139	C4591001 1179 11791139	16-55	24OCT2020	113255	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11791143	C4591001 1179 11791143	16-55	24OCT2020	113258	Placebo	24OCT2020/ Placebo	16NOV2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
11791144	C4591001 1179 11791144	16-55	24OCT2020	113277	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11791145	C4591001 1179 11791145	16-55	26OCT2020	113278	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
11791146	C4591001 1179 11791146	16-55	26OCT2020	113279	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791147	C4591001 1179 11791147	16-55	26OCT2020	113284	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791148	C4591001 1179 11791148	16-55	26OCT2020	113552	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791149	C4591001 1179 11791149	16-55	26OCT2020	113553	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11791150	C4591001 1179 11791150	16-55	26OCT2020	113554	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791152	C4591001 1179 11791152	16-55	26OCT2020	113557	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11791153	C4591001 1179 11791153	16-55	26OCT2020	113658	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11791154	C4591001 1179 11791154	16-55	26OCT2020	113659	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791158	C4591001 1179 11791158	16-55	28OCT2020	113662	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11791159	C4591001 1179 11791159	16-55	28OCT2020	113667	Placebo	28OCT2020/ Placebo	16NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791160	C4591001 1179 11791160	16-55	29OCT2020	114618	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11791161	C4591001 1179 11791161	16-55	29OCT2020	114621	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
11791162	C4591001 1179 11791162	16-55	29OCT2020	114625	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11791165	C4591001 1179 11791165	16-55	30OCT2020	114626	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11791166	C4591001 1179 11791166	16-55	30OCT2020	114981	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11791167	C4591001 1179 11791167	16-55	30OCT2020	114983	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11791170	C4591001 1179 11791170	16-55	30OCT2020	114984	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11791173	C4591001 1179 11791173	16-55	30OCT2020	114987	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11791174	C4591001 1179 11791174	16-55	30OCT2020	115074	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
11851002	C4591001 1185 11851002	16-55	26OCT2020	113501	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851005	C4591001 1185 11851005	16-55	26OCT2020	113502	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851008	C4591001 1185 11851008	16-55	27OCT2020	113508	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851009	C4591001 1185 11851009	16-55	27OCT2020	113512	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851010	C4591001 1185 11851010	16-55	27OCT2020	113876	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851011	C4591001 1185 11851011	16-55	27OCT2020	113880	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11851012	C4591001 1185 11851012	16-55	27OCT2020	113873	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851013	C4591001 1185 11851013	16-55	27OCT2020	113882	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851015	C4591001 1185 11851015	16-55	27OCT2020	113886	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851017	C4591001 1185 11851017	16-55	27OCT2020	113889	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851018	C4591001 1185 11851018	16-55	27OCT2020	113891	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851021	C4591001 1185 11851021	16-55	27OCT2020	113894	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851022	C4591001 1185 11851022†	16-55	27OCT2020	113933	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851023	C4591001 1185 11851023	16-55	27OCT2020	113938	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851024	C4591001 1185 11851024	16-55	27OCT2020	113942	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851025	C4591001 1185 11851025	16-55	27OCT2020	113944	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851028	C4591001 1185 11851028	16-55	27OCT2020	113969	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851029	C4591001 1185 11851029	16-55	27OCT2020	113972	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
11851030	C4591001 1185 11851030	16-55	27OCT2020	113977	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851032	C4591001 1185 11851032	16-55	27OCT2020	113980	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11851033	C4591001 1185 11851033	16-55	27OCT2020	114041	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11851036	C4591001 1185 11851036	16-55	27OCT2020	114045	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851037	C4591001 1185 11851037	16-55	27OCT2020	114052	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851038	C4591001 1185 11851038	16-55	27OCT2020	114089	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
11851039	C4591001 1185 11851039	16-55	27OCT2020	114091	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851040	C4591001 1185 11851040	16-55	27OCT2020	114094	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851041	C4591001 1185 11851041	16-55	29OCT2020	114096	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851043	C4591001 1185 11851043	16-55	29OCT2020	114572	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851048	C4591001 1185 11851048	16-55	29OCT2020	114576	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851049	C4591001 1185 11851049	16-55	29OCT2020	114577	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851050	C4591001 1185 11851050	16-55	29OCT2020	114580	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11851051	C4591001 1185 11851051	16-55	29OCT2020	114581	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851052	C4591001 1185 11851052	16-55	29OCT2020	114582	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11851053	C4591001 1185 11851053	16-55	29OCT2020	114584	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11851054	C4591001 1185 11851054	16-55	29OCT2020	114587	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851055	C4591001 1185 11851055	16-55	29OCT2020	114608	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo		
11851056	C4591001 1185 11851056	16-55	29OCT2020	114609	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
11851059	C4591001 1185 11851059	16-55	29OCT2020	114613	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11851060	C4591001 1185 11851060	16-55	29OCT2020	114615	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11851063	C4591001 1185 11851063	16-55	29OCT2020	114667	Placebo	29OCT2020/ Placebo	18NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851064	C4591001 1185 11851064	16-55	29OCT2020	114668	Placebo	29OCT2020/ Placebo	19NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11851066	C4591001 1185 11851066	16-55	29OCT2020	114669	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11851067	C4591001 1185 11851067	16-55	29OCT2020	114674	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
11941003	C4591001 1194 11941003	16-55	15OCT2020	107837	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941004	C4591001 1194 11941004	16-55	15OCT2020	107838	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
11941009	C4591001 1194 11941009	16-55	15OCT2020	107846	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941010	C4591001 1194 11941010	16-55	15OCT2020	107847	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11941012	C4591001 1194 11941012	16-55	15OCT2020	108246	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11941014	C4591001 1194 11941014	16-55	16OCT2020	108249	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11941016	C4591001 1194 11941016	16-55	16OCT2020	108250	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941019	C4591001 1194 11941019	16-55	16OCT2020	108254	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11941020	C4591001 1194 11941020	16-55	16OCT2020	108749	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941023	C4591001 1194 11941023	16-55	16OCT2020	108752	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941024	C4591001 1194 11941024	16-55	16OCT2020	108755	Placebo	16OCT2020/ Placebo	07NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941025	C4591001 1194 11941025	16-55	16OCT2020	108757	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941026	C4591001 1194 11941026	16-55	16OCT2020	108893	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941030	C4591001 1194 11941030	16-55	16OCT2020	108902	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941031	C4591001 1194 11941031	16-55	16OCT2020	108903	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941032	C4591001 1194 11941032	16-55	16OCT2020	108904	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941033	C4591001 1194 11941033	16-55	16OCT2020	109061	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11941034	C4591001 1194 11941034	16-55	17OCT2020	109064	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11941041	C4591001 1194 11941041	16-55	17OCT2020	109071	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941043	C4591001 1194 11941043	16-55	17OCT2020	109437	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11941044	C4591001 1194 11941044	16-55	17OCT2020	109439	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11941045	C4591001 1194 11941045	16-55	17OCT2020	109440	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11941046	C4591001 1194 11941046	16-55	17OCT2020	109442	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11941047	C4591001 1194 11941047	16-55	17OCT2020	109481	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
11941048	C4591001 1194 11941048	16-55	17OCT2020	109484	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941051	C4591001 1194 11941051	16-55	19OCT2020	109485	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11941052	C4591001 1194 11941052	16-55	19OCT2020	109492	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
11941053	C4591001 1194 11941053	16-55	19OCT2020	109793	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11941054	C4591001 1194 11941054	16-55	19OCT2020	109799	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941056	C4591001 1194 11941056	16-55	19OCT2020	109800	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
11941057	C4591001 1194 11941057	16-55	19OCT2020	109801	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
11941058	C4591001 1194 11941058	16-55	19OCT2020	109925	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
11941061	C4591001 1194 11941061	16-55	19OCT2020	109927	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
11941062	C4591001 1194 11941062	16-55	20OCT2020	109932	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941066	C4591001 1194 11941066	16-55	20OCT2020	109933	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
11941067	C4591001 1194 11941067	16-55	20OCT2020	110634	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11941069	C4591001 1194 11941069	16-55	20OCT2020	110637	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941071	C4591001 1194 11941071	16-55	20OCT2020	110639	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941072	C4591001 1194 11941072	16-55	20OCT2020	110641	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941080	C4591001 1194 11941080	16-55	21OCT2020	111272	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941081	C4591001 1194 11941081	16-55	21OCT2020	111273	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
11941082	C4591001 1194 11941082	16-55	21OCT2020	111275	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11941083	C4591001 1194 11941083	16-55	21OCT2020	111279	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941086	C4591001 1194 11941086	16-55	21OCT2020	111417	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11941087	C4591001 1194 11941087	16-55	21OCT2020	111418	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11941088	C4591001 1194 11941088	16-55	21OCT2020	111419	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941089	C4591001 1194 11941089	16-55	21OCT2020	111421	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941090	C4591001 1194 11941090	16-55	22OCT2020	111941	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11941091	C4591001 1194 11941091	16-55	22OCT2020	111945	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11941092	C4591001 1194 11941092	16-55	22OCT2020	111946	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11941093	C4591001 1194 11941093	16-55	22OCT2020	111950	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941096	C4591001 1194 11941096	16-55	22OCT2020	111991	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11941097	C4591001 1194 11941097	16-55	22OCT2020	111993	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
11941098	C4591001 1194 11941098	16-55	22OCT2020	111994	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11941100	C4591001 1194 11941100	16-55	22OCT2020	111999	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11941103	C4591001 1194 11941103	16-55	22OCT2020	112233	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
11941105	C4591001 1194 11941105	16-55	22OCT2020	112234	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
11941106	C4591001 1194 11941106	16-55	23OCT2020	112236	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
11951001	C4591001 1195 11951001	16-55	15OCT2020	107826	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951002	C4591001 1195 11951002	16-55	15OCT2020	107827	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951003	C4591001 1195 11951003	16-55	15OCT2020	107833	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11951004	C4591001 1195 11951004	16-55	15OCT2020	107835	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
11951005	C4591001 1195 11951005	16-55	15OCT2020	107851	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951008	C4591001 1195 11951008	16-55	15OCT2020	107852	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11951009	C4591001 1195 11951009	16-55	15OCT2020	107855	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11951010	C4591001 1195 11951010	16-55	15OCT2020	107856	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11951013	C4591001 1195 11951013	16-55	15OCT2020	107909	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951015	C4591001 1195 11951015	16-55	15OCT2020	107910	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11951017	C4591001 1195 11951017	16-55	15OCT2020	107913	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951018	C4591001 1195 11951018	16-55	15OCT2020	107919	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
11951019	C4591001 1195 11951019	16-55	15OCT2020	108005	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
11951020	C4591001 1195 11951020	16-55	15OCT2020	108009	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951021	C4591001 1195 11951021	16-55	15OCT2020	108014	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951022	C4591001 1195 11951022	16-55	15OCT2020	108015	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951023	C4591001 1195 11951023	16-55	16OCT2020	108605	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11951024	C4591001 1195 11951024	16-55	16OCT2020	108610	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11951026	C4591001 1195 11951026	16-55	16OCT2020	108611	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951027	C4591001 1195 11951027	16-55	16OCT2020	108614	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951029	C4591001 1195 11951029	16-55	16OCT2020	108654	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951030	C4591001 1195 11951030	16-55	16OCT2020	108655	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951032	C4591001 1195 11951032	16-55	16OCT2020	108660	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951035	C4591001 1195 11951035	16-55	16OCT2020	108662	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951040	C4591001 1195 11951040	16-55	16OCT2020	108704	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951041	C4591001 1195 11951041	16-55	16OCT2020	108707	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951042	C4591001 1195 11951042	16-55	16OCT2020	108710	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951043	C4591001 1195 11951043	16-55	16OCT2020	108712	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
11951047	C4591001 1195 11951047	16-55	16OCT2020	108917	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		
11951048	C4591001 1195 11951048	16-55	16OCT2020	108918	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951051	C4591001 1195 11951051	16-55	16OCT2020	108927	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951053	C4591001 1195 11951053	16-55	17OCT2020	108928	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11951054	C4591001 1195 11951054	16-55	17OCT2020	109374	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11951055	C4591001 1195 11951055	16-55	17OCT2020	109375	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11951056	C4591001 1195 11951056	16-55	17OCT2020	109379	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11951060	C4591001 1195 11951060	16-55	17OCT2020	109380	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951061	C4591001 1195 11951061	16-55	17OCT2020	109400	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)			
11951062	C4591001 1195 11951062	16-55	17OCT2020	109401	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951063	C4591001 1195 11951063	16-55	17OCT2020	109402	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11951064	C4591001 1195 11951064	16-55	17OCT2020	109399	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11951065	C4591001 1195 11951065	16-55	17OCT2020	109409	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951066	C4591001 1195 11951066	16-55	17OCT2020	109413	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
11951067	C4591001 1195 11951067	16-55	17OCT2020	109411	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11951068	C4591001 1195 11951068	16-55	17OCT2020	109415	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951070	C4591001 1195 11951070	16-55	17OCT2020	109427	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
11951071	C4591001 1195 11951071	16-55	17OCT2020	109429	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951072	C4591001 1195 11951072	16-55	17OCT2020	109430	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951073	C4591001 1195 11951073	16-55	17OCT2020	109431	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951074	C4591001 1195 11951074	16-55	17OCT2020	109448	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11951075	C4591001 1195 11951075	16-55	17OCT2020	109450	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11951076	C4591001 1195 11951076	16-55	17OCT2020	109453	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951077	C4591001 1195 11951077	16-55	17OCT2020	109455	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951079	C4591001 1195 11951079	16-55	17OCT2020	109547	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951080	C4591001 1195 11951080	16-55	17OCT2020	109548	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
11951081	C4591001 1195 11951081	16-55	17OCT2020	109550	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951082	C4591001 1195 11951082	16-55	17OCT2020	109552	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
11951083	C4591001 1195 11951083	16-55	17OCT2020	109613	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951084	C4591001 1195 11951084	16-55	17OCT2020	109615	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
11951085	C4591001 1195 11951085	16-55	18OCT2020	109620	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951089	C4591001 1195 11951089	16-55	18OCT2020	109622	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
11951090	C4591001 1195 11951090	16-55	18OCT2020	109686	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951091	C4591001 1195 11951091	16-55	18OCT2020	109691	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951092	C4591001 1195 11951092	16-55	18OCT2020	109692	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951093	C4591001 1195 11951093	16-55	18OCT2020	109694	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951098	C4591001 1195 11951098	16-55	18OCT2020	109712	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951099	C4591001 1195 11951099	16-55	18OCT2020	109716	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951100	C4591001 1195 11951100	16-55	18OCT2020	109718	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11951101	C4591001 1195 11951101	16-55	18OCT2020	109719	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11951104	C4591001 1195 11951104	16-55	18OCT2020	109721	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951105	C4591001 1195 11951105	16-55	18OCT2020	109722	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
11951106	C4591001 1195 11951106	16-55	18OCT2020	109724	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951107	C4591001 1195 11951107	16-55	18OCT2020	109732	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951108	C4591001 1195 11951108	16-55	18OCT2020	109733	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951109	C4591001 1195 11951109	16-55	18OCT2020	109735	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951113	C4591001 1195 11951113	16-55	18OCT2020	109739	Placebo	18OCT2020/ Placebo	07NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11951114	C4591001 1195 11951114	16-55	18OCT2020	109742	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951115	C4591001 1195 11951115	16-55	18OCT2020	109759	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951116	C4591001 1195 11951116	16-55	18OCT2020	109762	Placebo	18OCT2020/ Placebo	08NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
11951117	C4591001 1195 11951117	16-55	19OCT2020	109763	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951118	C4591001 1195 11951118	16-55	19OCT2020	109768	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951119	C4591001 1195 11951119	16-55	19OCT2020	109783	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951120	C4591001 1195 11951120	16-55	19OCT2020	109784	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951123	C4591001 1195 11951123	16-55	19OCT2020	109787	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo		
11951134	C4591001 1195 11951134	16-55	19OCT2020	109788	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
11951135	C4591001 1195 11951135	16-55	19OCT2020	109950	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11951136	C4591001 1195 11951136	16-55	19OCT2020	109956	Placebo	19OCT2020/ Placebo	08NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11951137	C4591001 1195 11951137	16-55	19OCT2020	109958	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951138	C4591001 1195 11951138	16-55	19OCT2020	109960	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11951139	C4591001 1195 11951139	16-55	19OCT2020	110036	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951140	C4591001 1195 11951140	16-55	19OCT2020	110038	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11951141	C4591001 1195 11951141	16-55	20OCT2020	110043	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11951142	C4591001 1195 11951142	16-55	20OCT2020	110044	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951146	C4591001 1195 11951146	16-55	20OCT2020	110650	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951147	C4591001 1195 11951147	16-55	20OCT2020	110648	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951148	C4591001 1195 11951148	16-55	20OCT2020	110649	Placebo	20OCT2020/ Placebo	08NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
11951153	C4591001 1195 11951153	16-55	20OCT2020	110653	Placebo	20OCT2020/ Placebo	08NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11951154	C4591001 1195 11951154	16-55	20OCT2020	110657	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
11951155	C4591001 1195 11951155	16-55	20OCT2020	110660	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
11951157	C4591001 1195 11951157	16-55	20OCT2020	110664	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	08NOV2020/ BNT162b2 (30 µg)		
11951158	C4591001 1195 11951158	16-55	20OCT2020	110665	Placebo	20OCT2020/ Placebo	08NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
11971001	C4591001 1197 11971001	16-55	15OCT2020	107862	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971003	C4591001 1197 11971003	16-55	15OCT2020	107864	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971005	C4591001 1197 11971005	16-55	15OCT2020	107866	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11971007	C4591001 1197 11971007	16-55	15OCT2020	107868	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
11971014	C4591001 1197 11971014	16-55	16OCT2020	108617	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971015	C4591001 1197 11971015	16-55	16OCT2020	108620	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971017	C4591001 1197 11971017	16-55	16OCT2020	108622	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11971018	C4591001 1197 11971018	16-55	16OCT2020	108628	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971019	C4591001 1197 11971019	16-55	16OCT2020	108645	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971020	C4591001 1197 11971020	16-55	16OCT2020	108641	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11971026	C4591001 1197 11971026	16-55	16OCT2020	108651	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971028	C4591001 1197 11971028	16-55	16OCT2020	108652	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971029	C4591001 1197 11971029	16-55	16OCT2020	108822	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971031	C4591001 1197 11971031	16-55	16OCT2020	108823	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
11971035	C4591001 1197 11971035	16-55	16OCT2020	108827	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
11971039	C4591001 1197 11971039	16-55	17OCT2020	108832	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11971040	C4591001 1197 11971040	16-55	17OCT2020	109387	Placebo	17OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971041	C4591001 1197 11971041	16-55	17OCT2020	109388	Placebo	17OCT2020/ Placebo	04NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971042	C4591001 1197 11971042	16-55	17OCT2020	109389	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971045	C4591001 1197 11971045	16-55	17OCT2020	109390	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
11971053	C4591001 1197 11971053	16-55	17OCT2020	109519	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971058	C4591001 1197 11971058	16-55	18OCT2020	109520	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971059	C4591001 1197 11971059	16-55	18OCT2020	109525	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971060	C4591001 1197 11971060	16-55	18OCT2020	109526	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971064	C4591001 1197 11971064	16-55	18OCT2020	109699	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971068	C4591001 1197 11971068	16-55	18OCT2020	109702	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971069	C4591001 1197 11971069	16-55	18OCT2020	109703	Placebo	18OCT2020/ Placebo	07NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971077	C4591001 1197 11971077	16-55	18OCT2020	109745	Placebo	18OCT2020/ Placebo	06NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
11971078	C4591001 1197 11971078	16-55	18OCT2020	109750	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971079	C4591001 1197 11971079	16-55	18OCT2020	109751	BNT162b2 (30 µg)	18OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
11971088	C4591001 1197 11971088	16-55	19OCT2020	109754	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
11971092	C4591001 1197 11971092	16-55	19OCT2020	109879	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
11971093	C4591001 1197 11971093	16-55	19OCT2020	109880	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
11971094	C4591001 1197 11971094	16-55	19OCT2020	109882	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
11971096	C4591001 1197 11971096	16-55	19OCT2020	109883	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12021007	C4591001 1202 12021007	16-55	28OCT2020	114296	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12021009	C4591001 1202 12021009	16-55	28OCT2020	114299	Placebo	28OCT2020/ Placebo	17NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12021010	C4591001 1202 12021010	16-55	28OCT2020	114300	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12021011	C4591001 1202 12021011	16-55	28OCT2020	114302	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12031001	C4591001 1203 12031001	16-55	16OCT2020	108632	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12031004	C4591001 1203 12031004	16-55	16OCT2020	108634	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031005	C4591001 1203 12031005	16-55	16OCT2020	108635	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12031008	C4591001 1203 12031008	16-55	16OCT2020	108636	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12031010	C4591001 1203 12031010	16-55	19OCT2020	109770	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12031015	C4591001 1203 12031015	16-55	19OCT2020	109771	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031020	C4591001 1203 12031020	16-55	20OCT2020	109773	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12031021	C4591001 1203 12031021	16-55	20OCT2020	109780	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12031026	C4591001 1203 12031026	16-55	20OCT2020	110623	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12031030	C4591001 1203 12031030	16-55	20OCT2020	110624	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12031031	C4591001 1203 12031031	16-55	20OCT2020	110625	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031032	C4591001 1203 12031032	16-55	21OCT2020	111260	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031033	C4591001 1203 12031033	16-55	21OCT2020	110632	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031034	C4591001 1203 12031034	16-55	21OCT2020	111261	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031037	C4591001 1203 12031037	16-55	21OCT2020	111265	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)			
12031041	C4591001 1203 12031041	16-55	21OCT2020	111268	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031042	C4591001 1203 12031042	16-55	21OCT2020	111281	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031044	C4591001 1203 12031044	16-55	21OCT2020	111290	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12031045	C4591001 1203 12031045	16-55	21OCT2020	111288	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12031047	C4591001 1203 12031047	16-55	23OCT2020	111292	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031048	C4591001 1203 12031048	16-55	23OCT2020	112625	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12031051	C4591001 1203 12031051	16-55	23OCT2020	112627	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031053	C4591001 1203 12031053	16-55	23OCT2020	112629	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12031056	C4591001 1203 12031056	16-55	23OCT2020	112631	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12031057	C4591001 1203 12031057	16-55	23OCT2020	112673	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12031058	C4591001 1203 12031058	16-55	23OCT2020	112676	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12031059	C4591001 1203 12031059	16-55	23OCT2020	112678	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12031060	C4591001 1203 12031060	16-55	23OCT2020	112684	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12031063	C4591001 1203 12031063	16-55	26OCT2020	113399	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12031064	C4591001 1203 12031064	16-55	26OCT2020	113394	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12031066	C4591001 1203 12031066	16-55	26OCT2020	113403	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12031067	C4591001 1203 12031067	16-55	26OCT2020	113404	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12031069	C4591001 1203 12031069	16-55	26OCT2020	113432	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12041001	C4591001 1204 12041001	16-55	24AUG2020	63367	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12041004	C4591001 1204 12041004	16-55	24AUG2020	63371	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12041005	C4591001 1204 12041005	16-55	25AUG2020	63376	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041006	C4591001 1204 12041006	16-55	25AUG2020	66325	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12041008	C4591001 1204 12041008	16-55	25AUG2020	66320	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12041009	C4591001 1204 12041009	16-55	26AUG2020	66327	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12041010	C4591001 1204 12041010	16-55	26AUG2020	66328	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041011	C4591001 1204 12041011	16-55	27AUG2020	70205	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041012	C4591001 1204 12041012	16-55	28AUG2020	70209	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041013	C4591001 1204 12041013	16-55	28AUG2020	70210	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12041015	C4591001 1204 12041015	16-55	28AUG2020	70215	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041017	C4591001 1204 12041017	16-55	08SEP2020	83388	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041018	C4591001 1204 12041018	16-55	08SEP2020	83383	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041019	C4591001 1204 12041019	16-55	31AUG2020	75944	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12041020	C4591001 1204 12041020	16-55	31AUG2020	75946	Placebo	31AUG2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041021	C4591001 1204 12041021	16-55	31AUG2020	75950	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041023	C4591001 1204 12041023	16-55	01SEP2020	75951	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12041025	C4591001 1204 12041025	16-55	01SEP2020	77433	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041026	C4591001 1204 12041026	16-55	01SEP2020	77432	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041027	C4591001 1204 12041027	16-55	02SEP2020	244912	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12041029	C4591001 1204 12041029	16-55	02SEP2020	77434	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12041030	C4591001 1204 12041030	16-55	02SEP2020	77435	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12041031	C4591001 1204 12041031	16-55	02SEP2020	78990	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041034	C4591001 1204 12041034	16-55	03SEP2020	78992	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12041038	C4591001 1204 12041038	16-55	04SEP2020	78993	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12041039	C4591001 1204 12041039	16-55	04SEP2020	79000	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12041040	C4591001 1204 12041040	16-55	04SEP2020	81931	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12041041	C4591001 1204 12041041	16-55	04SEP2020	81932	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12041043	C4591001 1204 12041043	16-55	04SEP2020	81934	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041044	C4591001 1204 12041044	16-55	04SEP2020	81935	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041046	C4591001 1204 12041046	16-55	08SEP2020	83389	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041047	C4591001 1204 12041047	16-55	08SEP2020	83391	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12041048	C4591001 1204 12041048	16-55	08SEP2020	83533	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041049	C4591001 1204 12041049	16-55	08SEP2020	83530	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12041051	C4591001 1204 12041051	16-55	08SEP2020	83536	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041052	C4591001 1204 12041052	16-55	08SEP2020	83534	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041055	C4591001 1204 12041055	16-55	08SEP2020	83909	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12041058	C4591001 1204 12041058	16-55	08SEP2020	83913	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12041059	C4591001 1204 12041059	16-55	08SEP2020	84497	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041060	C4591001 1204 12041060	16-55	08SEP2020	83914	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12041061	C4591001 1204 12041061	16-55	08SEP2020	83915	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041062	C4591001 1204 12041062	16-55	08SEP2020	84499	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041063	C4591001 1204 12041063	16-55	09SEP2020	84500	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041064	C4591001 1204 12041064	16-55	09SEP2020	84504	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041065	C4591001 1204 12041065	16-55	09SEP2020	84993	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041066	C4591001 1204 12041066	16-55	09SEP2020	84998	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12041067	C4591001 1204 12041067	16-55	09SEP2020	84995	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041070	C4591001 1204 12041070	16-55	09SEP2020	84999	Placebo	09SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041071	C4591001 1204 12041071	16-55	09SEP2020	85421	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041072	C4591001 1204 12041072	16-55	09SEP2020	85426	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041073	C4591001 1204 12041073	16-55	09SEP2020	85427	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12041074	C4591001 1204 12041074	16-55	09SEP2020	85432	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041075	C4591001 1204 12041075	16-55	09SEP2020	85733	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041076	C4591001 1204 12041076	16-55	09SEP2020	85735	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041077	C4591001 1204 12041077	16-55	09SEP2020	85738	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041078	C4591001 1204 12041078	16-55	09SEP2020	85740	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041079	C4591001 1204 12041079	16-55	10SEP2020	86278	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12041080	C4591001 1204 12041080	16-55	10SEP2020	86277	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12041081	C4591001 1204 12041081	16-55	10SEP2020	86280	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041082	C4591001 1204 12041082	16-55	10SEP2020	86283	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041084	C4591001 1204 12041084	16-55	10SEP2020	87138	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041086	C4591001 1204 12041086	16-55	10SEP2020	87139	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12041088	C4591001 1204 12041088	16-55	10SEP2020	87146	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041089	C4591001 1204 12041089	16-55	11SEP2020	87148	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041090	C4591001 1204 12041090	16-55	11SEP2020	87881	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041091	C4591001 1204 12041091	16-55	11SEP2020	87885	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041092	C4591001 1204 12041092	16-55	11SEP2020	87886	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041093	C4591001 1204 12041093	16-55	11SEP2020	87892	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041094	C4591001 1204 12041094	16-55	11SEP2020	88362	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041095	C4591001 1204 12041095	16-55	11SEP2020	88366	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12041096	C4591001 1204 12041096	16-55	11SEP2020	88368	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12041097	C4591001 1204 12041097	16-55	11SEP2020	88367	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041098	C4591001 1204 12041098	16-55	11SEP2020	88614	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12041099	C4591001 1204 12041099	16-55	11SEP2020	88617	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12041100	C4591001 1204 12041100	16-55	14SEP2020	88620	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041101	C4591001 1204 12041101	16-55	14SEP2020	88623	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12041102	C4591001 1204 12041102	16-55	14SEP2020	90006	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12041103	C4591001 1204 12041103	16-55	14SEP2020	90008	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12041105	C4591001 1204 12041105	16-55	15SEP2020	90010	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041107	C4591001 1204 12041107	16-55	16SEP2020	90015	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041108	C4591001 1204 12041108	16-55	16SEP2020	91025	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12041110	C4591001 1204 12041110	16-55	16SEP2020	91029	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041111	C4591001 1204 12041111	16-55	16SEP2020	91033	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041112	C4591001 1204 12041112	16-55	16SEP2020	91036	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041113	C4591001 1204 12041113	16-55	17SEP2020	92179	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041116	C4591001 1204 12041116	16-55	17SEP2020	92180	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12041118	C4591001 1204 12041118	16-55	17SEP2020	92181	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12041120	C4591001 1204 12041120	16-55	18SEP2020	92185	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041121	C4591001 1204 12041121	16-55	18SEP2020	93476	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041122	C4591001 1204 12041122	16-55	18SEP2020	93477	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12041123	C4591001 1204 12041123	16-55	18SEP2020	93479	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041124	C4591001 1204 12041124	16-55	18SEP2020	93481	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041125	C4591001 1204 12041125	16-55	18SEP2020	93750	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041127	C4591001 1204 12041127	16-55	18SEP2020	93752	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12041128	C4591001 1204 12041128	16-55	18SEP2020	93754	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041129	C4591001 1204 12041129	16-55	18SEP2020	93760	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12041131	C4591001 1204 12041131	16-55	18SEP2020	94062	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12041132	C4591001 1204 12041132	16-55	18SEP2020	94065	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041133	C4591001 1204 12041133	16-55	21SEP2020	94067	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041134	C4591001 1204 12041134	16-55	21SEP2020	94070	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041135	C4591001 1204 12041135	16-55	21SEP2020	95009	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041136	C4591001 1204 12041136	16-55	21SEP2020	95013	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041137	C4591001 1204 12041137	16-55	21SEP2020	95014	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12041138	C4591001 1204 12041138	16-55	21SEP2020	95019	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041139	C4591001 1204 12041139	16-55	22SEP2020	96127	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041140	C4591001 1204 12041140	16-55	22SEP2020	96129	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041141	C4591001 1204 12041141	16-55	22SEP2020	96135	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12041143	C4591001 1204 12041143†	16-55	22SEP2020	96136	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12041144	C4591001 1204 12041144	16-55	22SEP2020	96583	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041145	C4591001 1204 12041145	16-55	23SEP2020	96586	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12041147	C4591001 1204 12041147	16-55	23SEP2020	96588	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041149	C4591001 1204 12041149†	16-55	23SEP2020	96589	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041150	C4591001 1204 12041150	16-55	23SEP2020	97793	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041152	C4591001 1204 12041152†	16-55	23SEP2020	97796	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041153	C4591001 1204 12041153	16-55	23SEP2020	97797	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041154	C4591001 1204 12041154†	16-55	23SEP2020	97798	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12041155	C4591001 1204 12041155	16-55	23SEP2020	98298	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12041157	C4591001 1204 12041157	16-55	24SEP2020	98299	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041161	C4591001 1204 12041161	16-55	24SEP2020	98301	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041163	C4591001 1204 12041163†	16-55	24SEP2020	98303	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12041164	C4591001 1204 12041164†	16-55	24SEP2020	98959	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12041165	C4591001 1204 12041165†	16-55	20OCT2020	110894	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12041167	C4591001 1204 12041167	16-55	25SEP2020	98963	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12041168	C4591001 1204 12041168	16-55	25SEP2020	98966	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041170	C4591001 1204 12041170	16-55	25SEP2020	98967	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12041174	C4591001 1204 12041174	16-55	28SEP2020	101503	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12041176	C4591001 1204 12041176†	16-55	29SEP2020	101508	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12041177	C4591001 1204 12041177	16-55	29SEP2020	101510	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12041178	C4591001 1204 12041178	16-55	29SEP2020	101983	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041179	C4591001 1204 12041179	16-55	29SEP2020	101512	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041181	C4591001 1204 12041181	16-55	01OCT2020	101984	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12041182	C4591001 1204 12041182†	16-55	09OCT2020	105496	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041184	C4591001 1204 12041184	16-55	02OCT2020	101986	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041185	C4591001 1204 12041185	16-55	02OCT2020	101989	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041186	C4591001 1204 12041186	16-55	02OCT2020	103338	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12041187	C4591001 1204 12041187	16-55	05OCT2020	103342	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041188	C4591001 1204 12041188†	16-55	05OCT2020	103345	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12041189	C4591001 1204 12041189	16-55	05OCT2020	103347	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041190	C4591001 1204 12041190	16-55	06OCT2020	104288	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041191	C4591001 1204 12041191	16-55	06OCT2020	104292	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041192	C4591001 1204 12041192	16-55	06OCT2020	104294	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12041193	C4591001 1204 12041193†	16-55	07OCT2020	104296	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12041194	C4591001 1204 12041194†	16-55	07OCT2020	104911	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12041195	C4591001 1204 12041195	16-55	08OCT2020	104913	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12041197	C4591001 1204 12041197†	16-55	08OCT2020	104915	Placebo	08OCT2020/ Placebo			
12041199	C4591001 1204 12041199	16-55	08OCT2020	104916	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041202	C4591001 1204 12041202	16-55	08OCT2020	105487	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041203	C4591001 1204 12041203	16-55	08OCT2020	105489	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041204	C4591001 1204 12041204	16-55	09OCT2020	105494	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041205	C4591001 1204 12041205	16-55	09OCT2020	105941	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041206	C4591001 1204 12041206	16-55	09OCT2020	105945	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12041208	C4591001 1204 12041208	16-55	09OCT2020	105946	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12041209	C4591001 1204 12041209	16-55	09OCT2020	105950	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12041210	C4591001 1204 12041210†	16-55	09OCT2020	106134	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12041214	C4591001 1204 12041214	16-55	12OCT2020	106142	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041215	C4591001 1204 12041215	16-55	12OCT2020	106135	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041216	C4591001 1204 12041216†	16-55	12OCT2020	106625	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12041217	C4591001 1204 12041217	16-55	12OCT2020	106143	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041218	C4591001 1204 12041218	16-55	12OCT2020	106628	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041220	C4591001 1204 12041220	16-55	12OCT2020	106631	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041221	C4591001 1204 12041221	16-55	12OCT2020	106634	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12041222	C4591001 1204 12041222	16-55	13OCT2020	106880	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12041227	C4591001 1204 12041227	16-55	13OCT2020	106881	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12041228	C4591001 1204 12041228	16-55	13OCT2020	106885	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041233	C4591001 1204 12041233†	16-55	14OCT2020	106886	Placebo	14OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041234	C4591001 1204 12041234	16-55	14OCT2020	107705	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12041235	C4591001 1204 12041235	16-55	14OCT2020	107706	Placebo	14OCT2020/ Placebo	03NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041236	C4591001 1204 12041236	16-55	15OCT2020	107708	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041237	C4591001 1204 12041237	16-55	15OCT2020	108041	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041238	C4591001 1204 12041238	16-55	15OCT2020	108045	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041239	C4591001 1204 12041239	16-55	15OCT2020	107709	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041240	C4591001 1204 12041240	16-55	15OCT2020	108046	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12041241	C4591001 1204 12041241	16-55	15OCT2020	108173	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12041242	C4591001 1204 12041242	16-55	15OCT2020	108179	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12041243	C4591001 1204 12041243	16-55	15OCT2020	108051	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12041246	C4591001 1204 12041246	16-55	15OCT2020	108180	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12041247	C4591001 1204 12041247	16-55	15OCT2020	108182	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041248	C4591001 1204 12041248	16-55	15OCT2020	108463	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041252	C4591001 1204 12041252	16-55	16OCT2020	108471	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041253	C4591001 1204 12041253	16-55	16OCT2020	108467	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12041255	C4591001 1204 12041255	16-55	16OCT2020	108472	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041256	C4591001 1204 12041256	16-55	16OCT2020	109121	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041257	C4591001 1204 12041257	16-55	16OCT2020	109122	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12041258	C4591001 1204 12041258	16-55	16OCT2020	109127	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12041259	C4591001 1204 12041259	16-55	16OCT2020	109131	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12041260	C4591001 1204 12041260	16-55	19OCT2020	110010	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12041261	C4591001 1204 12041261	16-55	19OCT2020	110009	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
12041262	C4591001 1204 12041262	16-55	19OCT2020	110249	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12041263	C4591001 1204 12041263	16-55	19OCT2020	110018	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041264	C4591001 1204 12041264	16-55	19OCT2020	110016	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041265	C4591001 1204 12041265	16-55	19OCT2020	110250	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12041267	C4591001 1204 12041267	16-55	19OCT2020	110256	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12041268	C4591001 1204 12041268	16-55	20OCT2020	110258	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12041269	C4591001 1204 12041269	16-55	20OCT2020	110887	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12041270	C4591001 1204 12041270	16-55	20OCT2020	110889	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12041271	C4591001 1204 12041271	16-55	20OCT2020	110891	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12041272	C4591001 1204 12041272	16-55	21OCT2020	111377	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041273	C4591001 1204 12041273	16-55	21OCT2020	111378	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12041274	C4591001 1204 12041274	16-55	21OCT2020	111386	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041275	C4591001 1204 12041275	16-55	21OCT2020	111388	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041276	C4591001 1204 12041276	16-55	21OCT2020	111617	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041279	C4591001 1204 12041279	16-55	21OCT2020	111625	Placebo	21OCT2020/ Placebo	12NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12041280	C4591001 1204 12041280	16-55	21OCT2020	111624	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo		
12041281	C4591001 1204 12041281	16-55	21OCT2020	111627	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041283	C4591001 1204 12041283	16-55	23OCT2020	112793	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041284	C4591001 1204 12041284	16-55	23OCT2020	112803	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12041285	C4591001 1204 12041285	16-55	23OCT2020	112796	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12041286	C4591001 1204 12041286	16-55	23OCT2020	112804	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12041287	C4591001 1204 12041287	16-55	23OCT2020	112901	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12041288	C4591001 1204 12041288	16-55	23OCT2020	112904	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12041290	C4591001 1204 12041290	16-55	23OCT2020	112911	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12041292	C4591001 1204 12041292	16-55	23OCT2020	112912	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12041293	C4591001 1204 12041293	16-55	23OCT2020	113195	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12041294	C4591001 1204 12041294	16-55	23OCT2020	113192	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12051003	C4591001 1205 12051003	16-55	22OCT2020	111967	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051004	C4591001 1205 12051004	16-55	22OCT2020	111969	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051010	C4591001 1205 12051010	16-55	23OCT2020	112687	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12051011	C4591001 1205 12051011	16-55	27OCT2020	112689	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051012	C4591001 1205 12051012	16-55	27OCT2020	112690	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051013	C4591001 1205 12051013	16-55	27OCT2020	112693	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12051014	C4591001 1205 12051014	16-55	27OCT2020	113910	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12051015	C4591001 1205 12051015	16-55	27OCT2020	113912	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12051017	C4591001 1205 12051017	16-55	27OCT2020	113915	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12051021	C4591001 1205 12051021	16-55	28OCT2020	113918	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12051022	C4591001 1205 12051022	16-55	30OCT2020	114906	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12051023	C4591001 1205 12051023	16-55	30OCT2020	114913	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12051024	C4591001 1205 12051024	16-55	30OCT2020	114915	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12051025	C4591001 1205 12051025	16-55	30OCT2020	114916	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12051026	C4591001 1205 12051026	16-55	30OCT2020	114954	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051027	C4591001 1205 12051027	16-55	30OCT2020	114955	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12051028	C4591001 1205 12051028	16-55	30OCT2020	114959	BNT162b2 (30 µg)				
12051029	C4591001 1205 12051029	16-55	02NOV2020	114961	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051030	C4591001 1205 12051030	16-55	02NOV2020	115243	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12051032	C4591001 1205 12051032	16-55	03NOV2020	115247	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051033	C4591001 1205 12051033	16-55	03NOV2020	115248	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12051034	C4591001 1205 12051034	16-55	03NOV2020	115252	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051035	C4591001 1205 12051035	16-55	03NOV2020	115362	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051036	C4591001 1205 12051036	16-55	03NOV2020	115364	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12051041	C4591001 1205 12051041	16-55	04NOV2020	115371	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051042	C4591001 1205 12051042	16-55	04NOV2020	115372	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12051043	C4591001 1205 12051043	16-55	04NOV2020	115541	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12051044	C4591001 1205 12051044	16-55	04NOV2020	115543	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12051047	C4591001 1205 12051047	16-55	04NOV2020	115550	Placebo	04NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12051048	C4591001 1205 12051048	16-55	05NOV2020	115552	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12051049	C4591001 1205 12051049	16-55	05NOV2020	115723	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12051050	C4591001 1205 12051050	16-55	05NOV2020	115724	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12051051	C4591001 1205 12051051	16-55	05NOV2020	115726	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12051052	C4591001 1205 12051052	16-55	05NOV2020	115730	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12051054	C4591001 1205 12051054	16-55	05NOV2020	115807	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051061	C4591001 1205 12051061	16-55	06NOV2020	115811	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12051062	C4591001 1205 12051062	16-55	06NOV2020	115814	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051063	C4591001 1205 12051063	16-55	09NOV2020	115816	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12051064	C4591001 1205 12051064	16-55	09NOV2020	115975	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12051065	C4591001 1205 12051065	16-55	09NOV2020	115978	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051066	C4591001 1205 12051066	16-55	09NOV2020	115982	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12051067	C4591001 1205 12051067	16-55	09NOV2020	115984	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12051068	C4591001 1205 12051068	16-55	09NOV2020	115997	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12051069	C4591001 1205 12051069	16-55	09NOV2020	116004	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12051071	C4591001 1205 12051071	16-55	10NOV2020	116005	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12051073	C4591001 1205 12051073	16-55	10NOV2020	116008	Placebo	10NOV2020/ Placebo	01DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12051074	C4591001 1205 12051074	16-55	10NOV2020	116058	Placebo	10NOV2020/ Placebo	02DEC2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12051075	C4591001 1205 12051075	16-55	10NOV2020	116062	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12051077	C4591001 1205 12051077	16-55	10NOV2020	116063	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12051078	C4591001 1205 12051078	16-55	10NOV2020	116064	Placebo	10NOV2020/ Placebo		28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12051079	C4591001 1205 12051079	16-55	11NOV2020	116081	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12051080	C4591001 1205 12051080	16-55	11NOV2020	116084	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12071002	C4591001 1207 12071002	16-55	22OCT2020	111929	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12071003	C4591001 1207 12071003	16-55	23OCT2020	111934	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12071005	C4591001 1207 12071005	16-55	23OCT2020	111935	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071006	C4591001 1207 12071006	16-55	23OCT2020	111938	Placebo	23OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12071007	C4591001 1207 12071007	16-55	26OCT2020	113345	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071008	C4591001 1207 12071008	16-55	26OCT2020	113405	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071009	C4591001 1207 12071009	16-55	26OCT2020	113356	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12071010	C4591001 1207 12071010	16-55	26OCT2020	113352	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12071011	C4591001 1207 12071011	16-55	26OCT2020	113351	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071012	C4591001 1207 12071012	16-55	26OCT2020	113408	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12071013	C4591001 1207 12071013	16-55	26OCT2020	113415	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12071014	C4591001 1207 12071014	16-55	27OCT2020	113869	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12071016	C4591001 1207 12071016	16-55	27OCT2020	113867	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071018	C4591001 1207 12071018	16-55	27OCT2020	113861	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12071021	C4591001 1207 12071021	16-55	27OCT2020	113416	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12071023	C4591001 1207 12071023	16-55	28OCT2020	114282	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12071024	C4591001 1207 12071024	16-55	28OCT2020	114287	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)			
12071025	C4591001 1207 12071025	16-55	30OCT2020	114290	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12071026	C4591001 1207 12071026	16-55	30OCT2020	114292	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12071027	C4591001 1207 12071027	16-55	30OCT2020	114882	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12071028	C4591001 1207 12071028	16-55	30OCT2020	114883	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12071032	C4591001 1207 12071032	16-55	02NOV2020	114884	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12071033	C4591001 1207 12071033	16-55	02NOV2020	115182	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071036	C4591001 1207 12071036	16-55	02NOV2020	115181	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12071037	C4591001 1207 12071037	16-55	02NOV2020	114892	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12071038	C4591001 1207 12071038	16-55	02NOV2020	115186	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12071039	C4591001 1207 12071039	16-55	03NOV2020	115354	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12071040	C4591001 1207 12071040	16-55	03NOV2020	115358	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12071041	C4591001 1207 12071041	16-55	03NOV2020	115188	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12071042	C4591001 1207 12071042	16-55	03NOV2020	115350	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12071044	C4591001 1207 12071044	16-55	03NOV2020	115359	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12071045	C4591001 1207 12071045	16-55	03NOV2020	115387	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo		
12071046	C4591001 1207 12071046	16-55	03NOV2020	115391	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071047	C4591001 1207 12071047	16-55	04NOV2020	115393	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12071048	C4591001 1207 12071048	16-55	04NOV2020	115490	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12071049	C4591001 1207 12071049	16-55	04NOV2020	115396	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12071050	C4591001 1207 12071050	16-55	04NOV2020	115482	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12071051	C4591001 1207 12071051	16-55	04NOV2020	115484	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12071052	C4591001 1207 12071052	16-55	04NOV2020	115487	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12071053	C4591001 1207 12071053	16-55	04NOV2020	115510	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12071054	C4591001 1207 12071054	16-55	04NOV2020	115511	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12071057	C4591001 1207 12071057	16-55	05NOV2020	115512	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12071058	C4591001 1207 12071058	16-55	05NOV2020	115514	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12071059	C4591001 1207 12071059	16-55	05NOV2020	115709	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12071060	C4591001 1207 12071060	16-55	05NOV2020	115711	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12071061	C4591001 1207 12071061	16-55	06NOV2020	115868	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12071062	C4591001 1207 12071062	16-55	06NOV2020	115719	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12071064	C4591001 1207 12071064	16-55	06NOV2020	115869	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12071065	C4591001 1207 12071065	16-55	06NOV2020	115716	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12071066	C4591001 1207 12071066	16-55	06NOV2020	115871	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12071067	C4591001 1207 12071067	16-55	06NOV2020	115873	Placebo	06NOV2020/ Placebo	26NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12081001	C4591001 1208 12081001	16-55	22OCT2020	111894	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12081002	C4591001 1208 12081002	16-55	22OCT2020	111895	Placebo	22OCT2020/ Placebo	13NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081003	C4591001 1208 12081003	16-55	23OCT2020	111902	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081004	C4591001 1208 12081004	16-55	23OCT2020	111904	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12081005	C4591001 1208 12081005	16-55	26OCT2020	113323	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12081007	C4591001 1208 12081007	16-55	26OCT2020	113326	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12081008	C4591001 1208 12081008	16-55	26OCT2020	113327	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081009	C4591001 1208 12081009	16-55	26OCT2020	113330	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12081010	C4591001 1208 12081010	16-55	27OCT2020	113827	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081011	C4591001 1208 12081011	16-55	27OCT2020	113829	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12081012	C4591001 1208 12081012	16-55	27OCT2020	113835	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12081013	C4591001 1208 12081013	16-55	27OCT2020	113836	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081016	C4591001 1208 12081016	16-55	30OCT2020	114893	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081017	C4591001 1208 12081017	16-55	30OCT2020	114897	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12081018	C4591001 1208 12081018	16-55	30OCT2020	114902	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)			
12081019	C4591001 1208 12081019	16-55	30OCT2020	114904	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12081020	C4591001 1208 12081020	16-55	02NOV2020	115219	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12081021	C4591001 1208 12081021	16-55	02NOV2020	115221	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081022	C4591001 1208 12081022	16-55	02NOV2020	115222	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12081023	C4591001 1208 12081023	16-55	02NOV2020	115223	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12081024	C4591001 1208 12081024	16-55	02NOV2020	115253	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12081025	C4591001 1208 12081025	16-55	03NOV2020	115260	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081026	C4591001 1208 12081026	16-55	03NOV2020	115262	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12081027	C4591001 1208 12081027	16-55	03NOV2020	115263	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12081028	C4591001 1208 12081028	16-55	03NOV2020	115435	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12081029	C4591001 1208 12081029	16-55	03NOV2020	115441	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12081030	C4591001 1208 12081030	16-55	04NOV2020	115442	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081031	C4591001 1208 12081031	16-55	04NOV2020	115444	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12081032	C4591001 1208 12081032	16-55	04NOV2020	115519	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12081033	C4591001 1208 12081033	16-55	04NOV2020	115522	Placebo	04NOV2020/ Placebo	26NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12081034	C4591001 1208 12081034	16-55	04NOV2020	115523	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12081035	C4591001 1208 12081035	16-55	05NOV2020	115528	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081037	C4591001 1208 12081037	16-55	05NOV2020	115769	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12081038	C4591001 1208 12081038	16-55	05NOV2020	115774	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12081039	C4591001 1208 12081039	16-55	05NOV2020	115776	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12081040	C4591001 1208 12081040	16-55	06NOV2020	115778	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081042	C4591001 1208 12081042	16-55	06NOV2020	115895	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12081043	C4591001 1208 12081043	16-55	06NOV2020	115896	Placebo	06NOV2020/ Placebo	26NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12081044	C4591001 1208 12081044	16-55	06NOV2020	115897	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081045	C4591001 1208 12081045	16-55	06NOV2020	115899	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081046	C4591001 1208 12081046	16-55	06NOV2020	115915	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12081047	C4591001 1208 12081047	16-55	06NOV2020	115916	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12081048	C4591001 1208 12081048	16-55	09NOV2020	115917	Placebo	09NOV2020/ Placebo	02DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12081049	C4591001 1208 12081049	16-55	09NOV2020	115918	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12081050	C4591001 1208 12081050	16-55	10NOV2020	116033	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12081051	C4591001 1208 12081051	16-55	10NOV2020	116034	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12081052	C4591001 1208 12081052	16-55	10NOV2020	116040	Placebo	10NOV2020/ Placebo	01DEC2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12081053	C4591001 1208 12081053	16-55	10NOV2020	116043	Placebo	10NOV2020/ Placebo	03DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12081054	C4591001 1208 12081054	16-55	10NOV2020	116069	Placebo	10NOV2020/ Placebo	03DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12091001	C4591001 1209 12091001	16-55	22OCT2020	112015	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12091002	C4591001 1209 12091002	16-55	23OCT2020	112019	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12091003	C4591001 1209 12091003	16-55	23OCT2020	112020	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12091004	C4591001 1209 12091004	16-55	26OCT2020	112021	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12091006	C4591001 1209 12091006	16-55	28OCT2020	114270	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12091007	C4591001 1209 12091007	16-55	28OCT2020	114274	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12091008	C4591001 1209 12091008	16-55	30OCT2020	114277	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12091009	C4591001 1209 12091009	16-55	30OCT2020	114280	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12091010	C4591001 1209 12091010	16-55	02NOV2020	115194	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12091011	C4591001 1209 12091011	16-55	02NOV2020	115196	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12091013	C4591001 1209 12091013	16-55	02NOV2020	115197	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)			
12091015	C4591001 1209 12091015	16-55	03NOV2020	115203	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12091016	C4591001 1209 12091016	16-55	03NOV2020	115339	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12091017	C4591001 1209 12091017	16-55	03NOV2020	115341	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12091018	C4591001 1209 12091018	16-55	04NOV2020	115344	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12091019	C4591001 1209 12091019	16-55	04NOV2020	115346	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12091020	C4591001 1209 12091020	16-55	04NOV2020	115593	Placebo	04NOV2020/ Placebo	26NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12091021	C4591001 1209 12091021	16-55	05NOV2020	272976	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12101001	C4591001 1210 12101001	16-55	22OCT2020	111917	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101002	C4591001 1210 12101002	16-55	22OCT2020	111919	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101005	C4591001 1210 12101005	16-55	23OCT2020	111923	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12101006	C4591001 1210 12101006	16-55	23OCT2020	111927	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12101007	C4591001 1210 12101007	16-55	23OCT2020	112721	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101008	C4591001 1210 12101008	16-55	26OCT2020	112724	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101009	C4591001 1210 12101009	16-55	26OCT2020	112730	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12101010	C4591001 1210 12101010	16-55	26OCT2020	112732	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101011	C4591001 1210 12101011	16-55	26OCT2020	113443	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101012	C4591001 1210 12101012	16-55	26OCT2020	113444	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101013	C4591001 1210 12101013	16-55	27OCT2020	113445	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101014	C4591001 1210 12101014	16-55	27OCT2020	113450	Placebo	27OCT2020/ Placebo	16NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12101015	C4591001 1210 12101015	16-55	27OCT2020	113897	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101016	C4591001 1210 12101016	16-55	27OCT2020	113900	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101017	C4591001 1210 12101017	16-55	27OCT2020	113902	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101018	C4591001 1210 12101018	16-55	27OCT2020	113908	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12101019	C4591001 1210 12101019	16-55	27OCT2020	113946	Placebo	27OCT2020/ Placebo		05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12101020	C4591001 1210 12101020	16-55	27OCT2020	113949	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101021	C4591001 1210 12101021	16-55	27OCT2020	113951	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12101022	C4591001 1210 12101022	16-55	28OCT2020	113956	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12101023	C4591001 1210 12101023	16-55	28OCT2020	114305	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12101024	C4591001 1210 12101024	16-55	28OCT2020	114307	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12101025	C4591001 1210 12101025	16-55	30OCT2020	114309	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12101026	C4591001 1210 12101026	16-55	30OCT2020	114315	Placebo	30OCT2020/ Placebo	11DEC2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12101027	C4591001 1210 12101027	16-55	30OCT2020	114941	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101028	C4591001 1210 12101028	16-55	30OCT2020	114943	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12101029	C4591001 1210 12101029	16-55	30OCT2020	114945	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101030	C4591001 1210 12101030	16-55	30OCT2020	114949	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12101031	C4591001 1210 12101031	16-55	02NOV2020	115169	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12101032	C4591001 1210 12101032	16-55	02NOV2020	115173	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12101033	C4591001 1210 12101033	16-55	02NOV2020	115175	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12101034	C4591001 1210 12101034	16-55	02NOV2020	115179	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12101035	C4591001 1210 12101035	16-55	02NOV2020	115229	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12101036	C4591001 1210 12101036	16-55	02NOV2020	115232	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101037	C4591001 1210 12101037	16-55	03NOV2020	115233	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101038	C4591001 1210 12101038	16-55	03NOV2020	115235	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101039	C4591001 1210 12101039	16-55	03NOV2020	115410	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101040	C4591001 1210 12101040	16-55	03NOV2020	115414	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12101041	C4591001 1210 12101041	16-55	03NOV2020	115416	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101045	C4591001 1210 12101045	16-55	04NOV2020	115420	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101046	C4591001 1210 12101046	16-55	04NOV2020	115553	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101047	C4591001 1210 12101047	16-55	04NOV2020	115556	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12101048	C4591001 1210 12101048	16-55	04NOV2020	115563	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101049	C4591001 1210 12101049	16-55	04NOV2020	115564	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101050	C4591001 1210 12101050	16-55	05NOV2020	115735	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101051	C4591001 1210 12101051	16-55	05NOV2020	115736	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12101052	C4591001 1210 12101052	16-55	05NOV2020	115743	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12101053	C4591001 1210 12101053	16-55	05NOV2020	115744	Placebo	05NOV2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12101054	C4591001 1210 12101054	16-55	05NOV2020	115793	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12101055	C4591001 1210 12101055	16-55	06NOV2020	115800	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12101056	C4591001 1210 12101056	16-55	06NOV2020	115802	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
12101057	C4591001 1210 12101057	16-55	06NOV2020	115804	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12101058	C4591001 1210 12101058	16-55	06NOV2020	115902	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101059	C4591001 1210 12101059	16-55	06NOV2020	115905	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12101060	C4591001 1210 12101060	16-55	06NOV2020	115909	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12101061	C4591001 1210 12101061	16-55	09NOV2020	115910	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12121001	C4591001 1212 12121001	16-55	22OCT2020	112002	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12121002	C4591001 1212 12121002	16-55	22OCT2020	112003	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12121003	C4591001 1212 12121003	16-55	23OCT2020	112005	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12121004	C4591001 1212 12121004	16-55	23OCT2020	112012	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12121005	C4591001 1212 12121005	16-55	23OCT2020	112637	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12121006	C4591001 1212 12121006	16-55	23OCT2020	112639	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12121007	C4591001 1212 12121007	16-55	26OCT2020	112641	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12121008	C4591001 1212 12121008	16-55	26OCT2020	112648	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12121009	C4591001 1212 12121009	16-55	26OCT2020	113372	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12121010	C4591001 1212 12121010	16-55	26OCT2020	113373	Placebo	26OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12121011	C4591001 1212 12121011	16-55	26OCT2020	113376	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12121012	C4591001 1212 12121012	16-55	27OCT2020	113379	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12121013	C4591001 1212 12121013	16-55	27OCT2020	113852	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12121014	C4591001 1212 12121014	16-55	27OCT2020	113858	Placebo	27OCT2020/ Placebo	18NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12121015	C4591001 1212 12121015	16-55	27OCT2020	113859	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12121016	C4591001 1212 12121016	16-55	27OCT2020	113860	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12121017	C4591001 1212 12121017	16-55	30OCT2020	114870	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12121018	C4591001 1212 12121018	16-55	30OCT2020	114871	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12121019	C4591001 1212 12121019	16-55	30OCT2020	114875	Placebo	30OCT2020/ Placebo	20NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12121020	C4591001 1212 12121020†	16-55	03NOV2020	114877	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12121022	C4591001 1212 12121022	16-55	03NOV2020	115426	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12121023	C4591001 1212 12121023	16-55	03NOV2020	115429	BNT162b2 (30 µg)				
12121024	C4591001 1212 12121024	16-55	04NOV2020	115430	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12121025	C4591001 1212 12121025	16-55	04NOV2020	115432	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12121026	C4591001 1212 12121026	16-55	04NOV2020	115495	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12121027	C4591001 1212 12121027	16-55	04NOV2020	115497	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12121028	C4591001 1212 12121028	16-55	05NOV2020	115500	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12121029	C4591001 1212 12121029	16-55	05NOV2020	115502	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12121031	C4591001 1212 12121031	16-55	05NOV2020	274009	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12121032	C4591001 1212 12121032	16-55	05NOV2020	115757	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12121034	C4591001 1212 12121034	16-55	05NOV2020	115758	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12121035	C4591001 1212 12121035	16-55	06NOV2020	115760	Placebo	06NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12121036	C4591001 1212 12121036	16-55	06NOV2020	115764	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12131001	C4591001 1213 12131001	16-55	22OCT2020	111955	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12131002	C4591001 1213 12131002	16-55	22OCT2020	111956	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12131003	C4591001 1213 12131003	16-55	22OCT2020	111959	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131004	C4591001 1213 12131004	16-55	23OCT2020	111964	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12131005	C4591001 1213 12131005	16-55	23OCT2020	112662	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131006	C4591001 1213 12131006	16-55	23OCT2020	112663	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131008	C4591001 1213 12131008	16-55	23OCT2020	112668	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12131010	C4591001 1213 12131010	16-55	26OCT2020	113360	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12131012	C4591001 1213 12131012	16-55	26OCT2020	113362	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12131013	C4591001 1213 12131013	16-55	26OCT2020	113364	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12131014	C4591001 1213 12131014	16-55	02NOV2020	113366	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12131015	C4591001 1213 12131015	16-55	02NOV2020	115159	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12131016	C4591001 1213 12131016	16-55	02NOV2020	115161	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12131018	C4591001 1213 12131018	16-55	02NOV2020	115164	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12131019	C4591001 1213 12131019	16-55	02NOV2020	115168	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12131025	C4591001 1213 12131025	16-55	03NOV2020	115373	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131026	C4591001 1213 12131026	16-55	03NOV2020	115377	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12131028	C4591001 1213 12131028	16-55	03NOV2020	115379	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12131032	C4591001 1213 12131032	16-55	04NOV2020	115382	Placebo	04NOV2020/ Placebo	24NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12131033	C4591001 1213 12131033	16-55	04NOV2020	115565	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12131034	C4591001 1213 12131034	16-55	04NOV2020	115572	Placebo	04NOV2020/ Placebo	30NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12131035	C4591001 1213 12131035	16-55	05NOV2020	115574	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12131036	C4591001 1213 12131036	16-55	04NOV2020	115573	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12131037	C4591001 1213 12131037	16-55	05NOV2020	115697	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12131038	C4591001 1213 12131038	16-55	05NOV2020	115700	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12131039	C4591001 1213 12131039	16-55	05NOV2020	115702	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131040	C4591001 1213 12131040	16-55	05NOV2020	115704	Placebo	05NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131041	C4591001 1213 12131041	16-55	05NOV2020	115748	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12131042	C4591001 1213 12131042	16-55	05NOV2020	115750	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12131043	C4591001 1213 12131043	16-55	05NOV2020	115752	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12131044	C4591001 1213 12131044	16-55	05NOV2020	115754	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12131046	C4591001 1213 12131046	16-55	06NOV2020	115829	Placebo	06NOV2020/ Placebo			
12131050	C4591001 1213 12131050	16-55	06NOV2020	115838	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12131052	C4591001 1213 12131052	16-55	09NOV2020	115839	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12131053	C4591001 1213 12131053	16-55	09NOV2020	115937	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12131054	C4591001 1213 12131054	16-55	09NOV2020	115940	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12131055	C4591001 1213 12131055	16-55	09NOV2020	115942	Placebo	09NOV2020/ Placebo	02DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131056	C4591001 1213 12131056	16-55	09NOV2020	115945	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12131057	C4591001 1213 12131057	16-55	09NOV2020	115963	Placebo	09NOV2020/ Placebo	01DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12131059	C4591001 1213 12131059	16-55	09NOV2020	115965	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12131060	C4591001 1213 12131060	16-55	09NOV2020	115966	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141001	C4591001 1214 12141001	16-55	22OCT2020	111905	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12141004	C4591001 1214 12141004	16-55	23OCT2020	111907	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12141005	C4591001 1214 12141005	16-55	23OCT2020	111912	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12141007	C4591001 1214 12141007	16-55	26OCT2020	111916	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12141008	C4591001 1214 12141008	16-55	26OCT2020	113419	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141009	C4591001 1214 12141009	16-55	26OCT2020	113420	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12141012	C4591001 1214 12141012	16-55	30OCT2020	113422	Placebo	30OCT2020/ Placebo	18NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12141013	C4591001 1214 12141013	16-55	30OCT2020	113423	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12141014	C4591001 1214 12141014	16-55	30OCT2020	114929	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141015	C4591001 1214 12141015	16-55	30OCT2020	114931	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12141016	C4591001 1214 12141016	16-55	02NOV2020	114933	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)		
12141017	C4591001 1214 12141017	16-55	02NOV2020	114938	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12141018	C4591001 1214 12141018	16-55	02NOV2020	115208	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12141019	C4591001 1214 12141019	16-55	02NOV2020	115213	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12141020	C4591001 1214 12141020	16-55	02NOV2020	115214	Placebo	02NOV2020/ Placebo	20NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141022	C4591001 1214 12141022	16-55	03NOV2020	115216	Placebo	03NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141023	C4591001 1214 12141023	16-55	03NOV2020	115400	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12141024	C4591001 1214 12141024	16-55	03NOV2020	115402	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141025	C4591001 1214 12141025	16-55	03NOV2020	115403	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12141027	C4591001 1214 12141027	16-55	04NOV2020	115405	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141029	C4591001 1214 12141029	16-55	04NOV2020	115529	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12141030	C4591001 1214 12141030	16-55	04NOV2020	115531	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141031	C4591001 1214 12141031	16-55	04NOV2020	115532	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12141034	C4591001 1214 12141034	16-55	05NOV2020	115536	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12141036	C4591001 1214 12141036	16-55	05NOV2020	115781	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141037	C4591001 1214 12141037	16-55	05NOV2020	115785	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12141038	C4591001 1214 12141038	16-55	06NOV2020	115788	Placebo	06NOV2020/ Placebo	24NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141039	C4591001 1214 12141039	16-55	06NOV2020	115789	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12141040	C4591001 1214 12141040	16-55	06NOV2020	115877	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141041	C4591001 1214 12141041	16-55	06NOV2020	115879	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141042	C4591001 1214 12141042	16-55	06NOV2020	115881	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12141043	C4591001 1214 12141043	16-55	09NOV2020	115888	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12141044	C4591001 1214 12141044	16-55	09NOV2020	115951	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12141045	C4591001 1214 12141045	16-55	09NOV2020	115954	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12141047	C4591001 1214 12141047	16-55	09NOV2020	115957	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12141048	C4591001 1214 12141048	16-55	09NOV2020	115958	Placebo	09NOV2020/ Placebo	27NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12141049	C4591001 1214 12141049	16-55	10NOV2020	116022	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12141051	C4591001 1214 12141051	16-55	10NOV2020	116027	Placebo	10NOV2020/ Placebo	01DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12141052	C4591001 1214 12141052	16-55	10NOV2020	116031	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12141053	C4591001 1214 12141053	16-55	10NOV2020	116032	Placebo	10NOV2020/ Placebo	02DEC2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12141054	C4591001 1214 12141054	16-55	10NOV2020	116045	Placebo	10NOV2020/ Placebo	02DEC2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12141055	C4591001 1214 12141055	16-55	10NOV2020	116046	BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12171002	C4591001 1217 12171002	16-55	22OCT2020	111977	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12171003	C4591001 1217 12171003	16-55	22OCT2020	111978	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171005	C4591001 1217 12171005†	16-55	22OCT2020	111983	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171008	C4591001 1217 12171008	16-55	23OCT2020	111984	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171009	C4591001 1217 12171009	16-55	23OCT2020	112649	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12171010	C4591001 1217 12171010	16-55	23OCT2020	112651	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12171011	C4591001 1217 12171011	16-55	23OCT2020	112654	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171012	C4591001 1217 12171012	16-55	23OCT2020	112660	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12171013	C4591001 1217 12171013	16-55	26OCT2020	113334	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12171014	C4591001 1217 12171014	16-55	26OCT2020	113336	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171015	C4591001 1217 12171015†	16-55	26OCT2020	113340	Placebo	26OCT2020/ Placebo	17NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12171016	C4591001 1217 12171016	16-55	26OCT2020	113344	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12171017	C4591001 1217 12171017	16-55	26OCT2020	113381	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171018	C4591001 1217 12171018	16-55	27OCT2020	113383	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12171019	C4591001 1217 12171019	16-55	27OCT2020	113385	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12171020	C4591001 1217 12171020	16-55	27OCT2020	113390	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171021	C4591001 1217 12171021	16-55	27OCT2020	113837	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12171022	C4591001 1217 12171022	16-55	27OCT2020	113838	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12171023	C4591001 1217 12171023	16-55	27OCT2020	113843	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12171028	C4591001 1217 12171028	16-55	30OCT2020	113848	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171030	C4591001 1217 12171030	16-55	30OCT2020	114920	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12171031	C4591001 1217 12171031	16-55	30OCT2020	114923	Placebo	30OCT2020/ Placebo			
12171032	C4591001 1217 12171032	16-55	02NOV2020	114925	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171034	C4591001 1217 12171034	16-55	03NOV2020	114927	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12171035	C4591001 1217 12171035	16-55	03NOV2020	115328	Placebo	03NOV2020/ Placebo	24NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171037	C4591001 1217 12171037	16-55	03NOV2020	115329	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12171038	C4591001 1217 12171038	16-55	03NOV2020	115330	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12171039	C4591001 1217 12171039	16-55	04NOV2020	115336	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12171040	C4591001 1217 12171040	16-55	04NOV2020	115470	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12171041	C4591001 1217 12171041	16-55	04NOV2020	115475	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171042	C4591001 1217 12171042	16-55	04NOV2020	115476	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12171044	C4591001 1217 12171044	16-55	04NOV2020	115479	Placebo	04NOV2020/ Placebo			
12171045	C4591001 1217 12171045	16-55	04NOV2020	115578	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171046	C4591001 1217 12171046	16-55	05NOV2020	115582	Placebo	05NOV2020/ Placebo	25NOV2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12171047	C4591001 1217 12171047	16-55	05NOV2020	115583	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12171048	C4591001 1217 12171048	16-55	05NOV2020	115588	Placebo	05NOV2020/ Placebo	26NOV2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12171049	C4591001 1217 12171049	16-55	06NOV2020	115842	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171050	C4591001 1217 12171050	16-55	06NOV2020	115845	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12171051	C4591001 1217 12171051	16-55	06NOV2020	115847	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12171052	C4591001 1217 12171052	16-55	06NOV2020	115852	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12171053	C4591001 1217 12171053	16-55	06NOV2020	115855	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	26NOV2020/ BNT162b2 (30 µg)		
12171054	C4591001 1217 12171054	16-55	06NOV2020	115856	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12171055	C4591001 1217 12171055	16-55	06NOV2020	115859	Placebo	06NOV2020/ Placebo	27NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12171056	C4591001 1217 12171056	16-55	06NOV2020	115861	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	27NOV2020/ BNT162b2 (30 µg)		
12171059	C4591001 1217 12171059	16-55	09NOV2020	115987	BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12171061	C4591001 1217 12171061	16-55	09NOV2020	115993	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12171062	C4591001 1217 12171062	16-55	09NOV2020	115995	Placebo	09NOV2020/ Placebo	30NOV2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12181001	C4591001 1218 12181001	16-55	19OCT2020	110585	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12181003	C4591001 1218 12181003	16-55	21OCT2020	110589	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12181004	C4591001 1218 12181004	16-55	21OCT2020	110593	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12181005	C4591001 1218 12181005	16-55	23OCT2020	110595	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12181006	C4591001 1218 12181006	16-55	23OCT2020	113069	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12181007	C4591001 1218 12181007	16-55	27OCT2020	113071	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181008	C4591001 1218 12181008	16-55	28OCT2020	113079	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12181009	C4591001 1218 12181009	16-55	02NOV2020	113080	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181011	C4591001 1218 12181011	16-55	02NOV2020	115290	BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12181012	C4591001 1218 12181012	16-55	02NOV2020	115291	Placebo	02NOV2020/ Placebo	24NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12181013	C4591001 1218 12181013	16-55	03NOV2020	115296	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181014	C4591001 1218 12181014	16-55	11NOV2020	115300	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12181015	C4591001 1218 12181015	16-55	12NOV2020	116202	Placebo	12NOV2020/ Placebo	03DEC2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12181016	C4591001 1218 12181016	16-55	12NOV2020	116205	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
12181017	C4591001 1218 12181017	16-55	13NOV2020	116206	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12181018	C4591001 1218 12181018	16-55	13NOV2020	116209	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181019	C4591001 1218 12181019	16-55	13NOV2020	116225	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12181022	C4591001 1218 12181022	16-55	17NOV2020	116233	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12181023	C4591001 1218 12181023	16-55	17NOV2020	116235	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12181025	C4591001 1218 12181025	16-55	18NOV2020	116236	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12181026	C4591001 1218 12181026	16-55	18NOV2020	116506	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo		
12181027	C4591001 1218 12181027	16-55	19NOV2020	116507	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	
12181028	C4591001 1218 12181028	16-55	19NOV2020	116509	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12181030	C4591001 1218 12181030	16-55	20NOV2020	116510	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12181031	C4591001 1218 12181031	16-55	20NOV2020	116587	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12181032	C4591001 1218 12181032	16-55	20NOV2020	116592	Placebo	20NOV2020/ Placebo	09DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181034	C4591001 1218 12181034	16-55	23NOV2020	116593	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12181035	C4591001 1218 12181035	16-55	24NOV2020	116595	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12181036	C4591001 1218 12181036	16-55	24NOV2020	116885	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12181037	C4591001 1218 12181037	16-55	30NOV2020	116887	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181039	C4591001 1218 12181039	16-55	30NOV2020	116890	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181041	C4591001 1218 12181041	16-55	01DEC2020	116895	Placebo	01DEC2020/ Placebo		10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12181042	C4591001 1218 12181042	16-55	01DEC2020	117162	Placebo	01DEC2020/ Placebo		21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181043	C4591001 1218 12181043	16-55	01DEC2020	117166	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181044	C4591001 1218 12181044	16-55	02DEC2020	117167	Placebo	02DEC2020/ Placebo	22DEC2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12181045	C4591001 1218 12181045	16-55	02DEC2020	117169	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181046	C4591001 1218 12181046	16-55	02DEC2020	117234	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12181047	C4591001 1218 12181047	16-55	02DEC2020	117236	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12181048	C4591001 1218 12181048	16-55	03DEC2020	117243	Placebo	03DEC2020/ Placebo		22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181049	C4591001 1218 12181049	16-55	03DEC2020	117244	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12181050	C4591001 1218 12181050	16-55	03DEC2020	117428	Placebo	03DEC2020/ Placebo		23DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12181051	C4591001 1218 12181051	16-55	03DEC2020	117431	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12181052	C4591001 1218 12181052	16-55	03DEC2020	117432	Placebo	03DEC2020/ Placebo		23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12181053	C4591001 1218 12181053	16-55	07DEC2020	117436	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12181054	C4591001 1218 12181054	16-55	07DEC2020	117694	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12181055	C4591001 1218 12181055	16-55	07DEC2020	117697	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12181057	C4591001 1218 12181057	16-55	08DEC2020	117698	Placebo	08DEC2020/ Placebo		16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12181058	C4591001 1218 12181058	16-55	08DEC2020	117700	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12181059	C4591001 1218 12181059	16-55	10DEC2020	117826	BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
12191001	C4591001 1219 12191001	16-55	25SEP2020	100553	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12191002	C4591001 1219 12191002	16-55	25SEP2020	100555	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12191003	C4591001 1219 12191003	16-55	01OCT2020	100556	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12191004	C4591001 1219 12191004	16-55	01OCT2020	100559	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12191013	C4591001 1219 12191013	16-55	08OCT2020	105393	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12191014	C4591001 1219 12191014	16-55	08OCT2020	105396	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12191016	C4591001 1219 12191016	16-55	09OCT2020	105398	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12191017	C4591001 1219 12191017	16-55	13OCT2020	105400	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12191022	C4591001 1219 12191022	16-55	20OCT2020	111101	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12191023	C4591001 1219 12191023	16-55	20OCT2020	111102	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12191024	C4591001 1219 12191024	16-55	22OCT2020	111110	Placebo	22OCT2020/ Placebo	10NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	
12191026	C4591001 1219 12191026	16-55	26OCT2020	111111	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12191028	C4591001 1219 12191028	16-55	27OCT2020	114221	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12191029	C4591001 1219 12191029	16-55	29OCT2020	114225	Placebo	29OCT2020/ Placebo	23NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12191030	C4591001 1219 12191030	16-55	29OCT2020	114224	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12191033	C4591001 1219 12191033	16-55	12NOV2020	114229	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		
12191034	C4591001 1219 12191034	16-55	12NOV2020	116177	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12191035	C4591001 1219 12191035	16-55	13NOV2020	116184	Placebo	13NOV2020/ Placebo	02DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12191039	C4591001 1219 12191039	16-55	17NOV2020	116187	Placebo	17NOV2020/ Placebo	07DEC2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12191040	C4591001 1219 12191040	16-55	17NOV2020	116188	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12191042	C4591001 1219 12191042	16-55	23NOV2020	116706	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12191044	C4591001 1219 12191044	16-55	23NOV2020	116707	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12191047	C4591001 1219 12191047	16-55	25NOV2020	116708	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12191048	C4591001 1219 12191048	16-55	25NOV2020	116714	Placebo	25NOV2020/ Placebo	16DEC2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12191049	C4591001 1219 12191049	16-55	25NOV2020	116970	Placebo	25NOV2020/ Placebo	14DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12191050	C4591001 1219 12191050	16-55	30NOV2020	116971	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12191051	C4591001 1219 12191051	16-55	02DEC2020	116974	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12191053	C4591001 1219 12191053	16-55	03DEC2020	117396	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12191054	C4591001 1219 12191054	16-55	03DEC2020	116978	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12191056	C4591001 1219 12191056	16-55	03DEC2020	117395	Placebo	03DEC2020/ Placebo		22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12191058	C4591001 1219 12191058	16-55	07DEC2020	117397	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12191059	C4591001 1219 12191059	16-55	08DEC2020	117399	BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
12191062	C4591001 1219 12191062	16-55	08DEC2020	117775	Placebo	08DEC2020/ Placebo		18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12201003	C4591001 1220 12201003	16-55	28SEP2020	101525	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12201004	C4591001 1220 12201004	16-55	28SEP2020	101527	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12201009	C4591001 1220 12201009	16-55	02OCT2020	101529	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12201012	C4591001 1220 12201012	16-55	07OCT2020	101533	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201013	C4591001 1220 12201013	16-55	08OCT2020	105426	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12201015	C4591001 1220 12201015	16-55	15OCT2020	105431	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12201017	C4591001 1220 12201017	16-55	15OCT2020	105432	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo		
12201018	C4591001 1220 12201018	16-55	16OCT2020	105433	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12201020	C4591001 1220 12201020	16-55	16OCT2020	109218	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12201021	C4591001 1220 12201021	16-55	20OCT2020	109222	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12201022	C4591001 1220 12201022	16-55	20OCT2020	109224	Placebo	20OCT2020/ Placebo	12NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12201024	C4591001 1220 12201024	16-55	21OCT2020	109228	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12201025	C4591001 1220 12201025	16-55	26OCT2020	113756	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12201026	C4591001 1220 12201026	16-55	27OCT2020	113761	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201027	C4591001 1220 12201027	16-55	27OCT2020	113762	Placebo	27OCT2020/ Placebo	17NOV2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12201028	C4591001 1220 12201028	16-55	28OCT2020	113763	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12201029	C4591001 1220 12201029	16-55	28OCT2020	114533	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	
12201030	C4591001 1220 12201030	16-55	29OCT2020	114540	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12201031	C4591001 1220 12201031	16-55	30OCT2020	114541	BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12201032	C4591001 1220 12201032	16-55	02NOV2020	114542	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12201033	C4591001 1220 12201033	16-55	03NOV2020	115445	Placebo	03NOV2020/ Placebo	23NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12201035	C4591001 1220 12201035	16-55	03NOV2020	115446	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12201036	C4591001 1220 12201036	16-55	04NOV2020	115447	BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)			
12201037	C4591001 1220 12201037	16-55	05NOV2020	115451	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201039	C4591001 1220 12201039	16-55	11NOV2020	116105	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12201041	C4591001 1220 12201041	16-55	12NOV2020	116108	Placebo	12NOV2020/ Placebo	30NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12201042	C4591001 1220 12201042	16-55	13NOV2020	116114	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12201043	C4591001 1220 12201043	16-55	13NOV2020	116116	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12201044	C4591001 1220 12201044	16-55	13NOV2020	116251	Placebo	13NOV2020/ Placebo	04DEC2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12201045	C4591001 1220 12201045	16-55	16NOV2020	116256	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12201046	C4591001 1220 12201046	16-55	16NOV2020	116257	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12201047	C4591001 1220 12201047	16-55	16NOV2020	116260	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12201048	C4591001 1220 12201048	16-55	17NOV2020	116346	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12201050	C4591001 1220 12201050	16-55	17NOV2020	116351	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12201051	C4591001 1220 12201051	16-55	18NOV2020	116352	Placebo	18NOV2020/ Placebo	11DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12201052	C4591001 1220 12201052	16-55	18NOV2020	116356	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
12201053	C4591001 1220 12201053	16-55	19NOV2020	116539	Placebo	19NOV2020/ Placebo	09DEC2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12201056	C4591001 1220 12201056	16-55	20NOV2020	116540	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo		
12201057	C4591001 1220 12201057	16-55	20NOV2020	116543	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	11DEC2020/ BNT162b2 (30 µg)		
12201059	C4591001 1220 12201059	16-55	24NOV2020	116544	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12201061	C4591001 1220 12201061	16-55	25NOV2020	116934	Placebo	25NOV2020/ Placebo	15DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12201062	C4591001 1220 12201062	16-55	25NOV2020	116938	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12201063	C4591001 1220 12201063	16-55	25NOV2020	116939	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)		
12201065	C4591001 1220 12201065	16-55	02DEC2020	116941	Placebo	02DEC2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211002	C4591001 1221 12211002	16-55	13OCT2020	107094	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211003	C4591001 1221 12211003	16-55	15OCT2020	107095	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12211005	C4591001 1221 12211005	16-55	15OCT2020	107096	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12211006	C4591001 1221 12211006	16-55	15OCT2020	107097	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211007	C4591001 1221 12211007	16-55	16OCT2020	109338	Placebo	16OCT2020/ Placebo	07DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12211010	C4591001 1221 12211010	16-55	20OCT2020	109339	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12211011	C4591001 1221 12211011	16-55	20OCT2020	109343	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12211012	C4591001 1221 12211012	16-55	22OCT2020	112199	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12211013	C4591001 1221 12211013	16-55	22OCT2020	112198	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12211014	C4591001 1221 12211014	16-55	22OCT2020	109347	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211020	C4591001 1221 12211020	16-55	30OCT2020	112201	Placebo	30OCT2020/ Placebo	19NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211022	C4591001 1221 12211022	16-55	02NOV2020	112203	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211023	C4591001 1221 12211023	16-55	04NOV2020	115604	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12211024	C4591001 1221 12211024	16-55	18NOV2020	116379	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12211025	C4591001 1221 12211025	16-55	05NOV2020	115608	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12211026	C4591001 1221 12211026	16-55	05NOV2020	115606	Placebo	05NOV2020/ Placebo	24NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12211029	C4591001 1221 12211029	16-55	13NOV2020	116213	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12211030	C4591001 1221 12211030	16-55	12NOV2020	115610	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
12211031	C4591001 1221 12211031	16-55	13NOV2020	116218	Placebo	13NOV2020/ Placebo	03DEC2020/ Placebo		
12211032	C4591001 1221 12211032	16-55	13NOV2020	116217	Placebo	13NOV2020/ Placebo	03DEC2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211033	C4591001 1221 12211033	16-55	13NOV2020	116221	BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)		
12211036	C4591001 1221 12211036	16-55	16NOV2020	116287	BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12211037	C4591001 1221 12211037	16-55	16NOV2020	116290	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211038	C4591001 1221 12211038	16-55	16NOV2020	116292	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211040	C4591001 1221 12211040	16-55	17NOV2020	116294	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12211041	C4591001 1221 12211041	16-55	17NOV2020	116371	BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12211042	C4591001 1221 12211042	16-55	17NOV2020	116373	Placebo	17NOV2020/ Placebo	08DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211043	C4591001 1221 12211043	16-55	18NOV2020	116380	Placebo	18NOV2020/ Placebo	07DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12211044	C4591001 1221 12211044	16-55	18NOV2020	116419	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	08DEC2020/ BNT162b2 (30 µg)		
12211045	C4591001 1221 12211045	16-55	18NOV2020	116420	Placebo	18NOV2020/ Placebo	10DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211046	C4591001 1221 12211046	16-55	18NOV2020	116423	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12211047	C4591001 1221 12211047	16-55	23NOV2020	116564	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12211053	C4591001 1221 12211053	16-55	20NOV2020	116428	Placebo	20NOV2020/ Placebo	10DEC2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12211054	C4591001 1221 12211054	16-55	20NOV2020	116561	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12211055	C4591001 1221 12211055	16-55	23NOV2020	116562	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12211056	C4591001 1221 12211056	16-55	23NOV2020	116569	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12211062	C4591001 1221 12211062	16-55	24NOV2020	116851	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12211064	C4591001 1221 12211064	16-55	25NOV2020	116852	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12211065	C4591001 1221 12211065	16-55	25NOV2020	116857	Placebo	25NOV2020/ Placebo	14DEC2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12211067	C4591001 1221 12211067	16-55	30NOV2020	116860	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211068	C4591001 1221 12211068	16-55	30NOV2020	117093	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12211069	C4591001 1221 12211069	16-55	01DEC2020	117151	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211070	C4591001 1221 12211070	16-55	01DEC2020	117153	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12211071	C4591001 1221 12211071	16-55	01DEC2020	117154	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12211072	C4591001 1221 12211072	16-55	01DEC2020	117094	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12211073	C4591001 1221 12211073	16-55	01DEC2020	117099	Placebo	01DEC2020/ Placebo	21DEC2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12211074	C4591001 1221 12211074	16-55	01DEC2020	117100	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12211078	C4591001 1221 12211078	16-55	02DEC2020	117158	Placebo	02DEC2020/ Placebo		23DEC2020/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12211079	C4591001 1221 12211079	16-55	02DEC2020	117260	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12211080	C4591001 1221 12211080	16-55	02DEC2020	117257	Placebo	02DEC2020/ Placebo	21DEC2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12211081	C4591001 1221 12211081	16-55	02DEC2020	117265	Placebo	02DEC2020/ Placebo	22DEC2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12211082	C4591001 1221 12211082	16-55	03DEC2020	117268	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12211083	C4591001 1221 12211083	16-55	03DEC2020	117438	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12211087	C4591001 1221 12211087	16-55	07DEC2020	117440	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12211088	C4591001 1221 12211088	16-55	07DEC2020	117446	Placebo	07DEC2020/ Placebo	28DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12211089	C4591001 1221 12211089	16-55	08DEC2020	117447	Placebo	08DEC2020/ Placebo	28DEC2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12211090	C4591001 1221 12211090	16-55	08DEC2020	117726	Placebo	08DEC2020/ Placebo	19JAN2021/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12231001	C4591001 1223 12231001	16-55	26AUG2020	68430	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231003	C4591001 1223 12231003	16-55	27AUG2020	68434	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12231004	C4591001 1223 12231004	16-55	27AUG2020	68438	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231005	C4591001 1223 12231005	16-55	27AUG2020	68440	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12231008	C4591001 1223 12231008	16-55	27AUG2020	70097	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12231014	C4591001 1223 12231014	16-55	28AUG2020	70098	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12231016	C4591001 1223 12231016	16-55	28AUG2020	70104	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231022	C4591001 1223 12231022	16-55	28AUG2020	70108	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231024	C4591001 1223 12231024	16-55	28AUG2020	72425	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231025	C4591001 1223 12231025	16-55	28AUG2020	72426	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231026	C4591001 1223 12231026	16-55	28AUG2020	72428	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231027	C4591001 1223 12231027	16-55	28AUG2020	72431	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12231028	C4591001 1223 12231028	16-55	28AUG2020	72835	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231030	C4591001 1223 12231030	16-55	29AUG2020	72837	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12231031	C4591001 1223 12231031	16-55	29AUG2020	72839	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12231034	C4591001 1223 12231034	16-55	29AUG2020	72843	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231035	C4591001 1223 12231035	16-55	29AUG2020	73799	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231036	C4591001 1223 12231036	16-55	31AUG2020	73800	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12231041	C4591001 1223 12231041	16-55	31AUG2020	73801	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231044	C4591001 1223 12231044	16-55	31AUG2020	73802	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12231045	C4591001 1223 12231045	16-55	31AUG2020	75473	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12231050	C4591001 1223 12231050	16-55	31AUG2020	75476	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231051	C4591001 1223 12231051	16-55	01SEP2020	75478	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231053	C4591001 1223 12231053	16-55	01SEP2020	75479	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231054	C4591001 1223 12231054	16-55	01SEP2020	76459	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo		
12231055	C4591001 1223 12231055	16-55	01SEP2020	76464	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231057	C4591001 1223 12231057	16-55	01SEP2020	76465	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231061	C4591001 1223 12231061	16-55	01SEP2020	76466	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231062	C4591001 1223 12231062	16-55	01SEP2020	76878	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231063	C4591001 1223 12231063	16-55	01SEP2020	76880	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo		
12231064	C4591001 1223 12231064	16-55	01SEP2020	76885	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12231066	C4591001 1223 12231066	16-55	01SEP2020	76888	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231069	C4591001 1223 12231069	16-55	01SEP2020	77297	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231072	C4591001 1223 12231072	16-55	01SEP2020	77302	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231073	C4591001 1223 12231073	16-55	01SEP2020	77306	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12231074	C4591001 1223 12231074	16-55	01SEP2020	77308	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12231075	C4591001 1223 12231075	16-55	02SEP2020	77841	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12231077	C4591001 1223 12231077	16-55	02SEP2020	77842	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231079	C4591001 1223 12231079	16-55	02SEP2020	77847	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo		
12231082	C4591001 1223 12231082	16-55	02SEP2020	77848	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231083	C4591001 1223 12231083	16-55	02SEP2020	78166	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231084	C4591001 1223 12231084	16-55	02SEP2020	78167	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12231086	C4591001 1223 12231086	16-55	02SEP2020	78168	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231087	C4591001 1223 12231087	16-55	02SEP2020	78169	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231090	C4591001 1223 12231090	16-55	02SEP2020	78569	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12231094	C4591001 1223 12231094	16-55	02SEP2020	78570	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12231095	C4591001 1223 12231095	16-55	02SEP2020	78577	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12231099	C4591001 1223 12231099	16-55	03SEP2020	78578	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12231100	C4591001 1223 12231100	16-55	03SEP2020	79977	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12231101	C4591001 1223 12231101	16-55	03SEP2020	79979	Placebo	03SEP2020/ Placebo	07OCT2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12231105	C4591001 1223 12231105	16-55	04SEP2020	79982	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231111	C4591001 1223 12231111	16-55	05SEP2020	79983	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231112	C4591001 1223 12231112	16-55	05SEP2020	82752	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231113	C4591001 1223 12231113	16-55	05SEP2020	82754	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12231117	C4591001 1223 12231117	16-55	05SEP2020	82755	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231118	C4591001 1223 12231118	16-55	05SEP2020	82756	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231119	C4591001 1223 12231119	16-55	05SEP2020	82865	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231120	C4591001 1223 12231120	16-55	05SEP2020	82869	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12231121	C4591001 1223 12231121	16-55	08SEP2020	82871	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12231122	C4591001 1223 12231122	16-55	08SEP2020	82873	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231127	C4591001 1223 12231127	16-55	08SEP2020	83598	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo		
12231128	C4591001 1223 12231128	16-55	08SEP2020	83600	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231131	C4591001 1223 12231131	16-55	08SEP2020	83605	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231133	C4591001 1223 12231133	16-55	08SEP2020	83608	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12231135	C4591001 1223 12231135	16-55	09SEP2020	84798	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12231137	C4591001 1223 12231137	16-55	09SEP2020	84800	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231141	C4591001 1223 12231141	16-55	09SEP2020	84805	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231144	C4591001 1223 12231144	16-55	09SEP2020	84807	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231145	C4591001 1223 12231145	16-55	09SEP2020	85663	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231146	C4591001 1223 12231146	16-55	09SEP2020	85666	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12231147	C4591001 1223 12231147	16-55	09SEP2020	85668	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12231148	C4591001 1223 12231148	16-55	09SEP2020	85670	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12231150	C4591001 1223 12231150	16-55	09SEP2020	86129	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231151	C4591001 1223 12231151	16-55	09SEP2020	86132	Placebo	09SEP2020/ Placebo	02OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12231152	C4591001 1223 12231152	16-55	10SEP2020	86140	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12231153	C4591001 1223 12231153	16-55	10SEP2020	86133	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12231154	C4591001 1223 12231154	16-55	10SEP2020	86345	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12231157	C4591001 1223 12231157	16-55	10SEP2020	86350	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12231160	C4591001 1223 12231160	16-55	14SEP2020	89456	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231161	C4591001 1223 12231161	16-55	14SEP2020	86353	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231162	C4591001 1223 12231162	16-55	14SEP2020	86356	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
12231163	C4591001 1223 12231163	16-55	14SEP2020	89419	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12231164	C4591001 1223 12231164	16-55	14SEP2020	89454	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231166	C4591001 1223 12231166	16-55	14SEP2020	89458	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231170	C4591001 1223 12231170	16-55	14SEP2020	257124	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231171	C4591001 1223 12231171	16-55	14SEP2020	89464	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231172	C4591001 1223 12231172	16-55	14SEP2020	89947	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12231173	C4591001 1223 12231173	16-55	14SEP2020	89952	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12231174	C4591001 1223 12231174	16-55	15SEP2020	89953	Placebo	15SEP2020/ Placebo			
12231175	C4591001 1223 12231175	16-55	15SEP2020	89956	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231176	C4591001 1223 12231176	16-55	15SEP2020	90401	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231177	C4591001 1223 12231177	16-55	15SEP2020	90402	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
12231179	C4591001 1223 12231179	16-55	16SEP2020	90404	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231180	C4591001 1223 12231180	16-55	16SEP2020	90412	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231181	C4591001 1223 12231181	16-55	16SEP2020	91293	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231183	C4591001 1223 12231183	16-55	16SEP2020	91294	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12231184	C4591001 1223 12231184	16-55	16SEP2020	91297	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231186	C4591001 1223 12231186	16-55	16SEP2020	91298	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12231187	C4591001 1223 12231187	16-55	16SEP2020	91698	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12231188	C4591001 1223 12231188	16-55	16SEP2020	91700	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12231189	C4591001 1223 12231189	16-55	17SEP2020	91704	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12231190	C4591001 1223 12231190	16-55	20OCT2020	110782	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12231192	C4591001 1223 12231192	16-55	18SEP2020	91708	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231195	C4591001 1223 12231195	16-55	21SEP2020	94781	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
12231196	C4591001 1223 12231196	16-55	21SEP2020	94784	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12231197	C4591001 1223 12231197	16-55	21SEP2020	95839	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12231199	C4591001 1223 12231199	16-55	21SEP2020	94785	Placebo	21SEP2020/ Placebo	15OCT2020/ Placebo		
12231200	C4591001 1223 12231200	16-55	21SEP2020	94790	BNT162b2 (30 µg)				
12231201	C4591001 1223 12231201	16-55	21SEP2020	95842	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12231202	C4591001 1223 12231202	16-55	21SEP2020	95844	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12231204	C4591001 1223 12231204	16-55	22SEP2020	95847	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12231205	C4591001 1223 12231205	16-55	22SEP2020	96630	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12231210	C4591001 1223 12231210	16-55	29SEP2020	96632	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231211	C4591001 1223 12231211	16-55	29SEP2020	96633	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12231212	C4591001 1223 12231212	16-55	29SEP2020	96640	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12231213	C4591001 1223 12231213	16-55	30SEP2020	102162	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12231214	C4591001 1223 12231214	16-55	30SEP2020	102166	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12231216	C4591001 1223 12231216	16-55	30SEP2020	102167	Placebo	30SEP2020/ Placebo	30OCT2020/ Placebo		
12231219	C4591001 1223 12231219	16-55	30SEP2020	102169	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo		
12231220	C4591001 1223 12231220	16-55	01OCT2020	102953	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12231221	C4591001 1223 12231221	16-55	01OCT2020	102957	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo		
12231222	C4591001 1223 12231222	16-55	01OCT2020	102961	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12231223	C4591001 1223 12231223	16-55	06OCT2020	102964	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12231224	C4591001 1223 12231224	16-55	06OCT2020	104335	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231225	C4591001 1223 12231225	16-55	06OCT2020	104339	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12231226	C4591001 1223 12231226	16-55	07OCT2020	104340	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12231229	C4591001 1223 12231229	16-55	08OCT2020	104343	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231230	C4591001 1223 12231230	16-55	08OCT2020	105381	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12231231	C4591001 1223 12231231	16-55	08OCT2020	105384	Placebo	08OCT2020/ Placebo	27OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12231232	C4591001 1223 12231232	16-55	09OCT2020	105387	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12231233	C4591001 1223 12231233	16-55	12OCT2020	105388	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo		
12231234	C4591001 1223 12231234	16-55	12OCT2020	106482	BNT162b2 (30 µg)				
12231236	C4591001 1223 12231236	16-55	13OCT2020	106485	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12231237	C4591001 1223 12231237	16-55	13OCT2020	106487	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231238	C4591001 1223 12231238	16-55	14OCT2020	106488	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12231239	C4591001 1223 12231239	16-55	14OCT2020	107384	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12231241	C4591001 1223 12231241	16-55	14OCT2020	107386	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12231242	C4591001 1223 12231242	16-55	14OCT2020	107389	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12231243	C4591001 1223 12231243	16-55	14OCT2020	107390	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12231244	C4591001 1223 12231244	16-55	15OCT2020	107957	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12231245	C4591001 1223 12231245	16-55	15OCT2020	107959	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12231246	C4591001 1223 12231246	16-55	15OCT2020	107963	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12231247	C4591001 1223 12231247†	16-55	15OCT2020	107964	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231249	C4591001 1223 12231249	16-55	16OCT2020	108809	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12231251	C4591001 1223 12231251	16-55	16OCT2020	108813	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12231252	C4591001 1223 12231252	16-55	16OCT2020	108817	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo		
12231253	C4591001 1223 12231253	16-55	23OCT2020	112183	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12231256	C4591001 1223 12231256	16-55	20OCT2020	108818	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12231258	C4591001 1223 12231258	16-55	22OCT2020	110787	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12231260	C4591001 1223 12231260	16-55	20OCT2020	110785	Placebo	20OCT2020/ Placebo	09NOV2020/ Placebo	20DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12231264	C4591001 1223 12231264	16-55	21OCT2020	110786	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12231265	C4591001 1223 12231265	16-55	22OCT2020	112182	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12241034	C4591001 1224 12241034	16-55	17AUG2020	50976	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12241053	C4591001 1224 12241053	16-55	20AUG2020	50978	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241056	C4591001 1224 12241056	16-55	21AUG2020	60704	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12241058	C4591001 1224 12241058	16-55	21AUG2020	60706	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12241060	C4591001 1224 12241060	16-55	21AUG2020	60711	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12241065	C4591001 1224 12241065	16-55	24AUG2020	60712	Placebo	24AUG2020/ Placebo		01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241066	C4591001 1224 12241066	16-55	24AUG2020	63754	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12241067	C4591001 1224 12241067	16-55	24AUG2020	63756	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12241068	C4591001 1224 12241068	16-55	24AUG2020	63757	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12241069	C4591001 1224 12241069	16-55	24AUG2020	63758	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12241072	C4591001 1224 12241072	16-55	24AUG2020	64073	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12241074	C4591001 1224 12241074	16-55	24AUG2020	64077	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241075	C4591001 1224 12241075	16-55	25AUG2020	64078	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12241078	C4591001 1224 12241078	16-55	25AUG2020	64083	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12241079	C4591001 1224 12241079	16-55	25AUG2020	66071	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12241081	C4591001 1224 12241081	16-55	25AUG2020	66072	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12241083	C4591001 1224 12241083	16-55	26AUG2020	66075	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12241084	C4591001 1224 12241084	16-55	26AUG2020	67841	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12241085	C4591001 1224 12241085	16-55	26AUG2020	67844	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12241086	C4591001 1224 12241086	16-55	26AUG2020	67848	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12241088	C4591001 1224 12241088	16-55	27AUG2020	67851	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12241090	C4591001 1224 12241090	16-55	27AUG2020	70690	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241091	C4591001 1224 12241091	16-55	27AUG2020	70691	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241093	C4591001 1224 12241093	16-55	28AUG2020	70694	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12241096	C4591001 1224 12241096	16-55	28AUG2020	70695	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12241098	C4591001 1224 12241098	16-55	31AUG2020	74813	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12241104	C4591001 1224 12241104	16-55	31AUG2020	74814	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241105	C4591001 1224 12241105	16-55	31AUG2020	74815	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12241114	C4591001 1224 12241114	16-55	01SEP2020	74816	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12241117	C4591001 1224 12241117	16-55	01SEP2020	77035	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12241118	C4591001 1224 12241118	16-55	01SEP2020	77037	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12241119	C4591001 1224 12241119	16-55	01SEP2020	77039	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241121	C4591001 1224 12241121	16-55	04SEP2020	81392	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12241123	C4591001 1224 12241123	16-55	01SEP2020	77041	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12241124	C4591001 1224 12241124	16-55	01SEP2020	77621	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12241126	C4591001 1224 12241126	16-55	02SEP2020	77625	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12241128	C4591001 1224 12241128	16-55	02SEP2020	77629	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241131	C4591001 1224 12241131	16-55	03SEP2020	77632	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241132	C4591001 1224 12241132	16-55	03SEP2020	80141	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12241133	C4591001 1224 12241133	16-55	03SEP2020	80142	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241134	C4591001 1224 12241134	16-55	03SEP2020	80143	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241135	C4591001 1224 12241135	16-55	04SEP2020	80152	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241136	C4591001 1224 12241136	16-55	04SEP2020	81391	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12241137	C4591001 1224 12241137	16-55	04SEP2020	81396	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241138	C4591001 1224 12241138	16-55	04SEP2020	81399	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241139	C4591001 1224 12241139	16-55	04SEP2020	81726	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241141	C4591001 1224 12241141	16-55	04SEP2020	81729	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12241143	C4591001 1224 12241143	16-55	04SEP2020	81730	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12241144	C4591001 1224 12241144	16-55	04SEP2020	81732	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12241146	C4591001 1224 12241146	16-55	04SEP2020	82422	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12241147	C4591001 1224 12241147	16-55	08SEP2020	82425	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241150	C4591001 1224 12241150	16-55	08SEP2020	82430	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241151	C4591001 1224 12241151	16-55	08SEP2020	82431	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12241152	C4591001 1224 12241152	16-55	08SEP2020	83756	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12241155	C4591001 1224 12241155	16-55	16SEP2020	83761	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241156	C4591001 1224 12241156	16-55	16SEP2020	83763	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12241158	C4591001 1224 12241158†	16-55	18SEP2020	83764	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo		
12241160	C4591001 1224 12241160	16-55	24SEP2020	98778	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12241161	C4591001 1224 12241161	16-55	24SEP2020	98781	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12241162	C4591001 1224 12241162	16-55	24SEP2020	98784	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12241165	C4591001 1224 12241165	16-55	19NOV2020	98785	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12241166	C4591001 1224 12241166	16-55	20NOV2020	116554	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241167	C4591001 1224 12241167	16-55	20NOV2020	116556	Placebo	20NOV2020/ Placebo		04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241168	C4591001 1224 12241168	16-55	20NOV2020	116558	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12241169	C4591001 1224 12241169	16-55	23NOV2020	116559	Placebo	23NOV2020/ Placebo	15DEC2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12241170	C4591001 1224 12241170	16-55	23NOV2020	116661	Placebo				
12241171	C4591001 1224 12241171	16-55	23NOV2020	116663	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12241172	C4591001 1224 12241172	16-55	23NOV2020	116665	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241173	C4591001 1224 12241173	16-55	30NOV2020	116668	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12241174	C4591001 1224 12241174	16-55	30NOV2020	116981	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12241175	C4591001 1224 12241175	16-55	30NOV2020	116983	Placebo	30NOV2020/ Placebo		03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241176	C4591001 1224 12241176	16-55	30NOV2020	116985	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241177	C4591001 1224 12241177	16-55	30NOV2020	116988	Placebo	30NOV2020/ Placebo	21DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12241178	C4591001 1224 12241178	16-55	30NOV2020	117042	BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)	29DEC2020/ BNT162b2 (30 µg)		
12241179	C4591001 1224 12241179	16-55	30NOV2020	117043	Placebo	30NOV2020/ Placebo	29DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241180	C4591001 1224 12241180	16-55	03DEC2020	117044	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12241181	C4591001 1224 12241181	16-55	03DEC2020	117048	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12241182	C4591001 1224 12241182	16-55	03DEC2020	117401	Placebo	03DEC2020/ Placebo	22DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12241183	C4591001 1224 12241183	16-55	04DEC2020	117403	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12241184	C4591001 1224 12241184	16-55	04DEC2020	117405	Placebo	04DEC2020/ Placebo	28DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12241185	C4591001 1224 12241185	16-55	04DEC2020	117408	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12241186	C4591001 1224 12241186	16-55	04DEC2020	117583	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12241187	C4591001 1224 12241187	16-55	04DEC2020	117586	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12261194	C4591001 1226 12261194	16-55	14AUG2020	50013	Placebo	14AUG2020/ Placebo	05SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261204	C4591001 1226 12261204	16-55	17AUG2020	50204	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261205	C4591001 1226 12261205	16-55	17AUG2020	50206	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo		
12261206	C4591001 1226 12261206	16-55	17AUG2020	50207	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261207	C4591001 1226 12261207	16-55	17AUG2020	52148	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261208	C4591001 1226 12261208	16-55	17AUG2020	52149	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261210	C4591001 1226 12261210	16-55	17AUG2020	52152	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261213	C4591001 1226 12261213	16-55	17AUG2020	52151	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261214	C4591001 1226 12261214	16-55	17AUG2020	52232	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261215	C4591001 1226 12261215	16-55	17AUG2020	52234	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261216	C4591001 1226 12261216	16-55	21AUG2020	58574	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261217	C4591001 1226 12261217	16-55	17AUG2020	52237	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261218	C4591001 1226 12261218	16-55	17AUG2020	52239	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261220	C4591001 1226 12261220	16-55	17AUG2020	52461	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261223	C4591001 1226 12261223	16-55	17AUG2020	52462	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261226	C4591001 1226 12261226	16-55	17AUG2020	52464	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261227	C4591001 1226 12261227	16-55	17AUG2020	52468	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261228	C4591001 1226 12261228	16-55	17AUG2020	52507	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261229	C4591001 1226 12261229	16-55	17AUG2020	52511	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261230	C4591001 1226 12261230	16-55	17AUG2020	52508	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261231	C4591001 1226 12261231	16-55	17AUG2020	52509	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261232	C4591001 1226 12261232	16-55	17AUG2020	52581	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261233	C4591001 1226 12261233	16-55	17AUG2020	52584	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261234	C4591001 1226 12261234	16-55	17AUG2020	52656	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261235	C4591001 1226 12261235	16-55	17AUG2020	52580	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261236	C4591001 1226 12261236	16-55	17AUG2020	52654	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12261237	C4591001 1226 12261237	16-55	17AUG2020	52588	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261238	C4591001 1226 12261238	16-55	18AUG2020	52657	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261239	C4591001 1226 12261239	16-55	18AUG2020	53773	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261240	C4591001 1226 12261240	16-55	18AUG2020	52660	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261241	C4591001 1226 12261241	16-55	18AUG2020	53775	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261242	C4591001 1226 12261242	16-55	18AUG2020	53774	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261243	C4591001 1226 12261243	16-55	18AUG2020	53815	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261244	C4591001 1226 12261244	16-55	18AUG2020	53816	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261245	C4591001 1226 12261245	16-55	18AUG2020	53819	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261246	C4591001 1226 12261246	16-55	18AUG2020	53820	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261247	C4591001 1226 12261247	16-55	18AUG2020	53776	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261248	C4591001 1226 12261248	16-55	18AUG2020	53960	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12261249	C4591001 1226 12261249	16-55	27AUG2020	67932	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261250	C4591001 1226 12261250	16-55	18AUG2020	53962	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261251	C4591001 1226 12261251	16-55	18AUG2020	53963	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261254	C4591001 1226 12261254	16-55	18AUG2020	54104	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261256	C4591001 1226 12261256	16-55	18AUG2020	54105	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261257	C4591001 1226 12261257	16-55	18AUG2020	53967	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261258	C4591001 1226 12261258	16-55	18AUG2020	54108	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261259	C4591001 1226 12261259	16-55	18AUG2020	54111	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261261	C4591001 1226 12261261	16-55	18AUG2020	54247	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261262	C4591001 1226 12261262	16-55	18AUG2020	54250	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261263	C4591001 1226 12261263	16-55	18AUG2020	54249	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261264	C4591001 1226 12261264	16-55	18AUG2020	54254	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261266	C4591001 1226 12261266	16-55	18AUG2020	54308	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261267	C4591001 1226 12261267	16-55	18AUG2020	54311	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261269	C4591001 1226 12261269	16-55	18AUG2020	54414	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261270	C4591001 1226 12261270	16-55	18AUG2020	54312	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261271	C4591001 1226 12261271	16-55	18AUG2020	54315	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261272	C4591001 1226 12261272	16-55	19AUG2020	54417	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
12261273	C4591001 1226 12261273	16-55	19AUG2020	54418	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261274	C4591001 1226 12261274	16-55	19AUG2020	54424	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261275	C4591001 1226 12261275	16-55	19AUG2020	55645	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261276	C4591001 1226 12261276	16-55	19AUG2020	55641	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261277	C4591001 1226 12261277	16-55	19AUG2020	55644	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261278	C4591001 1226 12261278	16-55	19AUG2020	55648	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261279	C4591001 1226 12261279	16-55	19AUG2020	55702	Placebo	19AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261280	C4591001 1226 12261280	16-55	19AUG2020	55699	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261282	C4591001 1226 12261282	16-55	19AUG2020	55707	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261285	C4591001 1226 12261285	16-55	19AUG2020	55708	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261287	C4591001 1226 12261287	16-55	19AUG2020	55931	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261288	C4591001 1226 12261288	16-55	19AUG2020	55932	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261290	C4591001 1226 12261290	16-55	19AUG2020	55934	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261291	C4591001 1226 12261291	16-55	19AUG2020	55935	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261292	C4591001 1226 12261292	16-55	19AUG2020	56105	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261293	C4591001 1226 12261293	16-55	19AUG2020	56357	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261294	C4591001 1226 12261294	16-55	19AUG2020	56114	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261295	C4591001 1226 12261295	16-55	19AUG2020	56109	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261296	C4591001 1226 12261296	16-55	19AUG2020	56108	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261298	C4591001 1226 12261298	16-55	20AUG2020	56359	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12261299	C4591001 1226 12261299	16-55	20AUG2020	56366	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261300	C4591001 1226 12261300	16-55	20AUG2020	56368	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261301	C4591001 1226 12261301	16-55	20AUG2020	57799	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261302	C4591001 1226 12261302	16-55	20AUG2020	57801	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261303	C4591001 1226 12261303	16-55	20AUG2020	57804	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261304	C4591001 1226 12261304	16-55	20AUG2020	57870	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261305	C4591001 1226 12261305	16-55	20AUG2020	57807	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261306	C4591001 1226 12261306	16-55	20AUG2020	57869	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261307	C4591001 1226 12261307	16-55	20AUG2020	57872	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261308	C4591001 1226 12261308	16-55	20AUG2020	57875	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261312	C4591001 1226 12261312	16-55	20AUG2020	58026	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261313	C4591001 1226 12261313	16-55	20AUG2020	58029	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261314	C4591001 1226 12261314	16-55	20AUG2020	58033	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261319	C4591001 1226 12261319	16-55	20AUG2020	58035	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261321	C4591001 1226 12261321	16-55	20AUG2020	58313	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261322	C4591001 1226 12261322	16-55	20AUG2020	58316	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12261323	C4591001 1226 12261323	16-55	20AUG2020	58319	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261324	C4591001 1226 12261324	16-55	20AUG2020	58320	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261325	C4591001 1226 12261325	16-55	20AUG2020	58362	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261326	C4591001 1226 12261326	16-55	20AUG2020	58363	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261327	C4591001 1226 12261327	16-55	20AUG2020	58364	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261328	C4591001 1226 12261328	16-55	20AUG2020	58370	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12261330	C4591001 1226 12261330	16-55	20AUG2020	58566	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261331	C4591001 1226 12261331	16-55	20AUG2020	58571	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261332	C4591001 1226 12261332	16-55	20AUG2020	58572	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261336	C4591001 1226 12261336	16-55	21AUG2020	59917	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261337	C4591001 1226 12261337	16-55	21AUG2020	59918	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261338	C4591001 1226 12261338	16-55	21AUG2020	59919	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261340	C4591001 1226 12261340	16-55	21AUG2020	59920	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12261341	C4591001 1226 12261341	16-55	21AUG2020	59969	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261343	C4591001 1226 12261343	16-55	21AUG2020	59970	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261344	C4591001 1226 12261344	16-55	21AUG2020	59975	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261345	C4591001 1226 12261345	16-55	21AUG2020	59974	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261347	C4591001 1226 12261347	16-55	21AUG2020	60145	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261348	C4591001 1226 12261348	16-55	21AUG2020	60140	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261349	C4591001 1226 12261349	16-55	21AUG2020	60147	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261350	C4591001 1226 12261350	16-55	21AUG2020	60148	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12261351	C4591001 1226 12261351	16-55	21AUG2020	60269	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12261352	C4591001 1226 12261352	16-55	21AUG2020	60438	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261354	C4591001 1226 12261354	16-55	21AUG2020	60270	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261355	C4591001 1226 12261355	16-55	21AUG2020	60276	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261356	C4591001 1226 12261356	16-55	21AUG2020	60439	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261357	C4591001 1226 12261357	16-55	21AUG2020	60277	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261358	C4591001 1226 12261358	16-55	21AUG2020	60445	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261359	C4591001 1226 12261359	16-55	21AUG2020	60448	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261360	C4591001 1226 12261360	16-55	21AUG2020	60545	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261361	C4591001 1226 12261361	16-55	21AUG2020	60551	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261362	C4591001 1226 12261362	16-55	21AUG2020	60555	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261363	C4591001 1226 12261363	16-55	21AUG2020	60556	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261364	C4591001 1226 12261364	16-55	21AUG2020	60629	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12261365	C4591001 1226 12261365	16-55	21AUG2020	60630	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12261369	C4591001 1226 12261369	16-55	21AUG2020	60632	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261372	C4591001 1226 12261372	16-55	24AUG2020	63233	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261373	C4591001 1226 12261373	16-55	24AUG2020	60633	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261375	C4591001 1226 12261375	16-55	24AUG2020	63237	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261376	C4591001 1226 12261376	16-55	24AUG2020	63235	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261377	C4591001 1226 12261377	16-55	24AUG2020	63241	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12261379	C4591001 1226 12261379	16-55	24AUG2020	63281	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261380	C4591001 1226 12261380	16-55	24AUG2020	63287	Placebo	24AUG2020/ Placebo	13OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261382	C4591001 1226 12261382	16-55	24AUG2020	63290	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12261383	C4591001 1226 12261383	16-55	24AUG2020	63291	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261384	C4591001 1226 12261384	16-55	24AUG2020	63366	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12261385	C4591001 1226 12261385	16-55	24AUG2020	63445	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261387	C4591001 1226 12261387	16-55	24AUG2020	63441	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261390	C4591001 1226 12261390	16-55	24AUG2020	63446	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261391	C4591001 1226 12261391	16-55	24AUG2020	63448	Placebo	24AUG2020/ Placebo	13OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261392	C4591001 1226 12261392	16-55	24AUG2020	63678	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261393	C4591001 1226 12261393	16-55	24AUG2020	63685	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261394	C4591001 1226 12261394	16-55	24AUG2020	63681	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261395	C4591001 1226 12261395	16-55	24AUG2020	63686	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261396	C4591001 1226 12261396	16-55	24AUG2020	63785	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261397	C4591001 1226 12261397	16-55	25AUG2020	63787	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261399	C4591001 1226 12261399	16-55	25AUG2020	63788	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261400	C4591001 1226 12261400	16-55	25AUG2020	63793	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261403	C4591001 1226 12261403	16-55	25AUG2020	65334	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261404	C4591001 1226 12261404	16-55	25AUG2020	65336	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261405	C4591001 1226 12261405	16-55	25AUG2020	65339	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261406	C4591001 1226 12261406	16-55	25AUG2020	65343	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261407	C4591001 1226 12261407	16-55	25AUG2020	65516	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261408	C4591001 1226 12261408	16-55	25AUG2020	65519	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261409	C4591001 1226 12261409	16-55	25AUG2020	65522	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
12261410	C4591001 1226 12261410	16-55	25AUG2020	65523	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261411	C4591001 1226 12261411	16-55	25AUG2020	65743	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261412	C4591001 1226 12261412	16-55	25AUG2020	65748	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261413	C4591001 1226 12261413	16-55	25AUG2020	65749	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261414	C4591001 1226 12261414	16-55	25AUG2020	65752	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261415	C4591001 1226 12261415	16-55	25AUG2020	65873	Placebo	25AUG2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261416	C4591001 1226 12261416	16-55	25AUG2020	65882	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261417	C4591001 1226 12261417	16-55	25AUG2020	65883	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261418	C4591001 1226 12261418	16-55	25AUG2020	65884	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261420	C4591001 1226 12261420	16-55	26AUG2020	67099	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261421	C4591001 1226 12261421	16-55	26AUG2020	67101	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261422	C4591001 1226 12261422	16-55	26AUG2020	67108	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261423	C4591001 1226 12261423	16-55	26AUG2020	67105	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261424	C4591001 1226 12261424	16-55	26AUG2020	67208	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261425	C4591001 1226 12261425	16-55	26AUG2020	67211	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261426	C4591001 1226 12261426	16-55	26AUG2020	67215	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261427	C4591001 1226 12261427	16-55	26AUG2020	67216	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261428	C4591001 1226 12261428	16-55	26AUG2020	67352	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261429	C4591001 1226 12261429	16-55	26AUG2020	67350	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261430	C4591001 1226 12261430	16-55	26AUG2020	67353	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261431	C4591001 1226 12261431	16-55	26AUG2020	67356	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261432	C4591001 1226 12261432	16-55	26AUG2020	67604	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261433	C4591001 1226 12261433	16-55	26AUG2020	67485	Placebo	26AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261434	C4591001 1226 12261434	16-55	26AUG2020	67488	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261436	C4591001 1226 12261436	16-55	26AUG2020	67491	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261437	C4591001 1226 12261437	16-55	26AUG2020	67738	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261439	C4591001 1226 12261439	16-55	26AUG2020	67492	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261440	C4591001 1226 12261440	16-55	26AUG2020	67740	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261441	C4591001 1226 12261441	16-55	26AUG2020	67605	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261442	C4591001 1226 12261442	16-55	26AUG2020	67606	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12261443	C4591001 1226 12261443	16-55	26AUG2020	67611	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12261444	C4591001 1226 12261444	16-55	26AUG2020	67734	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261445	C4591001 1226 12261445	16-55	26AUG2020	67742	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261447	C4591001 1226 12261447	16-55	26AUG2020	67930	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261448	C4591001 1226 12261448	16-55	27AUG2020	67936	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261449	C4591001 1226 12261449	16-55	27AUG2020	67934	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261451	C4591001 1226 12261451	16-55	27AUG2020	69417	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261452	C4591001 1226 12261452	16-55	27AUG2020	69420	Placebo	27AUG2020/ Placebo	22SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261454	C4591001 1226 12261454	16-55	27AUG2020	69421	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261455	C4591001 1226 12261455	16-55	27AUG2020	69423	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo		
12261456	C4591001 1226 12261456	16-55	27AUG2020	69541	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261457	C4591001 1226 12261457	16-55	27AUG2020	69544	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261459	C4591001 1226 12261459	16-55	27AUG2020	69536	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261460	C4591001 1226 12261460	16-55	27AUG2020	69539	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261463	C4591001 1226 12261463	16-55	27AUG2020	69689	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261465	C4591001 1226 12261465	16-55	27AUG2020	69692	Placebo	27AUG2020/ Placebo	23SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261466	C4591001 1226 12261466	16-55	27AUG2020	69941	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261468	C4591001 1226 12261468	16-55	27AUG2020	69694	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261469	C4591001 1226 12261469	16-55	27AUG2020	69696	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261470	C4591001 1226 12261470	16-55	27AUG2020	70068	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261471	C4591001 1226 12261471	16-55	27AUG2020	69943	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261472	C4591001 1226 12261472	16-55	27AUG2020	69945	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261474	C4591001 1226 12261474	16-55	27AUG2020	69951	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261475	C4591001 1226 12261475	16-55	27AUG2020	70071	Placebo	27AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261476	C4591001 1226 12261476	16-55	27AUG2020	70061	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261478	C4591001 1226 12261478	16-55	27AUG2020	70065	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261479	C4591001 1226 12261479	16-55	27AUG2020	70233	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261480	C4591001 1226 12261480	16-55	27AUG2020	70231	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261482	C4591001 1226 12261482	16-55	27AUG2020	70234	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261483	C4591001 1226 12261483	16-55	27AUG2020	70235	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261484	C4591001 1226 12261484	16-55	31AUG2020	71638	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261485	C4591001 1226 12261485	16-55	27AUG2020	70385	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261486	C4591001 1226 12261486	16-55	27AUG2020	70390	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261488	C4591001 1226 12261488	16-55	27AUG2020	70392	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12261489	C4591001 1226 12261489	16-55	27AUG2020	70394	Placebo	27AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261490	C4591001 1226 12261490	16-55	28AUG2020	71471	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261491	C4591001 1226 12261491	16-55	28AUG2020	71469	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261492	C4591001 1226 12261492	16-55	28AUG2020	71454	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261493	C4591001 1226 12261493	16-55	28AUG2020	71456	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261494	C4591001 1226 12261494	16-55	28AUG2020	71457	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261495	C4591001 1226 12261495	16-55	28AUG2020	71476	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261496	C4591001 1226 12261496	16-55	28AUG2020	71460	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261497	C4591001 1226 12261497	16-55	28AUG2020	71475	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261498	C4591001 1226 12261498	16-55	28AUG2020	71538	Placebo	28AUG2020/ Placebo	19SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261500	C4591001 1226 12261500	16-55	28AUG2020	71542	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261501	C4591001 1226 12261501	16-55	28AUG2020	71543	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12261502	C4591001 1226 12261502	16-55	28AUG2020	71548	Placebo	28AUG2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261503	C4591001 1226 12261503	16-55	28AUG2020	71637	Placebo	28AUG2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261504	C4591001 1226 12261504	16-55	01SEP2020	76469	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261505	C4591001 1226 12261505	16-55	01SEP2020	76474	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261507	C4591001 1226 12261507	16-55	01SEP2020	71644	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12261508	C4591001 1226 12261508	16-55	01SEP2020	76479	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261509	C4591001 1226 12261509	16-55	01SEP2020	71643	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261511	C4591001 1226 12261511	16-55	01SEP2020	76529	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261512	C4591001 1226 12261512	16-55	01SEP2020	76478	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12261514	C4591001 1226 12261514	16-55	04SEP2020	81295	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261515	C4591001 1226 12261515	16-55	04SEP2020	80197	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261516	C4591001 1226 12261516	16-55	05SEP2020	82641	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261517	C4591001 1226 12261517	16-55	04SEP2020	81293	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261518	C4591001 1226 12261518	16-55	03SEP2020	80194	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261519	C4591001 1226 12261519	16-55	03SEP2020	76532	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261520	C4591001 1226 12261520	16-55	03SEP2020	76538	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261521	C4591001 1226 12261521	16-55	05SEP2020	81296	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261522	C4591001 1226 12261522	16-55	03SEP2020	76533	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12261524	C4591001 1226 12261524	16-55	03SEP2020	80189	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261525	C4591001 1226 12261525	16-55	03SEP2020	80192	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12261526	C4591001 1226 12261526	16-55	05SEP2020	81297	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261529	C4591001 1226 12261529	16-55	05SEP2020	82625	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261530	C4591001 1226 12261530	16-55	05SEP2020	82628	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261531	C4591001 1226 12261531	16-55	05SEP2020	82631	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261532	C4591001 1226 12261532	16-55	05SEP2020	82643	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261533	C4591001 1226 12261533	16-55	05SEP2020	82636	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261535	C4591001 1226 12261535	16-55	05SEP2020	82646	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261538	C4591001 1226 12261538	16-55	08SEP2020	83406	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261540	C4591001 1226 12261540	16-55	05SEP2020	82648	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12261542	C4591001 1226 12261542	16-55	05SEP2020	82668	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261543	C4591001 1226 12261543	16-55	05SEP2020	82665	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261544	C4591001 1226 12261544	16-55	05SEP2020	82670	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261545	C4591001 1226 12261545	16-55	05SEP2020	82687	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261546	C4591001 1226 12261546	16-55	05SEP2020	82672	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261547	C4591001 1226 12261547	16-55	07SEP2020	82852	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261548	C4591001 1226 12261548	16-55	05SEP2020	82688	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261549	C4591001 1226 12261549	16-55	05SEP2020	82693	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261551	C4591001 1226 12261551	16-55	05SEP2020	82694	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261553	C4591001 1226 12261553	16-55	05SEP2020	82697	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261554	C4591001 1226 12261554	16-55	05SEP2020	82698	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261555	C4591001 1226 12261555	16-55	05SEP2020	82706	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12261557	C4591001 1226 12261557	16-55	05SEP2020	82724	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261559	C4591001 1226 12261559	16-55	05SEP2020	82722	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261560	C4591001 1226 12261560	16-55	05SEP2020	82707	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261561	C4591001 1226 12261561	16-55	05SEP2020	82727	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12261562	C4591001 1226 12261562	16-55	05SEP2020	82730	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261563	C4591001 1226 12261563	16-55	05SEP2020	82761	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261564	C4591001 1226 12261564	16-55	05SEP2020	82762	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261566	C4591001 1226 12261566	16-55	05SEP2020	82767	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261567	C4591001 1226 12261567	16-55	05SEP2020	82768	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261568	C4591001 1226 12261568	16-55	05SEP2020	82800	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261569	C4591001 1226 12261569	16-55	05SEP2020	82793	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12261570	C4591001 1226 12261570	16-55	05SEP2020	82801	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12261571	C4591001 1226 12261571	16-55	05SEP2020	82803	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261572	C4591001 1226 12261572	16-55	05SEP2020	82807	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12261574	C4591001 1226 12261574	16-55	05SEP2020	82809	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261575	C4591001 1226 12261575	16-55	05SEP2020	82814	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261576	C4591001 1226 12261576	16-55	05SEP2020	82815	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12261577	C4591001 1226 12261577	16-55	05SEP2020	82841	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12261578	C4591001 1226 12261578	16-55	05SEP2020	82849	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261579	C4591001 1226 12261579	16-55	05SEP2020	82851	Placebo	05SEP2020/ Placebo	28SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261581	C4591001 1226 12261581	16-55	07SEP2020	83033	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261582	C4591001 1226 12261582	16-55	07SEP2020	83037	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261583	C4591001 1226 12261583	16-55	07SEP2020	83035	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261584	C4591001 1226 12261584	16-55	07SEP2020	83039	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261585	C4591001 1226 12261585	16-55	07SEP2020	83069	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261586	C4591001 1226 12261586	16-55	07SEP2020	83045	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261587	C4591001 1226 12261587	16-55	07SEP2020	83048	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261588	C4591001 1226 12261588	16-55	07SEP2020	83070	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261590	C4591001 1226 12261590	16-55	07SEP2020	83050	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261591	C4591001 1226 12261591	16-55	07SEP2020	83051	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261592	C4591001 1226 12261592	16-55	07SEP2020	83076	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261593	C4591001 1226 12261593	16-55	07SEP2020	83077	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261594	C4591001 1226 12261594	16-55	07SEP2020	83092	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12261595	C4591001 1226 12261595	16-55	07SEP2020	83090	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261596	C4591001 1226 12261596	16-55	07SEP2020	83084	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261597	C4591001 1226 12261597	16-55	07SEP2020	83107	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261598	C4591001 1226 12261598	16-55	07SEP2020	83113	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261599	C4591001 1226 12261599	16-55	07SEP2020	83114	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261600	C4591001 1226 12261600	16-55	07SEP2020	83086	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261601	C4591001 1226 12261601	16-55	07SEP2020	83116	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261602	C4591001 1226 12261602	16-55	07SEP2020	83118	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261603	C4591001 1226 12261603	16-55	07SEP2020	83121	Placebo	07SEP2020/ Placebo	02OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261604	C4591001 1226 12261604	16-55	07SEP2020	83127	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261606	C4591001 1226 12261606	16-55	07SEP2020	83128	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261607	C4591001 1226 12261607	16-55	07SEP2020	83159	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261609	C4591001 1226 12261609	16-55	07SEP2020	83129	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261610	C4591001 1226 12261610	16-55	07SEP2020	83137	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261611	C4591001 1226 12261611	16-55	07SEP2020	83138	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261612	C4591001 1226 12261612	16-55	07SEP2020	83140	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261614	C4591001 1226 12261614	16-55	07SEP2020	83157	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261615	C4591001 1226 12261615	16-55	07SEP2020	83181	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261616	C4591001 1226 12261616	16-55	07SEP2020	83163	Placebo	07SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261618	C4591001 1226 12261618	16-55	07SEP2020	83187	Placebo	07SEP2020/ Placebo	01OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12261619	C4591001 1226 12261619	16-55	07SEP2020	83186	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261620	C4591001 1226 12261620	16-55	07SEP2020	83180	Placebo	07SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261621	C4591001 1226 12261621	16-55	07SEP2020	83189	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261622	C4591001 1226 12261622	16-55	08SEP2020	83196	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261623	C4591001 1226 12261623	16-55	08SEP2020	83197	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261624	C4591001 1226 12261624	16-55	08SEP2020	83198	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261625	C4591001 1226 12261625	16-55	08SEP2020	83412	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261627	C4591001 1226 12261627	16-55	08SEP2020	83413	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12261628	C4591001 1226 12261628	16-55	08SEP2020	83415	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261629	C4591001 1226 12261629	16-55	08SEP2020	83623	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261630	C4591001 1226 12261630	16-55	08SEP2020	83628	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261631	C4591001 1226 12261631	16-55	08SEP2020	83630	Placebo	08SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261632	C4591001 1226 12261632	16-55	09SEP2020	83632	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261633	C4591001 1226 12261633	16-55	09SEP2020	84749	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261634	C4591001 1226 12261634	16-55	09SEP2020	84750	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261636	C4591001 1226 12261636	16-55	09SEP2020	84754	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261637	C4591001 1226 12261637	16-55	09SEP2020	84759	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261641	C4591001 1226 12261641	16-55	09SEP2020	85207	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261643	C4591001 1226 12261643	16-55	09SEP2020	85208	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261644	C4591001 1226 12261644	16-55	10SEP2020	85209	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261646	C4591001 1226 12261646	16-55	10SEP2020	85216	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
12261647	C4591001 1226 12261647	16-55	10SEP2020	86321	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261648	C4591001 1226 12261648	16-55	10SEP2020	86322	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261649	C4591001 1226 12261649	16-55	10SEP2020	86432	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261650	C4591001 1226 12261650	16-55	10SEP2020	86326	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261651	C4591001 1226 12261651	16-55	10SEP2020	86327	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12261653	C4591001 1226 12261653	16-55	10SEP2020	86433	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261654	C4591001 1226 12261654	16-55	10SEP2020	86717	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12261655	C4591001 1226 12261655	16-55	10SEP2020	86719	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261656	C4591001 1226 12261656	16-55	10SEP2020	86435	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261657	C4591001 1226 12261657	16-55	10SEP2020	86722	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261659	C4591001 1226 12261659	16-55	10SEP2020	86440	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261660	C4591001 1226 12261660	16-55	11SEP2020	86727	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261661	C4591001 1226 12261661	16-55	11SEP2020	87788	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12261664	C4591001 1226 12261664	16-55	12SEP2020	87791	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261665	C4591001 1226 12261665	16-55	12SEP2020	87795	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12261666	C4591001 1226 12261666	16-55	12SEP2020	89022	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12261667	C4591001 1226 12261667	16-55	12SEP2020	89027	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12261668	C4591001 1226 12261668	16-55	12SEP2020	89032	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261669	C4591001 1226 12261669	16-55	12SEP2020	89031	Placebo	12SEP2020/ Placebo	01OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261670	C4591001 1226 12261670	16-55	12SEP2020	89034	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261672	C4591001 1226 12261672	16-55	12SEP2020	89053	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261673	C4591001 1226 12261673	16-55	12SEP2020	89047	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261674	C4591001 1226 12261674	16-55	12SEP2020	89049	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261675	C4591001 1226 12261675	16-55	12SEP2020	89040	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261676	C4591001 1226 12261676	16-55	12SEP2020	89042	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261677	C4591001 1226 12261677	16-55	12SEP2020	89051	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261679	C4591001 1226 12261679	16-55	12SEP2020	89067	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261680	C4591001 1226 12261680	16-55	12SEP2020	89064	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261681	C4591001 1226 12261681	16-55	12SEP2020	89065	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261682	C4591001 1226 12261682	16-55	12SEP2020	89068	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12261683	C4591001 1226 12261683	16-55	12SEP2020	89071	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261684	C4591001 1226 12261684	16-55	12SEP2020	89069	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12261685	C4591001 1226 12261685	16-55	12SEP2020	89084	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261686	C4591001 1226 12261686	16-55	12SEP2020	89073	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261687	C4591001 1226 12261687	16-55	12SEP2020	89079	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261688	C4591001 1226 12261688	16-55	12SEP2020	89087	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261689	C4591001 1226 12261689	16-55	12SEP2020	89090	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261690	C4591001 1226 12261690	16-55	12SEP2020	89091	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261691	C4591001 1226 12261691	16-55	12SEP2020	89105	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261692	C4591001 1226 12261692	16-55	12SEP2020	89107	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261693	C4591001 1226 12261693	16-55	12SEP2020	89110	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261694	C4591001 1226 12261694	16-55	12SEP2020	89119	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261695	C4591001 1226 12261695	16-55	12SEP2020	89114	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261696	C4591001 1226 12261696	16-55	12SEP2020	89122	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261697	C4591001 1226 12261697	16-55	12SEP2020	89125	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12261698	C4591001 1226 12261698	16-55	14SEP2020	89127	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261699	C4591001 1226 12261699	16-55	14SEP2020	89298	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261701	C4591001 1226 12261701	16-55	14SEP2020	89306	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261702	C4591001 1226 12261702	16-55	14SEP2020	89307	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261703	C4591001 1226 12261703	16-55	14SEP2020	89300	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261704	C4591001 1226 12261704	16-55	14SEP2020	89385	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261705	C4591001 1226 12261705	16-55	14SEP2020	89390	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261706	C4591001 1226 12261706	16-55	14SEP2020	89386	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261707	C4591001 1226 12261707	16-55	14SEP2020	89392	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261709	C4591001 1226 12261709	16-55	14SEP2020	89447	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261710	C4591001 1226 12261710	16-55	14SEP2020	89583	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261711	C4591001 1226 12261711	16-55	14SEP2020	89449	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261712	C4591001 1226 12261712	16-55	14SEP2020	89579	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261713	C4591001 1226 12261713	16-55	14SEP2020	89451	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261714	C4591001 1226 12261714	16-55	14SEP2020	89448	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261715	C4591001 1226 12261715	16-55	14SEP2020	89636	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261716	C4591001 1226 12261716	16-55	14SEP2020	89576	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261717	C4591001 1226 12261717	16-55	14SEP2020	89584	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261718	C4591001 1226 12261718	16-55	14SEP2020	89641	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
12261719	C4591001 1226 12261719	16-55	14SEP2020	89638	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12261720	C4591001 1226 12261720	16-55	14SEP2020	89643	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261721	C4591001 1226 12261721	16-55	14SEP2020	89731	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261722	C4591001 1226 12261722	16-55	14SEP2020	89732	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12261723	C4591001 1226 12261723	16-55	15SEP2020	89735	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261724	C4591001 1226 12261724	16-55	15SEP2020	90131	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261725	C4591001 1226 12261725	16-55	15SEP2020	90129	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261726	C4591001 1226 12261726	16-55	15SEP2020	89737	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261728	C4591001 1226 12261728	16-55	15SEP2020	90133	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261729	C4591001 1226 12261729	16-55	15SEP2020	90135	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261730	C4591001 1226 12261730	16-55	15SEP2020	90199	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261731	C4591001 1226 12261731	16-55	15SEP2020	90204	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	
12261732	C4591001 1226 12261732	16-55	15SEP2020	90206	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261733	C4591001 1226 12261733	16-55	15SEP2020	90208	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261734	C4591001 1226 12261734	16-55	15SEP2020	90366	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261736	C4591001 1226 12261736	16-55	15SEP2020	90370	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261737	C4591001 1226 12261737	16-55	15SEP2020	90374	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261738	C4591001 1226 12261738	16-55	15SEP2020	90371	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261739	C4591001 1226 12261739	16-55	16SEP2020	90873	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261740	C4591001 1226 12261740	16-55	16SEP2020	90874	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12261741	C4591001 1226 12261741	16-55	16SEP2020	90876	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261742	C4591001 1226 12261742	16-55	16SEP2020	90875	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261743	C4591001 1226 12261743	16-55	16SEP2020	90920	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261745	C4591001 1226 12261745	16-55	16SEP2020	90922	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261746	C4591001 1226 12261746	16-55	16SEP2020	90978	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261747	C4591001 1226 12261747	16-55	16SEP2020	90923	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261748	C4591001 1226 12261748	16-55	16SEP2020	90925	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261750	C4591001 1226 12261750	16-55	16SEP2020	91089	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261751	C4591001 1226 12261751	16-55	16SEP2020	91093	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261752	C4591001 1226 12261752	16-55	16SEP2020	90982	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261753	C4591001 1226 12261753	16-55	16SEP2020	91094	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261754	C4591001 1226 12261754	16-55	16SEP2020	91095	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261756	C4591001 1226 12261756	16-55	16SEP2020	90979	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261757	C4591001 1226 12261757	16-55	16SEP2020	90985	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261759	C4591001 1226 12261759	16-55	16SEP2020	91172	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261760	C4591001 1226 12261760	16-55	16SEP2020	91179	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261761	C4591001 1226 12261761	16-55	16SEP2020	91173	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261762	C4591001 1226 12261762	16-55	16SEP2020	91176	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12261763	C4591001 1226 12261763	16-55	17SEP2020	91918	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261764	C4591001 1226 12261764	16-55	17SEP2020	91913	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261765	C4591001 1226 12261765	16-55	17SEP2020	91919	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261766	C4591001 1226 12261766	16-55	17SEP2020	91917	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261767	C4591001 1226 12261767	16-55	17SEP2020	91937	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261768	C4591001 1226 12261768	16-55	17SEP2020	91947	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261769	C4591001 1226 12261769	16-55	17SEP2020	91945	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261770	C4591001 1226 12261770	16-55	17SEP2020	91941	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261771	C4591001 1226 12261771	16-55	17SEP2020	91951	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261772	C4591001 1226 12261772	16-55	17SEP2020	91952	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261773	C4591001 1226 12261773	16-55	17SEP2020	91958	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261775	C4591001 1226 12261775	16-55	17SEP2020	91960	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261776	C4591001 1226 12261776	16-55	17SEP2020	92005	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261777	C4591001 1226 12261777	16-55	17SEP2020	91997	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261778	C4591001 1226 12261778	16-55	17SEP2020	92014	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261779	C4591001 1226 12261779	16-55	17SEP2020	92001	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261780	C4591001 1226 12261780	16-55	17SEP2020	92004	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261781	C4591001 1226 12261781	16-55	17SEP2020	92013	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12261784	C4591001 1226 12261784	16-55	17SEP2020	92016	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261789	C4591001 1226 12261789	16-55	17SEP2020	92018	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo		
12261790	C4591001 1226 12261790	16-55	17SEP2020	92230	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261791	C4591001 1226 12261791	16-55	17SEP2020	92236	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261792	C4591001 1226 12261792	16-55	17SEP2020	92287	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261794	C4591001 1226 12261794	16-55	17SEP2020	92227	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261795	C4591001 1226 12261795	16-55	17SEP2020	92292	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12261796	C4591001 1226 12261796	16-55	17SEP2020	92228	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261797	C4591001 1226 12261797	16-55	17SEP2020	92286	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12261798	C4591001 1226 12261798	16-55	17SEP2020	92379	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12261800	C4591001 1226 12261800	16-55	17SEP2020	92369	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261801	C4591001 1226 12261801	16-55	17SEP2020	92374	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261802	C4591001 1226 12261802	16-55	17SEP2020	92377	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261803	C4591001 1226 12261803	16-55	17SEP2020	92296	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12261805	C4591001 1226 12261805	16-55	17SEP2020	92429	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261806	C4591001 1226 12261806	16-55	17SEP2020	92430	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261807	C4591001 1226 12261807	16-55	17SEP2020	92434	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261809	C4591001 1226 12261809	16-55	17SEP2020	92438	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12261810	C4591001 1226 12261810	16-55	18SEP2020	93173	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261811	C4591001 1226 12261811	16-55	18SEP2020	93175	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261812	C4591001 1226 12261812	16-55	18SEP2020	93182	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261813	C4591001 1226 12261813	16-55	18SEP2020	93187	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261815	C4591001 1226 12261815	16-55	18SEP2020	93179	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261818	C4591001 1226 12261818	16-55	18SEP2020	93196	Placebo	18SEP2020/ Placebo	13OCT2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261819	C4591001 1226 12261819	16-55	18SEP2020	93193	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261820	C4591001 1226 12261820	16-55	18SEP2020	93195	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261821	C4591001 1226 12261821	16-55	18SEP2020	93209	Placebo	18SEP2020/ Placebo	22OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12261823	C4591001 1226 12261823	16-55	18SEP2020	93217	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261824	C4591001 1226 12261824	16-55	18SEP2020	93220	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261826	C4591001 1226 12261826	16-55	18SEP2020	93212	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261827	C4591001 1226 12261827	16-55	18SEP2020	93245	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261828	C4591001 1226 12261828	16-55	18SEP2020	93279	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261830	C4591001 1226 12261830	16-55	18SEP2020	93246	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261831	C4591001 1226 12261831	16-55	18SEP2020	93249	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261832	C4591001 1226 12261832	16-55	18SEP2020	93253	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261833	C4591001 1226 12261833	16-55	18SEP2020	93277	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261834	C4591001 1226 12261834	16-55	18SEP2020	93273	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261835	C4591001 1226 12261835	16-55	18SEP2020	93274	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261836	C4591001 1226 12261836	16-55	18SEP2020	93367	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261838	C4591001 1226 12261838	16-55	18SEP2020	93368	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261839	C4591001 1226 12261839	16-55	18SEP2020	93374	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261840	C4591001 1226 12261840	16-55	18SEP2020	93372	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261841	C4591001 1226 12261841	16-55	18SEP2020	93523	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261842	C4591001 1226 12261842	16-55	18SEP2020	93463	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261843	C4591001 1226 12261843	16-55	18SEP2020	93466	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261844	C4591001 1226 12261844	16-55	18SEP2020	93465	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12261845	C4591001 1226 12261845	16-55	18SEP2020	93469	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261846	C4591001 1226 12261846	16-55	18SEP2020	93584	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261847	C4591001 1226 12261847	16-55	18SEP2020	93524	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261848	C4591001 1226 12261848	16-55	18SEP2020	93586	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261849	C4591001 1226 12261849	16-55	18SEP2020	261715	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261850	C4591001 1226 12261850	16-55	18SEP2020	93525	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261851	C4591001 1226 12261851	16-55	18SEP2020	93526	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12261852	C4591001 1226 12261852	16-55	18SEP2020	93582	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261853	C4591001 1226 12261853	16-55	18SEP2020	93690	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261854	C4591001 1226 12261854	16-55	18SEP2020	93691	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261855	C4591001 1226 12261855	16-55	18SEP2020	93590	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261856	C4591001 1226 12261856	16-55	18SEP2020	93695	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261857	C4591001 1226 12261857	16-55	18SEP2020	93699	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261858	C4591001 1226 12261858	16-55	19SEP2020	94426	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261859	C4591001 1226 12261859	16-55	19SEP2020	94428	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261860	C4591001 1226 12261860	16-55	19SEP2020	94429	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261863	C4591001 1226 12261863	16-55	19SEP2020	94433	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261864	C4591001 1226 12261864	16-55	19SEP2020	94430	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261865	C4591001 1226 12261865	16-55	19SEP2020	94437	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12261866	C4591001 1226 12261866	16-55	19SEP2020	94438	Placebo	19SEP2020/ Placebo	08OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261867	C4591001 1226 12261867	16-55	19SEP2020	94442	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261868	C4591001 1226 12261868	16-55	19SEP2020	94457	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261869	C4591001 1226 12261869	16-55	19SEP2020	94459	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12261870	C4591001 1226 12261870	16-55	19SEP2020	94462	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261871	C4591001 1226 12261871	16-55	19SEP2020	94468	Placebo	19SEP2020/ Placebo	17OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261873	C4591001 1226 12261873	16-55	19SEP2020	94471	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261874	C4591001 1226 12261874	16-55	19SEP2020	94475	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261875	C4591001 1226 12261875	16-55	19SEP2020	94474	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12261876	C4591001 1226 12261876	16-55	19SEP2020	94483	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261877	C4591001 1226 12261877	16-55	19SEP2020	94476	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261878	C4591001 1226 12261878	16-55	19SEP2020	94486	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12261879	C4591001 1226 12261879	16-55	19SEP2020	94484	Placebo	19SEP2020/ Placebo	09OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261880	C4591001 1226 12261880	16-55	25SEP2020	99293	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261881	C4591001 1226 12261881	16-55	25SEP2020	94490	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261882	C4591001 1226 12261882	16-55	25SEP2020	99295	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261884	C4591001 1226 12261884	16-55	25SEP2020	99299	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261885	C4591001 1226 12261885	16-55	25SEP2020	99394	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12261886	C4591001 1226 12261886	16-55	25SEP2020	99300	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261887	C4591001 1226 12261887	16-55	25SEP2020	99395	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261888	C4591001 1226 12261888	16-55	25SEP2020	99398	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12261889	C4591001 1226 12261889	16-55	25SEP2020	99399	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261890	C4591001 1226 12261890	16-55	25SEP2020	99479	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261892	C4591001 1226 12261892	16-55	25SEP2020	99480	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261893	C4591001 1226 12261893	16-55	25SEP2020	99483	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261894	C4591001 1226 12261894	16-55	25SEP2020	99481	Placebo	25SEP2020/ Placebo		19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261895	C4591001 1226 12261895	16-55	25SEP2020	99569	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261896	C4591001 1226 12261896	16-55	25SEP2020	99572	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261897	C4591001 1226 12261897	16-55	25SEP2020	99578	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12261898	C4591001 1226 12261898	16-55	25SEP2020	99580	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12261899	C4591001 1226 12261899	16-55	25SEP2020	99620	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261900	C4591001 1226 12261900	16-55	25SEP2020	99621	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12261901	C4591001 1226 12261901	16-55	25SEP2020	99624	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261902	C4591001 1226 12261902	16-55	25SEP2020	99788	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12261904	C4591001 1226 12261904	16-55	25SEP2020	99627	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261905	C4591001 1226 12261905	16-55	25SEP2020	99789	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261906	C4591001 1226 12261906	16-55	28SEP2020	99792	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261907	C4591001 1226 12261907	16-55	28SEP2020	101238	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261908	C4591001 1226 12261908	16-55	28SEP2020	101237	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261909	C4591001 1226 12261909	16-55	28SEP2020	101248	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12261910	C4591001 1226 12261910	16-55	28SEP2020	101239	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261911	C4591001 1226 12261911	16-55	28SEP2020	101266	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261912	C4591001 1226 12261912	16-55	28SEP2020	101269	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12261914	C4591001 1226 12261914	16-55	28SEP2020	101271	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261917	C4591001 1226 12261917	16-55	28SEP2020	101272	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261918	C4591001 1226 12261918	16-55	28SEP2020	101345	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261919	C4591001 1226 12261919	16-55	28SEP2020	101352	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12261920	C4591001 1226 12261920	16-55	28SEP2020	101354	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12261922	C4591001 1226 12261922	16-55	28SEP2020	101356	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261923	C4591001 1226 12261923	16-55	29SEP2020	101753	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261924	C4591001 1226 12261924	16-55	29SEP2020	101757	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261925	C4591001 1226 12261925	16-55	29SEP2020	101764	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12261926	C4591001 1226 12261926	16-55	29SEP2020	101763	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12261927	C4591001 1226 12261927	16-55	29SEP2020	101765	Placebo	29SEP2020/ Placebo	05NOV2020/ Placebo		
12261928	C4591001 1226 12261928	16-55	29SEP2020	101769	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261929	C4591001 1226 12261929	16-55	29SEP2020	101775	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261930	C4591001 1226 12261930	16-55	29SEP2020	101787	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261931	C4591001 1226 12261931	16-55	29SEP2020	101776	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261932	C4591001 1226 12261932	16-55	29SEP2020	101781	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261933	C4591001 1226 12261933	16-55	29SEP2020	101783	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261934	C4591001 1226 12261934	16-55	29SEP2020	101788	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261935	C4591001 1226 12261935	16-55	29SEP2020	101831	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261936	C4591001 1226 12261936	16-55	29SEP2020	101835	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261937	C4591001 1226 12261937	16-55	29SEP2020	101826	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261938	C4591001 1226 12261938	16-55	29SEP2020	101842	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261939	C4591001 1226 12261939	16-55	29SEP2020	101843	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261940	C4591001 1226 12261940	16-55	29SEP2020	101836	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261941	C4591001 1226 12261941	16-55	29SEP2020	101846	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12261942	C4591001 1226 12261942	16-55	29SEP2020	101848	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261944	C4591001 1226 12261944	16-55	29SEP2020	101862	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12261945	C4591001 1226 12261945	16-55	29SEP2020	101866	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12261946	C4591001 1226 12261946	16-55	29SEP2020	101863	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261947	C4591001 1226 12261947	16-55	29SEP2020	101872	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261948	C4591001 1226 12261948	16-55	29SEP2020	101900	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261950	C4591001 1226 12261950	16-55	29SEP2020	101904	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12261951	C4591001 1226 12261951	16-55	29SEP2020	101906	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261952	C4591001 1226 12261952	16-55	30SEP2020	101907	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12261953	C4591001 1226 12261953	16-55	30SEP2020	102178	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261954	C4591001 1226 12261954	16-55	30SEP2020	102173	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12261956	C4591001 1226 12261956	16-55	30SEP2020	102180	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261957	C4591001 1226 12261957	16-55	30SEP2020	102184	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261958	C4591001 1226 12261958	16-55	30SEP2020	102223	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261959	C4591001 1226 12261959	16-55	30SEP2020	102228	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261960	C4591001 1226 12261960	16-55	30SEP2020	102232	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12261961	C4591001 1226 12261961	16-55	30SEP2020	102231	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261962	C4591001 1226 12261962	16-55	30SEP2020	102282	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261963	C4591001 1226 12261963	16-55	30SEP2020	102283	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261964	C4591001 1226 12261964	16-55	30SEP2020	102284	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261966	C4591001 1226 12261966	16-55	30SEP2020	102291	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261967	C4591001 1226 12261967	16-55	30SEP2020	102377	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12261968	C4591001 1226 12261968	16-55	30SEP2020	102378	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261970	C4591001 1226 12261970	16-55	30SEP2020	102381	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261971	C4591001 1226 12261971	16-55	30SEP2020	102385	Placebo	30SEP2020/ Placebo	03NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261972	C4591001 1226 12261972	16-55	30SEP2020	102415	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261973	C4591001 1226 12261973	16-55	01OCT2020	102416	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12261974	C4591001 1226 12261974	16-55	01OCT2020	102658	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261975	C4591001 1226 12261975	16-55	01OCT2020	102419	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261976	C4591001 1226 12261976	16-55	01OCT2020	102420	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261978	C4591001 1226 12261978	16-55	01OCT2020	102660	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261980	C4591001 1226 12261980	16-55	01OCT2020	102661	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12261981	C4591001 1226 12261981	16-55	01OCT2020	102690	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261982	C4591001 1226 12261982	16-55	01OCT2020	102664	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12261983	C4591001 1226 12261983	16-55	01OCT2020	102693	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261985	C4591001 1226 12261985	16-55	01OCT2020	102695	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12261987	C4591001 1226 12261987	16-55	01OCT2020	102751	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12261988	C4591001 1226 12261988	16-55	01OCT2020	102700	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12261989	C4591001 1226 12261989	16-55	01OCT2020	102752	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12261992	C4591001 1226 12261992	16-55	01OCT2020	102754	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12261994	C4591001 1226 12261994	16-55	01OCT2020	102797	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12261995	C4591001 1226 12261995	16-55	01OCT2020	102758	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12261996	C4591001 1226 12261996	16-55	01OCT2020	102798	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261997	C4591001 1226 12261997	16-55	01OCT2020	102800	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12261998	C4591001 1226 12261998	16-55	01OCT2020	102807	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12261999	C4591001 1226 12261999	16-55	01OCT2020	102821	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262000	C4591001 1226 12262000	16-55	01OCT2020	102823	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
12262001	C4591001 1226 12262001	16-55	01OCT2020	102832	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262002	C4591001 1226 12262002	16-55	01OCT2020	102858	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262003	C4591001 1226 12262003	16-55	01OCT2020	102828	Placebo	01OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262006	C4591001 1226 12262006	16-55	01OCT2020	102861	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262007	C4591001 1226 12262007	16-55	02OCT2020	102862	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262008	C4591001 1226 12262008	16-55	02OCT2020	102866	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262010	C4591001 1226 12262010	16-55	02OCT2020	103099	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262011	C4591001 1226 12262011	16-55	02OCT2020	103100	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262012	C4591001 1226 12262012	16-55	02OCT2020	103103	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262013	C4591001 1226 12262013	16-55	02OCT2020	103107	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262014	C4591001 1226 12262014	16-55	02OCT2020	103158	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262015	C4591001 1226 12262015	16-55	02OCT2020	103165	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262016	C4591001 1226 12262016	16-55	02OCT2020	103164	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262017	C4591001 1226 12262017	16-55	02OCT2020	103166	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262018	C4591001 1226 12262018	16-55	02OCT2020	103182	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262019	C4591001 1226 12262019	16-55	02OCT2020	103181	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262021	C4591001 1226 12262021	16-55	02OCT2020	103185	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262022	C4591001 1226 12262022	16-55	02OCT2020	103184	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12262023	C4591001 1226 12262023	16-55	02OCT2020	103245	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12262024	C4591001 1226 12262024	16-55	03OCT2020	103250	Placebo	03OCT2020/ Placebo	22OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262026	C4591001 1226 12262026	16-55	03OCT2020	103251	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262027	C4591001 1226 12262027	16-55	03OCT2020	103252	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262028	C4591001 1226 12262028	16-55	03OCT2020	103421	Placebo	03OCT2020/ Placebo	22OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262029	C4591001 1226 12262029	16-55	03OCT2020	103422	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12262030	C4591001 1226 12262030	16-55	03OCT2020	103424	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262034	C4591001 1226 12262034	16-55	03OCT2020	103430	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262035	C4591001 1226 12262035	16-55	03OCT2020	103444	Placebo	03OCT2020/ Placebo	29OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262036	C4591001 1226 12262036	16-55	03OCT2020	103434	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262037	C4591001 1226 12262037	16-55	03OCT2020	103438	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262038	C4591001 1226 12262038	16-55	03OCT2020	103451	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262039	C4591001 1226 12262039	16-55	03OCT2020	103439	Placebo	03OCT2020/ Placebo	22OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262040	C4591001 1226 12262040	16-55	03OCT2020	103450	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12262041	C4591001 1226 12262041	16-55	03OCT2020	103445	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262042	C4591001 1226 12262042	16-55	03OCT2020	103452	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12262044	C4591001 1226 12262044	16-55	03OCT2020	103461	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262045	C4591001 1226 12262045	16-55	03OCT2020	103467	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262046	C4591001 1226 12262046	16-55	03OCT2020	103459	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262047	C4591001 1226 12262047	16-55	03OCT2020	103468	Placebo	03OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262048	C4591001 1226 12262048	16-55	03OCT2020	103477	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262049	C4591001 1226 12262049	16-55	03OCT2020	103469	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262050	C4591001 1226 12262050	16-55	03OCT2020	103475	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262051	C4591001 1226 12262051	16-55	03OCT2020	103478	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262052	C4591001 1226 12262052	16-55	03OCT2020	103482	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262056	C4591001 1226 12262056	16-55	03OCT2020	103484	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262058	C4591001 1226 12262058	16-55	03OCT2020	103493	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262059	C4591001 1226 12262059	16-55	03OCT2020	103489	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262060	C4591001 1226 12262060	16-55	03OCT2020	103492	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262062	C4591001 1226 12262062	16-55	03OCT2020	103500	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262063	C4591001 1226 12262063	16-55	03OCT2020	103502	Placebo	03OCT2020/ Placebo	23NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12262064	C4591001 1226 12262064	16-55	03OCT2020	103503	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262065	C4591001 1226 12262065	16-55	03OCT2020	103506	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262067	C4591001 1226 12262067	16-55	03OCT2020	103508	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262068	C4591001 1226 12262068	16-55	05OCT2020	103514	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262070	C4591001 1226 12262070	16-55	05OCT2020	103515	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12262071	C4591001 1226 12262071	16-55	05OCT2020	103662	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262072	C4591001 1226 12262072	16-55	05OCT2020	103664	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262073	C4591001 1226 12262073	16-55	05OCT2020	103671	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262075	C4591001 1226 12262075	16-55	05OCT2020	103669	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262076	C4591001 1226 12262076	16-55	05OCT2020	103697	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262078	C4591001 1226 12262078	16-55	05OCT2020	103700	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262079	C4591001 1226 12262079	16-55	05OCT2020	103702	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262080	C4591001 1226 12262080	16-55	05OCT2020	103705	Placebo	05OCT2020/ Placebo	30OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262081	C4591001 1226 12262081	16-55	05OCT2020	103722	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262083	C4591001 1226 12262083	16-55	05OCT2020	103727	Placebo	05OCT2020/ Placebo	07NOV2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262084	C4591001 1226 12262084	16-55	05OCT2020	103729	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12262085	C4591001 1226 12262085	16-55	05OCT2020	103731	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262086	C4591001 1226 12262086	16-55	05OCT2020	103775	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262087	C4591001 1226 12262087	16-55	06OCT2020	103776	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262089	C4591001 1226 12262089	16-55	06OCT2020	103777	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262090	C4591001 1226 12262090	16-55	06OCT2020	103778	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262091	C4591001 1226 12262091	16-55	06OCT2020	104214	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262092	C4591001 1226 12262092	16-55	06OCT2020	104215	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262094	C4591001 1226 12262094	16-55	06OCT2020	104216	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262095	C4591001 1226 12262095	16-55	06OCT2020	104222	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12262096	C4591001 1226 12262096	16-55	06OCT2020	104309	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262097	C4591001 1226 12262097	16-55	07OCT2020	104310	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262099	C4591001 1226 12262099	16-55	07OCT2020	104317	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262103	C4591001 1226 12262103	16-55	07OCT2020	104318	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262104	C4591001 1226 12262104	16-55	07OCT2020	104766	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262105	C4591001 1226 12262105	16-55	07OCT2020	104769	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262106	C4591001 1226 12262106	16-55	08OCT2020	104771	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262107	C4591001 1226 12262107	16-55	08OCT2020	104776	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262108	C4591001 1226 12262108	16-55	08OCT2020	105258	Placebo	08OCT2020/ Placebo		10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262110	C4591001 1226 12262110	16-55	08OCT2020	105260	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262111	C4591001 1226 12262111	16-55	08OCT2020	105266	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262112	C4591001 1226 12262112	16-55	08OCT2020	105267	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262113	C4591001 1226 12262113	16-55	08OCT2020	105356	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262114	C4591001 1226 12262114	16-55	08OCT2020	105359	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12262115	C4591001 1226 12262115	16-55	08OCT2020	105360	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12262116	C4591001 1226 12262116	16-55	08OCT2020	105362	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262117	C4591001 1226 12262117	16-55	09OCT2020	105810	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262119	C4591001 1226 12262119	16-55	09OCT2020	105820	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262120	C4591001 1226 12262120	16-55	09OCT2020	105815	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12262121	C4591001 1226 12262121	16-55	09OCT2020	105817	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262122	C4591001 1226 12262122	16-55	09OCT2020	105875	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262123	C4591001 1226 12262123	16-55	09OCT2020	105871	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262124	C4591001 1226 12262124	16-55	09OCT2020	105915	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262125	C4591001 1226 12262125	16-55	09OCT2020	105916	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262126	C4591001 1226 12262126	16-55	09OCT2020	105873	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262127	C4591001 1226 12262127	16-55	09OCT2020	105914	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12262128	C4591001 1226 12262128	16-55	09OCT2020	105955	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262129	C4591001 1226 12262129	16-55	09OCT2020	105960	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12262130	C4591001 1226 12262130	16-55	09OCT2020	105878	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262131	C4591001 1226 12262131	16-55	09OCT2020	105961	Placebo	09OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262132	C4591001 1226 12262132	16-55	09OCT2020	105910	Placebo	09OCT2020/ Placebo	13NOV2020/ Placebo		
12262133	C4591001 1226 12262133	16-55	09OCT2020	105978	Placebo	09OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262134	C4591001 1226 12262134	16-55	09OCT2020	105962	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262135	C4591001 1226 12262135	16-55	09OCT2020	105981	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262136	C4591001 1226 12262136	16-55	09OCT2020	106004	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)		
12262137	C4591001 1226 12262137	16-55	09OCT2020	105982	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12262138	C4591001 1226 12262138	16-55	09OCT2020	105988	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262140	C4591001 1226 12262140	16-55	13OCT2020	106007	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262141	C4591001 1226 12262141	16-55	13OCT2020	106009	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262143	C4591001 1226 12262143	16-55	13OCT2020	106782	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262144	C4591001 1226 12262144	16-55	13OCT2020	106008	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262145	C4591001 1226 12262145	16-55	13OCT2020	106790	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262146	C4591001 1226 12262146	16-55	13OCT2020	106783	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12262148	C4591001 1226 12262148	16-55	13OCT2020	106784	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262149	C4591001 1226 12262149	16-55	13OCT2020	106806	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262151	C4591001 1226 12262151	16-55	13OCT2020	106811	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262152	C4591001 1226 12262152	16-55	13OCT2020	106814	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262153	C4591001 1226 12262153	16-55	13OCT2020	106816	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262154	C4591001 1226 12262154	16-55	13OCT2020	106831	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262157	C4591001 1226 12262157	16-55	13OCT2020	106833	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262159	C4591001 1226 12262159	16-55	13OCT2020	106836	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262162	C4591001 1226 12262162	16-55	13OCT2020	106837	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262163	C4591001 1226 12262163	16-55	13OCT2020	106889	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262164	C4591001 1226 12262164	16-55	13OCT2020	106891	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262165	C4591001 1226 12262165	16-55	13OCT2020	106895	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262166	C4591001 1226 12262166	16-55	13OCT2020	106893	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262167	C4591001 1226 12262167	16-55	13OCT2020	106941	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262168	C4591001 1226 12262168	16-55	13OCT2020	106942	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
12262169	C4591001 1226 12262169	16-55	13OCT2020	106945	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12262170	C4591001 1226 12262170	16-55	13OCT2020	106946	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262172	C4591001 1226 12262172	16-55	13OCT2020	106962	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262178	C4591001 1226 12262178	16-55	13OCT2020	106964	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262179	C4591001 1226 12262179	16-55	13OCT2020	106969	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12262181	C4591001 1226 12262181	16-55	13OCT2020	106971	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262182	C4591001 1226 12262182	16-55	14OCT2020	107321	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262183	C4591001 1226 12262183	16-55	14OCT2020	107322	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12262184	C4591001 1226 12262184	16-55	14OCT2020	107325	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262185	C4591001 1226 12262185	16-55	14OCT2020	107330	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262186	C4591001 1226 12262186	16-55	14OCT2020	107359	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262187	C4591001 1226 12262187	16-55	14OCT2020	107361	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262188	C4591001 1226 12262188	16-55	14OCT2020	107362	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262189	C4591001 1226 12262189	16-55	14OCT2020	107368	Placebo	14OCT2020/ Placebo		19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262190	C4591001 1226 12262190	16-55	14OCT2020	107490	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262191	C4591001 1226 12262191	16-55	14OCT2020	107492	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262192	C4591001 1226 12262192	16-55	15OCT2020	107493	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262193	C4591001 1226 12262193	16-55	15OCT2020	107876	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262194	C4591001 1226 12262194	16-55	15OCT2020	107495	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262195	C4591001 1226 12262195	16-55	15OCT2020	107880	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262196	C4591001 1226 12262196	16-55	15OCT2020	107881	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262197	C4591001 1226 12262197	16-55	15OCT2020	107882	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262198	C4591001 1226 12262198	16-55	15OCT2020	107885	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262199	C4591001 1226 12262199	16-55	15OCT2020	107887	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12262200	C4591001 1226 12262200	16-55	15OCT2020	107890	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262201	C4591001 1226 12262201	16-55	15OCT2020	107891	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262204	C4591001 1226 12262204	16-55	15OCT2020	107935	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262205	C4591001 1226 12262205	16-55	15OCT2020	107936	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262206	C4591001 1226 12262206	16-55	15OCT2020	107940	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262208	C4591001 1226 12262208	16-55	15OCT2020	107944	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262209	C4591001 1226 12262209	16-55	15OCT2020	107972	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262211	C4591001 1226 12262211	16-55	15OCT2020	107976	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262212	C4591001 1226 12262212	16-55	15OCT2020	107977	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262213	C4591001 1226 12262213	16-55	15OCT2020	107979	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262216	C4591001 1226 12262216	16-55	15OCT2020	108117	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262217	C4591001 1226 12262217	16-55	15OCT2020	108119	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262218	C4591001 1226 12262218	16-55	15OCT2020	108121	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12262219	C4591001 1226 12262219	16-55	15OCT2020	108164	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262220	C4591001 1226 12262220	16-55	15OCT2020	108122	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262221	C4591001 1226 12262221	16-55	15OCT2020	108162	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262223	C4591001 1226 12262223	16-55	16OCT2020	108170	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262224	C4591001 1226 12262224	16-55	16OCT2020	108689	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262225	C4591001 1226 12262225	16-55	16OCT2020	108172	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262226	C4591001 1226 12262226	16-55	16OCT2020	108697	Placebo	16OCT2020/ Placebo	07NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262227	C4591001 1226 12262227	16-55	16OCT2020	108698	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12262228	C4591001 1226 12262228	16-55	16OCT2020	108727	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262229	C4591001 1226 12262229	16-55	16OCT2020	108700	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	30NOV2020/ BNT162b2 (30 µg)		
12262230	C4591001 1226 12262230	16-55	16OCT2020	108729	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262231	C4591001 1226 12262231	16-55	16OCT2020	108730	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262232	C4591001 1226 12262232	16-55	16OCT2020	108734	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12262233	C4591001 1226 12262233	16-55	16OCT2020	108787	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12262234	C4591001 1226 12262234	16-55	16OCT2020	108789	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12262236	C4591001 1226 12262236	16-55	16OCT2020	108791	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262237	C4591001 1226 12262237	16-55	16OCT2020	108795	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262239	C4591001 1226 12262239	16-55	16OCT2020	108846	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262241	C4591001 1226 12262241	16-55	16OCT2020	108848	Placebo	16OCT2020/ Placebo	04NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262242	C4591001 1226 12262242	16-55	16OCT2020	108849	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12262243	C4591001 1226 12262243	16-55	16OCT2020	108953	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262244	C4591001 1226 12262244	16-55	16OCT2020	108854	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262245	C4591001 1226 12262245	16-55	16OCT2020	108957	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262246	C4591001 1226 12262246	16-55	16OCT2020	108958	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262247	C4591001 1226 12262247	16-55	16OCT2020	270063	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262249	C4591001 1226 12262249	16-55	16OCT2020	108963	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262251	C4591001 1226 12262251	16-55	16OCT2020	109027	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262252	C4591001 1226 12262252	16-55	16OCT2020	109031	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262255	C4591001 1226 12262255†	16-55	16OCT2020	109029	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262256	C4591001 1226 12262256	16-55	16OCT2020	109036	Placebo	16OCT2020/ Placebo	07NOV2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12262258	C4591001 1226 12262258	16-55	17OCT2020	109458	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262259	C4591001 1226 12262259	16-55	17OCT2020	109459	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262260	C4591001 1226 12262260	16-55	17OCT2020	109461	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262261	C4591001 1226 12262261	16-55	17OCT2020	109467	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12262262	C4591001 1226 12262262	16-55	17OCT2020	109470	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)		
12262263	C4591001 1226 12262263	16-55	17OCT2020	109469	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262267	C4591001 1226 12262267	16-55	17OCT2020	109477	Placebo	17OCT2020/ Placebo		19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262268	C4591001 1226 12262268	16-55	17OCT2020	109472	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12262269	C4591001 1226 12262269	16-55	17OCT2020	109493	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262270	C4591001 1226 12262270	16-55	17OCT2020	109500	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262272	C4591001 1226 12262272	16-55	17OCT2020	109494	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12262273	C4591001 1226 12262273	16-55	17OCT2020	109504	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262274	C4591001 1226 12262274	16-55	17OCT2020	109506	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262275	C4591001 1226 12262275	16-55	17OCT2020	109511	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262276	C4591001 1226 12262276	16-55	17OCT2020	109507	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262278	C4591001 1226 12262278	16-55	17OCT2020	109515	Placebo	17OCT2020/ Placebo	20NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262279	C4591001 1226 12262279	16-55	17OCT2020	109529	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262280	C4591001 1226 12262280	16-55	17OCT2020	109530	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262282	C4591001 1226 12262282	16-55	17OCT2020	109538	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12262283	C4591001 1226 12262283	16-55	17OCT2020	109571	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12262284	C4591001 1226 12262284	16-55	17OCT2020	109536	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262285	C4591001 1226 12262285	16-55	17OCT2020	109567	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262286	C4591001 1226 12262286	16-55	17OCT2020	109580	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262287	C4591001 1226 12262287	16-55	17OCT2020	109569	Placebo	17OCT2020/ Placebo	09NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262289	C4591001 1226 12262289	16-55	17OCT2020	109583	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262290	C4591001 1226 12262290	16-55	17OCT2020	109593	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262291	C4591001 1226 12262291	16-55	17OCT2020	109584	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12262292	C4591001 1226 12262292	16-55	17OCT2020	109576	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262293	C4591001 1226 12262293	16-55	17OCT2020	109591	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262294	C4591001 1226 12262294	16-55	17OCT2020	109585	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262295	C4591001 1226 12262295	16-55	17OCT2020	109601	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262297	C4591001 1226 12262297	16-55	17OCT2020	109596	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262298	C4591001 1226 12262298	16-55	17OCT2020	109598	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262299	C4591001 1226 12262299	16-55	17OCT2020	109602	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262300	C4591001 1226 12262300	16-55	17OCT2020	109610	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262301	C4591001 1226 12262301	16-55	17OCT2020	109637	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262303	C4591001 1226 12262303	16-55	17OCT2020	109609	Placebo	17OCT2020/ Placebo	07NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12262304	C4591001 1226 12262304	16-55	17OCT2020	109641	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262307	C4591001 1226 12262307	16-55	17OCT2020	109646	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12262309	C4591001 1226 12262309	16-55	17OCT2020	109643	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12262311	C4591001 1226 12262311	16-55	17OCT2020	109649	Placebo	17OCT2020/ Placebo	05NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12262313	C4591001 1226 12262313	16-55	19OCT2020	109653	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262314	C4591001 1226 12262314	16-55	19OCT2020	109656	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262315	C4591001 1226 12262315	16-55	19OCT2020	109660	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262316	C4591001 1226 12262316	16-55	19OCT2020	109829	Placebo	19OCT2020/ Placebo	13NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262317	C4591001 1226 12262317	16-55	19OCT2020	109833	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262318	C4591001 1226 12262318	16-55	19OCT2020	109835	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262319	C4591001 1226 12262319	16-55	19OCT2020	109839	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262320	C4591001 1226 12262320	16-55	19OCT2020	109866	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262321	C4591001 1226 12262321	16-55	19OCT2020	109869	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262322	C4591001 1226 12262322	16-55	19OCT2020	109870	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262326	C4591001 1226 12262326	16-55	19OCT2020	109871	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262327	C4591001 1226 12262327	16-55	19OCT2020	109938	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262329	C4591001 1226 12262329	16-55	19OCT2020	109940	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12262330	C4591001 1226 12262330	16-55	19OCT2020	109941	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12262331	C4591001 1226 12262331	16-55	19OCT2020	109947	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262334	C4591001 1226 12262334	16-55	19OCT2020	109997	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262335	C4591001 1226 12262335	16-55	19OCT2020	110005	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12262337	C4591001 1226 12262337	16-55	19OCT2020	110007	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12262338	C4591001 1226 12262338	16-55	19OCT2020	110006	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262339	C4591001 1226 12262339	16-55	19OCT2020	110049	Placebo	19OCT2020/ Placebo	19NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
12262340	C4591001 1226 12262340	16-55	19OCT2020	110053	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262341	C4591001 1226 12262341	16-55	19OCT2020	110055	Placebo	19OCT2020/ Placebo	07NOV2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262343	C4591001 1226 12262343	16-55	19OCT2020	110056	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262346	C4591001 1226 12262346	16-55	19OCT2020	110187	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12262347	C4591001 1226 12262347	16-55	19OCT2020	110239	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262348	C4591001 1226 12262348	16-55	19OCT2020	110180	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12262350	C4591001 1226 12262350	16-55	19OCT2020	110181	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262351	C4591001 1226 12262351	16-55	19OCT2020	110182	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12262352	C4591001 1226 12262352	16-55	20OCT2020	110241	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12262353	C4591001 1226 12262353	16-55	20OCT2020	110244	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12262354	C4591001 1226 12262354	16-55	20OCT2020	110245	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12262356	C4591001 1226 12262356	16-55	20OCT2020	110742	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12262357	C4591001 1226 12262357	16-55	20OCT2020	110743	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12291001	C4591001 1229 12291001	16-55	22SEP2020	95924	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12291002	C4591001 1229 12291002	16-55	22SEP2020	95925	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291004	C4591001 1229 12291004	16-55	22SEP2020	95926	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291006	C4591001 1229 12291006	16-55	23SEP2020	95931	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12291007	C4591001 1229 12291007	16-55	23SEP2020	97153	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12291008	C4591001 1229 12291008	16-55	23SEP2020	97152	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291009	C4591001 1229 12291009	16-55	23SEP2020	97154	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291010	C4591001 1229 12291010	16-55	23SEP2020	97178	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291011	C4591001 1229 12291011	16-55	23SEP2020	97155	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12291012	C4591001 1229 12291012	16-55	23SEP2020	97169	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291013	C4591001 1229 12291013	16-55	23SEP2020	97176	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291015	C4591001 1229 12291015	16-55	25SEP2020	97180	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291016	C4591001 1229 12291016	16-55	25SEP2020	99188	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12291019	C4591001 1229 12291019	16-55	25SEP2020	99190	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12291020	C4591001 1229 12291020	16-55	25SEP2020	99195	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12291021	C4591001 1229 12291021	16-55	25SEP2020	99192	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12291022	C4591001 1229 12291022	16-55	25SEP2020	99227	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12291024	C4591001 1229 12291024†	16-55	28SEP2020	99232	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291025	C4591001 1229 12291025	16-55	28SEP2020	99230	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
12291027	C4591001 1229 12291027†	16-55	28SEP2020	101177	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291029	C4591001 1229 12291029	16-55	28SEP2020	99231	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291030	C4591001 1229 12291030	16-55	28SEP2020	101188	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291031	C4591001 1229 12291031	16-55	28SEP2020	101180	Placebo	28SEP2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291032	C4591001 1229 12291032	16-55	28SEP2020	101185	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291033	C4591001 1229 12291033	16-55	28SEP2020	101213	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291035	C4591001 1229 12291035	16-55	28SEP2020	101214	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo		
12291037	C4591001 1229 12291037	16-55	28SEP2020	101215	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291042	C4591001 1229 12291042†	16-55	29SEP2020	101216	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291043	C4591001 1229 12291043	16-55	29SEP2020	101681	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo		
12291045	C4591001 1229 12291045†	16-55	29SEP2020	101686	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291046	C4591001 1229 12291046	16-55	29SEP2020	101691	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291047	C4591001 1229 12291047	16-55	29SEP2020	101688	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291048	C4591001 1229 12291048	16-55	29SEP2020	101722	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12291049	C4591001 1229 12291049	16-55	29SEP2020	101723	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12291051	C4591001 1229 12291051	16-55	29SEP2020	101726	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291052	C4591001 1229 12291052†	16-55	30SEP2020	102077	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12291055	C4591001 1229 12291055†	16-55	30SEP2020	102111	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291057	C4591001 1229 12291057	16-55	30SEP2020	101728	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291058	C4591001 1229 12291058†	16-55	30SEP2020	102101	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12291059	C4591001 1229 12291059	16-55	30SEP2020	102083	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291061	C4591001 1229 12291061	16-55	30SEP2020	102102	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291062	C4591001 1229 12291062	16-55	30SEP2020	102084	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12291063	C4591001 1229 12291063†	16-55	30SEP2020	102087	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291064	C4591001 1229 12291064	16-55	30SEP2020	102132	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291065	C4591001 1229 12291065	16-55	30SEP2020	102129	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12291066	C4591001 1229 12291066	16-55	30SEP2020	102112	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12291070	C4591001 1229 12291070†	16-55	01OCT2020	102609	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12291072	C4591001 1229 12291072†	16-55	01OCT2020	102133	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291073	C4591001 1229 12291073†	16-55	01OCT2020	102606	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291077	C4591001 1229 12291077	16-55	01OCT2020	102135	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291078	C4591001 1229 12291078	16-55	01OCT2020	102615	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291079	C4591001 1229 12291079	16-55	01OCT2020	102613	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12291081	C4591001 1229 12291081†	16-55	01OCT2020	102630	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291082	C4591001 1229 12291082	16-55	01OCT2020	102632	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12291083	C4591001 1229 12291083†	16-55	01OCT2020	102631	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo		
12291086	C4591001 1229 12291086†	16-55	02OCT2020	102639	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291088	C4591001 1229 12291088	16-55	02OCT2020	103005	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	13MAR2021/ BNT162b2 (30 µg)
12291091	C4591001 1229 12291091	16-55	02OCT2020	103040	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291092	C4591001 1229 12291092†	16-55	02OCT2020	103001	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291093	C4591001 1229 12291093	16-55	02OCT2020	103012	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291094	C4591001 1229 12291094	16-55	02OCT2020	103041	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291095	C4591001 1229 12291095	16-55	02OCT2020	103009	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291096	C4591001 1229 12291096†	16-55	02OCT2020	103042	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12291098	C4591001 1229 12291098	16-55	05OCT2020	103043	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12291099	C4591001 1229 12291099	16-55	05OCT2020	103555	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291100	C4591001 1229 12291100	16-55	05OCT2020	103558	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291101	C4591001 1229 12291101	16-55	05OCT2020	103563	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291103	C4591001 1229 12291103	16-55	05OCT2020	103590	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291104	C4591001 1229 12291104	16-55	05OCT2020	103591	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291105	C4591001 1229 12291105	16-55	05OCT2020	103562	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291107	C4591001 1229 12291107	16-55	05OCT2020	103595	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291108	C4591001 1229 12291108	16-55	05OCT2020	103598	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291109	C4591001 1229 12291109	16-55	05OCT2020	103634	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12291110	C4591001 1229 12291110	16-55	05OCT2020	103625	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12291112	C4591001 1229 12291112	16-55	05OCT2020	103632	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	
12291113	C4591001 1229 12291113†	16-55	06OCT2020	103636	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291114	C4591001 1229 12291114	16-55	06OCT2020	104029	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291115	C4591001 1229 12291115	16-55	06OCT2020	104022	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291116	C4591001 1229 12291116	16-55	06OCT2020	104070	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291117	C4591001 1229 12291117†	16-55	06OCT2020	104024	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291118	C4591001 1229 12291118	16-55	06OCT2020	104028	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291119	C4591001 1229 12291119	16-55	06OCT2020	104069	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291122	C4591001 1229 12291122	16-55	06OCT2020	104074	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291124	C4591001 1229 12291124	16-55	06OCT2020	104080	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291126	C4591001 1229 12291126†	16-55	06OCT2020	104106	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291127	C4591001 1229 12291127	16-55	06OCT2020	104109	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12291130	C4591001 1229 12291130†	16-55	07OCT2020	104567	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291131	C4591001 1229 12291131†	16-55	07OCT2020	104110	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291134	C4591001 1229 12291134†	16-55	07OCT2020	104539	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291135	C4591001 1229 12291135†	16-55	07OCT2020	104116	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		
12291136	C4591001 1229 12291136	16-55	07OCT2020	104542	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291138	C4591001 1229 12291138	16-55	07OCT2020	104544	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291139	C4591001 1229 12291139†	16-55	07OCT2020	104564	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291140	C4591001 1229 12291140†	16-55	07OCT2020	104543	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291141	C4591001 1229 12291141	16-55	07OCT2020	104611	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291142	C4591001 1229 12291142	16-55	07OCT2020	104563	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291143	C4591001 1229 12291143	16-55	07OCT2020	104568	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12291145	C4591001 1229 12291145	16-55	08OCT2020	104617	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291146	C4591001 1229 12291146	16-55	08OCT2020	104614	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12291149	C4591001 1229 12291149	16-55	08OCT2020	105093	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291151	C4591001 1229 12291151	16-55	08OCT2020	105098	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291152	C4591001 1229 12291152	16-55	08OCT2020	105133	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12291153	C4591001 1229 12291153	16-55	08OCT2020	105131	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291154	C4591001 1229 12291154	16-55	08OCT2020	104619	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291155	C4591001 1229 12291155	16-55	08OCT2020	105132	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291156	C4591001 1229 12291156	16-55	08OCT2020	105173	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12291157	C4591001 1229 12291157	16-55	08OCT2020	105136	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291158	C4591001 1229 12291158	16-55	08OCT2020	105096	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291159	C4591001 1229 12291159	16-55	08OCT2020	105100	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12291160	C4591001 1229 12291160	16-55	08OCT2020	105174	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12291165	C4591001 1229 12291165†	16-55	09OCT2020	105181	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291166	C4591001 1229 12291166†	16-55	09OCT2020	105656	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291167	C4591001 1229 12291167†	16-55	09OCT2020	105653	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291168	C4591001 1229 12291168	16-55	09OCT2020	105689	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291169	C4591001 1229 12291169	16-55	09OCT2020	105663	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291170	C4591001 1229 12291170†	16-55	09OCT2020	105664	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291171	C4591001 1229 12291171†	16-55	09OCT2020	105690	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291172	C4591001 1229 12291172	16-55	09OCT2020	105691	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291173	C4591001 1229 12291173	16-55	09OCT2020	267808	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12291174	C4591001 1229 12291174	16-55	12OCT2020	106265	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291175	C4591001 1229 12291175	16-55	12OCT2020	106276	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291176	C4591001 1229 12291176	16-55	12OCT2020	105696	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291177	C4591001 1229 12291177	16-55	12OCT2020	106282	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12291178	C4591001 1229 12291178†	16-55	12OCT2020	106278	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291179	C4591001 1229 12291179	16-55	12OCT2020	106283	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291180	C4591001 1229 12291180	16-55	12OCT2020	106279	Placebo	12OCT2020/ Placebo	06NOV2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12291181	C4591001 1229 12291181†	16-55	12OCT2020	106267	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291182	C4591001 1229 12291182	16-55	12OCT2020	106291	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291184	C4591001 1229 12291184	16-55	12OCT2020	106270	Placebo	12OCT2020/ Placebo	04NOV2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12291185	C4591001 1229 12291185	16-55	12OCT2020	106311	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291186	C4591001 1229 12291186	16-55	12OCT2020	106299	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291187	C4591001 1229 12291187	16-55	12OCT2020	106296	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291188	C4591001 1229 12291188	16-55	12OCT2020	106308	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
12291189	C4591001 1229 12291189	16-55	12OCT2020	106295	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291190	C4591001 1229 12291190	16-55	12OCT2020	106307	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12291192	C4591001 1229 12291192	16-55	13OCT2020	106752	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	
12291193	C4591001 1229 12291193	16-55	13OCT2020	106753	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291194	C4591001 1229 12291194†	16-55	13OCT2020	106312	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	22FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291195	C4591001 1229 12291195	16-55	13OCT2020	106745	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291196	C4591001 1229 12291196	16-55	13OCT2020	106755	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291197	C4591001 1229 12291197	16-55	13OCT2020	106758	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291198	C4591001 1229 12291198	16-55	13OCT2020	106774	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12291200	C4591001 1229 12291200	16-55	13OCT2020	106765	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291201	C4591001 1229 12291201	16-55	13OCT2020	106778	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12291202	C4591001 1229 12291202	16-55	13OCT2020	106759	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291204	C4591001 1229 12291204	16-55	13OCT2020	106766	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)			
12291205	C4591001 1229 12291205	16-55	13OCT2020	106770	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12291207	C4591001 1229 12291207	16-55	14OCT2020	107301	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12291209	C4591001 1229 12291209	16-55	14OCT2020	107313	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12291211	C4591001 1229 12291211†	16-55	14OCT2020	107306	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291212	C4591001 1229 12291212	16-55	14OCT2020	106779	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291213	C4591001 1229 12291213	16-55	14OCT2020	107305	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12291214	C4591001 1229 12291214	16-55	14OCT2020	107307	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo		
12291215	C4591001 1229 12291215†	16-55	14OCT2020	107315	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12291216	C4591001 1229 12291216	16-55	14OCT2020	107317	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12291217	C4591001 1229 12291217	16-55	15OCT2020	107318	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12301001	C4591001 1230 12301001	16-55	23SEP2020	97134	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12301002	C4591001 1230 12301002	16-55	23SEP2020	97135	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301004	C4591001 1230 12301004	16-55	23SEP2020	97139	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301005	C4591001 1230 12301005	16-55	23SEP2020	97144	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301006	C4591001 1230 12301006	16-55	23SEP2020	97230	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301008	C4591001 1230 12301008	16-55	23SEP2020	97231	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301009	C4591001 1230 12301009	16-55	23SEP2020	97237	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12301010	C4591001 1230 12301010	16-55	23SEP2020	97232	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12301011	C4591001 1230 12301011	16-55	23SEP2020	97553	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301012	C4591001 1230 12301012	16-55	23SEP2020	97556	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12301015	C4591001 1230 12301015	16-55	24SEP2020	97558	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301017	C4591001 1230 12301017	16-55	24SEP2020	97560	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301018	C4591001 1230 12301018	16-55	24SEP2020	98507	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301019	C4591001 1230 12301019	16-55	24SEP2020	98509	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301020	C4591001 1230 12301020	16-55	24SEP2020	98510	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301021	C4591001 1230 12301021	16-55	24SEP2020	98512	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo		
12301022	C4591001 1230 12301022	16-55	24SEP2020	98549	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301023	C4591001 1230 12301023	16-55	24SEP2020	98552	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12301024	C4591001 1230 12301024	16-55	25SEP2020	98553	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12301026	C4591001 1230 12301026	16-55	25SEP2020	98554	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301028	C4591001 1230 12301028	16-55	25SEP2020	99239	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301029	C4591001 1230 12301029	16-55	25SEP2020	99235	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301031	C4591001 1230 12301031	16-55	25SEP2020	99242	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301032	C4591001 1230 12301032	16-55	25SEP2020	99244	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301033	C4591001 1230 12301033	16-55	25SEP2020	99282	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301034	C4591001 1230 12301034	16-55	25SEP2020	99284	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301035	C4591001 1230 12301035	16-55	25SEP2020	99283	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301036	C4591001 1230 12301036	16-55	25SEP2020	99285	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301037	C4591001 1230 12301037	16-55	26SEP2020	100579	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12301038	C4591001 1230 12301038	16-55	26SEP2020	100580	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301039	C4591001 1230 12301039	16-55	26SEP2020	100588	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301040	C4591001 1230 12301040	16-55	26SEP2020	100595	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301041	C4591001 1230 12301041	16-55	26SEP2020	100585	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12301043	C4591001 1230 12301043	16-55	26SEP2020	100596	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301044	C4591001 1230 12301044	16-55	26SEP2020	100598	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12301045	C4591001 1230 12301045†	16-55	29SEP2020	101741	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)			
12301047	C4591001 1230 12301047	16-55	28SEP2020	100599	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301048	C4591001 1230 12301048	16-55	28SEP2020	101191	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301050	C4591001 1230 12301050	16-55	28SEP2020	101192	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301051	C4591001 1230 12301051	16-55	28SEP2020	101193	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301052	C4591001 1230 12301052	16-55	28SEP2020	101225	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301053	C4591001 1230 12301053	16-55	28SEP2020	101199	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301054	C4591001 1230 12301054	16-55	28SEP2020	101230	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301055	C4591001 1230 12301055	16-55	28SEP2020	101236	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301056	C4591001 1230 12301056	16-55	28SEP2020	101234	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301057	C4591001 1230 12301057	16-55	28SEP2020	101292	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12301058	C4591001 1230 12301058	16-55	28SEP2020	101293	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301060	C4591001 1230 12301060	16-55	28SEP2020	101294	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301062	C4591001 1230 12301062	16-55	29SEP2020	101296	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301063	C4591001 1230 12301063	16-55	29SEP2020	101670	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo		
12301064	C4591001 1230 12301064	16-55	29SEP2020	101671	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301065	C4591001 1230 12301065	16-55	29SEP2020	101672	Placebo	29SEP2020/ Placebo	26NOV2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301066	C4591001 1230 12301066	16-55	29SEP2020	101673	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301067	C4591001 1230 12301067	16-55	29SEP2020	101693	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301068	C4591001 1230 12301068	16-55	29SEP2020	101696	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301069	C4591001 1230 12301069	16-55	29SEP2020	101702	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301070	C4591001 1230 12301070	16-55	29SEP2020	101742	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301071	C4591001 1230 12301071	16-55	29SEP2020	101703	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301072	C4591001 1230 12301072	16-55	29SEP2020	101749	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301073	C4591001 1230 12301073†	16-55	29SEP2020	101750	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301074	C4591001 1230 12301074	16-55	30SEP2020	102018	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12301075	C4591001 1230 12301075	16-55	30SEP2020	102118	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301077	C4591001 1230 12301077	16-55	05OCT2020	103420	Placebo	05OCT2020/ Placebo	24OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301078	C4591001 1230 12301078	16-55	30SEP2020	102019	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12301079	C4591001 1230 12301079	16-55	30SEP2020	102020	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301080	C4591001 1230 12301080	16-55	30SEP2020	102024	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12301082	C4591001 1230 12301082	16-55	30SEP2020	102114	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301083	C4591001 1230 12301083	16-55	30SEP2020	102121	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301084	C4591001 1230 12301084	16-55	30SEP2020	102123	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12301085	C4591001 1230 12301085	16-55	30SEP2020	102262	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12301086	C4591001 1230 12301086†	16-55	30SEP2020	102264	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12301087	C4591001 1230 12301087	16-55	30SEP2020	102266	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301089	C4591001 1230 12301089	16-55	01OCT2020	102267	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301091	C4591001 1230 12301091	16-55	01OCT2020	102593	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301092	C4591001 1230 12301092	16-55	01OCT2020	102594	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301094	C4591001 1230 12301094	16-55	01OCT2020	102602	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301095	C4591001 1230 12301095	16-55	01OCT2020	102603	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12301097	C4591001 1230 12301097	16-55	01OCT2020	102761	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301099	C4591001 1230 12301099	16-55	02OCT2020	103111	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12301100	C4591001 1230 12301100	16-55	02OCT2020	102764	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12301101	C4591001 1230 12301101	16-55	02OCT2020	102765	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo		
12301102	C4591001 1230 12301102	16-55	02OCT2020	102772	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301103	C4591001 1230 12301103	16-55	02OCT2020	103026	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301104	C4591001 1230 12301104	16-55	02OCT2020	103030	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301105	C4591001 1230 12301105	16-55	02OCT2020	103034	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301106	C4591001 1230 12301106	16-55	02OCT2020	103035	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301107	C4591001 1230 12301107	16-55	02OCT2020	103049	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301108	C4591001 1230 12301108	16-55	02OCT2020	103052	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301109	C4591001 1230 12301109	16-55	02OCT2020	103058	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301110	C4591001 1230 12301110	16-55	02OCT2020	103059	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12301112	C4591001 1230 12301112	16-55	02OCT2020	103110	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12301113	C4591001 1230 12301113	16-55	02OCT2020	103114	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301114	C4591001 1230 12301114	16-55	03OCT2020	103116	Placebo	03OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12301115	C4591001 1230 12301115	16-55	03OCT2020	103385	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301116	C4591001 1230 12301116	16-55	03OCT2020	103387	Placebo	03OCT2020/ Placebo	24OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301117	C4591001 1230 12301117	16-55	03OCT2020	103389	Placebo	03OCT2020/ Placebo	24OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12301118	C4591001 1230 12301118	16-55	03OCT2020	103393	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301121	C4591001 1230 12301121	16-55	03OCT2020	103415	Placebo	03OCT2020/ Placebo	27OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301122	C4591001 1230 12301122	16-55	03OCT2020	103416	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301123	C4591001 1230 12301123	16-55	03OCT2020	103418	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12301124	C4591001 1230 12301124	16-55	05OCT2020	103541	Placebo	05OCT2020/ Placebo	27OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301125	C4591001 1230 12301125	16-55	05OCT2020	103546	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301129	C4591001 1230 12301129	16-55	05OCT2020	103614	Placebo	05OCT2020/ Placebo	28OCT2020/ Placebo		
12301130	C4591001 1230 12301130	16-55	05OCT2020	103619	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12301132	C4591001 1230 12301132	16-55	05OCT2020	103621	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
12301133	C4591001 1230 12301133	16-55	05OCT2020	103622	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12301134	C4591001 1230 12301134	16-55	05OCT2020	103675	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301135	C4591001 1230 12301135	16-55	05OCT2020	103676	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12301136	C4591001 1230 12301136	16-55	05OCT2020	103678	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301137	C4591001 1230 12301137	16-55	05OCT2020	103682	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301138	C4591001 1230 12301138	16-55	06OCT2020	103986	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301139	C4591001 1230 12301139†	16-55	06OCT2020	103987	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301140	C4591001 1230 12301140†	16-55	06OCT2020	103991	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301142	C4591001 1230 12301142	16-55	06OCT2020	103996	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301143	C4591001 1230 12301143	16-55	06OCT2020	104058	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301144	C4591001 1230 12301144	16-55	06OCT2020	104060	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301145	C4591001 1230 12301145	16-55	06OCT2020	104059	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301146	C4591001 1230 12301146	16-55	06OCT2020	104063	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301147	C4591001 1230 12301147	16-55	06OCT2020	104093	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301148	C4591001 1230 12301148	16-55	06OCT2020	104098	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)			
12301150	C4591001 1230 12301150	16-55	06OCT2020	104100	Placebo	06OCT2020/ Placebo			
12301151	C4591001 1230 12301151	16-55	06OCT2020	104101	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301152	C4591001 1230 12301152	16-55	06OCT2020	104129	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12301153	C4591001 1230 12301153	16-55	06OCT2020	104134	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12301154	C4591001 1230 12301154	16-55	06OCT2020	104135	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301157	C4591001 1230 12301157	16-55	06OCT2020	104137	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301158	C4591001 1230 12301158	16-55	06OCT2020	104249	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301159	C4591001 1230 12301159	16-55	06OCT2020	104254	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301161	C4591001 1230 12301161	16-55	07OCT2020	104256	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301162	C4591001 1230 12301162	16-55	07OCT2020	104259	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301163	C4591001 1230 12301163	16-55	07OCT2020	104513	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301164	C4591001 1230 12301164	16-55	07OCT2020	104521	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301165	C4591001 1230 12301165	16-55	07OCT2020	104519	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301166	C4591001 1230 12301166	16-55	07OCT2020	104522	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301170	C4591001 1230 12301170	16-55	07OCT2020	104553	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12301171	C4591001 1230 12301171	16-55	07OCT2020	104551	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301172	C4591001 1230 12301172	16-55	07OCT2020	104556	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301173	C4591001 1230 12301173	16-55	07OCT2020	104597	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12301174	C4591001 1230 12301174†	16-55	07OCT2020	104604	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301175	C4591001 1230 12301175	16-55	07OCT2020	104607	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12301176	C4591001 1230 12301176†	16-55	07OCT2020	104608	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12301177	C4591001 1230 12301177	16-55	07OCT2020	104681	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301181	C4591001 1230 12301181	16-55	08OCT2020	104686	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301182	C4591001 1230 12301182	16-55	08OCT2020	104690	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301183	C4591001 1230 12301183	16-55	08OCT2020	104691	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12301184	C4591001 1230 12301184†	16-55	08OCT2020	105116	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301185	C4591001 1230 12301185	16-55	08OCT2020	105115	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301186	C4591001 1230 12301186	16-55	08OCT2020	105117	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301187	C4591001 1230 12301187	16-55	08OCT2020	105119	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301188	C4591001 1230 12301188	16-55	08OCT2020	105153	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301189	C4591001 1230 12301189	16-55	08OCT2020	105157	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301190	C4591001 1230 12301190	16-55	08OCT2020	105158	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301191	C4591001 1230 12301191	16-55	08OCT2020	105160	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo		
12301192	C4591001 1230 12301192	16-55	08OCT2020	105189	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301193	C4591001 1230 12301193	16-55	08OCT2020	105194	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12301195	C4591001 1230 12301195	16-55	08OCT2020	105195	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301196	C4591001 1230 12301196	16-55	08OCT2020	105196	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo		
12301197	C4591001 1230 12301197	16-55	08OCT2020	105270	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301198	C4591001 1230 12301198	16-55	08OCT2020	105271	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12301199	C4591001 1230 12301199	16-55	09OCT2020	105276	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301200	C4591001 1230 12301200	16-55	09OCT2020	105630	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301201	C4591001 1230 12301201	16-55	09OCT2020	105279	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301202	C4591001 1230 12301202	16-55	09OCT2020	105633	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301203	C4591001 1230 12301203	16-55	09OCT2020	105637	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301204	C4591001 1230 12301204	16-55	09OCT2020	105635	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301205	C4591001 1230 12301205	16-55	09OCT2020	105666	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301206	C4591001 1230 12301206	16-55	09OCT2020	105669	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301207	C4591001 1230 12301207	16-55	09OCT2020	105727	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12301208	C4591001 1230 12301208	16-55	09OCT2020	105672	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301209	C4591001 1230 12301209	16-55	09OCT2020	105673	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301210	C4591001 1230 12301210	16-55	09OCT2020	105730	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301211	C4591001 1230 12301211	16-55	09OCT2020	105732	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301212	C4591001 1230 12301212	16-55	09OCT2020	105733	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301213	C4591001 1230 12301213	16-55	09OCT2020	105738	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301214	C4591001 1230 12301214	16-55	09OCT2020	105743	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301215	C4591001 1230 12301215	16-55	09OCT2020	105739	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301216	C4591001 1230 12301216	16-55	09OCT2020	105742	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301217	C4591001 1230 12301217	16-55	09OCT2020	105825	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301218	C4591001 1230 12301218	16-55	09OCT2020	105822	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301219	C4591001 1230 12301219	16-55	09OCT2020	105827	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12301220	C4591001 1230 12301220	16-55	09OCT2020	105830	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12301222	C4591001 1230 12301222	16-55	09OCT2020	105884	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12301223	C4591001 1230 12301223	16-55	09OCT2020	105885	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301224	C4591001 1230 12301224	16-55	09OCT2020	105888	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301225	C4591001 1230 12301225	16-55	09OCT2020	106014	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12301226	C4591001 1230 12301226	16-55	09OCT2020	106018	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12311191	C4591001 1231 12311191	16-55	14AUG2020	49988	Placebo	14AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
12311195	C4591001 1231 12311195	16-55	14AUG2020	50123	Placebo	14AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
12311200	C4591001 1231 12311200	16-55	14AUG2020	50125	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)			
12311211	C4591001 1231 12311211	16-55	14AUG2020	50163	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12311214	C4591001 1231 12311214	16-55	14AUG2020	50167	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311232	C4591001 1231 12311232	16-55	14AUG2020	50359	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311242	C4591001 1231 12311242	16-55	14AUG2020	50458	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311243	C4591001 1231 12311243	16-55	14AUG2020	50594	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311244	C4591001 1231 12311244	16-55	14AUG2020	50457	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo		
12311245	C4591001 1231 12311245	16-55	14AUG2020	50646	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311248	C4591001 1231 12311248	16-55	14AUG2020	50650	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311257	C4591001 1231 12311257	16-55	14AUG2020	50705	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311261	C4591001 1231 12311261	16-55	14AUG2020	50983	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311264	C4591001 1231 12311264	16-55	14AUG2020	50710	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311265	C4591001 1231 12311265	16-55	14AUG2020	50712	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311269	C4591001 1231 12311269	16-55	14AUG2020	50761	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311270	C4591001 1231 12311270	16-55	14AUG2020	50759	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311274	C4591001 1231 12311274	16-55	14AUG2020	50836	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311277	C4591001 1231 12311277	16-55	15AUG2020	51118	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311285	C4591001 1231 12311285	16-55	15AUG2020	51137	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311286	C4591001 1231 12311286	16-55	15AUG2020	50990	Placebo	15AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311287	C4591001 1231 12311287	16-55	15AUG2020	51101	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo		
12311294	C4591001 1231 12311294	16-55	15AUG2020	51105	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311297	C4591001 1231 12311297	16-55	15AUG2020	51125	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311298	C4591001 1231 12311298	16-55	15AUG2020	51129	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311301	C4591001 1231 12311301	16-55	15AUG2020	51158	Placebo	15AUG2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311302	C4591001 1231 12311302	16-55	15AUG2020	51143	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311304	C4591001 1231 12311304	16-55	15AUG2020	51152	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311306	C4591001 1231 12311306	16-55	15AUG2020	51164	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311311	C4591001 1231 12311311	16-55	15AUG2020	51282	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311314	C4591001 1231 12311314	16-55	15AUG2020	51165	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311317	C4591001 1231 12311317	16-55	15AUG2020	51259	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311320	C4591001 1231 12311320	16-55	15AUG2020	51234	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12311328	C4591001 1231 12311328	16-55	15AUG2020	51246	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311334	C4591001 1231 12311334	16-55	15AUG2020	51238	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311335	C4591001 1231 12311335	16-55	15AUG2020	51205	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311338	C4591001 1231 12311338	16-55	15AUG2020	51211	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311339	C4591001 1231 12311339	16-55	15AUG2020	51216	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311352	C4591001 1231 12311352	16-55	15AUG2020	51324	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311353	C4591001 1231 12311353	16-55	15AUG2020	51364	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311354	C4591001 1231 12311354	16-55	15AUG2020	51343	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311355	C4591001 1231 12311355	16-55	15AUG2020	51304	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311356	C4591001 1231 12311356	16-55	15AUG2020	51354	Placebo	15AUG2020/ Placebo			
12311359	C4591001 1231 12311359	16-55	15AUG2020	51370	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311360	C4591001 1231 12311360	16-55	15AUG2020	51318	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311361	C4591001 1231 12311361	16-55	15AUG2020	51375	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311362	C4591001 1231 12311362	16-55	15AUG2020	51344	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311364	C4591001 1231 12311364	16-55	15AUG2020	51377	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311367	C4591001 1231 12311367	16-55	15AUG2020	51387	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311371	C4591001 1231 12311371	16-55	15AUG2020	51397	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12311373	C4591001 1231 12311373	16-55	15AUG2020	51453	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311374	C4591001 1231 12311374	16-55	15AUG2020	51394	Placebo	15AUG2020/ Placebo			
12311376	C4591001 1231 12311376	16-55	15AUG2020	51367	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311385	C4591001 1231 12311385	16-55	15AUG2020	51426	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311387	C4591001 1231 12311387	16-55	15AUG2020	51509	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311389	C4591001 1231 12311389	16-55	15AUG2020	51434	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311391	C4591001 1231 12311391	16-55	15AUG2020	51486	Placebo	15AUG2020/ Placebo			
12311402	C4591001 1231 12311402	16-55	15AUG2020	51460	Placebo	15AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12311403	C4591001 1231 12311403	16-55	15AUG2020	51462	Placebo	15AUG2020/ Placebo	06SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311405	C4591001 1231 12311405	16-55	15AUG2020	51501	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311408	C4591001 1231 12311408	16-55	15AUG2020	51463	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311409	C4591001 1231 12311409	16-55	15AUG2020	51472	BNT162b2 (30 µg)				
12311410	C4591001 1231 12311410	16-55	15AUG2020	51473	Placebo	15AUG2020/ Placebo	06SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311412	C4591001 1231 12311412	16-55	15AUG2020	51482	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12311417	C4591001 1231 12311417	16-55	15AUG2020	51507	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12311420	C4591001 1231 12311420	16-55	15AUG2020	51532	Placebo	15AUG2020/ Placebo	15OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311422	C4591001 1231 12311422	16-55	15AUG2020	51547	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311423	C4591001 1231 12311423	16-55	15AUG2020	51575	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311428	C4591001 1231 12311428	16-55	15AUG2020	51523	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311429	C4591001 1231 12311429	16-55	15AUG2020	51519	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311431	C4591001 1231 12311431	16-55	15AUG2020	51526	Placebo	15AUG2020/ Placebo			
12311432	C4591001 1231 12311432	16-55	15AUG2020	51528	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311433	C4591001 1231 12311433	16-55	15AUG2020	51540	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311435	C4591001 1231 12311435	16-55	15AUG2020	51561	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311441	C4591001 1231 12311441	16-55	15AUG2020	51548	Placebo	15AUG2020/ Placebo			
12311443	C4591001 1231 12311443	16-55	15AUG2020	51550	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311445	C4591001 1231 12311445	16-55	15AUG2020	51571	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311448	C4591001 1231 12311448	16-55	15AUG2020	51586	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo		
12311449	C4591001 1231 12311449	16-55	15AUG2020	51588	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311462	C4591001 1231 12311462	16-55	15AUG2020	51605	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311463	C4591001 1231 12311463	16-55	15AUG2020	51606	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo		
12311467	C4591001 1231 12311467	16-55	15AUG2020	51638	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311469	C4591001 1231 12311469	16-55	15AUG2020	51617	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311470	C4591001 1231 12311470	16-55	15AUG2020	51641	Placebo	15AUG2020/ Placebo	04SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311473	C4591001 1231 12311473	16-55	15AUG2020	51625	Placebo	15AUG2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	
12311476	C4591001 1231 12311476	16-55	15AUG2020	51636	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311481	C4591001 1231 12311481	16-55	15AUG2020	51664	Placebo	15AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311486	C4591001 1231 12311486	16-55	15AUG2020	51642	BNT162b2 (30 µg)	15AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311491	C4591001 1231 12311491	16-55	16AUG2020	51680	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311492	C4591001 1231 12311492	16-55	16AUG2020	51686	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311494	C4591001 1231 12311494	16-55	16AUG2020	51681	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311495	C4591001 1231 12311495	16-55	16AUG2020	51673	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311496	C4591001 1231 12311496	16-55	16AUG2020	51723	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311497	C4591001 1231 12311497	16-55	16AUG2020	51754	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311499	C4591001 1231 12311499	16-55	16AUG2020	51712	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12311502	C4591001 1231 12311502	16-55	16AUG2020	51702	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311503	C4591001 1231 12311503	16-55	16AUG2020	51710	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311504	C4591001 1231 12311504	16-55	16AUG2020	51835	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311505	C4591001 1231 12311505	16-55	16AUG2020	229684	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311506	C4591001 1231 12311506	16-55	16AUG2020	51839	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311507	C4591001 1231 12311507	16-55	16AUG2020	51717	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311508	C4591001 1231 12311508	16-55	16AUG2020	51711	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311509	C4591001 1231 12311509	16-55	16AUG2020	51685	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311513	C4591001 1231 12311513	16-55	16AUG2020	51738	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311516	C4591001 1231 12311516	16-55	16AUG2020	51785	Placebo				
12311518	C4591001 1231 12311518	16-55	16AUG2020	51715	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311519	C4591001 1231 12311519	16-55	16AUG2020	51749	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311520	C4591001 1231 12311520	16-55	16AUG2020	51756	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311521	C4591001 1231 12311521	16-55	16AUG2020	51753	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311522	C4591001 1231 12311522	16-55	16AUG2020	51728	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311523	C4591001 1231 12311523	16-55	16AUG2020	51724	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311524	C4591001 1231 12311524	16-55	16AUG2020	51732	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo		
12311525	C4591001 1231 12311525	16-55	16AUG2020	51748	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311526	C4591001 1231 12311526	16-55	16AUG2020	51735	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311527	C4591001 1231 12311527	16-55	16AUG2020	51734	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311528	C4591001 1231 12311528	16-55	16AUG2020	51743	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311529	C4591001 1231 12311529	16-55	16AUG2020	51739	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311530	C4591001 1231 12311530	16-55	16AUG2020	51764	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311531	C4591001 1231 12311531	16-55	16AUG2020	51786	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12311532	C4591001 1231 12311532	16-55	16AUG2020	51765	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)			
12311534	C4591001 1231 12311534	16-55	16AUG2020	51768	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311535	C4591001 1231 12311535	16-55	16AUG2020	51773	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12311538	C4591001 1231 12311538	16-55	16AUG2020	51774	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311539	C4591001 1231 12311539	16-55	16AUG2020	51777	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311540	C4591001 1231 12311540	16-55	16AUG2020	51767	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo		
12311541	C4591001 1231 12311541	16-55	16AUG2020	51778	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311543	C4591001 1231 12311543	16-55	16AUG2020	51799	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311545	C4591001 1231 12311545	16-55	16AUG2020	51865	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311546	C4591001 1231 12311546	16-55	16AUG2020	51804	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311547	C4591001 1231 12311547	16-55	16AUG2020	51796	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311548	C4591001 1231 12311548	16-55	16AUG2020	51871	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311550	C4591001 1231 12311550	16-55	16AUG2020	51824	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311551	C4591001 1231 12311551	16-55	16AUG2020	51851	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311552	C4591001 1231 12311552	16-55	16AUG2020	51850	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311553	C4591001 1231 12311553	16-55	16AUG2020	51805	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12311555	C4591001 1231 12311555	16-55	16AUG2020	51843	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311556	C4591001 1231 12311556	16-55	16AUG2020	51808	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311557	C4591001 1231 12311557	16-55	16AUG2020	51825	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12311558	C4591001 1231 12311558	16-55	16AUG2020	51827	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311559	C4591001 1231 12311559	16-55	16AUG2020	51830	Placebo	16AUG2020/ Placebo			
12311565	C4591001 1231 12311565	16-55	16AUG2020	51852	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311566	C4591001 1231 12311566	16-55	16AUG2020	51853	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311567	C4591001 1231 12311567	16-55	16AUG2020	51857	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311568	C4591001 1231 12311568	16-55	16AUG2020	51858	Placebo	16AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12311569	C4591001 1231 12311569	16-55	16AUG2020	51873	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311570	C4591001 1231 12311570	16-55	16AUG2020	51885	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311571	C4591001 1231 12311571	16-55	16AUG2020	51883	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12311572	C4591001 1231 12311572	16-55	16AUG2020	51866	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311573	C4591001 1231 12311573	16-55	16AUG2020	51874	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311575	C4591001 1231 12311575	16-55	16AUG2020	51877	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311577	C4591001 1231 12311577	16-55	16AUG2020	51887	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311580	C4591001 1231 12311580	16-55	16AUG2020	51962	Placebo	16AUG2020/ Placebo	24SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12311581	C4591001 1231 12311581	16-55	16AUG2020	51891	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311582	C4591001 1231 12311582	16-55	16AUG2020	51979	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311584	C4591001 1231 12311584	16-55	16AUG2020	51894	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311585	C4591001 1231 12311585	16-55	16AUG2020	51921	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311587	C4591001 1231 12311587	16-55	16AUG2020	51905	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311588	C4591001 1231 12311588	16-55	16AUG2020	51910	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311590	C4591001 1231 12311590	16-55	16AUG2020	51900	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311591	C4591001 1231 12311591	16-55	16AUG2020	51914	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311592	C4591001 1231 12311592	16-55	16AUG2020	51919	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12311593	C4591001 1231 12311593	16-55	16AUG2020	51895	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311594	C4591001 1231 12311594	16-55	16AUG2020	51903	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311595	C4591001 1231 12311595	16-55	16AUG2020	51907	Placebo	16AUG2020/ Placebo	04SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311596	C4591001 1231 12311596	16-55	16AUG2020	51986	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311597	C4591001 1231 12311597	16-55	16AUG2020	51959	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311598	C4591001 1231 12311598	16-55	16AUG2020	51936	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311599	C4591001 1231 12311599	16-55	16AUG2020	51981	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12311600	C4591001 1231 12311600	16-55	16AUG2020	51924	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311601	C4591001 1231 12311601	16-55	16AUG2020	51933	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311602	C4591001 1231 12311602	16-55	16AUG2020	51927	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311604	C4591001 1231 12311604	16-55	16AUG2020	51949	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311605	C4591001 1231 12311605	16-55	16AUG2020	51951	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311606	C4591001 1231 12311606	16-55	16AUG2020	51934	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)		
12311607	C4591001 1231 12311607	16-55	16AUG2020	51964	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311608	C4591001 1231 12311608	16-55	16AUG2020	51999	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311609	C4591001 1231 12311609	16-55	16AUG2020	51937	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311611	C4591001 1231 12311611	16-55	16AUG2020	51942	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12311614	C4591001 1231 12311614	16-55	16AUG2020	51950	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311615	C4591001 1231 12311615	16-55	16AUG2020	51954	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311616	C4591001 1231 12311616	16-55	16AUG2020	52006	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311617	C4591001 1231 12311617	16-55	16AUG2020	51987	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311618	C4591001 1231 12311618	16-55	16AUG2020	52016	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311619	C4591001 1231 12311619	16-55	16AUG2020	51996	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311621	C4591001 1231 12311621	16-55	16AUG2020	52000	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311623	C4591001 1231 12311623	16-55	16AUG2020	51998	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311624	C4591001 1231 12311624	16-55	16AUG2020	52011	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311625	C4591001 1231 12311625	16-55	16AUG2020	52008	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311626	C4591001 1231 12311626	16-55	16AUG2020	52010	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311627	C4591001 1231 12311627	16-55	16AUG2020	52026	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311628	C4591001 1231 12311628	16-55	16AUG2020	52020	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311629	C4591001 1231 12311629	16-55	16AUG2020	52035	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311630	C4591001 1231 12311630	16-55	16AUG2020	52013	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12311631	C4591001 1231 12311631	16-55	16AUG2020	52097	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311633	C4591001 1231 12311633	16-55	16AUG2020	52036	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311634	C4591001 1231 12311634	16-55	16AUG2020	52022	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311636	C4591001 1231 12311636	16-55	16AUG2020	52029	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311637	C4591001 1231 12311637	16-55	16AUG2020	52038	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311638	C4591001 1231 12311638	16-55	16AUG2020	52045	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311640	C4591001 1231 12311640	16-55	16AUG2020	52059	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311641	C4591001 1231 12311641	16-55	16AUG2020	52068	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)			
12311642	C4591001 1231 12311642	16-55	16AUG2020	52053	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311643	C4591001 1231 12311643	16-55	16AUG2020	52039	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311645	C4591001 1231 12311645	16-55	16AUG2020	52055	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311646	C4591001 1231 12311646	16-55	16AUG2020	52106	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311647	C4591001 1231 12311647	16-55	16AUG2020	52050	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311648	C4591001 1231 12311648	16-55	16AUG2020	52072	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311649	C4591001 1231 12311649	16-55	16AUG2020	52078	Placebo	16AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311650	C4591001 1231 12311650	16-55	16AUG2020	52069	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311651	C4591001 1231 12311651	16-55	16AUG2020	52083	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311652	C4591001 1231 12311652	16-55	16AUG2020	52079	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311653	C4591001 1231 12311653	16-55	16AUG2020	52093	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311654	C4591001 1231 12311654	16-55	16AUG2020	52076	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311655	C4591001 1231 12311655	16-55	16AUG2020	52095	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311656	C4591001 1231 12311656	16-55	16AUG2020	52092	Placebo	16AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12311658	C4591001 1231 12311658	16-55	16AUG2020	52090	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311659	C4591001 1231 12311659	16-55	16AUG2020	52102	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311660	C4591001 1231 12311660	16-55	16AUG2020	52112	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo		
12311661	C4591001 1231 12311661	16-55	16AUG2020	52108	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311662	C4591001 1231 12311662	16-55	16AUG2020	52113	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311663	C4591001 1231 12311663	16-55	16AUG2020	52114	BNT162b2 (30 µg)	16AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311664	C4591001 1231 12311664	16-55	16AUG2020	52115	Placebo	16AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311665	C4591001 1231 12311665	16-55	17AUG2020	52158	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311666	C4591001 1231 12311666	16-55	17AUG2020	52161	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311668	C4591001 1231 12311668	16-55	17AUG2020	52164	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311669	C4591001 1231 12311669	16-55	17AUG2020	52165	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311671	C4591001 1231 12311671	16-55	17AUG2020	52178	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311673	C4591001 1231 12311673	16-55	17AUG2020	52169	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311676	C4591001 1231 12311676	16-55	17AUG2020	52175	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311678	C4591001 1231 12311678	16-55	17AUG2020	52288	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311679	C4591001 1231 12311679	16-55	17AUG2020	52221	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12311681	C4591001 1231 12311681	16-55	17AUG2020	52222	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311682	C4591001 1231 12311682	16-55	17AUG2020	52177	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311683	C4591001 1231 12311683	16-55	17AUG2020	52272	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311684	C4591001 1231 12311684	16-55	17AUG2020	52219	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311685	C4591001 1231 12311685	16-55	17AUG2020	52215	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311686	C4591001 1231 12311686	16-55	17AUG2020	52303	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311687	C4591001 1231 12311687	16-55	17AUG2020	52228	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311689	C4591001 1231 12311689	16-55	17AUG2020	52213	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311690	C4591001 1231 12311690	16-55	17AUG2020	52287	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311691	C4591001 1231 12311691	16-55	17AUG2020	52301	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311692	C4591001 1231 12311692	16-55	17AUG2020	52205	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311693	C4591001 1231 12311693	16-55	17AUG2020	52214	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311694	C4591001 1231 12311694	16-55	17AUG2020	52271	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311695	C4591001 1231 12311695	16-55	17AUG2020	52270	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311696	C4591001 1231 12311696	16-55	17AUG2020	52274	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311697	C4591001 1231 12311697	16-55	17AUG2020	52280	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12311698	C4591001 1231 12311698	16-55	17AUG2020	52284	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311701	C4591001 1231 12311701	16-55	17AUG2020	52309	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311702	C4591001 1231 12311702	16-55	17AUG2020	52311	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311704	C4591001 1231 12311704	16-55	17AUG2020	52316	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311705	C4591001 1231 12311705	16-55	17AUG2020	52492	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311708	C4591001 1231 12311708	16-55	17AUG2020	52317	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311710	C4591001 1231 12311710	16-55	17AUG2020	52320	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311711	C4591001 1231 12311711	16-55	17AUG2020	52313	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311712	C4591001 1231 12311712	16-55	17AUG2020	52350	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311714	C4591001 1231 12311714	16-55	17AUG2020	52356	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311715	C4591001 1231 12311715	16-55	17AUG2020	52351	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311718	C4591001 1231 12311718	16-55	17AUG2020	52481	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311719	C4591001 1231 12311719	16-55	17AUG2020	52411	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311721	C4591001 1231 12311721	16-55	17AUG2020	52418	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311722	C4591001 1231 12311722	16-55	17AUG2020	52358	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12311724	C4591001 1231 12311724	16-55	17AUG2020	52409	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311726	C4591001 1231 12311726	16-55	17AUG2020	52414	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311730	C4591001 1231 12311730	16-55	17AUG2020	52489	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311731	C4591001 1231 12311731	16-55	17AUG2020	52488	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311733	C4591001 1231 12311733	16-55	17AUG2020	52501	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311734	C4591001 1231 12311734	16-55	17AUG2020	52494	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311735	C4591001 1231 12311735	16-55	17AUG2020	52504	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311736	C4591001 1231 12311736	16-55	17AUG2020	52497	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311738	C4591001 1231 12311738	16-55	17AUG2020	52531	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311740	C4591001 1231 12311740	16-55	17AUG2020	52534	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311746	C4591001 1231 12311746	16-55	17AUG2020	52557	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311747	C4591001 1231 12311747	16-55	17AUG2020	52558	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311748	C4591001 1231 12311748	16-55	17AUG2020	52561	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12311749	C4591001 1231 12311749	16-55	17AUG2020	52540	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311750	C4591001 1231 12311750	16-55	17AUG2020	52539	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311751	C4591001 1231 12311751	16-55	17AUG2020	52556	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311752	C4591001 1231 12311752	16-55	17AUG2020	52610	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311754	C4591001 1231 12311754	16-55	17AUG2020	52630	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311755	C4591001 1231 12311755	16-55	17AUG2020	52607	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311756	C4591001 1231 12311756	16-55	17AUG2020	52605	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311759	C4591001 1231 12311759	16-55	17AUG2020	52633	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311760	C4591001 1231 12311760	16-55	17AUG2020	52608	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311761	C4591001 1231 12311761	16-55	17AUG2020	52625	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311763	C4591001 1231 12311763	16-55	17AUG2020	52636	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311764	C4591001 1231 12311764	16-55	17AUG2020	52642	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311765	C4591001 1231 12311765	16-55	17AUG2020	52648	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311766	C4591001 1231 12311766	16-55	17AUG2020	52647	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311768	C4591001 1231 12311768	16-55	17AUG2020	52645	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311769	C4591001 1231 12311769	16-55	17AUG2020	52798	Placebo	17AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311770	C4591001 1231 12311770	16-55	17AUG2020	52724	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311773	C4591001 1231 12311773	16-55	17AUG2020	52794	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311774	C4591001 1231 12311774	16-55	17AUG2020	52722	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311776	C4591001 1231 12311776	16-55	17AUG2020	52725	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311777	C4591001 1231 12311777	16-55	17AUG2020	52729	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311778	C4591001 1231 12311778	16-55	17AUG2020	52802	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311779	C4591001 1231 12311779	16-55	17AUG2020	52842	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311780	C4591001 1231 12311780	16-55	17AUG2020	52878	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311782	C4591001 1231 12311782	16-55	17AUG2020	52844	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311783	C4591001 1231 12311783	16-55	17AUG2020	52803	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311784	C4591001 1231 12311784	16-55	17AUG2020	52851	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311786	C4591001 1231 12311786	16-55	17AUG2020	52879	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311787	C4591001 1231 12311787	16-55	17AUG2020	52843	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311788	C4591001 1231 12311788	16-55	17AUG2020	52917	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311789	C4591001 1231 12311789	16-55	17AUG2020	52974	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311790	C4591001 1231 12311790	16-55	17AUG2020	52884	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311791	C4591001 1231 12311791	16-55	17AUG2020	52924	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311792	C4591001 1231 12311792	16-55	17AUG2020	52921	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311793	C4591001 1231 12311793	16-55	17AUG2020	52888	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311794	C4591001 1231 12311794	16-55	17AUG2020	52915	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311795	C4591001 1231 12311795	16-55	17AUG2020	52973	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311797	C4591001 1231 12311797	16-55	17AUG2020	53022	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311799	C4591001 1231 12311799	16-55	17AUG2020	52980	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311801	C4591001 1231 12311801	16-55	17AUG2020	52977	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12311802	C4591001 1231 12311802	16-55	17AUG2020	53031	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311804	C4591001 1231 12311804	16-55	17AUG2020	53024	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311807	C4591001 1231 12311807	16-55	17AUG2020	53093	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311809	C4591001 1231 12311809	16-55	17AUG2020	53171	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311811	C4591001 1231 12311811	16-55	17AUG2020	53028	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311812	C4591001 1231 12311812	16-55	17AUG2020	53264	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311813	C4591001 1231 12311813	16-55	17AUG2020	53098	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12311816	C4591001 1231 12311816	16-55	17AUG2020	53095	Placebo	17AUG2020/ Placebo			
12311817	C4591001 1231 12311817	16-55	17AUG2020	53309	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311818	C4591001 1231 12311818	16-55	17AUG2020	53170	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311819	C4591001 1231 12311819	16-55	17AUG2020	53106	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311820	C4591001 1231 12311820	16-55	17AUG2020	53271	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311821	C4591001 1231 12311821	16-55	17AUG2020	53113	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311823	C4591001 1231 12311823	16-55	17AUG2020	53172	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311824	C4591001 1231 12311824	16-55	17AUG2020	53167	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311825	C4591001 1231 12311825	16-55	17AUG2020	53314	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12311827	C4591001 1231 12311827	16-55	17AUG2020	53112	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311828	C4591001 1231 12311828	16-55	17AUG2020	53116	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311829	C4591001 1231 12311829	16-55	17AUG2020	53319	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12311830	C4591001 1231 12311830	16-55	17AUG2020	53258	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311831	C4591001 1231 12311831	16-55	17AUG2020	53266	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311833	C4591001 1231 12311833	16-55	17AUG2020	53267	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311834	C4591001 1231 12311834	16-55	17AUG2020	53315	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311836	C4591001 1231 12311836	16-55	17AUG2020	53260	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311837	C4591001 1231 12311837	16-55	17AUG2020	53323	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311838	C4591001 1231 12311838	16-55	17AUG2020	53322	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311839	C4591001 1231 12311839	16-55	17AUG2020	53332	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311841	C4591001 1231 12311841	16-55	17AUG2020	53249	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311842	C4591001 1231 12311842	16-55	17AUG2020	53329	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311843	C4591001 1231 12311843	16-55	17AUG2020	53378	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311844	C4591001 1231 12311844	16-55	17AUG2020	53369	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311845	C4591001 1231 12311845	16-55	17AUG2020	53259	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311846	C4591001 1231 12311846	16-55	17AUG2020	53379	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311847	C4591001 1231 12311847	16-55	17AUG2020	53380	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311849	C4591001 1231 12311849	16-55	17AUG2020	53421	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12311850	C4591001 1231 12311850	16-55	17AUG2020	53427	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311851	C4591001 1231 12311851	16-55	17AUG2020	53423	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311852	C4591001 1231 12311852	16-55	17AUG2020	53422	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311854	C4591001 1231 12311854	16-55	17AUG2020	53467	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311857	C4591001 1231 12311857	16-55	17AUG2020	53497	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311858	C4591001 1231 12311858	16-55	17AUG2020	53475	Placebo	17AUG2020/ Placebo	16OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311859	C4591001 1231 12311859	16-55	17AUG2020	53476	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311860	C4591001 1231 12311860	16-55	17AUG2020	53469	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311861	C4591001 1231 12311861	16-55	17AUG2020	53498	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311862	C4591001 1231 12311862	16-55	17AUG2020	53495	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo		
12311863	C4591001 1231 12311863	16-55	17AUG2020	53502	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311865	C4591001 1231 12311865	16-55	17AUG2020	53509	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311866	C4591001 1231 12311866	16-55	17AUG2020	53503	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311868	C4591001 1231 12311868	16-55	17AUG2020	53511	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311869	C4591001 1231 12311869	16-55	17AUG2020	53525	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311870	C4591001 1231 12311870	16-55	17AUG2020	53499	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311871	C4591001 1231 12311871	16-55	17AUG2020	53540	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311874	C4591001 1231 12311874	16-55	17AUG2020	53526	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12311875	C4591001 1231 12311875	16-55	17AUG2020	53530	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311876	C4591001 1231 12311876	16-55	17AUG2020	53534	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311877	C4591001 1231 12311877	16-55	17AUG2020	53543	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo		
12311879	C4591001 1231 12311879	16-55	17AUG2020	53544	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311881	C4591001 1231 12311881	16-55	22AUG2020	62127	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12311882	C4591001 1231 12311882	16-55	17AUG2020	53548	Placebo	17AUG2020/ Placebo	07SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311883	C4591001 1231 12311883	16-55	17AUG2020	53693	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311884	C4591001 1231 12311884	16-55	18AUG2020	53704	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311885	C4591001 1231 12311885	16-55	18AUG2020	53803	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311886	C4591001 1231 12311886	16-55	18AUG2020	53703	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311887	C4591001 1231 12311887	16-55	18AUG2020	53698	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311888	C4591001 1231 12311888	16-55	18AUG2020	53804	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311889	C4591001 1231 12311889	16-55	18AUG2020	53830	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311890	C4591001 1231 12311890	16-55	18AUG2020	53870	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311893	C4591001 1231 12311893	16-55	18AUG2020	53849	Placebo	18AUG2020/ Placebo	29SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311894	C4591001 1231 12311894	16-55	18AUG2020	53855	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)			
12311896	C4591001 1231 12311896	16-55	18AUG2020	53854	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311897	C4591001 1231 12311897	16-55	18AUG2020	53865	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311898	C4591001 1231 12311898	16-55	18AUG2020	53868	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311899	C4591001 1231 12311899	16-55	18AUG2020	53826	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12311900	C4591001 1231 12311900	16-55	18AUG2020	53829	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311901	C4591001 1231 12311901	16-55	18AUG2020	53835	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
12311903	C4591001 1231 12311903	16-55	18AUG2020	53809	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311905	C4591001 1231 12311905	16-55	18AUG2020	53863	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12311906	C4591001 1231 12311906	16-55	18AUG2020	54407	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311907	C4591001 1231 12311907	16-55	18AUG2020	53850	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12311908	C4591001 1231 12311908	16-55	18AUG2020	53810	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311911	C4591001 1231 12311911	16-55	18AUG2020	54091	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311913	C4591001 1231 12311913	16-55	18AUG2020	53900	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12311915	C4591001 1231 12311915	16-55	18AUG2020	53897	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311917	C4591001 1231 12311917	16-55	18AUG2020	54056	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311920	C4591001 1231 12311920	16-55	18AUG2020	53906	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311921	C4591001 1231 12311921	16-55	18AUG2020	53908	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311922	C4591001 1231 12311922	16-55	18AUG2020	53977	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311923	C4591001 1231 12311923	16-55	18AUG2020	53980	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311924	C4591001 1231 12311924	16-55	18AUG2020	53972	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12311926	C4591001 1231 12311926	16-55	18AUG2020	54038	Placebo				
12311928	C4591001 1231 12311928	16-55	18AUG2020	54053	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311929	C4591001 1231 12311929	16-55	18AUG2020	54094	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12311930	C4591001 1231 12311930	16-55	18AUG2020	54032	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311932	C4591001 1231 12311932	16-55	18AUG2020	54097	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311934	C4591001 1231 12311934	16-55	18AUG2020	53975	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12311938	C4591001 1231 12311938	16-55	18AUG2020	54125	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311939	C4591001 1231 12311939	16-55	18AUG2020	54064	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311940	C4591001 1231 12311940	16-55	18AUG2020	54059	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12311941	C4591001 1231 12311941	16-55	18AUG2020	54034	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311942	C4591001 1231 12311942	16-55	18AUG2020	54036	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311944	C4591001 1231 12311944	16-55	18AUG2020	54129	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311945	C4591001 1231 12311945	16-55	18AUG2020	54126	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311947	C4591001 1231 12311947	16-55	18AUG2020	54131	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311949	C4591001 1231 12311949	16-55	18AUG2020	54348	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311950	C4591001 1231 12311950	16-55	18AUG2020	54177	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12311951	C4591001 1231 12311951	16-55	18AUG2020	54175	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311952	C4591001 1231 12311952	16-55	18AUG2020	54184	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311954	C4591001 1231 12311954	16-55	18AUG2020	54179	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311955	C4591001 1231 12311955	16-55	18AUG2020	54210	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12311957	C4591001 1231 12311957	16-55	18AUG2020	54209	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311958	C4591001 1231 12311958	16-55	18AUG2020	54212	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311961	C4591001 1231 12311961	16-55	18AUG2020	54213	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311962	C4591001 1231 12311962	16-55	18AUG2020	54269	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311964	C4591001 1231 12311964	16-55	18AUG2020	54304	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311965	C4591001 1231 12311965	16-55	18AUG2020	54454	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12311967	C4591001 1231 12311967	16-55	18AUG2020	54317	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311968	C4591001 1231 12311968	16-55	18AUG2020	54297	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311969	C4591001 1231 12311969	16-55	18AUG2020	54302	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12311971	C4591001 1231 12311971	16-55	18AUG2020	54328	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311972	C4591001 1231 12311972	16-55	18AUG2020	54322	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311973	C4591001 1231 12311973	16-55	18AUG2020	54294	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311974	C4591001 1231 12311974	16-55	18AUG2020	54377	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12311975	C4591001 1231 12311975	16-55	18AUG2020	54439	Placebo	18AUG2020/ Placebo	18SEP2020/ Placebo		
12311976	C4591001 1231 12311976	16-55	18AUG2020	54350	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311980	C4591001 1231 12311980	16-55	18AUG2020	54319	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12311981	C4591001 1231 12311981	16-55	18AUG2020	54401	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311982	C4591001 1231 12311982	16-55	18AUG2020	54345	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12311983	C4591001 1231 12311983	16-55	18AUG2020	54346	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12311984	C4591001 1231 12311984	16-55	18AUG2020	54453	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12311985	C4591001 1231 12311985	16-55	18AUG2020	54386	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12311986	C4591001 1231 12311986	16-55	18AUG2020	54402	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12311989	C4591001 1231 12311989	16-55	18AUG2020	54405	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311990	C4591001 1231 12311990	16-55	18AUG2020	54388	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12311991	C4591001 1231 12311991	16-55	18AUG2020	54384	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)			
12311994	C4591001 1231 12311994	16-55	18AUG2020	54441	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12311996	C4591001 1231 12311996	16-55	18AUG2020	54448	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo		
12311997	C4591001 1231 12311997	16-55	18AUG2020	54447	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12311998	C4591001 1231 12311998	16-55	18AUG2020	54485	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12312001	C4591001 1231 12312001	16-55	18AUG2020	54457	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312002	C4591001 1231 12312002	16-55	18AUG2020	54456	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312004	C4591001 1231 12312004	16-55	18AUG2020	54521	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312005	C4591001 1231 12312005	16-55	18AUG2020	54490	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312007	C4591001 1231 12312007	16-55	18AUG2020	54530	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312008	C4591001 1231 12312008	16-55	18AUG2020	54496	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312009	C4591001 1231 12312009	16-55	18AUG2020	54492	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312010	C4591001 1231 12312010	16-55	18AUG2020	54522	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312011	C4591001 1231 12312011	16-55	18AUG2020	54523	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312013	C4591001 1231 12312013	16-55	18AUG2020	54587	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312015	C4591001 1231 12312015	16-55	18AUG2020	54567	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312019	C4591001 1231 12312019	16-55	18AUG2020	54557	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312020	C4591001 1231 12312020	16-55	18AUG2020	54590	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312021	C4591001 1231 12312021	16-55	18AUG2020	54582	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312022	C4591001 1231 12312022	16-55	18AUG2020	54704	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312024	C4591001 1231 12312024	16-55	18AUG2020	54561	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312027	C4591001 1231 12312027	16-55	18AUG2020	54568	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312028	C4591001 1231 12312028	16-55	18AUG2020	54728	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312029	C4591001 1231 12312029	16-55	18AUG2020	54708	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312030	C4591001 1231 12312030	16-55	18AUG2020	54584	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312031	C4591001 1231 12312031	16-55	18AUG2020	54725	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312033	C4591001 1231 12312033	16-55	18AUG2020	54703	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312034	C4591001 1231 12312034	16-55	18AUG2020	54711	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312035	C4591001 1231 12312035	16-55	18AUG2020	54734	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312036	C4591001 1231 12312036	16-55	18AUG2020	54731	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312037	C4591001 1231 12312037	16-55	18AUG2020	54812	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12312038	C4591001 1231 12312038	16-55	18AUG2020	54811	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312039	C4591001 1231 12312039	16-55	18AUG2020	54813	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312041	C4591001 1231 12312041	16-55	18AUG2020	54943	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo		
12312042	C4591001 1231 12312042	16-55	18AUG2020	54817	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312043	C4591001 1231 12312043	16-55	18AUG2020	55145	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312044	C4591001 1231 12312044	16-55	18AUG2020	55104	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312045	C4591001 1231 12312045	16-55	18AUG2020	55043	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312046	C4591001 1231 12312046	16-55	18AUG2020	55022	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312048	C4591001 1231 12312048	16-55	18AUG2020	55014	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312049	C4591001 1231 12312049	16-55	18AUG2020	54944	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312050	C4591001 1231 12312050	16-55	18AUG2020	54951	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo		
12312051	C4591001 1231 12312051	16-55	18AUG2020	55037	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312052	C4591001 1231 12312052	16-55	18AUG2020	55244	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12312053	C4591001 1231 12312053	16-55	18AUG2020	54948	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312055	C4591001 1231 12312055	16-55	18AUG2020	55019	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312056	C4591001 1231 12312056	16-55	18AUG2020	55108	Placebo	18AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312059	C4591001 1231 12312059	16-55	18AUG2020	55021	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312061	C4591001 1231 12312061	16-55	18AUG2020	55047	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312063	C4591001 1231 12312063	16-55	18AUG2020	55101	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312064	C4591001 1231 12312064	16-55	18AUG2020	55038	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312065	C4591001 1231 12312065	16-55	18AUG2020	55188	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312066	C4591001 1231 12312066	16-55	18AUG2020	55149	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312067	C4591001 1231 12312067	16-55	18AUG2020	55245	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312068	C4591001 1231 12312068	16-55	18AUG2020	55150	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312069	C4591001 1231 12312069	16-55	18AUG2020	55103	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12312071	C4591001 1231 12312071	16-55	18AUG2020	55152	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12312074	C4591001 1231 12312074	16-55	18AUG2020	55171	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312075	C4591001 1231 12312075	16-55	18AUG2020	55185	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312076	C4591001 1231 12312076	16-55	18AUG2020	55172	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312077	C4591001 1231 12312077	16-55	18AUG2020	55169	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12312078	C4591001 1231 12312078	16-55	18AUG2020	55176	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12312079	C4591001 1231 12312079	16-55	18AUG2020	55204	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312080	C4591001 1231 12312080	16-55	18AUG2020	55186	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312086	C4591001 1231 12312086	16-55	18AUG2020	55190	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312087	C4591001 1231 12312087	16-55	18AUG2020	55237	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312088	C4591001 1231 12312088	16-55	18AUG2020	55195	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312089	C4591001 1231 12312089	16-55	18AUG2020	55193	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312090	C4591001 1231 12312090	16-55	18AUG2020	55197	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312093	C4591001 1231 12312093	16-55	18AUG2020	55281	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312094	C4591001 1231 12312094	16-55	18AUG2020	55229	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312095	C4591001 1231 12312095	16-55	18AUG2020	55287	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312096	C4591001 1231 12312096	16-55	18AUG2020	55233	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312097	C4591001 1231 12312097	16-55	18AUG2020	55286	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312101	C4591001 1231 12312101	16-55	18AUG2020	55235	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312102	C4591001 1231 12312102	16-55	18AUG2020	55252	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312103	C4591001 1231 12312103	16-55	18AUG2020	55241	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312105	C4591001 1231 12312105	16-55	18AUG2020	55355	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312107	C4591001 1231 12312107	16-55	18AUG2020	55360	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312109	C4591001 1231 12312109	16-55	18AUG2020	55349	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312110	C4591001 1231 12312110	16-55	18AUG2020	55401	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312111	C4591001 1231 12312111	16-55	18AUG2020	55397	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312113	C4591001 1231 12312113	16-55	18AUG2020	55352	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312116	C4591001 1231 12312116	16-55	18AUG2020	55419	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312117	C4591001 1231 12312117	16-55	18AUG2020	55404	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312118	C4591001 1231 12312118	16-55	18AUG2020	55424	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312119	C4591001 1231 12312119	16-55	18AUG2020	55405	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo		
12312120	C4591001 1231 12312120	16-55	18AUG2020	55426	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312121	C4591001 1231 12312121	16-55	18AUG2020	55409	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312124	C4591001 1231 12312124	16-55	18AUG2020	55461	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312125	C4591001 1231 12312125	16-55	18AUG2020	55410	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312126	C4591001 1231 12312126	16-55	18AUG2020	55462	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312127	C4591001 1231 12312127	16-55	18AUG2020	55414	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312128	C4591001 1231 12312128	16-55	18AUG2020	55463	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312129	C4591001 1231 12312129	16-55	18AUG2020	55425	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312132	C4591001 1231 12312132	16-55	18AUG2020	55502	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12312133	C4591001 1231 12312133	16-55	18AUG2020	55429	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312134	C4591001 1231 12312134	16-55	18AUG2020	55537	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312135	C4591001 1231 12312135	16-55	18AUG2020	55460	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312136	C4591001 1231 12312136	16-55	18AUG2020	55498	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312137	C4591001 1231 12312137	16-55	18AUG2020	55542	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312138	C4591001 1231 12312138	16-55	18AUG2020	55531	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312139	C4591001 1231 12312139	16-55	18AUG2020	55495	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312140	C4591001 1231 12312140	16-55	18AUG2020	55517	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312141	C4591001 1231 12312141	16-55	18AUG2020	55529	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312142	C4591001 1231 12312142	16-55	18AUG2020	55526	Placebo	18AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312149	C4591001 1231 12312149	16-55	18AUG2020	55520	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312150	C4591001 1231 12312150	16-55	18AUG2020	55543	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312152	C4591001 1231 12312152	16-55	18AUG2020	55550	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12312153	C4591001 1231 12312153	16-55	18AUG2020	55534	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312154	C4591001 1231 12312154	16-55	18AUG2020	55581	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312155	C4591001 1231 12312155	16-55	18AUG2020	55524	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312157	C4591001 1231 12312157	16-55	18AUG2020	55504	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312159	C4591001 1231 12312159	16-55	18AUG2020	55582	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312160	C4591001 1231 12312160	16-55	18AUG2020	55602	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312164	C4591001 1231 12312164	16-55	18AUG2020	55606	Placebo	18AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312165	C4591001 1231 12312165	16-55	18AUG2020	55578	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312166	C4591001 1231 12312166	16-55	18AUG2020	55541	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312167	C4591001 1231 12312167	16-55	18AUG2020	55580	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312168	C4591001 1231 12312168	16-55	18AUG2020	55605	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312169	C4591001 1231 12312169	16-55	19AUG2020	55721	Placebo	19AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312170	C4591001 1231 12312170	16-55	19AUG2020	55695	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312171	C4591001 1231 12312171	16-55	19AUG2020	55739	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312172	C4591001 1231 12312172	16-55	19AUG2020	55753	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312173	C4591001 1231 12312173	16-55	19AUG2020	55668	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312174	C4591001 1231 12312174	16-55	19AUG2020	55667	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312175	C4591001 1231 12312175	16-55	19AUG2020	55713	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312176	C4591001 1231 12312176	16-55	19AUG2020	55781	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312177	C4591001 1231 12312177	16-55	19AUG2020	55669	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312179	C4591001 1231 12312179	16-55	19AUG2020	55611	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312180	C4591001 1231 12312180	16-55	19AUG2020	55751	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312183	C4591001 1231 12312183	16-55	19AUG2020	55741	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312184	C4591001 1231 12312184	16-55	19AUG2020	55671	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312185	C4591001 1231 12312185	16-55	19AUG2020	55724	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312186	C4591001 1231 12312186	16-55	19AUG2020	55717	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
12312187	C4591001 1231 12312187	16-55	19AUG2020	55710	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312188	C4591001 1231 12312188	16-55	19AUG2020	55687	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312190	C4591001 1231 12312190	16-55	19AUG2020	55743	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312191	C4591001 1231 12312191	16-55	19AUG2020	55756	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312192	C4591001 1231 12312192	16-55	19AUG2020	55723	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312193	C4591001 1231 12312193	16-55	19AUG2020	55749	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312194	C4591001 1231 12312194	16-55	19AUG2020	55691	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312195	C4591001 1231 12312195	16-55	19AUG2020	55760	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312196	C4591001 1231 12312196	16-55	19AUG2020	55722	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312198	C4591001 1231 12312198	16-55	19AUG2020	55688	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312200	C4591001 1231 12312200	16-55	19AUG2020	55738	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312202	C4591001 1231 12312202	16-55	19AUG2020	55758	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312203	C4591001 1231 12312203	16-55	19AUG2020	55709	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312204	C4591001 1231 12312204	16-55	19AUG2020	55763	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312205	C4591001 1231 12312205	16-55	19AUG2020	55766	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312210	C4591001 1231 12312210	16-55	19AUG2020	55785	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312211	C4591001 1231 12312211	16-55	19AUG2020	55786	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312212	C4591001 1231 12312212	16-55	19AUG2020	55792	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312213	C4591001 1231 12312213	16-55	19AUG2020	55890	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312214	C4591001 1231 12312214	16-55	19AUG2020	55895	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312216	C4591001 1231 12312216	16-55	19AUG2020	55942	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312218	C4591001 1231 12312218	16-55	19AUG2020	55892	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312219	C4591001 1231 12312219	16-55	19AUG2020	55937	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312221	C4591001 1231 12312221	16-55	19AUG2020	55979	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312224	C4591001 1231 12312224	16-55	19AUG2020	55948	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312225	C4591001 1231 12312225	16-55	19AUG2020	55975	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312226	C4591001 1231 12312226	16-55	19AUG2020	55946	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312227	C4591001 1231 12312227	16-55	19AUG2020	55977	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312228	C4591001 1231 12312228	16-55	19AUG2020	55984	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312236	C4591001 1231 12312236	16-55	19AUG2020	56015	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
12312239	C4591001 1231 12312239	16-55	19AUG2020	56010	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312242	C4591001 1231 12312242	16-55	19AUG2020	56013	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312243	C4591001 1231 12312243	16-55	19AUG2020	56020	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312244	C4591001 1231 12312244	16-55	19AUG2020	56093	Placebo	19AUG2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
12312245	C4591001 1231 12312245	16-55	19AUG2020	56177	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312247	C4591001 1231 12312247	16-55	19AUG2020	56094	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312249	C4591001 1231 12312249	16-55	19AUG2020	56101	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312251	C4591001 1231 12312251	16-55	19AUG2020	56184	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312252	C4591001 1231 12312252	16-55	19AUG2020	57108	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312254	C4591001 1231 12312254	16-55	19AUG2020	56102	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312255	C4591001 1231 12312255	16-55	19AUG2020	56182	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312257	C4591001 1231 12312257	16-55	19AUG2020	56396	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312258	C4591001 1231 12312258	16-55	19AUG2020	56258	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312259	C4591001 1231 12312259	16-55	19AUG2020	56253	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312260	C4591001 1231 12312260	16-55	19AUG2020	56304	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312263	C4591001 1231 12312263	16-55	19AUG2020	56249	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312264	C4591001 1231 12312264	16-55	19AUG2020	56186	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312266	C4591001 1231 12312266	16-55	19AUG2020	56259	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312267	C4591001 1231 12312267	16-55	19AUG2020	56300	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312268	C4591001 1231 12312268	16-55	19AUG2020	56301	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312269	C4591001 1231 12312269	16-55	19AUG2020	56418	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312270	C4591001 1231 12312270	16-55	19AUG2020	56394	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312271	C4591001 1231 12312271	16-55	19AUG2020	56425	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312272	C4591001 1231 12312272	16-55	19AUG2020	56402	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312274	C4591001 1231 12312274	16-55	19AUG2020	56397	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312275	C4591001 1231 12312275	16-55	19AUG2020	56307	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312276	C4591001 1231 12312276	16-55	19AUG2020	56861	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312281	C4591001 1231 12312281	16-55	19AUG2020	56426	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312282	C4591001 1231 12312282	16-55	19AUG2020	56534	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312283	C4591001 1231 12312283	16-55	19AUG2020	56571	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312284	C4591001 1231 12312284	16-55	19AUG2020	56502	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312286	C4591001 1231 12312286	16-55	19AUG2020	56508	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312287	C4591001 1231 12312287	16-55	19AUG2020	56512	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312288	C4591001 1231 12312288	16-55	19AUG2020	56427	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312289	C4591001 1231 12312289	16-55	19AUG2020	56528	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312291	C4591001 1231 12312291	16-55	19AUG2020	56567	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312292	C4591001 1231 12312292	16-55	19AUG2020	56527	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312295	C4591001 1231 12312295	16-55	19AUG2020	56546	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312296	C4591001 1231 12312296	16-55	19AUG2020	56509	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312297	C4591001 1231 12312297	16-55	19AUG2020	56536	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312298	C4591001 1231 12312298	16-55	19AUG2020	56539	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312299	C4591001 1231 12312299	16-55	19AUG2020	56544	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12312300	C4591001 1231 12312300	16-55	19AUG2020	56611	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312302	C4591001 1231 12312302	16-55	19AUG2020	56572	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312303	C4591001 1231 12312303	16-55	19AUG2020	56545	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312304	C4591001 1231 12312304	16-55	19AUG2020	56617	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312305	C4591001 1231 12312305	16-55	19AUG2020	56564	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312306	C4591001 1231 12312306	16-55	19AUG2020	56632	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312307	C4591001 1231 12312307	16-55	19AUG2020	56613	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312308	C4591001 1231 12312308	16-55	19AUG2020	56650	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312309	C4591001 1231 12312309	16-55	19AUG2020	56630	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312310	C4591001 1231 12312310	16-55	19AUG2020	56612	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312311	C4591001 1231 12312311	16-55	19AUG2020	56621	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312312	C4591001 1231 12312312	16-55	19AUG2020	56628	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312313	C4591001 1231 12312313	16-55	19AUG2020	56686	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312315	C4591001 1231 12312315	16-55	19AUG2020	56760	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312316	C4591001 1231 12312316	16-55	19AUG2020	56687	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312317	C4591001 1231 12312317	16-55	19AUG2020	56651	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312319	C4591001 1231 12312319	16-55	19AUG2020	56646	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312320	C4591001 1231 12312320	16-55	19AUG2020	56706	Placebo	19AUG2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
12312321	C4591001 1231 12312321	16-55	19AUG2020	56653	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312323	C4591001 1231 12312323	16-55	19AUG2020	56689	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312324	C4591001 1231 12312324	16-55	19AUG2020	56707	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312326	C4591001 1231 12312326	16-55	19AUG2020	56711	Placebo	19AUG2020/ Placebo		03MAR2021/ BNT162b2 (30 µg)	
12312327	C4591001 1231 12312327	16-55	19AUG2020	56692	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312329	C4591001 1231 12312329	16-55	19AUG2020	56705	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312330	C4591001 1231 12312330	16-55	19AUG2020	56763	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
12312331	C4591001 1231 12312331	16-55	19AUG2020	56759	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312333	C4591001 1231 12312333	16-55	19AUG2020	56761	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312334	C4591001 1231 12312334	16-55	19AUG2020	57196	Placebo	19AUG2020/ Placebo			
12312335	C4591001 1231 12312335	16-55	19AUG2020	57234	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312336	C4591001 1231 12312336	16-55	19AUG2020	57235	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312338	C4591001 1231 12312338	16-55	19AUG2020	57243	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312339	C4591001 1231 12312339	16-55	19AUG2020	56887	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312340	C4591001 1231 12312340	16-55	19AUG2020	56866	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312341	C4591001 1231 12312341	16-55	19AUG2020	56862	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312342	C4591001 1231 12312342	16-55	19AUG2020	56865	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312343	C4591001 1231 12312343	16-55	19AUG2020	57242	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312344	C4591001 1231 12312344	16-55	19AUG2020	56889	Placebo	19AUG2020/ Placebo	24SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312346	C4591001 1231 12312346	16-55	19AUG2020	57282	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312348	C4591001 1231 12312348	16-55	19AUG2020	56925	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312349	C4591001 1231 12312349	16-55	19AUG2020	56886	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312350	C4591001 1231 12312350	16-55	19AUG2020	56958	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312351	C4591001 1231 12312351	16-55	19AUG2020	56921	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo		
12312352	C4591001 1231 12312352	16-55	19AUG2020	56894	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312355	C4591001 1231 12312355	16-55	19AUG2020	56922	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312356	C4591001 1231 12312356	16-55	19AUG2020	56964	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312357	C4591001 1231 12312357	16-55	19AUG2020	57309	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312358	C4591001 1231 12312358	16-55	19AUG2020	57285	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312359	C4591001 1231 12312359	16-55	19AUG2020	56928	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312360	C4591001 1231 12312360	16-55	19AUG2020	56996	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312361	C4591001 1231 12312361	16-55	19AUG2020	56968	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312362	C4591001 1231 12312362	16-55	19AUG2020	57307	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312363	C4591001 1231 12312363	16-55	19AUG2020	56963	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312364	C4591001 1231 12312364	16-55	19AUG2020	57002	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312365	C4591001 1231 12312365	16-55	19AUG2020	57055	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312366	C4591001 1231 12312366	16-55	19AUG2020	57004	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312367	C4591001 1231 12312367	16-55	19AUG2020	56998	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312368	C4591001 1231 12312368	16-55	19AUG2020	57059	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312369	C4591001 1231 12312369	16-55	19AUG2020	57056	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312370	C4591001 1231 12312370	16-55	19AUG2020	57111	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312371	C4591001 1231 12312371	16-55	19AUG2020	57107	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312372	C4591001 1231 12312372	16-55	19AUG2020	57125	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312373	C4591001 1231 12312373	16-55	19AUG2020	57058	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12312374	C4591001 1231 12312374	16-55	19AUG2020	57310	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312375	C4591001 1231 12312375	16-55	19AUG2020	57192	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312376	C4591001 1231 12312376	16-55	19AUG2020	57128	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312378	C4591001 1231 12312378	16-55	19AUG2020	57467	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312379	C4591001 1231 12312379	16-55	19AUG2020	57109	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312381	C4591001 1231 12312381	16-55	19AUG2020	57189	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312382	C4591001 1231 12312382	16-55	19AUG2020	57131	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312384	C4591001 1231 12312384	16-55	19AUG2020	57134	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312385	C4591001 1231 12312385	16-55	19AUG2020	57313	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312388	C4591001 1231 12312388	16-55	19AUG2020	57187	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312390	C4591001 1231 12312390	16-55	19AUG2020	57348	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312391	C4591001 1231 12312391	16-55	19AUG2020	57281	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312394	C4591001 1231 12312394	16-55	19AUG2020	57349	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312395	C4591001 1231 12312395	16-55	19AUG2020	57286	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312396	C4591001 1231 12312396	16-55	19AUG2020	57407	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312397	C4591001 1231 12312397	16-55	19AUG2020	57469	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312398	C4591001 1231 12312398	16-55	19AUG2020	57352	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312399	C4591001 1231 12312399	16-55	19AUG2020	57443	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312400	C4591001 1231 12312400	16-55	19AUG2020	57461	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312401	C4591001 1231 12312401	16-55	19AUG2020	57345	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312402	C4591001 1231 12312402	16-55	19AUG2020	57386	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312403	C4591001 1231 12312403	16-55	19AUG2020	57379	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)			
12312405	C4591001 1231 12312405	16-55	19AUG2020	57381	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312406	C4591001 1231 12312406	16-55	19AUG2020	57537	Placebo	19AUG2020/ Placebo	07SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312407	C4591001 1231 12312407	16-55	19AUG2020	57402	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312408	C4591001 1231 12312408	16-55	19AUG2020	57439	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312409	C4591001 1231 12312409	16-55	19AUG2020	57401	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312410	C4591001 1231 12312410	16-55	19AUG2020	57533	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312411	C4591001 1231 12312411	16-55	19AUG2020	57410	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312412	C4591001 1231 12312412	16-55	19AUG2020	57388	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312413	C4591001 1231 12312413	16-55	19AUG2020	57442	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312414	C4591001 1231 12312414	16-55	19AUG2020	57542	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312415	C4591001 1231 12312415	16-55	19AUG2020	57546	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312417	C4591001 1231 12312417	16-55	19AUG2020	57445	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)		
12312418	C4591001 1231 12312418	16-55	19AUG2020	57552	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312419	C4591001 1231 12312419	16-55	19AUG2020	57541	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312420	C4591001 1231 12312420	16-55	19AUG2020	57581	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312421	C4591001 1231 12312421	16-55	19AUG2020	57470	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312422	C4591001 1231 12312422	16-55	19AUG2020	57582	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312424	C4591001 1231 12312424	16-55	19AUG2020	57593	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312425	C4591001 1231 12312425	16-55	19AUG2020	57591	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312426	C4591001 1231 12312426	16-55	19AUG2020	57595	Placebo	19AUG2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312427	C4591001 1231 12312427	16-55	19AUG2020	57550	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312428	C4591001 1231 12312428	16-55	19AUG2020	57598	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312429	C4591001 1231 12312429	16-55	19AUG2020	57556	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312430	C4591001 1231 12312430	16-55	19AUG2020	57625	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312433	C4591001 1231 12312433	16-55	19AUG2020	57586	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312434	C4591001 1231 12312434	16-55	19AUG2020	57631	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312435	C4591001 1231 12312435	16-55	19AUG2020	57594	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312436	C4591001 1231 12312436	16-55	19AUG2020	57633	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312438	C4591001 1231 12312438	16-55	19AUG2020	57636	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312439	C4591001 1231 12312439	16-55	19AUG2020	57621	Placebo	19AUG2020/ Placebo	02OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12312441	C4591001 1231 12312441	16-55	19AUG2020	57628	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312442	C4591001 1231 12312442	16-55	19AUG2020	57640	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312443	C4591001 1231 12312443	16-55	20AUG2020	57777	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312444	C4591001 1231 12312444	16-55	20AUG2020	57795	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312445	C4591001 1231 12312445	16-55	20AUG2020	57774	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312447	C4591001 1231 12312447	16-55	20AUG2020	57783	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312448	C4591001 1231 12312448	16-55	20AUG2020	57782	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312449	C4591001 1231 12312449	16-55	20AUG2020	57785	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312451	C4591001 1231 12312451	16-55	20AUG2020	57793	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
12312452	C4591001 1231 12312452	16-55	20AUG2020	57820	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312454	C4591001 1231 12312454	16-55	20AUG2020	57826	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12312455	C4591001 1231 12312455	16-55	20AUG2020	57810	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312456	C4591001 1231 12312456	16-55	20AUG2020	57816	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312457	C4591001 1231 12312457	16-55	20AUG2020	57852	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312460	C4591001 1231 12312460	16-55	20AUG2020	57796	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312461	C4591001 1231 12312461	16-55	20AUG2020	57823	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312462	C4591001 1231 12312462	16-55	20AUG2020	57849	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312464	C4591001 1231 12312464	16-55	20AUG2020	57884	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312466	C4591001 1231 12312466	16-55	20AUG2020	57831	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312467	C4591001 1231 12312467	16-55	20AUG2020	57922	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312468	C4591001 1231 12312468	16-55	20AUG2020	57888	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312469	C4591001 1231 12312469	16-55	20AUG2020	57846	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312471	C4591001 1231 12312471	16-55	20AUG2020	57817	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312472	C4591001 1231 12312472	16-55	20AUG2020	57919	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312473	C4591001 1231 12312473	16-55	20AUG2020	57828	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312474	C4591001 1231 12312474	16-55	20AUG2020	57928	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312475	C4591001 1231 12312475	16-55	20AUG2020	57856	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312476	C4591001 1231 12312476	16-55	20AUG2020	57930	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312477	C4591001 1231 12312477	16-55	20AUG2020	57887	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312478	C4591001 1231 12312478	16-55	20AUG2020	57886	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312479	C4591001 1231 12312479	16-55	20AUG2020	57917	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312481	C4591001 1231 12312481	16-55	20AUG2020	57931	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312482	C4591001 1231 12312482	16-55	20AUG2020	57933	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312483	C4591001 1231 12312483	16-55	20AUG2020	57940	Placebo				
12312486	C4591001 1231 12312486	16-55	20AUG2020	57977	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312487	C4591001 1231 12312487	16-55	20AUG2020	58130	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312488	C4591001 1231 12312488	16-55	20AUG2020	57978	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312491	C4591001 1231 12312491	16-55	20AUG2020	58038	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12312493	C4591001 1231 12312493	16-55	20AUG2020	58037	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312494	C4591001 1231 12312494	16-55	20AUG2020	57986	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312499	C4591001 1231 12312499	16-55	20AUG2020	57988	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312500	C4591001 1231 12312500	16-55	20AUG2020	58121	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312501	C4591001 1231 12312501	16-55	20AUG2020	58127	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312502	C4591001 1231 12312502	16-55	20AUG2020	58042	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312503	C4591001 1231 12312503	16-55	20AUG2020	58160	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312506	C4591001 1231 12312506	16-55	20AUG2020	58131	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312507	C4591001 1231 12312507	16-55	20AUG2020	58134	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312509	C4591001 1231 12312509	16-55	20AUG2020	58044	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312510	C4591001 1231 12312510	16-55	20AUG2020	58163	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312512	C4591001 1231 12312512	16-55	20AUG2020	58133	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312513	C4591001 1231 12312513	16-55	20AUG2020	58144	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312514	C4591001 1231 12312514	16-55	20AUG2020	58189	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312516	C4591001 1231 12312516	16-55	20AUG2020	58241	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312517	C4591001 1231 12312517	16-55	20AUG2020	58187	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312518	C4591001 1231 12312518	16-55	20AUG2020	58139	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312519	C4591001 1231 12312519	16-55	20AUG2020	58165	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312520	C4591001 1231 12312520	16-55	20AUG2020	58157	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312521	C4591001 1231 12312521	16-55	20AUG2020	58192	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312522	C4591001 1231 12312522	16-55	20AUG2020	58182	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312523	C4591001 1231 12312523	16-55	20AUG2020	58244	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312524	C4591001 1231 12312524	16-55	20AUG2020	58251	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312525	C4591001 1231 12312525	16-55	20AUG2020	58359	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312528	C4591001 1231 12312528	16-55	20AUG2020	58357	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
12312529	C4591001 1231 12312529	16-55	20AUG2020	58350	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
12312531	C4591001 1231 12312531	16-55	20AUG2020	58252	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312532	C4591001 1231 12312532	16-55	20AUG2020	58356	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312533	C4591001 1231 12312533	16-55	20AUG2020	58415	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312536	C4591001 1231 12312536	16-55	20AUG2020	58418	Placebo	20AUG2020/ Placebo	22SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312537	C4591001 1231 12312537	16-55	20AUG2020	58416	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312538	C4591001 1231 12312538	16-55	20AUG2020	58413	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312539	C4591001 1231 12312539	16-55	20AUG2020	58424	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312540	C4591001 1231 12312540	16-55	20AUG2020	58458	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312542	C4591001 1231 12312542	16-55	20AUG2020	58426	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312543	C4591001 1231 12312543	16-55	20AUG2020	58493	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312544	C4591001 1231 12312544	16-55	20AUG2020	58464	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312545	C4591001 1231 12312545	16-55	20AUG2020	58467	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312546	C4591001 1231 12312546	16-55	20AUG2020	58457	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312547	C4591001 1231 12312547	16-55	20AUG2020	58429	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312548	C4591001 1231 12312548	16-55	20AUG2020	58608	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12312550	C4591001 1231 12312550	16-55	20AUG2020	58533	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312552	C4591001 1231 12312552	16-55	20AUG2020	58529	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312553	C4591001 1231 12312553	16-55	20AUG2020	58601	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312554	C4591001 1231 12312554	16-55	20AUG2020	58431	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312557	C4591001 1231 12312557	16-55	20AUG2020	58502	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312559	C4591001 1231 12312559	16-55	20AUG2020	58497	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
12312560	C4591001 1231 12312560	16-55	20AUG2020	58499	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312561	C4591001 1231 12312561	16-55	20AUG2020	58532	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312562	C4591001 1231 12312562	16-55	20AUG2020	58534	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312563	C4591001 1231 12312563	16-55	20AUG2020	58605	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312566	C4591001 1231 12312566	16-55	20AUG2020	58609	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312570	C4591001 1231 12312570	16-55	20AUG2020	58639	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312572	C4591001 1231 12312572	16-55	20AUG2020	58637	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312573	C4591001 1231 12312573	16-55	20AUG2020	59047	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312575	C4591001 1231 12312575	16-55	20AUG2020	58769	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312576	C4591001 1231 12312576	16-55	20AUG2020	58723	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312577	C4591001 1231 12312577	16-55	20AUG2020	58799	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)			
12312578	C4591001 1231 12312578	16-55	20AUG2020	58725	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312580	C4591001 1231 12312580	16-55	20AUG2020	58804	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312581	C4591001 1231 12312581	16-55	20AUG2020	58724	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312582	C4591001 1231 12312582	16-55	20AUG2020	58771	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312583	C4591001 1231 12312583	16-55	20AUG2020	58638	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312584	C4591001 1231 12312584	16-55	20AUG2020	58728	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312585	C4591001 1231 12312585	16-55	20AUG2020	58798	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12312587	C4591001 1231 12312587	16-55	20AUG2020	58640	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312588	C4591001 1231 12312588	16-55	20AUG2020	58870	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312589	C4591001 1231 12312589	16-55	20AUG2020	58866	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312591	C4591001 1231 12312591	16-55	20AUG2020	58775	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312592	C4591001 1231 12312592	16-55	20AUG2020	58871	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312593	C4591001 1231 12312593	16-55	20AUG2020	58869	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312594	C4591001 1231 12312594	16-55	20AUG2020	58938	Placebo	20AUG2020/ Placebo			
12312596	C4591001 1231 12312596	16-55	20AUG2020	58803	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312597	C4591001 1231 12312597	16-55	20AUG2020	58937	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312600	C4591001 1231 12312600	16-55	20AUG2020	59028	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312601	C4591001 1231 12312601	16-55	20AUG2020	58947	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312602	C4591001 1231 12312602	16-55	20AUG2020	58779	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312605	C4591001 1231 12312605	16-55	20AUG2020	58948	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312606	C4591001 1231 12312606	16-55	20AUG2020	59054	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312607	C4591001 1231 12312607	16-55	20AUG2020	59021	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312608	C4591001 1231 12312608	16-55	20AUG2020	59134	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312609	C4591001 1231 12312609	16-55	20AUG2020	59024	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312610	C4591001 1231 12312610	16-55	20AUG2020	59056	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312611	C4591001 1231 12312611	16-55	20AUG2020	59030	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312612	C4591001 1231 12312612	16-55	20AUG2020	59067	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312613	C4591001 1231 12312613	16-55	20AUG2020	59055	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312615	C4591001 1231 12312615	16-55	20AUG2020	59060	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312616	C4591001 1231 12312616	16-55	20AUG2020	59138	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312617	C4591001 1231 12312617	16-55	20AUG2020	59179	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312618	C4591001 1231 12312618	16-55	20AUG2020	59082	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312620	C4591001 1231 12312620	16-55	20AUG2020	59108	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312621	C4591001 1231 12312621	16-55	20AUG2020	59105	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12312623	C4591001 1231 12312623	16-55	20AUG2020	59058	Placebo	20AUG2020/ Placebo			
12312626	C4591001 1231 12312626	16-55	20AUG2020	59139	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312627	C4591001 1231 12312627	16-55	20AUG2020	59068	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312628	C4591001 1231 12312628	16-55	20AUG2020	59178	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312629	C4591001 1231 12312629	16-55	20AUG2020	59114	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312630	C4591001 1231 12312630	16-55	20AUG2020	59185	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312632	C4591001 1231 12312632	16-55	20AUG2020	59202	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312633	C4591001 1231 12312633	16-55	20AUG2020	59177	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312634	C4591001 1231 12312634	16-55	20AUG2020	59204	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312636	C4591001 1231 12312636	16-55	20AUG2020	59225	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312638	C4591001 1231 12312638	16-55	20AUG2020	59230	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312639	C4591001 1231 12312639	16-55	20AUG2020	59115	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312640	C4591001 1231 12312640	16-55	20AUG2020	59232	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312641	C4591001 1231 12312641	16-55	20AUG2020	59207	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
12312642	C4591001 1231 12312642	16-55	20AUG2020	59268	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312644	C4591001 1231 12312644	16-55	20AUG2020	59298	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312645	C4591001 1231 12312645	16-55	20AUG2020	59227	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312647	C4591001 1231 12312647	16-55	20AUG2020	59209	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312648	C4591001 1231 12312648	16-55	20AUG2020	59304	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312649	C4591001 1231 12312649	16-55	20AUG2020	59261	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312651	C4591001 1231 12312651	16-55	20AUG2020	59263	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312652	C4591001 1231 12312652	16-55	20AUG2020	59361	Placebo	20AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312653	C4591001 1231 12312653	16-55	20AUG2020	59305	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312654	C4591001 1231 12312654	16-55	20AUG2020	59366	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312655	C4591001 1231 12312655	16-55	20AUG2020	59272	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312656	C4591001 1231 12312656	16-55	20AUG2020	59367	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312658	C4591001 1231 12312658	16-55	20AUG2020	59400	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312659	C4591001 1231 12312659	16-55	20AUG2020	59303	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312660	C4591001 1231 12312660	16-55	20AUG2020	59403	Placebo	20AUG2020/ Placebo		20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312662	C4591001 1231 12312662	16-55	20AUG2020	59422	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312663	C4591001 1231 12312663	16-55	20AUG2020	59397	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312664	C4591001 1231 12312664	16-55	20AUG2020	59426	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312665	C4591001 1231 12312665	16-55	20AUG2020	59468	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312666	C4591001 1231 12312666	16-55	20AUG2020	59427	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312669	C4591001 1231 12312669	16-55	20AUG2020	59471	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312670	C4591001 1231 12312670	16-55	20AUG2020	59475	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312671	C4591001 1231 12312671	16-55	20AUG2020	59402	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312672	C4591001 1231 12312672	16-55	20AUG2020	59526	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312673	C4591001 1231 12312673	16-55	20AUG2020	59360	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312674	C4591001 1231 12312674	16-55	20AUG2020	59527	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
12312675	C4591001 1231 12312675	16-55	20AUG2020	59532	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312676	C4591001 1231 12312676	16-55	20AUG2020	59533	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312677	C4591001 1231 12312677	16-55	20AUG2020	59474	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312678	C4591001 1231 12312678	16-55	20AUG2020	59548	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312679	C4591001 1231 12312679	16-55	20AUG2020	59423	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312680	C4591001 1231 12312680	16-55	20AUG2020	59574	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312681	C4591001 1231 12312681	16-55	20AUG2020	59538	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312683	C4591001 1231 12312683	16-55	20AUG2020	59539	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312684	C4591001 1231 12312684	16-55	20AUG2020	59577	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312685	C4591001 1231 12312685	16-55	20AUG2020	59544	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312686	C4591001 1231 12312686	16-55	20AUG2020	59621	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312687	C4591001 1231 12312687	16-55	20AUG2020	59573	Placebo	20AUG2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312688	C4591001 1231 12312688	16-55	20AUG2020	59622	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312690	C4591001 1231 12312690	16-55	20AUG2020	59627	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312693	C4591001 1231 12312693	16-55	20AUG2020	59575	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12312695	C4591001 1231 12312695	16-55	20AUG2020	59626	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312696	C4591001 1231 12312696	16-55	20AUG2020	59670	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312697	C4591001 1231 12312697	16-55	20AUG2020	59669	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312702	C4591001 1231 12312702	16-55	20AUG2020	59675	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo		
12312704	C4591001 1231 12312704	16-55	20AUG2020	59706	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312705	C4591001 1231 12312705	16-55	20AUG2020	59707	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312708	C4591001 1231 12312708	16-55	20AUG2020	59711	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12312709	C4591001 1231 12312709	16-55	20AUG2020	59680	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312710	C4591001 1231 12312710	16-55	20AUG2020	59732	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312712	C4591001 1231 12312712	16-55	20AUG2020	59735	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312713	C4591001 1231 12312713	16-55	20AUG2020	59712	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo		
12312714	C4591001 1231 12312714	16-55	20AUG2020	59757	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312715	C4591001 1231 12312715	16-55	20AUG2020	59759	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12312716	C4591001 1231 12312716	16-55	20AUG2020	59763	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312717	C4591001 1231 12312717	16-55	20AUG2020	59739	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312718	C4591001 1231 12312718	16-55	20AUG2020	59766	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312719	C4591001 1231 12312719	16-55	20AUG2020	59733	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312720	C4591001 1231 12312720	16-55	20AUG2020	59773	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312721	C4591001 1231 12312721	16-55	20AUG2020	59767	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312723	C4591001 1231 12312723	16-55	20AUG2020	59764	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12312724	C4591001 1231 12312724	16-55	20AUG2020	59802	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo		
12312725	C4591001 1231 12312725	16-55	20AUG2020	59775	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312727	C4591001 1231 12312727	16-55	21AUG2020	59811	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312728	C4591001 1231 12312728	16-55	21AUG2020	59804	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312729	C4591001 1231 12312729	16-55	21AUG2020	59930	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312730	C4591001 1231 12312730	16-55	21AUG2020	59946	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312731	C4591001 1231 12312731	16-55	21AUG2020	59966	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312732	C4591001 1231 12312732	16-55	21AUG2020	59932	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312734	C4591001 1231 12312734	16-55	21AUG2020	59936	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312735	C4591001 1231 12312735	16-55	21AUG2020	59933	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312737	C4591001 1231 12312737	16-55	21AUG2020	59958	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312738	C4591001 1231 12312738	16-55	21AUG2020	59806	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312739	C4591001 1231 12312739	16-55	21AUG2020	59942	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312740	C4591001 1231 12312740	16-55	21AUG2020	59931	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312741	C4591001 1231 12312741	16-55	21AUG2020	59952	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312742	C4591001 1231 12312742	16-55	21AUG2020	59938	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312743	C4591001 1231 12312743	16-55	21AUG2020	59948	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312744	C4591001 1231 12312744	16-55	21AUG2020	59955	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312746	C4591001 1231 12312746	16-55	21AUG2020	59929	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312747	C4591001 1231 12312747	16-55	21AUG2020	59999	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12312748	C4591001 1231 12312748	16-55	21AUG2020	59960	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312750	C4591001 1231 12312750	16-55	21AUG2020	60038	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312751	C4591001 1231 12312751	16-55	21AUG2020	60030	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312752	C4591001 1231 12312752	16-55	21AUG2020	59994	Placebo	21AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12312753	C4591001 1231 12312753	16-55	21AUG2020	60032	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312754	C4591001 1231 12312754	16-55	21AUG2020	59964	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312755	C4591001 1231 12312755	16-55	21AUG2020	60054	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312757	C4591001 1231 12312757	16-55	21AUG2020	60004	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12312759	C4591001 1231 12312759	16-55	21AUG2020	60114	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312760	C4591001 1231 12312760	16-55	21AUG2020	60040	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312761	C4591001 1231 12312761	16-55	21AUG2020	60056	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312762	C4591001 1231 12312762	16-55	21AUG2020	60003	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312763	C4591001 1231 12312763	16-55	21AUG2020	60163	Placebo	21AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12312765	C4591001 1231 12312765	16-55	21AUG2020	60077	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312769	C4591001 1231 12312769	16-55	21AUG2020	60061	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312770	C4591001 1231 12312770	16-55	21AUG2020	60060	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312771	C4591001 1231 12312771	16-55	21AUG2020	60085	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12312772	C4591001 1231 12312772	16-55	21AUG2020	60081	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12312773	C4591001 1231 12312773	16-55	21AUG2020	60080	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312774	C4591001 1231 12312774	16-55	21AUG2020	60113	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312775	C4591001 1231 12312775	16-55	21AUG2020	60172	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12312778	C4591001 1231 12312778	16-55	21AUG2020	60118	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312779	C4591001 1231 12312779	16-55	21AUG2020	60133	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12312785	C4591001 1231 12312785	16-55	21AUG2020	60125	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12312787	C4591001 1231 12312787	16-55	21AUG2020	60186	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312790	C4591001 1231 12312790	16-55	21AUG2020	60185	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312796	C4591001 1231 12312796	16-55	21AUG2020	60124	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312797	C4591001 1231 12312797	16-55	21AUG2020	60189	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12312798	C4591001 1231 12312798	16-55	21AUG2020	60171	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312800	C4591001 1231 12312800	16-55	21AUG2020	60128	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312803	C4591001 1231 12312803	16-55	21AUG2020	60164	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312804	C4591001 1231 12312804	16-55	21AUG2020	60132	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312805	C4591001 1231 12312805	16-55	21AUG2020	60188	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12312807	C4591001 1231 12312807	16-55	21AUG2020	60209	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312810	C4591001 1231 12312810	16-55	21AUG2020	60313	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312811	C4591001 1231 12312811	16-55	21AUG2020	60305	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312812	C4591001 1231 12312812	16-55	21AUG2020	60259	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312813	C4591001 1231 12312813	16-55	21AUG2020	60267	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12312814	C4591001 1231 12312814	16-55	21AUG2020	60216	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312815	C4591001 1231 12312815	16-55	21AUG2020	60215	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312819	C4591001 1231 12312819	16-55	21AUG2020	60309	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312822	C4591001 1231 12312822	16-55	21AUG2020	60214	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312823	C4591001 1231 12312823	16-55	21AUG2020	60258	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312824	C4591001 1231 12312824	16-55	21AUG2020	60268	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312825	C4591001 1231 12312825	16-55	21AUG2020	60343	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312826	C4591001 1231 12312826	16-55	21AUG2020	60315	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312827	C4591001 1231 12312827	16-55	21AUG2020	60344	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312829	C4591001 1231 12312829	16-55	21AUG2020	60345	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312831	C4591001 1231 12312831	16-55	21AUG2020	60425	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312833	C4591001 1231 12312833	16-55	21AUG2020	60348	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312835	C4591001 1231 12312835	16-55	21AUG2020	60389	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12312836	C4591001 1231 12312836	16-55	21AUG2020	60393	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312838	C4591001 1231 12312838	16-55	21AUG2020	60408	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312840	C4591001 1231 12312840	16-55	21AUG2020	60404	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312842	C4591001 1231 12312842	16-55	21AUG2020	60431	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12312844	C4591001 1231 12312844	16-55	21AUG2020	60391	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312845	C4591001 1231 12312845	16-55	21AUG2020	60401	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312846	C4591001 1231 12312846	16-55	21AUG2020	60434	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12312847	C4591001 1231 12312847	16-55	21AUG2020	60478	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312848	C4591001 1231 12312848	16-55	21AUG2020	60397	Placebo	21AUG2020/ Placebo			
12312849	C4591001 1231 12312849	16-55	21AUG2020	60412	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312850	C4591001 1231 12312850	16-55	21AUG2020	60476	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312851	C4591001 1231 12312851	16-55	21AUG2020	60499	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12312852	C4591001 1231 12312852	16-55	21AUG2020	60430	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312853	C4591001 1231 12312853	16-55	21AUG2020	60503	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312854	C4591001 1231 12312854	16-55	21AUG2020	60480	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312856	C4591001 1231 12312856	16-55	21AUG2020	60477	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		
12312857	C4591001 1231 12312857	16-55	21AUG2020	60523	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312858	C4591001 1231 12312858	16-55	21AUG2020	60557	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312859	C4591001 1231 12312859	16-55	21AUG2020	60526	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312860	C4591001 1231 12312860	16-55	21AUG2020	60527	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312861	C4591001 1231 12312861	16-55	21AUG2020	60560	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312862	C4591001 1231 12312862	16-55	21AUG2020	60497	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312864	C4591001 1231 12312864	16-55	21AUG2020	60500	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312865	C4591001 1231 12312865	16-55	21AUG2020	60530	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312867	C4591001 1231 12312867	16-55	21AUG2020	60565	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312868	C4591001 1231 12312868	16-55	21AUG2020	60566	Placebo	21AUG2020/ Placebo	08OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312870	C4591001 1231 12312870	16-55	21AUG2020	60593	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312871	C4591001 1231 12312871	16-55	21AUG2020	60595	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312873	C4591001 1231 12312873	16-55	21AUG2020	60597	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312874	C4591001 1231 12312874	16-55	21AUG2020	60594	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12312875	C4591001 1231 12312875	16-55	21AUG2020	60618	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312876	C4591001 1231 12312876	16-55	21AUG2020	60659	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312877	C4591001 1231 12312877	16-55	21AUG2020	60626	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312879	C4591001 1231 12312879	16-55	21AUG2020	60696	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312880	C4591001 1231 12312880	16-55	21AUG2020	60623	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12312882	C4591001 1231 12312882	16-55	21AUG2020	60619	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312883	C4591001 1231 12312883	16-55	21AUG2020	60719	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312884	C4591001 1231 12312884	16-55	21AUG2020	60691	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312886	C4591001 1231 12312886	16-55	21AUG2020	60661	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312888	C4591001 1231 12312888	16-55	21AUG2020	60663	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12312889	C4591001 1231 12312889	16-55	21AUG2020	60662	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312890	C4591001 1231 12312890	16-55	21AUG2020	60752	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312891	C4591001 1231 12312891	16-55	21AUG2020	60723	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312892	C4591001 1231 12312892	16-55	21AUG2020	60689	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312894	C4591001 1231 12312894	16-55	21AUG2020	60713	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312895	C4591001 1231 12312895	16-55	21AUG2020	60749	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312896	C4591001 1231 12312896	16-55	21AUG2020	60694	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12312897	C4591001 1231 12312897	16-55	21AUG2020	60756	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312899	C4591001 1231 12312899	16-55	21AUG2020	60721	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312900	C4591001 1231 12312900	16-55	21AUG2020	60790	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312901	C4591001 1231 12312901	16-55	21AUG2020	60754	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312903	C4591001 1231 12312903	16-55	21AUG2020	60792	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312904	C4591001 1231 12312904	16-55	21AUG2020	60788	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312905	C4591001 1231 12312905	16-55	21AUG2020	60786	Placebo	21AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12312906	C4591001 1231 12312906	16-55	21AUG2020	60838	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312910	C4591001 1231 12312910	16-55	21AUG2020	60844	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312911	C4591001 1231 12312911	16-55	21AUG2020	61011	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312912	C4591001 1231 12312912	16-55	21AUG2020	60922	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12312913	C4591001 1231 12312913	16-55	21AUG2020	60961	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312914	C4591001 1231 12312914	16-55	21AUG2020	60954	Placebo	21AUG2020/ Placebo	14SEP2020/ Placebo		
12312916	C4591001 1231 12312916	16-55	21AUG2020	60842	Placebo	21AUG2020/ Placebo		02MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312917	C4591001 1231 12312917	16-55	21AUG2020	61008	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312918	C4591001 1231 12312918	16-55	21AUG2020	60962	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12312919	C4591001 1231 12312919	16-55	21AUG2020	60917	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312920	C4591001 1231 12312920	16-55	21AUG2020	61052	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312921	C4591001 1231 12312921	16-55	21AUG2020	61005	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312922	C4591001 1231 12312922	16-55	21AUG2020	60920	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312923	C4591001 1231 12312923	16-55	21AUG2020	60840	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312924	C4591001 1231 12312924	16-55	21AUG2020	61007	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12312925	C4591001 1231 12312925	16-55	21AUG2020	61028	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312926	C4591001 1231 12312926	16-55	21AUG2020	61050	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312927	C4591001 1231 12312927	16-55	21AUG2020	60957	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312928	C4591001 1231 12312928	16-55	21AUG2020	61027	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312929	C4591001 1231 12312929	16-55	21AUG2020	61061	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312930	C4591001 1231 12312930	16-55	21AUG2020	61036	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312931	C4591001 1231 12312931	16-55	21AUG2020	61034	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12312932	C4591001 1231 12312932	16-55	21AUG2020	61063	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312933	C4591001 1231 12312933	16-55	21AUG2020	60928	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312934	C4591001 1231 12312934	16-55	21AUG2020	61087	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		
12312936	C4591001 1231 12312936	16-55	21AUG2020	61088	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312937	C4591001 1231 12312937	16-55	21AUG2020	61051	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312938	C4591001 1231 12312938	16-55	21AUG2020	61089	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312939	C4591001 1231 12312939	16-55	21AUG2020	61049	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312941	C4591001 1231 12312941	16-55	21AUG2020	61069	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312943	C4591001 1231 12312943	16-55	21AUG2020	61066	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312944	C4591001 1231 12312944	16-55	21AUG2020	61133	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312946	C4591001 1231 12312946	16-55	21AUG2020	61134	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12312947	C4591001 1231 12312947	16-55	21AUG2020	61095	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312948	C4591001 1231 12312948	16-55	21AUG2020	61135	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312951	C4591001 1231 12312951	16-55	21AUG2020	61157	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312952	C4591001 1231 12312952	16-55	21AUG2020	61140	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312953	C4591001 1231 12312953	16-55	21AUG2020	61184	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12312954	C4591001 1231 12312954	16-55	21AUG2020	61160	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312955	C4591001 1231 12312955	16-55	21AUG2020	61220	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312956	C4591001 1231 12312956	16-55	21AUG2020	61168	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12312957	C4591001 1231 12312957	16-55	21AUG2020	61166	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312958	C4591001 1231 12312958	16-55	21AUG2020	61186	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312959	C4591001 1231 12312959	16-55	21AUG2020	61192	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312960	C4591001 1231 12312960	16-55	21AUG2020	61187	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312962	C4591001 1231 12312962	16-55	21AUG2020	61224	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12312964	C4591001 1231 12312964	16-55	21AUG2020	61266	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312965	C4591001 1231 12312965	16-55	21AUG2020	61274	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312966	C4591001 1231 12312966	16-55	21AUG2020	61218	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312968	C4591001 1231 12312968	16-55	21AUG2020	61325	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12312969	C4591001 1231 12312969	16-55	21AUG2020	61225	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12312971	C4591001 1231 12312971	16-55	21AUG2020	61310	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312972	C4591001 1231 12312972	16-55	21AUG2020	61270	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312974	C4591001 1231 12312974	16-55	21AUG2020	61265	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		
12312975	C4591001 1231 12312975	16-55	21AUG2020	61304	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312976	C4591001 1231 12312976	16-55	21AUG2020	61302	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312979	C4591001 1231 12312979	16-55	21AUG2020	61307	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312982	C4591001 1231 12312982	16-55	21AUG2020	61389	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12312983	C4591001 1231 12312983	16-55	21AUG2020	61332	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312984	C4591001 1231 12312984	16-55	21AUG2020	61365	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12312985	C4591001 1231 12312985	16-55	21AUG2020	61386	Placebo	21AUG2020/ Placebo	02OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312986	C4591001 1231 12312986	16-55	21AUG2020	61370	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312988	C4591001 1231 12312988	16-55	21AUG2020	61431	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312989	C4591001 1231 12312989	16-55	21AUG2020	61327	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12312990	C4591001 1231 12312990	16-55	21AUG2020	61393	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312991	C4591001 1231 12312991	16-55	21AUG2020	61333	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12312992	C4591001 1231 12312992	16-55	21AUG2020	61372	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12312994	C4591001 1231 12312994	16-55	21AUG2020	61428	Placebo	21AUG2020/ Placebo	01OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12312995	C4591001 1231 12312995	16-55	21AUG2020	61369	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12312996	C4591001 1231 12312996	16-55	21AUG2020	61429	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313001	C4591001 1231 12313001	16-55	21AUG2020	61387	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313002	C4591001 1231 12313002	16-55	21AUG2020	61440	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12313005	C4591001 1231 12313005	16-55	21AUG2020	61441	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313006	C4591001 1231 12313006	16-55	21AUG2020	61443	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)			
12313007	C4591001 1231 12313007	16-55	21AUG2020	61432	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313008	C4591001 1231 12313008	16-55	21AUG2020	61458	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313009	C4591001 1231 12313009	16-55	21AUG2020	61463	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313011	C4591001 1231 12313011	16-55	21AUG2020	61469	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313012	C4591001 1231 12313012	16-55	21AUG2020	61468	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313013	C4591001 1231 12313013	16-55	21AUG2020	61480	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313014	C4591001 1231 12313014	16-55	21AUG2020	61476	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313015	C4591001 1231 12313015	16-55	21AUG2020	61442	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313018	C4591001 1231 12313018	16-55	21AUG2020	61509	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12313019	C4591001 1231 12313019	16-55	21AUG2020	61464	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313020	C4591001 1231 12313020	16-55	21AUG2020	61511	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313022	C4591001 1231 12313022	16-55	21AUG2020	61515	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313023	C4591001 1231 12313023	16-55	21AUG2020	61479	Placebo	21AUG2020/ Placebo	09SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313025	C4591001 1231 12313025	16-55	21AUG2020	61505	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313026	C4591001 1231 12313026	16-55	21AUG2020	61542	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313028	C4591001 1231 12313028	16-55	21AUG2020	61543	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313030	C4591001 1231 12313030	16-55	21AUG2020	61549	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12313031	C4591001 1231 12313031	16-55	21AUG2020	61541	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12313032	C4591001 1231 12313032	16-55	22AUG2020	61637	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313033	C4591001 1231 12313033	16-55	22AUG2020	61640	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313034	C4591001 1231 12313034	16-55	22AUG2020	61701	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313035	C4591001 1231 12313035	16-55	22AUG2020	61641	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313036	C4591001 1231 12313036	16-55	22AUG2020	61643	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313037	C4591001 1231 12313037	16-55	22AUG2020	61649	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313038	C4591001 1231 12313038	16-55	22AUG2020	61650	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313040	C4591001 1231 12313040	16-55	22AUG2020	61665	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313041	C4591001 1231 12313041	16-55	22AUG2020	61660	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313042	C4591001 1231 12313042	16-55	22AUG2020	61661	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313043	C4591001 1231 12313043	16-55	22AUG2020	61672	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313044	C4591001 1231 12313044	16-55	22AUG2020	61651	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313045	C4591001 1231 12313045	16-55	22AUG2020	61688	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313046	C4591001 1231 12313046	16-55	22AUG2020	61675	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313047	C4591001 1231 12313047	16-55	22AUG2020	61697	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313048	C4591001 1231 12313048	16-55	22AUG2020	61715	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313049	C4591001 1231 12313049	16-55	22AUG2020	61676	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313051	C4591001 1231 12313051	16-55	22AUG2020	61684	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313054	C4591001 1231 12313054	16-55	22AUG2020	61663	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313056	C4591001 1231 12313056	16-55	22AUG2020	61677	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313058	C4591001 1231 12313058	16-55	22AUG2020	61692	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313059	C4591001 1231 12313059	16-55	22AUG2020	61698	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo		
12313061	C4591001 1231 12313061	16-55	22AUG2020	61686	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313062	C4591001 1231 12313062	16-55	22AUG2020	61728	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313063	C4591001 1231 12313063	16-55	22AUG2020	61690	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313064	C4591001 1231 12313064	16-55	22AUG2020	61709	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313065	C4591001 1231 12313065	16-55	22AUG2020	61704	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313066	C4591001 1231 12313066	16-55	22AUG2020	61717	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313068	C4591001 1231 12313068	16-55	22AUG2020	61729	Placebo	22AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12313069	C4591001 1231 12313069	16-55	22AUG2020	61732	Placebo	22AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12313070	C4591001 1231 12313070	16-55	22AUG2020	61718	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313071	C4591001 1231 12313071	16-55	22AUG2020	61724	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313074	C4591001 1231 12313074	16-55	22AUG2020	61739	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313075	C4591001 1231 12313075	16-55	22AUG2020	61734	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313076	C4591001 1231 12313076	16-55	22AUG2020	61740	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313079	C4591001 1231 12313079	16-55	22AUG2020	61743	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313080	C4591001 1231 12313080	16-55	22AUG2020	61749	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313082	C4591001 1231 12313082	16-55	22AUG2020	61747	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313083	C4591001 1231 12313083	16-55	22AUG2020	61746	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313084	C4591001 1231 12313084	16-55	22AUG2020	61764	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313085	C4591001 1231 12313085	16-55	22AUG2020	61759	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313086	C4591001 1231 12313086	16-55	22AUG2020	61761	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313087	C4591001 1231 12313087	16-55	22AUG2020	61808	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313088	C4591001 1231 12313088	16-55	22AUG2020	61750	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313091	C4591001 1231 12313091	16-55	22AUG2020	61792	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313092	C4591001 1231 12313092	16-55	22AUG2020	61781	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313093	C4591001 1231 12313093	16-55	22AUG2020	61782	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313095	C4591001 1231 12313095	16-55	22AUG2020	61763	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313096	C4591001 1231 12313096	16-55	22AUG2020	61787	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313098	C4591001 1231 12313098	16-55	22AUG2020	61795	Placebo	22AUG2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	
12313099	C4591001 1231 12313099	16-55	22AUG2020	61796	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313105	C4591001 1231 12313105	16-55	22AUG2020	61793	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313106	C4591001 1231 12313106	16-55	22AUG2020	61817	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313107	C4591001 1231 12313107	16-55	22AUG2020	61799	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313108	C4591001 1231 12313108	16-55	22AUG2020	61829	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313109	C4591001 1231 12313109	16-55	22AUG2020	61816	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313110	C4591001 1231 12313110	16-55	22AUG2020	61809	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313111	C4591001 1231 12313111	16-55	22AUG2020	61826	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313113	C4591001 1231 12313113	16-55	22AUG2020	61833	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12313115	C4591001 1231 12313115	16-55	22AUG2020	61805	Placebo	22AUG2020/ Placebo		23FEB2021/ BNT162b2 (30 µg)	
12313116	C4591001 1231 12313116	16-55	22AUG2020	61819	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313117	C4591001 1231 12313117	16-55	22AUG2020	61825	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313120	C4591001 1231 12313120	16-55	22AUG2020	61837	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313122	C4591001 1231 12313122	16-55	22AUG2020	61834	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313123	C4591001 1231 12313123	16-55	22AUG2020	61841	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313124	C4591001 1231 12313124	16-55	22AUG2020	61954	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313125	C4591001 1231 12313125	16-55	22AUG2020	61845	Placebo	22AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12313127	C4591001 1231 12313127	16-55	22AUG2020	61933	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313128	C4591001 1231 12313128	16-55	22AUG2020	61869	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313129	C4591001 1231 12313129	16-55	22AUG2020	61846	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313130	C4591001 1231 12313130	16-55	22AUG2020	61865	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313132	C4591001 1231 12313132	16-55	22AUG2020	61916	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313134	C4591001 1231 12313134	16-55	22AUG2020	61909	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313136	C4591001 1231 12313136	16-55	22AUG2020	61901	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313137	C4591001 1231 12313137	16-55	22AUG2020	61875	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313138	C4591001 1231 12313138	16-55	22AUG2020	61873	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313139	C4591001 1231 12313139	16-55	22AUG2020	61918	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313140	C4591001 1231 12313140	16-55	22AUG2020	61905	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo		
12313141	C4591001 1231 12313141	16-55	22AUG2020	61924	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313143	C4591001 1231 12313143	16-55	22AUG2020	61911	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313145	C4591001 1231 12313145	16-55	22AUG2020	61917	Placebo	22AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313148	C4591001 1231 12313148	16-55	22AUG2020	61937	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313149	C4591001 1231 12313149	16-55	22AUG2020	61927	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313151	C4591001 1231 12313151	16-55	22AUG2020	61939	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313152	C4591001 1231 12313152	16-55	22AUG2020	61934	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313153	C4591001 1231 12313153	16-55	22AUG2020	61950	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313155	C4591001 1231 12313155	16-55	22AUG2020	61947	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313156	C4591001 1231 12313156	16-55	22AUG2020	61949	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313157	C4591001 1231 12313157	16-55	22AUG2020	61936	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313158	C4591001 1231 12313158	16-55	22AUG2020	61941	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313160	C4591001 1231 12313160	16-55	22AUG2020	61973	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313161	C4591001 1231 12313161	16-55	22AUG2020	61976	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313162	C4591001 1231 12313162	16-55	22AUG2020	61959	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313163	C4591001 1231 12313163	16-55	22AUG2020	61981	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313164	C4591001 1231 12313164	16-55	22AUG2020	61984	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313165	C4591001 1231 12313165	16-55	22AUG2020	62022	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313166	C4591001 1231 12313166	16-55	22AUG2020	62011	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313167	C4591001 1231 12313167	16-55	22AUG2020	62014	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313168	C4591001 1231 12313168	16-55	22AUG2020	62016	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313170	C4591001 1231 12313170	16-55	22AUG2020	62046	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313174	C4591001 1231 12313174	16-55	22AUG2020	62080	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313175	C4591001 1231 12313175	16-55	22AUG2020	62025	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
12313176	C4591001 1231 12313176	16-55	22AUG2020	62015	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313177	C4591001 1231 12313177	16-55	22AUG2020	62045	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313179	C4591001 1231 12313179	16-55	22AUG2020	62036	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313180	C4591001 1231 12313180	16-55	22AUG2020	62026	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313181	C4591001 1231 12313181	16-55	22AUG2020	62073	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12313182	C4591001 1231 12313182	16-55	22AUG2020	62035	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313183	C4591001 1231 12313183	16-55	22AUG2020	62030	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313184	C4591001 1231 12313184	16-55	22AUG2020	62043	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313186	C4591001 1231 12313186	16-55	22AUG2020	62039	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313188	C4591001 1231 12313188	16-55	22AUG2020	62070	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313189	C4591001 1231 12313189	16-55	22AUG2020	62047	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313190	C4591001 1231 12313190	16-55	22AUG2020	62055	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313191	C4591001 1231 12313191	16-55	22AUG2020	62068	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313192	C4591001 1231 12313192	16-55	22AUG2020	62059	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313193	C4591001 1231 12313193	16-55	22AUG2020	62077	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313194	C4591001 1231 12313194	16-55	22AUG2020	62093	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313195	C4591001 1231 12313195	16-55	22AUG2020	62062	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313197	C4591001 1231 12313197	16-55	22AUG2020	62064	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313198	C4591001 1231 12313198	16-55	22AUG2020	62122	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313199	C4591001 1231 12313199	16-55	22AUG2020	62100	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313201	C4591001 1231 12313201	16-55	22AUG2020	62118	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313202	C4591001 1231 12313202	16-55	22AUG2020	62094	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313203	C4591001 1231 12313203	16-55	22AUG2020	62098	Placebo	22AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313204	C4591001 1231 12313204	16-55	22AUG2020	62121	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313205	C4591001 1231 12313205	16-55	22AUG2020	62158	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313206	C4591001 1231 12313206	16-55	22AUG2020	62155	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313207	C4591001 1231 12313207	16-55	22AUG2020	62154	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
12313209	C4591001 1231 12313209	16-55	22AUG2020	62173	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313210	C4591001 1231 12313210	16-55	22AUG2020	62176	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313211	C4591001 1231 12313211	16-55	22AUG2020	62161	Placebo	22AUG2020/ Placebo			
12313212	C4591001 1231 12313212	16-55	22AUG2020	62166	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313213	C4591001 1231 12313213	16-55	22AUG2020	62223	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313214	C4591001 1231 12313214	16-55	22AUG2020	62199	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313215	C4591001 1231 12313215	16-55	22AUG2020	62195	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313216	C4591001 1231 12313216	16-55	22AUG2020	62169	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313218	C4591001 1231 12313218	16-55	22AUG2020	62204	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313219	C4591001 1231 12313219	16-55	22AUG2020	62205	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313223	C4591001 1231 12313223	16-55	22AUG2020	62239	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo		
12313224	C4591001 1231 12313224	16-55	22AUG2020	62194	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313225	C4591001 1231 12313225	16-55	22AUG2020	62219	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)			
12313226	C4591001 1231 12313226	16-55	22AUG2020	62222	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313227	C4591001 1231 12313227	16-55	22AUG2020	62197	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313228	C4591001 1231 12313228	16-55	22AUG2020	62212	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313229	C4591001 1231 12313229	16-55	22AUG2020	62201	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313231	C4591001 1231 12313231	16-55	22AUG2020	62244	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313232	C4591001 1231 12313232	16-55	22AUG2020	62268	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313235	C4591001 1231 12313235	16-55	22AUG2020	62248	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313236	C4591001 1231 12313236	16-55	22AUG2020	62253	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313237	C4591001 1231 12313237	16-55	22AUG2020	62224	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313238	C4591001 1231 12313238	16-55	22AUG2020	62237	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313243	C4591001 1231 12313243	16-55	22AUG2020	62254	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313244	C4591001 1231 12313244	16-55	22AUG2020	62260	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313245	C4591001 1231 12313245	16-55	22AUG2020	62257	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313246	C4591001 1231 12313246	16-55	22AUG2020	62265	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313249	C4591001 1231 12313249	16-55	22AUG2020	62407	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313250	C4591001 1231 12313250	16-55	22AUG2020	62299	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313251	C4591001 1231 12313251	16-55	22AUG2020	62261	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313253	C4591001 1231 12313253	16-55	22AUG2020	62357	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313255	C4591001 1231 12313255	16-55	22AUG2020	62297	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313256	C4591001 1231 12313256	16-55	22AUG2020	62301	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313257	C4591001 1231 12313257	16-55	22AUG2020	62360	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313258	C4591001 1231 12313258	16-55	22AUG2020	62272	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313259	C4591001 1231 12313259	16-55	22AUG2020	62308	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313260	C4591001 1231 12313260	16-55	22AUG2020	62327	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313263	C4591001 1231 12313263	16-55	22AUG2020	62362	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313264	C4591001 1231 12313264	16-55	22AUG2020	62330	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313265	C4591001 1231 12313265	16-55	22AUG2020	62413	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313266	C4591001 1231 12313266	16-55	22AUG2020	62367	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313268	C4591001 1231 12313268	16-55	22AUG2020	62332	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313269	C4591001 1231 12313269	16-55	22AUG2020	62331	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313270	C4591001 1231 12313270	16-55	22AUG2020	62412	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313271	C4591001 1231 12313271	16-55	22AUG2020	62423	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313272	C4591001 1231 12313272	16-55	22AUG2020	62414	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313274	C4591001 1231 12313274	16-55	22AUG2020	62418	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313276	C4591001 1231 12313276	16-55	22AUG2020	62424	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12313277	C4591001 1231 12313277	16-55	22AUG2020	62417	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313278	C4591001 1231 12313278	16-55	22AUG2020	62433	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313281	C4591001 1231 12313281	16-55	22AUG2020	62455	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313282	C4591001 1231 12313282	16-55	22AUG2020	62440	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313283	C4591001 1231 12313283	16-55	22AUG2020	62442	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313284	C4591001 1231 12313284	16-55	22AUG2020	62448	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313285	C4591001 1231 12313285	16-55	22AUG2020	62435	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313287	C4591001 1231 12313287	16-55	22AUG2020	62436	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313288	C4591001 1231 12313288	16-55	22AUG2020	62453	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313289	C4591001 1231 12313289	16-55	22AUG2020	62449	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12313290	C4591001 1231 12313290	16-55	22AUG2020	62457	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313291	C4591001 1231 12313291	16-55	22AUG2020	62444	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313292	C4591001 1231 12313292	16-55	22AUG2020	62460	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313293	C4591001 1231 12313293	16-55	22AUG2020	62465	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313296	C4591001 1231 12313296	16-55	22AUG2020	62466	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313297	C4591001 1231 12313297	16-55	22AUG2020	62480	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313298	C4591001 1231 12313298	16-55	22AUG2020	62472	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313300	C4591001 1231 12313300	16-55	22AUG2020	62485	Placebo	22AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313301	C4591001 1231 12313301	16-55	22AUG2020	62471	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313302	C4591001 1231 12313302	16-55	22AUG2020	62486	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313303	C4591001 1231 12313303	16-55	22AUG2020	62502	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313304	C4591001 1231 12313304	16-55	22AUG2020	62495	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313306	C4591001 1231 12313306	16-55	22AUG2020	62499	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo		
12313307	C4591001 1231 12313307	16-55	22AUG2020	62507	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313308	C4591001 1231 12313308	16-55	22AUG2020	62505	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313310	C4591001 1231 12313310	16-55	22AUG2020	62516	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313311	C4591001 1231 12313311	16-55	22AUG2020	62493	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313312	C4591001 1231 12313312	16-55	22AUG2020	62519	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313313	C4591001 1231 12313313	16-55	22AUG2020	62482	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313314	C4591001 1231 12313314	16-55	22AUG2020	62521	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12313315	C4591001 1231 12313315	16-55	22AUG2020	62497	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313316	C4591001 1231 12313316	16-55	22AUG2020	62527	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313317	C4591001 1231 12313317	16-55	22AUG2020	62509	Placebo	22AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313318	C4591001 1231 12313318	16-55	22AUG2020	62529	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo		
12313319	C4591001 1231 12313319	16-55	22AUG2020	62518	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313321	C4591001 1231 12313321	16-55	22AUG2020	62526	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313322	C4591001 1231 12313322	16-55	22AUG2020	62535	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313324	C4591001 1231 12313324	16-55	23AUG2020	62549	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313326	C4591001 1231 12313326	16-55	23AUG2020	62560	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313327	C4591001 1231 12313327	16-55	23AUG2020	62586	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313329	C4591001 1231 12313329	16-55	23AUG2020	62552	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313330	C4591001 1231 12313330	16-55	23AUG2020	62557	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313332	C4591001 1231 12313332	16-55	23AUG2020	62561	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313334	C4591001 1231 12313334	16-55	23AUG2020	62571	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313335	C4591001 1231 12313335	16-55	23AUG2020	62576	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313336	C4591001 1231 12313336	16-55	23AUG2020	62568	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313337	C4591001 1231 12313337	16-55	23AUG2020	62582	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313338	C4591001 1231 12313338	16-55	23AUG2020	62587	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313340	C4591001 1231 12313340	16-55	23AUG2020	62603	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313343	C4591001 1231 12313343	16-55	23AUG2020	62563	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313345	C4591001 1231 12313345	16-55	23AUG2020	62579	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
12313348	C4591001 1231 12313348	16-55	23AUG2020	62596	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313349	C4591001 1231 12313349	16-55	23AUG2020	62573	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313350	C4591001 1231 12313350	16-55	23AUG2020	62598	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313351	C4591001 1231 12313351	16-55	23AUG2020	62604	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313353	C4591001 1231 12313353	16-55	23AUG2020	62611	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313356	C4591001 1231 12313356	16-55	23AUG2020	62622	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313357	C4591001 1231 12313357	16-55	23AUG2020	62592	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313358	C4591001 1231 12313358	16-55	23AUG2020	62605	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313360	C4591001 1231 12313360	16-55	23AUG2020	62616	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313361	C4591001 1231 12313361	16-55	23AUG2020	62618	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313363	C4591001 1231 12313363	16-55	23AUG2020	62623	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313364	C4591001 1231 12313364	16-55	23AUG2020	62617	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313365	C4591001 1231 12313365	16-55	23AUG2020	62627	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313367	C4591001 1231 12313367	16-55	23AUG2020	62624	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313368	C4591001 1231 12313368	16-55	23AUG2020	62640	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313369	C4591001 1231 12313369	16-55	23AUG2020	62635	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313370	C4591001 1231 12313370	16-55	23AUG2020	62637	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313372	C4591001 1231 12313372	16-55	23AUG2020	62650	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313374	C4591001 1231 12313374	16-55	23AUG2020	62638	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12313375	C4591001 1231 12313375	16-55	23AUG2020	62649	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313376	C4591001 1231 12313376	16-55	23AUG2020	62657	Placebo	23AUG2020/ Placebo			
12313378	C4591001 1231 12313378	16-55	23AUG2020	62652	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313381	C4591001 1231 12313381	16-55	23AUG2020	62646	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313383	C4591001 1231 12313383	16-55	23AUG2020	62686	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313384	C4591001 1231 12313384	16-55	23AUG2020	62658	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313385	C4591001 1231 12313385	16-55	23AUG2020	62670	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313386	C4591001 1231 12313386	16-55	23AUG2020	62666	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313387	C4591001 1231 12313387	16-55	23AUG2020	62665	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313388	C4591001 1231 12313388	16-55	23AUG2020	62680	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313389	C4591001 1231 12313389	16-55	23AUG2020	62683	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313390	C4591001 1231 12313390	16-55	23AUG2020	62694	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313393	C4591001 1231 12313393	16-55	23AUG2020	62673	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo		
12313394	C4591001 1231 12313394	16-55	23AUG2020	62688	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313395	C4591001 1231 12313395	16-55	23AUG2020	62678	Placebo	23AUG2020/ Placebo		01MAR2021/ BNT162b2 (30 µg)	
12313399	C4591001 1231 12313399	16-55	23AUG2020	62691	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313400	C4591001 1231 12313400	16-55	23AUG2020	62710	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313402	C4591001 1231 12313402	16-55	23AUG2020	62704	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313404	C4591001 1231 12313404	16-55	23AUG2020	62703	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313405	C4591001 1231 12313405	16-55	23AUG2020	62695	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313406	C4591001 1231 12313406	16-55	23AUG2020	62714	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313407	C4591001 1231 12313407	16-55	23AUG2020	62715	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313408	C4591001 1231 12313408	16-55	23AUG2020	62721	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313409	C4591001 1231 12313409	16-55	23AUG2020	62716	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313412	C4591001 1231 12313412	16-55	23AUG2020	62722	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313413	C4591001 1231 12313413	16-55	23AUG2020	62723	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313414	C4591001 1231 12313414	16-55	23AUG2020	62756	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313415	C4591001 1231 12313415	16-55	23AUG2020	62754	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313416	C4591001 1231 12313416	16-55	23AUG2020	62728	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313417	C4591001 1231 12313417	16-55	23AUG2020	62787	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313419	C4591001 1231 12313419	16-55	23AUG2020	62773	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313421	C4591001 1231 12313421	16-55	23AUG2020	62743	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313422	C4591001 1231 12313422	16-55	23AUG2020	62741	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313425	C4591001 1231 12313425	16-55	23AUG2020	62758	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313427	C4591001 1231 12313427	16-55	23AUG2020	62772	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313428	C4591001 1231 12313428	16-55	23AUG2020	62788	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313429	C4591001 1231 12313429	16-55	23AUG2020	62790	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313430	C4591001 1231 12313430	16-55	23AUG2020	62782	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313431	C4591001 1231 12313431	16-55	23AUG2020	62747	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313432	C4591001 1231 12313432	16-55	23AUG2020	62761	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313433	C4591001 1231 12313433	16-55	23AUG2020	62789	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313434	C4591001 1231 12313434	16-55	23AUG2020	62817	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313435	C4591001 1231 12313435	16-55	23AUG2020	62770	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313437	C4591001 1231 12313437	16-55	23AUG2020	62793	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313438	C4591001 1231 12313438	16-55	23AUG2020	62792	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12313439	C4591001 1231 12313439	16-55	23AUG2020	62777	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313440	C4591001 1231 12313440	16-55	23AUG2020	62750	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313441	C4591001 1231 12313441	16-55	23AUG2020	62819	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313442	C4591001 1231 12313442	16-55	23AUG2020	62813	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313443	C4591001 1231 12313443	16-55	23AUG2020	62897	Placebo				
12313444	C4591001 1231 12313444	16-55	23AUG2020	62775	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313445	C4591001 1231 12313445	16-55	23AUG2020	62824	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313448	C4591001 1231 12313448	16-55	23AUG2020	62828	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313449	C4591001 1231 12313449	16-55	23AUG2020	62825	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313450	C4591001 1231 12313450	16-55	23AUG2020	62829	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313452	C4591001 1231 12313452	16-55	23AUG2020	62841	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313454	C4591001 1231 12313454	16-55	23AUG2020	62830	Placebo	23AUG2020/ Placebo			
12313456	C4591001 1231 12313456	16-55	23AUG2020	62839	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313459	C4591001 1231 12313459	16-55	23AUG2020	62850	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313460	C4591001 1231 12313460	16-55	23AUG2020	62845	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313462	C4591001 1231 12313462	16-55	23AUG2020	62846	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313463	C4591001 1231 12313463	16-55	23AUG2020	62852	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313465	C4591001 1231 12313465	16-55	23AUG2020	62875	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313466	C4591001 1231 12313466	16-55	23AUG2020	62857	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313467	C4591001 1231 12313467	16-55	23AUG2020	62868	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313469	C4591001 1231 12313469	16-55	23AUG2020	62859	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313470	C4591001 1231 12313470	16-55	23AUG2020	62878	Placebo	23AUG2020/ Placebo	22SEP2020/ Placebo		
12313471	C4591001 1231 12313471	16-55	23AUG2020	62888	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313473	C4591001 1231 12313473	16-55	23AUG2020	62866	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313474	C4591001 1231 12313474	16-55	23AUG2020	62865	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313475	C4591001 1231 12313475	16-55	23AUG2020	62872	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313476	C4591001 1231 12313476	16-55	23AUG2020	62906	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313479	C4591001 1231 12313479	16-55	23AUG2020	62899	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313481	C4591001 1231 12313481	16-55	23AUG2020	62873	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313483	C4591001 1231 12313483	16-55	23AUG2020	62902	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313484	C4591001 1231 12313484	16-55	23AUG2020	62879	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313486	C4591001 1231 12313486	16-55	23AUG2020	62890	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313487	C4591001 1231 12313487	16-55	23AUG2020	62909	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313488	C4591001 1231 12313488	16-55	23AUG2020	62896	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313489	C4591001 1231 12313489	16-55	23AUG2020	62889	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313490	C4591001 1231 12313490	16-55	23AUG2020	62914	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313491	C4591001 1231 12313491	16-55	23AUG2020	62915	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313492	C4591001 1231 12313492	16-55	23AUG2020	62918	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313493	C4591001 1231 12313493	16-55	23AUG2020	62956	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313494	C4591001 1231 12313494	16-55	23AUG2020	62928	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313497	C4591001 1231 12313497	16-55	23AUG2020	62923	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313498	C4591001 1231 12313498	16-55	23AUG2020	62945	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313499	C4591001 1231 12313499	16-55	23AUG2020	62924	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313500	C4591001 1231 12313500	16-55	23AUG2020	62950	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313501	C4591001 1231 12313501	16-55	23AUG2020	62932	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313504	C4591001 1231 12313504	16-55	23AUG2020	62966	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313505	C4591001 1231 12313505	16-55	23AUG2020	62949	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313506	C4591001 1231 12313506	16-55	23AUG2020	62967	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313507	C4591001 1231 12313507	16-55	23AUG2020	62959	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313508	C4591001 1231 12313508	16-55	23AUG2020	62974	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313509	C4591001 1231 12313509	16-55	23AUG2020	62964	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313510	C4591001 1231 12313510	16-55	23AUG2020	62976	Placebo	23AUG2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
12313512	C4591001 1231 12313512	16-55	23AUG2020	63019	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313513	C4591001 1231 12313513	16-55	23AUG2020	62977	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313514	C4591001 1231 12313514	16-55	23AUG2020	62997	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313515	C4591001 1231 12313515	16-55	23AUG2020	63015	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313516	C4591001 1231 12313516	16-55	23AUG2020	62998	Placebo	23AUG2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313517	C4591001 1231 12313517	16-55	23AUG2020	63003	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313518	C4591001 1231 12313518	16-55	23AUG2020	63006	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313519	C4591001 1231 12313519	16-55	23AUG2020	62978	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313520	C4591001 1231 12313520	16-55	23AUG2020	63009	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313521	C4591001 1231 12313521	16-55	23AUG2020	62994	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313525	C4591001 1231 12313525	16-55	23AUG2020	63017	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313526	C4591001 1231 12313526	16-55	23AUG2020	63028	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313527	C4591001 1231 12313527	16-55	23AUG2020	63011	Placebo				
12313528	C4591001 1231 12313528	16-55	23AUG2020	63033	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313529	C4591001 1231 12313529	16-55	23AUG2020	63032	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313533	C4591001 1231 12313533	16-55	23AUG2020	63021	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313534	C4591001 1231 12313534	16-55	23AUG2020	63046	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313535	C4591001 1231 12313535	16-55	23AUG2020	63036	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313537	C4591001 1231 12313537	16-55	23AUG2020	63037	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313539	C4591001 1231 12313539	16-55	23AUG2020	63047	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313540	C4591001 1231 12313540	16-55	23AUG2020	63060	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313541	C4591001 1231 12313541	16-55	23AUG2020	63041	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313542	C4591001 1231 12313542	16-55	23AUG2020	63063	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313543	C4591001 1231 12313543	16-55	23AUG2020	63064	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313544	C4591001 1231 12313544	16-55	23AUG2020	63073	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313546	C4591001 1231 12313546	16-55	23AUG2020	63074	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313547	C4591001 1231 12313547	16-55	23AUG2020	63048	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313548	C4591001 1231 12313548	16-55	23AUG2020	63077	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12313551	C4591001 1231 12313551	16-55	23AUG2020	63057	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313553	C4591001 1231 12313553	16-55	23AUG2020	63076	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313554	C4591001 1231 12313554	16-55	23AUG2020	63080	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313555	C4591001 1231 12313555	16-55	23AUG2020	63069	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313556	C4591001 1231 12313556	16-55	23AUG2020	63086	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313557	C4591001 1231 12313557	16-55	23AUG2020	63121	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313558	C4591001 1231 12313558	16-55	23AUG2020	63093	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313560	C4591001 1231 12313560	16-55	23AUG2020	63107	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313561	C4591001 1231 12313561	16-55	23AUG2020	63088	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313563	C4591001 1231 12313563	16-55	23AUG2020	63105	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313564	C4591001 1231 12313564	16-55	23AUG2020	63103	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313565	C4591001 1231 12313565	16-55	23AUG2020	63094	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313566	C4591001 1231 12313566	16-55	23AUG2020	63108	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313567	C4591001 1231 12313567	16-55	23AUG2020	63095	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313569	C4591001 1231 12313569	16-55	23AUG2020	63092	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313570	C4591001 1231 12313570	16-55	23AUG2020	63122	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313571	C4591001 1231 12313571	16-55	23AUG2020	63116	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313572	C4591001 1231 12313572	16-55	23AUG2020	63126	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313575	C4591001 1231 12313575	16-55	23AUG2020	63146	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313576	C4591001 1231 12313576	16-55	23AUG2020	63128	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313578	C4591001 1231 12313578	16-55	23AUG2020	63143	Placebo	23AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313579	C4591001 1231 12313579	16-55	23AUG2020	63123	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313580	C4591001 1231 12313580	16-55	23AUG2020	63145	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313581	C4591001 1231 12313581	16-55	23AUG2020	63125	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313583	C4591001 1231 12313583	16-55	23AUG2020	63159	Placebo	23AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313587	C4591001 1231 12313587	16-55	23AUG2020	63155	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313589	C4591001 1231 12313589	16-55	23AUG2020	63130	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313590	C4591001 1231 12313590	16-55	23AUG2020	63157	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313591	C4591001 1231 12313591	16-55	23AUG2020	63148	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313592	C4591001 1231 12313592	16-55	23AUG2020	63162	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)			
12313595	C4591001 1231 12313595	16-55	23AUG2020	63154	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313596	C4591001 1231 12313596	16-55	23AUG2020	63165	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313598	C4591001 1231 12313598	16-55	23AUG2020	63169	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313601	C4591001 1231 12313601	16-55	23AUG2020	63163	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313605	C4591001 1231 12313605	16-55	23AUG2020	63173	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313606	C4591001 1231 12313606	16-55	23AUG2020	63178	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313607	C4591001 1231 12313607	16-55	23AUG2020	63174	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313609	C4591001 1231 12313609	16-55	23AUG2020	63176	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo		
12313612	C4591001 1231 12313612	16-55	23AUG2020	63185	Placebo	23AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313613	C4591001 1231 12313613	16-55	23AUG2020	63192	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313614	C4591001 1231 12313614	16-55	23AUG2020	63187	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12313616	C4591001 1231 12313616	16-55	24AUG2020	64146	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313617	C4591001 1231 12313617	16-55	24AUG2020	63196	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313618	C4591001 1231 12313618	16-55	24AUG2020	64154	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313619	C4591001 1231 12313619	16-55	24AUG2020	64145	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
12313620	C4591001 1231 12313620	16-55	24AUG2020	64217	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313622	C4591001 1231 12313622	16-55	24AUG2020	64270	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
12313623	C4591001 1231 12313623	16-55	24AUG2020	64223	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313624	C4591001 1231 12313624	16-55	24AUG2020	64219	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313629	C4591001 1231 12313629	16-55	24AUG2020	64149	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313630	C4591001 1231 12313630	16-55	24AUG2020	64276	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313631	C4591001 1231 12313631	16-55	24AUG2020	64273	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313632	C4591001 1231 12313632	16-55	24AUG2020	64282	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313633	C4591001 1231 12313633	16-55	24AUG2020	64266	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313634	C4591001 1231 12313634	16-55	24AUG2020	64227	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313635	C4591001 1231 12313635	16-55	24AUG2020	64281	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313636	C4591001 1231 12313636	16-55	24AUG2020	64290	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313637	C4591001 1231 12313637	16-55	24AUG2020	64291	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313638	C4591001 1231 12313638	16-55	24AUG2020	64285	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313639	C4591001 1231 12313639	16-55	24AUG2020	64284	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313640	C4591001 1231 12313640	16-55	24AUG2020	64297	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313641	C4591001 1231 12313641	16-55	24AUG2020	219989	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313643	C4591001 1231 12313643	16-55	24AUG2020	64299	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313644	C4591001 1231 12313644	16-55	24AUG2020	64317	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313646	C4591001 1231 12313646	16-55	24AUG2020	64318	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313647	C4591001 1231 12313647	16-55	24AUG2020	64320	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313653	C4591001 1231 12313653	16-55	24AUG2020	64322	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313656	C4591001 1231 12313656	16-55	24AUG2020	64413	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313657	C4591001 1231 12313657	16-55	24AUG2020	64375	Placebo	24AUG2020/ Placebo		25FEB2021/ BNT162b2 (30 µg)	
12313658	C4591001 1231 12313658	16-55	24AUG2020	64416	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313659	C4591001 1231 12313659	16-55	24AUG2020	64379	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313660	C4591001 1231 12313660	16-55	24AUG2020	64421	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313661	C4591001 1231 12313661	16-55	24AUG2020	64377	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313662	C4591001 1231 12313662	16-55	24AUG2020	64431	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
12313663	C4591001 1231 12313663	16-55	24AUG2020	64380	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313664	C4591001 1231 12313664	16-55	24AUG2020	64432	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313665	C4591001 1231 12313665	16-55	24AUG2020	64415	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313666	C4591001 1231 12313666	16-55	24AUG2020	64448	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313667	C4591001 1231 12313667	16-55	24AUG2020	64419	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313668	C4591001 1231 12313668	16-55	24AUG2020	64454	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313669	C4591001 1231 12313669	16-55	24AUG2020	64488	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313670	C4591001 1231 12313670	16-55	24AUG2020	64491	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313671	C4591001 1231 12313671	16-55	24AUG2020	64449	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313672	C4591001 1231 12313672	16-55	24AUG2020	64492	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313673	C4591001 1231 12313673	16-55	24AUG2020	64428	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313675	C4591001 1231 12313675	16-55	24AUG2020	64446	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313677	C4591001 1231 12313677	16-55	24AUG2020	64531	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313679	C4591001 1231 12313679	16-55	24AUG2020	64487	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313680	C4591001 1231 12313680	16-55	24AUG2020	64538	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo		
12313681	C4591001 1231 12313681	16-55	24AUG2020	64535	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313682	C4591001 1231 12313682	16-55	24AUG2020	64565	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313683	C4591001 1231 12313683	16-55	24AUG2020	64589	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313684	C4591001 1231 12313684	16-55	24AUG2020	64616	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313685	C4591001 1231 12313685	16-55	24AUG2020	64536	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313689	C4591001 1231 12313689	16-55	24AUG2020	64660	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313693	C4591001 1231 12313693	16-55	24AUG2020	64651	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313694	C4591001 1231 12313694	16-55	24AUG2020	64624	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo		
12313695	C4591001 1231 12313695	16-55	24AUG2020	64615	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313696	C4591001 1231 12313696	16-55	24AUG2020	64598	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313697	C4591001 1231 12313697	16-55	24AUG2020	64592	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo		
12313698	C4591001 1231 12313698	16-55	24AUG2020	64679	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313699	C4591001 1231 12313699	16-55	24AUG2020	64597	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12313700	C4591001 1231 12313700	16-55	24AUG2020	64649	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313701	C4591001 1231 12313701	16-55	24AUG2020	64673	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313702	C4591001 1231 12313702	16-55	24AUG2020	64655	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313703	C4591001 1231 12313703	16-55	24AUG2020	64622	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313704	C4591001 1231 12313704	16-55	24AUG2020	64675	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313705	C4591001 1231 12313705	16-55	24AUG2020	64684	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313706	C4591001 1231 12313706	16-55	24AUG2020	64792	Placebo	24AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313707	C4591001 1231 12313707	16-55	24AUG2020	64686	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313709	C4591001 1231 12313709	16-55	24AUG2020	64693	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)			
12313710	C4591001 1231 12313710	16-55	24AUG2020	64685	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313711	C4591001 1231 12313711	16-55	24AUG2020	64687	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313713	C4591001 1231 12313713	16-55	24AUG2020	64759	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313714	C4591001 1231 12313714	16-55	24AUG2020	64712	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12313715	C4591001 1231 12313715	16-55	24AUG2020	64714	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313716	C4591001 1231 12313716	16-55	24AUG2020	64716	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313717	C4591001 1231 12313717	16-55	24AUG2020	64709	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313718	C4591001 1231 12313718	16-55	24AUG2020	64762	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313720	C4591001 1231 12313720	16-55	24AUG2020	64767	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313721	C4591001 1231 12313721	16-55	24AUG2020	64781	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313722	C4591001 1231 12313722	16-55	24AUG2020	64788	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313724	C4591001 1231 12313724	16-55	24AUG2020	64829	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313725	C4591001 1231 12313725	16-55	24AUG2020	64766	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313726	C4591001 1231 12313726	16-55	24AUG2020	64838	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313727	C4591001 1231 12313727	16-55	24AUG2020	64787	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313729	C4591001 1231 12313729	16-55	24AUG2020	64837	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313732	C4591001 1231 12313732	16-55	24AUG2020	64840	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313733	C4591001 1231 12313733	16-55	24AUG2020	64888	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313734	C4591001 1231 12313734	16-55	24AUG2020	64883	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313738	C4591001 1231 12313738	16-55	24AUG2020	64885	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313739	C4591001 1231 12313739	16-55	24AUG2020	64912	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313742	C4591001 1231 12313742	16-55	24AUG2020	64902	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313743	C4591001 1231 12313743	16-55	24AUG2020	64886	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313746	C4591001 1231 12313746	16-55	24AUG2020	64906	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313749	C4591001 1231 12313749	16-55	24AUG2020	64907	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12313750	C4591001 1231 12313750	16-55	24AUG2020	64930	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12313752	C4591001 1231 12313752	16-55	24AUG2020	64931	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313756	C4591001 1231 12313756	16-55	24AUG2020	64991	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313758	C4591001 1231 12313758	16-55	24AUG2020	64935	Placebo	24AUG2020/ Placebo		22FEB2021/ BNT162b2 (30 µg)	
12313759	C4591001 1231 12313759	16-55	24AUG2020	64932	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313762	C4591001 1231 12313762	16-55	24AUG2020	64949	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313764	C4591001 1231 12313764	16-55	24AUG2020	64956	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313765	C4591001 1231 12313765	16-55	24AUG2020	65008	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313766	C4591001 1231 12313766	16-55	24AUG2020	64959	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313769	C4591001 1231 12313769	16-55	24AUG2020	64985	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12313772	C4591001 1231 12313772	16-55	24AUG2020	64958	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313773	C4591001 1231 12313773	16-55	24AUG2020	64995	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313777	C4591001 1231 12313777	16-55	24AUG2020	64996	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313778	C4591001 1231 12313778	16-55	24AUG2020	64997	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313780	C4591001 1231 12313780	16-55	24AUG2020	65007	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313781	C4591001 1231 12313781	16-55	24AUG2020	65005	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313785	C4591001 1231 12313785	16-55	25AUG2020	65089	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313786	C4591001 1231 12313786	16-55	25AUG2020	65063	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313788	C4591001 1231 12313788	16-55	25AUG2020	65068	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313789	C4591001 1231 12313789	16-55	25AUG2020	65081	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313790	C4591001 1231 12313790	16-55	25AUG2020	65067	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313793	C4591001 1231 12313793	16-55	25AUG2020	65086	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313794	C4591001 1231 12313794	16-55	25AUG2020	65130	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313795	C4591001 1231 12313795	16-55	25AUG2020	65100	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313797	C4591001 1231 12313797	16-55	25AUG2020	65096	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313798	C4591001 1231 12313798	16-55	25AUG2020	65162	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313800	C4591001 1231 12313800	16-55	25AUG2020	65105	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313801	C4591001 1231 12313801	16-55	25AUG2020	65101	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313802	C4591001 1231 12313802	16-55	25AUG2020	65065	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313804	C4591001 1231 12313804	16-55	25AUG2020	65114	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313805	C4591001 1231 12313805	16-55	25AUG2020	65083	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313806	C4591001 1231 12313806	16-55	25AUG2020	65135	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313808	C4591001 1231 12313808	16-55	25AUG2020	65103	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313809	C4591001 1231 12313809	16-55	25AUG2020	65131	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313810	C4591001 1231 12313810	16-55	25AUG2020	65155	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12313811	C4591001 1231 12313811	16-55	25AUG2020	65132	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313814	C4591001 1231 12313814	16-55	25AUG2020	65106	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313815	C4591001 1231 12313815	16-55	25AUG2020	65110	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313816	C4591001 1231 12313816	16-55	25AUG2020	65178	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313818	C4591001 1231 12313818	16-55	25AUG2020	65185	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313819	C4591001 1231 12313819	16-55	25AUG2020	65160	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313821	C4591001 1231 12313821	16-55	25AUG2020	65177	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313822	C4591001 1231 12313822	16-55	25AUG2020	65159	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12313823	C4591001 1231 12313823	16-55	25AUG2020	65204	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313824	C4591001 1231 12313824	16-55	25AUG2020	65187	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12313825	C4591001 1231 12313825	16-55	25AUG2020	65205	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313827	C4591001 1231 12313827	16-55	25AUG2020	65208	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313830	C4591001 1231 12313830	16-55	25AUG2020	65243	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313831	C4591001 1231 12313831	16-55	25AUG2020	65240	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313832	C4591001 1231 12313832	16-55	25AUG2020	65211	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313836	C4591001 1231 12313836	16-55	25AUG2020	65245	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313837	C4591001 1231 12313837	16-55	25AUG2020	65246	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313840	C4591001 1231 12313840	16-55	25AUG2020	65253	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313841	C4591001 1231 12313841	16-55	25AUG2020	65249	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313842	C4591001 1231 12313842	16-55	25AUG2020	65277	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313843	C4591001 1231 12313843	16-55	25AUG2020	65251	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313847	C4591001 1231 12313847	16-55	25AUG2020	65281	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313848	C4591001 1231 12313848	16-55	25AUG2020	65282	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313851	C4591001 1231 12313851	16-55	25AUG2020	65255	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12313853	C4591001 1231 12313853	16-55	25AUG2020	65283	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313854	C4591001 1231 12313854	16-55	25AUG2020	65300	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313856	C4591001 1231 12313856	16-55	25AUG2020	65305	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313859	C4591001 1231 12313859	16-55	25AUG2020	65298	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313861	C4591001 1231 12313861	16-55	25AUG2020	65327	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313862	C4591001 1231 12313862	16-55	25AUG2020	65308	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313864	C4591001 1231 12313864	16-55	25AUG2020	65321	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313865	C4591001 1231 12313865	16-55	25AUG2020	65373	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313866	C4591001 1231 12313866	16-55	25AUG2020	65332	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313868	C4591001 1231 12313868	16-55	25AUG2020	65326	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313869	C4591001 1231 12313869	16-55	25AUG2020	65371	BNT162b2 (30 µg)				
12313870	C4591001 1231 12313870	16-55	25AUG2020	65378	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12313871	C4591001 1231 12313871	16-55	25AUG2020	65431	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313872	C4591001 1231 12313872	16-55	25AUG2020	65380	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313873	C4591001 1231 12313873	16-55	25AUG2020	65429	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313875	C4591001 1231 12313875	16-55	25AUG2020	65433	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313876	C4591001 1231 12313876	16-55	25AUG2020	65436	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12313877	C4591001 1231 12313877	16-55	25AUG2020	65557	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313878	C4591001 1231 12313878	16-55	25AUG2020	65553	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313879	C4591001 1231 12313879	16-55	25AUG2020	65638	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313881	C4591001 1231 12313881	16-55	25AUG2020	65558	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313884	C4591001 1231 12313884	16-55	25AUG2020	65560	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313886	C4591001 1231 12313886	16-55	25AUG2020	65820	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313888	C4591001 1231 12313888	16-55	25AUG2020	65634	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313889	C4591001 1231 12313889	16-55	25AUG2020	65641	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313892	C4591001 1231 12313892	16-55	25AUG2020	65671	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12313893	C4591001 1231 12313893	16-55	25AUG2020	65639	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313895	C4591001 1231 12313895	16-55	25AUG2020	65739	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313896	C4591001 1231 12313896	16-55	25AUG2020	65687	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313900	C4591001 1231 12313900	16-55	25AUG2020	65734	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313901	C4591001 1231 12313901	16-55	25AUG2020	65670	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12313902	C4591001 1231 12313902	16-55	25AUG2020	65679	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313903	C4591001 1231 12313903	16-55	25AUG2020	65691	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313904	C4591001 1231 12313904	16-55	25AUG2020	65686	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12313905	C4591001 1231 12313905	16-55	25AUG2020	65676	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313906	C4591001 1231 12313906	16-55	25AUG2020	65684	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313907	C4591001 1231 12313907	16-55	25AUG2020	65736	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313908	C4591001 1231 12313908	16-55	25AUG2020	65737	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313909	C4591001 1231 12313909	16-55	25AUG2020	65760	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313910	C4591001 1231 12313910	16-55	25AUG2020	65763	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313911	C4591001 1231 12313911	16-55	25AUG2020	65759	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313913	C4591001 1231 12313913	16-55	25AUG2020	65762	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12313915	C4591001 1231 12313915	16-55	25AUG2020	65819	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12313916	C4591001 1231 12313916	16-55	25AUG2020	65823	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313917	C4591001 1231 12313917	16-55	25AUG2020	65821	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313919	C4591001 1231 12313919	16-55	25AUG2020	65920	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313921	C4591001 1231 12313921	16-55	25AUG2020	65967	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313922	C4591001 1231 12313922	16-55	25AUG2020	65862	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313923	C4591001 1231 12313923	16-55	25AUG2020	65868	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12313924	C4591001 1231 12313924	16-55	25AUG2020	65965	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313925	C4591001 1231 12313925	16-55	25AUG2020	65912	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313927	C4591001 1231 12313927	16-55	25AUG2020	65959	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313930	C4591001 1231 12313930	16-55	25AUG2020	65968	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313931	C4591001 1231 12313931	16-55	25AUG2020	65872	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12313932	C4591001 1231 12313932	16-55	25AUG2020	65919	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313934	C4591001 1231 12313934	16-55	25AUG2020	65870	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313935	C4591001 1231 12313935	16-55	25AUG2020	65911	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313937	C4591001 1231 12313937	16-55	25AUG2020	65997	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313939	C4591001 1231 12313939	16-55	25AUG2020	65998	Placebo	25AUG2020/ Placebo	07OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313941	C4591001 1231 12313941	16-55	25AUG2020	66019	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313943	C4591001 1231 12313943	16-55	25AUG2020	66003	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313944	C4591001 1231 12313944	16-55	25AUG2020	66017	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12313945	C4591001 1231 12313945	16-55	25AUG2020	66021	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12313946	C4591001 1231 12313946	16-55	25AUG2020	66002	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313948	C4591001 1231 12313948	16-55	25AUG2020	66089	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12313949	C4591001 1231 12313949	16-55	25AUG2020	66026	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12313953	C4591001 1231 12313953	16-55	25AUG2020	66090	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313955	C4591001 1231 12313955	16-55	25AUG2020	66093	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313956	C4591001 1231 12313956	16-55	25AUG2020	66311	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313957	C4591001 1231 12313957	16-55	25AUG2020	66094	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313960	C4591001 1231 12313960	16-55	25AUG2020	66316	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12313963	C4591001 1231 12313963	16-55	25AUG2020	66314	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313964	C4591001 1231 12313964	16-55	25AUG2020	66382	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313965	C4591001 1231 12313965	16-55	25AUG2020	66308	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313966	C4591001 1231 12313966	16-55	25AUG2020	66346	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313967	C4591001 1231 12313967	16-55	25AUG2020	66459	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12313968	C4591001 1231 12313968	16-55	25AUG2020	66378	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313969	C4591001 1231 12313969	16-55	25AUG2020	66345	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313970	C4591001 1231 12313970	16-55	25AUG2020	66380	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12313971	C4591001 1231 12313971	16-55	25AUG2020	66417	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12313973	C4591001 1231 12313973	16-55	25AUG2020	66348	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313974	C4591001 1231 12313974	16-55	25AUG2020	66418	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313975	C4591001 1231 12313975	16-55	25AUG2020	66420	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313977	C4591001 1231 12313977	16-55	25AUG2020	66414	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12313978	C4591001 1231 12313978	16-55	25AUG2020	66458	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12313979	C4591001 1231 12313979	16-55	25AUG2020	66352	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12313981	C4591001 1231 12313981	16-55	25AUG2020	66381	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12313984	C4591001 1231 12313984	16-55	25AUG2020	66460	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313986	C4591001 1231 12313986	16-55	25AUG2020	66512	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12313987	C4591001 1231 12313987	16-55	25AUG2020	66450	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313988	C4591001 1231 12313988	16-55	25AUG2020	66514	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12313989	C4591001 1231 12313989	16-55	25AUG2020	66510	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12313991	C4591001 1231 12313991	16-55	25AUG2020	66516	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313993	C4591001 1231 12313993	16-55	25AUG2020	66583	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12313994	C4591001 1231 12313994	16-55	25AUG2020	66586	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12313995	C4591001 1231 12313995	16-55	25AUG2020	66617	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12313996	C4591001 1231 12313996	16-55	25AUG2020	66622	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12313998	C4591001 1231 12313998	16-55	25AUG2020	66592	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12313999	C4591001 1231 12313999	16-55	25AUG2020	66588	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314000	C4591001 1231 12314000	16-55	25AUG2020	66623	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314002	C4591001 1231 12314002	16-55	25AUG2020	66626	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314004	C4591001 1231 12314004	16-55	25AUG2020	66653	Placebo	25AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314005	C4591001 1231 12314005	16-55	25AUG2020	66679	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314006	C4591001 1231 12314006	16-55	25AUG2020	66654	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314007	C4591001 1231 12314007	16-55	25AUG2020	66680	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314008	C4591001 1231 12314008	16-55	25AUG2020	66664	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314009	C4591001 1231 12314009	16-55	25AUG2020	66659	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314010	C4591001 1231 12314010	16-55	25AUG2020	66927	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314011	C4591001 1231 12314011	16-55	25AUG2020	66774	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314013	C4591001 1231 12314013	16-55	25AUG2020	66777	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314016	C4591001 1231 12314016	16-55	25AUG2020	66750	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314017	C4591001 1231 12314017	16-55	25AUG2020	66682	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314018	C4591001 1231 12314018	16-55	25AUG2020	66684	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314020	C4591001 1231 12314020	16-55	25AUG2020	66752	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314021	C4591001 1231 12314021	16-55	25AUG2020	66760	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314022	C4591001 1231 12314022	16-55	25AUG2020	66759	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314023	C4591001 1231 12314023	16-55	25AUG2020	66779	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314028	C4591001 1231 12314028	16-55	25AUG2020	66783	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314030	C4591001 1231 12314030	16-55	25AUG2020	66821	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		
12314032	C4591001 1231 12314032	16-55	25AUG2020	66827	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314033	C4591001 1231 12314033	16-55	25AUG2020	66826	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314034	C4591001 1231 12314034	16-55	25AUG2020	66830	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314037	C4591001 1231 12314037	16-55	25AUG2020	66918	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314042	C4591001 1231 12314042	16-55	25AUG2020	66921	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314043	C4591001 1231 12314043	16-55	25AUG2020	66926	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314046	C4591001 1231 12314046	16-55	25AUG2020	66930	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo		
12314047	C4591001 1231 12314047	16-55	25AUG2020	66933	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314049	C4591001 1231 12314049	16-55	25AUG2020	66938	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314050	C4591001 1231 12314050	16-55	25AUG2020	66942	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314053	C4591001 1231 12314053	16-55	25AUG2020	66937	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314058	C4591001 1231 12314058	16-55	25AUG2020	66948	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314059	C4591001 1231 12314059	16-55	25AUG2020	67010	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314061	C4591001 1231 12314061	16-55	25AUG2020	66950	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314062	C4591001 1231 12314062	16-55	25AUG2020	66977	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo		
12314066	C4591001 1231 12314066	16-55	25AUG2020	66979	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314067	C4591001 1231 12314067	16-55	25AUG2020	66988	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314068	C4591001 1231 12314068	16-55	25AUG2020	66984	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314070	C4591001 1231 12314070	16-55	25AUG2020	67002	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314071	C4591001 1231 12314071	16-55	25AUG2020	66943	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12314073	C4591001 1231 12314073	16-55	25AUG2020	67004	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314074	C4591001 1231 12314074	16-55	26AUG2020	67113	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314075	C4591001 1231 12314075	16-55	26AUG2020	67115	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314076	C4591001 1231 12314076	16-55	26AUG2020	67012	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314077	C4591001 1231 12314077	16-55	26AUG2020	67114	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314078	C4591001 1231 12314078	16-55	26AUG2020	67116	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314080	C4591001 1231 12314080	16-55	26AUG2020	67139	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12314084	C4591001 1231 12314084	16-55	26AUG2020	67158	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314085	C4591001 1231 12314085	16-55	26AUG2020	67136	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314086	C4591001 1231 12314086	16-55	26AUG2020	67171	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314087	C4591001 1231 12314087	16-55	26AUG2020	67163	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314088	C4591001 1231 12314088	16-55	26AUG2020	67137	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314095	C4591001 1231 12314095	16-55	26AUG2020	67149	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314096	C4591001 1231 12314096	16-55	26AUG2020	67167	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314097	C4591001 1231 12314097	16-55	26AUG2020	67154	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314098	C4591001 1231 12314098	16-55	26AUG2020	67143	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314099	C4591001 1231 12314099	16-55	26AUG2020	67173	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314100	C4591001 1231 12314100	16-55	26AUG2020	67155	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314102	C4591001 1231 12314102	16-55	26AUG2020	67166	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314104	C4591001 1231 12314104	16-55	26AUG2020	67178	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314106	C4591001 1231 12314106	16-55	26AUG2020	67146	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314107	C4591001 1231 12314107	16-55	26AUG2020	67182	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314108	C4591001 1231 12314108	16-55	26AUG2020	67179	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314109	C4591001 1231 12314109	16-55	26AUG2020	67185	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314111	C4591001 1231 12314111	16-55	26AUG2020	67192	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314112	C4591001 1231 12314112	16-55	26AUG2020	67219	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314114	C4591001 1231 12314114	16-55	26AUG2020	67189	Placebo	26AUG2020/ Placebo	24SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314115	C4591001 1231 12314115	16-55	26AUG2020	67283	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314116	C4591001 1231 12314116	16-55	26AUG2020	67224	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314117	C4591001 1231 12314117	16-55	26AUG2020	67278	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314119	C4591001 1231 12314119	16-55	26AUG2020	67225	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314121	C4591001 1231 12314121	16-55	26AUG2020	67289	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314122	C4591001 1231 12314122	16-55	26AUG2020	67227	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314123	C4591001 1231 12314123	16-55	26AUG2020	67291	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314124	C4591001 1231 12314124	16-55	26AUG2020	67287	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314126	C4591001 1231 12314126	16-55	26AUG2020	67281	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314128	C4591001 1231 12314128	16-55	26AUG2020	67327	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314129	C4591001 1231 12314129	16-55	26AUG2020	67330	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314130	C4591001 1231 12314130	16-55	26AUG2020	67294	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314132	C4591001 1231 12314132	16-55	26AUG2020	67295	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314133	C4591001 1231 12314133	16-55	26AUG2020	67326	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314134	C4591001 1231 12314134	16-55	26AUG2020	67400	Placebo	26AUG2020/ Placebo			
12314135	C4591001 1231 12314135	16-55	26AUG2020	67388	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314137	C4591001 1231 12314137	16-55	26AUG2020	67333	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314138	C4591001 1231 12314138	16-55	26AUG2020	67387	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314140	C4591001 1231 12314140	16-55	26AUG2020	67397	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314141	C4591001 1231 12314141	16-55	26AUG2020	67396	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314142	C4591001 1231 12314142	16-55	26AUG2020	67392	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314143	C4591001 1231 12314143	16-55	26AUG2020	67398	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314144	C4591001 1231 12314144	16-55	26AUG2020	67441	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314145	C4591001 1231 12314145	16-55	26AUG2020	67406	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314150	C4591001 1231 12314150	16-55	26AUG2020	67459	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314151	C4591001 1231 12314151	16-55	26AUG2020	67434	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314152	C4591001 1231 12314152	16-55	26AUG2020	67437	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314154	C4591001 1231 12314154	16-55	26AUG2020	67444	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314155	C4591001 1231 12314155	16-55	26AUG2020	67463	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314156	C4591001 1231 12314156	16-55	26AUG2020	67465	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314159	C4591001 1231 12314159	16-55	26AUG2020	67464	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314160	C4591001 1231 12314160	16-55	26AUG2020	67522	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314161	C4591001 1231 12314161	16-55	26AUG2020	67521	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314162	C4591001 1231 12314162	16-55	26AUG2020	67523	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314166	C4591001 1231 12314166	16-55	26AUG2020	67526	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314167	C4591001 1231 12314167	16-55	26AUG2020	67595	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314169	C4591001 1231 12314169	16-55	26AUG2020	67590	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314171	C4591001 1231 12314171	16-55	26AUG2020	67654	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314172	C4591001 1231 12314172	16-55	26AUG2020	67594	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314173	C4591001 1231 12314173	16-55	26AUG2020	67651	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314175	C4591001 1231 12314175	16-55	26AUG2020	67658	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314178	C4591001 1231 12314178	16-55	26AUG2020	67598	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314179	C4591001 1231 12314179	16-55	26AUG2020	67701	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12314181	C4591001 1231 12314181	16-55	26AUG2020	67652	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314183	C4591001 1231 12314183	16-55	26AUG2020	67703	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314185	C4591001 1231 12314185	16-55	26AUG2020	67705	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
12314186	C4591001 1231 12314186	16-55	26AUG2020	67708	Placebo	26AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314188	C4591001 1231 12314188	16-55	26AUG2020	67745	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314191	C4591001 1231 12314191	16-55	26AUG2020	67796	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314192	C4591001 1231 12314192	16-55	26AUG2020	67754	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12314193	C4591001 1231 12314193	16-55	26AUG2020	67756	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314195	C4591001 1231 12314195	16-55	26AUG2020	67748	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314198	C4591001 1231 12314198	16-55	26AUG2020	68021	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314200	C4591001 1231 12314200	16-55	26AUG2020	67869	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo		
12314202	C4591001 1231 12314202	16-55	26AUG2020	67802	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314203	C4591001 1231 12314203	16-55	26AUG2020	67871	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314204	C4591001 1231 12314204	16-55	26AUG2020	67803	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314205	C4591001 1231 12314205	16-55	26AUG2020	67797	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12314210	C4591001 1231 12314210	16-55	26AUG2020	67874	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314212	C4591001 1231 12314212	16-55	26AUG2020	67873	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314215	C4591001 1231 12314215	16-55	26AUG2020	68022	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314217	C4591001 1231 12314217	16-55	26AUG2020	67941	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314218	C4591001 1231 12314218	16-55	26AUG2020	67940	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314219	C4591001 1231 12314219	16-55	26AUG2020	67945	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314223	C4591001 1231 12314223	16-55	26AUG2020	67946	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314224	C4591001 1231 12314224	16-55	26AUG2020	68031	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314225	C4591001 1231 12314225	16-55	26AUG2020	68023	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314229	C4591001 1231 12314229	16-55	26AUG2020	68036	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314230	C4591001 1231 12314230	16-55	26AUG2020	68033	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314232	C4591001 1231 12314232	16-55	26AUG2020	68035	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314235	C4591001 1231 12314235	16-55	26AUG2020	68034	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314236	C4591001 1231 12314236	16-55	26AUG2020	68142	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314238	C4591001 1231 12314238	16-55	26AUG2020	68397	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314239	C4591001 1231 12314239	16-55	26AUG2020	68355	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314242	C4591001 1231 12314242	16-55	26AUG2020	68350	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314243	C4591001 1231 12314243	16-55	26AUG2020	68423	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314244	C4591001 1231 12314244	16-55	26AUG2020	68356	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314245	C4591001 1231 12314245	16-55	26AUG2020	68151	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314246	C4591001 1231 12314246	16-55	26AUG2020	68402	Placebo	26AUG2020/ Placebo	29SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314247	C4591001 1231 12314247	16-55	26AUG2020	68148	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314249	C4591001 1231 12314249	16-55	26AUG2020	68150	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314251	C4591001 1231 12314251	16-55	26AUG2020	68351	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314252	C4591001 1231 12314252	16-55	26AUG2020	68513	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314256	C4591001 1231 12314256	16-55	26AUG2020	68520	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12314259	C4591001 1231 12314259	16-55	26AUG2020	68424	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314260	C4591001 1231 12314260	16-55	26AUG2020	68540	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314263	C4591001 1231 12314263	16-55	26AUG2020	68401	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314264	C4591001 1231 12314264	16-55	26AUG2020	68544	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314265	C4591001 1231 12314265	16-55	26AUG2020	68522	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314266	C4591001 1231 12314266	16-55	26AUG2020	68573	Placebo	26AUG2020/ Placebo			
12314267	C4591001 1231 12314267	16-55	26AUG2020	68394	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314268	C4591001 1231 12314268	16-55	26AUG2020	68579	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314269	C4591001 1231 12314269	16-55	26AUG2020	68417	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314270	C4591001 1231 12314270	16-55	26AUG2020	68644	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314271	C4591001 1231 12314271	16-55	26AUG2020	68426	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314272	C4591001 1231 12314272	16-55	26AUG2020	68636	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314273	C4591001 1231 12314273	16-55	26AUG2020	68524	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314274	C4591001 1231 12314274	16-55	26AUG2020	68641	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314276	C4591001 1231 12314276	16-55	26AUG2020	68720	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314277	C4591001 1231 12314277	16-55	26AUG2020	68546	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314278	C4591001 1231 12314278	16-55	26AUG2020	68725	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314279	C4591001 1231 12314279	16-55	26AUG2020	68576	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314280	C4591001 1231 12314280	16-55	26AUG2020	68728	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314283	C4591001 1231 12314283	16-55	26AUG2020	68543	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314284	C4591001 1231 12314284	16-55	26AUG2020	68772	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314287	C4591001 1231 12314287	16-55	26AUG2020	68584	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314288	C4591001 1231 12314288	16-55	26AUG2020	68775	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314290	C4591001 1231 12314290	16-55	26AUG2020	68828	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12314291	C4591001 1231 12314291	16-55	26AUG2020	68766	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314292	C4591001 1231 12314292	16-55	26AUG2020	68833	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314294	C4591001 1231 12314294	16-55	26AUG2020	68836	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314295	C4591001 1231 12314295	16-55	26AUG2020	68643	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314296	C4591001 1231 12314296	16-55	26AUG2020	68862	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314297	C4591001 1231 12314297	16-55	26AUG2020	68719	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314298	C4591001 1231 12314298	16-55	26AUG2020	68868	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314300	C4591001 1231 12314300	16-55	26AUG2020	68869	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314302	C4591001 1231 12314302	16-55	26AUG2020	68885	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314303	C4591001 1231 12314303	16-55	26AUG2020	68776	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314304	C4591001 1231 12314304	16-55	26AUG2020	68896	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314305	C4591001 1231 12314305	16-55	26AUG2020	68829	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314308	C4591001 1231 12314308	16-55	26AUG2020	68934	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
12314309	C4591001 1231 12314309	16-55	26AUG2020	68888	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314310	C4591001 1231 12314310	16-55	26AUG2020	68941	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314311	C4591001 1231 12314311	16-55	26AUG2020	68940	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314314	C4591001 1231 12314314	16-55	26AUG2020	68958	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12314317	C4591001 1231 12314317	16-55	26AUG2020	68895	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314318	C4591001 1231 12314318	16-55	26AUG2020	68968	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314319	C4591001 1231 12314319	16-55	26AUG2020	68870	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314320	C4591001 1231 12314320	16-55	26AUG2020	69008	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314322	C4591001 1231 12314322	16-55	26AUG2020	69009	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314324	C4591001 1231 12314324	16-55	26AUG2020	69013	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo		
12314325	C4591001 1231 12314325	16-55	26AUG2020	68942	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314326	C4591001 1231 12314326	16-55	26AUG2020	69015	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12314327	C4591001 1231 12314327	16-55	26AUG2020	68960	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314328	C4591001 1231 12314328	16-55	26AUG2020	69050	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314329	C4591001 1231 12314329	16-55	26AUG2020	68963	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314330	C4591001 1231 12314330	16-55	26AUG2020	69052	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314333	C4591001 1231 12314333	16-55	26AUG2020	69046	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314334	C4591001 1231 12314334	16-55	26AUG2020	69073	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314336	C4591001 1231 12314336	16-55	26AUG2020	69074	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314339	C4591001 1231 12314339	16-55	26AUG2020	69066	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo		
12314340	C4591001 1231 12314340	16-55	26AUG2020	69125	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314342	C4591001 1231 12314342	16-55	26AUG2020	69128	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314343	C4591001 1231 12314343	16-55	26AUG2020	69051	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314346	C4591001 1231 12314346	16-55	26AUG2020	69137	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314348	C4591001 1231 12314348	16-55	26AUG2020	69146	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314351	C4591001 1231 12314351	16-55	26AUG2020	69075	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314352	C4591001 1231 12314352	16-55	26AUG2020	69176	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314353	C4591001 1231 12314353	16-55	26AUG2020	69127	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314354	C4591001 1231 12314354	16-55	26AUG2020	69189	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314355	C4591001 1231 12314355	16-55	26AUG2020	69130	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314356	C4591001 1231 12314356	16-55	26AUG2020	69190	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314357	C4591001 1231 12314357	16-55	26AUG2020	69175	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314358	C4591001 1231 12314358	16-55	26AUG2020	69209	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314359	C4591001 1231 12314359	16-55	26AUG2020	69148	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314360	C4591001 1231 12314360	16-55	26AUG2020	69186	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314361	C4591001 1231 12314361	16-55	26AUG2020	69174	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314362	C4591001 1231 12314362	16-55	26AUG2020	69184	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314363	C4591001 1231 12314363	16-55	26AUG2020	69143	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12314366	C4591001 1231 12314366	16-55	26AUG2020	69191	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314368	C4591001 1231 12314368	16-55	26AUG2020	69213	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314371	C4591001 1231 12314371	16-55	27AUG2020	69433	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314372	C4591001 1231 12314372	16-55	27AUG2020	69403	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12314373	C4591001 1231 12314373	16-55	27AUG2020	69404	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314374	C4591001 1231 12314374	16-55	27AUG2020	69215	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314375	C4591001 1231 12314375	16-55	27AUG2020	69554	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314376	C4591001 1231 12314376	16-55	27AUG2020	69434	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314379	C4591001 1231 12314379	16-55	27AUG2020	69220	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314380	C4591001 1231 12314380	16-55	27AUG2020	69406	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314381	C4591001 1231 12314381	16-55	27AUG2020	69407	Placebo	27AUG2020/ Placebo			
12314385	C4591001 1231 12314385	16-55	27AUG2020	69435	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
12314387	C4591001 1231 12314387	16-55	27AUG2020	69428	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314388	C4591001 1231 12314388	16-55	27AUG2020	69467	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314389	C4591001 1231 12314389	16-55	27AUG2020	69455	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314391	C4591001 1231 12314391	16-55	27AUG2020	69490	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314392	C4591001 1231 12314392	16-55	27AUG2020	69449	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314393	C4591001 1231 12314393	16-55	27AUG2020	69453	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314394	C4591001 1231 12314394	16-55	27AUG2020	69472	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314395	C4591001 1231 12314395	16-55	27AUG2020	69469	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314396	C4591001 1231 12314396	16-55	27AUG2020	69471	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314397	C4591001 1231 12314397	16-55	27AUG2020	69456	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314400	C4591001 1231 12314400	16-55	27AUG2020	69491	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314402	C4591001 1231 12314402	16-55	27AUG2020	69495	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314404	C4591001 1231 12314404	16-55	27AUG2020	69492	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314405	C4591001 1231 12314405	16-55	27AUG2020	69547	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314406	C4591001 1231 12314406	16-55	27AUG2020	69549	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314407	C4591001 1231 12314407	16-55	27AUG2020	69574	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12314408	C4591001 1231 12314408	16-55	27AUG2020	69550	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314416	C4591001 1231 12314416	16-55	27AUG2020	69609	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12314417	C4591001 1231 12314417	16-55	27AUG2020	69575	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314418	C4591001 1231 12314418	16-55	27AUG2020	69612	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314419	C4591001 1231 12314419	16-55	27AUG2020	69569	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314421	C4591001 1231 12314421	16-55	27AUG2020	69628	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314422	C4591001 1231 12314422	16-55	27AUG2020	69605	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314423	C4591001 1231 12314423	16-55	27AUG2020	69618	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314424	C4591001 1231 12314424	16-55	27AUG2020	69620	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314425	C4591001 1231 12314425	16-55	27AUG2020	69577	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314427	C4591001 1231 12314427	16-55	27AUG2020	69643	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314429	C4591001 1231 12314429	16-55	27AUG2020	69610	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314430	C4591001 1231 12314430	16-55	27AUG2020	69627	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314433	C4591001 1231 12314433	16-55	27AUG2020	69645	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314434	C4591001 1231 12314434	16-55	27AUG2020	69650	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314435	C4591001 1231 12314435	16-55	27AUG2020	69652	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314436	C4591001 1231 12314436	16-55	27AUG2020	69755	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314440	C4591001 1231 12314440	16-55	27AUG2020	69752	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314442	C4591001 1231 12314442	16-55	27AUG2020	69756	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314444	C4591001 1231 12314444	16-55	27AUG2020	69826	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo		
12314445	C4591001 1231 12314445	16-55	27AUG2020	69824	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314447	C4591001 1231 12314447	16-55	27AUG2020	69758	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314449	C4591001 1231 12314449	16-55	27AUG2020	69828	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314450	C4591001 1231 12314450	16-55	27AUG2020	69893	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314451	C4591001 1231 12314451	16-55	27AUG2020	69831	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314452	C4591001 1231 12314452	16-55	27AUG2020	69894	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12314454	C4591001 1231 12314454	16-55	27AUG2020	69935	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314457	C4591001 1231 12314457	16-55	27AUG2020	69897	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314459	C4591001 1231 12314459	16-55	27AUG2020	69932	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314461	C4591001 1231 12314461	16-55	27AUG2020	69982	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314462	C4591001 1231 12314462	16-55	27AUG2020	69903	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314463	C4591001 1231 12314463	16-55	27AUG2020	69940	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12314464	C4591001 1231 12314464	16-55	27AUG2020	69981	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314466	C4591001 1231 12314466	16-55	27AUG2020	70001	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314467	C4591001 1231 12314467	16-55	27AUG2020	69986	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314468	C4591001 1231 12314468	16-55	27AUG2020	69939	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314470	C4591001 1231 12314470	16-55	27AUG2020	69983	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314471	C4591001 1231 12314471	16-55	27AUG2020	70012	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314474	C4591001 1231 12314474	16-55	27AUG2020	70050	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314475	C4591001 1231 12314475	16-55	27AUG2020	70009	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314477	C4591001 1231 12314477	16-55	27AUG2020	70054	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314478	C4591001 1231 12314478	16-55	27AUG2020	70004	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314479	C4591001 1231 12314479	16-55	27AUG2020	70056	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314480	C4591001 1231 12314480	16-55	27AUG2020	70133	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314482	C4591001 1231 12314482	16-55	27AUG2020	70055	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314486	C4591001 1231 12314486	16-55	27AUG2020	70137	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314489	C4591001 1231 12314489	16-55	27AUG2020	70144	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314490	C4591001 1231 12314490	16-55	27AUG2020	70192	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314491	C4591001 1231 12314491	16-55	27AUG2020	70143	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314492	C4591001 1231 12314492	16-55	27AUG2020	70185	Placebo	27AUG2020/ Placebo			
12314494	C4591001 1231 12314494	16-55	27AUG2020	70181	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314496	C4591001 1231 12314496	16-55	27AUG2020	70182	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314497	C4591001 1231 12314497	16-55	27AUG2020	70250	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314499	C4591001 1231 12314499	16-55	27AUG2020	70280	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314500	C4591001 1231 12314500	16-55	27AUG2020	70248	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314501	C4591001 1231 12314501	16-55	27AUG2020	70297	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314502	C4591001 1231 12314502	16-55	27AUG2020	70285	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314503	C4591001 1231 12314503	16-55	27AUG2020	70244	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314505	C4591001 1231 12314505	16-55	27AUG2020	70298	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314506	C4591001 1231 12314506	16-55	27AUG2020	70373	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314508	C4591001 1231 12314508	16-55	27AUG2020	70281	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314509	C4591001 1231 12314509	16-55	27AUG2020	70349	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314510	C4591001 1231 12314510	16-55	27AUG2020	70377	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314511	C4591001 1231 12314511	16-55	27AUG2020	70299	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314512	C4591001 1231 12314512	16-55	27AUG2020	70277	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314513	C4591001 1231 12314513	16-55	27AUG2020	70251	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314515	C4591001 1231 12314515	16-55	27AUG2020	70291	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314516	C4591001 1231 12314516	16-55	27AUG2020	70354	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314517	C4591001 1231 12314517	16-55	27AUG2020	70376	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314519	C4591001 1231 12314519	16-55	27AUG2020	70351	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314520	C4591001 1231 12314520	16-55	27AUG2020	70412	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314521	C4591001 1231 12314521	16-55	27AUG2020	70379	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314522	C4591001 1231 12314522	16-55	27AUG2020	70409	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314523	C4591001 1231 12314523	16-55	27AUG2020	70352	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314525	C4591001 1231 12314525	16-55	27AUG2020	70419	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314526	C4591001 1231 12314526	16-55	27AUG2020	70413	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314528	C4591001 1231 12314528	16-55	27AUG2020	70469	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314529	C4591001 1231 12314529	16-55	27AUG2020	70472	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314530	C4591001 1231 12314530	16-55	27AUG2020	70583	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314531	C4591001 1231 12314531	16-55	27AUG2020	70475	Placebo	27AUG2020/ Placebo	28SEP2020/ Placebo		
12314534	C4591001 1231 12314534	16-55	27AUG2020	70479	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314535	C4591001 1231 12314535	16-55	27AUG2020	70586	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314537	C4591001 1231 12314537	16-55	27AUG2020	70621	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314541	C4591001 1231 12314541	16-55	27AUG2020	70580	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314542	C4591001 1231 12314542	16-55	27AUG2020	70585	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314547	C4591001 1231 12314547	16-55	27AUG2020	70615	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314548	C4591001 1231 12314548	16-55	27AUG2020	70619	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314550	C4591001 1231 12314550	16-55	27AUG2020	70665	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314552	C4591001 1231 12314552	16-55	27AUG2020	70620	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314553	C4591001 1231 12314553	16-55	27AUG2020	70666	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314554	C4591001 1231 12314554	16-55	27AUG2020	70671	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314555	C4591001 1231 12314555	16-55	27AUG2020	70742	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314557	C4591001 1231 12314557	16-55	27AUG2020	70672	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314559	C4591001 1231 12314559	16-55	27AUG2020	70738	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314560	C4591001 1231 12314560	16-55	27AUG2020	70735	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314562	C4591001 1231 12314562	16-55	27AUG2020	70739	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314564	C4591001 1231 12314564	16-55	27AUG2020	70760	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314565	C4591001 1231 12314565	16-55	27AUG2020	70798	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314566	C4591001 1231 12314566	16-55	27AUG2020	70762	Placebo	27AUG2020/ Placebo	24SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314568	C4591001 1231 12314568	16-55	27AUG2020	70766	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12314571	C4591001 1231 12314571	16-55	27AUG2020	70767	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314573	C4591001 1231 12314573	16-55	27AUG2020	70794	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314574	C4591001 1231 12314574	16-55	27AUG2020	70804	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314575	C4591001 1231 12314575	16-55	27AUG2020	70867	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12314576	C4591001 1231 12314576	16-55	27AUG2020	70799	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314577	C4591001 1231 12314577	16-55	27AUG2020	70914	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314580	C4591001 1231 12314580	16-55	27AUG2020	70870	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
12314582	C4591001 1231 12314582	16-55	27AUG2020	70873	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314583	C4591001 1231 12314583	16-55	27AUG2020	70872	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314585	C4591001 1231 12314585	16-55	27AUG2020	70918	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314586	C4591001 1231 12314586	16-55	27AUG2020	70984	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314589	C4591001 1231 12314589	16-55	27AUG2020	70919	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314590	C4591001 1231 12314590	16-55	27AUG2020	71023	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)			
12314591	C4591001 1231 12314591	16-55	27AUG2020	70924	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314595	C4591001 1231 12314595	16-55	27AUG2020	70978	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314596	C4591001 1231 12314596	16-55	27AUG2020	71032	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314597	C4591001 1231 12314597	16-55	27AUG2020	70979	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314599	C4591001 1231 12314599	16-55	27AUG2020	71028	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314601	C4591001 1231 12314601	16-55	27AUG2020	70983	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314602	C4591001 1231 12314602	16-55	27AUG2020	71109	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314603	C4591001 1231 12314603	16-55	27AUG2020	71029	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314604	C4591001 1231 12314604	16-55	27AUG2020	71113	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314606	C4591001 1231 12314606	16-55	27AUG2020	71154	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314607	C4591001 1231 12314607	16-55	27AUG2020	71090	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314610	C4591001 1231 12314610	16-55	27AUG2020	71162	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314615	C4591001 1231 12314615	16-55	27AUG2020	71087	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12314616	C4591001 1231 12314616	16-55	27AUG2020	71164	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314620	C4591001 1231 12314620	16-55	27AUG2020	71202	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314621	C4591001 1231 12314621	16-55	27AUG2020	71085	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314622	C4591001 1231 12314622	16-55	27AUG2020	71203	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12314625	C4591001 1231 12314625	16-55	27AUG2020	71086	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314627	C4591001 1231 12314627	16-55	27AUG2020	71107	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314628	C4591001 1231 12314628	16-55	27AUG2020	71242	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314629	C4591001 1231 12314629	16-55	27AUG2020	71111	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314630	C4591001 1231 12314630	16-55	27AUG2020	71246	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314633	C4591001 1231 12314633	16-55	27AUG2020	71158	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314635	C4591001 1231 12314635	16-55	27AUG2020	71210	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314637	C4591001 1231 12314637	16-55	27AUG2020	71204	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314638	C4591001 1231 12314638	16-55	27AUG2020	71285	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314639	C4591001 1231 12314639	16-55	27AUG2020	71238	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314640	C4591001 1231 12314640	16-55	27AUG2020	71286	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314641	C4591001 1231 12314641	16-55	27AUG2020	71243	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314642	C4591001 1231 12314642	16-55	27AUG2020	71289	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314643	C4591001 1231 12314643	16-55	27AUG2020	71261	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314644	C4591001 1231 12314644	16-55	27AUG2020	71322	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314645	C4591001 1231 12314645	16-55	27AUG2020	71262	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314646	C4591001 1231 12314646	16-55	27AUG2020	71327	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314647	C4591001 1231 12314647	16-55	27AUG2020	71267	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314648	C4591001 1231 12314648	16-55	27AUG2020	71330	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314649	C4591001 1231 12314649	16-55	27AUG2020	71263	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314650	C4591001 1231 12314650	16-55	27AUG2020	71331	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314654	C4591001 1231 12314654	16-55	27AUG2020	71361	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314655	C4591001 1231 12314655	16-55	27AUG2020	71290	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12314656	C4591001 1231 12314656	16-55	27AUG2020	71364	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314665	C4591001 1231 12314665	16-55	28AUG2020	71509	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314666	C4591001 1231 12314666	16-55	28AUG2020	71365	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314667	C4591001 1231 12314667	16-55	28AUG2020	71366	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314670	C4591001 1231 12314670	16-55	28AUG2020	71484	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314671	C4591001 1231 12314671	16-55	28AUG2020	71487	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314672	C4591001 1231 12314672	16-55	28AUG2020	71478	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314674	C4591001 1231 12314674	16-55	28AUG2020	71518	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314677	C4591001 1231 12314677	16-55	28AUG2020	71522	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314678	C4591001 1231 12314678	16-55	28AUG2020	71510	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314679	C4591001 1231 12314679	16-55	28AUG2020	71524	Placebo	28AUG2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12314680	C4591001 1231 12314680	16-55	28AUG2020	71481	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314682	C4591001 1231 12314682	16-55	28AUG2020	71508	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314684	C4591001 1231 12314684	16-55	28AUG2020	71507	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314685	C4591001 1231 12314685	16-55	28AUG2020	71525	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314686	C4591001 1231 12314686	16-55	28AUG2020	71560	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314688	C4591001 1231 12314688	16-55	28AUG2020	71536	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314689	C4591001 1231 12314689	16-55	28AUG2020	71528	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314691	C4591001 1231 12314691	16-55	28AUG2020	71558	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314693	C4591001 1231 12314693	16-55	28AUG2020	71523	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314694	C4591001 1231 12314694	16-55	28AUG2020	71589	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314695	C4591001 1231 12314695	16-55	28AUG2020	71535	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314697	C4591001 1231 12314697	16-55	28AUG2020	71550	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314698	C4591001 1231 12314698	16-55	28AUG2020	71575	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314699	C4591001 1231 12314699	16-55	28AUG2020	71573	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314700	C4591001 1231 12314700	16-55	28AUG2020	71557	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
12314701	C4591001 1231 12314701	16-55	28AUG2020	71583	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314703	C4591001 1231 12314703	16-55	28AUG2020	71578	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314705	C4591001 1231 12314705	16-55	28AUG2020	71590	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314706	C4591001 1231 12314706	16-55	28AUG2020	71613	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314708	C4591001 1231 12314708	16-55	28AUG2020	71591	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314709	C4591001 1231 12314709	16-55	28AUG2020	71592	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314710	C4591001 1231 12314710	16-55	28AUG2020	71611	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314712	C4591001 1231 12314712	16-55	28AUG2020	71616	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314713	C4591001 1231 12314713	16-55	28AUG2020	71614	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
12314714	C4591001 1231 12314714	16-55	28AUG2020	71625	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314715	C4591001 1231 12314715	16-55	28AUG2020	71647	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314716	C4591001 1231 12314716	16-55	28AUG2020	71648	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314717	C4591001 1231 12314717	16-55	28AUG2020	71655	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12314718	C4591001 1231 12314718	16-55	28AUG2020	71623	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314719	C4591001 1231 12314719	16-55	28AUG2020	71626	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314721	C4591001 1231 12314721	16-55	28AUG2020	71622	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314722	C4591001 1231 12314722	16-55	28AUG2020	71677	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314723	C4591001 1231 12314723	16-55	28AUG2020	71651	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314727	C4591001 1231 12314727	16-55	28AUG2020	71803	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314730	C4591001 1231 12314730	16-55	28AUG2020	71750	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314731	C4591001 1231 12314731	16-55	28AUG2020	71672	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314734	C4591001 1231 12314734	16-55	28AUG2020	71680	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314735	C4591001 1231 12314735	16-55	28AUG2020	71678	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314738	C4591001 1231 12314738	16-55	28AUG2020	71749	Placebo				
12314739	C4591001 1231 12314739	16-55	28AUG2020	71762	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314740	C4591001 1231 12314740	16-55	28AUG2020	71751	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314742	C4591001 1231 12314742	16-55	28AUG2020	71761	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314743	C4591001 1231 12314743	16-55	28AUG2020	71745	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314744	C4591001 1231 12314744	16-55	28AUG2020	71793	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314745	C4591001 1231 12314745	16-55	28AUG2020	71758	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314746	C4591001 1231 12314746	16-55	28AUG2020	71790	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo		
12314749	C4591001 1231 12314749	16-55	28AUG2020	71816	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314750	C4591001 1231 12314750	16-55	28AUG2020	71792	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314751	C4591001 1231 12314751	16-55	28AUG2020	71815	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314752	C4591001 1231 12314752	16-55	28AUG2020	71764	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314754	C4591001 1231 12314754	16-55	28AUG2020	71794	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314756	C4591001 1231 12314756	16-55	28AUG2020	71805	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314757	C4591001 1231 12314757	16-55	28AUG2020	71814	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314760	C4591001 1231 12314760	16-55	28AUG2020	71806	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314761	C4591001 1231 12314761	16-55	28AUG2020	71819	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314764	C4591001 1231 12314764	16-55	28AUG2020	71809	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314768	C4591001 1231 12314768	16-55	28AUG2020	71873	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314771	C4591001 1231 12314771	16-55	28AUG2020	71882	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314772	C4591001 1231 12314772	16-55	28AUG2020	71884	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12314774	C4591001 1231 12314774	16-55	28AUG2020	71874	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314776	C4591001 1231 12314776	16-55	28AUG2020	71933	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314777	C4591001 1231 12314777	16-55	28AUG2020	71985	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314781	C4591001 1231 12314781	16-55	28AUG2020	71934	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314782	C4591001 1231 12314782	16-55	28AUG2020	71942	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314783	C4591001 1231 12314783	16-55	28AUG2020	71936	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314787	C4591001 1231 12314787	16-55	28AUG2020	71986	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314788	C4591001 1231 12314788	16-55	28AUG2020	71988	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314789	C4591001 1231 12314789	16-55	28AUG2020	72066	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314790	C4591001 1231 12314790	16-55	28AUG2020	71991	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314792	C4591001 1231 12314792	16-55	28AUG2020	72067	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314794	C4591001 1231 12314794	16-55	28AUG2020	72071	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314796	C4591001 1231 12314796	16-55	28AUG2020	72076	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314797	C4591001 1231 12314797	16-55	28AUG2020	72119	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314798	C4591001 1231 12314798	16-55	28AUG2020	72095	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314800	C4591001 1231 12314800	16-55	28AUG2020	72096	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314801	C4591001 1231 12314801	16-55	28AUG2020	72091	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314803	C4591001 1231 12314803	16-55	28AUG2020	72117	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314804	C4591001 1231 12314804	16-55	28AUG2020	72118	Placebo	28AUG2020/ Placebo	02OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12314806	C4591001 1231 12314806	16-55	28AUG2020	72100	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314809	C4591001 1231 12314809	16-55	28AUG2020	72152	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314813	C4591001 1231 12314813	16-55	28AUG2020	72154	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314814	C4591001 1231 12314814	16-55	28AUG2020	72149	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314815	C4591001 1231 12314815	16-55	28AUG2020	72122	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314816	C4591001 1231 12314816	16-55	28AUG2020	72176	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314817	C4591001 1231 12314817	16-55	28AUG2020	72153	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314818	C4591001 1231 12314818	16-55	28AUG2020	72182	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314819	C4591001 1231 12314819	16-55	28AUG2020	72234	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314824	C4591001 1231 12314824	16-55	28AUG2020	72183	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314826	C4591001 1231 12314826	16-55	28AUG2020	72184	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314832	C4591001 1231 12314832	16-55	28AUG2020	72237	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314833	C4591001 1231 12314833	16-55	28AUG2020	72235	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314834	C4591001 1231 12314834	16-55	28AUG2020	72286	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314835	C4591001 1231 12314835	16-55	28AUG2020	72283	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314836	C4591001 1231 12314836	16-55	28AUG2020	72291	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314838	C4591001 1231 12314838	16-55	28AUG2020	72289	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314840	C4591001 1231 12314840	16-55	28AUG2020	72240	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314842	C4591001 1231 12314842	16-55	28AUG2020	72313	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314843	C4591001 1231 12314843	16-55	28AUG2020	72312	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314844	C4591001 1231 12314844	16-55	28AUG2020	72316	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314845	C4591001 1231 12314845	16-55	28AUG2020	72315	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314846	C4591001 1231 12314846	16-55	28AUG2020	72401	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314847	C4591001 1231 12314847	16-55	28AUG2020	72403	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12314848	C4591001 1231 12314848	16-55	28AUG2020	72405	Placebo	28AUG2020/ Placebo			
12314851	C4591001 1231 12314851	16-55	28AUG2020	72595	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314852	C4591001 1231 12314852	16-55	28AUG2020	72539	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314853	C4591001 1231 12314853	16-55	28AUG2020	72537	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314854	C4591001 1231 12314854	16-55	28AUG2020	72540	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314855	C4591001 1231 12314855	16-55	28AUG2020	72603	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314857	C4591001 1231 12314857	16-55	28AUG2020	72728	Placebo	28AUG2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314858	C4591001 1231 12314858	16-55	28AUG2020	72409	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314859	C4591001 1231 12314859	16-55	28AUG2020	72544	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314862	C4591001 1231 12314862	16-55	28AUG2020	72698	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314864	C4591001 1231 12314864	16-55	28AUG2020	72639	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314866	C4591001 1231 12314866	16-55	28AUG2020	72730	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314868	C4591001 1231 12314868	16-55	28AUG2020	72604	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12314869	C4591001 1231 12314869	16-55	28AUG2020	72732	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314870	C4591001 1231 12314870	16-55	28AUG2020	72637	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12314872	C4591001 1231 12314872	16-55	28AUG2020	72690	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314873	C4591001 1231 12314873	16-55	28AUG2020	72736	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314874	C4591001 1231 12314874	16-55	28AUG2020	72630	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314876	C4591001 1231 12314876	16-55	28AUG2020	72596	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314877	C4591001 1231 12314877	16-55	28AUG2020	72696	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314878	C4591001 1231 12314878	16-55	28AUG2020	72694	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314880	C4591001 1231 12314880	16-55	28AUG2020	72638	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314883	C4591001 1231 12314883	16-55	28AUG2020	72800	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314884	C4591001 1231 12314884	16-55	28AUG2020	72797	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314885	C4591001 1231 12314885	16-55	28AUG2020	72806	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314886	C4591001 1231 12314886	16-55	28AUG2020	72805	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314889	C4591001 1231 12314889	16-55	28AUG2020	72812	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314890	C4591001 1231 12314890	16-55	28AUG2020	72815	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314892	C4591001 1231 12314892	16-55	28AUG2020	72920	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314893	C4591001 1231 12314893	16-55	28AUG2020	72868	Placebo	28AUG2020/ Placebo	25SEP2020/ Placebo		
12314894	C4591001 1231 12314894	16-55	28AUG2020	72865	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12314895	C4591001 1231 12314895	16-55	28AUG2020	72820	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314896	C4591001 1231 12314896	16-55	28AUG2020	72816	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314899	C4591001 1231 12314899	16-55	28AUG2020	72867	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314900	C4591001 1231 12314900	16-55	28AUG2020	72915	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314901	C4591001 1231 12314901	16-55	28AUG2020	72863	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314903	C4591001 1231 12314903	16-55	28AUG2020	72906	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314905	C4591001 1231 12314905	16-55	28AUG2020	72875	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314907	C4591001 1231 12314907	16-55	28AUG2020	72945	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314908	C4591001 1231 12314908	16-55	28AUG2020	72947	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314909	C4591001 1231 12314909	16-55	28AUG2020	72869	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314910	C4591001 1231 12314910	16-55	28AUG2020	72872	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314912	C4591001 1231 12314912	16-55	28AUG2020	72977	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314913	C4591001 1231 12314913	16-55	28AUG2020	72918	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12314914	C4591001 1231 12314914	16-55	28AUG2020	72978	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314917	C4591001 1231 12314917	16-55	28AUG2020	72925	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12314918	C4591001 1231 12314918	16-55	28AUG2020	72873	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12314919	C4591001 1231 12314919	16-55	28AUG2020	72914	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314921	C4591001 1231 12314921	16-55	28AUG2020	72919	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314922	C4591001 1231 12314922	16-55	28AUG2020	72984	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314923	C4591001 1231 12314923	16-55	28AUG2020	72910	Placebo	28AUG2020/ Placebo			
12314924	C4591001 1231 12314924	16-55	28AUG2020	72951	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12314925	C4591001 1231 12314925	16-55	28AUG2020	72943	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314928	C4591001 1231 12314928	16-55	28AUG2020	72985	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314929	C4591001 1231 12314929	16-55	28AUG2020	72990	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314930	C4591001 1231 12314930	16-55	28AUG2020	72989	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314931	C4591001 1231 12314931	16-55	28AUG2020	73025	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12314934	C4591001 1231 12314934	16-55	28AUG2020	72998	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314935	C4591001 1231 12314935	16-55	28AUG2020	73028	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314936	C4591001 1231 12314936	16-55	28AUG2020	73039	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314937	C4591001 1231 12314937	16-55	28AUG2020	72996	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314939	C4591001 1231 12314939	16-55	28AUG2020	73052	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12314940	C4591001 1231 12314940	16-55	28AUG2020	73030	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314943	C4591001 1231 12314943	16-55	28AUG2020	73047	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12314944	C4591001 1231 12314944	16-55	28AUG2020	73046	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314945	C4591001 1231 12314945	16-55	28AUG2020	73042	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314946	C4591001 1231 12314946	16-55	28AUG2020	73054	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314947	C4591001 1231 12314947	16-55	28AUG2020	73032	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314948	C4591001 1231 12314948	16-55	28AUG2020	73060	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314954	C4591001 1231 12314954	16-55	28AUG2020	73051	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314955	C4591001 1231 12314955	16-55	28AUG2020	73063	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12314959	C4591001 1231 12314959	16-55	28AUG2020	73064	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314962	C4591001 1231 12314962	16-55	28AUG2020	73066	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12314964	C4591001 1231 12314964	16-55	28AUG2020	73072	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12314967	C4591001 1231 12314967	16-55	28AUG2020	73138	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314968	C4591001 1231 12314968	16-55	28AUG2020	73136	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12314970	C4591001 1231 12314970	16-55	28AUG2020	73145	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12314974	C4591001 1231 12314974	16-55	28AUG2020	73139	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12314977	C4591001 1231 12314977	16-55	28AUG2020	73156	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12314980	C4591001 1231 12314980	16-55	28AUG2020	73149	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314983	C4591001 1231 12314983	16-55	28AUG2020	73141	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314984	C4591001 1231 12314984	16-55	28AUG2020	73152	Placebo	28AUG2020/ Placebo			
12314986	C4591001 1231 12314986	16-55	28AUG2020	73160	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314987	C4591001 1231 12314987	16-55	28AUG2020	73181	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12314992	C4591001 1231 12314992	16-55	28AUG2020	73166	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12314995	C4591001 1231 12314995	16-55	28AUG2020	73187	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314996	C4591001 1231 12314996	16-55	28AUG2020	73185	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12314998	C4591001 1231 12314998	16-55	28AUG2020	73191	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12314999	C4591001 1231 12314999	16-55	28AUG2020	73165	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315001	C4591001 1231 12315001	16-55	28AUG2020	73167	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
12315005	C4591001 1231 12315005	16-55	28AUG2020	73197	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315009	C4591001 1231 12315009	16-55	28AUG2020	73199	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315012	C4591001 1231 12315012	16-55	28AUG2020	73204	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315013	C4591001 1231 12315013	16-55	28AUG2020	73200	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315014	C4591001 1231 12315014	16-55	28AUG2020	73218	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315015	C4591001 1231 12315015	16-55	28AUG2020	73220	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315021	C4591001 1231 12315021	16-55	28AUG2020	73222	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315026	C4591001 1231 12315026	16-55	28AUG2020	73249	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315027	C4591001 1231 12315027	16-55	28AUG2020	73233	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315031	C4591001 1231 12315031	16-55	28AUG2020	73226	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315036	C4591001 1231 12315036	16-55	28AUG2020	73250	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315039	C4591001 1231 12315039	16-55	28AUG2020	73240	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315043	C4591001 1231 12315043	16-55	28AUG2020	73234	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315045	C4591001 1231 12315045	16-55	28AUG2020	73248	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315047	C4591001 1231 12315047	16-55	28AUG2020	73239	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315048	C4591001 1231 12315048	16-55	28AUG2020	73271	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315052	C4591001 1231 12315052	16-55	28AUG2020	73272	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315053	C4591001 1231 12315053	16-55	28AUG2020	73243	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12315054	C4591001 1231 12315054	16-55	28AUG2020	73273	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315055	C4591001 1231 12315055	16-55	29AUG2020	73274	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315056	C4591001 1231 12315056	16-55	29AUG2020	73277	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315057	C4591001 1231 12315057	16-55	29AUG2020	73278	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315059	C4591001 1231 12315059	16-55	29AUG2020	73304	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315060	C4591001 1231 12315060	16-55	29AUG2020	73282	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315061	C4591001 1231 12315061	16-55	29AUG2020	73339	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315062	C4591001 1231 12315062	16-55	29AUG2020	73288	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315063	C4591001 1231 12315063	16-55	29AUG2020	73330	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315064	C4591001 1231 12315064	16-55	29AUG2020	73306	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12315065	C4591001 1231 12315065	16-55	29AUG2020	73307	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315066	C4591001 1231 12315066	16-55	29AUG2020	73371	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315067	C4591001 1231 12315067	16-55	29AUG2020	73316	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315068	C4591001 1231 12315068	16-55	29AUG2020	73318	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315070	C4591001 1231 12315070	16-55	29AUG2020	73321	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315071	C4591001 1231 12315071	16-55	29AUG2020	73333	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315072	C4591001 1231 12315072	16-55	29AUG2020	73311	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315073	C4591001 1231 12315073	16-55	29AUG2020	73332	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315074	C4591001 1231 12315074	16-55	29AUG2020	73341	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315076	C4591001 1231 12315076	16-55	29AUG2020	73350	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315078	C4591001 1231 12315078	16-55	29AUG2020	73348	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315079	C4591001 1231 12315079	16-55	29AUG2020	73366	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315080	C4591001 1231 12315080	16-55	29AUG2020	73337	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315082	C4591001 1231 12315082	16-55	29AUG2020	73323	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315083	C4591001 1231 12315083	16-55	29AUG2020	73352	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315084	C4591001 1231 12315084	16-55	29AUG2020	73331	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315085	C4591001 1231 12315085	16-55	29AUG2020	73353	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315087	C4591001 1231 12315087	16-55	29AUG2020	73363	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315088	C4591001 1231 12315088	16-55	29AUG2020	73354	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315089	C4591001 1231 12315089	16-55	29AUG2020	73361	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315090	C4591001 1231 12315090	16-55	29AUG2020	73390	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315091	C4591001 1231 12315091	16-55	29AUG2020	73384	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315092	C4591001 1231 12315092	16-55	29AUG2020	73375	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315093	C4591001 1231 12315093	16-55	29AUG2020	73374	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315094	C4591001 1231 12315094	16-55	29AUG2020	73373	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315095	C4591001 1231 12315095	16-55	29AUG2020	73391	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12315098	C4591001 1231 12315098	16-55	29AUG2020	73394	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315099	C4591001 1231 12315099	16-55	29AUG2020	73397	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12315100	C4591001 1231 12315100	16-55	29AUG2020	73423	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315101	C4591001 1231 12315101	16-55	29AUG2020	73408	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315102	C4591001 1231 12315102	16-55	29AUG2020	73393	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315103	C4591001 1231 12315103	16-55	29AUG2020	73424	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315104	C4591001 1231 12315104	16-55	29AUG2020	73400	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315105	C4591001 1231 12315105	16-55	29AUG2020	73428	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315112	C4591001 1231 12315112	16-55	29AUG2020	73402	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315114	C4591001 1231 12315114	16-55	29AUG2020	73441	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315115	C4591001 1231 12315115	16-55	29AUG2020	73437	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315124	C4591001 1231 12315124	16-55	29AUG2020	73432	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315136	C4591001 1231 12315136	16-55	29AUG2020	73501	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315139	C4591001 1231 12315139	16-55	29AUG2020	73438	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315140	C4591001 1231 12315140	16-55	29AUG2020	73444	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315142	C4591001 1231 12315142	16-55	29AUG2020	73481	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315149	C4591001 1231 12315149	16-55	29AUG2020	73482	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315150	C4591001 1231 12315150	16-55	29AUG2020	73512	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315154	C4591001 1231 12315154	16-55	29AUG2020	73485	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315155	C4591001 1231 12315155	16-55	29AUG2020	73484	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315164	C4591001 1231 12315164	16-55	29AUG2020	73508	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315165	C4591001 1231 12315165	16-55	29AUG2020	73507	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315166	C4591001 1231 12315166	16-55	29AUG2020	73513	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315167	C4591001 1231 12315167	16-55	29AUG2020	73503	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315168	C4591001 1231 12315168	16-55	29AUG2020	73518	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315169	C4591001 1231 12315169	16-55	29AUG2020	73497	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315171	C4591001 1231 12315171	16-55	29AUG2020	73499	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315172	C4591001 1231 12315172	16-55	29AUG2020	73523	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315175	C4591001 1231 12315175	16-55	29AUG2020	73525	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315176	C4591001 1231 12315176	16-55	29AUG2020	73533	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315177	C4591001 1231 12315177	16-55	29AUG2020	73530	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315178	C4591001 1231 12315178	16-55	29AUG2020	73528	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315180	C4591001 1231 12315180	16-55	29AUG2020	73571	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315182	C4591001 1231 12315182	16-55	29AUG2020	73536	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315183	C4591001 1231 12315183	16-55	29AUG2020	73572	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315185	C4591001 1231 12315185	16-55	29AUG2020	73531	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315186	C4591001 1231 12315186	16-55	29AUG2020	73569	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315187	C4591001 1231 12315187	16-55	29AUG2020	73573	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315189	C4591001 1231 12315189	16-55	29AUG2020	73546	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12315190	C4591001 1231 12315190	16-55	29AUG2020	73548	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315191	C4591001 1231 12315191	16-55	29AUG2020	73589	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12315194	C4591001 1231 12315194	16-55	29AUG2020	73588	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315195	C4591001 1231 12315195	16-55	29AUG2020	73552	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315196	C4591001 1231 12315196	16-55	29AUG2020	73579	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315197	C4591001 1231 12315197	16-55	29AUG2020	73545	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315198	C4591001 1231 12315198	16-55	29AUG2020	73592	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315200	C4591001 1231 12315200	16-55	29AUG2020	73583	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315201	C4591001 1231 12315201	16-55	29AUG2020	73590	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315202	C4591001 1231 12315202	16-55	29AUG2020	73602	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12315203	C4591001 1231 12315203	16-55	29AUG2020	73586	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315204	C4591001 1231 12315204	16-55	29AUG2020	73594	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12315205	C4591001 1231 12315205	16-55	29AUG2020	73618	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315206	C4591001 1231 12315206	16-55	29AUG2020	73610	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315208	C4591001 1231 12315208	16-55	29AUG2020	73616	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315209	C4591001 1231 12315209	16-55	29AUG2020	73619	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315211	C4591001 1231 12315211	16-55	29AUG2020	73611	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315213	C4591001 1231 12315213	16-55	29AUG2020	73609	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315214	C4591001 1231 12315214	16-55	29AUG2020	73637	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315215	C4591001 1231 12315215	16-55	29AUG2020	73641	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315216	C4591001 1231 12315216	16-55	29AUG2020	73620	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315219	C4591001 1231 12315219	16-55	29AUG2020	73643	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315220	C4591001 1231 12315220	16-55	29AUG2020	73681	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315222	C4591001 1231 12315222	16-55	29AUG2020	73642	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315223	C4591001 1231 12315223	16-55	29AUG2020	73676	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12315224	C4591001 1231 12315224	16-55	29AUG2020	73725	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315225	C4591001 1231 12315225	16-55	29AUG2020	73710	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12315226	C4591001 1231 12315226	16-55	29AUG2020	73674	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315228	C4591001 1231 12315228	16-55	29AUG2020	73709	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315229	C4591001 1231 12315229	16-55	29AUG2020	73682	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315230	C4591001 1231 12315230	16-55	29AUG2020	73713	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315231	C4591001 1231 12315231	16-55	29AUG2020	73717	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315234	C4591001 1231 12315234	16-55	29AUG2020	73726	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315238	C4591001 1231 12315238	16-55	29AUG2020	73731	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315239	C4591001 1231 12315239	16-55	29AUG2020	73763	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315241	C4591001 1231 12315241	16-55	29AUG2020	73764	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315242	C4591001 1231 12315242	16-55	29AUG2020	73732	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315247	C4591001 1231 12315247	16-55	29AUG2020	73779	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo		
12315248	C4591001 1231 12315248	16-55	29AUG2020	73774	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315249	C4591001 1231 12315249	16-55	29AUG2020	73761	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315252	C4591001 1231 12315252	16-55	29AUG2020	73765	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315253	C4591001 1231 12315253	16-55	29AUG2020	73769	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315257	C4591001 1231 12315257	16-55	29AUG2020	73780	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315258	C4591001 1231 12315258	16-55	29AUG2020	73807	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315259	C4591001 1231 12315259	16-55	29AUG2020	73809	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315263	C4591001 1231 12315263	16-55	29AUG2020	73813	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315264	C4591001 1231 12315264	16-55	29AUG2020	73973	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12315265	C4591001 1231 12315265	16-55	29AUG2020	73815	Placebo	29AUG2020/ Placebo	29SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315268	C4591001 1231 12315268	16-55	29AUG2020	74007	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315269	C4591001 1231 12315269	16-55	29AUG2020	73975	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)			
12315270	C4591001 1231 12315270	16-55	29AUG2020	73919	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315271	C4591001 1231 12315271	16-55	29AUG2020	73917	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315272	C4591001 1231 12315272	16-55	29AUG2020	73924	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315275	C4591001 1231 12315275	16-55	29AUG2020	73921	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315276	C4591001 1231 12315276	16-55	29AUG2020	73994	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315277	C4591001 1231 12315277	16-55	29AUG2020	73982	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315278	C4591001 1231 12315278	16-55	29AUG2020	73941	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315279	C4591001 1231 12315279	16-55	29AUG2020	73954	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315280	C4591001 1231 12315280	16-55	29AUG2020	73952	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315281	C4591001 1231 12315281	16-55	29AUG2020	73938	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315282	C4591001 1231 12315282	16-55	29AUG2020	73947	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315283	C4591001 1231 12315283	16-55	29AUG2020	73959	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315284	C4591001 1231 12315284	16-55	29AUG2020	73958	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315285	C4591001 1231 12315285	16-55	29AUG2020	73945	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315286	C4591001 1231 12315286	16-55	29AUG2020	74000	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315287	C4591001 1231 12315287	16-55	29AUG2020	73974	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315288	C4591001 1231 12315288	16-55	29AUG2020	74008	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315289	C4591001 1231 12315289	16-55	29AUG2020	73990	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315291	C4591001 1231 12315291	16-55	29AUG2020	73991	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315292	C4591001 1231 12315292	16-55	29AUG2020	74022	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315294	C4591001 1231 12315294	16-55	29AUG2020	74030	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315295	C4591001 1231 12315295	16-55	29AUG2020	73995	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315296	C4591001 1231 12315296	16-55	29AUG2020	74046	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315297	C4591001 1231 12315297	16-55	29AUG2020	74003	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315298	C4591001 1231 12315298	16-55	29AUG2020	74049	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315299	C4591001 1231 12315299	16-55	29AUG2020	74027	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315300	C4591001 1231 12315300	16-55	29AUG2020	74057	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315302	C4591001 1231 12315302	16-55	29AUG2020	74058	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315304	C4591001 1231 12315304	16-55	29AUG2020	74060	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315306	C4591001 1231 12315306	16-55	29AUG2020	74098	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12315307	C4591001 1231 12315307	16-55	29AUG2020	74099	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315308	C4591001 1231 12315308	16-55	29AUG2020	74100	BNT162b2 (30 µg)				
12315309	C4591001 1231 12315309	16-55	29AUG2020	74026	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315310	C4591001 1231 12315310	16-55	29AUG2020	74107	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315311	C4591001 1231 12315311	16-55	29AUG2020	74047	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315312	C4591001 1231 12315312	16-55	29AUG2020	74110	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315313	C4591001 1231 12315313	16-55	29AUG2020	74045	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315316	C4591001 1231 12315316	16-55	29AUG2020	74115	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315317	C4591001 1231 12315317	16-55	29AUG2020	74064	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315318	C4591001 1231 12315318	16-55	29AUG2020	74123	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315319	C4591001 1231 12315319	16-55	29AUG2020	74104	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315320	C4591001 1231 12315320	16-55	29AUG2020	74126	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315322	C4591001 1231 12315322	16-55	29AUG2020	74130	Placebo	29AUG2020/ Placebo	23OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315325	C4591001 1231 12315325	16-55	29AUG2020	74118	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315326	C4591001 1231 12315326	16-55	29AUG2020	74132	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315329	C4591001 1231 12315329	16-55	29AUG2020	74114	Placebo	29AUG2020/ Placebo	01OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315330	C4591001 1231 12315330	16-55	29AUG2020	74134	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315333	C4591001 1231 12315333	16-55	29AUG2020	74127	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315334	C4591001 1231 12315334	16-55	29AUG2020	74156	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315337	C4591001 1231 12315337	16-55	29AUG2020	74153	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315338	C4591001 1231 12315338	16-55	29AUG2020	74160	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo		
12315340	C4591001 1231 12315340	16-55	29AUG2020	74138	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315342	C4591001 1231 12315342	16-55	29AUG2020	74163	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315343	C4591001 1231 12315343	16-55	29AUG2020	74173	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315347	C4591001 1231 12315347	16-55	29AUG2020	74176	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315348	C4591001 1231 12315348	16-55	29AUG2020	74175	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315349	C4591001 1231 12315349	16-55	29AUG2020	74177	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315351	C4591001 1231 12315351	16-55	29AUG2020	74180	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315352	C4591001 1231 12315352	16-55	29AUG2020	74171	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315353	C4591001 1231 12315353	16-55	29AUG2020	74195	Placebo	29AUG2020/ Placebo	06OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315355	C4591001 1231 12315355	16-55	29AUG2020	74192	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315357	C4591001 1231 12315357	16-55	29AUG2020	74189	Placebo	29AUG2020/ Placebo			
12315358	C4591001 1231 12315358	16-55	29AUG2020	74186	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315359	C4591001 1231 12315359	16-55	29AUG2020	74183	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315361	C4591001 1231 12315361	16-55	29AUG2020	74202	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315362	C4591001 1231 12315362	16-55	29AUG2020	74196	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315363	C4591001 1231 12315363	16-55	29AUG2020	74212	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315364	C4591001 1231 12315364	16-55	29AUG2020	74206	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo		
12315365	C4591001 1231 12315365	16-55	29AUG2020	74204	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315368	C4591001 1231 12315368	16-55	29AUG2020	74216	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315369	C4591001 1231 12315369	16-55	29AUG2020	74213	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315370	C4591001 1231 12315370	16-55	29AUG2020	74228	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315371	C4591001 1231 12315371	16-55	29AUG2020	74231	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315372	C4591001 1231 12315372	16-55	29AUG2020	74234	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315373	C4591001 1231 12315373	16-55	29AUG2020	74218	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315374	C4591001 1231 12315374	16-55	29AUG2020	74240	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315375	C4591001 1231 12315375	16-55	29AUG2020	74223	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315376	C4591001 1231 12315376	16-55	29AUG2020	74245	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315377	C4591001 1231 12315377	16-55	29AUG2020	74229	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315378	C4591001 1231 12315378	16-55	29AUG2020	74248	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315380	C4591001 1231 12315380	16-55	29AUG2020	74262	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12315381	C4591001 1231 12315381	16-55	29AUG2020	74247	Placebo	29AUG2020/ Placebo	17SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315386	C4591001 1231 12315386	16-55	30AUG2020	74264	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo		
12315391	C4591001 1231 12315391	16-55	30AUG2020	74329	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315393	C4591001 1231 12315393	16-55	30AUG2020	74318	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315394	C4591001 1231 12315394	16-55	30AUG2020	74300	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315397	C4591001 1231 12315397	16-55	30AUG2020	74303	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315400	C4591001 1231 12315400	16-55	30AUG2020	74266	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315401	C4591001 1231 12315401	16-55	30AUG2020	74271	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315402	C4591001 1231 12315402	16-55	30AUG2020	74326	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315406	C4591001 1231 12315406	16-55	30AUG2020	74307	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315407	C4591001 1231 12315407	16-55	30AUG2020	74309	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315408	C4591001 1231 12315408	16-55	30AUG2020	74301	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315409	C4591001 1231 12315409	16-55	30AUG2020	74344	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315412	C4591001 1231 12315412	16-55	30AUG2020	74349	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315413	C4591001 1231 12315413	16-55	30AUG2020	74330	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315414	C4591001 1231 12315414	16-55	30AUG2020	74333	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12315415	C4591001 1231 12315415	16-55	30AUG2020	74323	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315416	C4591001 1231 12315416	16-55	30AUG2020	74313	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315418	C4591001 1231 12315418	16-55	30AUG2020	74315	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315419	C4591001 1231 12315419	16-55	30AUG2020	74354	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315420	C4591001 1231 12315420	16-55	30AUG2020	74353	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315421	C4591001 1231 12315421	16-55	30AUG2020	74336	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315422	C4591001 1231 12315422	16-55	30AUG2020	74339	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315424	C4591001 1231 12315424	16-55	30AUG2020	74360	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12315426	C4591001 1231 12315426	16-55	30AUG2020	74347	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315427	C4591001 1231 12315427	16-55	30AUG2020	74365	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315429	C4591001 1231 12315429	16-55	30AUG2020	74367	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)			
12315430	C4591001 1231 12315430	16-55	30AUG2020	74368	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12315435	C4591001 1231 12315435	16-55	30AUG2020	74369	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12315436	C4591001 1231 12315436	16-55	30AUG2020	74375	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315437	C4591001 1231 12315437	16-55	30AUG2020	74372	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315440	C4591001 1231 12315440	16-55	30AUG2020	74377	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315441	C4591001 1231 12315441	16-55	30AUG2020	74386	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)			
12315445	C4591001 1231 12315445	16-55	30AUG2020	74384	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315446	C4591001 1231 12315446	16-55	30AUG2020	74397	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315448	C4591001 1231 12315448	16-55	30AUG2020	74398	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315449	C4591001 1231 12315449	16-55	30AUG2020	74387	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315450	C4591001 1231 12315450	16-55	30AUG2020	74415	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315451	C4591001 1231 12315451	16-55	30AUG2020	74396	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315453	C4591001 1231 12315453	16-55	30AUG2020	74404	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315454	C4591001 1231 12315454	16-55	30AUG2020	74388	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315457	C4591001 1231 12315457	16-55	30AUG2020	74412	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315459	C4591001 1231 12315459	16-55	30AUG2020	74421	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315460	C4591001 1231 12315460	16-55	30AUG2020	74414	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315461	C4591001 1231 12315461	16-55	30AUG2020	74410	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315462	C4591001 1231 12315462	16-55	30AUG2020	74419	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315463	C4591001 1231 12315463	16-55	30AUG2020	74417	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315464	C4591001 1231 12315464	16-55	30AUG2020	74440	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12315465	C4591001 1231 12315465	16-55	30AUG2020	74443	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315466	C4591001 1231 12315466	16-55	30AUG2020	74431	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315467	C4591001 1231 12315467	16-55	30AUG2020	74451	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315469	C4591001 1231 12315469	16-55	30AUG2020	74429	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315470	C4591001 1231 12315470	16-55	30AUG2020	74448	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315471	C4591001 1231 12315471	16-55	30AUG2020	74435	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315472	C4591001 1231 12315472	16-55	30AUG2020	74423	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315473	C4591001 1231 12315473	16-55	30AUG2020	74444	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315474	C4591001 1231 12315474	16-55	30AUG2020	74453	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315475	C4591001 1231 12315475	16-55	30AUG2020	74458	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315477	C4591001 1231 12315477	16-55	30AUG2020	74468	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315478	C4591001 1231 12315478	16-55	30AUG2020	74463	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315479	C4591001 1231 12315479	16-55	30AUG2020	74465	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315480	C4591001 1231 12315480	16-55	30AUG2020	74462	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315481	C4591001 1231 12315481	16-55	30AUG2020	74471	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315484	C4591001 1231 12315484	16-55	30AUG2020	74467	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315487	C4591001 1231 12315487	16-55	30AUG2020	74477	Placebo	30AUG2020/ Placebo	21SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315489	C4591001 1231 12315489	16-55	30AUG2020	74483	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315491	C4591001 1231 12315491	16-55	30AUG2020	74481	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315492	C4591001 1231 12315492	16-55	30AUG2020	74482	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315493	C4591001 1231 12315493	16-55	30AUG2020	74500	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12315494	C4591001 1231 12315494	16-55	30AUG2020	74497	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12315495	C4591001 1231 12315495	16-55	30AUG2020	74490	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315496	C4591001 1231 12315496	16-55	30AUG2020	74503	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315497	C4591001 1231 12315497	16-55	30AUG2020	74532	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	12MAR2021/ BNT162b2 (30 µg)	
12315498	C4591001 1231 12315498	16-55	30AUG2020	74489	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12315499	C4591001 1231 12315499	16-55	30AUG2020	74557	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315502	C4591001 1231 12315502	16-55	30AUG2020	74505	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315504	C4591001 1231 12315504	16-55	30AUG2020	74509	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315505	C4591001 1231 12315505	16-55	30AUG2020	74531	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315506	C4591001 1231 12315506	16-55	30AUG2020	74522	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315511	C4591001 1231 12315511	16-55	30AUG2020	74502	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315512	C4591001 1231 12315512	16-55	30AUG2020	74517	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315513	C4591001 1231 12315513	16-55	30AUG2020	74515	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315514	C4591001 1231 12315514	16-55	30AUG2020	74542	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315516	C4591001 1231 12315516	16-55	30AUG2020	74540	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12315517	C4591001 1231 12315517	16-55	30AUG2020	74519	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315518	C4591001 1231 12315518	16-55	30AUG2020	74526	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12315519	C4591001 1231 12315519	16-55	30AUG2020	74543	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315521	C4591001 1231 12315521	16-55	30AUG2020	74525	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315525	C4591001 1231 12315525	16-55	30AUG2020	74548	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12315526	C4591001 1231 12315526	16-55	30AUG2020	74558	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315527	C4591001 1231 12315527	16-55	30AUG2020	74550	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315528	C4591001 1231 12315528	16-55	30AUG2020	74561	Placebo	30AUG2020/ Placebo	28SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315529	C4591001 1231 12315529	16-55	30AUG2020	74581	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315532	C4591001 1231 12315532	16-55	30AUG2020	74552	Placebo	30AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315533	C4591001 1231 12315533	16-55	30AUG2020	74563	Placebo	30AUG2020/ Placebo	22SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315534	C4591001 1231 12315534	16-55	30AUG2020	74564	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12315535	C4591001 1231 12315535	16-55	30AUG2020	74577	Placebo	30AUG2020/ Placebo	21SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315537	C4591001 1231 12315537	16-55	30AUG2020	74569	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12315538	C4591001 1231 12315538	16-55	30AUG2020	74578	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315540	C4591001 1231 12315540	16-55	31AUG2020	74599	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315541	C4591001 1231 12315541	16-55	31AUG2020	74583	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315542	C4591001 1231 12315542	16-55	31AUG2020	74605	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315543	C4591001 1231 12315543	16-55	31AUG2020	74603	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315544	C4591001 1231 12315544	16-55	31AUG2020	74643	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315545	C4591001 1231 12315545	16-55	31AUG2020	74608	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315546	C4591001 1231 12315546	16-55	31AUG2020	74639	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315547	C4591001 1231 12315547	16-55	31AUG2020	74614	Placebo	31AUG2020/ Placebo	28SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315550	C4591001 1231 12315550	16-55	31AUG2020	74619	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315551	C4591001 1231 12315551	16-55	31AUG2020	74610	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315552	C4591001 1231 12315552	16-55	31AUG2020	74640	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315553	C4591001 1231 12315553	16-55	31AUG2020	74618	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12315554	C4591001 1231 12315554	16-55	31AUG2020	74637	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315558	C4591001 1231 12315558	16-55	31AUG2020	74687	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315559	C4591001 1231 12315559	16-55	31AUG2020	74692	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315560	C4591001 1231 12315560	16-55	31AUG2020	74684	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315561	C4591001 1231 12315561	16-55	31AUG2020	74691	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315563	C4591001 1231 12315563	16-55	31AUG2020	74706	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315566	C4591001 1231 12315566	16-55	31AUG2020	74709	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315567	C4591001 1231 12315567	16-55	31AUG2020	219995	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315568	C4591001 1231 12315568	16-55	31AUG2020	74710	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo		
12315572	C4591001 1231 12315572	16-55	31AUG2020	74711	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315575	C4591001 1231 12315575	16-55	31AUG2020	74827	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315576	C4591001 1231 12315576	16-55	31AUG2020	74828	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315577	C4591001 1231 12315577	16-55	31AUG2020	74835	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315578	C4591001 1231 12315578	16-55	31AUG2020	74832	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315580	C4591001 1231 12315580	16-55	31AUG2020	74876	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315581	C4591001 1231 12315581	16-55	31AUG2020	74875	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315583	C4591001 1231 12315583	16-55	31AUG2020	74880	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315585	C4591001 1231 12315585	16-55	31AUG2020	74882	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12315586	C4591001 1231 12315586	16-55	31AUG2020	74897	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315590	C4591001 1231 12315590	16-55	31AUG2020	74901	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
12315591	C4591001 1231 12315591	16-55	31AUG2020	74900	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315595	C4591001 1231 12315595	16-55	31AUG2020	74993	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315596	C4591001 1231 12315596	16-55	31AUG2020	74902	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315599	C4591001 1231 12315599	16-55	31AUG2020	74997	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315600	C4591001 1231 12315600	16-55	31AUG2020	74998	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)			
12315601	C4591001 1231 12315601	16-55	31AUG2020	75077	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315603	C4591001 1231 12315603	16-55	31AUG2020	75078	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315605	C4591001 1231 12315605	16-55	31AUG2020	75002	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315609	C4591001 1231 12315609	16-55	31AUG2020	75081	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315613	C4591001 1231 12315613	16-55	31AUG2020	75084	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315615	C4591001 1231 12315615	16-55	31AUG2020	75428	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315616	C4591001 1231 12315616	16-55	31AUG2020	75425	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315618	C4591001 1231 12315618	16-55	31AUG2020	75435	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12315621	C4591001 1231 12315621	16-55	31AUG2020	75436	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315622	C4591001 1231 12315622	16-55	31AUG2020	75546	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12315623	C4591001 1231 12315623	16-55	31AUG2020	75668	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo		
12315624	C4591001 1231 12315624	16-55	31AUG2020	75550	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315626	C4591001 1231 12315626	16-55	31AUG2020	75671	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315627	C4591001 1231 12315627	16-55	31AUG2020	75757	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315628	C4591001 1231 12315628	16-55	31AUG2020	75665	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12315629	C4591001 1231 12315629	16-55	31AUG2020	75705	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315630	C4591001 1231 12315630	16-55	31AUG2020	75551	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315633	C4591001 1231 12315633	16-55	31AUG2020	75673	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315635	C4591001 1231 12315635	16-55	31AUG2020	75791	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315636	C4591001 1231 12315636	16-55	31AUG2020	75704	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315637	C4591001 1231 12315637	16-55	31AUG2020	75711	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315638	C4591001 1231 12315638	16-55	31AUG2020	75713	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315639	C4591001 1231 12315639	16-55	31AUG2020	75553	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315641	C4591001 1231 12315641	16-55	31AUG2020	75716	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315642	C4591001 1231 12315642	16-55	31AUG2020	75720	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315643	C4591001 1231 12315643	16-55	31AUG2020	75724	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315644	C4591001 1231 12315644	16-55	31AUG2020	75706	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315645	C4591001 1231 12315645	16-55	31AUG2020	75758	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12315646	C4591001 1231 12315646	16-55	31AUG2020	75752	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315647	C4591001 1231 12315647	16-55	31AUG2020	75759	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315648	C4591001 1231 12315648	16-55	31AUG2020	75789	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315649	C4591001 1231 12315649	16-55	31AUG2020	75785	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315650	C4591001 1231 12315650	16-55	31AUG2020	75790	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315651	C4591001 1231 12315651	16-55	31AUG2020	75839	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315652	C4591001 1231 12315652	16-55	31AUG2020	75835	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
12315659	C4591001 1231 12315659	16-55	31AUG2020	75843	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12315663	C4591001 1231 12315663	16-55	31AUG2020	75844	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315666	C4591001 1231 12315666	16-55	31AUG2020	76014	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315667	C4591001 1231 12315667	16-55	31AUG2020	76018	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12315673	C4591001 1231 12315673	16-55	31AUG2020	76024	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12315674	C4591001 1231 12315674	16-55	31AUG2020	76020	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12315676	C4591001 1231 12315676	16-55	31AUG2020	76067	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315677	C4591001 1231 12315677	16-55	31AUG2020	76056	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12315678	C4591001 1231 12315678	16-55	31AUG2020	76055	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12315680	C4591001 1231 12315680	16-55	31AUG2020	76060	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12315681	C4591001 1231 12315681	16-55	31AUG2020	76057	Placebo	31AUG2020/ Placebo	22OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12315682	C4591001 1231 12315682	16-55	31AUG2020	76071	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12315684	C4591001 1231 12315684	16-55	31AUG2020	76070	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12321027	C4591001 1232 12321027	16-55	17AUG2020	50699	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321028	C4591001 1232 12321028	16-55	17AUG2020	50701	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12321030	C4591001 1232 12321030	16-55	17AUG2020	50703	Placebo	17AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321033	C4591001 1232 12321033	16-55	17AUG2020	53190	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12321036	C4591001 1232 12321036	16-55	18AUG2020	53193	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321037	C4591001 1232 12321037	16-55	18AUG2020	53200	BNT162b2 (30 µg)				
12321038	C4591001 1232 12321038	16-55	18AUG2020	53195	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12321040	C4591001 1232 12321040	16-55	18AUG2020	54571	Placebo	18AUG2020/ Placebo	08SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321042	C4591001 1232 12321042	16-55	18AUG2020	54572	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321043	C4591001 1232 12321043	16-55	18AUG2020	54577	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12321044	C4591001 1232 12321044	16-55	19AUG2020	54579	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321045	C4591001 1232 12321045	16-55	19AUG2020	55818	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321046	C4591001 1232 12321046	16-55	19AUG2020	55821	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321048	C4591001 1232 12321048	16-55	19AUG2020	55827	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo		
12321049	C4591001 1232 12321049	16-55	19AUG2020	55828	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12321052	C4591001 1232 12321052	16-55	19AUG2020	56465	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12321053	C4591001 1232 12321053	16-55	19AUG2020	56469	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321054	C4591001 1232 12321054	16-55	19AUG2020	56472	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo		
12321055	C4591001 1232 12321055	16-55	19AUG2020	56476	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12321056	C4591001 1232 12321056	16-55	19AUG2020	56549	Placebo	19AUG2020/ Placebo	23SEP2020/ Placebo		
12321057	C4591001 1232 12321057	16-55	19AUG2020	56553	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321060	C4591001 1232 12321060	16-55	19AUG2020	56554	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321061	C4591001 1232 12321061	16-55	19AUG2020	56559	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12321066	C4591001 1232 12321066	16-55	20AUG2020	58385	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321068	C4591001 1232 12321068	16-55	20AUG2020	58389	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12321069	C4591001 1232 12321069	16-55	24AUG2020	58393	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321070	C4591001 1232 12321070	16-55	24AUG2020	58394	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12321071	C4591001 1232 12321071	16-55	24AUG2020	63296	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12321072	C4591001 1232 12321072	16-55	24AUG2020	63353	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12321074	C4591001 1232 12321074	16-55	24AUG2020	63359	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12321079	C4591001 1232 12321079	16-55	24AUG2020	63361	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321080	C4591001 1232 12321080	16-55	24AUG2020	63362	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12321084	C4591001 1232 12321084	16-55	25AUG2020	63776	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12321086	C4591001 1232 12321086	16-55	25AUG2020	63777	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12321087	C4591001 1232 12321087	16-55	25AUG2020	63778	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12321089	C4591001 1232 12321089	16-55	25AUG2020	65525	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321090	C4591001 1232 12321090	16-55	25AUG2020	65526	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12321091	C4591001 1232 12321091	16-55	25AUG2020	65527	Placebo	25AUG2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321092	C4591001 1232 12321092	16-55	25AUG2020	65535	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321093	C4591001 1232 12321093	16-55	25AUG2020	65767	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12321094	C4591001 1232 12321094	16-55	25AUG2020	65829	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321095	C4591001 1232 12321095	16-55	26AUG2020	65830	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12321098	C4591001 1232 12321098	16-55	26AUG2020	65833	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12321099	C4591001 1232 12321099	16-55	26AUG2020	65834	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12321100	C4591001 1232 12321100	16-55	26AUG2020	67541	Placebo	26AUG2020/ Placebo		16FEB2021/ BNT162b2 (30 µg)	
12321101	C4591001 1232 12321101	16-55	26AUG2020	67543	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)			
12321104	C4591001 1232 12321104	16-55	26AUG2020	67547	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321108	C4591001 1232 12321108	16-55	26AUG2020	67552	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12321111	C4591001 1232 12321111	16-55	26AUG2020	68802	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12321112	C4591001 1232 12321112	16-55	26AUG2020	68803	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12321114	C4591001 1232 12321114	16-55	26AUG2020	68809	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321116	C4591001 1232 12321116	16-55	27AUG2020	68811	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12321119	C4591001 1232 12321119	16-55	27AUG2020	69665	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12321120	C4591001 1232 12321120	16-55	27AUG2020	69667	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12321121	C4591001 1232 12321121	16-55	27AUG2020	69668	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12321122	C4591001 1232 12321122	16-55	27AUG2020	69671	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321123	C4591001 1232 12321123	16-55	27AUG2020	69859	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12321124	C4591001 1232 12321124	16-55	27AUG2020	69861	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12321130	C4591001 1232 12321130	16-55	27AUG2020	69862	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12321132	C4591001 1232 12321132	16-55	31AUG2020	69863	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12321135	C4591001 1232 12321135	16-55	31AUG2020	74935	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321139	C4591001 1232 12321139	16-55	31AUG2020	74939	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12321140	C4591001 1232 12321140	16-55	31AUG2020	74943	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12321141	C4591001 1232 12321141	16-55	31AUG2020	75598	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321142	C4591001 1232 12321142	16-55	31AUG2020	74944	Placebo	31AUG2020/ Placebo		09FEB2021/ BNT162b2 (30 µg)	
12321145	C4591001 1232 12321145	16-55	01SEP2020	75600	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321146	C4591001 1232 12321146	16-55	01SEP2020	75601	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321147	C4591001 1232 12321147	16-55	01SEP2020	75604	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12321151	C4591001 1232 12321151	16-55	01SEP2020	76554	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321155	C4591001 1232 12321155	16-55	01SEP2020	76555	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
12321158	C4591001 1232 12321158	16-55	01SEP2020	76557	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321159	C4591001 1232 12321159	16-55	02SEP2020	76558	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12321160	C4591001 1232 12321160	16-55	02SEP2020	77849	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12321163	C4591001 1232 12321163	16-55	02SEP2020	77850	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
12321164	C4591001 1232 12321164	16-55	02SEP2020	77853	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12321167	C4591001 1232 12321167	16-55	02SEP2020	77856	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12321168	C4591001 1232 12321168	16-55	02SEP2020	78151	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12321169	C4591001 1232 12321169	16-55	02SEP2020	78152	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo		
12321172	C4591001 1232 12321172	16-55	02SEP2020	78156	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo		
12321173	C4591001 1232 12321173	16-55	02SEP2020	78158	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321174	C4591001 1232 12321174	16-55	03SEP2020	79553	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321175	C4591001 1232 12321175	16-55	03SEP2020	79556	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)			
12321177	C4591001 1232 12321177	16-55	03SEP2020	79557	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12321179	C4591001 1232 12321179	16-55	03SEP2020	79560	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321180	C4591001 1232 12321180	16-55	03SEP2020	79735	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321181	C4591001 1232 12321181	16-55	03SEP2020	79736	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo		
12321183	C4591001 1232 12321183	16-55	03SEP2020	79738	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12321185	C4591001 1232 12321185	16-55	03SEP2020	79743	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
12321186	C4591001 1232 12321186	16-55	03SEP2020	80038	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
12321189	C4591001 1232 12321189	16-55	03SEP2020	80039	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12321190	C4591001 1232 12321190	16-55	03SEP2020	80040	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321193	C4591001 1232 12321193	16-55	08SEP2020	80044	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12321195	C4591001 1232 12321195	16-55	08SEP2020	83429	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321198	C4591001 1232 12321198	16-55	08SEP2020	83431	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12321202	C4591001 1232 12321202	16-55	08SEP2020	83436	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo		
12321204	C4591001 1232 12321204	16-55	08SEP2020	83438	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321206	C4591001 1232 12321206	16-55	09SEP2020	84838	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321207	C4591001 1232 12321207	16-55	09SEP2020	84840	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321208	C4591001 1232 12321208	16-55	09SEP2020	84843	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
12321209	C4591001 1232 12321209	16-55	09SEP2020	84844	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo		
12321210	C4591001 1232 12321210	16-55	09SEP2020	84977	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321211	C4591001 1232 12321211	16-55	09SEP2020	84981	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321213	C4591001 1232 12321213	16-55	09SEP2020	84986	Placebo	09SEP2020/ Placebo			
12321214	C4591001 1232 12321214	16-55	09SEP2020	84988	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12321216	C4591001 1232 12321216	16-55	09SEP2020	85241	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12321219	C4591001 1232 12321219	16-55	10SEP2020	85244	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321220	C4591001 1232 12321220	16-55	10SEP2020	85245	Placebo	10SEP2020/ Placebo	24NOV2020/ Placebo		
12321221	C4591001 1232 12321221	16-55	10SEP2020	85249	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12321223	C4591001 1232 12321223	16-55	10SEP2020	86525	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo		
12321224	C4591001 1232 12321224	16-55	10SEP2020	86529	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12321225	C4591001 1232 12321225	16-55	10SEP2020	86531	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321226	C4591001 1232 12321226	16-55	10SEP2020	86534	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321229	C4591001 1232 12321229	16-55	10SEP2020	86755	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321231	C4591001 1232 12321231	16-55	10SEP2020	86760	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo		
12321232	C4591001 1232 12321232	16-55	10SEP2020	86762	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321233	C4591001 1232 12321233	16-55	10SEP2020	86763	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)			
12321236	C4591001 1232 12321236	16-55	11SEP2020	256838	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12321238	C4591001 1232 12321238	16-55	11SEP2020	87773	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12321241	C4591001 1232 12321241	16-55	11SEP2020	87776	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12321243	C4591001 1232 12321243	16-55	11SEP2020	87783	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321244	C4591001 1232 12321244	16-55	11SEP2020	87784	Placebo	11SEP2020/ Placebo			
12321246	C4591001 1232 12321246	16-55	11SEP2020	88157	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321247	C4591001 1232 12321247	16-55	11SEP2020	88162	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321248	C4591001 1232 12321248	16-55	11SEP2020	88163	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12321249	C4591001 1232 12321249	16-55	11SEP2020	88164	Placebo	11SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321250	C4591001 1232 12321250	16-55	11SEP2020	88278	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12321253	C4591001 1232 12321253	16-55	11SEP2020	88282	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321255	C4591001 1232 12321255	16-55	21SEP2020	88285	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
12321260	C4591001 1232 12321260	16-55	22SEP2020	88288	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12321262	C4591001 1232 12321262	16-55	22SEP2020	96320	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
12321263	C4591001 1232 12321263	16-55	23SEP2020	96322	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12321264	C4591001 1232 12321264	16-55	23SEP2020	96325	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321265	C4591001 1232 12321265	16-55	23SEP2020	96327	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12321266	C4591001 1232 12321266	16-55	23SEP2020	97457	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
12321267	C4591001 1232 12321267	16-55	23SEP2020	97459	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12321268	C4591001 1232 12321268	16-55	23SEP2020	97460	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12321271	C4591001 1232 12321271	16-55	24SEP2020	97468	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo		
12321272	C4591001 1232 12321272	16-55	24SEP2020	98609	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12321274	C4591001 1232 12321274	16-55	24SEP2020	98614	Placebo	24SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12321278	C4591001 1232 12321278	16-55	28SEP2020	98615	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo		
12321279	C4591001 1232 12321279	16-55	28SEP2020	98618	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12321280	C4591001 1232 12321280	16-55	28SEP2020	101382	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321282	C4591001 1232 12321282	16-55	29SEP2020	101385	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321283	C4591001 1232 12321283	16-55	29SEP2020	101389	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo		
12321285	C4591001 1232 12321285	16-55	30SEP2020	101392	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12321287	C4591001 1232 12321287	16-55	01OCT2020	102739	Placebo	01OCT2020/ Placebo			
12321288	C4591001 1232 12321288	16-55	01OCT2020	102745	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12321289	C4591001 1232 12321289	16-55	01OCT2020	102746	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12321291	C4591001 1232 12321291	16-55	01OCT2020	102747	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321292	C4591001 1232 12321292	16-55	01OCT2020	102835	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12321293	C4591001 1232 12321293	16-55	01OCT2020	102837	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)			
12321294	C4591001 1232 12321294	16-55	02OCT2020	102839	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321296	C4591001 1232 12321296	16-55	05OCT2020	103757	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321297	C4591001 1232 12321297	16-55	05OCT2020	102842	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
12321299	C4591001 1232 12321299	16-55	06OCT2020	103758	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)			
12321301	C4591001 1232 12321301	16-55	06OCT2020	103763	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12321302	C4591001 1232 12321302	16-55	06OCT2020	104237	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12321305	C4591001 1232 12321305	16-55	07OCT2020	104240	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12321307	C4591001 1232 12321307	16-55	07OCT2020	104242	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321308	C4591001 1232 12321308	16-55	07OCT2020	104244	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo		
12321310	C4591001 1232 12321310	16-55	07OCT2020	104852	Placebo	07OCT2020/ Placebo	25NOV2020/ Placebo		
12321311	C4591001 1232 12321311	16-55	08OCT2020	104857	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321312	C4591001 1232 12321312	16-55	08OCT2020	104854	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12321313	C4591001 1232 12321313	16-55	08OCT2020	104853	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo		
12321316	C4591001 1232 12321316	16-55	12OCT2020	106343	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321317	C4591001 1232 12321317	16-55	12OCT2020	106345	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo		
12321318	C4591001 1232 12321318	16-55	12OCT2020	106347	Placebo	12OCT2020/ Placebo	11NOV2020/ Placebo		
12321319	C4591001 1232 12321319	16-55	12OCT2020	106348	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321320	C4591001 1232 12321320	16-55	12OCT2020	106434	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321321	C4591001 1232 12321321	16-55	12OCT2020	106441	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321324	C4591001 1232 12321324	16-55	12OCT2020	106442	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo		
12321327	C4591001 1232 12321327	16-55	13OCT2020	106443	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321328	C4591001 1232 12321328	16-55	13OCT2020	106842	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321329	C4591001 1232 12321329	16-55	13OCT2020	106843	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321330	C4591001 1232 12321330	16-55	13OCT2020	106849	Placebo	13OCT2020/ Placebo	06NOV2020/ Placebo		
12321331	C4591001 1232 12321331	16-55	13OCT2020	106851	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321332	C4591001 1232 12321332	16-55	13OCT2020	106998	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo		
12321333	C4591001 1232 12321333	16-55	13OCT2020	107000	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12321335	C4591001 1232 12321335	16-55	14OCT2020	107003	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321336	C4591001 1232 12321336	16-55	14OCT2020	107393	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo		
12321337	C4591001 1232 12321337	16-55	14OCT2020	107005	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12321338	C4591001 1232 12321338	16-55	14OCT2020	107396	Placebo	14OCT2020/ Placebo	02NOV2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12321339	C4591001 1232 12321339	16-55	14OCT2020	107397	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321341	C4591001 1232 12321341	16-55	14OCT2020	107403	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12321343	C4591001 1232 12321343	16-55	14OCT2020	107502	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321344	C4591001 1232 12321344	16-55	14OCT2020	107503	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo		
12321346	C4591001 1232 12321346	16-55	14OCT2020	107504	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321347	C4591001 1232 12321347	16-55	14OCT2020	107510	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12321348	C4591001 1232 12321348	16-55	14OCT2020	107585	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12321350	C4591001 1232 12321350	16-55	15OCT2020	107590	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
12321351	C4591001 1232 12321351	16-55	15OCT2020	107595	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12321352	C4591001 1232 12321352	16-55	15OCT2020	107591	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12321353	C4591001 1232 12321353	16-55	15OCT2020	108102	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321354	C4591001 1232 12321354	16-55	15OCT2020	108104	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12321355	C4591001 1232 12321355	16-55	15OCT2020	108112	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
12321356	C4591001 1232 12321356	16-55	15OCT2020	108107	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321358	C4591001 1232 12321358	16-55	15OCT2020	108213	Placebo	15OCT2020/ Placebo	03NOV2020/ Placebo		
12321359	C4591001 1232 12321359	16-55	19OCT2020	108217	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321361	C4591001 1232 12321361	16-55	19OCT2020	108215	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)			
12321362	C4591001 1232 12321362	16-55	19OCT2020	108219	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12321364	C4591001 1232 12321364	16-55	19OCT2020	110142	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo		
12321366	C4591001 1232 12321366	16-55	19OCT2020	110147	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321370	C4591001 1232 12321370	16-55	20OCT2020	110148	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321371	C4591001 1232 12321371	16-55	20OCT2020	110149	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12321373	C4591001 1232 12321373	16-55	21OCT2020	111365	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12321374	C4591001 1232 12321374	16-55	21OCT2020	111366	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12321376	C4591001 1232 12321376	16-55	21OCT2020	111371	Placebo	21OCT2020/ Placebo	10NOV2020/ Placebo		
12321377	C4591001 1232 12321377	16-55	22OCT2020	111376	Placebo	22OCT2020/ Placebo	24NOV2020/ Placebo		
12321378	C4591001 1232 12321378	16-55	22OCT2020	112122	Placebo	22OCT2020/ Placebo	28DEC2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12321380	C4591001 1232 12321380	16-55	22OCT2020	112126	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12321382	C4591001 1232 12321382	16-55	22OCT2020	112129	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12321384	C4591001 1232 12321384	16-55	23OCT2020	112131	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
12321385	C4591001 1232 12321385	16-55	23OCT2020	112747	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321386	C4591001 1232 12321386	16-55	23OCT2020	112748	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		
12321391	C4591001 1232 12321391	16-55	23OCT2020	112749	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12321393	C4591001 1232 12321393	16-55	23OCT2020	112952	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12321394	C4591001 1232 12321394	16-55	23OCT2020	112754	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12321395	C4591001 1232 12321395	16-55	23OCT2020	112953	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12321396	C4591001 1232 12321396	16-55	23OCT2020	112960	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)			
12321397	C4591001 1232 12321397	16-55	23OCT2020	112958	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12321400	C4591001 1232 12321400	16-55	23OCT2020	113010	Placebo	23OCT2020/ Placebo			
12321401	C4591001 1232 12321401	16-55	23OCT2020	113012	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321402	C4591001 1232 12321402	16-55	26OCT2020	113013	Placebo	26OCT2020/ Placebo	27NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12321404	C4591001 1232 12321404	16-55	26OCT2020	113015	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321406	C4591001 1232 12321406	16-55	26OCT2020	113603	Placebo	26OCT2020/ Placebo	23NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321408	C4591001 1232 12321408	16-55	26OCT2020	113604	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12321412	C4591001 1232 12321412	16-55	27OCT2020	113605	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)			
12321413	C4591001 1232 12321413	16-55	27OCT2020	114054	Placebo	27OCT2020/ Placebo	24NOV2020/ Placebo		
12321414	C4591001 1232 12321414	16-55	27OCT2020	113608	Placebo	27OCT2020/ Placebo	24NOV2020/ Placebo		
12321415	C4591001 1232 12321415	16-55	27OCT2020	114056	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12321416	C4591001 1232 12321416	16-55	27OCT2020	114064	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321417	C4591001 1232 12321417	16-55	27OCT2020	114061	Placebo	27OCT2020/ Placebo	19NOV2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12321419	C4591001 1232 12321419	16-55	27OCT2020	114114	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)			
12321420	C4591001 1232 12321420	16-55	27OCT2020	114118	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321421	C4591001 1232 12321421	16-55	27OCT2020	114121	Placebo	27OCT2020/ Placebo	24NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	
12321422	C4591001 1232 12321422	16-55	27OCT2020	114123	Placebo	27OCT2020/ Placebo	30NOV2020/ Placebo		
12321423	C4591001 1232 12321423	16-55	27OCT2020	114175	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321424	C4591001 1232 12321424	16-55	27OCT2020	114176	Placebo	27OCT2020/ Placebo	25NOV2020/ Placebo		
12321425	C4591001 1232 12321425	16-55	28OCT2020	114178	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)			
12321426	C4591001 1232 12321426	16-55	28OCT2020	114180	Placebo	28OCT2020/ Placebo	24NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12321427	C4591001 1232 12321427	16-55	28OCT2020	114342	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12321428	C4591001 1232 12321428	16-55	28OCT2020	114347	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12321429	C4591001 1232 12321429	16-55	28OCT2020	114348	Placebo	28OCT2020/ Placebo			
12321430	C4591001 1232 12321430	16-55	28OCT2020	114350	Placebo	28OCT2020/ Placebo	25NOV2020/ Placebo		
12321431	C4591001 1232 12321431	16-55	28OCT2020	114437	BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12321433	C4591001 1232 12321433	16-55	29OCT2020	114438	Placebo	29OCT2020/ Placebo	25NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12321434	C4591001 1232 12321434	16-55	29OCT2020	114439	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12321435	C4591001 1232 12321435	16-55	29OCT2020	114447	Placebo	29OCT2020/ Placebo	24NOV2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12351003	C4591001 1235 12351003	16-55	03SEP2020	79709	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12351004	C4591001 1235 12351004	16-55	03SEP2020	79716	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12351005	C4591001 1235 12351005	16-55	03SEP2020	79715	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351006	C4591001 1235 12351006	16-55	03SEP2020	79719	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351007	C4591001 1235 12351007	16-55	03SEP2020	80381	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351008	C4591001 1235 12351008	16-55	03SEP2020	80383	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12351009	C4591001 1235 12351009	16-55	03SEP2020	80388	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351011	C4591001 1235 12351011	16-55	04SEP2020	80392	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12351013	C4591001 1235 12351013	16-55	04SEP2020	81641	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351014	C4591001 1235 12351014	16-55	04SEP2020	81644	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12351015	C4591001 1235 12351015	16-55	04SEP2020	81648	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12351016	C4591001 1235 12351016	16-55	04SEP2020	81651	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12351017	C4591001 1235 12351017	16-55	04SEP2020	82279	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12351019	C4591001 1235 12351019	16-55	04SEP2020	253364	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351020	C4591001 1235 12351020	16-55	05SEP2020	82282	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351023	C4591001 1235 12351023	16-55	05SEP2020	82283	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12351024	C4591001 1235 12351024	16-55	05SEP2020	82288	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351025	C4591001 1235 12351025	16-55	05SEP2020	82889	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12351026	C4591001 1235 12351026	16-55	05SEP2020	82893	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12351027	C4591001 1235 12351027	16-55	06SEP2020	82897	Placebo	06SEP2020/ Placebo		17DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351028	C4591001 1235 12351028	16-55	06SEP2020	82898	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12351029	C4591001 1235 12351029	16-55	06SEP2020	83011	Placebo	06SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351030	C4591001 1235 12351030	16-55	06SEP2020	83015	Placebo	06SEP2020/ Placebo	28SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12351033	C4591001 1235 12351033	16-55	07SEP2020	83017	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351034	C4591001 1235 12351034	16-55	08SEP2020	84296	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12351035	C4591001 1235 12351035	16-55	07SEP2020	83019	BNT162b2 (30 µg)	07SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351036	C4591001 1235 12351036	16-55	07SEP2020	83227	Placebo	07SEP2020/ Placebo	29SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351037	C4591001 1235 12351037	16-55	08SEP2020	83228	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351038	C4591001 1235 12351038	16-55	08SEP2020	83230	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351040	C4591001 1235 12351040	16-55	08SEP2020	83235	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351041	C4591001 1235 12351041	16-55	08SEP2020	84299	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351044	C4591001 1235 12351044	16-55	09SEP2020	84300	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351045	C4591001 1235 12351045	16-55	09SEP2020	84302	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351048	C4591001 1235 12351048	16-55	09SEP2020	85796	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12351049	C4591001 1235 12351049	16-55	09SEP2020	85797	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351050	C4591001 1235 12351050	16-55	09SEP2020	85798	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351052	C4591001 1235 12351052	16-55	10SEP2020	85802	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351053	C4591001 1235 12351053	16-55	10SEP2020	86705	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351054	C4591001 1235 12351054	16-55	10SEP2020	86715	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12351055	C4591001 1235 12351055	16-55	10SEP2020	86708	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12351057	C4591001 1235 12351057	16-55	10SEP2020	86712	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12351058	C4591001 1235 12351058	16-55	11SEP2020	87870	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12351059	C4591001 1235 12351059	16-55	11SEP2020	87872	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12351060	C4591001 1235 12351060	16-55	11SEP2020	87876	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351061	C4591001 1235 12351061	16-55	11SEP2020	87877	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351063	C4591001 1235 12351063	16-55	11SEP2020	88374	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351064	C4591001 1235 12351064	16-55	11SEP2020	88378	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351065	C4591001 1235 12351065	16-55	11SEP2020	88379	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12351066	C4591001 1235 12351066	16-55	11SEP2020	88381	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12351067	C4591001 1235 12351067	16-55	11SEP2020	88818	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12351068	C4591001 1235 12351068	16-55	12SEP2020	88821	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12351070	C4591001 1235 12351070	16-55	14SEP2020	88822	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12351071	C4591001 1235 12351071	16-55	14SEP2020	88827	Placebo	14SEP2020/ Placebo		18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12351072	C4591001 1235 12351072	16-55	14SEP2020	89562	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12351073	C4591001 1235 12351073	16-55	14SEP2020	89563	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12351074	C4591001 1235 12351074	16-55	14SEP2020	89571	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351079	C4591001 1235 12351079	16-55	15SEP2020	89572	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351083	C4591001 1235 12351083	16-55	15SEP2020	90462	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12351084	C4591001 1235 12351084	16-55	15SEP2020	90463	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12351088	C4591001 1235 12351088	16-55	16SEP2020	90464	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351089	C4591001 1235 12351089	16-55	16SEP2020	90466	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351090	C4591001 1235 12351090	16-55	16SEP2020	91349	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12351092	C4591001 1235 12351092	16-55	16SEP2020	91353	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351093	C4591001 1235 12351093	16-55	16SEP2020	91357	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12351097	C4591001 1235 12351097	16-55	17SEP2020	91358	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12351098	C4591001 1235 12351098	16-55	17SEP2020	92129	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12351100	C4591001 1235 12351100	16-55	17SEP2020	92132	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351101	C4591001 1235 12351101	16-55	17SEP2020	92139	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
12351103	C4591001 1235 12351103	16-55	17SEP2020	92140	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12351105	C4591001 1235 12351105	16-55	17SEP2020	92888	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12351106	C4591001 1235 12351106	16-55	17SEP2020	92890	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12351108	C4591001 1235 12351108	16-55	18SEP2020	92896	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351109	C4591001 1235 12351109	16-55	18SEP2020	92892	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12351110	C4591001 1235 12351110	16-55	18SEP2020	93548	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351112	C4591001 1235 12351112	16-55	18SEP2020	93550	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12351115	C4591001 1235 12351115	16-55	18SEP2020	93552	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12351116	C4591001 1235 12351116	16-55	18SEP2020	93553	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351119	C4591001 1235 12351119	16-55	18SEP2020	94122	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12351121	C4591001 1235 12351121	16-55	18SEP2020	94123	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351124	C4591001 1235 12351124	16-55	21SEP2020	94126	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351125	C4591001 1235 12351125	16-55	21SEP2020	94129	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12351126	C4591001 1235 12351126	16-55	28SEP2020	99706	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12351127	C4591001 1235 12351127	16-55	21SEP2020	95201	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351128	C4591001 1235 12351128	16-55	21SEP2020	95202	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12351130	C4591001 1235 12351130	16-55	21SEP2020	95203	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351131	C4591001 1235 12351131	16-55	21SEP2020	95206	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12351133	C4591001 1235 12351133	16-55	22SEP2020	96043	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351134	C4591001 1235 12351134	16-55	22SEP2020	96046	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351137	C4591001 1235 12351137	16-55	22SEP2020	96047	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12351138	C4591001 1235 12351138	16-55	22SEP2020	96052	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12351141	C4591001 1235 12351141	16-55	23SEP2020	97640	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12351142	C4591001 1235 12351142	16-55	23SEP2020	97644	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12351143	C4591001 1235 12351143	16-55	23SEP2020	97645	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12351144	C4591001 1235 12351144	16-55	23SEP2020	97647	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12351145	C4591001 1235 12351145	16-55	23SEP2020	97962	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351146	C4591001 1235 12351146	16-55	23SEP2020	97963	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351149	C4591001 1235 12351149	16-55	24SEP2020	97968	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351151	C4591001 1235 12351151	16-55	25SEP2020	97969	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12351152	C4591001 1235 12351152	16-55	25SEP2020	99701	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351153	C4591001 1235 12351153	16-55	25SEP2020	99702	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12351155	C4591001 1235 12351155	16-55	28SEP2020	99703	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351156	C4591001 1235 12351156	16-55	28SEP2020	101405	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
12351157	C4591001 1235 12351157	16-55	01OCT2020	101407	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12351158	C4591001 1235 12351158	16-55	02OCT2020	101408	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
12351159	C4591001 1235 12351159	16-55	02OCT2020	101414	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12351161	C4591001 1235 12351161	16-55	02OCT2020	103223	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12351162	C4591001 1235 12351162	16-55	02OCT2020	103224	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351165	C4591001 1235 12351165	16-55	08OCT2020	103225	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12351166	C4591001 1235 12351166	16-55	08OCT2020	103226	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12351167	C4591001 1235 12351167	16-55	09OCT2020	105934	Placebo				
12351168	C4591001 1235 12351168	16-55	09OCT2020	105936	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12351169	C4591001 1235 12351169	16-55	21OCT2020	110397	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12351170	C4591001 1235 12351170	16-55	09OCT2020	105937	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12351171	C4591001 1235 12351171	16-55	09OCT2020	105940	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12351172	C4591001 1235 12351172	16-55	09OCT2020	106181	Placebo	09OCT2020/ Placebo	28OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12351173	C4591001 1235 12351173	16-55	13OCT2020	106184	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12351174	C4591001 1235 12351174	16-55	13OCT2020	106191	Placebo	13OCT2020/ Placebo	05NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351175	C4591001 1235 12351175	16-55	14OCT2020	106192	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12351180	C4591001 1235 12351180	16-55	15OCT2020	107998	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12351181	C4591001 1235 12351181	16-55	15OCT2020	107999	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12351186	C4591001 1235 12351186	16-55	15OCT2020	108003	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12351187	C4591001 1235 12351187	16-55	16OCT2020	108004	Placebo	16OCT2020/ Placebo		25JAN2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12351188	C4591001 1235 12351188	16-55	16OCT2020	108905	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)			
12351189	C4591001 1235 12351189	16-55	16OCT2020	108911	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12351190	C4591001 1235 12351190	16-55	16OCT2020	108912	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12351191	C4591001 1235 12351191	16-55	16OCT2020	108914	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12351192	C4591001 1235 12351192	16-55	16OCT2020	109265	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351193	C4591001 1235 12351193	16-55	19OCT2020	109267	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12351195	C4591001 1235 12351195	16-55	19OCT2020	109270	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12351196	C4591001 1235 12351196	16-55	19OCT2020	109272	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12351197	C4591001 1235 12351197	16-55	19OCT2020	110393	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12351200	C4591001 1235 12351200	16-55	20OCT2020	110396	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351207	C4591001 1235 12351207	16-55	21OCT2020	110399	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12351208	C4591001 1235 12351208	16-55	21OCT2020	111582	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12351209	C4591001 1235 12351209	16-55	21OCT2020	111584	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12351212	C4591001 1235 12351212	16-55	21OCT2020	111587	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12351214	C4591001 1235 12351214	16-55	22OCT2020	111590	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351215	C4591001 1235 12351215	16-55	22OCT2020	112422	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12351217	C4591001 1235 12351217	16-55	23OCT2020	112425	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12351218	C4591001 1235 12351218	16-55	23OCT2020	112426	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12351219	C4591001 1235 12351219	16-55	23OCT2020	112430	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo		
12351222	C4591001 1235 12351222	16-55	23OCT2020	113129	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12351223	C4591001 1235 12351223	16-55	23OCT2020	113132	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12351224	C4591001 1235 12351224	16-55	26OCT2020	113137	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12351225	C4591001 1235 12351225	16-55	29OCT2020	113138	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12351226	C4591001 1235 12351226	16-55	29OCT2020	114683	Placebo	29OCT2020/ Placebo	17NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12351228	C4591001 1235 12351228	16-55	02NOV2020	114686	Placebo	02NOV2020/ Placebo	23NOV2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12351230	C4591001 1235 12351230	16-55	03NOV2020	114687	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12351231	C4591001 1235 12351231	16-55	03NOV2020	114688	BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)		
12351237	C4591001 1235 12351237	16-55	07DEC2020	117653	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12351240	C4591001 1235 12351240	16-55	07DEC2020	117654	Placebo	07DEC2020/ Placebo	30DEC2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12351241	C4591001 1235 12351241	16-55	07DEC2020	117659	BNT162b2 (30 µg)	07DEC2020/ BNT162b2 (30 µg)	28DEC2020/ BNT162b2 (30 µg)		
12411126	C4591001 1241 12411126	16-55	14AUG2020	50324	Placebo	14AUG2020/ Placebo	04SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411132	C4591001 1241 12411132	16-55	14AUG2020	50482	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	17DEC2020/ BNT162b2 (30 µg)		
12411134	C4591001 1241 12411134	16-55	14AUG2020	50538	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411135	C4591001 1241 12411135	16-55	14AUG2020	50542	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		
12411140	C4591001 1241 12411140	16-55	14AUG2020	50672	BNT162b2 (30 µg)	14AUG2020/ BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411142	C4591001 1241 12411142	16-55	17AUG2020	52121	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411143	C4591001 1241 12411143	16-55	17AUG2020	52123	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411144	C4591001 1241 12411144	16-55	17AUG2020	52125	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
12411145	C4591001 1241 12411145	16-55	17AUG2020	52126	Placebo	17AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411146	C4591001 1241 12411146	16-55	17AUG2020	52136	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411148	C4591001 1241 12411148	16-55	17AUG2020	52137	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411149	C4591001 1241 12411149	16-55	17AUG2020	52140	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411150	C4591001 1241 12411150	16-55	17AUG2020	52142	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411152	C4591001 1241 12411152	16-55	17AUG2020	52185	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411153	C4591001 1241 12411153	16-55	17AUG2020	52186	Placebo	17AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411154	C4591001 1241 12411154	16-55	17AUG2020	52188	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411155	C4591001 1241 12411155	16-55	17AUG2020	52192	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411156	C4591001 1241 12411156	16-55	17AUG2020	52253	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411157	C4591001 1241 12411157	16-55	17AUG2020	52256	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411158	C4591001 1241 12411158	16-55	17AUG2020	52259	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411159	C4591001 1241 12411159	16-55	17AUG2020	52262	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411161	C4591001 1241 12411161	16-55	17AUG2020	52388	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411163	C4591001 1241 12411163	16-55	17AUG2020	52389	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411164	C4591001 1241 12411164	16-55	17AUG2020	52390	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411165	C4591001 1241 12411165	16-55	17AUG2020	52393	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411166	C4591001 1241 12411166	16-55	17AUG2020	52747	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411167	C4591001 1241 12411167	16-55	17AUG2020	52748	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411168	C4591001 1241 12411168	16-55	17AUG2020	52750	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411170	C4591001 1241 12411170	16-55	17AUG2020	52756	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411171	C4591001 1241 12411171	16-55	17AUG2020	53071	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411175	C4591001 1241 12411175	16-55	17AUG2020	53073	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411177	C4591001 1241 12411177	16-55	17AUG2020	53076	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411178	C4591001 1241 12411178	16-55	17AUG2020	53077	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411179	C4591001 1241 12411179	16-55	17AUG2020	53361	Placebo	17AUG2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411180	C4591001 1241 12411180	16-55	17AUG2020	53363	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411181	C4591001 1241 12411181	16-55	17AUG2020	53364	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411183	C4591001 1241 12411183	16-55	17AUG2020	53367	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411184	C4591001 1241 12411184	16-55	17AUG2020	53478	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411185	C4591001 1241 12411185	16-55	17AUG2020	53480	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411186	C4591001 1241 12411186	16-55	17AUG2020	53482	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411188	C4591001 1241 12411188	16-55	17AUG2020	53488	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411189	C4591001 1241 12411189	16-55	17AUG2020	53563	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411190	C4591001 1241 12411190	16-55	17AUG2020	53570	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411194	C4591001 1241 12411194	16-55	17AUG2020	53571	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411195	C4591001 1241 12411195	16-55	17AUG2020	53572	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411197	C4591001 1241 12411197	16-55	17AUG2020	53662	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411198	C4591001 1241 12411198	16-55	17AUG2020	53664	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411203	C4591001 1241 12411203	16-55	18AUG2020	53667	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411204	C4591001 1241 12411204	16-55	18AUG2020	53668	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411205	C4591001 1241 12411205	16-55	18AUG2020	53754	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411206	C4591001 1241 12411206	16-55	18AUG2020	53756	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411207	C4591001 1241 12411207	16-55	18AUG2020	53761	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411208	C4591001 1241 12411208	16-55	18AUG2020	53762	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	
12411209	C4591001 1241 12411209	16-55	18AUG2020	53778	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411210	C4591001 1241 12411210	16-55	18AUG2020	53781	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411211	C4591001 1241 12411211	16-55	18AUG2020	53782	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo		
12411212	C4591001 1241 12411212	16-55	18AUG2020	53784	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12411213	C4591001 1241 12411213	16-55	18AUG2020	53910	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411214	C4591001 1241 12411214	16-55	18AUG2020	53911	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411215	C4591001 1241 12411215	16-55	18AUG2020	53918	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411216	C4591001 1241 12411216	16-55	18AUG2020	53920	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411217	C4591001 1241 12411217	16-55	18AUG2020	54066	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411219	C4591001 1241 12411219	16-55	18AUG2020	54072	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411220	C4591001 1241 12411220	16-55	18AUG2020	54074	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411221	C4591001 1241 12411221	16-55	18AUG2020	54076	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411222	C4591001 1241 12411222	16-55	18AUG2020	54197	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411223	C4591001 1241 12411223	16-55	18AUG2020	54200	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411224	C4591001 1241 12411224	16-55	18AUG2020	54204	Placebo	18AUG2020/ Placebo	18SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12411225	C4591001 1241 12411225	16-55	18AUG2020	54205	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411226	C4591001 1241 12411226	16-55	18AUG2020	54609	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411227	C4591001 1241 12411227	16-55	18AUG2020	54611	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411228	C4591001 1241 12411228	16-55	18AUG2020	54615	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411229	C4591001 1241 12411229	16-55	18AUG2020	54616	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411230	C4591001 1241 12411230	16-55	18AUG2020	54689	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411231	C4591001 1241 12411231	16-55	18AUG2020	54691	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411232	C4591001 1241 12411232	16-55	18AUG2020	54693	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411233	C4591001 1241 12411233	16-55	18AUG2020	54700	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411234	C4591001 1241 12411234	16-55	18AUG2020	54905	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411236	C4591001 1241 12411236	16-55	18AUG2020	54907	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411237	C4591001 1241 12411237	16-55	18AUG2020	54909	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411239	C4591001 1241 12411239	16-55	18AUG2020	54913	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411240	C4591001 1241 12411240	16-55	18AUG2020	55135	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411242	C4591001 1241 12411242	16-55	18AUG2020	55137	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411243	C4591001 1241 12411243	16-55	18AUG2020	55140	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411245	C4591001 1241 12411245	16-55	18AUG2020	55144	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411248	C4591001 1241 12411248	16-55	18AUG2020	55278	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411250	C4591001 1241 12411250	16-55	18AUG2020	55386	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411251	C4591001 1241 12411251	16-55	18AUG2020	55394	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411253	C4591001 1241 12411253	16-55	18AUG2020	55395	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411255	C4591001 1241 12411255	16-55	18AUG2020	55396	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411256	C4591001 1241 12411256	16-55	18AUG2020	55469	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411257	C4591001 1241 12411257	16-55	19AUG2020	55470	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411258	C4591001 1241 12411258	16-55	19AUG2020	55471	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411260	C4591001 1241 12411260	16-55	19AUG2020	55478	Placebo	19AUG2020/ Placebo		02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411261	C4591001 1241 12411261	16-55	19AUG2020	55625	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411262	C4591001 1241 12411262	16-55	19AUG2020	55627	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411263	C4591001 1241 12411263	16-55	19AUG2020	55629	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411264	C4591001 1241 12411264	16-55	19AUG2020	55632	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411265	C4591001 1241 12411265	16-55	19AUG2020	55676	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411266	C4591001 1241 12411266	16-55	19AUG2020	55677	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411267	C4591001 1241 12411267	16-55	19AUG2020	55680	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411268	C4591001 1241 12411268	16-55	19AUG2020	55682	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411269	C4591001 1241 12411269	16-55	19AUG2020	55770	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411270	C4591001 1241 12411270	16-55	19AUG2020	55771	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411271	C4591001 1241 12411271	16-55	19AUG2020	55772	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411272	C4591001 1241 12411272	16-55	19AUG2020	55780	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411273	C4591001 1241 12411273	16-55	19AUG2020	55889	Placebo	19AUG2020/ Placebo	23OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411274	C4591001 1241 12411274	16-55	19AUG2020	55914	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411275	C4591001 1241 12411275	16-55	19AUG2020	55918	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411276	C4591001 1241 12411276	16-55	19AUG2020	55919	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411277	C4591001 1241 12411277	16-55	19AUG2020	55924	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12411278	C4591001 1241 12411278	16-55	19AUG2020	56033	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411279	C4591001 1241 12411279	16-55	19AUG2020	56038	Placebo	19AUG2020/ Placebo		16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12411280	C4591001 1241 12411280	16-55	19AUG2020	56039	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411281	C4591001 1241 12411281	16-55	19AUG2020	56043	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411282	C4591001 1241 12411282	16-55	19AUG2020	56153	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411283	C4591001 1241 12411283	16-55	19AUG2020	56155	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411284	C4591001 1241 12411284	16-55	19AUG2020	56159	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411285	C4591001 1241 12411285	16-55	19AUG2020	56160	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411286	C4591001 1241 12411286	16-55	19AUG2020	56226	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411287	C4591001 1241 12411287	16-55	19AUG2020	56230	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411288	C4591001 1241 12411288	16-55	19AUG2020	56233	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411289	C4591001 1241 12411289	16-55	19AUG2020	56236	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411290	C4591001 1241 12411290	16-55	19AUG2020	56477	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411291	C4591001 1241 12411291	16-55	19AUG2020	56478	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411292	C4591001 1241 12411292	16-55	19AUG2020	56485	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411293	C4591001 1241 12411293	16-55	19AUG2020	56488	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411294	C4591001 1241 12411294	16-55	19AUG2020	56696	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411295	C4591001 1241 12411295	16-55	19AUG2020	56697	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411296	C4591001 1241 12411296	16-55	19AUG2020	56698	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411297	C4591001 1241 12411297	16-55	19AUG2020	56703	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411298	C4591001 1241 12411298	16-55	19AUG2020	56765	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411299	C4591001 1241 12411299	16-55	19AUG2020	56766	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411300	C4591001 1241 12411300	16-55	19AUG2020	56775	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411301	C4591001 1241 12411301	16-55	19AUG2020	56776	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411302	C4591001 1241 12411302	16-55	19AUG2020	56874	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411303	C4591001 1241 12411303	16-55	19AUG2020	56875	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411305	C4591001 1241 12411305	16-55	19AUG2020	56876	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411307	C4591001 1241 12411307	16-55	19AUG2020	56880	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411308	C4591001 1241 12411308	16-55	19AUG2020	57152	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411309	C4591001 1241 12411309	16-55	19AUG2020	57153	Placebo	19AUG2020/ Placebo	08SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411310	C4591001 1241 12411310	16-55	19AUG2020	57154	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411311	C4591001 1241 12411311	16-55	19AUG2020	57158	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411312	C4591001 1241 12411312	16-55	19AUG2020	57272	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411313	C4591001 1241 12411313	16-55	19AUG2020	57275	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411314	C4591001 1241 12411314	16-55	19AUG2020	57276	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411315	C4591001 1241 12411315	16-55	19AUG2020	57280	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
12411316	C4591001 1241 12411316	16-55	19AUG2020	57474	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411317	C4591001 1241 12411317	16-55	19AUG2020	57475	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411318	C4591001 1241 12411318	16-55	19AUG2020	57479	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411319	C4591001 1241 12411319	16-55	19AUG2020	57483	Placebo	19AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411323	C4591001 1241 12411323	16-55	20AUG2020	57754	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411324	C4591001 1241 12411324	16-55	20AUG2020	57756	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411326	C4591001 1241 12411326	16-55	20AUG2020	57758	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411327	C4591001 1241 12411327	16-55	20AUG2020	57760	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411328	C4591001 1241 12411328	16-55	20AUG2020	57762	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411329	C4591001 1241 12411329	16-55	20AUG2020	57765	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411330	C4591001 1241 12411330	16-55	20AUG2020	57767	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411331	C4591001 1241 12411331	16-55	20AUG2020	57769	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411332	C4591001 1241 12411332	16-55	20AUG2020	57833	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411333	C4591001 1241 12411333	16-55	20AUG2020	57839	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411334	C4591001 1241 12411334	16-55	20AUG2020	57841	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411335	C4591001 1241 12411335	16-55	20AUG2020	57844	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411336	C4591001 1241 12411336	16-55	20AUG2020	57944	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411337	C4591001 1241 12411337	16-55	20AUG2020	57945	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411338	C4591001 1241 12411338	16-55	20AUG2020	57948	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411339	C4591001 1241 12411339	16-55	20AUG2020	57949	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411341	C4591001 1241 12411341	16-55	20AUG2020	58111	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411342	C4591001 1241 12411342	16-55	20AUG2020	58117	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411343	C4591001 1241 12411343	16-55	20AUG2020	58119	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411344	C4591001 1241 12411344	16-55	20AUG2020	58120	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411345	C4591001 1241 12411345	16-55	20AUG2020	58277	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411346	C4591001 1241 12411346	16-55	20AUG2020	58283	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411347	C4591001 1241 12411347	16-55	20AUG2020	58286	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411348	C4591001 1241 12411348	16-55	20AUG2020	58288	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411349	C4591001 1241 12411349	16-55	20AUG2020	58378	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411350	C4591001 1241 12411350	16-55	20AUG2020	58380	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411351	C4591001 1241 12411351	16-55	20AUG2020	58381	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411353	C4591001 1241 12411353	16-55	20AUG2020	58382	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411354	C4591001 1241 12411354	16-55	20AUG2020	58740	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411355	C4591001 1241 12411355	16-55	20AUG2020	58741	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411356	C4591001 1241 12411356	16-55	20AUG2020	58743	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411357	C4591001 1241 12411357	16-55	20AUG2020	58744	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411358	C4591001 1241 12411358	16-55	20AUG2020	58889	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411359	C4591001 1241 12411359	16-55	20AUG2020	58897	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411360	C4591001 1241 12411360	16-55	20AUG2020	58898	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411361	C4591001 1241 12411361	16-55	20AUG2020	58899	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411362	C4591001 1241 12411362	16-55	20AUG2020	58989	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411363	C4591001 1241 12411363	16-55	20AUG2020	58990	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411365	C4591001 1241 12411365	16-55	20AUG2020	58992	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411366	C4591001 1241 12411366	16-55	20AUG2020	58995	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12411367	C4591001 1241 12411367	16-55	20AUG2020	59121	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12411368	C4591001 1241 12411368	16-55	20AUG2020	59122	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411369	C4591001 1241 12411369	16-55	20AUG2020	59124	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411370	C4591001 1241 12411370	16-55	20AUG2020	59128	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411372	C4591001 1241 12411372	16-55	20AUG2020	59241	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411373	C4591001 1241 12411373	16-55	20AUG2020	59242	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411374	C4591001 1241 12411374	16-55	20AUG2020	59247	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411375	C4591001 1241 12411375	16-55	20AUG2020	59345	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411376	C4591001 1241 12411376	16-55	20AUG2020	59347	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411377	C4591001 1241 12411377	16-55	20AUG2020	59348	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411378	C4591001 1241 12411378	16-55	20AUG2020	59351	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411379	C4591001 1241 12411379	16-55	20AUG2020	59489	Placebo	20AUG2020/ Placebo	08SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411380	C4591001 1241 12411380	16-55	20AUG2020	59492	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411381	C4591001 1241 12411381	16-55	20AUG2020	59495	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411382	C4591001 1241 12411382	16-55	20AUG2020	59500	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411383	C4591001 1241 12411383	16-55	20AUG2020	59587	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12411384	C4591001 1241 12411384	16-55	20AUG2020	59588	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411385	C4591001 1241 12411385	16-55	20AUG2020	59589	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411386	C4591001 1241 12411386	16-55	20AUG2020	59593	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411387	C4591001 1241 12411387	16-55	20AUG2020	59693	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411388	C4591001 1241 12411388	16-55	20AUG2020	59695	Placebo	20AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411389	C4591001 1241 12411389	16-55	20AUG2020	59699	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411390	C4591001 1241 12411390	16-55	20AUG2020	59702	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411393	C4591001 1241 12411393	16-55	21AUG2020	59886	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411395	C4591001 1241 12411395	16-55	21AUG2020	59887	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411396	C4591001 1241 12411396	16-55	21AUG2020	59890	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411398	C4591001 1241 12411398	16-55	21AUG2020	59893	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411399	C4591001 1241 12411399	16-55	21AUG2020	60066	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411400	C4591001 1241 12411400	16-55	21AUG2020	60067	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411401	C4591001 1241 12411401	16-55	21AUG2020	60069	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411402	C4591001 1241 12411402	16-55	21AUG2020	60075	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411403	C4591001 1241 12411403	16-55	21AUG2020	60198	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411407	C4591001 1241 12411407	16-55	21AUG2020	60200	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12411408	C4591001 1241 12411408	16-55	24AUG2020	60203	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411409	C4591001 1241 12411409	16-55	24AUG2020	60206	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411410	C4591001 1241 12411410	16-55	24AUG2020	63197	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411411	C4591001 1241 12411411	16-55	24AUG2020	63199	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411412	C4591001 1241 12411412	16-55	24AUG2020	63201	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411413	C4591001 1241 12411413	16-55	24AUG2020	63203	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411414	C4591001 1241 12411414	16-55	24AUG2020	63212	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411415	C4591001 1241 12411415	16-55	24AUG2020	63214	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12411416	C4591001 1241 12411416	16-55	24AUG2020	63215	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411417	C4591001 1241 12411417	16-55	24AUG2020	63220	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411418	C4591001 1241 12411418	16-55	24AUG2020	63246	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411419	C4591001 1241 12411419	16-55	24AUG2020	63248	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411420	C4591001 1241 12411420	16-55	24AUG2020	63252	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411421	C4591001 1241 12411421	16-55	24AUG2020	63253	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411422	C4591001 1241 12411422	16-55	24AUG2020	63269	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411423	C4591001 1241 12411423	16-55	24AUG2020	63274	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411424	C4591001 1241 12411424	16-55	24AUG2020	63277	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411426	C4591001 1241 12411426	16-55	24AUG2020	63279	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411427	C4591001 1241 12411427	16-55	24AUG2020	63341	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411431	C4591001 1241 12411431	16-55	24AUG2020	63342	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411432	C4591001 1241 12411432	16-55	24AUG2020	63349	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411433	C4591001 1241 12411433	16-55	24AUG2020	63352	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411435	C4591001 1241 12411435	16-55	24AUG2020	63606	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411436	C4591001 1241 12411436	16-55	24AUG2020	63607	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411437	C4591001 1241 12411437	16-55	24AUG2020	63613	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411438	C4591001 1241 12411438	16-55	24AUG2020	63614	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411439	C4591001 1241 12411439	16-55	24AUG2020	63967	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411440	C4591001 1241 12411440	16-55	24AUG2020	63970	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411441	C4591001 1241 12411441	16-55	24AUG2020	63973	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411442	C4591001 1241 12411442	16-55	24AUG2020	63975	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411443	C4591001 1241 12411443	16-55	24AUG2020	64016	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411444	C4591001 1241 12411444	16-55	24AUG2020	64018	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411445	C4591001 1241 12411445	16-55	24AUG2020	64021	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411446	C4591001 1241 12411446	16-55	24AUG2020	64024	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411447	C4591001 1241 12411447	16-55	24AUG2020	64195	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411449	C4591001 1241 12411449	16-55	24AUG2020	64198	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12411450	C4591001 1241 12411450	16-55	24AUG2020	64199	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411451	C4591001 1241 12411451	16-55	24AUG2020	64203	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411452	C4591001 1241 12411452	16-55	24AUG2020	64463	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411453	C4591001 1241 12411453	16-55	24AUG2020	64464	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411454	C4591001 1241 12411454	16-55	24AUG2020	64467	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411455	C4591001 1241 12411455	16-55	24AUG2020	64468	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411456	C4591001 1241 12411456	16-55	24AUG2020	64567	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411457	C4591001 1241 12411457	16-55	24AUG2020	64571	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411458	C4591001 1241 12411458	16-55	24AUG2020	64576	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411459	C4591001 1241 12411459	16-55	24AUG2020	64640	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411460	C4591001 1241 12411460	16-55	24AUG2020	64643	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411461	C4591001 1241 12411461	16-55	24AUG2020	64644	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411462	C4591001 1241 12411462	16-55	24AUG2020	64646	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411463	C4591001 1241 12411463	16-55	24AUG2020	64722	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411464	C4591001 1241 12411464	16-55	24AUG2020	64723	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411465	C4591001 1241 12411465	16-55	24AUG2020	64730	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411466	C4591001 1241 12411466	16-55	24AUG2020	64731	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411467	C4591001 1241 12411467	16-55	24AUG2020	64866	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411468	C4591001 1241 12411468	16-55	25AUG2020	64867	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411469	C4591001 1241 12411469	16-55	25AUG2020	64871	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411470	C4591001 1241 12411470	16-55	25AUG2020	64873	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411471	C4591001 1241 12411471	16-55	25AUG2020	65073	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411472	C4591001 1241 12411472	16-55	25AUG2020	65074	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411473	C4591001 1241 12411473	16-55	25AUG2020	65076	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411474	C4591001 1241 12411474	16-55	25AUG2020	65080	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411475	C4591001 1241 12411475	16-55	25AUG2020	65191	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411476	C4591001 1241 12411476	16-55	25AUG2020	65192	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411477	C4591001 1241 12411477	16-55	25AUG2020	65195	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411478	C4591001 1241 12411478	16-55	25AUG2020	65199	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411480	C4591001 1241 12411480	16-55	25AUG2020	65263	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411481	C4591001 1241 12411481	16-55	25AUG2020	65264	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411482	C4591001 1241 12411482	16-55	25AUG2020	65266	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)			
12411483	C4591001 1241 12411483	16-55	25AUG2020	65267	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411484	C4591001 1241 12411484	16-55	25AUG2020	65395	Placebo	25AUG2020/ Placebo	17SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411486	C4591001 1241 12411486	16-55	25AUG2020	65399	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411487	C4591001 1241 12411487	16-55	25AUG2020	65401	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411488	C4591001 1241 12411488	16-55	25AUG2020	65402	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411489	C4591001 1241 12411489	16-55	25AUG2020	65935	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411490	C4591001 1241 12411490	16-55	25AUG2020	65936	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12411491	C4591001 1241 12411491	16-55	25AUG2020	65938	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411492	C4591001 1241 12411492	16-55	25AUG2020	65943	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411493	C4591001 1241 12411493	16-55	25AUG2020	66197	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411494	C4591001 1241 12411494	16-55	25AUG2020	66201	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	
12411495	C4591001 1241 12411495	16-55	25AUG2020	66204	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12411497	C4591001 1241 12411497	16-55	25AUG2020	66205	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411499	C4591001 1241 12411499	16-55	25AUG2020	66557	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411500	C4591001 1241 12411500	16-55	25AUG2020	66561	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411501	C4591001 1241 12411501	16-55	25AUG2020	66563	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12411502	C4591001 1241 12411502	16-55	25AUG2020	66567	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411503	C4591001 1241 12411503	16-55	25AUG2020	66870	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12411504	C4591001 1241 12411504	16-55	25AUG2020	66872	Placebo	25AUG2020/ Placebo	16SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411505	C4591001 1241 12411505	16-55	25AUG2020	66873	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12411506	C4591001 1241 12411506	16-55	01SEP2020	66877	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411507	C4591001 1241 12411507	16-55	01SEP2020	76854	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411508	C4591001 1241 12411508	16-55	01SEP2020	76859	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411509	C4591001 1241 12411509	16-55	01SEP2020	76860	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411510	C4591001 1241 12411510	16-55	01SEP2020	76862	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411511	C4591001 1241 12411511	16-55	01SEP2020	77057	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411512	C4591001 1241 12411512	16-55	01SEP2020	77058	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411513	C4591001 1241 12411513	16-55	01SEP2020	77062	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12411514	C4591001 1241 12411514	16-55	01SEP2020	77063	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	
12411515	C4591001 1241 12411515	16-55	01SEP2020	77216	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411516	C4591001 1241 12411516	16-55	01SEP2020	77218	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411517	C4591001 1241 12411517	16-55	01SEP2020	77221	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411518	C4591001 1241 12411518	16-55	01SEP2020	77224	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411519	C4591001 1241 12411519	16-55	01SEP2020	77322	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411520	C4591001 1241 12411520	16-55	01SEP2020	77324	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411522	C4591001 1241 12411522	16-55	01SEP2020	77329	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411524	C4591001 1241 12411524	16-55	01SEP2020	77331	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411526	C4591001 1241 12411526	16-55	01SEP2020	77597	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	
12411527	C4591001 1241 12411527	16-55	01SEP2020	77598	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411528	C4591001 1241 12411528	16-55	01SEP2020	77604	Placebo	01SEP2020/ Placebo	28SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411530	C4591001 1241 12411530	16-55	01SEP2020	77607	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411531	C4591001 1241 12411531	16-55	01SEP2020	77718	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411532	C4591001 1241 12411532	16-55	01SEP2020	77720	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411535	C4591001 1241 12411535	16-55	02SEP2020	77721	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411536	C4591001 1241 12411536	16-55	02SEP2020	77726	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411537	C4591001 1241 12411537	16-55	02SEP2020	78401	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411538	C4591001 1241 12411538	16-55	02SEP2020	78404	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411539	C4591001 1241 12411539	16-55	02SEP2020	78405	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411540	C4591001 1241 12411540	16-55	02SEP2020	78410	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411541	C4591001 1241 12411541	16-55	02SEP2020	78461	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411542	C4591001 1241 12411542	16-55	02SEP2020	78470	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411543	C4591001 1241 12411543	16-55	02SEP2020	78463	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411544	C4591001 1241 12411544	16-55	02SEP2020	78472	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411546	C4591001 1241 12411546	16-55	02SEP2020	78618	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411547	C4591001 1241 12411547	16-55	02SEP2020	78620	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411548	C4591001 1241 12411548	16-55	02SEP2020	78622	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411549	C4591001 1241 12411549	16-55	02SEP2020	78623	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411552	C4591001 1241 12411552	16-55	02SEP2020	78750	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411553	C4591001 1241 12411553	16-55	02SEP2020	78752	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411555	C4591001 1241 12411555	16-55	02SEP2020	78754	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411556	C4591001 1241 12411556	16-55	02SEP2020	78759	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411557	C4591001 1241 12411557	16-55	02SEP2020	78941	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411558	C4591001 1241 12411558	16-55	02SEP2020	78944	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411561	C4591001 1241 12411561	16-55	02SEP2020	78945	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411562	C4591001 1241 12411562	16-55	02SEP2020	78950	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411563	C4591001 1241 12411563	16-55	02SEP2020	79109	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411564	C4591001 1241 12411564	16-55	02SEP2020	79114	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411565	C4591001 1241 12411565	16-55	02SEP2020	79115	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411566	C4591001 1241 12411566	16-55	02SEP2020	79117	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411567	C4591001 1241 12411567	16-55	02SEP2020	79230	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411568	C4591001 1241 12411568	16-55	02SEP2020	79233	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411569	C4591001 1241 12411569	16-55	02SEP2020	79235	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411570	C4591001 1241 12411570	16-55	02SEP2020	79237	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411572	C4591001 1241 12411572	16-55	03SEP2020	79798	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411573	C4591001 1241 12411573	16-55	03SEP2020	79801	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411574	C4591001 1241 12411574	16-55	03SEP2020	79802	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411575	C4591001 1241 12411575	16-55	03SEP2020	79804	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411576	C4591001 1241 12411576	16-55	03SEP2020	80045	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411577	C4591001 1241 12411577	16-55	03SEP2020	80047	Placebo	03SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411578	C4591001 1241 12411578	16-55	03SEP2020	80048	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12411579	C4591001 1241 12411579	16-55	03SEP2020	80053	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411580	C4591001 1241 12411580	16-55	03SEP2020	80117	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411581	C4591001 1241 12411581	16-55	03SEP2020	80118	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411582	C4591001 1241 12411582	16-55	03SEP2020	80119	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411583	C4591001 1241 12411583	16-55	03SEP2020	80122	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411584	C4591001 1241 12411584	16-55	03SEP2020	80262	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411586	C4591001 1241 12411586	16-55	03SEP2020	80264	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411587	C4591001 1241 12411587	16-55	03SEP2020	80267	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411588	C4591001 1241 12411588	16-55	03SEP2020	80541	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411589	C4591001 1241 12411589	16-55	03SEP2020	80272	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411590	C4591001 1241 12411590	16-55	03SEP2020	80543	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411592	C4591001 1241 12411592	16-55	03SEP2020	80544	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411593	C4591001 1241 12411593	16-55	03SEP2020	80548	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411594	C4591001 1241 12411594	16-55	03SEP2020	80609	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411595	C4591001 1241 12411595	16-55	03SEP2020	80610	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411596	C4591001 1241 12411596	16-55	03SEP2020	80612	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411598	C4591001 1241 12411598	16-55	03SEP2020	80613	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411599	C4591001 1241 12411599	16-55	03SEP2020	80733	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411600	C4591001 1241 12411600	16-55	03SEP2020	80737	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411601	C4591001 1241 12411601	16-55	03SEP2020	80739	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411602	C4591001 1241 12411602	16-55	03SEP2020	80740	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411603	C4591001 1241 12411603	16-55	03SEP2020	80816	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12411604	C4591001 1241 12411604	16-55	03SEP2020	80819	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411605	C4591001 1241 12411605	16-55	03SEP2020	80822	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411606	C4591001 1241 12411606	16-55	03SEP2020	80824	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411607	C4591001 1241 12411607	16-55	03SEP2020	80993	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411608	C4591001 1241 12411608	16-55	03SEP2020	81000	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411609	C4591001 1241 12411609	16-55	03SEP2020	81002	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411610	C4591001 1241 12411610	16-55	03SEP2020	81003	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411611	C4591001 1241 12411611	16-55	04SEP2020	81234	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411613	C4591001 1241 12411613	16-55	04SEP2020	81240	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12411616	C4591001 1241 12411616	16-55	04SEP2020	81241	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411617	C4591001 1241 12411617	16-55	04SEP2020	81242	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411619	C4591001 1241 12411619	16-55	04SEP2020	81629	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411624	C4591001 1241 12411624	16-55	04SEP2020	81632	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411625	C4591001 1241 12411625	16-55	04SEP2020	81635	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411626	C4591001 1241 12411626	16-55	04SEP2020	81639	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411629	C4591001 1241 12411629	16-55	04SEP2020	81990	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411630	C4591001 1241 12411630	16-55	04SEP2020	81995	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411631	C4591001 1241 12411631	16-55	04SEP2020	81998	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411632	C4591001 1241 12411632	16-55	04SEP2020	81999	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411633	C4591001 1241 12411633	16-55	04SEP2020	82110	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411634	C4591001 1241 12411634	16-55	04SEP2020	82113	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411635	C4591001 1241 12411635	16-55	04SEP2020	82116	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411636	C4591001 1241 12411636	16-55	04SEP2020	82117	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411637	C4591001 1241 12411637	16-55	04SEP2020	82254	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411638	C4591001 1241 12411638	16-55	04SEP2020	82255	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411639	C4591001 1241 12411639	16-55	04SEP2020	82258	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411640	C4591001 1241 12411640	16-55	04SEP2020	82263	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411641	C4591001 1241 12411641	16-55	04SEP2020	82398	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12411645	C4591001 1241 12411645	16-55	04SEP2020	82448	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411646	C4591001 1241 12411646	16-55	04SEP2020	82451	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411647	C4591001 1241 12411647	16-55	04SEP2020	82452	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411648	C4591001 1241 12411648	16-55	04SEP2020	82455	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411649	C4591001 1241 12411649	16-55	04SEP2020	82521	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12411650	C4591001 1241 12411650	16-55	04SEP2020	82524	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411651	C4591001 1241 12411651	16-55	04SEP2020	82525	Placebo	04SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411653	C4591001 1241 12411653	16-55	08SEP2020	82528	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12411654	C4591001 1241 12411654	16-55	09SEP2020	85076	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12411655	C4591001 1241 12411655	16-55	09SEP2020	85077	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411656	C4591001 1241 12411656	16-55	10SEP2020	85081	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411657	C4591001 1241 12411657	16-55	10SEP2020	85082	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411658	C4591001 1241 12411658	16-55	10SEP2020	86730	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411659	C4591001 1241 12411659	16-55	10SEP2020	86731	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411660	C4591001 1241 12411660	16-55	10SEP2020	86738	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411661	C4591001 1241 12411661	16-55	10SEP2020	86740	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411662	C4591001 1241 12411662	16-55	10SEP2020	87058	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411663	C4591001 1241 12411663	16-55	10SEP2020	87055	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411664	C4591001 1241 12411664	16-55	10SEP2020	87062	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411665	C4591001 1241 12411665	16-55	10SEP2020	87063	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411666	C4591001 1241 12411666	16-55	10SEP2020	87354	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411667	C4591001 1241 12411667	16-55	10SEP2020	87357	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12411668	C4591001 1241 12411668	16-55	10SEP2020	87361	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411672	C4591001 1241 12411672	16-55	14SEP2020	87364	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411673	C4591001 1241 12411673	16-55	14SEP2020	89372	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411674	C4591001 1241 12411674	16-55	14SEP2020	89370	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411677	C4591001 1241 12411677	16-55	14SEP2020	89375	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411678	C4591001 1241 12411678	16-55	14SEP2020	89376	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411679	C4591001 1241 12411679	16-55	14SEP2020	89645	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		
12411680	C4591001 1241 12411680	16-55	15SEP2020	89646	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411681	C4591001 1241 12411681	16-55	15SEP2020	89647	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411683	C4591001 1241 12411683	16-55	15SEP2020	89648	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411684	C4591001 1241 12411684	16-55	15SEP2020	90487	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411685	C4591001 1241 12411685	16-55	15SEP2020	90490	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411686	C4591001 1241 12411686	16-55	15SEP2020	90491	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411687	C4591001 1241 12411687	16-55	15SEP2020	90492	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411688	C4591001 1241 12411688	16-55	15SEP2020	90534	Placebo	15SEP2020/ Placebo		02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411689	C4591001 1241 12411689	16-55	15SEP2020	90540	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411690	C4591001 1241 12411690	16-55	15SEP2020	90542	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411692	C4591001 1241 12411692	16-55	15SEP2020	90544	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411693	C4591001 1241 12411693	16-55	15SEP2020	90569	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411694	C4591001 1241 12411694	16-55	15SEP2020	90570	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411695	C4591001 1241 12411695	16-55	15SEP2020	90574	Placebo	15SEP2020/ Placebo		29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411696	C4591001 1241 12411696	16-55	15SEP2020	90578	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411697	C4591001 1241 12411697	16-55	15SEP2020	90644	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411698	C4591001 1241 12411698	16-55	15SEP2020	90645	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411699	C4591001 1241 12411699	16-55	15SEP2020	90650	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411700	C4591001 1241 12411700	16-55	15SEP2020	90652	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411701	C4591001 1241 12411701	16-55	15SEP2020	90693	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411702	C4591001 1241 12411702	16-55	15SEP2020	90696	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411703	C4591001 1241 12411703	16-55	15SEP2020	90697	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411706	C4591001 1241 12411706	16-55	15SEP2020	90699	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411707	C4591001 1241 12411707	16-55	16SEP2020	90862	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411708	C4591001 1241 12411708	16-55	16SEP2020	90865	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411709	C4591001 1241 12411709	16-55	16SEP2020	90866	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411710	C4591001 1241 12411710	16-55	16SEP2020	90867	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411712	C4591001 1241 12411712	16-55	16SEP2020	90882	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411713	C4591001 1241 12411713	16-55	16SEP2020	90884	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411714	C4591001 1241 12411714	16-55	16SEP2020	90887	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411715	C4591001 1241 12411715	16-55	16SEP2020	90890	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411716	C4591001 1241 12411716	16-55	16SEP2020	90911	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411717	C4591001 1241 12411717	16-55	16SEP2020	90912	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411718	C4591001 1241 12411718	16-55	16SEP2020	90914	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411719	C4591001 1241 12411719	16-55	16SEP2020	90916	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411720	C4591001 1241 12411720	16-55	16SEP2020	90958	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411723	C4591001 1241 12411723	16-55	16SEP2020	90960	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411724	C4591001 1241 12411724	16-55	16SEP2020	90961	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411725	C4591001 1241 12411725	16-55	16SEP2020	90962	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411726	C4591001 1241 12411726	16-55	16SEP2020	91064	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411727	C4591001 1241 12411727	16-55	16SEP2020	91066	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411729	C4591001 1241 12411729	16-55	16SEP2020	91067	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411730	C4591001 1241 12411730	16-55	16SEP2020	91070	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411731	C4591001 1241 12411731	16-55	16SEP2020	91229	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411733	C4591001 1241 12411733	16-55	16SEP2020	91230	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411734	C4591001 1241 12411734	16-55	16SEP2020	91235	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12411735	C4591001 1241 12411735	16-55	16SEP2020	91239	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411736	C4591001 1241 12411736	16-55	16SEP2020	91337	Placebo	16SEP2020/ Placebo	05OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411740	C4591001 1241 12411740	16-55	16SEP2020	91340	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411741	C4591001 1241 12411741	16-55	16SEP2020	91345	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411742	C4591001 1241 12411742	16-55	16SEP2020	91348	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411743	C4591001 1241 12411743	16-55	16SEP2020	91388	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411744	C4591001 1241 12411744	16-55	16SEP2020	91389	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411745	C4591001 1241 12411745	16-55	16SEP2020	91390	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411747	C4591001 1241 12411747	16-55	16SEP2020	91396	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411749	C4591001 1241 12411749	16-55	16SEP2020	91471	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12411750	C4591001 1241 12411750	16-55	16SEP2020	91472	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411754	C4591001 1241 12411754	16-55	16SEP2020	91474	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411756	C4591001 1241 12411756	16-55	16SEP2020	91480	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411757	C4591001 1241 12411757	16-55	16SEP2020	91592	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411758	C4591001 1241 12411758	16-55	16SEP2020	91594	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411760	C4591001 1241 12411760	16-55	16SEP2020	91599	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411762	C4591001 1241 12411762	16-55	16SEP2020	91600	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411763	C4591001 1241 12411763	16-55	16SEP2020	91677	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411764	C4591001 1241 12411764	16-55	16SEP2020	91678	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411765	C4591001 1241 12411765	16-55	16SEP2020	91679	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411766	C4591001 1241 12411766	16-55	16SEP2020	91683	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)			
12411767	C4591001 1241 12411767	16-55	16SEP2020	91781	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411768	C4591001 1241 12411768	16-55	16SEP2020	91785	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411769	C4591001 1241 12411769	16-55	16SEP2020	91788	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411771	C4591001 1241 12411771	16-55	16SEP2020	91789	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411772	C4591001 1241 12411772	16-55	16SEP2020	91818	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411773	C4591001 1241 12411773	16-55	16SEP2020	91819	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411774	C4591001 1241 12411774	16-55	16SEP2020	91824	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411775	C4591001 1241 12411775	16-55	16SEP2020	91828	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411776	C4591001 1241 12411776	16-55	16SEP2020	91830	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12411777	C4591001 1241 12411777	16-55	16SEP2020	91832	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411778	C4591001 1241 12411778	16-55	16SEP2020	91837	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411779	C4591001 1241 12411779	16-55	16SEP2020	91839	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411780	C4591001 1241 12411780	16-55	16SEP2020	91867	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411781	C4591001 1241 12411781	16-55	16SEP2020	91869	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411782	C4591001 1241 12411782	16-55	16SEP2020	91873	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411784	C4591001 1241 12411784	16-55	16SEP2020	91876	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411785	C4591001 1241 12411785	16-55	16SEP2020	91892	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411786	C4591001 1241 12411786	16-55	16SEP2020	91893	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411787	C4591001 1241 12411787	16-55	16SEP2020	91895	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12411790	C4591001 1241 12411790	16-55	17SEP2020	91898	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411791	C4591001 1241 12411791	16-55	17SEP2020	91929	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411792	C4591001 1241 12411792	16-55	17SEP2020	91930	Placebo	17SEP2020/ Placebo	20OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411793	C4591001 1241 12411793	16-55	17SEP2020	91933	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411797	C4591001 1241 12411797	16-55	17SEP2020	91935	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411798	C4591001 1241 12411798	16-55	17SEP2020	91985	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411799	C4591001 1241 12411799	16-55	17SEP2020	91991	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411800	C4591001 1241 12411800	16-55	17SEP2020	91992	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411801	C4591001 1241 12411801	16-55	17SEP2020	91996	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411802	C4591001 1241 12411802	16-55	17SEP2020	92084	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411803	C4591001 1241 12411803	16-55	17SEP2020	92087	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411804	C4591001 1241 12411804	16-55	17SEP2020	92090	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411805	C4591001 1241 12411805	16-55	17SEP2020	92145	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411806	C4591001 1241 12411806	16-55	17SEP2020	92148	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411807	C4591001 1241 12411807	16-55	17SEP2020	92149	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411808	C4591001 1241 12411808	16-55	17SEP2020	92151	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411809	C4591001 1241 12411809	16-55	17SEP2020	92082	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12411810	C4591001 1241 12411810	16-55	17SEP2020	92273	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411812	C4591001 1241 12411812	16-55	17SEP2020	92276	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411813	C4591001 1241 12411813	16-55	17SEP2020	92281	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411814	C4591001 1241 12411814	16-55	17SEP2020	92284	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411815	C4591001 1241 12411815	16-55	17SEP2020	92393	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411816	C4591001 1241 12411816	16-55	17SEP2020	92397	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411817	C4591001 1241 12411817	16-55	17SEP2020	92398	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411818	C4591001 1241 12411818	16-55	17SEP2020	92403	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411819	C4591001 1241 12411819	16-55	17SEP2020	92477	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411820	C4591001 1241 12411820	16-55	17SEP2020	92478	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411823	C4591001 1241 12411823	16-55	17SEP2020	92481	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411824	C4591001 1241 12411824	16-55	17SEP2020	92483	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411826	C4591001 1241 12411826	16-55	17SEP2020	92622	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411827	C4591001 1241 12411827	16-55	17SEP2020	92626	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411828	C4591001 1241 12411828	16-55	17SEP2020	92630	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411830	C4591001 1241 12411830	16-55	17SEP2020	92631	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12411832	C4591001 1241 12411832	16-55	17SEP2020	92754	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411833	C4591001 1241 12411833	16-55	17SEP2020	92759	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411834	C4591001 1241 12411834	16-55	17SEP2020	92761	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411835	C4591001 1241 12411835	16-55	17SEP2020	92764	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411836	C4591001 1241 12411836	16-55	17SEP2020	92804	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411837	C4591001 1241 12411837	16-55	17SEP2020	92805	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411839	C4591001 1241 12411839	16-55	17SEP2020	92810	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411840	C4591001 1241 12411840	16-55	17SEP2020	92812	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411841	C4591001 1241 12411841	16-55	17SEP2020	92854	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411842	C4591001 1241 12411842	16-55	17SEP2020	92855	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411843	C4591001 1241 12411843	16-55	17SEP2020	92858	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411845	C4591001 1241 12411845	16-55	17SEP2020	92859	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12411846	C4591001 1241 12411846	16-55	17SEP2020	92946	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411847	C4591001 1241 12411847	16-55	17SEP2020	92949	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411848	C4591001 1241 12411848	16-55	17SEP2020	92950	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411849	C4591001 1241 12411849	16-55	17SEP2020	92951	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411850	C4591001 1241 12411850	16-55	17SEP2020	93005	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411851	C4591001 1241 12411851	16-55	17SEP2020	93006	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411854	C4591001 1241 12411854	16-55	17SEP2020	93010	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411855	C4591001 1241 12411855	16-55	17SEP2020	93013	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12411856	C4591001 1241 12411856	16-55	17SEP2020	93053	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411857	C4591001 1241 12411857	16-55	17SEP2020	93058	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411858	C4591001 1241 12411858	16-55	17SEP2020	93059	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411859	C4591001 1241 12411859	16-55	17SEP2020	93061	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411860	C4591001 1241 12411860	16-55	17SEP2020	93092	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411861	C4591001 1241 12411861	16-55	17SEP2020	93093	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411862	C4591001 1241 12411862	16-55	17SEP2020	93099	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411863	C4591001 1241 12411863	16-55	17SEP2020	93129	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411864	C4591001 1241 12411864	16-55	17SEP2020	93100	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411865	C4591001 1241 12411865	16-55	17SEP2020	93131	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12411866	C4591001 1241 12411866	16-55	17SEP2020	93132	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411867	C4591001 1241 12411867	16-55	17SEP2020	93133	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12411868	C4591001 1241 12411868	16-55	17SEP2020	93137	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411869	C4591001 1241 12411869	16-55	17SEP2020	93139	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411870	C4591001 1241 12411870	16-55	17SEP2020	93149	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411871	C4591001 1241 12411871	16-55	17SEP2020	93142	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12411872	C4591001 1241 12411872	16-55	17SEP2020	93153	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411873	C4591001 1241 12411873	16-55	17SEP2020	93145	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411874	C4591001 1241 12411874	16-55	17SEP2020	93158	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411875	C4591001 1241 12411875	16-55	17SEP2020	93152	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12411877	C4591001 1241 12411877	16-55	18SEP2020	93162	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411878	C4591001 1241 12411878	16-55	18SEP2020	93163	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411879	C4591001 1241 12411879	16-55	18SEP2020	93166	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411880	C4591001 1241 12411880	16-55	18SEP2020	93168	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411881	C4591001 1241 12411881	16-55	18SEP2020	93225	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411882	C4591001 1241 12411882	16-55	18SEP2020	93226	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411884	C4591001 1241 12411884	16-55	18SEP2020	93228	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411885	C4591001 1241 12411885	16-55	18SEP2020	93229	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411886	C4591001 1241 12411886	16-55	18SEP2020	93284	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411887	C4591001 1241 12411887	16-55	18SEP2020	93311	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12411888	C4591001 1241 12411888	16-55	18SEP2020	93312	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411889	C4591001 1241 12411889	16-55	18SEP2020	93313	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411892	C4591001 1241 12411892	16-55	18SEP2020	93315	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411893	C4591001 1241 12411893	16-55	18SEP2020	93391	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411894	C4591001 1241 12411894	16-55	18SEP2020	93398	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411895	C4591001 1241 12411895	16-55	18SEP2020	93399	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12411897	C4591001 1241 12411897	16-55	18SEP2020	93400	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12411898	C4591001 1241 12411898	16-55	18SEP2020	93437	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411899	C4591001 1241 12411899	16-55	18SEP2020	93440	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411900	C4591001 1241 12411900	16-55	18SEP2020	93441	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411901	C4591001 1241 12411901	16-55	18SEP2020	93448	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411903	C4591001 1241 12411903	16-55	18SEP2020	93498	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411904	C4591001 1241 12411904	16-55	18SEP2020	93502	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411905	C4591001 1241 12411905	16-55	18SEP2020	93503	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411906	C4591001 1241 12411906	16-55	18SEP2020	93505	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411907	C4591001 1241 12411907	16-55	18SEP2020	93775	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411908	C4591001 1241 12411908	16-55	18SEP2020	93776	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411909	C4591001 1241 12411909	16-55	18SEP2020	93778	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411911	C4591001 1241 12411911	16-55	18SEP2020	93784	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411912	C4591001 1241 12411912	16-55	18SEP2020	93869	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411913	C4591001 1241 12411913	16-55	18SEP2020	93874	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411914	C4591001 1241 12411914	16-55	18SEP2020	93876	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411915	C4591001 1241 12411915	16-55	18SEP2020	93880	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411917	C4591001 1241 12411917	16-55	18SEP2020	93930	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411919	C4591001 1241 12411919	16-55	18SEP2020	93931	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411920	C4591001 1241 12411920	16-55	18SEP2020	93936	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411921	C4591001 1241 12411921	16-55	18SEP2020	93939	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411924	C4591001 1241 12411924	16-55	18SEP2020	94014	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411925	C4591001 1241 12411925	16-55	18SEP2020	94015	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411926	C4591001 1241 12411926	16-55	18SEP2020	94018	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411927	C4591001 1241 12411927	16-55	18SEP2020	94020	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411929	C4591001 1241 12411929	16-55	18SEP2020	94149	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411930	C4591001 1241 12411930	16-55	18SEP2020	94152	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411931	C4591001 1241 12411931	16-55	18SEP2020	94153	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411932	C4591001 1241 12411932	16-55	18SEP2020	94154	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411935	C4591001 1241 12411935	16-55	18SEP2020	94217	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411936	C4591001 1241 12411936	16-55	18SEP2020	94219	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411937	C4591001 1241 12411937	16-55	18SEP2020	94223	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411939	C4591001 1241 12411939	16-55	18SEP2020	94225	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411940	C4591001 1241 12411940	16-55	18SEP2020	94233	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411942	C4591001 1241 12411942	16-55	18SEP2020	94234	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411943	C4591001 1241 12411943	16-55	18SEP2020	94237	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411944	C4591001 1241 12411944	16-55	18SEP2020	94239	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411945	C4591001 1241 12411945	16-55	18SEP2020	94265	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411947	C4591001 1241 12411947	16-55	18SEP2020	94267	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411948	C4591001 1241 12411948	16-55	18SEP2020	94270	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411949	C4591001 1241 12411949	16-55	18SEP2020	94274	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12411950	C4591001 1241 12411950	16-55	18SEP2020	94306	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411951	C4591001 1241 12411951	16-55	18SEP2020	94307	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411952	C4591001 1241 12411952	16-55	18SEP2020	94309	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411953	C4591001 1241 12411953	16-55	18SEP2020	94310	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411954	C4591001 1241 12411954	16-55	18SEP2020	94349	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411955	C4591001 1241 12411955	16-55	18SEP2020	94350	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12411956	C4591001 1241 12411956	16-55	18SEP2020	94354	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411957	C4591001 1241 12411957	16-55	18SEP2020	94358	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411958	C4591001 1241 12411958	16-55	18SEP2020	94362	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411960	C4591001 1241 12411960	16-55	18SEP2020	94365	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411961	C4591001 1241 12411961	16-55	18SEP2020	94366	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12411962	C4591001 1241 12411962	16-55	18SEP2020	94371	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411963	C4591001 1241 12411963	16-55	18SEP2020	94375	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12411965	C4591001 1241 12411965	16-55	21SEP2020	94377	Placebo	21SEP2020/ Placebo	22OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411967	C4591001 1241 12411967	16-55	21SEP2020	94379	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411968	C4591001 1241 12411968	16-55	21SEP2020	94382	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411969	C4591001 1241 12411969	16-55	21SEP2020	94601	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12411970	C4591001 1241 12411970	16-55	21SEP2020	94604	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411971	C4591001 1241 12411971	16-55	21SEP2020	94605	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12411972	C4591001 1241 12411972	16-55	21SEP2020	94611	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411973	C4591001 1241 12411973	16-55	21SEP2020	94637	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411974	C4591001 1241 12411974	16-55	21SEP2020	94640	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411975	C4591001 1241 12411975	16-55	21SEP2020	94642	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411977	C4591001 1241 12411977	16-55	21SEP2020	94645	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12411978	C4591001 1241 12411978	16-55	21SEP2020	94649	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411980	C4591001 1241 12411980	16-55	21SEP2020	94653	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411981	C4591001 1241 12411981	16-55	21SEP2020	94655	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411982	C4591001 1241 12411982	16-55	21SEP2020	94660	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411983	C4591001 1241 12411983	16-55	21SEP2020	94746	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411984	C4591001 1241 12411984	16-55	21SEP2020	94752	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411985	C4591001 1241 12411985	16-55	21SEP2020	94755	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411986	C4591001 1241 12411986	16-55	21SEP2020	94756	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411987	C4591001 1241 12411987	16-55	21SEP2020	94795	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12411988	C4591001 1241 12411988	16-55	21SEP2020	94797	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411990	C4591001 1241 12411990	16-55	21SEP2020	94802	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411991	C4591001 1241 12411991	16-55	21SEP2020	94803	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12411992	C4591001 1241 12411992	16-55	21SEP2020	95158	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12411993	C4591001 1241 12411993	16-55	21SEP2020	95161	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12411994	C4591001 1241 12411994	16-55	21SEP2020	95162	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411995	C4591001 1241 12411995	16-55	21SEP2020	95164	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12411996	C4591001 1241 12411996	16-55	21SEP2020	95179	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12411997	C4591001 1241 12411997	16-55	21SEP2020	95182	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12411998	C4591001 1241 12411998	16-55	21SEP2020	95185	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12411999	C4591001 1241 12411999	16-55	21SEP2020	95186	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412001	C4591001 1241 12412001	16-55	21SEP2020	95249	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412002	C4591001 1241 12412002	16-55	21SEP2020	95250	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412003	C4591001 1241 12412003	16-55	21SEP2020	95256	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412004	C4591001 1241 12412004	16-55	21SEP2020	95257	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412006	C4591001 1241 12412006	16-55	21SEP2020	95418	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412007	C4591001 1241 12412007	16-55	21SEP2020	95423	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412008	C4591001 1241 12412008	16-55	21SEP2020	95426	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412009	C4591001 1241 12412009	16-55	21SEP2020	95427	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412010	C4591001 1241 12412010	16-55	21SEP2020	95573	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412012	C4591001 1241 12412012	16-55	21SEP2020	95576	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12412013	C4591001 1241 12412013	16-55	21SEP2020	95579	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412014	C4591001 1241 12412014	16-55	21SEP2020	95582	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412015	C4591001 1241 12412015	16-55	28SEP2020	101453	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412016	C4591001 1241 12412016	16-55	28SEP2020	101456	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412018	C4591001 1241 12412018	16-55	28SEP2020	101459	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412019	C4591001 1241 12412019	16-55	28SEP2020	101463	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412020	C4591001 1241 12412020	16-55	28SEP2020	101516	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12412022	C4591001 1241 12412022	16-55	29SEP2020	101520	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412023	C4591001 1241 12412023	16-55	29SEP2020	101521	Placebo	29SEP2020/ Placebo	22OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412024	C4591001 1241 12412024	16-55	29SEP2020	101523	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412025	C4591001 1241 12412025	16-55	29SEP2020	101935	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412026	C4591001 1241 12412026	16-55	29SEP2020	101937	Placebo	29SEP2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412027	C4591001 1241 12412027	16-55	30SEP2020	101939	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412028	C4591001 1241 12412028	16-55	30SEP2020	101942	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412029	C4591001 1241 12412029	16-55	30SEP2020	102150	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412031	C4591001 1241 12412031	16-55	30SEP2020	102153	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12412032	C4591001 1241 12412032	16-55	30SEP2020	102157	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412034	C4591001 1241 12412034	16-55	30SEP2020	102160	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412035	C4591001 1241 12412035	16-55	30SEP2020	102185	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412036	C4591001 1241 12412036	16-55	30SEP2020	102188	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12412037	C4591001 1241 12412037	16-55	30SEP2020	102190	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412038	C4591001 1241 12412038	16-55	30SEP2020	102193	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412039	C4591001 1241 12412039	16-55	30SEP2020	102211	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412041	C4591001 1241 12412041	16-55	30SEP2020	102213	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412043	C4591001 1241 12412043	16-55	30SEP2020	102215	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412044	C4591001 1241 12412044	16-55	30SEP2020	102220	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412045	C4591001 1241 12412045	16-55	30SEP2020	102294	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412046	C4591001 1241 12412046	16-55	30SEP2020	102297	Placebo	30SEP2020/ Placebo	22OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12412048	C4591001 1241 12412048	16-55	30SEP2020	102303	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412049	C4591001 1241 12412049	16-55	30SEP2020	102304	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412050	C4591001 1241 12412050	16-55	30SEP2020	102404	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412051	C4591001 1241 12412051	16-55	30SEP2020	102407	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412052	C4591001 1241 12412052	16-55	30SEP2020	102411	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412053	C4591001 1241 12412053	16-55	30SEP2020	102412	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412054	C4591001 1241 12412054	16-55	30SEP2020	102426	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412055	C4591001 1241 12412055	16-55	30SEP2020	102431	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412056	C4591001 1241 12412056	16-55	30SEP2020	102434	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12412057	C4591001 1241 12412057	16-55	30SEP2020	102436	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412058	C4591001 1241 12412058	16-55	30SEP2020	102453	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412059	C4591001 1241 12412059	16-55	30SEP2020	102455	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412060	C4591001 1241 12412060	16-55	30SEP2020	102457	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412061	C4591001 1241 12412061	16-55	30SEP2020	102459	Placebo	30SEP2020/ Placebo	23OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412062	C4591001 1241 12412062	16-55	30SEP2020	102475	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412063	C4591001 1241 12412063	16-55	30SEP2020	102476	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412064	C4591001 1241 12412064	16-55	30SEP2020	102478	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412065	C4591001 1241 12412065	16-55	30SEP2020	102480	Placebo	30SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412066	C4591001 1241 12412066	16-55	30SEP2020	102497	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412067	C4591001 1241 12412067	16-55	30SEP2020	102499	Placebo	30SEP2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412069	C4591001 1241 12412069	16-55	01OCT2020	102501	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12412070	C4591001 1241 12412070	16-55	01OCT2020	102508	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412071	C4591001 1241 12412071	16-55	01OCT2020	102641	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412072	C4591001 1241 12412072	16-55	01OCT2020	102643	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412073	C4591001 1241 12412073	16-55	01OCT2020	102646	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412074	C4591001 1241 12412074	16-55	01OCT2020	102652	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412078	C4591001 1241 12412078	16-55	01OCT2020	102716	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412080	C4591001 1241 12412080	16-55	01OCT2020	102717	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412081	C4591001 1241 12412081	16-55	01OCT2020	102719	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412082	C4591001 1241 12412082†	16-55	01OCT2020	102722	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12412083	C4591001 1241 12412083	16-55	01OCT2020	102872	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412084	C4591001 1241 12412084	16-55	01OCT2020	102873	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412086	C4591001 1241 12412086	16-55	01OCT2020	102878	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412087	C4591001 1241 12412087	16-55	01OCT2020	102880	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412088	C4591001 1241 12412088	16-55	01OCT2020	102905	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412089	C4591001 1241 12412089	16-55	01OCT2020	102913	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412090	C4591001 1241 12412090	16-55	01OCT2020	102915	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412091	C4591001 1241 12412091	16-55	01OCT2020	102916	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412092	C4591001 1241 12412092	16-55	01OCT2020	102942	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412093	C4591001 1241 12412093	16-55	01OCT2020	102943	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412094	C4591001 1241 12412094	16-55	01OCT2020	102945	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12412095	C4591001 1241 12412095	16-55	01OCT2020	102951	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412096	C4591001 1241 12412096	16-55	01OCT2020	102966	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12412097	C4591001 1241 12412097	16-55	01OCT2020	102967	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12412098	C4591001 1241 12412098	16-55	01OCT2020	102969	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12412099	C4591001 1241 12412099	16-55	01OCT2020	102976	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412100	C4591001 1241 12412100	16-55	01OCT2020	102977	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412101	C4591001 1241 12412101	16-55	01OCT2020	102978	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412102	C4591001 1241 12412102	16-55	02OCT2020	102982	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412103	C4591001 1241 12412103	16-55	02OCT2020	102987	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412104	C4591001 1241 12412104	16-55	02OCT2020	103063	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412105	C4591001 1241 12412105	16-55	02OCT2020	103064	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412106	C4591001 1241 12412106	16-55	02OCT2020	103065	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412107	C4591001 1241 12412107	16-55	02OCT2020	103067	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412108	C4591001 1241 12412108	16-55	02OCT2020	103074	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412109	C4591001 1241 12412109	16-55	02OCT2020	103077	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412110	C4591001 1241 12412110	16-55	02OCT2020	103082	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412111	C4591001 1241 12412111	16-55	02OCT2020	103083	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412112	C4591001 1241 12412112	16-55	02OCT2020	103123	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412113	C4591001 1241 12412113	16-55	02OCT2020	103125	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412114	C4591001 1241 12412114	16-55	02OCT2020	103129	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12412117	C4591001 1241 12412117	16-55	02OCT2020	103131	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412118	C4591001 1241 12412118	16-55	02OCT2020	103146	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412119	C4591001 1241 12412119	16-55	02OCT2020	103151	Placebo	02OCT2020/ Placebo	22OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412120	C4591001 1241 12412120	16-55	02OCT2020	103152	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo		
12412121	C4591001 1241 12412121	16-55	02OCT2020	103154	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412122	C4591001 1241 12412122	16-55	02OCT2020	103171	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412123	C4591001 1241 12412123	16-55	02OCT2020	103173	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412124	C4591001 1241 12412124	16-55	02OCT2020	103178	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412126	C4591001 1241 12412126	16-55	02OCT2020	103179	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412127	C4591001 1241 12412127	16-55	02OCT2020	103255	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412128	C4591001 1241 12412128	16-55	02OCT2020	103257	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412130	C4591001 1241 12412130	16-55	02OCT2020	103260	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412131	C4591001 1241 12412131	16-55	02OCT2020	103263	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412132	C4591001 1241 12412132	16-55	02OCT2020	103301	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12412133	C4591001 1241 12412133	16-55	02OCT2020	103305	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412134	C4591001 1241 12412134	16-55	02OCT2020	103306	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412135	C4591001 1241 12412135	16-55	02OCT2020	103311	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12412136	C4591001 1241 12412136	16-55	02OCT2020	103376	Placebo	02OCT2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412137	C4591001 1241 12412137	16-55	05OCT2020	103377	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412138	C4591001 1241 12412138	16-55	05OCT2020	103382	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412139	C4591001 1241 12412139	16-55	05OCT2020	103384	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412140	C4591001 1241 12412140	16-55	06OCT2020	104192	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412141	C4591001 1241 12412141	16-55	06OCT2020	104195	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412142	C4591001 1241 12412142	16-55	06OCT2020	104198	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412143	C4591001 1241 12412143	16-55	06OCT2020	104200	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412148	C4591001 1241 12412148	16-55	07OCT2020	104719	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412149	C4591001 1241 12412149	16-55	07OCT2020	104724	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412150	C4591001 1241 12412150	16-55	07OCT2020	104726	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412151	C4591001 1241 12412151	16-55	07OCT2020	104728	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12412152	C4591001 1241 12412152	16-55	07OCT2020	104993	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12412153	C4591001 1241 12412153	16-55	07OCT2020	104994	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12412154	C4591001 1241 12412154	16-55	07OCT2020	105001	Placebo	07OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412155	C4591001 1241 12412155	16-55	07OCT2020	104997	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412156	C4591001 1241 12412156	16-55	07OCT2020	105011	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412157	C4591001 1241 12412157	16-55	07OCT2020	105013	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412158	C4591001 1241 12412158	16-55	07OCT2020	105014	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12412159	C4591001 1241 12412159	16-55	07OCT2020	105019	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12412160	C4591001 1241 12412160	16-55	07OCT2020	105015	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412161	C4591001 1241 12412161	16-55	07OCT2020	105020	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12412162	C4591001 1241 12412162	16-55	07OCT2020	105022	Placebo	07OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412163	C4591001 1241 12412163	16-55	08OCT2020	105026	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12412165	C4591001 1241 12412165	16-55	09OCT2020	106075	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12412166	C4591001 1241 12412166	16-55	13OCT2020	106077	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12412167	C4591001 1241 12412167	16-55	13OCT2020	106081	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412168	C4591001 1241 12412168	16-55	13OCT2020	106082	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412169	C4591001 1241 12412169	16-55	13OCT2020	107131	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12412170	C4591001 1241 12412170	16-55	13OCT2020	107132	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412171	C4591001 1241 12412171	16-55	13OCT2020	107135	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412172	C4591001 1241 12412172	16-55	13OCT2020	107138	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412173	C4591001 1241 12412173	16-55	13OCT2020	107179	Placebo	13OCT2020/ Placebo	03NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412174	C4591001 1241 12412174	16-55	14OCT2020	107183	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412175	C4591001 1241 12412175	16-55	14OCT2020	107185	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412176	C4591001 1241 12412176	16-55	14OCT2020	107187	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412177	C4591001 1241 12412177	16-55	14OCT2020	107333	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412179	C4591001 1241 12412179	16-55	14OCT2020	107334	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412180	C4591001 1241 12412180	16-55	14OCT2020	107340	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412181	C4591001 1241 12412181	16-55	14OCT2020	107343	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412182	C4591001 1241 12412182	16-55	14OCT2020	107429	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412183	C4591001 1241 12412183	16-55	14OCT2020	107431	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412186	C4591001 1241 12412186	16-55	14OCT2020	107433	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412187	C4591001 1241 12412187	16-55	14OCT2020	107436	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412188	C4591001 1241 12412188	16-55	14OCT2020	107633	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412190	C4591001 1241 12412190	16-55	14OCT2020	107634	BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412192	C4591001 1241 12412192	16-55	15OCT2020	107638	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412193	C4591001 1241 12412193	16-55	15OCT2020	107644	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412194	C4591001 1241 12412194	16-55	15OCT2020	108262	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412195	C4591001 1241 12412195	16-55	15OCT2020	108265	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412197	C4591001 1241 12412197	16-55	15OCT2020	108267	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412198	C4591001 1241 12412198	16-55	15OCT2020	108268	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		
12412199	C4591001 1241 12412199	16-55	15OCT2020	108284	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412201	C4591001 1241 12412201	16-55	15OCT2020	108286	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412202	C4591001 1241 12412202	16-55	15OCT2020	108287	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412203	C4591001 1241 12412203	16-55	15OCT2020	108290	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412204	C4591001 1241 12412204	16-55	15OCT2020	108356	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412206	C4591001 1241 12412206	16-55	15OCT2020	108357	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412207	C4591001 1241 12412207	16-55	15OCT2020	108361	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412208	C4591001 1241 12412208	16-55	15OCT2020	108362	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412209	C4591001 1241 12412209	16-55	15OCT2020	108404	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412210	C4591001 1241 12412210	16-55	15OCT2020	108406	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412211	C4591001 1241 12412211	16-55	15OCT2020	108407	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12412212	C4591001 1241 12412212	16-55	15OCT2020	108412	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412213	C4591001 1241 12412213	16-55	15OCT2020	108437	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412214	C4591001 1241 12412214	16-55	15OCT2020	108441	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412215	C4591001 1241 12412215	16-55	15OCT2020	108443	Placebo	15OCT2020/ Placebo	04NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412216	C4591001 1241 12412216	16-55	15OCT2020	108445	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412217	C4591001 1241 12412217	16-55	15OCT2020	108523	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412218	C4591001 1241 12412218	16-55	15OCT2020	108524	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412221	C4591001 1241 12412221	16-55	15OCT2020	108525	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412222	C4591001 1241 12412222	16-55	16OCT2020	108531	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412223	C4591001 1241 12412223	16-55	16OCT2020	108665	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412225	C4591001 1241 12412225	16-55	16OCT2020	108668	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412226	C4591001 1241 12412226	16-55	16OCT2020	108670	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412227	C4591001 1241 12412227	16-55	16OCT2020	108676	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412228	C4591001 1241 12412228	16-55	16OCT2020	108680	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412229	C4591001 1241 12412229	16-55	16OCT2020	108682	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412232	C4591001 1241 12412232	16-55	16OCT2020	108683	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412233	C4591001 1241 12412233	16-55	16OCT2020	108688	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412235	C4591001 1241 12412235	16-55	16OCT2020	108718	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412236	C4591001 1241 12412236	16-55	16OCT2020	108720	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412237	C4591001 1241 12412237	16-55	16OCT2020	108721	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412239	C4591001 1241 12412239	16-55	16OCT2020	108722	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412240	C4591001 1241 12412240	16-55	16OCT2020	108778	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412243	C4591001 1241 12412243	16-55	16OCT2020	108781	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412244	C4591001 1241 12412244	16-55	16OCT2020	108783	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412245	C4591001 1241 12412245	16-55	16OCT2020	108784	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412246	C4591001 1241 12412246	16-55	16OCT2020	108799	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412247	C4591001 1241 12412247	16-55	16OCT2020	108802	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12412248	C4591001 1241 12412248	16-55	16OCT2020	108806	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412249	C4591001 1241 12412249	16-55	16OCT2020	108808	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412252	C4591001 1241 12412252	16-55	16OCT2020	108859	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412253	C4591001 1241 12412253	16-55	16OCT2020	108861	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412254	C4591001 1241 12412254	16-55	16OCT2020	108863	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412255	C4591001 1241 12412255	16-55	16OCT2020	108868	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412256	C4591001 1241 12412256	16-55	16OCT2020	108881	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412257	C4591001 1241 12412257	16-55	16OCT2020	108882	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412258	C4591001 1241 12412258	16-55	16OCT2020	108886	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412259	C4591001 1241 12412259	16-55	16OCT2020	108887	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412260	C4591001 1241 12412260	16-55	16OCT2020	108929	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412261	C4591001 1241 12412261	16-55	16OCT2020	108930	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412262	C4591001 1241 12412262	16-55	16OCT2020	108931	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412264	C4591001 1241 12412264	16-55	16OCT2020	108939	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412267	C4591001 1241 12412267	16-55	16OCT2020	109097	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412268	C4591001 1241 12412268	16-55	16OCT2020	109100	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412269	C4591001 1241 12412269	16-55	16OCT2020	109102	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412270	C4591001 1241 12412270	16-55	16OCT2020	109105	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412271	C4591001 1241 12412271	16-55	16OCT2020	109133	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412274	C4591001 1241 12412274	16-55	16OCT2020	109134	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412275	C4591001 1241 12412275	16-55	16OCT2020	109138	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412276	C4591001 1241 12412276	16-55	16OCT2020	109144	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412277	C4591001 1241 12412277	16-55	16OCT2020	109230	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412278	C4591001 1241 12412278	16-55	16OCT2020	109237	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412279	C4591001 1241 12412279	16-55	16OCT2020	109238	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12412280	C4591001 1241 12412280	16-55	16OCT2020	109239	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412281	C4591001 1241 12412281	16-55	16OCT2020	109253	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412282	C4591001 1241 12412282	16-55	16OCT2020	109255	Placebo	16OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412283	C4591001 1241 12412283	16-55	16OCT2020	109256	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412284	C4591001 1241 12412284	16-55	16OCT2020	109260	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12412285	C4591001 1241 12412285	16-55	16OCT2020	109289	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412288	C4591001 1241 12412288	16-55	16OCT2020	109292	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412289	C4591001 1241 12412289	16-55	16OCT2020	109293	Placebo	16OCT2020/ Placebo	06NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412290	C4591001 1241 12412290	16-55	16OCT2020	109300	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412291	C4591001 1241 12412291	16-55	16OCT2020	109325	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412293	C4591001 1241 12412293	16-55	16OCT2020	109328	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12412294	C4591001 1241 12412294	16-55	16OCT2020	109333	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412295	C4591001 1241 12412295	16-55	16OCT2020	109336	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412296	C4591001 1241 12412296	16-55	16OCT2020	109356	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412299	C4591001 1241 12412299	16-55	16OCT2020	109358	BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)		
12412301	C4591001 1241 12412301	16-55	16OCT2020	109359	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412303	C4591001 1241 12412303	16-55	19OCT2020	109360	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412304	C4591001 1241 12412304	16-55	19OCT2020	109805	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412306	C4591001 1241 12412306	16-55	19OCT2020	109812	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412307	C4591001 1241 12412307	16-55	19OCT2020	109813	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412308	C4591001 1241 12412308	16-55	19OCT2020	109814	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412311	C4591001 1241 12412311	16-55	19OCT2020	109843	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412312	C4591001 1241 12412312	16-55	19OCT2020	109844	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412313	C4591001 1241 12412313	16-55	19OCT2020	109845	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412314	C4591001 1241 12412314	16-55	19OCT2020	109846	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412315	C4591001 1241 12412315	16-55	19OCT2020	109903	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412317	C4591001 1241 12412317	16-55	19OCT2020	109907	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412320	C4591001 1241 12412320	16-55	19OCT2020	109908	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412321	C4591001 1241 12412321	16-55	19OCT2020	109910	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412322	C4591001 1241 12412322	16-55	19OCT2020	109988	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412323	C4591001 1241 12412323	16-55	19OCT2020	109989	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12412324	C4591001 1241 12412324	16-55	19OCT2020	109990	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412327	C4591001 1241 12412327	16-55	19OCT2020	109991	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412328	C4591001 1241 12412328	16-55	19OCT2020	110023	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412329	C4591001 1241 12412329	16-55	19OCT2020	110025	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412330	C4591001 1241 12412330	16-55	19OCT2020	110029	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412331	C4591001 1241 12412331	16-55	19OCT2020	110030	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412332	C4591001 1241 12412332	16-55	19OCT2020	110070	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412333	C4591001 1241 12412333	16-55	19OCT2020	110074	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412334	C4591001 1241 12412334	16-55	19OCT2020	110075	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412335	C4591001 1241 12412335	16-55	19OCT2020	110078	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412336	C4591001 1241 12412336	16-55	19OCT2020	110165	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412337	C4591001 1241 12412337	16-55	19OCT2020	110169	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412338	C4591001 1241 12412338	16-55	19OCT2020	110171	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412339	C4591001 1241 12412339	16-55	19OCT2020	110174	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412341	C4591001 1241 12412341	16-55	19OCT2020	110288	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412342	C4591001 1241 12412342	16-55	19OCT2020	110290	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412343	C4591001 1241 12412343	16-55	19OCT2020	110293	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412344	C4591001 1241 12412344	16-55	19OCT2020	110294	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412345	C4591001 1241 12412345	16-55	19OCT2020	110325	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412346	C4591001 1241 12412346	16-55	19OCT2020	110329	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412347	C4591001 1241 12412347	16-55	19OCT2020	110330	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412348	C4591001 1241 12412348	16-55	19OCT2020	110331	Placebo	19OCT2020/ Placebo	16NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412350	C4591001 1241 12412350	16-55	19OCT2020	110346	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412351	C4591001 1241 12412351	16-55	19OCT2020	110349	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412352	C4591001 1241 12412352	16-55	19OCT2020	110350	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412353	C4591001 1241 12412353	16-55	19OCT2020	110352	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412354	C4591001 1241 12412354	16-55	19OCT2020	110360	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412355	C4591001 1241 12412355	16-55	19OCT2020	110362	Placebo	19OCT2020/ Placebo		08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412357	C4591001 1241 12412357	16-55	19OCT2020	110365	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412358	C4591001 1241 12412358	16-55	19OCT2020	110368	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412360	C4591001 1241 12412360	16-55	19OCT2020	110422	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412361	C4591001 1241 12412361	16-55	19OCT2020	110423	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412362	C4591001 1241 12412362	16-55	19OCT2020	110424	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412363	C4591001 1241 12412363	16-55	19OCT2020	110428	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412364	C4591001 1241 12412364	16-55	19OCT2020	110453	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412365	C4591001 1241 12412365	16-55	19OCT2020	110454	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412366	C4591001 1241 12412366	16-55	19OCT2020	110462	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12412367	C4591001 1241 12412367	16-55	19OCT2020	110464	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412368	C4591001 1241 12412368	16-55	19OCT2020	110477	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412369	C4591001 1241 12412369	16-55	19OCT2020	110481	Placebo	19OCT2020/ Placebo	11NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	
12412370	C4591001 1241 12412370	16-55	19OCT2020	110486	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412371	C4591001 1241 12412371	16-55	19OCT2020	110488	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412373	C4591001 1241 12412373	16-55	19OCT2020	110515	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412374	C4591001 1241 12412374	16-55	19OCT2020	110520	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412375	C4591001 1241 12412375	16-55	19OCT2020	110521	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412377	C4591001 1241 12412377	16-55	19OCT2020	110523	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412378	C4591001 1241 12412378	16-55	19OCT2020	110597	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12412379	C4591001 1241 12412379	16-55	19OCT2020	110601	Placebo	19OCT2020/ Placebo	09NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412380	C4591001 1241 12412380	16-55	20OCT2020	110603	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412381	C4591001 1241 12412381	16-55	20OCT2020	110605	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412382	C4591001 1241 12412382	16-55	20OCT2020	110669	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12412383	C4591001 1241 12412383	16-55	20OCT2020	110672	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412385	C4591001 1241 12412385	16-55	20OCT2020	110677	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412386	C4591001 1241 12412386	16-55	20OCT2020	110680	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412387	C4591001 1241 12412387	16-55	20OCT2020	110813	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412389	C4591001 1241 12412389	16-55	20OCT2020	110814	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412390	C4591001 1241 12412390	16-55	20OCT2020	110816	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412391	C4591001 1241 12412391	16-55	20OCT2020	110820	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412392	C4591001 1241 12412392	16-55	20OCT2020	110947	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412393	C4591001 1241 12412393	16-55	20OCT2020	110950	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412394	C4591001 1241 12412394	16-55	20OCT2020	110951	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412395	C4591001 1241 12412395	16-55	20OCT2020	110953	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412396	C4591001 1241 12412396	16-55	20OCT2020	110994	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412397	C4591001 1241 12412397	16-55	20OCT2020	110996	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412398	C4591001 1241 12412398	16-55	20OCT2020	110999	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412399	C4591001 1241 12412399	16-55	20OCT2020	111000	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412400	C4591001 1241 12412400	16-55	20OCT2020	111041	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412401	C4591001 1241 12412401	16-55	20OCT2020	111044	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412402	C4591001 1241 12412402	16-55	20OCT2020	111045	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412403	C4591001 1241 12412403	16-55	20OCT2020	111050	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412404	C4591001 1241 12412404	16-55	20OCT2020	111066	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412405	C4591001 1241 12412405	16-55	20OCT2020	111067	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412406	C4591001 1241 12412406	16-55	20OCT2020	111069	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
12412407	C4591001 1241 12412407	16-55	20OCT2020	111075	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412409	C4591001 1241 12412409	16-55	20OCT2020	111117	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412410	C4591001 1241 12412410	16-55	20OCT2020	111120	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412411	C4591001 1241 12412411	16-55	20OCT2020	111122	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
12412412	C4591001 1241 12412412	16-55	20OCT2020	111123	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412413	C4591001 1241 12412413	16-55	20OCT2020	111151	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412414	C4591001 1241 12412414	16-55	20OCT2020	111152	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412415	C4591001 1241 12412415	16-55	20OCT2020	111153	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412416	C4591001 1241 12412416	16-55	20OCT2020	111155	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412417	C4591001 1241 12412417	16-55	20OCT2020	111173	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412418	C4591001 1241 12412418	16-55	20OCT2020	111178	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12412419	C4591001 1241 12412419	16-55	20OCT2020	111183	Placebo	20OCT2020/ Placebo	10NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412420	C4591001 1241 12412420	16-55	21OCT2020	111184	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412421	C4591001 1241 12412421	16-55	21OCT2020	111475	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412422	C4591001 1241 12412422	16-55	21OCT2020	111481	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412423	C4591001 1241 12412423	16-55	21OCT2020	111479	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412424	C4591001 1241 12412424	16-55	21OCT2020	111482	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412425	C4591001 1241 12412425	16-55	21OCT2020	111679	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412426	C4591001 1241 12412426	16-55	21OCT2020	111680	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412427	C4591001 1241 12412427	16-55	21OCT2020	111682	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412428	C4591001 1241 12412428	16-55	21OCT2020	111688	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412429	C4591001 1241 12412429	16-55	21OCT2020	111702	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412430	C4591001 1241 12412430	16-55	21OCT2020	111706	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412431	C4591001 1241 12412431	16-55	21OCT2020	111711	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412432	C4591001 1241 12412432	16-55	21OCT2020	111712	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412433	C4591001 1241 12412433	16-55	21OCT2020	111773	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412434	C4591001 1241 12412434	16-55	21OCT2020	111776	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412435	C4591001 1241 12412435	16-55	21OCT2020	111779	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412436	C4591001 1241 12412436	16-55	22OCT2020	111783	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412437	C4591001 1241 12412437	16-55	22OCT2020	112025	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412438	C4591001 1241 12412438	16-55	22OCT2020	112026	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412439	C4591001 1241 12412439	16-55	22OCT2020	112033	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412440	C4591001 1241 12412440	16-55	22OCT2020	112036	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12412441	C4591001 1241 12412441	16-55	22OCT2020	112163	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412442	C4591001 1241 12412442	16-55	22OCT2020	112166	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412443	C4591001 1241 12412443	16-55	22OCT2020	112167	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412444	C4591001 1241 12412444	16-55	22OCT2020	112168	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412445	C4591001 1241 12412445	16-55	22OCT2020	112277	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412447	C4591001 1241 12412447	16-55	22OCT2020	112283	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412448	C4591001 1241 12412448	16-55	22OCT2020	112284	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412449	C4591001 1241 12412449	16-55	22OCT2020	112285	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412450	C4591001 1241 12412450	16-55	22OCT2020	112318	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412451	C4591001 1241 12412451	16-55	22OCT2020	112320	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412452	C4591001 1241 12412452	16-55	22OCT2020	112321	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412453	C4591001 1241 12412453	16-55	22OCT2020	112322	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412454	C4591001 1241 12412454	16-55	22OCT2020	112385	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412455	C4591001 1241 12412455	16-55	22OCT2020	112386	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412456	C4591001 1241 12412456	16-55	22OCT2020	112388	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412457	C4591001 1241 12412457	16-55	22OCT2020	112395	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412458	C4591001 1241 12412458	16-55	22OCT2020	112434	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412459	C4591001 1241 12412459	16-55	22OCT2020	112439	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412460	C4591001 1241 12412460	16-55	22OCT2020	112440	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412461	C4591001 1241 12412461	16-55	22OCT2020	112441	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412462	C4591001 1241 12412462	16-55	22OCT2020	112494	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12412463	C4591001 1241 12412463	16-55	22OCT2020	112500	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412464	C4591001 1241 12412464	16-55	22OCT2020	112504	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412465	C4591001 1241 12412465	16-55	22OCT2020	112496	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412466	C4591001 1241 12412466	16-55	22OCT2020	112541	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412467	C4591001 1241 12412467	16-55	22OCT2020	112547	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412468	C4591001 1241 12412468	16-55	22OCT2020	112548	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412470	C4591001 1241 12412470	16-55	22OCT2020	112549	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412471	C4591001 1241 12412471	16-55	22OCT2020	112554	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412472	C4591001 1241 12412472	16-55	22OCT2020	112557	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412473	C4591001 1241 12412473	16-55	22OCT2020	112556	Placebo	22OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412475	C4591001 1241 12412475	16-55	22OCT2020	112564	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12412476	C4591001 1241 12412476	16-55	22OCT2020	112605	Placebo	22OCT2020/ Placebo	20NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412477	C4591001 1241 12412477	16-55	22OCT2020	112608	Placebo	22OCT2020/ Placebo	11NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412478	C4591001 1241 12412478	16-55	22OCT2020	112610	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12412479	C4591001 1241 12412479	16-55	22OCT2020	112612	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412480	C4591001 1241 12412480	16-55	22OCT2020	112617	BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412482	C4591001 1241 12412482	16-55	23OCT2020	112619	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412485	C4591001 1241 12412485	16-55	23OCT2020	112620	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412486	C4591001 1241 12412486	16-55	23OCT2020	112621	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412490	C4591001 1241 12412490	16-55	23OCT2020	112699	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412491	C4591001 1241 12412491	16-55	23OCT2020	112700	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412493	C4591001 1241 12412493	16-55	23OCT2020	112701	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		
12412494	C4591001 1241 12412494	16-55	23OCT2020	112708	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412495	C4591001 1241 12412495	16-55	23OCT2020	112736	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412498	C4591001 1241 12412498	16-55	23OCT2020	112739	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412500	C4591001 1241 12412500	16-55	23OCT2020	112740	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412501	C4591001 1241 12412501	16-55	23OCT2020	112741	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12412502	C4591001 1241 12412502	16-55	23OCT2020	112781	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412504	C4591001 1241 12412504	16-55	23OCT2020	112783	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12412505	C4591001 1241 12412505	16-55	23OCT2020	112784	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412506	C4591001 1241 12412506	16-55	23OCT2020	112786	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412507	C4591001 1241 12412507	16-55	23OCT2020	112842	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412508	C4591001 1241 12412508	16-55	23OCT2020	112846	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412509	C4591001 1241 12412509	16-55	23OCT2020	112848	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412510	C4591001 1241 12412510	16-55	23OCT2020	112852	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412512	C4591001 1241 12412512	16-55	23OCT2020	112942	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412513	C4591001 1241 12412513	16-55	23OCT2020	112943	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12412515	C4591001 1241 12412515	16-55	23OCT2020	112946	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412516	C4591001 1241 12412516	16-55	23OCT2020	112962	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412517	C4591001 1241 12412517	16-55	23OCT2020	112964	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412518	C4591001 1241 12412518	16-55	23OCT2020	112965	Placebo	23OCT2020/ Placebo	19NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412519	C4591001 1241 12412519	16-55	23OCT2020	112937	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412523	C4591001 1241 12412523	16-55	23OCT2020	112968	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12412525	C4591001 1241 12412525	16-55	23OCT2020	113035	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412527	C4591001 1241 12412527	16-55	23OCT2020	113036	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412528	C4591001 1241 12412528	16-55	23OCT2020	113040	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412529	C4591001 1241 12412529	16-55	23OCT2020	113041	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12412530	C4591001 1241 12412530	16-55	23OCT2020	113058	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412532	C4591001 1241 12412532	16-55	23OCT2020	113060	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412534	C4591001 1241 12412534	16-55	23OCT2020	113066	Placebo	23OCT2020/ Placebo	19NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12412535	C4591001 1241 12412535	16-55	23OCT2020	113067	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412537	C4591001 1241 12412537	16-55	23OCT2020	113120	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412539	C4591001 1241 12412539	16-55	23OCT2020	113123	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12412540	C4591001 1241 12412540	16-55	23OCT2020	113126	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412543	C4591001 1241 12412543	16-55	23OCT2020	113127	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412544	C4591001 1241 12412544	16-55	23OCT2020	113141	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412546	C4591001 1241 12412546	16-55	23OCT2020	113143	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo		
12412547	C4591001 1241 12412547	16-55	23OCT2020	113144	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12412548	C4591001 1241 12412548	16-55	23OCT2020	113148	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412549	C4591001 1241 12412549	16-55	23OCT2020	113154	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12412550	C4591001 1241 12412550	16-55	23OCT2020	113156	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412551	C4591001 1241 12412551	16-55	23OCT2020	113158	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412552	C4591001 1241 12412552	16-55	23OCT2020	113163	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12412553	C4591001 1241 12412553	16-55	23OCT2020	113180	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12412554	C4591001 1241 12412554	16-55	23OCT2020	113183	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412556	C4591001 1241 12412556	16-55	23OCT2020	113184	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412557	C4591001 1241 12412557	16-55	23OCT2020	113186	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12412558	C4591001 1241 12412558	16-55	23OCT2020	113229	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412559	C4591001 1241 12412559	16-55	23OCT2020	113232	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12412560	C4591001 1241 12412560	16-55	23OCT2020	113233	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412561	C4591001 1241 12412561	16-55	23OCT2020	113236	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412562	C4591001 1241 12412562	16-55	23OCT2020	113237	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12412563	C4591001 1241 12412563	16-55	23OCT2020	113243	Placebo	23OCT2020/ Placebo	12NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12412564	C4591001 1241 12412564	16-55	23OCT2020	113244	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12412565	C4591001 1241 12412565	16-55	23OCT2020	113248	Placebo	23OCT2020/ Placebo	11NOV2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12412566	C4591001 1241 12412566†	16-55	04NOV2020	115625	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12461002	C4591001 1246 12461002	16-55	24SEP2020	98465	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12461004	C4591001 1246 12461004	16-55	24SEP2020	98468	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461005	C4591001 1246 12461005	16-55	25SEP2020	98469	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461006	C4591001 1246 12461006	16-55	25SEP2020	98470	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12461007	C4591001 1246 12461007	16-55	25SEP2020	99199	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461008	C4591001 1246 12461008	16-55	25SEP2020	99200	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12461009	C4591001 1246 12461009	16-55	25SEP2020	99201	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
12461010	C4591001 1246 12461010	16-55	25SEP2020	99207	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461011	C4591001 1246 12461011	16-55	25SEP2020	99257	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461012	C4591001 1246 12461012	16-55	25SEP2020	99260	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12461014	C4591001 1246 12461014	16-55	26SEP2020	99262	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12461015	C4591001 1246 12461015	16-55	26SEP2020	99263	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12461017	C4591001 1246 12461017	16-55	27SEP2020	100616	Placebo	27SEP2020/ Placebo	17OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12461018	C4591001 1246 12461018	16-55	27SEP2020	100617	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12461019	C4591001 1246 12461019	16-55	27SEP2020	100618	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12461020	C4591001 1246 12461020	16-55	27SEP2020	100619	Placebo	27SEP2020/ Placebo	17OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461021	C4591001 1246 12461021	16-55	27SEP2020	100627	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
12461022	C4591001 1246 12461022	16-55	28SEP2020	100629	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461023	C4591001 1246 12461023	16-55	28SEP2020	100631	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461024	C4591001 1246 12461024	16-55	28SEP2020	100636	Placebo	28SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12461025	C4591001 1246 12461025	16-55	28SEP2020	101166	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)			
12461026	C4591001 1246 12461026	16-55	28SEP2020	101171	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461028	C4591001 1246 12461028	16-55	28SEP2020	101172	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12461029	C4591001 1246 12461029	16-55	28SEP2020	101173	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461030	C4591001 1246 12461030	16-55	28SEP2020	101206	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12461031	C4591001 1246 12461031	16-55	28SEP2020	101207	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12461032	C4591001 1246 12461032	16-55	28SEP2020	101210	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12461033	C4591001 1246 12461033	16-55	28SEP2020	101212	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo		
12461034	C4591001 1246 12461034	16-55	29SEP2020	101659	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461036	C4591001 1246 12461036	16-55	29SEP2020	101660	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461037	C4591001 1246 12461037	16-55	29SEP2020	101661	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12461038	C4591001 1246 12461038	16-55	29SEP2020	101664	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12461039	C4591001 1246 12461039	16-55	29SEP2020	101804	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
12461041	C4591001 1246 12461041	16-55	30SEP2020	101806	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12461043	C4591001 1246 12461043	16-55	30SEP2020	101810	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12461044	C4591001 1246 12461044	16-55	30SEP2020	101808	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12461045	C4591001 1246 12461045	16-55	30SEP2020	102069	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461046	C4591001 1246 12461046	16-55	30SEP2020	102070	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12461047	C4591001 1246 12461047	16-55	30SEP2020	102072	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461049	C4591001 1246 12461049†	16-55	01OCT2020	102578	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12461050	C4591001 1246 12461050	16-55	01OCT2020	102076	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461052	C4591001 1246 12461052	16-55	01OCT2020	102569	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461053	C4591001 1246 12461053	16-55	01OCT2020	102572	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461055	C4591001 1246 12461055†	16-55	02OCT2020	103018	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461057	C4591001 1246 12461057	16-55	01OCT2020	102579	Placebo	01OCT2020/ Placebo	21OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12461058	C4591001 1246 12461058	16-55	01OCT2020	102666	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461059	C4591001 1246 12461059	16-55	01OCT2020	102667	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461060	C4591001 1246 12461060	16-55	02OCT2020	102668	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12461061	C4591001 1246 12461061	16-55	02OCT2020	102672	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461065	C4591001 1246 12461065	16-55	02OCT2020	103021	Placebo	02OCT2020/ Placebo	23OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461066	C4591001 1246 12461066	16-55	02OCT2020	103022	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12461067	C4591001 1246 12461067	16-55	02OCT2020	103023	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12461068	C4591001 1246 12461068	16-55	02OCT2020	103089	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12461069	C4591001 1246 12461069	16-55	02OCT2020	103090	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12461070	C4591001 1246 12461070	16-55	03OCT2020	103401	BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12461071	C4591001 1246 12461071	16-55	03OCT2020	103092	Placebo	03OCT2020/ Placebo	24OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12461072	C4591001 1246 12461072	16-55	03OCT2020	103096	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12461073	C4591001 1246 12461073†	16-55	05OCT2020	103407	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461074	C4591001 1246 12461074	16-55	03OCT2020	103402	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461075	C4591001 1246 12461075	16-55	03OCT2020	103406	Placebo	03OCT2020/ Placebo	23OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12461076	C4591001 1246 12461076	16-55	05OCT2020	266950	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461078	C4591001 1246 12461078	16-55	05OCT2020	103529	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461079	C4591001 1246 12461079	16-55	05OCT2020	103530	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461080	C4591001 1246 12461080	16-55	05OCT2020	103532	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461081	C4591001 1246 12461081	16-55	05OCT2020	103540	Placebo	05OCT2020/ Placebo	24OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461082	C4591001 1246 12461082	16-55	05OCT2020	103579	Placebo	05OCT2020/ Placebo	24OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12461084	C4591001 1246 12461084	16-55	05OCT2020	103580	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461085	C4591001 1246 12461085	16-55	05OCT2020	103581	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461086	C4591001 1246 12461086	16-55	05OCT2020	103585	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461087	C4591001 1246 12461087	16-55	06OCT2020	104014	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461088	C4591001 1246 12461088	16-55	06OCT2020	104016	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461089	C4591001 1246 12461089	16-55	06OCT2020	104018	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461090	C4591001 1246 12461090	16-55	06OCT2020	104019	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461092	C4591001 1246 12461092	16-55	06OCT2020	104045	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461093	C4591001 1246 12461093	16-55	06OCT2020	104046	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461094	C4591001 1246 12461094	16-55	06OCT2020	104050	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	05MAR2021/ BNT162b2 (30 µg)
12461095	C4591001 1246 12461095	16-55	06OCT2020	104055	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12461097	C4591001 1246 12461097	16-55	06OCT2020	104117	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461098	C4591001 1246 12461098	16-55	06OCT2020	104120	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461099	C4591001 1246 12461099	16-55	06OCT2020	104124	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12461100	C4591001 1246 12461100	16-55	06OCT2020	104128	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12461103	C4591001 1246 12461103	16-55	07OCT2020	104492	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461104	C4591001 1246 12461104	16-55	07OCT2020	104493	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461105	C4591001 1246 12461105	16-55	07OCT2020	104495	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461106	C4591001 1246 12461106	16-55	07OCT2020	104497	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461107	C4591001 1246 12461107	16-55	07OCT2020	104527	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461108	C4591001 1246 12461108	16-55	07OCT2020	104528	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461109	C4591001 1246 12461109	16-55	07OCT2020	104533	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461110	C4591001 1246 12461110	16-55	07OCT2020	104534	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461111	C4591001 1246 12461111	16-55	08OCT2020	105054	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12461112	C4591001 1246 12461112	16-55	08OCT2020	105058	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12461113	C4591001 1246 12461113	16-55	08OCT2020	105063	Placebo	08OCT2020/ Placebo	31OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461114	C4591001 1246 12461114	16-55	08OCT2020	105064	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461115	C4591001 1246 12461115	16-55	08OCT2020	105102	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461116	C4591001 1246 12461116	16-55	08OCT2020	105106	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12461117	C4591001 1246 12461117	16-55	08OCT2020	105107	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461118	C4591001 1246 12461118	16-55	08OCT2020	105110	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12461119	C4591001 1246 12461119	16-55	08OCT2020	105163	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461120	C4591001 1246 12461120	16-55	08OCT2020	105167	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461121	C4591001 1246 12461121	16-55	09OCT2020	105168	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461122	C4591001 1246 12461122	16-55	09OCT2020	105169	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461123	C4591001 1246 12461123	16-55	09OCT2020	105617	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
12461126	C4591001 1246 12461126	16-55	09OCT2020	105620	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461127	C4591001 1246 12461127	16-55	09OCT2020	105623	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461128	C4591001 1246 12461128	16-55	09OCT2020	105624	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	31OCT2020/ BNT162b2 (30 µg)		
12461129	C4591001 1246 12461129	16-55	09OCT2020	105785	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo		
12461130	C4591001 1246 12461130	16-55	10OCT2020	105786	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461131	C4591001 1246 12461131	16-55	10OCT2020	105789	Placebo	10OCT2020/ Placebo	31OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12461133	C4591001 1246 12461133	16-55	10OCT2020	105791	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12461134	C4591001 1246 12461134	16-55	10OCT2020	106234	Placebo	10OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12461135	C4591001 1246 12461135	16-55	10OCT2020	106236	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12461136	C4591001 1246 12461136	16-55	10OCT2020	106237	Placebo	10OCT2020/ Placebo	30OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461137	C4591001 1246 12461137	16-55	10OCT2020	106238	BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12461138	C4591001 1246 12461138	16-55	12OCT2020	106256	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12461139	C4591001 1246 12461139	16-55	12OCT2020	106258	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12461140	C4591001 1246 12461140	16-55	12OCT2020	106262	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12461142	C4591001 1246 12461142	16-55	12OCT2020	106264	Placebo	12OCT2020/ Placebo	02NOV2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471002	C4591001 1247 12471002	16-55	23SEP2020	97158	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
12471003	C4591001 1247 12471003	16-55	23SEP2020	97167	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471004	C4591001 1247 12471004	16-55	23SEP2020	97160	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471006	C4591001 1247 12471006	16-55	23SEP2020	97164	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12471009	C4591001 1247 12471009	16-55	23SEP2020	97186	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471010	C4591001 1247 12471010	16-55	23SEP2020	97187	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12471011	C4591001 1247 12471011	16-55	24SEP2020	97189	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471012	C4591001 1247 12471012	16-55	24SEP2020	97191	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471013	C4591001 1247 12471013	16-55	24SEP2020	98441	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471014	C4591001 1247 12471014	16-55	24SEP2020	98444	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471015	C4591001 1247 12471015	16-55	24SEP2020	98447	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471016	C4591001 1247 12471016	16-55	24SEP2020	98450	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471017	C4591001 1247 12471017	16-55	24SEP2020	98453	Placebo	24SEP2020/ Placebo	14OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471018	C4591001 1247 12471018	16-55	24SEP2020	98458	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12471019	C4591001 1247 12471019	16-55	24SEP2020	98459	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471020	C4591001 1247 12471020	16-55	24SEP2020	98460	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471021	C4591001 1247 12471021	16-55	24SEP2020	98479	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471022	C4591001 1247 12471022	16-55	24SEP2020	98481	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471023	C4591001 1247 12471023	16-55	24SEP2020	98484	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471025	C4591001 1247 12471025	16-55	24SEP2020	98488	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12471026	C4591001 1247 12471026	16-55	24SEP2020	98490	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471027	C4591001 1247 12471027	16-55	24SEP2020	98491	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471028	C4591001 1247 12471028	16-55	24SEP2020	98495	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471029	C4591001 1247 12471029	16-55	24SEP2020	98497	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	
12471030	C4591001 1247 12471030	16-55	24SEP2020	98514	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471031	C4591001 1247 12471031	16-55	24SEP2020	98516	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471032	C4591001 1247 12471032	16-55	24SEP2020	98518	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471033	C4591001 1247 12471033	16-55	24SEP2020	98524	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471034	C4591001 1247 12471034	16-55	24SEP2020	98530	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471035	C4591001 1247 12471035	16-55	24SEP2020	98531	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471036	C4591001 1247 12471036	16-55	24SEP2020	98533	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	
12471037	C4591001 1247 12471037	16-55	24SEP2020	98535	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471038	C4591001 1247 12471038	16-55	24SEP2020	98539	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471040	C4591001 1247 12471040	16-55	25SEP2020	98548	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471043	C4591001 1247 12471043	16-55	25SEP2020	98541	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471044	C4591001 1247 12471044	16-55	25SEP2020	98543	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
12471045	C4591001 1247 12471045	16-55	25SEP2020	99173	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471046	C4591001 1247 12471046	16-55	25SEP2020	99178	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471048	C4591001 1247 12471048	16-55	25SEP2020	99180	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471050	C4591001 1247 12471050	16-55	25SEP2020	99181	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471051	C4591001 1247 12471051	16-55	25SEP2020	99211	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471052	C4591001 1247 12471052	16-55	25SEP2020	99217	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471053	C4591001 1247 12471053	16-55	25SEP2020	99218	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471054	C4591001 1247 12471054	16-55	29SEP2020	101631	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471055	C4591001 1247 12471055	16-55	25SEP2020	99220	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471057	C4591001 1247 12471057	16-55	25SEP2020	99245	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12471058	C4591001 1247 12471058	16-55	25SEP2020	99248	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471059	C4591001 1247 12471059	16-55	25SEP2020	99255	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471060	C4591001 1247 12471060	16-55	25SEP2020	99256	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471061	C4591001 1247 12471061	16-55	25SEP2020	99307	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12471062	C4591001 1247 12471062	16-55	29SEP2020	101616	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471064	C4591001 1247 12471064	16-55	29SEP2020	101308	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471069	C4591001 1247 12471069	16-55	28SEP2020	99309	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471071	C4591001 1247 12471071	16-55	28SEP2020	99310	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471073	C4591001 1247 12471073	16-55	29SEP2020	101627	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471074	C4591001 1247 12471074	16-55	29SEP2020	101626	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471075	C4591001 1247 12471075	16-55	28SEP2020	101298	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471076	C4591001 1247 12471076	16-55	29SEP2020	101620	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471077	C4591001 1247 12471077	16-55	29SEP2020	101615	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471078	C4591001 1247 12471078	16-55	28SEP2020	101303	Placebo	28SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471079	C4591001 1247 12471079	16-55	28SEP2020	101256	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471080	C4591001 1247 12471080	16-55	29SEP2020	101632	Placebo	29SEP2020/ Placebo	19OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471081	C4591001 1247 12471081	16-55	29SEP2020	101640	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471082	C4591001 1247 12471082	16-55	28SEP2020	101259	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471084	C4591001 1247 12471084	16-55	28SEP2020	101307	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471085	C4591001 1247 12471085	16-55	28SEP2020	101255	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471086	C4591001 1247 12471086	16-55	29SEP2020	101610	Placebo	29SEP2020/ Placebo	21OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471087	C4591001 1247 12471087	16-55	28SEP2020	99312	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12471088	C4591001 1247 12471088	16-55	28SEP2020	101252	BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12471089	C4591001 1247 12471089	16-55	29SEP2020	101634	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471090	C4591001 1247 12471090	16-55	29SEP2020	101636	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471091	C4591001 1247 12471091	16-55	29SEP2020	101643	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471092	C4591001 1247 12471092	16-55	29SEP2020	101646	Placebo	29SEP2020/ Placebo	29OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471096	C4591001 1247 12471096	16-55	29SEP2020	101650	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471099	C4591001 1247 12471099	16-55	29SEP2020	101653	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471100	C4591001 1247 12471100	16-55	29SEP2020	101656	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471101	C4591001 1247 12471101	16-55	29SEP2020	101705	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471102	C4591001 1247 12471102	16-55	29SEP2020	101712	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471103	C4591001 1247 12471103	16-55	29SEP2020	101714	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471106	C4591001 1247 12471106	16-55	29SEP2020	101716	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12471107	C4591001 1247 12471107	16-55	29SEP2020	101729	Placebo	29SEP2020/ Placebo	20OCT2020/ Placebo		
12471108	C4591001 1247 12471108	16-55	29SEP2020	101735	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471109	C4591001 1247 12471109	16-55	30SEP2020	101736	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471111	C4591001 1247 12471111	16-55	30SEP2020	101740	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	18FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471112	C4591001 1247 12471112	16-55	30SEP2020	102032	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471113	C4591001 1247 12471113	16-55	30SEP2020	102033	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471114	C4591001 1247 12471114	16-55	30SEP2020	102036	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471115	C4591001 1247 12471115	16-55	30SEP2020	102039	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471118	C4591001 1247 12471118	16-55	30SEP2020	102044	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471120	C4591001 1247 12471120	16-55	30SEP2020	102045	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471121	C4591001 1247 12471121	16-55	30SEP2020	102046	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
12471122	C4591001 1247 12471122	16-55	30SEP2020	102052	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471123	C4591001 1247 12471123	16-55	30SEP2020	102058	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471124	C4591001 1247 12471124	16-55	30SEP2020	102057	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471125	C4591001 1247 12471125	16-55	30SEP2020	102053	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471126	C4591001 1247 12471126†	16-55	01OCT2020	102680	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471127	C4591001 1247 12471127	16-55	30SEP2020	102059	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471128	C4591001 1247 12471128	16-55	30SEP2020	102090	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471130	C4591001 1247 12471130	16-55	30SEP2020	102138	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471131	C4591001 1247 12471131	16-55	30SEP2020	102091	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471132	C4591001 1247 12471132	16-55	30SEP2020	102092	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471133	C4591001 1247 12471133	16-55	30SEP2020	102093	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471136	C4591001 1247 12471136	16-55	30SEP2020	102140	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471137	C4591001 1247 12471137	16-55	30SEP2020	102142	BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)		
12471139	C4591001 1247 12471139	16-55	30SEP2020	102146	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
12471140	C4591001 1247 12471140	16-55	01OCT2020	102547	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471141	C4591001 1247 12471141	16-55	01OCT2020	102551	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471142	C4591001 1247 12471142	16-55	01OCT2020	102555	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12471143	C4591001 1247 12471143	16-55	01OCT2020	102562	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471144	C4591001 1247 12471144	16-55	01OCT2020	102556	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471145	C4591001 1247 12471145	16-55	01OCT2020	102560	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12471147	C4591001 1247 12471147	16-55	01OCT2020	102568	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471148	C4591001 1247 12471148	16-55	01OCT2020	102586	Placebo	01OCT2020/ Placebo	03NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471149	C4591001 1247 12471149	16-55	01OCT2020	102565	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)			
12471150	C4591001 1247 12471150	16-55	01OCT2020	102589	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471151	C4591001 1247 12471151	16-55	01OCT2020	102590	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)			
12471152	C4591001 1247 12471152	16-55	01OCT2020	102621	Placebo	01OCT2020/ Placebo	26OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12471153	C4591001 1247 12471153	16-55	01OCT2020	102592	Placebo	01OCT2020/ Placebo	22OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471154	C4591001 1247 12471154	16-55	01OCT2020	102620	Placebo	01OCT2020/ Placebo	20OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471155	C4591001 1247 12471155	16-55	01OCT2020	102623	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12471156	C4591001 1247 12471156	16-55	01OCT2020	102627	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
12471158	C4591001 1247 12471158	16-55	05OCT2020	102682	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471159	C4591001 1247 12471159	16-55	05OCT2020	102685	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471161	C4591001 1247 12471161	16-55	05OCT2020	102686	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471162	C4591001 1247 12471162	16-55	05OCT2020	103569	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	
12471164	C4591001 1247 12471164	16-55	05OCT2020	103572	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471165	C4591001 1247 12471165	16-55	05OCT2020	103575	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471167	C4591001 1247 12471167†	16-55	06OCT2020	104087	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12471168	C4591001 1247 12471168	16-55	05OCT2020	103576	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471171	C4591001 1247 12471171	16-55	05OCT2020	103602	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471172	C4591001 1247 12471172	16-55	05OCT2020	103606	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471173	C4591001 1247 12471173	16-55	05OCT2020	103608	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471174	C4591001 1247 12471174	16-55	05OCT2020	103609	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471175	C4591001 1247 12471175	16-55	05OCT2020	103641	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471176	C4591001 1247 12471176	16-55	05OCT2020	103642	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471177	C4591001 1247 12471177	16-55	05OCT2020	103648	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12471178	C4591001 1247 12471178	16-55	05OCT2020	103645	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471179	C4591001 1247 12471179	16-55	05OCT2020	103652	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		
12471181	C4591001 1247 12471181	16-55	06OCT2020	103659	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471182	C4591001 1247 12471182	16-55	06OCT2020	103653	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471183	C4591001 1247 12471183	16-55	06OCT2020	103655	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471184	C4591001 1247 12471184	16-55	06OCT2020	103998	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471185	C4591001 1247 12471185	16-55	06OCT2020	104001	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471186	C4591001 1247 12471186	16-55	06OCT2020	104006	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12471189	C4591001 1247 12471189	16-55	06OCT2020	104007	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471190	C4591001 1247 12471190	16-55	06OCT2020	104035	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471193	C4591001 1247 12471193	16-55	06OCT2020	104036	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12471196	C4591001 1247 12471196	16-55	06OCT2020	104040	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471197	C4591001 1247 12471197	16-55	06OCT2020	104042	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12471198	C4591001 1247 12471198	16-55	06OCT2020	104083	Placebo	06OCT2020/ Placebo	27OCT2020/ Placebo		
12471199	C4591001 1247 12471199	16-55	06OCT2020	104084	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471200	C4591001 1247 12471200	16-55	06OCT2020	104086	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471201	C4591001 1247 12471201	16-55	07OCT2020	104477	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471202	C4591001 1247 12471202	16-55	07OCT2020	104482	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471203	C4591001 1247 12471203	16-55	07OCT2020	104486	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471204	C4591001 1247 12471204†	16-55	07OCT2020	104575	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	
12471205	C4591001 1247 12471205	16-55	07OCT2020	104487	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471206	C4591001 1247 12471206	16-55	07OCT2020	104502	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471208	C4591001 1247 12471208	16-55	07OCT2020	104506	Placebo	07OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471209	C4591001 1247 12471209	16-55	07OCT2020	104511	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471211	C4591001 1247 12471211	16-55	07OCT2020	104508	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471212	C4591001 1247 12471212	16-55	07OCT2020	104578	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471213	C4591001 1247 12471213	16-55	07OCT2020	104583	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471214	C4591001 1247 12471214	16-55	07OCT2020	104584	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471215	C4591001 1247 12471215	16-55	12OCT2020	105719	Placebo	12OCT2020/ Placebo	03NOV2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12471217	C4591001 1247 12471217	16-55	07OCT2020	104586	Placebo	07OCT2020/ Placebo	28OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12471218	C4591001 1247 12471218	16-55	08OCT2020	104588	Placebo	08OCT2020/ Placebo	28OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471220	C4591001 1247 12471220	16-55	08OCT2020	104594	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12471221	C4591001 1247 12471221	16-55	08OCT2020	104589	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471222	C4591001 1247 12471222	16-55	08OCT2020	105041	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471223	C4591001 1247 12471223	16-55	08OCT2020	105047	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471224	C4591001 1247 12471224	16-55	08OCT2020	105068	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471225	C4591001 1247 12471225	16-55	08OCT2020	105048	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471226	C4591001 1247 12471226	16-55	08OCT2020	105052	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo		
12471230	C4591001 1247 12471230	16-55	08OCT2020	105072	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12471231	C4591001 1247 12471231	16-55	08OCT2020	105074	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471232	C4591001 1247 12471232	16-55	08OCT2020	105080	Placebo	08OCT2020/ Placebo	29OCT2020/ Placebo		
12471233	C4591001 1247 12471233	16-55	08OCT2020	105081	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471236	C4591001 1247 12471236	16-55	08OCT2020	105088	Placebo	08OCT2020/ Placebo	30OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12471237	C4591001 1247 12471237	16-55	08OCT2020	105138	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471239	C4591001 1247 12471239	16-55	09OCT2020	105146	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12471240	C4591001 1247 12471240	16-55	08OCT2020	105140	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471241	C4591001 1247 12471241	16-55	09OCT2020	105605	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471242	C4591001 1247 12471242	16-55	09OCT2020	105613	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471244	C4591001 1247 12471244	16-55	09OCT2020	105614	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	
12471245	C4591001 1247 12471245	16-55	09OCT2020	105616	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471246	C4591001 1247 12471246	16-55	09OCT2020	105641	Placebo	09OCT2020/ Placebo	29OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	10MAR2021/ BNT162b2 (30 µg)
12471247	C4591001 1247 12471247	16-55	09OCT2020	105646	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471248	C4591001 1247 12471248	16-55	09OCT2020	105647	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12471250	C4591001 1247 12471250	16-55	09OCT2020	105652	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12471251	C4591001 1247 12471251	16-55	09OCT2020	105687	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471252	C4591001 1247 12471252	16-55	09OCT2020	105681	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12471253	C4591001 1247 12471253	16-55	09OCT2020	105684	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12471254	C4591001 1247 12471254	16-55	09OCT2020	105686	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12471255	C4591001 1247 12471255	16-55	09OCT2020	105702	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	09MAR2021/ BNT162b2 (30 µg)
12471256	C4591001 1247 12471256	16-55	09OCT2020	105703	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471257	C4591001 1247 12471257	16-55	09OCT2020	105706	Placebo	09OCT2020/ Placebo	30OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12471258	C4591001 1247 12471258	16-55	09OCT2020	105710	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12471260	C4591001 1247 12471260	16-55	09OCT2020	105715	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
12481001	C4591001 1248 12481001	16-55	26AUG2020	68729	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12481004	C4591001 1248 12481004	16-55	26AUG2020	68730	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12481005	C4591001 1248 12481005	16-55	26AUG2020	68732	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481007	C4591001 1248 12481007	16-55	27AUG2020	68735	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481009	C4591001 1248 12481009	16-55	27AUG2020	70122	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12481010	C4591001 1248 12481010	16-55	27AUG2020	70123	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12481011	C4591001 1248 12481011	16-55	27AUG2020	70127	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481012	C4591001 1248 12481012	16-55	27AUG2020	70132	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo		
12481013	C4591001 1248 12481013	16-55	27AUG2020	70950	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12481014	C4591001 1248 12481014	16-55	27AUG2020	70951	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12481016	C4591001 1248 12481016	16-55	28AUG2020	70952	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12481017	C4591001 1248 12481017	16-55	28AUG2020	70958	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12481018	C4591001 1248 12481018	16-55	28AUG2020	71862	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481019	C4591001 1248 12481019	16-55	28AUG2020	71864	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12481022	C4591001 1248 12481022	16-55	28AUG2020	71868	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12481023	C4591001 1248 12481023	16-55	28AUG2020	71870	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12481024	C4591001 1248 12481024	16-55	29AUG2020	73290	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481025	C4591001 1248 12481025	16-55	29AUG2020	73294	BNT162b2 (30 µg)				
12481031	C4591001 1248 12481031	16-55	29AUG2020	73295	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481032	C4591001 1248 12481032	16-55	29AUG2020	73300	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12481033	C4591001 1248 12481033	16-55	29AUG2020	73889	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481034	C4591001 1248 12481034	16-55	30AUG2020	73892	Placebo	30AUG2020/ Placebo	20SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481035	C4591001 1248 12481035	16-55	30AUG2020	73893	Placebo	30AUG2020/ Placebo	18SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481036	C4591001 1248 12481036	16-55	30AUG2020	73898	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481037	C4591001 1248 12481037	16-55	30AUG2020	74586	Placebo	30AUG2020/ Placebo	20SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12481038	C4591001 1248 12481038	16-55	30AUG2020	74587	BNT162b2 (30 µg)	30AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481046	C4591001 1248 12481046	16-55	31AUG2020	74590	Placebo	31AUG2020/ Placebo			
12481048	C4591001 1248 12481048	16-55	31AUG2020	74591	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)			
12481051	C4591001 1248 12481051	16-55	31AUG2020	75931	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12481054	C4591001 1248 12481054	16-55	31AUG2020	75934	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12481055	C4591001 1248 12481055	16-55	31AUG2020	75937	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)		
12481056	C4591001 1248 12481056	16-55	01SEP2020	75940	Placebo	01SEP2020/ Placebo	20SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481060	C4591001 1248 12481060	16-55	02SEP2020	78222	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481061	C4591001 1248 12481061	16-55	02SEP2020	78223	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		
12481062	C4591001 1248 12481062	16-55	02SEP2020	78224	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481063	C4591001 1248 12481063	16-55	02SEP2020	78488	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481065	C4591001 1248 12481065	16-55	04SEP2020	78489	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo		
12481066	C4591001 1248 12481066	16-55	05SEP2020	78490	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo	09JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12481067	C4591001 1248 12481067	16-55	05SEP2020	78496	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481068	C4591001 1248 12481068	16-55	05SEP2020	82817	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12481069	C4591001 1248 12481069	16-55	05SEP2020	82822	Placebo	05SEP2020/ Placebo	27SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481075	C4591001 1248 12481075	16-55	05SEP2020	82913	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12481076	C4591001 1248 12481076	16-55	05SEP2020	82825	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481077	C4591001 1248 12481077	16-55	05SEP2020	82826	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12481081	C4591001 1248 12481081	16-55	05SEP2020	82917	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12481082	C4591001 1248 12481082	16-55	05SEP2020	82920	Placebo	05SEP2020/ Placebo	25SEP2020/ Placebo		
12481085	C4591001 1248 12481085	16-55	05SEP2020	82923	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo		
12481086	C4591001 1248 12481086	16-55	05SEP2020	82964	Placebo	05SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12481087	C4591001 1248 12481087	16-55	05SEP2020	82966	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12481088	C4591001 1248 12481088	16-55	06SEP2020	82970	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)		
12481089	C4591001 1248 12481089	16-55	06SEP2020	82972	Placebo	06SEP2020/ Placebo	25SEP2020/ Placebo		
12481091	C4591001 1248 12481091	16-55	06SEP2020	83000	Placebo	06SEP2020/ Placebo	25SEP2020/ Placebo		
12481092	C4591001 1248 12481092	16-55	06SEP2020	82998	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12481093	C4591001 1248 12481093	16-55	06SEP2020	83004	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481094	C4591001 1248 12481094	16-55	06SEP2020	83006	Placebo	06SEP2020/ Placebo	03OCT2020/ Placebo		
12481097	C4591001 1248 12481097	16-55	06SEP2020	83026	BNT162b2 (30 µg)	06SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12481098	C4591001 1248 12481098	16-55	08SEP2020	83028	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12481099	C4591001 1248 12481099	16-55	08SEP2020	83030	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12481102	C4591001 1248 12481102	16-55	08SEP2020	83032	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12481103	C4591001 1248 12481103	16-55	08SEP2020	84414	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)		
12481104	C4591001 1248 12481104	16-55	08SEP2020	84415	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481106	C4591001 1248 12481106	16-55	09SEP2020	84418	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12481110	C4591001 1248 12481110	16-55	09SEP2020	84420	Placebo	09SEP2020/ Placebo			
12481114	C4591001 1248 12481114	16-55	10SEP2020	86334	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481118	C4591001 1248 12481118	16-55	11SEP2020	86335	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12481121	C4591001 1248 12481121	16-55	11SEP2020	86342	Placebo	11SEP2020/ Placebo	12OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481122	C4591001 1248 12481122	16-55	12SEP2020	86343	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481123	C4591001 1248 12481123	16-55	12SEP2020	89093	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12481125	C4591001 1248 12481125	16-55	12SEP2020	89094	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481126	C4591001 1248 12481126	16-55	12SEP2020	89097	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481130	C4591001 1248 12481130	16-55	12SEP2020	89100	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481131	C4591001 1248 12481131	16-55	12SEP2020	89166	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12481134	C4591001 1248 12481134	16-55	12SEP2020	89170	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481135	C4591001 1248 12481135	16-55	12SEP2020	89171	Placebo	12SEP2020/ Placebo	05OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481138	C4591001 1248 12481138	16-55	12SEP2020	89174	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12481144	C4591001 1248 12481144	16-55	13SEP2020	89262	Placebo	13SEP2020/ Placebo	02OCT2020/ Placebo		
12481145	C4591001 1248 12481145	16-55	13SEP2020	89264	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12481146	C4591001 1248 12481146	16-55	13SEP2020	89265	Placebo	13SEP2020/ Placebo	03OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12481147	C4591001 1248 12481147	16-55	13SEP2020	89269	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481150	C4591001 1248 12481150	16-55	13SEP2020	89274	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481151	C4591001 1248 12481151	16-55	13SEP2020	89282	BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12481153	C4591001 1248 12481153	16-55	13SEP2020	89283	Placebo	13SEP2020/ Placebo	03OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12481154	C4591001 1248 12481154	16-55	13SEP2020	89284	Placebo	13SEP2020/ Placebo	03OCT2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12481156	C4591001 1248 12481156	16-55	14SEP2020	89766	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481158	C4591001 1248 12481158	16-55	14SEP2020	89767	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481159	C4591001 1248 12481159	16-55	14SEP2020	89772	Placebo	14SEP2020/ Placebo	10OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12481161	C4591001 1248 12481161	16-55	14SEP2020	89773	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481162	C4591001 1248 12481162	16-55	14SEP2020	89912	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481164	C4591001 1248 12481164	16-55	14SEP2020	89916	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481165	C4591001 1248 12481165	16-55	14SEP2020	89918	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo		
12481166	C4591001 1248 12481166	16-55	14SEP2020	89919	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481169	C4591001 1248 12481169	16-55	15SEP2020	90550	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12481170	C4591001 1248 12481170	16-55	15SEP2020	90549	Placebo	15SEP2020/ Placebo	03OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481171	C4591001 1248 12481171	16-55	15SEP2020	90552	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481172	C4591001 1248 12481172	16-55	15SEP2020	90553	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo		
12481173	C4591001 1248 12481173	16-55	15SEP2020	90654	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481175	C4591001 1248 12481175	16-55	15SEP2020	90659	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)			
12481176	C4591001 1248 12481176	16-55	15SEP2020	90662	Placebo	15SEP2020/ Placebo	14OCT2020/ Placebo		
12481177	C4591001 1248 12481177	16-55	15SEP2020	90663	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481178	C4591001 1248 12481178	16-55	15SEP2020	90822	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo		
12481179	C4591001 1248 12481179	16-55	16SEP2020	90826	Placebo	16SEP2020/ Placebo	09OCT2020/ Placebo	06FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481185	C4591001 1248 12481185	16-55	16SEP2020	90830	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12481186	C4591001 1248 12481186	16-55	16SEP2020	90832	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481187	C4591001 1248 12481187	16-55	16SEP2020	91709	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481188	C4591001 1248 12481188	16-55	16SEP2020	91711	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481189	C4591001 1248 12481189	16-55	16SEP2020	91716	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481190	C4591001 1248 12481190	16-55	16SEP2020	91717	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481191	C4591001 1248 12481191	16-55	17SEP2020	91965	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12481192	C4591001 1248 12481192	16-55	17SEP2020	91970	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481193	C4591001 1248 12481193	16-55	17SEP2020	91971	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481194	C4591001 1248 12481194	16-55	17SEP2020	91967	Placebo	17SEP2020/ Placebo	19OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481195	C4591001 1248 12481195	16-55	17SEP2020	92093	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481198	C4591001 1248 12481198	16-55	17SEP2020	92095	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481199	C4591001 1248 12481199	16-55	17SEP2020	92103	Placebo	17SEP2020/ Placebo			

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481200	C4591001 1248 12481200	16-55	17SEP2020	92104	Placebo	17SEP2020/ Placebo	10OCT2020/ Placebo		
12481201	C4591001 1248 12481201	16-55	17SEP2020	92700	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12481202	C4591001 1248 12481202	16-55	17SEP2020	92701	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo		
12481204	C4591001 1248 12481204	16-55	18SEP2020	92702	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12481205	C4591001 1248 12481205	16-55	18SEP2020	92703	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481206	C4591001 1248 12481206	16-55	18SEP2020	93859	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12481208	C4591001 1248 12481208	16-55	18SEP2020	93860	Placebo	18SEP2020/ Placebo	10OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12481210	C4591001 1248 12481210	16-55	18SEP2020	93866	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12481211	C4591001 1248 12481211	16-55	18SEP2020	93863	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12481212	C4591001 1248 12481212	16-55	18SEP2020	94186	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481213	C4591001 1248 12481213	16-55	18SEP2020	94181	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12481215	C4591001 1248 12481215	16-55	20SEP2020	94187	Placebo	20SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12481216	C4591001 1248 12481216	16-55	20SEP2020	94188	BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12481217	C4591001 1248 12481217	16-55	20SEP2020	94577	BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481218	C4591001 1248 12481218	16-55	20SEP2020	94580	Placebo				
12481219	C4591001 1248 12481219	16-55	20SEP2020	94581	BNT162b2 (30 µg)	20SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12481220	C4591001 1248 12481220	16-55	20SEP2020	94587	Placebo	20SEP2020/ Placebo	09OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12481221	C4591001 1248 12481221	16-55	20SEP2020	94591	Placebo	20SEP2020/ Placebo	10OCT2020/ Placebo		
12481224	C4591001 1248 12481224	16-55	22SEP2020	94592	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481227	C4591001 1248 12481227	16-55	22SEP2020	94596	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481228	C4591001 1248 12481228	16-55	22SEP2020	94597	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12481229	C4591001 1248 12481229	16-55	22SEP2020	96269	Placebo	22SEP2020/ Placebo	11OCT2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12481230	C4591001 1248 12481230	16-55	22SEP2020	96271	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481231	C4591001 1248 12481231	16-55	22SEP2020	96272	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12481232	C4591001 1248 12481232	16-55	22SEP2020	96279	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12481233	C4591001 1248 12481233	16-55	22SEP2020	96487	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12481234	C4591001 1248 12481234	16-55	22SEP2020	96488	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12481235	C4591001 1248 12481235	16-55	22SEP2020	96493	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12481240	C4591001 1248 12481240	16-55	22SEP2020	96496	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12481243	C4591001 1248 12481243	16-55	22SEP2020	97004	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12481244	C4591001 1248 12481244	16-55	24SEP2020	97006	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	13JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12481245	C4591001 1248 12481245	16-55	05OCT2020	97007	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12481246	C4591001 1248 12481246	16-55	05OCT2020	97012	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)		
12481247	C4591001 1248 12481247	16-55	05OCT2020	103810	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
12481252	C4591001 1248 12481252	16-55	20OCT2020	103811	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	10NOV2020/ BNT162b2 (30 µg)		
12481253	C4591001 1248 12481253	16-55	24OCT2020	103813	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12511003	C4591001 1251 12511003	16-55	18AUG2020	55062	Placebo	18AUG2020/ Placebo	09SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12511005	C4591001 1251 12511005	16-55	19AUG2020	55066	BNT162b2 (30 µg)	19AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511007	C4591001 1251 12511007	16-55	19AUG2020	55063	Placebo	19AUG2020/ Placebo	12SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511013	C4591001 1251 12511013	16-55	20AUG2020	55070	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511016	C4591001 1251 12511016	16-55	20AUG2020	59165	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12511021	C4591001 1251 12511021	16-55	20AUG2020	59168	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12511022	C4591001 1251 12511022	16-55	21AUG2020	59174	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12511025	C4591001 1251 12511025	16-55	21AUG2020	59175	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12511027	C4591001 1251 12511027	16-55	21AUG2020	61099	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511030	C4591001 1251 12511030	16-55	22AUG2020	61103	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12511031	C4591001 1251 12511031	16-55	22AUG2020	61102	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12511032	C4591001 1251 12511032	16-55	22AUG2020	61107	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12511033	C4591001 1251 12511033	16-55	22AUG2020	61965	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12511037	C4591001 1251 12511037	16-55	22AUG2020	61970	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511039	C4591001 1251 12511039	16-55	22AUG2020	61969	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511040	C4591001 1251 12511040	16-55	22AUG2020	61971	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12511041	C4591001 1251 12511041	16-55	24AUG2020	63534	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12511044	C4591001 1251 12511044	16-55	24AUG2020	63544	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511045	C4591001 1251 12511045	16-55	24AUG2020	63537	Placebo	24AUG2020/ Placebo	15SEP2020/ Placebo	03MAR2021/ BNT162b2 (30 µg)	
12511046	C4591001 1251 12511046	16-55	24AUG2020	63541	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511049	C4591001 1251 12511049	16-55	24AUG2020	64554	Placebo	24AUG2020/ Placebo	14SEP2020/ Placebo		
12511051	C4591001 1251 12511051	16-55	25AUG2020	64555	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12511058	C4591001 1251 12511058	16-55	26AUG2020	64556	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12511059	C4591001 1251 12511059	16-55	26AUG2020	64563	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511060	C4591001 1251 12511060	16-55	26AUG2020	68849	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12511061	C4591001 1251 12511061	16-55	27AUG2020	68850	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511062	C4591001 1251 12511062	16-55	27AUG2020	68853	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12511065	C4591001 1251 12511065	16-55	28AUG2020	68855	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511066	C4591001 1251 12511066	16-55	28AUG2020	72187	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511068	C4591001 1251 12511068	16-55	28AUG2020	72189	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12511070	C4591001 1251 12511070	16-55	28AUG2020	72191	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo		
12511074	C4591001 1251 12511074	16-55	29AUG2020	72194	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511075	C4591001 1251 12511075	16-55	29AUG2020	73748	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12511077	C4591001 1251 12511077	16-55	29AUG2020	73747	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511079	C4591001 1251 12511079	16-55	29AUG2020	73754	Placebo	29AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511080	C4591001 1251 12511080	16-55	31AUG2020	73755	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo		
12511081	C4591001 1251 12511081	16-55	31AUG2020	75199	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511082	C4591001 1251 12511082	16-55	31AUG2020	75200	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12511083	C4591001 1251 12511083	16-55	31AUG2020	75202	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511084	C4591001 1251 12511084	16-55	31AUG2020	75204	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511089	C4591001 1251 12511089	16-55	01SEP2020	76351	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12511091	C4591001 1251 12511091	16-55	01SEP2020	76352	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12511093	C4591001 1251 12511093	16-55	01SEP2020	76354	Placebo	01SEP2020/ Placebo	24SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12511094	C4591001 1251 12511094	16-55	01SEP2020	76358	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511095	C4591001 1251 12511095	16-55	01SEP2020	77526	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)			
12511096	C4591001 1251 12511096	16-55	02SEP2020	77534	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511097	C4591001 1251 12511097	16-55	02SEP2020	77535	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12511098	C4591001 1251 12511098	16-55	02SEP2020	77536	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12511099	C4591001 1251 12511099	16-55	02SEP2020	78257	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12511101	C4591001 1251 12511101	16-55	02SEP2020	78259	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12511103	C4591001 1251 12511103	16-55	02SEP2020	78264	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12511104	C4591001 1251 12511104	16-55	02SEP2020	78266	Placebo	02SEP2020/ Placebo	21SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12511108	C4591001 1251 12511108	16-55	02SEP2020	79196	Placebo	02SEP2020/ Placebo	22SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511109	C4591001 1251 12511109	16-55	03SEP2020	79197	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511112	C4591001 1251 12511112	16-55	03SEP2020	79199	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12511113	C4591001 1251 12511113	16-55	03SEP2020	79204	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12511114	C4591001 1251 12511114	16-55	03SEP2020	80599	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12511115	C4591001 1251 12511115	16-55	03SEP2020	80600	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12511117	C4591001 1251 12511117	16-55	03SEP2020	80601	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo		
12511119	C4591001 1251 12511119	16-55	03SEP2020	80602	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo		
12511121	C4591001 1251 12511121	16-55	04SEP2020	81803	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511122	C4591001 1251 12511122	16-55	04SEP2020	81798	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12511123	C4591001 1251 12511123	16-55	04SEP2020	81799	Placebo	04SEP2020/ Placebo	28SEP2020/ Placebo		
12511124	C4591001 1251 12511124	16-55	04SEP2020	81805	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511127	C4591001 1251 12511127	16-55	08SEP2020	83458	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511128	C4591001 1251 12511128	16-55	08SEP2020	83460	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12511129	C4591001 1251 12511129	16-55	08SEP2020	83463	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12511130	C4591001 1251 12511130	16-55	08SEP2020	83461	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo		
12511131	C4591001 1251 12511131	16-55	08SEP2020	83819	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12511135	C4591001 1251 12511135	16-55	08SEP2020	83820	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12511137	C4591001 1251 12511137	16-55	09SEP2020	83822	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12511138	C4591001 1251 12511138	16-55	09SEP2020	83823	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511139	C4591001 1251 12511139	16-55	09SEP2020	85318	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12511140	C4591001 1251 12511140	16-55	09SEP2020	85323	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511141	C4591001 1251 12511141	16-55	09SEP2020	85322	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12511143	C4591001 1251 12511143	16-55	10SEP2020	85324	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
12511146	C4591001 1251 12511146	16-55	10SEP2020	86623	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511147	C4591001 1251 12511147	16-55	10SEP2020	86626	Placebo	10SEP2020/ Placebo	06OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511148	C4591001 1251 12511148	16-55	10SEP2020	86632	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12511149	C4591001 1251 12511149	16-55	10SEP2020	86629	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511150	C4591001 1251 12511150	16-55	10SEP2020	87127	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12511153	C4591001 1251 12511153	16-55	10SEP2020	87129	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12511154	C4591001 1251 12511154	16-55	11SEP2020	87132	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511155	C4591001 1251 12511155	16-55	11SEP2020	87135	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511156	C4591001 1251 12511156	16-55	11SEP2020	88493	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12511157	C4591001 1251 12511157	16-55	11SEP2020	88497	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12511159	C4591001 1251 12511159	16-55	11SEP2020	88498	Placebo	11SEP2020/ Placebo	01OCT2020/ Placebo		
12511161	C4591001 1251 12511161	16-55	14SEP2020	88500	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12511162	C4591001 1251 12511162	16-55	14SEP2020	89694	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511163	C4591001 1251 12511163	16-55	14SEP2020	89696	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511165	C4591001 1251 12511165	16-55	14SEP2020	89699	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511166	C4591001 1251 12511166	16-55	14SEP2020	89702	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12511168	C4591001 1251 12511168	16-55	14SEP2020	90041	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511171	C4591001 1251 12511171	16-55	15SEP2020	90042	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511173	C4591001 1251 12511173	16-55	15SEP2020	90043	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12511175	C4591001 1251 12511175	16-55	15SEP2020	90739	BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12511176	C4591001 1251 12511176	16-55	15SEP2020	90044	Placebo	15SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12511178	C4591001 1251 12511178	16-55	16SEP2020	90741	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12511179	C4591001 1251 12511179	16-55	16SEP2020	90744	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12511180	C4591001 1251 12511180	16-55	16SEP2020	90745	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511183	C4591001 1251 12511183	16-55	17SEP2020	92922	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12511184	C4591001 1251 12511184	16-55	18SEP2020	92924	Placebo	18SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511185	C4591001 1251 12511185	16-55	18SEP2020	92927	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12511187	C4591001 1251 12511187	16-55	18SEP2020	92930	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511188	C4591001 1251 12511188	16-55	18SEP2020	94206	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo		
12511191	C4591001 1251 12511191	16-55	21SEP2020	94208	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12511194	C4591001 1251 12511194	16-55	22SEP2020	94209	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12511195	C4591001 1251 12511195	16-55	22SEP2020	94212	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12511196	C4591001 1251 12511196	16-55	22SEP2020	96548	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
12511197	C4591001 1251 12511197	16-55	22SEP2020	96555	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12511198	C4591001 1251 12511198	16-55	22SEP2020	96552	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12511201	C4591001 1251 12511201	16-55	23SEP2020	96556	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511204	C4591001 1251 12511204	16-55	23SEP2020	97897	BNT162b2 (30 µg)				
12511205	C4591001 1251 12511205	16-55	23SEP2020	97891	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511207	C4591001 1251 12511207	16-55	23SEP2020	97898	Placebo	23SEP2020/ Placebo		20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12511208	C4591001 1251 12511208	16-55	24SEP2020	97900	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12511212	C4591001 1251 12511212	16-55	24SEP2020	99033	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511214	C4591001 1251 12511214	16-55	25SEP2020	99034	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12511215	C4591001 1251 12511215	16-55	25SEP2020	99037	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12511216	C4591001 1251 12511216	16-55	25SEP2020	99040	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12511217	C4591001 1251 12511217	16-55	25SEP2020	100253	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12511218	C4591001 1251 12511218	16-55	25SEP2020	100259	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12511219	C4591001 1251 12511219	16-55	25SEP2020	100262	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
12511220	C4591001 1251 12511220	16-55	28SEP2020	100263	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511221	C4591001 1251 12511221	16-55	29SEP2020	101885	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12511223	C4591001 1251 12511223	16-55	30SEP2020	101891	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511224	C4591001 1251 12511224	16-55	30SEP2020	101889	Placebo	30SEP2020/ Placebo	21OCT2020/ Placebo		
12511226	C4591001 1251 12511226	16-55	01OCT2020	101894	BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)		
12511228	C4591001 1251 12511228	16-55	05OCT2020	103856	Placebo	05OCT2020/ Placebo	26OCT2020/ Placebo		
12511229	C4591001 1251 12511229	16-55	06OCT2020	103857	BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12511231	C4591001 1251 12511231	16-55	06OCT2020	103860	Placebo	06OCT2020/ Placebo	26OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
12511232	C4591001 1251 12511232	16-55	07OCT2020	103863	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	28OCT2020/ BNT162b2 (30 µg)		
12511233	C4591001 1251 12511233	16-55	07OCT2020	104731	Placebo	07OCT2020/ Placebo	27OCT2020/ Placebo		
12511234	C4591001 1251 12511234	16-55	07OCT2020	104733	BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511238	C4591001 1251 12511238	16-55	08OCT2020	104738	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12511239	C4591001 1251 12511239	16-55	13OCT2020	106973	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12511240	C4591001 1251 12511240	16-55	13OCT2020	104739	Placebo	13OCT2020/ Placebo	02NOV2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12511241	C4591001 1251 12511241	16-55	14OCT2020	106974	Placebo	14OCT2020/ Placebo	06NOV2020/ Placebo		
12511242	C4591001 1251 12511242	16-55	14OCT2020	106975	Placebo	14OCT2020/ Placebo	05NOV2020/ Placebo	11MAR2021/ BNT162b2 (30 µg)	
12511245	C4591001 1251 12511245	16-55	15OCT2020	108390	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	03NOV2020/ BNT162b2 (30 µg)		
12511246	C4591001 1251 12511246	16-55	15OCT2020	106984	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12511247	C4591001 1251 12511247	16-55	16OCT2020	108391	Placebo	16OCT2020/ Placebo	05NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511252	C4591001 1251 12511252	16-55	20OCT2020	108393	Placebo	20OCT2020/ Placebo	11NOV2020/ Placebo		
12511253	C4591001 1251 12511253	16-55	20OCT2020	108395	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12511254	C4591001 1251 12511254	16-55	20OCT2020	110923	Placebo	20OCT2020/ Placebo	30NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
12511255	C4591001 1251 12511255	16-55	21OCT2020	110928	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12511256	C4591001 1251 12511256	16-55	21OCT2020	110929	Placebo	21OCT2020/ Placebo	11NOV2020/ Placebo		
12511259	C4591001 1251 12511259	16-55	26OCT2020	110931	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12511262	C4591001 1251 12511262	16-55	27OCT2020	114126	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12521016	C4591001 1252 12521016	16-55	18AUG2020	47655	BNT162b2 (30 µg)	18AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12521019	C4591001 1252 12521019	16-55	20AUG2020	58232	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)		
12521020	C4591001 1252 12521020	16-55	20AUG2020	58233	Placebo	20AUG2020/ Placebo	10SEP2020/ Placebo	01MAR2021/ BNT162b2 (30 µg)	
12521021	C4591001 1252 12521021	16-55	20AUG2020	231123	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12521023	C4591001 1252 12521023	16-55	21AUG2020	58234	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12521024	C4591001 1252 12521024	16-55	21AUG2020	58240	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12521029	C4591001 1252 12521029	16-55	27AUG2020	69474	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12521034	C4591001 1252 12521034	16-55	31AUG2020	69476	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12521035	C4591001 1252 12521035	16-55	04SEP2020	69477	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
12521036	C4591001 1252 12521036	16-55	08SEP2020	69478	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12521039	C4591001 1252 12521039	16-55	16SEP2020	91421	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12521041	C4591001 1252 12521041	16-55	22SEP2020	91422	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12541003	C4591001 1254 12541003	16-55	26AUG2020	68237	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541005	C4591001 1254 12541005	16-55	26AUG2020	68240	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12541007	C4591001 1254 12541007	16-55	26AUG2020	68241	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541008	C4591001 1254 12541008	16-55	26AUG2020	68244	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12541020	C4591001 1254 12541020	16-55	28AUG2020	73088	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541023	C4591001 1254 12541023	16-55	28AUG2020	73091	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)			
12541027	C4591001 1254 12541027	16-55	29AUG2020	73094	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541029	C4591001 1254 12541029	16-55	29AUG2020	73905	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541030	C4591001 1254 12541030	16-55	29AUG2020	73909	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541031	C4591001 1254 12541031	16-55	29AUG2020	73910	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	29JAN2021/ BNT162b2 (30 µg)
12541032	C4591001 1254 12541032	16-55	29AUG2020	73912	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12541033	C4591001 1254 12541033	16-55	29AUG2020	74251	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541034	C4591001 1254 12541034	16-55	29AUG2020	74252	Placebo	29AUG2020/ Placebo	18SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541035	C4591001 1254 12541035	16-55	29AUG2020	74256	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541036	C4591001 1254 12541036	16-55	29AUG2020	74258	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541038	C4591001 1254 12541038	16-55	29AUG2020	74288	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541039	C4591001 1254 12541039	16-55	29AUG2020	74289	Placebo	29AUG2020/ Placebo	19SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541040	C4591001 1254 12541040	16-55	29AUG2020	74292	BNT162b2 (30 µg)	29AUG2020/ BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)		
12541041	C4591001 1254 12541041	16-55	31AUG2020	74295	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12541042	C4591001 1254 12541042	16-55	31AUG2020	245929	Placebo	31AUG2020/ Placebo	19SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12541044	C4591001 1254 12541044	16-55	31AUG2020	75438	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541046	C4591001 1254 12541046	16-55	31AUG2020	75444	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541049	C4591001 1254 12541049	16-55	31AUG2020	75445	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541050	C4591001 1254 12541050	16-55	31AUG2020	75448	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	02FEB2021/ BNT162b2 (30 µg)
12541051	C4591001 1254 12541051	16-55	31AUG2020	76157	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541052	C4591001 1254 12541052	16-55	31AUG2020	76159	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12541053	C4591001 1254 12541053	16-55	31AUG2020	76162	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541054	C4591001 1254 12541054	16-55	31AUG2020	76166	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12541055	C4591001 1254 12541055	16-55	31AUG2020	76254	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541056	C4591001 1254 12541056	16-55	31AUG2020	76257	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541057	C4591001 1254 12541057	16-55	31AUG2020	76258	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12541058	C4591001 1254 12541058	16-55	31AUG2020	76260	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12541061	C4591001 1254 12541061	16-55	01SEP2020	77658	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541062	C4591001 1254 12541062	16-55	01SEP2020	77660	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12541063	C4591001 1254 12541063	16-55	01SEP2020	77664	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12541064	C4591001 1254 12541064	16-55	02SEP2020	77666	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12541066	C4591001 1254 12541066	16-55	02SEP2020	78546	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12541067	C4591001 1254 12541067	16-55	02SEP2020	78548	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541068	C4591001 1254 12541068	16-55	02SEP2020	78555	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541069	C4591001 1254 12541069	16-55	02SEP2020	78556	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	10FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12541071	C4591001 1254 12541071	16-55	02SEP2020	79445	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541072	C4591001 1254 12541072	16-55	02SEP2020	79447	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541073	C4591001 1254 12541073	16-55	02SEP2020	79455	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541075	C4591001 1254 12541075	16-55	02SEP2020	79454	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12541077	C4591001 1254 12541077	16-55	02SEP2020	79505	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541079	C4591001 1254 12541079	16-55	03SEP2020	79509	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12541080	C4591001 1254 12541080	16-55	03SEP2020	79512	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12541081	C4591001 1254 12541081	16-55	03SEP2020	80467	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12541082	C4591001 1254 12541082	16-55	03SEP2020	80473	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12541083	C4591001 1254 12541083	16-55	03SEP2020	80474	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12541084	C4591001 1254 12541084	16-55	03SEP2020	80475	Placebo	03SEP2020/ Placebo	26SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12541086	C4591001 1254 12541086	16-55	03SEP2020	81101	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12541087	C4591001 1254 12541087	16-55	03SEP2020	81104	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541089	C4591001 1254 12541089	16-55	03SEP2020	81108	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541090	C4591001 1254 12541090	16-55	04SEP2020	81109	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541091	C4591001 1254 12541091	16-55	04SEP2020	81871	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541094	C4591001 1254 12541094	16-55	04SEP2020	81872	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12541099	C4591001 1254 12541099	16-55	04SEP2020	81878	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12541100	C4591001 1254 12541100	16-55	04SEP2020	81880	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541101	C4591001 1254 12541101	16-55	04SEP2020	82614	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12541102	C4591001 1254 12541102	16-55	05SEP2020	82615	BNT162b2 (30 µg)	05SEP2020/ BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)		
12541104	C4591001 1254 12541104	16-55	05SEP2020	82616	Placebo	05SEP2020/ Placebo	26SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12541105	C4591001 1254 12541105	16-55	08SEP2020	82621	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541107	C4591001 1254 12541107	16-55	08SEP2020	84054	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12541109	C4591001 1254 12541109	16-55	08SEP2020	84056	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541110	C4591001 1254 12541110	16-55	08SEP2020	84058	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541111	C4591001 1254 12541111	16-55	08SEP2020	84062	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12541112	C4591001 1254 12541112	16-55	08SEP2020	84677	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12541113	C4591001 1254 12541113	16-55	08SEP2020	84682	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12541114	C4591001 1254 12541114	16-55	08SEP2020	84687	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12541115	C4591001 1254 12541115	16-55	09SEP2020	84688	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12541116	C4591001 1254 12541116	16-55	09SEP2020	85457	Placebo	09SEP2020/ Placebo			
12541117	C4591001 1254 12541117	16-55	10SEP2020	85459	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541119	C4591001 1254 12541119	16-55	10SEP2020	85460	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541120	C4591001 1254 12541120	16-55	10SEP2020	85462	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541121	C4591001 1254 12541121	16-55	10SEP2020	87692	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12541123	C4591001 1254 12541123	16-55	19SEP2020	94531	Placebo	19SEP2020/ Placebo	10OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12541124	C4591001 1254 12541124	16-55	19SEP2020	94532	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
12541126	C4591001 1254 12541126	16-55	11SEP2020	87694	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12541131	C4591001 1254 12541131	16-55	11SEP2020	87693	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	17FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12541133	C4591001 1254 12541133	16-55	11SEP2020	88985	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	27FEB2021/ BNT162b2 (30 µg)
12541134	C4591001 1254 12541134	16-55	11SEP2020	87696	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541135	C4591001 1254 12541135	16-55	11SEP2020	88988	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541139	C4591001 1254 12541139	16-55	11SEP2020	88990	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541140	C4591001 1254 12541140	16-55	12SEP2020	88992	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541142	C4591001 1254 12541142	16-55	12SEP2020	89228	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)			
12541144	C4591001 1254 12541144	16-55	12SEP2020	89231	BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541145	C4591001 1254 12541145	16-55	12SEP2020	89232	Placebo	12SEP2020/ Placebo	02OCT2020/ Placebo		
12541147	C4591001 1254 12541147	16-55	12SEP2020	89234	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12541148	C4591001 1254 12541148	16-55	12SEP2020	89249	Placebo	12SEP2020/ Placebo	03OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12541150	C4591001 1254 12541150	16-55	14SEP2020	89250	Placebo	14SEP2020/ Placebo	06OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12541151	C4591001 1254 12541151	16-55	14SEP2020	89257	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	03OCT2020/ BNT162b2 (30 µg)		
12541152	C4591001 1254 12541152	16-55	14SEP2020	89260	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541153	C4591001 1254 12541153	16-55	14SEP2020	90056	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12541154	C4591001 1254 12541154	16-55	14SEP2020	90057	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)			
12541155	C4591001 1254 12541155	16-55	16SEP2020	90058	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12541157	C4591001 1254 12541157	16-55	16SEP2020	90061	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	13FEB2021/ BNT162b2 (30 µg)	06MAR2021/ BNT162b2 (30 µg)
12541158	C4591001 1254 12541158	16-55	16SEP2020	91901	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12541159	C4591001 1254 12541159	16-55	16SEP2020	91904	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12541162	C4591001 1254 12541162	16-55	18SEP2020	91905	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
12541163	C4591001 1254 12541163	16-55	18SEP2020	91908	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12541164	C4591001 1254 12541164	16-55	19SEP2020	94530	Placebo	19SEP2020/ Placebo	10OCT2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12541165	C4591001 1254 12541165	16-55	19SEP2020	94538	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541166	C4591001 1254 12541166	16-55	19SEP2020	94567	BNT162b2 (30 µg)	19SEP2020/ BNT162b2 (30 µg)	10OCT2020/ BNT162b2 (30 µg)		
12541167	C4591001 1254 12541167	16-55	21SEP2020	94571	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
12541168	C4591001 1254 12541168†	16-55	22SEP2020	94574	Placebo	22SEP2020/ Placebo	15OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12541169	C4591001 1254 12541169	16-55	24SEP2020	98440	Placebo	24SEP2020/ Placebo	15OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541170	C4591001 1254 12541170	16-55	23SEP2020	94576	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12541171	C4591001 1254 12541171	16-55	23SEP2020	98117	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12541172	C4591001 1254 12541172	16-55	23SEP2020	98120	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541173	C4591001 1254 12541173	16-55	23SEP2020	98122	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12541174	C4591001 1254 12541174	16-55	23SEP2020	98125	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12541175	C4591001 1254 12541175	16-55	23SEP2020	98434	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541176	C4591001 1254 12541176	16-55	23SEP2020	98439	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12541177	C4591001 1254 12541177	16-55	23SEP2020	98430	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12541178	C4591001 1254 12541178	16-55	25SEP2020	100171	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12541179	C4591001 1254 12541179	16-55	25SEP2020	100173	Placebo	25SEP2020/ Placebo	17OCT2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	30JAN2021/ BNT162b2 (30 µg)
12541180	C4591001 1254 12541180	16-55	25SEP2020	100174	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12541181	C4591001 1254 12541181	16-55	25SEP2020	100179	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12541182	C4591001 1254 12541182	16-55	25SEP2020	100567	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12541183	C4591001 1254 12541183	16-55	26SEP2020	100569	BNT162b2 (30 µg)	26SEP2020/ BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)		
12541184	C4591001 1254 12541184	16-55	26SEP2020	100573	Placebo	26SEP2020/ Placebo	17OCT2020/ Placebo	27FEB2021/ BNT162b2 (30 µg)	
12541185	C4591001 1254 12541185	16-55	14OCT2020	100576	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541187	C4591001 1254 12541187	16-55	15OCT2020	108559	Placebo	15OCT2020/ Placebo	05NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541188	C4591001 1254 12541188	16-55	15OCT2020	108565	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12541189	C4591001 1254 12541189	16-55	15OCT2020	108566	Placebo	15OCT2020/ Placebo	06NOV2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12541190	C4591001 1254 12541190	16-55	15OCT2020	108567	BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12541193	C4591001 1254 12541193	16-55	17OCT2020	109678	BNT162b2 (30 µg)	17OCT2020/ BNT162b2 (30 µg)	07NOV2020/ BNT162b2 (30 µg)		
12541194	C4591001 1254 12541194	16-55	17OCT2020	109682	Placebo	17OCT2020/ Placebo	06NOV2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12541199	C4591001 1254 12541199	16-55	21OCT2020	109683	Placebo	21OCT2020/ Placebo	01DEC2020/ Placebo		
12541201	C4591001 1254 12541201	16-55	21OCT2020	109684	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)		
12541202	C4591001 1254 12541202	16-55	24OCT2020	113297	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
12541204	C4591001 1254 12541204	16-55	24OCT2020	113298	Placebo	24OCT2020/ Placebo	14NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12541208	C4591001 1254 12541208	16-55	24OCT2020	113303	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12541210	C4591001 1254 12541210	16-55	24OCT2020	113304	BNT162b2 (30 µg)	24OCT2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
12541211	C4591001 1254 12541211	16-55	24OCT2020	113309	Placebo	24OCT2020/ Placebo	12NOV2020/ Placebo	30JAN2021/ BNT162b2 (30 µg)	20FEB2021/ BNT162b2 (30 µg)
12581001	C4591001 1258 12581001	16-55	27AUG2020	69737	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12581002	C4591001 1258 12581002	16-55	27AUG2020	69743	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12581004	C4591001 1258 12581004	16-55	27AUG2020	69747	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12581007	C4591001 1258 12581007	16-55	31AUG2020	69748	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12581008	C4591001 1258 12581008	16-55	31AUG2020	75417	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12581009	C4591001 1258 12581009	16-55	01SEP2020	75421	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	24FEB2021/ BNT162b2 (30 µg)	
12581013	C4591001 1258 12581013	16-55	02SEP2020	75423	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581014	C4591001 1258 12581014	16-55	03SEP2020	75424	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12581016	C4591001 1258 12581016	16-55	03SEP2020	80350	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12581018	C4591001 1258 12581018	16-55	04SEP2020	80353	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12581022	C4591001 1258 12581022	16-55	09SEP2020	80355	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12581023	C4591001 1258 12581023	16-55	09SEP2020	80356	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12581026	C4591001 1258 12581026	16-55	11SEP2020	87761	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12581027	C4591001 1258 12581027	16-55	11SEP2020	87763	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12581033	C4591001 1258 12581033	16-55	17SEP2020	87768	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12581034	C4591001 1258 12581034	16-55	18SEP2020	87769	Placebo	18SEP2020/ Placebo	13OCT2020/ Placebo		
12581035	C4591001 1258 12581035	16-55	21SEP2020	94617	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581036	C4591001 1258 12581036	16-55	21SEP2020	94619	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12581037	C4591001 1258 12581037	16-55	21SEP2020	94621	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
12581038	C4591001 1258 12581038	16-55	21SEP2020	94623	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12581039	C4591001 1258 12581039	16-55	21SEP2020	95225	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
12581040	C4591001 1258 12581040	16-55	21SEP2020	95234	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12581043	C4591001 1258 12581043	16-55	22SEP2020	95235	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12581044	C4591001 1258 12581044	16-55	24SEP2020	95236	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12581045	C4591001 1258 12581045	16-55	24SEP2020	98718	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)		
12581046	C4591001 1258 12581046	16-55	28SEP2020	98719	Placebo	28SEP2020/ Placebo	19OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12581047	C4591001 1258 12581047	16-55	29SEP2020	98720	BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581048	C4591001 1258 12581048	16-55	30SEP2020	98723	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo		
12581049	C4591001 1258 12581049	16-55	30SEP2020	102271	Placebo	30SEP2020/ Placebo	20OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	
12581050	C4591001 1258 12581050	16-55	02OCT2020	102273	BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)		
12581053	C4591001 1258 12581053	16-55	05OCT2020	102275	BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12581054	C4591001 1258 12581054	16-55	06OCT2020	102276	Placebo	06OCT2020/ Placebo	28OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12581055	C4591001 1258 12581055	16-55	06OCT2020	104262	Placebo	06OCT2020/ Placebo	02NOV2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12581058	C4591001 1258 12581058	16-55	08OCT2020	104263	BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
12581059	C4591001 1258 12581059	16-55	09OCT2020	104264	BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		
12581060	C4591001 1258 12581060	16-55	09OCT2020	104268	Placebo	09OCT2020/ Placebo	02NOV2020/ Placebo		
12581061	C4591001 1258 12581061	16-55	12OCT2020	106325	BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)	02NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581062	C4591001 1258 12581062	16-55	13OCT2020	106329	BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)		
12581063	C4591001 1258 12581063	16-55	13OCT2020	106331	Placebo	13OCT2020/ Placebo	04NOV2020/ Placebo		
12581064	C4591001 1258 12581064	16-55	14OCT2020	106334	Placebo	14OCT2020/ Placebo	04NOV2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12581065	C4591001 1258 12581065	16-55	19OCT2020	110214	BNT162b2 (30 µg)	19OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12581066	C4591001 1258 12581066	16-55	19OCT2020	110218	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo		
12581067	C4591001 1258 12581067	16-55	19OCT2020	110219	Placebo	19OCT2020/ Placebo	10NOV2020/ Placebo		
12581069	C4591001 1258 12581069	16-55	20OCT2020	110223	BNT162b2 (30 µg)	20OCT2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
12581070	C4591001 1258 12581070	16-55	26OCT2020	113454	Placebo	26OCT2020/ Placebo	16NOV2020/ Placebo		
12581071	C4591001 1258 12581071	16-55	27OCT2020	113456	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	17NOV2020/ BNT162b2 (30 µg)		
12581072	C4591001 1258 12581072	16-55	27OCT2020	113459	BNT162b2 (30 µg)	27OCT2020/ BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)		
12581073	C4591001 1258 12581073	16-55	28OCT2020	113462	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12581074	C4591001 1258 12581074	16-55	28OCT2020	114427	Placebo	28OCT2020/ Placebo	18NOV2020/ Placebo		
12581075	C4591001 1258 12581075	16-55	29OCT2020	114429	BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)		
12601001	C4591001 1260 12601001	16-55	26AUG2020	67229	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12601002	C4591001 1260 12601002	16-55	26AUG2020	67232	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12601004	C4591001 1260 12601004	16-55	26AUG2020	67234	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	08JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12601005	C4591001 1260 12601005	16-55	26AUG2020	67237	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12601006	C4591001 1260 12601006	16-55	26AUG2020	68646	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12601007	C4591001 1260 12601007	16-55	26AUG2020	68647	Placebo	26AUG2020/ Placebo	15SEP2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12601009	C4591001 1260 12601009	16-55	27AUG2020	68648	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12601010	C4591001 1260 12601010	16-55	27AUG2020	68652	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601011	C4591001 1260 12601011	16-55	27AUG2020	69920	Placebo	27AUG2020/ Placebo	15SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12601012	C4591001 1260 12601012	16-55	27AUG2020	69922	Placebo	27AUG2020/ Placebo	18SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12601013	C4591001 1260 12601013	16-55	28AUG2020	69923	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12601014	C4591001 1260 12601014	16-55	28AUG2020	69924	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12601016	C4591001 1260 12601016	16-55	28AUG2020	72246	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12601017	C4591001 1260 12601017	16-55	28AUG2020	72252	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12601018	C4591001 1260 12601018	16-55	28AUG2020	72251	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
12601022	C4591001 1260 12601022	16-55	28AUG2020	72255	Placebo	28AUG2020/ Placebo	16SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12601023	C4591001 1260 12601023	16-55	31AUG2020	74748	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12601024	C4591001 1260 12601024	16-55	31AUG2020	74746	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601029	C4591001 1260 12601029	16-55	31AUG2020	74749	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601032	C4591001 1260 12601032	16-55	31AUG2020	74752	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601034	C4591001 1260 12601034	16-55	31AUG2020	75308	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12601036	C4591001 1260 12601036	16-55	31AUG2020	75309	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601038	C4591001 1260 12601038	16-55	01SEP2020	75312	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12601042	C4591001 1260 12601042	16-55	01SEP2020	75314	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12601044	C4591001 1260 12601044	16-55	01SEP2020	77023	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12601045	C4591001 1260 12601045	16-55	01SEP2020	77025	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12601047	C4591001 1260 12601047	16-55	01SEP2020	77026	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12601048	C4591001 1260 12601048	16-55	01SEP2020	77027	Placebo	01SEP2020/ Placebo	23SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601049	C4591001 1260 12601049	16-55	02SEP2020	77911	BNT162b2 (30 µg)				
12601050	C4591001 1260 12601050	16-55	02SEP2020	77914	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12601055	C4591001 1260 12601055	16-55	02SEP2020	77917	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12601058	C4591001 1260 12601058	16-55	04SEP2020	81517	Placebo	04SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12601061	C4591001 1260 12601061	16-55	04SEP2020	77918	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12601063	C4591001 1260 12601063	16-55	04SEP2020	81511	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12601065	C4591001 1260 12601065	16-55	04SEP2020	81513	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12601067	C4591001 1260 12601067	16-55	04SEP2020	252978	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12601068	C4591001 1260 12601068	16-55	04SEP2020	81519	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12601070	C4591001 1260 12601070	16-55	04SEP2020	82217	Placebo				

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601074	C4591001 1260 12601074	16-55	08SEP2020	82221	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601075	C4591001 1260 12601075	16-55	08SEP2020	82226	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12601076	C4591001 1260 12601076	16-55	08SEP2020	82227	Placebo	08SEP2020/ Placebo	01OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	22JAN2021/ BNT162b2 (30 µg)
12601077	C4591001 1260 12601077	16-55	08SEP2020	83564	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12601082	C4591001 1260 12601082	16-55	08SEP2020	83566	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12601084	C4591001 1260 12601084	16-55	08SEP2020	83567	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	15JAN2021/ BNT162b2 (30 µg)
12601085	C4591001 1260 12601085	16-55	08SEP2020	83568	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12601086	C4591001 1260 12601086	16-55	09SEP2020	84816	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12601091	C4591001 1260 12601091	16-55	09SEP2020	84817	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601092	C4591001 1260 12601092	16-55	09SEP2020	84819	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601094	C4591001 1260 12601094	16-55	09SEP2020	84820	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12601097	C4591001 1260 12601097	16-55	09SEP2020	85925	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo		
12601098	C4591001 1260 12601098	16-55	09SEP2020	85933	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12601099	C4591001 1260 12601099	16-55	10SEP2020	85935	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601100	C4591001 1260 12601100	16-55	10SEP2020	85936	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601104	C4591001 1260 12601104	16-55	10SEP2020	86826	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12601106	C4591001 1260 12601106	16-55	10SEP2020	86827	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12601107	C4591001 1260 12601107	16-55	10SEP2020	86833	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601108	C4591001 1260 12601108	16-55	10SEP2020	86836	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	14JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12601110	C4591001 1260 12601110	16-55	10SEP2020	87116	Placebo	10SEP2020/ Placebo	02OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601111	C4591001 1260 12601111	16-55	10SEP2020	87117	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12601112	C4591001 1260 12601112	16-55	10SEP2020	87121	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12601114	C4591001 1260 12601114	16-55	10SEP2020	87122	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601115	C4591001 1260 12601115	16-55	10SEP2020	87488	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12601116	C4591001 1260 12601116	16-55	11SEP2020	87492	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12601117	C4591001 1260 12601117	16-55	11SEP2020	87493	Placebo	11SEP2020/ Placebo	06OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12601118	C4591001 1260 12601118	16-55	11SEP2020	87495	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601119	C4591001 1260 12601119	16-55	11SEP2020	88806	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12601120	C4591001 1260 12601120	16-55	11SEP2020	88807	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12601123	C4591001 1260 12601123	16-55	15SEP2020	88808	Placebo	15SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12601125	C4591001 1260 12601125	16-55	16SEP2020	88816	Placebo	16SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12601126	C4591001 1260 12601126	16-55	17SEP2020	92117	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12601127	C4591001 1260 12601127	16-55	17SEP2020	92119	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12601128	C4591001 1260 12601128	16-55	17SEP2020	92120	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12601129	C4591001 1260 12601129	16-55	18SEP2020	92122	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo		
12601130	C4591001 1260 12601130	16-55	18SEP2020	93595	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12601132	C4591001 1260 12601132	16-55	18SEP2020	93598	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12611001	C4591001 1261 12611001	16-55	26AUG2020	67806	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12611002	C4591001 1261 12611002	16-55	26AUG2020	68441	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12611005	C4591001 1261 12611005	16-55	27AUG2020	68444	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611006	C4591001 1261 12611006	16-55	27AUG2020	68448	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12611007	C4591001 1261 12611007	16-55	27AUG2020	68452	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12611008	C4591001 1261 12611008	16-55	28AUG2020	72214	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12611009	C4591001 1261 12611009	16-55	28AUG2020	72215	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	07JAN2021/ BNT162b2 (30 µg)	28JAN2021/ BNT162b2 (30 µg)
12611010	C4591001 1261 12611010	16-55	28AUG2020	72218	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12611011	C4591001 1261 12611011	16-55	28AUG2020	72219	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)
12611013	C4591001 1261 12611013	16-55	31AUG2020	75342	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12611016	C4591001 1261 12611016	16-55	31AUG2020	75343	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	05JAN2021/ BNT162b2 (30 µg)	26JAN2021/ BNT162b2 (30 µg)
12611017	C4591001 1261 12611017	16-55	01SEP2020	75346	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12611020	C4591001 1261 12611020	16-55	01SEP2020	75351	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611022	C4591001 1261 12611022	16-55	01SEP2020	77515	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12611023	C4591001 1261 12611023	16-55	01SEP2020	77517	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12611024	C4591001 1261 12611024	16-55	01SEP2020	77520	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12611025	C4591001 1261 12611025	16-55	02SEP2020	77521	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12611026	C4591001 1261 12611026	16-55	02SEP2020	78281	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	11JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12611027	C4591001 1261 12611027	16-55	02SEP2020	78288	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12611028	C4591001 1261 12611028	16-55	02SEP2020	78289	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12611029	C4591001 1261 12611029	16-55	02SEP2020	78292	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611030	C4591001 1261 12611030	16-55	02SEP2020	79325	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12611031	C4591001 1261 12611031	16-55	02SEP2020	79328	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611032	C4591001 1261 12611032	16-55	03SEP2020	79329	Placebo	03SEP2020/ Placebo	23SEP2020/ Placebo	04JAN2021/ BNT162b2 (30 µg)	25JAN2021/ BNT162b2 (30 µg)
12611033	C4591001 1261 12611033	16-55	03SEP2020	79334	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12611034	C4591001 1261 12611034	16-55	03SEP2020	80359	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12611035	C4591001 1261 12611035	16-55	03SEP2020	80362	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611036	C4591001 1261 12611036	16-55	03SEP2020	80364	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12611038	C4591001 1261 12611038	16-55	03SEP2020	80367	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611039	C4591001 1261 12611039	16-55	03SEP2020	81116	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12611041	C4591001 1261 12611041	16-55	04SEP2020	81117	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	04FEB2021/ BNT162b2 (30 µg)
12611042	C4591001 1261 12611042	16-55	04SEP2020	81120	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12611043	C4591001 1261 12611043	16-55	04SEP2020	81122	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611046	C4591001 1261 12611046	16-55	04SEP2020	82543	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12611047	C4591001 1261 12611047	16-55	04SEP2020	82544	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12611049	C4591001 1261 12611049	16-55	08SEP2020	82546	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12611050	C4591001 1261 12611050	16-55	08SEP2020	82552	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12611051	C4591001 1261 12611051	16-55	08SEP2020	84187	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12611052	C4591001 1261 12611052	16-55	08SEP2020	84188	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12611053	C4591001 1261 12611053	16-55	08SEP2020	84192	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12611054	C4591001 1261 12611054	16-55	08SEP2020	84193	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
12611056	C4591001 1261 12611056	16-55	09SEP2020	85183	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12611057	C4591001 1261 12611057	16-55	09SEP2020	85186	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	06JAN2021/ BNT162b2 (30 µg)	27JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611058	C4591001 1261 12611058	16-55	09SEP2020	85187	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611059	C4591001 1261 12611059	16-55	09SEP2020	85190	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611060	C4591001 1261 12611060	16-55	09SEP2020	85943	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611062	C4591001 1261 12611062	16-55	09SEP2020	85944	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12611063	C4591001 1261 12611063	16-55	10SEP2020	85945	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12611064	C4591001 1261 12611064	16-55	10SEP2020	85947	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12611065	C4591001 1261 12611065	16-55	10SEP2020	86897	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12611067	C4591001 1261 12611067	16-55	10SEP2020	86899	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)
12611070	C4591001 1261 12611070	16-55	10SEP2020	86902	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	30DEC2020/ BNT162b2 (30 µg)	20JAN2021/ BNT162b2 (30 µg)
12611071	C4591001 1261 12611071	16-55	11SEP2020	86906	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12611074	C4591001 1261 12611074	16-55	11SEP2020	88649	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12611077	C4591001 1261 12611077	16-55	11SEP2020	88654	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12611078	C4591001 1261 12611078	16-55	14SEP2020	88658	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12611082	C4591001 1261 12611082	16-55	14SEP2020	88659	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641001	C4591001 1264 12641001	16-55	20AUG2020	58806	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641002	C4591001 1264 12641002	16-55	20AUG2020	58807	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641003	C4591001 1264 12641003	16-55	20AUG2020	58811	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12641004	C4591001 1264 12641004	16-55	20AUG2020	58813	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12641005	C4591001 1264 12641005	16-55	20AUG2020	58974	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12641006	C4591001 1264 12641006	16-55	20AUG2020	58975	Placebo	20AUG2020/ Placebo	12SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641008	C4591001 1264 12641008	16-55	21AUG2020	58976	Placebo	21AUG2020/ Placebo	13SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12641009	C4591001 1264 12641009	16-55	21AUG2020	58982	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641011	C4591001 1264 12641011	16-55	21AUG2020	60907	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641012	C4591001 1264 12641012	16-55	21AUG2020	60908	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641013	C4591001 1264 12641013	16-55	21AUG2020	60914	Placebo	21AUG2020/ Placebo	12SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641014	C4591001 1264 12641014	16-55	21AUG2020	60916	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641015	C4591001 1264 12641015	16-55	21AUG2020	61340	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641017	C4591001 1264 12641017	16-55	22AUG2020	61342	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	03FEB2021/ BNT162b2 (30 µg)
12641018	C4591001 1264 12641018	16-55	22AUG2020	61346	Placebo				
12641020	C4591001 1264 12641020	16-55	22AUG2020	61348	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641021	C4591001 1264 12641021	16-55	22AUG2020	62135	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641022	C4591001 1264 12641022	16-55	22AUG2020	62131	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641023	C4591001 1264 12641023	16-55	22AUG2020	62136	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641024	C4591001 1264 12641024	16-55	22AUG2020	62139	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641025	C4591001 1264 12641025	16-55	23AUG2020	62805	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641026	C4591001 1264 12641026	16-55	23AUG2020	62807	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641028	C4591001 1264 12641028	16-55	23AUG2020	62808	BNT162b2 (30 µg)	23AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641029	C4591001 1264 12641029	16-55	23AUG2020	62810	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641032	C4591001 1264 12641032	16-55	23AUG2020	62987	Placebo	23AUG2020/ Placebo	13SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641033	C4591001 1264 12641033	16-55	24AUG2020	62989	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641034	C4591001 1264 12641034	16-55	24AUG2020	62992	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641035	C4591001 1264 12641035	16-55	24AUG2020	62991	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641036	C4591001 1264 12641036	16-55	24AUG2020	63857	Placebo	24AUG2020/ Placebo	13SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641037	C4591001 1264 12641037	16-55	24AUG2020	63862	Placebo	24AUG2020/ Placebo	12SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641041	C4591001 1264 12641041	16-55	24AUG2020	63864	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641042	C4591001 1264 12641042	16-55	24AUG2020	63868	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12641043	C4591001 1264 12641043	16-55	25AUG2020	65777	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	13SEP2020/ BNT162b2 (30 µg)		
12641046	C4591001 1264 12641046	16-55	25AUG2020	65784	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641047	C4591001 1264 12641047	16-55	25AUG2020	65788	Placebo	25AUG2020/ Placebo	13SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641048	C4591001 1264 12641048	16-55	25AUG2020	65787	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641049	C4591001 1264 12641049	16-55	25AUG2020	66503	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641050	C4591001 1264 12641050	16-55	25AUG2020	66506	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641051	C4591001 1264 12641051	16-55	26AUG2020	66507	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641052	C4591001 1264 12641052	16-55	26AUG2020	66508	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641053	C4591001 1264 12641053	16-55	26AUG2020	67857	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12641055	C4591001 1264 12641055	16-55	26AUG2020	67858	Placebo	26AUG2020/ Placebo	18SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641056	C4591001 1264 12641056	16-55	26AUG2020	67861	Placebo	26AUG2020/ Placebo	17SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641058	C4591001 1264 12641058	16-55	26AUG2020	67864	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12641060	C4591001 1264 12641060	16-55	27AUG2020	70029	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641062	C4591001 1264 12641062	16-55	27AUG2020	70031	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641064	C4591001 1264 12641064	16-55	27AUG2020	70032	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12641065	C4591001 1264 12641065	16-55	27AUG2020	70035	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12641066	C4591001 1264 12641066	16-55	27AUG2020	70783	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641069	C4591001 1264 12641069	16-55	27AUG2020	70784	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641070	C4591001 1264 12641070	16-55	27AUG2020	70785	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12641071	C4591001 1264 12641071	16-55	28AUG2020	70786	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641072	C4591001 1264 12641072	16-55	28AUG2020	72126	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641073	C4591001 1264 12641073	16-55	28AUG2020	72128	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641075	C4591001 1264 12641075	16-55	28AUG2020	72134	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12641078	C4591001 1264 12641078	16-55	28AUG2020	72135	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641081	C4591001 1264 12641081	16-55	31AUG2020	75129	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641082	C4591001 1264 12641082	16-55	31AUG2020	75130	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641083	C4591001 1264 12641083	16-55	31AUG2020	75132	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641084	C4591001 1264 12641084	16-55	31AUG2020	75136	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641086	C4591001 1264 12641086	16-55	31AUG2020	75581	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12641087	C4591001 1264 12641087	16-55	01SEP2020	75586	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	12JAN2021/ BNT162b2 (30 µg)	01FEB2021/ BNT162b2 (30 µg)
12641088	C4591001 1264 12641088	16-55	01SEP2020	75582	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641089	C4591001 1264 12641089	16-55	01SEP2020	75587	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641090	C4591001 1264 12641090	16-55	01SEP2020	76772	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641091	C4591001 1264 12641091	16-55	01SEP2020	76775	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641092	C4591001 1264 12641092	16-55	01SEP2020	76776	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641093	C4591001 1264 12641093	16-55	01SEP2020	76778	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641094	C4591001 1264 12641094	16-55	01SEP2020	77253	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12641095	C4591001 1264 12641095	16-55	02SEP2020	77258	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12641096	C4591001 1264 12641096	16-55	02SEP2020	77260	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641100	C4591001 1264 12641100	16-55	02SEP2020	78737	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641101	C4591001 1264 12641101	16-55	02SEP2020	78738	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12641103	C4591001 1264 12641103	16-55	03SEP2020	78739	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12641104	C4591001 1264 12641104	16-55	03SEP2020	78743	Placebo	03SEP2020/ Placebo	09OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641105	C4591001 1264 12641105	16-55	03SEP2020	80060	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641106	C4591001 1264 12641106	16-55	03SEP2020	80062	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641108	C4591001 1264 12641108	16-55	03SEP2020	80063	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12641109	C4591001 1264 12641109	16-55	03SEP2020	80068	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12641110	C4591001 1264 12641110	16-55	03SEP2020	80671	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641113	C4591001 1264 12641113	16-55	04SEP2020	80677	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12641115	C4591001 1264 12641115	16-55	04SEP2020	80679	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641116	C4591001 1264 12641116	16-55	04SEP2020	80680	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12641118	C4591001 1264 12641118	16-55	04SEP2020	82194	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641119	C4591001 1264 12641119	16-55	08SEP2020	82197	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641120	C4591001 1264 12641120	16-55	08SEP2020	83766	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641122	C4591001 1264 12641122	16-55	08SEP2020	82198	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641123	C4591001 1264 12641123	16-55	08SEP2020	82203	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12641124	C4591001 1264 12641124	16-55	08SEP2020	83768	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12641125	C4591001 1264 12641125	16-55	08SEP2020	83770	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641126	C4591001 1264 12641126	16-55	08SEP2020	83774	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641127	C4591001 1264 12641127	16-55	08SEP2020	84091	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	16DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641129	C4591001 1264 12641129	16-55	09SEP2020	84093	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12641131	C4591001 1264 12641131	16-55	09SEP2020	84095	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641132	C4591001 1264 12641132	16-55	09SEP2020	84096	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641135	C4591001 1264 12641135	16-55	09SEP2020	85721	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641140	C4591001 1264 12641140	16-55	10SEP2020	85729	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641141	C4591001 1264 12641141	16-55	10SEP2020	85728	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641142	C4591001 1264 12641142	16-55	10SEP2020	85724	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641143	C4591001 1264 12641143	16-55	10SEP2020	87090	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641144	C4591001 1264 12641144	16-55	10SEP2020	87093	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12641145	C4591001 1264 12641145	16-55	10SEP2020	87098	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12641146	C4591001 1264 12641146	16-55	10SEP2020	87099	Placebo	10SEP2020/ Placebo	30SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641147	C4591001 1264 12641147	16-55	10SEP2020	87415	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641148	C4591001 1264 12641148	16-55	11SEP2020	87416	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12641150	C4591001 1264 12641150	16-55	11SEP2020	87420	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641151	C4591001 1264 12641151	16-55	11SEP2020	87421	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641152	C4591001 1264 12641152	16-55	11SEP2020	88531	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12641153	C4591001 1264 12641153	16-55	11SEP2020	88534	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641154	C4591001 1264 12641154	16-55	11SEP2020	88537	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641156	C4591001 1264 12641156	16-55	11SEP2020	88538	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12641157	C4591001 1264 12641157	16-55	16SEP2020	91379	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12641158	C4591001 1264 12641158	16-55	16SEP2020	91382	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641159	C4591001 1264 12641159	16-55	16SEP2020	91384	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo		
12641160	C4591001 1264 12641160	16-55	16SEP2020	91541	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12641162	C4591001 1264 12641162	16-55	16SEP2020	91542	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641165	C4591001 1264 12641165	16-55	16SEP2020	91545	Placebo	16SEP2020/ Placebo	06OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641166	C4591001 1264 12641166	16-55	16SEP2020	91549	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641167	C4591001 1264 12641167	16-55	16SEP2020	91878	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641168	C4591001 1264 12641168	16-55	16SEP2020	91877	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12641171	C4591001 1264 12641171	16-55	17SEP2020	91885	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12641172	C4591001 1264 12641172	16-55	17SEP2020	91886	Placebo	17SEP2020/ Placebo	06OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641173	C4591001 1264 12641173	16-55	17SEP2020	93067	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12641175	C4591001 1264 12641175	16-55	17SEP2020	93070	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12641176	C4591001 1264 12641176	16-55	17SEP2020	93072	Placebo	17SEP2020/ Placebo	09OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641177	C4591001 1264 12641177	16-55	18SEP2020	93074	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641179	C4591001 1264 12641179	16-55	18SEP2020	94279	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12641181	C4591001 1264 12641181	16-55	21SEP2020	94281	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641183	C4591001 1264 12641183	16-55	21SEP2020	94282	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641184	C4591001 1264 12641184	16-55	21SEP2020	94288	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
12641185	C4591001 1264 12641185	16-55	21SEP2020	95705	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641186	C4591001 1264 12641186	16-55	21SEP2020	95712	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641187	C4591001 1264 12641187	16-55	22SEP2020	95713	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641188	C4591001 1264 12641188	16-55	22SEP2020	95715	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12641189	C4591001 1264 12641189	16-55	22SEP2020	96522	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12641190	C4591001 1264 12641190	16-55	22SEP2020	96524	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641191	C4591001 1264 12641191	16-55	22SEP2020	96527	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	04JAN2021/ BNT162b2 (30 µg)
12641192	C4591001 1264 12641192	16-55	22SEP2020	96530	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12641193	C4591001 1264 12641193	16-55	22SEP2020	96942	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641197	C4591001 1264 12641197	16-55	22SEP2020	96947	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641200	C4591001 1264 12641200	16-55	23SEP2020	96948	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12641201	C4591001 1264 12641201	16-55	23SEP2020	96949	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641202	C4591001 1264 12641202	16-55	23SEP2020	97853	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	15DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641203	C4591001 1264 12641203	16-55	23SEP2020	97855	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12641204	C4591001 1264 12641204	16-55	23SEP2020	97857	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12641206	C4591001 1264 12641206	16-55	23SEP2020	97858	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641208	C4591001 1264 12641208	16-55	23SEP2020	98418	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12641209	C4591001 1264 12641209	16-55	21OCT2020	98423	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12641210	C4591001 1264 12641210	16-55	21OCT2020	98424	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12641211	C4591001 1264 12641211	16-55	21OCT2020	98428	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12641212	C4591001 1264 12641212	16-55	21OCT2020	111593	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12641213	C4591001 1264 12641213	16-55	21OCT2020	111597	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	07JAN2021/ BNT162b2 (30 µg)
12641215	C4591001 1264 12641215	16-55	21OCT2020	111598	BNT162b2 (30 µg)	21OCT2020/ BNT162b2 (30 µg)	09NOV2020/ BNT162b2 (30 µg)		
12641216	C4591001 1264 12641216	16-55	21OCT2020	111603	Placebo	21OCT2020/ Placebo	13NOV2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	05JAN2021/ BNT162b2 (30 µg)
12641218	C4591001 1264 12641218	16-55	21OCT2020	111848	Placebo	21OCT2020/ Placebo	09NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12641221	C4591001 1264 12641221	16-55	23OCT2020	111850	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12641225	C4591001 1264 12641225	16-55	23OCT2020	111851	Placebo	23OCT2020/ Placebo	13NOV2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12641226	C4591001 1264 12641226	16-55	23OCT2020	111853	BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)	13NOV2020/ BNT162b2 (30 µg)		
12641227	C4591001 1264 12641227	16-55	26OCT2020	113611	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12641228	C4591001 1264 12641228	16-55	26OCT2020	113612	BNT162b2 (30 µg)	26OCT2020/ BNT162b2 (30 µg)	16NOV2020/ BNT162b2 (30 µg)		
12651003	C4591001 1265 12651003	16-55	24AUG2020	64913	Placebo	24AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12651004	C4591001 1265 12651004	16-55	25AUG2020	64916	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12651006	C4591001 1265 12651006	16-55	25AUG2020	64921	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12651007	C4591001 1265 12651007	16-55	26AUG2020	64924	Placebo	26AUG2020/ Placebo	14SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651010	C4591001 1265 12651010	16-55	27AUG2020	70254	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12651013	C4591001 1265 12651013	16-55	27AUG2020	70255	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651016	C4591001 1265 12651016	16-55	27AUG2020	70258	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	02MAR2021/ BNT162b2 (30 µg)	
12651020	C4591001 1265 12651020	16-55	28AUG2020	70264	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12651021	C4591001 1265 12651021	16-55	28AUG2020	72966	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo		
12651022	C4591001 1265 12651022	16-55	28AUG2020	72969	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12651024	C4591001 1265 12651024	16-55	31AUG2020	72972	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12651025	C4591001 1265 12651025	16-55	31AUG2020	72974	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12651027	C4591001 1265 12651027	16-55	31AUG2020	75968	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651029	C4591001 1265 12651029	16-55	31AUG2020	75972	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12651030	C4591001 1265 12651030	16-55	31AUG2020	75973	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651031	C4591001 1265 12651031	16-55	31AUG2020	75975	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651032	C4591001 1265 12651032	16-55	01SEP2020	76747	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12651035	C4591001 1265 12651035	16-55	01SEP2020	76748	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651037	C4591001 1265 12651037	16-55	01SEP2020	76752	Placebo	01SEP2020/ Placebo	25SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651040	C4591001 1265 12651040	16-55	02SEP2020	76753	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12651041	C4591001 1265 12651041	16-55	02SEP2020	78631	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12651042	C4591001 1265 12651042	16-55	02SEP2020	78633	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651043	C4591001 1265 12651043	16-55	02SEP2020	78634	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651044	C4591001 1265 12651044	16-55	02SEP2020	78636	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12651047	C4591001 1265 12651047	16-55	03SEP2020	79997	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12651049	C4591001 1265 12651049	16-55	03SEP2020	79998	Placebo	03SEP2020/ Placebo	22SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651053	C4591001 1265 12651053	16-55	03SEP2020	80000	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12651055	C4591001 1265 12651055	16-55	03SEP2020	80004	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12651058	C4591001 1265 12651058	16-55	04SEP2020	81905	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651059	C4591001 1265 12651059	16-55	04SEP2020	81907	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12651060	C4591001 1265 12651060	16-55	04SEP2020	81910	Placebo	04SEP2020/ Placebo	23SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651061	C4591001 1265 12651061	16-55	04SEP2020	81915	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12651062	C4591001 1265 12651062	16-55	04SEP2020	82481	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12651063	C4591001 1265 12651063	16-55	04SEP2020	82485	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651064	C4591001 1265 12651064	16-55	04SEP2020	82488	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651065	C4591001 1265 12651065	16-55	08SEP2020	82491	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651066	C4591001 1265 12651066	16-55	08SEP2020	83780	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		
12651067	C4591001 1265 12651067	16-55	08SEP2020	83782	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12651072	C4591001 1265 12651072	16-55	08SEP2020	83783	Placebo	08SEP2020/ Placebo	28SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651073	C4591001 1265 12651073	16-55	08SEP2020	83785	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651076	C4591001 1265 12651076	16-55	09SEP2020	85361	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651079	C4591001 1265 12651079	16-55	09SEP2020	85367	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12651081	C4591001 1265 12651081	16-55	09SEP2020	85369	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12651082	C4591001 1265 12651082	16-55	09SEP2020	85370	Placebo	09SEP2020/ Placebo	28SEP2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	08FEB2021/ BNT162b2 (30 µg)
12651083	C4591001 1265 12651083	16-55	09SEP2020	86141	Placebo	09SEP2020/ Placebo	29SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651084	C4591001 1265 12651084	16-55	09SEP2020	86148	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	28SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651086	C4591001 1265 12651086	16-55	10SEP2020	86149	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651089	C4591001 1265 12651089	16-55	10SEP2020	86152	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12651090	C4591001 1265 12651090	16-55	10SEP2020	87197	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12651093	C4591001 1265 12651093	16-55	10SEP2020	87202	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12651096	C4591001 1265 12651096	16-55	10SEP2020	87203	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	11FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12651097	C4591001 1265 12651097	16-55	10SEP2020	87206	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651098	C4591001 1265 12651098	16-55	11SEP2020	88266	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12651099	C4591001 1265 12651099	16-55	11SEP2020	88269	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12651101	C4591001 1265 12651101	16-55	11SEP2020	88271	Placebo	11SEP2020/ Placebo	30SEP2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651104	C4591001 1265 12651104	16-55	11SEP2020	88272	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651106	C4591001 1265 12651106	16-55	14SEP2020	89670	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	05OCT2020/ BNT162b2 (30 µg)		
12651108	C4591001 1265 12651108	16-55	14SEP2020	89672	Placebo	14SEP2020/ Placebo	05OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651110	C4591001 1265 12651110	16-55	14SEP2020	89673	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12651111	C4591001 1265 12651111	16-55	14SEP2020	89680	Placebo	14SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651114	C4591001 1265 12651114	16-55	14SEP2020	90101	BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)	06OCT2020/ BNT162b2 (30 µg)		
12651124	C4591001 1265 12651124	16-55	16SEP2020	90105	Placebo	16SEP2020/ Placebo	08OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651126	C4591001 1265 12651126	16-55	16SEP2020	90106	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651128	C4591001 1265 12651128	16-55	16SEP2020	90111	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12651134	C4591001 1265 12651134	16-55	17SEP2020	92958	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12651136	C4591001 1265 12651136	16-55	17SEP2020	92959	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651138	C4591001 1265 12651138	16-55	17SEP2020	92962	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651139	C4591001 1265 12651139†	16-55	18SEP2020	92964	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12651142	C4591001 1265 12651142	16-55	18SEP2020	93954	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12651143	C4591001 1265 12651143†	16-55	18SEP2020	93955	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651144	C4591001 1265 12651144	16-55	18SEP2020	93960	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12651145	C4591001 1265 12651145	16-55	18SEP2020	93963	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	07OCT2020/ BNT162b2 (30 µg)		
12651146	C4591001 1265 12651146	16-55	18SEP2020	94342	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	15FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651147	C4591001 1265 12651147	16-55	18SEP2020	94343	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12651148	C4591001 1265 12651148	16-55	21SEP2020	94344	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12651149	C4591001 1265 12651149	16-55	21SEP2020	94345	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651151	C4591001 1265 12651151	16-55	21SEP2020	95586	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12651153	C4591001 1265 12651153	16-55	21SEP2020	95590	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
12651155	C4591001 1265 12651155	16-55	22SEP2020	95594	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651159	C4591001 1265 12651159†	16-55	22SEP2020	95595	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12651161	C4591001 1265 12651161	16-55	22SEP2020	97075	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651162	C4591001 1265 12651162	16-55	23SEP2020	97078	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
12651164	C4591001 1265 12651164†	16-55	23SEP2020	97079	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12651165	C4591001 1265 12651165	16-55	23SEP2020	97083	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	08MAR2021/ BNT162b2 (30 µg)
12651166	C4591001 1265 12651166	16-55	23SEP2020	97974	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
12651167	C4591001 1265 12651167	16-55	23SEP2020	97977	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12651168	C4591001 1265 12651168	16-55	23SEP2020	97978	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651170	C4591001 1265 12651170	16-55	24SEP2020	97981	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12651173	C4591001 1265 12651173	16-55	24SEP2020	98861	Placebo	24SEP2020/ Placebo	13OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651174	C4591001 1265 12651174	16-55	24SEP2020	98864	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12651175	C4591001 1265 12651175	16-55	24SEP2020	98865	BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
12651177	C4591001 1265 12651177	16-55	24SEP2020	98870	Placebo	24SEP2020/ Placebo	16OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12651180	C4591001 1265 12651180	16-55	25SEP2020	99907	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12651182	C4591001 1265 12651182†	16-55	25SEP2020	99911	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12651186	C4591001 1265 12651186†	16-55	25SEP2020	99912	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
12691001	C4591001 1269 12691001	16-55	17AUG2020	53227	Placebo	17AUG2020/ Placebo	08SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691002	C4591001 1269 12691002	16-55	17AUG2020	53228	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12691004	C4591001 1269 12691004	16-55	17AUG2020	53231	BNT162b2 (30 µg)	17AUG2020/ BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)		
12691006	C4591001 1269 12691006	16-55	19AUG2020	53236	Placebo	19AUG2020/ Placebo	09SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691007	C4591001 1269 12691007	16-55	19AUG2020	57162	Placebo	19AUG2020/ Placebo	10SEP2020/ Placebo		
12691010	C4591001 1269 12691010	16-55	20AUG2020	57163	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691011	C4591001 1269 12691011	16-55	20AUG2020	57164	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691013	C4591001 1269 12691013	16-55	20AUG2020	59504	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12691014	C4591001 1269 12691014	16-55	20AUG2020	57171	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo		
12691016	C4591001 1269 12691016	16-55	20AUG2020	59506	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691018	C4591001 1269 12691018	16-55	20AUG2020	59507	BNT162b2 (30 µg)	20AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691020	C4591001 1269 12691020	16-55	20AUG2020	59511	Placebo	20AUG2020/ Placebo	09SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691022	C4591001 1269 12691022	16-55	21AUG2020	60894	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12691025	C4591001 1269 12691025	16-55	21AUG2020	60896	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691026	C4591001 1269 12691026	16-55	21AUG2020	60901	Placebo	21AUG2020/ Placebo	10SEP2020/ Placebo		
12691027	C4591001 1269 12691027	16-55	21AUG2020	60902	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12691029	C4591001 1269 12691029	16-55	21AUG2020	61553	Placebo	21AUG2020/ Placebo	11SEP2020/ Placebo		
12691030	C4591001 1269 12691030	16-55	21AUG2020	61554	BNT162b2 (30 µg)	21AUG2020/ BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)		
12691031	C4591001 1269 12691031	16-55	22AUG2020	61560	Placebo	22AUG2020/ Placebo	11SEP2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
12691032	C4591001 1269 12691032	16-55	22AUG2020	61564	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	12SEP2020/ BNT162b2 (30 µg)		
12691033	C4591001 1269 12691033	16-55	22AUG2020	62141	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691034	C4591001 1269 12691034	16-55	22AUG2020	62142	Placebo	22AUG2020/ Placebo	10SEP2020/ Placebo	23DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12691037	C4591001 1269 12691037	16-55	22AUG2020	62150	BNT162b2 (30 µg)	22AUG2020/ BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)		
12691039	C4591001 1269 12691039	16-55	22AUG2020	62152	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	19DEC2020/ BNT162b2 (30 µg)	09JAN2021/ BNT162b2 (30 µg)
12691041	C4591001 1269 12691041	16-55	22AUG2020	62538	Placebo	22AUG2020/ Placebo	12SEP2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	16JAN2021/ BNT162b2 (30 µg)
12691042	C4591001 1269 12691042	16-55	24AUG2020	62540	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12691045	C4591001 1269 12691045	16-55	24AUG2020	62542	BNT162b2 (30 µg)	24AUG2020/ BNT162b2 (30 µg)	14SEP2020/ BNT162b2 (30 µg)		
12691047	C4591001 1269 12691047	16-55	25AUG2020	62548	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo		
12691048	C4591001 1269 12691048	16-55	25AUG2020	66054	Placebo	25AUG2020/ Placebo	14SEP2020/ Placebo	17DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12691050	C4591001 1269 12691050	16-55	25AUG2020	66059	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691051	C4591001 1269 12691051	16-55	25AUG2020	66061	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691055	C4591001 1269 12691055	16-55	25AUG2020	67027	Placebo	25AUG2020/ Placebo	15SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691056	C4591001 1269 12691056	16-55	25AUG2020	66064	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12691057	C4591001 1269 12691057	16-55	26AUG2020	67030	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691058	C4591001 1269 12691058	16-55	26AUG2020	67032	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12691059	C4591001 1269 12691059	16-55	26AUG2020	67036	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691060	C4591001 1269 12691060	16-55	26AUG2020	68705	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12691062	C4591001 1269 12691062	16-55	26AUG2020	68706	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	06JAN2021/ BNT162b2 (30 µg)
12691063	C4591001 1269 12691063	16-55	27AUG2020	68713	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12691064	C4591001 1269 12691064	16-55	27AUG2020	70928	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12691065	C4591001 1269 12691065	16-55	27AUG2020	68716	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691072	C4591001 1269 12691072	16-55	28AUG2020	70932	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	18DEC2020/ BNT162b2 (30 µg)	08JAN2021/ BNT162b2 (30 µg)
12691073	C4591001 1269 12691073	16-55	28AUG2020	70933	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691074	C4591001 1269 12691074	16-55	28AUG2020	70936	Placebo	28AUG2020/ Placebo	20SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691075	C4591001 1269 12691075	16-55	28AUG2020	72756	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691076	C4591001 1269 12691076	16-55	28AUG2020	72754	Placebo	28AUG2020/ Placebo	17SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12691078	C4591001 1269 12691078	16-55	28AUG2020	72757	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)		
12691081	C4591001 1269 12691081	16-55	28AUG2020	72760	Placebo	28AUG2020/ Placebo	14SEP2020/ Placebo		
12691084	C4591001 1269 12691084	16-55	31AUG2020	75379	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12691087	C4591001 1269 12691087	16-55	31AUG2020	75383	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691088	C4591001 1269 12691088	16-55	31AUG2020	75385	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691089	C4591001 1269 12691089	16-55	31AUG2020	75388	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12691091	C4591001 1269 12691091	16-55	01SEP2020	77011	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12691093	C4591001 1269 12691093	16-55	01SEP2020	77013	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28DEC2020/ BNT162b2 (30 µg)	18JAN2021/ BNT162b2 (30 µg)
12691094	C4591001 1269 12691094	16-55	01SEP2020	77015	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12691095	C4591001 1269 12691095	16-55	01SEP2020	77020	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691096	C4591001 1269 12691096	16-55	01SEP2020	77553	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12691097	C4591001 1269 12691097	16-55	01SEP2020	77554	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691099	C4591001 1269 12691099	16-55	02SEP2020	77559	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691103	C4591001 1269 12691103	16-55	02SEP2020	77560	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12691104	C4591001 1269 12691104	16-55	02SEP2020	79376	Placebo	02SEP2020/ Placebo	23SEP2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691105	C4591001 1269 12691105	16-55	02SEP2020	79379	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12691106	C4591001 1269 12691106	16-55	02SEP2020	79380	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12691107	C4591001 1269 12691107	16-55	02SEP2020	79377	Placebo	02SEP2020/ Placebo	24SEP2020/ Placebo		
12691108	C4591001 1269 12691108	16-55	03SEP2020	80155	Placebo	03SEP2020/ Placebo	24SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691110	C4591001 1269 12691110	16-55	03SEP2020	80633	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691113	C4591001 1269 12691113	16-55	03SEP2020	80634	Placebo	03SEP2020/ Placebo	25SEP2020/ Placebo	23JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
12691115	C4591001 1269 12691115	16-55	03SEP2020	80639	BNT162b2 (30 µg)	03SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12691116	C4591001 1269 12691116	16-55	04SEP2020	80640	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	24SEP2020/ BNT162b2 (30 µg)		
12691117	C4591001 1269 12691117	16-55	04SEP2020	82289	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12691119	C4591001 1269 12691119	16-55	04SEP2020	82292	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691121	C4591001 1269 12691121	16-55	08SEP2020	82293	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691122	C4591001 1269 12691122	16-55	08SEP2020	82298	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12691123	C4591001 1269 12691123	16-55	08SEP2020	84017	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	15FEB2021/ BNT162b2 (30 µg)
12691125	C4591001 1269 12691125	16-55	08SEP2020	84023	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12691126	C4591001 1269 12691126	16-55	09SEP2020	84024	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12691127	C4591001 1269 12691127	16-55	09SEP2020	84028	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		
12691129	C4591001 1269 12691129	16-55	09SEP2020	85877	Placebo	09SEP2020/ Placebo	30SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691130	C4591001 1269 12691130	16-55	09SEP2020	85879	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12691133	C4591001 1269 12691133	16-55	10SEP2020	85882	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12691136	C4591001 1269 12691136	16-55	10SEP2020	85888	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	01OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12691140	C4591001 1269 12691140	16-55	17SEP2020	92609	Placebo	17SEP2020/ Placebo	08OCT2020/ Placebo	16JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12691143	C4591001 1269 12691143	16-55	21SEP2020	92614	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12701003	C4591001 1270 12701003	16-55	25AUG2020	66116	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701004	C4591001 1270 12701004	16-55	25AUG2020	66115	BNT162b2 (30 µg)	25AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701007	C4591001 1270 12701007	16-55	26AUG2020	66117	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12701008	C4591001 1270 12701008	16-55	26AUG2020	66119	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo		
12701010	C4591001 1270 12701010	16-55	26AUG2020	68674	Placebo	26AUG2020/ Placebo	16SEP2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	05FEB2021/ BNT162b2 (30 µg)
12701011	C4591001 1270 12701011	16-55	26AUG2020	68675	BNT162b2 (30 µg)	26AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12701013	C4591001 1270 12701013	16-55	27AUG2020	68680	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701014	C4591001 1270 12701014	16-55	27AUG2020	68676	Placebo	27AUG2020/ Placebo	16SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701015	C4591001 1270 12701015	16-55	27AUG2020	70193	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)		
12701018	C4591001 1270 12701018	16-55	27AUG2020	70196	BNT162b2 (30 µg)	27AUG2020/ BNT162b2 (30 µg)	15SEP2020/ BNT162b2 (30 µg)		
12701020	C4591001 1270 12701020	16-55	27AUG2020	70199	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12701021	C4591001 1270 12701021	16-55	27AUG2020	70200	Placebo	27AUG2020/ Placebo	17SEP2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	14JAN2021/ BNT162b2 (30 µg)
12701022	C4591001 1270 12701022	16-55	28AUG2020	72077	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12701023	C4591001 1270 12701023	16-55	28AUG2020	72079	Placebo	28AUG2020/ Placebo	18SEP2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12701025	C4591001 1270 12701025	16-55	28AUG2020	72080	BNT162b2 (30 µg)	28AUG2020/ BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)		
12701030	C4591001 1270 12701030	16-55	31AUG2020	72082	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		
12701033	C4591001 1270 12701033	16-55	31AUG2020	75906	Placebo	31AUG2020/ Placebo	22SEP2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
12701034	C4591001 1270 12701034	16-55	31AUG2020	76139	BNT162b2 (30 µg)	31AUG2020/ BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701035	C4591001 1270 12701035	16-55	31AUG2020	76140	Placebo	31AUG2020/ Placebo	21SEP2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12701037	C4591001 1270 12701037	16-55	01SEP2020	76142	BNT162b2 (30 µg)	01SEP2020/ BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)		
12701041	C4591001 1270 12701041	16-55	01SEP2020	76143	Placebo	01SEP2020/ Placebo	21SEP2020/ Placebo		
12701045	C4591001 1270 12701045	16-55	01SEP2020	77693	Placebo	01SEP2020/ Placebo	22SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701046	C4591001 1270 12701046	16-55	02SEP2020	77701	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12701048	C4591001 1270 12701048	16-55	02SEP2020	77702	Placebo	02SEP2020/ Placebo	25SEP2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
12701051	C4591001 1270 12701051	16-55	02SEP2020	77704	BNT162b2 (30 µg)	02SEP2020/ BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)		
12701056	C4591001 1270 12701056	16-55	03SEP2020	80309	Placebo	03SEP2020/ Placebo	02NOV2020/ Placebo		
12701064	C4591001 1270 12701064	16-55	04SEP2020	80311	Placebo	04SEP2020/ Placebo	25SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701065	C4591001 1270 12701065	16-55	04SEP2020	80313	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701068	C4591001 1270 12701068	16-55	04SEP2020	80317	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)		
12701069	C4591001 1270 12701069	16-55	04SEP2020	82068	BNT162b2 (30 µg)	04SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12701071	C4591001 1270 12701071	16-55	08SEP2020	82069	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	16FEB2021/ BNT162b2 (30 µg)
12701074	C4591001 1270 12701074	16-55	08SEP2020	82070	Placebo	08SEP2020/ Placebo	29SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12701076	C4591001 1270 12701076	16-55	08SEP2020	82072	BNT162b2 (30 µg)	08SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12701082	C4591001 1270 12701082	16-55	09SEP2020	85916	Placebo	09SEP2020/ Placebo	01OCT2020/ Placebo	29DEC2020/ BNT162b2 (30 µg)	19JAN2021/ BNT162b2 (30 µg)
12701084	C4591001 1270 12701084	16-55	09SEP2020	85918	BNT162b2 (30 µg)	09SEP2020/ BNT162b2 (30 µg)	29SEP2020/ BNT162b2 (30 µg)		
12701085	C4591001 1270 12701085	16-55	10SEP2020	85920	Placebo	10SEP2020/ Placebo	29SEP2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701086	C4591001 1270 12701086	16-55	10SEP2020	85921	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701087	C4591001 1270 12701087	16-55	10SEP2020	86981	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	31DEC2020/ BNT162b2 (30 µg)	21JAN2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701088	C4591001 1270 12701088	16-55	10SEP2020	86982	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12701089	C4591001 1270 12701089	16-55	10SEP2020	86985	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701090	C4591001 1270 12701090	16-55	10SEP2020	86986	BNT162b2 (30 µg)	10SEP2020/ BNT162b2 (30 µg)	30SEP2020/ BNT162b2 (30 µg)		
12701091	C4591001 1270 12701091	16-55	10SEP2020	87655	Placebo	10SEP2020/ Placebo	01OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12701097	C4591001 1270 12701097	16-55	11SEP2020	87656	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701098	C4591001 1270 12701098	16-55	11SEP2020	87661	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701099	C4591001 1270 12701099	16-55	11SEP2020	87664	Placebo	11SEP2020/ Placebo	02OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
12701100	C4591001 1270 12701100	16-55	11SEP2020	88961	BNT162b2 (30 µg)	11SEP2020/ BNT162b2 (30 µg)	02OCT2020/ BNT162b2 (30 µg)		
12701107	C4591001 1270 12701107	16-55	15SEP2020	88964	Placebo	15SEP2020/ Placebo	05OCT2020/ Placebo	22DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12701118	C4591001 1270 12701118	16-55	16SEP2020	88965	Placebo	16SEP2020/ Placebo	07OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701119	C4591001 1270 12701119	16-55	16SEP2020	88970	BNT162b2 (30 µg)	16SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12701121	C4591001 1270 12701121	16-55	17SEP2020	92357	Placebo	17SEP2020/ Placebo	15OCT2020/ Placebo		
12701122	C4591001 1270 12701122	16-55	17SEP2020	92361	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12701123	C4591001 1270 12701123	16-55	17SEP2020	92363	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	19FEB2021/ BNT162b2 (30 µg)
12701124	C4591001 1270 12701124	16-55	17SEP2020	92365	BNT162b2 (30 µg)	17SEP2020/ BNT162b2 (30 µg)	08OCT2020/ BNT162b2 (30 µg)		
12701125	C4591001 1270 12701125	16-55	17SEP2020	93029	Placebo	17SEP2020/ Placebo	07OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12701128	C4591001 1270 12701128	16-55	18SEP2020	93030	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12701129	C4591001 1270 12701129	16-55	18SEP2020	93032	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		
12701131	C4591001 1270 12701131	16-55	18SEP2020	93036	Placebo	18SEP2020/ Placebo	08OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	12JAN2021/ BNT162b2 (30 µg)
12701132	C4591001 1270 12701132	16-55	18SEP2020	94169	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	09OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701133	C4591001 1270 12701133	16-55	18SEP2020	94174	Placebo	18SEP2020/ Placebo	09OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
12701134	C4591001 1270 12701134	16-55	18SEP2020	94178	Placebo	18SEP2020/ Placebo	07OCT2020/ Placebo	12FEB2021/ BNT162b2 (30 µg)	04MAR2021/ BNT162b2 (30 µg)
12701135	C4591001 1270 12701135	16-55	18SEP2020	94179	BNT162b2 (30 µg)	18SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
12701136	C4591001 1270 12701136	16-55	21SEP2020	94913	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	21DEC2020/ BNT162b2 (30 µg)	11JAN2021/ BNT162b2 (30 µg)
12701137	C4591001 1270 12701137	16-55	21SEP2020	94914	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12701141	C4591001 1270 12701141	16-55	21SEP2020	94915	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	24DEC2020/ BNT162b2 (30 µg)	13JAN2021/ BNT162b2 (30 µg)
12701142	C4591001 1270 12701142	16-55	21SEP2020	94919	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
12701146	C4591001 1270 12701146	16-55	04NOV2020	115666	Placebo	04NOV2020/ Placebo	23NOV2020/ Placebo		
12701147	C4591001 1270 12701147	16-55	04NOV2020	115667	Placebo	04NOV2020/ Placebo	25NOV2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12701148	C4591001 1270 12701148	16-55	05NOV2020	115668	BNT162b2 (30 µg)	05NOV2020/ BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701149	C4591001 1270 12701149	16-55	06NOV2020	115669	BNT162b2 (30 µg)	06NOV2020/ BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)		
12701150	C4591001 1270 12701150	16-55	06NOV2020	115928	Placebo	06NOV2020/ Placebo	25NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701151	C4591001 1270 12701151	16-55	11NOV2020	115932	BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12701152	C4591001 1270 12701152	16-55	11NOV2020	115933	Placebo	11NOV2020/ Placebo	02DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701153	C4591001 1270 12701153	16-55	12NOV2020	115934	BNT162b2 (30 µg)	12NOV2020/ BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)		
12701154	C4591001 1270 12701154	16-55	16NOV2020	116312	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	16FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
12701155	C4591001 1270 12701155	16-55	16NOV2020	116313	Placebo	16NOV2020/ Placebo	07DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
12701156	C4591001 1270 12701156	16-55	18NOV2020	116316	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12701157	C4591001 1270 12701157	16-55	18NOV2020	116320	BNT162b2 (30 µg)	18NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		
12701158	C4591001 1270 12701158	16-55	19NOV2020	116526	BNT162b2 (30 µg)	19NOV2020/ BNT162b2 (30 µg)	10DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701159	C4591001 1270 12701159	16-55	19NOV2020	116527	Placebo	19NOV2020/ Placebo	10DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	23FEB2021/ BNT162b2 (30 µg)
12701160	C4591001 1270 12701160	16-55	19NOV2020	116532	Placebo	19NOV2020/ Placebo	08DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)
12701161	C4591001 1270 12701161	16-55	20NOV2020	116536	BNT162b2 (30 µg)	20NOV2020/ BNT162b2 (30 µg)	09DEC2020/ BNT162b2 (30 µg)		
12701162	C4591001 1270 12701162	16-55	20NOV2020	116634	Placebo	20NOV2020/ Placebo	11DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12701163	C4591001 1270 12701163	16-55	23NOV2020	116638	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	14DEC2020/ BNT162b2 (30 µg)		
12701164	C4591001 1270 12701164	16-55	23NOV2020	116640	Placebo	23NOV2020/ Placebo	14DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
12701165	C4591001 1270 12701165	16-55	23NOV2020	116643	BNT162b2 (30 µg)	23NOV2020/ BNT162b2 (30 µg)	15DEC2020/ BNT162b2 (30 µg)		
12701166	C4591001 1270 12701166	16-55	24NOV2020	116840	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12701167	C4591001 1270 12701167	16-55	24NOV2020	116844	Placebo	24NOV2020/ Placebo	14DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12701168	C4591001 1270 12701168	16-55	24NOV2020	116847	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701169	C4591001 1270 12701169	16-55	24NOV2020	116848	BNT162b2 (30 µg)	24NOV2020/ BNT162b2 (30 µg)	16DEC2020/ BNT162b2 (30 µg)		
12701170	C4591001 1270 12701170	16-55	25NOV2020	116945	Placebo	25NOV2020/ Placebo	12JAN2021/ Placebo	09FEB2021/ BNT162b2 (30 µg)	01MAR2021/ BNT162b2 (30 µg)
12701171	C4591001 1270 12701171	16-55	25NOV2020	116947	Placebo	25NOV2020/ Placebo	18DEC2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701172	C4591001 1270 12701172	16-55	25NOV2020	116950	BNT162b2 (30 µg)	25NOV2020/ BNT162b2 (30 µg)	18DEC2020/ BNT162b2 (30 µg)		
12701175	C4591001 1270 12701175	16-55	01DEC2020	116952	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12701176	C4591001 1270 12701176	16-55	01DEC2020	117139	BNT162b2 (30 µg)	01DEC2020/ BNT162b2 (30 µg)	21DEC2020/ BNT162b2 (30 µg)		
12701178	C4591001 1270 12701178	16-55	01DEC2020	117141	Placebo	01DEC2020/ Placebo	22DEC2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	25FEB2021/ BNT162b2 (30 µg)
12701179	C4591001 1270 12701179	16-55	02DEC2020	117146	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12701182	C4591001 1270 12701182	16-55	02DEC2020	117147	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701183	C4591001 1270 12701183	16-55	02DEC2020	117270	Placebo	02DEC2020/ Placebo	23DEC2020/ Placebo	09FEB2021/ BNT162b2 (30 µg)	02MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
12701185	C4591001 1270 12701185	16-55	02DEC2020	117273	BNT162b2 (30 µg)	02DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12701186	C4591001 1270 12701186	16-55	03DEC2020	117274	BNT162b2 (30 µg)	03DEC2020/ BNT162b2 (30 µg)	22DEC2020/ BNT162b2 (30 µg)		
12701190	C4591001 1270 12701190	16-55	03DEC2020	117277	Placebo	03DEC2020/ Placebo	23DEC2020/ Placebo	08FEB2021/ BNT162b2 (30 µg)	03MAR2021/ BNT162b2 (30 µg)
12701193	C4591001 1270 12701193	16-55	04DEC2020	117619	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	23DEC2020/ BNT162b2 (30 µg)		
12701195	C4591001 1270 12701195	16-55	04DEC2020	117624	BNT162b2 (30 µg)	04DEC2020/ BNT162b2 (30 µg)	24DEC2020/ BNT162b2 (30 µg)		
12701196	C4591001 1270 12701196	16-55	04DEC2020	117625	Placebo	04DEC2020/ Placebo	24DEC2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
12701197	C4591001 1270 12701197	16-55	07DEC2020	117626	Placebo	07DEC2020/ Placebo	29DEC2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
44441003	C4591001 4444 44441003	16-55	21SEP2020	94871	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441004	C4591001 4444 44441004	16-55	21SEP2020	94858	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441007	C4591001 4444 44441007	16-55	21SEP2020	94872	Placebo	21SEP2020/ Placebo	04NOV2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441008	C4591001 4444 44441008	16-55	21SEP2020	94856	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441012	C4591001 4444 44441012	16-55	21SEP2020	94853	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441014	C4591001 4444 44441014	16-55	21SEP2020	95152	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441015	C4591001 4444 44441015	16-55	21SEP2020	94996	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441016	C4591001 4444 44441016	16-55	21SEP2020	94859	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441017	C4591001 4444 44441017	16-55	21SEP2020	94866	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441019	C4591001 4444 44441019	16-55	21SEP2020	94904	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441020	C4591001 4444 44441020	16-55	21SEP2020	94873	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441023	C4591001 4444 44441023	16-55	21SEP2020	94905	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441024	C4591001 4444 44441024	16-55	21SEP2020	94998	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441025	C4591001 4444 44441025	16-55	21SEP2020	94909	Placebo	21SEP2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
44441026	C4591001 4444 44441026	16-55	21SEP2020	94993	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441027	C4591001 4444 44441027	16-55	21SEP2020	94912	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441028	C4591001 4444 44441028	16-55	21SEP2020	95021	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441031	C4591001 4444 44441031	16-55	21SEP2020	94987	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441033	C4591001 4444 44441033	16-55	21SEP2020	94991	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
44441034	C4591001 4444 44441034	16-55	21SEP2020	95001	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441037	C4591001 4444 44441037	16-55	21SEP2020	94999	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441038	C4591001 4444 44441038	16-55	21SEP2020	95008	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441040	C4591001 4444 44441040	16-55	21SEP2020	95026	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441043	C4591001 4444 44441043	16-55	21SEP2020	95107	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)			
44441044	C4591001 4444 44441044	16-55	21SEP2020	95028	Placebo	21SEP2020/ Placebo		24FEB2021/ BNT162b2 (30 µg)	
44441045	C4591001 4444 44441045	16-55	21SEP2020	95032	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441048	C4591001 4444 44441048	16-55	21SEP2020	95108	Placebo	21SEP2020/ Placebo			
44441055	C4591001 4444 44441055	16-55	21SEP2020	95110	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441056	C4591001 4444 44441056	16-55	21SEP2020	95115	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441060	C4591001 4444 44441060	16-55	21SEP2020	95215	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441063	C4591001 4444 44441063	16-55	21SEP2020	95142	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441064	C4591001 4444 44441064	16-55	21SEP2020	95143	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441065	C4591001 4444 44441065	16-55	21SEP2020	95213	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441066	C4591001 4444 44441066	16-55	21SEP2020	95145	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441068	C4591001 4444 44441068	16-55	21SEP2020	95351	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441069	C4591001 4444 44441069	16-55	21SEP2020	95238	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441071	C4591001 4444 44441071	16-55	21SEP2020	95219	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44441072	C4591001 4444 44441072	16-55	21SEP2020	95265	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441073	C4591001 4444 44441073	16-55	21SEP2020	95216	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441075	C4591001 4444 44441075	16-55	21SEP2020	95241	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441076	C4591001 4444 44441076	16-55	21SEP2020	95269	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441077	C4591001 4444 44441077	16-55	21SEP2020	95239	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441079	C4591001 4444 44441079	16-55	21SEP2020	95246	Placebo	21SEP2020/ Placebo			



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441081	C4591001 4444 44441081	16-55	21SEP2020	95262	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441084	C4591001 4444 44441084	16-55	21SEP2020	95345	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441086	C4591001 4444 44441086	16-55	21SEP2020	95353	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441087	C4591001 4444 44441087	16-55	21SEP2020	95267	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441094	C4591001 4444 44441094	16-55	21SEP2020	95390	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441095	C4591001 4444 44441095	16-55	21SEP2020	95354	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44441100	C4591001 4444 44441100	16-55	21SEP2020	95400	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441101	C4591001 4444 44441101	16-55	21SEP2020	95383	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441102	C4591001 4444 44441102	16-55	21SEP2020	95395	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441103	C4591001 4444 44441103	16-55	21SEP2020	95448	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441105	C4591001 4444 44441105	16-55	21SEP2020	95384	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441106	C4591001 4444 44441106	16-55	21SEP2020	95398	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441108	C4591001 4444 44441108	16-55	21SEP2020	95389	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441110	C4591001 4444 44441110	16-55	21SEP2020	95393	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441113	C4591001 4444 44441113	16-55	21SEP2020	95447	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441115	C4591001 4444 44441115	16-55	21SEP2020	95445	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441120	C4591001 4444 44441120	16-55	21SEP2020	95466	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441121	C4591001 4444 44441121	16-55	21SEP2020	95468	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441123	C4591001 4444 44441123	16-55	21SEP2020	95475	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441125	C4591001 4444 44441125	16-55	21SEP2020	95451	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441126	C4591001 4444 44441126	16-55	21SEP2020	95474	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441134	C4591001 4444 44441134	16-55	21SEP2020	95548	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	04NOV2020/ BNT162b2 (30 µg)		
44441135	C4591001 4444 44441135	16-55	21SEP2020	95546	BNT162b2 (30 µg)				
44441138	C4591001 4444 44441138	16-55	21SEP2020	95610	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441139	C4591001 4444 44441139	16-55	21SEP2020	95545	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441142	C4591001 4444 44441142	16-55	21SEP2020	95634	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441143	C4591001 4444 44441143	16-55	21SEP2020	95538	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441144	C4591001 4444 44441144	16-55	21SEP2020	95650	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441147	C4591001 4444 44441147	16-55	21SEP2020	95620	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441149	C4591001 4444 44441149	16-55	21SEP2020	95611	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441150	C4591001 4444 44441150	16-55	21SEP2020	95662	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441154	C4591001 4444 44441154	16-55	21SEP2020	95681	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441155	C4591001 4444 44441155	16-55	21SEP2020	95638	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441156	C4591001 4444 44441156	16-55	21SEP2020	95683	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
44441157	C4591001 4444 44441157	16-55	21SEP2020	95655	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
44441159	C4591001 4444 44441159	16-55	21SEP2020	95633	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441160	C4591001 4444 44441160	16-55	21SEP2020	95653	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441162	C4591001 4444 44441162	16-55	21SEP2020	95657	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441163	C4591001 4444 44441163	16-55	21SEP2020	95635	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44441166	C4591001 4444 44441166	16-55	21SEP2020	95693	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441169	C4591001 4444 44441169	16-55	21SEP2020	95647	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441170	C4591001 4444 44441170	16-55	21SEP2020	95696	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441171	C4591001 4444 44441171	16-55	21SEP2020	95692	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441172	C4591001 4444 44441172	16-55	21SEP2020	95614	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441173	C4591001 4444 44441173	16-55	21SEP2020	95665	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441175	C4591001 4444 44441175	16-55	21SEP2020	95663	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
44441176	C4591001 4444 44441176	16-55	21SEP2020	95719	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441177	C4591001 4444 44441177	16-55	21SEP2020	95695	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441179	C4591001 4444 44441179	16-55	21SEP2020	95686	Placebo	21SEP2020/ Placebo			
44441180	C4591001 4444 44441180	16-55	21SEP2020	95747	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441184	C4591001 4444 44441184	16-55	21SEP2020	95742	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441187	C4591001 4444 44441187	16-55	21SEP2020	95720	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441190	C4591001 4444 44441190	16-55	21SEP2020	95744	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441191	C4591001 4444 44441191	16-55	21SEP2020	95698	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441192	C4591001 4444 44441192	16-55	21SEP2020	95779	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441194	C4591001 4444 44441194	16-55	21SEP2020	95756	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441197	C4591001 4444 44441197	16-55	21SEP2020	95723	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441198	C4591001 4444 44441198	16-55	21SEP2020	95781	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441199	C4591001 4444 44441199	16-55	21SEP2020	95743	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo		
44441201	C4591001 4444 44441201	16-55	21SEP2020	95753	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441203	C4591001 4444 44441203	16-55	21SEP2020	95755	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441205	C4591001 4444 44441205	16-55	21SEP2020	95787	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441206	C4591001 4444 44441206	16-55	21SEP2020	95788	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441207	C4591001 4444 44441207	16-55	21SEP2020	95725	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441209	C4591001 4444 44441209	16-55	21SEP2020	95791	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44441211	C4591001 4444 44441211	16-55	21SEP2020	95759	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441212	C4591001 4444 44441212	16-55	21SEP2020	95827	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441213	C4591001 4444 44441213	16-55	21SEP2020	95795	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441218	C4591001 4444 44441218	16-55	21SEP2020	95849	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441219	C4591001 4444 44441219	16-55	21SEP2020	95796	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441220	C4591001 4444 44441220	16-55	21SEP2020	95855	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441223	C4591001 4444 44441223	16-55	21SEP2020	95797	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441224	C4591001 4444 44441224	16-55	21SEP2020	95864	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo		
44441225	C4591001 4444 44441225	16-55	21SEP2020	95833	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441232	C4591001 4444 44441232	16-55	21SEP2020	95873	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441234	C4591001 4444 44441234	16-55	21SEP2020	95886	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441236	C4591001 4444 44441236	16-55	21SEP2020	95865	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441237	C4591001 4444 44441237	16-55	21SEP2020	95834	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441238	C4591001 4444 44441238	16-55	21SEP2020	95891	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441243	C4591001 4444 44441243	16-55	21SEP2020	95835	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441245	C4591001 4444 44441245	16-55	21SEP2020	95862	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441247	C4591001 4444 44441247	16-55	21SEP2020	95881	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441248	C4591001 4444 44441248	16-55	21SEP2020	95902	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441249	C4591001 4444 44441249	16-55	21SEP2020	95857	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441252	C4591001 4444 44441252	16-55	21SEP2020	95897	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441253	C4591001 4444 44441253	16-55	21SEP2020	95856	Placebo	21SEP2020/ Placebo	22OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441255	C4591001 4444 44441255	16-55	21SEP2020	95880	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441257	C4591001 4444 44441257	16-55	21SEP2020	95867	Placebo	21SEP2020/ Placebo	12OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441260	C4591001 4444 44441260	16-55	21SEP2020	95910	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441261	C4591001 4444 44441261	16-55	21SEP2020	95892	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441262	C4591001 4444 44441262	16-55	21SEP2020	95904	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441263	C4591001 4444 44441263	16-55	21SEP2020	95874	Placebo	21SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441265	C4591001 4444 44441265	16-55	21SEP2020	95900	Placebo	21SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441267	C4591001 4444 44441267	16-55	21SEP2020	95894	BNT162b2 (30 µg)	21SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441268	C4591001 4444 44441268	16-55	21SEP2020	95912	Placebo	21SEP2020/ Placebo	23OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441271	C4591001 4444 44441271	16-55	22SEP2020	95915	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441272	C4591001 4444 44441272	16-55	22SEP2020	95938	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441273	C4591001 4444 44441273	16-55	22SEP2020	95939	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)			
44441275	C4591001 4444 44441275	16-55	22SEP2020	95920	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441277	C4591001 4444 44441277	16-55	22SEP2020	95945	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441278	C4591001 4444 44441278	16-55	22SEP2020	95947	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441279	C4591001 4444 44441279	16-55	22SEP2020	95955	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441280	C4591001 4444 44441280	16-55	22SEP2020	95940	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441284	C4591001 4444 44441284	16-55	22SEP2020	95954	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441285	C4591001 4444 44441285	16-55	22SEP2020	95962	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441286	C4591001 4444 44441286	16-55	22SEP2020	95944	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
44441288	C4591001 4444 44441288	16-55	22SEP2020	95965	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441289	C4591001 4444 44441289	16-55	22SEP2020	95966	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441293	C4591001 4444 44441293	16-55	22SEP2020	95969	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441294	C4591001 4444 44441294	16-55	22SEP2020	95997	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441296	C4591001 4444 44441296	16-55	22SEP2020	95970	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441297	C4591001 4444 44441297	16-55	22SEP2020	95973	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441298	C4591001 4444 44441298	16-55	22SEP2020	96007	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441300	C4591001 4444 44441300	16-55	22SEP2020	95974	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441301	C4591001 4444 44441301	16-55	22SEP2020	95967	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441302	C4591001 4444 44441302	16-55	22SEP2020	95995	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441304	C4591001 4444 44441304	16-55	22SEP2020	95996	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441310	C4591001 4444 44441310	16-55	22SEP2020	96005	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441311	C4591001 4444 44441311	16-55	22SEP2020	96004	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441315	C4591001 4444 44441315	16-55	22SEP2020	96008	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441317	C4591001 4444 44441317	16-55	22SEP2020	96035	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441319	C4591001 4444 44441319	16-55	22SEP2020	96010	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441321	C4591001 4444 44441321	16-55	22SEP2020	96085	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441323	C4591001 4444 44441323	16-55	22SEP2020	96031	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441324	C4591001 4444 44441324	16-55	22SEP2020	96037	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441325	C4591001 4444 44441325	16-55	22SEP2020	96056	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441326	C4591001 4444 44441326	16-55	22SEP2020	96088	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441327	C4591001 4444 44441327	16-55	22SEP2020	96078	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
44441329	C4591001 4444 44441329	16-55	22SEP2020	96030	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441330	C4591001 4444 44441330	16-55	22SEP2020	96110	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441334	C4591001 4444 44441334	16-55	22SEP2020	96060	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441335	C4591001 4444 44441335	16-55	22SEP2020	96062	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441336	C4591001 4444 44441336	16-55	22SEP2020	96105	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441337	C4591001 4444 44441337	16-55	22SEP2020	96083	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441341	C4591001 4444 44441341	16-55	22SEP2020	96054	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441345	C4591001 4444 44441345	16-55	22SEP2020	96106	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441346	C4591001 4444 44441346	16-55	22SEP2020	263497	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441347	C4591001 4444 44441347	16-55	22SEP2020	96152	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441348	C4591001 4444 44441348	16-55	22SEP2020	96111	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441351	C4591001 4444 44441351	16-55	22SEP2020	96151	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441352	C4591001 4444 44441352	16-55	22SEP2020	96154	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441353	C4591001 4444 44441353	16-55	22SEP2020	96157	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441357	C4591001 4444 44441357	16-55	22SEP2020	96228	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441358	C4591001 4444 44441358	16-55	22SEP2020	96180	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441359	C4591001 4444 44441359	16-55	22SEP2020	96183	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441360	C4591001 4444 44441360	16-55	22SEP2020	96173	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441361	C4591001 4444 44441361	16-55	22SEP2020	96181	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441365	C4591001 4444 44441365	16-55	22SEP2020	96224	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441366	C4591001 4444 44441366	16-55	22SEP2020	96222	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441376	C4591001 4444 44441376	16-55	22SEP2020	96309	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441377	C4591001 4444 44441377	16-55	22SEP2020	96246	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441378	C4591001 4444 44441378	16-55	22SEP2020	96231	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441379	C4591001 4444 44441379	16-55	22SEP2020	96307	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441380	C4591001 4444 44441380	16-55	22SEP2020	96253	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441384	C4591001 4444 44441384	16-55	22SEP2020	96255	Placebo	22SEP2020/ Placebo	29OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441386	C4591001 4444 44441386	16-55	22SEP2020	96254	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441387	C4591001 4444 44441387	16-55	22SEP2020	96467	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441388	C4591001 4444 44441388	16-55	22SEP2020	96464	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441390	C4591001 4444 44441390	16-55	22SEP2020	96312	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441395	C4591001 4444 44441395	16-55	22SEP2020	96401	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441396	C4591001 4444 44441396	16-55	22SEP2020	96313	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo		
44441398	C4591001 4444 44441398	16-55	22SEP2020	96500	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441400	C4591001 4444 44441400	16-55	22SEP2020	96406	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441401	C4591001 4444 44441401	16-55	22SEP2020	96405	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441402	C4591001 4444 44441402	16-55	22SEP2020	96411	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441404	C4591001 4444 44441404	16-55	22SEP2020	96537	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441405	C4591001 4444 44441405†	16-55	22SEP2020	96465	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441407	C4591001 4444 44441407	16-55	22SEP2020	96501	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	19JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44441408	C4591001 4444 44441408	16-55	22SEP2020	96499	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441412	C4591001 4444 44441412	16-55	22SEP2020	96462	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441413	C4591001 4444 44441413	16-55	22SEP2020	96535	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441419	C4591001 4444 44441419	16-55	22SEP2020	96503	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441425	C4591001 4444 44441425	16-55	22SEP2020	96599	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441428	C4591001 4444 44441428	16-55	22SEP2020	96540	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441432	C4591001 4444 44441432	16-55	22SEP2020	96602	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
44441433	C4591001 4444 44441433	16-55	22SEP2020	96601	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441435	C4591001 4444 44441435	16-55	22SEP2020	96697	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441436	C4591001 4444 44441436	16-55	22SEP2020	96543	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441437	C4591001 4444 44441437	16-55	22SEP2020	96668	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441438	C4591001 4444 44441438	16-55	22SEP2020	96597	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441440	C4591001 4444 44441440	16-55	22SEP2020	96642	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441442	C4591001 4444 44441442	16-55	22SEP2020	96646	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441443	C4591001 4444 44441443	16-55	22SEP2020	96714	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441444	C4591001 4444 44441444	16-55	22SEP2020	96692	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441445	C4591001 4444 44441445	16-55	22SEP2020	96670	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441446	C4591001 4444 44441446	16-55	22SEP2020	96672	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441450	C4591001 4444 44441450	16-55	22SEP2020	96649	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441452	C4591001 4444 44441452	16-55	22SEP2020	96713	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441453	C4591001 4444 44441453	16-55	22SEP2020	96673	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441457	C4591001 4444 44441457	16-55	22SEP2020	96689	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441458	C4591001 4444 44441458	16-55	22SEP2020	96695	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441459	C4591001 4444 44441459	16-55	22SEP2020	96651	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
44441460	C4591001 4444 44441460	16-55	22SEP2020	96740	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441461	C4591001 4444 44441461	16-55	22SEP2020	96721	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441464	C4591001 4444 44441464	16-55	22SEP2020	96716	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441469	C4591001 4444 44441469	16-55	22SEP2020	96737	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo		
44441472	C4591001 4444 44441472	16-55	22SEP2020	96741	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441474	C4591001 4444 44441474	16-55	22SEP2020	96782	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441476	C4591001 4444 44441476	16-55	22SEP2020	96773	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441477	C4591001 4444 44441477	16-55	22SEP2020	96744	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441478	C4591001 4444 44441478	16-55	22SEP2020	96776	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441482	C4591001 4444 44441482	16-55	22SEP2020	96833	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441483	C4591001 4444 44441483	16-55	22SEP2020	96850	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441485	C4591001 4444 44441485	16-55	22SEP2020	96843	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441486	C4591001 4444 44441486	16-55	22SEP2020	96809	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441487	C4591001 4444 44441487	16-55	22SEP2020	96835	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441488	C4591001 4444 44441488	16-55	22SEP2020	96783	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441490	C4591001 4444 44441490	16-55	22SEP2020	96811	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441491	C4591001 4444 44441491	16-55	22SEP2020	96819	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441494	C4591001 4444 44441494	16-55	22SEP2020	96817	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441498	C4591001 4444 44441498	16-55	22SEP2020	96845	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441499	C4591001 4444 44441499	16-55	22SEP2020	96841	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441500	C4591001 4444 44441500	16-55	22SEP2020	96851	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441501	C4591001 4444 44441501	16-55	22SEP2020	96872	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441502	C4591001 4444 44441502	16-55	22SEP2020	96869	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441503	C4591001 4444 44441503	16-55	22SEP2020	96853	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441505	C4591001 4444 44441505	16-55	22SEP2020	96878	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441506	C4591001 4444 44441506	16-55	22SEP2020	96879	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441510	C4591001 4444 44441510	16-55	22SEP2020	96921	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441511	C4591001 4444 44441511	16-55	22SEP2020	96881	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441514	C4591001 4444 44441514	16-55	22SEP2020	96882	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441515	C4591001 4444 44441515	16-55	22SEP2020	96925	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441516	C4591001 4444 44441516	16-55	22SEP2020	96977	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441518	C4591001 4444 44441518	16-55	22SEP2020	96923	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441520	C4591001 4444 44441520	16-55	22SEP2020	96883	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441521	C4591001 4444 44441521	16-55	22SEP2020	96887	Placebo	22SEP2020/ Placebo	12OCT2020/ Placebo		
44441522	C4591001 4444 44441522	16-55	22SEP2020	96928	Placebo	22SEP2020/ Placebo			
44441523	C4591001 4444 44441523	16-55	22SEP2020	96955	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441524	C4591001 4444 44441524	16-55	22SEP2020	96954	Placebo	22SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441525	C4591001 4444 44441525	16-55	22SEP2020	96981	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441526	C4591001 4444 44441526	16-55	22SEP2020	96962	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441527	C4591001 4444 44441527	16-55	22SEP2020	96958	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441528	C4591001 4444 44441528	16-55	22SEP2020	96989	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441530	C4591001 4444 44441530	16-55	22SEP2020	96982	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441531	C4591001 4444 44441531	16-55	22SEP2020	96990	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441532	C4591001 4444 44441532	16-55	22SEP2020	96986	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441534	C4591001 4444 44441534	16-55	22SEP2020	96994	Placebo	22SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441536	C4591001 4444 44441536	16-55	22SEP2020	96997	BNT162b2 (30 µg)	22SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441538	C4591001 4444 44441538	16-55	23SEP2020	97197	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441539	C4591001 4444 44441539	16-55	23SEP2020	97252	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441541	C4591001 4444 44441541	16-55	23SEP2020	97216	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441542	C4591001 4444 44441542	16-55	23SEP2020	97273	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441544	C4591001 4444 44441544	16-55	23SEP2020	97194	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441546	C4591001 4444 44441546	16-55	23SEP2020	97205	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441549	C4591001 4444 44441549	16-55	23SEP2020	97289	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441550	C4591001 4444 44441550	16-55	23SEP2020	97257	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441553	C4591001 4444 44441553	16-55	23SEP2020	97250	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441554	C4591001 4444 44441554	16-55	23SEP2020	97213	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441555	C4591001 4444 44441555	16-55	23SEP2020	97201	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441556	C4591001 4444 44441556	16-55	23SEP2020	97199	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441557	C4591001 4444 44441557	16-55	23SEP2020	97208	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441558	C4591001 4444 44441558	16-55	23SEP2020	97221	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441559	C4591001 4444 44441559	16-55	23SEP2020	97258	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441560	C4591001 4444 44441560	16-55	23SEP2020	97276	Placebo	23SEP2020/ Placebo		05MAR2021/ BNT162b2 (30 µg)	
44441561	C4591001 4444 44441561	16-55	23SEP2020	97269	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441562	C4591001 4444 44441562	16-55	23SEP2020	97225	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441563	C4591001 4444 44441563	16-55	23SEP2020	97243	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441564	C4591001 4444 44441564	16-55	23SEP2020	97261	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441565	C4591001 4444 44441565	16-55	23SEP2020	97223	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441566	C4591001 4444 44441566	16-55	23SEP2020	97227	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441567	C4591001 4444 44441567	16-55	23SEP2020	97284	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441569	C4591001 4444 44441569	16-55	23SEP2020	97274	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)			
44441570	C4591001 4444 44441570	16-55	23SEP2020	97251	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441572	C4591001 4444 44441572	16-55	23SEP2020	97262	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)			
44441573	C4591001 4444 44441573	16-55	23SEP2020	97282	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441574	C4591001 4444 44441574	16-55	23SEP2020	97309	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441576	C4591001 4444 44441576	16-55	23SEP2020	97290	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441577	C4591001 4444 44441577	16-55	23SEP2020	97291	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441578	C4591001 4444 44441578	16-55	23SEP2020	97280	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441581	C4591001 4444 44441581	16-55	23SEP2020	97308	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441582	C4591001 4444 44441582	16-55	23SEP2020	97283	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441583	C4591001 4444 44441583	16-55	23SEP2020	97305	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441585	C4591001 4444 44441585	16-55	23SEP2020	97298	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441586	C4591001 4444 44441586	16-55	23SEP2020	97322	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441587	C4591001 4444 44441587	16-55	23SEP2020	97311	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441589	C4591001 4444 44441589	16-55	23SEP2020	97319	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441590	C4591001 4444 44441590	16-55	23SEP2020	97363	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441591	C4591001 4444 44441591	16-55	23SEP2020	97320	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441593	C4591001 4444 44441593	16-55	23SEP2020	97364	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441594	C4591001 4444 44441594	16-55	23SEP2020	97351	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441596	C4591001 4444 44441596	16-55	23SEP2020	97360	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441597	C4591001 4444 44441597	16-55	23SEP2020	97375	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441599	C4591001 4444 44441599	16-55	23SEP2020	97349	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441601	C4591001 4444 44441601	16-55	23SEP2020	97318	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441603	C4591001 4444 44441603	16-55	23SEP2020	97397	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441604	C4591001 4444 44441604	16-55	23SEP2020	97367	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441605	C4591001 4444 44441605	16-55	23SEP2020	97369	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441606	C4591001 4444 44441606	16-55	23SEP2020	97383	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441608	C4591001 4444 44441608	16-55	23SEP2020	97384	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441610	C4591001 4444 44441610	16-55	23SEP2020	97409	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441611	C4591001 4444 44441611	16-55	23SEP2020	97356	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo		
44441612	C4591001 4444 44441612	16-55	23SEP2020	97376	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441614	C4591001 4444 44441614	16-55	23SEP2020	97414	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441615	C4591001 4444 44441615	16-55	23SEP2020	97400	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441616	C4591001 4444 44441616	16-55	23SEP2020	97429	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441617	C4591001 4444 44441617	16-55	23SEP2020	97407	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441618	C4591001 4444 44441618	16-55	23SEP2020	97401	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441619	C4591001 4444 44441619	16-55	23SEP2020	97411	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441623	C4591001 4444 44441623	16-55	23SEP2020	97419	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441624	C4591001 4444 44441624	16-55	23SEP2020	97431	Placebo	23SEP2020/ Placebo	30OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441628	C4591001 4444 44441628	16-55	23SEP2020	97546	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441629	C4591001 4444 44441629	16-55	23SEP2020	97430	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441632	C4591001 4444 44441632	16-55	23SEP2020	97432	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo		
44441633	C4591001 4444 44441633	16-55	23SEP2020	97549	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441634	C4591001 4444 44441634	16-55	23SEP2020	97500	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441636	C4591001 4444 44441636	16-55	23SEP2020	97502	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441638	C4591001 4444 44441638	16-55	23SEP2020	97504	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441639	C4591001 4444 44441639	16-55	23SEP2020	97541	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441640	C4591001 4444 44441640	16-55	23SEP2020	97614	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44441643	C4591001 4444 44441643	16-55	23SEP2020	97618	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441644	C4591001 4444 44441644	16-55	23SEP2020	97550	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441649	C4591001 4444 44441649	16-55	23SEP2020	97617	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441650	C4591001 4444 44441650	16-55	23SEP2020	97623	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441652	C4591001 4444 44441652	16-55	23SEP2020	97805	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441654	C4591001 4444 44441654	16-55	23SEP2020	97633	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441658	C4591001 4444 44441658	16-55	23SEP2020	97654	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441659	C4591001 4444 44441659	16-55	23SEP2020	97630	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441660	C4591001 4444 44441660	16-55	23SEP2020	97625	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441662	C4591001 4444 44441662	16-55	23SEP2020	97632	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441663	C4591001 4444 44441663	16-55	23SEP2020	97652	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441664	C4591001 4444 44441664	16-55	23SEP2020	97665	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441668	C4591001 4444 44441668	16-55	23SEP2020	97649	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441669	C4591001 4444 44441669	16-55	23SEP2020	97713	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441670	C4591001 4444 44441670	16-55	23SEP2020	97657	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441672	C4591001 4444 44441672	16-55	23SEP2020	97686	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441673	C4591001 4444 44441673	16-55	23SEP2020	97672	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441675	C4591001 4444 44441675	16-55	23SEP2020	97662	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441676	C4591001 4444 44441676	16-55	23SEP2020	97693	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441677	C4591001 4444 44441677	16-55	23SEP2020	97690	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441678	C4591001 4444 44441678	16-55	23SEP2020	97718	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441679	C4591001 4444 44441679	16-55	23SEP2020	97720	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441680	C4591001 4444 44441680	16-55	23SEP2020	97692	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441681	C4591001 4444 44441681	16-55	23SEP2020	97671	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441682	C4591001 4444 44441682	16-55	23SEP2020	97732	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441683	C4591001 4444 44441683	16-55	23SEP2020	97717	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441685	C4591001 4444 44441685	16-55	23SEP2020	97730	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441686	C4591001 4444 44441686	16-55	23SEP2020	97726	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441688	C4591001 4444 44441688	16-55	23SEP2020	97731	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441694	C4591001 4444 44441694	16-55	23SEP2020	97807	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441695	C4591001 4444 44441695	16-55	23SEP2020	98038	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441696	C4591001 4444 44441696	16-55	23SEP2020	97935	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441699	C4591001 4444 44441699	16-55	23SEP2020	97945	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441700	C4591001 4444 44441700	16-55	23SEP2020	97926	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441705	C4591001 4444 44441705	16-55	23SEP2020	97816	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441707	C4591001 4444 44441707	16-55	23SEP2020	97813	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441710	C4591001 4444 44441710	16-55	23SEP2020	97929	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441711	C4591001 4444 44441711	16-55	23SEP2020	97940	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441712	C4591001 4444 44441712	16-55	23SEP2020	97937	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441715	C4591001 4444 44441715	16-55	23SEP2020	97949	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441716	C4591001 4444 44441716	16-55	23SEP2020	98043	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441717	C4591001 4444 44441717	16-55	23SEP2020	97927	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441719	C4591001 4444 44441719	16-55	23SEP2020	97958	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441721	C4591001 4444 44441721	16-55	23SEP2020	97952	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441722	C4591001 4444 44441722	16-55	23SEP2020	97948	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441724	C4591001 4444 44441724	16-55	23SEP2020	97953	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441725	C4591001 4444 44441725	16-55	23SEP2020	98044	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441726	C4591001 4444 44441726	16-55	23SEP2020	98045	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	01FEB2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
44441728	C4591001 4444 44441728	16-55	23SEP2020	98035	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441729	C4591001 4444 44441729	16-55	23SEP2020	98094	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441731	C4591001 4444 44441731	16-55	23SEP2020	98050	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441733	C4591001 4444 44441733	16-55	23SEP2020	98048	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441735	C4591001 4444 44441735	16-55	23SEP2020	98095	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441738	C4591001 4444 44441738	16-55	23SEP2020	98099	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441739	C4591001 4444 44441739	16-55	23SEP2020	98049	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441741	C4591001 4444 44441741	16-55	23SEP2020	98138	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441744	C4591001 4444 44441744	16-55	23SEP2020	98102	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441745	C4591001 4444 44441745	16-55	23SEP2020	98167	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441746	C4591001 4444 44441746	16-55	23SEP2020	98255	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441747	C4591001 4444 44441747	16-55	23SEP2020	98201	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441748	C4591001 4444 44441748	16-55	23SEP2020	98137	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441750	C4591001 4444 44441750	16-55	23SEP2020	98258	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441751	C4591001 4444 44441751	16-55	23SEP2020	98171	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441752	C4591001 4444 44441752	16-55	23SEP2020	98139	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441753	C4591001 4444 44441753	16-55	23SEP2020	98208	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441754	C4591001 4444 44441754	16-55	23SEP2020	98133	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441755	C4591001 4444 44441755	16-55	23SEP2020	98174	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441756	C4591001 4444 44441756	16-55	23SEP2020	98169	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441758	C4591001 4444 44441758	16-55	23SEP2020	98274	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441760	C4591001 4444 44441760	16-55	23SEP2020	98260	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441761	C4591001 4444 44441761	16-55	23SEP2020	98202	Placebo	23SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441763	C4591001 4444 44441763	16-55	23SEP2020	98212	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441764	C4591001 4444 44441764	16-55	23SEP2020	98327	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441765	C4591001 4444 44441765	16-55	23SEP2020	98259	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441766	C4591001 4444 44441766	16-55	23SEP2020	98280	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441767	C4591001 4444 44441767	16-55	23SEP2020	98284	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441768	C4591001 4444 44441768	16-55	23SEP2020	98323	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441769	C4591001 4444 44441769	16-55	23SEP2020	98283	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441770	C4591001 4444 44441770	16-55	23SEP2020	98338	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441771	C4591001 4444 44441771	16-55	23SEP2020	98369	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441772	C4591001 4444 44441772	16-55	23SEP2020	98360	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441773	C4591001 4444 44441773	16-55	23SEP2020	98336	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	13OCT2020/ BNT162b2 (30 µg)		
44441776	C4591001 4444 44441776	16-55	23SEP2020	98325	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441777	C4591001 4444 44441777	16-55	23SEP2020	98370	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441778	C4591001 4444 44441778	16-55	23SEP2020	98332	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44441779	C4591001 4444 44441779	16-55	23SEP2020	98356	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441780	C4591001 4444 44441780	16-55	23SEP2020	98334	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	12OCT2020/ BNT162b2 (30 µg)		
44441781	C4591001 4444 44441781	16-55	23SEP2020	98340	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo		
44441782	C4591001 4444 44441782	16-55	23SEP2020	98346	Placebo	23SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441783	C4591001 4444 44441783	16-55	23SEP2020	98362	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441784	C4591001 4444 44441784	16-55	23SEP2020	98355	Placebo	23SEP2020/ Placebo	14OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441785	C4591001 4444 44441785	16-55	23SEP2020	98345	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441786	C4591001 4444 44441786	16-55	23SEP2020	98386	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441788	C4591001 4444 44441788	16-55	23SEP2020	98358	Placebo	23SEP2020/ Placebo	13OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441789	C4591001 4444 44441789	16-55	23SEP2020	98379	Placebo	23SEP2020/ Placebo	22OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441791	C4591001 4444 44441791	16-55	23SEP2020	98367	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441793	C4591001 4444 44441793	16-55	23SEP2020	98380	Placebo	23SEP2020/ Placebo	12OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441795	C4591001 4444 44441795	16-55	23SEP2020	98387	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441796	C4591001 4444 44441796	16-55	23SEP2020	98389	BNT162b2 (30 µg)	23SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441797	C4591001 4444 44441797	16-55	25SEP2020	99269	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441798	C4591001 4444 44441798	16-55	25SEP2020	99271	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441799	C4591001 4444 44441799	16-55	25SEP2020	98392	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	21JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)
44441800	C4591001 4444 44441800	16-55	25SEP2020	99273	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441801	C4591001 4444 44441801	16-55	25SEP2020	99357	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441804	C4591001 4444 44441804	16-55	25SEP2020	99278	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441805	C4591001 4444 44441805	16-55	25SEP2020	99324	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441806	C4591001 4444 44441806	16-55	25SEP2020	99318	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441807	C4591001 4444 44441807	16-55	25SEP2020	99320	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441808	C4591001 4444 44441808	16-55	25SEP2020	99340	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441810	C4591001 4444 44441810	16-55	25SEP2020	99334	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441815	C4591001 4444 44441815	16-55	25SEP2020	99345	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441817	C4591001 4444 44441817	16-55	25SEP2020	99341	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441818	C4591001 4444 44441818	16-55	25SEP2020	99322	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
44441819	C4591001 4444 44441819	16-55	25SEP2020	99361	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441823	C4591001 4444 44441823	16-55	25SEP2020	99333	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441824	C4591001 4444 44441824	16-55	25SEP2020	99330	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441825	C4591001 4444 44441825	16-55	25SEP2020	99369	Placebo	25SEP2020/ Placebo	29OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441826	C4591001 4444 44441826	16-55	25SEP2020	99372	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441827	C4591001 4444 44441827	16-55	25SEP2020	99362	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441828	C4591001 4444 44441828	16-55	25SEP2020	99342	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441830	C4591001 4444 44441830	16-55	25SEP2020	99348	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441832	C4591001 4444 44441832	16-55	25SEP2020	99356	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	30OCT2020/ BNT162b2 (30 µg)		
44441833	C4591001 4444 44441833	16-55	25SEP2020	99368	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441835	C4591001 4444 44441835	16-55	25SEP2020	99371	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441837	C4591001 4444 44441837	16-55	25SEP2020	99387	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441839	C4591001 4444 44441839	16-55	25SEP2020	99383	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441840	C4591001 4444 44441840	16-55	25SEP2020	99381	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441841	C4591001 4444 44441841	16-55	25SEP2020	99402	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441842	C4591001 4444 44441842	16-55	25SEP2020	99388	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441843	C4591001 4444 44441843	16-55	25SEP2020	99413	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441849	C4591001 4444 44441849	16-55	25SEP2020	99409	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441850	C4591001 4444 44441850	16-55	25SEP2020	99408	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441851	C4591001 4444 44441851	16-55	25SEP2020	99417	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441852	C4591001 4444 44441852	16-55	25SEP2020	99411	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441854	C4591001 4444 44441854	16-55	25SEP2020	99486	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441855	C4591001 4444 44441855†	16-55	25SEP2020	99488	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441857	C4591001 4444 44441857	16-55	25SEP2020	99525	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441859	C4591001 4444 44441859	16-55	25SEP2020	99446	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441860	C4591001 4444 44441860	16-55	25SEP2020	99437	Placebo	25SEP2020/ Placebo	06NOV2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441861	C4591001 4444 44441861	16-55	25SEP2020	99440	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441862	C4591001 4444 44441862	16-55	25SEP2020	99445	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441863	C4591001 4444 44441863	16-55	25SEP2020	99422	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441864	C4591001 4444 44441864	16-55	25SEP2020	99415	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441868	C4591001 4444 44441868	16-55	25SEP2020	99539	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441870	C4591001 4444 44441870	16-55	25SEP2020	99522	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
44441871	C4591001 4444 44441871	16-55	25SEP2020	99491	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441872	C4591001 4444 44441872	16-55	25SEP2020	99492	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441874	C4591001 4444 44441874	16-55	25SEP2020	99527	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441875	C4591001 4444 44441875	16-55	25SEP2020	99541	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441877	C4591001 4444 44441877	16-55	25SEP2020	99537	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441878	C4591001 4444 44441878	16-55	25SEP2020	99528	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441881	C4591001 4444 44441881	16-55	25SEP2020	99597	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441883	C4591001 4444 44441883	16-55	25SEP2020	99543	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441885	C4591001 4444 44441885	16-55	25SEP2020	99596	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441886	C4591001 4444 44441886	16-55	25SEP2020	99607	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44441887	C4591001 4444 44441887†	16-55	25SEP2020	99797	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441888	C4591001 4444 44441888	16-55	25SEP2020	99593	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441889	C4591001 4444 44441889	16-55	25SEP2020	99605	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441891	C4591001 4444 44441891	16-55	25SEP2020	99612	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44441893	C4591001 4444 44441893	16-55	25SEP2020	99603	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44441895	C4591001 4444 44441895	16-55	25SEP2020	99614	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441896	C4591001 4444 44441896	16-55	25SEP2020	99642	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441898	C4591001 4444 44441898	16-55	25SEP2020	99651	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441900	C4591001 4444 44441900	16-55	25SEP2020	99693	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441903	C4591001 4444 44441903	16-55	25SEP2020	99641	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441904	C4591001 4444 44441904	16-55	25SEP2020	99643	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441907	C4591001 4444 44441907	16-55	25SEP2020	99689	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441909	C4591001 4444 44441909	16-55	25SEP2020	99740	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441910	C4591001 4444 44441910	16-55	25SEP2020	99739	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441912	C4591001 4444 44441912	16-55	25SEP2020	99691	Placebo	25SEP2020/ Placebo	13OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441913	C4591001 4444 44441913	16-55	25SEP2020	99690	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441915	C4591001 4444 44441915	16-55	25SEP2020	99744	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441916	C4591001 4444 44441916	16-55	25SEP2020	99742	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441917	C4591001 4444 44441917	16-55	25SEP2020	99761	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441918	C4591001 4444 44441918	16-55	25SEP2020	99762	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44441921	C4591001 4444 44441921	16-55	25SEP2020	99802	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441923	C4591001 4444 44441923	16-55	25SEP2020	99808	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441924	C4591001 4444 44441924	16-55	25SEP2020	99769	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441925	C4591001 4444 44441925	16-55	25SEP2020	99787	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441928	C4591001 4444 44441928	16-55	25SEP2020	99771	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44441929	C4591001 4444 44441929	16-55	25SEP2020	99833	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441931	C4591001 4444 44441931	16-55	25SEP2020	99827	Placebo	25SEP2020/ Placebo			
44441933	C4591001 4444 44441933	16-55	25SEP2020	99843	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441934	C4591001 4444 44441934	16-55	25SEP2020	99826	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441935	C4591001 4444 44441935	16-55	25SEP2020	99804	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441937	C4591001 4444 44441937	16-55	25SEP2020	99821	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441938	C4591001 4444 44441938	16-55	25SEP2020	99831	Placebo	25SEP2020/ Placebo	13OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441939	C4591001 4444 44441939	16-55	25SEP2020	99837	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441940	C4591001 4444 44441940	16-55	25SEP2020	99883	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441945	C4591001 4444 44441945	16-55	25SEP2020	99884	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo		
44441946	C4591001 4444 44441946	16-55	25SEP2020	99836	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441949	C4591001 4444 44441949	16-55	25SEP2020	100191	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44441950	C4591001 4444 44441950	16-55	25SEP2020	99881	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo		
44441951	C4591001 4444 44441951	16-55	25SEP2020	99886	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)			
44441952	C4591001 4444 44441952	16-55	25SEP2020	100047	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441953	C4591001 4444 44441953	16-55	25SEP2020	100041	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441954	C4591001 4444 44441954	16-55	25SEP2020	100039	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441955	C4591001 4444 44441955	16-55	25SEP2020	100045	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44441956	C4591001 4444 44441956	16-55	25SEP2020	100092	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44441957	C4591001 4444 44441957	16-55	25SEP2020	100111	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441958	C4591001 4444 44441958	16-55	25SEP2020	100053	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441959	C4591001 4444 44441959	16-55	25SEP2020	100055	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441961	C4591001 4444 44441961	16-55	25SEP2020	100057	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441962	C4591001 4444 44441962	16-55	25SEP2020	100115	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44441963	C4591001 4444 44441963	16-55	25SEP2020	100091	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441964	C4591001 4444 44441964	16-55	25SEP2020	100095	Placebo	25SEP2020/ Placebo	29OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441965	C4591001 4444 44441965	16-55	25SEP2020	100166	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441966	C4591001 4444 44441966	16-55	25SEP2020	100056	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44441967	C4591001 4444 44441967	16-55	25SEP2020	100159	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44441969	C4591001 4444 44441969	16-55	25SEP2020	100246	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44441970	C4591001 4444 44441970	16-55	25SEP2020	100094	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441971	C4591001 4444 44441971	16-55	25SEP2020	100112	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441972	C4591001 4444 44441972	16-55	25SEP2020	100202	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441973	C4591001 4444 44441973	16-55	25SEP2020	100158	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	29OCT2020/ BNT162b2 (30 µg)		
44441974	C4591001 4444 44441974	16-55	25SEP2020	100120	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44441975	C4591001 4444 44441975	16-55	25SEP2020	100194	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441976	C4591001 4444 44441976	16-55	25SEP2020	100193	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441977	C4591001 4444 44441977	16-55	25SEP2020	100181	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441979	C4591001 4444 44441979	16-55	25SEP2020	100195	Placebo	25SEP2020/ Placebo			
44441980	C4591001 4444 44441980	16-55	25SEP2020	100182	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44441982	C4591001 4444 44441982	16-55	25SEP2020	100209	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441983	C4591001 4444 44441983	16-55	25SEP2020	100163	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441984	C4591001 4444 44441984	16-55	25SEP2020	100186	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44441985	C4591001 4444 44441985	16-55	25SEP2020	100205	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	19FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441986	C4591001 4444 44441986	16-55	25SEP2020	100208	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441988	C4591001 4444 44441988	16-55	25SEP2020	100225	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44441990	C4591001 4444 44441990	16-55	25SEP2020	100244	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441991	C4591001 4444 44441991	16-55	25SEP2020	100248	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44441992	C4591001 4444 44441992	16-55	25SEP2020	100216	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44441994	C4591001 4444 44441994	16-55	25SEP2020	100218	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44441995	C4591001 4444 44441995	16-55	25SEP2020	100220	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44441996	C4591001 4444 44441996	16-55	25SEP2020	100228	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44441997	C4591001 4444 44441997	16-55	25SEP2020	100271	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442000	C4591001 4444 44442000	16-55	25SEP2020	100275	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442001	C4591001 4444 44442001	16-55	25SEP2020	100269	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44442003	C4591001 4444 44442003	16-55	25SEP2020	100276	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442004	C4591001 4444 44442004	16-55	25SEP2020	100251	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442005	C4591001 4444 44442005	16-55	25SEP2020	100303	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442006	C4591001 4444 44442006	16-55	25SEP2020	100304	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442007	C4591001 4444 44442007	16-55	25SEP2020	100302	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	04FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)
44442008	C4591001 4444 44442008	16-55	25SEP2020	100347	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442009	C4591001 4444 44442009	16-55	25SEP2020	100312	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442011	C4591001 4444 44442011	16-55	25SEP2020	100341	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442013	C4591001 4444 44442013	16-55	25SEP2020	100356	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442014	C4591001 4444 44442014	16-55	25SEP2020	100350	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442015	C4591001 4444 44442015	16-55	25SEP2020	100340	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44442016	C4591001 4444 44442016	16-55	25SEP2020	100360	Placebo	25SEP2020/ Placebo	19OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44442018	C4591001 4444 44442018	16-55	25SEP2020	100352	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442019	C4591001 4444 44442019	16-55	25SEP2020	100346	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442021	C4591001 4444 44442021	16-55	25SEP2020	100399	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442022	C4591001 4444 44442022	16-55	25SEP2020	100398	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	12FEB2021/ BNT162b2 (30 µg)



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442024	C4591001 4444 44442024	16-55	25SEP2020	100388	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442025	C4591001 4444 44442025	16-55	25SEP2020	100433	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442026	C4591001 4444 44442026	16-55	25SEP2020	100385	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442028	C4591001 4444 44442028	16-55	25SEP2020	100389	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442029	C4591001 4444 44442029	16-55	25SEP2020	100404	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442030	C4591001 4444 44442030†	16-55	25SEP2020	100448	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44442032	C4591001 4444 44442032	16-55	25SEP2020	100401	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442033	C4591001 4444 44442033	16-55	25SEP2020	100392	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442034	C4591001 4444 44442034	16-55	25SEP2020	100436	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442035	C4591001 4444 44442035	16-55	25SEP2020	100447	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442037	C4591001 4444 44442037	16-55	25SEP2020	100472	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442039	C4591001 4444 44442039	16-55	25SEP2020	100473	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442040	C4591001 4444 44442040	16-55	25SEP2020	100443	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442041	C4591001 4444 44442041	16-55	25SEP2020	100478	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442043	C4591001 4444 44442043	16-55	25SEP2020	100456	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442044	C4591001 4444 44442044	16-55	25SEP2020	100441	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442045	C4591001 4444 44442045	16-55	25SEP2020	100470	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442047	C4591001 4444 44442047	16-55	25SEP2020	100486	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442048	C4591001 4444 44442048	16-55	25SEP2020	100485	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442049	C4591001 4444 44442049	16-55	25SEP2020	100452	Placebo	25SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442050	C4591001 4444 44442050	16-55	25SEP2020	100493	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442051	C4591001 4444 44442051	16-55	25SEP2020	100494	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	14OCT2020/ BNT162b2 (30 µg)		
44442052	C4591001 4444 44442052	16-55	25SEP2020	100500	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo		
44442053	C4591001 4444 44442053	16-55	25SEP2020	100489	BNT162b2 (30 µg)	25SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442054	C4591001 4444 44442054	16-55	25SEP2020	100487	Placebo	25SEP2020/ Placebo	16OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44442055	C4591001 4444 44442055	16-55	25SEP2020	100503	Placebo	25SEP2020/ Placebo	14OCT2020/ Placebo	25JAN2021/ BNT162b2 (30 µg)	13FEB2021/ BNT162b2 (30 µg)
44442058	C4591001 4444 44442058	16-55	27SEP2020	100641	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442059	C4591001 4444 44442059	16-55	27SEP2020	100643	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442060	C4591001 4444 44442060	16-55	27SEP2020	100649	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442062	C4591001 4444 44442062	16-55	27SEP2020	100661	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442064	C4591001 4444 44442064	16-55	27SEP2020	100658	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442065	C4591001 4444 44442065	16-55	27SEP2020	100647	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442068	C4591001 4444 44442068	16-55	27SEP2020	100656	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442069	C4591001 4444 44442069	16-55	27SEP2020	100670	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442070	C4591001 4444 44442070	16-55	27SEP2020	100687	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442071	C4591001 4444 44442071	16-55	27SEP2020	100655	Placebo	27SEP2020/ Placebo	11NOV2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442072	C4591001 4444 44442072	16-55	27SEP2020	100637	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442073	C4591001 4444 44442073	16-55	27SEP2020	100692	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	18JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44442077	C4591001 4444 44442077	16-55	27SEP2020	100665	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442080	C4591001 4444 44442080	16-55	27SEP2020	100675	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442081	C4591001 4444 44442081	16-55	27SEP2020	100681	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442084	C4591001 4444 44442084	16-55	27SEP2020	100667	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	11NOV2020/ BNT162b2 (30 µg)		
44442085	C4591001 4444 44442085	16-55	27SEP2020	100676	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442086	C4591001 4444 44442086	16-55	27SEP2020	100703	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442087	C4591001 4444 44442087	16-55	27SEP2020	100686	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442088	C4591001 4444 44442088	16-55	27SEP2020	100701	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442090	C4591001 4444 44442090	16-55	27SEP2020	100685	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442091	C4591001 4444 44442091	16-55	27SEP2020	100680	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442093	C4591001 4444 44442093	16-55	27SEP2020	100705	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442094	C4591001 4444 44442094	16-55	27SEP2020	100709	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05FEB2021/ BNT162b2 (30 µg)	26FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442095	C4591001 4444 44442095	16-55	27SEP2020	100707	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442100	C4591001 4444 44442100	16-55	27SEP2020	100760	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442101	C4591001 4444 44442101	16-55	27SEP2020	100720	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	28JAN2021/ BNT162b2 (30 µg)	22FEB2021/ BNT162b2 (30 µg)
44442102	C4591001 4444 44442102	16-55	27SEP2020	100712	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442104	C4591001 4444 44442104	16-55	27SEP2020	100725	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442105	C4591001 4444 44442105	16-55	27SEP2020	100735	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44442106	C4591001 4444 44442106	16-55	27SEP2020	100710	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442107	C4591001 4444 44442107	16-55	27SEP2020	100749	Placebo	27SEP2020/ Placebo			
44442109	C4591001 4444 44442109	16-55	27SEP2020	100733	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442113	C4591001 4444 44442113	16-55	27SEP2020	100729	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442114	C4591001 4444 44442114	16-55	27SEP2020	100726	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442115	C4591001 4444 44442115	16-55	27SEP2020	100737	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442117	C4591001 4444 44442117	16-55	27SEP2020	100732	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442118	C4591001 4444 44442118	16-55	27SEP2020	100755	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442119	C4591001 4444 44442119	16-55	27SEP2020	100756	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442122	C4591001 4444 44442122	16-55	27SEP2020	100763	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442123	C4591001 4444 44442123	16-55	27SEP2020	100751	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442124	C4591001 4444 44442124	16-55	27SEP2020	100738	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442129	C4591001 4444 44442129	16-55	27SEP2020	100770	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442131	C4591001 4444 44442131	16-55	27SEP2020	100757	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442133	C4591001 4444 44442133	16-55	27SEP2020	100764	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442135	C4591001 4444 44442135	16-55	27SEP2020	100777	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442138	C4591001 4444 44442138	16-55	27SEP2020	100785	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442140	C4591001 4444 44442140	16-55	27SEP2020	100775	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442142	C4591001 4444 44442142	16-55	27SEP2020	100791	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442146	C4591001 4444 44442146	16-55	27SEP2020	100825	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442147	C4591001 4444 44442147	16-55	27SEP2020	100794	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442148	C4591001 4444 44442148	16-55	27SEP2020	100783	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442151	C4591001 4444 44442151	16-55	27SEP2020	100801	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	15JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442152	C4591001 4444 44442152	16-55	27SEP2020	100855	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442154	C4591001 4444 44442154	16-55	27SEP2020	100788	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442155	C4591001 4444 44442155	16-55	27SEP2020	100796	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44442156	C4591001 4444 44442156	16-55	27SEP2020	100809	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442157	C4591001 4444 44442157	16-55	27SEP2020	100793	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		
44442158	C4591001 4444 44442158	16-55	27SEP2020	100834	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442159	C4591001 4444 44442159	16-55	27SEP2020	100812	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442160	C4591001 4444 44442160	16-55	27SEP2020	100823	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	
44442161	C4591001 4444 44442161	16-55	27SEP2020	100829	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	29JAN2021/ BNT162b2 (30 µg)	18FEB2021/ BNT162b2 (30 µg)
44442162	C4591001 4444 44442162	16-55	27SEP2020	100832	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442163	C4591001 4444 44442163	16-55	27SEP2020	100827	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442165	C4591001 4444 44442165	16-55	27SEP2020	100826	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442167	C4591001 4444 44442167	16-55	27SEP2020	100839	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442168	C4591001 4444 44442168	16-55	27SEP2020	100814	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	26JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)
44442170	C4591001 4444 44442170	16-55	27SEP2020	100852	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442171	C4591001 4444 44442171	16-55	27SEP2020	100816	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442172	C4591001 4444 44442172	16-55	27SEP2020	100843	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442173	C4591001 4444 44442173	16-55	27SEP2020	100850	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442174	C4591001 4444 44442174	16-55	27SEP2020	100844	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442177	C4591001 4444 44442177	16-55	27SEP2020	100860	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442180	C4591001 4444 44442180	16-55	27SEP2020	100859	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442181	C4591001 4444 44442181	16-55	27SEP2020	100864	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442182	C4591001 4444 44442182	16-55	27SEP2020	100869	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442186	C4591001 4444 44442186	16-55	27SEP2020	100868	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442188	C4591001 4444 44442188	16-55	27SEP2020	100867	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442189	C4591001 4444 44442189	16-55	27SEP2020	100872	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	09FEB2021/ BNT162b2 (30 µg)
44442190	C4591001 4444 44442190	16-55	27SEP2020	100893	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442193	C4591001 4444 44442193	16-55	27SEP2020	100890	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442194	C4591001 4444 44442194	16-55	27SEP2020	100881	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)			
44442195	C4591001 4444 44442195	16-55	27SEP2020	100879	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44442196	C4591001 4444 44442196	16-55	27SEP2020	100889	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442197	C4591001 4444 44442197	16-55	27SEP2020	100915	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442198	C4591001 4444 44442198	16-55	27SEP2020	100907	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44442199	C4591001 4444 44442199	16-55	27SEP2020	100883	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442200	C4591001 4444 44442200	16-55	27SEP2020	100901	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442201	C4591001 4444 44442201	16-55	27SEP2020	100885	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	12MAR2021/ BNT162b2 (30 µg)
44442202	C4591001 4444 44442202	16-55	27SEP2020	100912	Placebo	27SEP2020/ Placebo	22OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442203	C4591001 4444 44442203	16-55	27SEP2020	100904	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442205	C4591001 4444 44442205	16-55	27SEP2020	100891	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442209	C4591001 4444 44442209	16-55	27SEP2020	100919	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
44442210	C4591001 4444 44442210	16-55	27SEP2020	100920	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442211	C4591001 4444 44442211	16-55	27SEP2020	100922	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442212	C4591001 4444 44442212	16-55	27SEP2020	100945	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442214	C4591001 4444 44442214	16-55	27SEP2020	100930	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442215	C4591001 4444 44442215	16-55	27SEP2020	100949	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442216	C4591001 4444 44442216	16-55	27SEP2020	100935	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442217	C4591001 4444 44442217	16-55	27SEP2020	100932	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442218	C4591001 4444 44442218	16-55	27SEP2020	100950	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44442219	C4591001 4444 44442219	16-55	27SEP2020	100947	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442220	C4591001 4444 44442220	16-55	27SEP2020	100941	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442221	C4591001 4444 44442221	16-55	27SEP2020	100979	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442222	C4591001 4444 44442222	16-55	27SEP2020	100936	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
44442224	C4591001 4444 44442224	16-55	27SEP2020	100960	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442226	C4591001 4444 44442226	16-55	27SEP2020	100986	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442227	C4591001 4444 44442227	16-55	27SEP2020	100974	Placebo	27SEP2020/ Placebo	29OCT2020/ Placebo	20JAN2021/ BNT162b2 (30 µg)	10FEB2021/ BNT162b2 (30 µg)
44442229	C4591001 4444 44442229	16-55	27SEP2020	100959	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	05MAR2021/ BNT162b2 (30 µg)	
44442230	C4591001 4444 44442230	16-55	27SEP2020	100948	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442232	C4591001 4444 44442232	16-55	27SEP2020	100978	Placebo	27SEP2020/ Placebo	11NOV2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442233	C4591001 4444 44442233	16-55	27SEP2020	100961	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442234	C4591001 4444 44442234	16-55	27SEP2020	100963	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442235	C4591001 4444 44442235	16-55	27SEP2020	100967	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442236	C4591001 4444 44442236	16-55	27SEP2020	100975	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442237	C4591001 4444 44442237	16-55	27SEP2020	100991	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442238	C4591001 4444 44442238	16-55	27SEP2020	100971	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442241	C4591001 4444 44442241	16-55	27SEP2020	101005	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442245	C4591001 4444 44442245	16-55	27SEP2020	100985	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442248	C4591001 4444 44442248	16-55	27SEP2020	101003	Placebo	27SEP2020/ Placebo	30OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442249	C4591001 4444 44442249	16-55	27SEP2020	100994	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	22JAN2021/ BNT162b2 (30 µg)	11FEB2021/ BNT162b2 (30 µg)
44442250	C4591001 4444 44442250	16-55	27SEP2020	100999	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442252	C4591001 4444 44442252	16-55	27SEP2020	101025	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442253	C4591001 4444 44442253	16-55	27SEP2020	101016	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442254	C4591001 4444 44442254	16-55	27SEP2020	101006	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	06MAR2021/ BNT162b2 (30 µg)	
44442255	C4591001 4444 44442255	16-55	27SEP2020	101011	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442256	C4591001 4444 44442256	16-55	27SEP2020	101020	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442258	C4591001 4444 44442258	16-55	27SEP2020	101040	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442260	C4591001 4444 44442260	16-55	27SEP2020	101035	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	26FEB2021/ BNT162b2 (30 µg)	
44442261	C4591001 4444 44442261	16-55	27SEP2020	101029	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442262	C4591001 4444 44442262	16-55	27SEP2020	101017	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442263	C4591001 4444 44442263	16-55	27SEP2020	101027	Placebo	27SEP2020/ Placebo			
44442268	C4591001 4444 44442268	16-55	27SEP2020	101023	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442269	C4591001 4444 44442269	16-55	27SEP2020	101044	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	14NOV2020/ BNT162b2 (30 µg)		



**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442270	C4591001 4444 44442270	16-55	27SEP2020	101062	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442273	C4591001 4444 44442273	16-55	27SEP2020	101052	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442274	C4591001 4444 44442274	16-55	27SEP2020	101033	Placebo	27SEP2020/ Placebo	11NOV2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44442275	C4591001 4444 44442275	16-55	27SEP2020	101066	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo		
44442277	C4591001 4444 44442277	16-55	27SEP2020	101055	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442278	C4591001 4444 44442278	16-55	27SEP2020	101061	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442279	C4591001 4444 44442279	16-55	27SEP2020	101053	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442280	C4591001 4444 44442280	16-55	27SEP2020	101063	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442281	C4591001 4444 44442281	16-55	27SEP2020	101056	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	04MAR2021/ BNT162b2 (30 µg)	
44442283	C4591001 4444 44442283	16-55	27SEP2020	101078	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442284	C4591001 4444 44442284	16-55	27SEP2020	101074	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	23FEB2021/ BNT162b2 (30 µg)	
44442285	C4591001 4444 44442285	16-55	27SEP2020	101075	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo		
44442286	C4591001 4444 44442286	16-55	27SEP2020	101076	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442287	C4591001 4444 44442287	16-55	27SEP2020	101118	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442288	C4591001 4444 44442288	16-55	27SEP2020	101081	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442291	C4591001 4444 44442291	16-55	27SEP2020	101083	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	22OCT2020/ BNT162b2 (30 µg)		
44442292	C4591001 4444 44442292	16-55	27SEP2020	101121	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	
44442293	C4591001 4444 44442293	16-55	27SEP2020	101090	Placebo	27SEP2020/ Placebo			
44442294	C4591001 4444 44442294	16-55	27SEP2020	101085	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442297	C4591001 4444 44442297	16-55	27SEP2020	101100	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	27JAN2021/ BNT162b2 (30 µg)	17FEB2021/ BNT162b2 (30 µg)

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442298	C4591001 4444 44442298	16-55	27SEP2020	101094	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442299	C4591001 4444 44442299	16-55	27SEP2020	101095	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442300	C4591001 4444 44442300	16-55	27SEP2020	101105	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442301	C4591001 4444 44442301	16-55	27SEP2020	101107	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	02FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
44442303	C4591001 4444 44442303	16-55	27SEP2020	101128	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	08MAR2021/ BNT162b2 (30 µg)	
44442304	C4591001 4444 44442304	16-55	27SEP2020	101104	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	25FEB2021/ BNT162b2 (30 µg)	
44442305	C4591001 4444 44442305	16-55	27SEP2020	101113	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442306	C4591001 4444 44442306	16-55	27SEP2020	101141	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442307	C4591001 4444 44442307	16-55	27SEP2020	101133	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	
44442308	C4591001 4444 44442308	16-55	27SEP2020	101111	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	09MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442310	C4591001 4444 44442310	16-55	27SEP2020	101160	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	
44442311	C4591001 4444 44442311	16-55	27SEP2020	101123	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	23OCT2020/ BNT162b2 (30 µg)		
44442312	C4591001 4444 44442312	16-55	27SEP2020	101131	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442313	C4591001 4444 44442313	16-55	27SEP2020	101130	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442314	C4591001 4444 44442314	16-55	27SEP2020	101155	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	15OCT2020/ BNT162b2 (30 µg)		
44442315	C4591001 4444 44442315	16-55	27SEP2020	101147	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	20FEB2021/ BNT162b2 (30 µg)	11MAR2021/ BNT162b2 (30 µg)
44442317	C4591001 4444 44442317	16-55	27SEP2020	101154	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)	16OCT2020/ BNT162b2 (30 µg)		
44442318	C4591001 4444 44442318	16-55	27SEP2020	101139	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	03FEB2021/ BNT162b2 (30 µg)	24FEB2021/ BNT162b2 (30 µg)
44442319	C4591001 4444 44442319	16-55	27SEP2020	101142	BNT162b2 (30 µg)	27SEP2020/ BNT162b2 (30 µg)			
44442321	C4591001 4444 44442321	16-55	27SEP2020	101152	Placebo	27SEP2020/ Placebo	16OCT2020/ Placebo	13MAR2021/ BNT162b2 (30 µg)	

**16.1.7.1.2 Listing of Randomization Scheme and Actual Vaccine Received –  
Phase 2/3 Subjects 16-55 Years of Age**

Subject Study Identifier <sup>a</sup>	Subject	Age Group (Years)	Randomization Date	Randomization Number	Randomization Vaccine Group	Vaccine Received			
						Date/ Dose 1	Date/ Dose 2	Date/ Dose 3	Date/ Dose 4
44442322	C4591001 4444 44442322	16-55	27SEP2020	101161	Placebo	27SEP2020/ Placebo	15OCT2020/ Placebo	10MAR2021/ BNT162b2 (30 µg)	

Note: † = Human immunodeficiency virus (HIV)-positive subject.

a. Subject Study Identifier = the current study 4-digit site number followed by the unique 4-digit subject identifier.

PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 29MAR2021 (23:11)

(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2\_unblinded/C4591001\_EUA\_1655/adsl\_1003\_1655

**16.1.7.2.1 Listing of Subjects Who Originally Received Placebo and Then Received BNT162b2 After Unblinding – 12 Through 15 Years of Age – Safety Population**

Subject	Date	Dose 1	Date	Dose 2	Vaccine Received					
					Date of Unblinding	Date	Dose 3	Date	Dose 4	
C4591001 1005 10051419	16DEC2020	Placebo	04JAN2021	Placebo	15FEB2021	24FEB2021	BNT162b2 (30 µg)			
C4591001 1006 10061229	08DEC2020	Placebo	29DEC2020	Placebo	15FEB2021	18FEB2021	BNT162b2	11MAR2021	BNT162b2 (30 µg)	
C4591001 1006 10061257	11DEC2020	Placebo	30DEC2020	Placebo	15FEB2021	19FEB2021	BNT162b2	12MAR2021	BNT162b2 (30 µg)	
C4591001 1006 10061266	15DEC2020	Placebo	06JAN2021	Placebo	23FEB2021	24FEB2021	BNT162b2 (30 µg)			
C4591001 1006 10061270	16DEC2020	Placebo	06JAN2021	Placebo	15FEB2021	18FEB2021	BNT162b2	11MAR2021	BNT162b2 (30 µg)	
C4591001 1007 10071524	08DEC2020	Placebo	29DEC2020	Placebo	10FEB2021	25FEB2021	BNT162b2 (30 µg)			
C4591001 1007 10071541	09DEC2020	Placebo	30DEC2020	Placebo	08FEB2021	09FEB2021	BNT162b2	02MAR2021	BNT162b2 (30 µg)	
C4591001 1008 10081858	28DEC2020	Placebo	19JAN2021	Placebo	16FEB2021	17FEB2021	BNT162b2	08MAR2021	BNT162b2 (30 µg)	
C4591001 1008 10081901	05JAN2021	Placebo	26JAN2021	Placebo	12FEB2021	15FEB2021	BNT162b2	08MAR2021	BNT162b2 (30 µg)	
C4591001 1009 10091208	15OCT2020	Placebo	06NOV2020	Placebo	22FEB2021	05MAR2021	BNT162b2 (30 µg)			
C4591001 1009 10091213	16OCT2020	Placebo	04NOV2020	Placebo	16FEB2021	22FEB2021	BNT162b2 (30 µg)			
C4591001 1009 10091266	01DEC2020	Placebo	21DEC2020	Placebo	22FEB2021	04MAR2021	BNT162b2 (30 µg)			
C4591001 1009 10091344	15DEC2020	Placebo	04JAN2021	Placebo	24FEB2021	01MAR2021	BNT162b2 (30 µg)			
C4591001 1009 10091384	05JAN2021	Placebo	25JAN2021	Placebo	19FEB2021	23FEB2021	BNT162b2 (30 µg)			

090177e196b257a8\Final\Final On: 03-Apr-2021 04:34 (GMT)

**16.1.7.2.1 Listing of Subjects Who Originally Received Placebo and Then Received BNT162b2 After Unblinding – 12 Through 15 Years of Age – Safety Population**

Subject	Date	Vaccine Received		Dose 2	Date of Unblinding		Dose 3	Date	Dose 4
		Dose 1	Date		Date	Date			
C4591001 1009 10091403	08JAN2021	Placebo	27JAN2021	Placebo	22FEB2021	24FEB2021	BNT162b2 (30 µg)		
C4591001 1016 10161316	16OCT2020	Placebo			23FEB2021	25FEB2021	BNT162b2 (30 µg)		
C4591001 1039 10391246	01DEC2020	Placebo	21DEC2020	Placebo	23FEB2021	26FEB2021	BNT162b2 (30 µg)		
C4591001 1039 10391251	07DEC2020	Placebo	04JAN2021	Placebo	02FEB2021	02FEB2021	BNT162b2 (30 µg)	25FEB2021	BNT162b2 (30 µg)
C4591001 1044 10441274	08DEC2020	Placebo	28DEC2020	Placebo	09FEB2021	17FEB2021	BNT162b2 (30 µg)	12MAR2021	BNT162b2 (30 µg)
C4591001 1044 10441280	09DEC2020	Placebo	29DEC2020	Placebo	26JAN2021	28JAN2021	BNT162b2 (30 µg)	17FEB2021	BNT162b2 (30 µg)
C4591001 1044 10441282	09DEC2020	Placebo	30DEC2020	Placebo	22FEB2021	03MAR2021	BNT162b2 (30 µg)		
C4591001 1044 10441292	17DEC2020	Placebo	05JAN2021	Placebo	08MAR2021	10MAR2021	BNT162b2 (30 µg)		
C4591001 1044 10441344	09JAN2021	Placebo	29JAN2021	Placebo	10FEB2021	19FEB2021	BNT162b2 (30 µg)		
C4591001 1044 10441368	11JAN2021	Placebo	03FEB2021	Placebo	08MAR2021	09MAR2021	BNT162b2 (30 µg)		
C4591001 1057 10571391	09DEC2020	Placebo	28DEC2020	Placebo	19FEB2021	24FEB2021	BNT162b2 (30 µg)		
C4591001 1057 10571402	14DEC2020	Placebo	06JAN2021	Placebo	15FEB2021	03MAR2021	BNT162b2 (30 µg)		
C4591001 1057 10571407	17DEC2020	Placebo	05JAN2021	Placebo	12FEB2021	12MAR2021	BNT162b2 (30 µg)		
C4591001 1077 10771295	28DEC2020	Placebo	20JAN2021	Placebo	22FEB2021	25FEB2021	BNT162b2 (30 µg)		

**16.1.7.2.1 Listing of Subjects Who Originally Received Placebo and Then Received BNT162b2 After Unblinding – 12 Through 15 Years of Age – Safety Population**

Subject	Date	Vaccine Received		Date	Dose 3	Date	Dose 4
		Dose 1	Dose 2				
C4591001 1123 11231454	15DEC2020	Placebo	07JAN2021	Placebo	15FEB2021	20FEB2021	BNT162b2 (30 µg)
C4591001 1123 11231460	17DEC2020	Placebo	08JAN2021	Placebo	15FEB2021	17FEB2021	BNT162b2 10MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1124 11241270	05JAN2021	Placebo	26JAN2021	Placebo	23FEB2021	23FEB2021	BNT162b2 (30 µg)
C4591001 1126 11261262	04DEC2020	Placebo	23DEC2020	Placebo	09FEB2021	10FEB2021	BNT162b2 03MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1126 11261275	15DEC2020	Placebo	06JAN2021	Placebo	04FEB2021	08FEB2021	BNT162b2 03MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1126 11261276	15DEC2020	Placebo	06JAN2021	Placebo	04FEB2021	08FEB2021	BNT162b2 03MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1126 11261305	30DEC2020	Placebo	21JAN2021	Placebo	22FEB2021	24FEB2021	BNT162b2 (30 µg)
C4591001 1139 11391166	11DEC2020	Placebo	30DEC2020	Placebo	08FEB2021	16FEB2021	BNT162b2 11MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1139 11391181	18DEC2020	Placebo	07JAN2021	Placebo	09FEB2021	15FEB2021	BNT162b2 08MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1139 11391212	28DEC2020	Placebo	19JAN2021	Placebo	12FEB2021	19FEB2021	BNT162b2 (30 µg)
C4591001 1139 11391235	05JAN2021	Placebo	28JAN2021	Placebo	08FEB2021	15FEB2021	BNT162b2 08MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1139 11391263	12JAN2021	Placebo	01FEB2021	Placebo	09FEB2021	19FEB2021	BNT162b2 12MAR2021 BNT162b2 (30 µg) (30 µg)
C4591001 1147 11471269	05DEC2020	Placebo	28DEC2020	Placebo	17FEB2021	24FEB2021	BNT162b2 (30 µg)
C4591001 1147 11471270	05DEC2020	Placebo	28DEC2020	Placebo	17FEB2021	24FEB2021	BNT162b2 (30 µg)

090177e196b257a8\Final\Final On: 03-Apr-2021 04:34 (GMT)



**16.1.7.2.1 Listing of Subjects Who Originally Received Placebo and Then Received BNT162b2 After Unblinding – 12 Through 15 Years of Age – Safety Population**

Subject	Date	Vaccine Received		Dose 2	Date of Unblinding	Date	Dose 3	Date	Dose 4
		Dose 1	Date						
C4591001 1147 11471271	05DEC2020	Placebo	28DEC2020	Placebo	17FEB2021	24FEB2021	BNT162b2 (30 µg)		
C4591001 1150 11501131	20OCT2020	Placebo	09NOV2020	Placebo	16FEB2021	23FEB2021	BNT162b2 (30 µg)		
C4591001 1150 11501182	08DEC2020	Placebo	28DEC2020	Placebo	16FEB2021	25FEB2021	BNT162b2 (30 µg)		
C4591001 1150 11501242	23DEC2020	Placebo	15JAN2021	Placebo	02MAR2021	10MAR2021	BNT162b2 (30 µg)		
C4591001 1150 11501244	28DEC2020	Placebo	20JAN2021	Placebo	09FEB2021	17FEB2021	BNT162b2 (30 µg)	08MAR2021	BNT162b2 (30 µg)
C4591001 1152 11521604	02DEC2020	Placebo	21DEC2020	Placebo	03MAR2021	11MAR2021	BNT162b2 (30 µg)		
C4591001 1152 11521629	04DEC2020	Placebo	23DEC2020	Placebo	05JAN2021	05JAN2021	BNT162b2 (30 µg)	25JAN2021	BNT162b2 (30 µg)

PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 02APR2021 (23:06)  
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2\_unblinded/C4591001\_BLA/adsl\_1003\_plc\_unb\_ped